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Preface to ”Anticancer Agents: Design, Synthesis and
Evaluation”
Current cancer therapies still have various limitations, such as multi-drug resistance, undesired
off-target effects, and unpredictable efficacies. The cancer-related mortality rate remains high. The
development of novel anticancer agents thus continues to be imperative to combat various deadly
cancers. The emerging molecular targets and signal pathways enable the development of novel
strategies for the rational design of new anticancer agents. Numerous well-established synthetic
methods and biological screening assays have paved the way for the discovery and development
of new anticancer agents. This Special Issue of Molecules is devoted to all aspects of recent studies
searching for new anticancer agents. Both original research and review articles focusing on the
rational design, synthesis, and/or biological evaluation of various agents (including small molecules,
natural products, intrinsic molecules, antibodies, and vaccines) as potential cancer therapeutics are
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Abstract: As protein–protein interactions (PPIs) are highly involved in most cellular processes,
the discovery of PPI inhibitors that mimic the structure of the natural protein partners is a promising
strategy toward the discovery of PPI inhibitors. In this review, we discuss recent advances in the
application of virtual screening for identifying mimics of protein partners. The classification and
function of the mimicking protein partner inhibitor discovery by virtual screening are described.
We anticipate that this review would be of interest to medicinal chemists and chemical biologists
working in the field of protein–protein interaction inhibitors or probes.
Keywords: protein–protein interactions; virtual screening; mimetics; drug discovery
1. Introduction
Protein–protein interactions (PPIs) are involved in the regulation of biological processes, including
cell proliferation, signal transduction, transcription, and apoptosis [1]. Since numerous ailments are
associated with abnormal PPIs, the inhibition of PPIs is an attractive approach for the generation of
new therapeutics. However, because of their large and amorphous interfaces, targeting PPIs is a great
challenge in pharmaceutical and academic research.
In recent years, computer-aided approaches became useful tools to assist scientists in
drug discovery. In particular, virtual screening emerged as a complementary technique to aid
high-throughput screening (HTS) in pharmaceutical development. Virtual screening can reduce the
number of compounds to be screened in bioassays, leading to a large reduction of time and cost [2,3].
Virtual screening strategies can be traditionally classified into two broad types: ligand-based virtual
screening (LBVS) and structure-based virtual screening (SBVS). LBVS strategies include approaches
such as pharmacophore-based methods, quantitative structure–activity relationships (QSAR), and
three-dimensional shape matching [4]. On the other hand, SBVS techniques mainly revolve around the
docking of molecules to three-dimensional (3D) structures of the biological target as determined by
X-ray crystallography, nuclear magnetic resonance (NMR), or homology modeling.
Recently, virtual screening found increasing use for identifying inhibitors against various targets.
Sun et al. constructed QSAR models of Sirtuin 1 (SIRT1) ligands and discovered 12 compounds as
inhibitors of SIRT1 through ligand-based virtual screening [5]. Yang et al. identified a potent and
selective KDM5A inhibitor using structure-based virtual screening [6]. Wu et al. reported mitoxantrone
as an inhibitor of NAE using virtual screening of an approved drug database [7]. Virtual screening
was also used to develop inhibitors of PPIs. Yang et al. described a compound as an inhibitor
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of the VHL–HIF1α interaction using structure-based virtual screening [8]. Zhong et al. utilized
structure-based virtual screening and identified a cytosine alkaloid compound as an inhibitor that
inhibited the menin–MLL interaction and another compound as a potential inhibitor of TLR1–TLR2
heterodimerization [9,10]. However, virtual screening still has many challenges and limitations that
need to be overcome, especially its high false positive rate, which limits virtual screening to initial
screening only [11].
The rational design of compounds that mimic key interactions at the protein–protein interface is
another successful strategy for PPI inhibitor discovery [12]. Compared with low-molecular-weight
compounds, mimetics can be more selective and show lower toxicity. Modification and optimization of
peptide mimetics can also improve structural stability, resulting in increased oral availability [13]. For
example, Groß et al. designed and synthesized a soluble peptide mimicking CXCR4 to interrupt the
gp-120 and CXCR4 interaction [14]. In this context, the combined utilization of mimicking strategies and
virtual screening has broad application prospects for drug discovery (Figure 1). Based on this strategy,
many mimetics targeting cancer-related PPIs were discovered using virtual screening, such as p53
mimetics for the MDM2–p53 interaction [15–20], BH3 mimetics for the Bcl-2–BH3 interaction [21–26],
and SMAC mimetics for the IAP–SMAC interaction [1,27–29]. Knowledge of the 3D structures of
proteins allows the use of different approaches for mimetics design. For the interruption of PPIs,
inhibitors may be larger in size than traditional drug compounds. Peptides and proteins mimetics
are increasingly considered to be viable therapeutics for PPI inhibitor discovery [30]. However, there
are still some challenges in protein or peptide mimetics design. For example, we still do not fully
understand folding and the physical forces that stabilize protein structures. Moreover, sequences
with many degrees of freedom can complicate the sequence search, which leads to a requirement for
effective methods to find sequences related to a particular structure and measure essential protein
folding criteria.
Figure 1. Mimicking strategy for inhibitor discovery by virtual screening [31]. (Reprinted with
permission from Copyright (2015) Wiley—VCH Verlag GmbH & Co. KGaA.).
In this review, we discuss the recent advances in the application of virtual screening to design
protein or peptide mimetics for PPI inhibitor discovery, and we summarize different methods for
virtual screening. The classification of mimicking strategies and the function of the mimicking protein
partner inhibitors discovered using virtual screening techniques are also described.
2
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2. Integrating Mimicking and Virtual Screening Strategy for Protein–Protein Interaction
Inhibitor Discovery
Recent studies indicated that certain types of PPIs are amenable for targeting by small molecules,
which can block the interaction between a protein and its peptide or protein partner via binding
at the proteinous interface [7,32–38]. As key residues of the protein or peptide may serve as a
beginning point for PPI inhibitor design, the effective mimicking of peptides in their biologically active
conformation and the development of mimicking ligands are important goals in science beyond the
development of PPI modulators. Meanwhile, virtual screening emerged as a complementary technique
to aid mimicking strategy in pharmaceutical development, complementing high-throughput screening
(HTS) techniques. Integrating mimicking and virtual screening is a potentially viable strategy for
protein–protein interaction inhibitor discovery. In this section, we describe the application of virtual
screening and a mimetic strategy for PPI inhibitor discovery and discuss their merits and drawbacks.
2.1. Virtual Screening for PPI Inhibitor Discovery
Virtual screening is a kind of computer-aided technique that is usually considered as an initial
step in the lead discovery process in order to enrich the library with active compounds and predict
experimental activity [11]. Usually, based on the information about the target or the ligands of reported
compounds, virtual screening is usually classified into two types: ligand-based virtual screening (LBVS)
and structure-based virtual screening (SBVS). LBVS strategies depend on the similarity or dissimilarity
of the compounds of interest, and they require a large amount of structure–activity data from a large
chemical compound library. One of the ligand-based approaches is QSAR modeling, which focuses
on achieving a correlation between the physicochemical and structural properties of the ligands and
their biological function and potency. QSAR modeling includes two-dimensional (2D-QSAR) and
three-dimensional QSAR (3D-QSAR). Scientists use 2D-QSAR and 3D-QSAR properties of ligands
to build up a model of biological activity, which can be applied to predict the activity of some new
compounds [39]. Compared with 3D-based algorithms, 2D-based algorithms are usually faster but may
be less accurate; moreover, 2D-based algorithms cannot find new active compounds with dissimilar
chemical structures [40]. Moreover, 2D- and 3D-QSAR do not consider ligand conformations, protein
structure and flexibility, or solvation effects. Another LBVS approach is based on the similarity of
compounds, which is a simple computational method with low cost, focusing on obtaining compounds
that are similar to known ligands. However, this method is easily influenced by human users because
it is difficult to objectively select the input molecules [41]. It is usually carried out by using common
chemical features from the 3D structures of some known ligands that represent interactions between
the ligands and the target. Pharmacophore modeling is another approach for LBVS. Based on analyzing
the structures of known inhibitors against a target, a ligand-based pharmacophore can be generated
that describes the spatial arrangement of chemical features of active compounds. However, under
many circumstances, it is hard to find a library with functionally and structurally diverse molecules
with quantitative activity data for a given protein. More importantly, the lack of publications with
negative results hinders the identification of inactive molecules, resulting often in the development of
qualitative common feature pharmacophores only from active compounds [41,42]. Finally, as LBVS
applications are generally based on the properties of the known ligands, the diversity of the hits
discovered are generally limited.
In contrast, SBVS techniques do not require knowledge of the biological activity of known
compounds. Instead, 3D structures of the protein must be known or inferred. Protein-ligand docking is
widely applied to identify compounds that are predicted to bind tightly to the active sites of the target.
During the SBVS process, the 3D structure of a target protein and a set of ligands are considered as
starting points and screened by virtual filtering, followed by docking and scoring to identify potential
lead candidates. Many algorithms were developed to perform SBVS, such as DOCK, GOLD, And
AUTODOCK, which can be used for identifying the binding mode and binding affinity between
protein and ligand [43]. After docking and scoring, a set of compounds with the highest predicted
3
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binding affinity against the target can be obtained [44]. One relatively new strategy that falls within
the purview of SBVS is the binding site comparison approach. This strategy, which can be utilized for
drug repurposing and polypharmacology, relies on the recognized fact that many different proteins
have similar binding sites [45]. Thus, binding sites in any given protein can be searched and matched
with specific chemical structures. Finally, the pharmacophoric approach can also be employed within
SBVS. If a high-resolution 3D structure of the target is available, a structure-based pharmacophore of
the binding site can be generated based on the structural features of the binding site. In this case, a
library of known inhibitors against the target is not needed. Compared to LBVS (Table 1), SBVS is
more likely to identify new scaffolds because it is based on physical interactions calculated in silico,
rather than relying on the similarity/dissimilarity of known ligand compounds. Thus, SBVS may be
able to identify inhibitors with unique mechanisms of action [11,46]. Another difference is that, unlike
LBVS, the docking model obtained by SBVS can be used for interaction analysis, in order to further
enhance the affinity or selectivity of the compounds.
Table 1. The advantages and limitations of structure-based virtual screening (SBVS) and ligand-based
virtual screening (LBVS). QSAR—quantitative structure–activity relationships.
Types Pros Cons
SBVS
1) Pharmacophore-based models Uses protein structure Increased screening time
2) Molecular docking Not biased towardexisting ligand structures Higher false positives




1) Similarity methods Simple and fast Requires existing ligands





Lack of consideration of
protein structural
framework
Receptor and ligand flexibility is crucial for predicting drug binding and evaluating thermodynamic
and kinetic properties. Molecular dynamics (MD) simulation is a technique for investigating atomic
and molecular motion, and it is widely and effectively used for analyzing the relationship between
the structure and function of molecules [47,48]. The main advantage of MD simulations is that
they can thoroughly sample the conformational space around both the protein and the ligand under
realistic conditions, accommodating both structural flexibility and entropic effects, thus allowing the
thermodynamics and kinetics of the drug–target interaction to be more accurately calculated [47].
Therefore, MD simulation can be combined with SBVS or LBVS to further understand the binding
mode of candidate molecules, thus accelerating the process of drug development [49]. Additionally,
MD simulations can be used to identify potential pockets and binding hotspots of PPIs [50]. Saez et
al. used MD simulations to predict the atomic interactions of the PcTx1–cASIC1 interaction and the
hotspot residues of their interface, which could be beneficial for designing therapeutically useful PcTx1
mimetics [51]. By combining structural information, MD, and functional experiments, they obtained
detailed insight into the molecular basis of this PPI. The TRAF6–Basigin interaction is implicated in
melanoma metastasis. Biswas et al. used MD simulations to study the interactions between individual
proteins and TRAF6–Basigin complexes, revealing conformation changes in the PPI and the adoption
of a helical conformation [52].
In terms of the chemical library used for SBVS or LBVS, different filters can be used. For
fragment-sized compounds, Congreve et al. described a “rule of three” with molecular weight < 300,
logP < 3, number of hydrogen bond donors and acceptors < 3, and number of rotatable bonds < 3 [53].
Alternatively, based on physicochemical properties, the “Pfizer’s Rule of 3/75" can be applied to
predict the toxicology of compounds. Compounds with calculated partition coefficient (ClogP) < 3 and
topological polar surface area (TPSA) > 75 are approximately 2.5 times more likely to be safe in in vivo
4
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assays [54]. However, overly strict application of filters may introduce bias, leading to the exclusion of
potentially active compounds. To assess the potency of the hits derived from virtual screening, IC50,
EC50, Ki, or Kd values can be calculated. Ripphausen considered four subdivisions of potency (<1,
>1–10, >10–100, and >100 μM), and suggested that docking hits are generally weakly potent, falling
into the 1–100 μM range [55].
As virtual screening is often used as first stage of the primary screening process, false positives
are a common problem. Based on six cases, Schierz et al. reported that the average percentage of
false positives from the high-throughput primary screen is quite high at 64% [56]. To eliminate false
positives, cross-referencing between primary and confirmatory screening assays is required. On the
other hand, selectivity is a crucial aspect for developing potent PPI inhibitors. Off-target effects can
arise when the compounds bind to other protein targets rather than their intended target, leading to
side effects [57]. Virtual screening can be used for resigning, repositioning, and predicting side effects
or toxicity of drugs, which can significantly decrease the time and cost of development compared to
the traditional drug discovery process [58,59]. In one example, Spahn et al. used a computational
simulation to create chemical modifications of fentanyl, an opioid pain killer with severe adverse
effects due to off-target effects throughout the body. The newly discovered compound, named NFEPP,
possesses a lower pKa and eliminates pain by selectively activating the MOR pathway in the inflamed
acidic area without causing side effects [60].
Taken together, virtual screening greatly decreases the time and money costs by processing
thousands of compounds in a short time in silico, thereby reducing the number of compounds
to be synthesized or purchased [61]. However, because virtual screening relies on analyzing the
physicochemical properties of compounds rather than biological activity directly, it has a high rate of
false positives or false negatives compared to cellular or phenotypic screens [62].
In order to improve the efficiency of screening for more bioactive PPI lead inhibitors, the mimicking
peptide strategy can be used. Virtual screening can be employed to target PPI surfaces or to mimic
“hotspot” residues. Peptide mimetics that mimic the bioactivity of the parent peptides can also show
improved pharmacokinetic and pharmacodynamic properties, such as bioavailability and stability [63].
It should be noted that the mimicking protein domain can be achieved with protein backbone scaffolds
or small molecules [30,31].
2.2. Structure-Based Mimicking Peptide Strategy for PPI Inhibitor Discovery
Peptides are utilized as feasible molecules to mimic protein binding sites [64]. Peptidomimetics
are non-peptide compounds that mimic the conformation and characteristics of peptide molecules
to interrupt PPIs [63]. In general, chemical synthetic, screening, and structure design approaches
are usually used for designing and extending the diversity of peptide-derived chemical structures,
as well as enhancing their metabolic stability [64]. Synthetic strategies can explore and expand
the chemical space for peptidomimetics. Screening strategies, including high-throughput screening
and fragment screening, are often used to identify hot hits and discover peptidomimetics based on
reported compounds [65]. Meanwhile, design strategies can use hotspot residues as starting points to
design analogues by mimicking key secondary-structure motifs involved in the PPI interface. Design
strategies can be subdivided into sub-structure search, de novo design, and bioisostere design [65]. As
peptides usually contain secondary structures such as α-helices and β-sheets, peptidomimetics for
inhibiting PPIs should be able to mimic these structures in order to be able to displace the natural
peptides [66]. Therefore, peptides that mimic α-helices or β-sheets of proteins are attractive targets for
drug discovery. α-helix structures are indispensable secondary structural elements which constitute
most structured protein domains and contribute greatly to the protein–protein interface. Main strategies
for synthesizing α-helix mimetics include (i) cross-linking of peptide side chains and the incorporation
of stabilizing caps at the N-terminus, (ii) use of foldamers to modulate backbone variations, and
(iii) introduction of projecting rod-like elements that mimic the side chains of an α-helix [31,67]. For
example, Ernst et al. designed a polyamide foldamer as an α-helix mimetic, leading to the synthesis
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of inhibitors of the Bak BH3/Bcl-xL complex [68]. Meanwhile, a β-strand is an extended structural
element between three and 10 amino acids long, and adjacent β-strand structures can be connected
laterally backbone hydrogen bonds, forming a twisted or pleated sheet. β-sheets play key roles in
maintaining the tertiary and quaternary structures of proteins, as well as PPIs. A number of strategies
were utilized to design β-strand and β-sheet mimetics: (i) incorporation of turn mimetics to nucleate
β-sheet generation, (ii) macrocyclization via covalent or noncovalent linkages, and (iii) introduction of
β-strand-enforcing residues [31]. In addition to α-helix structures and β-strand structure mimetics,
mimicking the turn structure of peptides is another potential approach for PPI inhibitor discovery.
Turn structures are anomalous secondary structures that differ from α-helix and β-sheet structures due
to the non-repetitive dihedral angles of the main chains. Turn motifs allow a peptide chain to fold
back, and are important for forming globular proteins [31,69,70]. For instance, Bartfai et al. designed a
β-turn mimetic that interrupted the interaction between IL-1RI and MyD88 in the TIR domains [71].
Gimeno and co-workers developed a classification of peptide mimetics depending on the extent
of similarity to the native peptide. Class A mimetics contain the parent peptide amino-acid sequence,
with the side chains being arranged to closely mimic the active conformation of the native peptide.
Class B mimetics possess further modification of the native sequence, including the introduction of
non-natural amino-acid residues, other small molecular motifs, or changes of the backbone sequence.
Class B mimetics include foldamers, β- and α/β-peptides, and peptoids. Class C mimetics are highly
modified structures with small molecular motifs and changes in the main chains of the peptide. Class
D mimetics mimic the method of action of the native peptide rather than through structural mimicry of
the side chains, and they can be developed via affinity optimization of class C mimetics or, alternatively,
they can be identified by virtual screening [31]. An alternative classification of peptide mimetics was
also described in the past two decades. Type I mimetics are short peptide sequences that mimic the
α-helical motif of a PPI interface. Type II mimetics are functional mimetics that are based on a small
molecular scaffold rather than a peptide scaffold. Type III mimetics include non-peptide templates
that mimic the topography of the original helix by retaining the spatial arrangement of key binding
residues [31,72,73]. In peptide mimetics design, one of the main challenges is that the topological
shapes of proteins are complex, leading to variations in the types of interactions, binding pockets, and
recognition sites formed [74]. This variability of PPIs is a crucial aspect that has to be mastered for the
design of peptide mimetics targeting PPIs.
2.3. Integration of Mimicking Strategies with VS for PPI Inhibitor Discovery
Effectively mimicking the bioactive conformation of a peptide is a critical part of developing
mimics as PPI inhibitors. However, developing mimetics with appropriate pharmacokinetic properties
is a key challenge to overcome [31]. To strike a balance for these two properties, applying virtual
screening can allow for simultaneous optimization of affinity and pharmacokinetic properties [75–77].
Thus, the integration of mimicking strategies and virtual screening is a complementary strategy for
efficiently developing PPI inhibitors. In this section, we introduce and classify mimicking strategies
using different virtual screening approaches (Figure 2).
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Figure 2. Different approaches for mimetics discovery based on structure-based virtual screening
(SBVS) and ligand-based virtual screening (LBVS) [78]. (Reprinted with permission from Copyright
(2002) Elsevier Science B.V.).
2.3.1. De Novo Peptide Design Approach
De novo peptide design is an attractive approach for constructing designed peptides with desired
structures and functions, including peptide mimetics targeting PPIs. De novo design can create novel
molecules that do not exist in known compound databases. This method only requires a scaffold library
and a few key anchor residues as a starting point. By knowledge of the structural features of the native
peptide, new inhibitors with the desired secondary structural characteristics can be built up de novo
according to the targeted binding site. The virtual de novo peptide design method can be considered
to comprise the following stages: (i) documentation of key anchor residues and the preparation of
the scaffold library, (ii) virtual screening to find scaffold fragments that the anchor residues can be
attached to, (iii) sequence design and structure refinement, and (iv) experimental validation [79]. There
are several advantages of de novo peptide design to developing protein mimics. The first one is that the
backbone of the natural protein sequence can be utilized as a template to initiate the design. Another
advantage is that knowledge of sequence/structure relationships and/or statistical forcefields from
native proteins can be used to guide the sequences of the designed peptides [80]. Therefore, de novo
peptide design approach is a complementary strategy for peptide mimetics discovery.
Using the joint application of the de novo peptide design approach and peptide mimetics design,
Li et al. designed PD-1-binding peptides by mimicking five residues (Y56, R113, A121, D122, and
Y123) of the ligand PD-L. The most potent peptide Ar5Y_4 had a KD value of 1.38 ± 0.39 μM, which
was comparable to the binding affinity of the PD-L1. Ar5Y_4 showed the ability to interrupt the
binding of PD-L1 to PD-1, providing a potential strategy for further optimization of PD-L1 peptide
mimetics [74,81]. Smadbeck et al. used a three-stage de novo peptide design approach to design
EZH2 inhibitory peptides. The approach comprises a sequence selection stage, a fold specificity
calculation stage, and an approximate binding affinity calculation stage. The novel peptide SQ037
showed the highest in vitro response, with an IC50 of 13.5 μM. Compared to the native and K27A
mutant control peptides, SQ037 had greater potency as an inhibitor and showed higher specificity to
EZH2 [79]. Ruiz-Gómez et al. optimized the de novo design approach for small scaffolds mimicking
protein recognition epitopes of large, non-structured, and discontinuous PPIs. They applied this novel
re-scaffolding approach to the de novo design of potent interleukin 10 (IL-10) ligands that mimic the
high-affinity receptor IL-10R1 [82]. Overall, these studies demonstrate that computer-aided de novo
design is an effective strategy for peptide mimetics discovery.
2.3.2. Fragment-Based Design Approach
The fragment-based design approach uses fragments with low molecular weight and small size as
starting points for modifying into high-affinity compounds. Compared with HTS, the fragment-based
design approach can result in higher hit rates and a higher probability of synthesizing an efficient
binding compound [83]. Hence, fragment-based approaches are particularly effective for generating
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small molecules or peptides targeting PPIs. The most common biophysical screening techniques
for the fragment-based design method include differential scanning calorimetry (DSF), ligand- or
protein-based nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), isothermal
titration calorimetry (ITC), or X-ray crystallography [1,74]. The fragment-based design approach is
widely applied to mimetics design. For example, Petros et al. discovered a high-affinity ligand for the
anti-apoptotic protein Bcl-XL using fragment-based screening. From NMR-based structural studies
and parallel synthesis, a potent BH3 mimetic ligand was obtained, which bound to Bcl-xL with an
inhibition constant (Ki) of 36 ± 2 nM [22,23]. Using NMR-based screening, parallel synthesis, and
structure-based design, further modification of this ligand was achieved by Oltersdorf and co-workers.
They discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XL,
and Bcl-w, which showed two to three orders of magnitude more potent affinity than previously
reported compounds [24]. Although ABT-737 showed great antitumor activity in murine tumor
xenograft models, it lacked oral bioavailability. Park et al. reported that targeted modifications at
three positions of ABT-737 led to a 20-fold improvement in the pharmacokinetic/pharmacodynamic
relationship (PK/PD). The resulting compound ABT-263 was orally available in a xenograft model of
human small-cell lung cancer, and induced complete tumor regressions in all animals [25]. Based on
ABT-263, Souers et al. redesigned and reported the first-in-class orally bioavailable Bcl-2-selective
inhibitor with potent anticancer activity in vitro and in vivo [26]. Fragment-based design, in concert
with computational approaches, show high promise for peptide mimetic design and discovery.
2.3.3. Pharmacophore-Based Design Approach
Pharmacophore-based approaches enables the virtual screening of large numbers of peptide
mimetics using a conventional pharmacophore broadly derived either using structure-based or
ligand-based methods, depending on whether a 3D structure of the target is available or not [74,84].
The pharmacophore-based approach can be divided into four steps: (i) atom typing, (ii) conformational
sampling, (iii) hypothetical pharmacophore construction, and (iv) virtual screening of candidate ligands
against the hypothetical pharmacophore [85]. Using the pharmacophore approach, Hansen et al.
synthesized small beta-peptidomimetics with anti-staphylococcal activity. Their research showed that
small β-peptidomimetics can mimic the antimicrobial activity of much larger antimicrobial peptides
(AMPs), making them promising candidates for treating bacterial infections [74,86]. Caporuscio et al.
developed compounds that showed micromolar potency against replication of HIV-1 in cells via a
target-based pharmacophore model mapping the CD4-binding site on HIV-1 gp-120 [87]. Hall et al.
conducted a two-round computational screening of potential peptide mimetic compounds in order to
develop inhibitors of the ανβ3 integrin receptor. Biological testing revealed that the peptide mimetic
molecules potently inhibited hantavirus with two thousand times more potency than the natural cyclic
peptide (cyclo-[CPFVKTQLC]). The second round of screening furnished molecules with improved
chemical diversity by building up the pharmacophore models [74,88]. Atatreh et al. started with a
3D pharmacophore and performed virtual screening to discover a series of MDM2–p53 interaction
inhibitors with inhibition activity at the submicromolar level, which showed anticancer activities
against different breast cancer cell lines [89]. Overall, the pharmacophore-based design approach is a
suitable method for peptide mimetics discovery when the target protein structure is unavailable.
2.3.4. Integration of Mimicking Strategies with LBVS for PPI Inhibitor Discovery
In contrast to structure-based approaches, LBVS uses the structures of known binders as
templates to discover and identify diverse bioactive compounds with high affinity. In general,
LBVS methods depend on the application of computational descriptors of molecular structure,
properties, or pharmacophore features, and they analyze relationships between active and database
or test compounds in various defined chemical descriptor spaces [90,91]. Three major methods are
usually utilized for LBVS: QSAR modeling, pharmacophore modeling, and the efficient similarity
method. QSAR modeling can be broadly divided into three steps: (i) collect compound data, (ii)
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develop and validate QSAR models, and (iii) use the models to identify compounds from a chemical
library. QSAR approaches are not computationally intensive, so they can be performed relatively
quickly [92]. However, ligand-based 2D- and 3D-QSAR models do not consider ligand conformations,
protein structure and flexibility, or solvation effects, which may lead to poor accuracy. When the
three-dimensional (3D) structure of a target is unknown, pharmacophore modeling can be utilized
to identify biologically active compounds via chemical features such as hydrogen bonding and
lipophilicity as the input data for flexible alignment. Ligand-based virtual screening involves two
different methods: (i) flexible alignment of molecules by considering only the atomic contributions,
and (ii) use of other chemical features that are unrelated to 3D pharmacophore representations, such
as hydrogen bonding and lipophilicity [84,93]. In the similarity method, compounds with similar
structures are assumed to have similar activities, allowing the topological, steric, electronic, and/or
physical properties of compounds to be predicted by comparison with known molecules [94]. Six
types of similarity are exploited: chemical similarity, molecular/2D similarity, 3D similarity, biological
similarity, global similarity, and local similarity [95]. In recent years, LBVS was increasingly applied to
identify active compounds as PPI inhibitors [96]. Švajger et al. used two parallel virtual screening
methods targeting the TLR4–MD-2 interface by mimicking interactions with MD-2 to discover novel
TLR4 antagonists. They identified a potent hit compound with an IC50 value of 16.6 μM and no
cytotoxic properties, which may be a potential agent to treat sepsis and neuropathic pain [97]. Varney
et al. previously reported the interaction of Lipid II with defensins, based on the 3D structure of
the human defensin peptide HNP1–Lipid II complex. They designed a pharmacophore model and
used it for screening for defensin mimetics, leading to the first Lipid II-targeted low-molecular-weight
compound, BAS00127538 [98]. Ambaye et al. used the co-crystal structure of a lead peptide antagonist
and combined a shape-based similarity search, molecular docking, and 2D-similarity searches to
identify nine novel phenylbenzamide-based antagonists of the Grb7 SH2 domain as potential Grb7
anticancer therapeutics [99].
3. Conclusions
Due to the critical roles of PPIs in disease, targeting PPIs is a potential therapeutic strategy.
High-throughput screening is a widely used technique in drug discovery; however, a large investment
into compounds and screening assays is required. Virtual screening is an emerging technology
for drug discovery because there is no need for physical compounds and bioassays for screening.
As we highlighted in this review, virtual screening is used for discovering mimetics of PPIs based
on different approaches, such as de novo peptide design approach, fragment-based design approach,
pharmacophore-based design approach, and ligand-based design approach. We anticipate that the
integration of virtual screening with mimicking strategies will become a powerful tool in cancer
research and that that this review could arouse the interest of chemical and biological scientists working
in the field of PPI inhibitors.
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Abstract: Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist
with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall
survival time and metastatic free survival time for patients with lethal castration-resistant prostate
cancer (CRPC), but also castration-resistant free survival time for patients with castration-sensitive
prostate cancer (CSPC). Enzalutamide has thus been approved by the US Food and Drug
Administration (FDA) for the treatment of both metastatic (in 2012) and non-metastatic (in 2018)
CRPC, as well as CSPC (2019). This is an inspiring drug discovery story created by an amazing
interdisciplinary collaboration. Equally important, the successful clinical use of enzalutamide
proves the notion that the second-generation AR antagonists can serve as hormonal therapeutics
for three forms of advanced prostate cancer. This has been further verified by the recent FDA
approval of the other two second-generation AR antagonists, apalutamide and darolutamide, for the
treatment of prostate cancer. This review focuses on the rational design and discovery of these three
second-generation AR antagonists, and then highlights their syntheses, clinical studies, and use.
Strategies to overcome the resistance to the second-generation AR antagonists are also reviewed.
Keywords: androgen receptor; prostate cancer; enzalutamide; apalutamide; darolutamide
1. Introduction
1.1. Prostate Cancer
Prostate cancer continues to be a main health concern due to the highest incidence and the second
highest cancer-related death rate in American men. In 2020, estimates indicate about 21% of all new
cancer cases will be attributed to prostate cancer, while over 33,000 deaths caused by prostate cancer
are projected to occur in the United States [1]. The critical driving force for prostate cancer is the
androgen receptor (AR)-regulated gene expression that is initiated by the binding of androgen to
AR [2]. Consequently, the mainstay therapy for castration-sensitive prostate cancer (CSPC) since
1941 is androgen deprivation therapy (ADT). However, after the initial response to ADT for about
18 to 24 months, most CSPC will inevitably shift to castration resistant prostate cancer (CRPC) [3].
In the CRPC stage, prostate cancer continues to grow under extremely low levels of male hormone
testosterone in serum. The majority of prostate cancer deaths in the United States are caused by
late state (metastatic) CRPC (mCRPC). Within the past decade, several new treatments have been
approved for three forms of prostate cancer: metastatic castration-sensitive prostate cancer (mCSPC),
Molecules 2020, 25, 2448; doi:10.3390/molecules25102448 www.mdpi.com/journal/molecules15
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non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant
prostate cancer (mCRPC). Table 1 lists the current treatments that have been approved by the US
Food & Drug Administration (FDA) since 2004, according to the information published on the official
website of the US FDA. Current treatments for prostate cancer can be classified into taxane-based
chemotherapeutics, hormonal therapy, immunotherapy, and radiotherapy. As illustrated in Table 1,
far more hormonal therapies than other categories have recently been approved by the US FDA for
prostate cancer.
Table 1. Current Treatments with Survival Benefit for Patients with Prostate Cancer.










17 June 2010 mCRPCafter docetaxel Chemotherapy
Xofigo radium-223 15 May 2013 mCRPC Radiotherapy
























7 February 2018 mCSPC Hormonal therapy
Erleada Apalutamide 14 February 2018 nmCRPC Hormonal therapy
Erleada Apalutamide 17 September 2019 mCSPC Hormonal therapy
XTANDI Enzalutamide 31 August 2012 mCRPCafter docetaxel Hormonal therapy
XTANDI Enzalutamide 13 July 2018 nmCRPC Hormonal therapy
NUBEQA Darolutamide 30 July 2019 nmCRPC Hormonal therapy
XTANDI Enzalutamide 16 December 2019 mCSPC Hormonal therapy
nmCRPC: non-metastatic castration-resistant prostate cancer. mCRPC: metastatic castration-resistant prostate cancer
mCSPC: metastatic castration-sensitive prostate cancer.
1.2. Hormonal Therapeutics
The timeline for the development of hormonal therapeutics for prostate cancer is illustrated
in Figure 1. The pioneering hormonal therapeutic for prostate cancer is the well-known androgen
deprivation therapy originally reported by Huggins and Hodges in 1941 [4]. At that point, orchiectomy
(surgical castration) and administration of high dose of estrogen (non-surgical castration) were
established to be two strategies to cut down the circulating testosterone to castrate (or near castrate)
levels, resulting in appreciable biochemical response in a cohort of eight patients with metastatic
prostate cancer. It was recognized by the Veterans Administration Cooperative Urological Research
Group in 1970s that treatment of patients with advanced prostate cancer with high dose of estrogen
led to good efficacy, but accompanying with enhanced mortality rate associated with cardiovascular
complications [5]. The serious undesired effect of estrogen urged the scientists to search for a safer
non-surgical castration strategy in 1980s. Encouraged by the finding that testicular production of
testosterone can be indirectly controlled by long-lasting elevation of gonadotropin-releasing hormone
(GnRH), GnRH agonists were designed and found to possess potential in suppressing prostate tumor
growth in vivo and in clinical settings [6,7]. Synthetic GnRH agonists, e.g., goserelin (Zoladex) [8]
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and leuprolide (Lupron) [9], were developed as a replacement for estrogen as a better non-surgical
castration strategy by the mid-1980s and have served as the centerpiece of ADT for CSPC since then.
To conquer the testosterone surge as well as other side effects caused by GnRH agonists, the US FDA
has approved degarelix (a GnRH antagonist) as an alternative medical castration for patients with
advanced CSPC in 2008. As compared with GnRH agonists, degarelix can provide rapid suppression
of prostate specific antigen (PSA) and testosterone so as to better control testosterone and prolong PSA
progression-free survival [10]. Degarelix is, thus, a better non-surgical castration therapy for those
CSPC patients at more advanced stages and with more apparent symptoms.
Figure 1. Timeline for the development of hormonal therapeutics for prostate cancer.
On the other hand, examination of antiandrogen compounds as another alternative to estrogen
castration was initiated in the late 1960s and early 1970s, leading to the development of three first
generation nonsteroidal androgen antagonists, flutamide (1), nilutamide, (2) and bicalutamide (3),
shown in Figure 2 [11]. These antiandrogen agents were revealed to competitively bind to the
ligand-binding domain on androgen receptors. Monotherapy of bicalutamide (the one with the
most extensive investigation) cannot offer better clinical benefit to patients with CSPC than ADT.
The combination therapy of bicalutamide with ADT is widely used by CSPC patients owing to the
greater safety profile than ADT alone, even though it does not grant significant overall survival
benefit [12].
Figure 2. First generation of nonsteroidal AR antagonists.
The clearer understanding of the structure and function of the androgen receptor revealed
that the androgen receptor plays a pivotal role for not only CSPC but also CRPC [13]. This notation
stimulated the successful design and discovery of three US FDA-approved second-generation androgen
receptor antagonists, enzalutamide (4) [14], apalutamide (5) [15], and darolutamide (6) [16] (Figure 3).
As illustrated in Table 2, enzalutamide (4) is now the first FDA-approved antiandrogen to treat three
forms of advanced prostate cancer after the US FDA approval of enzalutamide (4) on 16 December 2019
for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The intriguing discovery
17
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stories of these three successful second-generation nonsteroidal AR antagonists are reviewed in this
article. Their syntheses, clinical studies, and clinical use are highlighted as well. Current strategies to
overcome the resistance to these AR antagonists are also summarized.
 
Figure 3. Second generation of nonsteroidal AR antagonists.
Table 2. FDA-approved second-generation AR antagonists for prostate cancer.
Brand Name Generic Name mCRPC nmCRPC mCSPC
XTANDI enzalutamide yes yes yes
Erleada apalutamide no yes yes
NUBEQA darolutamide no yes no
nmCRPC: non-metastatic castration-resistant prostate cancer. mCRPC: metastatic castration-resistant prostate cancer.
mCSPC: metastatic castration-sensitive prostate cancer.
2. Discovery and Preclinical Studies
2.1. Enzalutamide (4) and Apalutamide (5)
Enzalutamide (4) and apalutamide (5) were discovered by the interdisciplinary collaboration of
Sawyers/Jung groups, which was motivated by the notion that “growth of castration-resistant prostate
cancer appears to depend upon continued androgen receptor signaling,” facilitated by the in vitro
AR-overexpressing prostate cancer cell models, and benefited from a complementary collaboration [17].
As illustrated in Figure 4, RU59063 (7) was selected as the original lead compound because it is a
potent and selective nonsteroidal AR agonist with high affinity for AR [18,19]. Enzalutamide (4) and
apalutamide (5) were eventually identified as two lead candidates for preclinical development on the
grounds of in vitro evaluation of their capability of agonistic and antagonistic activity of AR signaling
in a castration-resistant LNCaP/AR prostate cancer cell model [20]. The in vitro relative luciferase
activity and relative PSA level were measured using bicalutamide as positive control.
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Figure 4. Discovery of enzalutamide and apalutamide.
The structural modification started with substituting the ω-hydroxybutyl at N1 with azidoalkyl
and azidoaryl groups in the light of the hypothesis that the small polar azido group might function as
a bioisostere of the hydroxyl in RU59063 (7). The eastern side of RU59063 (7) was the first focus of
the chemical manipulation probably due to the fact that the electron-deficient aromatic ring on the
western side is a well-established pharmacophore for anti-androgenic activity [21]. Among the first set
of analogues, compound 8 was identified as the optimal derivative that had higher binding affinity
than bicalutamide. Further modification on compound 8 indicated that the 4-position of the N1-phenyl
ring can accommodate several different groups without losing the desired activity. Compound 9
with a 4-methyl on the N1-phenyl ring was chosen for further structure-activity relationship studies,
indicating that the location for the C-4 and C-5 on the thiohydantoin ring cannot be switched and
that the geminal dimethyl group on the thiohydantoin ring can be substituted by the cyclobutyl ring
in compound 10. On the basis of abovementioned promising in vitro bioassay data, compounds
9 and 10 were moved forward for in vivo evaluation in a castrate mice model with LAPC4/AR or
LNCaP/AR xenografts. Both compounds are more effective than bicalutamide in suppressing PSA
secretion, but with a short half-life due to rapid clearance. Considering that electron-rich N1-phenyl
ring and hydroxylation of the benzylic methyl, directly appending electron-withdrawing groups
to the N1-phenyl ring led to the discovery of 3-fluoroamide analogues 11 (also called RD162) and
enzalutamide (also called MDV3100). Both enzalutamide and RD162 (11) have greater (5–8 times)
AR binding affinity relative to bicalutamide in the LNCaP/AR cell line with high level expression of
wild-type AR. More importantly, their binding is specific to AR because only little or no binding to
other nuclear receptors was observed [14].
Both enzalutamide and RD162 (11) possess not only excellent in vivo anti-tumor efficacy in
the castrate mice model but also superb pharmacokinetic profile [14]. The in vivo pharmacokinetic
properties of RD162 (11) were first evaluated in mice. The results showed that, after a 24-h oral
treatment with a single 20 mg/kg dose, the plasma concentration (~23 μM) of RD162 (11) exceeds the
concentration (~1–10 μM) necessary to block AR activity. The in vivo pharmacodynamic experiments
suggest that RD162 (11) can significantly reduce AR transcriptional function and suppress LNCaP/AR
tumor cell proliferation. The excellent in vivo efficacy of RD162 (11) in castration-resistant prostate
tumor models was confirmed to be associated with AR suppression. This is because the effective dose
for antitumor efficacy in the LNCaP/AR model is closely correlated with that for AR transcriptional
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activity as measured by luciferase imaging experiments. The fact that enzalutamide instead of RD162
(11) was chosen, at that moment, as the drug candidate for further preclinical studies is simply because
enzalutamide can be prepared from an inexpensive starting material. Enzalutamide was successfully
approved by FDA, but was found to be associated with seizure side effect caused by antagonizing
GABAA receptor in the central nervous system [22]. With the hope to find out a second-generation
nonsteroidal AR antagonist with a high therapeutic index, apalutamide was later chosen for further
preclinical investigation because of its lower steady-state brain tissue level in mice.
As shown in Figure 4, apalutamide (5, also named ARN-509) has very similar chemical structure
to RD-162 (11) with only difference being the replacement of the N3-phenyl ring in RD162 (11) with a
N3-pyridyl ring in apalutamide. Apalutamide possesses comparable in vitro activity to enzalutamide,
but with greater anti-tumor efficacy in CRPC xenograft models and lower potential in causing seizure as
an adverse effect in the central nervous system [14,23]. Specifically, enzalutamide (4) and apalutamide
(5) were demonstrated to retain full antagonist activity in an AR overexpression setting and have a higher
binding affinity of up to 10-fold for AR when compared to bicalutamide (3). Both of them compete with
bicalutamide (3) for the same ligand-binding domain of AR. The selective binding of apalutamide (5)
for AR over other nuclear hormone receptors was observed. Unlike the first-generation AR antagonists,
both enzalutamide (4) and apalutamide (5) can interrupt multiple steps of the AR-signaling pathway,
including the androgen binding to AR, nuclear translocation of AR, DNA binding, and coactivator
recruitment. Good in vivo pharmacokinetic profiles, including good oral availability, long plasma
half-life, and low systemic clearance, were found for both enzalutamide and apalutamide in mouse
and dog models. However, apalutamide (5) has less chance than enzalutamide (4) to bind to plasma
proteins, and 2-fold higher concentration of free apalutamide (5) was detected in mouse and human
plasma. The in vivo pharmacodynamics studies of enzalutamide (4) and apalutamide (5) were carried
out in a CRPC animal model with LNCaP/AR-luc xenograft tumors. Both of them have potent in vivo
anti-tumor efficacy because they can significantly decrease androgen driven luciferase reporter-gene
activity and reduce tumor volume compared to vehicle. However, apalutamide (5) only needs 10 to
30 mg/kg/d to reach maximum efficacy in the castrate mouse model with the LNCaP/AR xenografts,
while enzalutamide (4) requires 30 to 100 mg/kg/d. Additionally, apalutamide exhibits antitumor
activity in a CSPC xenograft model. The above-mentioned data provide preclinical proofs for further
clinical development of apalutamide and enzalutamide for patients with CSPC and CRPC [14,23].
2.2. Darolutamide (6)
An AR transactivation screening of a group of nonsteroidal pyrazole-carboxamide and
imidazole-carboxamide derivatives in an AR-HEK293 cell model in combination with a lead
optimization process led to the discovery of darolutamide (6, also named ODM-201) [24]. Similar
to enzalutamide (4) and apalutamide (5), darolutamide (6) is a full antagonist that has high affinity
for AR in the AR overexpressing setting and suppresses nuclear translocation of AR. In contrast to
enzalutamide (4) and apalutamide (5), darolutamide (6) possesses the following features [24]: (i) a
different chemical scaffold that may bypass the side effects caused by enzalutamide (4) and apalutamide
(5); (ii) antagonistic effects towards AR mutants AR(F876L), AR(W741L), and AR(T877A) that facilitate
resistance to the first- and second-generation nonsteroidal AR antagonists; (iii) an inability to cross
over the brain–blood barrier, suggesting a lower seizure risk than observed with enzalutamide; (iv) not
increasing the concentration of serum testosterone in a mouse model; (v) having higher in vivo
antitumor efficacy in the mouse model, and (vi) a shorter half-life (1.6 h vs 18.3 h for enzalutamide).
Taken together, these promising preclinical results imply that darolutamide (6) is complementary to
enzalutamide (4) and apalutamide (5) and that darolutamide (6) is an excellent addition to the family
of the second generation of AR antagonists. However, higher dose and more frequent administration
are recommended for darolutamide (6) due to its shorter half-life.
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3. Syntheses
A detailed review of the development of synthetic approaches to enzalutamide, apalutamide,
and darolutamide was recently published [25].
3.1. Synthetic Approaches to Enzalutamide (4) and Apalutamide (5)
Structures of enzalutamide (4) and apalutamide (5) are highly functionalized and offer multiple
disconnection approaches to their synthesis. Each strategy is based on a key transformation of
advanced intermediates and the bulk of the synthetic effort is spent on synthesizing those intermediates.
The synthesis of the core structure of enzalutamide (4) and apalutamide (5) has been accomplished
using three main strategies, which are presented in Scheme 1. Strategy 1 and Strategy 2 construct the
thiohydantoin core toward the end of the synthesis, whereas Strategy 3 begins with the formation of
thiohydantoin and the aromatic rings are added later. Regardless of the strategy, the assembly of the
final drug begins from similar advanced aryl intermediates. Thus, the majority of process development
was focused on preparation of aniline derivatives D and E, and aryl halides H and I.
 
Scheme 1. Overview of synthetic approaches to hydantoin-based enzalutamide and apalutamide.
3.1.1. Strategy 1: Cyclization of Isothiocyanate
The first strategy is based on tandem condensation–cyclization cascade initiated by addition
of isothiocyanate B to the α-amino acid derivative C, which delivers the thiourea intermediate A
(Scheme 1). The compound A is not isolated, the nitrogen and the pendant carboxylic acid derivative
(Z = CO2H, CO2R, or CN) react to form the thiohydantoin core. Thus, the key intermediates in this
approach are isothiocyanate B and carboxylic acid intermediate C.
Sawyers and Jung disclosed the synthesis of 13 from aniline 12 and thiophosgene
(Scheme 2) [17,26–28], to which alternative approaches that avoid use of thiophosgene were later
developed [29–32]. The intermediate 12 needed for enzalutamide is commercially available. However,
the aniline precursor of isothiocyanate fragment 18 needed for preparation of apalutamide had
to be synthesized and proved to be a major challenge typical of heterocyclic amines containing
both electron-rich and electron poor substituents. All published approaches to 17 vary in the
order and method in which the substituents are added to 2-chloro-3-(trifluoromethyl)pyridine (14).
The initially disclosed synthesis uses nitration–reduction sequence to install the amine functional
group (Scheme 2). This strategy required uneconomical functional group interconversion (conversion
14 to hydroxypyridine 15, then back to chloride 16 after nitration) as well as protection of the amine.
The overall yield of this 7-step sequence is difficult to assess because yields for all steps were not
reported. Alternately, cyanation can be accomplished prior to reduction of the nitro group and thus
avoiding wasteful protection if a bromide is used instead of the chloride (steps i–k, Scheme 2) [33,34].
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Scheme 2. Synthesis of isothiocyanate fragments of enzalutamide and apalutamide. Reaction conditions:
(a) CSCl2, H2O; (b) AcOH, H2O, reflux; (c) HNO3, H2SO4, 90 ◦C; (d) POCl3, PCl5, 110–120 ◦C; H2,
(e) Raney Ni, THF; (f) Boc2O, pyridine, DMAP, rt; (g) KCN, CuCN, phenantroline, DMA, 110 ◦C;
(h) TFA, CH2Cl2; (i) POBr3, PBr3, Br2, 90–110 ◦C; (j) CuCN, phenantroline, CH3CONMe2, 160 ◦C;
(k) AcOH, Fe.
Highly hazardous nitration at elevated temperature can be avoided by installing the amine via
C–N cross-coupling reaction, although functional group interconversion (Cl to OH and back to Cl)
remains as part of the route (Scheme 3). Initially developed conditions for the cross-coupling delivered
23 in low yield (40%) [33,34], but the reaction conditions were later improved to reliably generate the
amine 23 in 71–85% yield [35,36]. Other routes to 17 were also disclosed, but they contain serious
inefficiencies are less likely to be adopted on process scale [33,34].
 
Scheme 3. Nitration-free synthesis of the substituted pyridine intermediate 17. Reaction conditions:
(a) NIS, DMF, CH3CN, 80 ◦C; (b) POCl3, DMF, microwave 130 ◦C; (c) PMBNH2, Pd(OAc)2, BINAP,
Et3N, CsCO3, toluene; (d) Zn(CN)2, Pd2(dba)3, dppf, DMF, 110 ◦C; (e) TFA, CH2Cl2.
Synthesis of the advanced intermediate C (R =CN, Scheme 1) can be accomplished in several ways.
In their initial route to enzalutamide, Sawyers and Jung reported preparation of 26 in 52% overall yield
in a 4-step sequence which begins with oxidation of 2-fluoro-4-nitrotoluene (24) to the corresponding
carboxylic acid [17], which was converted to an N-methyl amide 25 via the acid chloride intermediate.
Reduction of the nitro group to an amine and addition to acetone cyanohydrin furnish α-amino nitrile
26, which upon reaction with isothiocyanate 13 under microwave heating in DMF, gave enzalutamide
(4). In another approach, amino ester 29 was prepared in 4 steps from 4-bromo-2-fluorobenzoic acid
(27) in 64% yield by first converting the acid to the N-methyl amide followed by a SNAr reaction
with 2-aminoisobutyric acid and esterification. Although this route is shorter and the overall yield is
slightly higher than the synthesis of nitrile 26, on a process scale the likely starting material would
be 4-bromo-2-fluorotoluene which would add one additional step and likely reduce the overall yield
(Scheme 4).
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Scheme 4. Synthesis of the amino nitrile 26 (top) and amino ester 29 (bottom) for the assembly of
enzalutamide. Reaction conditions: (a) CrO3, H5IO6, CH3CN, CH2Cl2; (b) SOCl2, DMF, then MeNH2;
(c) Fe, AcOH, EtOAc, reflux; (d) 2-cyano-2-hydroxypropane, MgSO4, EtOAc, 80 ◦C; (e) 13, DFM,
microwave 100 ◦C; (f) SOCl2, DMF (cat), 2-PrOAc, 60 ◦C, then MeNH2; (g) 2-aminoisobutyric acid,
CuI, K2CO3, 2-acetylcyclohexanone, DMF, H2O, 105 ◦C; (h) MeI, K2CO3, DMF, H2O, 40 ◦C; 13, DMSO,
2-PrOAc, 83–83 ◦C.
The amino nitrile fragment needed for assembly of apalutamide was prepared similarly in a 4-step
sequence which begins with acylation of methyl amine with 2,4-difluorobenzoyl chloride (30) followed
by SNAr reaction with 4-methoxybenzyl amine under microwave conditions to give 31. Acid-mediated
deprotection and a Strecker reaction with cyclobutanone in the presence of sodium cyanide give amino
nitrile 32 (Scheme 5, top). Although this route is relatively short, it will be difficult to implement at
scale. The yield of the SNAr reaction is low (40%) due to poor regioselectivity; the yield of the Strecker
reaction was not reported. Additionally, use of cyanide at scale is challenging due to potential release
of HCN. The company Hinova developed this route into a 3-step preparation (69%–82% yield) of 32 in
which 2-fluoro-4-nitrobenzoic acid (33) was converted to a methyl amide followed by reduction of the
nitro group and a Strecker reaction with cyclobutanone with TMSCN as cyanide source (Scheme 5,
bottom) [37,38].
 
Scheme 5. Two options for synthesis of amino nitrile 32 for the assembly of apalutamide.
Reaction conditions: (a) MeNH2, THF; (b) PMBNH2, MeCN, microwave 190 ◦C; (c) TFA, CH2Cl2;
(d) cyclobutanone, NaCN; (e) 18, CSCl2, MeCONMe2, 80 ◦C, then HCl, MeOH; (f) Me2NH–HCl, CDI,
Et3N, CH2Cl2, rt; (g) Fe, AcOH, EtOAc, reflux; (h) cyclobutanone, TMSCN, AcOH, 80 ◦C.
Several companies subsequently explored other carboxylic acid derivatives, with the most
successful one being ester-based route shown in Scheme 6. Coupling between aryl bromide 36 and
cyclobutane amino acid 37 gives amino acid derivative 38 (step a, Scheme 6) [39,40]; alternatively,
acid 38 can be prepared from amine 40 and α-bromo acid 41 (step b, Scheme 6) [41]. Alkylation of
the carboxylic acid 38 followed by a reaction with isothiocyanide 18 delivered apalutamide in 47%
yield from 38. It is important to note that condensation/cyclization cascade of esters and isothiocyanate
delivers thiohydantoin in higher yield than the same reaction with the nitrile, but the higher yield
comes with trade-offs. First, one additional step will be needed to convert the ester to amide (MeNH2,
heat). Second, the cyclization reaction of isothiocyanate with esters produces alcohol by-product,
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which is reactive toward the isothiocyanate present in the reaction mixture. Therefore, excess of
isothiocyanate has to be used in this step and at least one equivalent is ultimately lost to alcoholysis.
 
Scheme 6. Cyclobutanecarboxylic acid-based approaches to the advanced intermediate 39 needed for
assembly of apalutamide. Reaction conditions: (a) DMF, K2CO3, CuCl, H2O, 100–105 ◦C; (b) i-Pr2Net,
Et3N, CH2Cl2, reflux; (c) MeI, DMF, K2CO3, rt; (d) 18, DMSO, 2-PrOAc, 90 ◦C.
Other iterations of Strategy 1 were also used in synthesis of apalutamide where the
thiohydantoin core was constructed prior to installation of the methyl benzamide (Scheme 7) [42,43].
Halogenated aniline 42 was subjected to a Strecker reaction with cyclobutanone and the
resulting amino nitrile 43 was reacted with isothiocyanate 13 formed in-situ from aniline 17 and
1,1′-thiocarbonylbis(pyridine-2(1H)-one (vide infra). Appending the methyl amide functional group
can then be accomplished in several ways (Scheme 7, step c): (i) Grignard synthesis of carboxylic
acid followed by CDI coupling with methyl amine; (ii) direct Pd-catalyzed amide formation with
methylamine and carbon monoxide; or (iii) Pd-catalyzed carbonylative esterification followed by a
conversion of the ester to the amide.
 
Scheme 7. Synthesis of thiohydantoin core of apalutamide and late-stage amide formation. Reaction
conditions: (a) cyclobutanone, NaCN, AcOH; (b) 17, 1,1′-thiocarbonylbis (pyridine-2(1H)-one, toluene,
100 ◦C then HCl, EtOH, DMA, 70 ◦C; (c) n-C5H11MgBr, THF, CO2, then CDI, MeNH2, THF; or
Pd(t-Bu3P)2, CO (5 bar), i-Pr2Net, MeNH2, THF, 60 ◦C; or Pd(OAc)2, dppf, i-Pr2NH, CO, MeOH, 60 ◦C,
then MeNH2, MeOH.
3.1.2. Strategy 2: Late Stage Cyclization of Amino Amide
The second strategy focuses on the late stage formation of thiohydantoin core through cyclization
of the amino amide M with thiophosgene or its surrogate (Scheme 1, Strategy 2). Depending on
the chosen disconnection, the amino amide M can be constructed by condensation of amine D with
amino acid N, or aryl-aryl cross-coupling of the amine D with bromide H. An application of this
strategy was reported by Meng and co-workers in their approach to enzalutamide, which started with
a carbodiimide coupling of aniline 12 and protected amino acid 45, affording amino amide 46 after
deprotection (Scheme 8). Copper-catalyzed aryl amination with methyl 4-bromo-2-fluorobenzoate (47)
affords amino amide 49, which undergoes the cyclization reaction with thiophosgene in the presence
of 8-fold excess of DMAP to provide ester 49 in 28% overall yield [44].
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Scheme 8. Synthesis of advanced intermediate ester 49 via late-stage formation of thiohydantoin.
Reaction conditions: (a) CDI, DBU, i-Pr2NEt, THF, 55–65 ◦C; (b) HCl, 2-PrOH; (c) methyl
4-bromo-2-fluorobenzoate (47), acetylacetone, CuI, K2CO3, DMF, 120–130 ◦C; CSCl2, DMAP, THF,
40–50 ◦C.
As illustrated in Scheme 9, a modified version of this strategy was used in the synthesis of
apalutamide. The key differences include more streamlined synthesis of the starting aniline 12, use of
Boc as protecting group for the amino acid 50, and use of 1,1′-thiocarbonylbis(pyridine-2(1H)-one (or
phenylthionochloroformate) as thiophosgene alternative for the formation of thiohydantoin core [45].
This route is a highly developed process that achieves synthesis of apalutamide in seven linear steps
with only three purifications. Accounting for two-step synthesis of hydroxypyridine 15 (see Scheme 2),
this route achieves preparation of apalutamide in nine linear steps.
 
Scheme 9. Synthesis of apalutamide via late-stage, thiophosgene-free cyclization. Reaction conditions:
(a) 12, CDI, DBU, i-Pr2NEt, THF, 60 ◦C; (b) HCl, 2-PrOH, 70 ◦C; (c) 28, DMA, KOAc, CuBr, TMEDA,
120 ◦C; (d) 1,1′-thiocarbonylbis(pyridine2(1H)-one, DMAP, DMA, 90 ◦C.
3.1.3. Strategy 3: Functionalization of Thiohydantoin
The third strategy focuses on the formation of thiohydanotin core first and then functionalization
the nitrogens (Strategy 3, Scheme 1). In comparison to the two strategies outlined above, this
one is relatively less developed. Nevertheless, it holds the most promise for large-scale synthesis
of enzalutamide because it is still highly divergent and, even more importantly, avoids use of
thiophosgene. The reported synthesis of enzalutamide using this approach begins with a reaction of
methyl 2-chloroisobutyrate (53) with thiourea in the presence of triethylamine to give thiohydantoin
54. Compound 54 then undergoes two SNAr reactions. Deprotonation with NaH in DMF followed by
addition of 4-bromo-3-(trifluoromethyl)benzonitrile (55) furnished compound 56, which is deprotonated
again and reacted with aryl bromide 28 to provide enzalutamide (Scheme 10) [32]. It should be noted
that, at the time of this writing, methyl 2-chloroisobutyrate is not widely available from commercial
sources and will have to be synthesized [46].
Scheme 10. Synthesis of enzalutamide via functionalization of thiohydantoin. Reaction conditions:
(a) thiourea, Et3N, DMF, 80–90 ◦C; (b) 4-bromo-3-(trifluoromethyl)- benzonitrile (55), NaH, DMF, rt;
(c) 28, NaH, DMF.
A hybrid variant of this strategy and Strategy 1 were also used in synthesis of apalutamide [47].
The ester 57 was first reacted with potassium isothiocyanate to give thiohydantoin 58, which was then
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coupled with aryl bromide 59 to give apalutamide. Both 57 and 58 can be purified by crystallization,
which is a significant advantage for process development (Scheme 11).
 
Scheme 11. Synthesis of apalutamide using atom-economical formation of isothiohydantoin core.
Reaction conditions: (a) KSCN, i-Pr2NEt, MeOH/H2O, reflux; (b) 59, K2CO3, CuI, DMF, 100–110 ◦C.
3.2. Synthesis of Darolutamide
The development of synthesis of darolutamide was mostly focused on process improvements,
such as isolation via crystallization, elimination of expensive and hazardous reagents, and the general
strategy remained unchanged since the original disclosure (Scheme 12) [48–51]. The synthesis relies on
cross-coupling and substitution chemistry with some protection/deprotection and functional group
interconversions. First, a pinacol boronic ester is installed on the THP-protected pyrazole 60 by treatment
with n-BuLi, then with triisopropylborane, and finally with pinacol. Palladium(II) acetate-catalyzed
Suzuki cross-coupling of 61 with aryl bromide 62 delivers intermediate 63. The nitrogen was deprotected
with aqueous acid and reacted with N-protected (S)-(+)-2-amino-1-propanol (64) under Mitsunobu
conditions followed by deprotection at low pH to give intermediate 65. The synthesis of darolutamide
diastereomers was completed by amide coupling of 65 with carboxylic acid 66 followed by reduction
of the methyl ketone with NaBH4 in ethanol.
 
Scheme 12. Synthesis of darolutamide. Reaction conditions: (a) n-BuLi, THF, toluene; (b) (i-PrO)3B;
(c) pinacol, AcOH; (d) 62, Pd(OAc)2, K2CO3, CH3CN/H2O, 70 ◦C; (e) aq HCl, MeOH, 10 ◦C; (f) 64,
PPh3, DIAD, EtOAc; (g) aq HCl, 45 ◦C; (h) 66, T3P, EtOAc, i-Pr2NEt, 10 ◦C; (i) NaBH4, EtOH.
4. Clinical Studies and Use of Second Generation Nonsteroidal AR Antagonists
Only those clinical studies directly associated with the US FDA approval of enzalutamide,
apalutamide, and darolutamide were highlighted in this review.
4.1. Enzalutamide
Enzalutamide (also named MDV3100; trade name: Xtandi) has been approved by the FDA in
2012, 2018, and 2019, respectively, for the treatment of mCRPC, nmCRPC, and mCSPC. Enzalutamide
possesses a generally good safety profile and is now widely used as a standard-of-care for the treatment
of three forms of prostate cancer. The clinical use of enzalutamide not only helps to better manage
prostate cancer but also verifies that androgen receptor signaling continues to be one of critical driving
forces for CRPC. Enzalutamide can be sequentially used with other therapeutic methods.
The earlier clinical trials of enzalutamide were initiated by its promising efficacy and drug-like
properties collected from the preclinical CRPC models. The competitive AR binding capability
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and clinically effective antitumor activity, together with tolerable safety profile of enzalutamide,
were verified in human by a phase I/II study that enrolled 140 patients with CRPC in both pre- and
post-chemotherapy settings [52]. The maximal tolerated dose for enzalutamide was determined to be
240 mg/day and the recommended dose for the advanced clinical trials was identified to be 160 mg/day.
In view of these inspiring early-stage clinical results, the first phase III trial of enzalutamide, named
AFFIRM, has been started to scrutinize enzalutamide versus placebo in patients with mCRPC in a
post-chemotherapy setting.
4.1.1. Enzalutamide for mCRPC
With overall survival as its primary end point, AFFIRM aimed to assess whether enzalutamide
can prolong the survival time of patients with mCRPC in a post-chemotherapy setting [53]. The clinical
benefits derived from AFFIRM as demonstrated by the primary end points and the secondary end
points were summarized in Table 3. The primary outcome from this phase III trials established
enzalutamide as the first nonsteroidal AR antagonist with significant increase in patient’s overall
survival time. The secondary outcome suggested that enzalutamide can appreciably slow cancer
progression, reduce PSA response, and improve patient’s quality of life when compared to placebo.
The major adverse effects of enzalutamide observed from AFFIRM are seizures, with 0.6% (five patients
out of 800) of patients from the enzalutamide treatment group being reported to have a seizure.
This study verified that AR and AR signaling continue to play a pivotal role for the progression of
CRPC. Enzalutamide was thus quickly approved by the US FDA on 31 August 2012, for the treatment
of late-stage mCRPC due to its capability of prolonging patient’s life.
Table 3. Major therapeutic benefits brought by enzalutamide based on AFFIRM.









Median OS (mo) 18.4 13.6 0.63
Secondary End Points
Median time to rPFS (mo) 8.3 2.9 0.4
Median time to first SRE (mo) 16.7 13.3 0.69
Median time to PSA progression (mo) 8.3 3 0.25
* PSA response (%) of no.
decline ≥90% from baseline 25 (731) 1 (3300
decline ≥50% from baseline 54 (731) 1 (330)
Serious AEs (%) 39.9 38.8
OS: Overall Survival; rPFS: Radiographic Progression-free Survival; SRE: Skeletal-related Event; PSA:
Prostate-specific Antigen; AEs: Adverse Events. * Does not include patients who discontinued or died during
the trial.
Inspired by the positive results from AFFIRM and the greater benefit observed in
chemotherapy-naïve patients in the phase I-II clinical trial [52], another phase III trial (named PREVAIL,
ClinicalTrials.gov number, NCT01212991) of enzalutamide was designed to explore the possibility
of extending the application of enzalutamide to patients with mCRPC before chemotherapy [54].
A total of 1717 patients with chemotherapy-naïve mCRPC were enrolled in this trial and randomized
into enzalutamide treatment (872; 160 mg daily) group and placebo group (845). Radiographic
progression-free survival and overall survival were used as the two primary end points. The clinical
benefits brought by enzalutamide treatment in this study with respect to all primary and secondary end
points are illustrated in Table 4. It can be concluded from these data that treatment with enzalutamide
resulted in a noticeable decrease in risk of radiographic progression and death, as well as a marked
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delay in the need of chemotherapy. Due to the promising results from PREVAIL phase III trial,
the clinical use of enzalutamide was therefore extended by the US FDA to chemotherapy-naïve patients
with mCRPC on 10 September 2014.
Table 4. Major therapeutic benefits brought by enzalutamide based on PREVAIL.









Median OS (mo) 18.4 13.6 0.63
Median time to rPFS (mo) 3.9 0.19
Secondary end points
Median time to first SRE (mo) 16.7 13.3 0.69
Median CC initiation time (mo) 28 10.8 0.35
Median time to PSA progression (mo) 11.2 2.8 0.17
* PSA response (%) of no.
decline ≥ 90% from baseline 47 (854) 1 (777)
decline ≥ 50% from baseline 78 (854) 3 (777)
* Serious AEs (%) of no. 44.1 (871) 3.5 (844)
OS: Overall Survival; rPFS: Radiographic Progression-free Survival; SRE: Skeletal-related Event; CC: Cytotoxic
Chemotherapy; PSA: Prostate-specific Antigen; AEs: Adverse Events. * Does not include patients who discontinued
or died during the trial.
4.1.2. Enzalutamide for nmCRPC
The patients with nmCRPC are refractory to ADT treatment and at the onset of metastasis. It has
therefore been recognized that new treatment strategies are urgently needed to reduce the risk for
metastasis in men with nmCRPC in accompany with a short PSA doubling time. PROSPER phase III
trial was designed to investigate whether enzalutamide can meet this need [55]. This study enrolled a
total of 1401 patients with nmCRPC and a PSA doubling time no more than 10 months. A total of
933 patients received enzalutamide treatment (160 mg daily) in combination with ADT; while the
remaining 468 patients were assigned to the placebo group with continued ADT. Metastasis-free
survival was set as the primary end point. As illustrated in Table 5, enzalutamide treatment is superior
to placebo with regards to the primary end point and most of the secondary end points. The clinical
results from the PROSPER trial highlighted that the risk of progression to mCRPC or death in the
enzalutamide treatment group has been lowered by 71% as compared with the placebo group. Because
of the promising results from the PROSPER phase III trial, enzalutamide was approved by the US
FDA, after Priority Review designation, on 13 July 2018, for the treatment of patients with nmCRPC.
This approval extends the enzalutamide treatment to patients with nmCRPC, and makes enzalutamide
the first FDA-approved oral medicine for both mCRPC and nmCRPC.
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Table 5. Major therapeutic benefits brought by enzalutamide based on PROSPER.









Median MFS (mo) 36.6 14.7 0.29
Median time to rPFS (mo) 3.9 0.19
Secondary end points
Median OS (mo)
Median time to C-FS (mo) 38.1 34
Median first time use of CC (mo) 39.7 0.38
Median time to PP (mo) 18.5 18.4 0.96
Median time to PSA progression (mo) 37.2 3.9 0.07
* PSA response (%)
decline ≥ 90% from baseline 55.9 0.4
decline ≥ 50% from baseline 76.3 2.4
decline to undetectable level 9.6 0
* Serious AEs (%) of no. 24.3 (930) 18.9 (465)
MFS: Metastasis Free Survival; rPFS: Radiographic Progression-free Survival; OS: Overall Survival; C-FS:
Chemotherapy-Free Survival; PP: Pain Progression; CC: Cytotoxic Chemotherapy; PSA: Prostate-specific Antigen;
AEs: Adverse Events; * Does not include patients who discontinued or died during the trial.
4.1.3. Enzalutamide for mCSPC
Patients with mCSPC is defined as those who have metastatic prostate cancer that still responds
to ADT. Up to 5% of annual prostate cancer incidences belong to mCSPC in the United States [56].
With ADT as the original standard of care, most of the patients with mCSPC inevitably progress to
high-risk mCRPC in 1–3 years. To help meet the needs of this big group of patients, the ARCHES Phase
III trial (ClinicalTrials.gov identifier: NCT02677896) [57] aimed to investigated whether enzalutamide
in combination with ADT can prolong radiographic progression-free survival using ADT alone as
control. The clinical outcomes from this trial pertaining to the primary end point (radiographic
progression-free survival) and key secondary end points are summarized in Table 6. A conclusion can
be drawn from these data that enzalutamide, plus ADT, demonstrate clinically significant improvement
in efficacy by prolonging the radiographic progression-free survival while maintaining the safety level,
as compared with ADT alone. The favorable results encouraged the US FDA to grant an extension of
enzalutamide for the treatment of mCSPC on 16 December 2019.
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Table 6. Major therapeutic benefits brought by enzalutamide based on ARCHES.









‡ Median time to rPFS based on ICR
via PCWG2 (mo)
19.4 0.39




Median OS (mo) 0.19
Time to NAT 30.2 0.28
Median time to CR (mo) 13.9 0.28
PSA undetctable rate (%) of no. 68.1 (511) 17.6 (506)
* Serious AEs (%) of no. 18.2 (572) 19.5 (574)
rPFS: Radiographic Progression-free Survival; OS: Overall Survival; NAT: New Antineoplastic Therapy; CR:
Castration resistance; PSA: Prostate-specific Antigen; AEs: Adverse Events; ‡ Radiographic Progression-Free
Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical
Trials Working Group 2 (PCWG2) Criteria; † rPFS Based on ICR of Bone Scan According to Protocol Assessment
Criteria; * Does not include patients who discontinued or died during the trial.
4.2. Apalutamide
The promising preclinical data of apalutamide were well-mirrored by its phase I clinical trial [23,58].
Thirty men with mCRPC were enrolled in its first-in-human study. Apalutamide displayed AR
inhibitory ability as evidenced by the 47% PSA response (defined as ≥50% reduction from baseline)
at 12 weeks at all tested doses from 30 to 480 mg. The pharmacokinetic profile of oral-administrated
apalutamide is linear and dose-dependent in the range of 30–480 mg. The rapid absorption was
demonstrated by the fact that it can be measured in the plasma at 30 min after oral intake and that it can
reach peak concentrations after 2–3 h. A half-life of 3–4 days was observed in the systematic circulation
and most enrolled patients reached a steady-state concentration after 3 weeks of non-interrupted
administration of apalutamide. A good safety profile observed from this clinical study further
confirmed the high therapeutic index evaluated from the preclinical models. A daily dose of 240 mg
was recommended for the follow-up clinical studies of apalutamide considering its dose to maximize
the tumor regression in preclinical models, along with peak plasma concentration, safety profile,
and efficacy in the phase I clinical study.
4.2.1. Apalutamide for nmCRPC
The SPARTAN trial is a randomized, double blind and multicenter phase III study that evaluated
the efficacy of apalutamide in nmCRPC. There were 1207 enrolled men with nmCRPC on ADT with a
PSA doubling time of over 10 months randomized to 2:1 to receive apalutamide with ADT or placebo
with ADT [59].
The first interim analysis, which concluded in May 2017, determined that there was statistical
significance in metastasis free survival (MFS), progression free survival (PFS), time to metastasis
and time to symptomatic progression (Table 7). Due to the compelling evidence shown, the safety
monitoring committee recommended that the placebo group be allowed to receive the treatment in July
2017. The second interim analysis continued to 2019 to better characterize the effect of apalutamide.
It was determined that the median MFS was 40.5 months for the treatment group and 16.2 months in
the placebo group with a 95% confidence interval. The four-year survival rate of apalutamide was
found to be 72% compared to 65% of the placebo group. When considering the patients that crossed
over from placebo to treatment, the four-year survival rate remained at 72% for apalutamide [59].
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Table 7. Major therapeutic benefits brought by apalutamide based on SPARTAN.









Median MFS (mo) 40.5 16.2 0.28
Secondary End Points
Median time to metastasis (mo) 40.5 16.6 0.28
Median time to PFS (mo) 40.5 14.7 0.29
Median OS (mo) 39.0
Median time to CC (mo)
* Serious AEs (%) of no. 24.8 (803) 23.1 (398)
MFS: Metastasis Free Survival; PFS: Progression Free Survival; OS: Overall Survival; CC: Cytotoxic Chemotherapy;
AEs: Adverse Events; * Does not include patients who discontinued or died during the trial.
Disease progression was the most frequent indicator for treatment discontinuation. Only 28% of
the treatment group compared to 37% of control experienced cancer progression for discontinuation.
Apalutamide treatment led to the extension of the second PFS rate by approximately 11.8 months
versus placebo. The four-year second PFS rate for the treatment had a 19% difference when compared
to the control [59]. Adverse effects were reported in 97% of patients in the treatment group and 94%
of patents in the control group [59,60]. Median overall survival (OS) was not reached in either the
treatment or placebo group, as the threshold of 427 deaths have not yet been reached as specified in
the O’Brien-Fleming boundary [59].
Overall, apalutamide showed a quarter reduction for risk of death when compared to placebo
as well as a higher subsequent life-prolongation, despite crossover. The resulting data for SPARTAN
included statistical significance in improving MFS and time to symptomatic progression compared to
placebo. The observations that apalutamide delays progression and death when combined with ongoing
ADT suggests that the drug may be advantageous to high-risk nmCRPC patients. FDA immediately
approved apalutamide for high-risk nmCRPC patients on 14 February 2018 [59].
4.2.2. Apalutamide for mCSPC
Apalutamide was approved by the US FDA, after a priority review, on 17 September 2019, to extend
its treatment from patients with nmCRPC to those with mCSPC based on the efficacy demonstrated by
its TITAN (NCT02489318) phase III trial. This clinical trial was designed as a randomized, double blind
and multicenter phase III study and aimed to assess the clinical efficacy of apalutamide in combination
with ADT (surgical or medical castration) in patients with mCSPC. A study of 1052 men with mCSPC
were randomized 1:1 to treatment and control groups. This involved patients regardless of disease
volume and with a history of docetaxel treatment and treatment for localized prostate cancer. At the
conclusion of the first interim analysis in November 2018, it was found that 68.2% of patients in the
apalutamide and ADT group had a 24-month radiographic progression-free survival compared to 47.5%
of the placebo group (Table 8). The overall survival, measured after 200 deaths, for 24-months is 82%
for apalutamide group and 73% for the placebo group. The average time for second progression-free
survival was also longer in the treatment group compared to that of the placebo group. Analysis
of adverse effects between apalutamide and placebo did not differ significantly [61]. In summary,
the TITAN trial revealed that apalutamide in combination with ADT resulted in life-prolongation and
radiographic progression-free survival relative to placebo with ADT while also preserving quality of
life for men with mCSPC [61].
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Table 8. Major therapeutic benefits brought by apalutamide based on TITAN.









OS (% alive) 82..4 73.5 0.67
rPFS (%) 68.2 47.5 0.48
Secondary End Points
Median time to PSA progression (mo) 12.9 0.26
* Serious AEs (%) of no. 19.2 (574) 20.3 (527)
OS: Overall Survival; rPFS: Radiographic Progression-free Survival; PSA: Prostate-specific Antigen; AEs: Adverse
Events; * Does not include patients who discontinued or died during the trial.
4.2.3. Indirect Comparison with Enzalutamide
In the lack of direct comparative studies, Chowdhury et al. conducted a matching-adjusted
indirect comparison (MAIC) of the efficacy and quality of life of apalutamide to that of enzalutamide
in nmCRPC using data collected from SPARTAN and PROSPER trials [62]. A total of 1171 patients
were matched from the SPARTAN trial (n = 1207) to the PROSPER trial (n = 1401). Relative to
enzalutamide, apalutamide was better tolerated based on adverse events with an overall decrease
in fatigue, low appetite, hypertension, and nausea occurrences. It was also associated with a better
health-related qualify of life based on the Functional Assessment of Cancer Therapy-Prostate score [63].
Additionally, the calculated hazard ratios for apalutamide versus enzalutamide were 0.77 for OS and
0.91 for MFS [62]. Based on these MAIC results, apalutamide demonstrates slightly better overall
tolerability and is associated with slightly higher efficacy in nmCRPC patients.
4.3. Darolutamide
It has recently been recognized that early and effective suppression of AR signaling may serve as a
good strategy to manage nmCRPC [64], which has been firmly supported by the obvious metastasis-free
survival benefits reported in the PROPER trial for enzalutamide and the SPARTAN trial for apalutamide.
The clinical phases I and II studies [65,66] suggest that darolutamide provides not only meaningful
antitumor efficacy but also a favorable safety profile in clinical settings. ARAMIS phase III trial was
thus conducted to further assess the treatment benefits and the possible adverse events of darolutamide
in men with nmCRPC. A total of 1509 men with nmCRPC and a PSA doubling time no more than
10 months were enrolled in this trial and were randomized in a 2:1 ratio to receive darolutamide (600 mg
twice daily) plus ADT or ADT alone. Metastasis free survival was employed as the primary end point,
and the appearance of metastasis was judged by blinded and independent central imaging review.
The therapeutic benefits of darolutamide were consistently and affirmatively judged by the primary
end point and the entire secondary end points (Table 9). Darolutamide in combination with ADT was
demonstrated to prolong metastasis-free survival by 22 months and to reduce the risk of metastasis or
death by 59% when compared with ADT alone. The therapeutic benefits brought by darolutamide,
enzalutamide, or apalutamide are generally similar in patients with nmCRPC. However, darolutamide
exhibited a good safety profile in this phase III trial with approximately similar incidence of adverse
events in the darolutamide treatment and placebo groups. The fact that darolutamide has less common
adverse effects in the phase III trial relative to enzalutamide and apalutamide is associated with its low
penetration of the blood-brain barrier as evidenced in preclinical studies. Darolutamide was approved
by the US FDA on 30 July 2019, for the treatment of nmCRPC in line with ARAMIS phase III trial [16].
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Table 9. Major therapeutic benefits brought by darolutamide based on ARAMIS.









Median MFS (mo) 40.4 18.4 0.41
Secondary End Points
Median OS (mo) 0.71
Median first time use of CC (mo) 38.2 0.43
Median time to PP (mo) 40.3 25.36 0.65
Median time to SSE (mo) 0.43
* Serious AEs (%) of no. 24.8 (954) 10.5 (554)
MFS: Metastasis Free Survival; OS: Overall Survival; PP: Pain Progression; SSE: Symptomatic Skeletal Event;
AEs: Adverse Events; * Does not include patients who discontinued or died during the trial.
5. Mechanism of Action of the Second-Generation AR Antagonists
The AR is a nuclear receptor and a ligand-dependent transcription factor that regulates
the expression of certain specific genes, including PSA. Its most potent native ligand is
5α-dihydrotestosterone (DHT) that is generated by intracellular metabolism of testosterone,
an endogenous androgen synthesized primarily in the testes. The DHT-AR binding drives the
AR translocation from cytoplasm to cell nucleus where the AR forms dimer and binds to the
androgen response elements in DNA. Co-activators (coregulatory proteins) are then recruited to boost
transcription, leading to prostate cancer cell proliferation and survival [2,3]. As shown in Figure 5,
castration therapies (both surgical or medical) and abiraterone acetate block the androgen production,
while AR antagonists restrain the AR function through competitively binding to the androgen binding
site of AR in cell cytoplasm. Intriguingly, enzalutamide, apalutamide, and darolutamide mechanistically
distinguish themselves from the first generation nonsteroidal AR antagonists by interfering several
stages in the AR signaling pathway [14,23,24]. In addition to competitively suppressing androgen-AR
binding, these second-generation nonsteroidal AR antagonists also inhibit the AR translocation from
cytoplasm to cell nucleus, the coactivator recruitment, and the AR-DNA binding.
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*First generation nonsteroidal AR antagonist 
Figure 5. Mechanism of action of different hormonal therapies in AR signaling pathway. * First
generation nonsteroidal AR antagonist.
6. Strategies to Overcome the Resistance to the Second-Generation AR Antagonists
In spite of the above-mentioned therapeutic benefits of three second-generation AR antagonists in
patients with mCRPC, nmCRPC, or mCSPC, a considerable portion of patients are primarily resistant
to the treatment. As summarized in Table 10, 63% of the patients with mCRPC after treating with
enzalutamide are still at risk of death; 28%–41% of the patients with nmCRPC under the treatment of
enzalutamide, apalutamide, or darolutamide, in combination with ADT, are on the line of progression
to metastasis or death; 31%–48% of patients of mCSPC under the treatment of enzalutamide or
apalutamide are exposed to radiographic progression or death. Additionally, acquired resistance
emerges with the time of treatment.
Table 10. Hazard Ratios for the primary end points in the phase III trials of three AR antagonists.




AFFIRM enzalutamide Median overall survival 0.63 mCRPC
PROPSER enzalutamide Median metastasis-free survival 0.29 nmCRPC
SPARTAN apalutamide Median metastasis-free survival 0.28 nmCRPC
ARAMIS darolutamide Median metastasis-free survival 0.41 nmCRPC
ARCHES enzalutamide Median rPFS 0.31 mCSPC
TITAN apalutamide Median rPFS 0.48 mCSPC
6.1. Mechanisms of the Resistance to the Second-Generation AR Antagonists
The accurate mechanisms of the resistance to the second-generation AR antagonists are still not very
clear. Several proposed mechanisms underlying the resistance to the second-generation AR antagonists
are summarized in Figure 6. These mechanisms can be classified into two categories: reactivating
androgen receptor signaling and bypassing androgen receptor signaling [67]. The reactivation of AR
signaling can be achieved by AR amplification and AR overexpression, AR gain-of-function mutations,
spliced AR variants (e.g., AR-V7), and intramolecular generation of androgens. The resistance can
also be gained through bypassing AR signaling pathway including glucocorticoid receptor takeover,
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epithelial-mesenchymal transition, neuroendocrine transformation, autophagy, and immune system
activation. More details about these proposed mechanisms have been comprehensively reviewed in
the literature [67–70].
 
Figure 6. Mechanisms of resistance to the second-generation AR antagonists.
6.2. Strategies to Overcome the Resistance to the Second-Generation AR Antagonists
6.2.1. Combination Therapy
Combination therapy through targeting multiple complementary mechanisms of action has
been recognized in recent years to be a promising strategy to overcome drug resistance [71]. Taking
advantage of currently available therapies for CRPC, development of their optimal combinations
as multifaceted therapies emerges as one of research hotspots in the field. Additionally, numerous
of enzalutamide-based combinations are currently under clinical investigation at different phases,
most of which have been tabulated by Tucci et al. in their review article [67]. With the goal to sensitize
enzalutamide, these combinations were designed based on the current proposed mechanisms of
resistance to the second-generation AR antagonists, as listed in Figure 6. For example, the CORT125281
(glucocorticoid receptor antagonist, NCT03437941), metformin (induces epithelial-mesenchymal
transition via suppression of transforming growth factor beta 1/signal transducer and activator
of transcription 3 (TGF-β1/STAT3) pathway, NCT02339168 and NCT02640534), galunisertib (TGF-β
inhibitor, NCT02452008), AZD5363 (protein kinase B (AKT) inhibitor, NCT0331054), pembrolizumab (an
anti-PD-1 checkpoint, NCT02861573 & NCT02787005), and AZD5069 (chemokine receptor antagonist,
NCT03177187) are currently in clinical studies in combination with enzalutamide.
6.2.2. Target AR with Other Strategies
AR is a nuclear steroid receptor that comprises three functional domains including the
ligand-binding domain (LBD, C-terminal end), the DNA-binding domain (DBD, central portion),
and the transactivation domain (NTD or TAD, N-terminal end) [3]. Enzalutamide, apalutamide,
and darolutamide competitively bind to the ligand-binding pocket of the LBD and inhibit the agonistic
action of intrinsic ligands. The compounds that still target AR but can overcome the resistance of the
second-generation AR antagonists include new LBD-targeted AR antagonists with novel chemical
scaffolds, TAD (or NTD)-targeted AR antagonists, DBD-targeted AR antagonists, and AR degraders.
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New AR antagonists that still bind to the LBD but with distinct chemical structures can overcome
the resistance due to the point mutations, which has been exemplified by the successful story of
darolutamide [72]. As abovementioned, darolutamide was developed targeting enzalutamide-resistant
prostate cancer. It was revealed to suppress the transcriptional activity of some AR mutants
including T878G that was responsible of converting enzalutamide into a partial AR agonist. Recently,
halogen-substituted anthranilic acid derivatives have been established as a new chemical scaffold that
inhibits the transactivation of both wild-type AR and AR mutants that render treatment resistance to
the first-generation and second-generation nonsteroidal AR antagonists [73].
Several compounds that target the TAD or DBD of the AR have been demonstrated to possess
potential in treating CRPC, which have been comprehensively summarized in an excellent review
article [3]. The EPI compounds that were first isolated from marine sponges and derived from
bisphenol A represent the most well-established inhibitors of AR-TAD. This group of compounds
down-regulates the expression of full length AR and truncated AR variants (e.g., AR-V7) through
suppressing tau-1 (transcriptional activation unit 1) and tau-5 of the TAD [74]. They inhibited
AR-positive prostate cancer cell proliferation in both in vitro and in vivo experiments and suppressed
the growth of AR-positive prostate cancer cell-derived tumors. The most developed EPI compound,
EPI-506, has advanced to a Phase I/II clinical trial (NCT02606123) in patients with mCRPC after
enzalutamide and/or abiraterone treatment.
Hairpin polyamide was developed as an AR antagonist that directly inhibits AR binding to DNA
and blocks the transcription processes mediated by AR [75]. Hairpin polyamide compounds may
be a good strategy to overcome the resistant to the second-generation AR antagonists because they
target the transcription driven by both AR and glucocorticoid receptor. Moreover, overexpression of
glucocorticoid receptor has been proposed to be one of the critical pathways leading to the resistance
of the second-generation AR antagonists.
A new strategy to combat the resistance of the second-generation AR antagonists is to target
AR protein for degradation, which is a completely different mechanism compared with those for AR
antagonists. Additionally, AR degradation has been reported to be a likely prerequisite for prostate
cancer tumor shrinkage based on an in vivo experiment [76]. AR degradation via proteolysis-targeting
chimeras (PROTACs) is currently the most intriguing development in this field because this technology
replaces the occupancy-driven mechanism for AR antagonist with an event-driven mechanism [77,78].
AR-PROTACs are bifunctional chimeras that can bring AR protein and the E3 ubiquitin ligase in close
proximity, resulting in AR ubiquitination and subsequent degradation. AR-PROTACs have been
verified in vitro and in vivo to be a better therapeutic strategy than AR antagonists for targeting AR
signaling [79]. ARV-110 is the first AR-PROTAC to enter a phase I clinical trial (NCT03888612) in 2019.
This clinical study aims to evaluate the pharmacokinetics, safety, and tolerability of ARV-110 in patients
with mCRPC who have received more than two systemic therapies.
Additionally, the association between metformin (an antidiabetic drug) and reduced prostate
cancer risk in patients with type 2 diabetics prompted a plethora of investigations on the therapeutic
effects of metformin. Metformin is undergoing several clinical trials for prostate cancer, which has been
summarized in the literature [80]. The mechanism of action underlying its anti-prostate cancer activity
has been extensively explored [80], with the crosstalk between adenosine monophosphate-activated
protein kinase (AMPK) activation and AR degradation as the most attractive one [81]. It may therefore be
a new strategy, especially for prostate cancer patients with diabetics, to use AMPK activators to overcome
the resistance to second-generation nonsteroidal AR antagonists. In addition, cyclin-dependent protein
kinase 9 (CDK9) is a druggable target for prostate cancer because CDK9 can not only phosphorylate
AR and activate AR transcriptional activity but also target anti-apoptotic proteins [82]. Therefore,
CDK9 inhibitors may serve as a better therapeutic strategy over the second-generation nonsteroidal
AR antagonists for the patients with CRPC.
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7. Conclusions
In conclusion, an interdisciplinary collaboration led the discovery of enzalutamide as the first
second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to
AR. Enzalutamide can significantly prolong not only overall survival time and metastatic free survival
time for patients with lethal CRPC, but also castration resistant free survival time for patients with
CSPC. Enzalutamide has thus been approved by the US Food and Drug Administration (FDA) for the
treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC, as well as CSPC (2019) on the
basis of the therapeutic benefits observed from AFFIRM, PREVAIL, PROSPER, and ARCHES Phase III
clinical trials. Encouraged by the positive clinical results of enzalutamide, two other second-generation
AR antagonists, apalutamide, and darolutamide have recently been approved by the FDA for the
treatment of prostate cancer. These three second-generation AR antagonists not only offer patients with
different stages of prostate cancer with alternative therapeutics, but also verified that AR signaling
pathway plays a pivotal role in the progression of both CSPC and CRPC. Several approaches have
been developed for the syntheses of these three second-generation AR antagonists, with three main
strategies for the syntheses of the core structure of enzalutamide and apalutamide. The drawback of
these AR antagonists as therapeutics for prostate cancer is the drug resistance, which can be developed
by reactivating or bypassing androgen receptor signaling pathway. Combination therapies taking
advantage of multiple complementary mechanisms of action and targeting AR with other mechanisms
may serve as good strategies to overcome the resistance.
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Abstract: A focused PROTAC library was developed to degrade both IGF-1R and Src proteins,
which are associated with various cancers. PROTACs with IGF-1R and Src degradation potentials
were synthesized by tethering different inhibitor warhead units and the E3 ligase (CRBN)
recruiting-pomalidomide with various linkers. The designed PROTACs 12a–b inhibited the
proliferation and migration of MCF7 and A549 cancer cells with low micromolar potency (1–5 μM) in
various cellular assays.
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1. Introduction
For the past two decades, targeted protein degradation strategies have been explored widely to
develop treatments for various diseases, particularly for cancers [1–4]. Proteolysis targeting chimeras
(PROTACs) have emerged as a novel therapeutic strategy in drug discovery for targeted protein
degradation [4–6]. PROTACs are heterobifunctional molecules that possess one warhead ligand that
binds to the target protein of interest (POI), and a second ligand that recruits an E3 ligase system,
which is connected by a chemical linker. The recruitment of the E3 ligase to the target protein results
in ubiquitination and the subsequent degradation of the target protein by the proteasome, which is
a distinct mechanism from the occupancy-driven modulation of enzyme function by conventional
small-molecule inhibitors. Initially described by Crews and Deshaies in 2001, PROTACs have been
successfully applied to numerous target proteins [7–12]. As opposed to the stoichiometric binding
of drugs that prevent the enzymatic activity of target proteins, PROTACs need to transiently bind to
their targets for degradation; this is promising for the potential to address therapeutic challenges in
targeting intractable proteins in the current drug discovery [13]. In addition, they can impede the
feedback-mediated increased expression of the target proteins that often result in pharmacological
inefficacy by small-molecule inhibitors [14,15].
Several E3 ligases have been used in PROTAC technology to degrade recruited target proteins,
which include β-TRCP, MDM2 and cIAP [7–9]. In addition, von Hippel-Lindau (VHL) and cereblon
(CRBN) have been extensively studied in relation to PROTAC-mediated protein degradation [2,16–18].
Cereblon (CRBN), which is a part of a cullin-RING ubiquitin ligase complex, was identified as the
target of thalidomide and its derivatives [19]. These phthalimide immunomodulatory drugs (IMiDs),
including lenalidomide, pomalidomide, and thalidomide, play a pivotal role in the treatment of
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multiple myeloma and now serve as potent binders of the CRBN. To date, PROTACs have been
successfully applied to various target proteins with different cellular locations, including estrogen and
androgen receptors, BET proteins, tau protein, FKBP12, and kinases [2,11,12,17,20,21]. In particular,
PROTACs, which hijack various cellular kinases, have resulted in effective target degradations [22–26].
Furthermore, the enhanced selectivity of kinase degraders, as compared to their parental kinase
inhibitors, were implicated as having potential applications for clinical study [23,27]. Currently,
many efforts are underway in medicinal chemistry to convert previously ineffective inhibitors to
selective PROTACs for a next-generation drug platform.
The insulin-like growth factor 1 receptor (IGF-1R) is a membrane receptor tyrosine kinase that
is implicated in several cancers, including prostate, breast, and lung cancers [28–30]. IGF-1R plays
a key role in the proliferation, transformation and survival of various cancer cells. Frequently,
its anti-apoptotic properties result in resistance to cytotoxic chemotherapeutic drugs or radiotherapy.
For these reasons, the IGF-1R signaling pathway has been a major target for the development of
anticancer agents [31,32]. Src, known as proto-oncogene tyrosine-protein kinase, is also associated with
cancer cell survival and resistance to targeted anticancer therapies [33]. In particular, Src activation is
related to the resistance of many anti-IGF-1R therapeutics. Indeed, a combined inhibition of IGF-1R and
the Src family kinases have been shown to enhance antitumor effects in various cancers by decreasing
the activated survival pathways [34,35]. We have also shown that the dual inhibition of IGF-1R and Src
could be a viable approach to develop effective anticancer therapies to overcome resistance [36].
In this study, we report the design and synthesis of IGF-1R/Src dual degraders using the
PROTAC strategy (Figure 1). The (5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (A) is
known as a potent c-Src inhibitor with an IC50 value of 720 nM from the enzyme inhibition
assay [37,38]. RBx10080307 (B) is known as an IGF-1R inhibitor with a cell free IC50 value of
277 nM [39,40]. A common structure, N2-phenyl-N4-(1H-pyrazol-3-yl)pyrimidine-2,4-diamine (C),
was derived and was connected with the pomalidomide as a ligand for cereblon for dual IGF-1R/Src
degradation. We reasoned that a common chemical structure would target both IGF-1R and Src,
bringing both proteins close to the E3 ligase for degradation in PROTACs. We also adopted previously
reported 2,4-bis-arylamino-1,3-pyrimidine (D) as an IGF-1R warhead [41], and the aminopyrazolo
[3,4-d]pyrimidine module (E) as a Src warhead for the PROTAC approach [42,43], and compared their
efficacy to those of 12 with the newly designed inhibitor units. Through extensive optimization of the
linker region, we have synthesized a series of dual IGF-1R/Src degraders. Among these, PROTACs 12a
and 12b were capable of inducing the degradation of both IGF-1R and Src proteins at 1–5 μM in the






Figure 1. Chemical structures of representative Src inhibitor A, IGF-1R inhibitors B, and a schematic
diagram of PROTACs for IGF-1R and Src.
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2. Results
2.1. Design and Synthesis
We developed a convergent synthetic route to prepare the designed dual IGF-1R/Src PROTAC
degraders and their control compounds (Scheme 1). We prepared 4a–b in two steps. An azidation was
first carried out from 2-chloropolyethoxy ethanols 1a-b to provide 2a–b [44], which were coupled with
4-flouronitrobenzene 3 to give 4a–b, respectively [45]. 4c was synthesized according to the previous
reports, as depicted in the supplementary information [46]. The reduction of azides 4a–c, in the presence
of triphenylphosphine, leads to the amine intermediates 5a–c, which were subsequently attached
with thalidomide derivative 6 to obtain 7a–c, followed by a reduction with Fe/NH4Cl to provide 8a–c.
PROTACs 10a–c were synthesized by coupling 8a–c with 2-chloro-4-arylamino-1,3-pyrimidines 9 in
DMSO. The key intermediates 8a–b were also treated with their corresponding reagents 11a or 11b,
to produce PROTACs 12a–d (Scheme 1) [36,47].
 
Scheme 1. Reagents and conditions: (a) NaN3, H2O, 80 ◦C, 16 h, 69–82%; (b) K2CO3, DMSO, 80 ◦C, 4 h,
53–61%; (c) Ph3P, THF-H2O, RT, 14 h, 61–85%; (d) DIPEA, DMF, 90 ◦C, 16 h; (e) Fe (powder), NH4Cl,
EtOH-H2O, 80 ◦C, 2 h (42–44% over 2 steps); (f) DMSO, 100 ◦C, 4 h (10a–c, 12a–b; 21–57%); (g) p-TsOH,
butanol, 100 ◦C, 4 h (12c–d; 22–32%).
The thalidomide-attached linkers 8a–b were also coupled with azidoacetic acid 13 in
the presence of EDC·HCl to provide 14a–b, which were further treated with N-substituted
4-aminopyrazolo[3–d]pyrimidines intermediate (15) in the presence of copper sulfate and sodium
ascorbate in THF/H2O/tBuOH to obtain the click products 16a–b via a copper (I)-catalyzed alkyne
azide 1,3-dipolar cycloaddition (CuAAC) reaction (Scheme 2). 8a-b reacted with the bromopropyl
group-attached pyrazolo[3,4-d]pyrimidin-4-amine (17) under the basic condition yielded PROTACs
18a-b. Next, N-propagylation of 8a–b under the basic condition afforded 20a-b, which were coupled
with azido intermediate (19) via the CuAAC reaction to obtain the desired triazole products 21a–b [36].
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Scheme 2. Reagents and conditions: (a) EDC·HCl, DIPEA, DMF, RT, 16 h, 40–62%; (b) CuSO4·5H2O,
sodium ascorbate, THF, t-Butanol-H2O, RT, 6 h, 26–27%; (c) K2CO3, DMF, 16 h, 50.5–50.8%; (d) Propargyl
bromide, K2CO3, DMF, 16 h, 52–55%; (e) CuSO4·5H2O, sodium ascorbate, THF, t-Butanol/H2O, RT, 6 h,
38–40%.
2.2. CPR3 (12a) and CPR4 (12b), Synthesized PROTAC Compounds, Inhibited Cancer Cell Proliferation
Next, we investigated the cell cytotoxicity of the synthesized PROTAC compounds 10a–c, 12a–d,
16a–d, 18a–b and 21a–b in both MCF7 (human breast cancer) and A549 (human lung cancer) cells.
As the cell permeability is more crucial for PROTAC compounds with higher molecular weights than
for conventional small-molecule inhibitors, we first screened the synthesized compounds via the MTT
assay. Cell growth inhibition was measured at the concentrations of 1 or 10 μM PROTAC compounds,
and the measured absorbance values were normalized to DMSO-treated cells. In Figure 2, CPR3 and
CPR4 inhibited cell growth dose-dependently in both MCF7 (Figure 2a) and A549 (Figure 2b) cells.
Compounds CPR3 and CPR4, with a methyl-1H-pyrazole group, showed significant growth inhibitions.
In contrast, other compounds did not show significant dose-dependent growth inhibitions. IC50 values
were further determined through the growth inhibition curve by varying the concentrations from
0.5 to 80 μM. The IC50 values of CPR3 and CPR4 were measured to be 3.3 and 2.7 μM in MCF7 cells
(Figure 2c), whereas they were 4.2 and 7.6 μM in A549 cells (Figure 2d), respectively. Taken together,
CPR3 and CPR4 showed anti-cancer potency by effectively inhibiting cancer cell growth.
2.3. CPR3 and CPR4 Degraded Both Src and IGF-1R Proteins
Cell growth inhibition is closely related to the post translational regulation of gene expression [48].
Therefore, we examined whether CPR3 and CPR4 reduce the expression level of the IGF-1R or Src
proteins, serving as a dual degrader. 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (NC)
was used as a negative control. In MCF7 cells, NC did not degrade Src or the IGF-1R protein,
whereas CPR3 and CPR4 all degraded Src and IGF-1R at 5 μM of concentration (Figure 3a). Similarly,
CPR3 and CPR4 also degraded Src and IGF-1R in A549 cells (Figure 3b). These results indicated that
CPR3 and CPR4 play a key role as a dual degrader for both IGF-1R and Src proteins.
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Figure 2. Inhibitory effect of PROTAC compounds on the viability of two different cancer cell lines,
MCF7 (a) and A549 (b). PROTAC compounds were treated at 1 or 10 μM of concentration for 3 days in
a complete RPMI-1640 medium. At various concentrations of CPR3 (c) or CPR4 (d), the IC50 value was
calculated through the growth curve in both cell lines. Cell viability was determined by the changes in
absorbance at 570 nm. * P ≤ 0.05 and ** P ≤ 0.01, as determined by Student’s t-test.
Figure 3. Immunoblotting for IGF-1R and Src in both MCF7 (a) and A549 (b) cells. The cells were
treated with CPR3 or CPR4 at 1 and 5 μM of concentration for 24 h. NC was used as a negative control
(5 μM). For detection of the protein expression, extracted lysate was incubated with IGF-1R or Src
antibody for 1 h.
2.4. Invasion and Migration Ability Were Suppressed by CPR3 and CPR4 Treatment in Both MCF7 and
A549 Cells
IGF-1R or Src mediated cancer cells were correlated with proliferation, differentiation, survival and
metastasis, promoting cell-cell signal transduction. The characteristics of cancer cells have resistance
to chemotherapy by processing the pathway related to the epithelial to mesenchymal transition
(EMT) [49]. Therefore, we tested cell migration and invasiveness through the treatment of CPR3 and
CPR4, which can block IGF-1R or Src in both MCF7 and A549 cells. In both cells, CPR3 and CPR4
significantly delayed the ratio of wound closure in a dose dependent manner, 1 or 5 μM (Figure 4),
suggesting a reduction of migration by interrupting the pathway of IGF-1R or Src. In addition, Figure 4
shows a decreased invasiveness of CPR3 and CPR4 in both MCF7 (Figure 5a) and A549 (Figure 5b)
cells. Cells with the ability to penetrate into the matrix were stained and counted on a bright field
microscopy. The number of cells was significantly reduced at 5 μM of concentration of CPR3 and
CPR4, as compared to DMSO (Figure 5). These results indicated that CPR3 and CPR4 can block the
IGF-1R/Src regulated cancer cell progressions, including migration and invasion.
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Figure 4. Wound healing images of MCF7 (a) and A549 (b) cells treated with CPR3 or CPR4 for
24 h. The PROTAC compound-treated cells were scratched with micropipette tip at 0 h. After 24 h,
the migration status was monitored by bright optical microscopy. * P≤ 0.05 and ** P≤ 0.01, as determined
by Student’s t-test.
Figure 5. Invasiveness images of MCF7 (a) and A549 (b) cells treated with CPR3 or CPR4 for 24 h.
The cells, resuspended in RPMI-1640 without serum, were reseeded on matrigel-coated insert transwell
for 24 h. After 24 h, the cells that migrated to the membrane of the transwell were stained with 0.1%
crystal violet and were counted with bright optical microscopy. * P ≤ 0.05 and ** P ≤ 0.01, as determined
by Student’s t-test.
2.5. PROTAC Compounds Inhibited the Cell Growth of Both MCF7 and A549 Cells in the Soft Agar Colony
Formation Assay
Next, we examined tumorigenesis by treatment with PROTAC compounds in both MCF7 and
A549 cells. It is well known that cancer cells differentiate rapidly and proliferate infinitely. In addition,
the capability of single cells to form into a colony is a hallmark of cancer cell survival and proliferation.
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To test cellular anchorage-independent growth in vitro, we performed the soft agar colony formation
assay after treatment with PROTAC compounds. In Figure 6, the number of colonies was significantly
increased in DMSO or NC in both MCF7 (Figure 6a) and A549 (Figure 6b) cells. In contrast to the
control group, the colony forming ability sharply declined with a 5 μM concentration of PROTAC
compounds. Moreover, the sizes of the colonies formed from a single cell were much smaller in
PROTAC compounds than in DMSO or NC. These results indicated that PROTAC compounds, with the
dual degradation of IGF-1R and Src, affected cell survival.
Figure 6. Soft agar colony formation images after treatment with CPR3 or CPR4 in both MCF7 (a) and
A549 (b) cells. CPR3 or CPR4 was treated at 5 μM of concentration, followed by an incubation period
of 2 weeks. The formed colonies were stained with 0.1% crystal violet and were detected on a bright
field microscopy. * P ≤ 0.05, as determined by Student’s t-test.
3. Discussion
In this study, we rapidly synthesized and screened PROTACs for dual degradation of IGF-1R and
Src by employing different warhead ligands and varied linker lengths and compositions, which brought
target proteins and E3 ligases into proximity for ubiquitination. Our work demonstrated that efficient
PROTAC molecules (12a–b), which had single warhead ligands that degraded two target proteins,
exhibited low micromolar anticancer activity, measured by different cellular assays, including cancer
cell proliferation, immunoblotting, wound healing assay, and soft agar colony formation assays.
Interestingly, the potency of the synthesized compounds obviously varied, depending on
the warhead units. Our data revealed that the previously reported Src or IGF-1R modules
(D and E) were not sufficient, as individual warheads, for dual PROTACs, whereas the
N2-phenyl-N4-(1H-pyrazol-3-yl)pyrimidine-2,4-diamine (C) exhibited better potency for dual
degradation. The induced degradation of the protein was found to be intrinsic to target proteins,
which are affected by numerous factors, including the linker length and composition, E3 ligase ligand,
spatial orientation of the formed ternary complex and their stability, cell permeability, and ubiquitination
efficiency. One important factor for PROTACs is a drug-like property with cell permeability, for which
atom numbers need to be minimized in the design of the chemical structure. Indeed, the linker size
with 7-10 atoms, between the warhead ligand and the E3 ligase ligand in PROTACs 12a–b, appears to
be sufficient for proximity-induced ubiquitination of Src or IGF-1R with the E3 ligase.
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The possibility of off-target degradation is still likely to happen with small-warhead ligands, due to
their promiscuity. However, recent advancements in PROTACs with promiscuous kinase inhibitors
have shown that efficiency is not directly correlated with the binding affinity of the ligands [27]. Rather,
it is more closely related to the geometry of the ternary complex of the target protein-PROTAC-E3
ligases, as well as to the efficiency of the proximity-induced enzymatic ubiquitin transfer. Further
optimization needs to be followed in regard to the optimal CRBN ligand orientation, nano to pico
molar potency, etc. However, our work demonstrated a facile preparation of efficient dual degraders,
which enrich our knowledge in establishing dual degradation as an alternative therapeutic strategy
in cancers.
4. Materials and Methods
4.1. Chemistry
4.1.1. General Information
All reagents and solvents were obtained from commercial suppliers and used as received unless
otherwise specified. All reactions were performed under nitrogen atmosphere using oven-dried
glassware and monitored by thin-layer chromatography (TLC) on a silica-coated plate (60 F254, Merck,
Darmstadt, Germany). Separated compounds on the TLC plate were visualized under UV light at
254 nm and 365 nm (VL-4.LC, Vilber Lourmat, Eberhardzell, Germany). Column chromatography
was carried out using a silica gel 230-400 mesh (ZEOprep, Zeochem, Lake Zurich, Switzerland) with
n-hexane, EtOAc, CH2Cl2 and MeOH as eluents. 1H NMR (400 MHz) and 13C NMR (125 MHz) spectra
were recorded using a FT-NMR Avance III HD (Bruker, Billerica, MA, USA) at ambient temperature.
Chemical shifts were reported in ppm (parts per million) relative to tetramethylsilane and coupling
constants (J) were expressed in hertz (Hz). The following abbreviations are used for multiplicities: s =
singlet; brs = broad singlet; d = doublet; t = triplet; q = quartet; m =multiplet; dd = doublet of doublets.
Mass-to-charge ratio (m/z) values were obtained by using high-resolution mass spectrometry (HRMS)
under fast atom bombardment (FAB) conditions with a JMS-700 MStation (JEOL, Tokyo, Japan).
4.1.2. Synthesis of 10a–c, 12a–d, 16a–b, 18a–b and 21a–b
General procedure for synthesis of 8a–c: A reaction mixture of 7a–c (11.036 mmol, 1.0 eq),
iron powder (10.363 mmol, 10 eq) and ammonium chloride (10.363 mmol, 10 eq) in ethanol-water (8:2)
was stirred for 2 h under N2 atmosphere at 80 ◦C. The reaction mixture was cooled down to room
temperature, filtered through celite bed, which was washed twice with ethyl acetate. Solvent was
removed under reduced pressure and the obtained residue was dissolved in ethyl acetate and
washed with water and brine solution. Organic layer was dried over anhydrous sodium sulfate.
Upon concentration under reduced pressure, the residue was purified by column chromatography on
silica gel to give 8a–c in 42–44% yield.
4-((2-(2-(4-aminophenoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (8a):
Yellow solid; yield 42.1%; Rf = 0.50 (methanol/dichloromethane = 0.5:9.5); 1H-NMR (400 MHz,
CDCl3) δ 8.57 (s, 1H), 7.43 (t, J = 8.8 Hz, 1H), 7.06 (d, J = 7.2 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H),
6.71 (d, J = 9.2 Hz, 2H), 6.58 (d, J = 9.2 Hz, 2H), 6.49 (t, J = 5.6 Hz, 1H), 4.87 (dd, J = 5.6, 12.0 Hz, 1H),
4.03 (t, J = 4.8 Hz, 2H), 3.80–3.74 (m, 4H), 3.45 (dd, J = 5.6, 11.2 Hz, 2H), 2.84–2.65 (m, 3H), 2.08–2.02
(m, 1H); 13C-NMR (125 MHz, CDCl3) δ 171.39, 169.18, 168.53, 167.59, 151.80, 146.77, 140.14, 135.95,
132.42, 116.75, 116.31 (2C), 115.87 (2C), 111.57, 110.24, 69.89, 69.63, 68.21, 48.78, 42.36, 31.32, 22.67;
HR-MS (FAB+) calcd for C23H25N406 [M + H]+ 453.1774, found 453.1777.
4-((2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoli ne-1,3-dione
(8b): Yellow solid; yield 44.7%; Rf = 0.50 (methanol/dichloromethane = 1:9); 1H-NMR (400 MHz,
CDCl3) δ 8.54 (s, 1H), 7.44 (t, J = 7.2 Hz, 1H), 7.05 (d, J = 7.2 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.71 (d,
J = 8.8 Hz, 2H), 6.58 (d, J = 8.8 Hz, 2H), 6.47 (t, J = 5.6 Hz, 1H), 4.84 (dd, J = 5.2, 12.0 Hz, 1H), 4.02 (t,
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J = 4.8 Hz, 2H), 3.79 (t, J = 5.2 Hz, 2H), 3.71–3.65 (m, 6H), 3.43 (dd, J = 5.6, 11.2 Hz, 3H), 2.77–2.64 (m,
3H), 2.04-2.00 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 171.29, 169.18, 168.46, 167.59, 151.85, 146.77,
140.11, 135.95, 132.42, 116.73, 116.30 (2C), 115.79 (2C), 111.53, 110.19, 70.70, 70.66, 69.92, 69.44, 68.07,
48.78, 42.32, 31.31, 22.65; HR-MS (FAB+) calcd for C25H29N407 [M + H]+ 497.2036, found 497.2029.
4-((2-(2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline
-1,3-dione (8c): Yellow solid; yield 42.9%; Rf = 0.50 (methanol/dichloromethane = 1:9); 1H-NMR
(400 MHz, CDCl3) δ 8.46 (s, 1H), 8.13 (d, J = 9.2 Hz, 2H), 7.44 (t, J = 8.4 Hz, 1H), 7.05 (d, J = 6.8 Hz,
1H), 6.93 (d, J = 9.2 Hz, 2H), 6.87 (d, J = 8.4 Hz, 1H), 6.44 (t, J = 5.6 Hz, 1H), 4.88 (dd, J = 6.0, 12.4 Hz,
1H), 4.17 (t, J = 4.4 Hz, 2H), 3.85 (t, J = 4.8 Hz, 2H), 3.70–3.64 (m, 10H), 3.42 (dd, J = 5.6, 11.1 Hz, 2H),
2.85–2.68 (m, 3H), 2.10–2.02 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 171.36, 169.18, 168.54, 167.49,
163.75, 146.68, 141.42, 135.92, 132.35, 125.73 (2C), 116.67, 114.48 (2C), 111.50, 110.10, 70.75, 70.54, 70.50,
69.40, 69.22, 68.10, 48.75, 42.26, 31.28, 22.63; HR-MS (FAB+) calcd for C27H33N4O8 [M +H]+ 541.2298,
found 541.2299.
General procedure for synthesis of 10a–c and 12a–b: A reaction mixture of 8a–c (0.044 mmol,
1.0 eq) and corresponding pyrimidines 9 or 11a–b (0.044 mmol, 1.0 eq) were dissolved in DMSO
(1.0 mL), and the resulting mixture was stirred for 16 h under N2 atmosphere at 90 ◦C. The progress of
the reaction was monitored by TLC. After completion of the reaction, 50 mL of cold water was added
and extracted with ethyl acetate (3 × 50 mL). The combined organic layer was dried over anhydrous
sodium sulfate. Upon concentration under reduced pressure, the residue was purified by column
chromatography on silica gel to give 10a–c and 12a–b, respectively. 21–57% yields.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(4-((4-(quinoline-3-ylamino)pyrimidin-2-yl)amino)pheno xy)ethoxy)
ethyl)amino)isoindoline-1,3-dione (10a, CPR-2): Yellow solid; yield 52.0%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 160.2–161.8 ◦C; 1H-NMR (400 MHz, MeOD + CDCl3) δ
8.81 (s, 1H), 8.70 (s, 1H), 7.90 (d, J = 5.6 Hz, 1H), 7.85–7.83 (m, 1H), 7.53–7.42 (m, 4H), 7.35 (d, J = 9.2 Hz,
2H), 6.98-6.95 (m, 2H), 6.87 (d, J = 9.2 Hz, 2H), 6.19 (d, J = 6.0 Hz, 1H), 4.85 (dd, J = 5.6, 12.4 Hz, 1H),
4.14 (t, J = 4.4 Hz, 2H), 3.87 (t, J = 4.8 Hz, 2H), 3.79 (t, J = 5.6 Hz, 2H), 3.48 (t, J = 5.2 Hz, 2H), 2.68–2.53
(m, 3H), 1.99–1.87 (m, 1H); 13C-NMR (125 MHz, MeOD + CDCl3) δ 174.08, 170.92, 170.46, 169.29, 162.30,
161.34, 156.69, 156.32, 147.99, 145.73, 144.42, 137.28, 134.97, 133.92, 133.60, 129.87, 128.86, 128.83 (2C),
128.26, 124.99, 124.87, 118.17, 116.25 (2C), 112,67, 111.33, 99.83, 71.05, 70.95, 69.10, 50.06, 43.45, 32.49,
23.85; HRMS (FAB+) calcd for C36H33N8O6 [M + H]+ 673.2523, found 673.2532.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(4-((4-(quinolin-3-ylamino)pyrimidin-2-yl)amino)phen oxy)ethoxy)
ethoxy)ethyl)amino)isoindoline-1,3-dione (10b, CPR-5): Yellow solid; yield 57.7%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 185.3–186.4 ◦C; 1H-NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H),
9.82 (s, 1H), 9.10 (s, 1H), 8.85 (s, 2H), 8.02 (d, J = 5.6 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.69 (brs, 1H),
7.54–7.49 (m, 5H), 7.08 (d, J = 8.8 Hz, 1H), 6.97 (d, J = 6.8 Hz, 1H), 6.83 (d, J = 9.2 Hz, 2H), 6.57 (t,
J = 6.0 Hz, 1H), 6.25 (d, J = 5.6 Hz, 1H), 4.99 (dd, J = 5.6, 12.8 Hz, 1H), 4.01 (t, J = 4.4 Hz, 2H), 3.72 (t,
J = 4.8 Hz, 2H), 3.60–3.56 (m, 6H), 3.46–3.40 (m, 2H), 2.85–2.76 (m, 1H), 2.53–2.48 (m, 2H), 1.96–1.91
(m, 1H); 13C-NMR (125 MHz, MeOD + CDCl3) δ 173.69, 170.58, 170.29, 169.04, 162.05, 161.17, 156.78,
156.05, 147.74, 145.64, 144.31, 137.07, 134.69, 133.73, 133.39, 129.66, 128.84, 128.64, 128.61, 128.09, 124.68,
124.61 (2C), 117.91, 115.97 (2C), 112.52, 111.07, 99.53, 71.82, 71.67, 70.91, 70.53, 68.82, 49.88, 43.21. 32.35,
23.68; HRMS (FAB+) calcd for C38H37N8O7 [M + H]+ 717.2785, found 717.2770.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(2-(4-((4-(quinolin-3-ylamino)pyrimidin-2-yl)amino)phenoxy)
ethoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione (10c, CPR-1): Yellow solid; yield 21.0%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 151.8–152.9 ◦C; 1H-NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H),
9.77 (s, 1H), 9.05 (s, 1H), 8.88 (brs, 1H), 8.86 (s, 1H), 8.03 (d, J = 5.6 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.70
(brs, 1H), 7.55–7.48 (m, 5H), 7.07 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 6.8 Hz, 1H), 6.84 (d, J = 9.2 Hz, 2H),
6.55 (t, J = 5.6 Hz, 1H), 6.25 (d, J = 5.6 Hz, 1H), 5.01 (dd, J = 5.0, 12.8 Hz, 1H), 4.01 (t, J = 4.4 Hz, 2H),
3.70 (t, J = 4.4 Hz, 2H), 3.58–3.52 (m, 10H), 3.40 (dd, J = 5.2, 10.8 Hz, 2H), 2.87–2.78 (m, 1H), 2.55–2.49
(m, 2H), 1.99–1.94 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 172.76, 170.03, 169.22, 167.68, 160.78, 159.85,
156.15, 154.50, 146.63, 145.50, 144.23, 135.89, 132.88, 132.86, 132.32, 128.72, 128.26, 127.63, 127.36, 126.94,
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123.82, 122.48 (2C), 116.67, 114.82 (2C), 111.51, 110.08, 97.51, 70.78, 70.68, 70.60 (2C), 69.74, 69.34, 67.72,
48.83, 42.28, 31.44, 22.79; HR-MS (FAB+) calcd for C40H41N8O8 [M + H]+ 761.3047, found 761.3039.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(4-((4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl) amino)
phenoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione (12a, CPR-3): Yellow solid; yield 32.6%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 158.1–159.3 ◦C; 1H-NMR (400 MHz, MeOD + CDCl3) δ 7.84 (d,
J = 6.0 Hz, 1H), 7.42 (dd, J = 7.2, 8.4 Hz, 1H), 7.34 (d, J = 9.2 Hz, 2H), 7.00 (d, J = 6.8 Hz, 1H), 6.90 (d,
J = 8.8 Hz, 1H), 6.83 (d, J = 8.8 Hz, 2H), 6.13 (s, 1H), 5.87 (s, 1H), 4.85 (dd, J = 5.6, 12.4 Hz, 1H), 4.08 (t,
J = 4.4 Hz, 2H), 3.80 (t, J = 4.8 Hz, 2H), 3.73 (t, J = 5.2 Hz, 2H), 3.44 (t, J = 5.2 Hz, 2H), 2.77–2.58 (m,
3H), 2.16 (s, 3H), 2.04–1.99 (m, 1H); 13C-NMR (125 MHz, DMSO-d6) δ 172.84, 170.11, 168.94, 167.31,
160.75, 159.39, 157.14, 150.01, 147.37, 146.40, 141.86, 138.84, 136.21, 132.11, 117.41, 115.46 (2C), 115.24
(2C), 110.70, 109.31, 104.99, 95.52, 69.09, 68.93, 67.64, 48.58, 41.71, 31.01, 22.16, 10.63; HR-MS (FAB+)
calcd for C31H32N9O6 [M + H]+ 626.2476, found 626.2477.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(4-((4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)
phenoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione (12b, CPR-4): Yellow solid; yield 44.5%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 176.2–177.5 ◦C; 1H-NMR (400 MHz, MeOD + CDCl3) δ 7.75 (d,
J = 6.4 Hz, 1H), 7.43 (dd, J = 7.2, 8.4 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 7.2 Hz, 1H), 6.91 (d,
J = 8.8 Hz, 1H), 6.86 (d, J = 9.2 Hz, 2H), 6.23 (s, 1H), 5.96 (s, 1H), 4.85 (dd, J = 5.2, 11.2 Hz, 1H), 4.08 (t,
J = 4.4 Hz, 2H), 3.83 (t, J = 4.8 Hz, 2H), 3.71–3.65 (m, 6H), 3.42 (t, J = 5.2 Hz, 2H), 2.75–2.65 (m, 3H),
2.18 (s, 3H), 2.06–1.98 (m, 1H); 13C-NMR (125 MHz, DMSO-d6) δ 172.80, 170.08, 168.94, 167.29, 160.72,
159.36, 157.06, 150.84, 147.35, 146.40, 140.13, 138.85, 136.20, 132.08, 117.44, 116.17 (2C), 115.31 (2C),
110.66, 109.24, 105.01, 95.47, 69.90, 69.79, 69.19, 68.91, 67.53, 48.55, 41.68, 30.98, 22.14, 10.62; HRMS
(FAB+) calcd for C33H36N9O7 [M + H]+ 670.2738, found 670.2745.
4-((2-(2-(4-((5-chloro-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenoxy) ethoxy)ethyl)
amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dion(12c, CPR-10): To the solution of 8a (30 mg,
0.066 mmol) in n-butanol (4.0 mL) were added 11b (16 mg, 0.066 mmol) and p-toluenesulfonic
acid monohydrate (13.5 mg, 0.066 mmol). The resulting mixture was stirred for 4 h under N2
atmosphere at 100 ◦C. The progress of reaction was monitored by TLC. After completion of the reaction,
the reaction mixture was cooled down to room temperature, saturated NaHCO3 solution was added to
adjust pH to 7, then extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried
over anhydrous sodium sulfate. After concentration of the reaction mixture under reduced pressure,
the residue was purified by column chromatography on silica gel to give 12c (13.19 mg, 32.5%) as a
yellow solid. Rf = 0.45 (methanol/dichloromethane = 1:9); mp 196.2–197.8 ◦C; 1H-NMR (400 MHz,
MeOD + CDCl3) δ 7.90 (s, 1H), 7.46 (t, J = 8.4 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 6.98 (dd, J = 7.2, 10.4 Hz,
2H), 6.85 (d, J = 8.8 Hz, 2H), 6.20 (s, 1H), 4.92 (dd, J = 6.0, 12.4 Hz, 1H), 4.11 (t, J = 4.4 Hz, 2H), 3.83 (t, J
= 4.4 Hz, 2H), 3.76 (t, J = 5.2 Hz, 2H), 3.47 (t, J = 5.2 Hz, 2H), 2.74–2.63 (m, 3H), 2.20 (s, 3H), 2.04–1.96
(m, 1H); 13C-NMR (125 MHz, DMSO-d6) δ 172.80, 170.07, 168.91, 167.28, 157.04, 156.78, 155.09, 149.72,
146.38, 145.70, 142.45, 138.74, 136.19, 132.09, 117.40, 115.44 (2C), 114.91 (2C), 113.15, 110.67, 109.28, 98.02,
69.08, 68.92, 67.63, 48.56, 41.70, 30.98, 22.14, 10.73; HR-MS (FAB+) calcd for C31H31ClN9O6 [M +H]+
660.2086, found 660.2077.
4-((2-(2-(2-(4-((5-chloro-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenoxy) ethoxy)
ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (12d, CPR-12): 12d was synthesized
according to the procedure for 12c. Yellow solid; yield 22.6%; Rf = 0.55 (EtOAc); mp 180.9–182.1 ◦C;
1H-NMR (400 MHz, CDCl3) δ 8.00 (brs, 1H), 7.94 (s, 1H), 7.60 (brs, 1H), 7.42 (t, J = 7.2 Hz, 1H), 7.30
(d, J = 9.2 Hz, 2H), 7.01 (d, J = 7.2 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.78–6.71 (m, 2H), 6.63 (brs, 1H),
6.42 (t, J = 5.6 Hz, 1H), 6.03 (s, 1H), 4.85 (dd, J = 5.6, 12.4 Hz, 1H), 4.11–4.08 (m, 2H), 3.84 (t, J = 4.8 Hz,
2H), 3.75–3.69 (m, 6H), 3.46–3.42 (m, 2H), 2.81–2.59 (m, 3H), 2.24 (s, 3H), 2.05–2.02 (m, 1H); 13C-NMR
(125 MHz, DMSO-d6) δ 172.79, 170.07, 168.93, 167.28, 157.04, 156.78, 155.10, 149.74, 146.40, 145.69,
142.41, 138.74, 136.19, 132.08, 117.42, 115.30 (2C), 114.92 (2C), 113.16, 110.65, 109.24, 98.01, 69.90, 69.79,
69.24, 68.91, 67.54, 48.56, 41.69, 30.98, 22.14, 10.73; HR-MS (FAB+) calcd for C33H35ClN9O7 [M +H]+
704.2348, found 704.2340.
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General procedure for synthesis of 14a–b: Dried round bottom flask with stir bar was charged
with azidoacetic acid 13 (0.06 mmol, 1.0 eq) and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC·HCl) (0.120 mmol, 2.0 eq) followed by slow addition of dry DMF (3 mL).
Then substituted alkyl amine 8a–b (0.06 mmol, 1.0 eq) was added, followed by addition of diisopropyl
ethylamine (0.018 mmol, 3.0 eq). The resulting mixture was stirred for 16 h at room temperature.
After completion of the reaction, cooled water was added to the reaction mixture, which was extracted
with ethyl acetate twice. Separated organic layer was dried with anhydrous sodium sulfate and solvent
was evaporated under reduced pressure. Crude product was purified by column chromatography on
silica gel using EtOAc: Hexane as mobile phase to get desired product 14a–b in 40–63% yields.
2-azido-N-(4-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethox y)phenyl)
acetamide (14a): Yellow solid; yield 40.6%; Rf = 0.50 (methanol/dichloromethane = 1:9); 1H-NMR
(400 MHz, CDCl3) δ 8.23 (s, 1H), 7.97 (s, 1H), 7.46 (t, J = 7.2 Hz, 1H), 7.38 (d, J = 9.2 Hz, 2H), 7.07 (d, J =
7.2 Hz, 1H), 6.88 (t, J = 8.8 Hz, 3H), 6.53 (brs, 1H), 4.88 (dd, J = 5.2 Hz, J = 12.0 Hz 1H), 4.14-4.10 (m,
4H), 3.84 (t, J = 4.8 Hz, 2H), 3.78 (t, J = 5.2 Hz, 2H), 3.46 (t, J = 5.2 Hz, 2H), 2.87–2.70 (m, 3H), 2.11–2.08
(m, 1H); 13C-NMR (125 MHz, CDCl3) δ 171.08, 169.17, 168.41, 167.59, 164.47, 156.01, 146.79, 136.02,
132.46, 130.08, 121.77 (2C), 116.74, 115.19 (2C), 111.69, 110.33, 69.80, 69.72, 67.88, 52.96, 48.84, 42.41,
31.40, 22.76; HR-MS (FAB+) calcd for C25H26N7O7 [M + H]+ 536.1894, found 536.1894.
2-azido-N-(4-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy) ethoxy)ethoxy)
phenyl)acetamide (14b): Yellow solid; yield 62.8%; Rf = 0.70 (ethyl acetate); 1H-NMR (400 MHz, CDCl3)
δ 8.08 (s, 1H), 7.93 (s, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.38 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 7.2 Hz, 1H),
6.90–6.84 (m, 3H), 6.46 (t, J = 6.4 Hz, 1H), 4.83 (dd, J = 6.8, 13.2 Hz, 1H), 4.12-4.07 (m, 4H), 3.84 (t, J =
4.8 Hz, 2H), 3.73–3.68 (m, 6H), 3.44 (dd, J = 5.6 Hz, 2H), 2.84–2.65 (m, 3H), 2.08–2.03 (m, 1H); 13C-NMR
(125 MHz, CDCl3) δ 170.93, 169.20, 168.28, 167.60, 164.42, 156.09, 146.82, 136.04, 132.49, 129.99, 121.83
(2C), 116.76, 115.01 (2C), 111.63, 110.24, 70.86, 70.76, 69.76, 69.49, 67.71, 52.96, 48.84, 42.41, 31.39, 22.71;
HR-MS (FAB+) calcd for C27H30N7O8 [M + H]+ 580.2156, found 580.2156.
3-(4-chlorophenyl)-1-(prop-2-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15): Compound 15 was
synthesized according to the reported procedure [36,50].
2-(4-((4-amino-3-(4-chlorophenyl)-1H-pyrazol[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol -1-yl)-N-(4-
(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)phen yl)acetamide (16a,
CPR-7): To a reaction mixture of 8a (12 mg, 0.022 mmol) and 15 (6.3 mg, 0.022 mmol) dissolved
in THF (1.0 mL) was added t-butanol (0.5 mL). Then CuSO4·5H2O (1.1 mg, 0.004 mmol) dissolved in
0.2 mL of water was added to it, followed by the addition of sodium ascorbate (3.55 mg, 0.017 mmol)
dissolved in 0.2 mL of water. The reaction mixture was stirred at room temperature for 6 h. The progress
of reaction was monitored by TLC. After completion of the reaction, solvent was evaporated, and the
residue was extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried over
anhydrous sodium sulfate. Upon concentration under reduced pressure, the residue was purified
by column chromatography on silica gel to give 16a (5 mg, 27.2%) as a yellow solid. Rf = 0.15
(methanol/ethyl acetate = 1:9); mp 186.3–187.6 ◦C; 1H-NMR (400 MHz, MeOD + CDCl3) δ 8.28 (s, 1H),
7.98 (s, 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.48-7.41 (m, 3H), 7.32 (d, J = 9.2 Hz, 2H), 6.99 (d, J = 6.8 Hz, 1H),
6.93 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 9.2 Hz, 2H), 5.71 (s, 2H), 5.15 (s, 2H), 4.87 (dd, J = 6.0, 12.4 Hz, 1H),
4.07 (t, J = 4.4 Hz, 2H), 3.80 (t, J = 4.8 Hz, 2H), 3.74 (t, J = 5.2 Hz, 2H), 3.44 (t, J = 5.2 Hz, 2H), 2.73–2.63
(m, 3H), 2.05–1.96 (m, 1H); 13C-NMR (125 MHz, MeOD + CDCl3) δ 173.62, 170.49, 170.22, 169.03,
164.18, 157.27, 156.78, 154.71, 147.73, 145.77, 143.70, 137.07, 136.73, 133.37, 131.74 (2C), 131.65 (2C),
130.76, 130.61, 126.08, 124.26, 122.55 (2C), 117.90, 115.99 (2C), 112.55, 112.16, 111.12, 70.73, 70.68, 68.78,




(16b, CPR-9): 16b was synthesized according to the procedure for 16a. Yellow solid; yield 26.8%; Rf =
0.20 (ethyl acetate); mp 192.8–194.1 ◦C; 1H-NMR (400 MHz, MeOD) δ 8.28 (s, 1H), 7.92 (s, 1H), 7.55 (d,
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J = 6.4 Hz, 2H), 7.46-7.38 (m, 4H), 7.31 (d, J = 9.2 Hz, 2H), 6.99 (d, J = 6.8 Hz, 1H), 6.86 (d, J = 8.4 Hz,
1H), 6.76 (d, J = 9.2 Hz, 2H), 5.69 (s, 2H), 5.09 (s, 2H), 4.77 (dd, J = 5.2, 12.4 Hz, 1H), 3.78 (t, J = 4.8 Hz,
2H), 3.68-3.58 (m, 6H), 3.39 (t, J = 5.2 Hz, 2H), 3.29-3.27 (m, 2H), 2.73-2.59 (m, 3H), 2.00–1.94 (m, 1H);
13C-NMR (125 MHz, MeOD + CDCl3) δ 173.69, 170.51, 170.29, 169.19, 169.12, 164.28, 157.73, 156.85,
147.78, 137.14, 136.81, 136.43, 133.42, 131.81 (2C), 131.64 (2C), 130.82, 130.67, 129.34, 126.22, 122.61 (2C),
119.64, 117.97, 117.61, 115.87 (2C), 112.53, 111.08, 71.75, 71.65, 70.79, 70.49, 68.66, 53.80, 43.50, 43.23,
32.36, 30.67, 23.70; HR-MS (FAB+) calcd for C41H40ClN12O8 [M + H]+ 863.2781, found 863.2768.
1-(3-bromopropyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (17): To a reaction mixture
of 22 (400 mg, 1.628 mmol) and 1,3-dibromo propane (394 mg, 1.953 mmol) dissolved in DMF (4.0 mL)
was added K2CO3 (562 mg, 4.070 mmol). The resulting mixture was stirred at room temperature for
16 h. The progress of the reaction was monitored by TLC. After completion of the reaction, cold water
was added and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried over
anhydrous sodium sulfate. Upon concentration under reduced pressure, the residue was purified
by column chromatography on silica gel to give 17 (388 mg, 65.0%) as a white solid. Rf = 0.80
(methanol/dichloromethane = 1:9); 1H-NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.62 (d, J = 8.8 Hz, 2H),
7.50 (d, J = 8.8 Hz, 2H), 5.90 (brs, 2H), 4.57 (t, J = 6.8 Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 2.54–2.47 (m, 2H);
13C-NMR (125 MHz, CDCl3) δ 157.84, 155.94, 154.66, 143.32, 135.36, 131.55, 129.68 (2C), 129.60 (2C),
98.38, 45.55, 32.52, 29.79; HR-MS (FAB+) calcd for C14H14BrClN5 [M + H]+ 366.0121, found 366.0121.
4-((2-(2-(4-((3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)amino)
phenoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(18a, CPR-8): To the
solution of 8a (20 mg, 0.044 mmol) in DMF (3.0 mL) were added potassium carbonate (12.21 mg,
0.066 mmol) and 17 (16.2 mg, 0.044 mmol). The reaction mixture was stirred for 16 h under N2
atmosphere at room temperature. The progress of reaction was monitored by TLC. After completion of
the reaction, cold water (20 mL) was added and extracted with ethyl acetate (3 x 20 mL). The combined
organic layer was dried over anhydrous sodium sulfate. Upon concentration under reduced pressure,
the residue was purified by column chromatography on silica gel to give 18a (16.5 mg, 50.6%) as a
yellow solid. Rf = 0.50 (methanol/dichloromethane = 1:9); mp 146.3–147.6 ◦C; 1H-NMR (400 MHz,
CDCl3) δ 8.35 (s, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.48–7.42 (m, 3H), 7.05 (d, J = 6.8 Hz, 1H), 6.89 (d, J =
8.4 Hz, 1H), 6.71 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 8.8 Hz, 2H), 6.46 (t, J = 6.0 Hz, 1H), 5.53 (brs, 2H), 4.84
(dd, J = 5.2, 12.4 Hz, 1H), 4.45 (td, J = 7.2, 2.8 Hz, 2H), 4.03 (t, J = 4.4 Hz, 2H), 3.91 (td, J = 6.8, 2.4 Hz,
2H), 3.78 (p, 2H), 3.74 (t, J = 5.2 Hz, 2H), 3.46 (dd, J = 5.6, 11.2 Hz, 2H), 2.88 (dd, J = 12.8, 2.8 Hz, 1H),
2.72–2.66 (m, 2H), 2.23 (p, 2H), 2.04–1.99 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 170.94, 169.29, 168.75,
167.69, 157.69, 155.86, 154.51, 151.75, 146.77, 142.98, 140.30, 135.93, 135.13, 132.49, 131.75, 129.79 (2C),
129.49 (2C), 116.69, 116.23 (2C), 115.91 (2C), 111.57, 110.37, 98.40, 69.94, 69.71, 68.21, 49.56, 44.84, 42.42,
38.29, 31.96, 27.73, 22.06; HR-MS (FAB+) calcd for C37H37ClN9O6 [M + H]+ 738.2555, found 738.2544.
4-((2-(2-(2-(4-((3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)amin o)phenoxy)
ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (18b, CPR-11): 18b was
synthesized according to the procedure for 18a. Yellow solid; yield 50.8%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 148.2–149.9 ◦C; 1H-NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.63
(d, J = 8.4 Hz, 2H), 7.49–7.42 (m, 3H), 7.05 (d, J = 6.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.70 (d, J = 8.8 Hz,
2H), 6.57 (d, J = 8.8 Hz, 2H), 6.44 (t, J = 5.6 Hz, 1H), 4.82 (dd, J = 4.8, 12.0 Hz, 1H), 4.49-4.20 (m, 2H),
4.01 (t, J = 4.8 Hz, 2H), 3.93–3.87 (m, 2H), 3.78 (t, J = 5.2 Hz, 2H), 3.70–3.63 (m, 6H), 3.43 (dd, J = 5.2,
10.8 Hz, 2H), 2.88–2.82 (m, 1H), 2.74–2.62 (m, 2H), 2.23 (p, 2H), 2.06–1.97 (m, 1H); 13C-NMR (125 MHz,
CDCl3) δ 170.94, 169.29, 168.75, 167.70, 157.65, 155.80, 154.49, 151.86, 146.77, 143.01, 140.19, 135.93,
135.14, 132.49, 131.74, 129.79 (2C), 129.50 (2C), 116.68, 116.25 (2C), 115.80 (2C), 111.52, 110.31, 98.39,
70.76, 70.71, 69.97, 69.53, 68.08, 49.55, 44.84, 42.37, 38.26, 31.94, 27.74, 22.04; HR-MS (FAB+) calcd for
C39H41ClN9O7 [M + H]+ 782.2817, found 782.2834.
1-(3-azidopropyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (19): To the solution of 17
(200 mg, 0.545 mmol) in DMF (2.0 mL) was added sodium azide (46.10 mg, 0.709 mmol) at room
temperature. The reaction mixture was stirred for 16 h under N2 atmosphere at room temperature.
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The progress of reaction was monitored by TLC. After completion of the reaction, cold water (50 mL)
was added and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried over
anhydrous sodium sulfate. Upon concentration under reduced pressure, the residue was purified
by column chromatography on silica gel to give 19 (119 mg, 66.1%) as a white solid. Rf = 0.50
(EtOAc/n-Hexane = 1:1); 1H-NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.50 (d, J =
8.4 Hz, 2H), 5.90 (brs, 2H), 4.52 (t, J = 6.4 Hz, 2H), 3.36 (t, J = 6.4 Hz, 2H), 2.23–2.17 (m, 2H); 13C-NMR
(125 MHz, CDCl3) δ 157.84, 155.96, 154.63, 143.31, 135.36, 131.55, 129.67 (2C), 129.60 (2C), 98.34, 48.71,
44.26, 28.93; HR-MS (FAB+) calcd for C14H14ClN8 [M + H]+ 329.1030, found 329.1033.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(4-(prop-2-yn-1-ylamino)phenoxy)ethoxy)ethyl)amino)iso indoline
-1,3-dione (20a): To the solution of 8a (50 mg, 0.110 mmol) in DMF (3.0 mL) were added potassium
carbonate (22.9 mg, 0.165 mmol) and propargyl bromide (14.5 mg, 0.110 mmol) at room temperature.
The reaction mixture was stirred for 16 h under N2 atmosphere at room temperature. The progress
of reaction was monitored by TLC. After completion of the reaction, cold water (20 mL) was added
and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous
sodium sulfate. Upon concentration under reduced pressure, the residue was purified by column
chromatography on silica gel to give 20a (30 mg, 55.4%) as a yellow solid. Rf = 0.60 (ethyl acetate =
100%); 1H-NMR (400 MHz, CDCl3) δ 7.45 (t, J = 8.4 Hz, 1H), 7.07 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 8.4 Hz,
1H), 6.73 (d, J = 8.8 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 6.49 (t, J = 5.6 Hz, 1H), 4.92 (dd, J = 7.6, 12.4 Hz,
1H), 4.55 (d, J = 2.4 Hz, 2H), 4.04 (t, J = 4.4 Hz, 2H), 3.81–3.74 (m, 4H), 3.47 (dd, J = 5.2, 10.8 Hz, 2H),
3.00–2.93 (m, 1H), 2.81–2.72 (m, 2H), 2.14 (s, 1H), 2.08–2.04 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ
170.11, 169.23, 167.96, 167.63, 151.77, 146.81, 140.30, 135.97, 132.46, 116.75, 116.23 (2C), 115.92 (2C),
111.61, 110.33, 77.94, 70.76, 69.94, 69.70, 68.22, 49.52, 42.42, 31.87, 29.62, 21.92; HR-MS (FAB+) calcd for
C26H27N4O6 [M + H]+ 491.1931, found 491.1938.
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(4-(prop-2-yn-1-ylamino)phenoxy)ethoxy)ethoxy)ethyl) amino)
isoindoline-1,3-dione (20b): 20b was synthesized according to the procedure for 20a. White solid; yield
52.5%; Rf = 0.60 (EtOAc/n-Hexane = 1:1); 1H-NMR (400 MHz, CDCl3) δ 7.45 (t, J = 8.4 Hz, 1H), 7.07
(d, J = 6.8 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.72 (d, J = 8.8 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 6.47 (t,
J = 5.6 Hz, 1H), 4.87 (dd, J = 4.8, 7.2 Hz, 1H), 4.55 (d, J = 2.4 Hz, 2H), 4.03 (t, J = 4.8 Hz, 2H), 3.81 (t,
J = 5.2 Hz, 2H), 3.72–3.66 (m, 6H), 3.44 (dd, J = 5.6, 11.2 Hz, 2H), 2.97–2.86 (m, 1H), 2.76–2.67 (m, 2H),
2.15 (s, 1H), 2.08–2.01 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 170.10, 169.23, 167.95, 167.66, 151.90,
146.81, 140.20, 135.98, 132.48, 116.74, 116.26 (2C), 115.82 (2C), 111.58, 110.30, 77.97, 70.77, 70.74, 69.99,




CPR-13): 21a was synthesized according to the procedure for 16a. Yellow solid; yield 40.1%; Rf = 0.45
(methanol/dichloromethane = 1:9); mp 159.1–160.6 ◦C; 1H-NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.69
(s, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.42 (t, J = 7.2 Hz, 1H), 7.01 (d, J = 7.2 Hz,
1H), 6.88 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 8.8 Hz, 2H), 6.57 (d, J = 8.8 Hz, 2H), 6.47 (t, J = 5.6 Hz, 1H),
5.13-5.04 (m, H), 4.92 (dd, J = 5.2, 12.4 Hz, 1H), 4.47 (t, J = 7.2 Hz, 2H), 4.34 (t, J = 6.8 Hz, 2H), 4.03 (t, J =
4.8 Hz, 2H), 3.78 (t, J = 4.8 Hz, 2H), 3.74 (t, J = 5.6 Hz, 2H), 3.44 (dd, J = 4.4, 10.0 Hz, 2H), 2.97–2.90 (m,
1H), 2.79–2.68 (m, 2H), 2.53 (p, 2H), 2.07-2.00 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 170.52, 169.25,
168.70, 167.80, 167.68, 159.35, 157.61, 155.89, 154.58, 146.79, 146.73, 143.55, 143.07, 135.94, 135.40, 132.46,
131.37, 129.69 (2C), 129.62 (2C), 123.83, 116.74, 116.44 (2C), 115.90 (2C), 111.56, 110.33, 69.92, 69.68,
68.23, 49.54, 47.58, 44.12, 42.39, 35.62, 31.91, 29.98, 22.04; HR-MS (FAB+) calcd for C40H40ClN12O6 [M +
H]+ 819.2882, found 819.2887.
4-((2-(2-(2-(4-(((1-(3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-1H-1,2,3-
triazol-4-yl)methyl)amino)phenoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
(21b, CPR-14): 21b was synthesized according to the procedure for 16a. Yellow solid; yield 38.3%; Rf =
0.250 (methanol/dichloromethane = 1:9); mp 164.5–165.9 ◦C; 1H-NMR (400 MHz, CDCl3) δ 8.35 (s, 1H),
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7.69 (s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.41 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 7.2 Hz,
1H), 6.87 (d, J = 8.8 Hz, 1H), 6.69 (d, J = 8.4 Hz, 2H), 6.57 (d, J = 8.4 Hz, 2H), 6.45 (t, J = 6.0 Hz, 1H),
5.12–5.03 (m, 2H), 4.88 (dd, J = 5.2, 11.6 Hz, 1H), 4.47 (t, J = 6.0 Hz, 2H), 4.36 (t, J = 7.2 Hz, 2H), 4.01 (t,
J = 5.2 Hz, 2H), 3.79 (t, J = 5.2 Hz, 2H), 3.71-3.65 (m, 6H), 3.44–3.40 (m, 2H), 2.93–2.87 (m, 1H), 2.75–2.64
(m, 2H), 2.55 (p, 2H), 2.04–1.98 (m, 1H); 13C-NMR (125 MHz, MeOD+CDCl3) 170.75, 169.10, 168.74,
167.77, 155.58, 154.17, 146.67, 146.60, 135.90, 135.39, 135.15, 133.28, 132.35, 132.27, 131.00, 130.89, 129.57
(2C), 129.51 (2C), 128.92, 128.67, 116.72 (2C), 111.40 (2C), 109.99, 109.50, 70.58, 70.52, 69.82, 69.37, 68.01,




MCF7 (human breast cancer) and A549 (human lung cancer) cells were obtained from the Korean
Cell Line Bank (KCLB, Seoul, Korea) and incubated in 5% CO2 at 37 ◦C. The cells were plated in
96-well culture plates (SPL Life Science Co., Gyeonggi-do, Republic of Korea) for 24 h. For cell viability
test, the synthesized PROTACs were treated at the various concentrations from 0 to 80 μM for 3 days.
After that, 100 μL of 20 mM MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
(Thermo Fisher Scientific, Rockford, IL, USA) (5 mg/mL) dissolved in RPMI-1640 medium was added
to the incubated well for 3 h. The supernatant was discarded and 100 μL of DMSO was reacted with
viable cells. The product of reaction was measured by absorbance at 570 nm using Mithras2 plate
reader (Berthold Technologies, Bad Wildbad, Germany).
4.2.2. Western Blot Assay
The PROTAC-treated MCF7 (human breast cancer) and A549 (human lung cancer) cells were
lysed with 1X lysis buffer containing protease inhibitor. Extracted protein lysate (20 μg) were loaded on
12% SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane
(ATTO, Tokyo, Japan). The membrane was blocked with 3% Bovine Serum Albumin (BSA) in
tris-phosphate buffer containing 0.1% Twin 20, and incubated with primary antibodies for 1 h at room
temperature. The following antibodies were IGF1Rβ (1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and Src (1:000, Cell Signaling Technology, Beverly, MA, USA) and GAPDH (1:200, Santa Cruz
Biotechnology) as internal control. The signal was reacted with ECL solution (GenDEPOT, Barker,
TX, USA) and detected on an Image Quant LAS 4000 biomolecular imager (GE Healthcare, Chicago,
IL, USA).
4.2.3. Wound Healing and Invasion Assay
MCF7 (human breast cancer) and A549 (human lung cancer) cells were treated with 1 or 5 μM of
PROTAC compounds for 24 h. After 24 h, the treated cells were collected and re-implanted (3 × 105)
on 24-well culture plates for 24 h. When cells reached confluence, wound healing assay was performed
by scratching with pipette tips. For invasion assay, matrigel (BD Biosciences, San Diego, CA, USA)
coated transwell (BD Biosciences, San Diego, CA, USA, 353097, 8 μm pore size) was used to mimic
extra cellular matrix in vitro. The PROTAC-treated cells (1 × 105) suspended in RPMI-1640 without
FBS were seeded into transwell and each of the insert wells was put in 24-well culture plates containing
RPMI-1640 with FBS. After incubation, the membrane of insert transwell was stained with 0.1% crystal
violet (Sigma Aldrich, St. Louis, USA). The wound closure or invasive images were analyzed based on
bright field microscopy.
4.2.4. Soft Agar Colony Formation Assay
To investigate growth ability on solid surface in vitro, a colony forming assay was performed by
using top and bottom agarose method. The base of layer was poured with 1.5 mL of 0.5% agarose
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(BD Biosciences, San Diego, CA, USA) containing RPMI-1640 with FBS and solidified. 1 mL of
PROTAC-treated cells (3 × 105) resuspended in complete medium with 0.3% agarose (BD Biosciences,
San Diego, CA, USA) was covered on the base of layer. The plates were incubated for approximately
2 weeks in 5% CO2 at 37 ◦C. Formed colony was counted on bright field microscopy.
5. Conclusions
We developed dual degrader PROTACs to target both IGF-1R and Src, which are associated with
various cancer cells. We evaluated the degradation potentials of the synthesized PROTAC compounds
by different cellular assays. Interestingly, PROTACs with a dual IGF-1R/Src inhibitor warhead (C),
which possess a common structure from the reported IGF-1R and Src inhibitors, showed significant
degradation potency, whereas previously reported individual modules, with similar sizes for Src or
IGF-1R, were not active in PROTACs. Our data support the notion that the binding affinities of warhead
ligands are not the sole determinant of PROTAC efficiency. Off-target effects, with promiscuous ligands,
may be counteracted with other factors, including the formation of a stable ternary complex with
target protein-E3 ligase, as well as efficient ubiquitination. Our dual degrader PROTACs, along with
various cell-based assays, indicated that the PROTACs developed in this study serve as valuable tools
to understand the mechanism and process of induced degradation of target proteins, which will result
in next-generation anticancer therapeutics.
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Abstract: N1-(α,β-Alkene)-substituted phenylpyrazolopyrimidine derivatives with acetyl and
functionalized phenyl groups at α- and β-positions, respectively, were synthesized by the reaction
of 3-phenylpyrazolopyrimidine (PhPP) with bromoacetone, followed by a chalcone reaction with
differently substituted aromatic aldehydes. The Src kinase enzyme assay revealed modest inhibitory
activity (half maximal inhibitory concentration, IC50 = 21.7–192.1μM) by a number of PhPP derivatives.
Antiproliferative activity of the compounds was evaluated on human leukemia (CCRF-CEM), human
ovarian adenocarcinoma (SK-OV-3), breast carcinoma (MDA-MB-231), and colon adenocarcinoma
(HT-29) cells in vitro. 4-Chlorophenyl carbo-enyl substituted 3-phenylpyrazolopyrimidine (10)
inhibited the cell proliferation of HT-29 and SK-OV-3 by 90% and 79%, respectively, at a concentration
of 50 μM after 96 h incubation. The compound showed modest inhibitory activity against c-Src (IC50
= 60.4 μM), Btk (IC50 = 90.5 μM), and Lck (IC50 = 110 μM), while it showed no activity against Abl1,
Akt1, Alk, Braf, Cdk2, and PKCa. In combination with target selection and kinase profiling assay,
extensive theoretical studies were carried out to explore the selectivity behavior of compound 10.
Specific interactions were also explored by examining the changing trends of interactions of tyrosine
kinases with the phenylpyrazolopyrimidine derivative. The results showed good agreement with the
experimental selectivity pattern among c-Src, Btk, and Lck.
Keywords: protein kinase; phenylpyrazolopyrimidine; antiproliferative activity; enzyme inhibition;
molecular simulation
1. Introduction
Cancer cells show the overexpression of different protein tyrosine kinases (PTKs). These enzymes
catalyze the phosphorylation of many protein substrates by the transfer of the γ-phosphate group from
ATP to specific tyrosine residues. PTKs have critical roles in signal transduction pathways.
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Src family kinases (SFKs) have nine different PTKs, including c-Src, c-Yes, Fyn, Lck, Lyn, Hck,
Frk, Blk, and c-Fgr of which Src is the prototype [1]. SFKs have essential roles in the regulation of a
wide variety of normal cellular signal transduction pathways, such as cell division, differentiation,
growth factor signaling, survival, adhesion, migration, and invasion [2]. Src tyrosine kinase expression
is frequently elevated in several tumors, including breast, colon, prostate, lung, ovary, and pancreas,
when it is compared with the adjacent healthy tissues. Src kinase was shown to be the critical modulator
of cancer cell metastasis and invasion [3].
In recent years, a number of small cell-permeable inhibitors of protein kinases were investigated
for the treatment of different cancers [4]. Different small molecules that were actively investigated as
kinase inhibitor include quinazolines [5], quinolinecarbonitriles [6], pyrazolopyrimidines [7,8], imidazo
[1,5-a]pyrazines [9], Calixarene [10], benzotriazines [11,12], indoles [13], and ATP- phosphopeptide
conjugates [14]. The research effort led to the generation of small molecules for the treatment of
different malignancies. Imatinib, a 2-phenylaminopyrimidine, was approved for the treatment of
chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs) [15]. Dasatinib
(BMS-354825), a pyrimidinylthiazole derivative, was approved to use in patients with CML after
imatinib treatment [16], and bosutinib (SKI-606), a 3-quinolinecarbonitrile analogue, is known
to suppress migration and invasion of human breast cancer cells [17]. Ibrutinib (Figure 1) is a
pyrazolopyrimidine-based [18] small-molecule kinase inhibitor that was approved for the treatment
of B-cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s
macroglobulinemia [19,20].
 
Figure 1. Chemical structures of 3-phenylpyrazolopyrimidine (PhPP) derivatives (PP1 and PP2)
and Ibrutinib.
A number of crystallographic studies showed that adenosine 5′-(β,γ-imido)triphosphate
(AMP-PNP), an ATP mimic, binds to the ATP-binding site of c-Src (Protein Data Bank (PDB)
2SRC) [21]. Furthermore, complexes of 3-phenylpyrazolopyrimidine (PhPP) derivatives (PP1 and PP2)
(Figure 1) act as ATP-binding site inhibitors of Hck (PDB 1QCF) and Lck (PDB 1QPE) [22]. Indeed,
the pyrazolopyrimidine core of PP1 and PP2 (Figure 1) mimics the adenine base of ATP in binding to the
nucleotide-binding site. In another study [8], we showed that the 3-phenyl group interacts with a large
hydrophobic pocket in the ATP-binding site, contributing significantly to Src kinase inhibitory activity.
There is also another cavity formed from side chains of helix αC and helix αD that is normally occupied
by a carbohydrate moiety followed by a triphosphate group of ATP. This cavity is mostly unfilled
by the tert-butyl of 3-phenylpyrazolopyrimidines (PP1 and PP2). Furthermore, we investigated the
variation of N1 substitution in 3-phenylpyrazolopyrimidines with different 1,2,3-triazoles containing
hydrophobic residues to interact with amino acids of this cavity and contribute to the enhancement of
Src kinase inhibitory potency [8]. The cysteine residue present in the cavity could be a potential target
to bind with PhPP molecules irreversibly, leading to a potential increase in kinase inhibition.
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Here, we describe the synthesis and evaluation of kinase inhibitory activity of N1-substituted
PhPP with α-acetyl-β-phenyl-alkene groups (Figure 2). We hypothesized that this substitution at the
N1 position of PhPP could contribute significantly to the kinase inhibition through generating specific
interactions. We further extended our study to investigate the selectivity profile of one of the active
compounds (10) with a panel of nine different kinases by applying MD and MMGBSA calculations.
This study helped to reveal the inhibitory mechanism of PhPP derivatives based on their distinct
structural characteristics required for its interaction with a specific kinase.
 
Figure 2. Chemical structures of N1-substituted PhPP with α-acetyl-β-phenyl-alkene groups (E and
Z isomers).
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2. Results and Discussion
2.1. Chemical Synthesis
The products were synthesized by following the chemical pathway shown in Scheme 1. The PhPP
(1) was synthesized according to a reported procedure [23]. The N1 of 1 was substituted with
bromoacetone in the presence of potassium carbonate as a base. Product 2 was confirmed by NMR,
which showed the disappearance of the proton peak of NH at 8.07 ppm of 1 and appearance of the peak
at 5.24 ppm and 2.21 ppm for CH2 and CH3, respectively, in 1H NMR. Furthermore, 13C NMR showed
peaks at 201.34 ppm, 56.15 ppm, and 27.14 ppm representing the carbonyl group, CH2, and CH3,
respectively, in product 2.
 
Scheme 1. Chemical synthesis of PhPP derivatives.
Next, the double bond group was introduced by the chalcone reaction. The anion of 2 generated
by sodium hydroxide was reacted with different benzaldehydes at room temperature to give product
3. The ratio of starting material and amount of solvent defined the formation of product and side
products. A higher concentration (i.e., less amount of solvent ethanol) and the presence of higher
equivalents of 2 than the aldehyde lead to a second internal Michael reaction where the anion of 2
reacts with product 3, leading to the formation of side product as indicated by Electrospray Ionization
Mass Spectrometry (ESI-MS) at 659 Da (data not shown). In an optimum condition, the aldehyde and
reactant 2 should be present in more than 1.4:1 equivalent, and solvent ethanol should be present in
approximately 20 mL for 26 mg (0.1 mmol) of 2. Out of two possible products after the conjugation of
2 with 4-methylbenzaldehyde, only product 3 was observed, suggesting the reaction of the carbanion
of methylene (CH2) group between the carbonyl and nitrogen rather than that of methyl (CH3).
The formation of product 3 was confirmed by ESI-MS by the presence of a mass peak at 370 Da [M +
H]+. This was confirmed by 1H NMR, which showed the absence of a peak at 5.24 ppm for CH2 of 2,
while the three protons for CH3 were present at 2.31 ppm. Correspondingly, in 13C NMR, the peak at
56.15 ppm (assigned to CH2) was absent in 3 while the peak at 26.13 ppm (assigned to CH3 with slight
upfield shift) was present. Furthermore, out of EZ possible isomers for the double bond, both the
isomers were present as indicated by NOE NMR spectra, possibly by rotation introduced due to
keto-enol tautomerism.
In the case of product 8, the chalcone reaction was carried with precaution to avoid the formation
of side products due to the presence of α-hydrogen in acetaldehyde. The anion of 2 was generated first
with 1.1 equivalent of sodium hydroxide over extended time and added to the solution of acetaldehyde
(1.2 equivalents). The reaction was quenched with acetic acid after 30 min. The product was confirmed
by ESI-MS and NMR. The products were purified by HPLC and showed a purity of 95–99%.
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2.2. Src-Kinase Assay
In vitro Src kinase assay for some of the compounds was conducted, as presented in Table 1.
As results indicated, the compounds were moderately active against the Src kinase. Among all the
tested compounds, compounds 6 and 4 were found to be the most potent with IC50 values of 21.7 and
24.7 μM, respectively. Compounds 3 and 7 exhibited IC50 values of 32.9 μM and 36.8, respectively.
Compound 5 showed the lowest activity with an IC50 of 192.1 μM. Since the compounds showed only
moderate Src kinase inhibitory activity, they were evaluated for antiproliferative activity first to find
the lead compound for further kinase inhibitory assays.
Table 1. In vitro Src kinase inhibition assay for the selected compounds.









a All experiments were repeated in triplicate. All the standard deviations were in the range of 6–13%.
2.3. Antiproliferative Activities
The effect of compounds on the cell proliferation of cancer cells was evaluated in vitro in a
human leukemia cell line (CCRF-CEM) according to the previously reported procedures [24,25], breast
adenocarcinoma (MDA-MB-231), ovarian adenocarcinoma (SK-OV-3), and colon adenocarcinoma (HT-29)
cell lines up to 72 h. Doxorubicin (Dox) was used as a positive control as shown previously [26–29].
These cell lines were selected to determine the antiproliferative activity against diverse cancer cells.
Compounds 10 and 11 consistently inhibited the cell proliferation 72–96 h in all cell lines. The percentage
of cell proliferation was significantly reduced in HT-29 cells in the presence of 10 and 11 when compared
with Dox and other compounds. Compound 10 was more effective in the order of HT-29 (90%) >
CCRF-CEM, SK-OV-3 (79%) >MDA-MB-231 (60%), while Dox showed HT-29 (75%) > CCRF-CEM,
SK-OV-3 (73%) >MDM-MB-231 (64%) after 96 h. Compounds 2, 7, 9, and 12 were found to be inactive
in reducing the cell proliferation in all the cell lines after 24–96 h while other compounds 3 and 13–15
exhibited comparable or slightly less antiproliferative activity (Figure 3A–D) than compounds 10
and 11 after 96 h. These data indicate that the presence of the chlorine group at the para position in
compounds 10 and 11 were effective in improving the antiproliferative activities. However, the absence
of phenyl and/or double bonds in compounds 2 and 8 significantly reduced the antiproliferative
activities versus 10 and 11. The presence of p-dimethylamino, m-nitro, and o-chlorine in 7, 9, and 12
were not productive while o-fluorine (13), p-fluorine (14), unsubstituted phenyl (15), and p-Cl (10 and
11) enhanced the antiproliferative activity. Compounds 5 and 6 with p-ph and p-methoxy exhibited
antiproliferative activity against some of the cell lines, with 5 being more active in HT-29 and 6 in
CCRF-CEM and SK-OV3 cells. However, their activity was generally less than compounds 3, 10, 11, 13,
and 14. Compounds 10 and 11 exhibited IC50 values of 25.5 μM and 34.3 μM, respectively, after 72 h
incubation against SK-OV-3 cells (Figure 4).
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Figure 3. Cont.
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Figure 3. Antiproliferative activity of PhPP derivatives (50 μM) and doxorubicin (Dox) (1 μM) against
CCRF-CEM (A), SK-OV-3 (B), HT-29 (C), and MDA-MB-231 (D) cell lines. All experiments were
repeated in triplicate.
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Figure 4. Dose-response curves of 10 (left) and 11 (right) after 72 h incubation against SK-OV-3 cells.
Compound 10 was selected for further evaluation against a panel of kinases to determine the
mechanism of activity. The results are shown in Table 2 against Abl1, Akt1, Alk, Braf, Btk, Cdk2,
cSrc, Lck, and PKCa enzymes. The data indicate modest activity against Btk, c-Src, and Lck while the
compound was inactive or showed very low inhibition activity against other kinases.




Control Compound IC50 (μM)
Abl1 NAa 0.85 b
Akt1 >150 0.012 b
Alk NA 0.01 b
Braf NA 0.018 c
Btk 95.4 0.067 b
Cdk2/Cyclin A1 NA 0.0039 b
c-Src 64.1 0.0085 b
Lck 110 0.011 b
PKCa NA 0.0016 b
a Not active (NA) indicates no inhibition or compound activity that could not be fit to an IC50 curve; b Staurosporine;
c GW5074.
2.4. Molecular Modeling
To rationalize the activity of compound 10, KEGG pathway and molecular dynamics simulation
studies were utilized to explore the specific behavior of the Z configuration compound 10 against
multiple kinases.
2.4.1. Target Identification
Conventional identification of drug targets is an expensive, time-consuming, and difficult process;
only a few drug targets can be identified. In contrast, the computational method permits a great
deal of analysis within a short period and brings a large number of potential drug targets from a
pool of information [30]. In the present study, an integrated in silico approach was used to identify
potential targets [31] for the active compound 10. Initially, the disease search tool in the KEGG database
was used against breast, ovarian, and colorectal cancer to extract the targets that may be involved
in these diseases (Figures 5–7) [32]. KEGG uses the knowledge of gene function and linking this
information with advanced order functional information by using systematic analysis. The schematic
presentation of the KEGG pathway shows genes marked as light-blue color as a drug target and
genes marked as pink as associated with the disease, whereas when the gene is linked with both
a disease and a drug target, its color is split into light blue and pink. There were several target
proteins involved in one pathway; therefore, protein-drug association servers Similarity Ensemble
Approach (SEA, http://sea.bkslab.org/) [33], Search Tool for the Retrieval of Interacting Genes (STRING,
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http://string-db.org) [34], and Search Tool for Interacting Chemicals (STITCH, http://stitch.embl.de/) [35]
were used. The STRING database was used to explain the molecular function, biological processes,
cellular components, and pathways of the target proteins. The SEA relates target proteins based on
set-wise chemical similarity among their compounds. A total of 14 potential targets (Btk, Itk, c-Src,
EGFR, Akt1, Fyn, Lyn, Lck, PKC, Abl1, Hck, Cdk2, Braf, and Her2) were selected based on the data
obtained from these servers that further proved the reliability of text mining and molecular docking.
 
Figure 5. The KEGG pathway for ovarian cancer.
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2.4.2. Docking Studies
The known compounds that were already reported as inhibitors of the target proteins, as well
as nature and crucial active site residues, were specified in their accessible complexes, used as a
positive control. Prior to docking, validation of the software and docking conditions was performed
by retrieving the control compounds from their crystal complexes and then redocking by MOE against
their relevant targets. The redocking results are presented in Table 3. After validation, docking of
compound 10 was performed with all 14 targets, and their docking scores were compared with the
control in order to select a target with the highest docking score. We observed that compound 10
presented good scores against Btk, Itk, c-Src, EGFR, Akt1, Fyn, Lyn, Lck, PKC, and Abl1 kinase as
compared to Hck, Cdk2, Braf, and Her2. The docking scores of compound 10 are presented in Table 4.
Table 3. Predicted binding affinity (docking scores in kcal/mol) and root-mean-square deviation (RMSD)
of control inhibitors against related proteins.















Table 4. MM/PBSA derived binding free energies of complexes computed from the MD simulations.
c-Src PKC Akt Alk Btk CDK2 Lck Abl1 Braf
VDWAALS −40.343 −46.197 −35.635 −35.533 −46.946 −50.067 −34.248 −40.962 −31.802
EEL −13.296 −19.577 −15.181 −3.935 −13.128 −29.554 −15.558 −18.300 −10.603
EPB/EGB 32.183 39.385 33.442 23.836 36.678 54.064 32.371 39.952 26.077
ESURF/ECAVITY/
ENPOLAR −5.024 −5.873 −3.961 −4.54 −5.820 −6.421 −4.623 −5.313 −4.283
DELTA G
binding (PB) −20.633 −21.653 −15.645 −5.210 −15.683 −6.893 −18.093 −9.629 −20.433
2.4.3. Structure Architecture of Kinases
The structure of all protein kinase domains is composed of a small, typically β-stranded N-lobe
linked with a small hinge region to a bigger α-helical C-lobe. In protein kinases, ATP binds to the
cavity that lies between N- and C-terminal lobes creating the kinase activation site, where the adenine
moiety of ATP is packed like a sandwich between hydrophobic residues, while it is associated with the
hinge region by hydrophilic contact. Typical kinase elements include the G-loop (glycine-rich residues
forming the active site roof), A-loop, or activation loop crucial for kinase activation and deactivation,
C-helix responsible for the selectivity of the active site, and the hinge region that plays a vital role in
inhibitor binding. The ATP-binding site categorized into five distinct regions: adenine region where
the adenine moiety of ATP forms a hydrogen bond with the hinge, hydrophobic region-I corresponds
to the entrance pocket, hydrophobic region-II also known as the selectivity pocket is determined by an
extremely conserved DFG (aspartate-phenylalanine-glycine) motif, a hydrophilic region where the
ATP sugar binds, and a solvent-exposed region for phosphate binding.
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2.4.4. Molecular Dynamic Simulation
Although X-ray crystallography and molecular docking are powerful techniques for biological
macromolecules, they are unable to examine the protein’s flexibility and they provide a momentary
binding mode. Therefore, MD simulation was used to investigate the ligand-protein interactions [36]
and the conformational changes which occur in the structure of kinases with respect to motions. Based
on the docking results, nine complexes were selected for further MD simulation to understand the
binding mechanism of compound 10 and its stability against multiple kinases.
c-Src
The stereo view of the binding mode of Src (PDB ID: 2SRC) is depicted in Figure 8A. It was found
that, initially, compound 10 was bound to the active site of Src kinase similar to a cognate ligand by
making a hydrogen bond with the NH group of Met341 and CO group of Glu339, while these bonds
were observed to undergo destabilization during the simulation. Comparatively, three new hydrogen
bonds were formed, involving the side chain amino group of Lys295 (solvent accessible area) and the
hydroxyl group of Ser345, which interact with the pyrazolopyrimidine scaffold located in the adenine
region of Src kinase. The spatial position of the compound was found to be different from the observed
dock pose because of major conformational changes during simulation.
 
Figure 8. Binding mode of Z configuration of compound 10 (khaki) with the active site residues of (A)
c-Src, (B) Lck, (C) Btk, (D) Akt, (E) Abl1, (F) Braf, (G) Alk, (H) PKC, and (I) Cdk2. Amino acid residues
involved in crucial interactions are labeled.
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The activation loop in the DFG-in conformation provides enough space to accommodate the ring
of compound 10, which may cause a collision with Phe405 of the DFG-out conformation. Moreover,
distinct hydrophobic interactions were also observed with Leu273, and Val281 (hydrophobic region I)
that maintain the binding mode of complexes. The MD results suggest that the non-flexible part of the
compound might be the reason for its moderate activity as compared to the reference compound.
Lck
The binding elements responsible for the modest activity of Lck kinase are depicted in Figure 8B.
Consistent with the results from other reported studies, compound 10 is well accommodated in the
ATP site of Lck by forming multiple hydrophobic, π-stacking, π-cation, and Van der Waals interactions
with Leu251, Ala271, Lys273, Thr316, Lys318, and Asp382. Due to the different conformation of the
DFG motif, compound 10 slightly moves toward the adenine region with its core pyrimidine ring in the
adenine region by forming a hydrophilic interaction with Met319. In the meantime, Phe385 of the DFG
motif is involved in a weak hydrophobic interaction due to the far distance. The chloro-benzene ring
engages the gatekeeper residue Thr316 via hydrophobic interaction, while the non-substituted benzene
ring occupies the extended hydrophobic pocket, forming π-stacking and Van der Waals interactions
with Leu251, Ala271, and Tyr318. The complex was further stabilized by the formation of a halogen
bond between the backbone of the carbonyl oxygen of Ile314 and the fluorine of the compound 10.
In summary, a marked similarity of interaction was observed with the reference compound except for
the hydrophilic interaction responsible for the inhibitory activity of Lck kinase.
Btk
The docked complex of BTK presented a number of hydrophilic and hydrophobic interactions with
the active site residues Leu408, Val416, Lys430, Thr474, Glu475, Met477, Leu528, Asp539, and Phe540.
The compound occupied the same position consistent with the reference compound. Molecular
dynamics studies revealed that compound 10 binding to BTK, is stable and it was found to involve
in hydrogen bond interactions with key residues of the glycine-rich P-loop like Leu408, Gly409,
and Asp539. Transient hydrogen bond interactions were also detected with crucial active site residues
Glu475 and Met477 of the hinge region, catalytic residue Lys430, and the DFG motif that is crucial for
kinase activity, indicating that compound 10 probably has the appropriate interaction profile with BTK
(Figure 8C).
Akt
According to the binding mode of the Akt complex [37], compound 10 adopts a Y-shape
conformation, where the presence of residues Phe469 and Phe472 that are essential for the regulatory
control of Akt1, make the pocket hydrophobic. Initially, the pyrimidine ring occupies the adenosine
portion of the binding site, forming hydrogen bonding to the hinge region of the kinase through Ala230
(Figure 8D). During the simulation, this hydrogen bond is replaced by hydrophobic interactions, while
the phenyl substituent presents a parallel aromatic interaction with Phe438. Moreover, residues Lys179,
Leu181, and Val164 also stabilize the compound by making hydrophobic contact. In general, theoretical
studies indicate that compound 10 stabilizes Akt via hydrophobic interactions; however, after losing
its interactions with the hinge region, the gatekeeper residue and the DFG motif lead to its low kinase
inhibitory properties.
Abl
The binding mode of the Abl1 complex (Figure 8E) showed that the compound is accommodated
in the lipophilic channel slightly away from the hinge region. The bent conformation of the molecule
does not allow its tight binding to the ATP site. This resultant compound is unable to mimic interaction
with the adenine moiety of ATP. Only a few hydrophobic interactions were observed with Glu305,
Val308, Leu473, and Asp400, but these interactions were also not found to be persistent throughout the
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md simulation. It is hypothesized that the absence of specific interactions of compound 10 with the
residues of the hinge region and DFG motif could be the reason for its inactivity.
Braf
According to the docking calculations, compound 10 is involved in a number of hydrophilic and
hydrophobic interactions with Braf kinase. However, after a short 50 ns production run, the simulated
binding mode provided a different picture to understand the selectivity trend. During the simulation,
these non-bonded interactions were weakened due to loop flipping of the motif from the DGF-in to the
DGF-out conformation. However, in order to accommodate the core pyrimidine ring, the benzene ring
was required to tilt out of the plane due to restricted space. As a result of this movement, intermolecular
interactions broke, which penalized the binding affinity of compound 10 for Braf (Figure 8F).
Alk
The binding interactions of the Alk with compound 10 are depicted in Figure 8G. The complex
obtained after simulation indicates that the compound partially aligned on the reference compound
ceritinib, and it was unable to form any hydrophilic interaction with the active site residues, especially
with the hinge region. A similar type of binding mode was observed in the case of PKC (Figure 8H)
and Cdk2 (Figure 8I).
2.4.5. Binding Free Energy Calculations
MM/PBSA is considered as the best choice for predicting the binding affinities of a protein-ligand
complex with implicit solvent at a low computational cost. It has the potential to recognize the true
binding structure of the complex from docking. In the present study, MM/PBSA was used to re-rank
the nine complexes after a short production run of 50 ns. The calculated binding free energy of all
complexes is presented in Table 4 [38]. The binding position and atomic interaction between protein
kinases and ligand are the main factors that play a role in measuring the binding affinity. The predicted
binding poses of compound 10 significantly overlaid with the reported inhibitors of c-Src, Lck, Btk,
and Akt, but partially aligned in the case of Braf and Alk. According to Table 4, the binding free
energy computed for c-Src, Lck, and Akt complexes was −20.63, −15.64, and −18.09, respectively,
which were more stable than ALK, CDK2, and Abl1 kinases, agreeing with the selectivity profile
observed experimentally. In order to comprehend the effect of the individual energy term in the
binding process, total binding free energy was decomposed into the Eele, Evdw, EGB, and ESURF
energy components. The values of these components indicated that van der Waals (ΔGvdw) energy
contributed significantly to the total binding free energy. The superior contribution of Van der Waals
interaction (Table 4) was in agreement with the fact that compound 10 mainly stabilizes via hydrophobic
interactions with the kinases.
3. Experimental Protocols
3.1. Materials and Methods
Bromoacetone was purchased from ChemService Inc. (West Chester, PA, USA). Anhydrous
dichloromethane, anhydrous pyridine, N,N-dimethylformamide (DMF), and other chemicals and
reagents were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI, USA). The chemical
structures of final products were characterized by nuclear magnetic resonance spectra (1H NMR,
13C NMR) determined on a Bruker (Billerica, MA, USA) NMR spectrometer (400 MHz) or a Varian
(Silicon Valley, CA, USA) NMR spectrometer (500 MHz). 13C NMR spectra were fully decoupled.
Chemical shifts were reported in parts per millions (ppm) using deuterated solvent peak as the standard.
The chemical structures of final products were confirmed by a high-resolution Biosystems QStar Elite
(QStar Technologies, Denver, CO, USA) time-of-flight electrospray mass spectrometer. Details of
procedures and spectroscopic data of the respective compounds are presented below. Final compounds
75
Molecules 2020, 25, 2135
were purified on a Phenomenex (Torrance, CA, USA) Prodigy 10 μm ODS reverse-phase column (2.1 cm
× 25 cm) with a Hitachi (Tokyo, Japan) HPLC system using a gradient system of acetonitrile or methanol
and water (CH3CN/CH3OH/H2O, 0−100%, pH 7.0, 60 min). The purity of final products (>99%) was
confirmed by analytical HPLC. The analytical HPLC was performed on the Hitachi analytical HPLC
system using a C18 Shimadzu (Kyoto, Japan) Premier 3 μm column (150 cm × 4.6 mm) using two
different isocratic systems, and a flow rate of 1 mL/min with UV detection at 265 nm.
3.2. Synthesis
3-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1): Compound 1 was synthesized according to a
previously reported procedure [23].
1-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-2-one (2): Compound 1 (156 mg,
0.73 mmol) and potassium carbonate (200 mg, 1.4 mmol) were taken in dry DMF (10 mL). Bromoacetone
(100 mg, 0.72 mmol) was diluted with dry DMF (5 mL) and was added dropwise to the reaction mixture
at room temperature. The reaction mixture was stirred for 4 h at room temperature. After completion
of the reaction, the solvent was removed under reduced pressure, added water (50 mL) and extracted
with dichloromethane. The organic layer was filtered through filter paper and dried over Na2SO4
(anhydrous). The crude product was further purified on silica gel flash chromatography using
dichloromethane and methanol (0–20%) as eluents. 160 mg, 81% yield. 1H-NMR (CDCl3, 500 MHz,
δ ppm): 8.3 (s, 1H), 7.7 (d, J = 11 Hz, 2H), 7.5–7.5 (m, 3H), 5.2 (s, 2H), 2.2 (s, 3H).13C NMR (CDCl3,
125 MHz, δ ppm): 201.3, 158.1, 156.2, 155.2, 145.4, 132.8, 129.4, 129.3, 128.4, 98.4, 56.1, 27.1. HR-MS
(ESI-TOF) (m/z): calculated for C14H13N5O + H+: 268.1193; found, 268.0852 [M + H]+.
General Procedure for the Synthesis of Pyrazolopyrimidine Chalcones:
Compound 2 (26 mg, 0.1 mmol) was dissolved in ethanol (5 mL). Sodium hydroxide (5 mg, 20 μL
of 250 mg/mL NaOH solution in water) was added to the compound 2 solution. The reaction mixture
solution was stirred for 15 min. Then, a solution of p-methylbenzaldehyde (24 mg, 0.2 mmol) in
ethanol (15 mL) was added to the reaction mixture. The reaction mixture was allowed to stir at room
temperature for 5 h. On completion of the reaction, the reaction mixture was neutralized with dilute
acetic acid in ethanol and purified over reverse phase HPLC using water and methanol as eluents to
obtain pure product 3 (22 mg, 61% yield). A similar procedure was adopted for the synthesis of other
pyrazolopyrimidine derivatives.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-p-tolylbut-3-en-2-one (3). (Yield: 61%).
1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.7 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.6–7.5 (m, 3H), 7.0 (d,
J = 8.2 Hz, 2H), 6.9 (d, J = 8.2 Hz, 2H), 2.3 (s, 3H), 2.9 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 194.3,
157.9, 156.9, 155.8, 146.8, 141.8, 140.5, 132.7, 131.8, 130.7, 129.6, 129.5, 129.4, 128.5, 26.1, 21.5. HR-MS
(ESI-TOF) (m/z): calculated for C22H19N5O + H+: 370.1662; found, 370.1534 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-m-tolylbut-3-en-2-one (4). (Yield: 64%).
1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.6–7.5 (m, 3H),
7.1–7.0 (m, 2H), 6.8 (s, 1H), 6.7 (d, J = 10 Hz, 1H), 2.3 (s, 3H), 2.2 (s, 3H). 13C NMR (CDCl3, 125 MHz,
δ ppm): 194.3, 157.8, 155.1, 154.9, 146.8, 140.6, 133.9, 131.7, 131.5, 130.2, 129.5, 129.4,128.6, 128.4, 26.2,
21.3. HR-MS (ESI-TOF) (m/z): calculated for C22H19N5O + H+: 370.1662; found, 370.1454 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-p-biphenylbut-3-en-2-one (5). (Yield: 59%).
1H-NMR (CDCl3, 500 MHz, δ ppm): 8.0 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 8.2 Hz, 2H), 7.6–7.6 (m, 3H),
7.6–7.4 (m, 9H), 2.3 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 191.9, 147.2, 135.2, 131.1, 130.3, 129.9,
129.9, 129.8, 129.4, 129.0, 128.7, 128.5, 128.5, 127.7, 127.3, 127.3, 127.2, 127.1, 127.0, 126.1, 22.5. HR-MS
(ESI-TOF) (m/z): calculated for C27H21N5O + H+: 432.1819; found, 432.1616 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(4-methoxyphenyl)but-3-en-2-one (6). (Yield:
63%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.6–7.5 (m, 3H),
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6.9 (d, J = 8.9 Hz, 2H), 6.7 (d, J = 8.9 Hz, 2H), 3.7 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm):
194.2, 161.9, 158.0, 156.9, 155.7, 146.9, 140.2, 132.8, 132.7, 130.6, 129.5, 129.4, 128.5, 124.3, 114.4, 98.9, 55.3,
26.0. HR-MS (ESI-TOF) (m/z): calculated for C22H19N5O2 + H+: 386.1612; found, 386.1573 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(4-(dimethylamino)phenyl)but-3-en-2-one
(7). (Yield: 66%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 8 Hz, 2H),
7.6–7.5 (m, 3H), 6.8 (d, J = 9.1 Hz, 2H), 6.4 (d, J = 9.1 Hz, 2H), 2.9 (s, 6H), 2.3 (s, 3H). 13C NMR (CDCl3,
125 MHz, δ ppm): 194.4, 162.1, 158.2, 157.1, 155.9, 147.1, 140.4, 133.0, 132.9, 130.8, 129.7, 129.6, 128.7,
124.5, 114.6, 99.0, 41.4, 26.3. HR-MS (ESI-TOF) (m/z): calculated for C23H22N6O + H+: 399.1928; found,
399.1981 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-pent-3-en-2-one (8). (Yield: 60%). 1H-NMR
(CDCl3, 500 MHz, δ ppm): 8.37 (s, 1H), 7.8–7.7 (m, 2H), 7.6–7.5 (m, 3H), 7.4 (q, J = 7.1 Hz, 1H), 2.3 (s,
3H), 1.8 (d, J = 7 Hz, 3H). 13C NMR (CDCl3, 100 MHz, δ ppm): 157.9, 156.3, 154.8, 141.7, 132.6, 129.6,
129.5, 129.5, 128.5. 128.4, 98.3, 56.2, 26.1, 14.6. HR-MS (ESI-TOF) (m/z): calcd for C16H15N5O + H+:
294.1349; found, 294.099 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(3-nitrophenyl)but-3-en-2-one (9). (Yield:
44%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.5–7.5 (m,
3H), 6.9 (d, J = 8.9 Hz, 2H), 6.7 (d, J = 8.9 Hz, 1H), 2.3 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm):
194.2, 161.9, 158.0, 156.9, 155.7, 146.9, 140.2, 132.8, 132.7, 130.6, 129.5, 129.4, 128.5, 124.3, 114.4, 98.9, 55.3,
26.0. HR-MS (ESI-TOF) (m/z): calculated for C21H16N6O3 +H+: 401.1357; found, 401.0957 [M +H]+,
801.1652 [2M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(4-chlorophenyl)but-3-en-2-one (10). (Yield:
57%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.1 (s, 1H), 7.9 (s, 1H), 7.6 (m, 2H), 7.5–7.5 (m, 3H), 7.2
(d, J = 8.6 Hz, 2H), 6.9 (d, J = 8.6 Hz, 2H), 2.4 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 192.4,
153.7, 153.5, 149.5, 147.2, 140.6, 137.9, 132.5, 131.5, 131.3, 130.9, 130.4, 130.1, 129.5, 128.1, 97.6, 55.3, 25.8.
HR-MS (ESI-TOF) (m/z): calculated for C21H16ClN5O + H+: 390.1116; found, 390.0951 [M + 1]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(2,4-dichlorophenyl)but-3-en-2-one (11).
(Yield: 58%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.5–7.5
(m, 3H), 6.9 (s, 1H), 6.7 (d, J = 8.6 Hz, 2H), 2.6 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 192.2, 153.7,
136.9, 136.2, 130.9, 130.2, 130.1, 129.8, 129.0, 128.2, 128.1, 127.5, 127.5, 97.6, 66.4, 53.4, 25.9. HR-MS
(ESI-TOF) (m/z): calculated for C21H15Cl2N5O + H+: 424.0726; found, 424.1220 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(2-chlorophenyl)but-3-en-2-one (12). (Yield:
57%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 8.2 (s, 1H), 7.6–7.5 (m, 5H), 7.3–7.2 (m, 4H), 2.6
(s, 3H). 13C-NMR (CDCl3, 125 MHz, δ ppm): 153.6, 153.3, 149.1, 146.5, 138.2, 132.0, 130.8, 130.2, 130.1,
129.3, 128.9, 128.1, 126.9, 52.5, 25.9. HR-MS (ESI-TOF) (m/z): calcd for C21H16ClN5O +H+: 390.1116;
found, 390.1427 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(2-fluorophenyl)but-3-en-2-one (13). (Yield:
62%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.7 (d, J = 7 Hz, 2H), 7.6–7.5 (m,
3H), 7.2–6.9 (m, 4H), 2.3 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 193.8, 158.1, 155.6, 147.4, 132.8,
132.7, 130.3, 131.7, 129.7, 129.5, 129.5, 129.3, 129.2, 128.4, 128.4, 128.4, 98.7, 26.2. HR-MS (ESI-TOF) (m/z):
calculated for C21H16FN5O + H+: 374.1412; found, 374.1526 [M + H]+.
3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(4-fluorophenyl)but-3-en-2-one (14). (Yield:
64%). 1H-NMR (CDCl3, 500 MHz, δ ppm): 8.1 (s, 1H), 7.8 (s, 1H), 7.5–7.4 (m, 5H), 6.9 (dd, J = 14 Hz,
J = 5.6 Hz, 2H), 6.8 (t, J = 7.6 Hz, 2H), 2.4 (s, 3H). 13C NMR (CDCl3, 125 MHz, δ ppm): 192.5, 153.7,
153.5, 147.2, 140.7, 132.5, 132.4, 130.9, 130.1, 130.0, 128.1, 128.1, 116.7, 116.5, 25.7. HR-MS (ESI-TOF)
(m/z): calculated for C21H16FN5O + H+: 374.1412; found, 374.1679 [M + H]+.
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3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-phenyl but-3-en-2-one (15). (Yield: 59%).
1H-NMR (CDCl3, 500 MHz, δ ppm): 8.2 (s, 1H), 8.0 (s, 1H), 7.7–7.6 (m, 5H), 7.4–6.9 (m, 5H), 2.5 (s, 3H).
13C-NMR (CDCl3, 125 MHz, δ ppm): 192.5, 153.7, 153.5, 147.2, 140.7, 132.5, 132.4, 130.9, 130.1, 130.0,
128.1, 128.1, 116.7, 116.5, 25.7. HR-MS (ESI-TOF) (m/z): calculated for C21H17N5O + H+: 356.1506;
found, 356.1703 [M + H]+.
3.3. Kinase Enzyme Assay
3.3.1. c-Src Kinase Activity Assay
The effect of compounds on the activity of c-Src kinase was assessed using a Transcreener®
ADP [2,8] fluorescence intensity (FI) Assay, from Bell Brook Labs, Madison, WI, USA, (catalog no.
3013-1K) according to the manufacturer’s protocol. A 384-well low-volume black non-binding surface
round-bottom microplate was purchased from Corning Inc. (Corning, NY, USA) (#3676). In summary,
the kinase reaction was started in the 384-well low volume black microplate with the incubation of 2.5μL
of the reaction cocktail (0.7 nM of His6-Src kinase domain in kinase buffer) with 2.5 μL of prediluted
compounds (dissolved in 10% DMSO, 4× target concentration) for 10 min at room temperature using
microplate shaker. The reaction cocktail was made using the kinase buffer HEPES (200 mM, pH 7.5),
MgCl2 (16 mM), EGTA (8 mM), DMSO (4%), Brij-35 (0.04%), and 2-mercaptoethanol (43 mM). The kinase
reaction was started by adding 5 μL of ATP/substrate (40 μM/600 μM) cocktail and incubated for 30 min
at room temperature on a microplate shaker. Src optimal peptide (AEEEIYGEFEAKKKK) was used
as the substrate for the kinase reaction. The kinase reaction was stopped by adding 10 μL of the 1×
ADP Detection Mixture to the enzyme reaction mixture and mixed using a plate shaker. The mixture
was incubated at room temperature for 1 h, and the fluorescence intensity was measured. The 1×
ADP Detection Mixture was prepared by adding ADP2 Antibody-IRDyeR QC-1 (10 μg/mL) and ADP
Alexa594 Tracer (8 nM) to Stop and Detect Buffer B(1×). The fluorescence Intensity measurements were
performed using a fluorescence intensity optical module using the excitation of 580 nm and emission
of 630 nm with bandwidths of 10 nm by Optima, BMG Labtech microplate reader (BMG Labtech,
Ortenberg, Germany). The IC50 values of the compounds were calculated using ORIGIN 6.0 (Origin
Lab, Microcal Software, Inc. Northhampton, MA, USA) software. IC50 is the concentration of the
compound that inhibited enzyme activity by 50%. All the experiments were carried out in triplicate.
3.3.2. Evaluation of Compound 10 Against a Panel of Kinases (Abl1, Akt1, Alk, Braf, Btk, Cdk2, cSrc,
Lck, and PKCa)
Compound 10 was evaluated for inhibitory activity against Abl1, Akt1, Alk, Braf, Btk, Cdk2, cSrc,
Lck, and PKCa, in duplicate by Reaction Biology Corporation. Compounds were tested in a five-dose
IC50 mode with four-fold serial dilution starting at 20 μM. Control compounds Staurosporine and
GW5074 were tested in a 10-dose IC50 starting at 20 μM with a four-fold or three-fold serial dilution,
respectively. All kinase reactions were performed at 200 μM ATP. The compounds were pre-incubated
with the enzyme and substrate mixture about 20 min, and then ATP was added to start the reaction.
The reaction was 2 h at room temperature. Curve fits were performed when the activities at the highest
concentration of compounds were less than 65%. The detailed experimental procedure is provided
here. An IC50 value of less than 0.04 nM or higher than 1 μM is estimated based on the best curve
fitting available. The substrates for kinases are shown in Table 5.
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Abl1 PR4348B 0.25 ABLtide 20 μM
c-Src P3044 0.6 pEY 0.2 mg/mL
Akt1 PR3878D 8 Crosstide 20 μM
Alk PV3867 1.5 pEY 0.2 mg/mL
Cdk2/Cyclin A1 C29-10BG 15 Histone H1 20 μM
PKCa PR1455C 0.5 Histone H1 + LipidActivator 20 μM
Braf PR6995A 30 MEK1 (K97R) 5 μM
Lck P3043 8 pEY +Manganese 0.2 mg/mL
Btk PV3363 8 pEY 0.2 mg/mL
Base Reaction buffer was prepared from 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02%
Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, and 1% DMSO. Required cofactors were added
individually to each kinase reaction. Testing compounds were dissolved in 100% DMSO to a specific
concentration. The serial dilution was conducted by Integra Viaflo Assist in DMSO. The substrate was
prepared in a freshly prepared reaction buffer. The required cofactors for each kinase were added to
the substrate solution. The kinase was added into the substrate solution, and the solution was gently
mixed. The compounds in 100% DMSO were added into the kinase reaction mixture by Acoustic
technology (Echo550; nanoliter range) and incubated for 20 min at room temperature. P-ATP (Specific
activity 10 μCi/μl) was added into the reaction mixture to initiate the reaction. The mixture was
incubated for 2 h at room temperature. The radioactivity was detected using the filter-binding method.
The kinase activity data were expressed as the percentage remaining kinase activity in test samples
compared to vehicle (dimethyl sulfoxide) reactions. IC50 values, and curve fits were obtained using
GraphPad Prism software (version 7, Informer Technologies, Inc., Los Angeles, CA, USA).
3.4. Cell Culture and Cell Proliferation Assay
3.4.1. Cell Culture
Human leukemia cell line CCRF-CEM (ATCC no. CCL-119), human ovarian adenocarcinoma cell
line SK-OV-3 (ATCC no. HTB-77), human breast carcinoma cell line MDA-MB-231 (ATCC no.HTB-26),
and human colon adenocarcinoma cell line HT-29 (ATCC no. HTB-38) were obtained from American
Type Culture Collection. Cells were grown on 75 cm2 cell culture flasks with RPMI-16 medium (for
leukemia cells) and EMEM (Eagle’s minimum essential medium) (for SK-OV-3, HT-29, MDA-MB-231
cells), supplemented with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin solution
(10,000 units of penicillin and 10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5%
CO2, 95% air at 37 ◦C.
3.4.2. Cell Proliferation Assay
The cell proliferation assay was carried out using a CellTiter 96 aqueous one-solution cell
proliferation assay kit (Promega, Madison, WI, USA). Briefly, upon reaching about 75–80% confluence,
5000 cells/well were plated in 96-well microplate in 100 μL of the medium. After seeding for 24 h,
the cells were treated with 50 μM compound in triplicate. Doxorubicin (10 μM) was used as a positive
control. At the end of the sample exposure period (72 h), 20 μL of CellTiter 96 aqueous solution
was added. The plate was returned to the incubator for 1 h in a humidified atmosphere at 37 ◦C.
The absorbance of the formazan product was measured at 490 nm using a microplate reader. The blank
control was recorded by measuring the absorbance at 490 nm with wells containing medium mixed
with CellTiter 96 aqueous solution but no cells. The percentage of cell survival was calculated as the
OD value of cells treated with test compound − OD value of culture medium/(OD value of control cells
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− OD value of culture medium) × 100%. The same strategy was used for generating a dose-response
graph for compound 10.
3.5. Molecular Modeling
3.5.1. Target Fishing
Potential targets were identified against the phenylpyrazolopyrimidine scaffold using a
combination of information integration, chemometric methods, and data mining approaches. Initially,
targets involved in breast, ovarian, and colorectal cancer pathways were extracted from the database
of KEGG. In the next step, protein network association servers STRING, STITCH, and SEA were used
to characterize the protein-ligand interactions. Similarly, the PhPP scaffold was also searched using
different search engines to understand protein-ligand interactions. Based on the above-mentioned
information, we selected fourteen different targets, including Btk, Itk, c-Src, EGFR [39], Braf, Fyn, Lyn,
Hck, Cdk2/4, Alk, Akt1 Lck, PKC, and Abl1 kinase. To understand the binding mechanism of active
compound 10 against all selected targets, molecular docking and MD simulations were performed.
3.5.2. Preparation of Complexes
Crystal structures of the Anaplastic lymphoma kinase [PDB ID: 4MKC], ABL1 kinase [PDB ID:
6HD4], Protein kinase B also known as AKT [PDB ID: 4GV1], bruton tyrosine kinase [PDB ID: 6DIS],
BRAF [PDB ID: 6B8U], c-Src kinase [PDB ID: 2SRC], CDK2 [PDB ID: 4KD1], LCK [PDB ID: 2OFU],
ITK [PDB ID: 4HUC], EGFR [PDB ID: 4HJO], FYN [PDB ID: 2DQ7], LYN [PDB ID: 2ZV9], HCK [PDB
ID: 1QCF], and PKCa [PDB ID: 3IW4] were retrieved from RCSB Protein Databank. The missing part
of the starting structures was constructed using MOE software (Molecular Operating Environment,
v2016.08, 2016). Compound partial charges were derived with the MMFF94x force field. All stabilizing
agents, water molecules, and ions present in the crystal structures were removed. The protonate 3D
module in MOE was used for assigning the protonation state to every titratable residue at physiological
conditions within the complexes. MOE docking suite was employed for docking studies. The standard
default settings were used with the London dG scoring function as a fitness function in all calculations.
3.5.3. MD Simulations
After analysis of docking results, nine complexes were subjected to all-atom MD simulation using
the graphics processing unit (GPU) version of the PMEMD.cuda engine provided with Amber18 [40].
The gaff [41] and ff14SB force field [42] were implemented to ligand and protein in all simulations,
respectively. Each complex was neutralized by adding counter ions, and the systems were solvated by
a cubic box of the TIP3P water model with a 10 Å box size from the solute. Systems were relaxed by
adjusting hydrogen position, while 1000 cycles of steepest descent, and 5000 cycles of the conjugate
gradient with restraints of 100 kcal·mol−1 were applied on heavy atoms. Finally, another minimization
of 5000 steps was performed to relax the system without any restraint. It was followed by equilibration
of each system by gradual heating from 0 K to 300 K in the NVT ensemble. Systems were further
equilibrated under the NPT ensemble (Pressure = 1 atm). The production run of 50 ns was performed
for each system using the isothermal-isobaric (NPT) ensemble at constant temperature and pressure
with periodic boundary conditions. The Particle Mesh Ewald Method (PMEM) [43] was used to
calculate long-range electrostatic interactions with cut off value of 8 Å for the non-bonded (electrostatics
and Van der Waals) interactions. An integration time step of 2 fs was set to integrate Newton’s equations
of motion. The SHAKE algorithm [44] was employed to restrain the bonds involving hydrogen atoms.
The trajectories were analyzed using CPPTRAJ module incorporated in AMBER suite. All visualization
was performed using Chimera and VMD.
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3.5.4. MM/PBSA Calculations
The binding free energy calculation for each complex was performed using the MM(GB/PB)SA
method based on 1000 frames extracted from the 50 ns trajectory. The equations associated with
binding free energy calculation were as follows:
ΔG = Gcomplex − (Greceptor + Gcompound) (1)
G = H − TS (2)
H = Evdw + Eele + Eint + Ggb + Gsurf (3)
The total binding free energy is ΔG, whereas the free energies for the complex, receptor,
and compound are represented as Gcomplex, Greceptor, and Gcompound, respectively. The terms H
and TΔS were used for the contribution of enthalpy and entropy. The binding free energy further
decomposed into electrostatic (Eele), Van der Waals interaction (Evdw), internal energy (Eint), and polar
(Ggb) and non-polar desolvation energy (Gsurf). The value of the dielectric constant was set to 1,
and the external was set to 80 for solute protein (εin). The Generalized Born (GB) model established
by Onufriev (GBOBC1) with modified Bondi radii (mbondi2) and igb = 2 implemented in AMBER18
was used to calculate the electrostatic contribution to the solvation free energy. The non-polar surface
area was calculated using the LCPO model. The offset (β) and surface tension (γ) values were set to
0.92 kcal/mol and 0.00542 kcal/(mol·Å2), respectively.
4. Conclusions
A number of novel N1-(α,β-alkene) substituted phenylpyrazolopyrimidine (PhPP) derivatives
with acetyl and functionalized phenyl groups at α- and β-positions were synthesized, and they showed
modest inhibitory activity (IC50 = 21.7–192.1 μM) against c-Src kinases. A number of para-chlorophenyl
substituted compounds, 10 and 11, consistently inhibited the cell proliferation 72–96 h in all cell lines
and were more effective against HT-29 cells. Compound 10 was also found to be modestly active
against c-Src, Lck, and Btk. The target-based study of these compounds was performed by text mining,
similarity search, and ligand-protein interaction pattern to identify potential targets. Further MD
simulation and binding free energy calculations were carried out to discriminate the selectivity of
the investigated compound with a panel of different kinases and provide more in-depth structural
insight into the interaction pattern involved in the inhibition process. The structural and energetic
features highlighted in this study can provide a theoretical basis for further research on selective
protein kinase inhibitors.
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Abstract: In the last step of estrogen biosynthesis, aromatase enzyme catalyzes the conversion of
androgens to estrogens. Aromatase inhibition is an important way to control estrogen-related diseases
and estrogen levels. In this study, sixteen of benzimidazole-triazolothiadiazine derivatives have been
synthesized and studied as potent aromatase inhibitors. First, these compounds were tested for their
anti-cancer properties against human breast cancer cell line (MCF-7). The most active compounds 5c,
5e, 5k, and 5m on MCF-7 cell line were subject to further in vitro aromatase enzyme inhibition assays
to determine the possible mechanisms of action underlying their activity. Compound 5e showed
slight less potent aromatase inhibitory activity than that of letrozole with IC50 = 0.032 ± 0.042 μM,
compared to IC50 = 0.024 ± 0.001 μM for letrozole. Furthermore, compound 5e and reference drug
letrozole were docked into human placental aromatase enzyme to predict their possible binding
modes with the enzyme. Finally, ADME parameters (absorption, distribution, metabolism, and
excretion) of synthesized compounds (5a–5p) were calculated by QikProp 4.8 software.
Keywords: aromatase; MCF-7; NIH3T3; benzimidazole; triazolothiadiazine; docking; ADME
1. Introduction
Aromatase is a member of the cytochrome P450 enzyme that catalyzes the biosynthesis of
estrogens from androgens [1,2]. Estrogen levels have been shown to be higher in breast cancer
cells. Inhibition of aromatase is one of the effective current therapeutic strategies for controlling
estrogen-dependent breast cancer. Therefore, one of the commonly used classes of drugs for the
management of estrogen-dependent cancer is aromatase inhibitors (AIs) [1,3,4].
Aromatase inhibitors that have been used clinically can be categorized as first-, second-, and third
generations based on their evolution time or steroidal or steroidal or non-steroidal aromatase inhibitors
(NSAIs) based on their structural similarity with steroids [5,6].
Aminoglutethimide is the prototype nonsteroidal inhibitor of aromatase. Problems with the
side effects and selectivity of aminoglutethimide led to the development of the second-generation
of nonsteroidal aromatase inhibitor (Fadrazole bearing imidazole structure) [7]. However, this
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compound still has some nonselective inhibitory activity with respect to progesterone, corticosterone,
and aldosterone biosynthesis. Competitive nonsteroidal inhibitors can also be constructed with
a triazole ring, which is found in the third generation of aromatase inhibitors [8–10]. Most of the
nonsteroidal aromatase inhibitors of therapeutic importance act covalently bind to the substrate-binding
site of aromatase by coordinate the heme iron [11–13]. Especially, the heterocyclic nitrogen atom of
triazole and imidazole plays an important role by coordinating with the heme iron of the aromatase
enzyme [12,13]. Some studies have shown that imidazole and triazole derivatives have promising
aromatase inhibition [14–17].
Recent clinical studies have shown that aromatase inhibitors, especially the third-generation, are
more effective than fulvestrant and tamoxifen because of their lower side effects and higher clinical
efficacy. Nevertheless, the development of acquired resistance after prolonged AIs therapy, undesirable
side effects (bone loss, cardiac events, increased rash, insomnia, headaches, and arthralgia) limits their
use in clinical practice. Thus, the search for new potent molecules that impair cancer growth, strongly
inhibit aromatase enzyme, and present fewer side effects is of major importance [18–21].
In the previous study, 3-[4-(5-methyl-1H-benzo[d]imidazol-2-yl)phenyl]-6- (substituted phenyl)
-7H-[1,2,4] triazolo [3,4-b] [1,3,4]thiadiazines derivatives have been synthesized and promising
compounds have been obtained that need further development as a new class of aromatase
inhibitors [22]. In this study, new benzimidazole-triazolothiadiazine derivatives were synthesized
and structure of these compounds was characterized by spectroscopic data. Their antiproliferative
activities against MCF-7 were evaluated. To identify the possible modes of action, aromatase inhibition
experiments were performed for the most active compounds against the MCF-7 cell line. Finally, in
silico prediction of pharmacokinetic profiles (ADME) were calculated for physicochemical properties
of these drug candidates.
2. Results and Discussion
2.1. Chemistry
Synthesis of the target compounds was accomplished according to the steps illustrated in Scheme 1.
Substituents of the synthesized compounds (5a–5p) were shown in Table 1. The starting intermediated
compound (1a,1b) was prepared by the reaction of 1,2-phenylenediamine and sodium metabisulfite
with 4-formylbenzoic acid methyl ester as described in a previous study [23]. The ester derivative
(1a,1b) reacted with hydrazine hydrate producing compounds 2a, 2b in a microwave synthesis reactor.
Then, the compounds-(5-substitüe-1H-benzimidazol-2-yl)benzoic acid hydrazide derivatives (2a,2b)
were treated with carbon disulfide in NaOH solution affording, after acidic treatment, compounds
3a, 3b. The reaction of compound 3a, 3b with hydrazine hydrate in the presence of ethanol produced
compounds 4a, 4b. Then cyclization of compounds 4a, 4b with appropriate phenacyl bromide in
the presence of anhydrous ethanol provided the desired final products (5a–5p). The characterization
of these new derivatives was done by their spectroscopic (1H NMR, 13C NMR and Mass) data.
1H NMR and 13C NMR spectra of the synthesized compounds were observed at the expected region.
Mass spectra (HRMS) of all the synthesized compounds showed that the molecular ion [M + H]+ peak
is in agreement with their molecular formula (see Supplementary Materials).
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Scheme 1. The reaction sequence for the synthesis of the compounds (5a–5p).
Table 1. The synthesized compounds (5a–5p).
Comp. R R1 R2
5a -H -H -H
5b -H -Cl -H
5c -H -F -H
5d -H -CH3 -H
5e -H -CN -H
5f -H -Br -H
5g -H -F -F
5h -H -Cl -Cl
5ı -Cl -H -H
5j -Cl -Cl -H
5k -Cl -F -H
5l -Cl -CH3 -H
5m -Cl -CN -H
5n -Cl -Br -H
5o -Cl -F -F
5p -Cl -Cl -Cl
2.2. Cytotoxicity Assay
The newly synthesized compounds were evaluated for their in vitro anticancer potential against
MCF-7 breast cancer cell lines by MTT assay [24] using cisplatin as a reference standard. The 50%
inhibitory concentration (IC50) values were determined for these compounds. In addition, the cytotoxic
activities of compounds 5c, 5e, 5k, and 5m were assessed against healthy NIH3T3 [25] cells, in order to
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express the selectivity toward carcinogenic cells. The IC50 values of test compounds were determined
as the mean IC50 of 4 independent experiments. Results are presented in Table 2, as IC50 values are
in μM and revealed that some of the tested compounds were remarkably more cytotoxic than the
cisplatin against MCF-7 cell lines. Concerning MCF-7 cell line, the most potent compounds were the
4-cyano derivatives 5e and 5m with IC50 = 0.016 ± 0.001 and 0.018 ± 0.001 μM, respectively compared
to IC50 = 0.020 ± 0.009 μM for the reference drug cisplatin. Furthermore, the most promising activity
was observed for the compounds 5c and 5k bearing 4-fluorophenyl derivatives with IC50= 0.119 ± 0.005
and 0.110 ± 0.005 μM, respectively compared to IC50 = 0.020 ± 0.009 μM for the reference drug cisplatin.
Table 2. IC50 (μM) values of compounds (5a–5p) (n = 4).
Comp. MCF-7 NIH3T3
5a 0.142 ± 0.007 -
5b 0.0414 ± 0.001 -
5c 0.119 ± 0.005 81.8 ± 2.4
5d 0.194 ± 0.006 -
5e 0.016 ± 0.001 ≥1000
5f 0.318 ± 0.019 -
5g 0.245 ± 0.004 -
5h 0.342 ± 0.017 -
5ı 0.205 ± 0.005 -
5j 0.258 ± 0.011 -
5k 0.110 ± 0.005 77.6 ± 2.1
5l 0.352 ± 0.019 -
5m 0.018 ± 0.001 ≥1000
5n 0.264 ± 0.011 -
5o 0.373 ± 0.011 -
5p 0.147 ± 0.001 -
Cisplatin 0.020 ± 0.009 ≥1000
Benzimidazole-triazolothiadiazine derivatives led to a promising increase in the anti-proliferative
activity. The synthesized compounds can be divided into two groups as nonsubstituted benzimidazole
and 5-chlorobenzimidazole. Test compounds showed variable activities against MCF-7. In particular,
compounds 5e and 5m displayed the highest cytotoxic activity against MCF-7 cell line. The most
active compounds 5e and 5m carried a 4-cyanophenyl substituent. The chlorine substituent in the fifth
position (5m) of the benzimidazole ring did not significantly affect the activity. Compounds 5c and 5k
carrying fluorine substituents in the fourth position of the phenyl ring showed lower activity than
compounds 5e and 5m bearing cyano group in the fourth position of the phenyl ring.
2.3. Aromatase Inhibition Assay
The in vitro anti-aromatase activity of the most active compounds 5c, 5e, 5k, and 5m was valued
using commercial fluorometric assay kit (Aromatase-CYP19A Inhibitor Screening kit, Bio Vision) with
letrozole as the reference drug. Results are presented in Table 3. The IC50 values of compounds were in
the sub-micromolar range (2.276 ± 0.106–0.03 2 ± 0.001 μM). The best value was shown by compound
5e with IC50 value (0.032 ± 0.001 μM).
Table 3. IC50 (μM) values of compounds 5c, 5e, 5k, 5m, and letrozole.
Comp. Aromatase Inhibition
5c 1.716 ± 0.042
5e 0.032 ± 0.001
5k 2.276 ± 0.106
5m 1.562 ± 0.064
Letrozole 0.024 ± 0.001
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2.4. Molecular Docking
After the most active derivative was selected as compound 5e according to in vitro aromatase
enzyme inhibition assay and letrozole, molecular docking studies were performed to explain its
binding modes with human aromatase enzyme active site. For this purpose, the crystal structure of
human aromatase enzyme (PDB ID: 3EQM) [26] was retrieved from the Protein Data Bank server
(www.pdb.org). The 2D and 3D docking poses of compound 5e are presented in Figures 1 and 2.
The docking poses of letrozole are presented in Figures 3 and 4.
According to docking poses, it is understood that compound 5e displays compatible settlement
with the enzyme active region. The benzimidazole ring in the structure forms two π–π interactions with
Arg115 and Phe134. Also, it can be seen from 2D docking pose, this compound is in interaction with
Hem molecules and Cys437 via its nitrogen atoms of triazolothiadiazine ring by salt bridge. There is
another π–π interaction between 4-cyanophenyl ring and HEM molecule. The nitrogen atom of cyano
group at C-4 position of phenyl ring interacts with hydroxyl of Ser314 doing hydrogen bonding. It is
thought that this interaction is important for compound 5e in terms of explaining its inhibitory activity.
It is seen that the presence of an electron withdrawing group such as cyano at this position is a positive
contribution to the activity.
As seen in the docking poses, letrozole is settled down in the enzyme active site properly.
For letrozole, it is seen that benzonitrile ring creates π–π interaction with HEM molecule. Another π–π
interaction is observed between 1,2,4-triazole ring and Arg115. Also, this 1,2,4-triazole ring forms
two hydrogen bonds via its second and fourth nitrogen atoms with amino groups of Ala438 and
Arg115, respectively.
Figure 1. Two-dimensional interaction mode of compound 5e in the enzyme active site (Human
aromatase PDB Code: 3EQM).
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Figure 2. The interacting mode of compound 5e in the active region of human aromatase. The inhibitor,
colored with maroon, and the important residues, colored with purple, in the active site of the enzyme
are presented by tube model.
Figure 3. Two-dimensional interaction mode of letrozole in the enzyme active site (Human aromatase
PDB Code: 3EQM).
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Figure 4. The interacting mode of letrozole in the active region of human aromatase. The inhibitor,
colored with orange, and the important residues, colored with turquoise, in the active site of the enzyme
are presented by tube model.
2.5. Theoretical Determination of ADME Properties
QikProp allows to provide acceptable ranges for comparing the predicted properties of compounds
with those of 95% of known drugs and estimate drug-likeness properties. The drug-likeness of a
compound was assessed according to Jorgensen’s rule of three [27], which regards PCaco (>22 nm/s),
logS (>−5.7), primary metabolites (PM) (<7), and Lipinski’s rule of five [28], which considers number
of hydrogen bond acceptors (≤10) and donors (≤5), molecular weight (<500 Da), and octanol/water
partition coefficient (≤5).
Table 4. presents the predicted ADME properties of all compounds. According to Lipinski’s rule
of five and Jorgensen’s rule of three, all compounds (5a–5p) are in accordance with the rule by causing
no more than one violation. Consequently, according to predictions of ADME properties, it can be
suggested that the active compounds may have a good pharmacokinetic profile.
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3. Materials and Methods
3.1. Chemistry
Whole chemicals employed in the synthetic procedure were purchased from Sigma-Aldrich
Chemicals (Sigma-Aldrich Corp., St. Louis, MO, USA) or Merck Chemicals (Merck KGaA, Darmstadt,
Germany). Melting points of the obtained compounds were determined by MP90 digital melting point
apparatus (Mettler Toledo, OH, USA) and were uncorrected. Microwave syntheses were realized by
using a Monowave 300 high-performance microwave reactor (Anton-Paar, Austria). 1H NMR and 13C
NMR spectra of the synthesized compounds were registered by a Bruker 300 MHz and 75 MHz digital
FT-NMR spectrometer (Bruker Bioscience, Billerica, MA, USA) in DMSO-d6, respectively. Splitting
patterns were designated as follows: s: singlet; d: doublet; t: triplet; m: multiplet in the NMR spectra.
Coupling constants (J) were reported as Hertz. M+1 peaks were determined by Shimadzu LC/MS
ITTOF system (Shimadzu, Tokyo, Japan). All reactions were monitored by thin-layer chromatography
(TLC) using Silica Gel 60 F254 TLC plates (Merck KGaA, Darmstadt, Germany).
3.1.1. Synthesis of 4-(5-substitüe-1H-benz[d]imidazol-2-yl)benzoic Acid Methyl Ester (1a,1b)
Yields: 82–78%. 4-(5-substitüe-1H-benz[d]imidazol-2-yl)benzoic acid hydrazide derivatives (2a,2b)
(yields: 76–72%) and 5-[4-(5(6)-substituted-1H-benz[d]imidazol-2-yl)phenyl]-1,3,4-oxadiazole-2-thiol
derivatives (3a,3b) (yields: 78–7 %) were prepared following the reported procedures [23].
3.1.2. 4-Amino-5-(4-(5-substitüe-1H-benzo[d]imidazol-2-yl)phenyl)-4H-1,2,4-triazole-3-thiol (4a,4b)
Compound 3a or 3b (0.02 mol) was dissolved in ethanol. Hydrazine hydrate (5 mL) was added
to the mixture. The reaction mixture was heated at 240 ◦C and 10 bar for 10 min under microwave
synthesis reactor (Anton-Paar Monowave 300). After the reaction ended, the product was washed with
water, dried, and crystallized using ethanol (96%) [22]. Yields: 68–64%.
3.1.3. 3-(4-(5-substitüe-1H-benzo[d]imidazol-2-yl)phenyl)-6-(substitüephenyl)-7H-[1,2,4]triazole
[3,4-b][1,3,4]thiadiazine (5a–5p)
Compound 4a or 4b (0.003 mol) and appropriate phenacyl bromide (0.003 mol) in ethanol was
heated under reflux for 8 h. After the reaction ended, the product was filtered and dried [22].
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-phenyl-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine (5a):
Yields: 77%. Mp 230.7–232.9 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.52 (2H, s, -CH2-), 7.52-7.55
(2H, m, aromatic CH), 7.59–7.67 (3H, m, Aromatic CH), 7.83–7.86 (2H, m, aromatic CH), 8.06–8.09
(2H, m, aromatic CH), 8.34 (2H, d, J=8.67 Hz, 1,4-disubstitutedbenzene), 8.43 (2H, d, J=8.64 Hz,
1,4-disubstitutedbenzene). 13C-NMR (75 MHz, DMSO-d6): δ = 23.31, 114.89, 125.84, 126.55, 128.13,
128.50, 129.13, 129.65, 132.64, 133.78, 134.17, 143.96, 149.21, 151.22, 156.82, 163.07. HRMS (m/z): [M +H]+
calcd for C23H16N6S: 409.1224; found: 409.1230.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5b): Yields: 72%. Mp 190.9–192.6 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.50 (2H, s, -CH2-), 7.56–7.59
(2H, m, aromatic CH), 7.65–7.70 (3H, m, aromatic CH), 7.86–7.89 (2H, m, aromatic CH), 8.06–8.09
(2H, m, aromatic CH), 8.31 (2H, d, J=8.61 Hz, 1,4-disubstitutedbenzene), 8.57 (2H, d, J=8.61 Hz, 1,4-
Disubstitutedbenzene). 13C-NMR (75 MHz, DMSO-d6): δ=23.27, 114.67, 125.49, 126.35, 128.87, 129.11,
129.32, 129.45, 129.73, 129.92, 130.11, 130.71, 132.62, 133.01, 137.50, 144.01, 148.52, 151.17, 156.87. HRMS
(m/z): [M + H]+ calcd for C23H15N6SCl: 443.0843; found: 443.0840.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-fluorophenyl)-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5c): Yields: 69%. Mp 274.2–277.1 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.50 (2H, s, -CH2-), 7.12 (1H, s,
aromatic CH), 7.29 (1H, s, aromatic CH), 7.46–7.52 (4H, m, aromatic CH), 7.81–7.84 (2H, m, aromatic CH),
8.33 (2H, d, J = 8.64 Hz, 1,4-disubstitutedbenzene), 8.51 (2H, d, J=8.76 Hz, 1,4-disubstitutedbenzene).
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13C-NMR (75 MHz, DMSO-d6): δ = 23.27, 114.32, 114.90, 116.76 (d, J = 21.98 Hz), 126.40, 127.68, 127.96,
128.43, 128.56, 128.69, 128.87, 128.95, 130.32 (d, J = 2.77 Hz), 130.78 (d, J = 8.43 Hz), 134.60, 143.66,
151.30, 155.71, 166.36 (d, J = 249.53 Hz). HRMS (m/z): [M + H]+ calcd for C23H15N6FS: 427.1137; found:
427.1136.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-methylphenyl)-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5d): Yields: 70%. Mp 207.5–209.1 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 2.41 (3H, s, CH3), 4.49 (2H,
s, -CH2-), 7.41 (2H, d, J = 8.13 Hz, 1,4-disubstitutedbenzene), 7.52–7.55 (2H, m, benzimidazole CH),
7.83–7.86 (2H, m, benzimidazole CH), 7.97 (2H, d, J = 8.25 Hz, 1,4-disubstitutedbenzene), 8.33 (2H, d,
J = 8.58 Hz, 1,4-disubstitutedbenzene), 8.43 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene). 13C-NMR
(75 MHz, DMSO-d6): δ=21.55, 23.18, 114.86, 125.84, 126.42, 128.08, 128.24, 128.47, 129.02, 129.22, 129.71,
130.20, 130.90, 134.11, 142.96, 144.00, 147.35, 149.13, 151.07, 156.69. HRMS (m/z): [M +H]+ calcd for
C24H18N6S: 423.1381; found: 423.1386.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-cyanophenyl)-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5e): Yields: 68%. Mp 259.3–263.1 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.53 (2H, s, -CH2-),
7.56–7.58 (2H, m, benzimidazole CH), 7.85–7.88 (2H, m, benzimidazole CH), 8.06 (2H, d, J = 8.37 Hz,
1,4-disubstitutedbenzene), 8.21 (2H, d, J = 8.46 Hz, 1,4-disubstitutedbenzene), 8.30 (2H, d, J = 8.49 Hz,
1,4-disubstitutedbenzene), 8.42 (2H, d, J = 8.49 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz,
DMSO-d6): δ = 23.35, 114.58, 114.71, 118.68, 125.51, 126.39, 127.20, 128.48, 128.74, 128.87, 129.19, 129.43,
129.84, 133.03, 133.44, 137.97, 143.97, 148.72, 151.25, 155.45. HRMS (m/z): [M +H]+ calcd for C24H15N7S:
434.1186; found: 434.1182.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-bromophenyl)-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5f): Yields: 74%. Mp 284.8–286.2 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.50 (2H, s, -CH2-), 7.53–7.56
(3H, m, aromatic CH), 7.81–7.85 (3H, m, aromatic CH), 7.99–8.02 (2H, m, aromatic CH), 8.32 (2H, d,
J = 8.64 Hz, 1,4-disubstitutedbenzene), 8.42 (2H, d, J = 8.70 Hz, 1,4-disubstitutedbenzene). 13C-NMR
(75 MHz, DMSO-d6): δ = 23.20, 114.91, 125.04, 125.96, 126.50, 127.03, 128.56, 129.19, 130.09, 130.90,
132.37, 132.67, 133.00, 142.94, 143.96, 147.34, 149.17, 151.22, 155.95. HRMS (m/z): [M +H]+ calcd for
C23H15N6SBr: 487.0311; found: 487.0335.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(2,4-difluorohenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5g): Yields: 72%. Mp 208.5–210.7 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.42 (2H, s,
-CH2-), 7.46–7.49 (4H, m, aromatic CH), 7.79–7.82 (3H, m, aromatic CH), 7.29–7.35 (2H, m, aromatic
CH), 8.45–8.51 (2H, m, aromatic CH). 13C-NMR (75 MHz, DMSO-d6): δ = 25.37, 113.01 (dd, J1 = 3.08 Hz,
J2 = 21.45 Hz), 106.08 (d, J = 26.01 Hz), 114.05, 114.45, 119.72 (dd, J1 = 3.02 Hz, J2 = 11.51 Hz), 126.56,
127.17, 128.25, 128.75, 129.15, 132.37, 132.67 (dd, J1 = 3.12 Hz, J2 = 10.36 Hz), 134.23, 135.55, 143.74,
148.22, 151.06, 153.70, 164.66 (d, J = 251.18 Hz), 164.83 (d, J = 250.91 Hz). HRMS (m/z): [M + H]+ calcd
for C23H14N6SF2: 445.1053; found: 445.1041.
3-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-6-(2,4-dichlorophenyl)-7H-[1,2,4]triazole[3,4-b] [1,3,4]
thiadiazine (5h): Yields: 77%. Mp 190.7–193.4 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.36 (2H,
s, -CH2-), 7.34–7.37 (3H, m, aromatic CH), 7.65 (1H, dd, J1 = 2.04 Hz, J2 = 8.34 Hz, aromatic
CH), 7.70–7.73 (2H, m, aromatic CH), 7.78–7.81 (1H, m, aromatic CH), 8.20 (2H, d, J = 8.64 Hz,
1,4-disubstitutedbenzene), 8.40 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz,
DMSO-d6): δ = 26.23, 115.05, 115.32, 124.22, 124.72, 126.99, 127.78, 128.08, 128.29, 128.57, 128.96, 129.59,
130.38, 132.93, 133.05, 133.74, 136.86, 143.65, 149.92, 151.62, 156.53. HRMS (m/z): [M +H]+ calcd for
C23H14N6SCl2: 477.0457; found: 477.0450.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-phenyl-7H-[1,2,4]triazole[3,4-b][1,3,4] thiadiazine
(5i): Yields: 80%. Mp: 247.3–249.6 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.50 (2H, s, -CH2-), 7.49 (1H,
dd, J1 = 1.89 Hz, J2=8.67 Hz, aromatic CH), 7.59–7.62 (3H, m, aromatic CH), 7.78–7.84 (2H, m, aromatic
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CH), 8.03–8.06 (2H, m, aromatic CH), 8.27 (2H, d, J = 8.64 Hz, 1,4-disubstitutedbenzene), 8.37 (2H, d,
J = 8.64 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz, DMSO-d6): δ = 23.32, 114.60, 116.29, 125.95,
126.40, 128.11, 128.47, 128.97, 129.20, 129.63, 129.94, 132.62, 133.27, 133.71, 135.39, 143.97, 150.42, 151.04,
156.76. HRMS (m/z): [M + H]+ calcd for C23H15N6SCl: 443.0826; found: 443.0840.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5j): Yields: 70%. Mp: 226.0–228.9 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.46 (2H, s,
-CH2-), 7.33–7.37 (1H, m, benzimidazole CH), 7.63 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene),
7.68–7.73 (2H, m, benzimidazole CH), 8.04 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene), 8.19 (2H, d,
J = 8.46 Hz, 1,4-disubstitutedbenzene), 8.39 (2H, d, J = 8.43 Hz, 1,4-disubstitutedbenzene). 13C-NMR
(75 MHz, DMSO-d6): δ = 23.13, 115.14, 116.51, 124.18, 127.79, 128.20, 128.33, 128.83, 128.98, 129.19,
129.68, 129.87, 130.51, 131.57, 132.60, 137.42, 143.58, 151.40, 155.59. HRMS (m/z): [M +H]+ calcd for
C23H14N6SCl2: 477.0427; found: 477.0450.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-fluorophenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5k): Yields: 71%. Mp: 249.1–250.9 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.48 (2H,
s, -CH2-), 7.38 (1H, dd, J1 = 1.98 Hz, J2 = 8.58 Hz, aromatic CH), 7.46–7.48 (2H, m, aromatic CH),
7.71–7.74 (1H, m, aromatic CH), 7.77 (1H, s, aromatic CH), 8.12–8.14 (2H, m, aromatic CH), 8.25 (2H, d,
J = 8.64 Hz, 1,4-disubstitutedbenzene), 8.40 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene). 13C-NMR
(75 MHz, DMSO-d6): δ = 23.45, 114.95, 116.45, 116.77 (d, J = 22.09 Hz), 124.83, 128.07, 128.21, 128.39,
128.84, 128.89, 130.30 (d, J = 2.99 Hz), 130.85 (d, J = 8.93 Hz), 135.26, 137.58, 143.69, 150.99, 151.27, 155.73,
164.82 (d, J = 249.42 Hz). HRMS (m/z): [M + H]+ calcd for C23H14N6FSCl: 461.0741; found: 461.0746.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-methylphenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5l): Yields: 65%. Mp: 250.7–252.3 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.46 (2H, s,
-CH2-), 7.40 (2H, d, J = 8.07 Hz, 1,4-disubstitutedbenzene), 7.45 (1H, dd, J1 = 1.95 Hz, J2 = 8.67 Hz,
benzimidazole CH), 7.76–7.79 (1H, m, benzimidazole CH), 7.82–7.83 (1H, m, benzimidazole CH), 7.95
(2H, d, J = 8.31 Hz, 1,4-disubstitutedbenzene), 8.28 (2H, d, J = 8.67 Hz, 1,4-disubstitutedbenzene), 8.37
(2H, d, J = 8.67 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz, DMSO-d6): δ = 21.54, 23.15, 114.88,
116.44, 125.26, 127.74, 128.08, 128.21, 128.95, 129.24, 129.72, 130.21, 130.90, 134.62, 136.89, 142.95, 143.90,
150.99, 151.15, 156.66. HRMS (m/z): [M + H]+ calcd for C24H17N6SCl: 457.0994; found: 457.0997.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-cyanophenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5m): Yields: 62%. Mp: 254.0–255.7 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.53 (2H,
s, -CH2-), 7.50 (1H, dd, J1 = 1.95 Hz, J2 = 8.70 Hz, benzimidazole CH), 7.85–7.86 (1H, m, aromatic
CH), 8.06–8.08 (3H, m, aromatic CH), 8.21 (2H, d, J = 8.61 Hz, 1,4-disubstitutedbenzene), 8.26 (2H, d,
J = 8.64 Hz, 1,4-disubstitutedbenzene), 8.38 (2H, d, J = 8.64 Hz, 1,4-disubstitutedbenzene). 13C-NMR
(75 MHz, DMSO-d6): δ = 23.30, 114.57, 114.71, 118.70, 125.83, 126.85, 128.48, 128.86, 129.11, 129.37,
129.81, 133.46, 133.58, 135.73, 137.98, 143.88, 150.56, 151.33, 155.41. HRMS (m/z): [M +H]+ calcd for
C24H14N7SCl: 468.0782; found: 468.0793.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(4-bromophenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5n): Yields: 76%. Mp: 243.4–247.3 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.48 (2H, s,
-CH2-), 7.43 (1H, dd, J1 = 1.98 Hz, J2 = 8.67 Hz, benzimidazole CH), 7.75 (1H, s, aromatic CH), 7.80–7.82
(3H, m, aromatic CH), 7.99 (2H, d, J = 8.70 Hz, 1,4-disubstitutedbenzene), 8.26 (2H, d, J = 8.58 Hz,
1,4-disubstitutedbenzene), 8.37 (2H, d, J = 8.64 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz,
DMSO-d6): δ=23.14, 115.01, 116.52, 124.92, 126.45, 128.10, 129.05, 130.07, 131.76, 132.00, 132.15, 132.67,
133.00, 141.45, 143.77, 148.89, 149.69, 151.39, 155.91. HRMS (m/z): [M +H]+ calcd for C23H14N6SClBr:
520.9930; found: 520.9945.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(2,4-difluorohenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5o): Yields: 66%. Mp: 182.2–185.0 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.39 (2H, s,
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-CH2-), 7.28–7.34 (1H, m, aromatic CH), 7.42–7.48 (1H, m, aromatic CH), 7.48–7.52 (2H, m, aromatic
CH), 7.77–7.83 (2H, m, aromatic CH), 7.93–8.01 (1H, m, aromatic CH), 8.25 (2H, d, J = 8.64 Hz,
1,4-disubstitutedbenzene), 8.44 (2H, d, J = 8.58 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz,
DMSO-d6): δ = 25.31, 105.76 (d, J = 26.01 Hz), 106.28, 113.19 (dd, J1 = 2.63 Hz, J2 = 20.86 Hz), 114.74,
116.39, 119.76 (dd, J1 = 3.73 Hz, J2 = 7.83 Hz), 125.45, 127.49, 128.32, 128.94, 129.14, 129.40, 132.71 (dd,
J1 = 3.21 Hz, J2 = 9.80 Hz), 134.22, 143.80, 151.60, 151.26, 153.78, 161.28 (d, J = 252.62 Hz), 164.46 (d,
J = 256.22 Hz). HRMS (m/z): [M + H]+ calcd for C23H13N6F2SCl: 479.0632; found: 479.0652.
3-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)-6-(2,4-dichlorophenyl)-7H-[1,2,4]triazole [3,4-b][1,3,4]
thiadiazine (5p): Yields: 68%. Mp: 114.4–116.5 ◦C. 1H-NMR (300 MHz, DMSO-d6): δ = 4.35 (2H, s,
-CH2-), 7.25 (1H, dd, J1 = 1.74 Hz, J2 = 8.52 Hz, aromatic CH), 7.65 (2H, dd, J1 = 2.07 Hz, J2 = 8.34 Hz,
aromatic CH), 7.88 (2H, d, J = 8.34 Hz, aromatic CH), 7.90 (1H, m, aromatic CH), 8.16 (2H, d, J = 8.61 Hz,
1,4-disubstitutedbenzene), 8.32 (2H, d, J = 8.58 Hz, 1,4-disubstitutedbenzene). 13C-NMR (75 MHz,
DMSO-d6): δ = 26.33, 106.76, 125.55, 127.29, 127.35, 128.58, 128.90, 129.64, 130.37, 131.63, 132.35, 132.96,
133.06, 133.44, 133.77, 136.56, 136.84, 143.51, 149.25, 151.77, 156.48. HRMS (m/z): [M +H]+ calcd for
C23H13N6SCl3: 511.0037; found: 511.0061.
3.2. Cytotoxicity Assay
The anticancer activity of compounds 5a–5p were screened according to the MTT assays. The MTT
assays were performed as previously described [24,25]. Cisplatin was used as the reference drug for
the MCF7 cell line in the MTT assays.
3.3. Aromatase Inhibition Assay
This method was carried out according to the kit procedure (Bio Vision, Aromatase (CYP19A)
Inhibitor Screening Kit (Fluorometric)). The compounds were dissolved in dimethyl sulfoxide (DMSO)
and added to the assay in at least seven concentrations ranging from 10−3–10−9 M. The recombinant
human aromatase stock was prepared by reconstituting with 1 mL of aromatase assay buffer.
The contents were mixed thoroughly by vortexing to obtain a homogeneous solution and the solution
was transferred to a 15-mL conical tube. The volume was brought to 2450 μL with the aromatase
assay buffer and 50 μl of NADPH production system (100X) was added for a final total volume of
2.5 mL. Letrozole was used as a positive inhibition control. For solvent control, a small aliquot of
aromatase assay buffer containing the organic solvent was used to dissolve the test compounds that
were prepared. Reaction wells containing test compounds and the corresponding no inhibitor controls
(which may also serve as a solvent control), as well as a background control (containing no fluorogenic
Aromatase Substrate) were prepared. The plate was incubated for at least 10 min at 37 ◦C to allow
test ligands to interact with the aromatase. After incubation, 30 μl of the aromatase substrate/NADP+
mixture was added to each well. Immediately (within 1 min), the fluorescence at Ex/Em = 488/527 nm
was measured.
3.4. Molecular Docking
A structure-based in silico procedure was applied to discover the binding modes of compound
5e to human aromatase enzyme active site. The crystal structures of human aromatase (PDB ID:
3EQM) [26] was retrieved from the Protein Data Bank server (www.pdb.org).
The structures of ligands were built using the Schrödinger Maestro [29] interface and then were
submitted to the Protein Preparation Wizard protocol of the Schrödinger Suite 2016 Update 2 [30].
The ligands were prepared by the LigPrep 3.8 [31] to assign the protonation states at pH 7.4 ± 1.0
and the atom types, correctly. Bond orders were assigned, and hydrogen atoms were added to the
structures. The grid generation was formed using Glide 7.1 [32]. Flexible docking runs were performed
with single precision docking mode (SP).
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3.5. Theoretical Determination of ADME Properties
Physicochemical parameters of obtained compounds (5a–5p) were evaluated by using QikProp
4.8 [33].
4. Conclusions
Inhibition of aromatase has proved to be an effective approach for the treatment of
hormone-dependent breast cancer in the postmenopausal women. Imidazole and triazole groups
are important rings for the development new potent aromatase inhibitors with high affinity for the
enzyme. A series of benzimidazole-triazolothiadiazine derivatives have been synthesized with different
substituents at benzimidazole and phenyl rings. The newly synthesized compounds were tested for
their anti-cancer properties against human breast cancer cell line (MCF-7). The synthesized compounds
were then tested in in vitro aromatase assay and two compounds (5e and 5m) exhibited activity similar
to letrozole.
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Abstract: The dihydropyranoindole scaffold was identified as a promising target for improving the
anti-cancer activity of HDAC inhibitors from the preliminary screening of a library of compounds.
A suitable methodology has been developed for the preparation of novel dihydropyranoindoles
via the Hemetsberger indole synthesis using azido-phenylacrylates, derived from the reaction of
corresponding alkynyl-benzaldehydes with methyl azidoacetate, followed by thermal cyclization in
high boiling solvents. Anti-cancer activity of all the newly synthesized compounds was evaluated
against the SH-SY5Y and Kelly neuroblastoma cells as well as the MDA-MB-231 and MCF-7 breast
adenocarcinoma cell lines. Biological studies showed that the tetracyclic systems had significant
cytotoxic activity at higher concentration against the neuroblastoma cancer cells. More importantly,
these systems, at the lower concentration, considerably enhanced the SAHA toxicity. In addition to
that, the toxicity of designated systems on the healthy human cells was found to be significantly less
than the cancer cells.
Keywords: dihydropyranoindole; anticancer; HDAC inhibitors; neuroblastoma; breast cancer
1. Introduction
Chemotherapy is one of the most widely used treatments for high-risk cancer patients [1,2]. A
range of well-known agents, namely Doxorubicin, Cyclophosphamide, Etoposide have been used
to combat various cancers in modern chemotherapeutic therapy [3,4]. However, a major problem
faced in chemotherapy is resistance to commonly-used anti-cancer drugs [5]. Therefore, development
of novel anti-cancer chemotherapeutic agents is of utmost importance in the area of drug discovery
and development.
The histone deacetylase (HDAC) inhibitors are a class of chemotherapeutic agents that hold
promise in cancer therapy [6,7]. HDAC inhibitors have been reported to suppress cell proliferation and
angiogenesis, induce cell differentiation and promote apoptosis in a number of cancer cell types [8,9].
Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to obtain meet FDA approval [10],
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and has been considered to be a highly promising anticancer therapeutic agent due to its potent
cytotoxic effect on a number of tumor cell types as well as low toxicity towards healthy normal
cells [11–13]. However, single agent treatment with SAHA has been found to be ineffective against
several cancers [14,15]. On the other hand, the combination of SAHA with other chemotherapeutic
agents with different mechanisms of action has been considered to be more promising as the drug
resistance caused by single agent therapies may be overcome [14,16]. Due to the significant cytotoxic
effects observed during clinical trials of SAHA in combination with a variety of chemotherapeutic
agents, many synthetic compounds have been produced and screened to identify molecules capable of
enhancing the cytotoxic activity of SAHA, while producing fewer side effects.
In order to provide a basis for this study, a subset (10,560 compounds) of the Walter & Eliza Hall
Institute (WEHI) compound library was screened to identify molecules that can act synergistically
with a clinical dose of SAHA to overcome drug resistance in SAHA-resistant MDA-MB-231 breast
cancer cell lines [17]. The compounds that reduced viability to <40% in the presence of SAHA but to
>70% in the absence of SAHA, with a difference of at least 55% between the two conditions have been
identified as hit molecules for their SAHA enhancing capability [17]. A structural analysis of the hit
molecules demonstrated that the main structural feature to be the presence of 5- or 6-membered fused
heterocyclic systems, most commonly containing one or more nitrogen atoms. Furthermore, these
fused systems typically involved 3 or 4 conjoined rings. Due to the ongoing experiments regarding the
hit molecules, the structures of these compounds are not discussed in this manuscript.
Identification of New Target Molecules
The starting point of the current work was the selection of a range of compounds exhibiting
structural similarity to the hits from compound library in order to expand the structural diversity of
the screening set. The six related monomeric dihydropyranoindoles 1–3 and dimeric furoquinolines
4–6 were selected in order to understand the effect of the indole and quinoline structures, as well as the
fused dihydropyran and furan rings, on biological activities (Figure 1). The molecules were tested
against SH-SY5Y neuroblastoma and MDA-MB-231 breast cancer cell lines, using the Alamar blue
(Resazurin) assay [18] to measure the cell viability. The same screening conditions were used with
WEHI screening. Briefly, the designated cells were exposed to 1 μM SAHA, 10 μM compound and the
combination of SAHA and compound for 72 h.
 
Figure 1. Six compounds from the NK library.
The in vitro assays revealed that the MDA-MB-231 were the more resistant cell lines than the
SH-SY5Y cell lines for the single and combination treatments of all compounds. The compounds 5
and 6, analogues of quinolines, displayed the lowest reduction on SH-SY5Y cell viability and also
no SAHA enhancement was found by the combination with SAHA (Figure S1A, see Supplementary
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Materials). In the case of compound 6, the single and combination treatments showed no inhibition of
MDA-MB-231 cell viability, while the 20% and 5% of inhibitions were obtained with the treatment
of compound 5 alone and combination with 1 μM SAHA (Figure S1B, see Supplementary Materials).
The compound 4 was the most active ligand among the quinoline candidates, with 30% inhibition of
SH-SY5Y cell viability in the absence of SAHA and 20% additional cytotoxic effect in the presence of
SAHA (Figure S1A, see Supplementary Materials). The designated compound displayed 25% reduction
on MDA-MB-231 cells, while no SAHA enhancement effect was obtained against the same cell line
(Figure S1B, see Supplementary Materials).
Overall, 1, 3 and 4 were determined as the most promising compounds as SAHA enhancer and it
was concluded that the indole heterocyclic systems 1 and 3 were found to be a potential target for the
SAHA enhancement with the higher differential values between in the absence and presence of SAHA
In order to further validate these compounds 1, 3 and 4 as viable lead structures, it was essential to
determine their toxicity towards normal and non-malignant cells. The most effective ligands were
screened against the MRC-5 normal human lung fibroblast cells, as described for cytotoxic assay. This
screen showed that the toxicity of 3 was found to be greater than 1 and 4 proposing that specificity
of 3 against the normal and cancer cells was not different (Figure S2, see Supplementary Materials).
The single treatment of compound 3 showed the cytotoxic activity with the values of 33% and 28%
reduction against the SH-SY5Y and MDA-MB-231 cells respectively, while the toxicity of this compound
against the MRC-5 cells was 26% and 30% greater than the SH-SY5Y and MDA-MB-231 cancer cells.
However, compounds 1 and 4 displayed non-toxic behavior on the MRC-5 healthy human cells with
values of 103% and 98% viable cells.
Based on the results of screening against the cancer cells and toxicity study on normal cells,
the indole heterocyclic system 1 was identified as promising leads for further development on
the enhancement of SAHA activity and compound 1 was also determined to be non-toxic across
the healthy human cells. The main work described in this manuscript focused on the synthesis,
characterization and in vitro biological evaluation of a series of targeted compounds based on tricyclic
and tetracyclic dihydropyrano derivatives. The effectiveness of the novel compounds as single agents
and in combination with a clinical dose of SAHA was determined against neuroblastoma and breast
cancer cells.
2. Results and Discussion
The preparation of dihydropyranoindole systems was achieved by two synthetic methods,
and the generality of these pathways were discussed in this paper. 3,4-Dihydroxybenzaldehyde
7 has been given as an example for the representation of two possible methods which could
be used for the preparation of the desired pyranoindole methyl 5,10-dihydro-7H-dipyrano
[3,2-e:2′,3′-g]indole-6-carboxylate 10 (Figure 2). The first method was to prepare the compound
10 via methyl hydroxyindole-2-carboxylate 8 which could be prepared by the Hemetsberger indole
synthesis [19]. Methyl hydroxyindole-2-carboxylate 8 on reacting with haloalkynes would give the
alkyne indole-ether 9 which upon Claisen cyclization would afford the desired dihydropyranoindole
10. As an alternative pathway, aryl ether benzaldehyde 11 would be prepared via simple alkylation
of phenol 7 with haloalkynes and the Hemetsberger indole synthesis would then be applied to build
the indole moiety. It is anticipated that thermal cyclization would yield the desired compound 10 in
one step.
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Figure 2. Two methods for the preparation of pyranoindole systems.
2.1. Preparation of Tetracyclic Dihydropyranoindole 10 Via (Method 1)
In the first synthetic method, methyl 5,6-dihydroxyindole-2-carboxylate 8 was generated via the
Hemetsberger indole synthesis by benzyl-protected benzaldehydes and the subsequent deprotection
afforded the corresponding hydroxyindoles. The 3,4-dihydroxybenzaldehyde 7 was reacted with benzyl
bromide in the presence of potassium carbonate in acetone to afford the protected carbaldehydes 12 [20]
in 88% yield (Scheme 1). Treatment of 3,4-dibenzyloxy benzaldehyde 12 with methyl azidoacetate
in methanol, in the presence of strong basic environment (sodium methoxide) gave the vinyl azido
intermediate 13 in 59% yield. Thermal decomposition of the arylazido 13 was performed by heating
at reflux in xylene, generating the methyl 5,6-dibenzyloxyindole-2-carboxylate 14 in 71% yield.
Hydrogenolysis of the benzyl group was carried out by treating the compound 14 with 5% w/w
palladium on carbon under hydrogen atmosphere at room temperature for 2 h, to yield the desired
methyl 5,6-dihydroxyindole-2-carboxylate 8 [21] in 77% yield. The dihydroxyindole 8 was reacted
with propargyl bromide in the presence of potassium carbonate in acetone (Scheme 1). The desired
dipropargyloxyindole intermediate 9 was prepared in 61% yield. The Claisen cyclization of 9
was explored in xylene, 1,2-dichlorobenzene and toluene. It was found that heating at reflux in
chlorobenzene gave the optimum result in terms of the completion of the reaction as well as the yield
and purity of the product. Using this approach, the desired tetracyclic dihydropyranoindole 10 was
isolated in 51% yield.
 
Scheme 1. Reagents and conditions: (i) Benzyl bromide, K2CO3, DMF, reflux, overnight; (ii) Methyl
azidoacetate, NaOMe, anhyd. MeOH, <−10 ◦C, 4 h; (iii) Xylene, reflux, 2 h, (iv) 5% Pd/C, H2,
MeOH/THF, 2h, rt, (v) Propargyl bromide, K2CO3, acetone, reflux, 4 h, 61%, (vi) Chlorobenzene, reflux
2 h, 52%.
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The possible reaction mechanism could be explained as in Figure 3. Methyl
5,6-bis(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate 9 undergoes an initial Claisen rearrangement
to generate intermediate A, which subsequently enolizes to produce 5,6-dihydroxyindole
derivative (intermediate B). A double hydride shift in intermediate B gives the keto
intermediate C, which undergoes an electrocyclic ring closing reaction to form methyl
5,10-dihydro-2H-dipyrano[3,2-e:2′,3′-g]indole-6-carboxylate 10.
 
Figure 3. Possible reaction mechanism.
The 1H-NMR spectrum of compound 10 in CDCl3 showed a singlet at 3.96 ppm corresponding
to the methyl ester protons, and two doublets of doublets at 4.91 and 4.96 ppm assigned to the two
CH2 groups. A multiplet at 5.87–5.97 ppm corresponded to H3 and H9, while another multiplet at
6.72–6.80 ppm corresponded to H4 and H8. Furthermore, H3 appeared as a doublet at 7.19 ppm and
the NH proton appeared as a broad singlet at δ 8.85 ppm. The DEPT 135 spectrum of compound 10
confirmed the structure of the molecule, displaying the loss of two CH carbon signals as a result of
cyclization of the alkyne group as well as the appearance of two negative signals at 64.68 and 64.72
ppm corresponding to the methylene carbon atoms in the product.
2.2. Alternative Pathway for the Preparation of Tetracyclic Dihydropyranoindole 10 (Method 2)
The alternative approach began with the reaction of 3,4-dihydroxybenzaldehyde 7 with propargyl
bromide under basic conditions (potassium carbonate), which afforded the propargyloxy benzaldehyde
11 [22] in 87% yield. At this point, two synthetic strategies using benzaldehyde 11 as a key intermediate
were envisioned (Scheme 2). The first route involved Claisen cyclization to build the dihydropyrano
rings 15, followed by the application of the Hemetsberger indole synthesis to construct the indole scaffold
via the unsaturated azido intermediate 16 (Route 1). The cyclization of the aryl ether intermediate
11 was attempted by refluxing in high-boiling solvents such as xylene, toluene, 1,2-dichlorobenzene
and chlorobenzene (Scheme 2). In all cases, the novel compound 15 was afforded in low yields, with
unreacted starting material being recovered as the major product. The highest yield (35%) was obtained
by the use of chlorobenzene. In order to synthesize the desired tetracyclic dihydropyranoindole 10, the
standard Hemetsberger indole synthesis was applied to new intermediate 15. The condensation of
benzaldehyde 15 with methyl azidoacetate was carried out at low temperature (ice-salt bath) in the
presence of sodium methoxide. The addition of a small amount of crushed ice to the reaction mixture
resulted in the isolation of azido ester 16 as an oily compound which was found to be unstable at room
temperature, and was hence used in the next step without further purification. It was postulated that
the presence of the dihydropyran ring caused the generation of an unstable azido ester intermediate.
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Thermal cyclization of the azido ester 16 was performed by heating at reflux in xylene, which afforded
the desired dihydropyranoindole 10 in 62% yield.
 
Scheme 2. Reagents and conditions: (a) Propargyl bromide, K2CO3, acetone, reflux, 4 h, (b) Methyl
azidoacetate, metallic Na, anhyd. MeOH, <−10 ◦C, 2 h (c) Chlorobenzene, reflux, 2 h, (d) Xylene, reflux,
4 h.
In the second route, it was anticipated that the indole heterocyclic system could be constructed
first, followed by the installation of dihydropyrano rings onto the indole moiety. Since the cyclization
of both aryl ether and unsaturated azide ester moieties require refluxing conditions in a high-boiling
solvent, it was predicted that the indole and dihydropyran rings could be prepared in one step from the
key azide intermediate 17 (Route 2). The benzaldehyde 11 was condensed with methyl azidoacetate
under strongly basic conditions at low temperature to generate the novel unsaturated stable azide
intermediate 17 in 63% yield (Scheme 2). Since xylene was the common solvent for the generation
of the indole moiety from the azido ester intermediate, the cyclization reaction was first carried out
in refluxing xylene. As anticipated, the thermal cyclization of intermediate 17 resulted in both the
decomposition of the azidocinnamate moiety and formation of the indole heterocyclic system, as well
as the cyclization of the propargyloxy moiety to furnish the fused pyran ring in a single step. Hence,
the desired tetracyclic dihydropyranoindole 10 was obtained in a yield of 72%.
Taken altogether, it was concluded that the first method is a less favorable synthetic pathway
consisting of six steps to prepare the desired dihydropyranoindole and also generating the lowest
of yield (51%) at the final step. In the case of the second method, route 1 was also found to be
an unfavorable synthetic method for further synthesis due to the low-yielding cyclization step to
generate the new tricyclic aldehyde 15, the formation of the unstable azido intermediate 16 from the
Hemestberger indole synthesis and the four step pathway for the desired dihydropyranoindole 10. On
the other hand, route 2 of the second strategy was deemed to be the most favorable synthetic route
towards dihydropyranoindoles, as it contained three steps to afford the desired dihydropyranoindole
and gave the highest yield of 72%. Thus, route 2 of the second method was chosen for further studies
in this study.
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2.3. The Preparation of Monomeric Hydropyrano System
The synthetic strategy (Route 2) was extended to the synthesis of indole systems containing a
single fused dihydropyran ring. Hence, 4-hydroxy-3-methoxy benzaldehyde 18 was reacted with
propargyl bromide in the presence of potassium carbonate to give aryl ether 19a [23] in 84% yield,
which was then reacted with methyl azidoacetate under basic conditions to give azidocinnamate 20a in
76% yield (Scheme 3). Interestingly, thermal cyclization of the 20a in xylene afforded the corresponding
propargyloxy indole 21a in the yield of 68% instead of the expected dihydropyranoindole system 22a.
Further heating of indole 21a in refluxing chlorobenzene afforded the desired dihydropyranoindole
22a in 77% yield.
 
Compound R1 R2 R3 
22a H H H 
22b H H Me 
22c Me Me H 
Scheme 3. Reagents and conditions: (a) Propargyl bromide or 3-chloro-3-methylbut-1-yne or
1-bromobut-2-yne, K2CO3, acetone, reflux, 4 h, (b) Methyl azidoacetate, metallic Na, anhyd. MeOH,
<−10 ◦C, 2 h (c) Xylene, reflux, 4 h, (d) Chlorobenzene, reflux, 2 h.
The 1H-NMR spectrum of compound 22a in CDCl3 showed the presence of two singlets at 3.94
ppm and 3.96 ppm corresponding to the methoxy and methyl ester protons, and doublets of doublets
at 4.96 ppm corresponding to the CH2 protons. Protons H8 and H9 appeared as multiplets in a range
of 5.89–5.95 ppm and 6.73–6.79 ppm respectively. Furthermore, H4 appeared as a singlet at 7.02 ppm,
while H3 was appeared as a doublet at 7.13 ppm (J = 2.1 Hz) due to its coupling with the NH proton,
which resonated as a broad singlet at 8.94 ppm. The DEPT 135 spectrum showed the presence of a
negative peak at 65.79 ppm corresponding to a methylene carbon atom. Furthermore, the spectrum
revealed the absence of the alkyne CH signal due to cyclization of the alkyne moiety in indole 21a.
The synthesis of tricyclic dihydropyranoindole systems containing methyl substituents
on the fused dihydropyran ring at different positions was also investigated. To achieve
this, 4-hydroxy-3-methoxybenzaldehyde 18 was reacted with 1-bromobut-2-yne and
3-chloro-3-methylbut-1-yne in the presence of potassium carbonate to give the aryl ether
aldehydes 19b [24] and 19c [25] in 92% and 84% yields, respectively (Scheme 3). The aldehydes
19b and 19c were treated with methyl azidoacetate in the presence of sodium methoxide to give
azidocinnamates 20b and 20c in yields of 61% and 62%. Finally, the thermal cyclization of the
unsaturated azide 20b and 20c in refluxing xylene generated the desired product 22c in 74% yields,
while the indole ether 21b was isolated in 67% yield. The desired dihydropyranoindole 22b was
obtained in 49% yield, by the further cyclization of 21b in refluxing chlorobenzene.
In the 1H-NMR spectrum of methyl 5-methoxy-7,7-dimethyl-1,7-dihydropyrano[2,3-g]indole-2-
carboxylate 22c,the two methyl groups appeared as a singlet at 1.55 ppm, while H8 and H9 appeared
as doublet signals at 5.71 and 6.66 ppm (J = 9.7 Hz). Furthermore, H4 appeared as a singlet at 7.01 ppm
and H3 appeared as a doublet at 7.13 ppm (J = 2.1 Hz), confirming that cyclization occurred at C7. In
the 1H-NMR spectrum of the cyclization product 22b, the olefinic proton on the dihydropyran ring
appeared as multiplet signals in the ranges of 5.65–5.68 ppm, due to coupling with the neighboring
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CH2 and CH3 groups. For compound 22b, the O-CH2 protons resonated as a multiplet at 4.77 ppm
and the methyl protons of the dihydropyran ring appeared as a quartet at 1.71 ppm.
The same synthetic route was applied to 3-hydroxy-4-methoxy benzaldehyde 23 in order
to generate an analogue with the dihydropyran ring fused at a different position. Thus,
hydroxybenzaldehyde 23 was reacted with propargyl bromide in the presence of potassium carbonate
to generate the intermediate ether 24a [26] in 87% yield, which upon reaction with methyl azidoacetate
in strongly basic conditions gave the azidocinnamate 25a in 72% yield (Scheme 4). Heating the
azidocinnamate 25a in refluxing xylene gave the propargyloxy indole 26a in 73% yield, which was
then cyclized in chlorobenzene to afford the desired dihydropyranoindole 27a in 74% yield.
The 1H-NMR spectrum of compound 27a in CDCl3 showed two singlet signals at 3.92 and 3.93
ppm corresponding to the methoxy and methyl ester protons, and doublets of doublets at 4.90 ppm
corresponding to the CH2 protons. H8 and H9 appeared as multiplets at 5.89–5.95 and 6.76–6.79 ppm
respectively. The H4 appeared as a singlet at 6.77 ppm, while H1 appeared as a doublet at 7.17 ppm
(J = 2.1 Hz). Moreover, the NH proton resonated as a broad singlet at δ 8.96 ppm. The formation of
the desired dihydropyranoindole was further confirmed by DEPT 135 spectroscopy which revealed
the presence of a negative peak at 65.71 ppm corresponding to the CH2 group accompanied by the
disappearance of the signal corresponding to the CH group of the starting alkyne 26a.
3-Hydroxy-4-methoxybenzaldehyde 23 was further treated with 1-bromobut-2-yne and
3-chloro-3-methylbut-1-yne under basic conditions to generate the corresponding intermediates
24b [24] and 24c [27] 89% and 82% yields, respectively (Scheme 4). The aryl ethers 24b and 24c were
condensed with methyl azidoacetate in the presence of sodium methoxide to generate the azidoacrylates
25b and 25c in 64% and 62% yields respectively. Thermal decomposition of the unsaturated azides
25b gave the indole ethers 26b in 71%, while the desired hydropyrano compound 27c was directly
isolated in 68% yield. The desired dihydropyranoindoles 27b was obtained in 54% yields respectively,
by the cyclization of 26b and in refluxing chlorobenzene. It was also of interest to construct new
dihydropyranoindole systems containing substituents other than a methyl group on a pyran ring. The
haloalkyne, 3-phenylprop-2-yn-1-ol, was treated with 3-hydroxy-4-methoxybenzaldehyde 23 in the
presence of potassium carbonate to produce the alkylated carbaldehyde 24d in 92% yield (Scheme 4).
The reaction between the aryl ether 24d with methyl azidoacetate afforded the unsaturated azido ester
25d in 64% yield. Finally, heating compound 25d in refluxing xylene afforded the corresponding indole
ether 26d in 74% yield, which further underwent thermal cyclization in chlorobenzene to furnish the
desired dihydropyranoindole 27d in 81% yield.
In the 1H-NMR spectrum of methyl 5-methoxy-7,7-dimethyl-3,7-dihydropyrano[3,2-e]indole-2-
carboxylate 27c, the two methyl groups appeared as a sharp singlet at 1.53 ppm. The H8 and H9 of the
dihydropyran ring appeared as two doublets at 5.73 and 6.68 ppm that coupled to each other with a
coupling constant of 9.7 Hz. H1 appeared as a doublet (J = 2.1 Hz) at 7.20 ppm while H4 was assigned
as a singlet at 6.79 ppm. In the 1H-NMR spectrum of the cyclization product 27b the olefinic protons
on the dihydropyran ring appeared as multiplet signals in range of 5.69–5.72, due to coupling with
the neighboring CH2 and CH3 groups. The characteristic O-CH2 protons resonated as a multiplet at
4.77 ppm, while the methyl group of the dihydropyran ring appeared at as a quartet 1.63 ppm. The
1H-NMR spectrum of compound 27d displayed the O-CH2 protons as a doublet at 4.85 ppm with a
coupling constant of 4.4 Hz, and the olefinic proton as a multiplet at 5.94–5.97 ppm. The aromatic
protons of phenyl ring appeared as multiplet in the range of 7.34–7.44 ppm. The H4 and H1 appeared
as two singlets at 5.98 and 6.88 ppm.
Similar attempts were made to the prepare methyl substituted tetracyclic dihydropyranoindole
compounds from the 3,4-dihydroxybenzaldehyde 7, 1-bromobut-2-yne and 3-chloro-3-methylbut-1-yne.
The benzaldehyde 7 was alkylated with 2 equivalents of 1-bromobut-2-yne in the presence of potassium
carbonate to generate the novel aryl ether 29 in 87% yield (Scheme 5). The benzaldehyde 29 was then
treated with methyl azidoacetate under strongly basic conditions to generate the azido compound
30 in 63% yield, which subsequently underwent thermal decomposition in refluxing xylene to afford
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the indole ether 31 in 65% yield. However, the cyclization of 31 could not be achieved in a number
of solvents, including chlorobenzene, toluene, xylene and 1,2-dichlorobenzene which resulted in the
formation of decomposed reaction mixture. The reaction between 3,4-dihydroxybenzaldehyde 7 and
3-chloro-3-methylbut-1-yne was investigated in an attempt to produce the dipropargyloxybenzaldehyde
intermediate 28 (Scheme 5). However, this reaction resulted in a black reaction mixture, presumably
due to decomposition.
Compound R1 R2 R3
27a H H H
27b H H Me
27c Me Me H
27d H H Ph
Scheme 4. Reagents and conditions: (a) Propargyl bromide or 3-chloro-3-methylbut-1-yne
or1-bromobut-2-yne or 3-phenylprop-2-yn-1-ol, K2CO3, acetone, reflux, 4 h, (b) Methyl azidoacetate,
metallic Na, anhyd. MeOH, <−10 ◦C, 2 h (c) Xylene, reflux, 4 h, (d) Chlorobenzene, reflux, 2 h.
 
Scheme 5. Reagents and conditions: (a) 1-Bromobut-2-yne or 3-Chloro-3-methyl-1-butyne, K2CO3,
acetone, reflux, 4 h, (b) methyl azidoacetate, metallic Na, anhdyrous MeOH, −10 ◦C, 2 h (c) Xylene,
reflux, 2 h, (d) Xylene, chlorobenzene, toluene, 1,2-dichlorobenzene reflux, overnight.
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2.4. Biological Study
2.4.1. Preliminary Biological Screening of Dihydropyranoindoles for SAHA Enhancement Activity
Novel dihydropyranoindole analogues were screened to determine the levels of SAHA
enhancement activity as well as their own cytotoxic profile against the SH-SY5Y and Kelly
neuroblastoma cells and the MDA-MB-231 and MCF-7 breast adenocarcinoma cell lines using the
Alamar blue (Resazurin) assay [18]. Briefly, the cells were allowed to attach for 24 h in a 96-well culture
plate before being exposed to the ligands at a concentration of 10 μM in DMSO for 72 h, either in the
presence or absence of SAHA. Comparative values for cell viability in each well were determined by a
Wallac 1420 Victor III spectrophotometer, which measured light absorbance in each well at 570 nm.
The mean and standard deviation (SD) values for each compound were calculated from at least three
replicate experiments. The anticancer activity of the compounds was evaluated by comparison to a
negative (DMSO) control. Figure 4 shows the tested novel dihydropyranoindoles synthesized in this
study and the compound 33 was selected from the NK library. In this assay, the cell lines were exposed
to SAHA, 10 μM of the compounds as well as the combination of SAHA with the compounds for 72 h.
 
Figure 4. Synthesized and selected compounds.
According to the results from the screening, the neuroblastoma cells were found to be the
more sensitive cells towards the treatment of new pyranoindoles, while these compounds showed a
moderate effect on the breast cancer cell lines (Figures S3A,B and S4A,B, see Supplementary Materials).
MDA-MB-231 cells were determined as the most resistant cell line for the single as well as the
combination treatments (Figure S3A, see Supplementary Materials). The dihydropyranoindole 27c
exhibited the greatest cell viability inhibition with the values of 34% and 35% in the absence and
presence of SAHA against the MDA-MB-231 cells. The SAHA enhancement was achieved by the
additional reduction value of 20% across MDA-MB-231 viability. MCF-7 cells showed an identical
pattern of sensitivity. However, most of the dihydropyranoindoles were able to reduce the viability by
the value of 20% (Figure S3, see Supplementary Materials).
Compound 33 displayed the highest reduction with the 35% inhibition, while compounds 27c and
22c generated similar reductions with the values of 20% and 22% on the same cell line. Unfortunately
the combination of pyranoindoles with 1 μM SAHA had very low SAHA enhancement by the average
values of 5% across the MCF-7 cell lines.
It was observed that dihydropyranoindoles had a variety of impact on the viability of
neuroblastoma cells (Kelly and SH-SY5Y) with the single and combination treatments (Figure S4A,B,
see Supplementary Materials). Out of all the novel ligands synthesized, ligand 33 had the strongest
cytotoxic activity with the reduction value of 50% at 10 μM, while ligands 27c and 10 showed similar
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inhibition behaviors by the average reduction value of 32% against Kelly cells for the single treatment.
The dihydropyranoindoles 27c and 33 displayed the enhancement of SAHA cytotoxicity with the
values of 24 and 22% respectively (Figure S4A, see Supplementary Materials). The value of 40%
SAHA enhancement was obtained by the combination of compound 33. However, the ligand 33 was
considered as self-toxic compound due to the reduction value for the single treatment. The levels of
individual cytotoxic efficiency against the SH-SY5Y were found to be higher than those observed on the
Kelly cells (Figure S4B, see Supplementary Materials). The compounds 27d and 10 showed the greatest
cytotoxic activity reducing 44% and 56% of the cells respectively. Most importantly, the enhancement
of SAHA activity was achieved by the treatment of almost all of the novel dihydropyranoindole
analogues showing at least 20% additional reduction to SAHA cytotoxicity. Although the highest
SAHA enhancement was obtained in the case of compound 10 with the value of 55%, it was not
considered as a promising enhancer since the single treatment also generated the greatest reduction
(56%) on the SH-SY5Y cell. The best enhancers were assigned as compounds 22a, 27a, 27c and 33 with
the reduction values of 25%, 29%, 30% and 31%respectively due to the lower toxicity but the higher
enhancement effects on SAHA cytotoxicity.
2.4.2. Determination of SAHA Enhancement Activity of Selected Dihydropyranoindoles at Lower
Concentrations
Since the levels of SAHA enhancement were found to be promising, further investigations were
carried out using five different concentrations (0.01, 0.1, 1, 10, 20 μM), using the Alamar blue (Resazurin)
assay [18] to determine whether the lower concentrations would provide higher enhancement of the
SAHA cytotoxicity or the cytotoxic manner would be dependent on the dose usage. The initial screening
revealed that the single treatment of dihydropyranoindoles 33, 27c and 10 at a concentration of 10 μM
showed the highest cytotoxic efficiency against the Kelly cells. The designated compounds were treated
with the Kelly cells by the combinations of 0.5 μM SAHA with the five different concentrations (0.01,
0.1, 1, 10, 20 μM) and the results are shown at Figure S5A,C (see Supplementary Materials). In general,
the single treatment of these compounds provided lower cytotoxic activity at the concentrations of
0.01, 0.1 and 1 μM compared with the values at 10 μM and the cell viability differentials between
the absence and presence of SAHA were greater than those at 10 μM concentrations, suggesting that
the designated compounds behave as suitable SAHA enhancers (Figure S5A,C, see Supplementary
Materials). Similar SAHA enhancement pattern was observed at the concentrations of 0.01, 0.1 and
1 μM for all three compounds, while the combination of 1 μM compound 27c or 10 with the 0.5 μM
SAHA revealed the best SAHA enhancement with the values of 24% and 25% additional inhibition
(Figure S5B,C, see Supplementary Materials).
In addition to those two compounds, compound 33 showed the greatest viability differentials
with the values of 61%, 63% and 65% at the concentrations of 0.01, 0.1 and 1 μM and the desired SAHA
enhancement was observed for all the concentrations. The lowest concentration of compound 33 (0.01
μM) revealed a remarkable reduction with the value of 25%, while the best combination for the highest
SAHA enhancement was determined as a 10:0.5 ratio of compound and SAHA with the additional
reduction value of 55% (Figure S5 A, see Supplementary Materials). It was concluded that the highest
cell viability differentials was achieved by the use of nanomolar concentrations in the case of all three
compounds and the best SAHA enhancer was determined as compound 33.
Similarly, in the case of the SH-SY5Y cell line, further investigations were undertaken with 27a,
33 and 27c which were chosen due to their highest additional effects on the SAHA cytotoxicity with
the lower toxicity behavior in the absence of SAHA. Compound 10 was also explored to determine
its cytotoxic behavior as well as the SAHA enhancement potential at lower concentrations. The
combinations of 1 μM SAHA with the five different concentrations (0.01, 0.1, 1, 10, 20 μM) of
designated compounds were treated with the SH-SY5Y cells and the results are shown at Figure S6A–D
(see Supplementary Materials).
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The SAHA enhancement pattern was found to be identical on SH-SY5Y value for all cases of
combinations of 27a with SAHA. The highest viability differential was obtained in the ratio 1:10 of
SAHA to compound with the reduction value of 35% (Figure S6A, see Supplementary Materials). The
dose-dependent pattern of single treatments of 33 and 27c suggested that these compounds displayed
higher toxicity at 20 μM with the values of 45% and 55% reductions. Furthermore, the combinations
of these compounds at the concentrations of 0.01, 0.1 and 1 μM with SAHA enhanced the SAHA
cytotoxicity in a similar manner and the best combinations were found to be as the ratio 1:10 of SAHA
to compound with the additional reduction values of 28% and 33% (Figure S6B,C, see Supplementary
Materials). The greatest cytotoxicity was obtained at a concentration of 20 μM of 10 alone with the
reduction values of 88% on SH-SY5Y cell viability and the ratio of 1:20 SAHA to compound combination
provided 94% cell death (Figure S6D, see Supplementary Materials).
More importantly, at the lower concentrations (0.01, 0.1 and 1 μM) of 10, the cytotoxicity was
found to be lower with the average reduction value of 25%. Encouragingly, the biggest cell viability
differential was obtained at the ratio of 1:10 SAHA to compound with the value of 44%, and the greatest
SAHA enhancement was also found as 37% at the same combination. It was concluded that 10 was the
most cytotoxic compound at higher concentration (20 μM, 88% reduction) and also it was found to be
the best SAHA enhancer at the ratio of 1:10 SAHA to compound combination.
2.4.3. SAR Study of Selected Dihydropyranoindoles
These observations suggested an important structure-activity relationship among 27a, 33, 27c
and 10. That is, the incorporation of tetracyclic dihydropyranoindoles 33 and 10 resulted in lower cell
viability reductions at higher concentrations (20 μM) and also this system was found to offer the best
enhancement with the ratio of 1:10 SAHA to compound combinations against both neuroblastoma
cancer cells (Kelly and SH-SY5Y). The SAR analysis revealed that the location of dihydropyran ring on
the benzene ring was important for the cytotoxic efficiency of tricyclic dihydropyranoindoles, The
compounds 27c, an example of dihydropyrano[3,2-e]indole system, was found to be more potent than
the dihydropyranoindole 22c which is a member of dihydropyrano[2,3-g]indole scaffold against both
neuroblastoma cells (Kelly and SH-SY5Y). In comparison of two tricyclic dihydropyranoindoles 27c
and 22c at 20 μM, it was found that the compound 27c reduced 20% more SH-SY5Y cell with the
combination of 1 μM SAHA than compound 22c, while the 20% SAHA enhancement was achieved
using the combination of compound 27c and SAHA but no SAHA enhancement was found with the
compound 22c in the case of Kelly cells. Furthermore, the dihydropyrano[2,3-g]indole analogues 22a
and 22b displayed the lowest reduction on Kelly cells in the presence and absence of SAHA. Similar
results were observed in the case of SH-SY5Y cells with the exception of 21% additional reduction on
SAHA enhancement obtained by the use of 22a.
2.4.4. Toxicity Study Against Normal Cells
While selected dihydropyranoindoles showed potent SAHA enhancement activity against Kelly
and SH-SY5Y neuroblastoma and MCF-7 and MDA-MB-231 breast cancer cells, they must be markedly
less toxic against the healthy cells in order to be considered as potential SAHA enhancers. Thus, the
dihydropyranoindoles 27a, 33, 27c and 10 were also examined for their toxicity effects on the MRC-5
and WI-38 lung fibroblasts in order to determine whether these compounds exhibited selectivity for
tumor cells (Figure S7A–D, see Supplementary Materials). Comparison of the cytotoxic activity and
toxicity levels of the dihydropyranoindoles against cancer cells and the healthy cells revealed that
the cancer cells were more sensitive to the dihydropyranoindoles compared to the normal cells. The
toxicity of 1 μM of SAHA reduced the viability of MRC-5 and WI-38 cells with the value of 9% and 24%
respectively, while 27a alone displayed a similar pattern of toxicity against normal cells with values
of 10% for MRC-5 and 22% for WI-38 at a concentration of 10 μM (Figure S7A, see Supplementary
Materials). The viability of MRC-5 and WI-38 were reduced 21% and 16%, 3% and 26% by the use of
33 and 10 alone (Figure S7B,C, see Supplementary Materials), while the highest toxicity levels were
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obtained in the case of 27c with the reduction values of 20% and 43% (Figure S7D, see Supplementary
Materials). The combination treatments were found to be quite identical to the reduction values of
single treatments of each compound. These observations demonstrated that 27a, 33 and 10 were either
less toxic or slightly less toxic than SAHA, while 27c displayed more toxicity than SAHA for both
normal cells.
3. Materials and Methods
3.1. General Information
Commercially available reagents were purchased from Fluka (Sydney, NSW, Australia), Aldrich
(Sydney, NSW, Australia), Acros Organics (Morris Plains, NJ, USA), Alfa Aesar (Lancashire, UK) and
Lancaster (Lancashire, UK) and purified if necessary. The synthetic procedures have been reported for
all compounds as general methods and appropriate references have been given for known compounds.
1H (300 MHz) and 13C-NMR (75 MHz) spectra were obtained in the designated solvents on a DPX
300 spectrometer (Bruker, Sydney, NSW, Australia). Melting points were measured using a Mel-Temp
melting point apparatus and are uncorrected. Infrared spectra were recorded on Avatar Series FT-IR
spectrophotometer as KBr disks (Thermo Nicolet, Waltham, MA, USA). Ultraviolet spectra were
measured using a Cary 100 spectrophotometer (Varian, Santa Clara, CA, USA) in the designated
solvents and data reported as wavelength (λ) in nm and adsorption coefficient (ε) in cm−1M−1.
High-resolution [ESI] mass spectra were recorded by the UNSW Bioanalytical Mass Spectrometry
Facility, on an Orbitrap LTQ XL (Thermo Scientific, Waltham, MA, USA) ion trap mass spectrometer
using a nanospray (nano-electrospray) ionization source.
3.1.1. GP-1: General Procedure for the Benzylation of Dihydroxybenzaldehydes
A solution of hydroxybenzaldehyde (1 equiv.), anhydrous potassium carbonate (per hydroxyl
group, 1 equiv.) and benzyl bromide (per hydroxyl group, 1 equiv.) in anhydrous DMF (100 mL)
was heated at reflux until TLC analysis showed consumption of the starting aldehyde (9 h). Upon
cooling to room temperature, the reaction mixture was diluted with water (300 mL) and the resulting
precipitate was collected via filtration and washed with water (2 × 250 mL). Upon drying, the residue
was recrystallized from dichloromethane and n-hexane to give the title compound.
3.1.2. GP-2: General Procedure for the Preparation of Vinyl-Azido Intermediates
A solution of sodium methoxide was prepared via the portion-wise addition of metallic sodium
(17 equiv.) to anhydrous methanol (30 mL) with stirring under nitrogen. A dropping funnel was
attached to the reaction flask and charged with the corresponding aldehyde (1 equiv.) and methyl
azidoacetate (10 equiv.) in methanol (15 mL). The contents of the funnel were added dropwise to the
sodium methoxide solution over 1.5 h under a nitrogen atmosphere. Once the addition was completed,
the reaction mixture was warmed to 5 ◦C, where it remained for 4 h. The heterogeneous mixture was
poured into crushed ice. The resulting precipitate was filtered, washed with water and dried to give
the title compound. The crude product was used in the next step without further purification.
3.1.3. GP-3: General Procedure for the Preparation of Methyl Benzyloxyindole-2-carboxylates
The vinyl azido intermediate (6.66 mmol) was dissolved in xylene (50 mL) and the reaction
mixture was heated under reflux for 6 h. After refluxing, the solvent was evaporated under reduced
pressure and the remaining residue was extracted with boiling hexane. Upon cooling, the resulting
solid was filtered to give crude product which was recrystallized from dichloromethane and n-hexane
to give the title compound.
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3.1.4. GP-4: General Procedure for the Hydrogenolysis of Methyl Dibenzyloxyindole-2-carboxylate
After vacuum/H2 cycles to remove air from the reaction flask, a stirred mixture of benzyloxyindole
(1 mmol) and 5% Pd/C (10% w/w) in THF/MeOH (1:1, 15 mL) was exposed to a hydrogen atmosphere
(1 atm) and stirred at room temperature for 2 h. The reaction mixture was filtered through a pad of
Celite® and the filtrate was then concentrated under reduced pressure. The crude product was purified
by flash column chromatography (SiO2), eluted with dichloromethane to give the title compounds.
3.1.5. GP-5: General Procedure for the Synthesis of Propargyloxybenzaldehydes:
Propargyl bromide (per hydroxyl group, 1.2 equiv.) was added to a mixture of potassium carbonate
(per hydroxyl group, 1 equiv.) and hydroxybenzaldehyde (1 equiv.) in acetone. The reaction mixture
was heated under reflux with stirring until no more starting material remained (~30 h). The reaction
mixture was cooled to room temperature and Et2O (100 mL) was added. The ethereal solution was
washed with NaOH (1 N, 3 × 50 mL). The organic layer was dried over MgSO4, concentrated under
reduced pressure and recrystallized from dichloromethane/n-hexane to give the compound.
3.1.6. GP-6 General Procedure for the Synthesis of Dihydropyranoindoles:
A solution of alkyne indole ethers (1.04 mmol) in chlorobenzene (20 mL) was heated under reflux
until TLC analysis showed consumption of the starting indole (12 h). The heating was discontinued and
the solvent was evaporated under reduced pressure. The crude product was purified using flash column
chromatography (SiO2), eluted with 30% dichloromethane/n-hexane, to give the dihydropyranoindole.
Methyl 2-azido-3-(3,4-dibenzyloxyphenyl)-propenoate (13) The title compound was prepared as described
in GP-2 from 3,4-dibenzyloxybenzaldehyde (12) (2.95 g, 9.3 mmol) and methyl azidoacetate (10.69 g, 93
mmol) in anhydrous methanol (30 mL) to give the product (2.27 g, 59%) as a pale yellow granular solid;
m.p. 114–116 ◦C; IR (KBr): vmax 2917, 2119, 1701, 1683, 1590, 1508, 1432, 1379, 1233, 1201, 1130, 999,
802, 728 cm−1; UV-vis (CH3CN): λmax325 (24,500); 1H-NMR: (300 MHz, CDCl3): δ 3.91 (s, 3H, CO2Me),
5.25 (s, 4H, 2 × O-CH2), 6.83 (s, 1H, CH=C), 7.35–7.52 (m, 12H, ArH), 7.64 (d, J = 2.2 Hz, 1H, H2′);
13C-NMR: (75.6 MHz, CDCl3): δ 52.7 (CO2Me), 70.9 (CH2), 71.3 (CH2), 113.8 (C2′), 116.6 (C5′), 123.3
(CH=C), 125.4 (C6′), 125.7 (ArC), 126.6 (ArC), 127.1 (2 × ArC), 127.2 (2 × ArC), 127.8 (ArC), 127.9 (ArC),
128.5 (2 × ArC), 128.6 (2 × ArC), 136.8 (C1′), 137.1 (CH=C), 148.3 (C4′), 150.1 (C3′), 164.1 (CO2Me);
HRMS (+ESI): Found m/z 438.1439 [M + Na]+, C24H21N3O4Na requires 438.1439.
Methyl 5,6-dibenzyloxyindole-2-carboxylate (14) The title compound was prepared as described in GP-3
from methyl 2-azido-3-(3′,4′-dibenzyloxyphenyl)propenoate (13) (2.76 g, 6.66 mmol) in xylene (50 mL)
to give the product (1.84 g, 71%) as a yellow granular solid; m.p. 148–150 ◦C; IR (KBr): vmax 3309, 2942,
2871, 2113, 1680, 1627, 1519, 1488, 1452, 1353, 1288, 1246, 1208, 1144, 1000, 918, 905, 839, 794 cm−1;
UV-vis (CH3CN): λmax 208 nm (ε 72,400 cm−1 M−1), 320 (31,700); 1H-NMR (300 MHz, CDCl3): δ 3.93 (s,
3H, CO2Me), 5.21 (s, 2H, O-CH2), 5.24 (s, 2H, O-CH2), 7.00 (s, 1H, H4), 7.01 (s, 1H, H7), 7.23 (d, J = 2.1
Hz, 1H, H3), 7.33–7.51 (m, 10H, ArH), 8.73 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): 51.8 (CO2Me),
71.3 (CH2), 72.0 (CH2), 97.0 (C7), 107.0 (C4), 108.8 (C3), 121.0 (ArC), 126.0 (C2), 127.0 (ArC), 127.2 (2
× ArC), 127.3 (ArC), 127.7 (2 × ArC), 127.8 (ArC), 128.4 (ArC), 128.5 (ArC), 132.4 (ArC), 137.0 (ArC),
137.4 (2 × ArC), 145.8 (C5), 149.9 (C6), 162.1 (CO2Me); HRMS (+ESI): Found m/z 410.1364 [M +Na]+,
C24H21NO4Na requires 410.1363.
Methyl 5,6-dihydroxyindole-2-carboxylate (8) The title compound was prepared as described in GP-4 from
methyl 5,6-dibenzyloxyindole-2-carboxylate (14) (0.387 g, 1.0 mmol) and 5% Pd/C catalyst (40 mg) in
methanol/THF mixture (15 mL) to give the product (159 mg, 77%) as yellow solid; m.p. 256–258 ◦C;
IR (KBr): vmax 3437, 3315, 2953, 2107, 1653, 1632, 1531, 1506, 1437, 1311, 1283, 1230, 1198, 1139, 992,
937, 849, 825, 767 cm−1; UV-vis (CH3CN): λmax 203 nm (ε 42,100 cm−1 M−1), 318 (27,000);1H-NMR
(300MHz, d6-DMSO): δ 3.82 (s, 3H, CO2Me), 6.79 (d, J = 0.8 Hz, 1H, H4), 6.88 (s, 1H, H3), 6.90 (d, J = 0.8
Hz, 1H, H7), 8.84 and 9.17 (bs, each 1H, OH), 11.28 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): 52.0
114
Molecules 2020, 25, 1377
(CO2Me), 97.3 (C7), 105.4 (C4), 108.4 (C3), 120.3 (ArC), 125.0 (C2), 133.2 (ArC), 142.3 (C5), 146.7 (C6),
162.5 (CO2Me); HRMS (+ESI): Found m/z 230.0423 [M + Na]+, C10H9NO4Na requires 230.0424.
Methyl 5,6-bis(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (9) The title compound was prepared as
described in GP-5 from methyl 5,6-dihydroxyindole-2-carboxylate (8) (993 mg, 4.8 mmol), potassium
carbonate (1.32 g, 9.6 mmol) and propargyl bromide (1.36 g, 10.6 mmol) in acetone to give the product
(828 mg, 61%) as a yellow solid;m.p. 170–172 ◦C; IR (KBr): νmax 3332, 3285, 2939, 2925, 2865, 2292,
2108, 1720, 1684, 1625, 1520, 1480, 1435, 1380, 1365, 1280, 1247, 1203, 1150 1024, 986, 892, 819, 805, 759,
720, 672 cm−1; UV-vis (CH3CN): λmax 209 nm (ε 28,300 cm−1 M−1), 313 (18,000); 1H-NMR (300 MHz,
CDCl3): δ 2.55 (t, J = 1.6 Hz, 1H, CH≡C), 2.57 (t, J = 1.6 Hz, 1H, CH≡C), 3.95 (s, 3H, CO2Me), 4.82 (d,
J = 2.4 Hz, 2H, O-CH2), 4.85 (d, J = 2.4 Hz, 2H, O-CH2), 7.10 (d, J = 0.7 Hz, 1H, H7), 7.16 (q, J = 0.9
Hz, 1H, H3), 7.31 (s, 1H, H4), 8.86 (bs, 1H, NH), 13C-NMR (75.6 MHz, CDCl3): δ51.8 (CO2Me), 57.0
(O-CH2), 57.5 (O-CH2), 75.7 (C≡CH), 75.7 (C≡CH), 78.6 (C≡CH), 79.1 (C≡CH), 97.2 (C7), 107.2 (C4),
108.9 (C3), 121.3 (aryl C), 126.4 (C2), 132.4 (aryl C), 144.2 (C4), 148.2 (C5), 162.1 (CO2Me); HRMS (+ESI):
Found m/z 306.0736 [M + Na]+, C16H13NO4Na requires 306.0737.
2,9-Dihydropyrano[3,2-h]chromene-5-carbaldehyde (15) The title compound was prepared as described
in GP-6 from 3,4-bis(prop-2-yn-1-yloxy)benzaldehyde (11) (214 mg, 1.04 mmol) in chlorobenzene (20
mL) to give the product (77 mg, 35%) as a white solid; m.p. 102–104 ◦C; IR (KBr): νmax 1680, 1570,
1490, 1440, 1340, 1301, 1205, 1102, 995, 945, 900, 898, 861, 745 cm−1; UV-vis (CH3CN): λmax 225 nm (ε
27,400 cm−1 M−1), 268 (18,800), 305 (17,500); 1H-NMR (300 MHz, CDCl3): δ 4.40 (dd, J = 3.0, 1.4 Hz,
2H, O-CH2), 4.79 (dd, J = 3.0, 1.4 Hz, 2H, O-CH2), 6.97 (d, J = 8.7 Hz, 2H, H4 and H7), 7.37 (s, 1H,
H6), 7.40–7.42 (m, 2H, H3 and H8), 9.80 (s, 1H, CHO); 13C-NMR (75.6 MHz, CDCl3): δ71.3 (O-CH2),
71.5 (O-CH2), 119.6 (C6), 120.6 (aryl C), 121.6 (C4), 121.8 (C7), 125.3 (aryl C), 126.5 (C3), 126.9 (C8),
127.1 (C5), 147.9 (aryl C), 154.3 (aryl C), 190.7 (CHO); HRMS (+ESI): Found m/z 237.0533 [M +Na]+,
C13H10O3Na requires 237.0528.
3,4-Bis(but-2-yn-1-yloxy)benzaldehyde (29) The title compound was prepared as described in GP-5 from
3,4-dihydroxybenzaldehyde (7) (660 mg, 4.8 mmol), potassium carbonate (1.32 g, 9.6 mmol) and
1-bromobut-2-yne (1.40 g, 10.6 mmol) in acetone to give the product (1.01 g, 87%) as a white solid;
m.p. 86–88 ◦C; IR (KBr): νmax 1688, 1582, 1499, 1431, 1375, 1248, 1201, 1125, 987, 920, 857, 797, 729
cm−1; UV-vis (CH3CN): λmax 228 nm (ε 31,500 cm−1 M−1), 272 (22,200), 303 (14,800); 1H-NMR (300
MHz, CDCl3): δ 1.85–1.87 (m, 6H, 2 × C-CH3), 4.79 (q, J = 2.3 Hz, 2H, O-CH2), 4.82 (q, J = 2.3 Hz, 2H,
O-CH2), 7.17 (d, J = 8.2 Hz, 1H, H5), 7.52 (dd, J = 8.2, 1.9 Hz, 1H, H6), 7.57 (d, J = 1.9 Hz, 1H, H2),
9.89 (s, 1H, CHO); 13C-NMR (75.6 MHz, CDCl3): δ 3.6 (C-CH3), 3.7 (C-CH3), 57.2 (2 × O-CH2), 73.1
(C-CH3), 73.3 (C-CH3), 84.6 (C≡C(CH3)), 84.9 (C≡C(CH3)), 112.0 (C5), 112.7 (C2), 126.4 (C6), 130.3 (aryl
C), 147.9 (C4′), 152.9 (C3′), 190.8 (CHO); HRMS (+ESI): Found m/z 265.0840 [M +Na]+, C15H14O3Na
requires 265.0835.
4-Methoxy-3-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (24d) The title compound was prepared as
described in GP-5 from 3-hydroxy-4-methoxybenzaldehyde 23 (730 mg, 4.8 mmol), potassium carbonate
(662 mg, 4.8 mmol) and 3-phenylprop-2-yn-1-yl-4-methylbenzenesulfonate (1.66 g, 5.8 mmol) in acetone
to give the product (1.17 g, 92%) as a white solid; m.p. 112–114 ◦C; IR (KBr): νmax 1673, 1579, 1506,
1430, 1378, 1256, 1221, 1165, 1130, 1012, 931, 874, 810, 754, 686 cm−1; UV-vis (CH3CN): λmax 232 nm (ε
45,500 cm−1 M−1), 272 (21,500), 302 (14,800); 1H-NMR (300 MHz, CDCl3): δ 4.00 (s, 3H, OMe), 5.08 (s,
2H, O-CH2), 7.03 (d, J = 8.2 Hz, 1H, H5), 7.30–7.33 (m, 3H, ArH), 7.34–7.45 (m, 2H, ArH), 7.54 (dd, J =
8.2, 1.9 Hz, 1H, H6), 7.68 (d, J = 1.9 Hz, 1H, H2), 9.90 (s, 1H, CHO); 13C-NMR (75.6 MHz, CDCl3): δ
56.2 (OMe), 57.5 (O-CH2), 83.0 (C≡C(Ph)), 88.0 (C-Ph), 110.9 (C5), 112.1 (C2), 122.1 (aryl C), 127.1 (2 ×
aryl CH), 127.8 (aryl CH), 128.8 (C6), 130.0 (aryl C), 131.9 (2 × aryl CH), 147.5 (C4), 155.0 (C3), 190.7
(CHO); HRMS (+ESI): Found m/z 289.0837 [M + Na]+, C17H14O3Na requires 289.0835.
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Methyl (Z)-2-azido-3-(3,4-bis(prop-2-yn-1-yloxy)phenyl) acrylate (17) The title compound was prepared as
described in GP-2 from 3,4-bis(prop-2-yn-1-yloxy)benzaldehyde (11) (558 mg, 2.6 mmol) and methyl
azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the product (582 mg, 63%)
as a pale yellow granular solid; m.p. 114–116 ◦C; IR (KBr): νmax 2954, 2123, 1709, 1594, 1506, 1433,
1378, 1239, 1133, 1081, 1009, 793, 745, 683 cm−1; UV-vis (CH3CN): λmax 327 nm (ε 19,100 cm−1 M−1);
1H-NMR (300 MHz,CDCl3): δ 2.57 (t, J = 2.4 Hz, 1H, CH≡C), 2.59 (t, J = 2.4 Hz, 1H, CH≡C), 3.92 (s, 3H,
CO2Me), 4.83 (d, J = 2.4 Hz, 4H, 2 × O-CH2), 6.91 (s, 1H, CH=C), 7.09 (d, J = 8.5 Hz, 1H, H5′), 7.44 (dd,
J = 8.5, 2.0 Hz, 1H, H6′), 7.77 (d, J = 2.0 Hz, 1H, H2′), 13C-NMR (75.6 MHz, CDCl3): δ 52.8 (CO2Me),
56.6 (OMe), 57.0 (2 × O-CH2), 76.1 (C≡CH), 76.2 (C≡CH), 77.2 (C≡CH), 77.4 (C≡CH), 113.8 (C5′), 116.6
(C2′), 123.9 (CH=C), 125.3 (C6′), 125.6 (aryl C), 146.9 (aryl C), 148.5 (aryl C), 164.1 (CO2Me); HRMS
could not be determined due to the unstable properties of the compound
Methyl (Z)-2-azido-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)acrylate (25a) The title compound was
prepared as described in GP-2 from 4-methoxy-3-(prop-2-yn-1-yloxy)benzaldehyde (24a) (494 mg,
2.6 mmol) and methyl azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the
product (537 mg, 72%) as a pale yellow granular solid; m.p. 116–118 ◦C; IR (KBr): νmax 2951, 2101,
1698, 1592, 1507, 1432, 1379, 1254, 1214, 1139, 1084, 1016, 809, 745 cm−1; UV-vis (CH3CN): λmax 235 nm
(ε 16,600 cm−1 M−1), 330 (27,100); 1H-NMR (300 MHz, CDCl3): δ 2.58 (t, J = 2.4 Hz, 1H, CH≡C), 3.94 (s,
3H, OMe), 3.94 (s, 3H, CO2Me), 4.83 (d, J = 2.4 Hz, 2H, O-CH2), 6.90 (s, 1H, CH=C), 6.93 (d, J = 8.5
Hz, 1H, H5′), 7.43 (dd, J = 8.5, 2.0 Hz, 1H, H6′), 7.76 (d, J = 2.0 Hz, 1H, H2′); 13C-NMR (75.6 MHz,
CDCl3): δ 52.8 (CO2Me), 55.9 (OMe), 56.8 (O-CH2), 76.0 (C≡CH), 77.4 (C≡CH), 111.2 (C5′), 116.1 (C2′),
123.4 (CH=C), 125.6 (C6′), 125.0 (aryl C), 126.1 (CH=C), 146.3 (C4′), 150.8 (C3′), 164.1 (CO2Me); HRMS
(+ESI): Found m/z 310.0800 [M + Na]+, C14H13N3O4Na requires 310.0798.
Methyl (Z)-2-azido-3-(3-methoxy-4-(prop-2-yn-1-yloxy) phenyl)acrylate (20a) The title compound was
prepared as described in GP-2 from 3-methoxy-4-(prop-2-yn-1-yloxy)benzaldehyde (19a) (494 mg, 2.6
mmol) and methyl azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the product
(567 mg, 76%) as a pale yellow granular solid; m.p. 120–122 ◦C; IR (KBr): νmax 2920, 2122, 1704, 1592,
1509, 1450, 1345, 1243, 1206, 1141, 1008, 922, 804, 764 cm−1; UV-vis (CH3CN): λmax 323 nm (ε 17,500
cm−1 M−1); 1H-NMR (300 MHz, CDCl3): δ 2.56 (t, J = 2.4 Hz, 1H, CH≡C), 3.94 (s, 3H, OMe), 3.95 (s, 3H,
CO2Me), 4.83 (d, J = 2.4 Hz, 2H, O-CH2), 6.91 ( s, 1H, CH=C), 7.06 (d, J = 8.5 Hz, 1H, H5′), 7.43 (dd, J =
8.5, 1.9 Hz, 1H, H6′), 7.56 (d, J = 1.9 Hz, 1H, H2′); 13C-NMR (75.6 MHz, CDCl3): δ 52.8 (CO2Me), 55.9
(OMe), 56.5 (O-CH2), 76.2 (C≡CH), 77.4 (C≡CH), 113.3 (C5′), 113.5 (C2′), 123.7 (CH=C), 124.4 (C6′),
125.5 (aryl C), 127.3 (CH=C), 147.9 (C3′), 149.1 (C4′), 164.1 (CO2Me); HRMS could not be determined
due to the unstable properties of the compound.
Methyl (Z)-2-azido-3-(3,4-bis(but-2-yn-1-yl)oxy)phenyl) acrylate (30) The title compound was prepared as
described in GP-2 from 3,4-bis(but-2-yn-1-yloxy)benzaldehyde (29) (629 mg, 2.6 mmol) and methyl
azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the product (555 mg, 63%) as a
pale yellow granular solid; m.p. 124–126 ◦C; IR (KBr): νmax 2918, 2119, 1712, 1687, 1590, 1506, 1432,
1373, 1314, 1243, 1128, 992, 804, 745 cm−1; UV-vis (CH3CN): λmax 307 nm (ε 14,500 cm−1 M−1); 1H-NMR
(300 MHz, CDCl3): δ 1.87 (t, J = 2.3 Hz, 6H, 2 × C-CH3), 3.93 (s, 3H, CO2Me), 4.79 (q, J = 2.3 Hz, 2H,
O-CH2), 4.82 (q, J = 2.3 Hz, 2H, O-CH2), 6.91 (s, 1H CH=C), 7.05 (d, J = 8.5 Hz, 1H, H5′), 7.44 (dd, J =
8.5, 1.8 Hz, 1H, H6′), 7.73 (d, J = 2.0 Hz, 1H, H2′); 13C-NMR (75.6 MHz, CDCl3): δ 3.7 (2×C-CH3), 52.8
(CO2Me), 57.1 (OMe), 57.2 (O-CH2), 57.5 (O-CH2), 73.9 (2×C-CH3), 84.2 (C≡C(CH3)), 84.9 (C≡C(CH3)),
113.2 (C5′), 116.0 (C2′), 125.3 (CH=C), 125.8 (C6′), 126.5 (aryl C), 126.6 (CH=C), 147.9 (C4′), 148.8 (C3),
164.2 (CO2Me); HRMS could not be determined due to the unstable properties of the compound.
Methyl (Z)-2-azido-3-(3-(but-2-yn-1-yloxy)-4-methoxyphenyl) acrylate (25b) The title compound was
prepared as described in GP-2 from 3-(but-2-yn-1-yloxy)-4-methoxybenzaldehyde (24b) (530 mg, 2.6
mmol) and methyl azidoacetate (2.9 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the product
(500 mg, 64%) as a pale yellow granular solid; m.p. 96–98 ◦C; IR (KBr): νmax 2951, 2101, 1698, 1592,
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1507, 1431, 1379, 1254, 1139, 1016, 810, 745 cm−1; UV-vis (CH3CN): λmax 327 nm (ε 25,700 cm−1 M−1);
1H-NMR (300 MHz, CDCl3): δ 1.89 (t, J = 2.3 Hz, 3H, CH3), 3.93 (s, 3H, OMe), 3.94 (s, 3H, CO2Me),
4.78 (q, J = 2.3 Hz, 2H, O-CH2), 6.91 (d, J = 8.5 Hz, 1H, H5′), 6.92 (s, 1H, CH=C), 7.41 (dd, J = 8.5, 2.0
Hz, 1H, H6′), 7.73 (d, J = 2.0 Hz, 1H, H2′); 13C-NMR (75.6 MHz, CDCl3): δ 3.7 (C-CH3), 52.8 (CO2Me),
55.9 (OMe), 57.4 (O-CH2), 73.7 (C-CH3), 84.3 (C≡C(CH3)), 111.0 (C5′), 115.6 (C2′), 123.3 (CH=C), 125.6
(C6′), 125.9 (aryl C), 126.0 (CH=C), 146.7 (C4′), 150.7 (C3′), 164.2 (CO2Me); HRMS (+ESI): Found m/z
324.0944 [M + Na]+, C15H15N3O4Na requires 324.0955.
Methyl (Z)-2-azido-3-(4-(but-2-yn-1-yloxy)-3-methoxyphenyl)acrylate (20b) The title compound was
prepared as described in GP-2 from 4-(but-2-yn-1-yloxy)-3-methoxybenzaldehyde (19b)(530 mg,
2.6 mmol) and methyl azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give the
product (477 mg, 61%) as a pale yellow granular solid; m.p. 94–96 ◦C; IR (KBr): νmax 2920, 2120, 1702,
1592, 1509, 1434, 1377, 1244, 1140, 1011, 801, 763 cm−1; UV-vis (CH3CN): λmax 324 nm (ε 14,900 cm−1
M−1); 1H-NMR (300 MHz, CDCl3): δ 1.87 (t, J = 2.3 Hz, 3H, CH3), 3.94 (s, 3H, OMe), 3.94 (s, 3H,
CO2Me), 4.77 (q, J = 2.3 Hz, 2H, O-CH2), 6.90 (s, 1H, CH=C), 7.05 (d, J = 8.5 Hz, 1H, H5′), 7.38 (dd, J =
8.5, 1.8, Hz, 1H, H6′), 7.53 (d, J = 1.8 Hz, 1H, H2′); 13CNMR (75.6 MHz, CDCl3): δ 3.7 (C-CH3), 52.8
(CO2Me), 55.9 (OMe), 57.1 (O-CH2), 73.5 (C-CH3), 84.4 (C≡C(CH3)), 112.9 (C5′), 113.3 (C2′), 123.4 (aryl
C), 124.5 (CH=C), 125.8 (C6′), 126.8 (CH=C), 14.34 (C3′), 149.0 (C4′), 164.2 (CO2Me); HRMS (+ESI):
Found m/z 324.0955 [M + Na]+, C15H15N3O4Na requires 324.0955.
Methyl (Z)-2-azido-3-(4-methoxy-3-((3-phenylprop-2-yn-1-yl) oxy)phenyl)acrylate (25d) The title compound
was prepared as described in GP-2 from 4-methoxy-3-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde
(24d) (692 mg, 2.6 mmol) and methyl azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL)
to give the product (632 mg, 67%) as a pale yellow granular solid; m.p. 118–120 ◦C; IR (KBr): νmax
2921, 2827, 2119, 1674, 1612, 1580, 1506, 1431, 1378, 1275, 1232, 1129, 1008, 966. 873, 809, 753, 686 cm−1;
UV-vis (CH3CN): λmax 234 nm (ε 57,700 cm−1 M−1), 272 (22,600), 306 (21,800); 1H-NMR (300 MHz,
CDCl3): δ 3.93 (s, 3H, OMe), 3.96 (s, 3H, CO2Me), 5.04 (d, J = 6.0 Hz, 2H, O-CH2), 6.91 (s, 1H, CH≡C),
6.92 (d, J = 8.0 Hz, 1H, H5′), 7.09 (dd, J = 8.0, 1.8 Hz, 1H, H6′), 7.27–7.33 (m, 3H, ArH), 7.43–7.46 (m,
2H, ArH), 7.85 (d, J = 1.8 Hz, 1H, H2′); 13C-NMR (75.6 MHz, CDCl3): δ 52.6 (CO2Me), 55.9 (OMe), 57.5
(O-CH2), 83.9 (C-Ph), 87.5 (C≡C(Ph)), 111.1 (C5′), 116.0 (C2′), 120.4 (aryl C), 125.7 (CH=C), 126.0 (C6′),
126.1 (aryl C), 128.3 (2×aryl CH), 128.6 (CH=C), 130.6 (aryl CH), 131.9 (2×aryl CH), 146.7 (C4′), 150.9
(C3′), 164.2 (CO2Me); HRMS (+ESI): Found m/z 386.1099 [M + Na]+, C20H17N3O4Na requires 386.1117.
Methyl (Z)-2-azido-3-(4-methoxy-3-((2-methylbut-3-yn-2-yl) oxy)phenyl)acrylate (25c) The title compound
was prepared as described in GP-2 from 4-methoxy-3-((2-methylbut-3-yn-2-yl)oxy)benzaldehyde (24c)
(567 mg, 2.6 mmol) and methyl azidoacetate (2.99 g, 26.0 mmol) in anhydrous methanol (30 mL) to give
the product (507 mg, 62%) as a pale yellow granular solid; m.p. 122–124 ◦C; IR (KBr): νmax 2988, 2835,
2094, 1691, 1619, 1565, 1506, 1425, 1374, 1253, 1138, 1084, 1027, 962. 891, 799, 756, 687 cm−1; UV-vis
(CH3CN): λmax 238 nm (ε 16,800 cm−1 M−1), 328 (35,400); 1H-NMR (300 MHz, CDCl3): δ 1.70 (s, 6H, 2
× C-CH3), 2.59 (d, J = 0.9 Hz, 1H, CH≡C), 3.87 (s, 3H, OMe), 3.92 (s, 3H, CO2Me), 6.91 (s, 1H, CH=C),
6.90 (d, J = 8.5 Hz, 1H, H5′), 7.45 (dd, J = 1.9, 8.5 Hz, 1H, H6′), 8.16 (d, J = 2.0 Hz, 1H, H2′);13C-NMR
(75.6 MHz, CDCl3): δ 29.3 (2×C-CH3), 52.7 (CO2Me), 55.7 (OMe), 73.6 (C≡CH), 74.1 (C-(CH3)2), 86.1
(C≡CH), 111.5 (C5′), 123.2 (C2′), 124.8 (CH=C), 125.7 (C6′), 125.9 (aryl C), 127.4 (CH=C), 144.2 (C4′),
153.9 (C3′), 164.2 (CO2Me); HRMS (+ESI): Found m/z 338.1099 [M + Na]+, C16H17N3O4Na requires
338.1117.
Methyl (Z)-2-azido-3-(3-methoxy-4-((2-methylbut-3-yn-2-yl)oxy)phenyl)acrylate (20c) The title compound
was prepared as described in GP-2 from 3-methoxy-4-((2-methylbut-3-yn-2-yl)oxy)benzaldehyde (19c)
(567 mg, 2.6 mmol) and methyl azidoacetate (2.1 g, 26. mmol) in anhydrous methanol (30 mL) to give
the product (524 mg, 62%) as a pale yellow granular solid; m.p. 116–118 ◦C; IR (KBr): νmax 2975, 2802,
2112, 1703, 1635, 1565, 1512, 1400, 1387, 1212, 1100, 1052, 998, 957, 888, 765, 745, 677 cm−1; UV-vis
(CH3CN): λmax 328 nm (ε 17,100 cm−1 M−1); 1H-NMR (300 MHz, CDCl3): δ 1.72 (s, 6H, 2 × C-CH3),
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2.60 (d, J = 0.9 Hz, 1H, CH≡C), 3.89 (s, 3H, OMe), 3.93 (s, 3H, CO2Me), 6.91 (s, 1H, CH=C), 7.33 (dd, J =
8.5, 1.9 Hz, 1H, H6′), 7.45 (d, J = 8.5 Hz, 1H, H5′), 7.52 (d, J = 1.9 Hz, 1H, H2′); 13C-NMR (75.6 MHz,
CDCl3): δ 29.4 (2 × C-CH3), 52.8 (CO2Me), 55.9 (OMe), 73.9 (C≡CH), 73.9 (C-(CH3)2) 85.8 (C≡CH),
113.9 (C5′), 121.5 (C2′), 123.8 (CH=C), 123.9 (C6′), 125.7 (aryl C), 128.5 (CH=C), 146.1 (C3′), 152.0 (C4′),
164.1 (CO2Me); HRMS (+ESI): Found m/z 338.1104 [M + Na]+, C16H17N3O4Na requires 338.1117.
Methyl 6-methoxy-5-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (26a) The title compound was prepared
as described in GP-3 from methyl (Z)-2-azido-3-(3-(but-2-yn-1-yloxy)-4-methoxyphenyl)acrylate (25a)
(596 mg, 2.08 mmol) in xylene (20 mL) to give the product (196 mg, 73%) as a yellow solid; m.p. 164–166
◦C; IR (KBr): νmax 3325, 3259, 2953, 2925, 2123, 1671, 1624, 1520, 1480, 1440, 1367, 1320, 1249, 1208, 1185,
1146, 1005, 890, 833, 766, 694 cm−1; UV-vis (CH3CN): λmax 208 nm (ε 40,600 cm−1 M−1), 318 (28,700);
1H-NMR (300 MHz, CDCl3): δ 2.55 (t, J = 2.4 Hz, 1H, CH≡C), 3.95 (s, 3H, OMe), 3.96 (s, 3H, CO2Me),
4.82 (d, J = 2.4 Hz, 2H, O-CH2), 6.90 (d, J = 0.8 Hz, 1H, H4), 7.16 (q, J = 0.9 Hz, 1H, H3), 7.28 (s, 1H,
H7), 8.91 (bs, 1H, NH), 13C-NMR (75.6 MHz, CDCl3): δ 51.8 (CO2Me), 56.0 (OMe), 57.3 (O-CH2), 75.7
(C≡CH), 78.7 (C≡CH), 94.0 (C7), 106.6 (C4), 109.0 (C3), 120.2 (aryl C), 125.9 (C2), 132.9 (aryl C), 143.7
(C6), 150.6 (C5), 162.3 (CO2Me); HRMS (+ESI): Found m/z 282.0725 [M + Na]+, C14H13NO3Na requires
282.0742.
Methyl 5-methoxy-6-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (21a) The title compound was prepared
as described in GP-3 from methyl (Z)-2-azido-3-(4-(but-2-yn-1-yloxy)-3-methoxyphenyl)acrylate (20a)
(596 mg, 2.08 mmol) in xylene (20 mL) to give the product (183 mg, 68%) as a yellow solid; m.p. 152–154
◦C; IR (KBr): νmax 3325, 3241, 2999, 2937, 2113, 1681, 1638, 1522, 1475, 1452, 1360, 1280, 1237, 1211,
1195, 1143, 1003, 924, 843, 819, 761, 675 cm−1; UV-vis (CH3CN): λmax 209 nm (ε 35,800 cm−1 M−1), 308
(21,400); 1H-NMR (300 MHz, CDCl3): δ 2.57 (t, J = 2.4 Hz, 1H, CH≡C), 3.95 (s, 3H, OMe), 3.96 (s, 3H,
CO2Me), 4.85 (d, J = 2.4 Hz, 2H, O-CH2), 7.08 (d, J = 0.8 Hz, 1H, H4), 7.11 (s, 1H, H7), 7.15 (q, J = 0.9 Hz,
1H, H3), 8.87 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 51.8 (CO2Me), 56.2 (OMe), 56.9 (O-CH2),
76.1 (C≡CH), 77.4 (C≡CH), 96.8 (C7), 103.0 (C4), 108.7 (C3), 121.4 (aryl C), 126.1 (C2), 131.6 (aryl C),
146.6 (C5), 147.6 (C6), 162.2 (CO2Me); HRMS (+ESI): Found m/z 282.0726 [M +Na]+, C14H13NO3Na
requires 282.0742.
Methyl 5,6-bis(but-2-yn-1-yloxy)-1H-indole-2-carboxylate (31) The title compound was prepared as
described in GP-3 from methyl (Z)-2-azido-3-(3,4-bis(but-2-yn-1-yloxy)phenyl)acrylate (30) (704 mg,
2.08 mmol) in xylene (20 mL) to give the product 210 mg, 65%) as a yellow solid; m.p. 146–148 ◦C; IR
(KBr): νmax 3332, 2912, 2294, 2120, 1682, 1644, 1519, 1434, 1379, 1244, 1204, 1145, 984, 891, 819, 765 cm−1;
UV-vis (CH3CN): λmax 210 nm (ε 39,600 cm−1 M−1), 317 (24,900); 1H-NMR (300 MHz, CDCl3): δ 1.87
(q, J = 2.4 Hz, 6H, 2 × C-CH3), 3.96 (s, 3H, CO2Me), 4.76 (q, J = 2.4 Hz, 2H, O-CH2), 4.79 (q, J = 2.4
Hz, 2H, O-CH2), 7.08 (d, J = 0.7 Hz, 1H, H4), 7.16 (q, J = 0.9 Hz, 1H, H3), 7.25 (s, 1H, H7), 9.03 (bs,
1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 3.7 (2 × C-CH3), 51.8 (CO2Me), 57.4 and 57.8 (O-CH2), 73.9
(C-CH3), 74.2 (C-CH3), 83.8 (C≡C(CH3)), 84.2 (C≡C(CH3)), 96.5 (C7), 106.1 (C4), 108.9 (C3), 120.9 (aryl
C), 126.0 (C2), 132.5 (aryl C), 144.4 (C5), 148.5 (C6), 162.3 (CO2Me); HRMS (+ESI): Found m/z 334.1046
[M + Na]+, C18H17NO4Na requires 334.1050.
Methyl 5-(but-2-yn-1-yloxy)-6-methoxy-1H-indole-2-carboxylate (26b) The title compound was prepared as
described in GP-3 from methyl (Z)-2-azido-3-(3-(but-2-yn-1-yloxy)-4-methoxyphenyl)acrylate (25b)
(626 mg, 2.08 mmol) in xylene (20 mL) to give the product (201 mg, 71%) as a yellow solid; m.p. 160–162
◦C; IR (KBr): νmax 3324, 3258, 3009, 2918, 2795, 2123, 2108, 1672, 1600, 1520, 1490, 1425, 1400, 1385, 1346,
1249, 1208, 1185, 1146, 1005, 980, 890, 833, 766 cm−1; UV-vis (CH3CN): λmax 208 nm (ε 27,700 cm−1
M−1), 319 (18,900);1H-NMR (300 MHz, CDCl3): δ 1.88 (q, J = 2.4 Hz, 3H, C-CH3), 3.95 (s, 3H, OMe),
3.96 (s, 3H, CO2Me), 4.77 (q, J = 2.4 Hz, 2H, O-CH2), 6.88 (d, J = 0.7 Hz, 1H, H4), 7.16 (q, J = 0.9 Hz, 1H,
H3), 7.23 (s, 1H, H7), 8.82 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 5.2 (C-CH3), 53.2 (CO2Me),
57.4 (OMe), 59.1 (O-CH2), 75.5 (C-CH3), 85.3 (C≡C), 95.2 (C7), 107.1 (C4), 110.4 (C3), 121.7 (aryl C),
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127.1 (C2), 134.0 (aryl C), 145.5 (C6), 151.9 (C5), 163.7 (CO2Me); HRMS (+ESI): Found m/z 296.0884 [M +
Na]+, C15H15NO4Na requires 296.0899.
Methyl 6-(but-2-yn-1-yloxy)-5-methoxy-1H-indole-2-carboxylate (21b) The title compound was prepared as
described in GP-3 from methyl (Z)-2-azido-3-(4-(but-2-yn-1-yloxy)-3-methoxyphenyl)acrylate (20b)
(626 mg, 2.08 mmol) in xylene (20 mL) to give the product (190 mg, 67%) as a yellow solid; m.p. 164–166
◦C; IR (KBr): νmax 3324, 3224, 3005, 2936, 2835, 2215, 2108, 1680, 1584, 1495, 1455, 1433, 1362, 1285, 1243,
1228, 1146, 1045, 988, 946, 846, 819, 760, 672 cm−1; UV-vis (CH3CN): λmax 210 nm (ε 37,100 cm−1 M−1),
319 (22,300); 1H-NMR (300 MHz, CDCl3): δ 1.87 (q, J = 2.4 Hz, 3H, C-CH3), 3.94 (s, 3H, OMe), 3.96 (s,
3H, CO2Me), 4.80 (q, J = 2.4 Hz, 2H, O-CH2), 7.06 (d, J = 0.7 Hz, 1H, H4), 7.08 (s, 1H, H7), 7.14 (q, J =
0.9 Hz, 1H, H3), 9.01 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 3.7 (C-CH3), 51.8 (CO2Me), 56.1
(OMe), 57.4 (O-CH2), 73.8 (C-CH3), 84.3 (C≡C(CH3)), 96.2 (C7), 102.7 (C4), 108.7 (C3), 121.0 (aryl C),
125.8 (C2), 131.8 (aryl C), 146.1 (C5), 148.0 (C6), 162.3 (CO2Me); HRMS (+ESI): Found m/z 296.0883 [M +
Na]+, C15H15NO4Na requires 296.0889.
Methyl 6-methoxy-5-((3-phenylprop-2-yn-1-yl)oxy)-1H-indole-2-carboxylate (26d)
The title compound was prepared as described in GP-3 from methyl
(Z)-2-azido-3-(4-methoxy-3-((3-phenylprop-2-yn-1-yl)oxy)phenyl)acrylate (25d) (754 mg, 2.08
mmol) in xylene (20 mL) to give the product (257 mg, 74%) as a yellow solid; m.p. 138–140 ◦C; IR
(KBr): νmax 3326, 2984, 2924, 2740, 2113, 1675, 1645, 1520, 1480, 1439, 1381, 1247, 1195, 1145, 996, 845,
823, 761, 672 cm−1; UV-vis (CH3CN): λmax 203 nm (ε 58,900 cm−1 M−1), 318 (22,200); 1H-NMR (300
MHz, CDCl3): δ 3.95 (s, 3H, OMe), 3.98 (s, 3H, CO2Me), 5.04 (s, 2H, O-CH2), 6.90 (s, 1H, H4), 7.17 (q, J
= 0.9 Hz, 1H, H3), 7.31 (s, 1H, H7), 7.32–7.36 (m, 3H, ArCH), 7.44–7.47 (m, 2H, ArCH), 8.84 (bs, 1H,
NH); 13C-NMR (75.6 MHz, CDCl3): δ 51.8 (CO2Me), 56.0 (OMe), 58.2 (O-CH2), 84.1 (C≡C(Ph)), 87.4
(C-Ph), 93.9 (C7), 106.6 (C4), 109.0 (C3), 120.3 (aryl C), 122.4 (aryl C), 125.8 (C2), 128.2 (2 × aryl CH),
128.5 (aryl CH), 131.8 (2 × aryl CH), 132.8 (aryl C), 144.0 (C6), 150.7 (C5), 162.2 (CO2Me); HRMS (+ESI):
Found m/z 336.1221 [M + H]+, C20H18NO4 requires 336.1236.
Methyl 5,10-dihydro-7H-dipyrano[3,2-e:2′,3′-g]indole-6-carboxylate (10) Method 2: Route
2 The title compound was prepared as described in GP-3 from methyl
(Z)-2-azido-3-(3,4-bis(prop-2-yn-1-yloxy)phenyl) acrylate (9) (646 mg, 2.08 mmol) in xylene
(20 mL) to give the product (61.4 mg, 72%) as a yellow solid; m.p. 168–170 ◦C; IR (KBr): νmax 3415,
3328, 2947, 2831, 2341, 2116, 1674, 1640, 1575, 1524, 1486, 1441, 1400, 1274, 1213, 1158, 1135, 1025, 1000,
920, 813, 755 cm−1; UV-vis (CH3CN): λmax 225 nm (ε 24,100 cm−1 M−1), 269 (13,800), 360 (13,000);
1H-NMR (300 MHz, CDCl3): δ 3.96 (s, 3H, CO2Me), 4.91 (dd, J = 3.8, 1.8 Hz, 2H, O-CH2), 4.94 (dd, J =
3.8, 1.8 Hz, 2H, O-CH2), 5.87–5.97 (m, 2H, H3 and H9), 6.72–6.80 (m, 2H, H4 and H8), 7.19 (d, J =
2.1 Hz, 1H, H5), 8.85 (s, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ52.0 (CO2Me), 65.7 (O-CH2), 65.8
(O-CH2), 106.5 (C5), 107.0 (aryl C), 115.3 (aryl C), 118.8 (C4), 119.3 (C8), 120.8 (aryl C), 121.8 (C3), 121.9
(C9), 126.5 (C6), 128.8 (aryl C), 138.1 (aryl C), 141.7 (aryl C), 162.3 (CO2Me); HRMS (+ESI): Found m/z
306.0736 [M + Na]+, C16H13NO4Na requires 306.0737.
This compound was also prepared by the methods described below. Method 1: The title compound
was prepared as described in GP-6 from methyl 5,6-bis(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate
(16) (118 mg, 0.42 mmol) in chlorobenzene (30 mL) to give the product (43.5 mg, 51%) as a yellow solid.
Method 2: Route 1 The title compound was prepared as described in GP-6 from methyl
(Z)-2-azido-3-(2H,10H-pyrano[4,3-h]chromen-5-yl)acrylate (17) (646 mg, 2.08 mmol) in xylene (20 mL)
to give the product (52.9 mg, 62%) as a yellow solid.
Methyl 5-methoxy-3,7-dihydropyrano[3,2-e]indole-2-carboxylate (27a) The title compound was prepared as
described in GP-6 from methyl 6-methoxy-5-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (26a) (108
mg, 0.42 mmol) in chlorobenzene (30 mL) to give the product (80 mg, 74%) as a yellow solid; m.p.
166–168 ◦C; IR (KBr): νmax 3325, 2948, 2839, 2340, 2110, 1677, 1637, 1515, 1439, 1271, 1193, 1143, 1098,
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998, 931, 883, 808, 752 cm−1; UV-vis (CH3CN): λmax 212 nm (ε 37,400 cm−1 M−1), 271 (13,300), 322
(30,600); 1H-NMR (300 MHz, CDCl3): δ 3.92 (s, 3H, OMe), 3.93 (s, 3H, CO2Me), 4.90 (dd, J = 3.7, 1.7 Hz,
2H, O-CH2), 5.89–5.95 (m, 1H, H8), 6.76–6.79 (m, 1H, H9), 6.79 (s, 1H, H4), 7.17 (d, J = 2.1 Hz, 1H, H1),
8.96 (s, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 51.8 (CO2Me), 56.0 (OMe), 65.7 (O-CH2), 93.8 (C4),
106.1 (C1), 114.9 (aryl C), 118.3 (aryl C), 121.6 (C9), 121.8 (C8), 126.0 (C2), 132.2 (aryl C), 139.3 (aryl
C), 148.8 (C5), 162.2 (CO2Me); HRMS (+ESI): Found m/z 282.0731 [M + Na]+, C14H13NO4Na requires
282.0737.
Methyl 5-methoxy-1,7-dihydropyrano[2,3-g]indole-2-carboxylate (22a) The title compound was prepared as
described in GP-6 from methyl 5-methoxy-6-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (21a) (108
mg, 0.42 mmol) in chlorobenzene (30 mL) to give the product (83 mg, 77%) as a yellow solid; m.p.
188–190 ◦C; IR (KBr): νmax 3327, 2944, 2827, 2366, 2106, 1677, 1528, 1444, 1306, 1221, 1148, 1101, 989, 955,
831, 755 cm−1; UV-vis (CH3CN): λmax 226 nm (ε 28,100 cm−1 M−1), 290 (16,700), 339 (18,400); 1H-NMR
(300 MHz, CDCl3): δ 3.94 (s, 3H, OMe), 3.96 (s, 3H, CO2Me), 4.96 (dd, J = 3.8, 1.8 Hz, 2H, O CH2),
5.89–5.95 (m, 1H, H8), 6.75–6.79 (m, 1H, H9), 7.02 (s, 1H, H4), 7.13 (d, J = 2.1 Hz, 1H, H3), 8.94 (s, 1H
NH); 13C-NMR (75.6 MHz, CDCl3): δ51.9 (CO2Me), 56.2 (OMe), 65.7 (O-CH2), 103.1 (C4), 107.1 (aryl
C), 109.2 (C3), 119.3 (aryl C), 120.8 (C8), 121.0 (C9), 126.0 (C2), 128.7 (aryl C), 137.6 (aryl C), 145.2 (C5),
162.3 (CO2Me); HRMS (+ESI): Found m/z 282.0738 [M + Na]+, C14H13NO4Na requires 282.0737.
Methyl 5-methoxy-9-methyl-3,7-dihydropyrano[3,2-e]indole-2-carboxylate (27b) The title compound was
prepared as described in GP-6 from methyl 5-(but-2-yn-1-yloxy)-6-methoxy-1H-indole-2-carboxylate
(26b) (114 mg, 0.42 mmol) in chlorobenzene (30 mL) to give the product (62 mg, 54%) as a yellow solid;
m.p. 196–198 ◦C; IR (KBr): νmax 3310, 2948, 2925, 2833, 2106, 1675, 1640, 1517, 1495, 1439, 1366, 1274,
1265, 1194, 1146, 1080, 1004, 960, 880, 815, 765, 672 cm−1; UV-vis (CH3CN): λmax 213 nm (ε 28,900 cm−1
M−1), 267 (9,500), 322 (24,200); 1H-NMR (300 MHz, CDCl3): δ 1.63 (s, 3H, C-CH3), 3.94 (s, 3H, OMe),
3.95 (s, 3H, CO2Me), 4.77 (q, J = 2.4 Hz, 2H, O-CH2), 5.69–5.72 (m, 1H, H8), 6.87 (s, 1H, H1), 7.23 (s,
1H, H4), 8.82 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 22.6 (C-CH3), 51.8 (CO2Me), 56.1 (OMe),
65.2 (O-CH2), 93.8 (C4), 109.3 (C1), 117.4 (aryl C), 117.9 (aryl C), 118.3 (C8), 126.5 (C2), 132.0 (C-CH3),
132.9 (aryl C), 140.4 (aryl C), 149.0 (C5), 162.2 (CO2Me); HRMS (+ESI): Found m/z 296.0887 [M + Na]+,
C15H15NO4Na requires 296.0893.
Methyl 5-methoxy-9-methyl-1,7-dihydropyrano[2,3-g]indole-2-carboxylate (22b) The title compound was
prepared as described in GP-6 from methyl 6-(but-2-yn-1-yloxy)-5-methoxy-1H-indole-2-carboxylate
(21b) (114 mg, 0.42 mmol) in chlorobenzene (30 mL) to give the product (56 mg, 49%) as a yellow solid;
m.p. 176–178 ◦C; IR (KBr): νmax 3410, 2980, 2930, 2845, 1695, 1645, 1606, 1534, 1445, 1430, 1385, 1375,
1232, 1189, 1139, 1096, 1040, 998, 981, 927, 857, 744, 712cm−1; UV-vis (CH3CN): λmax 224 nm (ε 32,500
cm−1 M−1), 286 (22,200), 337 (23,500); 1H-NMR (300 MHz, CDCl3): δ 1.71 (s, 3H, C-CH3), 3.94 (s, 3H,
OMe), 3.96 (s, 3H, CO2Me), 4.77 (q, J = 1.6 Hz, 2H, O-CH2), 5.65–5.68 (m, 1H, H8), 7.05 (s, 1H, H4),
7.14 (d, J = 2.1 Hz, 1H, H3), 8.81 (bs, 1H, NH), 13C-NMR (75.6 MHz, CDCl3): δ 20.8 (C-CH3), 51.8
(CO2Me), 56.2 (OMe), 65.4 (O-CH2), 103.2 (C4), 108.9 (C3), 109.9 (aryl C), 117.7 (C8), 121.9 (aryl C),
126.0 (C2), 128.7 (C-CH3), 129.3 (aryl C), 144.2 (aryl C), 145.4 (C5), 162.1 (CO2Me); HRMS (+ESI): Found
m/z 296.0886 [M + Na]+, C15H15NO4Na requires 296.0893.
Methyl 5-methoxy-9-phenyl-3,7-dihydropyrano[3,2-e]indole-2-carboxylate (27d) The
title compound was prepared as described in GP-6 from methyl
6-methoxy-5-((3-phenylprop-2-yn-1-yl)oxy)-1H-indole-2-carboxylate (26d) (140 mg, 0.42 mmol) in
chlorobenzene (30 mL) to give the product (113 mg, 81%) as a yellow solid; m.p. 188–190 ◦C; IR (KBr):
νmax 3311, 2949, 2816, 2114, 1684, 1639, 1598, 1515, 1500, 1438, 1400, 1360, 1260, 1241, 1193, 1141, 1042,
1011, 995, 920, 823, 759, 703 cm−1; UV-vis (CH3CN): λmax 274 nm (ε 11,600 cm−1 M−1), 326 (26,400);
1H-NMR (300 MHz, CDCl3): δ 3.82 (s, 3H, OMe), 4.00 (s, 3H, CO2Me), 4.85 (d, J = 4.4 Hz, 2H, O-CH2),
5.94–5.97 (m, 1H, H8), 5.98 (s, 1H, H4), 6.88 (s, 1H, H1), 7.30–7.34 (m, 2H, ArH), 7.41–7.44 (m, 3H, ArH),
8.76 (bs, 1H, NH), 13C-NMR (75.6 MHz, CDCl3): δ 51.7 (CO2Me), 58.1 (OMe), 65.1 (O-CH2), 94.2 (C4),
120
Molecules 2020, 25, 1377
109.4 (C1), 117.0 (aryl C), 117.5 (aryl C), 125.0 (C2), 120.4 (C8), 127.9 (aryl CH), 128.3 (2 × arylCH), 128.5
(2 × aryl CH), 132.8 (aryl C), 139.4 (C-Ph), 139.4 (aryl C), 141.1 (aryl C), 149.0 (C5), 162.1 (CO2Me);
HRMS (+ESI): Found m/z 358.1057 [M + Na]+, C20H17NO4Na requires 358.1055.
Methyl 5-methoxy-7,7-dimethyl-3,7-dihydropyrano[3,2-e] indole-2-carboxylate (27c)
The title compound was prepared as described in GP-3 from methyl
(Z)-2-azido-3-(4-methoxy-3-((2-methylbut-3-yn-2-yl)oxy)phenyl)acrylate (25c) (654 mg, 2.08
mmol) in xylene (20 mL) to give the product (220 mg, 68%) as a yellow solid; m.p. 144–146 ◦C; IR
(KBr): νmax 3316, 2962, 2975, 2111, 1681, 1625, 1600, 1510, 1439, 1400, 1366, 1270, 1230, 1192, 1131, 1075,
999, 934, 887, 818, 754, 728 cm−1; UV-vis (CH3CN): λmax 219 nm (ε 40,000 cm−1 M−1), 271 (13,500), 323
(31,100); 1H-NMR (300 MHz, CDCl3): δ 1.53 (s, 6H, 2 × CH3), 3.92 (s, 3H, OMe), 3.95 (s, 3H, CO2Me),
5.73 (d, J = 9.7 Hz, 1H, H8), 6.68 (d, J = 9.7 Hz, 1H, H9), 6.79 (s, 1H, H4), 7.19 (d, J = 2.1 Hz, 1H, H1),
9.00 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 27.3 (2 × C-CH3), 51.7 (CO2Me), 58.1 (OMe), 76.2
(C-(CH3)2), 93.1 (C4), 106.1 (C1), 113.4 (aryl C), 118.2 (aryl C), 119.3 (C9), 125.7 (C2), 130.6 (C8), 132.0
(aryl C), 138.1 (aryl C), 149.5 (C5), 162.3 (CO2Me); HRMS (+ESI): Found m/z 310.1044 [M + Na]+,
C16H17NO4Na requires 310.1050.
Methyl 5-methoxy-7,7-dimethyl-1,7-dihydropyrano[2,3-g] indole-2-carboxylate (22c)
The title compound was prepared as described in GP-3 from methyl
(Z)-2-azido-3-(3-methoxy-4-((2-methylbut-3-yn-2-yl)oxy)phenyl)acrylate (20c) (654 mg, 2.08
mmol) in xylene (20 mL) to give the product (203 mg, 74%) as a yellow solid; m.p. 158–160 ◦C; IR
(KBr): νmax 3338, 2955, 2919, 2845, 2111, 1676, 1640, 1595, 1534, 1444, 1370, 1350, 1310, 1265, 1217, 1195,
1134, 1099, 1050, 985, 960, 880, 826, 760, 714 cm−1; UV-vis (CH3CN): λmax 226 nm (ε 29,600 cm−1 M−1),
262 (15,200), 341 (19,000); 1H-NMR (300 MHz, CDCl3): δ 1.55 (s, 6H, 2 × CH3), 3.93 (s, 3H, OMe), 3.96
(s, 3H, CO2Me), 5.71 (d, J = 9.7 Hz, 1H, H8), 6.66 (d, J = 9.7 Hz, 1H, H9), 7.02 (s, 1H, H4), 7.13 (d, J = 2.1
Hz, 1H, H3), 8.95 (bs, 1H, NH); 13C-NMR (75.6 MHz, CDCl3): δ 27.4 (2 × C-CH3), 51.8 (CO2Me), 56.5
(OMe), 76.6 (C-(CH3)2), 103.3 (C4), 105.8 (aryl C), 109.3 (C3), 116.8 (C9), 120.6 (aryl C), 125.7 (C2), 128.9
(aryl C), 129.8 (C8), 142.3 (aryl C), 149.9 (C5), 162.4 (CO2Me); HRMS (+ESI): Found m/z 288.1228 [M +
H]+, C16H18NO4 requires 288.1236.
3.2. Cell Biology Techniques
The SH-SY5Y and Kelly human neuroblastoma cell lines were generously donated by Dr. J.
Biedler (Memorial Sloan-Kettering Cancer Center, New York, NY, USA). The MDA-MB-231 and MCF-7
breast cancer cell lines were purchased from the American Type Culture Collection. All cell lines
were cultured under standard conditions at 37 ◦C in 5% CO2 as an adherent monolayer in Dulbecco’s
modified Eagle’s medium supplemented with l-glutamine (DMEM) (Invitrogen, Waltham, MA, USA)
and 10% fetal calf serum (FCS) (Thermo Fisher Scientific, Waltham, MA, USA).
Method for Cell Viability Assays
Cell viability was measured by the standard Alamar blue assay, as previously described [18].
Briefly, cells were allowed to attach for 24 h in 96-well culture plates. The cells were then continuously
exposed to serial dilutions of the hydrazide-hydrazone derivatives for 72 h, either in the presence
or absence of SAHA (0.5 or 1 μM), with five replicate wells for each determination. Cell viability
was determined by the addition of 22 μL of Alamar blue reagent, recorded at comparative 0 h
and 5 h values, using a Wallac 1420 Victor III spectrophotometer (GMI, Ramsey, MN, USA), which
measured light absorbance in each well at 570 nm. The cell viability of each plate was calculated as
a percentage compared to matched DMSO controls (0.5%). The mean (+/’SEM) is shown for three
independent experiments.
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3.3. Statistical Analysis
Results of the cell viability studies were statistically analyzed using the two-tailed, unpaired
Student’s t-test. Results are expressed as mean values with 95% confidence intervals.
4. Conclusions
The studies presented in this study have contributed to the investigation of the potential of
dihydropyranoindoles to act as SAHA enhancers for the treatment of neuroblastoma and breast cancer
cells. To the best of our knowledge, this is the first study which was carried out on the combination
of SAHA with dihydropyranoindoles. The desired tricyclic and tetracyclic dihydropyranoindoles was
achieved by the reaction of corresponding hydroxybenzaldehydes with haloalkynes followed by the
application of the Hemetsberger indole synthesis to yield the related indoles. Claisen cyclization
in the presence of chlorobenzene afforded the desired compounds in good yields. Some of the
dihydropyranoindoles were successfully synthesized from the corresponding azido intermediates in one
step by the thermal decomposition step of the Hemetsberger indole synthesis. The biological studies
revealed that the breast cancer cells displayed significant resistance towards the combination treatments
of the dihydropyranoindoles compared to the neurobalstoma cells. It was also found that tetracyclic
analogues of dihydropyranoindoles 33 and 10 were found to be more favorable for the enhancement
of SAHA activity, while only dihydropyrano[3,2-e]indole tricyclic systems 27a and 27c resulted in the
additional reduction of the SAHA cytotoxicity against the neuroblastoma cell lines. Taken altogether, the
tetracyclic dihydropyranoindole 10 was determined as the most cytotoxic compound at the concentration
20 μM, while the lower concentration of the designated compound displayed the best enhancement on
SAHA activity with the value of 44% additional reduction at the ratio of 1:10 SAHA to compound.
Supplementary Materials: The following figures are available online: Figure S1 Cell viability of A) SH-SY5Y, B)
MDA-MB-231 cancer cells treated with the selected six compounds 1–6 (10 μM) over 72 h. Error bars represent
mean values (±S.D.) for three independent determinations. Figure S2. Comparative toxicity of compounds 1, 3
and 4 (10 μM) against SH-SY5Y, MDA-MB-231 and MRC-5 cell lines after 72 h exposure. Error bars represent
mean values (±S.D.) for three independent determinations. Figure S3. Cell viability of A) MCF-7 p < 0.01 B)
MDA-MB-231 p < 0.05 breast cancer cells treated with 10 μM compounds over 72 h, in the presence or absence
of 1 μM of SAHA. Error bars represent mean values (±S.D.) for three independent determinations Figure S4.
Cell viability of A) Kelly p ≥ 0.05 (ns) B) SH-SY5Y p < 0.0005 neuroblastoma cancer cellstreated with 10 μM
compounds over 72 h, in the presence or absence of 1 μM of SAHA. Error bars represent mean values (±S.D.) for
three independent determinations. Figure S5. Cell viability of KELLY neuroblastoma cancer cells treated with
compounds A) 33 p < 0.01 B) 27c p < 0.05 and C) 10 p < 0.05 at different concentrations (0.01, 0.1, 1, 10, 20 μM)
over 72 h in the absence and presence of SAHA. Error bars represent mean values (±S.D.) for three independent
determinations. Figure S6. Cell viability of SH-SY5Y neuroblastoma cancer cells treated with compounds A) 27a,
p < 0.0005 B) 33, p < 0.0005 C) 10, p < 0.01 and D) 27c, p < 0.01 at different concentrations (0.01, 0.1, 1, 10, 20 μM)
over 72 h in the absence and presence of SAHA. Error bars represent mean values (±S.D.) for three independent
determinations. Figure S7. Comparative toxicity of compounds A) 27a, p < 0.05 B) 33, p < 0.05 C) 10, p < 0.05
and D) 27c, p < 0.0005 (10 μM) against cancer cells (Kelly, SH-SY5Y, MCF-7 and MDA-MB-231) and human lung
fibroblasts (WI-38 and MRC-5) cell lines after 72 h exposure. Error bars represent mean values (±S.D.) for three
independent determinations.
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Abstract: In this article, we report the design, synthesis, photodynamic properties, and in vitro
evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor
Talazoparib. In order to yield a photoactivatable, inactive prodrug, photoactivatable protecting groups
(PPGs) were employed to mask the key pharmacophore of Talazoparib. Our study confirmed the
good stability and photolytic effect of prodrugs. A PARP-1 enzyme inhibition assay and PARylation
experiment showed that the inhibitory activity of the prodrug was reduced 380 times and more
than 658 times, respectively, which proved that the prodrug’s expected activity was lost after PPG
protection. In BRCA1- and BRCA2-deficient cell lines, the inhibitory activity of the compound was
significantly restored after ultraviolet (UV) irradiation. The results indicate that the photoactivatable
prodrug strategy is an interesting approach for studying PARP inhibitors. Meanwhile, the described
photoactivatable prodrug also provided a new biological tool for the mechanism research of PARP.
Keywords: Talazoparib; PARP inhibitor; prodrug; o-nitro-benzyl; photoactivatable protecting groups
1. Introduction
DNA repair in normal cells mainly relies on the base excision repair (BER) pathway for single-strand
DNA breaks and the homologous recombination (HR) pathway for double-strand DNA breaks [1].
Poly (ADP-ribose) polymerase (PARP) plays a key role in the repair of single-strand DNA breaks,
through its ability to bind to DNA gaps and recruit other DNA repair enzymes in the BER pathway [1–4].
The tumor suppressor proteins encoded by the breast cancer genes BRCA1 and BRCA2 participate in
the HR of double-strand DNA breaks [5]. Usually, in tumor cells with BRCA1 and BRCA2 mutations or
defects, the inhibition of the PARP enzyme can lead to the accumulation of single-strand DNA breaks,
owing to the HR repair pathway being blocked, which causes further double-strand DNA breaks and
finally results in the death of tumor cells [6–8]. Currently, PARP inhibitors have been a hot topic in
the tumor research area. Among them, Olaparib, Rucaparib, Niraparib, and Talazoparib have been
approved for the treatment of BRCA-deficient breast, ovarian, fallopian tube, and primary peritoneal
cancers [9]. In addition, PARP inhibitors are also used in combination with some kinase inhibitors,
and show significant synergistic antitumor effects on prostate cancer, pancreatic cancer, gastric cancer,
acute leukemia, and non-small-cell lung cancer [10–13]. The number of diseases illustrate the huge
potential for therapeutic agents and for biological probes in PARP research.
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Talazoparib (trade name: Talzenna), an oral PARP inhibitor developed by Pfizer, was approved
by the U.S. Food and Drug Administration (FDA) on 16 October 2018 [14,15]. It is currently the most
active compound among the PARP inhibitors, with an IC50 of 0.57 nM, which is 4–10 times lower
than that of the other PARP inhibitors [16]. The clinical dose of Talazoparib is only 1 mg (once a day).
In contrast, to achieve similar effects as Talazoparib, the dosage of Olaparib [17] and Niraparib [18] are
400 mg (twice a day) and 300 mg (once a day), respectively. In addition, while Talazoparib is highly
effective in killing tumor cells, there may still be serious side effects, such as myelodysplastic syndrome
or acute myeloid leukemia [14,19]. In light of the immense significance of PARP inhibitors, we aimed
to develop a relevant, photoactivatable Talazoparib prodrug.
Photoactivatable prodrugs are usually designed by blocking a key pharmacophore moiety of
the inhibitor using photoactivatable protecting groups (PPGs), which have been widely used in
biology and medicine in recent years as a non-invasive approach [20–22]. This method can provide
temporal and spatial control for the release of bioactive substance by UV irradiation. Thus, highly active
inhibitors can be generated in irradiated areas of interest at defined points in time. The photoactivatable
prodrugs can serve as a novel biological tool for kinetic or mechanistic studies. Moreover, blocked
inhibitors may minimize the systemic side effects of Talazoparib, in order to enable a higher dosage of
inactive prodrugs.
The o-nitrobenzyl system and its derivatives are one of the most commonly used PPGs [23–26].
The photolysis mechanism is intramolecular rearrangement. As shown in Figure 1, under 365 nm
UV irradiation, carbonyl compounds containing o-nitrobenzyl can form a highly active bi-radical,
which will undergo hydrogen abstraction on the carbon atom at the γ position and release the parent
drugs [26–29]. The advantages of such PPG technology are a high release speed and easy chemical
synthesis. At the same time, the UV release wavelength of 365 nm involves less DNA damage than
wavelengths shorter than 300 nm, and is harmless to tissues and cells at low doses [29,30]. This method
has potential clinical application value [25,26]. For example, irradiation can be temporarily applied
to the lesion site during or after surgery to release active substances for killing residual cancer cells,
thereby preventing postoperative recurrence. Optical fibres and endoscopic probes can also be used to
transmit the required light to the action site to treat some superficial tumors.
 
Figure 1. Photolysis mechanism of o-nitrobenzyl upon 365 nm UV irradiation and the inferred drug
release process of the Talazoparib prodrug.
In this study, we report the design, synthesis, photodynamic properties, and in vitro evaluation
of a photoactivatable prodrug for the PARP-1 inhibitor Talazoparib. We used the concept of PPGs
to covalently bond o-nitrobenzyl derivatives (herein designated as compound 2) to the lactam
pharmacophore of Talazoparib, under the guidance of molecular docking; this disrupts its key
hydrogen bonding interaction with the PARP protein residue to yield an inactive photoactivatable
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prodrug, i.e., compound 3. Our research proved that newly designed prodrug 3 showed good stability
and could be rapidly deprotected after UV radiation. A PARP-1 enzyme inhibition assay and PARylation
experiment showed that inhibitory activity of the PPG-protected prodrug was greatly reduced by
380 and more than 658 times, respectively. In addition, in BRCA1- and BRCA2-deficient cell lines,
the inhibitory activity of the prodrug 3 was significantly restored after transitory UV irradiation, and the
data implies that inhibitory activity could increase with prolonged irradiation time. The results of this
preliminary study indicate that the photoactivatable prodrug strategy was an interesting approach for
studying PARP inhibitors. Meanwhile, the described photoactivatable prodrugs also provide a novel
biological tool for the signal transduction research.
2. Results and Discussion
2.1. Molecular Modelling
Molecular docking of the Tazaloparib into the catalytic domain of PARP-1 (catPARP-1) revealed
that its lactam moiety was the key pharmacodynamic group (PDB ID 4PJT). N and O atoms on the
lactam moiety could form hydrogen bonds with the Gly863 and Ser904 residues of PARP-1, respectively
(Figure 2A) [31,32]. To block its pharmacophoric features, we linked PPGs (namely, compound 2) to
the lactam moiety to form compound 3, and simulated the action mode of this compound in the same
activity pocket. Consistent with our hypothesis, no proper binding of compound 3 to the enzyme active
sites were found during the docking; that is, the PPGs blocked the interaction of the lactam moiety with
the Gly863 and Ser904 residues (Figure 2B). In addition, the introduction of PPGs led to spatial conflict,
which rendered compound 3 unable to maintain the same binding mode as Talazoparib, and the
whole molecule was turned over by a certain angle degree (Figure 2C). Inspired by this docking result,
we synthesised compound 3 and carried out the following series of photochemical characterisations
and biological evaluations.
Figure 2. Predicted ligand binding models relative to the catalytic domain of poly (ADP-ribose)
polymerase 1 (catPARP-1). (A) The co-crystallized binding modes of Talazoparib and the catPARP-1
protein were taken from PDB ID 4PJT. (B) Predicted co-crystallized binding poses of compound 3
in a complex with catPARP-1. (C) Superimposition of the binding models of Tazaloparib (blue) and
compound 3 (red) with catPARP-1 protein (green).
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2.2. Chemistry
As shown in Scheme 1, Talazoparib could generate the intermediate compound 4 under the action
of n-Butyllithium. Compound 4 subsequently underwent a nucleophilic substitution reaction with
compound 2 to generate the photoactivatable target compound 3.
 
Scheme 1. Synthesis of compound 3. Reagents: (a) n-BuLi, tetrahydrofuran (THF), N2, –80 ◦C, 10 min;
(b) THF, N2, 0 ◦C, 1 h.
2.3. Stability Assays and UV Cleavage Test In Vitro
2.3.1. UV Stability of Talazoparib
Talazoparib should have sufficient stability at the light radiation wavelength used; otherwise,
it will be degraded immediately after release or even before the breaking of the PPG covalent bond.
Therefore, we first evaluated the UV stability of Talazoparib at a wavelength of 365 nm. To this end,
we used a UV cross-linker with an emission wavelength of 365 nm (4.1 mWs/cm2) to irradiate 2.63 mM
Talazoparib in methanol, and took aliquots of the sample at different times for high-performance
liquid chromatography (HPLC) analysis. The result indicated that there was no significant loss of
Talazoparib in the peak area within 10 min, showing good UV stability (Figure 3A). In addition,
the UV/vis absorption spectra of Talazoparib and compound 3 was shown in supplementary materials
(See Figure S1).
 
Figure 3. Stability assays and UV cleavage test in vitro. Compounds were irradiated at 365 nm
(4.1 mW/cm2). Samples were determined on a C18 column using a water/acetonitrile (ACN) gradient.
The detection wavelength for high-performance liquid chromatography (HPLC) analysis was 220 nm.
The peak area or peak area percentage was plotted against the irradiation time. (A) UV stability of
Talazoparib: 2.63 mM Talazoparib in methanol were irradiated up to 10 min, and aliquot samples
at different time points were analyzed by HPLC. Talazoparib was stable under the described UV
irradiation. (B) Phosphate-buffered saline (PBS) stability of the photoactivatable prodrug: 20 μM
compound 3 in pH = 7.4 PBS (containing 10% DMSO) were incubated at 37 ◦C for 48 h and analyzed
by HPLC. The peak area of compound 3 did not show significant changes. (C) UV cleavage test on
compound 3: 20 μM of the compound in methanol was irradiated at 365 nm for 5 min and analyzed by
HPLC. By progressing irradiation, compound 3 was converted into Talazoparib.
2.3.2. Stability of the Photoactivatable Prodrug in Phosphate-Buffered Saline
The synthesised photoactivatable prodrug should be sufficiently stable. If a high dose of inactive
prodrugs were converted to the parent drug in advance, this might produce some undesirable toxic
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and side effects. Therefore, we tested the stability of compound 3 in phosphate-buffered saline (PBS)
with the same pH as blood. Then 20 μM of compound 3 were added to pH = 7.4 PBS containing 10%
dimethyl sulfoxide, which was incubated in a 37 ◦C thermostatic incubator for 48 h under normal
brightness, during which samples of equal concentration were taken at different time points for HPLC
analysis. The results were plotted according to the sampling time points and the peak areas of the
compound (Figure 3B). The peak area of compound 3 did not show significant changes within 48 h,
indicating that the compound 3 had good stability in PBS.
2.3.3. UV Release of the Photoactivatable Prodrug
A photoactivatable prodrug needs to not only have good stability, but also be rapidly and
effectively released at the irradiated site. Therefore, we tested the photolysis of compound 3. Figure 3C
shows the release situation of compound 3 (20 μM in methanol) after UV irradiation. Under the current
experimental conditions, compound 3 could rapidly and completely release Talazoparib in 3 min.
In addition, the release experiment also provided a reference for the irradiation duration to be used for
the subsequent cell experiments.
2.4. Enzymatic Experiments In Vitro
2.4.1. Inhibition of the PARP-1 Enzyme
According to the guidance of molecular docking, after the PPG was introduced at the lactam
pharmacophore of Talazoparib, the prodrug 3 should have had a reduced inhibitory effect on the
PARP-1 enzyme. Therefore, we evaluated the inhibitory activities of Talazoparib and compound
3 on PARP-1. As shown in the dose-dependent curve in Figure 4A, the inhibitory activity of the
PPG-inactivated compound 3 was significantly lower than that of Talazoparib. The IC50 values of
Talazoparib and compound 3 were 0.005 and 1.919 μM, respectively, indicating that the inhibitory
activity was reduced by 380 times (Table 2). This was consistent with the prediction from the molecular
docking. The test results strongly proved that the interaction between the inhibitor and PARP-1 enzyme
could be significantly blocked after introducing PPG to the lactam pharmacophore of Talazoparib.
Table 1. Inhibitory activity of Talazoparib and compound 3 on poly (ADP-ribose) (PAR) polymerization.





Figure 4. (A) Dose–response curve of Talazoparib and compound 3 on PARP-1 enzyme inhibition.
Compound 3 showed a significant decrease in the inhibitory activity compared to the active Talazoparib
to PARP-1 enzyme. Error bars represent standard deviation from duplicate determinations, and results
are shown as mean ± standard deviation (SD). The IC50 value is presented in Table 2. (B) Dose–response
curve of Talazoparib and compound 3 on PARylation assay. The ability of compound 3 to inhibit the
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polymerization of PAR significant decreased compared to the active Talazoparib in Hela cells. Error bars
represented standard deviation from duplicate determinations, and results are shown as mean ± SD.
The IC50 value is presented in Table 1.
Table 2. Poly (ADP-ribose) polymerase 1 (PARP-1) enzyme inhibitory activity of Talazoparib and
compound 3.





The inhibitory activity of compounds on the PARP-1 enzyme could also be evaluated at the cellular
level by using a hydrogen peroxide solution to damage the DNA of cells. Under normal circumstances,
PARP-1 would be activated immediately, and the poly (ADP-ribose) polymer would be synthesised
with NAD+ as the substrate. In the presence of a PARP-1 inhibitor, however, the biological function
of PARP-1 would be inhibited. Therefore, the inhibitory activity on PARP-1 can be determined by
detecting the level of poly (ADP-ribose) [16,33]. From the data in Figure 4B and Table 1, it can be seen
that Talazoparib showed a strong inhibitory effect on poly ADP-ribosylation in HeLa cells, with an
IC50 value of less than 0.0005 μM, whereas compound 3 showed a weak inhibitory effect, with an IC50
value of 0.329 μM, a decrease of 658 times at least.
2.5. Compound’s Cytotoxicity Assay in the Absence and Presence of UV Irradiation
After confirming that the introduction of PPG could block the inhibitory activity of Talazoparib
on PARP-1, we speculated that compound 3 should also have less cytotoxicity than Talazoparib.
To verify this idea, cell proliferation inhibition experiments were conducted. As Talazoparib should
only be applied to BRCA1 or BRCA2-defective cell lines, the principle is simultaneous inhibition
of the BER pathway and HR repair pathway of DNA to produce a synthetic lethality effect and
consequently, the apoptosis of the tumour cells. Therefore, we selected the well-recognized BRCA1-
and BRCA2-defective cell lines MX-1 and Capan-1 for the following tests. The results indicate that
Talazoparib exhibited effective cytotoxicity in the MX-1 and Capan-1 cell lines (IC50 values: 0.015 μM
and 0.003 μM, respectively). In contrast, the PPG-inactivated compound 3 showed no significant
cytotoxicity, with IC50 values of 1.873 μM and 0.863 μM, respectively (Figure 5 and Table 3).
 
Figure 5. Dose–response curves of compound 3 in the absence and presence of ultraviolet irradiation.
Cells were incubated for 1 h with the compounds and were then irradiated at 365 nm (4.1 mW/cm2).
Cell growth was determined 10 days after incubation with the compounds. Irradiated compounds
showed left-shifted dose–response curve compared to that of the unirradiated compounds. Error bars
represent the standard deviation from duplicate determinations, and results are shown as mean ± SD.
The IC50 value is presented in Table 3.
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Table 3. Capan-1 and MX-1 cell inhibitory activities of Talazoparib and compound 3 in the absence and
presence ultraviolet radiation.
Test Compound MX-1 Cell (UV + 1 min) IC50 (μM) Capan-1 Cell (UV + 3 min IC50 (μM)
Talazoparib (UV-) 0.015 0.003
3 (UV-) 1.873 0.863
3 (UV+) 0.577 0.092
Next, we tested whether the inhibitory activity of compound 3 could be restored after UV
irradiation. In order to negate the influence of UV irradiation on cells, to avoid interfering with the
experiment results, we first measured the maximum tolerance of cells to UV light. As shown in
Figure 6, the MX-1 cell line was relatively sensitive to UV irradiation, and could tolerate an irradiation
duration of 1 min, whereas further extension of the duration would affect cell proliferation. In contrast,
the Capan-1 cell line could tolerate UV irradiation for a relatively long time, and approximately 85%
of the cells were still alive after irradiation for 5 min. On the basis of the principle of maximising
drug release, while ensuring normal cell proliferation as much as possible, we determined the UV
irradiation durations for the MX-1 and Capan-1 cells to be 1 min and 3 min, respectively.
Figure 6. Cellular ultraviolet light tolerance test. Cells were irradiated at 365 nm (4.1 mW/cm2) for
indicated periods of time, and cell growth was determined after 10 days. The MX-1 cell line was
relatively sensitive to UV irradiation. Radiation over 1 min affected cell proliferation. In contrast,
the Capan-1 cell line tolerated UV irradiation for a relatively long time.
As shown in Table 3, the inhibitory activity of compound 3 on MX-1 cells after UV irradiation
was approximately three times higher than that on the non-irradiated group (IC50 values: 1.873 μM
vs. 0.577 μM, respectively). However, it did not reach the same level of inhibition as the parent drug
Talazoparib, likely because the irradiation duration of 1 min was not enough to allow the release of all
the compound 3. Therefore, we tested the Capan-1 cells that could tolerate a longer UV irradiation
duration. To our delight, the IC50 value of compound 3 for Capan-1 cells was 0.092 μM after 3 min of
irradiation, which was nine times higher than that of the non-irradiated group (IC50 value: 0.863 μM).
Further analysis was needed to determine the reason why the inhibitory activity of compound 3 still
did not reach the same level as Talazoparib after UV irradiation. We simulated the same cytotoxicity
experimental conditions to evaluate the photolysis of 10 μM compound 3 (10 μM is the starting
concentration of compound 3 in cytotoxicity experiments) in a 96-well plate. The results showed that
compound 3 was not released completely after 3 min UV irradiation (see Figure S2).
The above cytotoxicity experiment data indicated that compound 3 could significantly restore the
effective activity of Talazoparib after being irradiated by UV light, and the data from both cells imply
that inhibitory activity could increase with prolonged irradiation time. However, owing to the limited
types of BRCA-deficient cells that could be selected for study and their restrictive UV light tolerance,
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compound 3 did not reach the same level of inhibitory activity as Talazoparib. The experimental results
could provide inspiration for future research.
2.6. Verification of the Toxicity of Leaving Photoactivatable Protecting Groups
Subsequently, the leaving PPG after irradiation was also evaluated for its cytotoxicity. Compound 3
was obviously not suitable for verifying this, since it released active Talazoparib after its photocleavage.
Therefore, we used an indirect test method by synthesising compound 6 via the nucleophilic substitution
reaction between the non-cytotoxic Boc-protected amino acid L-alanine (Boc-Ala), as reported in the
literature, and compound 2 under the catalysis of potassium carbonate (Scheme 2), and examined
compound 6′s effect on cell proliferation before and after irradiation [25,26].
Scheme 2. Synthesis of compound 6. Reagents: (c) K2CO3, reflux, 5 h.
We first evaluated the photolysis of compound 6, and the experimental results showed that 20 μM
of compound 6 in methanol solution were almost completely released within 20 min (see Figure S3).
Next, we used the same initial concentration as that of compound 3 for the measurement. To fully
release the drug, we UV-irradiated compound 6 at different concentrations for 20 min, and then added
each sample to cells for co-culture. As a result, compound 6 showed no significant cytotoxicity in
MX-1 and Capan-1 cells both before and after irradiation (Figure 7 and Table 4). Since the Boc–Ala
released after irradiation was not cytotoxic, the results verified that the leaving PPG at the indicated
concentrations did not cause any cytotoxicity. This therefore proved that the cytotoxicity of compound 3
after irradiation could be attributed entirely to the released Talazoparib.
Figure 7. Dose–response curves of compound 6 in the absence and presence of ultraviolet radiation in
the MX-1 and Capan-1 cells. After 20 min of irradiation at 365 nm (4.1 mW/cm2), the compounds were
transferred to 96-well plates and incubated with the cells. Cell growth was determined 10 days after
incubation with the compounds. Irradiated compounds showed similar dose–response curves as that
of unirradiated compounds. Error bars represent standard deviation from duplicate determinations,
and results are shown as mean ± SD. The IC50 value is presented in Table 4.
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Table 4. MX-1 and Capan-1 cell inhibitory activities of compound 6 in the absence and presence
ultraviolet radiation.
Test Compound MX-1 Cell IC50 (μM) Capan-1 Cell IC50 (μM)
6 (UV-) >10 >10
6 (UV+) >10 >10
3. Materials and Methods
3.1. Molecular Docking
The catPARP-1 crystal structure (PDB ID 4PJT) was downloaded from the Protein Data Bank.
Molecular docking was carried out using Gold (The Cambridge Crystallographic Data Centre).
Before docking calculations, water molecules of the crystal structure were deleted, and hydrogen atoms
were added. The whole 4PJT was defined as a receptor, and the site sphere was selected based on the
active site of 4PJT. Compound 3 was placed during the molecular docking procedure. After the end of
molecular modelling, types of interactions of the docked protein with ligand were analyzed.
3.2. Chemistry
All of the reagents and solvents were purchased from Innochem (Beijing, China), Aladdin
(Shanghai, China), Energy Chemical (Shanghai, China), TCI (Tokyo, Japan), Ark Pharm (Libertyville,
IL, USA), and used without additional purification. Anhydrous solvents were stored in sure-seal
bottles under dry nitrogen. Analytical thin-layer chromatography was conducted on pre-coated silica
gel plates (Yantai Dexin Biotechnology Co., Ltd., Yantai, China). Visualization was accomplished with
254 nm and 365 nm UV light. Column chromatography was performed using silica gel (200–300 mesh;
Qingdao Ocean Chemical Engineering Co., Ltd., Qingdao, China).
Nuclear magnetic resonance (NMR) spectra were obtained on a JNM-ECA-400 400 MHz
spectrometer (JEOL Ltd., Tokyo, Japan). Chemical shifts were reported in ppm and TMS was used as
the internal standard. Coupling constants (J) are given in Hertz. Spin multiplicities were reported as
the following abbreviations: s (singulet), d (doublet), dd (doublet doublet), t (triplet), q (quadruplet),
m (multiplet). The mass spectrometry (MS) systems were the API 3000 triple-quadrupole mass
spectrometer equipped with a Turbo Ion Spray electrospray ionization (ESI) source (AB Sciex, Concord,
ON, Canada). HPLC analysis was performed using an Agilent 1260 Series (California, CA, USA).
3.2.1. Synthesis of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2-
((6-nitrobenzo[d][1,3]dioxol-5-yl)methyl)-2,7,8,9-tetrahydro-3H pyrido[4,3,2-de]phthalazin-3-one (3)
To a solution of Talazoparib (70 mg, 0.18 mmol) in anhydrous tetrahydrofuran (THF) (30 mL)
was added to a 100 mL, two-necked flask with a magnetic stir bar. The flask was evacuated and
backfilled with argon three times. Then 2.5 M n-Butyllithium (108 μL, 0.27 mmol) in hexanes were
added the reaction solution, and the mixture was cooled at −80 ◦C. After stirring for 10 min, a solution
of 5-(bromomethyl)-6-nitrobenzo[d][1,3] dioxole (93.9 mg, 0.27 mmol) in anhydrous THF was slowly
added to the mixture, was warmed to 0 ◦C, and stirred overnight. When the reaction was completed,
the mixture was carefully quenched by ammonium chloride saturated solution, and was extracted with
ethyl acetate (50 mL × 3). The combined organic layers were washed with brine, dried over anhydrous
sodium sulfate, and concentrated. The crude product was purified by column chromatography
(dichloromethane/methanol = 50:1) to give compound 3 (46 mg, yield 45.7%) as a light yellow solid;
1H NMR (400 MHz, DMSO-d6) δ 7.79 (s, 1H); 7.73 (s, 1H); 7.63 (s, 1H); 7.53–7.45 (m, 2H); 7.20–7.13
(m, 2H); 7.10 (dd, J = 9.0, 2.4 Hz, 1H); 6.93 (dd, J = 11.1, 2.5 Hz, 1H); 6.61 (s, 1H); 6.22–6.21 (m, 2H);
5.40–5.29 (m, 2H); 5.08–5.00 (m, 2H); 3.56 (s, 3H). ESI m/z (M + H)+ calculated for C27H20F2N7O5+
560.15 found 560.15.
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3.2.2. (6-Nitrobenzo[d][1,3]dioxol-5-yl)methyl (tert-butoxycarbonyl)-l-alaninate (6)
To a solution of (tert-butoxycarbonyl)-l-alanine (190 mg, 1.0 mmol) in acetone, potassium carbonate
(207.31 mg, 1.50 mmol) and compound 3 were added. Then the mixture was stirred and heated at reflux
for 5 h. After the reaction completed, the mixture was cooled to room temperature and removed under
reduced pressure. The residue was dissolved in water and then the aqueous solution was extracted
with dichloromethane (50 mL × 3). The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column
chromatography (ethyl acetate/petroleum ether = 5:1) to give compound 6 (264 mg, yield 71.4%) as a
light yellow solid; 1H NMR (400 MHz, DMSO-d6) δ 7.74 (s, 1H); 7.46 (d, J = 7.3 Hz, 1H); 7.22 (s, 1H),
6.26 (s, 2H); 5.43–5.32 (m, 2H); 4.15–4.08 (m, 1H); 1.38 (s, 9H); 1.27 (d, J = 7.4 Hz, 3H). ESI m/z (M +Na)+
calculated for C16H20N2NaO8+ 391.11 found 391.11.
3.3. Talazoparib UV Stability Assays
Talazoparib was dissolved in methanol (2.63 mM), and the solution was divided into six equal
portions for UV irradiation at 365 nm by using an UV crosslinker (CL-1000L UVP Crosslinker, 5 × 8 W;
Analytikjena, IL, USA). The irradiation times were 1 min, 2 min, 3 min, 4 min, 5 min, and 10 min.
The irradiated solution was transferred to a volumetric flask and diluted to the same volume with
methanol. Then HPLC analysis was performed to detect the compound peak area. Samples were
determined on an Agilent Eclipse Plus C18 column (4.6 × 150 mm, 5 μm particle size; California,
CA, USA) using a mobile phase A (water) and mobile phase B (acetonitrile (ACN)) to elute. The gradient
changed from 70% A to 30% A in 10 min, then continuing to elute with 30% A for 5 min. The flow rate
was 1 mL/min, and the detection wavelength was 220 nm.
3.4. Phosphate-Buffered Saline Stability of the Photoactivatable Prodrug
Twenty μM of the test compound in pH = 7.4 PBS, containing 10% DMSO, were transferred to
13 1 mL volumetric flasks in equal volumes, incubated at 37 ◦C. The volumetric flasks were taken out
at 0 min, 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h, and 7 days, and were frozen
at −80 ◦C. The samples were thawed in sequence and diluted to the same volume with methanol.
Then HPLC analysis was performed to detect the compound peak area. Samples were determined on
an Agilent Eclipse Plus C18 column (4.6 × 150 mm, 5 μm particle size; California, CA, USA) using a
mobile phase A (water) and mobile phase B (ACN) to elute. The gradient changed from 70% A to 30%
A in 10 min, continuing to elute with 30% A for 5 min. The flow rate was 1 mL/min, and the detection
wavelength was 220 nm.
3.5. UV Cleavage Test for Photoactivatable Prodrug
The compound was dissolved in methanol (20 μM), and the solution were irradiated at 365 nm by
using an UV crosslinker. Every minute from 0 to 10 min, aliquot samples (200 μL) were determined on
an Agilent Eclipse Plus C18 column (4.6 × 150 mm, 5 μm particle size) using mobile phase A (water)
and mobile phase B (ACN) to elute. The gradient changed from 70% A to 30% A in 10 min, continuing
to elute with 30% A for 5 min. The flow rate was 1 mL/min and the detection wavelength was 220 nm.
The peak areas percentage of the compounds at each time point were plotted against the sampling time.
3.6. PARP-1 Enzyme Inhibition Assay
A PARP-1 Chemiluminescent Assay Kit (Cat# 80569, BPS, San Diego, CA, USA) was used to
detect the ability of compounds to inhibit PARP-1 enzyme activity. All experimental steps followed the
operating manual. Firstly, each well was precoated with 25 μL 1× histone mixture that was diluted in
PBS by incubation at 4 ◦C overnight. The wells were blocked by adding 100 μL of blocking buffer,
then incubated at room temperature for 90 min. Then 12.5 μL of the prepared 1× PARP assay mixture
and 1× activated DNA in 1× PARP buffer were added into each well of the assay plate, and 2.5 μL of
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compound or solvent control were added at varying concentrations. The reaction was initiated by the
addition of 10 μL 1 ng/μL PARP-1 enzyme in 1× PARP buffer at room temperature for 60 min. Next,
the reaction solution was added with 25 μL of diluted Streptavidin-HRP (1:50 in blocking buffer) to
each well at room temperature for an additional 30 min. Finally, 25 μL of Horseradish Peroxidase
(HRP) chemiluminescent substrate A and 25 μL of HRP chemiluminescent substrate B were mixed
on ice, and the mixture was added by 50 μL per well. The luminescent signal was measured using a
multi-function microplate reader, and IC50 values were calculated using GraphPad Prism 8.0 software.
3.7. PARylation Assay
The cellular PARylation assay evaluated the ability of test compounds to inhibit polymerization
of PAR. Hela cells were seeded in 96-well plates (10,000 cells/well) in 200 μL of cell complete medium,
and were allowed to adhere for 4 h at 37 ◦C in a humidified atmosphere of 5% CO2. The medium
was then removed from the plates, and the cells were treated with varying concentrations of test
compounds for 18 h. 100 μL serum-free medium with 500 μM H2O2 solution was added, and the plate
was kept at 37 ◦C for 5 min. Next, cells were fixed for 20 min with prechilled methanol at −20 ◦C
and were incubated with 60 μL Poly(ADP-ribose) monoclonal antibody (1:2000) (prepared at 1x PBS
containing 0.05% Tween-20 with 1% bovine serum albumin) at 37 ◦C for 2 h, followed by incubation
with 60 μL IRDye 800CW goat anti-mouse IgG (diluted to 1:5000) and DNA stain DRAQ5 (1:5000)
(prepared at 1× PBS containing 0.05% Tween-20 with 1% bovine serum albumin) at 37 ◦C for 2 h.
The fluorescent signal was normalized with the DRAQ5 signal, and IC50 values were calculated using
GraphPad Prism 8.0 software.
3.8. Cell Proliferation Assay
To assess the cytotoxicity of test compounds on BRCA-deficient cells using a CellTiter-Glo
assay. MX-1 cells (BRCA1-deficient) and Capan-1 cells (BRCA2-deficient) were seeded in 96-well plates
at densities that allowed linear growth for 10 days, and adhered overnight at 37 ◦C in a humidified
atmosphere of 5% CO2. Cells were treated in their recommended growth medium containing varying
concentrations of test compounds. When the cells were incubated with the test compounds for 1 h, the cell
culture plates were irradiated to the corresponding time with an ultraviolet crosslinker (for compounds
that did not require UV irradiation, this step could be omitted). After 10 days of incubation, CellTiter-Glo
Reagent (Promega, Madison, WI, USA) was added to the plates, which continued to be incubated
for 30 min at room temperature. Chemiluminescence values were recorded by a multiplate reader,
and IC50 values were calculated using GraphPad Prism 8.0 software.
4. Conclusions
In summary, this paper reports, for the first time, a photoactivatable Talazoparib prodrug.
During the research process, we blocked the key lactam pharmacophore of Talazoparib with PPGs
under the guidance of computer molecular docking. The in vitro enzyme inhibition assay and
PARylation experiment proved that the inhibitory activity of the PPG-inactivated compound was
greatly reduced (by 380 and more than 658 times, respectively). In BRCA1- and BRCA2- deficient cell
lines, the prodrug could significantly restore the effective activity of Talazoparib after being irradiated
by UV light, and the data imply that inhibitory activity could increase with prolonged irradiation
time. However, because of the limitations of the relatively few types of BRCA-deficient cells that could
be selected for study, as well as their restricted tolerance to UV light, we could not obtain the same
level of inhibitory activity from the irradiated prodrug as from the parent drug. Further structural
optimisation of the compound and appropriate cell selection would be helpful for further research on
this photoactivatable Talazoparib prodrug strategy.
In conclusion, the results of this preliminary study prove that the photoactivatable prodrug
strategy was an interesting approach for studying PARP inhibitors. On the one hand, the described
photoactivatable prodrug could provide a new biological tool for the mechanism research of PARP.
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On the other hand, photoactivatable prodrug also create new possibilities for therapeutic applications.
However, this requires profound research on the prodrug’ stability, toxicity, and bioavailability,
and further cell and animal studies will be planned to address these questions.
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Abstract: Immunotherapies have emerged as promising complementary treatments for ovarian cancer
(OC), but its effective and direct role on OC cells is unclear. This study examined the combinatory effects
of the protein aggregate magnesium–ammonium phospholinoleate–palmitoleate anhydride, known as
P-MAPA, and the human recombinant interleukin-12 (hrIL-12) on cell migration/invasion, apoptosis,
toll-like receptor (TLR)-mediated inflammation, and cytokine/chemokine profile in human OC cell
line SKOV-3. P-MAPA and IL-12 showed cancer cell toxicity under low doses after 48 h. Although
apoptosis/necrosis and the cell cycle were unchanged by the treatments, P-MAPA enhanced the
sensitivity to paclitaxel (PTX) and P-MAPA associated with IL-12 significantly reduced the migratory
potential and invasion capacity of SKOV-3 cells. P-MAPA therapy reduced TLR2 immunostaining and
the myeloid differentiation factor 88 (MyD88), but not the TLR4 levels. Moreover, the combination of
P-MAPA with IL-12 attenuated the levels of MyD88, interferon regulatory factor 3 (IRF3) and nuclear
factor kappa B (NF-kB p65). The IL-12 levels were increased and P-MAPA stimulated the secretion of
cytokines IL-3, IL-9, IL-10, and chemokines MDC/CCL22 and, regulated on activation, normal T cells
expressed and secreted (RANTES)/CCL5. Conversely, combination therapy reduced the levels of IL-3,
IL-9, IL-10, MDC/CCL22, and RANTES/CCL5. Collectively, P-MAPA and IL-12 reduce cell dynamics
and effectively target the TLR-related downstream molecules, eliciting a protective effect against
chemoresistance. P-MAPA also stimulates the secretion of anti-inflammatory molecules, possibly
having an immune response in the OC microenvironment.
Keywords: ovarian cancer; P-MAPA; IL-12; TLR signaling; inflammation; chemoresistance
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1. Introduction
Ovarian cancer (OC) is the fifth largest cause of cancer-related death in the United States and is the
most lethal of all gynecological malignancies [1]. OC originates from the ovarian surface epithelium,
fallopian tube (fimbriae region) or endometriosis-related tissue, and often exhibits a late diagnosis
due to the lack of clear signs or symptoms in the early stages of development [2–5]. Unfortunately,
there is no screening method for achieving the best curative result, and traditional chemotherapy and
surgery are limited for patients with advanced OC [6]. After cisplatin and paclitaxel (PTX) resistance,
several patients become susceptible to developing recurrent OC and metastasis [7]. Therefore, new
therapeutic options that overcome chemoresistance and enhance drug sensitivity are promising for the
treatment of OC.
Immunotherapies have demonstrated great efficiency by activating host immune responses
into the OC microenvironment [8]; however, what is happening with the cancer cells as
a direct result of immunostimulation requires further investigation. We recently reported
the effect of the immunomodulatory agent termed protein aggregate magnesium-ammonium
phospholinoleate-palmitoleate anhydride (P-MAPA), a natural biopolymer extracted from the
Aspergillus oryzae, which exhibits a number of antitumor responses in different experimental models of
cancer [9–11]. In association with cisplatin, P-MAPA showed a greater survival rate and a reduced OC
volume in addition to the increased expression of proteins involved in toll-like receptor (TLR)-mediated
inflammatory response (canonical and non-canonical pathways) in OC-bearing animals [11]. Recent
studies also supported the immunological mechanism of action of P-MAPA through the activation of
TLR2 and TLR4 signaling in both cancer and infections, in addition to regulating the activity of T cells
(especially CD4+T and CD8+T cells) and natural killer (NK) cells [9,10]. Importantly, P-MAPA did not
show toxicity in preclinical in vitro (V-79 Chinese hamster cell line) and in vivo models (Swiss mice,
Wistar rats, and monkeys) nor in human clinical trial phase I [9]; its effects in cancer treatment have
been tested in non-muscle invasive urinary bladder cancer [9,10] and in OC [11]. The directive role of
P-MAPA on human OC cells, considering its feasibility, sensibility, resistance, and toxicity, has not
been explored yet.
TLRs are transmembrane molecules that signal via myeloid differentiation factor 88 (MyD88)
or TLR-associated activator of interferon (TRIF) to induce cell proliferation, chemoresistance, and
cytokine/chemokine production [12]. Most importantly, TLRs can trigger a different response depending
on the cell type (e.g., cancer cell or immune cell), and particularly, TLR4 has been reported to be a
precursor of the immune escape of OC cells [13,14]. The crosstalk between the immunoadjuvant and
the OC cells targeting the TLR signaling and related cytokine secretion has never been proposed as to
their impact and specific response.
Interleukin-12 (IL-12) is a cytokine related to innate and adaptive immunity, being mainly produced
by the antigen-presenting cells (APCs), such as B lymphocytes, dendritic cells (DCs), and others [15,16].
It acts on T and NK cells stimulating a cytotoxic CD8+ response and inducing cytokine production,
especially interferon-γ (IFN-γ) [15,17]; IL-12 is involved in the differentiation of naïve T cells into
a polarized T helper 1 (Th1) immune response. Patients with recurrent OC who underwent IL-12
treatment, in a well-established dosage regimen, showed significant tumor regression [18]; the major
challenge involving the treatment with IL-12 is related to the adverse effects due to its high diffusion and
toxicity (e.g., lymphopenia and irreversible elevation of transaminases at 600 ng/kg and neutropenia,
fatigue, and headache at 300 ng/kg) [19], and a more precise and direct administration may limit
their undesirable effects. Notably, a phase II study involving intraperitoneal infusions of recombinant
IL-12 in patients with residual disease ≤1 cm showed to be well-tolerated after fist-line therapy for
OC-related peritoneal carcinomatosis [19]. Recently, Cohen et al. [16] studied the relationship between
membrane-bound IL-12 in tumor cells and the potential to disrupt protumorigenic signaling and
tumor outgrowth within peritoneal cavities; IL-12 significantly led to a tumor refractory state, thereby
delaying the onset of metastatic disease.
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Because P-MAPA is thought to increase IFN-γ levels, which may potentiate the Thelper
(Th1)-mediated immune response, and adjuvant therapies with IL-12 have long been proposed
as beneficial for patients with OC, this study investigates the effects of P-MAPA and IL-12, alone or
in combination, on cancer cell activities with focus to the TLR-mediated inflammatory process and
cytokines/chemokines profiling in human SKOV-3 cell line.
2. Results
2.1. P-MAPA and IL-12 Reduce Cell Viability and Induce Apoptosis in the Presence of PTX in SKOV-3 Cells
An MTT assay was carried out using three biological and technical replicates to unravel the most
suitable dose and period of treatment. Based on previous results, the SKOV-3 cells were challenged with
P-MAPA at doses of 25 μg/mL, 50 μg/mL, and 100 μg/mL, and rhIL-12 at doses of 0.5 ng/mL, 1 ng/mL,
and 2 ng/mL for 24 h, 48 h, and 72 h. Then, we tested three different cell concentrations to achieve
the better treatment response (1 × 103 cells, 1 × 104 cells, and 5 × 104 cells; Supplementary Figure S1).
The SKOV-3 cell viability was efficiently reduced after the low-dose P-MAPA treatment (25 μg/mL
for 48 h; viability was reduced by ~27%), and then started to increase after 72 h exposure (Figure 1A).
Treatment with rhIL-12 also showed reduction in cell viability at an intermediate dose of 1 ng/mL
mainly after 48-h exposure (Figure 1B; viability reduction by ~25% after 48 h). Combinatory therapy
with P-MAPA and IL-12 also reduced the cell viability by about 33% (Figure 1C), and the treatment
doses were set at 25 μg/mL of P-MAPA and 1 ng/mL of IL-12. Annexin V- fluorescein isothiocyanate
(FITC)/Propidium iodide (PI) staining was used to effectively determine the apoptosis/necrosis rate
induced by P-MAPA and rhIL-12 immunotherapies. In this study, we set early apoptosis (Annexin
V-FITC+/PI−) as apoptosis and late apoptosis (Annexin V+/PI+) and necrosis (Annexin V−/PI+) as
necrosis. The apoptosis index was not influenced by P-MAPA, IL-12, or P-MAPA+IL-12 (Figure 1D,E),
which pointed out that these agents are unable to induce cell death at this concentration. We also
observed that P-MAPA and IL-12 did not alter the cell cycle significantly (Figure 1F,G). These data
indicate that these immunotherapeutic agents do not have a direct and high toxic effect to the cell,
which is, in fact, expected from immunotherapies. Because the treatments did not promote cell death or
cell proliferation, the reduction of cell viability might have been a result of decreased cell metabolism,
because the MTT test indirectly reflects the mitochondrial activity.
To better understand whether P-MAPA and IL-12 therapies potentially increase the effect of
standard chemotherapy, they were tested in association with PTX (Figure 2A,B). After 48 h, P-MAPA
decreased cell viability in association with different doses of PTX compared with cells treated with
PTX only (~30% reduction with 5 μM PTX; ~30% reduction with 2.5 μM PTX; ~24% reduction with
1.25 μM PTX and ~34% reduction with 0.625 μM PTX). Because IL-12 had no effect on cell viability
when associated with PTX, the decreased cell viability observed after combining P-MAPA with IL-12
in association with doses of PTX is probably due to the P-MAPA effect (~19% reduction with 5 μM
PTX, ~30% reduction with 2.5 μM PTX, ~30% reduction with 1.25 μM PTX, and ~38% reduction
with 0.625 μM PTX). To confirm these effects on SKOV-3 cell death, an Annexin V-FITC/PI assay was
performed using the lowest dose of PTX (0.625 μM). Concordantly, with the MTT results, P-MAPA and
P-MAPA+IL-12 increased cell death in association with PTX at dose of 0.625 μM. The apoptosis/necrosis
ratio of PTX was 0.64 and became higher when associated with P-MAPA (1.18) or P-MAPA+IL-12
(0.88), thus enhancing the P-MAPA effect as apoptotic inductor. Finally, PTX significantly increased the
number of cells in G0/G1 and decreased cells in G2/M phase of the cell cycle, thus inducing cell cycle
arrest. In this case, the addition of P-MAPA and IL-12 did not potentiate the PTX effects in cell cycle
(Figure 2D,E).
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Figure 1. Protein aggregate magnesium–ammonium phospholinoleate–palmitoleate anhydride
(P-MAPA) and interleukin-12 (IL-12) suppress cell viability without changing the apoptosis rate
and cell cycle. SKOV-3 cells were treated with various concentrations of P-MAPA (A) and IL-12 (B) for
24, 48, and 72 h, and the cytotoxicity (expressed as percentage) was assayed by MTT; (C) Cell viability
(%) after standardization of treatments (25 μg P-MAPA and 1 ng IL-12) after 48 h exposure; 1 × 103
SKOV-3 cells showed the best reproducibility. (D) Representative apoptotic index in SKOV-3 cells
treated with P-MAPA and IL-12 for 48 h detected by annexin V/PI flow cytometry. (E) Percentage
of cells in apoptosis and necrosis. (F) Representative cell cycle analysis in SKOV-3 cells treated with
P-MAPA and IL-12 for 48 h detected by PI and RNAase flow cytometry. (G) Percentage of PI+ cells
in G0/G1, S, and G2/M phases. The samples were assayed in three technical and biological replicates.
Results are expressed as the mean ± SD and described as column chart. * p < 0.05 vs. different doses at
48 h; # p < 0.05 vs. control group.
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Figure 2. P-MAPA and P-MAPA+IL-12 reduce cell viability and apoptosis/necrosis rate in the presence
of PTX. (A) Cell viability was assessed by an MTT assay; SKOV-3 cells were treated with various
concentrations of PTX alone or in association with P-MAPA and IL-12 for 48 h. * p < 0.05 vs. PTX and
PTX+IL-12 groups. (B) Percentage of cells in apoptosis and necrosis after exposure to 0.625 μM PTX
plus P-MAPA, IL-12, or P-MAPA+IL-12. * p < 0.05. (C) Representative apoptotic index in SKOV-3 cells
detected by Annexin V/PI flow cytometry. (D) Representative cell cycle analysis in SKOV-3 cells treated
with PTX, P-MAPA and IL-12 for 48 h detected by PI and RNase flow cytometry. (E) Percentage of PI+
cells in the G0/G1, S, and G2/M phases. The samples were assayed in three technical and biological
replicates.* p < 0.05 vs. control group. Results are expressed as the mean ± SD.
2.2. Combination of P-MAPA with IL-12 Is Essential to Reduce Cell Migration Whereas P-MAPA Alone
Decreased The Invasive Potential of SKOV-3 Cells
To investigate the inhibitory effect of P-MAPA and IL-12 as a single or combinatory treatment on
SKOV-3 cells, a wound-healing assay was performed in different periods. Although the treatment with
IL-12 showed a reduced migration rate (~ 17%) after 36 h and 48 h exposure, cells treated with P-MAPA
migrated significantly less (~ 13%) only at 48 h exposure (Figure 3A,B). Combination of P-MAPA and
IL-12 reduced the migratory potential of cells after 36 h and 48 h treatment (>20%), being the most
efficient after 36 h (Figure 3A,B); this overall analysis suggests that IL-12 was more effective than
P-MAPA in delaying wound closure. SKOV-3 cells that were treated with 0.9% saline solution (control
group) had an accelerated growth and migration rate when compared with all the treatments. Because
the wound-healing assay might be biased by cell proliferation, transwell migration and invasion assays
were performed and effectively showed that P-MAPA reduced cell migration when administered alone
or in association with IL-12 (Figure 4A). When Geltrex® was added to the chambers, the number of
invasive cells was reduced after P-MAPA treatment in comparison to IL-12 treatment or its association
(Figure 4B).
2.3. Immunotherapy with P-MAPA and IL-12 Significantly Reduced the TLR-Mediated Downstream Molecules
Involved in the Inflammatory Process of SKOV-3 Cells
One of the most important factors responsible for the acquisition of malignant phenotypes of OC
cells is associated with chemoresistance to treatments and uncovering new agents that downregulate
the inflammatory pathway(s) may be of significant interest. To evaluate whether P-MAPA or IL-12
play a role on OC-related inflammation, TLR2- and TLR4-mediated pathways were evaluated through
canonical and non-canonical signaling. Although the expressions of TLR2 and TLR4 did not vary
significantly, the downstream target molecules were affected by the treatments (Figure 5A,B). P-MAPA
and IL-12 alone or in combination led to a profound reduction in the MyD88 levels (0.53-, 0.48-, and
0.61-fold reduction, respectively vs. the control group; Figure 5A,B). We also evaluated the NF-kB
p65 expression in the extracts of SKOV-3 cells, and notably, IL-12 alone or combined with P-MAPA
induced a significant reduction in the p65 levels (0.66- and 0.63-fold reduction, respectively vs. control
group; Figure 5A,B). To explore the non-canonical pathway, the TRIF and IRF3 levels were measured.
Although the TRIF levels were unchanged after the treatments (p > 0.05), P-MAPA, IL-12, and the
combination of P-MAPA with IL-12 induced a significant decrease in the IRF3 levels (0.70-, 0.43-, and
0.71-fold reduction, respectively vs. the control group; Figure 5A,B). These findings provide evidence
that P-MAPA and IL-12 potentially act on MyD88-dependent and MyD88-independent pathways,
which also encourages the possibility that these immunomodulatory agents could even increase the
chemosensitivity of other therapeutics.
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Figure 3. Migratory potential of SKOV-3 cells determined by wound-healing assay. (A) Percentage of
wound closure after 0, 6, 12, 24, 36, and 48 h. * p < 0.05, # p < 0.01 vs. control group. (B) Photographs
of each wound-healing analysis at 0, 24, 36, and 48 h which were representative for specific closing
area; vertical black bars were used to show the incision edges (10×magnification). The samples were
assayed in three technical and biological replicates.
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Figure 4. Effects of P-MAPA and IL-12 alone or in combination on the migration and invasion capacity
of SKOV-3 cells. (A) Cell migration was measured by the amount of cells located in the lower part
of the insert. (B) Cell invasion was determined by the amount of cells located in the lower part of
the insert previously covered by Geltrex®. Representative images of the assay were obtained at 20×
magnification. The samples were assayed in three technical and biological replicates. Results are
expressed as the mean ± SD; * p < 0.05; CT, control group.
To further investigate and elucidate the location and the relative expression levels of the TLR2
and TLR4 receptors, an immunofluorescence assay was performed on SKOV-3 cells. As evidenced
by the cellular fluorescence level, the P-MAPA treatment significantly decreased the expression
level of cytoplasmic and nuclear TLR2 (48% fluorescence reduced vs. the control group; Figure 5C).
On the contrary, IL-12 and the combination of P-MAPA and IL-12 promoted the highest TLR2
immunofluorescence intensity (135% and 151% fluorescence level, respectively vs. P-MAPA; Figure 5C),
which suggests that IL-12 is responsible for restoring TLR2 activation after P-MAPA therapy in SKOV-3
cells. Lastly, the relative immunofluorescence of the TLR4 was unchanged after the treatments
(Figure 5D).
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2.4. P-MAPA Stimulates the Secretion of Pro- and Anti-Inflammatory Molecules, Whereas Its Association with
IL-12 Induced the Synthesis of Inflammatory Cytokines in SKOV-3 Cells
To determine which cytokines/chemokines are secreted by the SKOV-3 cells and how P-MAPA
and IL-12 act to regulate its production, a wide range of these molecules were evaluated in both
supernatants (Figure 6A) and cellular extracts (Figure 6B). As expected, the IL-12 levels were higher
in the cells treated with IL-12 and P-MAPA+IL-12 (244% and 243% fold-increased, respectively vs.
the control group, and 154% and 155% fold-increased, respectively vs. the P-MAPA group; Figure 6A);
IL-12 was slightly elevated with P-MAPA, even at low concentrations.
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Figure 5. TLR2- and TLR4-mediated signaling pathways are involved with inflammatory process and
chemoresistance in human OC. (A) Representative protein profiles of TLR2, TLR4, MyD88, TRIF, IRF3,
and NF-kB; fractions containing 50 μg protein were pooled from 5 samples per group. (B) Individual
blots were used for densitometric analysis of the TLR2 and TLR4 levels and related downstream
molecules (MyD88, TRIF, IRF3, and NF-kB) after normalization to the β-actin. Data are expressed as
the mean ± SD. * p < 0.05 vs. control group. Relative fluorescence intensity of TLR2 (C) and TLR4
(D) receptors. The values are expressed as the mean ± SD. The samples were assayed in three technical
and biological replicates. * p < 0.05. Confocal imaging of TLR2 (E) and TLR4 (F) immunostaining
using fluorescein isothiocyanate (FITC)-conjugated antibodies anti-TLR2 and anti-TLR4 was obtained
in SKOV-3 cells (Alexafluor®488, bar = 50 μm). DAPI was used for nuclear staining and merged
images were performed using Image J software. Negative controls were used. CT, control; DAPI,
4′,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate.
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Figure 6. Multiplex analysis of cytokines and chemokines produced by SKOV-3 cells in response to
P-MAPA and IL-12 treatments. (A) Concentrations of IFN-γ, IL-3, IL-9, IL-10, IL-12, RANTES, and
MDC were altered in the supernatants of cell culture. (B) Levels of IL-4, IL-8, and MIP-1α were altered
in SKOV-3 cell extracts. All data are expressed as the mean ± SD. * p < 0.05 as compared with the
corresponding group; One-way ANOVA complemented by the Tukey test. The samples were assayed
in three technical and biological replicates. CT, control; IFN-γ, interferon gamma; RANTES, regulated
on activation, normal T cell expressed and secreted; MDC, macrophage-derived chemokine; MIP-1α,
macrophage inflammatory protein 1-alpha.
Comparing the treatments, P-MAPA significantly stimulated the secretion of IFN-γ (24% vs.
the control, IL-12 and P-MAPA+IL-12 groups; Figure 6A), which is probably related to the activation
of the Th1 response. P-MAPA also stimulated IL-10 (21% vs. control, 23% vs. IL-12 and 32% vs.
P-MAPA+IL-12 groups), MDC/CCL22 (31% vs. control and IL-12 groups, and 45% vs. P-MAPA+IL-12),
and, regulated on activation, normal T cells expressed and secreted (RANTES)/CCL5 (25% vs. the control,
27% vs. the IL-12, and 30% vs. the P-MAPA+IL-12 groups). Furthermore, P-MAPA increased IL-3 and
treatment with IL-12 or P-MAPA+IL-12 promoted a reduction in its levels (13% and 17% reduction,
respectively vs. P-MAPA; Figure 6A). Treatment with P-MAPA also increased the IL-9 levels (25%
increased vs. the control and P-MAPA+IL-12 groups; Figure 6A). A part of these results suggests the
secretion of molecules involved in the Th2 response (e.g., IL-10, CCL22), but their regulatory signaling
combined with other molecules released by immune cells into the OC microenvironment could not be
proved to have a favorable or unfavorable effect. The IL-4 levels were internally elevated in SKOV-3
cells (Figure 6B) after therapies with IL-12 alone or combined with P-MAPA (169% and 254% increased
vs. the control group and 198% and 293% increased vs. the P-MAPA group, respectively). Interestingly,
the association of P-MAPA with IL-12 induced the highest production of intracellular IL-8 (37% vs.
the control group) and MIP-1α (11% vs. control group; Figure 6B). In brief, cytokines that were not
significantly influenced by P-MAPA and IL-12 included IL-1β, IL-2, IL-6, IL-7, IL-13, IL-15, IL-17, IP-10,
MCP-1, and MIP-1β (Supplementary Tables S1 and S2).
3. Discussion
We reported that lower doses of P-MAPA efficiently reduce cell invasion, whereas P-MAPA
in combination with IL-12 reduces cell migration in addition to attenuating the TLR-mediated
inflammatory response in human SKOV-3 cells (Figure 7). Although these compounds have
individually showed important effects in reducing OC volume and mass while enhancing overall
survival and immunostimulation in animals and humans [11,16], this study is the first to describe a
therapeutic rationale against human OC, thus revealing the mechanisms underlying cancer cell-related
inflammatory aspects rather than those of immune cells.
P-MAPA and IL-12 elicited a decrease in cell metabolism, but no effect on cell apoptosis/necrosis
and cell cycle was observed. Although an MTT assay is largely used as the viability/toxicity assay, it
could be biased by decreased metabolism activity. This utilizes mitochondrial machinery to convert a
colorless tetrazolium salt solution into purple formazan crystals [20]. Once we had pursued a treatment
dose with low cell toxicity but considerable modulatory potential, we believed that either P-MAPA or
IL-12 may be changing OC cell metabolism to a reduced activity (metabolomics could be of significant
value to find the targets more precisely). The impact of this reduction was indeed confirmed by the
migration and invasion assays. P-MAPA was able to reduce the migration and invasion capacity,
and the delayed wound closure in IL-12-treated cells may be likely due to its decreased metabolic
activity. Given that lower doses of P-MAPA and IL-12 are recommended to be well-tolerated, OC cell
apoptosis could be prevented by the low-level toxicity of chemicals; conversely, these concentrations
are safely used to activate immune responses and modulate cell metabolism. When associated with
PTX, P-MAPA was able to increase cell death and apoptosis/necrosis ratio without potentiating the
PTX effects on cell cycle. In accordance with a previous study in which approximately 50% of SKOV-3
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cells died after 48 h exposure to 5 μM of PTX [21], we observed that P-MAPA not only was effective to
increase cell death in the presence of PTX but also to maintain cell toxicity even after considerably
lower levels of PTX. This increase in cell death might be a result of apoptosis induction, since the
apoptosis/necrosis ratio was significantly higher in animals treated with the combination of P-MAPA
and PTX. Because apoptosis lead to the release of the damage-associated molecular pattern (DAMP),
this higher ratio may facilitate immunogenic cell death (ICD) [22].
 
Figure 7. Schematic view of the effects of P-MAPA and IL-12 on human SKOV-3 cells. The effect of each
treatment is shown by its representative color. Up and down arrows indicate whether the treatment
increased or decreased, respectively, such as cellular function or molecule at these levels. The treatments
reduced the downstream molecules (MyD88, NF-kB, and IRF3, with the exception of P-MAPA in
reducing NF-kB) of both canonical and non-canonical toll-like receptor (TLR) signaling pathways, and
only P-MAPA significantly downregulated the TLR2 levels. The intracellular cytokine/chemokine
levels were increased after treatment with IL-12 (IL-4) or P-MAPA+IL-12 (IL-4, IL-8 and MIP-1α);
P-MAPA was more effective in increasing the secretion of the following cytokines/chemokines: IFN-γ,
IL-3, IL-9, IL-10, RANTES/CCL5, MDC/CCL22). As expected, IL-12 was used to treat SKOV-3 cells
and appeared increased after IL-12 and P-MAPA+IL-12 treatments. Although IL-12 only reduced the
SKOV-3 cells’ wound closure, P-MAPA efficiently regulated the cellular dynamics by reducing the
wound closure, cell migration and invasion. The combination of P-MAPA with IL-12 decreased the
period of wound closure and cell migration rate. MyD88, myeloid differentiation primary response
88; NF-kB, nuclear factor kappa B; TRIF, TIR-domain-containing adapter-inducing interferon-β;
IRF-3, interferon regulatory factor 3; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; P-MAPA,
protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride; IL, interleukin;
MIP-1α, macrophage inflammatory protein 1α; IFN-γ, interferon gamma; RANTES, regulated on
activation, normal T cell expressed and secreted; MDC, macrophage-derived chemokine; CCL, C-C
motif chemokine ligand.
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The pro-inflammatory actions of TLR signaling in cancer cells and immune cells may severely
affect tumor progression [23], and, particularly, the immunosuppressive OC microenvironment needs
to be continuously immunostimulated [23,24]. Although TLR4 was unchanged by the treatments,
P-MAPA induces a reduction in the TLR2 levels together with downstream molecules in SKOV-3 cells.
Additionally, we found TLR2 nuclear expression in SKOV-3 cells treated with P-MAPA. Although we
are not the first to observe nuclear staining of TLR2 and TLR4 [25], the effect of the switch of cytoplasmic
to nuclear expression in SKOV-3 cells remains unclear. Based on our results, this nuclear expression
seems not to have any negative effect favoring cancer development. Although the TLR2-induced
MyD88-dependent pathway is related to an increase in IL-12 secretion [26], the immunoregulatory
mechanisms whereby IL-12 restores TLR2 to levels close to control remain to be elucidated. In immune
cells, P-MAPA has reportedly been described as a TLR4 agonist [9–11], thereby enhancing the synthesis
of cytokines and activating a Th1-polarized response. Our data evidenced the protective effect of
P-MAPA in attenuating TLR2-mediated signaling in OC cells. The activation of TLR, especially via
MyD88, is associated with increased tumor growth, chemoresistance, and the early recurrence of ovarian
epithelial tumors [7,27]. In addition, OC expressing high levels of MyD88 presents a higher proliferative
index and increased production of pro-inflammatory cytokines and chemokines [7,28,29]. Importantly,
the association of P-MAPA and IL-12 decreased the levels of MyD88 in SKOV-3 cells compared
with their respective control; because P-MAPA and P-MAPA + IL-12 also significantly decreased the
migratory and invasive potential of the cells, it can be suggested that the MyD88-dependent signaling
pathway may be one of the mechanisms by which SKOV-3 cells promote migration and invasion. It
has also been reported that increased expression of MyD88 is related to a decreased sensitivity to
chemotherapy (e.g., PTX) in the MyD88-negative OC A2780 cell line [30]; moreover, the activation of
MyD88 and NF-kB in MyD88-positive SKOV-3 cells promoted cell proliferation and tumor growth,
likely due to the increased secretion of pro-inflammatory cytokines, thus rendering the cells PTX
resistant [13]. In this line, the downregulation of MyD88 and NF-kB may be a possible mechanism by
which P-MAPA improves the chemosensitivity of PTX in SKOV-3 cells.
The activation of TLR4/MyD88/NF-kB signaling by ligands is strongly related to an inflammatory
microenvironment, thereby contributing to a more aggressive OC phenotype and poorer clinical
outcomes in women [31]. In SKOV-3 cells, silencing the membrane-associated RING-CH (MARCH),
an ubiquitin ligase that downregulates MHC class II expression, resulted in reduced cell migration and
invasion in addition to inhibition of NF-kB signaling [32], thus reinforcing that NF-kB may play a role
in the regulation of numerous cellular dynamics. Taken together, the combination of P-MAPA and
IL-12 was efficient to induce the downregulation of both MyD88 and NF-kB, which can be of great
value to enhance the overall survival of patients while attenuating OC progression and metastasis.
TRIF activation is responsible for triggering the TLR non-canonical pathway, thus activating
several transcriptional factors, such as NF-kB, IRF3 and AP-1, and resulting in cytokines and type I IFN
production [33,34]. Although few studies have explored the role of TRIF/IRF3 in OC cells, they seem to
be critical for therapy [35]. Recently, Chuffa et al. [23] reported the downregulation of TRIF and IRF3
in OC-induced rats, whereby the immunomodulatory agent dramatically reduced the volume and
mass of ovarian tumors. Importantly, P-MAPA and IL-12, either alone or in association, significantly
downregulated IRF3 levels, evidencing the potential of immunotherapies to act by both canonical and
non-canonical TLR pathways.
Immunostimulatory and immunosuppressive molecules can contribute to either inhibiting or
enhancing anti-tumor immune activity of such a response by immunotherapy. We screened a number
of molecules displaying important effects in OC, but most of them displayed no changes in SKOV-3
cells after P-MAPA and IL-12 treatments. Treatment of SKOV-3 with rhIL-12 showed its availability in
both IL-12 and P-MAPA+IL-12 groups, thus proving that the agent was present in the supernatants;
whether IL-12 therapy was still capable of stimulating more IL-12 production by the cells is uncertain.
IL-3 levels are stimulated by P-MAPA therapy, and this increase might be protective for patients during
OC chemotherapy; administration of rhIL-3 to patients with platelet count < 75,000/mm3 is effective to
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fight thrombocytopenia and neutropenia after chemotherapy [36]. Moreover, IL-3 is able to intensify
the dose of carboplatin for primary advanced OC [37]. P-MAPA also enhanced IL-9 secretion by
SKOV-3 cells, and this effect seems to have a dual impact on the immune system. IL-9 was initially
recognized as a T-cell growth factor with oncogenic potential. However, Th9 cell-secreted IL-9 has
been revisited for the immunity of some tumors [38]. IL-9 activates innate immune cells like mast cells,
contributing to tumor growth prevention [38], and in addition to Th9 cell-derived IL-3, induction of
adaptive anti-cancer responses that favor DCs survival has been reported in various cancers [39].
Regulatory T (Treg) cells can infiltrate into solid OC or ascitic fluid, contributing to an
immunosuppressive microenvironment by secreting IL-10 and TGFB-1 while reducing the IFN-γ
levels [40]. Because these cytokines participate either in stimulating or inhibiting the activities of other
immune cells, P-MAPA seems to work as a double-edge sword regarding the SKOV-3 cells. Although
mechanistically unclear, P-MAPA contributes partially to reducing the immunosuppression, likely due
to the increased levels of IFN-γ rather than IL-10. In fact, high IFN-γ secretion meets our proposal by
enhancing OC-cell immunogenicity through the recruitment of CD8+T and natural killer (NK) cells,
in addition to increasing the anti-tumor activity of macrophages; we recently found that P-MAPA
reduces Treg cells and stimulates CD8+T effector cells in OC-bearing animals (unpublished data).
Recently, the expression of programmed death-ligand 1 (PD-L1) on tumor cells represents an important
pathway by which malignant cells evade the immune system. In SKOV-3 cells, PD-L1 was variably
found in the surface and cytoplasm [41], and its expression was correlated with high levels of TNF-α,
IL-10, and IL-6 released from tumor-associated macrophages (TAMs). Because P-MAPA and IL-12
attenuated the downstream mediators of the TLR signaling, the altered expression of some cytokines
may be independent of TLR-mediated inflammatory response.
A complex network represented by chemokines and its receptors, growth factors, inflammatory
products, and other molecules (e.g., NF-kB), is responsible for tumor progression or rejection.
Chemokines signal not only for tumor cells but may control tumor development through activation of
specific receptors expressed in a variety of cells, thereby regulating the traffic of infiltrating macrophages,
lymphocytes, DCs, and neutrophils [42]. The secretion of CCL5, which binds to the CCR4 receptor, is
strongly associated with the presence of tumor-infiltrating CD8+T cells; the upregulation of its receptor
in activated vaccine-primed T cells improved tumor homing in OC [43]. In SKOV-3 cells, the levels of
CCL22/MDC and CCL5/RANTES were higher after P-MAPA therapy. Although these chemokines
appear to be associated with a poor prognosis when released by immune cells, the functional meaning
of their production by OC cells as to their significance in the OC microenvironment remains to be
investigated. CCL22 is secreted by DCs and macrophages and acts on target cells by interacting with
the CCR4 receptor located in the cell surface [44]. CCL22 is correlated to the chemoattraction of Treg
cells in advanced stages of OC, and its expression was increased in response to IFN-γ signaling [45].
This finding partially corroborates our results in which both CCL22 and IFN-γ were higher in SKOV-3
cells after P-MAPA therapy; in contrast, P-MAPA does not promote elevation in the number of Treg cells
(data not shown). A previous study by Giuntoli et al. [46] showed that ascites specimens originating
from patients with malignant OC were accomplished by elevated levels of IL-6, IL-8, IL-10, IL-15,
IP-10, MCP-1, MIP-1β, and VEGF, in contrast to significantly reduced levels of IL-2, IL-5, IL-7, IL-17,
and CCL5/RANTES. Although controversial, IL-8 production by human OC cells plays a role in
controlling tumor growth [47], and MIP-1α is involved in the recruitment of Th1 and cytotoxic effector
T cells [48]. We found a higher secretion IL-8 and MIP-1α after combinatory treatment of P-MAPA and
IL-12. Partially supporting our results, IL-8 levels have already been reported to be augmented in OC,
even after the downregulation of NF-kB [49]; however, the alternative mechanism involved with this
production remains unclear. Additionally, we observed increased levels of RANTES after P-MAPA
treatment. RANTES is responsible for recruiting T cells, macrophages, eosinophils, and basophils into
the inflammatory sites. In addition to IL-2 and IFN-γ, RANTES is thought to induce the activation and
proliferation of NK cells while enhancing the anti-tumor response in animal models [46]. In addition
to the overexpression of VEGF and MCP-1, a reduction in RANTES levels is associated with activating
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pathways for tumor growth. Normally, OCs produce large amounts of RANTES, and this production is
correlated with the infiltration of TAMs, CD8+T cells, and tumor progression [50,51]; these chemokines
are further related to the acquisition of polarized immune responses (Th1 versus Th2). Although some
negative effects are associated with the efficacy of chemotherapy related to RANTES, therapy with
P-MAPA may be helpful against tumor expansion.
4. Materials and Methods
4.1. Cell Line and Cell Culture
The human OC cell line SKOV-3 was purchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA). The SKOV-3 cells were routinely incubated in RPMI 1640 (Life Technologies,
Grand Island, NY, USA) supplemented with 10% Fetal Bovine Serum (FBS) and 1% anti-anti solution
(100 mg/mL penicillin G, and 100 μg/mL streptomycin (Merck, Darmstadt, Germany). The culture
medium was changed every 2 to 3 days. All cells were maintained at 37 ◦C in a humidified atmosphere
of 5% CO2.
4.2. Treatments with P-MAPA and IL-12
To evaluate the in vitro effect of the treatments, different doses of P-MAPA (25 μg/mL, 50 μg/mL,
and 100 μg/mL) were tested in accordance with Favaro et al. [9]. Initially, 5 mg P-MAPA was diluted
in 1 mL of saline solution to achieve the desired stock solution of 5 mg/mL, which were then diluted
in the cell culture medium to obtain the testing doses. For the treatment with recombinant (rh)IL-12,
concentrations of 0.5 ng/mL, 1 ng/mL, and 2 ng/mL were diluted in the culture medium based on the
previous report by Su et al. [52]. For the combination of P-MAPA and IL-12, the most effective dose
and incubation period were determined after performing an MTT assay. The saline solution was used
as a solvent vehicle control and prepared in the same volume and dilution for both treatments. All
experiments were performed at 0, 24, 48, and 72 h time exposure and assayed in three technical and
biological replicates.
4.3. Cell Cytotoxicity (MTT Assay)
The SKOV-3 cells were seeded in a 96-well plate at a density of 1 × 103 cells/well. The cellular
activity and/or toxicity were evaluated in different concentrations of P-MAPA and IL-12 and periods (0,
24, and 48 h) to define the best treatment protocol. For this experiment, the choice of dose and period
of treatment was the combination of high cellular viability with low toxicity and efficient signaling
regulation. Thereafter, different doses of PTX were associated with P-MAPA and IL-12 to verify the
sensitivity effects. An MTT solution (5 mg/mL) was added to the wells for 4 h, and the crystals were
diluted with DMSO under agitation. The concentration was determined by an Epoch microplate
reader (BioTek Instruments, Highland Park, PO, USA) at 540 nm, being the reference curve fixed
at 650 nm. The percentage of crystal formation was calculated by fixing the control group crystal
formation as 100%.
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4.4. Apoptosis Rate by Annexin V-FITC/PI Staining
During the apoptosis process, cells normally externalize the phospholipid phosphatidylserine (PS),
which binds with high affinity to Annexin V in the presence of calcium. Herein, we used the Annexin
V assay with the BD PharmingenTM Annexin V-FITC Apoptosis Detection Kit (ApoAlert Annexin V,
Clontech, CA, USA). The SKOV-3 cells (1 × 105 cells) were placed in a 6-well plate and left for 6 h to
attach. The cells were then treated with 25 μg/mL of P-MAPA, 1 ng/mL of rhIL-12 or their association
for 48 h. In addition, P-MAPA and IL-12 were added to the lowest dose of PTX (0.625 μM) to confirm
chemosensitivity. After the treatment period, cells were trypsinized and centrifuged (Centrifuge
5804 R, Eppendorf, Hamburg, Germany)) for 10 min at 1200 rpm for culture medium removal. The cell
pellet was washed twice with phosphate-buffered saline (PBS) and centrifuged at 10,000 rpm for 30 s,
followed by resuspension with 100 μL Annexin V binding buffer and incubation with Annexin V and
propidium iodide (PI) for 15 min in the dark at room temperature. After the incubation, the prepared
cells were then analyzed by flow cytometry in a FACSCantoTMII with FACSDiva (BD Biosciences,
Clontech, CA, USA) software. The flow cytometric results were analyzed by the FlowJo software
(vX.10.6 version, Tree Stars Inc., Ashland, OR, USA).
4.5. Cell Cycle Determination by PI Staining
The cell cycle stages (G0/G1, S, and G2/M) were performed by flow cytometry analysis through
the DNA content measurement of nuclei stained with PI dye. After all the treatments, the SKOV-3
cells (1 × 105) were trypsinized, washed with PBS, and centrifuged for 5 min at 1500 rpm. After the
cells were fixed in 70% cold ethanol at 4 ◦C for 1 h, they were incubated with PI staining solution of
50 μg/mL PI and 10 mg/mL RNase A for 1 h at room temperature in a dark room. Flow cytometry
was performed in a FACSCantoTMII with FACSDiva (BD Biosciences, Clontech, CA, USA) software to
analyze DNA content. The relative ratios of cells in the G0/G1, S, and G2/M phases were calculated
using FlowJo software (vX.10.6 version, Tree Stars Inc.).
4.6. Wound-Healing Assay
The wound-healing method was performed to verify the effects of P-MAPA and rhIL-12 alone or
in combination on cell migration capacity. Briefly, 3 × 105 SKOV-3 cells were placed in 6-well plates
with a serum-free culture medium for cell starvation. When the cells reached high confluence, a wound
was created through the confluent cell monolayer using an angled tip at 45◦, and the SKOV-3 cells
were then immediately treated with the pre-determined doses of P-MAPA, rhIL-12, or both, diluted in
2 mL of complete RPMI 1640 medium. Images were obtained at 0 h, 6 h, 12 h, 24 h, 36 h, and 48 h until
the wound closure. Migration area (%) was measured using Image-J software. All experiments were
analyzed in biological and technical triplicate.
4.7. Cell Migration Using Transwell Insert
To evaluate the migratory potential of the cells, 1 × 104 SKOV-3 cells were seeded in triplicates into
the upper chambers of 24-well ThinCert™ cell culture inserts (GBO, Americana, SP, Brazil) with PVDF
filters (8.0 μm pore size) containing the corresponding treatment diluted in serum free RPMI 1640
medium. In the lower chamber, RPMI supplemented with 10% FBS was added as a chemotactic factor.
After the plates were incubated at 37 ◦C and 5% CO2 for 24 h, the cells in the upper chamber were gently
removed with a cotton swab. The cells that had migrated to the lower surface of the insert through the
8.0 μm pore were fixed in methanol for 8 min and stained with hematoxylin for 45 s. The migrated cells
were photographed with 20× objectives under an inverted microscope (ZeissAxiovert®, Germany).
Four non-overlapped images were randomly analyzed for each well and the migrated cells were
counted using Image J software.
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4.8. Invasion Assay
The invasion assay was performed using a 24-well ThinCert™ cell culture insert (GBO, Americana,
SP, Brazil) with PVDF filters (8.0 μm pore size). Briefly, 24-well plates were previously coated with
Geltrex® (ThermoFisher, Waltham, MA, USA), which mimics the biological basement membrane
matrix, and 1× 104 cells were placed in the upper chamber with a serum-free culture medium containing
the treatments. After 24 h, the invasive potential was determined by the amount of cells capable of
crossing the barrier when chemotactically attracted by the RPMI 1640 medium supplemented with
10% FBS in the lower chamber. The protocol of cell fixing and staining was the same described for cell
migration. Finally, four non-overlapped images were randomly analyzed per well and the invasive
cells were counted using Image J software.
4.9. Immunofluorescence Assay
After the SKOV-3 cells were seeded in coverslips and treated with P-MAPA, rhIL-12, or their
association for 48 h, they were fixed in methanol for 8 min at room temperature and then washed in
sterile ice-cold PBS. To avoid nonspecific bindings, a blocking solution containing 3% (v/v) bovine
serum albumin (BSA) was added for 1 h. Then, cells were incubated overnight with rabbit polyclonal
anti-TLR2 and anti-TLR4 antibodies diluted 1:200 (Abcam, Cambridge, MA) for 4 h, followed by post
incubation with secondary polyclonal anti-IgG conjugated to FITC (1:200 dilution in 1% BSA, Santa
Cruz Biotechnology, Inc., CA) for 1 h. After the reactions, 4,6-diamidino-2-phenylindole (DAPI; Sigma,
St Louis, MO) was used for nuclei staining. Positive staining was analyzed using a confocal fluorescence
microscope Zeiss Axiophot II (Carl Zeiss, Oberköchen, Germany) at different magnification (excitation
filter 590 nm, emission filter 650 nm) and for DAPI staining (excitation filter 365 nm, emission filter
485 nm). The relative fluorescence in FITC images was calculated using Image J software.
4.10. Western Blot Analysis
After the treatments, five replicates of each experiment were used. After being washed with
cold PBS, 1 × 106 SKOV-3 cells were added to radioimmunoprecipitation assay buffer (RIPA) lysis
buffer containing protease inhibitors and rapidly frozen for 24 h. Under constant agitation for
30 min at 4 ◦C, the cells were resuspended and transferred to 1.5 mL tubes and centrifuged for 20
min at 12,000 rpm. Protein quantification was performed using a Bradford assay, and the same
amount of protein (40 μg) was solubilized in 1.5×Laemmli buffer and then used for 4–20% SDS-PAGE
(Bio-Rad Laboratories, Hercules, CA, USA). After electrophoresis was carried out on tris-glycine
running buffer system (120 V for 2 h), the proteins were electro-transferred (350 mA) to nitrocellulose
membranes, and then blocked with 3% BSA in tris-buffered saline plus tween 20 (TBS-T) solution
for 1 h. Afterward, the proteins were incubated with respective primary antibodies (1:500; Abcam,
Cambridge, UK) at 4 ◦C overnight: anti-TLR2, anti-TLR4, anti-MyD88, anti-NF-kB p65, anti-TRIF,
anti-IRF3. Subsequently, the membranes were washed three times and then incubated for 90 min with
specific secondary antibodies (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:20,000 in 1% BSA. After
sequential washes, positive reactions were performed using ECL kit (Thermo Fisher Scientific, MA).
All of the blots were calculated using individual samples obtained from three replicates/group and
were represented as the mean optical density (band intensity/housekeeping protein). β-actin was used
as the endogenous control.
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4.11. Cytokine and Chemokine Assay
Levels of different cytokines and chemokines were determined in both supernatants and cell
homogenates using a MilliPlex® Map Kit (EMD Millipore, Darmstadt, Germany) with a standard
20-plex detection kit according to the manufacturer’s protocols. The human cytokine/chemokine Panel I
kit (cat. no. HCYTOMAG-60K) included the following analytes: interferon-gamma (IFN-γ), interleukin
(IL)-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-9, IL- 10, IL-12, IL-13, IL-15, IL-17, IP-10, macrophage-derived
chemokine (MDC/CCL22), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory
protein-1 (MIP)-1α, MIP-1β, and regulated upon activation normal T cell expressed and secreted
(RANTES/CCL5). The concentrations were ranged between 0 and the lowest detectable level in each
assay before log transformation. The analyses combined fluorescent cytometry and ELISA technology,
so that each magnetic bead was added to a specific anti-cytokine to achieve a specific binding. For this
experiment, the levels of analytes varied from 0.4 to 3500 pg/mL and the intra-assay CV was < 10%,
inter-assay CV < 15%. No cross-reactivity was observed among cytokines and other molecules.
The fluorescence intensity was measured using the MAGPIX system (Luminex Corporation, Austin,
TX, USA).
4.12. Statistical Analysis
All data were evaluated using the analysis of variance (ANOVA) and presented as the
mean ± standard deviation (SD). Significant results were then compared by Tukey or Newman-Keuls
post hoc tests, and statistical significance was set at p < 0.05 for all analyses. Data were analyzed and
constructed using GraphPad Prism 5.0 scientific graphing software (GraphPad Software, San Diego,
CA, USA).
5. Conclusions
In summary, we demonstrated that P-MAPA in association with IL-12, both considered potent
immunomodulatory agents, exhibited anti-cancer activities on human SKOV-3 cells. Although P-MAPA
combined with IL-12 promotes a reduction in cell viability and cell migration, P-MAPA alone reduces
the invasion capacity and enhances apoptosis in the presence of PTX. Similarly to either P-MAPA or
IL-12 alone, the combinatory therapy induced the downregulation of TLR-downstream molecules
involved with inflammation, which may result in protection against chemoresistance; these effects
seem to be associated with TLR2 suppression rather than TLR4 signaling. P-MAPA alone stimulated
the secretion of pro- and anti-inflammatory mediators, and its association with IL-12 increased the
production of IL-4, -8, and MIP-1α by the SKOV-3 cells; this may promote changes in the immune
responsiveness of the OC microenvironment. In addition to the effect on OC-infiltrated immune cells,
these immunotherapies might provide a sustained opportunity for a novel combined strategy against
malignant OC cells.
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Supplementary Materials: The following are available online. Figure S1: MTT assay was tested with different
cell densities to find the most appropriate strategy for cell counting. SKOV-3 cells at density of 1 × 103 were
representative to determine cell viability; Table S1: Multiplex assay of the cytokines and chemokines (pg/mL)
in the supernatant of cell culture; Table S2: Multiplex assay of the cytokines and chemokines (pg/mL) in the
SKOV-3 cells.
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IRF3 Interferon regulatory factor 3
MyD88 Myeloid differentiation factor 88
NF-kB p65 Nuclear factor kappa B subunit p65
NK natural killer cells
OC ovarian cancer
PBS phosphate-buffered saline
P-MAPA Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride
PTX paclitaxel
RIPA Radioimmunoprecipitation assay buffer
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
TBS-T Tris-Buffered Saline plus Tween 20
CD4 + T CD4-positive T cells
CD8 + T CD8-positive T cells
Th1 T helper 1
TLR (s) Toll-like receptor (s)
TLR2 Toll-like receptor 2
TLR4 Toll-like receptor 4
TRIF TIR domain-containing adaptor inducing interferon-beta
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Spíšek, R. Dynamics of T-cell infiltration during thecourse of ovarian cancer: The gradual shift from a Th17
effector cell response toa predominant infiltration by regulatory T-cells. Int. J. Cancer 2013, 132, 1070–1079.
46. Giuntoli, R.L., 2nd; Webb, T.J.; Zoso, A.; Rogers, O.; Diaz-Montes, T.P.; Bristow, R.E.; Oelke, M. Ovarian
cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity.
Anticancer Res. 2009, 29, 2875–2884.
47. Lee, L.F.; Hellendall, R.P.; Wang, Y.; Haskill, J.S.; Mukaida, N.; Matsushima, K.; Ting, J.P. IL-8 reduced
tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 2000, 164, 2769–2775.
[CrossRef]
48. Colvin, E.K. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front. Oncol.
2014, 4, 137. [CrossRef]
49. Tino, A.B.; Chitcholtan, K.; Sykes, P.H.; Garrill, A. Resveratrol and acetyl-resveratrol modulate activity of
VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. J. Ovarian Res. 2016,
9, 84. [CrossRef]
50. Milliken, D.; Scotton, C.; Raju, S.; Balkwill, F.; Wilson, J. Analysis of chemokinesand chemokine receptor
expression in ovarian cancer ascites. Clin. Cancer Res. 2002, 8, 1108–1114.
160
Molecules 2020, 25, 5
51. Soria, G.; Ben-Baruch, A. The inflammatory chemokines CCL2 and CCL5 in breastcancer. Cancer Lett. 2008,
267, 271–285. [CrossRef] [PubMed]
52. Su, W.; Ito, T.; Oyama, T.; Kitagawa, T.; Yamori, T.; Fujiwara, H.; Matsuda, H. The direct effect of IL-12
on tumor cells: IL-12 acts directly on tumor cells to activate NF-kB and enhance IFN-g-mediated STAT1
phosphorylation. Biochem. Biophys. Res. Commun. 2001, 280, 503–5121. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Design, Synthesis, and Biological Evaluation of
Pyridineamide Derivatives Containing a 1,2,3-Triazole
Fragment as Type II c-Met Inhibitors
Hehua Xiong †, Jianxin Cheng †, Jianqing Zhang, Qian Zhang, Zhen Xiao, Han Zhang,
Qidong Tang * and Pengwu Zheng *
School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China;
18296154955@163.com (H.X.); cjx3159@163.com (J.C.); zhang1405474771@163.com (J.Z.);
15797966937@163.com (Q.Z.); xz950420@163.com (Z.X.); zbl1045762244@163.com (H.Z.)
* Correspondence: tangqidongcn@126.com (Q.T.); zhengpw@jxstnu.edu.cn (P.Z.); Tel.: +86-791-8380-2393 (P.Z.)
† These authors contribute equally to this work.
Academic Editor: Qiao-Hong Chen
Received: 21 November 2019; Accepted: 10 December 2019; Published: 18 December 2019
Abstract: A series of 4-(pyridin-4-yloxy)benzamide derivatives containing a 1,2,3-triazole fragment
were designed, synthesized, and their inhibitory activity against A549, HeLa, and MCF-7 cancer cell
lines was evaluated. Most compounds exhibited moderate to potent antitumor activity against the
three cell lines. Among them, the promising compound B26 showed stronger inhibitory activity
than Golvatinib, with IC50 values of 3.22, 4.33, and 5.82 μM against A549, HeLa, and MCF-7 cell
lines, respectively. The structure–activity relationships (SARs) demonstrated that the modification of
the terminal benzene ring with a single electron-withdrawing substituent (fluorine atom) and the
introduction of a pyridine amide chain with a strong hydrophilic group (morpholine) to the hinge
region greatly improved the antitumor activity. Meanwhile, the optimal compound B26 showed
potent biological activity in some pharmacological experiments in vitro, such as cell morphology
study, dose-dependent test, kinase activity assay, and cell cycle experiment. Finally, the molecular
docking simulation was performed to further explore the binding mode of compound B26 with c-Met.
Keywords: 4-(pyridin-4-yloxy)benzamide; 1,2,3-triazole; c-Met; inhibitor
1. Introduction
Cancer has become a serious threat to human life and health [1,2]. c-Met tyrosine kinase is a kind
of type III tyrosine kinase, which is closely related to cellular activities [3] such as growth, reproduction,
metastasis, etc. However, abnormal expression of c-Met kinases in cells usually triggers the occurrence,
invasion, and metastasis of various cancer diseases [4]. c-Met kinase has been found overexpressed in
various cancer cells and has become an attractive target for cancer treatment [5,6]. Nowadays, developing
small molecule c-Met kinase inhibitors has become a hotspot in the treatment of human cancer [7].
c-Met inhibitors are classified as type I and type II inhibitors according to the binding mode of
inhibitors with c-Met. Usually, c-Met inhibitors of type I are single-target inhibitors that bind to the
hinge region of the ATP pocket, and c-Met inhibitors of type II are multitarget inhibitors that bind
to the hinge region and an extra hydrophobic pocket [8,9]. With the development of biology and
pharmacology, the intracellular mechanisms have been elucidated, and research in small molecule
inhibitors has made significant progress. Type II c-Met inhibitors possess more potent inhibitory activity
and better tolerance to drug resistance through binding to kinases of multiple types. Cabozantinib,
a c-Met inhibitor of type II, was approved by the FDA for treatment of prostate cancer in 2012. Some
representative c-Met inhibitors (type II) in the clinical trial phase are listed in Figure 1, including
Molecules 2020, 25, 10; doi:10.3390/molecules25010010 www.mdpi.com/journal/molecules163
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Golvatinib, BMS-777607, Altriatinib, and TAS-115 [10–12]. Furthermore, according to the structure
characteristics of inhibitors, the skeleton of c-Met inhibitor (type II) was summarized into blocks A, B,
C, and D by our research group, as shown in Figure 1 [13].
 
Figure 1. Some representative c-Met inhibitors of type II and the summarized skeleton.
We explored the SARs of c-Met inhibitors (type II) bearing pyridinamide structure using Golvatinib
as a lead compound in this study. In order to guide our modification of the lead compound, a molecular
docking simulation of Golvatinib and c-Met protein was performed, as shown in Figure 2. The docking
results indicated that blocks A and C, which possessed hydrogen bonding interactions with residues
Met1160, Asp1222, and Lys1110, played a key role in maintaining the inhibitory activity against c-Met.
Therefore, the modification was mainly concentrated on blocks A and C. Firstly, a pyridylamide
structure in block A, including hydrogen bond donor and hydrogen bond acceptor atoms, was
introduced into the meta position of pyridine in order to enhance the interaction with the hinge region
residues, and then some alkyl chains bearing morpholine or thiophene groups were connected to the
terminal of the pyridine amide structure for better water solubility of compounds. Then, a 1,2,3-triazole
fragment with good biological activity and two hydrogen bond acceptor atoms was introduced to
block C for more tight combination between the compounds and c-Met. In addition, considering
the steric hindrance problem [14], H/F atoms and different substituents were introduced in blocks
B and D, respectively, to explore their effects on biological activity of target compounds. Finally,
a series of small molecule inhibitors containing the 1,2,3-triazole fragment were designed, synthesized,
and biologically evaluated.
 
Figure 2. Design strategy of target compounds based on the molecular simulation and structure–activity
relationships (SARs).
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2. Results and Discussion
2.1. Chemistry
The synthesis route of target compounds B1–B27 is shown in Scheme 1. Firstly, the commercially
available pyridinecarboxylic acid 6 was reacted with SOCl2 using NaBr as catalyst to yield
4-chloropicolinoyl chloride 7, which was then converted into ethyl 4-chloropicolinate 8 with ethanol. Next,
4-chloropicolinate 8 was subjected to nucleophilic substitute with p-nitrophenol or 2-fluoro-4-nitrophenol
using chlorobenzene as solvent to give picolinate analogues 9a–9b, which were then dissolved in
1,4-dioxane and hydrolyzed with NaOH aqueous solution to obtain picolinic acid analogues 10a–10b.
Intermediates 10a–10b were reacted with SOCl2 to get the corresponding acyl chlorides and then
connected with amines (including propan-1-amine, 2-(thiophen-2-yl)ethan-1-amine, pyrrolidine and
3-morpholinopropan-1-amine) to obtain picolinamide analogues 11a–11e. Finally, the key intermediates
12a–12e were produced by the reduction of 11a–11e with hydrazine hydrate as reducing agent. Other
intermediates 13a–13i, which have been reported in our previous research [15], were combined with
intermediates 12a–12e by a nucleophilic substitute reaction to get the target compounds B1–B27.
The structural information of the target compounds was confirmed by 1H-NMR, 13C-NMR,
and TOF MS (ES+), which were consistent with the structures depicted.
 
Scheme 1. The synthetic route for target compounds B1–B27. Reagents and conditions: (i) NaBr,
SOCl2, 85 ◦C, 18 h; (ii) triethylamine, dichloromethane (DCM), EtOH, 0 ◦C, 1 h; (iii) p-nitrophenol
or 2-fluoro-4-nitrophenol, chlorobenzene, 135 ◦C, 4 h; (iv) 1,4-dioxane, sodium hydroxide (10%), r.t.,
0.5 h; (v) SOCl2, amines, Et3N, DCM, 0–85 ◦C, 1 h; (vi) EtOH, activated carbon, FeCl3·6H2O, hydrazine
hydrate (80%), 90 ◦C, 4 h. (vii) EtOH, activated carbon, FeCl3·6H2O, hydrazine hydrate (80%), 90 ◦C,
4 h; (vii) DCM, NaHCO3, 0 ◦C, 1 h.
2.2. Antitumor Activity of Compounds B1–B27 Against A549, HeLa, and MCF-7 Cell Lines and SAR Analysis
The antitumor activity of target compounds against A549, HeLa, and MCF-7 cell lines was
evaluated to investigate their inhibitory activity against cancer cells [16]. The antitumor activities of
compounds were displayed as the IC50 (half-inhibitory concentration) values, as shown in Tables 1 and 2.
Most compounds exhibited moderate to potent antitumor activity against three cell lines. Compounds
B25–B27 possessed more potent inhibitory activity than Golvatinib, as shown in Table 2, with IC50
values in the range of 3.22–13.60 μM. The optimal compound B26 showed excellent inhibitory activity
against A549, HeLa, and MCF-7 cell lines with IC50 values of 3.22 ± 0.12, 4.33 ± 0.09, and 5.82 ± 0.09 μM,
respectively, which were more efficient than Golvatinib (8.14 ± 0.45, 15.17 ± 0.17, and 16.91 ± 0.29 μM).
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Table 1. Antitumor activities of the target compounds B1–B18 against A549, HeLa, and MCF-7 cell lines.
 
Compd. R2 R3 Z




4-H CH3 46.55 ± 1.90 52.31 ± 5.42 63.05 ± 2.44
B2 4-F CH3 21.30 ± 0.66 42.06 ± 6.03 32.13 ± 0.86
B3 2-OCF3 CH3 32.67 ± 1.16 53.94 ± 4.23 48.71 ± 3.26
B4 4-Cl CF3 56.26 ± 2.26 48.23 ± 1.59 120.76 ± 1.25
B5 2-CF3 CF3 35.57 ± 1.03 59.55 ± 2.94 270.40 ± 12.35
B6 3-F-4-F CF3 256.30 ± 10.37 170.38 ± 13.69 NA a
B7 3-Cl-4-F CF3 221.98 ± 21.46 295.65 ± 15.37 NA
B8 2-Cl-5-CF3 CF3 238.07 ± 17.84 NA NA
B9 4-Cl-3-CF3 CF3 357.24 ± 14.50 NA NA
B10
F
4-H CH3 33.31 ± 1.25 41.55 ± 2.26 60.50 ± 3.99
B11 4-F CH3 19.70 ± 0.89 46.57 ± 1.59 29.11 ± 1.30
B12 2-OCF3 CH3 24.24 ± 0.71 53.04 ± 1.11 42.26 ± 1.09
B13 4-Cl CF3 46.13 ± 3.59 55.43 ± 2.30 82.48 ± 2.34
B14 2-CF3 CF3 32.94 ± 2.33 40.68 ± 1.09 84.45 ± 12.34
B15 3-F-4-F CF3 123.07 ± 10.23 240.60 ± 22.49 332.01 ± 20.08
B16 3-Cl-4-F CF3 150.58 ± 12.21 270.24 ± 13.56 NA
B17 2-Cl-5-CF3 CF3 223.34 ± 10.89 NA NA
B18 4-Cl-3-CF3 CF3 246.70 ± 21.23 NA NA
Golvatinib b 8.14 ± 0.45 15.17 ± 0.17 16.91 ± 0.29
a NA: Low inhibitory activity, b Used as the positive control.
Table 2. Antitumor activities of the target compounds B10–B12 and B19–B27 against A549, HeLa,
and MCF-7 cell lines.
 
Compd. R1 R3




4-H 33.31 ± 1.25 41.55 ± 2.26 60.50 ± 3.99
B11 4-F 19.70 ± 0.89 46.57 ± 1.59 29.11 ± 1.30
B12 2-OCF3 24.24 ± 0.71 53.04 ± 1.11 42.26 ± 1.09
B19 4-H 27.25 ± 0.79 32.31 ± 2.11 39.08 ± 0.97
B20 4-F 12.10 ± 0.31 21.84 ± 1.93 19.12 ± 0.21
B21 2-OCF3 17.72 ± 0.42 29.55 ± 2.04 41.10 ± 1.21
B22
 
4-H 19.88 ± 0.75 45.18 ± 3.89 33.80 ± 1.11
B23 4-F 12.52 ± 0.37 15.19 ± 0.96 a 35.11 ± 3.05
B24 2-OCF3 13.34 ± 0.58 19.73 ± 0.83 44.82 ± 2.96
B25 4-H 6.43 ± 0.21 10.51 ± 0.68 13.60 ± 0.86
B26 4-F 3.22 ± 0.12 4.33 ± 0.09 5.82 ± 0.09
B27 2-OCF3 4.91 ± 0.09 5.72 ± 0.17 9.34 ± 0.52
Golvatoinib b 8.14 ± 0.45 15.17 ± 0.17 16.91 ± 0.29
a Bold values show the IC50 values of the target compounds lower than the values of the positive control; b Used as
the positive control.
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According to the antitumor activity of compounds B1–B27 listed in Tables 1 and 2, the SARs
were summarized as follows. Overall, the F atom on the meta-central benzene ring provided stronger
inhibitory activity against cancer cells than H atom, for example, compounds B1–B8 displayed less
inhibitory activity than compounds B9–B18. A single substitution (such as H/F/OCF3/Cl/CF3) linked
to the terminal benzene ring was favorable for maintaining the biological activity, such as compounds
B1–B5 and B10–B15 that possessed moderate antitumor activity with IC50 values less than 60 μM
against A549 and HeLa cell lines. However, the double substituents connected to the terminal benzene
ring obviously impaired the inhibitory activity of compounds B6–B9 and B15–B18, whose IC50 values
were more than 120 μM against three cell lines. A possible explanation would be that the introduction
of two substituents to the terminal benzene ring may create steric hindrance, which made it difficult
for compounds to extend into the hydrophobic pocket and to bind tightly to c-Met kinase.
Inspired by the inhibitory activity of compounds B1–B3 and B10–B12, as shown in Table 1, the F
atom of the central benzene ring and the single group (H, F, or OCF3) of the terminal benzene ring
were reserved to perform a SAR study of the pyridine amide moiety. Hydrophilic groups, including
morpholine or thiophene groups attached to the terminal of pyridine amide, have a great contribution
to inhibitory activity of the compounds B22–B27 (with IC50 values in the range of 3.22–45.18 μM).
In summary, introducing morpholino groups and F atoms to the pyridylpropyl amide and the
terminal benzene ring, respectively, made significant advances in the inhibitory activity.
2.3. Dose-Dependent Test of Compound B26 Against A549 Cells
To explore the relationship between concentrations and antitumor activity of compound B26, we
carried out a dose-dependent test based on the MTT method [16], in which A549 cells were treated with
seven different concentrations of compound B26 (0.137, 0.411, 1.234, 3.704, 11.11, 33.33, and 100 μM),
using Golvatinib as a positive control, as seen in Figure 3. The results revealed that compound B26
could effectively inhibit cancer cells in a dose-dependent manner. Notably, compound B26 inhibited
A549 cells more than 50% at the concentration of 3.704 μM, while the inhibitory rate of Golvatinib was
less than 40% at the same concentration.
Figure 3. Relationship between concentration and inhibition rate of compound B26 against A549 cells.
2.4. Cell Cycle Study of A549 Cells Treated with Compound B26
To further investigate the inhibitory pattern of compound B26 on the growth of cancer cells, cell
cycle distribution analysis [17] was carried out on A549 cells, as shown in Figure 4. Compound B26 at
concentrations of 5, 10, and 15 μM and Golvatinib at a concentration of 5 μM were delivered to A549
cells for 24 h, as shown in Figure 4. With the increased concentration of compound B26, the percentage
of cells blocked in G0/G1 phase was increased from 65.44% to 79.18%, while the percentage in the S
phase decreased from 21.91% to 16.56%. There was no significant change in G2/M phase. The result
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showed that compound B26 (74.41%) and Golvatinib (74.77%) had the same inhibitory effect on A549
cells at the concentration of 5 μM, both of which could block cells in the G0/G1 phase.
Figure 4. Cell cycle study of A549 cells treated with compound B26 and Golvatinib.
2.5. c-Met Enzyme Assay of Compounds B25–B27 and Staurosporine
Compounds B25, B26, and B27, possessing potent antitumor activity against A549, HeLa,
and MCF-7 cell lines, were selected to investigate their c-Met kinase assay by mobility shift assay
method [18] with staurosporine as a positive control, which was used to insure the reliability of the
experimental data. Compound B26 exhibited potent inhibitory activity against c-Met with an inhibition
rate of 36% at the concentration of 0.625 μM, as shown in Table 3.
Table 3. c-Met kinase activity of selected compounds B25, B26, B27, and staurosporine.





2.6. Molecular Docking Simulation of Compounds (B26 and Golvatinib) and c-Met
Next, we further explored the binding mode of compound B26 and Golvatinib with c-Met
kinase (PDB: 3LQ8, extracted from the PDB database) through molecule docking simulation using
AutoDock 4.2 software [19], as shown in Figure 5. The docking results indicated that compound
B26 and Golvatinib in an extended conformation formed strong hydrogen bonding interactions with
residues Met1160, Asp1222, and Lys1110, as shown in Figure 5a–d. Interestingly, the pyridylamide
structure of compound B26 formed a bidentate hydrogen bond with residue Met1160, as shown in
Figure 5a,b, which may offer a stronger ability of compound B26 to bind with c-Met. Compound B26
formed more hydrogen bonding interactions with Met1160 than Golvatinib, which may explain the
better antitumor activity of compound B26.
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Figure 5. Figure 5a, 5b, and 5c are partial views, two-dimensional partial views, and integral cavity
views of the docking results of c-Met (PDB code: 3LQ8) and compound B26, respectively. Figure 5d
shows partial views of c-Met and Golvatinib. The c-Met protein and compounds are displayed by
cartoons and sticks, respectively. Hydrogen bonding interactions between compounds and c-Met are
indicated with dashed lines or arrows in red.
3. Experimental Section
3.1. Chemistry
Unless specifically required, all reagents used in the experiments were purchased as commercial
analytical grade and used without further purification. Frequently used solvents (dichloromethane,
ethyl acetate, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, etc.) were absolutely anhydrous. Flash
column chromatography was performed on silica gel (300 mesh) using a mixture of petroleum ether
(PE) and ethyl acetate (EA). The reaction process was monitored by thin-layer chromatography (TLC,
SH-GH254) and spots were visualized with ultraviolet analyzer (light in 254 or 365 nm). 1H-NMR
and 13C-NMR spectra analysis of compounds was implemented in Bruker 400 MHz spectrometer
(Bruker Bioscience, Billerica, MA, USA) using tetramethylsilane (TMS) as an internal standard at room
temperature. Mass spectrometry (MS) of target compounds was carried out Waters High Resolution
Quadrupole Time of Flight Tandem Mass Spectrometry (Waters, Xevo G2-XS Tof). The melting point of
the compounds was measured by SGW X-4 micro melting point instrument. The purity of compounds
was determined by an Agilent 1260 liquid chromatograph equipped with an Inertex-C18 column,
and all were more than 95%.
3.1.1. Preparation of 4-Chloropicolinoyl Chloride (7)
Pyridinecarboxylic acid 6 (10.00 g, 0.081 mol), NaBr (0.10 g, 0.001 mol), and a drop of
N,N-dimethylformamide (DMF) were added in thionyl chloride (SOCl2, 50 mL) and stirred at
85 ◦C for 18 h. The reaction was monitored by TLC. After completion of the reaction, the solvent was
removed under vacuum to obtain a yellow liquid, which was dissolved in DCM for further use.
3.1.2. Preparation of Ethyl 4-Chloropicolinate (8)
Dichloromethane (30 mL), ethanol (16.43 g, 0.170 mol), and triethylamine (17.17 g, 0.170 mol)
were successively added to a beaker and stirred at 0 ◦C for 0.5 h. Subsequently, a mixture of
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4-chloropicolinoyl chloride 7 (16.43 g, 0.110 mol) and DCM (5 mL) was added dropwise, stirred at 0 ◦C
for 0.5 h, and monitored by TLC. After completion of the reaction, NaOH solution was added to the
mixture to adjust the pH value 9–10. Ultimately, the organic layers were combined and dried to obtain
a brown liquid.
3.1.3. Preparation of Ethyl 4-(4-Nitrophenoxy)picolinate (9a) and Ethyl4-(2-Fluoro-4-Nitrophenoxy)
picolinate (9b)
Intermediate 8 (13.22 g, 0.071 mol) and p-nitrophenol or 2-fluoro-4-nitrophenol (0.026 mol) were
dissolved in chlorobenzene (40 mL) and then stirred at 130 ◦C for 4 h. The completion of the reaction
was monitored by TLC. After completion of the reaction, the cold petroleum ether (100 mL) was poured
into the reaction solvent and stirred at room temperature for 0.5 h. Next, petroleum ether (100 mL) was
poured off to give a viscous liquid, which was then dissolved in DCM (300 mL) and extracted with
aqueous solution of NaOH. The organic layer was combined, dried, and concentrated under vacuum
to get a pale yellow solid.
3.1.4. Preparation of 4-(4-Nitrophenoxy)picolinic Acid (10a) and 4-(2-Fluoro-4-Nitrophenoxy)picolinic
Acid (10b)
Intermediates 9a–9b (0.035 mol) were dissolved in 1,4-dioxane (50 mL) and stirred at room
temperature for 0.5 h. A solution of 10% NaOH (2.28 mL, 0.057 mol) was then added dropwise to the
above mixture, stirred at room temperature for 0.5 h, and monitored by TLC. After completion of the
reaction, the solvent was evaporated under vacuum to give a white solid. The white solid was then
dissolved in saturated NaCl solution (500 mL) and stirred at room temperature for 10 h. Subsequently,
after the pH of the solution was adjusted to 2–3 by 75% hydrochloric acid (HCl), a yellow solid was
precipitated, filtered, and dried.
3.1.5. Preparation of 4-(4-Nitrophenoxy)picolinamide or 4-(2-Fluoro-4-Nitrophenoxy)picolinamide
Analogues (11a–11e)
Intermediates 10a–10b (0.020 mol) and one drop of DMF were successively dissolved in SOCl2
(50 mL) and stirred at 85 ◦C for 0.5 h. Then reaction solvent was concentrated in vacuum, dissolved
in DCM (8 mL), and added dropwise to a mixture of DCM (50 mL), ammonia analogs (0.020 mol),
and triethylamine (0.020 mol). The reaction solution was stirred at 0 ◦C for 0.5 h, and monitored by
TLC. Finally, a gray slid was obtained by the same post-treatment method as that used for preparation
of ethyl 4-chloropicolinate 8.
3.1.6. Preparation of 4-(4-Aminophenoxy)picolinamide or 4-(2-Fluoro-4-aminophenoxy)picolinamide
Analogues (12a–12e)
Intermediates 11a–11e (0.016 mol), activated carbon (1.92 g, 0.160 mol), and FeCl3·6H2O (0.43 g,
0.016 mol) were dissolved in ethanol (30 mL) and stirred at 90 ◦C for 0.5 h. Then, 80% hydrazine
hydrate (8.00 g, 0.128 mol) was added dropwise and stirred for 3.5 h. The reaction was monitored by
TLC. After completion of the reaction, the solution was filtered, concentrated, and recrystallized to
give a green solid.
3.1.7. Preparation of 5-Methyl-1-Phenyl-1H-1,2,3-Triazole-4-Carbonyl Chloride or 1-Phenyl-5-
(trifluoromethyl)-1H-1,2,3-Triazole-4-Carbonyl Chloride Analogues (13i–13e)
The preparation of intermediates 13a–13i was carried out according to our previous research [15].
3.1.8. Preparation of Target Compounds B1–B27
Intermediates 12a–12e (0.002 mol) and sodium bicarbonate (4.20 g, 0.005 mol) were dissolved
in DCM and stirred at 0 ◦C for 0.5 h. The solution of intermediates 13a–13i (0.002 mol) and DCM
were added dropwise to the above mixture, and stirred at 0 ◦C for 0.5 h. The reaction was monitored
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by TLC. After completion of the reaction, the solution was extracted with a mixture of DCM/NaOH
(500 mL) three times and then the organic layers were combined, dried over sodium sulfate, evaporated,
and purified by chromatographic column to possess a light yellow or white solid.
4-(4-(5-methyl-1-phenyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide (B1) Light yellow
solid; Yield: 78.5%; m.p.: 116.8–117.1 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.75 (s, 1H), 8.82 (s,
1H), 8.52 (d, J = 5.5 Hz, 1H), 8.03 (s, 1H), 8.01 (s, 1H), 7.67 (s, 2H), 7.64 (d, J = 6.4 Hz, 2H), 7.43 (s, 1H),
7.23 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 4.5 Hz, 1H), 3.22 (dd, J = 12.8, 6.3 Hz, 2H), 2.59 (s, 3H), 1.50 (dt,
J = 14.1, 7.0 Hz, 2H), 0.84 (t, J = 7.2 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C25H24N6O3:
457.1988, found, 457.1986.
4-(4-(1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide (B2) Light
yellow solid; Yield: 59.3%; m.p.: 110.4–110.8 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.64 (s, 1H),
8.71 (s, 1H), 8.40 (d, J = 5.6 Hz, 1H), 7.91 (s, 1H), 7.89 (s, 1H), 7.65 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 4.6 Hz,
1H), 7.39 (t, J = 8.7 Hz, 2H), 7.31 (d, J = 2.1 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 3.1 Hz, 1H), 3.10
(dd, J = 13.3, 6.6 Hz, 2H), 2.46 (s, 3H), 1.38 (dt, J = 14.2, 7.1 Hz, 2H), 0.72 (t, J = 7.3 Hz, 3H). TOF MS ES+
(m/z): [M + H]+, calcd for C25H23FN6O3: 475.1894, found, 475.1896.
4-(4-(5-methyl-1-(2-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B3) White solid; Yield: 78.2%; m.p.: 97.7–98.0 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.81 (s,
1H), 8.81 (s, 1H), 8.52 (d, J = 5.3 Hz, 1H), 8.03 (s, 1H), 8.01 (s, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.84 (d,
J = 7.6 Hz, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.2 Hz, 1H), 7.42 (s, 1H), 7.23 (d, J = 8.6 Hz, 2H), 7.18
(d, J = 0.8 Hz, 1H), 3.22 (d, J = 6.2 Hz, 2H), 2.46 (s, 3H), 1.51 (dd, J = 14.0, 7.0 Hz, 2H), 0.84 (t, J = 7.2 Hz,
3H). TOF MS ES+ (m/z): [M + H]+, calcd for C26H23F3N6O4: 541.1811, found, 541.1813.
4-(4-(1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B4) White solid; Yield: 66.4%; m.p.: 159.0–159.2 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 11.19
(s, 1H), 8.80 (s, 1H), 8.52 (d, J = 5.5 Hz, 1H), 7.99 (s, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.79 (d, J = 4.4 Hz,
3H), 7.75 (d, J = 8.7 Hz, 1H), 7.42 (s, 1H), 7.27 (d, J = 8.7 Hz, 2H), 7.19 (d, J = 5.5 Hz, 1H), 3.23 (dd,
J = 13.2, 6.7 Hz, 2H), 1.57–1.47 (m, 2H), 0.84 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ
165.73, 163.13, 156.58, 152.54, 150.36(2,C), 149.46, 142.31, 136.19, 135.84, 134.09, 129.70(2,C), 128.22(2,C),
122.40(2,C), 121.33(2,C), 114.18(2,C), 108.95, 40.58, 22.34, 11.27. TOF MS ES+ (m/z): [M + H]+, calcd for
C25H20ClF3N6O3: 545.1316, found, 545.1317.
N-propyl-4-(4-(5-(trifluoromethyl)-1-(2-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)
picolinamide (B5) White yellow solid; Yield: 69.4%; m.p.: 163.4–163.7 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 11.26 (s, 1H), 8.80 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.15–8.09 (m, 2H), 8.05 (d, J = 7.2 Hz, 1H), 8.00
(d, J = 7.7 Hz, 3H), 7.43 (s, 1H), 7.27 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 2.7 Hz, 1H), 3.23 (dd, J = 12.4,
6.0 Hz, 2H), 1.57–1.47 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ 165.72,
163.14, 156.20, 152.53, 150.36(2,C), 149.53, 141.89, 135.72, 134.28(2,C), 132.86, 132.02, 130.02(2,C), 127.71,
122.60(2,C), 121.29(2,C), 114.17(2,C), 108.96, 40.57, 22.33, 11.24. TOF MS ES+ (m/z): [M + H]+, calcd for
C26H20F6N6O3: 579.1580, found, 579.1573.
4-(4-(1-(3,4-difluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B6) Light yellow solid; Yield: 85.0%; m.p.: 97.6–97.8 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 11.21
(s, 1H), 8.80 (s, 1H), 8.52 (d, J = 4.9 Hz, 1H), 8.12 (s, 1H), 7.98 (d, J = 6.9 Hz, 2H), 7.81 (d, J = 8.9 Hz,
1H), 7.74 (s, 1H), 7.41 (s, 1H), 7.27 (d, J = 6.9 Hz, 2H), 7.20 (d, J = 2.3 Hz, 1H), 3.26–3.19 (m, 2H), 1.52
(dd, J = 13.7, 6.8 Hz, 2H), 0.84 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ 165.73,
163.13, 156.48, 152.54, 150.36(2,C), 149.48, 142.09, 135.81, 131.59, 124.44, 122.46(2,C), 121.32(2,C), 118.63,
118.44, 117.06, 116.86, 114.19(2,C), 108.93, 40.58, 22.34, 11.26. TOF MS ES+ (m/z): [M +H]+, calcd for
C25H19F5N6O3: 547.1517, found, 547.1517.
4-(4-(1-(3-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B7) White solid; Yield: 81.6%; m.p.: 153.6–153.9 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 11.23 (s,
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1H), 8.80 (t, J = 5.9 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 7.99 (s, 1H), 7.97 (s, 1H), 7.79 (d, J = 4.0 Hz, 3H),
7.42 (s, 1H), 7.27 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 3.8 Hz, 1H), 3.23 (dd, J = 13.3, 6.5 Hz, 2H), 1.57–1.47 (m,
2H), 0.84 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ 165.73, 163.15, 156.61, 152.52,
150.33(2,C), 149.45, 142.38, 136.20, 135.87, 134.06, 129.69(2,C), 128.18(2,C), 122.39(2,C), 121.29(2,C),
114.13(2,C), 108.99, 40.58, 22.34, 11.25. TOF MS ES+ (m/z): [M + H]+, calcd for C25H19ClF4N6O3:
563.1222, found, 563.1216.
4-(4-(1-(2-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-
propylpicolinamide (B8) White solid; Yield: 56.7%; m.p.: 143.3–143.7 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 11.30 (s, 1H), 8.81 (s, 1H), 8.65 (s, 1H), 8.53 (d, J = 4.9 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.15
(d, J = 7.9 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.42 (s, 1H), 7.27 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 2.1 Hz,
1H), 3.22 (dd, J = 12.2, 6.0 Hz, 2H), 1.52 (dq, J = 13.9, 7.1 Hz, 2H), 0.84 (t, J = 7.1 Hz, 3H). 13C-NMR
(100 MHz, DMSO-d6, ppm) δ 165.72, 163.14, 156.13, 152.54, 150.37(2,C), 149.56, 141.97, 135.71, 135.05,
133.58, 131.78(2,C), 131.49, 130.44, 127.03, 122.63(2,C), 121.28(2,C), 114.18(2,C), 108.96, 40.58, 22.33,
11.25. TOF MS ES+ (m/z): [M + H]+, calcd for C26H19ClF6N6O3: 613.1190, found, 613.1189.
4-(4-(1-(4-chloro-3-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-
propylpicolinamide (B9) Light yellow solid; Yield: 66.3%; m.p.: 155.5–155.8 ◦C; 1H-NMR (400 MHz,
DMSO-d6, ppm) δ 11.21 (s, 1H), 8.81 (s, 1H), 8.53 (d, J = 5.3 Hz, 1H), 8.44 (s, 1H), 8.17 (d, J = 8.1 Hz, 1H),
8.10 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.7 Hz, 2H), 7.41 (s, 1H), 7.27 (d, J = 8.6 Hz, 2H), 7.19 (d, J = 2.9 Hz,
1H), 3.22 (dd, J = 12.8, 6.2 Hz, 2H), 1.52 (dq, J = 14.8, 7.4 Hz, 2H), 0.84 (t, J = 7.3 Hz, 3H). TOF MS ES+
(m/z): [M + H]+, calcd for C26H19ClF6N6O3: 613.1190, found, 613.1188.
4-(2-fluoro-4-(5-methyl-1-phenyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide (B10) White
solid; Yield: 76.8%; m.p.: 143.3–143.7 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.96 (s, 1H), 8.83 (s,
1H), 8.54 (d, J = 5.4 Hz, 1H), 8.11 (d, J = 13.2 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.67 (d, J = 2.6 Hz, 5H),
7.48–7.39 (m, 2H), 7.23 (d, J = 4.7 Hz, 1H), 3.23 (dd, J = 12.9, 6.3 Hz, 2H), 2.59 (s, 3H), 1.57–1.47 (m, 2H),
0.84 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ 165.66, 163.43, 160.15, 153.09, 150.87(2,C),
138.46, 138.29, 135.61, 130.48, 130.09(3,C), 125.84(3,C), 124.07, 117.64, 113.82, 109.37, 108.46, 41.02, 22.73,
11.67, 9.86. TOF MS ES+ (m/z): [M + H]+, calcd for C25H23FN6O3: 475.1894, found, 475.1894.
4-(2-fluoro-4-(1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B11) White solid; Yield: 65.1%; m.p.: 143.5–143.8 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.95 (s,
1H), 8.82 (s, 1H), 8.54 (d, J = 5.1 Hz, 1H), 8.10 (d, J = 12.7 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.76 (s, 2H),
7.51 (t, J = 8.4 Hz, 2H), 7.44 (d, J = 12.9 Hz, 2H), 7.22 (d, J = 2.5 Hz, 1H), 3.22 (d, J = 6.0 Hz, 2H), 2.58 (s,
3H), 1.51 (dd, J = 13.9, 6.9 Hz, 2H), 0.84 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ
165.65, 164.20, 163.42, 161.74, 160.11, 153.08, 150.88, 138.75, 138.22, 131.99, 128.44, 128.35, 124.08, 117.65,
117.18(2,C), 116.95, 113.83, 109.60, 109.38, 108.44, 41.01, 22.73, 11.67, 9.78. TOF MS ES+ (m/z): [M + H]+,
calcd for C25H22F2N6O3: 493.1800, found, 493.1797.
4-(2-fluoro-4-(5-methyl-1-(2-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-propylpicolinamide
(B12) Light yellow solid; Yield: 63.2%; m.p.: 132.6–132.9 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ
10.99 (s, 1H), 8.82 (s, 1H), 8.55 (d, J = 5.6 Hz, 1H), 8.10 (d, J = 13.2 Hz, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.85
(d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.4 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 7.41 (d,
J = 2.5 Hz, 1H), 7.23 (dd, J = 5.5, 2.6 Hz, 1H), 3.26–3.20 (m, 2H), 2.46 (s, 3H), 1.58–1.47 (m, 2H), 0.85 (t,
J = 7.4 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C26H22F4N6O4: 559.1717, found, 559.1717.
4-(4-(1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)-2-fluorophenoxy)-N-propylpicolinamide
(B13) Light yellow solid; Yield: 76.3%; m.p.: 176.5–176.8 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ
11.37 (s, 1H), 8.81 (s, 1H), 8.55 (d, J = 5.3 Hz, 1H), 8.06 (d, J = 12.8 Hz, 1H), 7.79 (d, J = 7.4 Hz, 5H),
7.48 (d, J = 8.9 Hz, 1H), 7.44 (s, 1H), 7.27–7.20 (m, 1H), 3.23 (d, J = 6.1 Hz, 2H), 1.52 (dd, J = 14.1,
7.1 Hz, 2H), 0.84 (t, J = 7.3 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C25H19ClF4N6O3: 563.1222,
found, 563.1216.
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4-(2-fluoro-4-(5-(trifluoromethyl)-1-(2-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-
propylpicolinamide (B14) Light yellow solid; Yield: 79.6%; m.p.: 172.8–173.1 ◦C; 1H-NMR (400 MHz,
DMSO-d6, ppm) δ 11.43 (s, 1H), 8.82 (s, 1H), 8.55 (d, J = 5.3 Hz, 1H), 8.12 (s, 1H), 8.09 (d, J = 4.7 Hz, 1H),
8.05 (s, 1H), 8.00 (d, J = 9.1 Hz, 2H), 7.84 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 8.9 Hz, 1H), 7.44 (s, 1H), 7.24 (d,
J = 2.5 Hz, 1H), 3.23 (d, J = 5.6 Hz, 2H), 1.55–1.49 (m, 2H), 0.84 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz,
DMSO-d6, ppm) δ 165.15, 163.01, 156.39, 152.70, 150.48(2,C), 141.52, 134.25(2,C), 134.18, 132.86, 132.00,
129.99(2,C), 127.65, 123.86(2,C), 117.59, 113.43(2,C), 109.61, 109.39, 108.12, 40.60, 22.31, 11.21. TOF MS
ES+ (m/z): [M + H]+, calcd for C26H22F4N6O3: 543.1614, found, 543.1616.
4-(4-(1-(3,4-difluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)-2-fluorophenoxy)-N-propylpicolinamide
(B15) White solid; Yield: 55.4%; m.p.: 134.4–134.8 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 11.40
(s, 1H), 8.83 (s, 1H), 8.55 (d, J = 5.4 Hz, 1H), 8.13 (d, J = 9.0 Hz, 1H), 8.06 (d, J = 13.0 Hz, 1H), 7.82
(d, J = 7.0 Hz, 2H), 7.74 (s, 1H), 7.48 (t, J = 8.8 Hz, 1H), 7.42 (s, 1H), 7.25 (d, J = 2.0 Hz, 1H), 3.22 (d,
J = 6.2 Hz, 2H), 1.52 (d, J = 7.1 Hz, 2H), 0.84 (t, J = 7.1 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for
C26H19F7N6O3: 597.1485, found, 597.1486.
4-(4-(1-(3-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)-2-fluorophenoxy)-N-
propylpicolinamide (B16) White solid; Yield: 59.7%; m.p.: 163.3–163.5 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 11.39 (s, 1H), 8.82 (t, J = 5.8 Hz, 1H), 8.56 (d, J = 5.6 Hz, 1H), 8.23 (d, J = 4.8 Hz, 1H), 8.06
(d, J = 12.9 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (t, J = 8.9 Hz, 1H), 7.48 (t,
J = 9.0 Hz, 1H), 7.42 (s, 1H), 7.25 (d, J = 5.4 Hz, 1H), 3.23 (dd, J = 13.3, 6.5 Hz, 2H), 1.53 (dt, J = 14.5,
7.4 Hz, 2H), 0.85 (t, J = 7.4 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C25H18ClF5N6O3: 581.1127,
found, 581.1128.
4-(4-(1-(2-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)-2-
fluorophenoxy)-N-propylpicolinamide (B17) White solid; Yield: 64.5%; m.p.: 154.1–154.4 ◦C; 1H-NMR
(400 MHz, DMSO-d6, ppm) δ 11.48 (s, 1H), 8.83 (s, 1H), 8.65 (s, 1H), 8.55 (d, J = 5.0 Hz, 1H), 8.21 (d,
J = 7.8 Hz, 1H), 8.15 (d, J = 8.2 Hz, 1H), 8.07 (d, J = 12.9 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.49 (t,
J = 8.8 Hz, 1H), 7.43 (s, 1H), 7.25 (d, J = 1.4 Hz, 1H), 3.23 (d, J = 6.0 Hz, 2H), 1.52 (dd, J = 13.9, 6.9 Hz,
2H), 0.84 (t, J = 7.3 Hz, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C26H18ClF7N6O3: 631.1089,
found, 631.1089.
4-(4-(1-(4-chloro-3-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamido)-2-
fluorophenoxy)-N-propylpicolinamide (B18) White solid; Yield: 55.9%; m.p.: 153.4–153.7 ◦C; 1H-NMR
(400 MHz, DMSO-d6, ppm) δ 11.41 (s, 1H), 8.83 (s, 1H), 8.56 (d, J = 5.3 Hz, 1H), 8.45 (s, 1H), 8.18 (d,
J = 8.4 Hz, 1H), 8.12–8.01 (m, 2H), 7.84 (d, J = 8.4 Hz, 1H), 7.48 (t, J = 8.9 Hz, 1H), 7.42 (s, 1H), 7.25
(s, 1H), 3.26–3.19 (m, 2H), 1.52 (dq, J = 14.4, 7.0 Hz, 2H), 0.84 (t, J = 7.2 Hz, 3H). TOF MS ES+ (m/z):
[M + H]+, calcd for C26H18ClF7N6O3: 631.1089, found, 631.1096.
N-(3-fluoro-4-((2-(pyrrolidine-1-carbonyl)pyridin-4-yl)oxy)phenyl)-5-methyl-1-phenyl-1H-1,2,3-triazole-4-
carboxamide (B19) Light yellow solid; Yield: 63.2%; m.p.: 169.7–170.0 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 10.94 (s, 1H), 8.50 (d, J = 4.4 Hz, 1H), 8.09 (d, J = 12.9 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.65 (d,
J = 14.4 Hz, 5H), 7.42 (t, J = 8.6 Hz, 1H), 7.13 (d, J = 14.2 Hz, 2H), 3.59 (s, 2H), 3.45 (s, 2H), 2.59 (s, 3H),
1.82 (s, 4H). TOF MS ES+ (m/z): [M + H]+, calcd for C26H23FN6O3: 487.1897, found, 487.1902.
N-(3-fluoro-4-((2-(pyrrolidine-1-carbonyl)pyridin-4-yl)oxy)phenyl)-1-(4-fluorophenyl)-5-methyl-1H-1,2,3-
triazole-4-carboxamide (B20) Light yellow solid; Yield: 66.4%; m.p.: 164.3–164.7 ◦C; 1H-NMR (400 MHz,
DMSO-d6, ppm) δ 10.94 (s, 1H), 8.51 (d, J = 5.3 Hz, 1H), 8.09 (d, J = 13.2 Hz, 1H), 7.84 (d, J = 8.4 Hz,
1H), 7.75 (d, J = 3.2 Hz, 2H), 7.51 (t, J = 8.4 Hz, 2H), 7.42 (t, J = 8.9 Hz, 1H), 7.18 (s, 1H), 7.12 (d,
J = 4.6 Hz, 1H), 3.59 (s, 2H), 3.45 (s, 2H), 2.57 (s, 3H), 1.81 (s, 4H). TOF MS ES+ (m/z): [M +H]+, calcd
for C26H22F2N6O3: 505.1800, found, 505.1807.
N-(3-fluoro-4-((2-(pyrrolidine-1-carbonyl)pyridin-4-yl)oxy) phenyl)-5-methyl-1-(2-(trifluoromethoxy)phenyl)-
1H-1,2,3-triazole-4-carboxamide (B21) White solid; Yield: 66.5%; m.p.: 176.3–176.6 ◦C; 1H-NMR (400 MHz,
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DMSO-d6, ppm) δ 11.00 (s, 1H), 8.51 (d, J = 4.9 Hz, 1H), 8.09 (d, J = 12.8 Hz, 1H), 7.89 (d, J = 7.3 Hz,
1H), 7.85 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.2 Hz, 1H), 7.75–7.70 (m, 1H), 7.43 (t, J = 8.6 Hz, 1H), 7.16
(s, 1H), 7.11 (d, J = 1.9 Hz, 1H), 3.60 (s, 2H), 3.46 (s, 2H), 2.46 (s, 3H), 1.82 (s, 4H). TOF MS ES+ (m/z):
[M + H]+, calcd for C27H22F4N6O4: 571.1717, found, 571.1722.
4-(2-fluoro-4-(5-methyl-1-phenyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(2-(thiophen-2-yl)ethyl)picolinamide
(B22) Light yellow solid; Yield: 61.9%; m.p.: 124.6–125.0 ◦C; 1H NMR (400 MHz, DMSO-d6, ppm) δ
10.97 (s, 1H), 8.98 (t, J = 5.9 Hz, 1H), 8.55 (d, J = 5.6 Hz, 1H), 8.11 (d, J = 13.2 Hz, 1H), 7.86 (d, J = 8.8 Hz,
1H), 7.67 (d, J = 2.3 Hz, 5H), 7.48–7.41 (m, 2H), 7.32 (d, J = 4.9 Hz, 1H), 7.24 (d, J = 3.0 Hz, 1H), 6.96-6.91
(m, 1H), 6.89 (d, J = 2.6 Hz, 1H), 3.54 (dd, J = 13.4, 6.8 Hz, 2H), 3.06 (t, J = 7.1 Hz, 2H), 2.59 (s, 3H). TOF
MS ES+ (m/z): [M + H]+, calcd for C28H23FN6O3S: 543.1614, found, 543.1616.
4-(2-fluoro-4-(1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(2-(thiophen-2-yl)
ethyl)picolinamide (B23) White solid; Yield: 51.7%; m.p.: 110.4–110.8 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 10.99 (s, 1H), 9.00 (t, J = 5.7 Hz, 1H), 8.57 (d, J = 5.6 Hz, 1H), 8.13 (d, J = 13.2 Hz, 1H), 7.88
(d, J = 8.8 Hz, 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.77 (d, J = 4.8 Hz, 1H), 7.54 (t, J = 8.7 Hz, 2H), 7.47 (d,
J = 9.1 Hz, 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.34 (d, J = 4.6 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H), 6.98–6.94 (m,
1H), 6.91 (s, 1H), 3.55 (dd, J = 13.3, 6.8 Hz, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.60 (s, 3H). TOF MS ES+ (m/z):
[M + H]+, calcd for C28H22F2N6O3S: 561.1520, found, 561.1529.
4-(2-fluoro-4-(5-methyl-1-(2-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(2-(thiophen-
2-yl)ethyl)picolinamide (B24) White solid; Yield: 56.6%; m.p.: 103.4–103.7 ◦C; 1H-NMR (400 MHz,
DMSO-d6, ppm) δ 10.98 (s, 1H), 8.94 (s, 1H), 8.55 (d, J = 5.3 Hz, 1H), 8.10 (d, J = 13.2 Hz, 1H), 7.88 (d,
J = 6.4 Hz, 2H), 7.84 (d, J = 7.0 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.72 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 8.8 Hz,
2H), 7.31 (d, J = 4.1 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 6.96–6.92 (m, 1H), 6.90 (s, 1H), 3.55 (d, J = 6.2 Hz,
2H), 3.07 (t, J = 6.9 Hz, 2H), 2.47 (s, 3H). TOF MS ES+ (m/z): [M + H]+, calcd for C29H22F4N6O4S:
627.1437, found, 627.1439.
4-(2-fluoro-4-(5-methyl-1-phenyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(3-morpholinopropyl)picolinamide
(B25) White solid; Yield: 42.6%; m.p.: 108.3–108.6 ◦C; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 10.67
(s, 1H), 9.05 (s, 1H), 8.53 (s, 1H), 8.03 (d, J = 7.5 Hz, 2H), 7.67 (s, 5H), 7.45 (s, 1H), 7.23 (d, J = 7.6 Hz,
1H), 7.17 (s, 1H), 3.64 (s, 4H), 3.36 (s, 2H), 2.60 (s, 3H), 2.44 (s, 6H), 1.72 (s, 2H). 13C-NMR (100 MHz,
DMSO-d6, ppm) δ 166.25, 163.53, 159.92, 152.85, 150.72, 149.29, 138.56, 138.11, 136.82, 135.67, 130.44,
130.10(2,C), 125.83(2,C), 122.70(2,C), 121.51(2,C), 114.53, 109.30, 66.25(2,C), 56.81, 53.53(2,C), 38.36,
25.59, 9.85. TOF MS ES+ (m/z): [M + H]+, calcd for C29H30FN7O4: 560.2421, found, 560.2416.
4-(2-fluoro-4-(1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(3-morpholinopropyl)
picolinamide (B26) White solid; Yield: 39.3%; m.p.: 108.5–108.9 ◦C; 1H-NMR (400 MHz, DMSO-d6,
ppm) δ 10.73 (s, 1H), 9.10 (s, 1H), 8.52 (d, J = 3.7 Hz, 1H), 8.03 (d, J = 7.9 Hz, 2H), 7.76 (s, 2H), 7.52
(d, J = 6.9 Hz, 2H), 7.43 (s, 1H), 7.23 (d, J = 7.9 Hz, 2H), 3.61 (s, 4H), 3.35 (s, 2H), 2.59 (s, 3H), 2.34 (s,
6H), 1.68 (s, 2H). 13C-NMR (100 MHz, DMSO-d6, ppm) δ 166.25, 163.48, 159.87, 152.90, 150.69, 149.33,
138.38, 136.78, 132.06, 128.39, 128.30, 122.71(2,C), 121.46(2,C), 117.16(2,C), 116.93(2,C), 114.50, 109.32,
66.54(2,C), 57.08, 53.77(2,C), 38.55, 25.80, 9.74. TOF MS ES+ (m/z): [M +H]+, calcd for C29H29F2N7O4:
578.2327, found, 578.2347.
4-(2-fluoro-4-(5-methyl-1-(2-(trifluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)phenoxy)-N-(3-
morpholinopropyl)picolinamide (B27) White solid; Yield: 41.0%; m.p.: 97.6–97.9 ◦C; 1H-NMR (400 MHz,
DMSO-d6, ppm) δ 10.78 (s, 1H), 9.05 (s, 1H), 8.54 (s, 1H), 7.99 (d, J = 5.2 Hz, 2H), 7.86 (d, J = 3.8 Hz,
2H), 7.79 (s, 1H), 7.73 (s, 1H), 7.41 (s, 1H), 7.23 (d, J = 6.1 Hz, 2H), 3.91 (d, J = 8.3 Hz, 2H), 3.85 (d,
J = 11.1 Hz, 2H), 3.36 (d, J = 5.0 Hz, 2H), 3.06 (s, 4H), 2.45 (s, 2H), 1.98 (s, 2H). TOF MS ES+ (m/z):
[M + H]+, calcd for C30H29F4N7O5: 643.1059, found, 643.1094.
1H-NMR spectra of representative target compounds (B1, B6, B12, B13, B20, B25, and B26),
13C-NMR spectra of representative target compounds (B6, B7, B10, B11, B14, B25, and B26),
174
Molecules 2020, 25, 10
and TOF-MS spectra of representative target compounds (B13, B17, B19, B21, B22, B25, and B26) can
be seen in the Supplementary Materials.
3.2. Antitumority Assay
The antitumor activities of target compounds were determined by the MTT method using
Golvatinib as a positive control. All cancer cell lines (A549, HeLa, and MCF-7) were cultured with
Dulbecco Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute (1640) containing
10% fetal bovine serum and 0.1% penicillin–streptomycin, under ambient conditions of 5% CO2 and
37 ◦C. Cells were digested with an appropriate amount of Trypsin–EDTA solution to obtain the cell
suspension, which was diluted with medium and inoculated into 96-well plates at 5*104 cells per well.
After cells were incubated for 24 h, the target compounds diluted by medium to suitable concentrations
were added into 96-well plates, and the cells were cultured continue for 72 h. Next, the medium
was removed, and then thiazolyl blue tetrazolium bromide (MTT) was added to each well to treat
cells for 3.5 h. Ultimately, dimethyl sulfoxide (DMSO) was added to each well after removal of MTT
and the absorbance values were measured with the ELISA (enzyme-linked immunosorbent assay)
reader. All antitumor activities were tested for three times. The IC50 values were the average of
three measurements and were calculated using the Bacus Laboratories Incorporated Slide Scanner
(Bliss) software.
3.3. Dose-Dependent Test
The dose-dependent effect of compound B26 on A549 cells was tested by the MTT method using
Golvatinib as a positive control. The experimental procedure was identical to that of the cytotoxic
activity, wherein the concentration of the test compound was configured to be seven and the cytotoxic
activity was five. Seven different concentrations of compound B26 treated on A549 cells to obtain
the corresponding inhibition rates. Experimental data was obtained by Orange (2018 64 bit) software
based on the inhibition rate.
3.4. Cell Morphology Studies
Cell morphology studies aimed to explore the morphological changes of A549 cells with and
without treatment with compound B26, and the cell morphology was visualized by acridine orange
(AO) staining. The culture environment of A549 cells was consistent with that in the antitumor activity
experiments. Cells were digested with Trypsin–EDTA solution to get the cell suspension, which was
diluted with 1640 medium and inoculated into a 24-well plate at 2*104 cells per well. After incubating
for 12 h, compound B26 diluted to suitable concentrations by 1640 medium was added into a 24-well
plate, and cell culture was continued for 12 h. Then, the 1640 medium in the well plate was removed
and every well were washed three times with phosphate buffer saline (PBS). After washing with PBS
three times, A549 cells were treated with AO for 15 min. A549 cells were washed three times with
PBS again, and the cell morphology distribution was observed directly by a fluorescence microscope.
Ultimately, the picture is exported via computer.
3.5. Cell Cycle Study
A549 cells were seeded into six-well plates at 1*105 cells per well and incubated for 24 h.
Then, the medium containing DMEM (control, without compound) or compound B26 with different
concentrations was added to the culture plate, and A549 cells were further cultured for 24 h. Then,
A549 cells were collected into a centrifuge tube and fixed with a small amount of ice-cold 70% ethanol
at 4 ◦C for 6–12 h. Cells washed three times with PBS were incubated with Rnase (1 mg/mL, diluted
with PBS) for 30 min at room temperature. Finally, propidium iodide (PI) was added to staining
without light for 30 min at room temperature, and the DNA content was measured by flow cytometry
within 1 h. Experimental data was obtained by Modify software.
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3.6. c-Met Kinase Assay
The kinase assay was implemented through Mobility shift assay. The Mixture the configured
available Brij-35 (0.0015%) and 50 mM HEPES (pH = 7.5) to get a kinase buffer base. Then, compounds
B25, B26, and B27 were configured to five concentrations using dimethyl sulfoxide. The kinase buffer
containing the compounds or dimethyl sulfoxide was added to 96-well plates and mixed on the shaker
for fifteen minutes. Next, the solution was transferred in duplicate from a 96-well plate to a 384-well
plate, and then an enzyme solution (c-Met kinase mixed with kinase buffer) was added to each well.
After incubation of the 384-well plate for 10 min at room temperature, a 2.5*peptide solution (formed
by the addition of FAM-labeled peptide and ATP to the kinase base buffer) was added to each well.
After incubation at 28 ◦C for a certain period of time, a stop buffer was added to each well for stop the
reaction. The inhibition value is obtained by converting the conversion data on the caliper. The formula
is that percent inhibition = (max − conversion) / (max −min) * 100. Among them, “max” stands for
DMSO control, “min” stands for low control. Finally, the IC50 values were obtained by fitting the
inhibition rate data using the XLFit excel add-in version software.
3.7. Molecular Docking Study
All the molecular docking simulations were performed by the AutoDock 4.2 software. The crystal
structure of c-Met (PDB code: 3LQ8) used in the docking was downloaded from http://www.rcsb.org/.
The preparation process of the protein for docking mainly involves the addition of hydrogen atoms
and charges, elimination of unrelated water molecules, immobilization of exact residues, and removal
of endogenous ligands (Foretinib), etc. The preparation process of the molecules for docking mainly
includes the addition of hydrogen atoms and charges. Then the prepared molecules (target compounds)
were docked to the certified binding site of c-Met protein. Subsequently, the genetic algorithm was
used for energy optimization. All the docking results were modified and processed by PyMOL 1.8.x
software (https://pymol.org).
4. Conclusions
In conclusion, a series of 4-(pyridin-4-yloxy)benzamide derivatives bearing a triazole fragment
were designed and synthesized. In addition, we evaluated them for antitumor activity against three
cancer cell lines and c-Met kinase activity (only for compounds B25–B27) in vitro. The pharmacological
results indicated that most compounds showed moderate antitumor activity against the three cancer
cell lines. In particular, compound B26 showed excellent inhibitory activity with IC50 values of
3.22, 4.33, and 5.82 μM against A549, HeLa, and MCF-7 cell lines, which were more potent than
Golvatinib, respectively. The SARs study indicated that the introduction of a morpholino group in the
hydrophilic region was more favorable than an alkane chain in terms of antitumor activity, and a single
electron-withdrawing substituent (such as a fluorine atom) on the terminal phenyl ring improved the
inhibitory activity of the target compounds. Further studies will be carried out in the near future.
Supplementary Materials: The Supplementary Materials are available online at http://www.mdpi.com/1420-3049/
25/1/10/s1.
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Abstract: In previous work, we applied the rotation-limiting strategy and introduced a substituent
at the 3-position of the pyrazolo [3,4-d]pyrimidin-4-amine as the affinity element to interact with
the deeper hydrophobic pocket, discovered a series of novel quinazolinones as potent PI3Kδ
inhibitors. Among them, the indole derivative 3 is one of the most selective PI3Kδ inhibitors
and the 3,4-dimethoxyphenyl derivative 4 is a potent and selective dual PI3Kδ/γ inhibitor.
In this study, we replaced the carbonyl group in the quinazolinone core with a sulfonyl group,
designed a series of novel 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as PI3Kδ inhibitors.
After the reduction of nitro group in N-(2,6-dimethylphenyl)-2-nitrobenzenesulfonamide 5 and
N-(2,6-dimethylphenyl)-2-nitro-5-fluorobenzenesulfonamide 6, the resulting 2-aminobenzenesulfonamides
were reacted with trimethyl orthoacetate to give the 3-methyl-2H-benzo[e][1,2,4]thiadiazine
1,1-dioxide derivatives. After bromination of the 3-methyl group, the nucleophilic substitution
with the 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine provided the respective iodide derivatives,
which were further reacted with a series of arylboronic acids via Suzuki coupling to furnish
the 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives 15a–J and 16a–d. In agreement with the
quinazolinone derivatives, the introduction of a 5-indolyl or 3,4-dimethoxyphenyl at the affinity pocket
generated the most potent analogues 15a and 15b with the IC50 values of 217 to 266 nM, respectively.
In comparison with the quinazolinone lead compounds 3 and 4, these 2H-benzo[e][1,2,4]thiadiazine
1,1-dioxide derivatives exhibited much decreased PI3Kδ inhibitory potency, but maintained the high
selectivity over other PI3K isoforms. Unlike the quinazolinone lead compound 4 that was a dual
PI3Kδ/γ inhibitor, the benzthiadiazine 1,1-dioxide 15b with the same 3,4-dimethoxyphenyl moiety
was more than 21-fold selective over PI3Kγ. Moreover, the introducing of a fluorine atom at the
7-position of the 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide core, in general, was not favored for the
PI3Kδ inhibitory activity. In agreement with their high PI3Kδ selectivity, 15a and 15b significantly
inhibited the SU-DHL-6 cell proliferation.
Keywords: PI3Ks; PI3Kδ inhibitors; 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide; anticancer;
anticancer agents
1. Introduction
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that regulate numerous biological
functions, including cell growth, proliferation, differentiation, motility, and intracellular trafficking,
through the phosphorylation of the phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the lipid
Molecules 2019, 24, 4299; doi:10.3390/molecules24234299 www.mdpi.com/journal/molecules179
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second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3) [1–3]. There are three classes of
the PI3K enzyme, of which class I PI3Ks are the mostly studied and further divided into subgroups
IA (PI3Kα, PI3Kβ, and PI3Kδ) and IB (PI3Kγ) based on the signaling pathways and the regulatory
proteins to which they bind [4,5]. The class IA PI3K isoforms mediate the signal transduction from
receptor tyrosine kinases [6], while the IB isoform PI3Kγ is principally activated by G-protein coupled
receptors [7]. PI3Kα and PI3Kβ are ubiquitously expressed, while PI3Kδ and PI3Kγ are dominantly
expressed in leukocytes [8–10]. All the class I PI3K isoforms are implicated in cancer [11–16]. There are
also mounting evidences that support a therapeutic role for inhibition of PI3Kα in diabetes [17,18],
PI3Kβ in thrombosis [19,20], PI3Kδ and PI3Kγ in both rheumatoid arthritis and asthma [21–24],
PI3Kδ in activated PI3Kδ syndrome (APDS) [25–27], and PI3Kγ in idiopathic pulmonary fibrosis [28].
Therefore, the development of PI3K isoform selective inhibitors is a promising therapeutic strategy
for the treatment of these PI3Ks-related diseases. The selective PI3Kδ inhibitor idelalisib (Figure 1)
is approved by FDA for follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) and
for chronic lymphocytic leukemia (CLL) in combination with rituximab [29,30]. The dual PI3Kδ/γ
inhibitor duvelisib (Figure 1) is approved for adult patients with relapsed or refractory CLL or SLL,
and relapsed or refractory FL after at least two prior systemic therapies [31]. However, in the clinical
application of idelalisib, infectious and autoimmune toxicities were observed, and the unique toxicities
are associated with inhibition of different isoforms of the PI3K enzyme [32]. To improve the isoform
selectivity of the quinazolinone-based PI3Kδ inhibitors, in previous work, we introduced a pyrazolo
[3,4-d]pyrimidin-4-amine moiety as the hinge region binding group, a substituent at the 3-position of
the pyrazolo[3,4-d]pyrimidine core as the affinity element to interact with the deeper hydrophobic
pocket, and a 2,6-dimethylphenyl to limit the free rotation of the 3-phenyl in idelalisib, discovered
the indole derivative 3 as one of the most selective PI3Kδ inhibitors (IC50 = 8.6 nM) with more than
3630-fold, 390-fold and 40-fold selective for PI3Kδ over PI3Kα, β and γ, and the 3,4-dimethoxyphenyl
derivative 4 as a potent and selective dual PI3Kδ/γ inhibitor (IC50 = 8.4 nM for PI3Kδ, IC50 = 62
nM for PI3Kγ) with more than 1400-fold, 820-fold selective for PI3Kδ over PI3Kα and PI3Kβ [33].
Considering the importance of sulfonamides in drug discovery [34–36], we replaced the carbonyl
group in the quinazolinone core, and reported here the synthesis and preliminary evaluation of
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as PI3Kδ inhibitors.
 
Figure 1. Selective PI3Kδ and dual PI3Kδ/γ inhibitors.
2. Results and Discussion
2.1. Chemistry
All the new 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives were prepared following a
general synthetic route shown in Scheme 1. The 2-nitrobenzene-1-sulfonamides 5 and 6 were readily
prepared according to the reported method by the reaction of 2-nitrobenzene-1-sulfonyl chloride or
5-fluoro-2-nitrobenzene-1-sulfonyl chloride with 2,6-dimethylbenzenamine in methanol and water
solution in the presence of CH3COONa under refluxing conditions [37]. Reduction of the nitro
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group to amine was carried out using hydrazine monohydrate in the presence of ferric chloride
and activated charcoal in methanol under reflux conditions in excellent yields (95% and 99%). The
resulting 2-aminobenzenesulfonamides 7 and 8 were reacted with trimethyl orthoacetate to give the
corresponding 3-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives 9 and 10 in 51% and
40%, respectively. In the bromination of the allyl methyl group using N-bromosuccinimide (NBS),
the main compounds were found to be the dibrominated products. Therefore, compounds 9 and
10 were reacted with only 0.5 equivalent of NBS in glacial acetic acid to give the monobrominated
derivatives 11 and 12 in moderate yields (79% and 72% based on NBS). Nucleophilic substitution
of 11 and 12 with 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine, which was readily prepared from
5-amino-1H-pyrazole-4-carbonitrile in two steps by the known procedures [38], resulted in the iodides
13 and 14 in 86 and 58% yields, respectively. Finally, the incorporation of the affinity elements was
achieved through the Suzuki coupling of 13 and 14 with the appropriate boronic acid in dioxane and
water catalyzed by Pd(PPh3)4 under refluxing conditions, and the target 2H-benzo[e][1,2,4]thiadiazine
1,1-dioxide derivatives 15a–J and 16a–d were obtained in 34–91% and 51–84% yields. The structures of
these 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives were characterized by 1H-nuclear magnetic
resonance (NMR) and 13C-NMR (please refer to the Supplementary Materials).
Scheme 1. Synthesis of 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives.
2.2. PI3Kδ Inhibitory Activity and Isoform Selectivity
Compounds 15a–J were first tested for their inhibitory activity against PI3Kδ using the ADP-Glo
luminescent assay [39], using a pan-PI3K inhibitor PI-103 as a positive control [40]. As shown
in Table 1, the substitution at the 3-position of the pyrazolo[3,4-d]pyrimidine with 5-indolyl or
3,4-dimethoxyphenyl led to the relative potent analogues 15a and 15b with IC50 values of 217
to 266 nM, respectively. The 6-methoxypyridin-3-yl derivative 15d exhibited moderate PI3Kδ
181
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inhibitory activity (IC50 = 498 nM), whereas the 3-fluoro-4-methoxyphenyl analogue 15c only had
marginal activity. In comparison with 15b, the substitution of the 3,4-dimethoxypheny group
for 2,3-dihydrobenzo[b][1,4]dioxin-6-yl (15e), benzo[d][1,3]dioxol-5-yl (15f), 4-methoxyphenyl (15g),
3-methoxyphenyl (15h), 4-(trifluoromethoxy)phenyl (15i), and phenyl (15j) was not tolerated, indicating
the subtle requirements at the affinity pocket of PI3Kδ.
Table 1. PI3Kδ inhibitory activity of 15a–j and 16a–d.





15b 266 ± 31
15c 980 ± 45























16d 823 ± 69
PI-103 1.6 ± 0.1
a The IC50 values are shown as the mean ± SD from two separate experiments.
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In order to increase the inhibitory activity of compound 15a–d, a fluorine atom was introduced at
the 7-position of the 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide, and compounds 16a–d were prepared
and evaluated for their PI3Kδ inhibitory activity. In comparison with 15a, the fluorinated compound
16a lost its activity (Table 1), and compounds 16b and 16d showed almost 2-fold decrease in potency.
In contrast, compound 16c with a 3-fluoro-4-methoxyphenyl moiety at the affinity pocket showed a
slight increase in potency.
Compared with the leading quinazolinone derivatives 3 and 4, these 2H-benzo[e][1,2,4]-thiadiazine
1,1-dioxide derivatives 15a–j and 16a–d showed much decreased PI3Kδ inhibitory activity. However,
the most potent derivatives 15a and 15b proved to be selective PI3Kδ inhibitors (Table 2). The indole
derivative 15a showed significantly lower potency against other three isoforms of class I PI3K and
was more than 140-fold selective for PI3Kδ over PI3Kα, β and γ. The 3,4-dimethoxyphenyl derivative
15b was more than 60-fold, 90-fold and 20-fold selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ,
respectively. In comparison with the lead 4, 15b was more selective over PI3Kγ (21-fold vs. 7-fold).





PI3Kα PI3Kβ PI3Kδ PI3Kγ SU-DHL-6
15a >50,000 30596 ± 875 217 ± 28 >50,000 2.13 ± 0.09
15b 16364 ± 768 24189 ± 495 266 ± 31 5838 ± 135 2.50 ± 0.11
PI-103 6.5 ± 0.7 23 ± 1.6 1.6 ± 0.1 78 ± 4.3 0.039 ± 0.011 b
a The IC50 or GI50 values are shown as the mean ± SD from two separate experiments; b CAL-101 was the
positive control.
2.3. SU-DHL-6 Cell Growth Inhibitory Activity
The selective PI3Kδ inhibitors 15a and 15b were further evaluated for their antiproliferative activity
against human B-cell SU-DHL-6. 15a and 15b significantly inhibited SU-DHL-6 cell proliferation
with the GI50 of 2.13 and 2.50 μM, respectively (Table 2), which were in consistent with their PI3Kδ
inhibitory potency.
2.4. Molecular Modeling Study
Molecular docking studies were conducted on the new discovered selective PI3Kδ inhibitors 15a
and 15b. As shown in Figure 2, the pyrazolo[3,4-d]pyrimidine portion in both compounds 15a and
15b forms hydrogen bonds with Glu826 and Val828 in the hinge region.
 
Figure 2. Molecular docking studies of 15a (left) and 15b (right).
Both inhibitors bind to the PI3Kδ isoform in an ‘induced fit’ conformation in which the
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide moiety is sandwiched between Trp760 and Met752 as
these residues move apart to create the specificity pocket. The indol-5-yl (15a) in the specificity pocket
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forms an additional hydrogen bond with Asp787. Like the carbonyl oxygen in 3 and 4, one sulfonyl
oxygen in both 15a and 15b acts as hydrogen bond acceptor from the H2O2278. In compound 15b, only
the 3-methoxy group forms hydrogen bonding with Lys779, while in lead 4, the 3-methoxy interacts
with Tyr813 and Asp911, the 4-methoxy interacts with Lys779 [33]. These differences may contribute
its less potency against PI3Kδ than 4. In comparison with 3 and 4, the lack of a 8-fluorine at the
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide core in 15a and 15b may also be related to their lower PI3Kδ
inhibitory activity.
3. Materials and Methods
3.1. General Chemical Experimental Procedures
1H- and 13C-NMR spectra were recorded on a Bruker-600 NMR spectrometer (Brucker Co., Ltd.,
Zurich, Switzerland). All spectra were recorded at room temperature for DMSO or CDCl3 solutions.
High resolution mass spectra (HRMS) were obtained on a 6520 QTOF instrument (Agilent Technologies
Inc., Santa Clara, CA, USA by electrospray ionization (ESI). Melting points were determined on an X-6
micromelting point apparatus (Beijing Tech. Co., Ltd., Beijing, China) without corrections. Column
chromatography was performed on silica gel (200–300 mesh). All reactions involving oxygen- or
moisture sensitive compounds were carried out under a dry N2 atmosphere using anhydrous solvents.
Unless otherwise noted, reagents were added by syringe.
2-Amino-N-(2,6-dimethylphenyl)benzenesulfonamide (7)
To a stirred solution of N-(2,6-dimethylphenyl)-2-nitrobenzenesulfonamide (5, 19.4 g, 63.3 mmol)
in methanol (200 mL), ferric chloride (5.1 g, 19 mmol) and activated charcoal (6.5 g) was added and
refluxed for 30 min. 80% Hydrazine monohydrate (31.7 g, 633 mmol) was then added dropwise and
refluxed for 5 h. After filtration, the filtrate was concentrated and the residue was dissolved in EtOAc
(200 mL), washed with brine, dried over anhydrous Na2SO4. After filtration and evaporation, the
residue was purified by silica gel chromatography (EtOAc/hexane = 1:3) to give 7 (16.5 g, 95%) as a
white solid, m.p. 144–146 ◦C; lit. [41] m.p. 144–145 ◦C.
2-Amino-N-(2,6-dimethylphenyl)-5-fluorobenzenesulfonamide (8)
According to the procedures described for the synthesis of 7, compound 8 were obtained as a
colorless solid (16 g) in 99% yield, m.p. 185–186 ◦C; 1H-NMR (DMSO-d6) δ 9.44 (s, 1H, SO2NH), 7.21
(td, J = 9.0, 3.0 Hz, 1H, Ar-H), 7.07 (td, J = 8.4, 1.5 Hz, 1H, Ar-H), 7.01 (d, J = 7.8 Hz, 2H, Ar-H), 6.97 (dd,
J = 8.4, 3.0 Hz, 1H, Ar-H), 6.85 (dd, J = 9.0, 4.8 Hz, 1H, Ar-H), 5.85 (s, 2H, NH2), 2.04 (s, 6H, 2,6-(CH3)2);
MS (ESI) calcd. for C14H14FN2O2S [M − H]−: 293.1, found: 293.3.
2-(2,6-Dimethylphenyl)-3-methy-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (9)
A mixture of 7 (5 g, 18.1 mmol), trimethyl orthoacetate (50 mL) and 4Ă molecular sieve (10 g)
was refluxed for 10 h. After cooling to room temp., the mixture was concentrated and the residue was
dissolved in EtOAc (200 mL), washed with brine, dried over anhydrous Na2SO4. After filtration and
evaporation, the residue was purified by silica gel chromatography (EtOAc/hexane = 1:5) to give 9
(2.8 g, 51%) as a white solid, m.p. 162–163 ◦C; 1H-NMR (CDCl3) δ 7.89 (d, J = 7.8 Hz, 1H, Ar-H), 7.70
(td, J = 8.4, 1.2 Hz, 1H, Ar-H), 7.60 (d, J = 8.4 Hz, 1H, Ar-H), 7.47 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.21
(t, J = 7.2 Hz, 1H, Ar-H), 7.18 (d, J = 7.8 Hz, 2H, Ar-H), 2.22 (s, 6H, 2,6-(CH3)2), 2.11 (s, 3H, 3-CH3);
13C-NMR (CDCl3) δ 154.34, 142.55, 138.58, 133.51, 132.59, 129.99, 129.27, 127.65, 127.23, 126.90, 121.01,
23.38, 18.62; MS (ESI) m/z calcd. for C16H17N2O2S [M + H]+ 301.1, found 301.0.
2-(2,6-Dimethylphenyl)-7-fluoro-3-methy-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (10)
According to the procedures described for the synthesis of 9, compound 10 were obtained as a
colorless solid (6.9 g) in 40% yield, m.p. 150–151 ◦C; 1H-NMR (DMSO-d6) δ 7.89 (dt, J = 7.2, 1.5 Hz,
184
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1H, Ar-H), 7.73 (dd, J = 7.2, 1.2 Hz, 2H, Ar-H), 7.36 (t, J = 7.2 Hz, 1H, Ar-H), 7.29 (d, J = 7.8 Hz, 2H,
Ar-H), 2.13 (s, 6H, 2,6-(CH3)2), 2.06 (s, 3H, 3-CH3); 13C-NMR (DMSO-d6) δ 160.28 (d, JC–F = 249.2 Hz),
154.02, 139.26 (d, JC–F = 3.0 Hz), 138.59, 132.62, 130.88 (d, JC–F = 7.6 Hz), 130.66, 129.79, 127.96 (d, JC–F
= 9.1 Hz), 122.58 (d, JC–F = 24.2 Hz), 107.95 (d, JC–F = 27.2 Hz), 23.25, 18.47; MS (ESI) m/z calcd. for
C16H16FN2O2S [M + H]+ 319.1, found 319.0.
3-Bromomethyl-2-(2,6-dimethylphenyl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (11)
Compound 9 (1.0 g, 3.3 mmol) was dissolved in glacial acetic acid (10 mL), and then NBS (0.3 g, 1.65
mmol) was added. After the mixture was stirred at room temperature for 0.5 h, distilled water (50 mL)
was added. The mixture was extracted by dichloromethane, washed with brine, dried over anhydrous
Na2SO4. After filtration and evaporation, the residue was purified by silica gel chromatography
(EtOAc/hexane = 1:10) to give 11 (0.5 g) with a conversion yield of 79% as a white solid, m.p. 150–151◦C;
1H-NMR (CDCl3) δ 7.90 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.75 (td, J = 8.4, 1.2 Hz, 1H, Ar-H), 7.69 (dd, J
= 7.8, 0.6 Hz, 1H, Ar-H), 7.55 (td, J = 8.4, 1.2 Hz, 1H, Ar-H), 7.29 (t, J = 7.8 Hz, 1H, Ar-H), 7.19 (d, J
= 7.8 Hz, 2H, Ar-H), 3.97 (s, 2H, CH2Br), 2.24 (s, 6H, 2,6-(CH3)2); 13C-NMR (CDCl3) δ 151.86, 142.16,
138.89, 133.69, 132.14, 130.36, 129.51, 128.37, 128.25, 127.79, 121.00, 28.91, 18.95; MS (ESI) m/z calcd. for
C16H16BrN2O2S [M + H]+ 379.0 and 381.0, found 381.3 and 383.4.
3-Bromomethyl-2-(2,6-dimethylphenyl)-7-fluoro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (12)
According to the procedures described for the synthesis of 11, compound 12 were obtained as a
colorless solid (0.65 g) in 72% conversion yield, m.p. 185–186 ◦C; 1H-NMR (DMSO-d6) δ 7.95 (dd, J =
8.4, 3.0 Hz, 1H, Ar-H), 7.84 (dd, J = 10.8, 5.4 Hz, 1H, Ar-H), 7.79 (td, J = 10.8, 3.0 Hz, 1H, Ar-H), 7.37
(t, J = 8.4 Hz, 1H, Ar-H), 7.29 (d, J = 9.0 Hz, 2H, Ar-H), 4.10 (s, 2H, CH2Br), 2.14 (s, 6H, 2,6-(CH3)2);
13C-NMR (DMSO-d6) δ 161.21 (d, JC–F = 250.6 Hz), 151.77, 138.82, 132.20, 131.54 (d, JC–F = 9.1 Hz),
130.94, 129.97, 129.28, 128.60 (d, JC–F = 9.1 Hz), 122.87 (d, JC–F = 24.2 Hz), 108.32 (d, JC–F = 25.7 Hz),
30.02, 18.72; MS (ESI) m/z calcd.for C16H15BrFN2O2S [M + H]+ 397.0 and 399.0, found 397.2 and 399.1.
3-((4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-2H-
benzo[e]-[1,2,4]thiadiazine 1,1-dioxide (13)
To a solution of 11 (1.1 g, 2.9 mmol) and 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.1 g,
4.4 mmol) in DMF (8 mL), K2CO3 (0.8 g, 5.8 mmol) was added. After stirring at 60 ◦C for 5 h, the
mixture was poured into water (100 mL), extracted by EtOAc. The organic layer was washed with
brine, dried over anhydrous Na2SO4. After filtration and evaporation, the residue was purified by
silica gel chromatography (EtOAc/hexane = 1:10) to give 13 (1.4 g, 86%) as a white solid, m.p. 242–243
◦C; 1H-NMR (DMSO-d6) δ 8.07 (s, 1H, Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.80 (td, J = 7.8, 1.2
Hz, 1H, Ar-H), 7.65 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.43 (d, J = 7.8 Hz, 1H, Ar-H), 7.25 (t, J = 7.2 Hz, 1H,
Ar-H), 7.17 (d, J= 7.2 Hz, 2H, Ar-H), 5.12 (s, 2H, NCH2), 2.07 (s, 6H, 2,6-(CH3)2); 13C-NMR (CDCl3) δ
162.77, 161.35, 159.35, 156.17, 146.35, 143.45, 139.66, 136.44, 135.32, 134.48, 133.91, 133.26, 132.44, 108.30,
95.82, 60.13, 54.33, 23.17; MS (ESI) m/z calcd. for C21H19IN7O2S [M + H]+ 560.0, found 560.2.
3-((4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-7-fluoro-2H-benzo-
[e][1,2,4]thiadiazine 1,1-dioxide (14)
Following the procedures described for the synthesis of 13, compound 14 were obtained as a
white solid (1.6 g) in 58% yield, m.p. 243–244 ◦C; 1H-NMR (DMSO-d6) δ 8.08 (s, 1H, Ar-H), 7.92 (dd, J
= 11.4, 4.2 Hz, 1H, Ar-H), 7.68 (td, J = 13.2, 4.2 Hz, 1H, Ar-H), 7.54 (dd, J = 13.2, 7.2 Hz, 1H, Ar-H),
7.26 (dd, J = 13.2, 10.2 Hz, 1H, Ar-H), 7.17 (d, J = 11.4 Hz, 2H, Ar-H), 5.13 (s, 2H, NCH2), 2.06 (s, 6H,
2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 160.89 (d, JC–F = 250.7 Hz), 158.02, 156.61, 154.57, 150.89, 138.69,
131.55, 131.46 (d, JC–F = 7.6 Hz), 130.64, 129.76, 128.54 (d, JC–F = 7.6 Hz), 122.71 (d, JC–F = 22.7 Hz),
108.28 (d, JC–F = 25.7 Hz), 103.55, 91.13, 79.59, 49.55, 18.40; MS (ESI) m/z calcd. for C21H18FIN7O2S [M +
H]+ 578.0, found 578.0.
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3-((4-Amino-3-(1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15a)
To a solution of 13 (180 mg, 0.30 mmol) in dioxane (4 mL) and distilled water (1.5 mL) was added
1H-indol-5-ylboronic acid (88 mg, 0.55 mmol), sodium carbonate anhydrous (103 mg, 0.97 mmol) and
Pd(PPh3)4 (12 mg, 0.03 mmol). The mixture was degassed with N2, and refluxed for 4 h. After cooling
to room temperature, EtOAc (50 mL) and distilled water (10 mL) were added, and the organic layer was
washed brine, dried over Na2SO4. After filtration and evaporation, the residue was purified by silica
gel chromatography (EtOAc/hexane = 1:1) to give 15a (161 mg, 91%) as a white solid, m.p. 216–217 ◦C;
1H-NMR (CDCl3) δ 11.32 (s, 1H, NH), 8.09 (s, 1H, Ar-H), 7.95 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.81 (td, J
= 7.8, 1.2 Hz, 2H, Ar-H), 7.65 (td, J = 7.8, 0.6 Hz, 1H, Ar-H), 7.57 (d, J = 8.4 Hz, 1H, Ar-H), 7.52 (d, J =
7.8 Hz, 1H, Ar-H), 7.45 (t, J = 3.0 Hz, 1H, Ar-H), 7.38 (dd, J = 8.4, 1.8 Hz, 1H, Ar-H), 7.25 (t, J = 7.8 Hz,
1H, Ar-H), 7.15 (d, J = 7.8 Hz, 2H, Ar-H), 6.55 (t, J = 8.4, 1.8 Hz, 1H, Ar-H), 5.20 (s, 2H, NCH2), 2.04
(s, 6H, 2,6-(CH3)2); 13C-NMR (CDCl3) δ 158.53, 156.22, 155.43, 152.04, 146.79, 141.79, 138.70, 136.53,
134.86, 131.96, 130.48, 129.70, 129.09, 128.51, 128.47, 127.83, 127.04, 123.90, 121.76, 121.20, 120.52, 112.68,
102.22, 97.86, 49.61, 18.35; HRMS (ESI) m/z calcd. for C29H25N8O2S [M + H]+ 549.1816, found 549.1829.
3-((4-Amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15b)
According to the procedures described for the synthesis of 15a, compound 15b were obtained as a
white solid (61 mg) in 75% yield, m.p. 220–222 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.09 (s,
1H, Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.81 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.65 (td, J = 7.2, 1.2
Hz, 1H, Ar-H), 7.50 (d, J = 8.4 Hz, 1H, Ar-H), 7.26 (t, J = 7.8 Hz, 1H, Ar-H), 7.15–7.19 (m, 4H, Ar-H),
7.12 (d, J = 8.4 Hz, 1H, Ar-H), 5.18 (s, 2H, NCH2), 3.81 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 2.02 (s, 6H,
2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 158.50, 156.26, 155.50, 151.98, 149.83, 149.51, 145.20, 141.74, 138.71,
134.86, 131.98, 130.50, 129.70, 129.13, 128.47, 127.84, 125.53, 121.19, 121.03, 112.71, 111.99, 97.70, 79.63,
56.04, 55.89, 49.64, 18.32; HRMS (ESI) m/z calcd. for C29H28N7O4S [M + H]+ 570.1918, found 570.1921.
3-((4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-
(2,6-dimethyl-phenyl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15c)
According to the procedures described for the synthesis of 15a, compound 15c were obtained as a
white solid (59 mg) in 66% yield, m.p. 226–227 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.10 (s, 1H,
Ar-H), 7.94 (d, J = 7.8 Hz, 1H, Ar-H), 7.81 (t, J = 7.8 Hz, 1H, Ar-H), 7.65 (t, J = 7.8 Hz, 1H, Ar-H), 7.49 (d,
J = 8.4 Hz, 1H, Ar-H), 7.43–7.38 (m, 2H, Ar-H), 7.33 (t, J = 8.4 Hz, 1H, Ar-H), 7.25 (t, J = 7.8 Hz, 1H,
Ar-H), 7.15 (d, J = 7.8 Hz, 2H, Ar-H), 5.18 (s, 2H, NCH2), 3.90 (s, 3H, OCH3), 2.02 (s, 6H, 2,6-(CH3)2);
13C-NMR (DMSO-d6) δ 158.50, 156.33, 155.58, 152.84, 152.03 (d, JC–F = 244.6 Hz), 151.85, 148.13 (d, JC–F
= 9.1 Hz), 144.02, 141.72, 138.69, 134.86, 131.93, 130.51, 129.71, 128.82 (d, JC–F = 95.1 Hz), 127.82, 125.78
(d, JC–F = 6.0 Hz), 125.21, 121.20, 116.11 (d, JC–F = 19.6 Hz), 114.91, 97.67, 79.65, 56.57, 49.64, 18.32;
HRMS (ESI) m/z calcd. for C28H25FN7O3S [M + H]+ 558.1718, found 558.1733.
3-((4-Amino-3-(6-methoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15d)
According to the procedures described for the synthesis of 15a, compound 15d were obtained as
a white solid (41 mg) in 47% yield, m.p. 248–249 ◦C; 1H-NMR (DMSO-d6) δ 8.39 (d, J = 1.8 Hz, 1H,
Ar-H), 8.31 (s, 1H, NH), 8.11 (s, 1H, Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.92 (dd, J = 8.4, 2.4 Hz,
1H, Ar-H), 7.81 (td, J = 8.4, 1.2 Hz, 1H, Ar-H), 7.65 (td, J =7.8, 1.2 Hz, 1H, Ar-H), 7.49 (d, J = 7.8 Hz, 1H,
Ar-H), 7.26 (t, J = 7.8 Hz, 1H, Ar-H), 7.16 (d, J = 7.8 Hz, 2H, Ar-H), 6.98 (d, J = 8.4 Hz, 1H, Ar-H), 5.20 (s,
2H, NCH2), 3.92 (s, 3H, OCH3), 2.03 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 164.14, 158.60, 156.38,
155.61, 151.81, 146.69, 142.36, 141.71, 139.29, 138.69, 134.87, 131.91, 130.51, 129.70, 129.13, 128.50, 127.80,
122.70, 121.19, 111.48, 97.92, 79.64, 53.89, 49.66, 18.33; HRMS (ESI) m/z calcd. for C27H25N8O4S [M +
H]+ 541.1765, found 541.1781.
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3-((4-Amino-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-
(2,6-dimethylphenyl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15e)
According to the procedures described for the synthesis of 15a, compound 15e were obtained as a
white solid (71 mg) in 64% yield, m.p. 225–226 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.08 (s, 1H,
Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.82 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.65 (td, J = 7.8, 1.2 Hz,
1H, Ar-H), 7.51 (d, J = 8.4 Hz, 1H, Ar-H), 7.24 (t, J = 8.4 Hz, 1H, Ar-H), 7.14 (d, J = 7.8 Hz, 2H, Ar-H),
7.11–7.09 (m, 2H, Ar-H), 7.02 (d, J = 7.8 Hz, 1H, Ar-H), 5.18 (s, 2H, NCH2), 4.30 (s, 4H, OCH2CH2O),
2.01 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 158.45, 156.25, 155.47, 151.92, 144.79, 144.60, 144.23,
141.74, 138.66, 134.86, 131.94, 130.47, 129.68, 129.12, 128.48, 127.83, 126.18, 121.59, 121.19, 118.30, 117.23,




According to the procedures described for the synthesis of 15a, compound 15f were obtained as a
white solid (29 mg) in 34% yield, m.p. > 250 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.08 (s, 1H,
Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.82 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.65 (td, J = 7.8, 1.2 Hz,
1H, Ar-H), 7.50 (d, J = 7.8 Hz, 1H, Ar-H), 7.25 (t, J = 7.8 Hz, 1H, Ar-H), 7.15 (d, J = 7.2 Hz, 2H, Ar-H),
7.12–7.09 (m, 2H, Ar-H), 7.07 (d, J = 8.4, 1H, Ar-H), 6.10 (s, 2H, OCH2O), 5.17 (s, 2H, NCH2), 2.01 (s,
6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 158.44, 156.28, 155.47, 151.89, 148.36, 144.98, 141.73, 138.67,
134.87, 131.93, 130.49, 129.70, 129.14, 128.50, 127.82, 126.85, 122.65, 121.19, 109.44, 108.80, 101.89, 97.65,
79.64, 49.62, 18.30; HRMS (ESI) m/z calcd. for C28H24N7O4S [M + H]+ 554.1605, found 554.1614.
3-((4-Amino-3-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-2H-
benzo[e][1,2,4]thiadiazine 1,1-dioxide (15g)
According to the procedures described for the synthesis of 15a, compound 15g were obtained as a
white solid (45 mg) in 74% yield, m.p. 248–249 ◦C; 1H-NMR (DMSO-d6) δ 8.32 (s, 1H, NH), 8.09 (s, 1H,
Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.82 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.65 (td, J = 7.8, 1.2 Hz,
1H, Ar-H), 7.57 (d, J = 8.4 Hz, 2H, Ar-H), 7.50 (d, J = 8.4 Hz, 1H, Ar-H), 7.25 (t, J = 7.8 Hz, 1H, Ar-H),
7.15 (d, J = 7.8 Hz, 2H, Ar-H), 7.11 (d, J = 8.4 Hz, 2H, Ar-H), 5.19 (s, 2H, NCH2), 3.82 (s, 3H, OCH3),
2.02 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ160.18, 158.51, 156.26, 155.51, 151.92, 145.03, 141.75,
138.69, 134.85, 131.93, 130.48, 129.95, 129.69, 129.10, 128.49, 127.82, 125.43, 121.19, 115.12, 97.70, 79.63,
55.72, 49.60, 18.34; HRMS (ESI) m/z calcd. for C28H26N7O3S [M + H]+ 540.1812, found 540.1829.
3-((4-Amino-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-2H-
benzo[e][1,2,4]thiadiazine 1,1-dioxide (15h)
According to the procedures described for the synthesis of 15a, compound 15h were obtained as
a white solid (46 mg) in 59% yield, m.p. 221–222 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H), 8.10 (s, 1H,
Ar-H), 7.94 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.82 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.63 (td, J = 7.8, 1.2 Hz,
1H, Ar-H), 7.50 (d, J = 7.8 Hz, 1H, Ar-H), 7.47 (t, J = 7.8 Hz, 1H, Ar-H), 7.26 (t, J = 7.8 Hz, 1H, Ar-H),
7.23 (d, J = 7.8 Hz, 1H, Ar-H), 7.20–7.11 (m, 3H, Ar-H), 7.06 (dd, J = 8.4, 2.4 Hz, 1H, Ar-H), 5.21 (s, 2H,
NCH2), 3.82 (s, 3H, OCH3), 2.02 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 160.11, 158.43, 156.31,
155.56, 151.88, 145.02, 141.72, 138.70, 134.87, 134.36, 131.95, 130.86, 130.51, 129.71, 129.14, 128.48, 127.83,
121.20, 120.76, 115.19, 113.85, 97.74, 79.64, 55.63, 49.68, 18.32; HRMS (ESI) m/z calcd. for C28H26N7O3S
[M + H]+ 540.1812, found 540.1825.
3-((4-Amino-3-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-
2-(2,6-dimethyl-phenyl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (15i)
According to the procedures described for the synthesis of 15a, compound 15i were obtained as a
white solid (61 mg) in 61% yield, m.p. 206–207 ◦C; 1H-NMR (DMSO-d6) δ 8.12 (s, 1H, Ar-H), 7.94 (dd, J
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= 8.4, 1.2 Hz, 1H, Ar-H), 7.81 (dt, J = 8.4, 1.2 Hz, 1H, Ar-H), 7.76 (d, J =8.4 Hz, 2H, Ar-H), 7.65 (dt, J
= 8.4, 0.6 Hz, 1H, Ar-H), 7.52 (d, J = 7.8 Hz, 2H, Ar-H), 7.48 (d, J = 7.8 Hz, 1H, Ar-H), 7.26 (t, J = 7.8
Hz, 1H, Ar-H), 7.16 (d, J = 7.8 Hz, 2 H, Ar-H), 5.21 (s, 2H), 2.03 (s, 6H); 13C-NMR (DMSO-d6) δ 158.52,
156.38, 155.72, 151.77, 149.08, 143.91, 141.70, 138.70, 134.87, 132.28, 131.90, 130.59, 130.53, 129.72, 129.14,
128.50, 127.80, 122.10, 121.21, 120.57 (q, JC–F = 256.70 Hz), 97.73, 49.68, 18.34; HRMS (ESI) m/z calcd. for
C28H23F3N7O3S [M + H]+ 594.1530, found 594.1547.
3-((4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-2H-
benzo[e]-[1,2,4]thiadiazine 1,1-dioxide (15j)
According to the procedures described for the synthesis of 15a, compound 15j were obtained as a
white solid (40 mg) in 73% yield, m.p. 193–194 ◦C; 1H-NMR (DMSO-d6) δ 8.30 (s, 1H, NH), 8.09 (s, 1H,
Ar-H), 7.92 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.80 (td, J = 7.8, 1.2 Hz, 1H, Ar-H), 7.66–7.62 (m, 3H, Ar-H),
7.54 (t, J = 7.8 Hz, 2H, Ar-H), 7.52–7.32 (m, 2H, Ar-H), 7.24 (t, J = 7.8 Hz, 2H, Ar-H), 7.14 (d, J = 7.8 Hz,
2H, Ar-H), 5.19 (s, 2H, NCH2), 2.01 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 1158.46, 156.31, 155.60,
151.86, 145.16, 141.72, 138.69, 134.54, 133.53, 132.51, 131.99, 131.92, 130.51, 130.47, 129.71, 129.67, 129.27,
129.20, 128.60, 127.81, 121.20, 97.73, 79.65, 49.65, 18.34; HRMS (ESI) m/z calcd. for C27H24N7O2S [M +
H]+ 510.1707, found 510.1722.
3-((4-Amino-3-(1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-7-fluoro-
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (16a)
According to the procedures described for the synthesis of 15a, compound 16a were obtained as a
white solid (65 mg) in 73% yield, m.p. 132–133 ◦C; 1H-NMR (DMSO-d6) δ 8.30 (s, 1H, NH), 8.08 (s, 1H,
Ar-H), 7.91 (dd, J = 7.2, 2.4 Hz, 1H, Ar-H), 7.81 (brs, 1H, Ar-H), 7.69 (td, J = 9.6, 3.0 Hz, 1H, Ar-H),
7.61 (dd, J = 9.0, 4.8 Hz, 1H, Ar-H), 7.56 (d, J = 8.4 Hz, 1H, Ar-H), 7.44 (t, J = 3.0 Hz, 1H, Ar-H), 7.36
(dd, J = 8.4, 1.8 Hz, 1H, Ar-H), 7.25 (t, J = 7.28Hz, 1H, Ar-H), 7.16 (t, J = 7.8 Hz, 2H, Ar-H), 6.54 (s, 1H,
3-CH-indolyl), 5.20 (s, 2H, NCH2), 2.01 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 160.08 (d, JC–F =
250.7 Hz), 158.52, 156.23, 155.41, 151.51, 146.84, 138.68, 138.61 (d, JC–F = 3.0 Hz), 136.53, 131.81, 131.44
(d, JC–F = 9.1 Hz), 130.55, 129.74, 128.66 (d, JC–F = 9.1 Hz), 128.46, 127.05, 123.87, 122.67 (d, JC–F = 24.2
Hz), 121.74, 120.52, 112.67, 108.19 (d, JC–F = 27.2 Hz), 102.21, 97.85, 79.65, 49.57, 18.32; HRMS (ESI) m/z
calcd. for C29H24FN8O2S [M + H]+ 567.1721, found 567.1739.
3-((A-amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-7-
fluoro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (16b)
According to the procedures described for the synthesis of 15a, compound 16b were obtained as a
white solid (47 mg) in 51% yield, m.p. 229–230 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.09 (s,
1H, Ar-H), 7.91 (dd, J = 7.2, 2.4 Hz, 1H, Ar-H), 7.69 (td, J = 9.0, 2.4 Hz, 1H, Ar-H), 7.59 (dd, J = 9.0,
4.8 Hz, 1H, Ar-H), 7.26 (t, J = 7.8 Hz, 1H, Ar-H), 7.21–7.10 (m, 5H, Ar-H), 5.19 (s, 2H, NCH2), 3.82 (s,
3H, OCH3), 3.81 (s, 3H, OCH3), 2.01 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 160.78 (d, JC–F = 250.7
Hz), 158.51, 156.27, 155.49, 151.46, 149.84, 149.52, 145.24, 138.70, 138.57 (d, JC–F = 3.0 Hz), 131.84, 131.41
(d, JC–F = 7.6 Hz), 130.57, 129.74, 128.69 (d, JC–F = 7.6 Hz), 125.52, 122.66 (d, JC–F = 24.2 Hz), 121.03,
112.72, 112.02, 108.20 (d, JC–F = 27.2 Hz), 97.71, 79.65, 56.04, 55.89, 49.60, 18.31; HRMS (ESI) m/z calcd.
for C29H27FN7O4S [M + H]+ 588.1824, found 588.1838.
3-((4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-
(2,6-dimethyl-phenyl)-7-fluoro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (16c)
According to the procedures described for the synthesis of 15a, compound 16c were obtained as
a white solid (76 mg) in 84% yield, m.p. 201–202 ◦C; 1H-NMR (DMSO-d6) δ 8.31 (s, 1H, NH), 8.09
(s, 1H, Ar-H), 7.91 (dd, J = 7.2, 3.0 Hz, 1H, Ar-H), 7.69 (td, J = 7.4, 2.4 Hz, 1H, Ar-H), 7.59 (dd, J =
9.0, 4.2 Hz, 1H, Ar-H), 7.44–7.38 (m, 2H, Ar-H), 7.33 (t, J = 9.0 Hz, 1H, Ar-H), 7.26 (t, J = 7.2 Hz, 1H,
Ar-H), 7.15 (d, J = 7.8 Hz, 2H, Ar-H), 5.19 (s, 2H, NCH2), 3.90 (s, 3H, OCH3), 2.01 (s, 6H, 2,6-(CH3)2);
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13C-NMR (DMSO-d6) δ 160.89 (d, JC–F = 250.7 Hz), 158.50, 156.34, 155.56, 152.02 (d, JC–F = 246.1 Hz),
151.32, 148.14 (d, JC–F = 10.6 Hz), 144.06, 138.68, 138.62 (d, JC–F = 19.6 Hz), 131.78, 131.44 (d, JC–F = 7.6
Hz), 130.59, 129.74, 128.66 (d, JC–F = 7.6 Hz), 125.76 (d, JC–F = 7.6 Hz), 125.21, 122.68 (d, JC–F = 22.7 Hz),
116.11 (d, JC–F = 19.6 Hz), 114.92, 108.21 (d, JC–F = 25.7 Hz), 97.67, 79.63, 56.59, 49.61, 18.30; HRMS (ESI)
m/z calcd. for C28H24F2N7O3S [M + H]+ 576.1624, found 576.1637.
3-((4-Amino-3-(6-methoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-(2,6-dimethylphenyl)-
7-fluoro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (16d)
According to the procedures described for the synthesis of 15a, compound 16d were obtained as a
white solid (51 mg) in 58% yield, m.p. 225–226 ◦C; 1H-NMR (DMSO-d6) δ 8.38 (s, 1H, NH), 8.31 (s, 1H,
Ar-H), 8.10 (s, 1H, Ar-H), 7.90 (d, J = 8.4 Hz, 2H, Ar-H), 7.69 (t, J = 7.2 Hz, 1H, Ar-H), 7.59 (dd, J = 9.0,
4.2 Hz, 1H, Ar-H), 7.25 (t, J = 7.2 Hz, 1H, Ar-H), 7.15 (d, J = 8.4 Hz, 2H, Ar-H), 6.97 (d, J = 8.4 Hz, 1H,
Ar-H), 5.20 (s, 2H, NCH2), 3.92 (s, 3H, OCH3), 2.01 (s, 6H, 2,6-(CH3)2); 13C-NMR (DMSO-d6) δ 164.15,
160.89 (d, JC–F = 250.7 Hz), 158.60, 156.39, 155.59, 151.29, 146.69, 142.41, 139.29, 138.69, 138.54 (d, JC–F =
3.0 Hz), 131.77, 131.45 (d, JC–F = 7.6 Hz), 130.59, 129.74, 128.66 (d, JC–F = 9.1 Hz), 122.75, 122.68, 122.67
(d, JC–F = 22.7 Hz), 111.48, 108.20 (d, JC–F = 27.2 Hz), 97.93, 79.64, 53.89, 49.63, 18.32; HRMS (ESI) m/z
calcd. for C27H24FN8O3S [M + H]+ 559.1671, found 559.1678.
3.2. PI3K Kinase Assay
The ADP-Glo luminescent assay was used for PI3Kδ, PI3Kβ and PI3Kγ isoforms and the kinase-Glo
luminescent assay was used for PI3Kα according to the standard protocols of Promega [40]. PI-103
was used as a positive control. The compounds were tested from 1 μM or 10 μM, 3-fold dilution, in
duplicate for 10 concentrations. The kinase reaction was done in 384-well plate (Corning, Los Altos,
MA, USA). Each well was loaded with test compounds (in 100% DMSO) and reaction buffer containing
PI substrate. After the PI3K proteins were then added, the reaction was started by the addition of PIP2
and ATP prepared in the reaction buffer and ran for either 60 (for PI3Kα, PI3Kβ, and PI3Kγ) or 120 min
(for PI3Kδ). ADP-Glo reagent was then added to terminate the reavtion. The plates were then read in a
Synergy 2 reader (BioTek, Shanghai, China) for luminescence detection.
3.3. Cell Proliferation Assay
Cell proliferation was evaluated by The CellTiter-Glo luminescent cell viability assay (Promega,
Shanghai, China) was used to evaluate the inhibitory activity of compounds 15a and 15b following the
manufacturer’s protocol. In brief, SU-DHL-6 (ATCC) cells were seeded in 96-well plates (Corning, Los
Altos, MA, USA) at density of 1 × 104 cells per well, and incubated with medium alone or with the
tested compounds at the indicated concentrations (50 μM in DMSO, 3-fold dilution, in duplicate for
10 concentrations). 50 μL CellTiter-Glo (Promega, Shanghai, China) reagent was added to each well to
induce cell lysis, and the plate was incubated at room temperature for 10 min to stabilize luminescent
signal. After 100 μL of the mixture from each well was transferred to a new 96-well black plate, the
fluorescence signal was read on EnVision (Shanghai, China) and the data were analysized by XLFit 4
software (IDBS, Berlin, Germany).
3.4. Molecular Docking
X-ray cocrystal structure of PI3Kδ enzyme was downloaded from RCSB Protein Date Bank (PDB
ID: 2WXH) [42]. The molecular docking of 15a and 15b was carried out following the same procedures
as reported for compounds 3 and 4 [33].
4. Conclusions
In a continuous study to find more potent and selective PI3Kδ inhibitors based on the
rotation-limiting strategy, we substituted the carbonyl in the quinazolinone core for the sulfonyl
group, designed and synthesized a series of novel 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives
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15a–J and 16a–d. In agreement with the quinazolinone derivatives, the introduction of a 5-indolyl or
3,4-dimethoxyphenyl at the affinity pocket generated the most potent analogues 15a and 15b with the
IC50 values of 217 to 266 nM, respectively. In comparison with the quinazolinone lead compounds
3 and 4, the 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives exhibited much reduced PI3Kδ
inhibitory activity, but maintained high selectivity over other PI3K isoforms. Unlike the quinazolinone
lead compound 4 that was a dual PI3Kδ/γ inhibitor, the 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 15b
was more than 21-fold selective over PI3Kγ. This may provide a structural base for the further design
of more potent and selective PI3Kδ inhibitors. In agreement with their high PI3Kδ inhibitory activity,
15a and 15b exhibited high antiproliferative potency against B-cell leukemia SU-DHL-6 cells.
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Abstract: Three series of novel thienopyrimidine derivatives 9a–l, 15a–l, and 18a–h were designed
and synthesized, and their IC50 values against four cancer cell lines HepG-2, A549, PC-3, and MCF-7
were evaluated. Most compounds show moderate cytotoxicity against the tested cancer cell lines.
The most promising compound 9a showed moderate activity with IC50 values of 12.32 ± 0.96, 11.30 ±
1.19, 14.69 ± 1.32, and 9.80 ± 0.93 μM, respectively. The inhibitory activities of compounds 9a and
15a against PI3Kα and mTOR kinase were further evaluated. Compound 9a exhibited PI3Kα kinase
inhibitory activity with IC50 of 9.47 ± 0.63 μM. In addition, docking studies of compounds 9a and 15a
were also investigated.
Keywords: Thienopyrimidine; Pyrazole; PI3Kα inhibitor
1. Introduction
The PI3K-Akt-mTOR signaling pathway plays an important role in tumorigenesis and
development [1,2]. The activation of related proteins in this pathway is closely related to the
occurrence and development of tumors. In recent years, the development of small molecule drugs
to effectively inhibit the overexpression of this pathway has become a research hotspot in cancer
therapy [3]. Moreover, the study of the complex co-crystals structure of protein and small molecular
Ligand also promoted the development of new drugs [4–6]. Many small molecule inhibitors targeting
PI3K-Akt–mTOR signaling pathway have entered clinical studies, and some of them were even
approved by FDA, such as PI3K inhibitor GDC-0941 [7]; AKT inhibitor GSK2110183 [8]; mTOR
inhibitor AZD2014 (Figure 1) [9], Rapamycin, Deforolimus. PI3Kα is the most important isoform in
cell proliferation in response to growth factor-tyrosine kinase pathway activation. There are currently
more than ten PI3Kα inhibitors undergoing clinical trials. Many research groups are attempting to
develop some more PI3Kα inhibitors.
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Figure 1. Structures of representative clinical PI3K/mTOR dual inhibitors and target compounds.
The thienopyrimidine core is widely used in small molecule inhibitors of the PI3K-Akt-mTOR
signaling pathway. Among them, thienopyrimidine derivative GDC-0941 developed by Genentech, is
the first PI3K inhibitor entering the clinical stage. Right after, several analogues of GDC-0941 were
obtained. Two of them, GNE-477 and GDC-0980 (Figure 1), exhibited excellent activities and were
regarded as potent PI3K/mTOR inhibitors [10,11]. Research showed that thienopyrimidines core were
very important to the activity of these compounds, and it was considered to be an active pharmacophore.
In our previous research, several series of thienopyrimidine-containing compounds were designed
and synthesized [12–14], one representative compound EJMC20159364-16i (Figure 1) exhibited the
best in vitro cytotoxic activity and kinase inhibitory activity (PI3K, mTOR). SARs of this series of
compounds were summarized. The results showed that the introduction of the flexible hydrazinyl
linker at the pyrimidine 2 position helps to increase the cytotoxic activity of the target compounds.
Continuous to this work, the hydrazinyl linker was kept unchanged in the new designed compounds,
and we constructed a pyrazole ring on the hydrazinyl as a new flexible linker to connect with the
aryl group, hoping to increase the compounds’ inhibitory activity by improving the interaction of
the compounds with the receptor (Figure 2). As a result, two series of thieno[2,3-d]pyrimidines
and thieno[3,2-d]pyrimidines containing pyrazole unit (9a–l, 15a–l) were designed and synthesized.
Inspired by GDC-0084, in order to investigate the influence of the thienopyrimidine core to the
activity, a flexible cyclohexane was introduced to the target compounds, resulting in a series of tricyclic
thienopyrimidine compounds 21a–h. It is expected to increase the cytotoxic activity and increase
the interaction of the compounds with the enzyme to enhance the activity and selectivity. Finally,
three series of thienopyrimidine derivatives containing pyrazole structure (9a–l, 15a–l, 21a–h) were
designed, synthesized and evaluated for their cytotoxic activity.
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Figure 2. The design concept based on the co-crystal structure of GDC-0941 with protein.
2. Results and Discussion
2.1. Chemistry
The synthetic routes for thienopyrimidine derivatives 9a–l, 15a–l, and 21a–h are outlined in
Schemes 1 and 2. Condensation of the 4-substituted benzaldehydes (1a–d) with the 4-substituted
acetophenones (2a–e) produced the corresponding chalcones 3a–l (Scheme 1). Treatment of 5 with
POCl 3 afforded 2,4-dichlorothieno[2,3-d]pyrimidine 6, which was then treated with morpholine to
give 4-(2-chlorothieno[2,3-d]pyrimidin-4-yl)morpholine 7. Treatment of 7 with hydrazine gave the key
intermediate 8. Intermediate 8 condensed with the corresponding chalcones 3a–l to afford the target
compounds 9a–l. The synthesis of compounds 15a–l and 21a–h was similar to that of compounds
9a–l (Scheme 2). Generated by condensation reaction between 8 chalcone 3a–l, there appears a chiral
carbon atom at C-5 position of pyrazole of all of the compounds. The similar reaction was reported
in previous research and the structures of target compounds can be easily identified. The structures
of target compounds were confirmed by 1H-NMR, 13C-NMR, and TOF MS (ESI+), which were in
agreement with the structures depicted.
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Scheme 1. Synthetic routes of chalcones 3a–l. Reagents and conditions: a 10% NaOH, EtOH, r.t., 24 h.
 
Scheme 2. Synthetic routes of target compounds 9a–l, 15a–l, and 21a–h. Reagents and conditions: a 5
eq urea, 180 ◦C, 2h; b POCl3, DMF (cat.), reflux, 8 h; c 2.1 eq morpholine, MeOH, 0 ◦C, 30 min, r.t., 2h; d
80% hydrazine monohydrate, reflux, 8h; e Glacial acetic acid, H2SO4 (78%), 100 ◦C.
2.2. Biological Discussion
All target compounds were evaluated for their cytotoxic activities against A549 (human lung
cancer), PC-3 (human prostate cancer), MCF-7 (human breast cancer), HepG2 (human hepatoma) cell
lines. In addition, the activity against PI3Kα/mTOR kinase of the most promising compounds 9a and
15a was further evaluated. The results expressed as IC50 were summarized in Tables 1–3.
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ClogP b tPSA b
PC-3 A549 MCF-7 HepG2
9a 4-H 4-H 12.32 ± 0.96 11.30 ± 1.19 14.69 ± 1.32 9.80 ± 0.93 6.67 28.07
9b 4-H 4-OCH3 15.36 ± 1.26 21.22 ± 2.75 14.12 ± 2.1 13.08 ± 1.20 6.59 37.3
9c 4-F 4-F 18.21 ± 1.55 24.23 ± 0.15 22.37 ± 0.17 17.36 ± 0.98 6.95 28.07
9d 4-F 4-OCH3 22.15 ± 1.67 >50 20.62 ± 1.90 17.98 ± 2.12 6.73 37.3
9e 4-Br 4-CH3 23.16 ± 1.96 >50 30.06 ± 2.86 21.63 ± 2.35 8.03 28.07
9f 4-Br 4-F >50 15.37 ± 0.85 27.72 ± 2.71 13.49 ± 1.69 7.67 28.07
9g 4-Br 4-H 30.12 ± 3.01 22.78 ± 2.15 28.46 ± 3.9 28.85 ± 2.34 7.53 28.07
9h 3,4-di Cl 4-H 32.13 ± 2.96 38.53 ± 3.14 26.81 ± 2.13 23.70 ±2.08 7.97 28.07
9i 3,4-di Cl 4-F 27.65± 2.34 17.75 ± 1.64 29.53 ± 1.87 23.70 ± 2.11 8.12 28.07
9j 3,4-di Cl 4-Br 28.32 ± 2.16 >50 39.34 ± 2.51 >50 8.83 28.07
9k 3,4-di Cl 4-OCH3 33.54 ± 3.26 40.65 ± 3.85 25.30 ± 2.20 20.88 ± 1.98 7.89 37.3
9l 3,4-di Cl 4-CH3 28.36 ± 2.58 >50 >50 30.70 ± 0.15 8.47 28.07
15a 4-H 4-H 15.53 ± 1.21 16.90 ± 1.61 17.03 ± 1.68 13.14 ± 1.48 6.67 28.07
15b 4-H 4-OCH3 25.45 ± 2.32 >50 >50 34.62 ± 2.82 6.58 37.3
15c 4-F 4-F 25.31 ± 2.39 39.03 ± 3.32 37.12 ± 2.99 18.90 ± 1.86 6.95 28.07
15d 4-F 4-OCH3 22.13 ± 2.13 25.83 ± 1.99 35.15 ± 2.04 18.02 ± 1.30 6.73 37.3
15e 4-Br 4-CH3 37.12 ± 3.16 45.78 ± 0.81 >50 24.41 ± 1.14 8.03 28.07
15f 4-Br 4-F 26.45 ± 2.57 42.09 ± 0.08 36.17 ± 1.13 19.90 ± 1.10 7.67 28.07
15g 4-Br 4-H 24.22 ± 2.26 21.73 ± 1.47 32.14 ± 0.89 21.36 ± 1.86 7.53 28.07
15h 3,4-di Cl 4-H 27.15 ± 2.53 33.23 ± 2.14 >50 21.15 ± 1.97 7.97 28.07
15i 3,4-di Cl 4-F 18.48 ± 1.73 >50 >50 15.56 ± 1.30 8.12 28.07
15j 3,4-di Cl 4-Br 32.97 ±3.22 41.78 ± 0.81 >50 28.97 ± 2.49 8.83 28.07
15k 3,4-di Cl 4-OCH3 26.57 ± 2.38 31.05 ± 0.39 >50 19.86 ± 1.88 7.89 37.3
15l 3,4-di Cl 4-CH3 23.68 ±1.94 31.79 ± 0.52 >50 21.59 ± 1.86 8.47 28.07
GDC-0941c - - 4.35 ± 0.33 6.99 ± 0.21 0.20 ± 0.08 0.07 ± 0.03 3.20 76.85
The value “>50” indicates that no inhibitory effect at 50 μM compound concentration. a The values are an average
of two separate determinations; b Calculated by ChemBioDraw Ultra 15.0; c used as a positive control.




ClogP b tPSA b
PC-3 A549 MCF-7 HepG2
21a 3,4-di Cl 4-OCH3 31.75 ± 0.95 27.68 ± 0.10 >501 32.37 ± 1.84 8.23 28.07
21b 4-Br 4-CH3 20.64 ± 0.63 11.59 ± 0.11 15.29 ± 0.83 12.43 ± 0.96 7.44 28.07
21c 4-H 4-H >50 41.99 ± 1.49 >50 6>50 8.56 28.07
21d 4-F 4-OCH3 25.28 ± 0.75 17.75± 1.1 29.53 ± 1.87 23.70 ± 0.11 8.79 28.07
21e 4-Br 4-F >50 >50 >50 38.71 ± 1.72 7.86 28.07
21f 4-Br 4-H >50 >50 >50 >50 8.84 28.07
21g 3,4-diCl 4-Br >50 >50 >50 >50 8.63 28.07
21h 3,4-diCl 4-H >50 23.53 ± 0.82 >50 >50 7.95 28.07
GDC-0941
c - - 4.35 ± 0.33 6.99 ± 0.21 0.20 ± 0.08 0.07 ± 0.03 3.20 76.85
The value “>50” indicates that no inhibitory effect at 50 μM compound concentration. a The values are an average
of two separate determinations; b Calculated by ChemBioDraw Ultra 15.0; c used as a positive control.
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9a 4-H 4-H 9.47 ± 0.63 39.9 ± 7.6
15a 4-H 4-H 25.68 ± 2.33 >50
PI-103 b - - 0.019 ± 0.004 0.011 ± 0.002
a The values are an average of two separate determinations. b used as a positive control.
As illustrated in Tables 1 and 2, most of the target compounds exhibited moderate cytotoxic
activities. The compounds whose skeleton are thieno[2,3-d]pyrimidine (9a–1) has slightly stronger
inhibitory activity against the tested cancer cell lines than the compounds whose skeleton are
thieno[3,2-d]pyrimidine (15a–l and 21a–h). The most promising compound 9a showed moderate to
well inhibitory activity with IC50 values of 12.32 ± 0.96, 11.30 ± 1.19, 14.69 ± 1.32, and 9.80 ± 0.93
μM, respectively.
It is worth noting that when R1 of the aryl group is an electron-withdrawing group (EWG) and R2
is a H atom, the inhibitory activity of the compounds (9g–h, 15g–h, and 21a–h) against cancer cells is
decreased, especially for MCF-7 and A549 cells. The effect is greater than that of HepG2 and PC-3
cancer cell lines. Among them, the inhibitory activity of the compound 15h against MCF-7 cells was
IC50 > 50 μM, which means that the inhibitory activity was almost lost. When the C-3 and C-4 positions
of the aryl group were both replaced by chlorine, the activity of the compounds (9h–l, 15h–l) is slightly
lower than that of the compounds (9b–g, 15b–g) substituted by F or Br atoms.
When R1 of the aryl group was hydrogen atom and R2 was an electron-donating group, the
inhibitory activities of the compounds 9b and 15b against the tested cancer cells decreased. The
compound 15b which contained the core skeleton thieno[3,2-d]pyrimidine was more obvious in this
respect, and its IC 50 values for A549 and MCF-7 were both higher than 50 μM. When R 1 of the
aryl group was an electron withdrawing group, the inhibitory activity against cancer cells of the
compounds 9c–l and 15c–l tended to decrease irrespective whether the substituent of R2 was an electron
withdrawing group or an electron donating group. Comparing the difference in activity between 9e–f
and 15e–f, it is easily to find that the effect of the electron withdrawing group on the activity is slightly
less than that of the electron-donating group. As shown in Table 3, compounds 21a–h exhibited poor
cytotoxic activity against the tested cell lines. This may attributed to the introduction of the tricyclic
thieno-pyrimidine structure, resulting in an increase in steric hindrance which reduces the solubility of
the compound at physiological pH and the relative molecular mass of the compound exceeds 500.
Finally, the inhibitory activity against PI3Kα kinase and mTOR kinase of selected compounds 9a
and 15a were further examined. As shown in Table 3, enzymatic activity results of compounds 9a and
15a exhibited a moderate to excellent inhibitory activity against PI3Kα kinase. The inhibitory activity
of the compounds against PI3Kα kinase is better than that of mTOR kinase.
2.3. Molecular Docking Study of Compounds 9a and 15a.
To further explore the binding modes of target compounds (9a and 15a) with the active site of
PI3Kα, molecular docking simulation studies were carried out by the AutoDock 4.2 software. Based on
in vitro inhibition results, we selected compounds 9a and 15a as ligand examples, and the structures
of PI3Kα (PDB code: 3TL5) were selected as the docking models. The best-scoring ligand–protein
complex (Figure 3) was used for binding site analysis.
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Figure 3. Docking modes of 9a and 15a. (A) Overview of the binding site of compound 9a with PI3Kα
(3TL5) kinase. (B) Binding model of compound 9a with PI3Kα (3TL5) kinase. (C) Overview of the
binding site of compound 15a with PI3Kα (3TL5) kinase. (D) Binding model of compound 15a with
PI3Kα (3TL5) kinase.
The binding models of compounds 9a and 15a to the 3TL5 protein are approximately the same as
our previously assumed binding model (Figure 3A,C). The detailed binding models of compounds 9a
and 15a with the active site of PI3Kα kinase are shown in Figure 3. In the docking model of compound
9a with PI3Kα (Figure 3B), we can easily see that the oxygen atom on the morphine ring formed a
hydrogen bond with the hinge region residue VAL882. After careful observation of the binding model
of compound 15a with 3TL5 protein kinase (Figure 3D), it is not difficult to find that the N atom on the
pyrimidine ring of thieno[3,2-d]pyrimidine formed a hydrogen bond interaction with residue SER806.
Compared with the original ligand GDC-0980, the hydrogen bonding interaction between compounds
9a and 15a with protein is reduced, which may be one of the reasons why this series of compounds
failed to achieve excellent cytotoxic activity.
3. Experimental Section
3.1. General Information
Unless otherwise required, all reagents used in the experiment were purchased as commercial
analytical grade and used without further purification. Frequently used solvents (Ethanol, petroleum
ether, ethyl acetate, dichloromethane, etc.) were absolutely anhydrous. All actions were monitored
through GF254 thin-layer chromatography plate (Qingdao Haiyang Chemical Co., Ltd., Qingdao,
China) and spots were visualized with iodine or light (in 254 nm or 365 nm). The structure of the target
compound was confirmed by 1H-NMR and 13C-NMR spectra at room temperature on Bruker 400 MHz
spectrometer (Bruker Bioscience, Billerica, MA, USA) with tetramethylsilane (TMS) as an internal
standard. Mass spectrometry (MS) was performed on Waters High Resolution Quadrupole Time of
Flight Tandem Mass Spectrometry (QTOF) (Waters Corporation, Milford, MA, USA). The purity of the
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compound was determined by Agilent 1260 liquid chromatograph (Agilent Technologies Inc., Palo
Alto, CA, USA) fitted with an Inertex-C18 column. All target compounds had the purity of ≥95%.
3.2. Chemistry
3.2.1. General Procedure for the Preparation of Compounds 3a–l
Compounds 3a–l were synthesized according to the reported procedures by our research group [15].
3.2.2. General Procedure for the Preparation of Compounds 8, 14 and 20
Compound 5 was obtained by a cyclization reaction starting from commercially available
methyl 2-aminothiophene-3-carboxylate (4) and urea. Subsequently, compound 5 is subjected
to a chlorination reaction with POCl3 to give compound 6. Compound 6 was substituted by
morphine and hydrazine hydrate respectively to obtain key intermediate 8. Similarly, we used
commercially available methyl 2-aminothiophene-3-carboxylate (10) or commercial available methyl
2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (16) as the starting material to obtain
intermediates 14 or 20 through a similar reaction condition. Detailed synthesis of key intermediates 8,
14, and 20, and their precursors 7, 11, 12, and 13. can be found in the article reported by our research
group [13].
3.2.3. General Procedure for the Preparation of Target Compounds 9a–l, 15a–l, and 21a–h.
A mixture of different substituted chalcone 3a–l (1.5 mmol) and 4-(2-mercaptothieno[2,3-d]
pyrimidin-4-yl) morpholine (8) or 4-(2-mercaptothieno[3,2-d]pyrimidin -4-yl)morpholine (14)
or 4-(2-hydrazinyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)morpholine (20) were
dissolved (1.5 mmol, 8/14/20) in 25 mL of glacial acetic acid. Subsequently, the reaction solution was
stirred at 100–110 ◦C for 1.5 h under the action of 2–3 drops concentrated H2SO4 (78%) as a catalyst
and monitored by thin-layer chromatography (TLC). The reaction mixture was concentrated under
reduced pressure. After the completion of concentrated, the mixture was filtered and the precipitate
was washed with ethanol. If the purify of the compound is not high enough, recrystallization by 95%
EtOH or column chromatography (EtOAc:PE = 1:3) are needed. The obtained solids were then dried
to give the target compounds 9a–l, 15a–l, and 18a–h with the yield ranging from 30%–60%.
4-(2-(3-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)
morpholine (9a). Light yellow solid, mp 202–205 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.42 (d,
J = 5.3 Hz, 1H), 7.95 (d, J = 8.7 Hz, 2H), 7.73 (s, 1H), 7.62 (m, J = 16.2, 7.0 Hz, 2H), 7.33 (d, J = 8.1 Hz,
1H), 7.12 (d, J = 8.4 Hz, 2H), 5.85–5.75 (m, 1H), 4.08 (m, J = 17.7, 11.6 Hz, 1H), 3.85 (s, 3H), 3.84–3.75 (m,
3H), 3.67 (s, 3H), 3.60–3.54 (m, 1H), 3.50–3.46 (m, 2H). HRMS (ESI): m/z calcd for (C27H25N3OS + H)+:
440.1797; found: 440.1834.
4-(2-(5-(4-bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)
morpholine (9b). Light yellow solid, m.p. 280–282 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.18 (d,
J = 5.5 Hz, 1H), 7.90 (dd, J = 8.4, 5.5 Hz, 2H), 7.63 (dd, J = 8.4, 5.0 Hz, 2H), 7.37 (dd, J = 13.9, 7.0 Hz,
3H), 7.30–7.26 (m, 1H), 5.79 (dd, J = 12.1, 6.1 Hz, 1H), 3.95 (dd, J = 17.8, 12.2 Hz, 1H), 3.82–3.65 (m, 6H),
3.59 (d, J = 7.7 Hz, 3H). HRMS (ESI): m/z calcd for (C28H27N3O2S + H)+: 470.1902; found: 470.1946.
4-(2-(3,5-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)Morpholine (9c).Yellow
solid, m.p. 225–227 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.47 (d, J = 5.6 Hz, 1H), 8.13 (s, 2H),
7.63 (s, 1H), 7.50–7.42 (m, 4H), 7.25 (t, J = 8.5 Hz, 2H), 5.88 (s, 1H), 4.13 (d, J = 12.1 Hz, 1H), 3.87 (s,
4H), 3.70 (s, 3H), 3.49 (s, 1H), 3.22 (s, 1H). HRMS (ESI): m/z calcd for (C27H23F2N3OS + H)+: 476.1608;
found: 476.1598.
4-(2-(3-(3,4-dichlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)
morpholine (9d).Yellow solid, m.p. 286–289 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.73 (d,
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J = 7.5 Hz, 2H), 7.54 (d, J = 7.9 Hz, 2H), 7.31 (d, J = 6.6 Hz, 3H), 7.25 (d, J = 7.8 Hz, 2H), 5.74 (d,
J = 6.6 Hz, 1H), 3.95–3.84 (m, 1H), 3.76–3.63 (m, 6H), 3.59 (s, 2H), 3.49 (d, J = 5.9 Hz, 1H). HRMS (ESI):
m/z calcd for (C28H26FN3O2S + H)+: 488.1808; found: 488.1853.
4-(2-(3-(3,4-Dichlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidine-4-yl)morpholine
(9e). Yellow solid, m.p. 228.3~229.1 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.07 (d, J = 5.4 Hz, 1H),
7.77 (d, J = 7.1 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 7.6 Hz, 3H), 7.25 (d, J = 5.5 Hz, 2H), 5.72 (dd,
J = 12.1, 5.7 Hz, 1H), 3.87 (dd, J = 18.0, 12.3 Hz, 1H), 3.71 (s, 2H), 3.66–3.58 (m, 4H), 3.54 (s, 2H), 3.18
(dd, J = 18.1, 5.8 Hz, 1H). HRMS (ESI): m/z calcd for (C28H26BrN3OS + H)+: 534.1041; found: 534.0991.
4-(2-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidine-4-yl)morpholine (9f).
Orange solid, m.p. 237.6~239.1 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.17 (d, J = 4.9 Hz, 1H),
7.79 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 4.7 Hz, 1H), 7.29 (d, J = 7.3 Hz, 2H), 7.24 (d, J = 7.7 Hz, 3H), 7.03 (d,
J = 8.3 Hz, 2H), 5.69 (d, J = 6.4 Hz, 1H), 3.98–3.87 (m, 2H), 3.80 (s, 3H), 3.68 (s, 4H), 3.57 (s, 4H). HRMS
(ESI): m/z calcd for (C27H23BrFN3OS + H)+: 538.0790; found: 538.0882.
4-(2-(3-(3,4-dichlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine
(9g). Yellow solid, m.p. 207.4~208.2 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.43 (d, J = 5.4 Hz,
1H), 7.90 (d, J = 7.6 Hz, 2H), 7.74 (s, 1H), 7.62 (dd, J = 15.4, 6.7 Hz, 2H), 7.41–7.29 (m, 3H), 5.80 (dd,
J = 11.6, 6.2 Hz, 1H), 4.09 (dd, J = 18.2, 11.5 Hz, 1H), 3.82 (s, 4H), 3.67 (s, 3H), 3.48 (s, 2H), 2.40 (s, 3H).
HRMS (ESI): m/z calcd for (C27H24BrN3OS + H)+: 520.0884; found: 520.0865.
4-(2-(3-(4-bromophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidine-4-yl)morpholine (9h).
Light yellow solid, m.p. 222.8~223.9 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.11 (d, J = 5.0 Hz,
1H), 7.73 (d, J = 7.5 Hz, 2H), 7.54 (d, J = 7.9 Hz, 2H), 7.31 (d, J = 6.6 Hz, 3H), 7.25 (d, J = 7.8 Hz, 2H),
5.74 (d, J = 6.6 Hz, 1H), 3.95–3.84 (m, 1H), 3.76–3.63 (m, 6H), 3.59 (s, 2H), 3.13 (d, J = 13.7 Hz, 1H),
2.40 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.89, 157.95, 156.29, 150.82, 145.81, 134.03, 132.46,
131.45, 131.41, 129.81, 129.71(2,C), 129.17, 128.43, 126.68(2,C), 126.29, 124.43, 106.60, 66.29(2,C), 61.90,
46.26(2,C).HRMS (ESI): m/z calcd for (C27H23Cl2N3OS + H)+: 508.1017; found: 508.1059.
4-(2-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine (9i). Light
yellow solid, m.p. 231.7~233.2 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.04 (d, J = 5.5 Hz, 1H),
7.77 (d, J = 7.6 Hz, 2H), 7.48–7.37 (m, 3H), 7.30–7.17 (m, 6H), 5.71 (dd, J = 12.0, 5.3 Hz, 1H), 3.87 (dd,
J = 17.4, 12.2 Hz, 1H), 3.63 (dt, J = 19.1, 10.7 Hz, 6H), 3.49 (d, J = 13.7 Hz, 2H), 3.45–3.40 (m, 1H). HRMS
(ESI): m/z calcd for (C27H22Cl2FN3OS + H)+: 528.0898; found: 528.0891.
4-(2-(3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidin-4-yl)
morpholine (9j). Light yellow solid, m.p. 215.8~216.8 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm):
7.91–7.86 (m, 2H), 7.50 (t, J = 5.0 Hz, 1H), 7.39–7.24 (m, 4H), 7.16 (t, J = 8.8 Hz, 1H), 7.06 (d, J = 8.6 Hz,
2H), 5.72 (dd, J = 11.0, 5.3 Hz, 1H), 4.07–3.96 (m, 1H), 3.82 (s, 3H), 3.74 (s, 4H), 3.65–3.56 (m, 3H), 3.48 (s,
2H). HRMS (ESI): m/z calcd for (C27H22BrCl2N3OS + H)+: 588.0100; found: 588.0110.
4-(2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]Pyrimidin-4-yl)
morpholine (9k). Yellow solid, m.p. 221.2~222.0 ◦C; 1H -NMR (400 MHz, DMSO-d6) δ (ppm): 8.14 (d,
J = 5.6 Hz, 1H), 7.93–7.85 (m, 2H), 7.55 (d, J = 8.2 Hz, 2H), 7.39–7.30 (m, 3H), 7.27 (d, J = 8.3 Hz, 2H),
5.77 (dd, J = 11.9, 5.4 Hz, 1H), 3.93 (dd, J = 17.7, 12.3 Hz, 1H), 3.80–3.65 (m, 6H), 3.59 (d, J = 10.2 Hz,
2H), 3.19 (dd, J = 17.9, 5.8 Hz, 1H). HRMS (ESI): m/z calcd for (C28H25Cl2N3O2S + H)+: 538.1123;
found: 538.1199.
4-(2-(3-(4-bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[2,3-d]pyrimidine-4-Morpholine (9l).
Light yellow solid, m.p. 221.2~222.0 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.05 (d, J = 5.5 Hz,
1H), 7.76 (d, J = 7.3 Hz, 2H), 7.50 7.39 (m, 5H), 7.21 (dd, J = 17.0, 6.8 Hz, 3H), 5.70 (d, J = 6.7 Hz, 1H),
3.86 (d, J = 5.2 Hz, 1H), 3.69 (t, J = 10.6 Hz, 2H), 3.64–3.57 (m, 4H), 3.53 (t, J = 9.8 Hz, 2H), 3.12 (d,
J = 5.5 Hz, 1H). HRMS (ESI): m/z calcd for (C28H25Cl2N3OS + H)+: 522.1174; found: 522.1203.
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4-(2-(3-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)
morpholine (15a). Light yellow solid, m.p. 131.2~132.5 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.73
(d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 6.2 Hz, 1H), 7.19 (d, J = 6.0 Hz, 2H), 7.02 (d,
J = 8.5 Hz, 2H), 5.69 (dd, J = 12.0, 5.5 Hz, 1H), 3.92–3.84 (m, 1H), 3.81 (s, 3H), 3.62 (dd, J = 22.9, 8.6 Hz,
6H), 3.51 (d, J = 8.6 Hz, 2H), 3.17 (dd, J = 17.7, 5.6 Hz, 1H). HRMS (ESI): m/z calcd for(C27H25N3OS +
H)+: 440.1797; found: 440.1808.
4-(2-(5-(4-bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)
morpholine (15b). Light yellow solid, m.p. 265.3~266.3 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.69
(d, J = 7.8 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 6.2 Hz, 1H), 7.27 (d, J = 7.8 Hz, 2H), 7.20 (d,
J = 7.8 Hz, 2H), 5.69 (dd, J = 12.2, 5.1 Hz, 1H), 3.93–3.82 (m, 1H), 3.62 (dd, J = 23.2, 8.0 Hz, 6H), 3.51 (d,
J = 7.4 Hz, 2H), 3.12 (d, J = 18.1 Hz, 1H). HRMS (ESI): m/z calcd for (C28H27N3O2S + H)+: 470.1902;
found: 470.1939.
4-(2-(3,5-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)Morpholine (15c).
Yellow solid, m.p. 254.7~255.4 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.88–7.82 (m, 2H), 7.39 (d,
J = 6.1 Hz, 1H), 7.29 (dd, J = 16.3, 8.0 Hz, 4H), 7.19 (d, J = 6.1 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 5.73 (dd,
J = 12.2, 5.2 Hz, 1H), 3.92–3.83 (m, 1H), 3.62 (dd, J = 20.8, 8.0 Hz, 6H), 3.51 (d, J = 8.0 Hz, 2H), 3.13 (dd,
J = 18.0, 5.0 Hz, 1H). HRMS (ESI): m/z calcd for (C27H23F2N3OS + H)+: 476.1608; found: 476.1640.
4-(2-(3-(3,4-dichlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrmidin-4-yl)
morpholine (15d). Yellow solid, m.p. 237.7~238.8 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.60
(d, J = 7.9 Hz, 2H), 7.48 (d, J = 6.8 Hz, 2H), 7.31 (d, J = 5.8 Hz, 1H), 7.19 (d, J = 7.8 Hz, 2H), 7.11 (d,
J = 6.4 Hz, 2H), 5.62 (d, J = 6.1 Hz, 1H), 3.82–3.73 (m, 1H), 3.55 (s, 2H), 3.51 (d, J = 7.4 Hz, 4H), 3.43
(d, J = 8.8 Hz, 2H), 3.08 (d, J = 12.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 162.70, 162.39, 161.13,
160.78, 157.90, 156.38, 140.04, 128.77, 128.03, 121.75, 115.91(2,C), 115.77(2,C), 114.63(3,C), 110.46, 66.28,
62.03, 55.83, 47.11, 42.77. HRMS (ESI): m/z calcd for (C28H26FN3O2S + H)+: 488.1808; found: 488.1842.
4-(2-(3-(3,4-Dichlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidine-4-yl)morpholine
(15e). Yellow solid, m.p. 263–265 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.80 (d, J = 6.9 Hz,
2H), 7.61–7.55 (m, 2H), 7.49–7.44 (m, 3H), 7.43–7.39 (m, 1H), 7.21 (d, J = 6.2 Hz, 2H), 5.73 (dd, J = 12.2,
5.8 Hz, 1H), 3.89 (dd, J = 17.7, 12.2 Hz, 1H), 3.69–3.56 (m, 6H), 3.53–3.48 (m, 2H), 3.20 (dd, J = 17.8,
5.8 Hz, 1H). HRMS (ESI): m/z calcd for (C28H26BrN3OS + H)+: 534.1041; found: 534.1008.
4-(2-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidine-4-y)morpholine
(15f). Yellow solid, m.p. 235–237 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.78 (d, J = 8.5 Hz,
2H), 7.42 (d, J = 6.1 Hz, 1H), 7.30 (d, J = 7.2 Hz, 2H), 7.25 (d, J = 6.2 Hz, 4H), 7.04 (d, J = 8.6 Hz, 2H),
5.73–5.65 (m, 1H), 3.91 (dd, J = 18.0, 12.1 Hz, 1H), 3.82 (s, 3H), 3.66–3.53 (m, 6H), 3.46 (s, 2H), 3.16 (d,
J = 17.8 Hz, 1H). HRMS (ESI): m/z calcd for (C27H23BrFN3OS + H)+: 538.0790; found: 538.0832.
4-(2-(3-(3,4-dichlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine
(15g). Yellow solid, m.p. 267–268 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.69 (d, J = 7.7 Hz, 2H),
7.57 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 6.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 6.3 Hz, 2H), 5.70 (dd,
J = 11.9, 5.6 Hz, 1H), 3.91–3.82 (m, 1H), 3.65–3.56 (m, 6H), 3.51 (d, J = 8.4 Hz, 2H), 3.21–3.13 (m, 1H),
2.35 (s, 3H). HRMS (ESI): m/z calcd for (C27H24BrN3OS + H)+: 517.0823; found: 517.0798.
4-(2-(3-(4-bromophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidine-4-yl)morpholine
(15h). Yellow solid, m.p. 255–257 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.68 (d, J = 8.1 Hz, 2H),
7.50 (d, J = 8.3 Hz, 2H), 7.40 (t, J = 6.6 Hz, 1H), 7.29 (d, J = 10.6 Hz, 2H), 7.22 – 7.17 (m, 3H), 5.69 (dd,
J = 11.7, 4.7 Hz, 1H), 3.92–3.83 (m, 1H), 3.63–3.55 (m, 6H), 3.50 (d, J = 11.1 Hz, 2H), 3.09 (dd, J = 17.6,
5.7 Hz, 1H), 2.35 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.77, 158.31, 154.66, 151.51, 145.64, 132.28,
131.46, 131.41, 129.95, 129.76, 129.17(2,C), 128.46, 126.76(2,C), 126.26, 121.64, 117.97, 110.41, 66.32(2,C),
61.88, 46.96(2,C), 42.01.HRMS (ESI): m/z calcd for (C27H23Cl2N3OS + H)+: 508.1017; found: 508.1044.
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4-(2-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine (15i). Yellow solid,
m.p. 266–267 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.04 (d, J = 5.5 Hz, 1H), 7.77 (d, J = 7.6 Hz,
2H), 7.56–7.35 (m, 3H), 7.32–7.15 (m, 6H), 5.71 (dd, J = 12.0, 5.3 Hz, 1H), 3.87 (dd, J = 17.4, 12.2 Hz, 1H),
3.70–3.54 (m, 6H), 3.50 (s, 2H), 3.09 (dd, J= 17.6, 5.3 Hz, 1H). HRMS (ESI): m/z calcd for (C27H22Cl2FN3OS
+ H)+: 526.0923; found: 526.0889.
4-(2-(3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidin-4-yl)
morpholine (15j). Yellow solid, m.p. 271–272 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.74 (d,
J = 7.9 Hz, 2H), 7.35 (d, J = 6.0 Hz, 1H), 7.26–7.17 (m, 3H), 7.07 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.6 Hz,
2H), 5.63 (dd, J = 11.8, 5.6 Hz, 1H), 3.85 (d, J = 17.8 Hz, 1H), 3.73 (s, 3H), 3.55 (dd, J = 25.4, 8.6 Hz,
7H), 3.09 (d, J = 16.8 Hz, 2H). HRMS (ESI): m/z calcd for (C27H22BrCl2N3OS +H)+: 588.0100; found:
588.0132.
4-(2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]Pyrimidin-4-yl)morpholine
(15k). Yellow solid, m.p. 251–252 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.75 (s, 2H), 7.41 (d,
J = 7.6 Hz, 2H), 7.31 (d, J = 5.5 Hz, 1H), 7.21 (t, J = 8.0 Hz, 2H), 7.12 (d, J = 7.9 Hz, 3H), 5.62 (d,
J = 6.8 Hz, 1H), 3.85–3.74 (m, 1H), 3.53 (d, J = 13.2 Hz, 6H), 3.44 (d, J = 8.9 Hz, 2H), 3.05 (d, J = 17.7 Hz,
1H). HRMS (ESI): m/z calcd for (C28H25Cl2N3O2S + H)+: 538.1123; found: 538.1161.
4-(2-(3-(4-bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thieno[3,2-d]pyrimidine-4-Morpholine (15l).
Yellow solid, m.p. 244–245 ◦C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.79 (d, J = 7.3 Hz, 2H), 7.50 (d,
J = 8.3 Hz, 2H), 7.44 (t, J = 8.0 Hz, 3H), 7.40 (d, J = 6.2 Hz, 1H), 7.24–7.18 (m, 3H), 5.71 (dd, J = 12.1,
5.7 Hz, 1H), 3.89 (dd, J = 17.5, 12.6 Hz, 1H), 3.62 (dd, J = 23.5, 8.5 Hz, 6H), 3.51 (d, J = 8.0 Hz, 2H), 3.13
(dd, J = 17.7, 5.6 Hz, 1H). HRMS (ESI): m/z calcd for (C28H25Cl2N3OS +H)+: 522.1174; found: 522.1201.
4-(2-(3-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo
[4,5]thieno[2,3-d]pyrimidin-4-yl)morpholine (21a). Dark blue solid, m.p. 252–253 ◦C; ESI-MS [M +H]+
m/z: 594.5; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.73 (d, J = 8.7 Hz, 2H), 7.56 (d, J = 7.0 Hz, 2H),
7.20 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 7.0 Hz, 2H), 5.67 (d, J = 5.7 Hz, 1H), 3.88 (d, J = 17.1 Hz, 1H), 3.81 (s,
3H), 3.62 (d, J = 5.4 Hz, 2H), 3.58 (s, 2H), 3.18 (d, J = 12.1 Hz, 3H), 2.99 (s, 2H), 2.73 (s, 4H), 1.81 (s, 4H).
4-(2-(3-(4-bromophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahdrobenzo[4,5]thieno
[2,3-d]pyrimidin-4-yl)morpholine (21b). Dark blue solid, m.p. 243–244 ◦C; ESI-MS [M + H]+ m/z:
588.5; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.69 (d, J = 7.9 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.27
(d, J = 7.7 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 5.70 (dd, J = 12.3, 5.4 Hz, 1H), 3.88 (dd, J = 17.7, 12.3 Hz,
1H), 3.64 (s, 2H), 3.57 (s, 2H), 3.15 (d, J = 16.2 Hz, 3H), 2.99 (s, 2H), 2.74 (s, 4H), 2.35 (s, 3H), 1.78 (d,
J = 13.4 Hz, 4H).
4-(2-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thiophene[2,3-d]pyramidin
-4-yl)morpholine (21c). Dark blue solid, m.p. 212–213 ◦C; ESI-MS [M + H]+ m/z: 495.6; 1H NMR
(400 MHz, DMSO-d6) δ (ppm): 7.82–7.79 (m, 2H), 7.46 (d, J = 7.6 Hz, 3H), 7.29 (d, J = 7.3 Hz, 2H), 7.23
(dd, J = 9.2, 1.9 Hz, 3H), 5.73 (dd, J = 12.1, 5.5 Hz, 1H), 3.92 (dd, J = 17.7, 12.1 Hz, 1H), 3.65–3.60 (m,
2H), 3.55 (d, J = 6.5 Hz, 2H), 3.14 (dd, J = 17.7, 5.7 Hz, 3H), 3.02–2.94 (m, 2H), 2.74 (s, 4H), 1.80 (d,
J = 28.8 Hz, 4H).
4-(2-(3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo
[4,5]thieno[2,3-d]pyrimidin-4-yl)morpholine (21d). Dark blue solid, m.p. 189-193 ◦C; ESI-MS [M + H]+
m/z: 543.6; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.74 (d, J = 8.7 Hz, 2H), 7.28–7.23 (m, 2H), 7.12 (t,
J = 8.8 Hz, 2H), 7.02 (d, J = 8.8 Hz, 2H), 5.71 (dd, J = 12.0, 5.4 Hz, 1H), 3.87 (d, J = 5.0 Hz, 1H), 3.81 (s,
3H), 3.68–3.61 (m, 2H), 3.57 (d, J = 6.4 Hz, 2H), 3.20–3.12 (m, 3H), 3.00 (s, 2H), 2.73 (s, 4H), 1.79 (d,
J = 29.8 Hz, 4H).
4-(2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]
thieno[2,3-d]pyrimidin-4-yl)morpholine (21e). Dark blue solid, m.p. 272–273 ◦C; ESI-MS [M +H]+ m/z:
592.5; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.85 (d, J = 6.4 Hz, 2H), 7.50 (d, J = 7.3 Hz, 2H), 7.30 (s,
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2H), 7.20 (d, J = 8.0 Hz, 2H), 5.77–5.66 (m, 1H), 3.91 (t, J = 16.3 Hz, 1H), 3.63 (s, 2H), 3.58 (s, 2H), 3.18 (s,
3H), 3.01 (s, 2H), 2.74 (s, 4H), 1.79 (d, J = 18.0 Hz, 4H).
4-(2-(3-(4-bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno
[2,3-d]pyrimidin-4-yl)morpholine (21f). Dark blue solid, m.p. 257–259 ◦C; ESI-MS [M +H]+ m/z: 574.5;
1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.80 (d, J = 7.8 Hz, 2H), 7.48 (dd, J = 17.6, 7.9 Hz, 5H), 7.20 (d,
J = 8.4 Hz, 2H), 5.73 (dd, J = 11.9, 5.5 Hz, 1H), 3.91 (dd, J = 17.9, 12.1 Hz, 1H), 3.64 (d, J = 6.0 Hz, 2H),
3.57 (s, 2H), 3.15 (dd, J = 17.8, 5.5 Hz, 3H), 3.02 (s, 2H), 2.74 (s, 4H), 1.78 (d, J = 18.3 Hz, 4H).
4-(2-(5-(4-bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo
[4,5]thieno[2,3-d]pyrimidin-4-yl)morpholine (21g). Dark blue solid, m.p. 231–234 ◦C; ESI-MS [M +H]+
m/z: 643.4; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.71 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.3 Hz, 2H),
7.57 (d, J = 11.3 Hz, 2H), 7.22 (d, J = 8.8 Hz, 1H), 5.71 (dd, J = 11.9, 5.9 Hz, 1H), 3.89 (dd, J = 18.0,
12.5 Hz, 1H), 3.62 (s, 2H), 3.57 (s, 2H), 3.21 (dd, J = 17.9, 6.2 Hz, 3H), 2.99 (s, 2H), 2.73 (s, 4H), 1.78 (d,
J = 37.6 Hz, 4H).
4-(2-(3-(3,4-dichlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno
[2,3-d]pyrimidin-4-yl)morpholine (21h). Dark blue solid, m.p. 293–294 ◦C; ESI-MS [M + H]+ m/z:
563.1; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.80 (d, J = 6.5 Hz, 2H), 7.58 –7.55 (m, 2H), 7.46 (d,
J = 7.6 Hz, 3H), 7.23–7.19(m, 1H), 5.73 (dd, J = 12.1, 5.9 Hz, 1H), 3.92 (dd, J = 17.8, 12.2 Hz, 1H), 3.63 (d,
J = 6.2Hz, 2H), 3.58 (d, J = 6.4Hz, 2H), 3.21 (dd, J = 18.1, 6.3 Hz, 3H), 3.01 (s, 2H), 2.74 (s, 4H), 1.79 (d,
J = 23.9 Hz, 4H).
3.3. Cytotoxicity Assay In Vitro
The in vitro cytotoxic activities of Compounds 9a–l, 15a–l, and 21a–h were evaluated with A549,
PC-3, HepG2, and MCF-7 cell lines by the standard MTT assay, with GDC-0941 as a positive control.
The cancer cell lines were cultured in minimum essential medium (MEM) supplement with 10% fetal
bovine serum (FBS). Approximately, 4 × 10 3 cells, suspended in MEM medium, were plated onto
each well of a 96-well plate and incubated in 5% CO2 at 37 ◦C for 24 h. The test compounds at the
indicated final concentrations were added to the culture medium, and cell cultures continued for 72
h. Fresh MTT was added to each well at a terminal concentration of 5 μg/mL and incubated with
cells at 37 ◦C for 4 h. The formazan crystals were dissolved in 100 μL of DMSO in each well, and the
absorbency at 492 nm (for absorbance of MTT formazan) and 630 nm (for the reference wavelength)
was measured with an enzyme linked immunosorbent assay (ELISA) reader (MR-96A Mindray Elisa
Microplate Reader, Guangzhou, China). All compounds were tested three times in each of the cell
lines. The results expressed as inhibition rates or IC50 was the averages of two determinations and
calculated using the Bacus Laboratories Inc. Slide Scanner (Bliss) software (the Bacus Laboratories Inc.
Slide Scanner (BLISS) system, Lombard, IL, USA).
3.4. mTOR Kinase Assay
The potent compounds 9a and 15a were tested for their activities against mTOR enzyme using
Kinase-Glo® Luminescent Kinase Assay (Promega, Madison, WI, USA), with NVPBEZ-235 and
PI103 as positive controls. The kinase reaction was done in a 384-well black plate. Each well was
loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI
substrate (l-α-phosphatidylinositol); Avanti Polar Lipids (Avanti Polar Lipids, Inc., Alabaster, AL,
USA); prepared in 3% octyl-glucoside) and the mTOR protein 2.5 nM was then added to it. The
reaction was started by the addition of 5 μL of 10 μM ATP prepared in the reaction buffer (50 mM
HEPES pH 7.5, 1 mM EGTA, 3 mM MnCl2, 10 mM MgCl2, 2 mM DTT and 0.01% Tween-20) and was
incubated for 60 min. It was terminated by the addition of 10 μL Kinase-Glo buffer. The plates were
then read in Synergy 2 readers (BioTek, Winooski, VT, USA) for luminescence detection. The assay was
repeated two times and the results expressed as IC50 (inhibitory concentration 50%) were the averages
of two determinations.
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3.5. PI3Kα Kinase Assay
The potent compounds 9a and 15a were tested for their activity against PI3Kα using a Kinase-Glo®
Luminescent Kinase Assay (Promega, Madison, WI, USA), with GDC-0941 and PI103 as positive controls.
The kinase reaction occurred in a 384-well black plate. Each well was loaded with 50 μL of test items
(in 90% DMSO) and 5 μL of reaction buffer containing 10μg/mL PI substrate (l-α-phosphatidylinositol;
Avanti Polar Lipids (Avanti Polar Lipids, Inc.); prepared in 3% octyl-glucoside), and the PI3Kα protein
(10 nM) was then added to it. The reaction was started by the addition of 5 μL of 1 μM Adenosine
triphosphate (ATP) prepared in the reaction buffer and incubated for 60 min for p110α. It was
terminated by the addition of 10 μL of Kinase-Glo buffer. The plates were then read in a Synergy 2
reader (BioTek, Winooski, VT, USA) for luminescence detection. The assay was repeated two times and
the results expressed as IC50 (inhibitory concentration 50%) were the averages of two determinations.
3.6. Docking Studies
Molecular docking simulation studies were carried out by the AutoDock 4.2 software (The Scripps
Research Institute, San Diego, CA, USA). The docking tutorial we used and the detailed AutoDock
basic operational methods can be found at: http://autodock.scripps.edu/faqs-help/tutorial. The protein
preparation process of flexible docking mainly includes fixing the exact residues, adding hydrogen
atoms, removing irrelevant water molecules, adding charges, etc. The potent compounds were selected
as ligand examples, and the structures of PI3Kα (PDB code: 3TL5, http://www.pdb.org/) were selected
as the docking models. Only the best-scoring ligand–protein complexes were used for the binding site
analyses. All the docking results were processed and modified in Open-Source PyMOL 1.8.x software
(https://pymol.org).
4. Conclusions
Three series of thienopyrimidine derivatives containing pyrazole structure were designed and
synthesized. In addition, we evaluated their cytotoxic activities against four cancer cell lines in vitro.
The pharmacological indicated that most of the compounds showed moderate cytotoxic activity against
the tested cancer cell lines. What is more, the inhibitory activities of the compounds 9a and 15a
against PI3Kα and mTOR kinase were further investigated. Compound 9a exhibited moderate levels
of inhibition activity against four cancer cell lines and PI3Kα kinase. Although compound 9a did
not reach the same level of inhibition as the positive control drug, it also gave us new direction for
developing novel thienopyrimidines containing the pyrazole linker group as PI3Kα inhibitor.
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Abstract: A series of 16-(α-alkoxyalkane)-17-hydrazino-estra-1(10),2,4-trien[17,16-c]-3-ol (3a–l) and
estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol derivatives (4a–d) were synthesized from corresponding
arylidines 2a,b which was prepared from estrone 1 as starting material. Condensation of 1 with
aldehydes gave the corresponding arylidine derivatives 2a,b which were treated with hydrazine
derivatives in alcohols to give the corresponding derivatives 3a–l, respectively. Additionally,
treatment of 2a,b with methyl- or phenylhydrazine in ethanolic potassium hydroxide afforded the
corresponding N-substituted pyrazoline derivatives 4a–d, respectively. All these derivatives showed
potent anti-ovarian cancer both in vitro and in vivo. The mechanism of anti-ovarian cancer was
suggested to process via topoisomerase II and V600EBRAF inhibition.
Keywords: estrone derivatives; hydrazine; N-substituted pyrazoline; anti-ovarian cancer;
topoisomerase II inhibitor; kinase inhibitor
1. Introduction
Synthetic alterations of estrone lead to discovering of compounds with diverse biological activities,
for example with antitumor effect [1], as anti-breast cancer agent [2] and with antioxidant activity [3].
Estrone derivatives with antitumor activities must be devoid completely of the estrogenic activities [4–6].
The inversion of the configuration at C-13 lead to estrone derivatives with antitumor activities devoid
from hormonal actions due to conformational change for the overall molecule resulting from the cis
junction of rings C and D [4,7]. Some recent publications report on the syntheses and in vitro biological
evaluation of several 13α-estrone derivatives [8–11]. These derivatives exhibited biological activities
with substantial anti-proliferative or enzyme inhibitory potentials. Most literature data are mainly
focusing on 13α-estrone substitution in ring D, while modified derivatives with ring A substitutions
are rarely reported [12].
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Cancer is considered one of the most significant causes of death worldwide. Ovarian cancer is
one of the major causes for death among adult females [13]. Cancer is characterized by abnormal cell
proliferation bypassing normal cell growth and death mechanisms. Recently, DNA topoisomerase
II inhibitors have been researched as a potential target, which interferes with cancer growth and
development [14]. Topoisomerase II inhibition leads finally to cell cycle inhibition and apoptosis in
abnormal cancer cells [15]. BRAF kinase inhibition is another possible control mechanism, which was
also developed to interfere with cancer cell growth [16]. BRAF kinase constitutes a major signaling
process integrated in the RAS-MEK proliferation process. The activation of MEK by BRAF signals
finally induces cell proliferation and survival [17]. Inhibiting BRAF activity results in inhibition of the
proliferation signals, and thus inhibiting cancer cell development and growth [18].
In view of these observations and in continuation of our previous work in heterocyclic chemistry [19–22],
the current work aimed at evaluating the effect or remote long cage distortion caused by introducing some
moieties in both 16 and 17 locations of ring D. We screened some of synthesized estrone candidates for
their anti-ovarian cancer potential both in vitro and in vivo. Furthermore, the inhibitory effects of the
synthesized compounds were investigated against topoisomerase II and V600EBRAF kinase inhibitors.
2. Results and Discussion
2.1. Results
2.1.1. Chenical Synthesis
A series of 17-hydrazino-estratrienol (3a–l) and pyrazolinestratrienol (4a–d) were synthesized
from corresponding arylidines 2a,b which was prepared from estrone 1 as starting material.
Treatment of aryledine derivatives 2a,b with hydrazine hydrate, in refluxing methanol or
ethanol afforded the corresponding 17-hydrazino-16-α-methoxymethane estrone derivatives 3a,b
and 17-hydrazino-16-α-ethoxyethane estrone derivatives 3c,d, respectively.
Also, reaction of compounds 2a,b with N-methyl hydrazine, in refluxing methanol or ethanol
afford 17-N-methyl hydrazino-16-α-methoxymethane estrone derivatives 3e,f and 17-N-methyl
hydrazino-16-α-ethoxyethane estrone derivatives 3g,h respectively.
Additionally, when compounds 2a,b reacted with N-phenyl hydrazine, under the same conditions
afford the corresponding 17-N-phenylhydrazino- 16-α-methoxymethane estrone derivatives 3i,j and
17-N-phenylhydrazino- 16-α-ethoxyethane estrone derivatives 3k,l, respectively. Finally, condensation
of 2a,b with CH3NHNH2 or PhNHNH2 in refluxing dioxane afforded the corresponding N-substituted
pyrazoline derivatives 4a–d, respectively (Scheme 1).
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Scheme 1. Synthetic route for compounds 2–4.
2.1.2. Biological Screening
In Vitro Cytotoxic Activities
The cytotoxicity of some synthesized derivatives against SKOV-3 cancer cell line in vitro was
performed with the MTT assay. The obtained results showed that all synthesized compounds showed
potent in vitro cytotoxic activities against SKOV-3 cells at the nanomolar level. Moreover, the effect of
the synthesized compounds was dose-dependent. From the obtained IC50 values (Figure 1), prepared
compounds can be arranged discerningly in the following order: 3a, 3b, 3c, 3d, 3e, 3f, 3g, 3h, 3i, 3j, 3k,
3l, 4a, 4b, 4c, 4d (Figure 1). Compounds 3a–l are characterized with the presence of hydrazine group
rather than the pyrazoline group present in compounds 4a–d. Furthermore, the alkyl group is found
to be more active than the aromatic group. Generally Cpd. 3a showed highest cytotoxic activity with
IC50 value of 4.23 ± 0.12 nM, while Cpd. 4d was the least active, where its IC50 value was about 9.5%
of that obtained for Cpd. 3a.
The effect of resveratrol (RES) and doxorubicin (DOX) on SKOV-3 showed IC50 of 55 and
250 nM, respectively.
The cytotoxicity of the newly synthesized compounds against fibroblast were as follow IC50
3a (1.2 μM), 3b (2.45 μM), 3c (5.67 μM), 3d (7.44 μM), 3e (8.11 μM), 3f (9.20 μM), 3g (11.18 μM),
3h(16.22 μM), 3i (15.13 μM), 3j (16.20 μM), 3k (17.78 μM), 3l (20.21 μM), 4a (23.34 μM), 4b (24.55 μM),
4c (25.55 μM), 4d (30.34 μM).
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Figure 1. In vitro Cytotoxicity activities of the tested compounds against SKOV-3 cells.
In Vivo Anti-Ovarian Cancer
The in vivo anti-ovarian cancer activities of the tested compounds were evaluated using mouse
xenograft model. Figure 2 represents the percentages of decrease in tumor growth upon treatment
with different synthesized compounds. The obtained results showed that all compounds potentially
reduced tumor growth over a period of 40 days of treatment, in comparison to control treatments,
which showed normal tumor growth development. Moreover, it can be seen that the reduction in
tumor size started directly from the 5th day of treatment, where the reduction percentage ranged
from 45.7 ± 0.05% to 54.71 ± 0.01%. The reduction in tumor growth increased significantly reaching
its maximal by the end of treatment period (40 days). The highest reduction in tumor growth was
recorded for occurred Cpd. 3a, which significantly decreased tumor growth by about 93.61 ± 0.7%.
It can also be seen that Cpd. 3a, was the most potent for in vivo treatment, where its effect was more
obvious starting from day15 of treatment, where the reduction percentage in tumor size due to other
compounds was more or less within the same range. We also can see that the in vivo results are
coincided with those obtained for in vitro results, where the reduction in tumor size followed the same
descending order: 3a, 3b, 3c, 3d, 3e, 3f, 3g, 3h, 3i, 3j, 3k, 3l, 4a, 4b, 4c, and 4d.
Figure 2. Percentages of decrease in tumor volume in nude mice in response to different
synthesized derivatives.
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2.1.3. Inhibition of Topoisomerase II Activities
In order to further investigate the possible mechanism of action of the newly synthesized derivatives,
we investigated their inhibitory effects on topoisomerase II. Results obtained (Figure 3) showed that
all synthesized compounds showed potential inhibitory effects against topoisomerase II. Furthermore,
the inhibitory effect was also found to follow the same descending order obtained before during in vitro
and in vivo investigation: 3a, 3b, 3c, 3d, 3e, 3f, 3g, 3h, 3i, 3j, 3k, 3l, 4a, 4b, 4c, and 4d. Cpd. 3a showed
the most inhibitory action for topoisomerase II with IC50 value of 3.45 ± 0.13 nM, which was about 7,9%
of that obtained for the lest potent compound (IC50 for Cpd. 4d: 43.56 ± 0.98 nM).
Figure 3. IC50 of Topoisomerase II Inhibitor activities of the tested compounds.
2.1.4. In Vitro Kinase Assay
The in vitro kinase assay of synthesized derivatives was investigated against both WTBRAF
(BRAF kinase wild type) and V600EBRAF (mutant BRAF kinase). Results obtained in Figure 4 showed
that all synthesized compounds were highly active inhibitors for V600EBRAF compared with moderate
activities against WTBRAF. Again, the descending order of activities was as follow 3a, 3b, 3c, 3d,
3e, 3f, 3g, 3h, 3i, 3j, 3k, 3l, 4a, 4b, 4c, and 4d. Compound 3a recorded the most active inhibition
(IC50: 0.041 ± 0.0016 and 4.23 ± 0.12 μM for mutant and wild type BRAF kinase, respectively.
Furthermore, it can be seen that the inhibitory effect of Cpd. 3a was much more superior to that
obtained for different positive control drugs (0.48, 3.87 and 0.97 μM for Sorafenib, Dabrafenib and
Vemurafenib, respectively.
Figure 4. IC50 values of synthesized for both WTBRAF and V600EBRAF.
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2.2. Discussion
Within the framework of the current work we synthesized new estrone derivatives from their
corresponding arylidines. The newly synthesized derivatives showed potential cytotoxic activities
against SKOV-3 cells. Moreover, in vivo investigations revealed that the synthesized compounds were
able to potentially reduce tumor volume growth over a treatment period of 45 days.
The newly introduced 1-alkoxy benzyl moiety alone or combined with the 17- hydrazino- moities
make remote destortion of the structure cage that completely elminate any hormonal activities
of te estrone molceules and deviate the biological activities towards the aniticancer ones, so we
investigated this property and tried to find the mechnisms of anticancer actions of these newly
synthesized compounds.
In search for the possible mechanism of action of the anticancer activities of the tested compounds,
we investigated the possibility of the compounds to inhibit both topoisomerase II and kinase
enzymes. Results showed that the prepared compounds can potentially serve as inhibitors for
these enzymes. The cytotoxic activities of the prepared estrone derivatives can be due to the inhibition
of 17-hydroxysteroid dehydrogenases. We have previously reported on the anti-breast cancer activities
of different estrone derivatives [23], and explained that their anticancer activities can be attributed to
the inhibition of 17-hydroxysteroid dehydrogenase [24].
Concerning topoisomerase II and V600EBRAF kinase inhibition, our results suggest that the newly
synthesized compounds exert their cytotoxic action against SKOV-3 cancer cells by interfering with
the metabolic activity of these enzymes, thus preventing cancer cells from obtaining proliferation
signaling molecules essential for their growth and survival [16,17]. Different activities of the prepared
compounds may be attributed to the structure activity relationship of these compounds.
Hydrazine derivatives are generally potent than pyrazoline ones, due to their open chain structure
as well as their higher electron density. Furthermore, it can be suggested that N-methyl derivatives
are more active than N-phenyl ones. On the other hand, hydrazine derivatives can be divided into
more active α-methoxyl derivatives and the less active α-ethoxyl, and then the least active N-phenyl
derivatives. This can be explained due to the fact that phenyl group act as a withdrawing group. On the
other hand, the weaker effect of α-ethoxyl derivatives than the α-methoxyl ones can be attributed
to their bulky nature. This effect can be observed among different series of compound 3. As the
bulky nature of the substituted groups increase, accordingly more steric hindrance can be observed,
leading to decreased cytotoxic activities.
3. Materials and Methods
3.1. Chemical Synthesis
“Melting points reported are inaccurate. IR spectra were registered on Shimadzu FT-IR 8300 E
(Shimadzu Corporation, Kyoto, Japan) spectrophotometer using the (KBr) disk technique. The 1H-NMR
spectra were determined with bruker 600 MHz NMR spectrometer. The chemical shifts are expressed
on the δ (ppm) scale using TMS as the standard reference. Mass spectra were recorded on Finnigan
SSQ operating at 70 ev. Elemental analysis determined on a Perkin Elmer 240 (Microanalysis),
Microanalysis Center, Cairo University, Cairo, Egypt”.
3.1.1. Synthesis of 3-Hydroxy-16-[substituted]-estra-1(10),2,4-trien-17-ones (2a,b)
“A mixture of (1) (0.54 g, 20 mmol) and formaldehyde or acetaldehyde (20 mmol) in EtOH (50 mL)
and aqueous KOH (10 mL, 30%) was stirred for 24 h at room temperature. The formed solid was
collected by filtration, crystallized from ethanol to give compounds 2a [25] and 2b, respectively”.
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3-Hydroxy-16-[ethylene]-estra-1(10),2,4-trien-17-one (2b)
Yield 97%, mp 198–200 ◦C, [α]25D =+ 71 (c 1, MeOH). IR (KBr, cm–1): 3340 (OH), 2944 (CH, aliphatic),
1743 (C=O), 1642 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β), 0.90 (3H, s, CH3-18),
1.01 (1H, m, H-11β), 1.12 (1H, m, H-7α), 1.15 (1H, m, H-12α), 1.25 (1H, m, H-14α), 1.44 (1H, m, H-15β),
1.63 (1H, m, H-15α), 1.72 (1H, m, H-7β), 2.01 (1H, m, H-9α), 2.13 (1H, m, H-11α), 2.50 (1H, m, H-12β),
2.56 (1H, m, H-6α), 2.66 (1H, m, H-6β), 4.90 (1H, s, OH, disappeared with D2O), 5.75 (1H, dd, H-2),
6.67 (1H, d, H-4), 2.08 (3H, d, CH3, enone), 6.41 (1H, s, enone proton), 7.12 (1H, d, H-1). 13C NMR:
(150 MHz, CDCl3): δ 13.52, 21.73, 25.51, 26.64, 27.48, 29.75, 36.35, 38.61, 43.81, 48.92, 50.43, 112.79,
115.53, 126.56, 128.48, 132.50, 137.02, 138.44, 153.82, 210.02 (20 C). MS (EI): m/z 296 (100%) [M+]. Anal.
Calcd for C20H24O2 (296.40): Calcd C, 81.04; H, 8.16. Found C, 81.00; H, 8.10.
3.1.2. Synthesis of 16-(α-alkoxy-alkane)-17-hydrazino-estra-1(10),2,4-trien[17,16-c]-3-ol and their
N-substituted derivatives (3a–l)
“A mixture of 2a,b (14 mmol) and hydrazine derivatives, namely, hydrazine hydrate, methyl
hydrazine or phenyl hydrazine (8 mmol) in absolute methanol or ethanol (30 mL) was refluxed for
5–10 h. The solvent was concentrated under reduced pressure, the formed precipitate was filtered off,
washed with water, dried and crystallized from ethanol to give the corresponding derivatives 3a–l,
respectively”.
16-(α-Methoxy-methane)-17-hydrazino-estra-1(10),2,4-trien-[17,16-c]-3-ol (3a)
Yield 80%, mp 199–201 ◦C, [α]25D = + 81 (c 1, MeOH). IR (KBr, cm–1): 3444–3377 (NH, NH2),
3345 (OH), 2951 (CH, aliphatic), 1638 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β),
0.90 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.11 (1H, m, H-7α), 1.14 (1H, m, H-12α), 1.26 (1H, m, H-14 α),
1.39 (1H, m, H-15β), 1.58 (1H, m, H-15α), 1.68 (1H, m, H-7β), 2.01(1H, m, H-9α), 1.84 (1H, m, CH,
16-Hα), 2.11 (1H, m, H-11α), 2.49 (1H, m, H-12β), 2.61 (1H, m, H-6α), 2.66 (1H, m, H-6β), 2.83 (1H, d,
H-17), 3.48 (3H, s, OCH3), 4.65 (2H, m, NH2, disappeared with D2O), 4.80 (2H, d, CH2-O), 4.87 (1H,
s, OH, disappeared with D2O), 5.70 (1H, dd, H-2), 6.61 (1H, d, H-4), 7.10 (1H, d, H-1), 7.70 (1H, br.s,
NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.58, 21.76, 25.57, 26.76, 28.00, 29.78,
36.38, 38.65, 43.89, 48.40, 50.45, 59.45, 69.11, 112.37, 115.56, 126.53, 132.81, 138.46, 153.84, 167.02 (20 C).
MS (EI): m/z 330 (90%) [M+]. Anal. Calcd for C20H30N2O2 (330.46): Calcd C, 72.69; H, 9.15; N, 8.48.
Found C, 72.60; H, 9.10; N, 8.40.
16-(α-Methoxy-ethane)-17-hydrazino-estra-1(10),2,4-trien[17,16-c]-3-ol (3b)
Yield 57%, mp. 308–310 ◦C, [α]25D = + 112 (c 1, MeOH). IR (KBr, cm–1): 3448-3377 (NH, NH2),
3348 (OH), 2959 (CH, aliphatic), 1634 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.59 (1H, m, H-8β),
0.91 (3H, s, CH3-18), 1.01 (1H, m, H-11β), 1.12 (1H, m, H-7α), 1.14 (1H, m, H-12 α), 1.26 (1H, m, H-14 α),
1.39 (1H, m, H -15 β), 1.58 (1H, m, H-15α), 1.42 (3H, m, CH3,C-16 ethane), 1.69 (1H, m, H-7β), 2.02(1H,
m, H-9α), 1.83 (1H, m, CH, H-16α), 2.11 (1H, m, H-11α), 2.49 (1H, m, H-12β), 2.61 (1H, m, H-6α),
2.66 (1H, m, H-6β), 2.83 (1H, d, H-17), 3.48 (3H, s, OCH3), 4.65 (2H, s, NH2, disappeared with D2O),
4.84 (1H, d, CH-O), 4.99 (1H, s, OH, disappeared with D2O), 5.72 (1H, dd, H-2), 6.61 (1H, d, H-4),
7.11 (1H, d, H-1), 7.78 (1H, bs, NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.58,
21.77, 22.22, 25.57, 26.47, 28.00, 29.78, 36.68, 38.47, 43.89, 48.69, 50.45, 59.45, 69.11, 112.37, 115.56, 126.55,
132.48, 138.46, 153.54, 167.76 (21 C). MS (EI): m/z 344 (11%) [M+]. Anal. Calcd for C21H32N2O2 (344.49):
Calcd C, 73.22; H, 9.36; N, 8.13. Found C, 73.18; H, 9.30; N, 8.10.
16-(α-Ethoxy-methane)-17-hydrazino-estra-1(10),2,4-trien-[17,16-c]-3-ol (3c)
Yield 56%, mp 219–221 ◦C, [α]25D = + 77 (c 1, MeOH). IR (KBr, cm–1): 3445–3376 (NH, NH2),
3346 (OH), 2951 (CH, aliphatic), 1638 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β),
0.90 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.11 (1H, m, H-7α), 1.15 (1H, m, H-12α), 1.21 (3H, m, CH3,
213
Molecules 2019, 24, 2054
ethoxyl), 1.25 (1H, m, H-14α), 1.36 (1H, m, H-15β), 1.57 (1H, m, H-15α), 1.68 (1H, m, H-7β), 2.01 (1H, m,
H-9α), 1.84 (1H, m, CH, H-16α), 2.10 (1H, m, H-11α), 2.50 (1H, m, H-12β), 2.60 (1H, m, H-6α), 2.70 (1H,
m, H-6β), 6.61 (1H, d, H-4), 2.80 (1H, d, H-17), 3.50 (2H, m, OCH2), 4.70 (2H, m, NH2, disappeared with
D2O), 4.80 (2H, d, CH-O), 4.87 (1H, s, OH, disappeared with D2O), 5.70 (1H, dd, H-2), 7.10 (1H, d, H-1),
7.70 (1H, br.s, NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.65, 18.74, 21.57, 25.17,
26.38, 28.04, 29.64, 36.54, 38.15, 44.11, 48.44, 50.54, 68.45, 69.11, 112.44, 115.67, 126.34, 131.11, 138.46,
153.84, 161.47 (21 C). MS (EI): m/z 344 (35%) [M+]. Anal. Calcd for C21H32N2O2 (344.49): Calcd C,
73.22; H, 9.36; N, 8.13. Found C, 73.16; H, 9.30; N, 8.10.
16-(α-Ethoxy-ethane)-17-hydrazino-estra-1(10),2,4-trien-[17,16-c]-3-ol (3d)
Yield 90%, mp 223–225 ◦C, [α]25D = + 95 (c 1, MeOH). IR (KBr, cm–1): 3440-3370 (NH, NH2),
3350 (OH), 2951 (CH, aliphatic), 1631 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.57 (1H, m, H-8β),
0.90 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.10 (1H, m, H-7α), 1.15 (1H, m, H-12α), 1.20 (3H, m, CH3,
ethoxyl), 1.24 (1H, m, H-14α), 1.36 (1H, m, H-15β), 1.45 (3H, m, CH3,C-16 ethane), 1.59 (1H, m, H-15α),
1.71 (1H, m, H-7β), 1.96 (1H, m, H-9α), 1.82 (1H, m, CH, H-16α), 2.10 (1H, m, H-11α), 2.50 (1H, m,
H-12β), 2.62 (1H, m, H-6α), 2.67 (1H, m, H-6β), 2.86 (1H, d, H-17), 3.48 (2H, m, OCH2), 4.64 (2H, s,
NH2, disappeared with D2O), 4.83 (1H, d, CH-O), 4.88 (1H, s, OH, disappeared with D2O), 5.74 (1H,
dd, H-2), 6.65 (1H, d, H-4), 7.12 (1H, d, H-1), 7.78 (1H, br.s, NH, disappeared with D2O). 13C NMR:
(150 MHz, CDCl3): δ 13.55, 18.79, 22.07, 22.28, 25.47, 26.52, 27.77, 28.09, 36.68, 37.97, 44.09, 48.11, 51.41,
68.43, 69.13, 112.56, 115.57, 126.37, 133.18, 137.87, 155.56, 162.74 (22 C). MS (EI): m/z 358 (45%) [M+].
Anal. Calcd for C22H34N2O2 (358.51): Calcd C, 73.70; H, 9.56; N, 7.81. Found C, 73.64; H, 9.52; N, 7.75.
16-(α-Methoxy-methane)-17-[N-methyl-hydrazino]estra-1(10),2,4-trien[17,16-c]-3-ol (3e)
Yield 76%, mp 222–224 ◦C, [α]25D = + 66 (c 1, MeOH). IR (KBr, cm–1): 3443–3371 (NH), 3344 (OH),
2953 (CH, aliphatic), 1634 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β), 0.92 (3H, s,
CH3-18), 1.03 (1H, m, H-11β), 1.10 (1H, m, H-7α), 1.14 (1H, m, H-12α), 1.25 (1H, m, H-14α), 1.37 (1H, m,
H-15β), 1.57 (1H, m, H-15α), 1.66 (1H, m, H-7β), 2.00 (1H, m, H-9α), 1.84 (1H, m, CH, H-16α), 2.13 (1H,
m, H-11α), 2.32 (3H, s, NCH3), 2.48 (1H, m, H-12β), 2.63 (1H, m, H-6α), 2.68 (1H, m, H-6β), 2.84 (1H, d,
H-17), 3.49 (3H, s, OCH3), 4.86 (2H, d, CH-O), 4.87 (1H, s, OH, disappeared with D2O), 5.72 (1H, dd,
H-2), 6.63 (1H, d, H-4), 7.11 (1H, d, H-1), 7.76 (1H, brs, NH, disappeared with D2O), 7.99 (1H, bs, NH,
disappeared with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.53, 21.44, 25.67, 26.36, 28.03, 29.23, 36.33,
38.43, 43.83, 47.47, 48.43, 50.34, 59.35, 69.31, 112.36, 115.67, 126.52, 132.32, 138.21, 153.45, 162.32 (21 C).
MS (EI): m/z 344 (45%) [M+]. Anal. Calcd for C21H32N2O2 (344.50): Calcd C, 73.22; H, 9.36; N, 8.13.
Found C, 73.15; H, 9.31; N, 8.09.
16-(α-Methoxy-ethane)-17-[N-methyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3f)
Yield 57%, mp 310–312 ◦C, [α]25D = + 112 (c 1, MeOH). IR (KBr, cm–1): 3443–3374 (NH), 3344 (OH),
2955 (CH, aliphatic), 1628 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.58 (1H, m, H-8β), 0.90 (3H, s,
CH3-18), 1.00 (1H, m, H-11β), 1.10 (1H, m, H-7α), 1.14 (1H, m, H-12α), 1.26 (1H, m, H-14 α), 1.39 (1H,
m, H-15 β), 1.60 (1H, m, H-15α), 1.44 (3H, m, CH3, C-16 ethane), 1.70 (1H, m, H-7β), 2.00 (1H, m,
H-9α), 1.82 (1H, m, CH, H-16α), 2.11 (1H, m, H-11α), 2.36 (3H, s, NCH3), 2.51 (1H, m, H-12β), 2.62 (1H,
m, H-6α), 2.65 (1H, m, H-6β), 2.85 (1H, d, H-17), 3.44 (3H, s, OCH3), 4.83 (1H, d, CH-O), 4.99 (1H, s,
OH, disappeared with D2O), 5.74 (1H, dd, H-2), 6.65 (1H, d, H-4), 7.13 (1H, d, H-1), 7.73 (1H, br.s,
NH, disappeared with D2O), 7.99 (1H, m, NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3):
δ 13.78, 21.54, 22.27, 25.97, 26.69, 28.03, 29.43, 36.45, 38.54, 43.68, 47.88, 48.57, 50.86, 59.46, 69.15, 112.54,
115.69, 126.46, 132.90, 138.75, 153.45, 163.60 (22 C). MS (EI): m/z 358 (100%) [M+]. Anal. Calcd for
C22H34N2O2 (358.50): Calcd C, 73.70; H, 9.56; N, 7.81. Found C, 73.60; H, 9.49; N, 7.75.
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16-(α-Ethoxy-methane)-17-[N-methyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3g)
Yield 90%, mp 286–288 ◦C, [α]25D = + 121 (c 1, MeOH). IR (KBr, cm–1): 3441–3379 (NH), 3348 (OH),
2957 (CH, aliphatic), 1636 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β), 0.91 (3H, s,
CH3-18), 1.01 (1H, m, H-11β), 1.13 (1H, m, H-7α), 1.15 (1H, m, H-12α), 1.22 (3H, m, CH3, ethoxyl),
1.25 (1H, m, H-14α), 1.37 (1H, m, H-15β), 1.58 (1H, m, H-15α), 1.69 (1H, m, H-7β), 2.00 (1H, m, H-9 α),
1.81 (1H, m, CH, H-16α), 2.12 (1H, m, H-11α), 2.33 (3H, s, NCH3), 2.54 (1H, m, H-12β), 2.65 (1H, m,
H-6α), 2.76 (1H, m, H-6β), 2.87 (1H, d, H-17), 3.50 (2H, m, OCH2), 4.85 (2H, d, CH2-O), 4.98 (1H, s,
OH, disappeared with D2O), 5.74 (1H, dd, H-2), 6.65 (1H, d, H-4), 7.10 (1H, d, H-1), 7.76 (1H, br.s,
NH, disappeared with D2O), 7.95 (1H, m, NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3):
δ 13.35, 18.45, 21.43, 25.78, 26.80, 28.14, 29.88, 36.47, 38.90, 44.41, 47.37, 48.34, 50.54, 68.66, 69.67, 113.34,
115.55, 125.54, 131.53, 137.99, 154.44, 162.27 (22 C). MS (EI): m/z 358 (100%) [M+]. Anal. Calcd for
C22H34N2O2 (358.50): Calcd C, 73.70; H, 9.56; N, 7.81. Found C, 73.62; H, 9.50; N, 7.74.
16-(α-Ethoxy-ethane)-17-[N-methyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3h)
Yield 78%, mp 280–282 ◦C, [α]25D = + 135 (c 1, MeOH). IR (KBr, cm–1): 3441–3371 (NH), 3351 (OH),
2951 (CH, aliphatic), 1631 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.60 (1H, m, H-8β), 0.93 (3H,
s, CH3-18), 1.04 (1H, m, H-11β), 1.11 (1H, m, H-7α), 1.16 (1H, m, H-12α), 1.19 (3H, m, CH3,ethoxyl),
1.23 (1H, m, H-14α), 1.37 (1H, m, H-15β), 1.46 (3H, m, CH3,C-16 ethane), 1.61 (1H, m, H-15α), 1.72
(1H, m, H-7β), 1.82 (1H, m, CH, H-16α), 1.93 (1H, m, H-9α), 2.10 (1H, m, H-11α), 2.50 (1H, m, H-12β),
2.34 (3H, s, NCH3), 2.63 (1H, m, H-6α), 2.62 (1H, m, H-6β), 2.85 (1H, d, H-17), 3.43 (2H, m, OCH2), 4.64
(1H, s, OH, disappeared with D2O), 4.83 (1H, d, CH-O), 5.72 (1H, dd, H-2), 6.64 (1H, d, H-4), 7.10 (1H,
d, H-1), 7.75 (1H, br.s, NH, disappeared with D2O), 7.88 (1H, s, NH, disappeared with D2O). 13C NMR:
(150 MHz, CDCl3): δ 13.53, 18.67, 22.43, 22.90, 25.67, 26.78, 27.45, 28.29, 36.89, 37.65, 44.65, 47.35, 48.68,
51.90, 68.78, 69.13, 112.56, 115.56, 126.34, 133.55, 137.43, 155.34, 163.34 (23 C). MS (EI): m/z 372 (100%)
[M+]. Anal. Calcd for C23H36N2O2 (372.54): Calcd C, 74.15; H, 9.74; N, 7.52. Found C, 74.05; H, 9.68;
N, 7.48.
16-(α-Methoxy-methane)-17-[N-phenyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3i)
Yield 67%, mp 312–314 ◦C, [α]25D = + 95 (c 1, MeOH). IR (KBr, cm–1): 3430–3367 (NH), 3345 (OH),
3068 (CH, aromatic), 2951 (CH, aliphatic), 1638 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61(1H, m,
H-8β), 0.91 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.12 (1H, m, H-7α), 1.15 (1H, m, H-12α), 1.28 (1H, m,
H-14α), 1.40 (1H, m, H-15β), 1.60 (1H, m, H-15α), 1.68 (1H, m, H-7β), 2.02 (1H, m, H-9α), 1.86 (1H, m,
CH, H-16α), 2.12 (1H, m, H-11α), 2.49 (1H, m, H-12 β), 2.59 (1H, m, H-6α), 2.65 (1H, m, H-6β), 2.84 (1H,
d, H-17), 3.47 (3H, s, OCH3), 4.80 (2H, d, CH-O), 4.87 (1H, s, OH, disappeared with D2O), 5.70 (1H, dd,
H-2), 6.61 (1H, d, H-4), 7.10 (1H, d, H-1), 7.28-7.48 (5H, m, Ar-H), 7.76 (1H, br.s, NH, disappeared with
D2O), 7.99 (1H, s, NH, disappeared with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.45, 21.76, 25.76, 26.67,
28.45, 29.66, 36.43, 38.65, 43.45, 48.40, 50.87, 59.45, 69.67, 112.43, 112.76, 115.66, 119.11, 126.68, 129.45,
132.67, 138.53, 152.55, 153.79, 161.02 (26 C). MS (EI): m/z 406 (77%) [M+]. Anal. Calcd for C26H34N2O2
(406.56): Calcd C, 76.81; H, 8.43; N, 6.89. Found C, 76.75; H, 8.40; N, 6.80.
16-(α-Methoxy-ethane)-17-[N-phenyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3j)
Yield 66%, mp 229–231 ◦C, [α]25D = + 147 (c 1, MeOH). IR (KBr, cm–1): 3433–3363 (NH), 3346 (OH),
3066 (CH, aromatic), 2955 (CH, aliphatic), 1635 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.62 (1H,
m, H-8β), 0.92 (3H, s, CH3-18), 1.02 (1H, m, H-11β), 1.13 (1H, m, H-7α), 1.18 (1H, m, H-12α), 1.26 (1H,
m, H-14α), 1.39 (1H, m, H-15β), 1.42 (3H, m, CH3, C-16 ethane), 1.58 (1H, m, H-15α), 1.69 (1H, m,
H-7β), 1.83 (1H, m, CH, H-16α), 2.03 (1H, m, H-9α), 2.10 (1H, m, H-11α), 2.52 (1H, m, H-12β), 2.62 (1H,
m, H-6α), 2.65 (1H, m, H-6β), 2.85 (1H, d, H-17), 3.49 (3H, s, OCH3), 4.86 (1H, d, CH-O), 4.89 (1H, s,
OH, disappeared with D2O), 5.71 (1H, dd, H-2), 6.61 (1H, d, H-4), 7.12 (1H, d, H-1), 7.27-7.49 (5H, m,
Ar-H), 7.77 (1H, br.s, NH, disappeared with D2O), 7.97 (2H, s, NH, disappeared with D2O). 13C NMR:
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(150 MHz, CDCl3): δ 13.52, 21.78, 22.92, 25.67, 26.45, 28.10, 29.90, 36.17, 38.47, 43.80, 48.69, 50.55, 59.25,
69.11, 112.12, 112.78, 115.54, 119.17, 126.46, 129.53, 132.79, 138.78, 152.42, 153.76, 163.11 (27 C). MS (EI):
m/z 420 (81%) [M+]. Anal. Calcd for C27H36N2O2 (420.58): Calcd C, 77.10; H, 8.63; N, 6.66. Found C,
77.00; H, 8.58; N, 6.60.
16-(α-Ethoxy-methane)-17-[N-phenyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3k)
Yield 60%, mp 338–340 ◦C, [α]25D = + 155 (c 1, MeOH). IR (KBr, cm–1): 3431–3362 (NH), 3343 (OH),
3064 (CH, aromatic), 2956 (CH, aliphatic), 1637 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.63 (1H,
m, H-8β), 0.90 (3H, s, CH3-18), 1.01 (1H, m, H-11β), 1.11 (1H, m, H-7α), 1.16 (1H, m, H-12α), 1.21 (3H,
m, CH3, ethoxyl), 1.24 (1H, m, H-14α), 1.36 (1H, m, H-15β), 1.59 (1H, m, H-15α), 1.68 (1H, m, H-7β),
2.00 (1H, m, H-9α), 1.84 (1H, m, CH, H-16α), 2.11 (1H, m, H-11α), 2.50 (1H, m, H-12β), 2.61 (1H, m,
H-6α), 2.70 (1H, m, H-6β), 6. disappeared (1H, d, H-4), 2.80 (1H, d, H-17), 3.53 (2H, m, OCH2), 4.80 (2H,
d, CH-O), 4.84 (1H, s, OH, exchangeable with D2O), 5.70 (1H, dd, H-2), 7.15 (1H, d, H-1), 7.26-7.47
(5H, m, Ar-H), 7.76 (1H, br.s, NH, disappeared with D2O), 7.98 (1H, m, NH, disappeared with D2O).
13C NMR: (150 MHz, CDCl3): δ 13.64, 18.74, 21.57, 25.17, 26.30, 28.05, 29.64, 36.54, 38.15, 44.18, 48.46,
50.55, 68.43, 69.13, 112.49, 112.72, 115.60, 119.11, 126.34, 129.50, 131.11, 138.49, 152.40, 153.84, 162.47
(27 C). MS (EI): m/z 420 (88%) [M+]. Anal. Calcd for C27H36N2O2 (420.58): Calcd C, 77.10; H, 8.63; N,
6.66. Found C, 77.02; H, 8.57; N, 6.61.
16-(α-Ethoxy-ethane)-17-[N-phenyl-hydrazino]-estra-1(10),2,4-trien-[17,16-c]-3-ol (3l)
Yield 96%, mp 288–300 ◦C, [α]25D = + 95 (c 1, MeOH). IR (KBr, cm–1): 3431–3367 (NH), 3343 (OH),
3068 (CH, aromatic), 2951 (CH, aliphatic), 1631 (C=C). 1H NMR: (600 MHz, CDCl3): δ ppm 0.58 (1H, m,
H-8β), 0.91 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.10 (1H, m, H-7α), 1.14 (1H, m, H-12α), 1.21 (3H, m,
CH3, ethoxyl), 1.24 (1H, m, H-14α), 1.36 (1H, m, H-15β), 1.44 (3H, m, CH3, C-16 ethane), 1.60 (1H, m,
H-15α), 1.71 (1H, m, H-7β), 1.97 (1H, m, H-9 α), 1.83 (1H, m, CH, H-16α), 2.11 (1H, m, H-11α), 2.51 (1H,
m, H-12β), 2.62 (1H, m, H-6α), 2.67 (1H, m, H-6 β), 2.88 (1H, d, H-17), 3.49 (2H, m, OCH2), 4.84 (1H, d,
CH-O), 4.87 (1H, s, OH, disappeared with D2O), 5.73 (1H, dd, H-2), 6.62 (1H, d, H-4), 7.13 (1H, d, H-1),
7.23-7.47 (5H, m, Ar-H), 7.77 (1H, br.s, NH, disappeared with D2O), 7.87 (1H, m, NH, disappeared
with D2O). 13C NMR: (150 MHz, CDCl3): δ 13.56, 18.77, 22.27, 22.32, 25.76, 26.78, 27.34, 28.29, 36.54,
37.90, 44.21, 48.23, 51.32, 68.34, 69.56, 112.67, 112.77, 115.56, 119.10, 126.45, 129.50, 133.47, 137.23, 152.55,
155.51, 163.73 (28 C). MS (EI): m/z 434 (93%) [M+]. Anal. Calcd for C28H38N2O2 (434.61): Calcd C,
77.38; H, 8.81; N, 6.45. Found C, 77.30; H, 8.75; N, 6.40.
3.1.3. Synthesis of pyrazoline-3-ol derivatives (4a–d)
A mixture of 2a,b (4 mmol) and hydrazine derivatives, namely, methy hydrazine or phenyl
hydrazine (16 mmol) in dioxane (25 mL) was refluxed for 5 h. The mixture was evaporated under
vacuum, the residue formed was triturated with water, filtered off, washed with water, dried and
crystallized from MeOH to give derivatives 4a–d, respectively.
1‘-Methyl-1‘H-estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol (4a)
Yield 96%, mp 117–119 ◦C, [α]25D =+ 109 (c 1, MeOH). IR (KBr, cm–1): 3351 (OH), 2946 (CH, aliphatic),
1627 (C=C), 1610 (C=N). 1H NMR: (600 MHz, CDCl3): δ ppm 0.61 (1H, m, H-8β), 0.94 (3H, s, CH3-18),
1.08 (1H, m, H-11β), 1.13 (1H, m, H-7α), 1.18 (1H, m, H-12α), 1.27 (1H, m, H-14α), 1.41 (1H, m, H-15β),
1.66 (1H, m, H-15α), 1.74 (1H, m, H-7β), 1.84 (1H, m, CH, H-16α), 2.01 (1H, m, H-9α), 2.10 (3H, s,
NCH3), 2.22 (1H, m, H-11α), 2.42 (1H, m, H-12β), 2.52 (1H, m, H-6α), 2.66 (1H, m, H-6β), 2.84 (2H, d,
pyrazoline-5′), 4.95 (1H, s, OH, disappeared with D2O), 5.75 (1H, dd, H-2), 6.65 (1H, d, H-4), 7.15 (1H,
d, H-1). 13C NMR: (150 MHz, CDCl3): δ 14.60, 22.56, 25.35, 26.46, 28.77, 29.56, 36.68, 38.68, 43.34, 45.36,
48.21, 50.24, 64.45, 112.46, 115.57, 126.44, 132.56, 138.45, 152.67, 156.46 (20 C). MS (EI): m/z 310 (100%)
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[M+]. Anal. Calcd for C20H26N2O (310.43): Calcd C, 77.38; H, 8.44; N, 9.02. Found C, 77.29; H, 8.36; N,
8.98.
1‘-Methyl -1‘H-5‘-methyl-estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol (4b)
Yield 88%, mp 216–218 ◦C, [α]25D =+ 111 (c 1, MeOH). IR (KBr, cm–1): 3351 (OH), 2946 (CH, aliphatic),
1627 (C=C), 1617 (C=N). 1H NMR: (600 MHz, CDCl3): δ ppm 0.62 (1H, m, H-8β), 0.92 (3H, s, CH3-18),
1.02 (1H, m, H-11β), 1.05 (3H, s, CH3-5′-methyl), 1.10 (1H, m, H-7α), 1.14 (1H, m, H-12α), 1.25 (1H,
m, H-14α), 1.40 (1H, m, H-15β), 1.66 (1H, m, H -15α), 1.77 (1H, m, H-7β), 1.88 (1H, m, CH, H-16α),
2.00 (1H, m, H-9α), 2.17 (3H, s, N-CH3), 2.20 (1H, m, H-11α), 2.47 (1H, m, H-12β), 2.57 (1H, m, H-6α),
2.66 (1H, m, H-6β), 2.84 (1H, m, pyrazoline-5′), 4.88 (1H, s, OH, disappeared with D2O), 5.79 (1H, dd,
H-2), 6.68 (1H, d, H-4), 7.19 (1H, d, H-1). 13C NMR: (150 MHz, CDCl3): δ 13.35, 21.80, 24.27, 25.30,
26.07, 28.20, 29.77, 36.76, 38.70, 43.67, 45.67, 48.50, 50.70, 64.45, 112.37, 115.54, 126.46, 132.40, 138.77,
153.44, 155.42 (21 C). MS (EI): m/z 324 (100%) [M+]. Anal. Calcd for C21H28N2O (324.45): Calcd C,
77.74; H, 8.70; N, 8.63. Found C, 77.66; H, 8.64; N, 8.58.
1‘-Phenyl-1‘H-estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol (4c)
Yield 70%, mp 255–257 ◦C, [α]25D = + 128 (c 1, MeOH). IR (KBr, cm–1): 3347 (OH), 3071 and 3061
(CH, aromatic), 2931 (CH, aliphatic), 1633 (C=C), 1614 (C=N). 1H NMR: (600 MHz, CDCl3): δ ppm
0.60 (1H, m, H-8β), 0.90 (3H, s, CH3-18), 1.00 (1H, m, H-11β), 1.10 (1H, m, H-7α), 1.20 (1H, m, H-12α),
1.28 (1H, m, H-14α), 1.49 (1H, m, H-15β), 1.68 (1H, m, H-15α), 1.77 (1H, m, H-7β), 1.86 (1H, m, CH,
H-16α), 2.04 (1H, m, H-9α), 2.26 (1H, m, H-11α), 2.48 (1H, m, H -12β), 2.54 (1H, m, H-6α), 2.64 (1H, m,
H-6β), 2.84 (2H, d, pyrazoline-5‘), 5.00 (1H, s, OH, disappeared with D2O), 5.71 (1H, dd, H-2), 6.70 (1H,
d, H-4), 7.10 (1H, d, H-1), 7.28-7.40 (5H, m, Ar-H). 13C NMR: (150 MHz, CDCl3): δ 13.49, 21.24, 25.55,
26.46, 28.51, 29.67, 36.64, 38.45, 43.35, 50.73, 58.26, 64.45, 112.10, 112.48, 115.46, 119.31, 126.10, 129.20,
132.52, 138.79, 152.20, 153.13, 163.48 (25 C). MS (EI): m/z 372 (81%) [M+]. Anal. Calcd for C25H28N2O
(372.50): Calcd C, 80.61; H, 7.58; N, 7.52. Found C, 80.52; H, 7.50; N, 7.48.
1‘-Phenyl-1‘H-5‘-methyl-estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol (4d)
Yield 75%, mp 214–216 ◦C, [α]25D =+ 127 (c 1, MeOH). IR (KBr, cm–1): 3345 (OH), 3068 (CH, aromatic),
2949 (CH, aliphatic), 1625 (C=C), 1614 (C=N). 1H NMR: (600 MHz, CDCl3): δ ppm 0.62 (1H, m, H-8β),
0.93 (3H, s, CH3-18), 1.02 (1H, m, H-11β), 1.05 (3H, s, CH3-5‘-methyl), 1.12 (1H, m, H-7α), 1.17 (1H,
m, H-12α), 1.27 (1H, m, H-14α), 1.41 (1H, m, H-15β), 1.71 (1H, m, H -15α), 1.77 (1H, m, H-7β), 1.87
(1H, m, CH, H-16α), 2.02 (1H, m, H-9α), 2.22 (1H, m, H-11α), 2.46 (1H, m, H -12β), 2.54 (1H, m, H-6α),
2.65 (1H, m, H-6β), 3.83 (1H, s, pyrazoline-5‘), 4.91 (1H, s, OH, disappeared with D2O), 5.81 (1H, dd,
H-2), 6.73 (1H, d, H-4), 7.21 (1H, d, H-1), 7.28-7.48 (5H, m, Ar-H). 13C NMR: (150 MHz, CDCl3): δ 13.81,
21.89, 24.25, 25.80, 26.35, 28.34, 29.23, 36.56, 38.67, 43.34, 48.55, 50.67, 64.44, 112.70, 115.34, 119.10, 126.76,
129.50, 132.45, 138.56, 152.40, 154.36, 163.56, 164.55 (26 C). MS (EI): m/z 386 (23%) [M+]. Anal. Calcd for
C26H30N2O (386.52): Calcd C, 80.79; H, 7.82; N, 7.25. Found C, 80.70; H, 7.76; N, 7.20.
3.2. Biological Screening
3.2.1. In Vitro Cytotoxic Activities
The cytotoxic activities of the synthesized derivatives against ovarian cancer cell lines (SKOV-3)
were evaluated using standard MTT assay [26,27]. SKOV-3 cells cultivated on DMEM medium
supplemented with 10% FBS, 100×, 1% antibiotic/antimycotic solution and 3.6 g/L NaHCO3 were
used. Cells were incubated under standard laboratory conditions [28,29]. Before testing compounds,
cells were trypsinized, centrifuged and prepared as per our developed protocol [30,31]. MTT assay relies
on the enzymatic conversion of the MTT substrate into purple formazan by living cells mitochondrial
enzymes. Shortly, 96 well plates were seeded (10,000 cells/100 μL/well), then incubated for 24 h
at standard conditions. Afterwards, cells were exposed to different concentrations from prepared
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compounds and incubated for another 24 h. Thereafter, MTT (10 μL, 5 mg/mL, PBS) were added to
each well, and plates were incubated for 4 h. Supernatants were then replaced discarded with 200 μL
of DMSO to dissolve the precipitated formazan crystals. Formazan absorbance, proportional to living
cell number, was read at 550 nm using a microplate reader. Viability percentages were calculated
and the corresponding IC50 values were obtained from the linear regression of the calibration curve.
For comparison, doxorubicin (DOX) and resveratrol (RES) were used as positive controls. Furthermore,
the effect of the newly synthesized derivatives was tested against normal fibroblast cell line to assess
their toxicities.
3.2.2. In Vitro Anti-Ovarian Xenograft Model
Anti-ovarian cancer xenograft animal model was developed in nude mouse using SKOV-3 cells
according to McCauley et al. [32]. Treatment protocol was approved by the University of South Dakota,
Institutional Animal Care and Use Committee (study protocol 50-01-05-08B). Immunodeficient
(athymic nude-Foxn1nu) female mice were inoculated (1 × 106 cells/site). Upon tumor development,
(av. volume ~50 mm3), 10-mice groups were implanted s.c. with constant release pellets containing
tested compound (1 μM/gm) or placebo. Animal and tumor development were monitored measured
every 5 days after pellet implantation, using standardized Caliper in two perpendicular diameters
of the implant according to our previous work [2]. Due to large tumor volumes, (5-fold difference
between largest and smallest tumor), relative tumor volumes were used for comparison. Relative tumor
volume = Vtvolume at time t/V0initial volume.
3.2.3. Topoisomerase II Inhibition
The inhibitory effects of the synthesized compounds against topoisomerase II were investigated
using relaxation assay according to Goyeneche, et al. [33]. Topoisomerase II was purified from
P388 cells, where enzyme unit corresponds to the activity required complete relaxation of 0.125 g of
supercoiled pBR-322 DNA at 30 ◦C for 1 h. The assay was performed as per protocol and samples
were subjected to electrophoresis (0.7% agarose gels, TBE buffer. Ethidium bromide-stained DNA was
examined under UV light.
3.2.4. In Vitro Kinase Inhibition
Protein Expression and Purification
BRAF wild-type and V600E mutant kinase domains were expressed and purified according to
Nakamura et al. [34]. Shortly, Sf 9 cells infected with BRAF kinase domain containing baculovirus
were resuspended, sonicated, and then cleared using ultracentrifugation. Afterwards, the cleared
lysate with mixed with equilibrated Talon resin, and the resin then washed with 10 column volumes
of wash buffer and then eluted with buffer (25 mM Tris, pH 7.0, 250 mM NaCl, 160 mM imidazole,
10% glycerol). The eluant was then diluted, concentrated using Superdex 200 gel filtration column,
purified as previously described and finally stored at –80 ◦C until use.
In Vitro ELISA-Based Kinase Assay
“This method was adopted from Nakamura et al. [34] and Qin et al. [35]. The previously prepared
GST MEK-His protein was diluted in TTBS buffer (100 μL, 50 μg/mL), and then bound to 96-plate wells
coated with glutathione (Pierce Biotechnology). Two DMSO-dilutions of each compound (1 μL) were
added to 50 μL (50mM HEPES, pH7.0, 0.7 pmol of BRAFV600E kinase). Tubes were incubated at ambient
temperature for 1 h, then added to GST-MEK-His-plate wells. Afterwards, 50 μL of phosphorylation
buffer were added to start kinase reaction (37 ◦C/30 min/shaking). Reaction was stopped, then substrate
was added, and the signal was recorded. The high throughput inhibitor screening was carried out
according to standard assay conditions at different concentrations, to generate a sigmoidal dose
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response curve, a four-parameter logistic model using GraphPad Prism, for BRAF proteins, which was
used to obtain corresponding IC50 values”.
3.2.5. Statistical Analysis
“Measurements were carried out in thrice and data are represented as means ± SEM. Significance
was calculated by Student’s t-test using SPSS software (SPSS Inc., Paris, France). * p <0.05, ** p < 0.01,
*** p < 0.001. IC50 values were calculated using GraphPad Prism software, GraphPad Software,
San Diego, CA, USA [36]”.
4. Conclusions
During the current investigation, we synthesized a series of 17-hydrazino- and 17,16-c-pyrazoline
estrone derivatives. Prepared compounds exhibited potential in vitro and in vivo anti-ovarian cancer
activity against SKOV-3 cells. Compound 3a was found to be the most potent with an IC50 value
of 4.23 ± 0.12 nM. Additionally, in vivo xenograft ovarian cancer model showed that Cpd. 3a was
able to reduce tumor growth by 93.61 ± 0.7% after 40 days of treatment. Furthermore, the newly
synthesized compounds were able to interfere with tumor proliferation through inhibiting the activity of
topoisomerase II and V600EBRAF, where the obtained IC50 values for both enzymes were 3.45 ± 0.13 nM
and 0.041 ± 0.0016 μM, respectively.
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Abstract: Xanthone scaffold has been regarded as an attractive chemical tool in the search for
bioactive molecules with antitumor activity, and in particular two xanthone derivatives,
12-hydroxy-2,2-dimethyl-3,4-dihydro-2H,6H-pyrano [3,2-b]xanthen-6-one (4) and 3,4-dimethoxy-9-
oxo-9H-xanthene-1-carbaldehyde (5), were described as a murine double minute 2 (MDM2)-p53
inhibitor and a TAp73 activator, respectively. The xanthone 5 was used as a starting point for the
construction of a library of 3,4-dioxygenated xanthones bearing chemical moieties of described
MDM2-p53 inhibitors. Eleven aminated xanthones were successfully synthesized and initially
screened for their ability to disrupt the MDM2-p53 interaction using a yeast cell-based assay. With
this approach, xanthone 37 was identified as a putative p53-activating agent through inhibition
of interaction with MDM2. Xanthone 37 inhibited the growth of human colon adenocarcinoma
HCT116 cell lines in a p53-dependent manner. The growth inhibitory effect of xanthone 37 was
associated with the induction of G1-phase cell cycle arrest and increased protein expression levels
of p53 transcriptional targets. These results demonstrated the potential usefulness of coupling
amine-containing structural motifs of known MDM2-p53 disruptors into a 3,4-dioxygenated xanthone
scaffold in the design of novel and potent p53 activators with antitumor activity and favorable
drug-like properties. Moreover, in silico docking studies were performed in order to predict the
binding poses and residues involved in the potential MDM2-p53 interaction.
Keywords: antitumor activity; computational docking; MDM2-p53 interaction; xanthones;
yeast-based assays
1. Introduction
The tumor suppressor p53 acts as a transcription factor, triggering the expression of multiple
downstream target genes that play a pivotal role in the regulation of cell cycle arrest, apoptosis,
senescence, and DNA repair [1–6]. Upon cellular stress stimuli, the activation of the p53 pathway
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may compromise the tumorigenesis, circumventing the proliferation of damaged cells with oncogenic
potential. Inactivation of the p53 function represents one of the most common events in human
cancers [7]. In approximately half of all human cancer cells, the p53 inactivation is caused by mutations
within the p53 gene (TP53) or by post-translational modifications of its gene product [8]. In those
tumors retaining the wild type (wt) p53 function, the tumor suppressor activity of p53 can be abolished
by multiple mechanisms [9], mainly by direct interaction between p53 and its primary endogenous
inhibitor, the murine double minute 2 (MDM2) protein [10,11]. The oncoprotein MDM2 physically
interacts with the amino-terminal domain of p53 and negatively regulates its activity by blocking
p53-mediated transactivation [12,13], by inducing the export of p53 from nucleus to the cytoplasm [14],
and by promoting E3 ubiquitin ligase-mediated p53 degradation via the proteasomal pathway [15,16].
Targeting the MDM2-p53 interaction with small molecules has been regarded an attractive approach
for the reactivation of the p53 pathway in wt p53-expressing tumors [17,18]. Since the seminal work of
Vassilev et al. reporting the discovery of nutlin-3A (1, Figure 1) as the first inhibitor of MDM2-p53
interaction [19], an impressive number of MDM2-p53 disruptors from a huge diversity of chemical
families have been identified in recent years, entering some of them into clinical trials [20,21].
Figure 1. Chemical structures of nutlin-3A (1), gambogic acid (2), α-mangostin (3), 12-hydroxy-2,2-
dimethyl-3,4-dihydro-2H,6H-pyrano[3,2-b]xanthen-6-one (4), and 3,4-dimethoxy-9-oxo-9H-xanthene-
1-carbaldehyde (5).
Xanthones represent a privileged class of compounds with a multiplicity of biological activities,
in particular with antitumor activity against several human tumor cell lines [22–36]. Intriguingly,
our research group has demonstrated that the antitumor activity of some derivatives can be
correlated to the disruption of the MDM2-p53 complex and the activation of a p53-dependent
pathway [30,31]. In fact, implementing a yeast-based assay, the naturally occurring xanthones gambogic
acid (2, Figure 1) and α-mangostin (3, Figure 1) were found to revert the inhibitory effect of MDM2
on p53-induced growth inhibition and on p53 transcriptional activity [30]. The synthetic xanthone
12-hydroxy-2,2-dimethyl-3,4-dihydro-2H,6H-pyrano [3,2-b]xanthen-6-one (4, Figure 1) was identified as
a potential MDM2-p53 disruptor, using an in silico virtual screening strategy against MDM2 protein and
a yeast-based assay [31]. Its molecular mechanism was corroborated in MDM2-overexpressing human
tumor cell lines with wt p53. In fact, xanthone 4 selectively upregulated the p53 transcriptional activity,
increasing the protein expression levels of p53-target genes in HCT116 human colon adenocarcinoma
cells [31]. Nevertheless, xanthone 4 is highly hydrophobic and poorly water soluble, which could limit
its in vivo use. Interestingly, Chen and co-workers explored the antitumor activity of xanthone 4 either
in combination or hybridized with 5,6-dimethylxanthone-4-acetic acid (DMXAA) [37], a xanthone
derivative with tumor-vascular disrupting activity. A very recent study reported the discovery of
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3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (5, Figure 1) as a new TAp73 activator via disruption
of its interaction with both MDM2 and mutant p53 [36].
Herein, based on the 3,4-oxygenated pattern of substitution of xanthones 4 and 5 (Figure 2A), and
on chemical moieties derived from known MDM2-p53 disruptors, namely the molecules 1 [19], 6 [38],
7 [39], and 8 [40] (Figure 2B), we followed a molecular hybridization approach for the construction of
novel 3,4-oxygenated xanthone derivatives (Figure 2D). In the present work, we opted to synthesize a
library of aminated xanthones (Figure 2D) via a strategy of reductive amination of the xanthone 5 with
a set of commercially available amine precursors (9–19) containing structural motifs of MDM2-p53
disruptors (Figure 2C). The introduction of amine moieties in the xanthone scaffold may contribute
to a potential enhancement of drug-like properties, a critical parameter for the identification of
promising drug candidates. The ability of the synthesized ligands to disrupt the MDM2-p53 interaction
and to activate a p53-dependent pathway was further investigated using the previously established
yeast-based assay and in human cancer cell lines. In silico docking studies were performed in order to
predict the binding poses and residues involved in the potential MDM2-p53 interaction.
2. Results and Discussion
2.1. Chemistry
2.1.1. Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (5)
In the present work, xanthone 5 was used as a starting precursor for the synthesis of a set
of aminated xanthones with a 3,4-dioxygenated pattern of substitution. Recently, the multi-step
synthesis of compound 5 has been reported [36] as consisting in: (i) a Friedel-Crafts acylation of
1,2,3-trimethoxybenzene (20) with the commercially available reagent 2-methoxybenzoyl chloride
(21); (ii) an intramolecular nucleophilic aromatic substitution of (2-hydroxy-3,4-dimethoxyphenyl)
(2-methoxyphenyl)methanone (22) and consecutive regioselective demethylation of the methoxy group
at position C-4 under conventional heating; (iii) a Duff formylation at position C-1 of 4-hydroxy-3-
methoxy-9H-xanthen-9-one (23); and (iv) a methylation of the hydroxyl group at position C-4 of
4-hydroxy-3-methoxy-9-oxo-9H-xanthene-1-carbaldehyde (24) (Scheme 1A). The difficulty in achieving
a regioselective demethylation at position C-4 necessary for Duff formylation at position C-1 demanded
the planning of an optimized synthetic route more appropriate for scaling-up. We hypothesized that
the implementation of an analog precursor of 20 with a suitable substituent at position C-1 might
provide a useful alternative for the synthesis of 5, avoiding the troublesome demethylation and Duff
formylation processes. Herein, the commercially available 1,2,3-trimethoxy-5-methylbenzene (25) was
selected for the Friedel-Crafts acylation with the acyl chloride 21 and the Lewis acid aluminum chloride
to furnish the intermediate (2-hydroxy-3,4-dimethoxy-6-methylphenyl)(2-methoxyphenyl)methanone
(26). Subsequent intramolecular nucleophilic aromatic substitution followed by elimination of methanol
under basic conditions and microwave (MW) irradiation provided the 3,4-dimethoxy-1-methyl-
9H-xanthen-9-one (27) in good yield quantity. This two-step methodology for the construction
of xanthone analogues of 27 has been previously described in the literature [32,41–43]. With the
application of MW methodology in the basic cyclization of 26 instead of the conventional heating
employed in the synthesis of 23, the reaction time was reduced from 48 h to 6 h. Furthermore,
xanthone 27 was obtained in higher reaction yield under MW irradiation (63% yield (27) vs. 38%
yield (23)). Subsequently, the Vohl-Ziegler bromination of 27, using dibenzoyl peroxide (DBP) and
N-bromosuccinimide (NBS) as a radical initiator and a brominating agent, respectively, afforded
the 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one (28) as the major product. A solvolytic
displacement of bromine atoms of the xanthone 28 was effectively attained using 1-butyl-3-
methylimidazolium tetrafluoroborate and water, under conventional heating, and furnished xanthone
5 in 64% yield quantity (Scheme 1B). Of note, the two-step procedure of Vohl-Ziegler bromination and
subsequent solvolytic displacement required lower reaction times (4.5 h (2 steps from 27 to 5) vs. 54 h
(2 steps from 23 to 5) and allowed the preparation of xanthone 5 in higher reaction yields (51% yield
(2 steps from 27 to 5) vs. 28% yield (2 steps from 23 to 5)), compared to the Duff formylation/methylation
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pathway. Overall, the replacement of starting precursor 20 by the methylated derivative 25 at position
C-1 of the aromatic ring was critical for the successful optimization of the preparation of xanthone 5.
Figure 2. Strategy of molecular hybridization used for the construction of the library of aminated
xanthones (D) by conjugation of the 3,4-dioxygenated substitution pattern of xanthones 4 and 5 (A)
with the chemical moieties of known murine double minute 2 (MDM2)-p53 inhibitors (C), namely the
molecules 1 (IC50 = 0.09 μM), 6 (IC50 = 2.6 μM), 7 (KI = 0.656 μM), and 8 (KI = 0.023 μM) (B).
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Scheme 1. (A) Synthetic route for the preparation of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde
(5) from 1,2,3-trimethoxybenzene (20). (B) Optimized synthetic route for the preparation of the xanthone
5 using the starting precursor 1,2,3-trimethoxy-5-methylbenzene (25). The compound numbering
used concerns the nuclear magnetic resonance (NMR) assignments. Note: [BmIm]BF4 = 1-butyl-
3-methylimidazolium tetrafluoroborate; DBP = dibenzoyl peroxide; HMTA = hexamethylenetetramine;
NBS = N-bromosuccinimide. a Isolated yields.
2.1.2. Synthesis of a Library of Aminated Xanthones (30–40)
A library of aminated xanthones 30–40 with a 3,4-dioxygenated pattern of substitution was
obtained through a one-pot reductive amination of xanthone 5 with the appropriate amine precursors
9–19 (Scheme 2). In one-pot reductive aminations, the selection of the reducing agent is critical for
their efficiency, since a suitable agent must reduce the Schiff base intermediate selectively over the
carbonylated compounds. As an attempt to investigate the best reaction conditions, a solid-supported
reactant containing borohydride (MP-BH4) combined with methanol were initially employed, since
it was successfully used in the reductive amination of a xanthone derivative (data not shown).
When these conditions were applied to the reductive amination of 5, the starting precursor was not
completely consumed and the alcohol derivative 1-(hydroxymethyl)-3,4-dimethoxy-9H-xanthen-9-one
(29) was the major product formed. The replacement of the above-mentioned conditions by the milder
reducing agent sodium triacetoxyborohydride (STAB) and the solvent tetrahydrofuran allowed a total
consumption of the xanthone 5, favoring the one-pot amination/reduction pathway. Under the reaction
conditions described in the Scheme 2, eleven aminated xanthones 30–40 were successfully synthesized
in moderate to good yields (11 examples, 39–73% yields).
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Scheme 2. Reductive amination of 5 with appropriate amine precursors 9–19 for the synthesis of
aminated xanthones 30–40 with a 3,4-dioxygenated substitution pattern. The compound numbering
used concerns the NMR assignments. a Isolated yields.
The structure elucidation of the xanthones 5 and 27–40 was established on the basis of high-
resolution mass spectrometry (HRMS) (Figures S1–S15) and nuclear magnetic resonance (NMR)
techniques (Figures S16–S45). The 13C-NMR assignments were determined by bidimensional
heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC)
experiments (Supplementary Materials).
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2.2. Biological Activity Evaluation
2.2.1. Effect of Synthesized Xanthone Derivatives 30–40 on the MDM2-p53 Interaction Using A
Yeast-Based Screening Assay
Our group has previously developed a yeast-based screening assay to search for potential inhibitors
of the MDM2-p53 interaction [30,31,44–46]. In this yeast cell system, the expression of human wt
p53 induces a growth inhibition proportional to the degree of its activity (Figure 3, p53, dimethyl
sulfoxide (DMSO)). On the other hand, this p53 inhibitory effect is reversed by yeast co-expression
of human MDM2 (Figure 3, MDM2-p53, DMSO). This established yeast screening assay was used
to study the potential inhibitory effect of 1-20 μM of xanthone derivatives 30–40 on the MDM2-p53
interaction. Figure 3 represents the maximal effect achieved with xanthone derivatives 30–40 at 10 μM.
The results showed that only the xanthone 37 caused a significant reversion of the inhibitory effect
of MDM2 on p53 (77.01 ± 7.35% of reversion, n = 3), with an almost complete reestablishment of the
p53 growth inhibitory effect (63.55 ± 4.26% vs. 69.22 ± 2.23%; Figure 3, DMSO-treated p53-expressing
yeast vs. xanthone 37-treated MDM2-p53-expressing yeast). It should be noted that xanthone 37 did
not interfere with the growth of control yeast (transformed with empty vectors) or yeast expressing
human p53 alone (data not shown). As such, these results indicated that the xanthone 37 behaved as
a potential p53-activating agent through inhibition of interaction with MDM2, and it was, therefore,
selected for further investigation in human cancer cells.
Figure 3. Effect of xanthones 30–40 on the MDM2-p53 interaction using a yeast-based assay. Effect of
10 μM xanthone derivatives 30–40 and nutlin-3A on the growth of yeast co-expressing p53 and MDM2
after 42 h treatment; results were plotted setting as 100% the growth of yeast transformed with the
empty vector (control yeast); nutlin-3A (inhibitor of the MDM2-p53 interaction) was used as positive
control. Data are mean ± standard error of the mean (SEM) of three independent experiments; mean
values were statistically analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple
comparisons test, with significant differences from yeast co-expressing MDM2-p53 treated with DMSO.
Note: * p < 0.05; ** p < 0.01.
2.2.2. Evaluation of the Antitumor Activity of Xanthone 37 in Human Cancer Cell Lines
Using the sulforhodamine B (SRB) assay, it was confirmed that xanthone 37 inhibited the growth
of human HCT116 p53+/+ colon cancer cells, with an IC50 (concentration that causes 50% growth
inhibition) value of 8.67 ± 0.59 μM (n = 4), and of the MDM2-overexpressing human HepG2 liver
carcinoma cells, with an IC50 value of 18.95 ± 0.39 μM (n = 4), after 48 h treatment.
To evaluate the dependency of the antitumor activity of xanthone 37 on the p53 pathway, we next
determined the impact of xanthone 37 on the colony forming ability of HCT116 p53+/+ cells and on the
respective p53-knockout (HCT116 p53−/−), using a colony formation assay (Figure 4A). The results
showed a significant reduction of the growth inhibitory activity of xanthone 37, at 3–5 μM in HCT116
p53+/+ cells, demonstrating a p53-dependent antitumor effect of xanthone 37. Accordingly, 10 and
20 μM of xanthone 37 caused a G1-phase cell cycle arrest in HCT116 p53+/+ cells, but not in HCT116
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p53−/− cells (Figure 4B) after 24 h treatment. It is of note that apoptosis analysis was also investigated
by Annexin-V assay; nevertheless, apoptotic events were not detected at 10 and 20 μM of xanthone
37, after 24 and 48 h treatment. In accordance with these results, we also observed that xanthone 37
upregulated the protein expression levels of MDM2, p53, and p21, in HCT116 p53+/+ cells for 24 h
treatment (Figure 4C).
Figure 4. Xanthone 37 inhibits the colony forming capability of HCT116 cells through induction of cell
cycle arrest and in a p53-dependent manner. (A) Evaluation of colony forming ability in HCT116 p53+/+
and HCT116 p53−/− colon cancer cells after 11 days treatment with 3-10 μM of xanthone 37; results were
plotted setting as 100% the colonies formed after treatment with dimethyl sulfoxide (DMSO). (B) Effect of
10 and 20 μM of xanthone 37 on cell cycle progression of HCT116 p53+/+ and HCT116 p53−/− cells, after
24 h treatment. (C) Effect of 10 and 20 μM of xanthone 37 on the expression levels of MDM2, p53, and
p21 in HCT116 p53+/+ cells analyzed by Western Blot after 24 h treatment. Immunoblots represent one
of three independent experiments; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as
loading control. (A,B) Data are mean ± SEM of three independent experiments; values significantly
different from HCT116 p53−/− cells using two-way ANOVA with Sidak’s multiple comparisons test (A)
or DMSO using Student’s t-test (B) are indicated: * p < 0.05; ** p < 0.01.
Altogether, these results indicated that xanthone 37 had an in vitro p53-dependent antitumor
activity mediated by induction of cell cycle arrest.
2.3. In Slico Studies
It is common knowledge that the amino-terminal (residues 18–26) p53 α-helical peptide interacts
with a deep hydrophobic cleft within the amino-terminal domain of MDM2 [47]. The MDM2 binding
site consists of a large and a small pocket that interact with Phe19/Trp23 and Leu26 of p53, respectively
(Figure 5A) [48]. The crystal structure of the MDM2 complexed with the transactivation domain of p53
(Protein Data Bank (PDB) id 1YCR [49]) allowed the visual inspection of the interactions between the
Phe19, Trp23, and Leu26 residues of p53 and their respective pockets. Hydrogen-bonding interactions
are established between the indole group of Trp23 and carbonyl backbone of Leu54, and between the
NH backbone of Phe19 and the carbamoyl group of Gln72. Additional interactions are established
between p53 and Leu57, Gly58, Ile61, Met62, Val75, Val93, and His96 residues of MDM2 (Figure 5B).
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Figure 5. (A) Crystallographic p53 (for simplification, only Phe19, Trp23, and Leu26 residues are
represented as purple sticks) bound to the three pockets of MDM2 (solid surface). (B) Binding mode
of crystallographic p53 (for simplification, only residues Phe19, Trp23, and Leu26, are represented as
purple sticks) in the hydrophobic cleft of MDM2 (transparent surface); MDM2 amino acid residues
involved in interactions with p53 are represented as green sticks. Structural data were obtained from
the X-ray crystal structure of MDM2-p53 complex (Protein Data Bank (PDB) id 1YCR). MDM2 is
represented as surface, where carbon, oxygen, nitrogen, and sulfur are represented in green, red, blue,
and yellow, respectively. Hydrogen-bonding interactions are depicted with a dashed blue line. Other
types of interactions are represented as a dashed red line.
The 1.6 Å X-ray crystal structure of the small-molecule inhibitor of MDM2-p53 interaction 1
in complex with MDM2 (PDB id 4HG7 [50]) was selected for further molecular docking studies of
the aminated xanthone derivatives 30–40 onto MDM2 protein, using the MDM2-p53 disruptors 1–4
as positive controls. In this work, AutoDock Vina [51] was the software chosen to predict docking
conformations, as it has been described as being the best software in predicting crystallographic
MDM2-p53 inhibitor poses (root-mean-square deviation (RMSD) < 1.0 Å) by redocking tests [52].
Docking scores for the most stable binding poses of xanthones 30–40 on MDM2 were determined
using the AutoDock Vina software [51]. The predicted docking scores for known MDM2-p53
inhibitors (positive controls 1–4) ranged from −7.7 to −8.0 kcal·mol−1 (Table 1). The most stable
binding conformation of the synthesized xanthones 30–40 exhibited docking scores from −5.9 to
−7.4 kcal·mol−1, therefore being in the same range of binding affinity as the positive controls (Table 1).
Amongst the tested compounds, the xanthone 37 was identified as the most active compound
in the yeast-based screening assay. In addition, the predicted free energy values for the most stable
binding pose of xanthone 37 were more negative than the majority of the remaining ligands. Therefore,
the xanthone 37 was further analyzed in terms of docking poses and residues potentially involved in the
interaction with MDM2. Figure 6A shows the most stable conformation of xanthone 37 as suggested by
the docking protocol. The xanthone 37 was predicted to interact within the p53-binding site, mimicking
the key hydrophobic residues of p53 when bound to MDM2 (docking score of −7.3 kcal·mol−1).
Similarly to the binding mode of 1 within the p53-binding site (Figure 6B), no hydrogen-bonding
interactions between the xanthone 37 and the MDM2 residues are predicted to be established. The
p-fluorobenzylamino group of xanthone 37 occupies the Trp23 pocket and makes π-stacking interactions
with Phe91 residue, amide-π interactions with the Leu57 and Gly58 residues, and CH-π interactions
with the Leu54, Leu57, Gly58, Ile61, Val93, and Ile99 residues. Interestingly, the docking conformation
of p-fluorobenzylamino group and the p-chlorophenyl ring of 1 are identical and superimposable
(Figure 6A,B). The methoxy groups of the xanthone scaffold are oriented to the Leu26 pocket and
make CH-CH interactions with the Leu54 residue. The adopted scaffold orientation of the xanthone 37
in the hydrophobic cleft where p53 is supposed to bind allows additional interactions to be formed,
strengthening the binding of xanthone 37 to MDM2. For example, apart from the Gly58 residue of
MDM2, the non-substituted aromatic ring of the xanthone scaffold is predicted to establish π-stacking
231
Molecules 2019, 24, 1975
interactions with the Phe55 residue, and amide-π and CH-π interactions with the Gln59 residue.
The establishment of additional interactions within the MDM2 protein that are not observed in the
MDM2-p53 binding have been described for a considerable number of high-affinity p53-activating
agents [17]. The visual inspection of the xanthone 37 also suggests that an enhancement of its binding
affinity towards MDM2 protein can be achieved by molecular modifications in the xanthone scaffold of
37 in order to optimize its interaction with the amino acid residues surrounding the Phe19 pocket.
Table 1. Docking scores (kcal·mol−1) of xanthones 30–40 and positive controls 1–4 onto MDM2 target.
Xanthones 30–40












Inhibitors of MDM2-p53 Interaction





Figure 6. (A) Predicted binding pose of the xanthone 37 (purple sticks) in the binding site of MDM2.
(B) MDM2 (transparent surface) in complex with the crystallographic nutlin-3A (1, purple sticks). MDM2
is represented as a transparent surface, where carbon, oxygen, nitrogen, and sulfur are represented
in green, red, blue, and yellow, respectively. Small molecule-MDM2 interactions are depicted with a
dashed red line. MDM2 residues involved in interactions with the ligands are represented as green
sticks and labeled.
3. Materials and Methods
3.1. Chemistry
All reagents and solvents were purchased from Sigma Aldrich (Sigma-Aldrich Co. Ltd., Gillinghan,
UK) and no further purification process was implemented. Solvents were evaporated using a rotary
evaporator under reduced pressure, Buchi Waterchath B-480. Microwave (MW) reactions were
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performed using an Ethos MicroSYNTH 1600 Microwave Labstation from Milestone (Thermo Unicam,
Portugal). The internal reaction temperature was controlled by a fiber optic probe sensor. All reactions
were monitored by thin-layer chromatography (TLC) carried out on precoated plates with 0.2 mm of
thickness using Merck silica gel 60 (GF254) with appropriate mobile phases. Compounds 30–40 were
easily detectable at 254 nm or 365 nm and after revelation with a solution of ninhydrin in ethanol
3 mg·mL−1 (activated by heat).
Flash column chromatography using silica gel 60 (0.040–0.063 mm, Merck, Darmstadt, Germany),
flash cartridge chromatography (GraceResolv®, Grace Company, Deerfield, IL, USA), and Discovery®
DSC-SCX SPE cationic exchange cartridge (Grace Company, Deerfield, IL, USA) were used in the
purification of the synthesized compounds. Melting points (m.p.) were measured in a Köfler microscope
(Wagner and Munz, Munich, Germany) and are uncorrected. 1H- and 13C-nuclear magnetic resonance
(NMR) spectra were recorded at the University of Aveiro, Department of Chemistry in CDCl3 or
DMSO-d6 (Deutero GmbH, Ely, UK) at room temperature on a Bruker Avance 300 spectrometer
(300.13 MHz for 1H and 75.47 MHz for 13C, Bruker Biosciences Corporation, Billerica, MA, USA).
Chemical shifts are expressed in δ (ppm) values relative to tetramethylsilane (TMS) as an internal
reference. Coupling constants are reported in hertz (Hz). 13C-NMR assignments were made by
bidimensional heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond
correlation (HMBC) NMR experiments (long-range C, H coupling constants were optimized to 7 Hz)
or by comparison with the assignments of similar molecules. High-resolution mass spectroscopy
(HRMS) spectra were measured on a Bruker FTMS APEX III mass spectrometer (Bruker Corporation,
Billerica, MA, USA) and recorded as electrospray ionization (ESI) mode in Centro de Apoio Cientifico e
Tecnolóxico á Investigación (CACTI, University of Vigo, Pontevedra, Spain). The following compounds
were synthesized and purified by the described procedures.
3.1.1. Synthesis of 3,4-dimethoxy-1-methyl-9H-xanthen-9-one (27)
Xanthone 27 (9.34 g, 63% yield) was synthesized from 1,2,3-trimethoxy-5-methylbenzene (25) and
characterized according to the previously described procedure [42].
3.1.2. Synthesis of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one (28)
A mixture of 27 (2.52 g, 9.32 mmol), N-bromosuccinimide (3.32 g, 18.7 mmol), and dibenzoyl
peroxide (0.68 g, 2.8 mmol) in carbon tetrachloride (25 mL) was refluxed (85 ◦C) for 2 h. The reaction
was monitored using n-hexane/ethyl acetate in a proportion of 8:2. Once the reaction was completed,
the resulting orange suspension was cooled at 0 ◦C and stirred for 30 min in an ice bath. The solid was
filtered and washed with cold carbon tetrachloride. The filtrate was evaporated under reduced pressure
and further purified by flash column chromatography (SiO2, n-hexane/ethyl acetate in gradient) to
obtain the 28 as a white powder.
For 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one (28): White powder (3.14 g, 80% yield);
melting point (m.p.) 125–127 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.91 (1H, s, H-1), 8.30 (1H, dd,
J = 8.0 and 1.6 Hz, H-8), 7.77 (1H, s, H-2), 7.73 (1H, ddd, J = 8.4, 7.0, and 1.6 Hz, H-6), 7.54 (1H, d,
J = 8.4 Hz, H-5), 7.39 (1H, ddd, J = 7.5, H-7), 4.11 (3H, s, 4-OCH3), 4.05 (3H, s, 3-OCH3) ppm; 13C-NMR
(CDCl3, 75.47 MHz): δ = 177.8 (C-9), 156.5 (C-3), 155.0 (C-10a), 150.4 (C-4a), 139.5 (C-4), 137.6 (C-1),
135.0 (C-6), 126.9 (C-8), 124.3 (C-7), 122.0 (C-8a), 117.6 (C-5), 111.9 (C-2), 110.8 (C-9a), 61.9 (3-OCH3),
56.6 (4-OCH3), 39.2 (C-1′) ppm. HRMS (ESI+): m/z [C16H12Br2O5 + H]+ calcd. for [C16H13Br2O5]:
426.91751; found: 426.91709.
3.1.3. Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (5)
Xanthone 28 (3.14 g, 7.34 mmol) was added to a solution of 1-butyl-3-methylimidazolium
tetrafluoroborate and water (6 mL, 5:1). The mixture was heated at 100 ◦C with stirring for 2.5 h. The
reaction was monitored using n-hexane/ethyl acetate in a proportion of 7:3. After completion of the
reaction, the resulting suspension was cooled at room temperature, diluted with water (10 mL), and
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extracted with ethyl acetate (5 × 100 mL). The combined organic layers were dried over anhydrous
sodium sulfate, and after filtration of the solution, the solvent was evaporated under reduced pressure.
The crude product was then purified by flash column chromatography (SiO2, n-hexane/ethyl acetate in
gradient). A light yellow powder corresponding to 5 was obtained.
For 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (5): Light yellow powder (1.33 g, 64%
yield); m.p. > 330 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 11.21 (1H, s, H-1′), 8.31 (1H, dd, J = 8.0 and
1.7 Hz, H-8), 7.77 (1H, ddd, J = 8.5, 7.0, and 1.7 Hz, H-6), 7.60 (1H, dd, J = 8.5 and 0.8 Hz, H-5), 7.56 (1H,
s, H-2), 7.43 (1H, ddd, J = 8.0, 7.0, and 0.8 Hz, H-7), 4.11 (3H, s, 4-OCH3), 4.07 (3H, s, 3-OCH3) ppm;
13C-NMR (CDCl3, 75.47 MHz): δ = 192.8 (C-1′), 177.9 (C-9), 156.3 (C-3), 155.5 (C-10a), 150.9 (C-4a),
140.7 (C-4), 135.1 (C-6), 133.5 (C-1), 126.7 (C-8), 124.5 (C-7), 121.9 (C-8a), 117.8 (C-5), 116.1 (C-9a), 108.5
(C-2), 61.8 (4-OCH3), 56.6 (3-OCH3) ppm. HRMS (ESI+): m/z [C16H12O5 + H]+ calcd. for [C16H13O5]:
285.07575; found: 285.07598; [C16H12O5 +Na]− calcd. for [C16H12NaO5]: 307.05769; found 307.05750.
3.1.4. Synthesis of 1-(hydroxymethyl)-3,4-dimethoxy-9H-xanthen-9-one (29)
Xanthone 29 (52 mg, 52% yield) was synthesized from xanthone 5 and characterized according to
the previously described procedure [36].
3.1.5. General Procedure for the Synthesis of Xanthones (30–40)
Xanthone 5 (40 mg, 0.141 mmol) was dissolved in tetrahydrofuran (3 mL) and the appropriate
amine precursors 9–19 (0.197 mmol) were added to the solution under N2 gas. After the addition of a
4.0 equimolar quantity of sodium triacetoxyborohydride (119 mg, 0.563 mmol), the resulting mixture
was stirred at room temperature for 30 min. Subsequently, a 3.0 equimolar quantity of acetic acid (24 μL
0.423 mmol) was added to the solution, The reaction was carried out at room temperature for 12 h
under N2 gas. For monitoring the synthesis of xanthones 30–40 by TLC, two chromatographic systems
were employed: (i) n-hexane/ethyl acetate (7:3) and methanol/triethylamine (10:0.1) for xanthones
30–36; (ii) n-hexane/ethyl acetate (7:3) and chloroform/acetone/triethylamine (5:5:0.1) for xanthones
37–40. Once completed of the reaction, three distinct work-up approaches were employed.
(a) For xanthones 30–32: the solvent was evaporated under reduced pressure and the resulting
crude product was basified with sodium hydroxide (10 mL, 5%, m/v) and extracted with chloroform
(3 × 10 mL). The combined organic phases were then acidified and extracted with hydrochloric acid
5 M (3 × 30 mL). Afterwards, the aqueous phases were gathered and then basified with sodium
hydroxide (100 mL, 20%, m/v). The crude product was extracted successively with chloroform (3 ×
100 mL). The organic layers were gathered and dried over anhydrous sodium sulfate. After filtration,
the solution was concentrated under reduced pressure, and the resulting crude product was purified
by flash cartridge chromatography (SiO2, chloroform/acetone/ammonium hydroxide, 90:10:1) to afford
the xanthones 30, 31, and 32 as pure compounds.
For 3,4-dimethoxy-1-(((2-morpholinoethyl)amino)methyl)-9H-xanthen-9-one (30): Green powder
(35 mg, 62% yield); m.p. 125–126 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.25 (1H, dd, J = 8.0 and
1.6 Hz, H-8), 7.72 (1H, ddd, J = 8.1, 7.0, and 1.6 Hz, H-6), 7.57 (1H, dd, J = 8.4 and 0.8 Hz, H-5), 7.38 (1H,
ddd, J = 8.0, 7.1, and 0.9 Hz, H-7), 7.09 (1H, s, H-2), 4.34 (2H, s, H-1′); 4.04 (3H, s, 4-OCH3), 4.01 (3H,
s, 3-OCH3), 3.66 (4H, t, J = 4.6 Hz, H-5′), 2.90 (2H, t, J = 6.1 Hz, H-2′), 2.60 (2H, t, J = 6.1 Hz, H-3′),
2.47 (4H, t, J = 4.3 Hz, H-4′) ppm; 13C-NMR (CDCl3, 75.47 MHz): δ = 178.0 (C-9), 156.5 (C-3), 155.3
(C-10a), 152.1 (C-4a), 137.0 (C-1), 136.0 (C-4), 134.6 (C-6), 126.5 (C-8), 124.1 (C-7), 122.1 (C-8a), 117.7
(C-5), 114.6 (C-9a), 111.6 (C-2), 67.0 (C-5′), 61.5 (4-OCH3), 57.4 (C-2′), 56.4 (3-OCH3), 53.7 (C-1′), 53.5
(C-4′), 45.3 (C-3′) ppm. HRMS (ESI+): m/z [C22H26N2O5 + H]+ calcd. for [C22H27N2O5]: 399.19145;
found: 399.19060.
For 1-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (31):
White powder (35 mg, 65% yield); m.p. 84–85 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.25 (1H, dd,
J = 8.0 and 1.6 Hz, H-8), 7.69 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.54 (1H, dd, J= 7.4 and 0.7, H-5),
7.53 (1H, s, H-2), 7.35 (1H, ddd, J = 8.0, 7.1, and 1.0 Hz, H-7), 4.36 (2H, s, H-1′); 4.05 (3H, s, 4-OCH3),
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4.02 (3H, s, 3-OCH3), 2.65 (2H, t, J = 7.2 Hz, H-3′), 2.44 (2H, t, J = 7.5 Hz, H-5′), 2.39 (3H, s, H-2′),
2.28 (6H, s, H-6′), 1.82 (2H, m, J = 7.3 Hz, H-4′) ppm; 13C-NMR (CDCl3, 75.47 MHz): δ = 178.1 (C-9),
156.6 (C-3), 155.2 (C-10a), 151.9 (C-4a), 135.2 (C-1), 135.0 (C-4), 134.2 (C-6), 126.6 (C-8), 123.9 (C-7),
122.4 (C-8a), 117.6 (C-5), 114.5 (C-9a), 109.0 (C-2), 61.5 (4-OCH3), 60.1 (C-1′), 57.8 (C-5′), 56.4 (3-OCH3),
56.1 (C-3′), 45.3 (C-6′), 42.5 (C-2′), 25.3 (C-4′) ppm. HRMS (ESI+): m/z [C22H28N2O4 +H]+ calcd. for
[C22H29N2O4]: 385.21218; found: 385.21139.
For 1-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one (32): Yellow
powder (40 mg, 71% yield); m.p. 129–130 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.25 (1H, dd, J = 8.0
and 1.6 Hz, H-8), 7.68 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.53 (1H, dd, J = 8.4 and 0.7 Hz, H-5), 7.48
(1H, s, H-2), 7.35 (1H, ddd, J = 8.0, 7.1, and 1.0 Hz, H-7), 4.32 (2H, s, H-1′), 4.03 (3H, s, 4-OCH3), 4.01
(3H, s, 3-OCH3), 3.63 (2H, t, J = 5.4 Hz), 2.58 (2H, t, J = 5.4 Hz) ppm; 13C-NMR (CDCl3, 75.47 MHz): δ
= 178.1 (C-9), 156.5 (C-3), 155.2 (C-10a), 152.0 (C-4a), 138.8 (C-1), 134.8 (C-4), 134.2 (C-6), 126.6 (C-8),
123.9 (C-7), 122.5 (C-8a), 117.5 (C-5), 114.6 (C-9a), 108.2 (C-2), 61.5 (4-OCH3), 60.2 (C-1′), 59.3 (C-5′),
57.7 (C-4′), 56.2 (3-OCH3), 53.5 (C-3′), 53.2 (C-2′) ppm. HRMS (ESI+): m/z [C22H26N2O5 +H]+ calcd.
for [C22H27N2O5]: 399.19145; found: 399.19059.
(b) For xanthones 33–36: the solvent was evaporated under reduced pressure and the crude
product was extracted with chloroform (3 × 10 mL). The organic phases were gathered, dried over
anhydrous sodium sulfate, and after filtration, the resulting solution was concentrated under reduced
pressure. Then, a solid phase extraction using a cation exchange cartridge Discovery® DSC-SCX was
applied to further purify the crude product. Initially, an activation of the cartridge with methanol
(100 mL) was carried out followed by loading the cartridge with the sample. Then, the elution was
performed with the following solvents/solutions: (i) dichloromethane/methanol (5:5), (ii) methanol, and
(iii) ammonium hydroxide/methanol (2%, v/v). The fractions obtained from the elution with ammonium
hydroxide/methanol (2%, v/v) were gathered and the solvent was evaporated under reduced pressure.
A flash cartridge chromatography with chloroform/acetone/ammonium hydroxide (90:10:1) was also
performed to obtain the xanthones 33, 34, 35, and 36 as pure compounds.
For 1-(((2-(diethylamino)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (33): Green
powder (28 mg, 52% yield); m.p. 68–69 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.27 (1H, dd, J
= 8.0 and 1.4 Hz, H-8), 7.71 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.56 (1H, dd, J = 8.4 and 0.7 Hz, H-5),
7.37 (1H, ddd, J = 8.0, 7.1, and 1.0 Hz, H-7), 7.14 (1H, s, H-2), 4.39 (2H, s, H-1′); 4.05 (3H, s, 4-OCH3),
4.01 (3H, s, 3-OCH3), 2.87 (2H, t, J = 6.4 Hz, H-2′), 2.68 (2H, t, J = 6.4 Hz, H-3′), 2.55 (4H, m, J = 7.1
Hz, H-4′), 1.01 (6H, t, J = 7.1 Hz, H-5′) ppm; 13C-NMR (CDCl3, 75.47 MHz): δ = 178.1 (C-9), 156.5
(C-3), 155.3 (C-10a), 152.1 (C-4a), 137.4 (C-1), 135.8 (C-4), 134.5 (C-6), 126.6 (C-8), 124.0 (C-7), 122.2
(C-8a), 117.7 (C-5), 114.5 (C-9a), 111.1 (C-2), 61.5 (4-OCH3), 56.4 (3-OCH3), 53.4 (C-3′), 52.4 (C-1′), 46.9
(C-4′), 46.8 (C-2′), 11.6 (C-5′) ppm. HRMS (ESI+): m/z [C22H28N2O4 +H]+ calcd. for [C22H29N2O4]:
385.21218; found: 385.21150.
For 4-((3,4-dimethoxy-9-oxo-9H-xanthen-1-yl)methyl)piperazin-2-one (34): Orange powder
(20 mg, 39% yield); m.p. 245–247 ◦C. 1H-NMR (DMSO-d6, 300.13 MHz): δ = 8.13 (1H, dd, J =
8.0 and 1.5 Hz, H-8), 7.82 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.65 (1H, dd, J = 8.4 and 0.6, H-5),
7.45 (1H, ddd, J = 8.0, 7.1, and 1.0 Hz, H-7), 7.36 (1H, s, H-2), 4.24 (2H, s, H-1′); 3.98 (3H, s, 4-OCH3),
3.90 (3H, s, 3-OCH3), 3.20 (2H, t, J = 5.3 Hz, H-5′), 3.13 (2H, s, H-2′), 2.66 (2H, t, J = 5.3 Hz, H-4′) ppm;
13C-NMR (DMSO-d6, 75.47 MHz): δ = 176.7 (C-9), 168.0 (C-3′), 156.2 (C-3), 154.6 (C-10a), 151.8 (C-4a),
136.9 (C-1), 135.0 (C-4), 134.7 (C-6), 126.1 (C-8), 124.3 (C-7), 121.8 (C-8a), 117.7 (C-5), 113.7 (C-9a), 109.2
(C-2), 60.9 (4-OCH3), 58.5 (C-1′), 57.2 (C-5′), 56.3 (3-OCH3), 48.7 (C-2′), 30.7 (C-4′) ppm. HRMS (ESI+):
m/z [C20H20N2O5 + H]+ calcd. for [C20H21N2O5]: 369.14450; found: 369.14369.
For 1-((5-amino-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one (35):
White powder (23 mg, 39% yield); m.p. 171–172 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.26 (1H, dd,
J = 8.0 and 1.4 Hz, H-8), 7.69 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.57 (1H, s, H-2), 7.54 (1H, dd, J =
8.4 and 0.7 Hz, H-5), 7.35 (1H, ddd, J = 8.0, 7.1, and 1.0 Hz, H-7), 6.99 (1H, t, J = 7.7 Hz, H-7′), 6.57
(1H, d, J = 7.8 Hz, H-6′), 6.53 (1H, d, J = 7.6 Hz, H-8′), 4.48 (2H, s, H-1′); 4.02 (3H, s, 4-OCH3), 3.97
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(3H, s, 3-OCH3), 3.81 (2H, s, H-10′), 2.93 (2H, t, J = 5.9 Hz, H-2′), 2.66 (2H, t, J = 5.9 Hz, H-3′) ppm;
13C-NMR (CDCl3, 75.47 MHz): δ = 178.2 (C-9), 156.7 (C-3), 155.2 (C-10a), 151.9 (C-4a), 144.1 (C-5′),
139.3 (C-1), 136.3 (C-9′), 134.8 (C-4), 134.2 (C-6), 126.6 (C-8), 126.4 (C-7′), 123.8 (C-7), 122.5 (C-8a), 119.5
(C-4′), 117.6 (C-5), 117.1 (C-8′), 114.5 (C-9a), 112.7 (C-6′), 108.0 (C-2), 61.5 (4-OCH3), 60.1 (C-1′), 56.7
(C-10′), 56.3 (3-OCH3), 51.0 (C-2′), 24.9 (C-3′) ppm. HRMS (ESI+): m/z [C25H24N2O4 +H]+ calcd. for
[C25H25N2O4]: 417.18088; found: 417.18018.
For 3,4-dimethoxy-1-(piperidin-1-ylmethyl)-9H-xanthen-9-one (36): Yellow powder (31 mg, 62%
yield); m.p. 108-109 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.25 (1H, dd, J = 8.0 and 1.6 Hz, H-8), 7.66
(1H, ddd, J = 8.5, 8.0, and 1.6 Hz, H-6), 7.56 (1H, s, H-2), 7.52 (1H, dd, J = 8.3 and 0.7 Hz, H-5), 7.33 (1H,
ddd, J = 7.9, 7.1, and 0.9 Hz, H-7), 4.26 (2H, s, H-1′); 4.03 (3H, s, 4-OCH3), 4.01 (3H, s, 3-OCH3), 2.57 (4H,
t, J = 4.6 Hz, H-2′), 1.65 (4H, m, J = 5.5 Hz, H-3′), 1,50 (2H, m, J = 5.5 Hz, H-4′) ppm; 13C-NMR (CDCl3,
75.47 MHz) ppm: δ = 177.5 (C-9), 156.1 (C-3), 154.7 (C-10a), 151.3 (C-4a), 138.9 (C-4), 134.2 (C-1), 133.8
(C-6), 126.0 (C-8), 123.3 (C-7), 121.9 (C-8a), 117.1 (C-5), 113.9 (C-9a), 107.8 (C-2), 60.8 (4-OCH3), 56.1
(3-OCH3), 55.7 (C-2′), 54.3 (C-1′), 25.7 (C-3′), 23.8 (C-4′) ppm. HRMS (ESI+): m/z [C21H23NO4 +H]+
calcd. for [C21H24NO4]: 354.16998; found: 354.16939.
(c) For xanthones 37–40: the solvent was evaporated under reduced pressure and the resulting
crude product was basified with sodium hydroxide (10 mL, 5%, m/v) and extracted with chloroform
(3 × 10 mL). The combined organic phases were then acidified and extracted with hydrochloric acid
5 M (3 × 30 mL). The resulting organic phase was dried over anhydrous sodium sulfate and, after
filtration, the solution was concentrated under reduced pressure. Then, a solid phase extraction using
a cation exchange cartridge Discovery® DSC-SCX was applied to further purify the crude product.
Initially, an activation of the cartridge with methanol (100 mL) was carried out followed by loading the
cartridge with the sample. Then, the elution was performed with the following solvents/solutions:
(i) dichloromethane/methanol (5:5), (ii) methanol, and (iii) ammonium hydroxide/methanol (2%, v/v).
The fractions obtained from the elution with ammonium hydroxide/methanol (2%, v/v) were gathered
and the solvent was evaporated under reduced pressure to furnish the xanthones 37, 38, 39, and 40 as
pure compounds.
For 1-(((4-fluorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (37): White powder,
(34 mg, 61% yield); m.p. 163–165 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.28 (1H, dd, J = 8.0 and
1.6 Hz, H-8), 7.71 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.55 (1H, dd, J = 8.5 and 0.8 Hz, H-5), 7.40
(1H, ddd, J = 8.0, 7.0, and 0.8 Hz, H-7), 7.36 (2H, m, H-5′), 7.01 (2H, m, H-4′), 6.96 (1H, s, H-2), 4.30
(2H, s, H-1′), 4.01 (3H, s, 4-OCH3), 4.01 (3H, s, 3-OCH3), 3.85 (2H, s, H-2′) ppm; 13C-NMR (CDCl3,
75.47 MHz): δ = 178.1 (C-9), 160.3 (C-6′), 156.3 (C-3), 155.3 (C-10a), 152.2 (C-4a), 138.6 (C-4), 135.9
(C-3′), 135.7 (C-1), 134.5 (C-6), 129.8 (C-5′), 126.7 (C-8), 124.0 (C-7), 122.2 (C-8a), 117.7 (C-5), 115.3 (C-4′),
114.7 (C-9a), 110.9 (C-2), 61.5 (4-OCH3), 56.3 (3-OCH3), 53.3 (C-1′), 52.5 (C-2′) ppm. HRMS (ESI+): m/z
[C23H20FNO4 + H]+ calcd. for [C23H21FNO4]: 394.14491; found: 394.14410.
For 1-(((4-chlorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (38): Light yellow
powder (35 mg, 61% yield); m.p. 162–163 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.25 (1H, dd,
J = 8.0 and 1.6 Hz, H-8), 7.79 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.66 (2H, m, H-5′), 7.60 (1H, dd, J
= 8.5 and 0.9 Hz, H-5), 7.43 (1H, ddd, J = 8.0, 7.0, and 0.9 Hz, H-7), 7.39 (1H, s, H-2), 7.38 (2H, m, H-4′),
4.53 (2H, s, H-2′); 4.33 (2H, s, H-1′), 4.07 (3H, s, 4-OCH3), 4.01 (3H, s, 3-OCH3) ppm; 13C-NMR (CDCl3,
75.47 MHz): δ = 179.6 (C-9), 157.0 (C-3), 155.5 (C-10a), 152.0 (C-4a), 137.7 (C-4), 135.8 (C-1), 135.6 (C-6),
131.7 (C-5′), 129.5 (C-4′), 129.4 (C-3′), 127.3 (C-6′), 126.6 (C-8), 124.6 (C-7), 121.3 (C-8a), 117.9 (C-5),
115.5 (C-2), 114.8 (C-9a), 61.6 (4-OCH3), 57.1 (3-OCH3), 51.3 (C-1′), 50.7 (C-2′) ppm. HRMS (ESI+): m/z
[C23H20ClNO4 + H]+ calcd. for [C23H21ClNO4]: 410.11536; found: 410.11466.
For (R)-1-(((1-(4-chlorophenyl)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (39): White
powder (39 mg, 65% yield); m.p. 163–164 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.26 (1H, dd, J =
8.0 and 1.6 Hz, H-8), 7.79 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.70 (2H, m, H-6′), 7.59 (1H, dd,
J = 8.5 and 0.8 Hz, H-5), 7.43 (1H, ddd, J = 8.0, 7.0, and 0.8 Hz, H-7), 7.42 (2H, m, H-5′), 7.25 (1H,
s, H-2), 4.54 (2H, s, H-1′); 4.27 (1H, q, J = 6.8 Hz, H-1′), 4.04 (3H, s, 4-OCH3), 4.01 (3H, s, 3-OCH3),
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1.83 (3H, d, J = 6.8 Hz, H-3′) ppm; 13C-NMR (CDCl3, 75.47 MHz): δ = 179.6 (C-9), 156.8 (C-3), 155.4
(C-10a), 151.9 (C-4a), 137.6 (C-4), 135.5 (C-6), 134.5 (C-1), 131.8 (C-7′), 129.8 (C-6′), 129.5 (C-5′), 127.3
(C-4′), 126.6 (C-8), 124.6 (C-7), 121.3 (C-8a), 117.9 (C-5), 115.6 (C-2), 114.9 (C-9a), 61.6 (4-OCH3), 58.9
(C-2′), 57.0 (3-OCH3), 50.2 (C-1′), 20.2 (C-3′) ppm. HRMS (ESI+): m/z [C24H22ClNO4 +H]+ calcd. for
[C24H23ClNO4]: 424.13101; found: 424.13018.
For 1-(((4-bromobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (40): White powder
(47 mg, 73% yield); m.p. 161–162 ◦C. 1H-NMR (CDCl3, 300.13 MHz): δ = 8.27 (1H, dd, J = 8.0 and
1.6 Hz, H-8), 7.73 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.58 (1H, dd, J = 8.5 and 0.8 Hz, H-5), 7.48
(2H, m, H-5′), 7.39 (2H, m, H-4′), 7.38 (1H, ddd, J = 8.0, 7.0, and 0.8 Hz, H-7), 7.08 (1H, s, H-2), 4.31
(2H, s, H-1′); 4.01 (3H, s, 4-OCH3), 4.01 (3H, s, 3-OCH3), 3.88 (2H, s, H-2′) ppm; 13C-NMR (CDCl3,
75.47 MHz): δ = 178.6 (C-9), 156.5 (C-3), 155.3 (C-10a), 152.2 (C-4a), 136.4 (C-4), 136.2 (C-1), 134.9 (C-6),
131.8 (C-5′), 130.7 (C-4′), 128.4 (C-3′), 126.6 (C-8), 124.2 (C-7), 121.9 (C-8a), 121.8 (C-6′), 117.7 (C-5),
114.7 (C-9a), 112.5 (C-2), 61.6 (4-OCH3), 56.7 (3-OCH3), 52.7 (C-1′), 52.0 (C-2′) ppm. HRMS (ESI+): m/z
[C23H20BrNO4 + H]+ calcd. for [C23H21BrNO4]: 454.06485; found: 454.06385.
3.2. Biological Evaluation
3.2.1. Yeast Strains and Growth Conditions
For the yeast assay, the previously obtained Saccharomyces cerevisiae cells co-expressing human
p53 or human MDM2, as well as yeast control (transformed with empty vectors) [30,31], were used.
To induce expression of human proteins, yeast cells were grown in selective induction medium with 2%
(w/w) galactose and 2% (w/w) raffinose, in the presence of 1–20 μM of xanthones 30–40 or 0.1% DMSO,
at 30 ◦C under continuous orbital shaking (200 rpm) for approximately 42 h, as described [30,31].
Yeast cell growth was analyzed by counting the number of colony-forming units (CFU) after 2 days
incubation at 30 ◦C on Sabouraud Dextrose Agar plates from Liofilchem (Frilabo, Porto, Portugal).
Results were estimated considering 100% growth as the number of CFU obtained with untreated yeast
co-expressing p53 and MDM2.
3.2.2. Human Cancer Cell Lines and Culture Conditions
Human colon adenocarcinoma HCT116 cell lines expressing wt p53 (HCT116 p53+/+) and its
p53-null isogenic derivative (HCT116 p53−/−) were provided by B. Vogelstein (The Johns Hopkins
Kimmel Cancer Center, Baltimore, MD, USA). Human liver HepG2 carcinoma cell lines were
purchased from ATCC (Rockville, MD, USA). Cancer cells were cultured in RPMI-1640 medium
with ultraglutamine (Lonza, VWR, Carnaxide, Portugal), and supplemented with 10% fetal bovine
serum (FBS; Merck Millipore, VWR). Cells were maintained at 37 ◦C in a humidified atmosphere of
5% CO2.
3.2.3. Cell Proliferation Assay
Cell proliferation was determined using the SRB assay, as described [30,31]. Briefly, cells were
seeded in 96-well plates at 5.0 × 103 cells/well for HCT116 p53+/+ cells and 4.0 × 103 cells/well for
HepG2 and 24 h later treated with serial dilutions (3.13–50 μM) of xanthone 37 or 0.25% DMSO for 48
h. IC50 values were determined from the concentration-response curves.
3.2.4. Colony Formation Assay
HCT116 p53+/+ and HCT116 p53−/− cells were seeded in a 6-well plate at 1.0 × 103 cells/well
and treated with 3, 4, 5, 7, and 10 μM of xanthone 37 or DMSO at the time of seeding. After 11 days
incubation, colonies were fixed using 10% of methanol and 10% acetic acid for 10 min and stained with
0.5% crystal violet (Sigma-Aldrich) in 1:1 methanol/water for 15 min. Colonies with more than 20 cells
were counted.
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3.2.5. Cell Cycle Analysis
HCT116 p53+/+ and HCT116 p53−/− cells were seeded in a 6-well plate at 1.5 × 105 cells/well for
24 h and treated with 10 and 20 μM of xanthone 37 or DMSO for 24 h. Cells were collected, fixed, and
stained with propidium iodide (Fluka, Sigma-Aldrich). Cell cycle was analyzed by flow cytometry, as
described [45].
3.2.6. Western Blot Analysis
HCT116 p53+/+ were seeded in a 6-well plate at 1.5 × 105 cells/well for 24 h and treated with 10 and
20μM of xanthone 37 or DMSO for 24 h. Total protein extracts of cancer cells were obtained and analyzed
by Western blot, as described [45]. Membranes were probed with a mouse monoclonal anti-p53 (DO-1),
anti-MDM2 (D-12), or with a rabbit polyclonal anti-p21 (C-19), followed by an anti-mouse or anti-rabbit
horseradish-peroxidase (HRP)-conjugated secondary antibody. For loading control, membranes were
stripped and re-probed with mouse monoclonal anti-GAPDH (6C5). All antibodies were purchased
from Santa Cruz Biotechnology (Frilabo, Porto, Portugal). The signal was detected with enhanced
chemiluminescence (ECL) Amersham Kit from GE Healthcare (VWR) and with Molecular Imager®
ChemiDoc™ XRS+ System, using Image Lab™ software.
3.2.7. Statistical Analysis
Data’s statistical analysis was performed using the Prism 7 program (GraphPad Software Inc.,
California, USA). Differences between means were tested for significance using one-way ANOVA with
Tukey’s multiple comparisons test, two-way ANOVA with Sidak’s multiple comparisons test, and
Student’s t-test (* p < 0.05; ** p < 0.01).
3.3. In Silico Studies onto MDM2
The chemical structures of gambogic acid (2), α-mangostin (3), 12-hydroxy-2,2-dimethyl-3,4-
dihydro-2H,6H-pyrano[3,2-b]xanthen-6-one (4), and the xanthones 30–40 were drawn using
ChemSketch (Advanced Chemistry Development, Inc. (ACD/Labs), Canada); the structure of known
MDM2-p53 inhibitor nutlin-3A (1) was obtained from PubChem [53]. The three-dimensional (3D)
structures of the xanthones and 1 were minimized using the ArgusLab version 4.0.1 software for
Windows by Hamiltonian (quantum mechanics) using the Parameterized Model number 3 (PM3)
semi-empirical method [54]. The 3D structure of MDM2 was extracted from Protein Data Bank (PDB
id 4HG7) [50]. Docking simulations involving MDM2 and the small molecules were undertaken in
AutoDock Vina (Scripps Research Institute, USA) [51]. AutoDock Vina considered the macromolecular
target conformation as a rigid unit, while the ligands were allowed to be flexible and adaptable
to the target. Vina explored the lowest binding affinity conformations and returned nine different
conformations for each ligand. AutoDock Vina was run using an exhaustiveness of 8 and a grid
box with the dimensions of 19.7 Å, 26.1 Å, and 14.1 Å, engulfing the binding cavity occupied by the
crystallographic nutlin-3A (PDB id 4HG7). Ligand conformations and interactions with the binding
cavity were visualized using PyMOL version 1.3 [55]. In order to validate the docking approach for
the macromolecular target structure used, nutlin-3A was docked onto the binding cavity of MDM2
using AutoDock Vina, and the obtained docking conformation was compared to crystallographic
nutlin-3A (PDB id 4HG7) using RMSD (not shown). Docking scores of xanthones and positive controls
were compared.
4. Conclusions
An alternative and efficient strategy for the preparation of carbaldehydic xanthones was
successfully developed. The use of a precursor with a methyl substituent at position C-1 revealed to be
crucial for the optimization of the synthesis of 5. The newly described approach required lower reaction
times and enabled the preparation of xanthone 5 in a higher global yield. In this work, a series of eleven
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aminated xanthones (30–40) possessing a 3,4-dioxygenated pattern of substitution was efficiently
constructed in moderate to good yields. From this group of compounds, xanthone 37 was identified
for the first time as a putative p53-activating agent, using a yeast-based screening assay. Xanthone 37
was revealed to inhibit the growth of human HCT116 p53+/+ colon cancer cells, being that this effect is
associated with cell cycle arrest through activation of the p53 pathway. Nevertheless, further studies
are required to confirm the mechanism of action of 37, which may lead to the identification of a novel
xanthone derivative with promising antitumor activity.
These results demonstrated the potential usefulness of coupling amine-containing structural motifs
of known MDM2-p53 disruptors into the 3,4-dioxygenated xanthone scaffold as a starting point for the
design of novel and improved p53-activating agents with antitumor activity and drug-like properties.
Supplementary Materials: The following are available online. Figure S1–S15: HRMS spectra of the xanthone
derivatives 5 and 27–40. Figure S16–S45: 1H- and 13C-NMR spectra of the xanthone derivatives 5 and 27–40.
Author Contributions: A.L. performed the in silico studies and the synthesis of xanthones and wrote the
manuscript. A.L., A.S.G., and J.B.L. performed biological experiments and analyzed the data. P.B. contributed to
the experimental synthetic work. M.E.S. and L.S. conceived and designed the study, coordinated the experimental
work, and wrote the manuscript. A.P. coordinated the in silico studies. M.M.M.P., M.E.S., and L.S. provided
financial support for the study, analyzed the data, and wrote the manuscript.
Funding: The authors thank to national funds provided by FCT—Foundation for Science and Technology and
European Regional Development Fund (ERDF) and COMPETE under the Strategic Funding UID/Multi/
04423/2019, UID/QUI/50006/2019 (UCIBIO/REQUIMTE) the projects (3599-PPCDT) PTDC/DTP-FTO/1981/2014—
POCI-01-0145-FEDER-016581, POCI-01-0145-FEDER-028736, and PTDC/MAR-BIO/4694/2014 (POCI-01-0145-
FEDER-016790; 3599-PPCDT). FCT fellowships: PD/BD/114046/2015 (A.S. Gomes), SFRH/BD/128673/2017 (J. B.
Loureiro), and the Programa Operacional Capital Humano (POCH), specifically the BiotechHealth Programme
(PD/00016/2012).
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Lane, D.P. Cancer. p53, guardian of the genome. Nature 1992, 358, 15–16. [CrossRef]
2. Shaw, P.H. The role of p53 in cell cycle regulation. Pathol. Res. Pract. 1996, 192, 669–675. [CrossRef]
3. Toledo, F.; Wahl, G.M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer
2006, 6, 909–923. [CrossRef] [PubMed]
4. Vazquez, A.; Bond, E.E.; Levine, A.J.; Bond, G.L. The genetics of the p53 pathway, apoptosis and cancer
therapy. Nat. Rev. Drug Discov. 2008, 7, 979–987. [CrossRef] [PubMed]
5. Rufini, A.; Tucci, P.; Celardo, I.; Melino, G. Senescence and aging: The critical roles of p53. Oncogene 2013, 32,
5129–5143. [CrossRef] [PubMed]
6. Williams, A.B.; Schumacher, B. p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med.
2016, 6, a026070. [CrossRef]
7. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature (London, U.K.) 2000, 408, 307–310.
[CrossRef] [PubMed]
8. Hainaut, P.; Hollstein, M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res. 1999,
77, 81–137.
9. Wang, X. p53 regulation: Teamwork between RING domains of MDM2 and MDMX. Cell Cycle 2011, 10,
4225–4229. [CrossRef] [PubMed]
10. Wu, X.; Bayle, J.H.; Olson, D.; Levine, A.J. The p53-MDM2 autoregulatory feedback loop. Genes Dev. 1993, 7,
1126–1132. [CrossRef] [PubMed]
11. Momand, J.; Wu, H.H.; Dasgupta, G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene
2000, 242, 15–29. [CrossRef]
12. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The MDM2 oncogene product forms a
complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237–1245. [CrossRef]
13. Oliner, J.D.; Pietenpol, J.A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K.W.; Vogelstein, B. Oncoprotein MDM2
conceals the activation domain of tumor supressor p53. Nature (London, U.K.) 1993, 362, 857–860. [CrossRef]
239
Molecules 2019, 24, 1975
14. Roth, J.; Dobbelstein, M.; Freedman, D.A.; Shenk, T.; Levine, A.J. Nucleo-cytoplasmic shuttling of the HDM2
oncoprotein regulated the levels of the p53 protein via a pathway used by the human immunodeficiency
vírus ver protein. EMBO J. 1998, 17, 554–564. [CrossRef]
15. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. MDM2 promotes the rapid degradation of p53. Nature 1997, 387,
296–299. [CrossRef] [PubMed]
16. Pant, V.; Lozano, G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 2014,
28, 1739–1751. [CrossRef] [PubMed]
17. Zhao, Y.; Aguilar, A.; Bernard, D.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein
interaction (MDM2 inhibitors) in clinical trials for cancer treatment: Miniperspective. J. Med. Chem. 2014, 58,
1038–1052. [CrossRef] [PubMed]
18. Wang, S.; Zhao, Y.; Aguilar, A.; Bernard, D.; Yang, C.Y. Targeting the MDM2-p53 protein-protein interaction
for new cancer therapy: Progress and challenges. Cold Spring Harb. Perspect. Med. 2017, 7, a026245.
[CrossRef]
19. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.;
Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of
MDM2. Science 2004, 303, 844–848. [CrossRef]
20. Lemos, A.; Leão, M.; Soares, J.; Palmeira, A.; Pinto, M.; Saraiva, L.; Sousa, M.E. Medicinal chemistry strategies
to disrupt p53-MDM2/MDMX interaction. Med. Res. Rev. 2016, 36, 789–844. [CrossRef]
21. Tisato, V.; Voltan, R.; Gonelli, A.; Secchiero, P.; Zauli, G. MDM2/X inhibitors under clinical evaluation:
Perspectives for the management of hematological malignancies and pediatric cancer. J. Hematol. Oncol.
2017, 10, 133. [CrossRef] [PubMed]
22. Pinto, M.M.M.; Sousa, M.E.; Nascimento, M.S. Xanthone derivatives: New insights in biological activities.
Curr. Med. Chem. 2005, 12, 2517–2538. [CrossRef] [PubMed]
23. Pouli, N.; Marakos, P. Fused xanthone derivatives as antiproliferative agents. Anticancer Agents Med. Chem.
2009, 9, 77–98. [CrossRef]
24. Pedro, M.; Cerqueira, F.; Sousa, M.E.; Nascimento, M.S.J.; Pinto, M. Xanthones as inhibitors of growth of
human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg. Med.
Chem. 2002, 10, 3725–3730. [CrossRef]
25. Sousa, E.P.; Silva, A.M.S.; Pinto, M.M.M.; Pedro, M.M.; Cerqueira, F.A.M.; Nascimento, M.S.J. Isomeric
kielcorins and dihydroxyxanthones: Synthesis, structure elucidation, and inhibitory activities of growth of
human cancer cell lines and on the proliferation of human lymphocytes in vitro. Helv. Chim. Acta 2002, 85,
2862–2876. [CrossRef]
26. Castanheiro, R.A.; Pinto, M.M.; Silva, A.M.; Cravo, S.M.; Gales, L.; Damas, A.M.; Nazareth, N.;
Nascimento, M.S.J.; Eaton, G. Dihydroxyxanthones prenylated derivatives: Synthesis, structure elucidation,
and growth inhibitory activity on human tumor cell lines with improvement of selectivity for MCF-7. Bioorg.
Med. Chem. 2007, 15, 6080–6088. [CrossRef]
27. Sousa, E.; Paiva, A.; Nazareth, N.; Gales, L.; Damas, A.M.; Nascimento, M.S.J.; Pinto, M. Bromoalkoxyxanthones
as promising antitumor agents: Synthesis, crystal structure and effect on human tumor cell lines. Eur. J.
Med. Chem. 2009, 44, 3830–3835. [CrossRef]
28. Palmeira, A.; Paiva, A.; Sousa, E.; Seca, H.; Almeida, G.M.; Lima, R.T.; Fernandes, M.X.; Pinto, M.;
Vasconcelos, M.H. Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone.
Chem. Biol. Drug Des. 2010, 76, 43–58. [CrossRef]
29. Paiva, A.M.; Sousa, M.E.; Camoes, A.; Nascimento, M.S.J.; Pinto, M.M.M. Prenylated xanthones:
Antiproliferative effects and enhancement of the growth inhibitory action of 4-hydroxytamoxifen in estrogen
receptor-positive breast cancer cell line. Med. Chem. Res. 2012, 21, 552–558. [CrossRef]
30. Leão, M.; Gomes, S.; Pedraza-Chaverri, J.; Machado, N.; Sousa, E.; Pinto, M.; Inga, A.; Pereira, C.; Saraiva, L.
α-Mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast-based
approach. J. Nat. Prod. 2013, 76, 774–778. [CrossRef]
31. Leão, M.; Pereira, C.; Bisio, A.; Ciribilli, Y.; Paiva, A.M.; Machado, N.; Palmeira, A.; Fernandes, M.X.; Sousa, E.;
Pinto, M.; Inga, A.; Saraiva, L. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a
yeast-based approach. Biochem. Pharmacol. 2013, 85, 1234–1245. [CrossRef]
240
Molecules 2019, 24, 1975
32. Fernandes, C.; Masawang, K.; Tiritan, M.E.; Sousa, E.; de Lima, V.; Afonso, C.; Bousbaa, H.; Sudprasert, W.;
Pedro, M.; Pinto, M. New chiral derivatives of xanthones: Synthesis and investigation of enantioselectivity
as inhibitors of growth of human tumor cell lines. Bioorg. Med. Chem. 2014, 22, 1049–1062. [CrossRef]
33. Barbosa, J.; Lima, R.T.; Sousa, D.; Gomes, A.S.; Palmeira, A.; Seca, H.; Choosang, K.; Pakkong, P.; Bousbaa, H.;
Pinto, M.M.; et al. Screening a small library of xanthones for antitumor activity and identification of a hit
compound which induces apoptosis. Molecules 2016, 21, 81. [CrossRef]
34. Cidade, H.; Rocha, V.; Palmeira, A.; Marques, C.; Tiritan, M.E.; Ferreira, H.; Lobo, J.S.; Almeida, I.F.;
Sousa, M.E.; Pinto, M. In silico and in vitro antioxidant and cytotoxicity evaluation of oxygenated xanthone
derivatives. Arab. J. Chem. 2017. [CrossRef]
35. Alves, A.; Correia-da-Silva, M.; Nunes, C.; Campos, J.; Sousa, E.; Silva, P.M.A.; Bousbaa, H.; Rodrigues, F.;
Ferreira, D.; Costa, P.C.; et al. Discovery of a new xanthone against glioma: Synthesis and development of
(pro)liposome formulations. Molecules 2019, 24, 409. [CrossRef]
36. Gomes, S.; Raimundo, L.; Soares, J.; Loureiro, J.B.; Leão, M.; Ramos, H.; Monteiro, M.N.; Lemos, A.;
Moreira, J.; Pinto, M.; et al. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with
promising antitumor activity against neuroblastoma. Cancer Lett. 2019, 446, 90–102. [CrossRef]
37. Liu, J.; Zhou, F.; Zhang, L.; Wang, H.; Zhang, J.; Zhang, C.; Jiang, Z.; Li, Y.; Liu, Z.; Chen, H.
DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target
functions. Eur. J. Med. Chem. 2018, 143, 1768–1778. [CrossRef]
38. Hardcastle, I.R.; Liu, J.; Valeur, E.; Watson, A.; Ahmed, S.U.; Blackburn, T.J.; Bennaceur, K.; Clegg, W.;
Drummond, C.; Endicott, J.A.; et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53
protein-protein interaction: Structure-activity studies leading to improved potency. J. Med. Chem. 2011, 54,
1233–1243. [CrossRef]
39. Twarda-Ciapa, A.; Krzanik, S.; Kubica, K.; Guzik, K.; Labuzek, B.; Neochoritis, C.G.; Khoury, K.; Kowalska, K.;
Czub, M.; Dubin, G.; et al. 1,4,5-Trisubstituted imidazole-based p53-MDM2/MDMX antagonists with aliphatic
linkers for conjugation with biological carriers. J. Med. Chem. 2017, 60, 4234–4244. [CrossRef]
40. Gicquel, M.; Gomez, C.; Alvarez, M.C.G.; Pamlard, O.; Guérineau, V.; Jacquet, E.; Bignon, J.; Voituriez, A.;
Marinetti, A. Inhibition of p53-murine double minute 2 (MDM2) interactions with 3,3′-spirocyclopentene
oxindole derivatives. J. Med. Chem. 2018, 61, 9386–9392. [CrossRef]
41. Quillinan, A.J.; Schelnmann, F. Studies in the xanthone series. Part XII. A general synthesis of polyoxygenated
xanthones from benzophenone precursors. J. Chem. Soc. Perkin Trans. 1973, 1, 1329–1337. [CrossRef]
42. Resende, D.I.S.P.; Pereira-Terra, P.; Inácio, Â.S.; da Costa, P.M.; Pinto, E.; Sousa, E.; Pinto, M.M.M. Lichen
xanthones as models for new antifungal agents. Molecules 2018, 23, 2617. [CrossRef]
43. Martins, E.; Silva, V.; Lemos, A.; Palmeira, A.; Puthongking, P.; Sousa, E.; Rocha-Pereira, C.; Ghanem, C.I.;
Carmo, H.; Remião, F.; et al. Newly synthesized oxygenated xanthones as potential P-glycoprotein activators:
In vitro, ex vivo, and in silico studies. Molecules 2019, 24, 707. [CrossRef]
44. Soares, J.; Espadinha, M.; Raimundo, L.; Ramos, H.; Gomes, A.S.; Gomes, S.; Loureiro, J.B.; Inga, A.; Reis, F.;
Gomes, C.; et al. DIMP53-1: A novel small-molecule dual inhibitor of p53-MDM2/X interactions with
multifunctional p53-dependent anticancer properties. Mol. Oncol. 2017, 11, 612–627. [CrossRef]
45. Soares, J.; Pereira, N.A.; Monteiro, Â.; Leão, M.; Bessa, C.; dos Santos, D.J.; Raimundo, L.; Queiroz, G.;
Bisio, A.; Inga, A.; et al. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a
p53-pathway through potential inhibition of the p53-MDM2 interaction. Eur. J. Pharm. Sci. 2015, 66, 138–147.
[CrossRef]
46. Soares, J.; Raimundo, L.; Pereira, N.A.; dos Santos, D.J.; Pérez, M.; Queiroz, G.; Leão, M.; Santos, M.M.M.;
Saraiva, L. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of
p53 interaction with murine double minute proteins. Pharmacol. Res. 2015, 95–96, 42–52. [CrossRef]
47. Chen, L.; Yin, H.; Farooqi, B.; Sebti, S.; Hamilton, A.D.; Chen, J. p53 α-helix mimetics antagonize p53/MDM2
interaction and activate p53. Mol. Cancer Ther. 2005, 4, 1019–1025. [CrossRef]
48. Kalid, O.; Ben-Tal, N. Study of MDM2 binding to p53-analogues: Affinity, helicity, and applicability to drug
design. J. Chem. Inf. Model. 2009, 49, 865–876. [CrossRef]
49. Kussie, P.H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A.J.; Pavletich, N.P. Structure of the
MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948–953.
[CrossRef]
241
Molecules 2019, 24, 1975
50. Anil, B.; Riedinger, C.; Endicott, J.A.; Nobie, M.E. The structure of an MDM2-nutlin-3a complex solved by
the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr. D Biol. Crystallogr. 2013, 69,
1358–1366. [CrossRef]
51. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and the accuracy of docking with a new scoring
function, efficient optimization and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef] [PubMed]
52. Bharatham, N.; Bharatham, K.; Shelat, A.A.; Bashford, D. Ligand binding mode prediction by docking:
MDM2/MDMX inhibitors as a case study. J. Chem. Inf. Model. 2014, 54, 648–659. [CrossRef] [PubMed]
53. Wang, Y.; Xiao, J.; Sujek, T.O.; Zhang, J.; Wang, J.; Bryant, S.H. PubChem: A public information system for
analyzing bioactivities of small molecules. Nucleic Acids Res. 2009, 37, 623–633. [CrossRef] [PubMed]
54. Kini, R.M.; Evans, H.J. Molecular modeling of proteins: A strategy for energy minimization by molecular
mechanics in the AMBER force field. J. Biomol. Struct. Dyn. 1991, 9, 475–488. [CrossRef] [PubMed]
55. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and AutoDock/Vina.
J. Comput. Aided Mol. Des. 2010, 24, 417–422. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 5, 16–40 are available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Design and Synthesis of Indoleamine
2,3-Dioxygenase 1 Inhibitors and Evaluation of Their
Use as Anti-Tumor Agents
Hui Wen †, Yuke Liu †, Shufang Wang, Ting Wang, Gang Zhang, Xiaoguang Chen, Yan Li,
Huaqing Cui, Fangfang Lai * and Li Sheng *
State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China;
wenhui@imm.ac.cn (H.W.); liuyuke@imm.ac.cn (Y.L.); wangshufang@imm.ac.cn (S.W.);
wangtingdlf@imm.ac.cn (T.W.); gzhang@imm.ac.cn (G.Z.); chxg@imm.ac.cn (X.C.);
yanli@imm.ac.cn (Y.L.); hcui@imm.ac.cn (H.C.)
* Correspondence: laifangfang@imm.ac.cn (F.L.); shengli@imm.ac.cn (L.S.);
Tel.: +86-10-63165185 (F.L.); Fax: +86-10-63017757 (F.L.)
† These two authors contributed equally to this paper.
Academic Editor: Qiao-Hong Chen
Received: 14 May 2019; Accepted: 4 June 2019; Published: 5 June 2019
Abstract: Indoleamine 2,3-dioxygenase (IDO) 1 is the key enzyme for regulating tryptophan
metabolism and is an important target for interrupting tumor immune escape. In this study,
we designed four series of compounds as potential IDO1 inhibitors by attaching various fragments
or ligands to indole or phenylimidazole scaffolds to improve binding to IDO1. The compounds
were synthesized and their inhibitory activities against IDO1 and tryptophan 2,3-dioxygenase were
evaluated. The cytotoxicities of the compounds against two tumor cell lines were also determined.
Two compounds with a phenylimidazole scaffold (DX-03-12 and DX-03-13) showed potent IDO1
inhibition with IC50 values of 0.3–0.5 μM. These two IDO1 inhibitors showed low cell cytotoxicity,
which indicated that they may exert their anti-tumor effect via immune modulation. Compound
DX-03-12 was investigated further by determining the in vivo pharmacokinetic profile and anti-tumor
efficacy. The pharmacokinetic study revealed that DX-03-12 had satisfactory properties in mice, with
rapid absorption, moderate plasma clearance (∼36% of hepatic blood flow), acceptable half-life (∼4.6 h),
and high oral bioavailability (∼96%). Daily oral administration of 60 mg/kg of compound DX-03-12
decreased tumor growth by 72.2% after 19 days in a mouse melanoma cell B16-F10 xenograft model
compared with the untreated control. Moreover, there was no obvious weight loss in DX-03-12-treated
mice. In conclusion, compound DX-03-12 is a potent lead compound for developing IDO1 inhibitors
and anti-tumor agents.
Keywords: indoleamine 2,3-dioxygenase; inhibitor; anti-tumor; immune modulation;
tryptophan metabolism
1. Introduction
Tryptophan metabolism is an important pathway for cancer immunotherapy [1–3]. The accumulation
of tryptophan can activate T cells, and a decrease in tryptophan concentration affects the regular function of
T cells and interferes with the differentiation of naïve T cells. The accumulation of tryptophan metabolites,
such as l-kynurenine and other downstream kynurenines (3-hydroxykynurenine and 3-hydroxyanthranilic
acid), is toxic to T cells and induces T cell apoptosis. Thus, increasing tryptophan degradation inhibits the
immune response [4–6].
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Indoleamine 2,3-dioxygenase (IDO; E.C. 1.12.11.17) 1 is a monomeric 41 kDa enzyme that
contains heme and converts l-tryptophan to N-formylkynurenine in non-hepatic tissues [7].
Tryptophan 2,3-dioxygenase (TDO; E.C. 1.13.11.11) also catalyzes the degradation of l-tryptophan to
N-formylkynurenine [8]. However, these two enzymes are genetically distinct and have low sequence
homology [8].
IDO1 is an important enzyme in tryptophan metabolism and contributes to creating peripheral
immune tolerance by degrading l-tryptophan, which suppresses the function of T cells, and by
producing N-formylkynurenine, which inhibits T cells [8]. In addition, IDO1 can also trigger other
activators of anti-tumor immunity. Notably, IDO1 is overexpressed in a range of cancer tissues [4–6].
Thus, blocking the activity of IDO1 is a potential strategy for tumor immunotherapy.
The crystal structures of recombinant human IDO1 have been resolved [9,10], and biochemical
studies have revealed that the heme iron in the active site of IDO1 binding and forms adducts with
exogenous ligands including O2−, NO, CO, H2S, and CN− [9,11–14]. IDO1 tolerates various substrates,
whereas TDO has strict substrate specificity. This difference can be used to develop selective IDO1
inhibitors [8].
During the development of anti-tumor drugs, potent IDO1 inhibitors were discovered, and
intensive efforts have been made to develop potent IDO1/TDO inhibitors with various structural
scaffolds. Some typical examples of IDO1/TDO inhibitors are shown in Figure 1 [1,15–21]. The indole
and phenylimidazole scaffolds have produced several potent IDO1 inhibitors. For example, IDO1
inhibitors indoximod (pathway IC50 = 450 nM) and PF-0684003 (IDO1 IC50 = 410 nM) are indole
derivatives [13], and GDC-0919 (IDO1 IC50 = 13 nM) and AMCL-17g (IDO1 IC50 = 77 nM) are
phenylimidazole derivatives [20].
Figure 1. Reported IDO1 inhibitors. Indoximod and PF-0684003 have an indole scaffold and GDC-0919
and AMCL-17g have a phenylimidazole scaffold.
In this study, in the early stages of searching for new IDO1 inhibitors, we used indole and
phenylimidazole as the core scaffolds. Four series of compounds were designed with different
strategies. The compounds were synthesized and the IDO1/TDO inhibitory activities were determined.
The in vivo pharmacokinetic profile and anti-tumor efficacy of a potent IDO1 inhibitor were evaluated
to explore its potential as an anti-tumor agent.
2. Results and Discussion
2.1. Design Strategy for the Four Compound Series
Four series of compounds were designed (Figure 2) to explore the structure–activity relationship
(SAR). The SAR information was used for further optimization. Indole is derived from tryptophan
and phenylimidazole is an IDO1 inhibitor [18]. Thus, tryptophan and phenylimidazole fit into the
active site of IDO1, and they were selected as the core scaffolds for designing the inhibitors. As we
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mentioned in the introduction, several exogenous ligands including hydroxylamine, O2−, NO, CO,
H2S, and CN− were able to bind with the heme iron in the active site of IDO1 [9,11–14]. We attached
various fragments and ligands to these scaffolds to strengthen the binding to the active site of IDO1.
In series 1, several ligands, such as hydroxylamine and SO, that interact strongly with heme iron
were linked to the double bond of the indole scaffold. We hoped to observe a synergistic effect between
the ligand and the indole ring in the IDO1 binding. Series 2 was based on compound PF-0684003
(Figure 1), which is an IDO1 inhibitor developed by Pfizer. The structure of PF-0684003 co-crystalized
with IDO1 revealed that there was no interaction between PF-0684003 and the heme iron, which is
usually observed between other IDO1 inhibitors and IDO1 [13]. Thus, several potential heme binding
ligands, such as hydroxylamine and SO, were added to the structure of PF-0684003 to enhance the
inhibitory activity.
Phenylimidazole is a weak IDO1 inhibitor. Crystal structures have revealed that the imidazole
ring binds with the heme iron [18,19]. Thus, in series 3 and 4, we used phenylimidazole as the scaffold,
and we attached fragments to either the imidazole ring (series 3) or the phenyl ring (series 4). These
fragments were intended to improve the binding in the active site of IDO1 through various interactions,
such as hydrogen bonds and π–π interactions.
Figure 2. Design strategies of the four series of inhibitors. Because the parent compounds of series 1
and 2, indole and PF-0684003, respectively, do not interact with the heme iron, various heme binding
ligands were attached to the indole scaffold. The imidazole ring interacts with the heme iron, and thus
various fragments were attached to the phenyl ring in series 3 and the imidazole ring in series 4 to
strengthen the binding to the active site of IDO1.
2.2. Synthesis of Selected Compounds
Although the compounds were classified into four series for examining the SAR, the structural
diversity meant that they required a variety of synthetic routes. We describe representative synthetic
schemes for four compounds. Syntheses for all the compounds are included in the Experimental section.
Scheme 1 shows the synthesis of DX-02-05. In the presence of a Lewis acid, ethyl
5-fluoro-1H-indole-2-carboxylate underwent a condensation reaction with 1H-pyrrole-2,5-dione to yield
compound DX-02-03. Alcohol 1 was obtained by reducing DX-02-03, and then 1 was directly oxidized
with MnO2 to produce aldehyde 2. Aldehyde 2 was condensed with hydroxylamine hydrochloride to
245
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obtain compound DX-02-04. Finally, the double bond in DX-02-04 was reduced with NaBH3CN to
obtain compound DX-02-05.
Scheme 1. Synthesis of DX-02-05. (a) BF3-Et2O, ClCH2CH2Cl, yield = 55%; (b) LiAlH4, CH3OH,
yield = 86%; (c) MnO2, dry dichloromethane, yield = 91%; (d) hydroxylamine hydrochloride, DIPEA,
CH3OH, yield = 66%; (e) NaBH3CN, 12 N HCl, CH3OH, yield = 43%.
Scheme 2 shows the synthesis of DX-02-07. Sulfur substitution of 5-fluoroindolin-2-one
was performed with P2S5 to produce compound 3. Under basic conditions, compound 4 was
obtained through an SN2 substitution reaction with CH3I. A condensation reaction between 4 and
1H-pyrrole-2,5-dione was performed at 120 ◦C to obtain sulfide DX-02-06, which was oxidized to
racemic sulfoxide DX-02-07.
 
Scheme 2. Synthesis of DX-02-07. (a) P2S5, NaHCO3, dry tetrahydrofuran, yield = 75%; (b) CH3I,
K2CO3, acetone, yield = 83%; (c) 1H-pyrrole-2,5-dione, CH3CO2H, yield = 61%; (d) m-CPBA, dry
dichloromethane, yield = 35%.
Scheme 3 shows the synthesis of DX-03-12. First, the imidazole starting material was protected
with trityl chloride to avoid various side reactions. Compound 6 was obtained by the Suzuki–Miyaura
reaction with a boronic acid [22]. The methyl group was removed by BBr3 to expose the hydroxyl
group in compound 7. Compound 8 was prepared in parallel by melting 3-chloropropylamine and
isobenzofuran-1,3-dione together. Compounds 7 and 8 were subjected to an SN2 nucleophilic reaction
to obtain compound 9 under strong basic conditions. This step had a low yield, which was explained by
the high steric hindrance of the large molecules and the weak nucleophilicity of compound 7. The amine
protecting group was removed with hydrazine hydrate to obtain compound 10. Compound 10 was
reacted with trifluoromethanesulfonylchloride under basic conditions to give compound 11. Finally,
DX-03-12 was obtained by removing the protecting group on the imidazole with acetic acid.
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Scheme 3. Synthesis of DX-03-12. (a) Trityl Chloride, DIPEA, dry DMF, yield = 78%;
(b) (2-methoxyphenyl)boronic acid, K3PO4, 14% Pd(PPh3)4, DMF, inert atmosphere, yield = 63%;
(c) BBr3, inert atmosphere, dry dichloromethane, yield = 65%; (d) solvent-free melt, yield = 55%;
(e) KOH, dry DMF, yield = 71%; (f) hydrazine hydrate, CH3OH; (g) trifluoromethanesulfonylchloride,
DIPEA, dry dichloromethane, yield = 67%; (h) AcOH, CH3OH, yield = 86%.
Scheme 4 shows the synthesis of DX-04-02. 2-Iodoimidazole was substituted with
trifluoromethylbenzyl bromide to give compound 12. Compound 12 underwent a Suzuki–Miyaura
coupling reaction with (5-chloro-2-methoxyphenyl)boronic acid to obtain DX-04-01. Finally, the methyl
group was removed with BBr3 to obtain DX-04-02.
Scheme 4. Synthesis of DX-04-02. (a) DIPEA, dry DMF; (b) (5-chloro-2-methoxyphenyl)boronic acid,
K3PO4, Pd(PPh3)4, DMF, inert atmosphere, yield = 72%; (c) BBr3, inert atmosphere, yield = 53%.
2.3. In Vitro Biological Evaluation
We prepared the four series of compounds using the synthetic schemes in Section 2.2. Twelve
commercially available compounds were purchased (see Section 3.1). In total, we screened
50 compounds in vitro for their IDO1 and TDO inhibitory activities and cell cytotoxicities against
tumor cell lines H460 and MCF7 (Table 1). NLG919 was the reported potent IDO1/TDO inhibitor,
and Taxol are known commercial anti-cancer drug. They were used as the reference compounds in
this study.
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DX-01-01 9.7% 8.9% NA NA
DX-01-02
 




10.3% 10.1% 26.3% 37.6%
DX-01-04
 
3.3% 6.0% 15.1% 24.3%
DX-01-05 10.2% 10.5% 5.9% 29.7%
DX-01-06
 
6.2% 8.4% 11.2% 25.7%
DX-01-07 7.4% 16.9% 22.2% 34.6%
DX-01-08
 
10.9% 3.2% NA NA
DX-01-09
 








- 3.8% NA NA
DX-01-12
 
47.1% 33.9% NA NA
DX-01-13 19.7% 8.1% 23.1% 10.1%
DX-01-14
 
11.1 μM 38.2% NA NA
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DX-01-15 21.3 μM 35.4% NA NA
DX-01-16
 
23.2 μM 19.7% 44.5% 20.9%
DX-01-17
 
17.7 μM 42.2% NA NA
DX-01-18 5.4% - NA NA
DX-01-19
 




15.7% 3.8% NA NA
DX-01-21
 
9.7% 9.2% NA NA
DX-01-22
 
13.2% 4.5% NA NA
NLG919 0.064 μM 0.085 μM NA NA
Taxol NA NA 6 nM 15 nM
a When the calculated IC50 of a compound is >50 μM, we show the inhibition rate (%) at 50 μM. -: no detectable
inhibition. NA: not tested.
The IDO1 and TDO inhibitory activities of the 22 compounds in series 1 were measured (Table 1).
The series 1 compounds contained heme binding fragments including CO, NO, CN, H2S, imidazole,
and hydroxylamine; however, the inhibition data showed that most compounds in series 1 exhibited
marginal IDO1/TDO inhibition. However, four compounds (DX-01-14, DX-01-15, DX-01-16, and
DX-01-17) containing hydroxylamine had moderate IDO1 inhibitory activities. The most active IDO1
inhibitor in series 1 was compound DX-01-14 with an IC50 of 11.1 μM. In addition, cell cytotoxicity
screening showed that most of the compounds were not toxic to mammalian cancer cell lines.
Generally speaking, these molecules have a rather low molecular weight, and the rather small
moiety causes them hard to bind tightly inside the active center of IDO1. Thus, a poor SAR was
observed for this series of compounds. Interestingly, for these four active compounds, they all contain
the fragment of hydroxylamine. This may suggest that hydroxylamine is the ideal ligand to attach to
the double bond of the indole scaffold, while still maintaining the binding with the heme iron.
Series 2 included seven compounds, which were all PF-0684003 derivatives (Table 2). However,
the in vitro IDO1/TDO inhibitory activities of all these PF-0684003 derivatives were lower than that of
the parent compound, and none were IDO1/TDO inhibitors. The cytotoxicity study demonstrated that
these PF-0684003 derivatives were not toxic to cancer cell lines.
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6.3% - NA NA
DX-02-02
 
7.2% 2.3% NA NA
DX-02-03 21.6% 15.4% 21.7% 22.1%
DX-02-04
 
40.2% 14.5% NA NA
DX-02-05 12.5% 16.3% NA NA
DX-02-06 22.6% 19.6% 30.1% 19.9%
DX-02-07
 
20.1% 13.9% 15.2% 11.0%
NLG919 0.064 μM 0.085 μM NA NA
Taxol NA NA 6 nM 15 nM
a When the calculated IC50 of a compound is >50 μM, we show the inhibition rate (%) at 50 μM. -: no detectable
inhibition. NA: not tested.
The structure of PF-0684003 co-crystallized with IDO1 shows that PF-0684003 binds tightly in the
active site of IDO1 but does not interact with the heme iron [18]. In the present study, the addition of
the heme binding ligands [14] (SO and hydroxylamine in DX-02-07 and DX-02-05, respectively) to the
double bond of the indole ring abrogated the IDO1 inhibition, similar to the optimization reported in a
previous study.
Series 3 contains 13 phenylimidazole derivatives (Table 3). Compounds DX-03-01 to DX-03-10
showed marginal IDO1/TDO inhibition and weak cell cytotoxicities. However, compounds DX-03-11,
DX-03-12, and DX-03-13 are potent IDO1 inhibitors with IC50 values of 0.3–2.4 μM. Interestingly, these
three compounds show marginal TDO inhibition activity, and thus are IDO1/TDO selective inhibitors.
In addition, these compounds are not toxic to mammalian cancer cell lines.
Compound DX-03-01 is a known compound [18], which binds to the active site in IDO1.
The imidazole ring interacts with the heme iron, and the hydroxyl group binds to the nearby
Ser167 in the active site [7]. However, the substitution of the hydroxyl group with hydroxylamine
(DX-03-01 to DX-03-10) did not produce IDO1 inhibitors with higher activity. In DX-03-10 to DX-03-13,
the hydroxyl group was used to attach an alkyl chain bearing terminal groups used in other reported
IDO1 inhibitors [17,19]. The terminal fragments, such as sulfamide and urea, are important to maintain
the binding [17,19].
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DX-03-01 26.3% 10.3% NA NA
DX-03-02 24.2% 13.9% NA NA
DX-03-03 19.4% 11.1% 5.0% 22.2%
DX-03-04 11.9% 20.3% 12.7% 34.7%
DX-03-05
 
31.3% 12.1% NA NA
DX-03-06 25.6% 12.9% NA NA
DX-03-07 33.5% 15.1% NA NA
DX-03-08
 
15.6% 11.1% NA NA
DX-03-09
 
5.3% 6.4% 40.5% 37.7%
DX-03-10 13.2% 21.5% 7.6% 24.7%
DX-03-11
 
2.4 μM 38.2% NA NA
DX-03-12 0.3 μM 36.4% 19.3% 6.6%
DX-03-13
 
0.5 μM 38.9% 13.79 21.39
NLG919 0.064 μM 0.085 μM NA NA
Taxol NA NA 6 nM 15 nM
a When the calculated IC50 of a compound is >50 μM, we show the inhibition rate (%) at 50 μM. -: no detectable
inhibition. NA: not tested.
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Series 4 contains eight phenylimidazole derivatives (Table 4). Most compounds in this series
showed marginal IDO1 inhibition, but compound DX-04-05 showed moderate IDO1 inhibition.
However, compound DX-04-06, in which the hydroxyl group was methylated, showed decreased IDO1
inhibition. Most compounds in this series were toxic to the cancer cell lines H460 and MCF7 with an
IC50 of around 10−5 M, which indicates the compounds also interrupt the function of other targets in
the cells.










DX-04-01 46.2% 26.5% 11.96 μM 8.53μM
DX-04-02 9.7% 18.0% 7.69 μM 35.72 μM
DX-04-03 8.7% 17.3% 11.48 μM 15.44 μM
DX-04-04 11.9% 23.8% 5.49 μM 20.95 μM
DX-04-05
 




13.5% 23.6% 48.37 μM 49.34 μM
DX-04-07
 
38.2% 21.4% 27.4 μM 12.28 μM
DX-04-08
 
21.2% 11.2% 7.5% 24.9%
NLG919 0.064 μM 0.085 μM NA NA
Taxol NA NA 6 nM 15 nM
a When the calculated IC50 of a compound is >50 μM, we show the inhibition rate (%) at 50 μM. -: no detectable
inhibition. NA: not tested.
In series 4, the design strategy was to attach fragments to the imidazole ring instead of the phenyl
ring in series 3. However, this strategy does not maintain the IDO1 inhibitory activity. In addition,
the free hydroxyl group in series 4 appears to be important for forming a hydrogen bond with an
amino acid residue, such as Ser167 [7], in the active site; methylating this hydroxyl group decreased
IDO1 inhibition (DX-04-05 versus DX-04-06).
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In summary, based on the SAR study, compounds DX-03-12 and DX-03-13 showed potent IDO1
inhibition activity, and compound DX-03-13 has some structure similarity as previous published
patent (WO2011/056652Al) [23]. Thus, the most potent IDO1 inhibitor DX-03-12 was used as the lead
compound for further study.
2.4. Pharmacokinetic Study of DX-03-12
The in vivo pharmacokinetic properties of compound DX-03-12 were evaluated in male ICR mice.
DX-03-12 was administered orally either as a bolus at a dose of 30 mg/kg or intravenously at a dose of
3 mg/kg. The plasma concentration-time profiles are shown in Figure 3. The pharmacokinetic parameters
were determined by non-compartmental analysis (Table 5). After intravenous administration (3 mg/kg),
compound DX-03-12 showed a moderate clearance of 33.3 mL/min/kg, which was approximately 36% of
mouse hepatic blood flow (90 mL/min/kg). The volume of distribution in the steady state was 10 L/kg,
suggesting that there was an extensive distribution of compound DX-03-12 in tissues. Compound DX-03-12
was rapidly absorbed after oral administration of 30 mg/kg. The plasma concentration was quantifiable at
the first sampling time point (5 min) and remained detectable at 24 h. The maximum plasma concentration
of compound DX-03-12 of 2963 ng/mL was observed 1 h post-dose. Compound DX-03-12 was eliminated
relatively slowly with a half-life of 4.6 h. The oral bioavailability of compound DX-03-12 was calculated to
be 96%.
The pharmacokinetic study revealed that compound DX-03-12 showed rapid absorption and
almost complete oral bioavailability in mice. After oral administration of 30 mg/kg in mice, it exhibited
a long half-life (4.6 h) due to moderate plasma clearance. The pharmacokinetic properties of compound
DX-03-12 in mice indicate that it has the potential to be a once-a-day drug.







t1/2β h 4.61 3.49
Tmax h 1 0.033
Cmax ng/mL 2963 2138
AUC(0-t) h*ng/mL 12,902 1346
AUC(0-∞) h*ng/mL 13,094 1500
Vss L/kg - 10.1
Cl mL/min/kg - 33.3
F% 96 -
Figure 3. Mean plasma concentration-time profile in male ICR mice after administration of a single
oral (30 mg/kg) or intravenous (3 mg/kg) dose of compound DX-03-12. PO stands for per os, which
means oral administration of drug; iv stands for intravenous administration of drug.
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2.5. In Vivo Anti-Tumor Efficacy Study of Compound DX-03-12
To determine whether the compound was effective against tumors in vivo, the anti-tumor effect of
DX-03-12 was evaluated in a B16F10 subcutaneous xenograft model in syngeneic mice (Figure 4). Oral
and intraperitoneal (i.p.) administration (30 or 60 mg/kg/day) of DX-03-12 significantly decreased the
growth of melanoma B16F10 xenograft tumors in a dose-dependent manner. DX-03-12 oral treatment
resulted in a 72.2% decrease in tumor weight and i.p. treatment resulted in a 72.3% decrease at a dose
of 60 mg/kg compared with the control tumor after 19 days treatment. DX-03-12 had no obvious effect
on the body weight of the mice and the peripheral white blood cells, which indicated that DX-03-12
had low toxicity in mice. In this study, the classic first line anti-cancer drug cyclophosphamide (CTX)
was used as the reference drug.
Figure 4. In vivo anti-tumor activity of DX-03-12 in B16F10 xenograft mice. (A,B) Tumors from each
group after 19 days of treatment. Mice bearing B16F10 xenografts were dosed orally or i.p. with
vehicle (0.5% methylcellulose), CTX (Cyclophosphamide, orally, 60 mg/kg twice a week), DX-03-12
(i.p., 30 mg/kg/day), DX-03-12 (i.p., 60 mg/kg/day), DX-03-12 (orally, 30 mg/kg/day), or DX-03-12 (orally,
60 mg/kg/day). Results are expressed as the mean ± SD (n = 5–7 for each group). * p < 0.05 and
*** p < 0.001 versus vehicle. (C) The body weight from each group after the treatment. There is no
obvious body weight difference among all of the groups. (D) The white blood cells detected in the
blood of all groups of animals. There is also no obvious WBC difference among all of the groups.
3. Experiment Section
3.1. Chemistry
Reagents and solvents were obtained from commercial suppliers and used as received. 1H-NMR
spectra were obtained on an NMR spectrometer (Mercury, Varian, San Diego, CA, USA; 400 MHz).
Electrospray ionization (ESI) mass spectra and high-resolution mass spectroscopy (HRMS) were
performed with a liquid chromatograph/mass selective detector time-of-flight mass spectrometer
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(LC/MSD TOF, Agilent Technologies, Santa Clara, CA, USA). silica gel column chromatography was
performed with silica gel 60G (Qingdao Haiyang Chemical, Qingdao, China). Purity was determined
using HPLC, LC/MS and NMR spectroscopy. All of the synthesized compounds have the purity over
than 95%.
Several commercial available compounds were purchased from Beijing innochem Co. Ltd. (Beijing,
China). They are DX-01-01, DX-01-08, DX-01-09, DX-01-10, DX-01-11, DX-01-12, DX-01-18, DX-01-19,
DX-01-20, DX-01-21, DX-01-22, DX-03-01.
3.1.1. Preparation of (R/S) 3-(5-fluoro-2-((hydroxyamino)methyl)-1H-indol-3-yl)pyrrolidine-2,5-dione
(DX-02-05)
Preparation of (R/S) Ethyl 3-(2,5-dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carboxylate (DX-02-03)
Ethyl 5-fluoro-1H-indole-2-carboxylate (2 g, 9.7 mmol) and 1H-pyrrole-2,5-dione (1.40 g, 14.4 mmol)
were added to dry 1,2-dichloroethane (50 mL), and 46.5% BF3-Et2O (3.54 g, 11.6 mmol) was added to
reaction mixture at 20 ◦C. After the reaction mixture was stirred at 90 ◦C, until the starting material
disappeared in thin layer chromatography (TLC), the reaction mixture was distilled in vacuo, and
dichloromethane (50 mL) was added to the mixture. The organic extract was washed twice with
saturated aqueous NaHCO3 and NaCl (20 mL) respectively, and the organic extract was dried over
Na2SO4. After solvent was removed under vacuum, the product was purified as a white solid by
silica gel column chromatography, 1.62 g, yield 55%. 1H-NMR (400 MHz, DMSO-d6): δ = 12.00 (s, 1H,
NH-indolyl), 11.31 (s, 1H, NH), 7.49–7.45 (m, 2H, H-indolyl), 7.18 (td, J = 9.2, 2.6 Hz, 1H, H-indolyl),
4.82 (dd, J = 9.6, 6.6 Hz, 1H, CH), 4.33–4.27 (m, 2H, CH2), 3.08 (dd, J = 17.7, 9.6 Hz, 1H, CH’H”), 2.70
(dd, J = 17.7, 6.6 Hz, 1H, CH’H”), 1.30 (t, J = 7.1 Hz, 3H, CH3). 13C-NMR (101 MHz, CD3OD): δ =182.17,
180.15, 162.66, 160.66, 134.24, 129.01, 126.54, 119.11, 115.66, 114.82, 104.78, 62.19, 39.68, 39.37, 14.63.
HRMS (ESI): m/z [M + H]+ calculated for C15H14O4N2F: 305.09321; found: 305.09290.
Preparation of (R/S) 3-(5-fluoro-2-(hydroxymethyl)-1H-indol-3-yl) pyrrolidine-2,5-dione (1)
Ethyl 3-(2,5-dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carboxylate (DX-02-03, 1.3 g, 4.3 mmol)
were added to dry CH3OH (20 mL), LiAlH4 (0.13 g, 4.3 mmol) was added to reaction mixture gradually
at 20 ◦C. The reaction mixture was stirred at 20 ◦C until the starting material disappeared in TLC.
The reaction mixture was distilled in vacuo, and ethyl acetate (50 mL) was added to the mixture.
The organic extract was washed twice with saturated aqueous NaCl (20 mL), and the organic extract
was dried over Na2SO4. After solvent was removed under vacuum, the product was purified as a
white solid by silica gel column chromatography, 0.97 g, yield 86%. 1H-NMR (400 MHz, CD3OD):
δ = 7.30 (dd, J = 8.8, 4.4 Hz, 1H, H-phenyl), 6.93 (dd, J = 9.9, 2.4 Hz, 1H, H-phenyl), 6.89–6.83 (m,
1H, H-phenyl), 4.72 (d, J = 1.3 Hz, 2H, CH2), 4.46 (dd, J = 9.7, 5.6 Hz, 1H, CH), 3.20 (dd, J = 18.4,
9.7 Hz, 1H, CH’H”), 2.81 (dd, J = 18.4, 5.6 Hz, 1H, CH’H”). 13C-NMR (101 MHz, CD3OD): δ = 182.67,
180.16, 160.22, 157.85, 139.57, 133.85, 127.82, 113.46, 110.70, 103.45, 56.67, 39.93, 39.00. HRMS (ESI): m/z
[M + H]+ calculated for C13H12N2O3F: 263.08265; found: 263.08160.
Preparation of (R/S) 3-(2,5-dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carbaldehyde (2)
3-(5-Fluoro-2-(hydroxymethyl)-1H-indol-3-yl)pyrrolidine-2,5-dione (1, 0.8 g, 3.1 mmol) was added
to dry dichloridemethane (20 mL), MnO2 (0.36 g, 4.1 mmol) was added to reaction mixture gradually
at 20 ◦C. The reaction mixture was stirred at 20 ◦C until the starting material disappeared in TLC.
The reaction mixture was filtered, the solvent was removed under vacuum, and the product was
purified as a white solid by silica gel column chromatography, 0.73g, yield 91%. 1H-NMR (400 MHz,
CD3OD): δ = 10.00 (s, 1H, CHO), 7.50 (dd, J = 9.1, 4.3 Hz, 1H, H-phenyl), 7.27 (dd, J = 9.5, 2.3 Hz,
1H, H-phenyl), 7.19 (td, J = 9.1, 2.4 Hz, 1H, H-phenyl), 4.91 (dd, J = 9.7, 6.0 Hz, 1H, CH), 3.29–3.21
(m, 1H, CH’H”), 2.84 (dd, J = 18.1, 6.0 Hz, 1H, CH’H”). 13C-NMR (101 MHz, CD3OD): δ = 183.66,
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181.23, 179.66, 160.59, 158.30, 135.75, 135.36, 127.61, 117.26, 115.66, 105.59, 39.77, 39.35. HRMS (ESI):
m/z [M + H]+ calculated for C13H10N2O3F: 261.06700; found: 261.06638.
Preparation of (R/S) (E)-3-(2,5-dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carbaldehyde oxime
(DX-02-04)
3-(2,5-Dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carbaldehyde (0.5 g, 1.92 mmol) was added to
dry CH3OH (30 mL), then N,N-Diisopropylethylamine (0.5 g, 3.84 mmol) and hydroxylamine hydro
-chloride (0.13 g, 1.92 mmol) were added respectively at 20 ◦C. The reaction mixture was stirred at
60 ◦C until the starting material disappeared in TLC. After solvent was removed under vacuum,
the product was purified as a white solid by silica gel column chromatography, 0.35 g, yield 66%.
1H-NMR (400 MHz, CD3OD): δ = 8.22 (s, 1H, =CH), 7.32 (dd, J = 8.8, 4.4 Hz, 1H, H-indolyl), 7.06–6.86
(m, 2H, H-indolyl), 4.63 (dd, J = 9.7, 5.9 Hz, 1H, CH), 3.19 (dd, J = 18.3, 9.7 Hz, 1H, CH’H”), 2.81 (dd,
J = 18.7, 6.2 Hz, 1H, CH’H”). 13C-NMR (101 MHz, CD3OD): δ =181.92, 179.89, 160.31, 157.98, 141.03,
136.51, 134.81, 132.30, 113.78, 112.58, 103.95, 39.83, 38.66. HRMS (ESI): m/z [M + H]+ calculated for
C13H11N3O3F: 276.07790; found: 276.07718.
Preparation of (R/S) 3-(5-fluoro-2-((hydroxyamino)methyl)-1H-indol-3-yl) pyrrolidine-2,5-dione
(DX-02-05)
3-(2,5-Dioxopyrrolidin-3-yl)-5-fluoro-1H-indole-2-carbaldehyde oxime (DX-02-04, 0.3 g, 1.1 mmol)
was added to CH3OH (20 mL), then NaBH3CN (0.07 g, 1.1 mmol) was added at 20 ◦C. 12N HCl was
added to reaction mixture continuously to keep acidic. The reaction mixture was stirred at 20 ◦C until
the starting material disappeared in TLC. After solvent was removed under vacuum, the product was
purified as a white solid by silica gel column chromatography, 0.13 g, yield 43%. 1H-NMR (400 MHz,
CD3OD): δ = 7.30 (dd, J = 8.8, 4.5 Hz, 1H, H-indolyl), 6.93–6.88 (m, 1H, H-indolyl), 6.88–6.82 (m, 1H,
H-indolyl), 4.50 (dd, J = 9.7, 5.5 Hz, 1H, CH), 4.12 (d, J = 3.6 Hz, 2H, CH2NH), 3.21 (dd, J = 18.5, 9.7
Hz, 1H, CH’H”), 2.85 (dd, J = 18.5, 5.5 Hz, 1H, CH’H”). 13C-NMR (101 MHz, CD3OD): δ = 160.27,
157.92, 135.20, 130.85, 130.02, 113.00, 110.85, 110.54, 104.55, 104.31, 50.48, 38.34, 30.37. HRMS (ESI):
m/z [M + H]+ calculated for C13H13N3O3F: 278.09355; found: 278.09291.
3.1.2. Preparation of (R/S) 3-(5-fluoro-2-(methylsulfinyl)-1H-indol-3-yl)pyrrolidine-2,5-dione
(DX-02-07)
Preparation of 5-fluoroindoline-2-thione (3)
5-fluoroindolin-2-one (2 g, 13 mmol) and P2S5 (2.92 g, 13 mmol) were added to dry tetrahydrofuran
(30 mL). After the reaction mixture was stirred at room temperature for 1 h. Until the starting material
disappeared in thin layer chromatography (TLC), the NaHCO3 (3.43 g, 39 mmol) was added gradually.
After stirring at room temperature for 1 h, the reaction mixture was distilled in vacuo, dichloromethane
(50 mL) was added to the mixture. The organic extract was washed twice with saturated aqueous
NaCl (20 mL), and the organic extract was dried over Na2SO4. After solvent was removed under
vacuum, the product was obtained as yellow crystals by re-crystallization using ethanol, 1.62 g, yield
75%. 1H-NMR (400 MHz, CDCl3): δ = 10.14 (s, 1H, NH), 7.05–6.95 (m, 1H, H-phenyl), 6.94–6.89 (m, 1H,
H-phenyl), 4.08 (s, 1H, CH2). 13C-NMR (101 MHz, CDCl3)): δ = 203.39, 159.10, 140.24, 132.15, 114.87,
112.47, 110.47, 49.15. HRMS (ESI): m/z [M + H]+ calculated for C8H7NFS: 168.02777; found: 168.02773.
Preparation of 5-fluoro-2-(methylthio)-1H-indole (4)
5-fluoroindoline-2-thione (3, 1 g, 6 mmol), CH3I (0.99 g, 7 mmol) and K2CO3 (0.97 g, 7 mmol) were
added to acetone (30 mL), and the reaction mixture was stirred at room temperature until the starting
material disappeared in TLC. The reaction mixture was distilled in vacuo, ethyl acetate (50 mL) was
added to the mixture. The organic extract was washed twice with saturated aqueous NaCl (20 mL), and
the organic extract was dried over Na2SO4. After solvent was removed under vacuum, the product
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was purified as a white solid by silica gel column chromatography, 0.90 g, yield 83%. 1H-NMR (400
MHz, CDCl3): δ = 8.04 (s, 1H, NH), 7.23–7.13 (m, 2H, H-indolyl), 6.91 (s, 1H, H-indolyl), 6.49 (s, 1H,
H-indolyl), 2.52 (s, 3H, CH3). 13C-NMR (101 MHz, CDCl3): δ = 159.18, 156.85, 133.57, 129.02, 110.94,
110.47, 105.31, 104.73, 18.86. HRMS (ESI): m/z [M + H]+ calculated for C9H9NFS: 182.04342; found:
182.04425.
Preparation of (R/S) 3-(5-fluoro-2-(methylthio)-1H-indol-3-yl)pyrrolidine-2,5-dione (DX-02-06)
5-Fluoro-2-(methylthio)-1H-indole (4, 0.5 g, 2.7 mmol) and 1H-pyrrole-2,5-dione (0.54 g, 5.4 mmol)
were added to dry CH3CO2H (30 mL), and the reaction mixture was stirred at 120 ◦C until the starting
material disappeared in TLC. The reaction mixture was distilled in vacuo, ethyl acetate (100 mL) was
added to the mixture. The organic extract was washed twice with saturated aqueous NaCl (30 mL), and
the organic extract was dried over Na2SO4. After solvent was removed under vacuum, the product was
purified as a white solid by silica gel column chromatography, 0.47 g, yield 61%. 1H-NMR (400MHz,
CD3OD): δ = 7.28 (dd, J = 8.9, 4.5 Hz, 1H, H-phenyl), 7.00 (dd, J = 9.7, 2.4 Hz, 1H, H-phenyl), 6.91 (td,
J = 9.2, 2.5 Hz, 1H, H-phenyl), 4.56 (dd, J = 9.8, 5.6 Hz, 1H, CH), 3.22 (dd, J = 18.3, 9.8 Hz, 1H, CH’H”),
2.77 (dd, J = 18.3, 5.6 Hz, 1H, CH’H”), 2.41 (s, 3H, CH3). 13C-NMR (101 MHz, CD3OD): δ = 182.38,
180.11, 160.26, 135.05, 132.13, 127.67, 116.34, 113.18, 111.70, 103.25, 40.35, 39.10, 19.59. HRMS (ESI): m/z
[M + H]+ calculated for C13H12O2N2FS: 279.05980; found: 279.05930.
Preparation of (R/S) 3-(5-fluoro-2-(methylsulfinyl)-1H-indol-3-yl)pyrrolidine-2,5-dione (DX-02-07)
3-(5-Fluoro-2-(methylthio)-1H-indol-3-yl)pyrrolidine-2,5-dione (DX-02-06, 0.2 g, 0.7 mmol) was
added to dry dichloridemethane (20 mL), and 3-Chloroperoxybenzoic acid (0.15 g, 0.9 mmol) was
added gradually at 0 ◦C. The reaction mixture was stirred at 0 ◦C until the starting material disappeared
in TLC, and Na2S2O3 (0.11 g, 0.7 mmol) was added to the mixture. After reaction mixture was stirred
for 20 min, the reaction mixture was washed twice with saturated aqueous NaCl (20 mL), and the
organic extract was dried over Na2SO4. After solvent was removed under vacuum, the product was
purified as a white solid by silica gel column chromatography, 0.074 g, yield 35%. 1H-NMR (400MHz,
DMSO-d6): δ = 12.28 (s, 1H, NH), 11.51 (s, 1H, NH), 7.51–7.48 (m, 1H, H-phenyl), 7.19–7.13 (m, 2H,
H-phenyl), 4.61 (ddd, J = 26.8, 9.7, 5.8 Hz, 1H, CH), 3.18 (ddd, J = 18.0, 9.7, 2.3 Hz, 1H, CH’H”), 2.98 (d,
J = 16.7 Hz, 3H, CH3), 2.76 (ddd, J = 41.8, 18.1, 5.8 Hz, 1H, CH’H”). 13C-NMR (101 MHz, DMSO-d6):
δ = 179.74, 177.94, 158.72, 138.29, 134.14, 125.83, 114.50, 113.93, 113.53, 104.46, 41.67, 38.62, 38.11. HRMS
(ESI): m/z [M + H]+ calculated for C13H12O3N2FS: 295.05472; found: 295.05508.
3.1.3. Preparation of N-(3-(2-(1H-imidazol-5-yl)phenoxy)propyl)-1,1,1-trifluoromethane sulfonamide
(DX-03-12)
Preparation of 4-iodo-1-trityl-1H-imidazole (5)
4-Iodo-1H-imidazole (5 g, 25.8 mmol) and N,N-diisopropylethylamine (6.65 g, 51.5 mmol) were
added to dry dimethylformamide (30 mL), and (chloromethanetriyl)tribenzene (7.89 g, 28.4 mmol)
was added to reaction mixture gradually at 20 ◦C. After the reaction mixture was stirred at 20 ◦C
until the starting material disappeared in thin layer chromatography (TLC), the reaction mixture was
distilled in vacuo, ethyl acetate (200 mL) was added to the mixture. The organic extract was washed
twice with saturated aqueous NaCl (40 mL), and the organic extract was dried over Na2SO4. After
solvent was removed under vacuum, the product was purified as a white solid by silica gel column
chromatography, 8.77 g, yield 78%. 1H-NMR (400 MHz, CDCl3): δ = 7.38–7.33 (m, 10H, H-phenyl,
H-imidazolyl), 7.13–7.09 (m, 6H, H-phenyl), 6.92 (d, J = 1.4 Hz, 1H, H-imidazolyl). 13C-NMR (101 MHz,
CDCl3): δ = 141.83, 140.56, 129.72 (6C), 128.29 (3C), 128.18 (6C), 127.91, 126.89 (3C), 75.84. HRMS (ESI):
m/z [M + H]+ calculated for C22H18N2I: 437.05092; found: 437.04934.
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Preparation of 4-(2-methoxyphenyl)-1-trityl-1H-imidazole (6)
4-Iodo-1-trityl-1H-imidazole (5, 2 g, 4.58 mmol), (5-chloro-2-methoxyphenyl)boronic acid
(0.852 g, 4.58 mmol), K3PO4 (2.9 g, 13.7 mmol), Pd(PPh3)4 (0.74 g, 0.64 mmol) were added to
dry dimethylformamide (30 mL). The reaction mixture was stirred at 100 ◦C under inert atmosphere,
until the starting material disappeared in TLC. The reaction mixture was distilled in vacuo, and ethyl
acetate (100 mL) was added to the mixture. The organic extract was washed twice with saturated
aqueous NaCl (20 mL), and the organic extract was dried over Na2SO4. After solvent was removed
under vacuum, the product was purified as a white solid by silica gel column chromatography, 1.2 g,
yield 63%. 1H-NMR (400 MHz, CDCl3): δ = 7.51–7.32 (m, 12H, H-phenyl, H-imidazolyl), 7.15–7.04 (m,
8H, H-phenyl, H-imidazolyl), 6.94 (d, J = 8.1 Hz, 1H, H-phenyl), 3.99 (s, 3H, CH3). HRMS (ESI): m/z
[M + H]+ calculated for C29H25N2O: 417.19614; found: 417.19647.
Preparation of 2-(1-trityl-1H-imidazol-4-yl)phenol (7)
4-(2-Methoxyphenyl)-1-trityl-1H-imidazole (6, 1.0 g, 2.4 mmol) was added to dry
dichloridemethane (20 mL), BBr3 (0.71 g, 2.9 mmol) was added to reaction mixture gradually at
−70 ◦C. The reaction mixture was stirred under inert atmosphere until the starting material disappeared
in TLC. The reaction mixture was diluted with dichloridemethane (50 mL), and was washed twice with
saturated aqueous NaCl (20 mL), then the organic extract was dried over Na2SO4. After solvent was
removed under vacuum, the product was purified as a white solid by silica gel column chromatography,
0.63 g, yield 65%. 1H-NMR (400 MHz, DMSO-d6): δ = 11.19 (s, 1H, OH), 7.49–7.36 (m, 2H, H-phenyl),
7.33–7.10 (m, 16H, H-phenyl, H-imidazolyl), 6.84–6.70 (m, 2H, H-phenyl), 6.45 (s, 1H, H-phenyl).
13C-NMR (101 MHz, DMSO-d6): δ = 147.24, 141.47, 137.70, 136.55, 128.71 (6C), 127.80 (6C), 127.56,
127.24 (3C), 126.99 (3C), 126.10, 118.39, 117.87, 115.68, 74.61. HRMS (ESI): m/z [M + H]+ calculated for
C28H23N2O: 403.18049; found: 403.18134.
Preparation of 2-(3-chloropropyl)isoindoline-1,3-dione (8)
3-Chloropropan-1-amine (3.77 g, 40.5 mmol) and isobenzofuran-1,3-dione (2 g, 13.5 mmol) were
mixed without solvent, and the reaction mixture was stirred at 140 ◦C (molten condition), until the
starting material disappeared in TLC. The reaction mixture was distilled in vacuo, ethyl acetate (100 mL)
was added to the mixture. The organic extract was washed twice with saturated aqueous NaCl (20 mL),
and the organic extract was dried over Na2SO4. After solvent was removed under vacuum, the product
was purified as a white solid by silica gel column chromatography, 1.66 g, yield 55%. 1H-NMR (400
MHz, DMSO-d6): δ = 7.85–7.78 (m, 4H, H-phenyl), 3.73–3.62 (m, 4H, CH2, CH2), 2.08–2.01(m, 2H,
CH2). 13C-NMR (101 MHz, DMSO-d6): δ = 167.38 (2C), 133.75 (2C), 131.19 (2C), 122.43 (2C), 42.31,
34.60, 30.39. HRMS (ESI): m/z [M + H]+ calculated for C11H11ClNO2: 224.04728; found: 224.04683.
Preparation of 2-(3-(2-(1-trityl-1H-imidazol-5-yl)phenoxy)propyl)isoindoline-1,3-dione (9)
2-(1-Trityl-1H-imidazol-4-yl)phenol (7, 0.5 g, 1.2 mmol) and KOH (0.14 g, 2.5 mmol) were added
to dry dimethylformamide (20 mL), after the reaction mixture was stirred at 20 ◦C for 15 min,
2-(3-chloropropyl)isoindoline-1,3-dione (8, 0.294 g, 1.32 mmol) was added to reaction mixture at 20 ◦C.
After the reaction mixture was stirred at 60 ◦C until the starting material disappeared in thin layer
chromatography (TLC), the reaction mixture was distilled in vacuo, ethyl acetate (100 mL) was added
to the mixture. The organic extract was washed twice with saturated aqueous NaCl (20 mL), and the
organic extract was dried over Na2SO4. After solvent was removed under vacuum, the product was
purified as a white solid by silica gel column chromatography, 0.5 g, yield 71%. 1H-NMR (400 MHz,
DMSO-d6): δ = 8.08 (dd, J = 7.7, 1.6 Hz, 1H, H-phenyl), 7.88–7.81 (m, 4H, H-phenyl, H-imidazolyl),
7.44–7.35 (m, 10H, H-phenyl), 7.17–7.13 (m, 7H, H-phenyl, H-imidazolyl), 7.12–7.08 (m, 1H, H-phenyl),
6.97 (t, J = 7.5 Hz, 1H, H-phenyl), 6.92 (d, J = 8.2 Hz, 1H, H-phenyl), 3.93 (t, J = 6.4 Hz, 2H, CH2), 3.43
(t, J = 6.5 Hz, 2H, CH2), 1.82–1.69 (m, 2H, CH2). 13C-NMR (101 MHz, DMSO-d6): δ = 167.25, 154.09,
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141.77, 137.17, 134.72, 133.82, 131.11, 128.71 (6C), 128.65 (3C), 127.69, 127.66 (6C), 127.46, 127.36 (3C),
126.71, 125.92, 122.47, 121.86, 121.01, 120.60, 119.93, 111.33, 74.14, 64.42, 33.61, 27.54. HRMS (ESI): m/z
[M + H]+ calculated for C39H32N3O3: 590.24382; found: 590.24541.
Preparation of 3-(2-(1-trityl-1H-imidazol-4-yl)phenoxy)propan-1-amine (10)
2-(3-(2-(1-Trityl-1H-imidazol-4-yl)phenoxy)propyl)isoindoline-1,3-dione (9, 0.4 g, 0.68 mmol) and
35% hydrazine hydrate (0.12 g, 1.35 mmol) were added to CH3OH, and the reaction mixture was stirred
at 50 ◦C under inert atmosphere. After the starting material disappeared in thin layer chromatography
(TLC), the reaction mixture was distilled in vacuo, ethyl acetate (100 mL) was added to the mixture.
The organic extract was washed twice with saturated aqueous NaHCO3 and NaCl (20 mL) respectively,
and the organic extract was dried over Na2SO4. After solvent was removed under vacuum, the
unpurified product was added to the next step directly.
Preparation of 1,1,1-trifluoro-N-(3-(2-(1-trityl-1H-imidazol-4-yl)phenoxy)propyl) Methane
Sulfonamide (11)
3-(2-(1-Trityl-1H-imidazol-4-yl)phenoxy)propan-1-amine (crude 10, 0.3 g, 0.65 mmol) and
N,N-diisopropylethylamine (0.168 g, 1.3 mmol) were added to dry dichloridemethane (20 mL),
and trifluoromethanesulfonylchloride (0.12 g, 0.71 mmol) was added to reaction mixture gradually at
20 ◦C. After the starting material disappeared in thin layer chromatography (TLC), the reaction mixture
was distilled in vacuo, the reaction mixture was diluted with dichloridemethane (50 mL), and the
organic extract was washed twice with saturated aqueous NaCl (20 mL), and the organic extract was
dried over Na2SO4. After solvent was removed under vacuum, the product 11 was purified as a white
solid by silica gel column chromatography, 0.257 g, yield 67%. 1H-NMR (400 MHz, CDCl3): δ = 7.80 (s,
1H, NH), 7.43–7.32 (m, 10H, H-phenyl, H-imidazolyl), 7.23–7.16 (m, 8H, H-phenyl, H-imidazol), 7.07 (d,
J = 1.5 Hz, 1H, H-phenyl), 6.97–6.86 (m, 2H, H-phenyl), 4.16 (t, J = 5.2 Hz, 2H, CH2), 3.57–3.46 (m, 2H,
CH2), 2.19–2.06 (m, 2H, CH2). 13C-NMR (101 MHz, CDCl3): δ= 154.95, 142.08, 139.92, 138.22, 129.77
(6C), 128.56 (3C), 128.36, 128.15 (3C), 128.09 (6C), 121.68, 120.87, 119.04, 118.47, 111.86, 75.75, 67.83,
43.24, 29.80. HRMS (ESI): m/z [M + H]+ calculated for C32H29N3O3F3S: 592.18762; found: 592.18616.
Preparation of N-(3-(2-(1H-imidazol-5-yl)phenoxy)propyl)-1,1,1-trifluoromethane Sulfonamide
(DX-03-12)
1,1,1-Trifluoro-N-(3-(2-(1-trityl-1H-imidazol-4-yl)phenoxy)propyl)methanesulfonamide (11, 0.2 g,
0.34 mmol) and AcOH (0.5 mL) were added to CH3OH (10 mL), and the reaction mixture was stirred at
20 ◦C. After the starting material disappeared in thin layer chromatography (TLC), the reaction mixture
was distilled in vacuo, the product was purified as a white solid by silica gel column chromatography,
0.101 g, yield 86%. 1H-NMR (400 MHz, DMSO-d6): δ =7.99 (d, J = 7.4 Hz, 1H, H-phenyl), 7.72 (s, 1H,
H-imidazolyl), 7.49 (s, 1H, H-imidazolyl), 7.18 (t, J = 7.8 Hz, 1H, H-phenyl), 7.03 (d, J = 8.1 Hz, 1H,
H-phenyl), 6.98 (t, J = 7.5 Hz, 1H, H-phenyl), 4.15 (t, J = 6.0 Hz, 2H, CH2), 3.40 (t, J = 6.8 Hz, 2H, CH2),
2.06–2.09 (m, 2H, CH2). 13C-NMR (101 MHz, DMSO-d6): δ = 154.86, 135.47, 134.49, 127.46, 127.25,
124.99, 122.69, 120.97, 118.57, 112.34, 65.09, 41.39, 30.14. HRMS (ESI): m/z [M + H]+ calculated for
C13H15O3N3F3S: 350.07807; found: 350.07782.
3.1.4. Preparation of 4-chloro-2-(1-(4-(trifluoromethyl)benzyl)-1H-imidazol-4-yl) Phenol (DX-04-02)
Preparation of 4-iodo-1-(4-(trifluoromethyl)benzyl)-1H-imidazole (12)
4-Iodo-1H-imidazole (1 g, 5.2 mmol) and N,N-diisopropylethylamine (1.34 g, 10.4 mmol) were
added to dry dimethylformamide (20 mL), and 1-(bromomethyl)-4-(trifluoromethyl)benzene (1.48 g,
6.2 mmol) was added to reaction mixture at 20 ◦C. After the reaction mixture was stirred at 20 ◦C
until the starting material disappeared in thin layer chromatography (TLC), the reaction mixture was
distilled in vacuo, dichloromethane (50 mL) was added to the mixture. The organic extract was washed
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twice with saturated aqueous NaHCO3 and NaCl (20 mL) respectively, and the organic extract was
dried over Na2SO4. After solvent was removed under vacuum, the unpurified product was added to
the next step directly.
Preparation of 4-(5-chloro-2-methoxyphenyl)-1-(4-(trifluoromethyl)benzyl)-1H-imidazole (DX-04-01)
4-Iodo-1-(4-(trifluoromethyl)benzyl)-1H-imidazole (crude 12, 0.5 g, 1.4 mmol), (5-chloro-2-
methoxyphenyl)boronic acid (0.27 g, 1.4 mmol), K3PO4 (0.9 g, 4.3 mmol), Pd(PPh3)4 (0.23 g, 0.2 mmol)
were added to dry dimethylformamide (10 mL). The reaction mixture was stirred at 100 ◦C under
inert atmosphere, until the starting material disappeared in TLC. The reaction mixture was distilled in
vacuo, ethyl acetate (50 mL) was added to the mixture. The organic extract was washed twice with
saturated aqueous NaCl (20 mL), and the organic extract was dried over Na2SO4. After solvent was
removed under vacuum, DX-04-01 was purified as a white solid by silica gel column chromatography,
0.37 g, yield 72%. 1H-NMR (400 MHz, CD3OD): δ = 7.94 (d, J = 2.5 Hz, 1H, H-phenyl), 7.81 (s, 1H,
H-imidazolyl), 7.65–7.63 (m, 3H, H-imidazolyl, H-phenyl), 7.40 (d, J = 8.0 Hz, 2H, H-phenyl), 7.15 (dd,
J = 8.7, 2.5 Hz, 1H, H-phenyl), 6.96 (d, J = 8.8 Hz, 1H, H-phenyl), 5.34 (s, 2H, CH2), 3.86 (s, 3H, CH3).
13C-NMR (101 MHz, CD3OD): δ = 156.09, 142.76, 138.77, 137.13, 131.46, 129.05 (2C), 128.22, 127.44,
126.92 (2C), 124.85, 124.18, 121.78, 113.52, 112.48, 56.17, 51.22. HRMS (ESI): m/z [M +H]+ calculated
forC18H15ON2ClF3: 367.08195; found: 367.08374.
Preparation of 4-chloro-2-(1-(4-(trifluoromethyl)benzyl)-1H-imidazol-4-yl)phenol (DX-04-02)
4-(5-Chloro-2-methoxyphenyl)-1-(4-(trifluoromethyl)benzyl)-1H-imidazole (DX-04-01, 0.3 g,
0.82 mmol) was added to dry dichloridemethane (20 mL), BBr3 (0.24 g, 0.98 mmol) was added
to reaction mixture gradually at −70 ◦C. The reaction mixture was stirred under inert atmosphere until
the starting material disappeared in TLC. The reaction mixture was diluted with dichloridemethane
(50 mL), and was washed twice with saturated aqueous NaCl (20 mL), then the organic extract was
dried over Na2SO4. After solvent was removed under vacuum, DX-04-02 was purified as a white
solid by silica gel column chromatography, 0.15 g, yield 53%. 1H-NMR (400 MHz, CD3OD): δ = 7.85
(s, 1H, H-imidazolyl), 7.70–7.65 (m, 3H, H-imidazolyl, H-phenyl), 7.63 (d, J = 2.6 Hz, 1H, H-phenyl),
7.45 (d, J = 8.1 Hz, 2H, H-phenyl), 7.02 (dd, J = 8.7, 2.6 Hz, 1H, H-phenyl), 6.80 (d, J = 8.7 Hz, 1H,
H-phenyl), 5.37 (s, 2H, CH2). 13C-NMR (101 MHz, CD3OD): δ = 155.21, 142.66, 140.49, 137.67, 129.87,
129.60, 129.12 (2C), 128.42, 126.89 (2C), 126.06, 125.01, 121.01, 118.79, 118.28, 51.17. HRMS (ESI): m/z
[M + H]+ calculated forC17H13ON2ClF3: 353.06630; found: 353.06635.
3.1.5. Preparation of 4-methyl-1H-indole-3-carboxylic Acid (DX-01-02)
Methyl 4-methyl-1H-indole-3-carboxylate (200 mg, 1.06 mmol) used hydrolysis reaction (2 N
NaOH water solution) to afford DX-01-02 (white solid, 151 mg, yield 82%). 1H-NMR (400 MHz,
CD3OD): δ = 8.18 (dd, J = 3.9, 1.9 Hz, 1H, H-indolyl), 7.30 (d, J = 8.0 Hz, 1H, H-indolyl), 7.17 (t,
J = 7.7 Hz, 1H, H-indolyl), 7.01 (dd, J = 7.3, 0.7 Hz, 1H, H-indolyl), 2.77 (s, 3H, CH3). 13C-NMR
(101 MHz, CD3OD): δ = 139.17, 133.89, 126.39, 125.96, 125.68, 120.61, 117.71, 112.19, 111.02, 23.30.
HRMS (ESI): m/z [M + H]+ calculated for C10H10NO2: 176.07061; found: 176.07129.
3.1.6. Preparation of 5-methyl-1H-indole-3-carboxylic Acid (DX-01-03)
Methyl 5-methyl-1H-indole-3-carboxylate (200 mg, 1.06 mmol) used hydrolysis reaction (2 N
NaOH water solution) to afford DX-01-03 (white solid, 150 mg, yield 81%). 1H-NMR (400 MHz,
CD3OD): δ = 8.15 (d, J = 1.8 Hz, 1H, H-indolyl), 8.07 (s, 1H, H-indolyl), 7.39 (d, J = 8.3 Hz, 1H,
H-indolyl), 7.15 (dd, J = 8.3, 1.1 Hz, 1H, H-indolyl), 2.46 (s, 3H, CH3). 13C-NMR (101 MHz, CD3OD):
δ = 137.41, 134.35, 127.80, 127.00, 122.51, 120.09, 117.20, 113.08, 110.78, 21.77. HRMS (ESI): m/z [M + H]+
calculated for C10H10NO2: 176.07061; found: 176.07094.
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3.1.7. Preparation of 5-nitro-1H-indole-3-carboxylic Acid (DX-01-04)
Methyl 5-nitro-1H-indole-3-carboxylate (200 mg, 0.91 mmol) used hydrolysis reaction (2 N NaOH
water solution) to afford DX-01-04 (white solid, 172 mg, yield 92%). 1H-NMR (400 MHz, CD3OD):
δ = 8.99 (d, J = 2.2 Hz, 1H, H-indolyl), 8.14 (s, 1H, H-indolyl), 8.12 (dd, J = 9.0, 2.3 Hz, 1H, H-indolyl),
7.58 (d, J = 9.0 Hz, 1H, H-indolyl). 13C-NMR (101 MHz, CD3OD): δ = 167.81, 144.32, 141.16, 136.51,
127.01, 118.93, 118.80, 113.45, 111.10, 49.00. HRMS (ESI): m/z [M + H]+ calculated for C9H7N2O4:
207.04003; found: 207.03940.
3.1.8. Preparation of 6-nitro-1H-indole-3-carboxylic Acid (DX-01-05)
Methyl 6-nitro-1H-indole-3-carboxylate (200 mg, 0.91 mmol) used hydrolysis reaction (2 N NaOH
water solution) to afford DX-01-05 (white solid, 168 mg, yield 90%). 1H-NMR (400 MHz, CD3OD):
δ = 8.38 (d, J = 1.5 Hz, 1H, H-indolyl), 8.22 (s, 1H, H-indolyl), 8.18 (d, J = 8.9 Hz, 1H, H-indolyl), 8.05
(dd, J = 8.8, 1.7 Hz, 1H, H-indolyl). 13C-NMR (101 MHz, CD3OD): δ = 167.87, 144.97, 138.31, 136.78,
132.29, 122.19, 117.33, 109.89, 109.69. HRMS (ESI): m/z [M +H]+ calculated for C9H7N2O4: 207.04003;
found: 207.03949.
3.1.9. Preparation of 5-methoxy-1H-indole-3-carboxylic Acid (DX-01-06)
Methyl 5-methoxy-1H-indole-3-carboxylate (200 mg, 0.97 mmol) used hydrolysis reaction (2 N
NaOH water solution) to afford DX-01-06 (white solid, 140 mg, yield 75%). 1H-NMR (400 MHz,
CD3OD): δ = 7.88 (s, 1H, H-indolyl), 7.57 (d, J = 2.4 Hz, 1H, H-indolyl), 7.31 (d, J = 8.8 Hz, 1H,
H-indolyl), 6.83 (dd, J = 8.8, 2.5 Hz, 1H, H-indolyl), 3.83 (s, 3H, CH3). 13C-NMR (101 MHz, CD3OD):
δ = 156.99, 133.58, 128.36, 115.37, 114.23, 113.88, 113.61, 104.51, 103.64, 56.06. HRMS (ESI): m/z [M + H]+
calculated for C10H10NO3: 192.06552; found: 192.06645.
3.1.10. Preparation of 7-bromo-1H-indole-3-carboxylic Acid (DX-01-07)
Methyl 7-bromo-1H-indole-3-carboxylate (200 mg, 0.79 mmol) used hydrolysis reaction (2 N
NaOH water solution) to afford DX-01-07 (white solid, 160 mg, yield 85%). 1H-NMR (400 MHz,
CD3OD): δ = 8.06 (dd, J = 8.0, 0.9 Hz, 1H, H-indolyl), 7.98 (s, 1H, H-indolyl), 7.36 (dd, J = 7.6, 0.7 Hz, 1H,
H-indolyl), 7.08 (t, J = 7.8 Hz, 1H, H-indolyl). 13C-NMR (101 MHz, CD3OD): δ = 168.56, 138.29, 134.03,
129.07, 126.24, 123.59, 121.46, 117.02, 106.02. HRMS (ESI): m/z [M + H]+ calculated for C9H7NO2Br:
239.96547; found: 239.96452.
3.1.11. Preparation of (E) 1H-indole-3-carbaldehyde Oxime (DX-01-13)
1H-indole-3-carbaldehyde (200 mg, 1.38 mmol) following the similar procedure described for
the preparation of DX-02-04 afforded DX-01-13 (white solid, 158 mg, yield 72%). 1H-NMR (400 MHz,
DMSO-d6): δ = 11.56 (s, 1H, OH), 11.17 (s, 1H, NH), 8.26 (s, 1H, =CH), 8.22 (d, J = 1.3 Hz, 1H, H-indolyl),
7.97 (d, J = 7.9 Hz, 1H, H-indolyl), 7.44 (d, J = 8.1 Hz, 1H, H-indolyl), 7.16 (t, J = 7.5 Hz, 2H, H-indolyl).
13C-NMR (101 MHz, CD3OD): δ = 146.89, 138.66, 132.19, 127.98, 123.30, 121.40, 118.79, 112.59, 107.56.
HRMS (ESI): m/z [M + H]+ calculated for C9H9ON2: 161.07094; found: 161.07076.
3.1.12. Preparation of N-((1H-indol-3-yl)methyl)hydroxylamine (DX-01-14)
DX-01-13 (100 mg, 0.62 mmol) following the similar procedure described for the preparation of
DX-02-05 afforded DX-01-14 (white solid, 70 mg, yield 69%). 1H-NMR (400 MHz, DMSO-d6): δ = 10.87
(s, 1H, NH-indolyl), 7.58 (d, J = 7.8 Hz, 1H, H-indolyl), 7.34 (d, J = 8.1 Hz, 1H, H-indolyl), 7.29 (br, 1H,
NH), 7.24 (s, 1H, H-indolyl), 7.06 (t, J = 8.0 Hz, 1H, H-indolyl), 6.99–6.95 (m, 1H, H-indolyl), 5.66 (br, 1H,
OH), 4.04 (s, 2H, CH2). 13C-NMR (101 MHz, CD3OD): δ = 138.02, 128.61, 125.94, 122.58, 120.11, 119.41,
112.28, 110.24, 55.80. HRMS (ESI): m/z [M + H]+ calculated for C9H11ON2: 163.08659; found: 163.08611.
261
Molecules 2019, 24, 2124
3.1.13. Preparation of N-((5-(o-tolyl)-1H-indol-3-yl)methyl)hydroxylamine (DX-01-15)
5-Bromo-1H-indole-3-carbaldehyde (300 mg, 1.34 mmol) and o-tolylboronic acid (183 mg,
1.34 mmol) following the similar procedure described for the preparation of DX-03-12 and DX-02-05
afforded DX-01-15 (white solid, 145 mg, yield 43% from 5-bromo-1H-indole-3-carbaldehyde). 1H-NMR
(400 MHz, CD3OD): δ = 7.57–7.39 (m, 3H, H-phenyl, H-indolyl), 7.26–7.04 (m, 5H, H-phenyl, H-indolyl),
5.13 (s, 2H, CH2), 2.24 (s, 3H, CH3). 13C-NMR (101 MHz, CD3OD): δ = 144.63, 137.29, 136.60, 135.38,
131.19, 131.12, 128.56, 127.79, 126.62, 125.69, 124.87, 119.47, 112.33, 107.61, 62.12, 29.31. HRMS (ESI): m/z
[M + H]+ calculated for C16H17N2O: 253.13354; found: 253.13471.
3.1.14. Preparation of (E)-1H-indole-2-carbaldehyde Oxime (DX-01-16)
1H-indole-2-carbaldehyde (200 mg, 1.38 mmol) following the similar procedure described for
the preparation of DX-02-04 afforded DX-01-16 (white solid, 117 mg, yield 53%). 1H-NMR (400 MHz,
DMSO-d6): δ = 11.29 (s, 1H, OH), 11.17 (s, 1H, NH), 8.14 (s, 1H, =CH), 7.52 (d, J = 8.0 Hz, 1H, H-indolyl),
7.37 (d, J = 8.2 Hz, 1H, H-indolyl), 7.12 (t, J = 7.6 Hz, 1H, H-indolyl), 6.98 (t, J = 7.5 Hz, 1H, H-indolyl),
6.56 (s, 1H, H-indolyl). 13C-NMR (101 MHz, CD3OD): δ = 142.67, 138.93, 132.77, 129.48, 124.71, 122.20,
120.89, 112.84, 108.61. HRMS (ESI): m/z [M +H]+ calculated for C9H9ON2: 161.07094; found: 161.07077.
3.1.15. Preparation of N-((1H-indol-2-yl)methyl)hydroxylamine (DX-01-17)
DX-01-16 (60 mg, 0.37 mmol) following the similar procedure described for the preparation of
DX-02-05 afforded DX-01-17 (white solid, 39 mg, yield 65%). 1H-NMR (400 MHz, DMSO-d6): δ = 10.88
(s, 1H, NH-indolyl), 7.46–7.39 (m, 2H, H-indolyl, NH), 7.32 (d, J = 8.3 Hz, 1H, H-indolyl), 7.03–6.97
(m, 1H, H-indolyl), 6.93 (t, J = 8.1 Hz, 1H), 6.28 (s, 1H, H-indolyl), 6.17 (br, 1H, OH), 4.00 (s, 2H, CH2).
13C-NMR (101 MHz, CD3OD): δ = 137.98, 136.56, 122.09, 120.86, 120.84, 120.01, 111.84, 101.86, 51.98.
HRMS (ESI): m/z [M + H]+ calculated for C9H11ON2: 163.08659; found: 163.08636.
3.1.16. Preparation of (E)-3-((1H-indol-3-yl)methylene)pyrrolidine-2,5-dione (DX-02-01)
1H-indole-3-carbaldehyde (500 mg, 3.45 mmol) and 1H-pyrrole-2,5-dione (401 mg, 4.14 mmol)
following the similar procedure described for the preparation of DX-02-04 afforded DX-02-01 (white
solid, 398 mg, yield 51% from 1H-indole-3-carbaldehyde). 1H-NMR (400 MHz, DMSO-d6): δ = 11.94 (s,
1H, NH-indolyl), 11.18 (s, 1H, NH), 7.81 (dd, J = 12.1, 5.1 Hz, 2H, H-indolyl, =CH), 7.70 (t, J = 2.1 Hz,
1H, H-indolyl), 7.54–7.41 (m, 1H, H-indolyl), 7.21–7.16 (m, 2H, H-indolyl), 3.52 (d, J = 2.2 Hz, 2H).
HRMS (ESI): m/z [M + H]+ calculated for C13H11O2N2: 227.08150; found: 227.08134.
3.1.17. Preparation of (R/S) 3-((1H-indol-3-yl)methyl)pyrrolidine-2,5-dione (DX-02-02)
DX-02-01 (200 mg, 3.45 mmol) following the similar procedure described for the preparation
of DX-02-04 afforded DX-02-02 (white solid, 65 mg, yield 32%). 1H-NMR (400 MHz, DMSO-d6):
δ = 11.06 (s, 1H, NH-indolyl), 10.91 (s, 1H, NH), 7.51 (d, J = 7.8 Hz, 1H, H-indolyl), 7.33 (d, J = 8.0 Hz,
1H, H-indolyl), 7.16 (s, 1H, H-indolyl), 7.06 (t, J = 7.5 Hz, 1H, H-indolyl), 6.97 (t, J = 7.5 Hz, 1H,
H-indolyl), 3.20–3.12 (m, 1H, CH’H”), 2.95 (dd, J = 14.0, 8.5 Hz, 1H, CH’H”), 2.70–2.61 (m, 2H,
H-pyrrolidine-2,5-dione), 2.34 (dd, J = 18.0, 3.5 Hz, 1H, H-pyrrolidine-2,5-dione). HRMS (ESI): m/z
[M + H]+ calculated for C13H13N2O2: 229.09715; found: 229.09663
3.1.18. Preparation of (E) 2-(1H-imidazol-4-yl)benzaldehyde Oxime (DX-03-02)
Compound 5 (400 mg, 0.92 mmol) and (2-formylphenyl)boronic acid (138 mg, 0.92 mmol) following
the similar procedure described for the preparation of DX-03-12 and DX-02-04 afforded DX-03-02
(white solid, 98 mg, yield 57% from (2-formylphenyl)boronic acid). 1H-NMR (400 MHz, CD3OD):
δ = 8.32 (s, 1H, =CH), 7.85–7.84 (m, 1H, H-phenyl), 7.79 (s, 1H, H-imidazolyl), 7.52 (d, J = 7.7 Hz,
1H, H-phenyl), 7.42–7.38 (m, 1H, H-phenyl), 7.34–7.30 (m, 1H, H-phenyl), 7.12 (s, 1H, H-imidazolyl).
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13C-NMR (100 MHz, DMSO-d6): δ = 148.70, 136.36, 133.83, 130.10, 129.50, 129.27, 128.72, 128.34, 127.09,
126.20. HRMS (ESI): m/z [M + H]+ calculated for C10H10ON3: 188.08184; found: 188.08191.
3.1.19. Preparation of N-(2-(1H-imidazol-4-yl)benzyl)hydroxylamine (DX-03-03)
Compound DX-03-02 (50 mg, 0.27 mmol) following the similar procedure described for the
preparation of DX-02-04 afforded DX-03-03 (white solid, 32 mg, yield 63%). 1H-NMR (400 MHz,
CD3OD): δ = 7.75 (s, 1H, H-imidazolyl), 7.53 (d, J = 1.7 Hz, 1H, H-phenyl), 7.47–7.44 (m, 1H, H-phenyl),
7.35–7.27 (m, 3H, H-imidazolyl, H-phenyl), 4.04 (s, 2H). HRMS (ESI): m/z [M + H]+ calculated for
C10H12ON3: 190.09749; found: 190.09737.
3.1.20. Preparation of (E) 2-(2H-tetrazol-5-yl)benzaldehyde Oxime (DX-03-04)
2-(2H-tetrazol-5-yl)benzaldehyde (200 mg, 1.15 mmol) following the similar procedure described
for the preparation of DX-03-12 and DX-02-04 afforded DX-03-04 (white solid, 78 mg, yield 36% from
2-(2H-tetrazol-5-yl)benzaldehyde). 1H-NMR (400 MHz, DMSO-d6): δ = 11.23 (s, 1H, OH), 11.07 (s,
1H, H-tetrazolyl), 8.29 (s, 1H, =CH), 7.73–7.56 (m, 4H, H-phenyl). 13C-NMR (101 MHz, DMSO-d6):
δ = 156.17, 137.81, 132.14, 130.64, 129.27, 127.64, 116.84, 110.69. HRMS (ESI): m/z [M +H]+ calculated
for C8H8N5O: 190.07234; found: 190.07158.
3.1.21. Preparation of (E) 5-chloro-2-(1H-imidazol-4-yl)benzaldehyde Oxime (DX-03-05)
Compound 5 (300 mg, 0.69 mmol) and (4-chloro-2-formylphenyl)boronic acid (127 mg, 0.69 mmol)
following the similar procedure described for the preparation of DX-03-12 and DX-02-04 afforded
DX-03-05 (white solid, 70 mg, yield 46% from (4-chloro-2-formylphenyl)boronic acid). 1H-NMR
(400 MHz, DMSO-d6): δ = 12.38 (s, 1H, OH), 11.32 (s, 1H, NH-imidazolyl), 8.77 (s, 1H, =CH), 7.80
(s, 1H, H-imidazolyl), 7.74 (s, 1H, H-imidazolyl), 7.63 (d, J = 2.4 Hz, 1H, H-phenyl), 7.44–7.42 (m,
2H, H-phenyl). 13C-NMR (101 MHz, DMSO-d6): δ = 147.77, 138.56, 136.60, 133.12, 131.72, 131.48,
131.05, 129.25, 125.42, 116.28. HRMS (ESI): m/z [M + H]+ calculated for C10H9ClN3O: 222.04287;
found: 222.04330.
3.1.22. Preparation of (E) 2-fluoro-6-(1H-imidazol-4-yl)benzaldehyde Oxime (DX-03-06)
Compound 5 (300 mg, 0.69 mmol) and (3-fluoro-2-formylphenyl)boronic acid (116 mg, 0.69 mmol)
following the similar procedure described for the preparation of DX-03-12 and DX-02-04 afforded
DX-03-06 (white solid, 75 mg, yield 53% from (3-fluoro-2-formylphenyl)boronic acid). 1H-NMR
(400 MHz, DMSO-d6): δ = 12.37 (s, 1H, OH), 11.24 (s, 1H, NH-imidazolyl), 8.37 (s, 1H, =CH), 7.76
(s, 1H, H-imidazolyl), 7.52 (s, 1H, H-imidazolyl), 7.36–7.13 (m, 3H, H-phenyl). 13C-NMR (101 MHz,
DMSO-d6): δ = 161.48, 159.00, 144.68, 136.29, 130.27, 124.36, 122.95, 117.89, 116.35, 113.98. HRMS (ESI):
m/z [M + H]+ calculated for C10H9FN3O: 206.07242; found: 206.07250.
3.1.23. Preparation of (E) 2-(1H-imidazol-4-yl)-5-methoxybenzaldehyde Oxime (DX-03-07)
Compound 5 (300 mg, 0.69 mmol) and (2-formyl-4-methoxyphenyl)boronic acid (124 mg,
0.69 mmol) following the similar procedure described for the preparation of DX-03-12 and DX-02-04
afforded DX-03-07 (white solid, 113 mg, yield 76% from (2-formyl-4-methoxyphenyl)boronic acid).
1H-NMR (400 MHz, CD3OD): δ = 8.73 (s, 1H, H-imidazolyl), 7.78 (s, 1H, H-imidazolyl), 7.52–7.38
(m, 3H, H-phenyl), 7.15 (s, 1H, H-phenyl), 7.10–6.96 (m, 4H, H-phenyl), 3.85 (s, 3H, CH3). 13C-NMR
(101 MHz, CD3OD): δ = 141.55, 137.87, 133.07, 132.61, 121.44, 118.60, 117.79, 116.37, 113.90, 110.95,
55.90. HRMS (ESI): m/z [M + H]+ calculated for C11H12N3O2: 218.09240; found: 218.09206.
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3.1.24. Preparation of (E) 4-(1H-imidazol-4-yl)-2′-(trifluoromethyl)-[1,1′-biphenyl]-3-carbaldehyde
Oxime (DX-03-08)
Compound 5 (300 mg, 0.69 mmol) and (3-formyl-2′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)
boronic acid (202 mg, 0.69 mmol) following the similar procedure described for the
preparation of DX-03-12 and DX-02-04 afforded DX-03-08 (white solid, 82mg, yield 36% from
(3-formyl-2′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)boronic acid). 1H-NMR (400 MHz, DMSO-d6):
δ = 12.38 (s, 1H, OH), 11.14 (s, 1H, NH-imidazolyl), 8.85(s, 1H, H-imidazolyl), 7.86–7.79 (m, 2H,
H-imidazolyl, H-phenyl), 7.73–7.63 (m, 4H, H-phenyl), 7.46 (br, 2H, H-phenyl), 7.33 (s, 1H, H-phenyl).
13C-NMR (101 MHz, DMSO-d6): δ = 148.54, 140.58, 137.83, 136.56, 132.89, 132.57, 130.11, 129.84, 129.53,
128.94, 128.64, 126.58, 126.32, 126.23, 126.04, 123.22, 116.04. HRMS (ESI): m/z [M +H]+ calculated for
C17H13F3N3O: 332.10052; found: 332.10123.
3.1.25. Preparation of (E) 3-(1H-imidazol-4-yl)-[1,1′-biphenyl]-4-carbaldehyde Oxime (DX-03-09)
Compound 5 (300 mg, 0.69 mmol) and (4-formyl-[1,1′-biphenyl]-3-yl)boronic acid (156 mg,
0.69 mmol) following the similar procedure described for the preparation of DX-03-12 and DX-02-04
afforded DX-03-09 (white solid, 81 mg, yield 45% from (4-formyl-[1,1′-biphenyl]-3-yl)boronic acid).
1H-NMR (400 MHz, DMSO-d6): δ = 11.01 (s, 1H, OH), 10.34 (s, 1H, NH-imidazolyl), 8.55 (s, 1H,
=CH), 8.39 (s, 1H, H-imidazolyl), 8.12 (s, 1H, H-imidazolyl), 7.58 (br, 1H, H-phenyl), 7.48–7.22 (m, 2H,
H-phenyl), 7.11–7.02 (m, 2H, H-phenyl), 6.87–6,81 (m, 2H, H-phenyl), 6.50 (s, 1H, H-phenyl). HRMS
(ESI): m/z [M + H]+ calculated for C16H14N3O: 264.11314; found: 264.11346.
3.1.26. Preparation of 4-(2-((4-(trifluoromethyl)benzyl)oxy)phenyl)-1,2,3-thiadiazole (DX-03-10)
2-(1,2,3-Thiadiazol-4-yl)phenol (100 mg, 0.56 mmol) and 1-(bromomethyl)-4-(trifluoromethyl)benzene
(134 mg, 0.56 mmol) following the similar procedure described for the preparation of 12 afforded DX-03-10
(white solid, 128 mg, yield 68%). 1H-NMR (400 MHz, DMSO-d6): δ = 9.39 (s, 1H, H-thiadiazolyl), 8.26 (d, J
= 7.5 Hz, 1H, H-phenyl), 7.76 (d, J = 8.2 Hz, 2H, H-phenyl), 7.70 (d, J = 8.5 Hz, 2H, H-phenyl), 7.48–7.43
(m, 1H, H-phenyl), 7.31 (d, J = 7.7 Hz, 1H, H-phenyl), 7.17 (t, J = 7.5 Hz, 1H, H-phenyl), 5.44 (s, 2H, CH2).
HRMS (ESI): m/z [M +H]+ calculated for C16H12F3N2OS: 337.06169; found: 337.06116.
3.1.27. Preparation of N-(3-(2-(1H-imidazol-5-yl)phenoxy)propyl)-aminesulfonamide (DX-03-11)
Compound 9 (200 mg, 0.34 mmol) following the similar procedure described for the preparation
of DX-03-12 afforded DX-03-11 (white solid, 45 mg, yield 45% from compound 9). 1H-NMR (400 MHz,
CD3OD): δ = 8.67 (s, 1H, NH-imidazolyl), 8.08 (s, 1H, H-imidazolyl), 7.83 (s, 1H, H-imidazolyl), 7.69 (d,
J = 7.7 Hz, 1H, H-phenyl), 7.40 (t, J = 7.1 Hz, 1H, H-phenyl), 7.16 (d, J = 8.2 Hz, 1H, H-phenyl), 7.08 (t,
J = 7.4 Hz, 1H, H-phenyl), 4.20 (t, J = 6.0 Hz, 2H, CH2), 3.44 (t, J = 6.9 Hz, 2H, CH2), 2.11–2.03 (m, 2H,
CH2). HRMS (ESI): m/z [M + H]+ calculated for C12H17O3N4S: 297.10159; found: 297.10115.
3.1.28. Preparation of 1-(3-(2-(1H-imidazol-5-yl)phenoxy)propyl)-3-(4-(trifluoromethyl) phenyl)urea
(DX-03-13)
Compound 9 (200 mg, 0.34 mmol) following the similar procedure described for the preparation
of DX-03-12 afforded DX-03-13 (white solid, 77 mg, yield 56% from compound 9). 1H-NMR (400 MHz,
DMSO-d6): δ = 12.24 (s, 1H, NH-imidazolyl), 8.90 (s, 1H, H-imidazolyl), 8.01 (d, J = 7.4 Hz, 1H,
H-phenyl), 7.75 (s, 1H, H-imidazolyl), 7.61–7.54 (m, 5H, H-phenyl), 7.21–7.15 (m, 1H, H-phenyl), 7.06
(d, J = 7.8 Hz, 1H, H-phenyl), 7.02–6.94 (m, 1H, H-phenyl), 6.48 (t, J = 5.7 Hz, 1H, H-phenyl), 4.14 (t,
J = 6.1 Hz, 2H, CH2), 3.38–3.32 (m, 2H, CH2), 2.08–1.97 (m, 2H, CH2). 13C-NMR (101 MHz, DMSO-d6):
δ = 155.42, 155.08, 144.71, 135.42, 129.17, 127.38, 127.13, 126.38 (2C), 123.78, 122.81, 121.53, 121.21,
120.86, 117.71 (2C), 112.33, 65.82, 36.89, 29.98. HRMS (ESI): m/z [M + H]+ calculated for C20H20O2N4F3:
405.15329; found: 405.15302.
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3.1.29. Preparation of 1-(3-bromo-4-fluorobenzyl)-4-(5-chloro-2-methoxyphenyl)-1H-imidazole
(DX-04-03)
2-Bromo-4-(bromomethyl)-1-fluorobenzene (500 mg, 1.88 mmol) following the similar procedure
described for the preparation of DX-04-02 afforded DX-04-03 (white solid, 480 mg, yield 65% from
2-bromo-4-(bromomethyl)-1-fluorobenzene). 1H-NMR (400 MHz, CD3OD): δ = 7.95 (d, J = 2.7 Hz,
1H, H-phenyl), 7.78 (d, J = 1.3 Hz, 1H, H-imidazolyl), 7.64 (d, J = 1.3 Hz, 1H, H-imidazolyl), 7.57 (dd,
J = 6.5, 2.2 Hz, 1H, H-phenyl), 7.30–7.24 (m, 1H, H-phenyl), 7.20 (d, J = 8.5 Hz, 1H, H-phenyl), 7.16 (dd,
J = 8.8, 2.7 Hz, 1H, H-phenyl), 6.98 (d, J = 8.8 Hz, 1H, H-phenyl), 5.22 (s, 2H, CH2), 3.88 (s, 3H, CH3).
13C-NMR (101 MHz, CD3OD): δ = 161.35, 158.96, 156.10, 138.33, 137.40, 133.91, 129.70, 128.04, 127.36,
126.81, 125.19, 121.53, 117.84, 113.47, 110.01, 56.13, 50.30. HRMS (ESI): m/z [M + H]+ calculated for
C17H14ON2BrClF: 394.99566; found: 394.99728.
3.1.30. Preparation of 2-(1-(3-bromo-4-fluorobenzyl)-1H-imidazol-4-yl)-4-chlorophenol (DX-04-04)
DX-04-03 (200 mg, 0.51 mmol) following the similar procedure described for the preparation
of DX-04-02 afforded DX-04-04 (white solid, 116 mg, yield 60%). 1H-NMR (400 MHz, DMSO-d6):
δ = 9.12 (s, 1H, H-imidazolyl), 8.40 (s, 1H, H-imidazolyl), 8.01 (s, 1H, H-imidazolyl), 7.89 (dd, J = 6.5,
1.7 Hz, 1H, H-phenyl), 7.56–7.49 (m, 1H, H-phenyl), 7.45 (t, J = 8.6 Hz, 1H, H-phenyl), 7.34 (dd, J =
8.8, 2.5 Hz, 1H, H-phenyl), 7.00 (d, J = 8.8 Hz, 1H, H-phenyl), 5.42 (s, 2H, CH2). 13C-NMR (101 MHz,
CD3OD): δ = 161.85, 159.35, 154.93, 136.62, 134.79, 130.61, 130.34, 126.90, 125.53, 119.70, 118.77, 118.32,
118.09, 117.92, 110.27, 51.71. HRMS (ESI): m/z [M + H]+ calculated for C16H12ON2BrClF: 380.98001;
found: 380.98065.
3.1.31. Preparation of 4-chloro-2-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)phenol (DX-04-05)
DX-04-06 (300 mg, 0.81 mmol) following the similar procedure described for the preparation
of DX-04-02 afforded DX-04-05 (white solid, 176 mg, yield 61%). 1H-NMR (400 MHz, DMSO-d6):
δ = 10.49 (s, 1H, OH), 7.85 (s, 1H, H-triazolyl), 7.64 (d, J = 8.1 Hz, 2H, H-phenyl), 7.34 (dd, J = 8.8, 2.7
Hz, 1H, H-phenyl), 7.20 (d, J = 8.1 Hz, 2H, H-phenyl), 7.16 (d, J = 2.7 Hz, 1H, H-phenyl), 6.98 (d, J = 8.8
Hz, 1H, H-phenyl), 5.62 (s, 2H, CH2). 13C-NMR (101 MHz, CD3OD): δ = 155.39, 140.99, 136.49, 134.75,
132.46, 131.76, 131.11, 129.36 (2C), 126.49 (2C), 125.38, 124.09, 118.30, 116.15, 53.27. HRMS (ESI): m/z
[M + H]+ calculated for C16H12ON3ClF3: 354.06155; found: 354.06015.
3.1.32. Preparation of 4-(5-chloro-2-methoxyphenyl)-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazole
(DX-04-06)
4-chloro-2-ethynyl-1-methoxybenzene (500 mg, 3.01 mmol) and 1-(bromomethyl)-4-
(trifluoromethyl)benzene (717 mg, 3.01 mmol) following the similar procedure described
for the preparation of DX-04-02 afforded DX-04-06 (white solid, 675 mg, yield 61% from
4-chloro-2-ethynyl-1-methoxybenzene). 1H-NMR (400 MHz, CD3OD): δ = 7.71 (s, 1H, H-triazolyl), 7.50
(d, J = 8.1 Hz, 2H, H-phenyl), 7.40 (dd, J = 8.9, 2.7 Hz, 1H, H-phenyl), 7.14 (d, J = 8.1 Hz, 2H, H-phenyl),
7.09 (d, J = 2.6 Hz, 1H, H-phenyl), 7.03 (d, J = 8.9 Hz, 1H, H-phenyl), 5.55 (s, 2H, CH2), 3.64 (s, 3H,
CH3). 13C-NMR (101 MHz, CD3OD): δ = 154.74, 143.61, 131.20, 130.91, 129.93 (2C), 129.81, 129.39,
127.59, 127.02 (2C), 125.98, 125.64, 118.63, 117.43, 55.31, 55.04. HRMS (ESI): m/z [M + H]+ calculated for
C17H14ON3ClF3: 368.07720; found: 368.07599.
3.1.33. Preparation of 4-chloro-2-(5-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)phenol (DX-04-07)
DX-04-08 (200 mg, 0.57 mmol) following the similar procedure described for the preparation of
DX-04-02 afforded DX-04-07 (white solid, 144 mg, yield 75%). 1H-NMR (400 MHz, DMSO-d6): δ = 15.28
(s, 1H, H-triazolyl), 9.91 (s, 1H, NH-triazolyl), 7.75–7.68 (m, 4H, H-phenyl), 7.37 (br, 2H, H-phenyl),
6.94 (s, 1H, H-phenyl). 13C-NMR (101 MHz, CD3OD): δ = 155.58, 142.95, 137.77, 136.14, 131.62, 131.27,
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130.86, 128.63 (2C), 126.43 (2C), 125.31, 124.28, 119.14, 118.53. HRMS (ESI): m/z [M + H]+ calculated for
C15H10ON3ClF3: 340.04590; found: 340.04453.
3.1.34. Preparation of 4-(5-chloro-2-methoxyphenyl)-5-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole
(DX-04-08)
4-chloro-2-ethynyl-1-methoxybenzene (300 mg, 1.81 mmol) and 1-iodo-4-(trifluoromethyl)benzene
(491 mg, 1.81 mmol) following the similar procedure described for the preparation of DX-04-02 afforded
DX-04-08 (white solid, 338 mg, yield 53% from 4-chloro-2-ethynyl-1-methoxybenzene). 1H-NMR
(400 MHz, DMSO-d6): δ = 15.41 (s, 1H, NH-triazolyl), 7.74 (d, J = 8.1 Hz, 2H, H-phenyl), 7.68–7.59
(m, 2H, H-phenyl), 7.54 (d, J = 8.9 Hz, 1H, H-phenyl), 7.48 (d, J = 2.7 Hz, 1H, H-phenyl), 7.15 (s, 1H,
H-phenyl), 3.42 (s, 3H, CH3). 13C-NMR (101 MHz, CD3OD): δ = 157.20, 136.42, 131.71, 131.59, 131.14,
129.65, 128.37 (2C), 126.96, 126.75, 126.40 (2C), 124.27, 121.57, 114.17, 55.99. HRMS (ESI): m/z [M + H]+
calculated for C16H12ON3ClF3: 354.06155; found: 354.06079.
3.2. Pharmacological Method
3.2.1. Enzyme-Based IDO1s or TDOs Activity Assay
The compounds on IDO1 or TDO activity were determined as follows [16,24,25]: A standard
reaction mixture (100 μL) containing 100 mM potassium phosphate buffer (pH 6.5), 40 mM ascorbic acid
(neutralized with NaOH), 200 μg/mL catalase, 20 μM methylene blue and 0.05 μM rhIDO1 or rhTDO
was added to the solution containing the substrate l-tryptophan and the test sample at a determined
concentration. The reaction was carried out at 37 ◦C for 45 min and stopped by adding 20μL of 30% (w/v)
trichloroacetic acid. After heating at 65 ◦C for 15 min, 100 μL of 2% (w/v) p-dimethylaminobenzaldehyde
in acetic acid was added to each well. The yellow pigment derived from kynurenine was measured at
492 nm using a SYNERGY-H1 microplate reader (Biotek Instruments, Inc., Winooski, VT, USA). IC50
was analyzed using the GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA).
3.2.2. Cell Culture
B16-F10 mouse melanoma cells, NCI-H460 human lung cancer cell line and MCF7 were obtained
from American Type Culture Collection (ATCC). All the cell lines were cultured with Dulbecco’
modified Eagle’s medium (DMEM) (Invitrogen Corporation, Waltham, MA, USA) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Waltham, MA, USA) and 1% penicillin streptomycin
(Invitrogen) at 37 ◦C in 5% CO2.
3.2.3. Cell Viability Assay
The in vitro inhibitory effects of the compounds were measured by MTT assay [26]. Briefly,
different kinds of cells were plated in 96-well plates at a density of 2000/well. After attachment for
overnight at 37 ◦C, the cells were treated with the compounds at various concentrations. After 72 h
culture, the MTT reagent was added to each well, and plates were incubated for another 4 h at 37 ◦C.
Then, the blue-purple crystal formamidine was dissolved in DMSO after discarding the supernatant.
Samples were measured using microplate reader at a wavelength of 570 nm (Biotek Instruments, Inc.,
Winooski, VT, USA). IC50 values were calculated with GraphPad Prism 8.0 software.
3.2.4. Mice
C57BL/6 mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd.
(Beijing Vital River Laboratory Animal Technology Co., Ltd, Beijing, China). Studies involving mice
were approved by the Experimental Animal Management and Welfare Committee at the Institute of
Materia Medica, Peking Union Medical College.
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3.2.5. Pharmacokinetic Studies
The animal Care and Welfare Committee of Institute of Materia Medica, Chinese Academy of
Medical Sciences approved all animal care, housing, and laboratory procedures. Male ICR mice
were used in the single dose pharmacokinetic studies. Compound DX-03-12 was prepared as
3 mg/mL suspension with 0.5% CMC (containing 0.3% Tween 80) for oral use and was formulated
as 3 mg/mL solution with 5% DMSO in saline for intravenous injection. Twenty mice were divided
into two groups, 10 in each group. After fasting 12 h with free access to water, mice were treated
with a 3 mg/kg i.v. or 30 mg/kg oral dose of compound DX-03-12. Blood samples (50 μL) were
collected at 5, 15, 30 min, 1, 2, 4, 6, 8, 12 and 24 h after oral administration and 2, 5, 15, 30 min,
1, 2, 4, 6, 8, 12 and 24 h after intravenous injection. After centrifugation, the plasma samples
(15 μL) were precipitated by five volumes of acetonitrile. The supernatant were analyzed by liquid
chromatography/tandem mass spectrometry (Agilent Technologies, Santa Clara, CA, USA) with a
Zobax C18 column (50 mm × 2.1 mm, 3.5 μm). Compound detection was performed with the mass
spectrometer in MRM (multiple reaction monitoring, Agilent Technologies, Santa Clara, CA, USA)
negative ionization mode. The selected reaction monitoring transitions were m/z 348.5→160 for
compound DX-03-12. The pharmacokinetic parameters were calculated with WinNonlin software V6.3
using non-compartmental analysis (Pharsight Corporation, Mountain View, CA, USA).
3.2.6. In Vivo Studies
The mouse melanoma cells B16F10 were cultured and harvested in saline. At day 0 of the
experiment, 1 × 106 cells were injected subcutaneously into mice, and treatment was initiated at
day 1 following the mice enrolled randomly in control and experimental groups [27]. For control
group, 0.5% CMCNa was orally administered every day. Compound DX-03-12 was dissolved in
0.5% CMC for oral treatment or dissolved in saline for intraperitoneal treatment. When the mice
were sacrificed, the tumors were stripped and weighted. The tumor growth inhibition (TGI) was
calculated as TGI = (1 – tumor weight treatment/tumor weight vehicle) × 100%. The statistical analysis
was performed with GraphPad Prism 8.0 software and the significance level was evaluated with a
one-way ANOVA model.
4. Conclusions
We designed four series of IDO1 inhibitors using indole and phenylimidazole as the scaffolds.
The design strategies were based on the mechanism of IDO1, focusing on the interaction between the
inhibitor and the heme iron. The four series of compounds were synthesized and their IDO1 and TDO
inhibition was evaluated. Most compounds showed marginal IDO1 inhibition, but eight compounds
showed moderate IDO1 inhibition. In particular, DX-03-12 and DX-03-13 showed IDO1 inhibition with
IC50s of 0.3 and 0.5 μM and low cell cytotoxicities against two cancer cell lines. A pharmacokinetic
study showed that DX-03-12 had satisfactory properties, with rapid absorption, moderate plasma
clearance, acceptable half-life, and high oral bioavailability. The in vivo anti-tumor efficacy in a B16F10
subcutaneous xenograft mouse model showed that DX-03-12 orally administered at a dose of 60 mg/kg
inhibited tumor growth by 72.2% compared with the control tumors. In summary, IDO1 inhibitor
DX-03-12 exhibits promising drug like properties, good pharmacokinetic properties, low cellular
toxicity, and impressive in vivo anti-tumor efficacy.
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Abstract: A series of novel 7,9-O-linked macrocyclic taxoids together with modification at the C2
position were synthesized, and their cytotoxicities against drug-sensitive and P-glycoprotein and
βIII-tubulin overexpressed drug-resistant cancer cell lines were evaluated. It is demonstrated that
C-seco taxoids conformationally constrained via carbonate containing-linked macrocyclization display
increased cytotoxicity on drug-resistant tumors overexpressing both βIII and P-gp, among which
compound 22b, bearing a 2-m-methoxybenzoyl group together with a five-atom linker, was identified
as the most potent. Molecular modeling suggested the improved cytotoxicity of 22b results from
enhanced favorable interactions with the T7 loop region of βIII.
Keywords: taxoids; βIII-tubulin; P-glycoprotein; drug resistance
1. Introduction
Antitubulin agent paclitaxel (1a, Figure 1) and its semi-synthetic derivative docetaxel (1b, Figure 1)
are successfully used in the clinic for the treatment of ovarian, breast, and non-small cell lung and
prostate cancers and Kaposi’s sarcoma.
Figure 1. Structures of paclitaxel (1a), docetaxel (1b), and IDN5390 (2).
However, their clinical uses are severely restricted by drug resistance. Various resistance
mechanisms toward taxane-based anticancer drugs have been revealed, among which only
overexpression of P-glycoprotein (P-gp) and βIII-tubulin have been confirmed clinically [1–4].
A great deal of effort has been made to overcome multi-drug resistance (MDR) mediated
by overexpression of P-gp. Nevertheless, many taxane-based drug candidates targeting P-gp
overexpression did not achieve the expected efficacy in clinical trials [5,6].
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A correlation between βIII-tubulin overexpression and poor prognosis has been reported in
several human tumors, including various advanced malignancies upon treatment of taxanes, such as
breast, non-small cell lung, and ovarian cancers [7–10]. It was reported that a C-seco taxane IDN5390
(2, Figure 1) is more active than paclitaxel in several paclitaxel-resistant human ovarian adenocarcinoma
cell lines (e.g., A2780TC1, A2780TC3, and OVCAR-3), expressing high βIII-tubulin and P-gp levels.
However, IDN5390 was nearly 10-fold less active than paclitaxel in paclitaxel-sensitive cells [11].
To find a modified taxane effective against both paclitaxel-sensitive and -resistant tumors, the
7,9-O-linked C-seco taxoid 3 (Figure 2) was synthesized in our lab and shown to exhibit significant
activity enhancement against drug-sensitive Hela andβIII-tubulin overexpressing HeLa-βIII tumor cells
compared to the C-seco paclitaxel derivative 4 (an analog of IDN5390, Figure 2) [12]. Those macrocyclic
taxoids provided a successful example for the compromise between structural pre-organization and
sufficient flexibility in the C ring of C-seco taxoids to improve the cytotoxicity against tumor cells that
overexpress βIII tubulin [12].
Figure 2. Structures of the 7,9-O-linked C-seco taxoid 3 and C-seco paclitaxel derivative 4.
It has long been observed that modification of taxane at the C2 position could play a critical role in
its interaction with tubulin. Consistent with this observation, the 7,9-O-linked C-seco taxoid with C2
modification 5 (Figure 3) was much more cytotoxic than the C-seco taxoid 6 (Figure 3) in drug-resistant
A2780AD and KB-V1 cells (P-gp overexpression) and Hela-βIII (βIII overexpression) [12]. It was
demonstrated that the meta-substitution (i.e., -OMe, -F, -Cl) of the C2-benzoate moiety of C-seco
taxoids derivatives 7a–c (Figure 3) could increase the interaction of C-seco-taxoids with βIII-tubulin to
overcome paclitaxel-resistance [13].
Figure 3. Structures of the 7,9-O-linked C-seco taxoid 5 and C-seco taxoids 6, 7a–c.
In order to explore the effect of macrocyclization in a different way from that employed in our
previous study (i.e., via the carbonate formation to restrict the conformation), the synthesis and
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biological activity assessment of a series of 7,9-O-linked macrocyclic taxoids together with modification
at the C2 position were performed and are reported here.
2. Results and Discussion
2.1. Chemistry
Our synthesis began with the preparation of 2′-tert-butyldimethylsilyl-paclitaxel 12a, which was
then converted to 10-deacetylpaclitaxel 13a upon treatment with hydrazine hydrate in methanol.
Synthesis of the analogues 12b–e of 2′-tert-butyldimethylsilyl-paclitaxel with modifications at the
C2 positions was then realized by selective C2 debenzoylation and then elaboration with various
m-substituted benzoyl group. C2-modified 10-deacetylpaclitaxel 13b–e were afforded in the same
manner as compound 13a. Then the compounds 13a–e were oxidized by copper (II) diacetate to furnish
14a–e as a mixture of two epimers. Reductive trapping of the ring C-seco tautomers 15a–e were obtained
by treatment with l-selectride. Subsequent deprotection with pyridine hydrofluoride (HF-pyridine)
afforded 16a–e. The 9-OH in 15a–e was hydroxylalkylated by 2-bromoethanol or 3-bromo-1-propanol
in the presence of potassium carbonate and potassium iodide in N,N-dimethylformamide (DMF).
Cyclization of compounds 17a–e could be accomplished by treatment with a slight excess of triphosgene,
affording the cyclic carbonate analogues 19a–e. Desilylation of 19a–e with HF-pyridine afforded
macrocyclic analogues 21a–e. Accordingly, macrocyclic taxoids 22a–e bearing a linkage with one more
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Scheme 1. (a) tert-ButyldiMethylsilyl chloride (TBDMSCl), imidazole, DMF, 2 h, 60 ◦C, and;
triethylchlorosilane (TESCl), imidazole, DMF, overnight, r.t., 90.1%; (b) Triton-B, tetrahydrofuran
(THF), 15 min, −40 ◦C, 47.7%; (c) (10a) m-anisic acid, N, N′-diisopropylcarbodiimide (DIC),
4-dimethylaminopyridine (DMAP), toluene, overnight, 60 ◦C, 72.5%; (10b) m-fluorobenzoic acid,
DIC, DMAP, toluene, overnight, 60 ◦C, 91.4%; (10c) m-chlorobenzoic acid, DIC, DMAP, toluene,
overnight, 60 ◦C, 84.2%; (10d) m-trifluoromethyl acid, DIC, DMAP, toluene, overnight, 60 ◦C, 84.2%;
(d) HF -pyridine, THF, overnight, r.t.; (11a) 81.8%; (11b) 91.9%; (11c) 85.1%; (11d) 91.0%; (e) TBDMSCl,
imidazole, DMF, 4 h, r.t.; (f) NH2NH2·H2O, C2H5OH, 2 h, r.t. (e and f two steps), (13a) 87.9%, (13b)
99.0%; (13c) 93.5%; (13d) 83.0%; (13e) 90.1%; (g) Cu(OAc)2·H2O, CH3OH, overnight, r.t., (14a) 85.8%;
(14b) 69.5%; (14c) 79.0%; (14d) 84.9%; (14e) 81.9%; (h) l-selectride, THF, 15 min, −20 ◦C, (15a) 81.2%;
(15b) 88.7%; (15c) 79.2%; (15d) 58.8%; (15e) 76.5%; (i) HF/Py, THF, overnight, r.t., (16a) 77.4%; (16b)
65.2%; (16c) 59.3%; (16d) 60.3%; (16e) 55.5%; (j) 2-bromoethanol, K2CO3, KI, DMF, 5–9 h, r.t., (17a)
52.4%; (17b) 56.1%; (17c) 53.2%; (17d) 60.9%; (17e) 49.9%; (k) 3-bromo-1-propanol, K2CO3, KI, DMF,
4–9 h, r.t., (18a) 72.4%; (18b) 75.3%; (18c) 69.7%; (18d) 52.6%; (18e) 71.8%; (l) triphosgene, pyridine,
DCM, 3–5 h, 0 ◦C to r.t., (19a) 15.9%; (19b) 32.7%; (19c) 32.1%; (19d) 36.1%; (19e) 30.5%; (20a) 24.9%;
(20b) 28.6%; (20c) 27.1%; (20d) 23.6%; (20e) 26.7%; (m) HF/Py, THF, 30 h, r.t., (21a) 46.2%; (21b) 54.1%;
(21c) 52.2%; (21d) 48.7%; (21e) 63.7%; (22a) 51.0%; (22b) 59.2%; (22c) 51.5%; (22d) 65.4%; (22e) 59.5%.
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2.2. Bioactivity Evaluation of Taxoids 21a–e and 22a–e
Taxoids 21a–e, 22a–e, and 16a–e were evaluated for their in vitro cytotoxicities against cervical
carcinoma HeLa cells and their corresponding drug-resistant cell lines (HeLa-βIII).
As shown in Table 1, all the 7,9-O-linked macrocyclic analogues (21a–e, 22a–e) possessed a
remarkably higher potency against HeLa and HeLa-βIII cells than their corresponding C-seco taxoids
analogues 16a–e. The R/S values (IC50 in drug resistant cells/IC50 in drug sensitive cells) of all
macrocyclic analogues were lower than those of their corresponding C-seco taxoids analogues
16a–e. These findings demonstrate that conformational restraint via carbonate-containing linked
macrocyclization can improve the cytotoxicity against human carcinoma cell lines overexpressing
βIII tubulin.
Furthermore, all of the 7,9-O-linked macrocyclic analogues bearing the four-atom linker (21a–e)
turned out to be generally more potent against sensitive HeLa cells and HeLa-βIII cells than the
corresponding macrocyclic analogues bearing the five-atom linker (22a–e). Since the cytotoxicity of
21a–d was approximately equal to that of paclitaxel, these results suggest that a four-atom tether is
optimal in these macrocyclic C-seco taxoids.
For the effect of C2 modifications in these macrocyclic C-seco taxoids, we found similar results as
previously reported [12,13]. Pepe et al. studied the cytotoxicity of a series of C-seco taxoids, whereby
the introduction of a substituent (-OMe, -F, -Cl) to the meta-position of the C2 benzoyl moiety increased
potency against the βIII-tubulin-overexpressing, paclitaxel-resistant cell line A2780TC3 [13]. Taxoid 6
bearing a 2-(m-azido) benzyloxy group and synthesized in our lab exhibited higher binding affinity for
microtubulin (MT) than its corresponding taxoids bearing a 2-benzyloxy group [12]. The 7,9-O-linked
C-seco taxoid bearing a 2-(m-azido) benzyloxy group 5 was significantly more active than 6 on
drug-resistant A2780AD, HeLa-βIII, and KB-V1 cells [12].
We investigated this effect in the 7,9-O-linked C-seco taxoids 21b–e and 22b–e reported here. Thus,
introduction of a meta substituent (-OMe, -F, -Cl) on derivatives bearing the four-atom linker showed
similar cytotoxicity against HeLa sensitive cell lines and Hela-βIII cells lines as their corresponding
C-seco taxoid 21a bearing a 2-benzyloxy group. In contrast, the meta-substituted (-OMe, -F, -Cl)
derivatives bearing five-atom linker possessed higher potency against HeLa-βIII cells lines than its
corresponding C-seco taxoid 22a (by a factor of 3.1–8.9). Nonetheless, the 2-m-CF3 analogues 21e and
22e were considerably less cytotoxic against both drug sensitive and resistant cells by one to two orders
of magnitude.
The growth inhibition effects of the 7,9-O-linked macrocyclic analogues were also measured on
human breast cancer MCF-7 cells and their corresponding P-gp-overexpressing drug-resistant MCF-7/R
cells. As shown in Table 1, the 7,9-O-linked macrocyclic analogues possessed remarkable potency
against MCF-7/R cells compared to their C-seco counterparts, except for the 2-m-CF3 derivatives.
Strikingly, macrocyclic taxoids bearing the five-atom linker were almost inactive. The cytotoxicity
against MCF-7/R cells of the 7,9-O-linked macrocyclic derivatives (-OMe, -F, -Cl) bearing the five-atom
linker were slightly higher than that of the compouds bearing the four-atom linker. Compounds
22b–d (-OMe, -F, -Cl) bearing the five-atom linker and 21a, 21d (-H, -Cl) bearing the four-atom linker
displayed lower R/S values than that of paclitaxel. All in all, 22b turned out to be the best compound
in the whole series.
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2.3. Binding Mode of 22b and Rationale for the Increased Affinity for the βIII Isotype
Inspection of the paclitaxel-β-tubulin complex in high-resolution cryo-electron microscopy
(cryo-EM) structures of mammalian microtubules reveals a very tight fit between the bulky drug and
the taxane-binding site, in which the M-loop is structured as an α-helix [14]. The oxetane ring oxygen of
paclitaxel (1a) accepts a hydrogen bond from the backbone NH of Thr276, whereas the C-3′ benzamide
carbonyl oxygen acts as a hydrogen bond acceptor for Nε of His229. These two hydrogen bonds are
likely to be present in the 22b:β-tubulin complex as well (Figure 4), and definitely contribute to the
binding affinity, but these two residues are common to both βIIB and βIII isotypes. In the search for
sequence differences that can account for the resistance to taxanes, a lot of emphasis has been placed
on the Ser→Ala replacement at position 277, but we believe that the most important replacement in
relation to drug resistance possibly involves Cys241→Ser. The reason is that, as a consequence of this
substitution, disulfide bond formation with Cys356 is precluded in the βIII isotype and the T7 loop
region, which closes over the bound taxane, is likely to be more flexible. By directing the macrocyclic
region of 22b towards this loop, favorable interactions within the taxane-binding site are enhanced and
the affinity towards the βIII isotype is improved. We hypothesize that the improved cytotoxicity of
22b relative to 1a, and the other taxanes described here, results from enhanced favorable interactions
with the T7 loop region of βIII, an isotype in which Cys356 cannot engage in a disulfide bond with the
amino acid present at position 241 (Ser).
Figure 4. 22b docked into homology models of human tubulins IIb and III bound to guanosine
diphosphate (GDP)-Mg2+. Colored in magenta and labeled are those residues close to the taxane-binding
site that differ between these two isotypes.
As shown in this modelling study, the binding of these taxoids to microtubules are similar to that
of paclitaxel. Although cyclization does increase the cytotoxicity either in drug-sensitive and -resistant
cells in most cases, the 7,9-O-linked macrocyclic taxoids only showed comparable cytotoxicity to that
of paclitaxel. The enhanced activity is not only arisen from the known C-2 modifications [15,16], but
also from the cyclization of the cleaved C-ring of taxane.
277




All chemicals and reagents were purchased from Beijing Innochem Science and Technology
Co. Ltd. (Beijing, China), Sinopharm Chemical Reagent Co. Ltd. (Beijing, China), and thin-layer
chromatography (TCI). The 200–300 mesh silica gel used for flash column chromatography was
purchased from Rushanshi Shuangbang Xincailiao Co. Ltd. (Rushan, Shandong, China). Visualization
on TLC (analytical thin layer chromatography) was achieved by the use of UV light (254 nm) and
treatment with phosphomolybdic acid or KMnO4 followed by heating. All solvents were purified
and dried according to the standard procedures. The purification was performed on flash column
chromatography. The high performance liquid chromatography (HPLC)- electrospray ionization
(ESI)-mass spectrometry (MS) analysis was carried out in an Agilent 1260 Infinity HPLC system (Agilent
Technologies, Waldbronn, Germany) equipped with a reversed phase 4.68 × 50 mm (1.8 um) XDB-C18
Column and consisted of a binary solvent delivery system, an auto sampler, a column temperature
controller, and an UV detector. The mass spectra were acquired by a 6120 Quadrupole LC-MS mass
spectrometer (Agilent Technologies, Waldbronn, Germany) connected to the HPLC system via an ESI
interface. Proton and carbon magnetic resonance spectra (1H-NMR and 13C-NMR) were recorded on a
Bruker BioSpin AG 300 or 400 MHz spectrometer or Varian 300, 400, or 600 MHz spectrometer.1H-NMR
data were reported as follows: Chemical shifts, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, m=multiplet), coupling constant(s) in Hz, integration. All tested compounds 16a–e,
21a–e, and 22a–e were ≥95% pure by HPLC (column XDB C18 4.6 × 50 mm 1.8 μm, mobile phase:
acetonitrile-water (10:90–100:0 gradient in 4.5 min), flow rate 1.0 mL/min, detected at 220 nm).
3.1.2. General Experimental Procedure for Compounds 14a–e
2′-O-(tert-Butyldimethylsilyl)-10-dehydro-10-deacetylpaclitaxel (14a). To a solution of 13a (261.3 mg,
0.282 mmol) in methanol (8 mL) was added Cu(OAc)2·H2O (282 mg, 1.41 mmol). The suspension was
stirred at room temperature overnight (open air) and then diluted with ethyl acetate. The organic
phase was washed sequentially with saturated aqueous NaCl (50 mL), 2 N NH3 to remove copper
salts and saturated aqueous NH4Cl. After drying (Na2SO4) and evaporation under reduced pressure,
the crude product was purified by silica gel chromatography (ethyl acetate: petroleum ether = 1:2)
to give a 4:1 mixture of epimers 14a (14-β-OH and 14-α-OH, 223.8 mg, 85.8% total yield). 1H-NMR
(CDCl3, 600 MHz) δ: 8.19 (d, J = 7.8 Hz, 1H, Ar-H), 7.73 (d, J = 7.8 Hz, 2H, Ar-H), 7.48 (m, 11H, Ar-H),
7.06 (d, J = 9.0 Hz, 1H, NH), 6.28 (t, J = 8.7 Hz, 1H, H-13), 5.87 (d, J = 7.2 Hz, 1H, H-2), 5.79 (dd,
J = 1.5, 8.7 Hz, 1H, H-3′), 4.93 (m, 1H, H-5), 4.67 (d, J = 1.8 Hz, 1H, H-2′), 4.50 (d, J = 11.4 Hz, 1H, H-7),
4.44 (d, J = 8.4 Hz, 1H, H- 20a), 4.38 (d, J = 9.0 Hz, 1H, H-20b), 4.04 (d, J = 7.2 Hz, 1H, H-3), 3.88 (m,
1H, OH-7), 2.67 (s, 3H, CH3), 2.48 (dd, J = 9.6, 15.6 Hz, 1H, H-6a), 2.29 (m, 2H, H-14b, H-14a), 2.19
(m, 1H, H-6b), 1.86 (s, 3H, CH3), 1.75 (s, 3H, CH3), 1.21 (s, 3H, CH3), 1.13 (s, 3H, CH3), 0.79 (s, 9H,
SiC(CH3)3), −0.04 (s, 3H, Si(CH3)), −0.30 (s, 3H, Si(CH3)). (For the chemical characterization refer to
http://dx.doi.org/10.1016/j.ejmech.2017.06.001)
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-methoxybenzoyl)-7-epi-10-dehydro-10-deacetylpaclitaxel (14b).
69.5% yield as a 4:1 mixture of two epimers; 1H-NMR (CDCl3, 400 MHz) δ: 7.80 (d, J = 7.7 Hz, 1H,
Ar-H), 7.74 (d, J = 7.2 Hz, 2H, Ar-H), 7.41 (m, 10H, Ar-H), 7.21 (dd, J = 2.0, 8.0 Hz, Ar-H), 7.09 (d,
J = 9.1 Hz, 1H, NH), 6.27 (t, J = 8.9 Hz, 1H, H-13), 5.89 (d, J = 7.2 Hz, 1H, H-2), 5.79 (dd, J = 2.2, 9.4
Hz, 1H, H-3′), 4.94 (m, 1H, H-5), 4.67 (d, J = 2.0 Hz, 1H, H-2′), 4.50 (d, J = 11.2 Hz, 1H, H-7), 4.47 (d,
J = 8.8 Hz, 1H, H- 20a), 4.38 (d, J = 8.6 Hz, 1H, H-20b), 4.05 (d, J = 7.1 Hz, 1H, H-3), 3.90 (s, 3H, OCH3),
3.88 (m, 1H, OH-7), 2.67 (s, 3H, CH3), 2.49 (dd, J = 9.8, 15.4 Hz, 1H, H-6a), 2.29 (m, 2H, H-14b, H-14a),
1.86 (s, 3H, CH3), 2.25 (m, 1H, H-6b), 1.75 (s, 3H, CH3), 1.21(s, 3H, CH3), 1.13 (s, 3H, CH3), 0.81 (s, 9H,
SiC(CH3)3), −0.02 (s, 3H, Si(CH3)), −0.26 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 207.8, 188.7,
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172.2, 170.9, 167.0, 166.9, 159.8, 143.3, 141.1, 138.2, 134.1, 131.9, 130.3, 130.0, 128.8 (2C), 128.1, 127.0,
126.4, 122.7, 120.5, 114.4, 82.7, 81.8, 79.2, 77.4, 75.3, 75.1, 70.7, 57.2, 55.5 (2C), 40.3, 39.4, 36.3, 35.4, 26.9,
26.1, 25.5, 22.9, 18.2, 15.0, 14.4, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found 954.4, [M + 23], found 976.4,
C52H63NO14Si: 953.40 (see supplementary materials).
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-fluorobenzoyl)-7-epi-10-dehydro-10-deacetylpaclitaxel (14c).
79.0% yield as a 4:1 mixture of two epimers; 1H-NMR (CDCl3, 400 MHz) δ: 8.02 (d, J = 8.0 Hz, 1H,
Ar-H), 7.89–7.86 (m, 1H, Ar-H), 7.73 (d, J = 7.2 Hz, 2H, Ar-H), 7.59–7.33 (m, 10H, Ar-H), 7.07 (d,
J = 9.2 Hz, 1H, BzNH), 6.27 (t, J = 8.8 Hz, 1H, H-13), 5.86 (d, J = 7.2 Hz, 1H, H-2), 5.80 (dd, J = 2.0, 9.2 Hz,
1H, H-3′), 4.95 (dd, J = 4.0, 8.0 Hz, 1H, H-5), 4.68 (d, J = 2.4 Hz, 1H, H-2′), 4.48 (d, J = 11.2 Hz, 1H, H-7),
4.44 (d, J = 8.8 Hz, 1H, H- 20a), 4.36 (d, J = 8.8 Hz, 1H, H-20b), 4.05 (d, J = 7.2 Hz, 1H, H-3), 3.92–3.88
(m, 1H, OH-7), 2.68 (s, 3H, COCH3), 2.48 (dd, J = 9.6, 15.2 Hz, 1H, H-6a), 2.31–2.29 (m, 2H, H-14b,
H-14a), 2.22 (dd, J = 8.4, 15.6 Hz, 1H, H-6b), 1.99 (br, 1H, OH), 1.86 (s, 3H, CH3), 1.76 (s, 3H, CH3), 1.22
(s, 3H, CH3), 1.13 (s, 3H, CH3), 0.81 (s, 9H, SiC(CH3)), −0.02 (s, 3H, Si(CH3)), −0.26 (s, 3H, Si(CH3)2);
13C-NMR (CDCl3, 100 MHz) δ: 207.8, 188.6, 172.3, 171.2, 170.9, 167.0, 165.9 (d, 4JC-F = 2.9 Hz), 162.7
(d, 1JC-F = 246.5 Hz), 143.5, 140.9, 138.2, 134.1, 131.9, 131.3 (d, 3JC-F = 7.3 Hz), 130.7 (d, 3JC-F = 7.6 Hz),
128.83 (2C), 128.77 (2C), 128.1, 127.0 (2C), 126.4 (2C), 126.1 (d, 4JC-F = 3.1 Hz), 120.0 (d, 2JC-F = 21.1 Hz),
117.1 (d, 2JC-F = 23.1 Hz), 82.8, 81.7, 79.4, 75.5, 75.3, 70.6, 57.2, 55.6, 40.3, 39.5, 36.3, 35.4, 26.1, 25.5 (3C),
22.9 (2C), 18.2, 15.0, 14.5, 14.2, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found 942.4, [M + 23], found 964.3,
C51H60FNO13Si: 941.38.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-chlorobenzoyl)-7-epi-10-dehydro-10-deacetylpaclitaxel (14d).
84.9% yield as a 4:1 mixture of two epimers; 1H-NMR (CDCl3, 400 MHz) δ: 8.18 (s, 1H, Ar-H), 8.11 (d,
J = 7.6 Hz, 1H, Ar-H), 7.73 (d, J = 7.6 Hz, 2H, Ar-H), 7.62 (d, J = 7.6 Hz, 1H, Ar-H), 7.55–7.50 (m, 2H,
Ar-H), 7.44–7.35 (m, 7H, Ar-H), 7.08 (d, J = 8.8 Hz, 1H, BzNH), 6.25 (t, J = 8.8 Hz, 1H, H-13), 5.84 (d,
J = 7.2 Hz, 1H, H-2), 5.79 (dd, J = 8.8 Hz, 1H, H-3′), 4.96 (m, 1H, H-5), 4.67 (d, J = 2.0 Hz, 1H, H-2′),
4.47 (d, J = 11.2 Hz, 1H, H-7), 4.44 (d, J = 8.4 Hz, 1H, H- 20a), 4.35 (d, J = 8.4 Hz, 1H, H-20b), 4.05 (d,
J = 7.2 Hz, 1H, H-3), 3.89 (m, 1H, OH-7), 2.68 (s, 3H, CH3), 2.48 (dd, J = 10.0, 15.4 Hz, 1H, H-6a), 2.29
(m, 2H, H-14b, H-14a), 2.23 (m, 1H, H-6b), 1.86 (s, 3H, CH3), 1.76 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.13 (s,
3H, CH3), 0.82 (s, 9H, SiC(CH3)3), −0.02 (s, 3H, Si(CH3)), −0.26 (s, 3H, Si(CH3)); 13C-NMR (CDCl3,
100 MHz) δ: 207.8, 188.6, 172.2, 170.9, 165.7, 143.5, 140.9, 138.2, 134.9, 134.1, 133.9, 131.9, 130.9, 130.4,
130.3, 128.83 (2C), 128.77 (2C), 128.5, 128.1, 127.0 (2C), 126.5 (2C), 82.7, 81.7, 79.4, 75.4, 75.3, 70.7, 60.4,
57.2, 55.6, 40.2, 39.4, 36.3, 35.3, 29.7, 26.1, 25.5 (2C), 22.9, 22.8, 18.2, 14.9, 14.5, −5.2, −5.8; LC-MS (ESI,
m/z): [M + 1], found 958.4, [M + 23], found 980.4, C51H60ClNO13Si: 957.35.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-trifluoromethyl)-7-epi-10-dehydro-10-deacetylpaclitaxel (14e).
81.9% yield as a 4:1 mixture of two epimers; 1H-NMR (CDCl3, 400 MHz) δ: 8.50 (s, 1H, Ar-H), 8.43 (d,
J = 7.6 Hz, 1H, Ar-H), 7.91 (d, J = 8.0 Hz, 1H, Ar-H), 7.72 (d, J = 7.8 Hz, 3H, Ar-H), 7.51 (m, 1H, Ar-H),
7.41 (m, 7H, Ar-H), 7.06 (d, J = 9.2 Hz, 1H, BzNH), 6.24 (t, J = 8.6 Hz, 1H, H-13), 5.88 (d, J = 7.6 Hz,
1H, H-2), 5.78 (dd, J = 1.6, 9.2 Hz, 1H, H-3′), 4.97 (m, 1H, H-5), 4.67 (d, J = 2.0 Hz, 1H, H-2′), 4.45 (d,
J = 11.2 Hz, 1H, H-7), 4.42 (d, J = 8.5 Hz, 1H, H-20a), 4.37 (d, J = 8.6 Hz, 1H, H-20b), 4.09 (d, J = 7.6 Hz,
1H, H-3), 3.90 (m, 1H, OH-7), 2.66 (s, 3H, CH3), 2.51 (dd, J = 9.6, 15.5 Hz, 1H, H-6a), 2.30 (m, 2H, H-14b,
H-14a), 2.26 (m, 1H, H-6b), 1.87 (s, 3H, CH3), 1.77 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.15 (s, 3H, CH3), 0.83
(s, 9H, SiC(CH3)3), −0.02 (s, 3H, Si(CH3)), −0.24 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 207.7,
188.6, 172.1, 171.0, 167.1, 165.6, 143.6, 140.9, 138.3, 134.2, 133.6, 131.9, 131.4 (q, 2JC-F = 33.2 Hz), 130.3
(q, 3J = 3.4 Hz), 130.3, 130.1, 129.9, 128.9, 128.8, 128.1, 127.1 (q, 3JC-F = 4.0 Hz), 127.0, 126.5, 123.7 (q,
1JC-F = 273.6 Hz), 82.8, 81.7, 79.5, 75.6, 75.3, 70.7, 57.2, 55.6, 40.3, 39.5, 36.3, 35.4, 26.1, 25.6, 22.9, 22.7,
18.2, 14.9, 14.5, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found 992.0, C52H60F3NO13Si: 991.38.
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3.1.3. General Experimental Procedure for Compounds 15a–e
2′-tert-Butyldimethylsilyl-10-dehydro-7-8-seco-10-deacetylpaclitaxel (15a). l-selectride (1M solution in THF,
0.8 mL) was added, dropwise, to a solution of 14a (171.5 mg, 0.186 mmol) in THF (4.1 mL) at −20 ◦C.
After 15 min, the reaction was quenched by addition of cold ethyl acetate (50.0 mL) and 2 N H2SO4
(4.0 mL). The reaction mixture was extracted with ethyl acetate and the combined organic phases were
washed with a saturated aqueous NaHCO3 and saturated aqueous NH4Cl. The resulting solution was
dried over anhydrous MgSO4 and the solvent evaporated under reduced pressure to give a crude
product. The crude product was purified by silica gel chromatography (ethyl acetate: petroleum
ether = 1:1) which gave product 15a (139.5 mg, 81.2% yield) as a white solid
2′-tert-Butyldimethylsilyl-2-debenzoyl-2-(3-methoxybenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel (15b).
White solid; yield 88.7%; 1H-NMR (CDCl3, 400 MHz) δ: 7.73–7.70 (m, 3H, Ar-H), 7.55 (s, 1H, Ar-H),
7.42 (m, 10H, Ar-H), 7.14 (dd, J = 2.3, 8.2 Hz, 1H, BzNH), 6.47 (s, 1H, OH-9), 6.29 (t, J = 8.0 Hz, 1H,
H-13), 5.91 (d, J = 8.8 Hz, 1H, H-3′), 5.60 (d, J = 9.2 Hz, 1H, H-2), 5.24 (brs, 2H, H-5, H-20a), 4.72 (d,
J = 1.6 Hz, 1H, H-2′), 4.29 (d, J = 6.8 Hz, 1H, H-3), 4.20 (brs, 1H, H-7a), 3.96 (brs, 1H, OH), 3.85 (s, 4H,
OCH3, H-7b), 2.82 (brs, 1H, H-6a), 2.71 (brs, 1H, OH), 2.26 (dd, J = 9.6, 15.6 Hz, 2H, H-14a, H-14b),
2.09–2.02 (m, 4H, CH3, H-6b), 1.87 (brs, 6H, 2 × CH3), 1.28 (s, 3H, CH3), 1.10 (s, 3H, CH3), 0.79 (s, 9H,
SiC(CH3)3), −0.11 (s, 3H, Si(CH3)), −0.28 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.2, 171.2,
171.1, 168.9, 167.4, 167.2, 159.8, 148.9, 142.1, 138.2, 133.9, 131.9, 130.5, 130.3, 128.7 (4C), 128.0, 127.1
(2C), 126.7 (2C), 124.6, 122.2, 119.5, 115.0, 86.3, 76.1, 75.1, 70.6, 59.2, 55.8, 55.5, 43.1, 36.6, 25.5 (3C), 23.4,
22.2, 21.5, 18.3, 14.8, 14.4, −5.6, −6.0; LC-MS (ESI, m/z): [M + 1], found 956.4, [M + 23], found 978.4,
C52H65NO14Si: 955.42.
2′-tert-Butyldimethylsilyl-2-debenzoyl-2-(3-fluorobenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel (15c).
White solid; yield 79.2%; 1H-NMR (CDCl3, 400 MHz) δ: 7.94 (d, J = 7.8 Hz, 1H, Ar-H), 7.76 (d,
J = 8.7 Hz, 1H, Ar-H), 7.68 (d, J = 7.4 Hz, 2H, Ar-H), 7.53–7.44 (m, 3H, Ar-H), 7.40–7.30 (m, 8H, NH,
Ar-H), 6.48 (s, 1H, OH-9), 6.30 (t, J = 8.0 Hz, 1H, H-13), 5.92 (d, J = 9.0 Hz, 1H, H-3′), 5.60 (d, J = 9.5 Hz,
1H, H-2), 5.25 (brs, 2H, H-5, H-20a), 4.71 (d, J = 2.1 Hz, 1H, H-2′), 4.30 (d, J = 7.8 Hz, 1H, H-3), 4.19 (brs,
1H, H-20b), 3.96 (brs, 1H, H-7a), 3.80 (brs, 1H, H-7b), 2.78 (brs, 1H, H-6a), 2.69 (brs, 1H, H-14a), 2.26
(dd, J = 9.5, 15.6 Hz, 1H, H-14b), 2.10–2.00 (ovelap, 1H, H-6b), 1.90 (s, 3H, CH3), 1.86 (overlap and
brs, 6H, 2 × CH3), 1.27 (s, 3H, CH3), 1.10 (s, 3H, CH3), 0.78 (s, 9H, SiC(CH3)3), −0.09 (s, 3H, Si(CH3)),
−0.29 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.1, 171.2, 171.0, 168.8, 167.4, 166.4, 131.0 (d,
1JC-F = 248.1 Hz), 128.8 (2C), 128.1, 127.1, 126.7, 125.8 (d, 4JC-F = 2.6 Hz), 124.6, 121.1 (d, 2JC-F = 21.3 Hz),
116.7 (d, 2JC-F = 22.6 Hz), 86.5, 80.7, 76.1, 75.5, 70.5, 59.0, 55.8, 44.5, 43.2, 36.7, 25.6, 22.3, 21.6, 18.3, 14.9,
14.5, −5.4, −5.9; LC-MS (ESI, m/z): [M + 1], found 944.4, [M + 23], found 966.4, C51H62FNO13Si: 943.40.
2′-tert-Butyldimethylsilyl-2-debenzoyl-2-(3-chlorobenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel (15d).
White solid; yield 58.8%; 1H-NMR (CDCl3, 400 MHz) δ: 8.05 (d, J = 7.6 Hz, 2H, Ar-H), 8.01 (s, 1H,
Ar-H), 7.68 (d, J = 7.6 Hz, 2H, Ar-H), 7.57 (d, J = 8.0 Hz, 1H, Ar-H), 7.41–7.31 (m, 9H, NH, Ar-H),
6.49 (s, 1H, OH-9), 6.29 (t, J = 8.4 Hz, 1H, H-13), 5.92 (d, J = 9.3 Hz, 1H, H-3′), 5.59 (d, J = 9.5 Hz, 1H,
H-2), 5.23 (brs, 2H, H-5, H-20a), 4.71 (d, J = 1.6 Hz, 1H, H-2′), 4.30 (d, J = 6.9 Hz, 1H, H-3), 4.18 (brs,
1H, H- 20b), 3.98 (brs, 1H, H-7a), 3.83 (brs, 1H, H-7b), 2.78 (brs, 1H, H-6a), 2.67 (brs, 1H, H-14a), 2.25
(dd, J = 9.6, 15.6 Hz, 1H, H-14b), 2.05 (m, 1H, H-6b), 1.89 (s, 3H, CH3), 1.85 (brs, 6H, 2 × CH3), 1.26
(s, 3H, CH3), 1.10 (s, 3H, CH3), 0.78 (s, 9H, SiC(CH3)3), −0.11 (s, 3H, Si(CH3)), −0.28 (s, 3H, Si(CH3));
13C-NMR (CDCl3, 100 MHz) δ: 191.1, 171.0, 168.7, 167.4, 166.3, 148.9, 142.0, 138.0, 137.1, 135.0, 133.9,
131.9, 131.0, 130.6, 129.6, 128.7 (2C), 128.1, 128.0, 127.0 (2C), 126.7 (2C), 124.5, 86.4, 87.0, 80.5, 76.0, 75.4,
70.5, 55.7, 43.1, 36.6, 29.7, 26.9, 25.5 (3C), 22.2, 21.5, 18.3, 14.8, 14.5, −5.5, −6.0; LC-MS (ESI, m/z): [M + 1],
found 960.0, [M + 23], found 981.9, C51H62ClNO13Si: 959.37.
2′-tert-Butyldimethylsilyl-2-debenzoyl-2-(3-trifluoromethylbenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel
(15e). White solid; yield 76.5%; 1H-NMR (CDCl3, 400 MHz) δ: 8.38 (d, J = 7.9 Hz, 2H, Ar-H), 7.84 (d,
J = 7.9 Hz, 2H, Ar-H), 7.48 (m, 11H, NH, Ar-H), 6.51 (s, 1H, OH-9), 6.29 (t, J = 8.4 Hz, 1H, H-13), 5.89 (d,
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J = 9.3 Hz, 1H, H-3′), 5.62 (d, J = 9.4 Hz, 1H, H-2), 5.25 (brs, 2H, H-5, H-20a), 4.72 (brs, 1H, H-2′), 4.32
(d, J = 6.8 Hz, 1H, H-3), 4.24 (brs, 1H, H- 20b), 3.94 (brs, 1H, H-7a), 3.76 (brs, 1H, H-7b), 2.78 (brs, 1H,
H-6a), 2.66 (brs, 1H, H-14a), 2.28 (dd, J = 9.5, 15.6 Hz, 1H, H-14b), 2.05 (m, 1H, H-6b), 1.92 (s, 3H,
CH3), 1.85 (brs, 6H, 2 × CH3), 1.27 (s, 3H, CH3), 1.11 (s, 3H, CH3), 0.78 (s, 9H, SiC(CH3)3), −0.08 (s,
3H, Si(CH3)), −0.29 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.0, 170.9, 167.5, 166.2, 148.9,
142.1, 137.9, 133.9, 133.1, 131.9, 131.4 (q, 2JC-F = 33.3 Hz), 130.2, 128.7, 128.0, 126.9, 126.7 (q, 3JC-F = 4.1
Hz), 126.5, 123.5 (q, 1JC-F = 273.7 Hz), 87.2, 86.3, 80.6, 75.8, 75.6, 74.5, 70.4, 67.6, 59.0, 55.7, 44.4, 43.2,
38.3, 36.6, 29.7, 29.1, 25.5, 22.1, 21.5, 18.2, 14.8, 14.4, −5.5, −6.0; LC-MS (ESI, m/z): [M + 1], found 994.3,
[M + 23], found 1016.3, C52H62F3NO13Si: 993.39.
3.1.4. General Experimental Procedure for Compounds 16a–e
10-Dehydro-7,8-seco-10-deacetylpaclitaxel (16a). To a solution of of 15a (19.8 mg, 0.0214 mmol) in THF
(1.4 mL) was added, dropwise, 0.3 mL of HF-pyridine (v/v = 1:2) at 0 ◦C, and the reaction mixture was
stirred at room temperature for 30 h. The reaction was quenched with saturated aqueous NaHCO3,
diluted with ethyl acetate, washed with saturated NH4Cl. The organic layer dried over anhydrous
Na2SO4 and then concentrated under reduced pressure. Purification of the crude product by silica
gel chromatography (ethyl acetate: petroleum ether = 2:1) gave product 16a as a white solid (13.4 mg,
77.4% yield). 1H-NMR (CDCl3, 400 MHz) δ: 8.04 (d, J = 7.6 Hz, 2H, Ar-H), 7.69 (d, J = 7.2 Hz, 2H,
Ar-H), 7.57 (t, J = 7.4 Hz, 1H, Ar-H), 7.48–7.44 (m, 5H, Ar-H), 7.38–7.27 (m, 6H, NH, Ar-H), 6.47 (s, 1H,
OH-9), 6.16 (t, J = 7.5 Hz, 1H, H-13), 5.86 (dd, J = 2.8, 9.4 Hz, 1H, H-3′), 5.60 (d, J = 9.5 Hz, 1H, H-2), 5.20
(brs, 1H, H-5), 5.16 (d, J = 11.4 Hz, 1H, H-20a), 4.78 (d, J = 3.0 Hz, 1H, H-2′), 4.27 (d, J = 8.1 Hz, 1H, H-3),
4.20 (brs, 1H, H-20b), 3.89 (brs, 1H, H-7a), 3.68 (dt, J = 6.2, 10.1 Hz, 1H, H-7b), 2.77 (brs, 1H, H-6a), 2.61
(brs, 1H, H-14a), 2.38 (dd, J = 9.7, 15.9 Hz, 1H, H-14b), 2.29 (brs, 1H, OH), 2.10–2.07 (m, 1H, H-6b), 1.83
(brs, 6H, 2 × CH3), 1.75 (s, 3H, CH3), 1.20 (s, 3H, CH3), 1.07 (s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz)
δ: 191.0, 172.4, 169.0, 167.3, 167.2, 148.8, 142.2, 138.0, 136.7, 133.8, 133.6, 132.0, 129.7, 129.3, 129.0, 128.8,
128.7, 128.1, 127.1, 127.0, 124.6, 86.9, 86.2, 80.5, 74.8, 73.7, 70.7, 59.6, 54.8, 43.0, 36.6, 29.7, 24.9, 22.1, 21.2,
18.4, 14.6, 14.5; LC-MS (ESI, m/z): [M + 1], found 812.0, [M + 23], found 834.0, C45H49NO13: 811.32.
2-Debenzoyl-2-(3-methoxybenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel (16b). White solid; yield 65.2%;
1H-NMR (CDCl3, 400 MHz) δ: 7.72 (d, J = 7.6 Hz, 2H, Ar-H), 7.60 (d, J = 7.1 Hz, 1H, Ar-H), 7.47–7.43
(m, 5H, Ar-H), 7.36–7.31 (m, 5H, Ar-H), 7.29–7.25 (m, 1H, Ar-H), 7.10 (d, J = 8.1 Hz, 1H, NH), 6.49 (brs,
1H, OH-9), 6.09 (t, J = 7.4 Hz, 1H, H-13), 5.81 (d, J = 9.2 Hz, 1H, H-3′), 5.58 (d, J = 9.5 Hz, 1H, H-2), 5.20
(brs, 1H, H-5), 5.14 (d, J = 11.3 Hz, 1H, H-20a), 4.73 (brs, 1H, H-2′), 4.24 (d, J = 7.2 Hz, 1H, H-3), 4.19
(brs, 1H, H-20b), 3.87 (brs, 1H, H-7a), 3.79 (s, 3H, OCH3), 3.65 (brs, 1H, H-7b), 2.74 (brs, 1H, H-6a), 2.56
(brs, 1H, H-14a), 2.40 (dd, J = 9.9, 15.9 Hz, 1H, H-14b), 2.35 (brs, 1H, OH-1), 2.09 (m, 1H, H-6b), 1.83
(brs, 6H, 2 × CH3), 1.69 (s, 3H, CH3), 1.17 (s, 3H, CH3), 1.06 (s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz)
δ: 191.1, 172.4, 169.0, 167.1, 159.8, 148.8, 142.1, 138.1, 136.7, 133.6, 131.9, 130.7, 130.1, 129.0, 128.7, 128.6,
128.2, 128.1, 127.1, 124.5, 121.8, 119.5, 114.8, 86.9, 86.1, 80.4, 74.8, 73.7, 70.5, 59.7, 55.5, 55.0, 44.5, 42.9,
36.6, 29.8, 29.7, 24.9, 22.2, 21.1, 14.6, 14.5; LC-MS (ESI, m/z): [M + 1], found 842.4, [M + 23], found 864.3,
C46H51NO14: 841.33.
2-Debenzoyl-2-(3-fluorobenzoyl)-10-dehydro-7, 8-seco-10-deacetylpaclitaxel (16c). White solid; yield 59.3%,
1H-NMR (CDCl3, 300 MHz) δ: 7.90 (d, J = 7.7 Hz, 1H, Ar-H), 7.75–7.68 (m, 3H, Ar-H), 7.48–7.44 (m, 4H,
Ar-H), 7.41–7.31 (m, 6H, Ar-H), 7.24 (d, J = 8.0 Hz, 1H, NH), 6.46 (brs, 1H, OH-9), 6.20 (t, J = 7.9Hz,
1H, H-13), 5.88 (d, J = 7.6 Hz, 1H, H-3′), 5.59 (d, J =9.5 Hz, 1H, H-2), 5.19 (overlap, J = 11.5 Hz, 2H,
H-20a, H-5), 4.81 (brs, 1H, H-2′), 4.46 (brs, 1H, OH), 4.29 (d, J = 7.9Hz, 1H, H-3), 4.22 (brs, 1H, H-20b),
3.92 (brs, 1H, H-7a), 3.70 (brs, 1H, H-7b), 3.39 (brs, 1H, OH), 2.77 (brs, 1H, H-6a), 2.60 (brs, 1H, H-14a),
2.37 (dd, J = 9.7, 15.8 Hz, 1H, H-14b), 2.09 (m, 1H, H-6b), 1.85 (brs, 6H, 2 × CH3), 1.78 (s, 3H, CH3),
1.64 (brs, 1H, OH-1), 1.22 (s, 3H, CH3), 1.09 (s, 3H, CH3); 13C-NMR (CDCl3, 75 MHz) δ: 190.9, 172.4,
167.2, 166.2, 162.7 (d, 1JC-F = 248.7 Hz), 148.9, 142.1, 137.9, 133.6, 132.0, 131.4 (d, 2JC-F = 7.4 Hz), 130.8
(d, 3JC-F = 7.9 Hz), 128.9, 128.7, 128.2, 127.0, 126.9, 125.5, 124.4, 121.0 (d, 2JC-F = 21.2 Hz), 116.5 (d,
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2JC-F = 23.5 Hz), 86.8, 86.2, 80.5, 75.2, 74.7, 73.6, 70.7, 59.5, 54.6, 42.9, 36.5, 29.7, 29.3, 24.9, 22.1, 21.2, 14.7,
14.5; LC-MS (ESI, m/z): [M + 1], found 830.3, [M + 23], found 852.3, C45H48FNO13: 829.31.
2-Debenzoyl-2-(3-chlorobenzoyl)-10-dehydro-7, 8-seco-10-deacetylpaclitaxel (16d). White solid; yield 60.3%;
1H-NMR (CDCl3, 400 MHz) δ: 7.98 (d, J = 7.5 Hz, 2H, Ar-H), 7.72 (d, J = 7.0 Hz, 2H, Ar-H), 7.56 (d,
J = 8.4 Hz, 1H, Ar-H), 7.47–7.42 (m, 4H, Ar-H), 7.40–7.29 (m, 6H, NH, Ar-H), 6.49 (brs, 1H, OH-9),
6.15 (t, J = 7.8 Hz, 1H, H-13), 5.86 (d, J = 8.1 Hz, 1H, H-3′), 5.58 (d, J = 9.5 Hz, 1H, H-2), 5.21 (brs,
1H, H-5), 5.14 (d, J =11.0 Hz, 1H, H-20a), 4.79 (d, J = 2.8 Hz, 1H, H-2′), 4.27 (d, J =7.8 Hz, 1H, H-3),
4.20 (brs, 1H, H-20b), 3.89 (brs, 1H, H-7a), 3.71–3.67 (m, 1H, H-7b), 2.75 (brs, 1H, H-6a), 2.59 (brs, 1H,
H-14a), 2.38 (dd, J = 9.7, 15.8 Hz, 1H, H-14b), 2.25 (brs, 1H, OH), 2.09 (m, 1H, H-6b), 2.00 (m, 1H,
OH), 1.84 (brs, 6H, 2 × CH3), 1.74 (s, 3H, CH3), 1.20 (s, 3H, CH3), 1.07 (s, 3H, CH3); 13C-NMR (CDCl3,
100 MHz) δ: 191.0, 172.5, 167.2, 166.0, 148.9, 142.1, 138.1, 135.0, 133.8, 133.7, 132.0, 131.1, 130.4, 129.5,
128.8, 128.7, 128.1, 127.9, 127.0, 124.3, 86.9, 86.2, 80.4, 75.3, 74.7, 73.6, 70.6, 59.6, 54.8, 50.8, 42.9, 36.6,
29.7, 29.5, 29.3, 24.9, 22.2, 21.2, 14.6, 14.5; LC-MS (ESI, m/z): [M + 1], found 845.9, [M + 23], found 867.8,
C45H48ClNO13: 845.28.
2-Debenzoyl-2-(3-trifluoromethylbenzoyl)-10-dehydro-7,8-seco-10-deacetylpaclitaxel (16e). White solid; yield
55.5%; 1H-NMR (CDCl3, 400 MHz) δ: 8.33 (d, J = 7.7 Hz, 1H, Ar-H), 8.25 (brs, 1H, NH), 7.85 (d,
J = 7.4 Hz, 1H, Ar-H), 7.68–7.62 (m, 3H, Ar-H), 7.48–7.45 (m, 3H, Ar-H), 7.40–7.29 (m, 6H, Ar-H), 6.47
(brs, 1H, OH-9), 6.18 (t, J = 7.9 Hz, 1H, H-13), 5.87 (d, J = 7.6 Hz, 1H, H-3′), 5.62 (d, J = 9.4 Hz, 1H, H-2),
5.18 (overlap, J = 11.5 Hz, 2H, H-20a, H-5), 4.80 (d, J = 2.8 Hz, 1H, H-2′), 4.62 (brs, 1H, OH), 4.28 (d,
J = 7.6 Hz, 1H, H-3), 4.24 (brs, 1H, H-20b), 3.90 (brs, 1H, H-7a), 3.68 (brs, 1H, H-7b), 3.38 (brs, 1H, OH),
2.77 (brs, 1H, H-6a), 2.58 (brs, 1H, H-14a), 2.37 (dd, J = 9.7, 15.7 Hz, 1H, H-14b), 2.05 (brs, 1H, OH),
2.03–1.98 (m, 1H, H-6b), 1.84 (brs, 6H, 2 × CH3), 1.78 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.09 (s, 3H, CH3);
13C-NMR (CDCl3, 100 MHz) δ: 190.9, 172.4, 167.2, 166.0, 148.9, 142.1, 138.0, 133.7, 133.0, 132.0, 131.7,
130.3, 130.0, 129.7, 128.9, 128.7, 128.2, 127.0 (2C), 126.4, 124.8, 124.2, 122.1, 86.9, 86.2, 80.5, 75.4, 74.7, 73.5,
70.7, 59.6, 54.7, 43.0, 36.6, 31.9, 29.7, 25.5, 22.1, 21.2, 14.6, 14.4; LC-MS (ESI, m/z): [M + 1], found 880.0,
[M + 23], found 901.9, C46H48F3NO13: 879.31.
3.1.5. General Experimental Procedure for Compounds 17a–e
2′-O-(tert-Butyldimethylsilyl)-9-O-(2-hydroxyethyl)-10-dehydro-7, 8-seco-10-deacetylpaclitaxel (17a). To a
mixture of 15a (50 mg, 0.0540 mmol), potassium carbonate (104 mg, 0.754 mmol), and potassium iodide
(18 mg, 0.108 mmol) in DMF (0.9 mL) was added 2-bromoethanol (54 μL 0.762 mmol), dropwise, at 0 ◦C.
The reaction mixture was stirred for 9 h at room temperature and then was diluted with ethyl acetate.
The organic phase was washed with saturated aqueous NH4Cl. The organic layer was dried over
anhydrous Na2SO4 and then concentrated under reduced pressure. Purification of the crude product
by silica gel chromatography (ethyl acetate: petroleum ether = 1:1) gave product 17a as a white solid
(19 mg, 52.4% yield). 1H-NMR (CDCl3, 300 MHz) δ: 8.09 (d, J = 7.2 Hz, 2H, Ar-H), 7.62 (d, J = 7.2 Hz,
2H, Ar-H), 7.57 (d, J = 7.5 Hz, 1H, Ar-H), 7.49 (t, J = 7.5 Hz, 2H, Ar-H), 7.36 (m, 8H, Ar-H), 6.30 (t,
J = 8.4 Hz, 1H, H-13), 5.88 (d, J = 9.0 Hz, 1H, H-3′), 5.57 (d, J = 9.6 Hz, 1H, H-2), 5.28 (overlap, 2H, H-5,
H-20a), 4.69 (d, J = 1.8 Hz, 1H, H-2′), 4.26 (d, J = 7.8 Hz, 1H, H-3), 4.20 (m, 2H, H-20b, OCH2CH2OCO),
3.94 (m, 1H, OCH2CH2OCO), 3.87 (m, J = 1.8, 6.3, 8.7, 12.0 Hz, 1H, H-7a), 3.74 (overlap, 2H, H-7b,
OCH2CH2OCO), 3.62 (m, 1H, OCH2CH2OCO), 2.71 (m, 2H, H-6a, H-14a), 2.25 (dd, J = 9.3, 15.9 Hz, 2H,
H-6b, H-14b), 1.97 (s, 3H, CH3), 1.92 (s, 3H, CH3), 1.82 (s, 3H, CH3), 1.27 (s, 3H, CH3), 1.16 (s, 3H, CH3),
0.76 (s, 9H, SiC(CH3)3), −0.08 (s, 3H, Si(CH3)), −0.33 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ:
192.3, 170.7, 168.7, 167.3, 153.8, 144.0, 139.4, 138.0, 133.7 (2C), 131.8, 129.9 (2C), 128.9 (2C), 128.6 (4C),
127.9, 126.9 (2C), 126.4 (2C), 87.1, 87.7, 85.7, 79.9, 75.6, 75.4, 74.6, 73.8, 70.5, 61.8, 58.7, 55.6, 42.9, 36.6,
25.4 (3C), 22.9, 22.0, 18.1, 15.3, 14.6, −5.5, −6.1; LC-MS (ESI, m/z): [M + 1], found 970.5, [M + 23], found
992.4, C53H67NO14Si: 969.43.
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2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-methoxybenzoyl)-9-O-(2-hydroxyethyl)-10-dehydro-7,8-seco-
10-deacetylpaclitaxel (17b). White solid; yield 56.1%; 1H-NMR (CDCl3, 400 MHz) δ: 7.72–7.66 (m, 3H,
Ar-H), 7.54 (s, 1H, Ar-H), 7.47–7.43 (m, 2H, Ar-H), 7.42–7.29 (m, 8H, Ar-H), 7.12 (dd, J = 2.0, 8.4 Hz, 1H,
BzNH), 6.29 (t, J = 8.5 Hz, 1H, H-13), 5.88 (d, J = 9.3 Hz, 1H, H-3′), 5.59 (d, J = 9.6 Hz, 1H, H-2), 5.26
(overlap, 2H, H-5, H-20a), 4.72 (s, 1H, H-2′), 4.26 (d, J = 6.4 Hz, 1H, H-3), 4.19–4.15 (m, 1H, H-20b),
3.94–3.64 (m, 9H, OCH3, OCH2CH2OH, H-7a, H-7b), 2.61 (br, 2H, H-6b, H-14b), 2.25 (dd, J = 9.6, 15.6
Hz, 2H, H-6a, H-14a), 2.03 (s, 3H, OAc), 1.93 (s, 6H, 2 × CH3), 1.26 (s, 3H, CH3), 1.16 (s, 3H, CH3), 0.77
(s, 9H, SiC(CH3)3), −0.10 (s, 3H, Si(CH3)), −0.30 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 192.4,
171.2, 170.9, 168.8, 167.3, 167.0, 162.6, 159.7, 144.1, 138.1, 133.8, 131.8, 130.4, 130.2, 128.6 (2C), 127.9,
127.0 (2C), 126.6 (2C), 122.2, 119.5, 114.9, 85.7, 79.8, 75.8, 74.8, 61.8, 58.9, 55.7, 55.5, 42.9, 36.6, 36.5, 31.9,
31.4, 29.7, 25.5 (3C), 22.9, 22.1, 18.2, 15.2, 14.6, −5.5, −6.1; LC-MS (ESI, m/z): [M + 1], found 1000.5,
[M + 23], found 1022.5, C54H69NO16Si: 999.44.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-fluorobenzoyl)-9-O-(2-hydroxyethyl)-10-dehydro-7,8-seco-
10-deacetylpaclitaxel (17c). White solid; yield 53.2%; 1H-NMR (CDCl3, 400 MHz) δ: 7.93 (d, J = 7.8 Hz,
1H, Ar-H), 7.76 (d, J = 8.8 Hz, 1H, Ar-H), 7.63 (d, J = 7.6 Hz, 2H, Ar-H), 7.52–7.28 (m, 11H, NH, Ar-H),
6.29 (t, J = 8.1 Hz, 1H, H-13), 5.89 (d, J = 9.2 Hz, 1H, H-3′), 5.58 (d, J = 9.6 Hz, 1H, H-2), 5.35–5.15
(overlap, 2H, H-5, H-20a), 4.70 (d, J = 1.9 Hz, 1H, H-2′), 4.26 (d, J = 7.6 Hz, 1H, H-3), 4.20–4.16 (m, 2H,
H-20b, OCH2CH2OCO), 3.95 (brs, 1H, OCH2CH2OCO), 3.89–3.84 (ddd, J = 2.3, 6.8, 8.7, 12.4 Hz, 1H,
H-7a), 3.80–3.70 (overlap, 2H, H-7b, OCH2CH2OCO), 3.60–3.58 (m, 1H, OCH2CH2OCO), 2.71–2.63 (m,
2H, H-6a, H-14a), 2.25 (dd, J = 9.6, 15.8 Hz, 2H, H-6b, H-14b), 2.03 (s, 3H, CH3), 1.91(s, 3H, CH3), 1.87
(brs, 3H, CH3), 1.83 (brs, 2H, 2 × OH), 1.26 (s, 3H, CH3), 1.15 (s, 3H, CH3), 0.73 (s, 9H, SiC(CH3)3),
−0.08 (s, 3H, Si(CH3)), −0.32 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 192.3, 171.2, 170.8, 168.6,
167.4, 166.2, 162.7 (d, 1JC-F = 248.3 Hz), 144.0, 137.9, 133.9, 131.9, 131.2 (d, 3JC-F = 7.4 Hz), 131.0 (d,
3JC-F = 7.7 Hz), 128.7 (2C), 128.0, 127.0, 126.5, 125.8 (d, 4JC-F = 2.6 Hz), 121.0 (d, 2JC-F = 21.2 Hz), 116.3
(d, 2JC-F = 22.9 Hz), 85.8, 80.0, 75.7, 75.2, 70.5, 61.9, 58.7, 55.6, 45.7, 42.9, 36.7, 25.5, 22.9, 22.1, 18.2, 15.3,
14.6, 13.7, −5.4, −6.0; LC-MS (ESI, m/z): [M + 1], found 988.0, C53H66FNO14Si: 987.42.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-chlorobenzoyl)-9-O-(2-hydroxyethyl)-10-dehydro-7,8-seco-
10-deacetylpaclitaxel (17d). White solid; yield 60.9%; 1H-NMR (CDCl3, 400 MHz) δ: 8.06 (d, J = 8.8 Hz,
2H, Ar-H), 7.63 (d, J = 7.5 Hz, 2H, Ar-H), 7.57 (d, J = 8.2 Hz, 1H, Ar-H), 7.50–7.43 (m, 3H, Ar-H),
7.43–7.33 (m, 8H, Ar-H, BzNH), 6.31 (t, J = 8.0 Hz, 1H, H-13), 5.90 (d, J = 9.2 Hz, 1H, H-3′), 5.59 (d,
J = 9.6 Hz, 1H, H-2), 5.32–5.28 (overlap, 2H, H-5, H-20b), 4.71 (d, J = 1.9 Hz, 1H, H-2′), 4.28 (d, J = 7.6
Hz, 1H, H-3), 4.24–4.20 (m, 2H, H-20a, OCH2CH2OH), 3.98–3.95 (m, 1H, OCH2CH2OH), 3.93–3.89 (m,
1H, H-7b), 3.78–3.72 (overlap, 2H, H-7a, OCH2CH2OH), 3.65 (br, 1H, OCH2CH2OH), 2.72–2.68 (m, 2H,
H-6b, H-14b), 2.26 (dd, J = 7.2, 13.4 Hz, 2H, H-6a, H-14a), 1.98 (s, 3H, CH3), 1.93 (brs, 1H, OH), 1.85
(brs, 2H, OH), 1.29 (brs, 6H, CH3), 1.18 (s, 3H, CH3), 0.78 (s, 9H, SiC(CH3)3), −0.08 (s, 3H, Si(CH3)),
−0.30 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 192.3, 170.8, 167.4, 166.3, 144.0, 137.9, 135.0,
133.9 (2C), 132.0, 130.8, 130.7, 129.7, 128.8 (2C), 128.7 (2C), 128.2, 128.1, 127.0 (2C), 126.6 (2C), 85.9, 75.8,
75.3, 70.5, 62.0, 55.6, 43.0, 36.7, 32.0, 29.7, 29.4, 27.3, 25.5 (3C), 23.0, 22.7, 22.2, 18.3, 15.3, 14.7, 14.2, −5.4,
−6.0; LC-MS (ESI, m/z): [M + 1], found 1004.4, [M + 23], found 1026.4, C53H66ClNO14Si: 1003.39.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-trifluoromethylbenzoyl)-9-O-(2-hydroxyethyl)-10-dehydro-7,
8-seco-10-deacetylpaclitaxel (17e). White solid; yield 49.9%; 1H-NMR (CDCl3, 400 MHz) δ: 7.83 (d,
J = 7.7 Hz, 2H, Ar-H), 7.68 (t, J = 7.8 Hz, 1H, Ar-H), 7.58 (d, J = 7.3 Hz, 1H, Ar-H), 7.45 (t, J = 7.4 Hz,
2H, Ar-H), 7.35 (m, 8H, Ar-H), 6.29 (t, J = 8.2 Hz, 1H, H-13), 5.87 (d, J = 8.7 Hz, 1H, H-3′), 5.60 (d,
J = 9.65 Hz, 1H, H-2), 5.26 (overlap, 2H, H-5, H-20a), 4.70 (d, J = 1.3 Hz, 1H, H-2′), 4.28 (d, J = 6.8 Hz,
1H, H-3), 4.19 (m, 2H, H-20b, OCH2CH2OCO), 3.98 (m, 1H, OCH2CH2OCO), 3.87 (m, J = 1.8, 6.3, 8.7,
12.0 Hz, 1H, H-7a), 3.75 (overlap, 2H, H-7b, OCH2CH2OCO), 3.66 (m, 1H, OCH2CH2OCO), 2.65 (m,
2H, H-6a, H-14a), 2.24 (dd, J = 6.7, 16.3 Hz, 2H, H-6b, H-14b), 1.97 (s, 3H, CH3), 1.92 (s, 3H, CH3), 1.82
(s, 3H, CH3), 1.26 (s, 3H, CH3), 1.17 (s, 3H, CH3), 0.77 (s, 9H, SiC(CH3)3), −0.08 (s, 3H, Si(CH3)), −0.32
(s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 192.3, 170.8, 167.6, 166.1, 144.1, 137.8, 133.9, 133.2,
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132.0, 131.4 (q, 2JC-F = 33.2 Hz), 130.3, 130.2 (q, 3JC-F = 3.5 Hz), 130.0, 128.8, 128.7, 128.1, 126.9, 126.8 (q,
3JC-F = 3.6 Hz), 126.5, 123.6 (q, 1JC-F = 273.8 Hz), 85.8, 75.6, 75.4, 70.5, 62.0, 58.4, 55.6, 43.0, 36.7, 31.9,
29.8, 29.7, 29.6 (2C), 29.3 (2C), 27.2, 25.5, 23.0, 22.7, 22.1, 18.4, 18.2, 15.3, 14.6, 14.1, −5.4, −6.0; LC-MS
(ESI, m/z): [M + 1], found 1038.4, [M + 23], found 1060.4, C54H66F3NO14Si: 1037.42.
3.1.6. General Experimental Procedure for Compounds 19a–e
2′-O-(tert-Butyldimethylsilyl)-macrocyclic taxoid (19a). To a solution of 17a (19 mg, 0.0196 mmol) in
dichloromethane (4.2 mL) was added, dropwise, pyridine (22 μL, 0.266 mmol) and triphosgene (8.7 mg,
0.0293 mmol) at 0 ◦C, then the reaction mixture was stirred at room temperature for 5 h. The reaction
was diluted with ethyl acetate, washed with saturated NaCl. The organic layer was dried over
anhydrous Na2SO4 and then concentrated under reduced pressure. Purification of the crude product
by silica gel chromatography (ethyl acetate: petroleum ether = 1:3) gave product 19a as a white solid
(3.1 mg, 15.9% yield). 1H-NMR (CDCl3, 400 MHz) δ: 8.17 (d, J = 7.2 Hz, 2H, Ar-H), 7.75 (d, J = 7.2 Hz,
2H, Ar-H), 7.63 (t, J = 7.2 Hz, 1H, Ar-H), 7.54 (t, J = 7.6 Hz, 2H, Ar-H), 7.50 (d, J = 7.6 Hz, 1H, Ar-H),
7.43 (d, J = 7.6 Hz, 2H, Ar-H), 7.39 (t, J = 7.2 Hz, 2H, Ar-H), 7.34–7.29 (m, 3H, Ar-H), 7.08 (d, J = 9.2 Hz,
1H, NH), 6.27 (t, J = 8.8 Hz, 1H, H-13), 5.76 (d, J = 8.4 Hz, 1H, H-3′), 5.60 (d, J = 7.6 Hz, 1H, H-2), 4.84
(overlap, 2H, H-5, OCH2CH2OCO), 4.79 (d, J = 7.6 Hz, 1H, H-3), 4.67 (d, J = 2.0 Hz, 1H, H-2′), 4.57 (dd,
J = 6.8, 12.0 Hz, 1H, OCH2CH2OCO), 4.49 (dd, J = 6.8, 12.0 Hz, 1H, OCH2CH2OCO), 4.46 (d, J = 8.4 Hz,
1H, H-20a), 4.35 (d, J = 8.4 Hz, 1H, H-20b), 4.32 (dd, J = 5.2, 13.6 Hz, 1H, OCH2CH2OCO), 4.13 (ddd,
J = 6.4, 10.8, 17.2 Hz, 1H, H-7a), 4.02 (ddd, J = 8.8, 11.6, 17.2 Hz, 1H, H-7b), 2.55 (s, 3H, 4-OAc), 2.35 (m,
3H, H-6a, H-6b, H-14a), 2.18 (dd, J = 8.8, 15.2 Hz, 1H, H-14b), 1.84 (s, 3H, CH3), 1.25 (s, 3H, CH3), 1.24
(s, 3H, CH3), 1.19 (s, 3H, CH3), 0.79 (s, 9H, SiC(CH3)3), −0.03 (s, 3H, Si(CH3)), −0.30 (s, 3H, Si(CH3));
13C-NMR (CDCl3, 150 MHz) δ: 192.1, 171.0, 169.4, 166.9, 166.8, 152.4, 151.5, 144.5, 139.7, 138.3, 134.6,
134.1, 133.8, 131.8, 130.2 (2C), 129.0, 128.8 (2C), 128.7, 127.9, 127.0 (2C), 126.3 (2C), 89.6, 84.7, 78.6, 76.1,
75.3, 75.2, 71.4, 70.6, 68.9, 65.9, 55.6, 42.9, 42.4, 36.5, 31.0, 26.2, 25.5 (3C), 22.9, 21.6, 18.1, 14.4, 13.6, −5.3,
−5.9; LC-MS (ESI, m/z): [M + 1], found 996.4, [M + 23], found 1018.4, C54H65NO15Si: 995.41.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-methoxybenzoyl)-macrocyclic taxoid (19b). White solid; yield
32.7%; 1H-NMR (CDCl3, 400 MHz) δ: 7.80 (d, J = 1.2, 7.6 Hz, 1H, Ar-H), 7.77 (d, J = 6.8 Hz, 2H, Ar-H),
7.67 (dd, J = 1.5, 2.5 Hz, 1H, Ar-H), 7.55–7.51 (m, 1H, Ar-H), 7.49–7.39 (m, 3H, Ar-H), 7.40–7.31 (m, 5H,
Ar-H), 7.20–7.17 (m, 1H, Ar-H), 7.08 (d, J = 9.2 Hz, 1H, BzNH), 6.28 (t, 1H, H-13), 5.76 (dd, J = 1.6, 8.9 Hz,
H-3′), 5.62 (d, J = 7.5 Hz, 1H, H-2), 4.87 (d, J = 7.6 Hz, 1H, H-20b), 4.85 (d, J = 4.8 Hz, 1H, H-5), 4.81 (d,
J = 7.5 Hz, 1H, H-20a), 4.68 (d, J = 2.0 Hz, 1H, H-2′), 4.60–4.32 (m, 5H, H-7a, H-7b, H-16a, H-16b, H-3),
4.18–4.03 (m, H-15a, H-15b), 3.91 (s, 3H, OCH3), 2.55 (d, J = 1.3 Hz, 6H, 2 × CH3), 2.41–2.35 (m, 3H,
H-14b, H-6a, H-6b), 2.24–2.20 (m, 1H, H-14a), 1.84 (d, J = 1.2 Hz, 3H, COCH3), 1.26 (s, 3H, CH3), 1.21 (s,
3H, CH3), 0.81 (s, 9H, SiC(CH3)3), −0.008 (s, 3H, Si(CH3)), −0.28 (s, 3H, Si(CH3)); 13C-NMR (CDCl3,
100 MHz) δ: 192.2, 171.1, 169.4, 166.9, 166.8, 159.8, 152.5, 151.6, 144.6, 139.7, 138.4, 134.7, 134.2, 131.9,
130.4, 130.0, 128.82 (2C), 128.78 (2C), 128.0, 127.0 (2C), 126.4 (2C), 122.6, 120.3, 114.7, 89.6, 84.8, 78.5,
75.4, 75.3, 71.5, 70.7, 69.0, 65.9, 55.6, 43.0, 42.5, 36.5, 31.1, 29.7, 26.3, 25.6 (3C), 22.9, 21.6, 18.2, 14.4, 13.7,
−5.2,−5.8; LC-MS (ESI, m/z): [M + 1], found 1026.4, [M + 23], found 1048.4, C55H67NO16Si: 1025.42.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-fluorobenzoyl)-macrocyclic taxoid (19c). White solid; yield
32.1%; 1H-NMR (CDCl3, 400 MHz) δ: 8.01(d, J = 7.8 Hz, 1H, Ar-H), 7.84–7.87 (m, 1H, Ar-H), 7.75–7.73
(m, 2 H, Ar-H), 7. 56–7.49 (m, 2H, Ar-H), 7.44–7.31 (m, 8H, Ar-H), 7.09 (d, J = 9.0 Hz, 1H, NH), 6.28 (t,
J = 8.8 Hz,1H, H-13), 5.78 (dd, J = 1.4, 9.1 Hz, 1H, H-3′), 5.61 (d, J = 7.6 Hz, 1H, H-2), 4.87–4.82 (overlap,
2H, OCH2CH2OCO, H-5), 4.83 (d, J = 7.5 Hz, 1H, H-3), 4.69 (d, J = 2.0 Hz, 1H, H-2′), 4.58 (dd, J = 6.4,
11.9 Hz, 1H, OCH2CH2OCO), 4.51 (dd, J = 6.4, 13.7 Hz, 1H, OCH2CH2OCO), 4.46 (d, J = 8.2 Hz, 1H,
H-20a), 4.36–4.30 (overlap, 2H, OCH2CH2OCO, H-20b), 4.16–4.09 (m, 1H, H-7a), 4.06–3.99 (m, 17.2 Hz,
1H, H-7b), 2.57 (s, 3H, COCH3), 2.56 (s, 3H, 4-OAc), 2.39–2.31 (m, 3H, H-6a, H-6b, H-14a), 2.18 (dd,
J = 8.4, 15.4 Hz, 1H, H-14b), 1.90 (brs, 1H, OH), 1.84 (s, 3H, CH3), 1.23 (s, 3H, CH3), 1.19 (s, 3H, CH3),
0.80 (s, 9H, SiC(CH3)3), −0.29 (s, 3H, Si(CH3)), −0.03 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz)
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δ: 192.1, 171.1, 169.4, 167.0, 165.7, 162.7 (d, 1JC-F = 247.8 Hz), 152.5, 151.6, 144.5, 139.8, 138.4, 134.5,
134.2, 131.9, 131.3 (d, 3JC-F = 7.6Hz), 130.6 (d, 3JC-F = 7.6 Hz), 128.8 (2C), 128.0, 127.0, 126.5, 126.0 (d,
4JC-F = 3.0 Hz), 121.0 (d, 2JC-F = 21.4 Hz), 117.1 (d, 2JC-F = 23.3 Hz), 89.6, 84.7, 78.6, 76.1, 75.7, 75.3, 71.5,
70.7, 68.9, 65.9, 55.6, 43.0, 42.5, 36.4, 31.0, 26.3, 25.6, 22.8, 21.6, 18.2, 14.4, 13.6, −5.2, −5.8; LC-MS (ESI,
m/z): [M + 1], found 1014.4, [M + 23], found 1036.4, C54H64FNO15Si: 1013.40.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-chlorobenzoyl)-macrocyclic taxoid (19d). White solid; yield
36.1%; 1H-NMR (CDCl3, 400 MHz) δ: 8.19 (t, J = 1.6 Hz, 1H, Ar-H), 8.10–8.07 (m, 1H, Ar-H), 7.77–7.75
(m, 2H, Ar-H), 7.64–7.61 (m, 1H, Ar-H), 7.55–7.49 (m, 2H, Ar-H), 7.46–7.33 (m, 7H, Ar-H), 7.08 (d,
J = 9.2 Hz, 1H, BzNH), 6.25 (m, 1H, H-13), 5.76 (dd, J = 1.6, 9.0 Hz, 1H, H-3′), 5.59 (d, J = 7.6 Hz, 1H,
H-2), 4.89–4.81 (m, 3H, OCH2CH2OCO, H-5, H-3), 4.68 (d, J = 2.0 Hz, 1H, H-2′), 4.57 (dd, J = 6.6,
11.9 Hz, 1H, OCH2CH2OCO), 4.50 (dd, J = 6.5, 11.8 Hz, 1H, OCH2CH2OCO), 4.44 (d, J = 8.0 Hz, 1H,
H-20a), 4.38–4.32 (m, 2H, OCH2CH2OCO, H-20b), 4.15–4.10 (m, 1H, H-7a), 4.07–4.01 (m, J = 17.2 Hz,
1H, H-7b), 2.56 (s, 3H, CH3), 2.55 (s, 3H, CH3), 2.41–2.30 (m, 3H, H-6a, H-6b, H-14a), 2.25–2.18 (m, 1H,
H-14b), 1.84 (d, J = 1.2 Hz, 3H, CH3), 1.25 (s, 3H, CH3), 1.20 (s, 3H, CH3), 0.82 (s, 9H, SiC(CH3)3), −0.01
(s, 3H, Si(CH3)), −0.26 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 192.1, 171.1, 169.4, 165.6, 152.5,
151.7, 144.5, 139.8, 138.4, 134.9, 134.5, 133.6, 131.8, 131.0, 130.3, 128.81 (2C), 128.79 (2C), 128.4, 128.0,
127.0 (2C), 126.5 (2C), 89.6, 84.7, 78.7, 77.3, 75.6, 75.3, 70.8, 69.0, 55.7, 43.0, 42.5, 36.4, 29.7, 26.3, 25.6 (3C),
22.8, 21.6, 18.2, 14.4, 13.6, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found 1030.4, [M + 23], found 1052.4,
C54H64ClNO15Si: 1029.37.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-trifluoromethylbenzoyl)-macrocyclic taxoid (19e). White solid;
yield 30.5%; 1H-NMR (CDCl3, 400 MHz) δ: 8.51 (s, 1H, Ar-H), 8.41 (d, J = 7.8 Hz, 1H, Ar-H), 7.92
(d, J = 7.8 Hz, 1H, Ar-H), 7.76–7.72 (m, 3H, Ar-H), 7.55–7.51 (m, 1H, Ar-H), 7.47–7.40 (m, 4H, Ar-H),
7.37–7.33 (m, 3H, Ar-H), 7.09 (d, J = 9.1 Hz, 1H, NH), 6.24 (t, J = 8.8 Hz, 1H, H-13), 5.76 (dd, J = 1.0,
9.0 Hz, 1H, H-3′), 5.63 (d, J = 7.6 Hz, 1H, H-2), 4.91–4.84 (m, 3H, H-3, H-5, OCH2CH2OCO), 4.67 (d,
J = 1.8 Hz, 1H, H-2′), 4.58 (dd, J = 6.8, 11.8 Hz, 1H, OCH2CH2OCO), 4.52 (dd, J = 6.8, 13.7 Hz, 1H,
OCH2CH2OCO), 4.44 (d, J = 8.1 Hz, 1H, H-20a), 4.38–4.33 (m, 2H, OCH2CH2OCO, H-20b), 4.11–4.18
(m, 1H, H-7a), 4.09–4.02 (m, J = 17.2 Hz, 1H, H-7b), 2.55 (s, 3H, 4-OAc), 2.42–2.36 (m, 3H, H-6a, H-6b,
H-14a), 2.29–2.20 (m,1H, H-14b), 1.94 (s, 1H, OH), 1.86 (d, J = 1.04 Hz, 3H, CH3), 1.29 (s, 3H, CH3), 1.26
(s, 3H, CH3), 1.22 (s, 3H, CH3), 0.84 (s, 9H, SiC(CH3)3), −0.004 (s, 3H, Si(CH3)), −0.24 (s, 3H, Si(CH3));
13C-NMR (CDCl3, 100 MHz) δ: 192.0, 171.1, 169.3, 167.0, 165.4, 152.5, 151.6, 144.5, 139.8, 138.4, 134.4,
134.3, 133.6, 131.8, 131.4 (q, 2JC-F = 33.2 Hz), 130.3 (q, 3JC-F = 3.4 Hz), 130.2, 129.7, 128.8, 128.0, 127.0,
126.9 (q, 3JC-F = 4.3 Hz), 126.5, 123.7 (q, 1JC-F = 273.8 Hz), 89.6, 84.7, 78.7, 76.0, 75.8, 75.2, 71.5, 70.8, 69.0,
65.9, 55.7, 43.0, 42.4, 36.4, 31.0, 29.0, 26.3, 25.6, 22.7, 21.6, 18.2, 14.4, 13.6, −5.2,−5.8; LC-MS (ESI, m/z):
[M + 1], found 1064.4, [M + 23], found 1086.4, C55H64F3NO15Si: 1063.40.
3.1.7. General Procedure for the Syntheses of Compounds 21a–e
Macrocyclic taxoid (21a)
To a solution of of 19a (32.3 mg, 0.0464 mmol) in THF (8 mL) was added, dropwise, 1.53 mL of
HF-pyridine (v/v = 1:2) at 0 ◦C, and the reaction mixture was stirred at room temperature for 30 h.
The reaction was quenched with saturated aqueous NaHCO3, diluted with ethyl acetate, and washed
with saturated NH4Cl. The organic layer was dried over anhydrous Na2SO4 and then concentrated
under reduced pressure. Purification of the crude product by silica gel chromatography (ethyl acetate:
petroleum ether = 2:1) gave product 21a as a white solid (13.2 mg, 46.2% yield). 1H-NMR (CDCl3,
400 MHz) δ: 8.14 (d, J = 7.0 Hz, 2H, Ar-H), 7.73 (d, J = 8.6 Hz, 2H, Ar-H), 7.62 (t, J = 7.5 Hz, 1H, Ar-H),
7.52–7.45 (m, 5H, Ar-H), 7.40–7.30 (m, 5H, Ar-H), 7.22 (d, J = 9.1 Hz, 1H, NH), 6.20 (t, J = 8.5 Hz, 1H,
H-13), 5.78 (dd, J = 2.5, 9.1 Hz, 1H, H-3′), 5.58 (d, J = 7.5 Hz, 1H, H-2), 4.80–4.74 (overlap, 4H, H-5, H-2′,
H-3, OCH2CH2OCO), 4.52 (dd, J = 6.4, 12.0 Hz, 1H, OCH2CH2OCO), 4.45–4.44 (overlap, 2H, H-20a,
OCH2CH2OCO), 4.31-4.25 (overlap, 2H, H-20b, OCH2CH2OCO), 4.07–3.91 (overlap, 2H, H-7b, H-7a),
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2.56 (br, 1H, OH-2′), 2.51 (s, 3H, CH3), 2.35 (s, 3H, CH3), 2.33–2.25 (overlap, 4H, H-14a, H-14b, H-6a,
H-6b), 1.68 (s, 3H, CH3), 1.18 (s, 3H, CH3), 1.16 (s, 3H, CH3); 13C-NMR (CDCl3, 150 MHz) δ: 191.8,
172.4, 169.7, 166.9, 166.8, 152.4, 151.5, 144.8, 138.6, 137.9, 135.0, 133.9, 133.6, 132.0, 130.1 (2C), 129.0 (2C),
128.8 (4C), 128.3, 127.0 (2C), 89.4, 84.7, 78.4, 76.1, 75.1, 73.1, 71.8, 71.5, 68.9, 65.8, 54.8, 42.8, 42.4, 36.4,
30.9, 29.7, 26.3, 22.5, 21.2, 14.0, 13.7; LC-MS (ESI, m/z): [M + 1], found 882.8, [M + 23], found 904.4,
C48H51NO15: 881.33.
2-Debenzoyl-2-(3-methoxybenzoyl)-macrocyclic taxoid (21b). White solid; yield 54.1%; 1H-NMR (CDCl3,
400 MHz) δ: 7.76–7.74 (m, 3H, Ar-H), 7.66-7.65 (m, 1H, Ar-H), 7.53–7.46 (m, 8H, Ar-H), 7.36–7.32 (m,
1H, Ar-H), 7.03 (d, J = 8.9 Hz, 1H, NH), 6.17 (t, J = 8.2 Hz, 1H, H-13), 5.79 (dd, J = 2.3, 9.0 Hz, 1H, H-3′),
5.59 (d, J = 7.5 Hz, 1H, H-2), 4.84–4.77 (overlap, 4H, H-5, H-2′, H-3, OCH2CH2OCO), 4.55 (dd, J = 6.5,
11.9 Hz, 1H, OCH2CH2OCO), 4.45 (dd, J = 6.6, 13.2 Hz, 1H, OCH2CH2OCO), 4.43 (d, J = 7.5 Hz, 1H,
H-20a), 4.36 (d, J = 8.29 Hz, 1H, H-20b), 4.32 (dd, J = 5.2, 13.8 Hz, 1H, OCH2CH2OCO), 4.12–3.96 (m,
2H, H-7b, H-7a), 3.88 (s, 3H, OAc), 3.62 (brs, 1H, OH-2′), 2.53 (s, 3H, CH3), 2.36 (s, 3H, CH3), 2.40–2.27
(overlap, 4H, H-14a, H-14b, H-6a, H-6b), 1.93 (brs, 1H, OH-1), 1.68 (d, 3H, CH3), 1.23 (s, 3H, CH3),
1.18 (s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.9, 172.4, 169.7, 167.0, 166.7, 159.8, 152.4, 151.5,
144.8, 138.6, 138.0, 135.1, 133.7, 132.0, 130.3 (2C), 130.0, 129.8, 129.7, 129.0 (2C), 128.7 (4C), 128.3, 127.0
(2C), 122.5, 120.0, 115.0, 89.4, 84.7, 78.4, 76.2, 75.3, 73.2, 71.7, 71.5, 68.9, 65.8, 55.5, 54.9, 42.8, 42.4, 36.4,
31.9, 30.9, 29.7, 26.3, 22.5, 21.2, 14.0, 13.7; LC-MS (ESI, m/z): [M + 1], found 912.3, [M + 23], found 934.3,
C49H53NO16: 911.34.
2-Debenzoyl-2-(3-fluorobenzoyl)-macrocyclic taxoid (21c). White solid; yield 52.2%; 1H-NMR (CDCl3,
400 MHz) δ: 7.97–7.92 (m, 1H, Ar-H), 7.86–7.83 (ddd, J = 1.5, 2.5, 9.2 Hz, 1H, Ar-H), 7.75–7.72 (m, 2H,
Ar-H), 7.54–7.47 (m, 4H, Ar-H), 7.43–7.39 (m, 4 H, Ar-H), 7.37–7.32 (m, 2H, Ar-H), 7.02 (d, J = 9.1 Hz, 1H,
NH), 6.17 (dd, J = 7.5, 8.8 Hz, 1H, H-13), 5.79 (dd, J = 2.4, 9.0 Hz, 1H, H-3′), 5.57 (d, J = 7.6 Hz, 1H, H-2),
4.84–4.78 (overlap, 4H, H-5, H-2′, H-3, OCH2CH2OCO), 4.55 (dd, J = 6.4, 11.9 Hz, 1H, OCH2CH2OCO),
4.47–4.40 (m, 2H, H-20b, H-20a), 4.34–4.29 (m, 2H, OCH2CH2OCO), 4.12–3.96 (m, 2H, H-7b, H-7a), 3.62
(d, J = 4.9 Hz, 1H, OH-2′), 2.53 (s, 3H, CH3), 2.36 (s, 3H, CH3), 2.35–2.25 (m, 4H, H-14a, H-14b, H-6a,
H-6b), 1.93 (brs, 1H, OH-1), 1.68 (d, J = 1.2 Hz, 3H, CH3), 1.23 (s, 3H, CH3), 1.18 (s, 3H, CH3); 13C-NMR
(CDCl3, 100 MHz) δ: 191.8, 172.4, 169.6, 167.1, 165.6 (d, JC-F = 3.2 Hz, CO), 162.4 (d, 1JC-F = 247.8 Hz),
152.4, 151.6, 144.7, 138.7, 138.0, 134.8, 133.7, 132.0, 131.3 (d, 3JC-F = 7.6 Hz), 130.5 (d, 3JC-F = 7.8 Hz),
129.9 (d, 4JC-F = 3.9 Hz), 129.7, 129.0, 128.7, 128.4, 127.0, 126.0, 121.0 (d, 2JC-F = 21.3 Hz), 117.0 (d,
2JC-F = 23.3 Hz), 89.5, 84.7, 78.5, 76.0, 75.5, 73.2, 71.7, 71.5, 68.9, 65.7, 55.0, 42.8, 42.4, 36.3, 30.9, 26.3,
25.5, 22.7, 22.4, 21.2, 14.1, 14.0, 13.6; LC-MS (ESI, m/z): [M + 1], found 900.0, [M + 23], found 922.0,
C48H50FNO15: 899.32.
2-Debenzoyl-2-(3-chlorobenzoyl)-macrocyclic taxoid (21d). White solid; yield 48.7%; 1H-NMR (CDCl3,
400 MHz) δ: 8.16 (t, 1H, Ar-H), 8.06–8.03 (m, 1H, Ar-H), 7.75–7.72 (m, 2H, Ar-H), 7.61 (ddd, J = 1.1, 2.1,
8.0 Hz, 1H, Ar-H), 7.53–7.45 (m, 4H, Ar-H), 7.43–7.39 (m, 4 H, Ar-H), 7.36–7.32 (m, 1H, Ar-H), 7.01
(d, J = 9.1 Hz, 1H, NH), 6.17 (td, J =1.3, 8.7 Hz, 1H, H-13), 5.78 (dd, J = 2.3, 9.0 Hz, 1H, H-3′), 5.56 (d,
J = 7.6 Hz, 1H, H-2), 4.84–4.78 (overlap,4H, H-5, H-2′, H-3, OCH2CH2OCO), 4.55 (dd, J = 6.4, 11.9 Hz,
1H, OCH2CH2OCO), 4.47–4.38 (m, 2 H, H-20b, H20a), 4.34–4.29 (m, 2H, OCH2CH2OCO), 4.11–3.96
(m, 2H, H-7b, H-7a), 3.62 (brs, 1H, OH-2′), 2.52 (s, 3H, CH3), 2.37 (s, 3H, CH3), 2.42–2.27 (overlap, 4H,
H-14a, H-14b, H-6a, H-6b), 2.0 (brs, 1H, OH-1), 1.68 (d, J = 1.2 Hz, 3H, CH3), 1.23 (s, 3H, CH3), 1.18 (s,
3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.8, 172.4, 169.6, 167.1, 165.5, 152.4, 151.6, 144.7, 138.7,
138.0, 134.8 (2C), 133.8, 133.7, 132.0, 130.9, 130.2 (2C), 129.0, 128.7, 128.4 (2C), 127.1, 127.0, 89.4, 84.7,
78.4, 76.0, 75.5, 73.1, 71.7, 71.5, 68.9, 65.7, 55.0, 42.8, 42.4, 36.3, 30.9, 26.2, 22.4, 21.2, 14.0, 13.6; LC-MS
(ESI, m/z): [M + 1], found 916.3, [M + 23], found 938.3, C48H50ClNO15: 915.29.
2-Debenzoyl-2-(3-trifluoromethylbenzoyl)-macrocyclic taxoid (21e). White solid; yield 63.7%; 1H-NMR
(CDCl3, 400 MHz) δ: 8.47 (s, 1H, Ar-H), 8.36 (d, J = 7.9 Hz, 1H, Ar-H), 7.90 (d, J = 7.8 Hz, 1H, Ar-H),
7.73–7.67 (m, 3H, Ar-H), 7.46–7.52 (m, 3 H, Ar-H), 7.43–7.32 (m, 5H, Ar-H), 6.94 (d, J = 9.0 Hz, 1H,
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NH), 6.16 (dd, J = 7.5, 8.8 Hz, 1H, H-13), 5.77 (dd, J = 2.0, 8.9 Hz, 1H, H-3′), 5.60 (d, J = 7.5 Hz,
1H, H-2), 4.85–4.78 (overlap, 4H, H-5, H-2′, H-3, OCH2CH2OCO), 4.55 (dd, J = 6.6, 12.0 Hz, 1H,
OCH2CH2OCO), 4.45 (dd, J = 6.7, 13.6 Hz, 1H, OCH2CH2OCO), 4.39 (d, J = 8.0 Hz, 1 H, H-20b),
4.33 (dd, 1H, OCH2CH2OCO), 4.31 (d, J = 7.7 Hz, 1H, H-20a),4.12-3.97 (m, 2H, H-7b, H-7a), 3.53 (d,
J = 6.9 Hz, 1H, OH-2′), 2.53 (s, 3H, CH3), 2.34 (s, 3H, CH3), 2.46–2.28 (m, 4H, H-14a, H-14b, H-6a,
H-6b), 1.93 (brs, 1H, OH-1), 1.70 (d, J = 1.2 Hz, 3H, CH3), 1.24 (s, 3H, CH3),1.15 (s, 3H, CH3); 13C-NMR
(CDCl3, 100 MHz) δ: 192.0, 171.1, 169.3, 167.0, 165.4, 152.5, 151.6, 144.5, 139.8, 138.4, 134.4, 134.3, 133.6,
131.8, 131.4 (q, 2JC-F = 33.2 Hz), 130.3 (q, 3JC-F = 3.4 Hz), 130.2, 129.7, 128.8, 128.0, 127.0, 126.9 (q,
3JC-F = 4.3 Hz), 126.5, 123.7 (q, 1JC-F = 273.8 Hz), 89.6, 84.7, 78.7, 76.0, 75.8, 75.2, 71.5, 70.8, 69.0, 65.9,
55.7, 43.0, 42.4, 36.4, 31.0, 29.0, 26.3, 25.6, 22.7, 21.6, 18.2, 14.4, 13.6, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1],
found 950.3, [M + 23], found 972.3, C49H50F3NO15: 949.31.
3.1.8. General Experimental Procedure for Compounds 18a–e
2′-O-(tert-Butyldimethylsilyl)-9-O-(3-hydroxyethyl)-10-dehydro-7, 8-seco-10-deacetylpaclitaxel (18a). To a
mixture of 15a (65 mg, 0.0703 mmol), potassium carbonate (67.8 mg, 0.491 mmol) and potassium
iodide (11.7 mg, 0.0705 mmol) in DMF (0.65 mL) was added 3-bromo-1-propanol (44 μL 0.487 mmol),
dropwise, at 0 ◦C. The reaction mixture was stirred for 4 h at room temperature and then was diluted
with ethyl acetate. The organic phase was washed with saturated aqueous NH4Cl. The organic layer
was dried over anhydrous Na2SO4 and then concentrated under reduced pressure. Purification of the
crude product by silica gel chromatography (ethyl acetate: petroleum ether = 1:1) gave product 18a
as a white solid (50 mg, 72.4% yield). 1H-NMR (CDCl3, 400 MHz) δ: 8.10 (d, J = 7.6 Hz, 2H, Ar-H),
7.62 (d, J = 7.6 Hz, 2H, Ar-H), 7.58 (t, J = 7.2 Hz, 1H, Ar-H), 7.47 (dd, J = 7.6, 14.8 Hz, 2H, Ar-H),
7.43–7.40 (m, 1H, Ar-H), 7.38–7.36 (m, 4H, Ar-H), 7.30–7.29 (m, 3H, Ar-H), 6.30 (t, J = 8.4 Hz, 1H,
H-13), 5.88 (d, J = 9.6 Hz, 1H, H-3′), 5.57 (d, J = 9.6 Hz, 1H, H-2), 5.30–5.27 (overlap, 2H, H-5, H-20a),
4.69 (d, J = 2.0 Hz, 1H, H-2′), 4.26 (d, J = 7.6 Hz, 1H, H-3), 4.20 (brs, 1H, H-20b), 4.00-3.95 (m, 2H,
OCH2CH2CH2OCO), 3.91–3.83 (m, 3H, OCH2CH2CH2OCO, H-7a), 3.76 (brs, 1H, H-7b), 2.75–2.64 (m,
2H, H-6a, H-14a), 2.27–2.21 (m, 2H, H-6b, H-14b), 1.92–1.90 (m, 5H, CH3, OCH2CH2CH2OCO), 1.96 (s,
3H, CH3), 1.81 (brs, 3H, CH3), 1.27 (s, 3H, CH3), 1.18 (s, 3H, CH3), 0.76 (s, 9H, SiC(CH3)3), −0.08 (s, 3H,
Si(CH3)), −0.33 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.6, 170.7, 168.7, 167.3 (2C), 153.1,
152.8, 144.1, 137.9, 133.8, 133.7, 131.9, 129.9 (2C), 128.9 (2C), 128.7 (4C), 128.6, 127.9 (2C), 126.5 (2C), 82.1,
79.9, 75.7, 74.7, 70.5, 68.8, 60.4, 59.3, 58.8, 55.6, 42.8, 36.6, 32.2, 25.4 (3C), 23.2, 22.1, 18.2, 14.9, 14.2, −5.5,
−6.1; LC-MS (ESI, m/z): [M + 23], found 1006.0, C54H69NO14Si: 983.45.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-methoxybenzoyl)-9-O-(3-hydroxyethyl)-10-dehydro-7,8-seco-
10-deacetylpaclitaxel (18b). White solid; yield 75.3%; 1H-NMR (CDCl3, 400 MHz) δ: 7.71–7.65 (m, 3H,
Ar-H), 7.53 (m, 1H, Ar-H), 7.46–7.41 (m, 2H, Ar-H), 7.11 (dd, J = 2.4, 8.0 Hz, 1H, BzNH), 6.28 (t,
J = 8.6 Hz, 1H, H-13), 5.87 (d, J = 9.2 Hz, 1H, H-3′), 5.58 (d, J = 9.5 Hz, 1H, H-2), 5.29–5.26 (overlap,
2H, H-5, H-20a), 4.72 (d, J = 2.1 Hz, 1H, H-2′), 4.26 (d, J = 6.6 Hz, 1H, H-3), 4.21 (brs, 1H, H-20b),
4.00-3.95 (m, 2H, OCH2CH2CH2O), 3.98–3.86 (m, 3H, OCH2CH2CH2O, H-7b), 3.83 (overlap, 4H,
OCH3, H-7a), 2.77–2.66 (m, 2H, H-6b, H-14b), 2.27–2.21 (m, 2H, H-6a, H-14a), 1.96 (s, 3H, CH3), 1.92
(brs, 2H, OCH2CH2CH2O), 1.83 (m, 2H, OH), 1.84 (brs, 3H, CH3), 1.26 (s, 3H, CH3), 1.19 (s, 3H, CH3),
0.78 (s, 9H, SiC(CH3)3), −0.09 (s, 3H, Si(CH3)), −0.29 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ:
191.6, 171.2, 170.9, 168.9, 167.3, 167.2, 159.8, 144.4, 138.1, 133.8, 131.9, 130.4, 130.3, 128.7 (2C), 128.7 (2C),
128.0, 127.0 (2C), 126.7 (2C), 122.3, 119.6, 114.9, 85.8, 79.9, 75.8, 74.9, 70.7, 68.8, 59.3, 59.0, 55.7, 55.5, 42.8,
36.6, 32.3, 25.5 (3C), 25.2, 23.2, 22.2, 18.2, 14.9, 14.5, −5.5, −6.0; LC-MS (ESI, m/z): [M + 1], found 1014.4,
[M + 23], found 1036.4, C55H71NO16Si: 1013.46.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-fluorobenzoyl)-9-O-(3-hydroxyethyl)-10-dehydro-7, 8-seco-
10-deacetylpaclitaxel (18c). White solid; yield 69.7%; 1H-NMR (CDCl3, 400 MHz) δ: 7.93 (d, J = 7.6 Hz,
1H, Ar-H), 7.75 (d, J = 8.9 Hz, 1H, Ar-H), 7.63 (d, J = 7.5 Hz, 1H, Ar-H), 7.52–7.28 (m, 11H, NH, Ar-H),
6.29 (t, J = 8.1 Hz, 1H, H-13), 5.89 (d, J = 9.2 Hz, 1H, H-3′), 5.57 (d, J = 9.6 Hz, 1H, H-2), 5.28–5.26
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(overlap, 2H, H-5, H-20a), 4.70 (d, J = 2.0 Hz, 1H, H-2′), 4.27 (d, J = 8.1 Hz, 1H, H-3), 4.19 (brs, 1H,
H-20b), 3.99–3.94 (m, 2H, OCH2CH2CH2OH), 3.88–3.81 (m, 3H, OCH2CH2CH2OH, H-7a), 3.76 (brs,
1H, H-7b), 2.72–2.63 (m, 2H, H-6a, H-14a), 2.24 (dd, 1H, J = 9.5, 15.8 Hz, H-14b), 2.06– 1.98 (overlap,
1 H, H-6b), 1.95 (s, 3H, CH3), 1.93–1.87 (m, 4H, CH3, OCH2CH2CH2OH), 1.83 (brs, 3H, CH3), 1.26 (brs,
3H, CH3), 1.17 (s, 3H, CH3), 0.77 (s, 9H, SiC(CH3)3), −0.09 (s, 3H, Si(CH3)), −0.32 (s, 3H, Si(CH3));
13C-NMR (CDCl3, 100 MHz) δ: 191.5, 171.2, 170.8, 168.6, 167.4, 166.3, 162.7 (d, 1JC-F = 248.2 Hz), 144.3,
137.9, 133.9, 131.9, 131.2 (d, 2JC-F = 7.3 Hz), 131.0 (d, 3JC-F = 7.7 Hz), 128.8, 128.7, 128.0, 127.0, 126.5,
125.8 (d, 4JC-F = 2.6 Hz), 121.0 (d, 2JC-F = 21.2 Hz), 116.6 (d, 2JC-F = 22.8 Hz), 85.9, 80.0, 75.8, 75.2, 70.5,
68.9, 59.3, 55.6, 42.8, 36.7, 32.3, 25.5, 23.2, 22.1, 18.2, 15.0, 14.5, −5.4, −6.0; LC-MS (ESI, m/z): [M + 1],
found 1002.0, [M + 23], found 1025.0, C54H68FNO14Si: 1001.44.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-chlorobenzoyl)-9-O-(3-hydroxyethyl)-10-dehydro-7,8-seco-
10-deacetylpaclitaxel (18d). White solid; yield 52.6%; 1H-NMR (CDCl3, 400 MHz) δ: 8.03 (d, J = 7.6 Hz,
1H, Ar-H), 8.00–7.96 (m, J = 7.6 Hz, 1H, Ar-H), 7.65 (d, J = 7.6 Hz, 2H, Ar-H), 7.54 (t, J = 7.2 Hz, 1H,
Ar-H), 7.48–7.44 (m, 2H, Ar-H), 7.43–7.40 (m, 1H, Ar-H), 7.38–7.36 (m, 4H, Ar-H), 7.39–7.28 (m, 7H,
Ar-H), 6.30 (t, J = 8.4 Hz, 1H, H-13), 5.88 (d, J = 9.6 Hz, 1H, H-3′), 5.57 (d, J = 9.6 Hz, 1H, H-2), 5.30–5.27
(overlap, 2H, H-5, H-20a), 4.71 (s, 1H, H-2′), 4.26 (d, J = 7.6 Hz, 1H, H-3), 4.18 (brs, 1H, H-20b),
3.99–3.93 (m, 2H, OCH2CH2CH2O), 3.79–3.40 (m, 3H, OCH2CH2CH2O, H-7a), 3.73–3.64 (brs, 1H,
H-7b), 2.94 (s, 3H, CH3), 2.84 (s, 3H, CH3), 2.66 (br, 2H, H-6a, H-14a), 2.29–2.22 (m, 2H, H-6b, H-14b),
1.93 (s, 3H, CH3), 1.93–1.86 (m, 5H, CH3, OCH2CH2CH2O), 1.82 (brs, 3H, CH3), 1.24 (s, 3H, CH3), 1.16
(s, 3H, CH3), 0.76 (s, 9H, SiC(CH3)3), −0.11 (s, 3H, Si(CH3)), −0.31 (s, 3H, Si(CH3)); 13C-NMR (CDCl3,
100 MHz) δ: 191.5, 171.1, 170.8, 167.4, 165.9, 162.5, 144.3, 137.9, 134.8, 133.9, 133.7, 131.8, 131.0, 130.6,
129.5, 128.7 (2C), 128.6 (2C), 128.1, 127.9, 126.9 (2C), 126.5 (2C), 85.8, 75.7, 75.2, 70.5, 68.8, 67.9, 60.4, 59.2,
55.6, 42.7, 36.6, 36.4, 32.3, 31.4, 25.4 (3C), 23.2, 22.1, 21.0, 18.2, 14.5, 14.2, −5.5, −6.1; LC-MS (ESI, m/z):
[M + 1], found 1018.4, [M + 23], found 1040.4, C54H68ClNO14Si: 1017.41.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-trifluoromethylbenzoyl)-9-O-(3-hydroxyethyl)-10-dehydro-7,
8-seco-10-deacetylpaclitaxel (18e). White solid; yield 71.8%; 1H-NMR (CDCl3, 400 MHz): δ 8.38 (d,
J = 7.8 Hz, 2H, Ar-H), 7.83 (d, J = 7.7 Hz, 2H, Ar-H), 7.68 (t, J = 7.8 Hz, 1H, Ar-H), 7.44 (dd, J = 15.4,
8.0 Hz, 2H, Ar-H), 7.47–7.41 (m, 1H, Ar-H), 7.40–7.36 (m, 4H, Ar-H), 7.30–7.29 (m, 3H, Ar-H), 6.29
(t, J = 8.5 Hz, 1H, H-13), 5.86 (d, J = 8.6 Hz, 1H, H-3′), 5.59 (d, J = 9.5 Hz, 1H, H-2), 5.26 (overlap,
2H, H-5, H-20a), 4.70 (d, J = 2.0 Hz, 1H, H-2′), 4.29 (d, J = 7.3 Hz, 1H, H-3), 4.21 (brs, 1H, H-20b),
4.00–3.96 (m, 2H, OCH2CH2CH2OH), 3.90–3.87 (m, 3H, OCH2CH2CH2OH, H-7a), 3.75 (brs, 1H,
H-7b), 2.70–2.60 (m, 2H, H-6a, H-14a), 2.28–2.22 (m, 2H, H-6b, H-14b), 1.97 (s, 3H, CH3), 1.94–1.92 (m,
5H, CH3, OCH2CH2CH2OH), 1.81 (brs, 3H, CH3), 1.27 (s, 3H, CH3), 1.19 (s, 3H, CH3), 0.76 (s, 9H,
SiC(CH3)3), −0.08 (s, 3H, Si(CH3)), −0.32 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.5, 170.8,
167.5, 144.3, 137.9, 133.9, 133.2, 132.0, 131.4 (q, 2JC-F = 33.3 Hz), 130.2 (q, 3JC-F = 4.0 Hz), 130.0, 128.8,
128.1, 126.9, 126.8 (q, 3JC-F = 3.9 Hz), 126.5, 123.6 (q, 1JC-F = 274.2 Hz), 85.9, 75.6, 75.4, 70.5, 59.4, 55.6,
42.9, 36.7, 32.3, 25.5, 18.2, 14.6, −5.4, −6.0; LC-MS (ESI, m/z): [M + 1], found 1052.4, [M + 23], found
1074.4, C55H68NO14F3Si: 1051.44.
3.1.9. General Experimental Procedure for Compounds 20a–e
2′-O-(tert-Butyldimethylsilyl)-macrocyclic taxoid (20a). To a solution of 18a (26.2 mg, 0.0266 mmol) in
dichloromethane (5.7 mL) was added, dropwise, pyridine (11 μL, 0.133 mmol) and triphosgene (8.7 mg,
0.0293 mmol) at 0 ◦C, then the reaction mixture was stirred at room temperature for 3.5 h. The reaction
was diluted with ethyl acetate, then washed with saturated NaCl. The organic layer was dried over
anhydrous Na2SO4 and then concentrated under reduced pressure. Purification of the crude product
by silica gel chromatography (ethyl acetate: petroleum ether = 1:3) gave product 20a as a white solid
(6.7 mg, 24.9% yield). 1H-NMR (CDCl3, 400 MHz) δ: 8.17 (d, J = 8.0 Hz, 2H, Ar-H), 7.75 (d, J = 7.6 Hz,
2H, Ar-H), 7.63 (t, J = 7.2 Hz, 1H, Ar-H), 7.56–7.49 (m, 3H, Ar-H), 7.44–7.29 (m, 7H, Ar-H), 7.09 (d,
J = 9.2 Hz, 1H, NH), 6.27 (t, J = 8.8 Hz, 1H, H-13), 5.76 (d, J = 8.8 Hz, 1H, H-3′), 5.60 (d, J = 8.0 Hz, 1H,
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H-2), 4.80 (d, J = 7.6 Hz, 2H, H-5, H-3), 4.67 (brs, 1H, H-2′), 4.63 (m, 1H, OCH2CH2CH2OCO), 4.53 (dd,
J = 6.4, 11.6 Hz, 1H, OCH2CH2CH2OCO), 4.47 (d, J = 8.4 Hz, 1H, H-20a), 4.42 (dd, J = 4.0, 7.2 Hz, 1H,
OCH2CH2CH2OCO), 4.34 (d, J = 8.4 Hz, 1H, H-20b), 4.11 (overlap, 2H, H-7a, OCH2CH2CH2OCO),
3.98 (dt, J = 6.0, 11.6 Hz, 1H, H-7b), 2.66 (m, 1H, H-6a), 2.56 (s, 3H, CH3), 2.52 (s, 3H, CH3), 2.42–2.11
(m, 5H, H-6b, H-14a, H-14b, OCH2CH2CH2O), 1.82 (s, 3H, CH3), 1.24 (s, 3H, CH3), 1.17 (s, 3H, CH3),
0.79 (s, 9H, SiC(CH3)3), −0.04 (s, 3H, Si(CH3)), −0.31 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 150 MHz)
δ: 191.6, 170.7, 169.7, 169.3, 166.7, 166.6, 153.6, 152.4, 144.1, 138.8, 138.1, 135.5, 133.6, 131.6, 130.2 (2C),
130.0, 128.7, 128.6, 128.5, 127.7, 126.8 (2C), 126.1 (2C), 90.3, 84.4, 78.4, 76.1, 75.2, 75.0, 70.4, 68.9, 65.8,
64.2, 55.4, 42.6 (2C), 36.4, 30.8, 28.8, 25.9, 25.3 (3C), 22.5, 21.5, 17.9, 14.5, 14.1, −5.5, −6.1; LC-MS (ESI,
m/z): [M + 23], found 1032.0, C55H67NO15Si: 1009.43.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-methoxybenzoyl)-macrocyclic taxoid (20b). White solid; yield
28.6%; 1H-NMR (CDCl3, 400MHz) δ: 7.79 (d, J = 7.6 Hz, 1H, Ar-H), 7.76 (d, J = 7.2 Hz, 2H, Ar-H),
7.67–7.66 (m, 1H, Ar-H), 7.55–7.50 (m, 1H, Ar-H), 7.48–7.42 (m, 3H, Ar-H), 7.40–7.29 (m, 5H, Ar-H),
7.19–7.16 (m, 1H, Ar-H), 7.09 (d, J = 8.8 Hz, 1H, BzNH), 6.27 (t, J = 8.8 Hz, 1H, H-13), 5.76 (dd,
J = 1.5, 9.0 Hz, 1H, H-3′), 5.62 (d, J = 7.64 Hz, 1H, H-2), 4.85–4.82 (m, 2H, H-5, H-3), 4.69–4.63 (m, 2H,
H-2′, OCH2CH2CH2OCO), 4.56–4.51 (m, 1H, OCH2CH2CH2OCO), 4.48–4.38 (m, 3H, H-20a, H-20b,
OCH2CH2CH2OCO), 4.16–4.07 (m, 2H, H-7a, OCH2CH2CH2OCO), 4.01–3.96 (m, 1H, H-7b), 3.90 (s,
3H, OCH3), 2.72–2.62 (m, 1H, H-6a), 2.57 (s, 3H, CH3), 2.53 (s, 3H, CH3), 2.43–2.36 (m, 1H, H-6b),
2.35–2.28 (m, 1H, H-14a), 2.16–2.14 (m, 2H, H-14b, OCH2CH2CH2O), 1.82 (d, J = 1.1 Hz, 3H, CH3), 1.25
(s, 3H, CH3), 1.18 (s, 3H, CH3), 0.88 (s, 9H, SiC(CH3)3), −0.014 (s, 3H, Si(CH3)), −0.29 (s, 3H, Si(CH3));
13C-NMR (CDCl3, 100 MHz) δ: 190.8, 171.3, 171.2, 169.2, 166.9, 166.8, 159.8, 144.8, 138.3, 134.2, 131.8,
130.6, 130.1, 128.8 (2C), 128.7 (2C), 128.0, 127.0 (2C), 126.6 (2C), 122.3, 120.0, 114.5, 85.1, 77.4, 77.3, 76.8,
75.3, 74.9, 70.8, 67.8, 60.4, 55.8, 55.5, 42.8, 41.6, 40.4, 36.6, 33.0, 29.7, 25.5 (3C), 23.2, 22.4, 21.0, 18.2, 14.5,
14.2, −5.3,−5.8; LC-MS (ESI, m/z): [M + 1], found 1040.5, [M + 23], found 1062.5, C56H69NO16Si: 1039.44.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-fluorobenzoyl)-macrocyclic taxoid (20c). White solid; yield
27.1%; 1H-NMR (CDCl3, 400 MHz) δ: 8.00 (d, J = 7.7 Hz, 1H, Ar-H), 7.87 (d, J = 8.8 Hz, 1H, Ar-H), 7.77
(d, J = 7.32 Hz, 1H, Ar-H), 7.57–7.51 (m, 2H, Ar-H), 7.46–7.33 (m, 8H, Ar-H), 7.10 (d, J = 9.0 Hz, 1H,
NH), 6.26 (t, J = 8.5 Hz, 1H, H-13), 5.78 (d, J = 8.5 Hz, 1H, H-3′), 5.60 (d, J = 7.7 Hz, 1H, H-2), 4.85–4.82
(overlap, 2H, H-5, H-3), 4.72–4.63 (overlap, 2H, OCH2CH2CH2OCO, H-2′), 4.55 (dt, J = 5.5, 10.3 Hz,
1H, OCH2CH2CH2OCO), 4.47–4.42 (overlap, 2H, OCH2CH2CH2OCO, H-20a), 4.37 (d, J = 8.2 Hz,
1H, H-20b), 4.14–4.10 (overlap, 2H, H-7a, OCH2CH2CH2OCO), 3.99 (dt, J = 6.4, 11.3 Hz, 1H, H-7b),
2.73–2.64 (m, 1H, H-6a), 2.57 (s, 3H, CH3), 2.54 (s, 3H, CH3), 2.42–2.18 (m, 5H, H-6b, H-14a, H-14b,
OCH2CH2CH2O), 2.10 (brs, 1H, OH), 1.83 (s, 3H, CH3), 1.25 (s, 3H, CH3), 1.18 (s, 3H, CH3), 0.82 (s,
9H, SiC(CH3)3), −0.008 (s, 3H, Si(CH3)), −0.27 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.8,
171.0, 169.5, 166.9, 165.7 (d, 5JC-F = 3.0 Hz, ArCO), 162.6 (d, 1JC-F = 247.8 Hz), 153.8, 152.6, 144.3, 139.1,
138.4, 135.5, 134.2, 131.8, 131.3 (d, 3JC-F = 7.5 Hz), 130.6 (d, 3JC-F = 7.7 Hz), 128.8, 128.7, 127.9, 127.0,
126.4, 126.0 (d, 4JC-F = 2.6 Hz), 120.9 (d, 2JC-F = 21.1 Hz), 117.0 (d, 2JC-F = 23.2 Hz), 90.6, 84.6, 78.6,
77.4, 77.1, 76.7, 76.2, 75.8, 75.3, 70.6, 69.2, 66.0, 64.4, 55.6, 42.8 (2C), 36.5, 31.0, 29.0, 26.1, 25.5 (3C),
22.7, 21.7, 18.2, 14.7, 14.4, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found 1028.4, [M + 23], found 1050.4,
C55H66FNO15Si: 1027.42.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-chlorobenzoyl)-macrocyclic taxoid (20d). White solid; yield
23.6%; 1H-NMR (CDCl3, 400 MHz) δ: 8.20 (t, J = 1.6 Hz, 1H, Ar-H), 8.12–8.09 (m, 1H, Ar-H), 7.77 (d,
J = 7.2 Hz, 1H, Ar-H), 7.65–7.62 (m, 1H, Ar-H), 7.56–7.51 (m, 2H, Ar-H), 7.47–7.33 (m, 7H, Ar-H), 7.09 (d,
J = 9.0 Hz, 1H, BzNH), 6.26 (t, J = 8.8 Hz, 1H, H-13), 5.77 (dd, J = 1.5, 8.98 Hz, 1H, H-3′), 5.60 (d, J = 7.8 Hz,
1H, H-2), 4.85–4.82 (dd, J = 3.5, 11.0 Hz, 2H, H-5, H-17b), 4.72–4.64 (m, 2H, OCH2CH2CH2OCO,
H-2′), 4.59–4.53 (m, 1H, OCH2CH2CH2OCO), 4.49–4.43 (m, 2H, OCH2CH2CH2OCO, H-20a), 4.38
(d, J = 8.4 Hz, 1H, H-20b), 4.15–4.10 (m, 2H, OCH2CH2CH2OCO, H-20a), 4.02–3.96 (m, 1H, H-7b),
2.74–2.65 (m, 1H, H-6a), 2.57 (s, 3H, CH3), 2.55 (s, 3H, CH3), 2.42–2.20 (m, 5H, H-6b, H-14a, H-14b,
OCH2CH2CH2O), 1.84 (d, J = 1.0 Hz, 3H, CH3), 1.26 (s, 3H, CH3), 1.19 (s, 3H, CH3), 0.83 (s, 9H,
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SiC(CH3)3), −0.005 (s, 3H, Si(CH3)), −0.26 (s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 190.7, 171.2,
169.1, 167.0, 165.7, 144.8, 138.3, 135.5, 135.0, 134.3, 133.9, 131.8, 131.1, 130.5, 129.9, 128.8 (2C), 128.7 (2C),
128.2, 128.0, 127.0 (2C), 126.7 (2C), 90.6, 84.6, 78.7, 76.2, 75.8, 75.3, 70.7, 67.8, 55.7, 42.8, 41.6, 36.5, 34.7,
31.6, 29.7, 25.6 (3C), 22.7, 22.4, 18.2, 14.5, 14.1, −5.3, −5.8; LC-MS (ESI, m/z): [M + 1], found 1044.0,
[M + 23], found 1065.9, C55H66ClNO15Si: 1043.39.
2′-O-(tert-Butyldimethylsilyl)-2-debenzoyl-2-(3-trifluoromethylbenzoyl)-macrocyclic taxoid (20e). White solid;
yield 26.7%; 1H-NMR (CDCl3, 400MHz) δ: 8.50 (s, 1H, Ar-H), 8.41 (d, J = 7.8 Hz, 1H, Ar-H), 7.92 (d,
J = 7.9 Hz, 1H, Ar-H), 7.55–7.51 (m, 1H, Ar-H), 7.48–7.33 (m, 8H, Ar-H), 7.09 (d, J = 9.0 Hz, 1H, NH),
6.26–6.21 (m, 1H, H-13), 5.76 (dd, J =1.4, 9.1 Hz, 1H, H-3′), 5.64 (d, J = 7.8 Hz, 1H, H-2), 4.89–4.83 (m,
2H, H-5, H-3), 4.69–4.63 (m, 2H, OCH2CH2CH2OCO, H-2′), 4.60–4.55 (m, 1H, OCH2CH2CH2OCO),
4.49–4.43 (m, 2H, OCH2CH2CH2OCO, H-20a), 4.37 (d, J = 8.0 Hz,1H, H-20b), 4.13 (t, J = 7.7 Hz, 2H,
H-7a, OCH2CH2CH2OCO), 2.75–2.67 (m, 1H, H-6a), 4.02–3.96 (m, 1H, H-7b), 2.58 (s, 3H, CH3), 2.53 (s,
3H, CH3), 2.45–2.18 (m, 5H, H-6b, H-14a, H-14b, OCH2CH2CH2O), 1.84 (d, J =1.0 Hz, 1H, CH3), 1.26
(s, 3H, CH3), 1.25 (s, 3H, CH3), 1.20 (s, 3H, CH3), 0.83 (s, 9H, SiC(CH3)3), −0.006 (s, 3H, Si(CH3)), −0.25
(s, 3H, Si(CH3)); 13C-NMR (CDCl3, 100 MHz) δ: 191.7, 171.1, 167.0, 165.5, 153.9, 152.7, 135.4, 134.3,
133.6, 131.8, 131.4 (q, 2J = 33.3 Hz), 130.9, 130.3 (q, 3J = 3.9 Hz), 130.2, 129.7, 128.8, 128.0, 127.0, 126.9 (q,
3J = 3.8 Hz), 126.5, 123.7 (q, 1J = 273.8 Hz), 90.6, 84.7, 78.7, 76.2, 75.8, 75.3, 70.8, 69.2, 66.0, 64.5, 55.7,
42.9, 42.8, 36.5, 31.0, 29.0, 26.1, 22.6, 21.6, 18.2, 14.6, 14.4, −5.2, −5.8; LC-MS (ESI, m/z): [M + 1], found
1078.4, [M + 23], found 1100.4, C56H66F3NO15Si: 1077.42.
3.1.10. General Procedure for the Syntheses of Compounds 22a–e
Macrocyclic taxoid (22a)
To a solution of of 20a (29.6 mg, 0.0293 mmol) in THF (8 mL) was added, dropwise, 0.47 mL of
HF-pyridine (v/v = 1:2) at 0 ◦C, and the reaction mixture was stirred at room temperature for 30 h.
The reaction was quenched with saturated aqueous NaHCO3, diluted with ethyl acetate, and washed
with saturated NH4Cl. The organic layer was dried over anhydrous Na2SO4 and then concentrated
under reduced pressure. Purification of the crude product by silica gel chromatography (ethyl acetate:
petroleum ether = 2:1) gave product 22a as a white solid (13.4 mg, 51.0% yield). 1H-NMR (CDCl3,
400 MHz) δ: 7.16 (d, J = 7.1 Hz, 2H, Ar-H), 7.75 (d, J = 7.0 Hz, 2H, Ar-H), 7.64 (t, J = 7.5 Hz, 1H,
Ar-H), 7.54–7.50 (m, 3H, Ar-H), 7.49–7.47 (m, 2H, Ar-H), 7.43–7.39 (m, 4H, Ar-H), 7.36–7.32 (m,1H,
Ar-H), 7.04 (d, J = 9.1 Hz, 1H, NH), 6.18 (dd, J = 8.7 Hz, 1H, H-13), 5.81 (dd, J = 2.4, 9.1 Hz, 1H, H-3′),
5.59 (d, J = 7.7 Hz, 1H, H-2), 4.81–4.79 (overlap, 3H, H-5, H-3, H-2′), 4.61 (dt, J = 5.4, 11.0 Hz, 1H,
OCH2CH2CH2OCO), 4.52 (dt, J = 6.9, 12.0 Hz, 1H, OCH2CH2CH2OCO), 4.44 (overlap, 2H, H-20a,
OCH2CH2CH2OCO), 4.41–4.33 (m, 1H, H-20b), 4.34–4.28 (overlap, J = 6.7 Hz, H-7a), 4.08 (overlap,
2H, H-7a, OCH2CH2CH2OCO), 3.95 (m, 1H, H-7b), 3.58 (brs, 1H, OH-2′), 2.66–2.61 (m, 1H, H-6a),
2.55 (s, 3H, CH3), 2.37–2.33 (brs, 3H, CH3), 2.30–2.12 (overlap, 3H, H-6b, H-14a, H-14b), 1.67 (brs, 2H,
OCH2CH2CH2OCO), 1.23 (s, 3H, CH3), 1.16 (s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.6, 172.4,
169.8, 167.0, 166.9, 153.8, 152.6, 144.6, 138.0 (2C), 136.1, 133.9, 133.7, 130.2 (2C), 129.1, 129.0 (2C), 128.9,
128.8 (2C), 128.7 (2C), 128.3, 127.0 (2C), 90.5, 84.7, 78.5, 76.3, 75.3, 73.2, 71.7, 69.2, 65.6, 64.4, 54.8, 42.9,
42.7, 36.5, 31.0, 29.0, 26.2, 22.4, 21.3, 14.7, 14.0; LC-MS (ESI, m/z): [M + 1], found 896.3, [M + 23], found
918.3, C49H53NO15: 895.34.
2-Debenzoyl-2-(3-methoxybenzoyl)-macrocyclic taxoid (22b). White solid; yield 59.2%; 1H-NMR (CDCl3,
400 MHz) δ: 7.75 (d, J = 7.4 Hz, 3H, Ar-H), 7.65 (dd, J =1.42, 2.3 Hz, 1H, Ar-H), 7.52–7.38 (m, 9H, Ar-H),
7.17 (dd, J = 2.1, 8.2 Hz, 1H, Ar-H), 7.06 (d, J = 9.0 Hz, 1H, NH), 6.15 (t, J = 8.2 Hz, 1H, H-13), 5.78 (dd,
J = 2.1, 8.9 Hz, 1H, H-3′), 5.59 (d, J = 7.6 Hz, 1H, H-2), 4.80–4.76 (overlap, 3H, H-5, H-3, H-2′), 4.60 (dt,
J = 5.6, 11.2 Hz, 1H, OCH2CH2CH2OCO), 4.51 (dt, J = 5.7, 11.2 Hz, 1H, OCH2CH2CH2OCO), 4.44–4.37
(overlap, J = 5.6 Hz, 2H, OCH2CH2CH2OCO, H-20a), 4.36 (d, J = 8.3 Hz, 1H, H-20b), 4.07 (overlap, 2H,
H-7a, OCH2CH2CH2OCO), 3.97–3.91 (m, 1H, H-7b), 3.87 (s, 3H, OCH3), 3.66 (d, J = 4.1 Hz, 1H, OH-2′),
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2.67–2.56 (m, 1H, H-6a), 2.55 (s, 3H, CH3), 2.34 (s, 3H, CH3), 2.40–2.30 (m, 2H, OCH2CH2CH2OCO),
2.28–2.12 (m, 3H, H-6b, H-14a, H-14b), 2.02 (brs, 1H, OH-1), 1.65 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.15 (s,
3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.6, 172.3, 169.8, 167.0, 166.8, 159.8, 153.7, 152.6, 144.6,
138.1, 137.9, 136.1, 133.7, 132.0, 130.3, 129.8, 129.0, 128.7, 128.3, 127.1, 127.0, 122.4, 112.0, 115.0, 90.4, 84.7,
78.4, 76.3, 75.3, 73.3, 71.7, 69.2, 66.0, 64.4, 55.5, 54.9, 42.8, 42.7, 36.5, 31.0, 29.0, 26.1, 22.4, 21.2, 14.7, 14.0;
LC-MS (ESI, m/z): [M + 1], found 926.3, [M + 23], found 948.3, C50H55NO16: 925.35.
2-Debenzoyl-2-(3-fluorobenzoyl)-macrocyclic taxoid (22c). White solid; yield 51.5%; 1H-NMR (CDCl3,
400 MHz) δ: 7.96 (d, J = 7.69 Hz, 1 H, Ar-H), 7.84 (d, J = 9.1 Hz, 1H, Ar-H), 7.74 (d, J = 7.7 Hz, 2H, Ar-H),
7.53–7.46 (m, 4 H, Ar-H), 7.40 (t, J = 7.5 Hz, 4H, Ar-H), 7.36–7.32 (m, 2H, Ar-H), 7.05 (d, J = 9.0 Hz, 1H,
NH), 6.15 (t, J = 8.6 Hz, 1H, H-13), 5.78 (dd, J = 2.0, 9.0 Hz, 1H, H-3′), 5.57 (d, J = 7.7 Hz, 1H, H-2),
4.81–4.79 (overlap, 3H, H-5, H-3, H-2′), 4.60 (dt, J = 5.3, 10.7 Hz, 1H, OCH2CH2CH2OCO), 4.52 (dt,
J = 5.4, 10.8 Hz, 1H, OCH2CH2CH2OCO), 4.44–4.40 (ovelap, 2H, H-7a, OCH2CH2CH2OCO), 4.40 (d,
J = 8.0 Hz, 1H, H-20a), 4.32 (d, J = 8.1 Hz, 1H, H-20b), 4.07 (t, J = 7.5 Hz, 2H, OCH2CH2CH2OCO), 3.93
(dt, J = 5.9, 11.9 Hz, 1H, H-7b), 3.69 (brs, 1H, OH-2′), 2.68–2.58 (m, 1H, H-6a), 2.54 (s, 3H, CH3), 2.34 (s,
3H, CH3), 2.33–2.26 (m, 2H, OCH2CH2CH2OCO), 2.24–2.16 (m, 3H, H-6b, H-14a, H-14b), 1.97 (brs, 1H,
OH-1), 1.65 (br, 3H, CH3), 1.22 (s, 3H, CH3), 1.15 (s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.5,
172.4, 169.7, 167.0, 165.7 (d, JC-F = 2.8 Hz, CO), 162.6 (d, 1JC-F =247.9 Hz), 153.8, 152.6, 144.5, 138.1 (2C),
135.9, 133.8, 131.9, 131.3 (d, 3JC-F = 7.5 Hz), 130.5 (d, 3JC-F = 7.6 Hz), 129.0, 128.7, 128.3, 127.0 (2C), 126.0
(d, 4JC-F = 2.9 Hz), 121.0 (d, 2JC-F = 21.3 Hz), 116.9 (d, 2JC-F = 23.3 Hz), 90.5, 84.6, 78.5, 76.2, 75.6, 73.3,
71.6, 69.2, 66.0, 64.4, 55.0, 42.8, 42.7, 36.4, 30.9, 29.3, 29.0, 26.1, 22.3, 21.3, 14.6, 14.0; LC-MS (ESI, m/z):
[M + 1], found 914.3, [M + 23], found 936.3, C49H52FNO15: 913.33.
2-Debenzoyl-2-(3-chlorobenzoyl)-macrocyclic taxoid (22d). White solid; yield 65.4%; 1H-NMR (CDCl3,
400 MHz) δ: 8.16 (t, J = 1.8 Hz, 1H, Ar), 8.06–8.04 (m, 1 H, Ar-H), 7.75–7.73 (m, 2H, Ar-H), 7.61 (ddd,
J =1.0, 2.0, 8.0 Hz, 1H, Ar-H), 7.43–7.39 (m, 4H, Ar-H), 7.52–7.45 (m, 4 H, Ar-H), 7.37–7.32 (m, 1H,
Ar-H), 7.01 (d, J = 9.0 Hz, 1H, NH), 6.15 (dd, J = 7.4, 8.7 Hz, 1H, H-13), 5.78 (dd, J = 2.3, 9.0 Hz,
1H, H-3′), 5.57 (d, J = 7.7 Hz, 1H, H-2), 4.81–4.79 (overlap, 3H, H-5, H-3, H-2′), 4.60 (dt, J = 5.3, 10.7
Hz, 1H, OCH2CH2CH2OCO), 4.53 (dt, J = 5.5, 11.3 Hz, 1H, OCH2CH2CH2OCO), 4.45–4.44 (m, 1H,
OCH2CH2CH2OCO), 4.39 (d, J = 8.2 Hz, 1H, H-20a), 4.33 (d, J = 8.2 Hz, 1H, H-20b), 4.08 (overlap,
J = 7.62 Hz, 2H, H-7a, OCH2CH2CH2OCO), 3.96–3.90 (m, 1H, H-7b), 3.60 (brs, 1H, OH-2′), 2.68–2.58
(m, 1H, H-6a), 2.54 (s, 3H, CH3), 2.35 (s, 3H, CH3), 2.44–2.30 (m, 2H, OCH2CH2CH2OCO), 2.28–2.16
(m, 3H, H-6b, H-14a, H-14b), 1.97 (brs, 1H, OH-1), 1.65 (d, J =1.7 Hz, 3H, CH3), 1.23 (s, 3H, CH3), 1.16
(s, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) δ: 191.5, 172.4, 169.7, 167.0, 165.5, 153.8, 152.6, 144.5, 138.0,
135.9, 134.8, 133.8, 133.7, 132.0, 130.9, 130.2 (2C), 129.0, 128.7, 128.4, 127.1, 127.0, 90.4, 84.6, 78.5, 76.1,
75.5, 73.2, 71.7, 69.2, 65.9, 64.4, 55.0, 42.8, 42.7, 36.4, 30.9, 29.0, 26.1, 22.3, 21.2, 14.6, 14.0; LC-MS (ESI,
m/z): [M + 1], found 930.3, [M + 23], found 952.3, C49H52ClNO15: 929.30.
2-Debenzoyl-2-(3-trifluoromethylbenzoyl)-macrocyclic taxoid (22e). White solid; yield 59.5%; 1H-NMR
(CDCl3, 400 MHz) δ: 8.46 (s, 1 H, Ar), 8.36 (d, J = 7.8 Hz, 1H, Ar-H), 7.90 (d, J =7.7 Hz, 1H, Ar-H),
7.73–7.67 (m, 3 H, Ar-H), 7.51–7.47 (m, 3H, Ar-H), 7.42–7.32 (m, 5H, Ar-H), 6.98 (d, J = 9.0 Hz, 1H,
NH), 6.15 (t, J = 8.1 Hz, 1H, H-13), 5.77 (dd, J = 2.0, 9.0 Hz, 1H, H-3′), 5.61 (d, J = 7.7 Hz, 1H, H-2),
4.84–4.78 (overlap, 3H, H-5, H-3, H-2′), 4.62–4.51 (m, 2H, OCH2CH2CH2OCO), 4.45–4.41 (m, 2H, H-7a,
OCH2CH2CH2OCO), 4.39 (d, J = 8.0 Hz, 1H, H-20a), 4.31 (d, J = 8.2 Hz, 1H, H-20b), 4.07 (t, J = 7.6 Hz,
1H, OCH2CH2CH2OCO), 3.93 (dt, J = 6.9, 11.6 Hz, 1H, H-7b), 3.62 (brs, 1H, OH-2′), 2.66–2.58 (m, 1H,
H-6a), 2.54 (s, 3H, CH3), 2.44–2.35 (m, 2H, OCH2CH2CH2OCO), 2.32 (s, 3H, CH3), 2.28–2.16 (m, 3H,
H-6b, H-14a, H-14b), 1.97 (brs, 1H, OH-1), 1.67 (br, 3H, CH3), 1.23 (s, 3H, CH3), 1.17 (s, 3H, CH3);
13C-NMR (CDCl3, 75 MHz) δ: 191.6, 172.4, 169.7, 167.0, 165.4, 153.7, 152.6, 144.5, 138.1 (2C), 135.8, 133.7,
133.6, 131.9, 131.3 (d, 2JC-F = 33.2 Hz), 130.3 (d, 3JC-F = 3.7 Hz), 130.1, 129.6, 129.0, 128.7, 128.4, 127.1,
127.0, 126.9 (d, 3JC-F = 3.2 Hz), 125.5, 90.5, 84.6, 78.5, 76.1, 75.6, 73.1, 71.7, 69.2, 66.0, 64.4, 55.0, 42.8, 42.7,
36.3, 30.9, 29.3, 28.9, 26.1, 22.2, 21.2, 14.6, 14.0; LC-MS (ESI, m/z): [M + 1], found 964.4, [M + 23], found
986.3, C50H52F3NO15: 963.33.
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3.2. Cell Assays
Cell viability after taxoids treatment was evaluated using CCK-8 assay. Briefly, 3000 cells per well
were seeded in 96-well plates and incubated under normal conditions for 24 h. Cells were treated
with different concentrations of the test agent for 72 h, then the medium was removed, 100 μL of
CCK-8 working solution was added to each well for 1 h at 37 ◦C. The absorbance was measured
at 450 nm with a microplate reader (Tecan Trading, AG, Switzerland). Vehicle-only treated cells
served as the indicator of 100% cell viability. The 50% inhibitory concentration (IC50) was defined
as the concentration that reduced the absorbance of the vehicle-only treated wells by 50% in the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
3.3. Model Building and Molecular Dynamics Simulations
The X-ray crystal structure of paclitaxel provided a template for the construction of 18b and
22b using the molecular editing tools implemented in PyMOL [17]. Geometry optimization of 18b
and 22b was achieved by means of the updated AM1 hamiltonian implemented in the sqm program,
which also produced atomic charge distributions for both ligands that can reproduce the molecular
electrostatic potential. The ff14SB AMBER force field was used to assign bonded and non-bonded
parameters to protein and ligand atoms [18,19]. 18b was immersed in a cubic box containing TIP3P
water molecules and simulated under periodic boundary conditions for 50 ns at 300 K. Subsequent
gradual cooling, from 300 to 273 K over 1 ns, of snapshots taken regularly every 2.5 ns, followed by
energy minimization until the root-mean-square of the Cartesian elements of the gradient was less
than 0.1 kcal·mol−1·Å−1, provided representative structures of this molecule; those displaying the
shortest distance between the free hydroxyl groups were chosen to build 22b by means of a C=O
linkage. The simulated macromolecular ensemble representing a short piece of a microtubule with
bound 22b was constructed as previously reported for D-seco taxol derivatives [20].
4. Conclusions
In summary, this study demonstrated that C-seco taxoids conformationally constrained via
carbonate-containing linked macrocyclization display increased cytotoxicity on drug-resistant tumors
overexpressing both βIII and P-gp, compared to the non-cyclized C-seco taxoid counterparts Among
them, compound 22b, bearing a 2-m-methoxybenzoyl group together with a five-atom linker, was
identified as the most potent compound in the series.
Supplementary Materials: The supplementary materials are available online, cell lines and culture [21],
establishment of model multidrug-resistant breast cancer cell line MCF-7/ADR. Copies of ESI-MS, HPLC,
1H-NMR and 13C-NMR spectra for representative compounds.
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Abstract: Zampanolide is a promising microtubule-stabilizing agent (MSA) with a unique chemical
structure. It is superior to the current clinically used MSAs due to the covalent nature of its binding
to β-tubulin and high cytotoxic potency toward multidrug-resistant cancer cells. However, its further
development as a viable drug candidate is hindered by its limited availability. More importantly,
conversion of its chemically fragile side chain into a stabilized bioisostere is envisioned to enable
zampanolide to possess more drug-like properties. As part of our ongoing project aiming to develop its
mimics with a stable side chain using straightforward synthetic approaches, 2-fluorobenzyl alcohol was
designed as a bioisosteric surrogate for the side chain based on its binding conformation as confirmed
by the X-ray structure of tubulin complexed with zampanolide. Two new zampanolide mimics
with the newly designed side chain have been successfully synthesized through a 25-step chemical
transformation for each. Yamaguchi esterification and intramolecular Horner–Wadsworth–Emmons
condensation were used as key reactions to construct the lactone core. The chiral centers at C17
and C18 were introduced by the Sharpless asymmetric dihydroxylation. Our WST-1 cell proliferation
assay data in both docetaxel-resistant and docetaxel-naive prostate cancer cell lines revealed that
compound 6 is the optimal mimic and the newly designed side chain can serve as a bioisostere for
the chemically fragile N-acetyl hemiaminal side chain in zampanolide.
Keywords: natural product; anticancer agent; synthesis; zampanolide
1. Introduction
Prostate cancer is still one of the big health concerns, as evidenced by its high incidence
and mortality rate in American men. In 2019, 174,650 new prostate cancer cases that account for
nearly 20% of all cancer cases and 31,620 prostate cancer deaths are projected to occur in the United
States [1]. Prostate cancer is driven by the androgen receptor (AR)-regulated gene expression that is
initiated by the binding of androgen to the AR [2]. Androgen deprivation therapy (ADT) has thus been
the main treatment for prostate cancer over 70 years. However, the median duration of ADT response
is merely 18–24 months due to inevitable progression to castration-resistant prostate cancer (CRPC) [3].
Consequently, approximately 30,000 prostate cancer deaths in the United State each year are caused
by CRPC as well as resistance to the current treatments. The critical driving force for the continued
progression of lethal CRPC is the reactivation of AR transcriptional activity [4,5]. The current first-line
and second-line chemotherapeutics for CRPC are two microtubule-stabilizing cytotoxic agents (MSA),
docetaxel and cabazitaxel [6–8]. Promotion of mitotic arrest is the initially well-established mechanism
underlying the action of MSAs as anticancer agents [9]. The MSAs were recently revealed to impair
AR transcriptional activity by suppressing nuclear importation of AR as downstream of microtubule
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stabilization [10]. This alternative mechanism is independent of MSA-induced mitotic arrest and can
explain in part the efficacy of MSA in AR-driven CRPC.
The marine macrolide (−)-zampanolide (1, Figure 1) [11] has been demonstrated as a unique
and promising MSA, which distinguishes it from the current clinically used MSAs due to (1) the covalent
nature of its binding to the taxane pocket in β-tubulin as confirmed by a high-resolution X-ray structure
of zampanolide in complex with α,β-tubulin, and (2) the very high cytotoxic potency as evidenced by
low nanomolar IC50 values in suppressing multidrug-resistant cancer cell proliferation [12].
Figure 1. Zampanolide, desTHP-(−)-zampanolide, desTHPzampanolide mimics 3 and 4.
Although (−)-zampanolide has shown great potential in becoming a more effective
chemotherapeutic for CRPC, no in vivo assessment of its antitumor efficacy, pharmacokinetics,
and toxicity in animal models has so far been reported yet mainly because of its limited supply.
Unfortunately, the supply issue of (−)-zampanolide cannot be addressed either by isolation from marine
sponge sources or by current reported total syntheses. The best yield for isolation of (−)-zampanolide
from marine sponge sources is merely 0.001% [12,13], and the highest yield for its syntheses is only
0.9% [14–18]. More importantly, the chemically fragile N-acyl hemiaminal side chain of zampanolide can
compromise its pharmacokinetic profiles as well as the feasibility as a viable drug candidate. The easy
cleavage of the N-acyl hemiaminal side chain has been confirmed by a thermolysis reaction carried
out by Professor Smith and his coworkers [16], and the instability of zampanolide in CDCl3 has been
reported by Higa and coworkers when they first identified its structure [13]. The N-acyl hemiaminal side
chain of zampanolide is, however, very vital to retain its excellent cytotoxic potency, and the derivative
without the side chain has 10- to 1000-fold less potency in certain cell models [12,19,20]. Our previous
study has confirmed that a suitably designed side chain (e.g., the side chain in desTHPzampanoide
mimics 3 and 4) can function as a bioisostere for the chemically unstable N-acyl hemiaminal side chain
in desTHPzampanolide (2) [21]. However, the bioisosteric side chains that we reported previously
do not contain a hydroxyl substituent, corresponding to the C20 alcohol of zampanolide that is
hydrogen-bonded to the carbonyl oxygen of Thr276 in β-tubulin. As part of our ongoing project to
develop simplified and stabilized zampanolide mimics, this paper presents the design, total synthesis,
and antiproliferative evaluation of zampanolide mimics in which the N-acyl hemiaminal side chain is
substituted by more stable 2-fluorobenzyl alcohol appendages.
2. Results and Discussion
2.1. Design of New Zampanolide Mimics
The first group of side chains in the zampanolide mimics (e.g., 3–4) previously published by
us [21] do not contain a hydroxyl group in order to render a more simplified synthesis. However,
the binding conformation confirmed by the high-resolution crystal structure of zampanolide tubulin
complex [22] indicates the hydroxyl group at the C20 position in zampanolide is hydrogen-bonded
to the carbonyl oxygen of Thr276 in β-tubulin. With this point in mind, a new side chain (S-2) was
designed as a bioisosteric substitution for the N-acyl hemiaminal side chain, an unstable moiety in
zampanolide but important for its potent cytotoxic properties. The stabilized side chain (S-2) was
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designed to replace the chemically fragile N-acylhemiaminal moiety (blue circle in Figure 2) with
a benzyl alcohol. The 20OH group is retained in the target side chain so that it can be hydrogen-bonded
to the main-chain carbonyl oxygen of Thr276 in β-tubulin. The 1′O atom of zampanolide’s side chain is
replaced with fluorine atom in the designed side chain so that it can be hydrogen-bonded to the NH
group of Thr276 in β-tubulin. The E,Z-hexadienoyl amide in zampanolide side chain is replaced with
a planar conjugate phenyl ring to preserve the hydrophobic contacts between the proposed side chain
and residues of β-tubulin. The Almann’s desTHP-dactylolide and its enantiomer [23] were further
adopted as the core structure of the new zampanolide mimics (5 and 6) in the current study because of
the acceptable in vitro potency of desTHP-(−)-zampanolide (2) and the practical synthesis of the core.
Consequently, we set 5 and 6 as our new target mimics of zampanolide in this study.
Figure 2. Design of a new stabilized side chain for zampanolide mimics.
2.2. Synthesis
Our retrosynthetic analysis of the zampanolide mimics 5 and 6, using Yamaguchi esterification
and intramolecular Horner–Wadsworth–Emmons condensation as key reactions, is illustrated in
Scheme 1. The Yamaguchi esterification was employed to connect Fragment C1–C8 (carboxylic acid 9)
with Fragment C9–C18 (alcohol 7 or 8) via the ester bond between C1 and C17. The intramolecular
Horner–Wadsworth–Emmons condensation was used to close the macrolactone ring at C8–C9.
These two key reactions were successfully applied to our syntheses of desTHPdactylolide and the mimics
of desTHPzampanolides [21,23]. The known Fragment C1–C8 (9) was readily synthesized via 10 steps
from commercially available 2-butyn-1-ol according to the reported procedure [24].
Scheme 1. Retrosynthetic analysis of zampanolide mimics 5 and 6.
The preparation of Fragment C9–C18 (7 and 8) with the desired side chain is shown in Scheme 2.
The chiral centers at C17 and C18 in the Fragment C9–C18 (7 and 8) were introduced by the Sharpless
asymmetric dihydroxylation using the commercially available AD-mix formulations (AD-mix-α
and AD-mix-β, respectively) with the ligand and the osmium salt as the critical trace component (0.6%
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by wt) and ferricyanide and carbonate as the bulk ingredient (99.4% by wt.) [25]. Compound (E)-ethyl
3-(2-fluorophenyl)acrylate was synthesized by the Wittig reaction of the commercially available
2-fluorobenzaldehyde (10) with ethyl 2-(triphenyl- phosphoranylidene)acetate (11) according to
the procedure described in the literature [26]. (E)-3-(2-Fluorophenyl)prop-2-en-1-ol (13) was synthesized
by reducing (E)-ethyl 3-(2-fluorophenyl)acrylate (12) with diisobutylaluminium hydride (DIBAL)
based on the procedure reported in the literature [27]. The Sharpless asymmetric dihydroxylation of
the allylic alcohol (13) with AD-mix-α or AD-mix-βwas performed following the standard experimental
procedure reported in the literature and sulfonamide was used to accelerate the hydrolysis of osmate
ester [25]. Epoxy alcohols (18 with R,R configuration, 19 with S,S configuration) have been synthesized
by sequential selective mesylation of primary alcohol (14 or 15) and intermolecular Williamson
ether synthesis [28]. The hydroxy group in epoxy alcohols (18 with R,R configuration, 19 with S,S
configuration) was then protected as the corresponding methoxymethyl (MOM) ethers (20 with
R,R configuration, 21 with S,S configuration). Iodo ether 22 was prepared using the optimized
protocol previously developed in our laboratory [23]. Its lithiation with tert-butyllithium followed by
nucleophilic reaction with epoxy MOM ether (20 with R,R configuration, 21 with S,S configuration)
in toluene at −90 ◦C mediated by boron trifluoride etherate furnished Fragment C9–C18 (7 with R,R
configuration, 8 with S,S configuration) in 22–23% overall yield from 22.
Scheme 2. Synthesis of Fragment C9–C18 (7 and 8).
As illustrated in Scheme 3, the union of Fragment C1–C8 (alcohol 9) and Fragment C9–C18
(carboxylic acid, 7 with R,R configuration, 8 with S,S configuration) has been accomplished
by the Yamaguchi esterification to yield bis-TBS ethers (23 with R,R configuration, 24 with S,S
configuration). Removal of the protecting TBS groups at C7 and C9 with HF-pyridine complex
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followed by double oxidation of the corresponding diol (25 with R,R configuration and 26 with S,S
configuration) with Dess–Martin periodinane afforded the keto aldehydes (27 with R,R configuration,
28 with S,S configuration). Without further chromatographic purification, the crude keto aldehydes
were directly subjected to the synthesis of zampanolide mimics (29 with R,R configuration, 30 with S,S
configuration) through the intramolecular HWE condensation catalyzed by Ba(OH)2. Since extractive
work-up resulted in significant hydrolysis of the ester [21], the reaction was quenched by filtration of
the reaction mixture through a pad of silica gel and the crude product was subjected to preparative
TLC purification. The MOM group in 29 was initially planned to be removed using methanolic HCl,
but the methanol participated in a Michael addition to the enone, which resulted in the byproduct 31
(Scheme 4). The removal of the MOM with HCl was, therefore, carried out using THF rather than
methanol as solvent, leading to the desired zampanolide mimics (5 with R,R configuration at C17
and C18, 6 with S,S configuration at C17 and C18).
Scheme 3. Synthesis of zampanolide mimics 5 and 6.
Scheme 4. Deprotection of MOM ether 29 with methanolic HCl.
2.3. Antiproliferative Activity toward Prostate Cancer Cell Lines
The in vitro antiproliferative activity of two pairs of enantiomeric macrolides, 5 and 6, 29 and 30,
has been assessed against a panel of prostate cancer cell lines, including three docetaxel-sensitive
prostate cancer cell models (PC-3 DU145, and LNCaP) and two docetaxel-resistant prostate cancer
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cell lines (PC-3/DTX and DU145/DTX). WST-1 cell proliferation assay was used for the in vitro
evaluation according to the procedure described in the Experimental Section. Docetaxel was used
as a positive control while DMSO as a negative control. The half-maximal inhibitory concentrations
(IC50 values) were measured by WST-1 cell proliferation assay after 3 days of exposure, calculated from
the dose–response curves, and presented as the mean ± standard deviation of the mean in Table 1.
The IC50 values for these four new zampanolide mimics are in the range of 1.00–9.36 μM. Mimic 6
has a set of smallest IC50 values (1.00–3.91 μM) among the four test macrolides. As summarized in
Figure 3, the IC50 values of new mimic 6 are very close to those for mimic 3 (0.86–2.97 μM) and mimic 32
(1.92–3.16 μM). The mimic 3 has been evidenced to have similar potency as desTHPzampanolide 2 with
the N-acetyl hemiaminal side chain of zampanolide against prostate cancer cells [21]. The side chain in
mimic 6 was thus identified as a new bioisostere for the chemically unstable N-acetyl hemiaminal side
chain of zampanolide. The relative resistance for Mimic 6 of PC-3/DTX over PC-3 and DU145/DTX
over DU145 is 0.59 and 0.44, respectively.




a R/S a IC50: (μM)
a R/S a IC50: (μM)
PC-3 PC-3/DTX DU145 DU145/DTX LNCaP
Docetaxel 0.0019 ± 0.0006 2.34 ± 0.25 1232 0.0012 ± 0.0003 8.58 ± 0.39 7150 0.0002 ± 0.00005
3 b 0.88 ± 0.19 2.97 ± 0.09 1.3 0.86 ± 0.25 2.78 ± 0.16 3.2 0.76 ± 0.29
4 b 0.35 ± 0.05 0.30 ± 0.05 0.9 0.29 ± 0.03 0.46 ± 0.10 1.6 0.35 ± 0.02
29 9.36 ± 0.15 3.97 ± 0.24 0.42 3.98 ± 0.57 4.42 ± 0.55 1.1 5.29 ± 0.49
5 8.72 ± 2.21 3.63 ± 0.11 0.42 3.87 ± 0.23 5.03 ± 1.11 1.3 6.51 ± 0.60
30 5.80 ± 0.21 3.71 ± 0.72 0.64 2.28 ± 0.51 4.30 ± 0.79 1.9 3.15 ± 0.19
6 3.91 ± 0.73 2.31 ± 0.32 0.59 2.27 ± 0.39 1.00 ± 0.91 0.44 1.92 ± 0.29
a The relative resistance of the two cell lines obtained by dividing the IC50 value of the resistance cell line by that of
the parental cell line. b These data were reported in our previous paper [21].
Figure 3. Comparison of antiproliferative potency among different zampanolide mimics.
3. Materials and Methods
3.1. General Procedures
Optical rotations were measured on a RUDOLPH Research Analytical Autopol III Automatic
Polarimeter (RUDOLPH Research Analytical, Hackettstown, NJ, USA). IR spectra were recorded
on a Nicolet Nexus 470 FTIR spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
High-Resolution MS were obtained on an Orbitrap mass spectrometer (Thermo Fisher Scientific,
Waltham, MA, USA) with electrospray ionization (ESI). NMR spectra (see Supplementary Materials) were
obtained on a Bruker Fourier 300 spectrometer (Billerica, MA, USA) in CDCl3. The chemical shifts are given
in ppm referenced to the respective solvent peak, and coupling constants are reported in Hz. Anhydrous
THF and dichloromethane were purified by PureSolv MD 7 Solvent Purification System from Innovative
Technologies (MB-SPS-800) (Herndon, VA, USA). All other reagents and solvents were purchased from
commercial sources (Fisher Scientific, Portland, OR, USA) and were used without further purification.
Silica gel column chromatography was performed using silica gel (32–63 μM). Preparative thin-layer
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chromatography (PTLC) separations were carried out on thin-layer chromatography plates loaded with
silica gel 60 GF254 (EMD Millipore Corporation, Berlington, MA, USA). Starting materials 22 and 9 were
synthesized using the procedure previously described by us [23]. (E)-ethyl 3-(2-fluorophenyl)acrylate
(12) was prepared from commercially available 2-fluorobenzaldehyde (10, CAS 446-52-6) according to
the reported procedure [26]. (E)-3-(2-Fluorophenyl)prop-2-en-1-ol (13) was synthesized by reducing
(E)-ethyl 3-(2-fluorophenyl)acrylate (12) with DIBAL based on the procedure reported in the literature [27].
Its structure was confirmed by 1H NMR and high resolution mass spectrometry (HRMS) data (calculated
for C9H10FO (M +H): 153.0716; Found: 153.0710).
3.2. Synthesis of (1R,2R)-1-(2-Fluorophenyl)propane-1,2,3-triol [(17R,18R) triol 14]
AD-mix-α (5.9 g) was dissolved in a mixture of tert-butyl alcohol (21 mL) and water (21 mL).
The solution was stirred vigorously at room temperature until two clear phases were observed. At this
point, the lower aqueous phase emerged as bright yellow. Methanesulfonamide (399 mg, 4.2 mmol,
1 equiv) was added and the reaction mixture was cooled down to 0 ◦C. A solution of 13 (640 mg,
4.2 mmol, 1 equiv) in 1 mL of tert-butyl alcohol was then added. The resulting mixture was stirred
vigorously at 0 ◦C overnight and the reaction progress was monitored with TLC. The reaction was
quenched by adding solid sodium sulfate (6.3 g) at 0 ◦C. The mixture was warmed to room temperature
and stirred for 30–60 min. The tert-butyl alcohol was removed under vacuum, and saturated sodium
bicarbonate (30 mL) and water (300 mL) were added to the residue. The mixture was stirred for
additional 30 min and then extracted with ethyl acetate (150 mL × 3). The combined extracts were
rinsed with brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was
purified through column chromatography eluting with ethyl acetate. The product after purification,
with quantitative yield, still contained a trace amount of methanesulfonamide, which is good enough
to be used for the next-step reaction. 1H NMR (300 MHz, CDCl3) δ. 7.38 (t, J = 7.2 Hz, 1H, aromatic H),
7.21 (dd, J = 13.5, 5.7 Hz, 1H, aromatic H), 7.06 (t, J = 7.5 Hz, 1H, aromatic H), 6.95 (t, J = 8.4 Hz, 1H,
aromatic H), 4.88 (d, J = 6.3 Hz, 1H, H-18), 4.23 (br.s, 3H, 3 ×OH), 3.77 (q, J = 5.1 Hz, 1H, H-17), 3.45 (d, J
= 4.8 Hz, 2H, H2-16). 13C NMR (75 MHz, CDCl3) δ 159.9 (d, JCF = 243.8 Hz), 129.6, 128.5, 127.9 (d, JCF
= 12.8 Hz), 124.6, 115.4 (d, JCF = 21.8 Hz), 75.3, 68.8, 63.5. IR (film) νmax: 3384, 2988, 1617, 1490, 1455,
1320, 1222, 1054 cm−1. HRMS (ESI): m/z calculated for C9H12FO3 [M + H]+: 187.0770. Found: 187.0766.
3.3. Synthesis of (2R,3R)-3-(2-Fluorophenyl)-2,3-dihydroxypropyl methanesulfonate [(17R,18R) mesylate 16]
To a solution of triol 14 (1.37 g, 7.39 mmol) in pyridine (15 mL, 0.5 M), methane sulfonyl chloride
(0.57 mL, 7.39 mmol) was added dropwise at 0 ◦C under argon. The reaction mixture was stirred
at room temperature for 20 h and the reaction progress was monitored by TLC (Hexane/EtOAc, 1:1,
v/v). The reaction was quenched by diluting with ethyl acetate (800 mL), and the resulting solution was
rinsed with brine (50 mL × 3) and dried over anhydrous sodium sulfate. After removing the organic
solvent, the residue was subjected to column chromatography, using 40% ethyl acetate in hexane
as eluent, to give the desired product. Colorless oil; 81% yield. 1H NMR (300 MHz, CDCl3) δ 7.47 (dt, J
= 7.5, 1.8 Hz, 1H, aromatic H), 7.34–7.27 (m, 1H, aromatic H), 7.17 (dt, J = 7.5, 0.9 Hz, 1H, aromatic H),
7.04 (ddd, J = 10.5, 8.1, 0.9 Hz, 1H, aromatic H), 5.00 (d, J = 5.7 Hz, 1H, H-18), 4.27–4.16 (m, 2H, H2-16),
4.06–4.01 (m, 1H, H-17), 3.18 (br.s, 2H, 2 × OH), 3.03 (s, 3H, SO2CH3). 13C NMR (75 MHz, CDCl3)
δ 159.9 (d, JCF = 244.3 Hz), 130.1 (d, JCF = 8.3 Hz), 128.4 (d, JCF = 3.8 Hz), 127.0 (d, JCF = 12.8 Hz),
124.8 (d, JCF = 3.8 Hz), 115.7 (d, JCF = 21.8 Hz), 72.9, 70.4, 67.9 (d, JCF = 2.3 Hz), 37.6. IR (film) νmax:
3502, 3029, 2940, 1617, 1587, 1490, 1456, 1346, 1171 cm−1. HRMS (ESI): m/z calculated for C10H14FO5S
[M + H]+: 265.0546. Found: 265.0547.
3.4. Synthesis of (R)-(2-Fluorophenyl)((R)-oxiran-2-yl)methanol [(17R,18R) epoxide 18]
To a suspension of sodium hydride (275 mg, 60%, 6.87 mmol, 1.5 equiv) in anhydrous THF (36 mL),
a solution of 16 (1.21 g, 4.58 mmol, 1 equiv) in anhydrous THF was added at about −30 ◦C under
argon. The reaction mixture was stirred at 0 ◦C overnight and the reaction progress was monitored
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with TLC (hexane:EtOAc, 3:1). The mixture was filtered through a silica gel pad eluting with ethyl
acetate. After concentration to remove the solvent, the residue was subjected to PTLC purification
eluting with toluene:EtOAc (3:1, v/v) to furnish the desired epoxide. Colorless oil; 57% yield. 1H NMR
(300 MHz, CDCl3) δ 7.57 (dd, J = 7.8, 1.8 Hz, 1H, aromatic H), 7.35–7.28 (m, 1H, aromatic H), 7.20 (dt,
J = 7.5, 1.2 Hz, 1H, aromatic H), 7.06 (ddd, J = 10.5, 8.1, 1.2 Hz, 1H, aromatic H), 4.84 (t, J = 6.6 Hz,
1H, H-18), 3.26–3.22 (m, 1H, H-17), 2.92–2.85 (overlapped, 2H, H2-16), 2.47 (d, J = 5.7 Hz, 1H, OH).
13C NMR (75 MHz, CDCl3) δ 159.9 (d, JCF = 244.5 Hz), 129.6 (d, JCF = 8.3 Hz), 127.9 (d, JCF = 4.5 Hz),
127.3 (d, JCF = 13.5 Hz), 124.5 (d, JCF = 3.8 Hz), 115.4 (d, JCF = 21.8 Hz), 68.7 (d, JCF = 2.3 Hz), 55.6, 45.5
(d, J = 2.3 Hz). IR (film) νmax: 3420, 3067, 3002, 2928, 1617, 1586 1488, 1456, 1224 cm−1. HRMS (ESI): m/z
calculated for C9H10FO2 [M + H]+: 169.0665. Found: 169.0657.
3.5. Synthesis of (R)-2-((R)-(2-Fluorophenyl)(methoxymethoxy)methyl)oxirane [(17R,18R)MOM ether 20]
To a solution of alcohol 18 (716 mg, 4.3 mmol) in DMF (4.2 mL), sodium hydride (204 mg, 60%,
5.1 mmol) was added at 4 ◦C, and the mixture was stirred at 4 ◦C for 30 min. Methoxymethyl
chloride (0.39 mL, 5.1 mmol) followed by tetrabutylammonium iodide (157 mg, 0.43 mmol) was
added to the reaction mixture. The reaction was proceeded with stirring at room temperature for 20 h.
The reaction mixture was diluted with ethyl acetate (300 mL) and diethyl ether (300 mL) and then rinsed
with brine (50 mL × 3). The organic layer was dried over anhydrous sodium sulfate and concentrated
to give a crude mass, which was purified by column chromatography eluting with hexane/ethyl acetate
(3:1, v/v) to furnish the MOM ether 20 as a pale-yellow oil in 67% yield. 1H NMR (300 MHz, CDCl3)
δ 7.51 (dt, J = 7.2, 1.8 Hz, 1H, aromatic H), 7.33–7.25 (m, 1H, aromatic H), 7.17 (dt, J = 7.5, 1.2 Hz, 1H,
aromatic H), 7.04 (ddd, J = 9.9, 8.1, 1.2 Hz, 1H, aromatic H), 4.75 (d, J = 6.9 Hz, 1H, OCH2OCH3), 4.67
(d, J = 6.9 Hz, 1H, OCH2OCH3), 4.62 (d, J = 6.6 Hz, 1H, H-18), 3.36 (s, 3H, OCH3), 3.26–3.22 (m, 1H,
H-17), 2.73–2.72 (overlapped, 2H, H2-16). 13C NMR (75 MHz, CDCl3) δ 160.3 (d, J = 244.5 Hz), 129.8
(d, J = 8.3 Hz), 128.6 (d, J = 4.5 Hz), 125.2 (d, J = 14.3 Hz), 124.4 (d, J = 3.0 Hz), 115.5 (d, J = 21.8 Hz),
94.6, 73.0, 55.6, 54.4, 44.2 (d, J = 2.3 Hz). IR (film) νmax: 2891, 1615, 1587, 1488, 1455, 1022 cm−1. HRMS
(ESI): m/z calculated for C11H14FO3 [M + H]+: 213.0927. Found: 213.0921.
3.6. Synthesis of (5R,6R,E)-5-(2-Fluorophenyl)-8,16,16,17,17-pentamethyl-2,4,11,15-tetraoxa-16-
silaoctadec-8-en-6-ol [(17R,18R) Fragment C9–C18 (7)]
To a solution of vinyliodide 22 (164 mg, 0.44 mmol; co-evaporated twice with pentane) in toluene
(3 mL) at −78 ◦C, tert-butyllithium (0.46 mL, 1.9 M, 0.89 mmol) was added, and the mixture was
stirred at −78 ◦C for 45 min prior to being cooled down to −90 ◦C. Epoxide 20 (188 mg, 0.89 mmol;
co-evaporated twice with pentane) in toluene (1.5 mL) was added dropwise to make sure that interior
temperature lower than −78 ◦C. The reaction solution was re-cooled to −90 ◦C before BF3•OEt2
(0.11 mL, 0.89 mmoL) was added dropwise. The resulting solution was then stirred at −78 ◦C overnight
prior to being quenched with ethyl acetate (15 mL) and saturated aqueous sodium bicarbonate (35 mL)
was added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate
(60 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated
in Vacuum to remove ethyl acetate. The crude mass was subjected to PTLC purification over silica
gel using hexane/ethyl acetate (4:1, v/v) as eluent to yield secondary alcohol 7 as a pale-yellow oil in
23% yield. 1H NMR (300 MHz, CDCl3) δ. 7.41 (dt, J = 7.2, 1.5 Hz, 1H, aromatic H), 7.32–7.24 (m, 1H,
aromatic H), 7.15 (dt, J = 7.5, 0.9 Hz, 1H, aromatic H), 7.53 (ddd, J = 9.9, 8.1, 0.9 Hz, 1H, aromatic H),
5.41 (t, J = 6.6 Hz, 1H, H-14), 4.81 (d, J = 6.3 Hz, 1H, H-17), 4.62 (d, J = 6.9 Hz, 1H, OCH2OCH3), 4.58
(d, J = 6.6 Hz, 1H, OCH2OCH3), 3.94 (d, J = 6.6 Hz, 2H, H2-13), 3.67 (t, J = 6.3 Hz, 2H, H2-11), 3.46
(t, J = 6.3 Hz, 2H, H2-9), 3.36 (s, 3H), OCH3), 1.75 (quin, J = 6.3 Hz, 2H, H2-10), 1.64 (s, 3H, 15-CH3),
0.87 (s, 9H, TBS), 0.03 (s, 6H, TBS). 13C NMR (75 MHz, CDCl3) δ 160.9 (d, JCF = 244.8 Hz), 136.4, 129.8,
129.1, 128.7, 126.1 (d, JCF = 13.5 Hz), 124.5 (d, JCF = 3.8 Hz), 115.6 (d, JCF = 21.8 Hz), 95.3, 75.6, 72.5 (d,
JCF = 12.1 Hz), 67.3, 67.0, 60.2, 56.2, 43.0, 33.2, 26.1, 26.07, 18.5, 16.6, 16.5. IR (film) νmax: 3420, 2929,
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7-((tert-butyldimethylsilyl)oxy)-8-(diethoxyphosphoryl)-5- methylocta-2,4-dienoate [(17R,18R) ester 23]
To a solution of Fragment C1–C8 (9, 37 mg, 0.09 mmol; co-evaporated with pentane twice) in
toluene (0.5 mL) at room temperature, trimethylamine (28 μL, 0.20 mmol) and 2,4,6-trichlorobenzoyl
chloride (18 μL, 0.12 mmol) was sequentially added, and the reaction mixture was stirred at room
temperature for 1.5 h. A solution of alcohol 7 (35 mg, 0.08 mmol) and DMAP (9.3 mg, 0.08 mmol) in
toluene (0.5 mL) was then added to the reaction mixture. The reaction was allowed to proceed with
stirring at room temperature for 19 h prior to being quenched with water (5 mL) and saturated aqueous
sodium bicarbonate (5 mL). The mixture was extracted with ethyl acetate (5 mL × 3), the combined
organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuum. PTLC
purification of the crude product over silica gel eluting with hexane/ethyl acetate (60:40, v/v) yielded
the ester 23 as a mixture of diastereoisomers in a 1:1 ratio as a colorless oil in 77% yield. 1H NMR
(300 MHz, CDCl3) δ 7.50 (dd, J = 15.0, 11.7 Hz, H-3), 7.42 (t, J = 7.5 Hz, 1H, aromatic H), 7.25–7.20
(m, 1H, aromatic H), 7.10 (t, J = 7.5 Hz, 1H, aromatic H), 7.00 (t, J = 8.4 Hz, 1H, aromatic H), 6.03 (d, J =
11.4 Hz, H-4), 5.75 (d, J = 15.3 Hz, 1H, H-2), 5.43–5.37 (m, 1H, H-17), 5.33 (t, J = 6.6 Hz, 1H, H-14), 5.08
(d, J = 5.4 Hz, 1H, H-18), 4.58 (d, J = 6.6 Hz, 1H, -OCH2OCH3), 4.51 (d, J = 6.6 Hz, 1H, OCH2OCH3),
4.18–4.04 (overlapped, 5H, 2 x OCH2CH3, H-7), 3.93–3.79 (m, 2H, H2-13), 3.64 (t, J = 6.3 Hz, 2H, H2-11),
3.40 (t, J = 6.3 Hz, 2H, H2-9), 3.32 (s, 3H, -OCH2OCH3), 2.58–2.48 (m, 2H, H2-16), 2.33–2.24 (m, 2H,
H2-8), 2.00–1.92 (m, 2H, H2-6), 1.87 (s, 3H, 5-CH3), 1.72 (quin, J = 6.3 Hz, 2H, H2-10), 1.64 (1.63) (s, 3H,
15-CH3), 1.31 (t, J = 7.2 Hz, 6H, 2 × OCH2CH3), 0.86 (s, 9H, TBS), 0.81 (0.80) (s, 9H, TBS), 0.04 (0.03)
(s, 3H, TBS), 0.01 (s, 6H, TBS), −0.04(−0.05) (s, 3H, TBS). 13C NMR (75 MHz, CDCl3) δ 166.8 (166.7),
160.8 (d, J = 244.5 Hz), 146.4 (d, J = 9.8 Hz), 141.6, 135.2 (d, J = 3.8 Hz), 129.7, 129.0, 126.8, 125.7 (d, J =
13.5 Hz), 125.1, 124.3, 119.3, 115.6 (115.3), 95.0, 72.9, 72.3, 67.3, 66.8, 61.7(61.6), 60.5, 60.1, 56.1, 41.8 (41.2),
36.1, 34.3, 33.1, 27.0, 26.11, 26.05, 25.90, 25.87, 25.2, 25.0, 18.5, 18.0, 16.6 (16.5), −4.6, −5.2. IR (film) νmax:
2929, 2856, 1716, 1489, 1251, 1020 cm−1. HRMS (ESI): m/z calculated for C43H77FO10PSi2 [M + H]+:
859.4777. Found: 859.4756.
3.8. Synthesis of (2E,4Z)-(1R,2R,E)-1-(2-Fluorophenyl)-6-(3-hydroxypropoxy)-1-(methoxymethoxy)
-4-methylhex-4-en-2-yl 8-(diethoxyphosphoryl)-7-hydroxy-5-methylocta-2,4-dienoate [(17R,18R) diol 25]
To a solution of di-TBS ether 23 (90 mg, 0.105 mmol) in THF (4.2 mL) at 0 ◦C in a plastic
bottle, hydrogen fluoride-pyridine complex (70%, 1.0 mL) was added dropwise. The solution was
stirred at 0 ◦C for 5 min and then at room temperature for 16 h. Saturated sodium bicarbonate
(30 mL) was added to quench the reaction and the suspension was extracted with ethyl acetate
(30 mL × 3). The combined organic extracts were dried over anhydrous sodium sulfate and the dried
extract was concentrated under vacuum. The crude product was purified by PTLC, eluting with
dichloromethane/methanol (93:7. v/v), and the pure diol was washed out from the PTLC silica gel with
acetone as a pale-yellow oil in 92% yield. 1H NMR (300 MHz, CDCl3) δ 7.50 (7.49) (dd, J = 15.3, 11.7 Hz,
1H, H-3), 7.43 (t, J = 9.0 Hz, 1H, aromatic H), 7.30–7.23 (m, 1H, aromatic H), 7.13 (7.12) (t, J = 7.5 Hz, 1H,
aromatic H), 7.031 (7.028) (dd, J = 10.2, 9.0 Hz, 1H, aromatic H), 6.11 (d, J = 11.4 Hz, 1H, H-4), 5.80 (d, J
= 15.3 Hz, 1H, H-2), 5.47–5.40 (m, 1H, H-17), 5.32 (t, J = 5.7 Hz, 1H, H-14), 5.09 (d, J = 5.7 Hz, 1H, H-18),
4.58 (d, J = 6.9 Hz, 1H, -OCH2OCH3), 4.51 (d, J = 6.9 Hz, 1H, OCH2OCH3), 4.18–4.06 (overlapped, 5H,
2 × OCH2CH3, H-7), 3.90 (t, J = 5.7 Hz, 2H, H2-13), 3.69 (3.68) (t, J = 5.7 Hz, 2H, H2-11), 3.48 (3.47) (t, J
= 5.7 Hz, 2H, H2-9), 3.33 (3.32) (s, 3H, -OCH2OCH3), 3.03 (s, 2H, 2 × OH), 2.66–2.53 (m, 1H, H-16),
2.46–2.19 (m, 3H, H2-8 & H-16), 1.92 (S, 3H, 5-CH3), 1.96–1.88 (m, 2H, H2-6), 1.75 (quin, J = 5.7 Hz,
2H, H2-10), 1.65 (s, 3H, 15-CH3), 1.33 (t, J = 7.2 Hz, 6H, 2 × OCH2CH3). 13C NMR (75 MHz, CDCl3)
δ 167.0 (166.8), 160.9 (d, J = 247.5 Hz), 146.0, 140.8 (d, J = 17.3 Hz), 135.7 (d, J = 9.0 Hz), 129.8, 129.0,
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126.8, 125.6 (d, J = 12.8 Hz), 124.8 (d, J = 11.3 Hz), 124.4, 119.7 (d, J = 11.3 Hz), 115.7 (115.4), 94.9, 73.0,
72.4, 68.8, 67.4, 65.3, 62.2, 61.8, 56.1, 41.1, 34.6 (34.5), 32.7, 32.3, 25.3, 25.0, 16.6 (16.5). IR (film) νmax:
3366, 2929, 1711, 1633, 1488, 1222, 1019 cm−1. HRMS (ESI): m/z calculated for C31H49FO10P [M +H]+:
631.3048. Found: 631.3041.
3.9. Synthesis of (R,3E,9E,11Z,15E)-6-((R)-(2-Fluorophenyl)(methoxymethoxy)methyl)-4,12-
dimethyl-1,7-dioxacyclooctadeca-3,9,11,15-tetraene-8,14-dione [(17R,18R) macrolactone 29]
To a solution of diol 25 (65 mg, 0.10 mmol) in dichloromethane (6.2 mL) at room temperature,
Dess–Martin periodinane (DMP, 131 mg, 0.30 mmol) was added. The reaction mixture was stirred for
30 min before a second portion of DMP (131 mg, 0.30 mmol) was added. The reaction was allowed to
proceed with stirring at room temperature for an additional 1 h. The reaction mixture was poured into
a stirred mixture of saturated sodium bicarbonate (30 mL) and saturated sodium thiosulfate (30 mL),
and the resulting suspension was stirred for 30 min before being extracted with dichloromethane
(30 mL × 3). The combined organic extracts were dried over anhydrous sodium sulfate and the dried
extract was concentrated under vacuum. The crude product was used for the next reaction without
further purification. To a solution of the crude ketoaldehyde (0.10 mmol) obtained above in THF
(103 mL) at 0 ◦C was added water (2.2 mL) followed by activated barium hydroxide (15 mg, 0.08 mmol).
The reaction mixture was stirred at 0 ◦C for 30 min and at room temperature for 2.5 h, then was filtered
through a pad of sodium sulfate and a pad of silica gel that was rinsed with ethyl acetate. After
evaporation of the solvent, the crude product was subjected to PTLC purification, using hexane/ethyl
acetate (73:37) as eluent, to yield the pure macrolactone 29. Colorless oil, 46% yield for two steps. [α]:
−15.6 (c = 0.23, MeOH). 1H NMR (300 MHz, CDCl3) δ 7.60 (dd, J = 15.0, 11.4 Hz, 1H, H-3), 7.46 (dt, J
= 7.5, 1.8 Hz, 1H, aromatic H), 7.33–7.25 (m, 1H, aromatic H), 7.16 (dt, J = 7.5, 1.2 Hz, 1H, aromatic
H), 7.05 (ddd, J = 9.9, 8.4, 1.2 Hz, 1H, aromatic H), 6.82 (dt, J = 16.2, 6.6 Hz, 1H, H-9), 6.12 (d, J =
11.4 Hz, 1H, H-4), 6.01 (d, J = 16.2 Hz, 1H, H-8), 5.91 (d, J = 15.0 Hz, 1H, H-2), 5.51 (ddd, J = 11.4,
6.3, 1.2 Hz, 1H, H-17), 5.27 (dd, J = 7.8, 4.8 Hz, 1H, H-14), 5.12 (d, J = 6.3 Hz, 1H, H-18), 4.60 (d, J =
6.9 Hz, 1H, O-CH2OCH3), 4.53 (d, J = 6.9 Hz, 1H, OCH2OCH3), 3.99 (dd, J = 12.0, 8.1 Hz, 1H, H-16),
3.88–3.81 (m, 2H, H2-13), 3.47–3.28 (m, 2H, H2-11), 3.34 (s, 3H, OCH2OCH3), 3.14 (d, J = 12.6 Hz, 1H,
H-16), 2.43–2.36 (m, 2H, H2-10), 2.33 (d, J = 12.0 Hz, 1H, H-6), 2.05 (d, J = 12.1 Hz, 1H, H-6), 1.83 (s,
3H, 5-CH3), 1.63 (S, 3H, 15-CH3). 13C NMR (75 MHz, CDCl3) δ 197.2, 166.6, 160.9 (d, J = 244.5 Hz),
146.8, 142.5, 139.7, 138.9, 134.3, 130.3, 128.9 125.9 (d, J = 7.5 Hz), 125.6 (d, J = 13.5 Hz), 125.2 (d, J =
5.6 Hz), 124.5, 120.9 (d, J = 5.3 Hz), 115.6 (d, J = 21.8 Hz), 94.9, 72.9, 72.6, 67.9, 67.8, 56.0, 46.0, 41.4, 33.1,
24.09, 16.7. IR (film) νmax: 2931, 1713, 1633, 1489, 1358, 1226, 1030 cm−1. HRMS (ESI): m/z calculated for
C27H34FO6 [M + H]+: 473.2339. Found: 473.2333.
3.10. Synthesis of (R,3E,9E,11Z,15E)-6-((R)-(2-Fluorophenyl)(hydroxy)methyl)-4,12-dimethyl-
1,7-dioxacyclooctadeca-3,9,11,15-tetraene-8,14-dione [(17R,18R) macrolactone 5]
To a solution of 29 (30 mg, 0.064 mmol) in a mixture of tetrahydrofuran/water (0.92 mL, 1:1,
v/v), concentrated hydrochloric acid (130 μL) was added. The two more portions of concentrated
hydrochloric acid (130μL× 2) were added sequentially after each one-hour stirring at room temperature.
The reaction mixture was stirred at room temperature overnight before the reaction was quenched by
adding saturated ammonium chloride (60 mL). The subsequent mixture was extracted with ethyl acetate
(40 mL × 3). The combined extracts were dried over anhydrous sodium sulfate and the solvents were
evaporated in vacuum. The crude product was purified over preparative thin layer chromatography
eluting with toluene/ethyl acetate (3:1, v/v) to furnish the desired product (11 mg). Colorless syrup,
41% yield. 1H NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 15.0, 11.7 Hz, 1H, H-3), 7.49 (dt, J = 7.5, 1.8 Hz,
1H, aromatic H), 7.31–7.27 (m, 1H, aromatic H), 7.17 (dt, J = 7.5, 1.2 Hz, 1H), 7.05 (ddd, J = 10.2, 8.1,
0.9 Hz, 1H), 6.83 (dt, J = 15.9, 6.9 Hz, 1H, H-9), 6.12 (d, J = 11.4 Hz, 1H, H-4), 6.02 (d, J = 16.2 Hz, 1H,
H-8), 5.91 (d, J = 15.0 Hz, 1H, H-2), 5.48–5.38 (m, 1H, H-17), 5.27 (t, J = 6.0 Hz, 1H, H-14), 5.10 (d, J
= 6.3 Hz, 1H, H-18), 3.99 (dd, J = 12.0, 8.1 Hz, 1H, H-16), 3.86 (br.s, 1H, H-13), 3.82 (br.s, 1H, H-13),
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3.51–3.36 (m, 2H, H2-11), 3.18 (d, J = 12.9 Hz, 1H, H-16), 2.44–2.34 (m, 3H, H2-10, H-6), 2.06 (d, J =
14.4 Hz, 1H, H-6), 1.83 (s, 3H, 5-CH3), 1.62 (s, 3H, 15-CH3). 13C NMR (75 MHz, CDCl3) δ 197.2, 167.0,
160.1 (d, JCF = 244.5 Hz), 146.9, 143.0, 140.1 (d, JCF = 12.8 Hz), 134.2, 130.2, 129.9, 128.8, 127.6 (d, JCF =
12.8 Hz), 126.0, 125.2, 124.6, 120.7, 115.6 (d, JCF = 21.8 Hz), 79.4, 74.4, 70.3, 68.0, 45.9, 41.4, 33.0, 24.1,
16.7. [α]: −15.2 (c = 0.16, MeOH). IR (film) νmax: 3428, 2924, 2854, 1706, 1633, 1558, 1488, 1360, 1221,
1036 cm−1. HRMS (ESI): m/z calculated for C25H30FO5 [M + H]+: 429.2077. Found: 429.2074.
3.11. Synthesis of (1S,2S)-1-(2-Fluorophenyl)propane-1,2,3-triol [(17S,18S) triol 15]
Triol 15 was prepared in 68% yield from 13 catalyzed by AD-mix-β using a similar procedure
used to synthesize its antipode 14. 1H NMR (300 MHz, CDCl3) δ 7.39 (t, J = 7.5 Hz, 1H, aromatic H),
7.22 (dd, J = 13.8, 7.2 Hz, 1H, aromatic H), 7.07 (t, J = 7.5 Hz, 1H, aromatic H), 6.96 (t, J = 9.3 Hz, 1H,
aromatic H), 4.90 (d, J = 6.3 Hz, 1H, H-18), 4.21 (br.s, 3H, 3 × OH), 3.78 (dd, J = 10.2, 4.8 Hz, 1H, H-17),
3.48 (d, J = 4.8 Hz, 2H, H2-16). 13C NMR (75 MHz, CDCl3) δ 160.0 (d, JCF = 244.5 Hz), 129.6, 128.5
(d, JCF = 16.5 Hz), 127.8 (d, JCF = 12.8 Hz), 124.6, 115.5 (d, JCF = 21.8 Hz), 75.4, 68.8, 63.4. IR (film) νmax:
3375, 2930, 1781, 1489, 1456, 1319 cm−1. HRMS (ESI): m/z calculated for C9H12FO3 [M + H]+: 187.0770.
Found: 187.0765.
3.12. Synthesis of (2S,3S)-3-(2-Fluorophenyl)-2,3-dihydroxypropyl methanesulfonate [(17S,18S) mesylate 17]
Mesylate 17 was prepared from triol 15 as a colorless oil in 72% yield, employing a procedure
similar to that used for the mesylation of triol 14. 1H NMR (300 MHz, CDCl3) δ 7.48 (dt, J = 7.5, 1.8 Hz,
1H, Aromatic H), 7.32–7.29 (m, 1H, aromatic H), 7.18 (dt, J = 8.4, 0.9 Hz, 1H, aromatic H), 7.05 (ddd, J
= 9.3, 8.1, 0.9 Hz, 1H, aromatic H), 5.01 (d, J = 5.7 Hz, 1H, H-18), 4.28–4.15 (m, 2H, H2-16), 4.08–4.03
(m, 1H, H-17), 3.04 (s, 3H, SO2CH3). 13C NMR (75 MHz, CDCl3) δ 159.9 (d, JCF = 244.5 Hz, 1H), 130.1,
128.4, 127.0 (d, JCF = 12.8 Hz, 1H), 124.8, 115.7 (d, JCF = 21.8 Hz, 1H), 72.9, 70.3, 67.9, 37.6. IR (film) νmax:
3482, 3029, 2939, 1616, 1587, 1489, 1456, 1332, 1168 cm−1. HRMS (ESI): m/z calculated for C10H14FO5S
[M + H]+: 265.0546. Found: 265.0542.
3.13. Synthesis of (S)-(2-Fluorophenyl)((S)-oxiran-2-yl)methanol [(17S,18S) epoxide 19]
Epoxide 19 (52%, pale yellow oil) was obtained from mesylate 17 according to the internal
Williamson ether synthesis procedure employed for the conversion of mesylate 16 to epoxide 18. 1H
NMR (300 MHz, CDCl3) δ 7.57 (dt, J = 7.5, 1.8 Hz, 1H, aromatic H), 7.35–7.25 (m, 1H, aromatic H), 7.20
(dt, J = 7.5, 1.2 Hz, 1H, aromatic H), 7.06 (ddd, J = 10.5, 8.1, 1.2 Hz, 1H, aromatic H), 4.83 (d, J = 5.1 Hz,
1H, H-18), 3.26–3.21 (m, 1H, H-17), 2.92–2.84 (m, 2H, H2-16). 13C NMR (75 MHz, CDCl3) δ 160.0 (d, JCF
= 244.5 Hz), 129.8, 127.6 (d, JCF = 9.0 Hz), 127.4 (d, JCF = 13.5 Hz), 124.7, 115.6 (d, JCF = 21.0 Hz), 68.6,
55.4, 45.6. IR (film) νmax: 3482, 3029, 2939, 1617, 1587, 1489, 1456, 1331, 1168 cm−1. HRMS (ESI): m/z
calculated for C9H10FO2 [M + H]+: 169.0665. Found: 169.0659.
3.14. Synthesis of (S)-2-((S)-(2-Fluorophenyl)(methoxymethoxy)methyl)oxirane [(17S,18S) MOM ether 21]
MOM ether 21 was prepared from epoxide 19 as a pale-yellow oil in 73% yield employing
a procedure similar to that used for conversion of 18. 1H NMR (300 MHz, CDCl3) δ 7.44 (dt, J = 7.5,
1.8 Hz, 1H, aromatic H), 7.32–7.27 (m, 1H, aromatic H), 7.17 (dt, J = 7.5, 0.9 Hz, 1H, aromatic H), 7.05
(ddd, J = 10.2, 8.4, 1.2 Hz, 1H, aromatic H), 4.76 (d, J = 6.6 Hz, 1H, -OCH2OCH3), 4.68 (d, J = 6.9 Hz,
1H, H-18), 4.63 (d, J = 6.6 Hz, 1H, -OCH2OCH3), 3.37 (s, 3H, -OCH2OCH3), 3.27 – 3.23 (m, 1H, H-17),
2.75–2.73 (m, 2H, H2-16). 13C NMR (75 MHz, CDCl3) δ 160 (d, JCF = 245.3 Hz), 129.9 (d, JCF = 8.3 Hz),
128.7 (d, JCF = 3.8 Hz), 125.3 (d, JCF = 14.3 Hz), 124.5 (d, JCF = 3.8 Hz), 115.7 (d, JCF = 21.8 Hz), 94.8,
73.1, 55.8, 54.6, 44.4. IR (film) νmax: 2891, 2825, 1616, 1587, 1488, 1455, 1149, 1022 cm−1. HRMS (ESI):
m/z calculated for C11H14FO3 [M + H]+: 213.0927. Found: 213.0920.
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3.15. Synthesis of (5S,6S,E)-5-(2-Fluorophenyl)-8,16,16,17,17-pentamethyl-2,4,11,15-tetraoxa-16-
silaoctadec-8-en-6-ol [(17S, 18S) Fragment C9–C18 (8)]
(17S,18S) Fragment C9–C18 (8) was synthesized as a colorless oil in 22% yield from MOM ether
21 in a similar way to the synthesis of its antipode (17R,18R) Fragment C9–C18 (7). 1H NMR (300
MHz, CDCl3) δ 7.41 (dt, J = 7.5, 1.8 Hz, 1H, aromatic H), 7.32–7.24 (m, 1H, aromatic H), 7.15 (dt, J = 7.5,
1.2 Hz, 1H, aromatic H), 7.03 (ddd, J = 10.2, 8.4, 1.2 Hz, 1H, aromatic H), 5.41 (t, J = 6.6 Hz, 1H, H-14),
4.81 (d, J = 6.6 Hz, 1H, H-18), 4.63 (d, J = 6.6 Hz, 1H, OCH2OCH3), 4.58 (d, J = 6.6 Hz, 1H, OCH2OCH3),
3.95 (d, J = 6.6 Hz, 2H, H2-13), 3.82 (dt, J = 10.2, 5.7 Hz, 1H, H-17), 3.67 (t, J = 6.0 Hz, 2H, H2-11), 3.46
(t, J = 6.6 Hz, 2H, H2-9), 3.36 (s, 3H, OCH3), 2.23 (dd, J = 12.6, 9.6 Hz, 1H, H-16), 2.05 (dd, J = 12.6,
2.7 Hz, 1H, H-16), 1.76 (quin, J = 6.3 Hz, 2H, H2-10), 1.64 (s, 3H, 15-CH3), 0.87 (s, 9H, TBS), 0.03 (s, 6H,
TBS). 13C NMR (75 MHz, CDCl3) δ 160.9 (d, JCF = 244.7 Hz), 136.4, 129.2, 128.9, 128.6, 126.1 (d, JCF =
12.8 Hz), 124.5, 115.5, 95.3, 75.6, 72.7, 67.3, 67.0, 60.2, 56.2, 43.0, 33.2, 26.0, 18.5, 16.6, 16.5. IR (film) νmax:
3461, 2928, 2855, 1616, 1586, 1252, 1090, 1031 cm−1. HRMS (ESI): m/z calculated for C24H42FO5Si [M +
H]+: 457.2786. Found: 457.2782.
3.16. Synthesis of (2E,4Z)-(5S,6S,E)-5-(2-Fluorophenyl)-8,16,16,17,17-pentamethyl-2,4,11,15-
tetraoxa-16-silaoctadec-8-en-6-yl 7-((tert-butyldimethylsilyl)oxy)-8-(diethoxyphosphoryl)-
5-methylocta-2,4-dienoate [(17S,18S) ester 24]
(17S,18S) Ester 24 was obtained as a pale-yellow oil in 91% yield from (17S,18S) Fragment C9–C18
(8) and Fragment C1–C8 (9), according to the esterification procedure employed for the preparation
of ester 23. 1H NMR (300 MHz, CDCl3) δ 7.50 (dd, J = 14.4, 12.0 Hz, 1H, H-3), 7.42 (t, J = 7.2 Hz, 1H,
aromatic H), 7.34–7.21 (m, 1H, aromatic H), 7.10 (t, J = 7.5 Hz, 1H, aromatic H), 7.01 (t, J = 9.3 Hz, 1H,
aromatic H), 6.03 (d, J = 11.7 Hz, 1H, H-4), 5.76 (d, J = 15.0 Hz, 1H, H-2), 5.45–5.37 (m, 1H, H-17), 5.33
(t, J = 6.0 Hz, 1H, H-14), 5.08 (d, J = 5.1 Hz, 1H, H-18), 4.58 (d, J = 6.9 Hz, 1H, OCH2OCH3), 4.51 (d, J =
6.6 Hz, 1H, OCH2OCH3), 4.23–4.04 (m, 5H, 2 × OCH2CH3, H-7), 3.93–3.80 (m, 2H, H2-13), 3.65 (t, J
= 6.6 Hz, 2H, H2-11), 3.41 (t, J = 6.3 Hz, H2-9), 3.32 (s, 3H, OCH2OCH3), 2.58–2.54 (m, 2H, H2-16),
2.33–2.28 (m, 2H, H2-8), 2.03–1.93 (m, 2H, H2-6), 1.87 (s, 3H, 5-CH3), 1.77–1.70 (m, 2H. H2-10), 1.64
(s, 3H, 15-CH3), 1.31 (t, J = 6.9 Hz, 6H, 2 × OCH2CH3), 0.90 (0.88) (s, 3H, TBS), 0.86 (s, 6H, TBS), 0.81
(0.80) (s, 9H, TBS), 0.08 (0.04) (s, 6H, TBS), 0.02 (-0.04) (s, 6H, TBS). 13C NMR (75 MHz, CDCl3) δ 166.7,
160.8 (d, JCF = 245.3 Hz), 146.5 (146.4), 146.3 (146.2), 135.7 (135.2), 129.8, 129.0, 126.8, 125.8 (125.6),125.1
(124.7), 124.3 119.2, 115.5 (d, JCF = 27.5 Hz), 95.0, 72.9, 72.3, 68.9, 66.8, 61.8, 61.7, 60.1, 56.1, 41.7 (41.2),
36.0 (34.2), 33.1, 32.3, 29.8, 27.0, 26.0, 25.9, 25.8, 24.9, 18.5, 18.1, 18.0, 16.6, 16.5. IR (film) νmax: 2928,
2856, 1714, 1636, 1250, 1020 cm−1. HRMS (ESI): m/z calculated for C43H77FO10PSi2 [M + H]+: 859.4777.
Found: 859.4774.
3.17. Synthesis of (2E,4Z)-(1S,2S,E)-1-(2-Fluorophenyl)-6-(3-hydroxypropoxy)-1-(methoxymethoxy)-
4-methylhex-4-en-2-yl 8-(diethoxyphosphoryl)-7-hydroxy-5-methylocta-2,4-dienoate [(17S,18S) diol 26]
(17S,18S) Diol 26 was obtained as a colorless syrup in 65% yield according to the TBS deprotection
procedure used for the conversion of (17R,18R) ester 23 to (17R,18R) diol 25. 1H NMR (300 MHz,
CD3COCD3) δ 7.63–7.55 (m, 1H, H-3), 7.52 (t, J = 7.8 Hz, 1H, aromatic H), 7.41–7.33 (m, 1H, aromatic
H), 7.23 (t, J = 7.2 Hz, 1H, aromatic H), 7.14 (t, J = 9.0 Hz, 1H, aromatic H), 6.16 (d, J = 11.4 Hz, 1H, H-4),
5.80 (d, J = 15.0 Hz, 1H, H-2), 5.46 (quin, J = 5.1 Hz, 1H, H-17), 5.31 (t, J = 6.6 Hz, 1H, H-14), 5.10 (d, J =
5.7 Hz, 1H, H-18), 4.61 (d, J = 6.6 Hz, 1H, -OCH2OCH3), 4.51 (d, J = 6.6 Hz, 1H, -OCH2OCH3), 4.22–4.04
(overlapped, 5H, 2 × –OCH2CH3, H-7), 3.88 (d, J = 6.0 Hz, 2H, H2-13), 3.57 (t, J = 4.8 Hz, 2H, H2-11),
3.40 (t, J = 6.3 Hz, 2H, H2-9), 3.30 (s, 3H, -OCH2OCH3), 2.92 (br.s, 2H, 2 × OH), 2.60–2.57(overlapped,
2H, H2-16), 2.29 (d, J = 9.3 Hz, 2H, H2-8), 2.07–2.04 (m, 2H, H2-6), 1.95 (s, 3H, 5-CH3), 1.68 (quin, J
= 6.0 Hz, H2-10), 1.65 (s, 3H, 15-CH3), 1.29 (t, J = 7.2 Hz, 6H, 2 × –OCH2CH3). 13C NMR (75 MHz,
CDCl3) δ 166.0, 160.7 (d, JCF = 243.8 Hz), 147.0 (d, JCF = 9.8 Hz), 140.8, 134.2, 129.8, 129.3, 125.8 (d, JCF
= 9.8 Hz), 125.6, 125.4 (d, JCF = 4.5 Hz), 124.3, 119.1, 115.3 (115.0), 94.7, 72.3, 66.8, 66.7, 65.5, 61.4(61.3),
61.2 (61.1), 59.1, 55.1, 41.2, 40.7, 34.6, 33.02(32.98), 32.0, 24.4, 15.91(15.86), 15.7(15.6). IR (film) νmax: 3381,
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2927, 1709, 1633, 1488, 1019 cm−1. HRMS (ESI): m/z calculated for C31H49FO10P [M +H]+: 631.3048.
Found: 631.3045.
3.18. Synthesis of (2E,4Z)-(1S,2S,E)-1-(2-Fluorophenyl)-1-(methoxymethoxy)-4-methyl-6-(3-oxopropoxy)
hex-4-en-2-yl 8-(diethoxyphosphoryl)-5-methyl-7-oxoocta-2,4-dienoate [ketoaldehyde (17S,18S) 28]
The crude product was obtained from (17S,18S) diol 26 employing the oxidation procedure used
for the synthesis of its antipode 27. After being confirmed by its 1H NMR data, the crude product
was directly used for the next step reaction without further purification. 1H NMR (300 MHz, CDCl3)
δ 9.72 (t, J = 1.8 Hz, 1H, CHO), 7.41 (dt, J = 7.5, 1.8 Hz, 1H, aromatic H), 7.31 (dd, J = 15.0, 11.7 Hz,
1H, H-3), 7.29–7.22 (m, 1H), 7.11 (dt, J = 7.5, 0.9 Hz, 1H), 7.51 (ddd, J = 10.2, 8.1, 0.9 Hz, 1H), 6.17 (d, J
= 11.1 Hz, 1H, H-4), 5.83 (d, J = 15.0 Hz, 1H, H-2), 5.45–5.38 (m, 1H), 5.31 (t, J = 5.7 Hz, 1H, H-14),
5.07 (d, J = 5.4 Hz, 1H), 4.57 (d, J = 6.9 Hz, 1H, OCH2OCH3), 4.50 (d, J = 6.9 Hz, 1 H, OCH2OCH3),
4.20–4.11 (m, 5H, 2 × OCH2CH3, H-7), 3.90 (t, J = 7.2 Hz, 2H, H2-13), 3.65 (t, J = 6.0 Hz, 2H, H2-11), 3.31
(s, 3H, OCH3), 3.10 (d, J = 22.8 Hz, 2H, H2-8), 2.39–2.19 (m, 2H, H2-10), 1.87 (s, 3H, 5-CH3), 1.63 (s, 3H,
15-CH3).
3.19. Synthesis of (S,3E,9E,11Z,15E)-6-((S)-(2-Fluorophenyl)(methoxymethoxy)methyl)-4,12-
dimethyl-1,7-dioxacyclooctadeca-3,9,11,15-tetraene-8,14-dione [(17S,18S) macrolide 30]
(17S,18S) Macrolide 30 was synthesized according to the HWE ring closing procedure employed
for the conversion of 27 to 29. Colorless syrup, 68% yield for two steps. [α]: +8.1 (c = 0.22, MeOH).
1H NMR (300 MHz, CDCl3) δ 7.59 (dd, J = 15.0, 11.4 Hz, 1H, H-3), 7.46 (dt, J = 7.5, 1.8 Hz, 1H, aromatic
H), 7.36–7.25 (m, 1H, aromatic H), 7.15 (dt, J = 7.5, 1.2 Hz, 1H, aromatic H), 7.04 (ddd, J = 9.9, 8.1,
1.2 Hz, 1H, aromatic H), 6.81 (dt, J = 15.9, 6.9 Hz, 1H, H-9), 6.11 (d, J = 11.4 Hz, 1H, H-4), 6.00 (d, J
= 16.2 Hz, 1H, H-8), 5.90 (d, J = 15.0 Hz, 1H, H-2), 5.50 (dd, J = 11.4, 6.3 Hz, 1H, H-17), 5.26 (dd, J =
7.5, 4.5 Hz, 1H, H-14), 5.11 (d, J = 6.3 Hz, 1H, H-18), 4.59 (d, J = 6.9 Hz, 1H,–OCH2OCH3), 4.52 (d, J =
6.6 Hz, 1H, –OCH2OCH3), 3.98 (dd, J = 12.0, 8.1 Hz, 1H, H-16), 3.88 – 3.81 (overlapped, 2H, H2-13),
3.46 – 3.31 (overlapped, 2H, H2-11), 3.33 (s, 3H, OCH3), 3.14 (d, J = 12.6 Hz, 1H, H-16), 2.42–2.35 (m,
2H, H2-10), 2.33 (d, J = 11.7 Hz, 1H, H-6), 2.04 (d, J = 11.7 Hz, 1H, H-6), 1.82 (s, 3H, 5-CH3), 1.63 (s, 3H,
15-CH3). 13C NMR (75 MHz, CDCl3) δ 197.1, 166.6, 160.9 (d, JCF = 244.5 Hz), 146.8, 142.5, 139.8, 134.3,
130.2, 129.9, 129.0, 125.9 (d, JCF = 7.5 Hz), 125.5 (d, J = 13.5 Hz), 125.2 (d, JCF = 4.5 Hz), 124.5, 120.9 (d,
JCF = 3.8 Hz), 115.6 (d, JCF = 21.0 Hz), 94.9, 72.9, 72.6, 67.9, 67.8, 56.0, 45.9, 41.4, 33.1, 24.1, 16.7. IR (film)
νmax: 2925, 2854, 1714, 1669, 1634, 1489, 1359, 1280 cm−1. HRMS (ESI): m/z calculated for C27H34FO6
[M + H]+: 473.2339. Found: 473.2332.
3.20. Synthesis of (S,3E,9E,11Z,15E)-6-((S)-(2-Fluorophenyl)(hydroxy)methyl)-4,12-dimethyl-
1,7-dioxacyclooctadeca-3,9,11,15-tetraene-8,14-dione [(17S,18S) zampanolide mimic 6]
(17S,18S) Zampanolide mimic 6 was obtained according to the MOM deprotection procedure
used for the conversion of (17R,18R) macrolide 29 to (17S,18S) zampanolide mimic 5. Colorless syrup,
45% yield. [α]: +15.6 (c = 0.15, MeOH). 1H NMR (300 MHz, CD3COCD3) δ 7.61 (dd, J = 15.0, 11.1 Hz,
1H, H-3), 7.34 (dd, J = 14.4, 7.2 Hz, 1H, aromatic H), 7.21 (t, J = 7.5 Hz, 1H, aromatic H), 7.10 (dd, J =
10.5, 8.1 Hz, 1H, aromatic H), 6.83 (dt, J = 16.2, 6.3 Hz, 1H, H-9), 6.20 (d, J = 11.1 Hz, 1H, H-4), 6.06 (d, J
= 15.9 Hz, H-8), 5.88 (d, J = 12.6 Hz, 1H, H-2), 5.44 (dd, J = 11.1, 5.4 Hz, 1H, H-17), 5.27 (t, J = 5.4 Hz,
1H, H-14), 5.17 (t, J = 5.4 Hz, 1H, H-18), 4.81 (d, J = 5.4 Hz, 1H, OH), 4.07–3.97 (m, 1H, H-16), 3.90 (d, J
= 12.9 Hz, 1H, H-13), 3.83 (dd, J = 12.3, 4.5 Hz, 1H, H-13), 3.48– 3.32 (m, 2H, H2-11), 3.17 (d, J = 12.6 Hz,
1H, H-16), 2.42–2.33 (overlapped, 3H, H2-10, H-6), 2.19 (d, J = 13.8 Hz, 1H, H-6), 1.81 (s, 3H, 5-CH3),
1.64 (s, 3H, 15-CH3). 13C NMR (75 MHz, CD3COCD3) δ 196.5, 166.5, 160.5 (d, JCF = 242.3 Hz), 146.6,
142.7, 139.8, 134.7, 130.6, 129.7, 129.5, 126.3, 126.2, 125.7, 124.8, 121.7, 115.6, 73.8, 69.0, 68.9, 68.2, 45.8,
41.6, 33.2, 23.8, 16.3. IR (film) νmax: 3447, 2916, 2855, 1710, 1669, 1633, 1489, 1456, 1359, 1281, 1148 cm−1.
HRMS (ESI): m/z calculated for C25H30FO5 [M + H]+: 429.2077. Found: 429.2073.
307
Molecules 2020, 25, 362
3.21. Cell Culture
All cell lines were initially purchased from American Type Culture Collection (ATCC). The PC-3,
PC-3/DTX, and LNCaP prostate cancer cell lines were routinely cultured in RPMI-1640 medium
supplemented with 10% FBS and 1% penicillin/streptomycin. Cultures were maintained in a high
humidity environment supplemented with 5% carbon dioxide at a temperature of 37 ◦C. The DU145
and DU145/DTX prostate cancer cells were routinely cultured in Eagle’s Minimum Essential Medium
(EMEM) supplemented with 10% FBS and 1% penicillin/streptomycin.
The procedure illustrated in the literature [29,30] was adapted to establish docetaxel-resistant
prostate cancer cell lines. Specifically, docetaxel-resistant DU145 and PC-3 cell lines (DU145/DTX
and PC-3/DTX) were developed over a period of one year by stepwise increased concentrations of
docetaxel. Cells were repeatedly conserved in an appropriate concentration of docetaxel, starting with
IC50 value of the respective parent cell lines. Docetaxel-containing media will be replaced every 2–3 days.
The concentration of docetaxel was increased when cells exhibited resistance to treatments.
3.22. WST-1 Cell Proliferation Assay
PC-3, PC-3/DTX, DU145, DU145/DTX, or LNCaP cells were placed in 96-well plates at a density of
3200 cells each well in 200 μL of culture medium. The cells were then treated with synthesized mimics,
or positive reference separately at different doses for 3 days, while equal treatment volumes of DMSO
were used as vehicle control. After the cells were cultured in a CO2 incubator at 37 ◦C for three days,
the premixed WST-1 cell proliferation reagent (10 μL, Clontech) was added to each well. The cells
were incubated for additional 3 h at 37 ◦C before mixing gently for one minute on an orbital shaker
to ensure homogeneous distribution of color. A microplate-reader (Synergy HT, BioTek) was used
to measure the absorbance of each well at a wavelength of 430 nm. The half-maximal inhibitory
concentration (IC50 value) is the concentration of each compound that inhibits cell proliferation by 50%
under the experimental conditions. Each of IC50 value is represented as the average from triplicate
determinations that were reproducible and statistically significant. The IC50 values were calculated
based on dose–response curves from at least five dosages for each compound.
3.23. Statistical Analysis
All data are represented as the mean ± standard deviation (S.D.) for the number of experiments
indicated. Other differences between treated and control groups were analyzed using the Student’s
t-test. A p-value < 0.05 was considered statistically significant.
4. Conclusions
In summary, two new zampanolide mimics have been designed and each of them has been achieved
through a 25-step chemical transformation starting from commercially available 2-butyn-1-ol. Yamaguchi
esterification and intramolecular Horner–Wadsworth–Emmons condensation were employed as crucial
reactions to build up the C-17 and C-1 ester moiety and to close the lactone ring. The chiral centers at C17
and C18 in the Fragment C9–C18 (7 and 8) were introduced by the Sharpless asymmetric dihydroxylation
using the commercially available AD-mix formulations. Our WST-1 cell proliferation assay data in
both docetaxel-resistant and docetaxel-sensitive prostate cancer cell lines revealed that compound 6 is
the optimal mimic and the newly designed side chain can act as a bioisostere for the chemically fragile
N-acetyl hemiminal side chain in zampanolide.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/2/362/s1,
NMR spectra (1H and 13C) of the zampanolide mimics 5 and 6, as well as the macrolides 30 and 31, and intermediates
7–8, 14–21, and 23–26.
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Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland; szymon.sobczak@amu.edu.pl (S.S.);
katran@amu.edu.pl (A.K.)
3 Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences,
Rudolfa Weigla 12, 53-114 Wrocław, Poland; ewa.maj@hirszfeld.pl (E.M.);
joanna.wietrzyk@hirszfeld.pl (J.W.)
* Correspondence: adhucz@amu.edu.pl; Tel.: +48-618291673
Academic Editor: Qiao-Hong Chen
Received: 29 January 2020; Accepted: 3 March 2020; Published: 5 March 2020
Abstract: Colchicine, a pseudoalkaloid isolated from Colchicum autumnale, has been identified as
a potent anticancer agent because of its strong antimitotic activity. It was shown that colchicine
modifications by regioselective demethylation affected its biological properties. For demethylated
colchicine analogs, 10-demethylcolchicine (colchiceine, 1) and 1-demethylthiocolchicine (3), a series
of 12 colchicine derivatives including 5 novel esters (2b–c and 4b–d) and 4 carbonates (2e–f and
4e–f) were synthesized. The antiproliferative activity assay, together with in silico evaluation of
physicochemical properties, confirmed attractive biological profiles for all obtained compounds. The
substitutions of H-donor and H-acceptor sites at C1 in thiocolchicine position provide an efficient
control of the hydration affinity and solubility, as demonstrated for anhydrate 3, hemihydrate 4e and
monohydrate 4a.
Keywords: colchicine analogs; thiocolchicine; colchiceine; antimitotic agents; antiproliferative
activity; hydrates
1. Introduction
Colchicine (Figure 1) is a pseudoalkaloid produced by Colchicum autumnale [1]. Its beneficial
applications have been known for centuries, as colchicine was used by ancient Greeks and Egyptians
to treat swelling and inflammation [2]. Presently, colchicine is considered as the first-line therapy
for gout, pericarditis and familial Mediterranean fever [1,3–5]. The most interesting property of
colchicine is its high affinity for binding to the tubulin in cancer cells, leading to the inhibition of
microtubule polymerization and mitosis arrest [6–8]. These unique properties have attracted great
interest to colchicine as an anticancer-drug candidate, however its use is limited by its toxicity towards
normal cells [9–11]. For this reason, new derivatives obtained through chemical modifications guided
by structure–activity relations are intensively investigated. This research is aimed at reducing the
colchicine toxicity and preserving the antimitotic and anticancer properties [12–24]. As it turns out,
tubulin interacts with trimethoxyphenyl ring A and tropolone ring C, making the methoxy groups
at C1, C2 and C10, as well as the C9-keto group, crucial for colchicine’s antimitotic activity [25–27].
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Unfortunately, colchicine is also prone to isomerization, resulting in isocolchicine (Figure 1) with
500 times lower affinity for binding to tubulin than colchicine itself [28].
Figure 1. Structures of colchicine, lumicolchicine, isocolchicine, colchiceine, isocolchiceine
and thiocolchicine.
Colchiceine (Figure 1) is a C10 demethylated colchicine analog characterized by much lower
toxicity [29,30]. It is, next to lumicolchicine (Figure 1), the main product of colchicine degradation and
can naturally occur in plant extracts together with colchicine [31]. Elguero et al. [32] have established
that colchiceine (as well as its C10-acylated analog) can occur in two tautomeric forms, from which the
isoform is slightly more dominant. This equilibrium between colchiceine and isocolchiceine (Figure 1)
exists also in the solid state, which has been confirmed by X-ray diffraction studies [33]. The tendency
of colchiceine towards tautomerization, in combination with the loss of the C10-methoxy group, may
be responsible for its poor antimitotic activity. In contrast, colchiceine shows better bacteriostatic
and antifungal activity than colchicine, because its free hydroxyl group may increase its binding
affinity towards the cell walls of pathogens [29,33].Interestingly, the replacement of the C10-methoxy
group with thiomethyl in a colchicine analog thiocolchicine (Figure 1) decreases its isomerization.
Thiocolchicine is more stable, exhibits lower toxicity and has a higher binding affinity to tubulin [34–36].
As could be expected, demethylation of thiocolchicine at C1/C2/C3 positions leads to a lower binding
ability to tubulin and lower toxicity [37–39]. As the removal of the methoxy groups from colchicine’s
structure reduces its toxicity but also lowers its binding affinity to tubulin, we decided to replace these
groups with a bigger substituent, such as an ester or carbonate moiety, to investigate an effect of this
modification on biological activity [40].
For this reason, we carried out a series of regioselective demethylation reactions of colchicine
and thiocolchicine, in order to to obtain colchiceine (1) and 1-demethylthiocolchicine (3). On the basis
of 1 and 3, we synthesized a series of 12 mono- and double-modified colchicine analogs. Within
these analogs, we present 5 novel esters (2b–c and 4b–d) and 4 novel carbonates (2e–f and 4e–f).
The pathways used for these syntheses are depicted in Scheme 1.
We also evaluated the antiproliferative activity of these derivatives using three human cancer cell
lines, human lung adenocarcinoma (A549), human breast adenocarcinoma (MCF-7) and human colon
adenocarcinoma cell line (LoVo), and one normal murine embryonic fibroblast cell line (BALB/3T3).
Moreover, on the basis of the in silico calculations, we were able to predict the physicochemical
properties of the obtained compounds and check their compliance with Lipiński’s rule of 5, permitting
evaluation of its drug-likeness.
2. Results and Discussion
2.1. Chemistry
A series of colchicine esters and carbonates substituted at C1 and C10 positions in colchicine were
synthesized by performing regioselective demethylation reactions of C1 and C10 methoxy groups,
respectively. At first, we performed regioselective demethylation of the colchicine C10 methoxy group
by treating colchicine with a mixture of glacial acetic acid and 0.1N hydrochloric acid (i). Reaction
resulted in precipitation of yellow solid [41], which was further recrystallized in acetone, leading to
growth of good quality, large single crystals. Performed X-ray diffraction analysis proved them to be a
colchiceine (1, Scheme 1) hemihydrate of the same structure as that reported by Mackay et al. [33], in
which the unit-cell accommodates two tautomeric forms: colchiceine and isocolchiceine.
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Scheme 1. Synthesis of novel colchicine analogs. The obtained crystal structure of 1 was identical to
the one proposed by Mackey et al. [33]. Reagents and conditions: (i) glacial acetic acid, hydrochloric
acid, 100 ◦C, 6h; (iii) MeOH/H2O, CH3SNa, RT, 24h; (iv) DCM, acetyl chloride, SnCl4, 0 ◦C → RT,
48h; (v) MeOH/H2O, LiOH, RT, 1h; (ii,vi) DCM, Et3N, respective acyl chloride/chloroformate, 0 ◦C→
RT, 24h.
Colchicine was also treated with sodium methanethiolate (iii) to obtain thiocolchicine [42]. By
using a slightly modified method proposed by Bladé-Font [43] (iv,v), thiocolchicine was regioselectively
demethylated at the C1 methoxy group, leading to 1-demethylthiocolchicine (3) with 40% yield. This
regioselective demethylation was confirmed by X-ray analysis (Figure 2). Finally, compounds 1 and 3
were treated with respective acyl chlorides or chloroformates (ii, vi) to give single modified derivatives
2a–f and double modified derivatives 4a–f with 38%–58% yields (Scheme 1).
Figure 2. (a) Molecule of 1-demethylthiocolchicine (3) and (b) its crystal structure projected along the
crystal direction [100].
The purity and structure of synthesized colchicine derivatives 1, 2a–f, 3 and 4a–f were determined
on the basis of ESI-MS, NMR and X-ray analysis. The specific data can be found in Section 3 and in
Supplementary Materials. The disappearance of the signal at about 56.5 ppm in the 13C NMR spectrum
of colchicine, assigned to the C10 methoxy group, is the evidence of the formation of colchiceine (1).
Moreover, in the spectra of derivatives 2a–2f, an additional signal from the carbonyl group can be
observed in the range 164.1–174.3 ppm for esters 2a–2d, and 151.9–152.5 ppm for carbonates 2e–f. A
shift of the signal corresponding to the C10 methoxy group from 56.5 to 15.1 ppm is evidence for the
introduction of the thiomethyl group at position C10, and the absence of one of the signals around 61
ppm assigned to the C1 methoxy group is evidence of 1-demethylthiocolchicine (3) formation. An
additional signal corresponding to the carbonyl carbon atom can be observed in the range 168.3–174.7
ppm for esters 4a–4d and in the range 152.8–152.9 ppm for carbonates 4e–f.
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2.2. In Silico Calculations of the Physicochemical Properties
We used the Molinspiration online database (http://www.molinspiration.com, free of charge) to
predict the physicochemical properties of all synthesized compounds and collected them in Table 1 [44].
Table 1. Physicochemical properties of the synthesized compounds based on the Molinspiration
database [44].
Compound MW clogP tPSA n(O,N) N(OH,NH) Rotb MV
1 385.42 0.83 94.10 7 2 4 346.63
2a 427.45 0.60 100.18 8 1 6 383.14
2b 441.48 1.27 100.18 8 1 7 399.94
2c 455.51 1.51 100.18 8 1 7 416.53
2d 489.52 2.92 100.18 8 1 7 437.99
2e 443.45 0.95 109.41 9 1 7 392.12
2f 457.48 1.33 109.41 9 1 8 408.93
3 401.48 1.89 84.86 6 2 4 355.77
4a 443.52 1.66 90.94 7 1 6 392.28
4b 457.55 2.33 90.94 7 1 7 409.08
4c 471.57 2.57 90.94 7 1 7 425.67
4d 505.59 3.98 90.94 7 1 7 447.13
4e 459.52 2.02 100.18 8 1 7 401.27
4f 473.55 2.39 100.18 8 1 8 418.07
colchicine 399.44 1.10 83.11 7 1 5 364.15
MW: Molecular weight; clogP: calculated log octanol/water partition coefficient; tPSA: total polar surface area;
n(O,N): number of hydrogen acceptors; n(OH,NH): number of hydrogen donors; Rotb: rotatable bonds; MV:
molecular volume.
According to Lipinski’s rule of 5, most “drug-like” molecules should have logP ≤ 5, molecular
weight ≤ 500, number of hydrogen bond acceptors ≤ 10 and number of hydrogen bond donors ≤ 5.
Additionally, it was demonstrated that a total polar surface area (tPSA) < 140 and number of rotatable
bonds < 10, in combination with logP < 5, are crucial for both good bioavailability and permeability
through biological membranes [45].
The demethylation of the C1 and C10 position of colchicine, both in 1 and 3, increases the number
of H-donor sites while the substitution of colchicine’s C10 methoxy group with thiomethyl results in a
decreased number of H-acceptor sites in 3. Additionally, the demethylation of the C1 and C10 position
of colchicine reduces the number of rotatable bonds. Substitution of a hydroxyl group, both in 1 and
3, with an ester or carbonate substituent, increases the number of H-acceptor sites and reduces the
number of H-donor sites to that of colchicine. According to the performed calculations, all synthesized
compounds 2a–e and 4a–e have a rather lipophilic character, with the clogP values between 0.60 and
3.98. Conducted syntheses allowed us to obtain compounds with less lipophilic character than that of
colchicine for compounds 1, 2a and 2e, with clogP values 0.83, 060 and 0.95, respectively. Interestingly,
esters and carbonates in the C10 position (2a–e) are in general less lipophilic than corresponding esters
and carbonates in the C1 position (4a–e). Except for 4d, whose molecular weight is above 500, the
calculations for all colchicine analogs are in agreement with Lipinski’s descriptors. Importantly, in
order to be active, a drug should not have more than one violation [46]. This, in combination with the
number of rotatable bonds between 4 and 8, as well as tPSA between 84.86 and 100.18, confirm good
physicochemical profiles of all obtained compounds.
2.3. X-ray Analysis
The structures of compounds 3, 4a and 4e were additionally confirmed by X-ray diffraction.
Selected crystallographic data are collected in Table 2, and more detailed information can be found in
Supplementary Information. The single crystals of 3, 4a, 4e were obtained by slow evaporation from an
ethyl acetate mixture. The 1-Demethylthiocolchicine (3) crystallizes in the orthorhombic space group
P212121 (Figure 2) while the crystals of 4a and 4e are monoclinic, space group P21. The substitution
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at the C1 atom with acetyl ester (4a) and methyl carbonate (4e), and the following change in the
ratio between H-bond acceptors and donors, increases the tendency of these colchicine derivatives to
co-crystallize with water; hence, monohydrate 4a·H2O and hemihydrate 4e·1/2H2O were obtained.
Molecules 4a and 4e significantly differ in conformation (Figure 3).The arrangement of the C2
methoxy group, which can be described by the C1-C2-O2-C18 torsion angle, changed from −122.36◦ to
108.75◦ in 4a and 4e, respectively. Together with increasing mass of the C1 moiety, the twist between the
planar phenyl and tropolone rings around the C13-C16 bond increases, altering the C1-C16-C13-C12
angle from 45.43◦ in 3, through 58.54◦ in 4a, to 60.11◦ in 4e.
Figure 3. Comparison of the molecular conformation from the X-ray analysis studies
between (a) molecule 4a and (b) 4e, superimposed with respect to the benzene ring on the
1-demethylthiocolchicine (molecule 3), highlighted with a light-green color.
Table 2. Selected crystallographic data for compounds 3, 4a·H2O and 4e·1/2H2O.
Label 3 4a·H2O 4e·1/2H2O
Formula C21H22NO5S C23H25NO6S · H2O C23H25NO7S· 1/2H2O
CCDC number 1966196 1966194 1966195
Crystal system orthorhombic monoclinic monoclinic
Space group P212121 P21 P21
Unit cell
dimensions
a (Å) 9.1005(17) 10.600(2) 10.8835(10)
b (Å) 11.866(2) 6.9635(11) 9.2158(6)
c (Å) 17.881(4) 16.712(3) 12.0632(12)
β (◦) 90 107.07(2) 104.613(9)
Volume (Å3) 1930.8(7) 1179.2(4) 1170.80(18)
Z/Z’ 4/1 2/1 2/1
Dx (g/cm3) 1.378 1.300 1.329
The presence of water significantly alters the pattern of H-bonds between 3 and 4a·H2O and
4e·1/2H2O. Although in all structures amide nitrogen participates in the formation of intermolecular
contacts, only in 3 are the NH···S, of 2.793(2) Å, and NH···O4, of 2.370(3) Å,bonds formed. In a
monohydrate crystal 4a·H2O, water interrupts the NH···O4 interaction observed in the crystal structure
of 3, accepting NH amide proton, of 2.086(1) Å and further donating its H-atoms to the HO-H···O4′,
of 2.007(3) Å, and HO-H···O5′, of 1.994(3) Å bond. Much weaker H-bonds are present in the crystal
structure of 4e·1/2H2O. Despite the presence of a water molecule in the crystal structure of 4e·1/2H2O,
the strong NH···O5′ bond, of 2.033(2) Å is present again. The disordered by location at half-occupied
sites water molecule is involved in formation of a weak HO-H···O5′’ interaction of 2.538(1) Åand the
H-bond at the disordered terminal carbonyl at C9. Due to the HO-H···O4′ of 2.241(1) Å bond, the
occupational disorder of H2O is passed onto the orientation of 4e molecules as illustrated in Figure 3.
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Depending on the presence or absence of this water molecule, its adjacent molecule 4e is slightly shifted
in the crystal structure. This disorder is most apparent for the terminal carbonyl at C9 (dislocated by
0.358 Å) and thiomethyl at C10 (dislocated by 0.625 Å).
2.4. Antiproliferative Activity
The antiproliferative activity of all synthesized colchicine analogs 1, 2a–f, 3, 4a–f was tested
in vitro against three human cancer cell lines: human lung adenocarcinoma (A549), human breast
adenocarcinoma (MCF-7) and human colon adenocarcinoma cell line (LoVo). For a more accurate
evaluation of cytotoxic activity, the effect on normal murine embryonic fibroblast cell line (BALB/3T3)
was also tested according to the previously published procedure [12]. Detailed information concerning
antiproliferation assay can be found in Supplementary Materials. The mean values of IC50 ± SD of the
tested compounds are collected in Table 3.
Table 3. Antiproliferative activity (IC50) of 10-demethylcolchicine (colchiceine, 1), 1-demethylthiocolchicine
(3) and their derivatives(2a–f, 4a–f) compared to the antiproliferative activity of colchicine and standard









IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM)
1 12.99 ± 1.79 0.79 11.23 ± 2.52 0.91 6.00 ± 1.88 1.71 10.25 ± 0.96
2a 12.47 ± 2.77 0.68 10.03 ± 2.18 0.85 6.18 ± 1.48 1.37 8.50 ± 0.50
2b 9.97 ± 0.70 0.75 7.56 ± 2.84 0.99 2.39 ± 1.20 3.13 7.47 ± 0.50
2c 20.39 ± 11.30 0.41 11.95 ± 1.54 0.70 6.47 ± 0.35 1.30 8.42 ± 1.14
2d 8.75 ± 0.33 1.02 8.21 ± 3.35 1.09 4.87 ± 2.17 1.83 8.92 ± 3.93
2e 0.98 ± 0.16 0.84 0.98 ± 0.33 0.84 0.48 ± 0.32 1.70 0.82 ± 0.11
2f 9.67 ± 0.84 0.86 9.07 ± 1.90 0.92 6.41 ± 1.57 1.30 8.36 ± 0.17
3 0.82 ± 0.02 0.74 0.12 ± 0.05 4.92 0.11 ± 0.03 5.38 0.61 ± 0.14
4a 0.48 ± 0.15 1.36 0.10 ± 0.02 6.85 0.11 ± 0.02 5.92 0.65 ± 0.12
4b 0.97 ± 0.04 0.77 0.96 ± 0.13 0.78 0.50 ± 0.19 1.53 0.75 ± 0.10
4c 0.89 ± 0.07 0.80 0.86 ± 0.10 0.83 0.56 ± 0.06 1.27 0.71 ± 0.03
4d 0.60 ± 0.31 0.75 0.78 ± 0.22 0.58 0.10 ± 0.08 4.71 0.45 ± 0.23
4e 0.90 ± 0.09 0.87 1.02 ± 0.10 0.77 0.43 ± 0.19 1.84 0.78 ± 0.06
4f 0.96 ± 0.13 1.08 0.95 ± 0.20 1.09 0.79 ± 0.16 1.31 1.03 ± 0.20
colchicine 0.07 ± 0.01 0.63 0.01 ± 0.01 4.30 0.01 ± 0.01 5.38 0.04 ± 0.01
cisplatin 3.60 ± 0.25 0.81 3.05 ± 0.67 0.95 3.80 ± 0.28 0.77 2.91 ± 1.83
doxorubicin 0.16 ± 0.03 0.25 0.15 ± 0.05 0.26 0.08 ± 0.03 0.49 0.04 ± 0.03
The IC50 value is defined as the concentration of a compound at which 50% growth inhibition is observed. Human
lung adenocarcinoma (A549), human breast adenocarcinoma (MCF-7), human colon adenocarcinoma cell line (LoVo)
and normal murine embryonic fibroblast cell line (BALB/3T3). The SI (Selectivity Index) was calculated for each
compound, using the formula SI = IC50 for normal cell line BALB/3T3/IC50 for the respective cancerous cell line. A
beneficial SI > 1.0 indicates a drug with efficacy against tumor cells greater than the toxicity against normal cells.
All colchicine analogs showed stronger antiproliferative activity against all tested cancer cell
lines than the conventional chemotherapeutic, cisplatin. In general, the IC50 values are better for
colchicines doubly modified at C1 and C10 positions (3, 4a–f) than for the analogs singly modified at
position C10 only (1, 2a–f). Compound 4a, with a thiomethyl group at position C10 and an acetyl ester
substituent at C1, showed the highest activity against all tested cell lines (IC50 = 0.48 ± 0.15, 0.10 ± 0.02,
0.11 ± 0.02 μM for A549, MCF-7, LoVo cancer cell lines, respectively).
All tested colchicine analogs exhibit higher SI values than doxorubicin, which indicates the
therapeutic potential of the synthesized compounds. Compound 3, 1-demethylthiocolchicine, as well
as its acylated analog 4a, showed high SI values against MCF-7 (SI = 4.92, SI = 6.88) as well as LoVo
cell lines (SI = 5.36, SI = 5.95). From among analogs modified exclusively at position C10, compound
2b with propionyl ester substituent revealed a higher SI value towards LoVo cell line (SI = 3.13).
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3. Materials and Methods
3.1. General
Information concerning reagents and solvents, as well as equipment used for measurements, can
be found in the Supplementary Materials.
3.1.1. Synthesis and Characterization of 10-Demethylcolchicine (colchiceine, 1), Thiocolchicine and
1-Demethylthiocolchicine (3)
Information concerning the synthesis of 10-demethylcolchicine (colchiceine, 1), thiocolchicine and
1-demethylthiocolchicine (3) can be found in Supplementary Materials.
3.1.2. General Route for Synthesis of Compounds 2a–f and 4a–f
To a solution of 1 or 3 (100 mg, 0.25 mmol) in dichloromethane (DCM, 10 mL) cooled to 0 ◦C,
Et3N (1 mL, 7 mmol) and respective acyl chloride or chloroformate were added (excess). The mixture
was first stirred at 0 ◦C for 30 min and then for the next 24h at RT. Reaction time was determined by
TLC. After that time the solution was filtered to remove triethylamine hydrochloride, the DCM was
evaporated under reduced pressure and the residue was purified by CombiFlash® (chloroform/acetone,
increasing concentration gradient) to give respective compounds as amorphous yellow solids.
3.1.3. Characterization of Acetyl Ester of Colchiceine 2a
Amorphous yellow solid, yield 49%, m.p 120–122 ◦C; 1H NMR (CDCl3, 400 MHz) δ 7.50 (1H, s),
7.31 (1H, d, J = 11.3 Hz), 7.22 (1H, d, J = 11.3 Hz), 6.53 (1H, s), 4.60 (1H, dt, J = 12.7, 6.5 Hz), 3.91 (3H, s),
3.88 (3H, s), 3.66 (3H, s, 2.50 (1H, dd, J = 13.6, 6.3 Hz), 2.35 (3H, s), 2.26–2.17 (1H, m), 1.96 (3H, s), 1.87
(1H, td, J = 12.1, 6.9 Hz). 13C NMR (CDCl3, 101 MHz) δ 169.9, 168.2, 153.9, 151.0, 148.6, 141.8, 141.5,
137.0, 134.5, 131.2, 130.3, 125.2, 107.4, 61.6, 61.3, 56.0, 52.1, 36.8, 29.7, 22.7, 20.7. ESI-MS (m/z): [M + H]+
428, [M + Na]+ 450, [M + K]+ 466, [2M + Na]+ 877.
3.1.4. Characterization of Propionyl Ester of Colchiceine 2b
Amorphous yellow solid, yield 52%, m.p 133-135 ◦C; 1H NMR (CDCl3, 400 MHz) δ 7.50 (1H, s),
7.30 (1H, d, J = 11.3 Hz), 7.22 (1H, d, J = 11.2 Hz), 6.52 (1H, s), 4.66–4.57 (1H, m), 3.91 (3H, s), 3.88 (3H,
s), 3.66 (3H, s), 2.66 (2H, q, J = 7.4 Hz), 2.50 (1H, dd, J = 13.5, 6.3 Hz), 2.35 (1H, ddd, J = 12.7, 10.3,
6.0 Hz), 2.24–2.16 (1H, m), 1.97 (3H, s), 1.87 (2H, td, J = 12.0, 6.7 Hz), 1.26 (3H, t, J = 7.6 Hz). 13C NMR
(CDCl3, 101 MHz) δ 171.8, 169.9, 153.9, 151.1, 148.9, 141.7, 141.6, 136.7, 134.5, 130.9, 130.5, 125.2, 107.4,
61.7, 61.4, 56.1, 52.1, 36.9, 29.8, 27.4, 22.8, 9.0. ESI-MS (m/z): [M + Na]+ 464, [2M + Na]+ 905.
3.1.5. Characterization of Isobutyryl Ester of Colchiceine 2c
Yellowish brown oil, yield 55%; 1H NMR (CDCl3, 400 MHz) δ 7.56 (1H, s), 7.28 (1H, d, J = 11.0 Hz),
7.23 (1H, d, J = 10.6 Hz), 6.52 (1H, s), 4.64 (1H, dt, J = 12.2, 6.8 Hz), 3.91 (3H, s), 3.88 (3H, s), 3.65 (3H,
s), 2.90–2.82 (1H, m), 2.54–2.47 (1H, m), 2.36 (1H, td, J = 13.2, 6.9 Hz), 2.24–2.12 (2H, m), 1.96 (3H, s),
1.92–1.85 (1H, m), 1.35 (3H, d, J = 1.4 Hz), 1.33 (3H, d, J = 1.3 Hz). 13C NMR (CDCl3, 101 MHz) δ 174.3,
170.0, 153.9, 151.1, 150.3, 142.1, 141.5, 136.0, 134.5, 131.6, 130.1, 125.2, 107.4, 61.7, 61.3, 56.0, 52.1, 36.6,
34.0, 29.8, 26.4, 22.7, 19.0. ESI-MS (m/z): [M + Na]+ 478, [2M + Na]+ 933.
3.1.6. Characterization of Benzyl Ester of Colchiceine 2d
Amorphous yellow solid, yield 41%, m.p 123–125 ◦C; 1H NMR (CDCl3, 400 MHz) δ 8.18 (2H, d,
J = 7.4 Hz), 7.65–7.60 (2H, m), 7.49 (1H, ddd, J = 4.8, 3.1, 1.1 Hz), 7.34 (2H, s), 6.53 (1H, s), 4.66–4.58
(1H, m), 3.93 (3H, d, J = 0.9 Hz,), 3.90 (3H, d, J = 0.7 Hz), 3.68 (3H, d, J = 1.1 Hz), 2.49 (1H, dd, J = 13.4,
4.9 Hz), 2.42–2.32 (1H, m), 2.17–2.06 (1H, m), 1.86 (3H, d, J = 4.0 Hz), 1.84–1.78 (1H, m). 13C NMR
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(CDCl3, 101 MHz) δ 169.9, 164.1, 153.9, 151.1, 142.0, 141.6, 134.5, 133.8, 130.4, 128.9, 128.5, 125.3, 107.4,
61.7, 61.4, 56.1, 52.0, 36.9, 29.8, 22.7. ESI-MS (m/z): [M + H]+ 490, [M + Na]+ 512, [M + K]+ 528.
3.1.7. Characterization of Methyl Carbonate of Colchiceine 2e
Amorphous yellowish brown solid, yield 58%, m.p 115–118 ◦C; 1H NMR (CDCl3, 400 MHz) δ 7.57
(1H, s), 7.32 (1H, d, J = 20.5 Hz), 6.54 (1H, s), 4.62 (1H, dt, J = 11.8, 6.0 Hz), 3.92 (3H, s)*, 3.92 (3H, s)*,
3.89 (3H, s), 3.68 (3H, s), 2.52 (1H, dd, J = 13.4, 6.1 Hz), 2.37 (1H, td, J = 13.0, 6.7 Hz), 2.29–2.18 (1H, m),
1.99 (3H, s), 1.91 (1H, dd, J = 19.0, 12.2 Hz). 13C NMR (CDCl3, 101 MHz) δ 169.9, 154.1, 152.5, 151.1,
141.6, 134.5, 125.1, 107.4, 61.7, 61.3, 56.1, 55.8, 52.2, 37.2, 29.8, 22.8. ESI-MS (m/z): [M +H]+ 444, [M +
Na]+ 466, [M + K]+ 482, [2M + Na]+ 909.
3.1.8. Characterization of Ethyl Carbonate of Colchiceine 2f
Yellowish brown oil, yield 55%; 1H NMR (CDCl3, 400 MHz) δ 7.46 (1H, s), 7.40–7.32 (1H, m,
J = 6.2 Hz), 7.30–7.21 (1H, m), 6.55 (1H, s), 4.62 (1H, dt, J = 12.6, 6.4 Hz), 4.36 (2H, q, J = 7.1 Hz), 3.93
(3H, s, J = 2.9 Hz), 3.90 (3H, s), 3.68 (3H, s), 2.54 (1H, dd, J = 13.6, 6.4 Hz), 2.41 (1H, td, J = 13.1, 7.1 Hz),
2.32–2.21 (1H, m), 2.01 (3H, s), 1.94–1.84 (1H, m), 1.41 (3H, t, J = 7.1 Hz). 13C NMR (CDCl3, 101 MHz) δ
169.9, 154.0, 151.9, 151.1, 141.6, 134.5, 125.1, 107.4, 65.4, 61.7, 61.3, 56.1, 52.1, 37.2, 29.8, 22.8, 14.1. ESI-MS
(m/z): [M + H]+ 458, [M + Na]+ 480, [M + K]+ 496, [2M + Na]+ 937.
3.1.9. Characterization of Acetyl Ester of 1-demethylthiocolchicine 4a
Amorphous yellow solid, yield 45%, m.p 168-172 ◦C; 1H NMR (DMSO-d6, 400 MHz) δ 8.51 (1H, d,
J = 7.7 Hz), 7.23 (1H, d, J = 10.8 Hz), 7.02 (1H, s), 6.97 (1H, s), 6.92 (1H, d, J = 10.3 Hz), 3.89 (3H, s), 3.74
(3H, s), 2.65 (1H, dd, J = 13.5, 6.0 Hz), 2.41 (3H, s), 2.32–2.24 (1H, m), 2.22 (3H, s), 2.12–2.01 (1H, m),
1.85 (3H, s, J = 6.3 Hz), 1.84–1.77 (1H, m, J = 12.1, 6.8 Hz). 13C NMR (DMSO-d6, 101 MHz) δ 181.2,
168.9, 168.2, 157.7, 152.8, 150.4, 140.8, 139.3, 136.4, 134.4, 132.7, 128.2, 126.4, 124.6, 109.9, 60.1, 56.0, 50.7,
36.2, 29.1, 22.5, 20.3, 14. ESI-MS (m/z): [M + Na]+ 466, [2M + Na]+ 909.
3.1.10. Characterization of Propionyl Ester of 1-demethylthiocolchicine 4b
Amorphous yellow solid, yield 47%, m.p 136-140 ◦C; 1H NMR (DMSO-d6, 400 MHz) δ 8.52 (1H, d,
J = 7.7 Hz), 7.23 (1H, d, J = 10.7 Hz), 7.03 (1H, s), 6.98 (1H, s), 6.92 (1H, d, J = 10.2 Hz), 4.34 (1H, dt,
J = 11.8, 7.1 Hz), 3.90 (3H, s), 3.76–3.71 (3H, m), 2.66 (1H, dd, J = 13.2, 6.4 Hz), 2.41 (3H, s), 2.33–2.19
(2H, m), 2.08 (2H, ddd, J = 11.4, 9.8, 5.4 Hz), 1.84–1.78 (1H, m), 1.11 (3H, t, J = 7.5 Hz). 13C NMR
(DMSO-d6, 101 MHz) δ 181.2, 172.3, 168.3, 157.7, 152.8, 150.5, 140.9, 139.2, 136.4, 134.4, 132.9, 128.3,
126.4, 124.7, 109.9, 60.1, 56.0, 50.7, 36.2, 29.1, 26.7, 22.6, 14.5, 9.2. ESI-MS (m/z): [M + H]+ 458, [M +
Na]+ 480, [M + K]+ 496, [2M + Na]+ 937.
3.1.11. Characterization of Isobutyryl Ester of 1-demethylthiocolchicine 4c
Amorphous yellow solid, yield 49%, m.p 165-167 ◦C; 1H NMR (DMSO-d6, 101 MHz) δ 8.50 (1H,
d, J = 7.8 Hz), 7.22 (1H, d, J = 10.6 Hz), 7.03 (1H, s), 6.98 (1H, s), 6.91 (1H, d, J = 8.8 Hz), 4.35 (1H, dt,
J = 11.7, 7.3 Hz), 3.90 (3H, s), 3.72 (3H, s), 2.74 (1H, dt, J = 13.9, 6.9 Hz), 2.66 (1H, dd, J = 13.6, 6.1 Hz),
2.39 (3H, s), 2.34–2.25 (1H, m), 2.09 (1H, td, J = 12.7, 5.9 Hz), 1.86 (3H, s), 1.81 (1H, dd, J = 12.0, 6.9 Hz,
1.16 (3H, d, J = 3.5 Hz), 1.14 (3H, d, J = 3.5 Hz). 13C NMR (DMSO-d6, 101 MHz) δ 181.2, 174.7, 168.3,
157.7, 152.7, 150.4, 140.8, 139.2, 136.4, 134.4, 132.9, 128.3, 126.3, 124.8, 109.9, 60.1, 56.1, 50.7, 36.2, 33.3,
29.1, 22.6, 18.8, 14.6. ESI-MS (m/z): [M + Na]+ 494, [2M + Na]+ 965.
3.1.12. Characterization of Benzyl Ester of 1-demethylthiocolchicine 4d
Amorphous yellow solid, yield 38%, m.p 166-170 ◦C; 1H NMR (DMSO-d6, 101 MHz) δ 8.52 (1H,
s), 8.07 (2H, d, J = 7.3 Hz), 7.77–7.71 (1H, m), 7.63–7.56 (2H, m), 7.22–7.12 (1H, m), 7.06 (1H, s), 7.02
(1H, s), 4.49–4.40 (1H, m), 3.94 (3H, s), 3.74 (3H, s), 2.72 (1H, dd, J = 13.0, 5.9 Hz), 2.36 (1H, dd, J = 7.4,
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5.5 Hz,), 2.31 (3H, s), 2.13 (2H, ddd, J = 19.4, 12.8, 6.9 Hz,), 1.87 (3H, s).13C NMR (DMSO-d6, 101 MHz)
δ 181.1, 168.3, 157.7, 152.9, 150.6, 141.0, 139.4, 136.3, 134.6, 134.2, 129.8, 129.1, 128.4, 128.3, 126.2, 124.9,
110.2, 60.3, 56.1, 50.8, 36.3, 29.2, 22.6, 14.5. ESI-MS (m/z): [M + Na]+ 528, [2M + Na]+ 1033.
3.1.13. Characterization of Methyl Carbonate of 1-demethylthiocolchicine 4e
Amorphous yellow solid, yield 53%, m.p 158-162 ◦C; 1H NMR (DMSO-d6, 101 MHz) δ 8.55 (1H d,
J = 7.6 Hz), 7.26 (1H, d, J = 10.6 Hz), 7.05–6.99 (3H, m), 4.34 (1H, dt, J = 11.8, 7.0 Hz), 3.91 (3H, s), 3.82
(3H, s), 3.79 (3H, s), 2.69 (1H, dd, J = 13.5, 6.2 Hz), 2.43 (3H, s), 2.29 (1H, ddd, J = 18.6, 12.3, 5.4 Hz),
2.09 (1H, ddd, J = 18.7, 12.5, 6.2 Hz), 1.88 (3H, s), 1.86–1.80 (1H, m). 13C NMR (DMSO-d6, 101 MHz) δ
181.2, 168.4, 157.9, 152.9, 152.8, 150.5, 140.8, 139.3, 136.0, 134.5, 133.2, 128.2, 126.4, 124.3, 110.2, 60.4,
56.14, 56.07, 50.8, 36.1, 29.1, 22.6, 14.4. ESI-MS (m/z): [M + H]+ 460, [M + Na]+ 482, [M + K]+ 498, [2M
+ Na]+ 941.
3.1.14. Characterization of Ethyl Carbonate of 1-demethylthiocolchicine 4f
Amorphous yellow solid, yield 48%, m.p 165-167 ◦C; 1H NMR (DMSO-d6, 400 MHz) δ 8.52 (1H, d,
J = 7.6 Hz), 7.23 (1H, d, J = 10.7 Hz), 7.01 (3H, t, J = 10.3 Hz), 4.33 (1H, dt, J = 12.6, 7.5 Hz), 4.27–4.20
(2H, m), 3.90 (3H, s), 3.78 (3H, s), 2.67 (1H, dd, J = 13.2, 6.6 Hz), 2.41 (3H, s), 2.34–2.23 (1H, m), 2.08 (3H,
s), 1.87 (3H, s), 1.85–1.78 (1H, m), 1.22 (3H, t, J = 7.1 Hz). 13C NMR (DMSO-d6, 101 MHz) δ 181.2, 168.4,
157.9, 152.8, 152.4, 150.5, 140.8, 139.3, 136.2, 134.5, 133.1, 128.2, 126.3, 124.4, 110.2, 65.1, 60.3, 56.1, 50.8,
36.1, 29.1, 22.6, 14.4, 14.0. ESI-MS (m/z): [M + Na]+ 496, [M + K]+ 512, [2M + Na]+ 969.
3.2. Antiproliferative Activity
Detailed information concerning antiproliferative activity assay is given in Supplementary Materials.
3.3. X-ray Measurements
X-ray measurements and detailed crystallographic data are given in Supplementary Materials.
4. Conclusions
On the basis of regioselectively demethylated colchicine analogs, colchiceine (1) and
1-demethylthiocolchicine (3), we have designed and synthesized a series of 12 colchicine derivatives
bearing ester and carbonate substituents, including 9 entirely novel derivatives (2b,c,e,f and 4b,c,d,e,f).
Derivatives 4a·H2O and 4e·1/2H2O, with acetyl ester and methyl carbonate moieties, display reduced
hydrophilic properties and crystallize as hydrates, which affects their biological activity and increases
their solubility. The control over water co-crystallization from monohydrate to hemihydrate has been
achieved through the number of H-donor and acceptor sites. These features can be invaluable for
the regulation of the bioaccessibility and pharmaceutical processing of this group of compounds [47].
The synthesized derivatives exhibit a considerable in vitro antiproliferative activity against three
human cancer cell lines. Compound 4a, carrying the thiomethyl group at position C10 and acetyl ester
substituent at C1, showed the highest activity and selectivity index values. The biological evaluation
has been supported by prediction of physicochemical properties, which are consistent with Lipinski’s
rule of five for all synthesized analogs.
Supplementary Materials: The following are available online: General procedures, experimental details, as well
as an elaborate description of the X-ray diffraction sudies and in vitro methods used.
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Abstract: Colchicine is a well-known compound with strong antiproliferative activity that has had
limited use in chemotherapy because of its toxicity. In order to create more potent anticancer agents,
a series of novel colchicine derivatives have been obtained by simultaneous modification at C7 (amides
and sulfonamides) and at C10 (methylamino group) positions and characterized by spectroscopic
methods. All the synthesized compounds have been tested in vitro to evaluate their cytotoxicity
toward A549, MCF-7, LoVo, LoVo/DX and BALB/3T3 cell lines. Additionally, the activity of the
studied compounds was investigated using computational methods involving molecular docking of
the colchicine derivatives to β-tubulin. The majority of the obtained derivatives exhibited higher
cytotoxicity than colchicine, doxorubicin or cisplatin against tested cancer cell lines. Furthermore,
molecular modeling studies of the obtained compounds revealed their possible binding modes into
the colchicine binding site of tubulin.
Keywords: anticancer agents; colchicine amide; colchicine sulfonamide; tubulin inhibitors; docking
studies; crystal structure
1. Introduction
Microtubules, which are composed of α- and β-tubulin heterodimers, are involved in a large
number of processes, such as intracellular transport, cell shape development, cell division and cell
motility. During cell division microtubules form the mitotic spindle that in normal cells correctly
separates the chromosomes into two daughter cells. In cancer cells the rate of mitosis is typically
increased but chromosome segregation is imperfect leading to aneuploidy. Microtubules formed
during mitosis are considered as an ideal target for anticancer drugs since no cell can divide without
the force generated by microtubules. Therefore, many inhibitors of microtubule dynamics have been
investigated for their potential use as cancer chemotherapy drugs [1–7]. One of these compounds is
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colchicine 1 (see Scheme 1), a well–known tropolone alkaloid isolated from Colchicum autumnale, which
has been shown to exhibit very high cytotoxic effects. It binds to tubulin at the colchicine binding
site and induces conformational change in the tubulin dimer making it incompetent for microtubule
assembly. As a result, the cell cycle is blocked and apoptosis is induced [8–14]. Unfortunately, colchicine
is too toxic to be useful as an antitumor agent [8,15–21]. Nevertheless, it has found use in therapy, e.g.,
for the treatment of familial Mediterranean fever, Behcet’s disease or acute gout [22–27].
Scheme 1. Synthesis of doubly modified colchicine derivatives (2–21), changes at C7 and C10
positions are highlighted in red. Reagents and conditions: (a) NHCH3/EtOH, reflux; (b) 2M HCl,
reflux; (c) RC(O)Cl or RSO2Cl, Et3N, DCM, 0 ◦C to RT for 4, 8, 13, 15–16, 18 and 21; (d) RCOOH,
EDCI, DCM, RT for 5–7, 9–12 and 14; (e) (1) N-(tert-butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-
1,4-dihydropyridin-1-ylsulfonyl]azanide, DCM, RT, (2) 4M HCl/EtOAc, RT for 17; (f) ClCH2CH2SO2Cl,
Et3N, DCM, 0 ◦C to RT; (g) morpholine, DCM, RT.
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Therefore, over the past few decades much interest has been focused on structural modifications
of 1 in the hope of improving its therapeutic index [28–31]. Numerous double-modified colchicine
derivatives have been synthesized with the group at position C7 substituted by various amide
and sulfonamide moieties as well as with replacement of the methoxy group at position C10 by
a group containing either a nitrogen or a sulfur atom and their biological activities have been
determined [28,29,32–36]. These results have shown that new derivatives may have lower toxicity
with respect to normal cells while maintaining high antitumor activity. In addition, from the chemical
point of view, such a change at position C10 allows obtaining compounds more resistant to acid
hydrolysis [29,30,33]. We have decided to check various amide and sulfonamide moieties because they
have long been valued for their rich biological and chemical profiles and have emerged as a promising
class of compounds in drug discovery [37–41].
Herein, we report the synthesis, crystallographic and spectroscopic analysis of a series of
structurally different derivatives of colchicine obtained by its modification at position C7 (various
amide, sulfonamide or sulfamide moieties) and at position C10 (methylamino group). We also describe
the results of in vitro antiproliferative activity evaluation of colchicine (1) and the obtained colchicine
derivatives (2–21) against four human cancer cell lines and one normal murine embryonic fibroblast
cell line. To acquire more knowledge about the molecular mechanism of action of the investigated
compounds (1–21), we also present results of in silico molecular docking study of the colchicine binding
site (CBS) of β-tubulin.
2. Results and Discussion
2.1. Chemistry
To investigate the effect of methylamino group at position C10 and, at the same time, various
amide, sulfonamide and sulfamide moieties at position C7 of colchicine 1 on its antiproliferative activity,
eighteen new derivatives (4–21) were synthesized. To facilitate the structure-activity relationship
analysis (SAR) we designed compounds with different side chains at position C7: alkyl chains of
various length, straight and branched (4–8), unsaturated alkyl chain (19), alkyl chains of various
lengths containing halogen atoms (9–11), an aromatic group without or with substituents (12–16, 21),
and compounds containing an amino group 17–18 and 20.
The general route for the synthesis of colchicine derivatives 2–21 is depicted in Scheme 1. Colchicine
(1) was treated with methylamine solution in ethanol to give 10-methylamino-10-demethoxycolchicine
(2) with 80% yield, according to the method described earlier [42]. The replacement of water
solution of methylamine by ethanol solution eliminated the work up after the reaction and
permitted obtaining comparable final yields. Next, hydrolysis of 2 with 2M HCl yielded
N-deacetyl-10-methylamino-10-demethoxycolchicine (3). Compounds 4–16, 18–19 and 21 were
readily available from 3 by treatment with respective acid/ sulfonamide/ sulfamide chloride
in the presence of triethylamine or with the corresponding carboxylic acid and carbodiimide
as a condensing agent. Compound 17 was prepared using a N-(tert-butoxycarbonyl)-N-
[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]azanide and further modified by
removal of the tert-butoxycarbonyl group from amine with HCl [43]. Vinylsulfonamide 19 was
synthesized from 2-chloroethanesulfonyl chloride and 3 through sulfonylation and in situ β-elimination
of HCl. Compound 19 was used as the Michael acceptor with an electron-deficient double bond for the
reaction with morpholine to produce compound 20 [44,45]. All synthesized compounds were isolated
in pure form after column chromatography.
The purity and structures of the obtained compounds 2–21 were determined using the LC-MS,
1H and 13C NMR methods and are shown in the Supplementary Materials and discussed below.
The characteristic signals of -OCH3 group at position C10 of 1 in the 1H NMR and 13C NMR spectra
were observed as a singlet at 4.0 ppm and at 56.5 ppm, respectively. These signals vanish after the
reaction of colchicine with methylamine proving the substitution of the -OCH3 group in the tropolone
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ring of 1. After the introduction of -NHCH3 at position C10 the signals of this group in the obtained
derivatives (2–21) were visible approx. at 3.1 ppm as a doublet and approx. at 7.4 ppm as a quartet in
1H NMR and approx. at 29.5 ppm in 13C NMR. The chemical shifts of the amide moiety can be found
in the range 7.9–9.7 ppm in 1H NMR and in the range 164.2–175.2 ppm in 13C NMR, depending on the
substituent used. The ESI mass spectrometry confirmed the structure of the obtained compounds by the
presence of an m/z signals assigned to the corresponding pseudomolecular ions of these compounds.
2.2. X-ray Crystal Analysis
Structural characterization of the colchicine derivatives is very important in order to understand
their anticancer properties stemming from their interaction with tubulin as well as to enable
structure–activity relationship analysis (SAR) and related investigation. Therefore, structural analyses
of all crystals that were suitable for X-ray analysis of single crystals were performed. Crystals of 6,
11, 12, 14, 18 and 19 suitable for the X-ray single crystal analysis were obtained by recrystallization of
the respective colchicine derivatives from acetonitrile, whereas crystals 15 and 16 from ethyl acetate
solutions. All crystals were measured at room (295 K) and low (100 K) temperature. Details of the
data collection parameters, crystallographic data and the final agreement parameters are listed in
Supplementary Table S1. In the temperature range from 295 K to 100 K, no structural phase transitions
were observed in the crystals studied, although for colchicine derivative 11 at low temperature some
disorder of the -CF3 group in the -CH2-CH2-CF3 group at atom C21 could be observed. Colchicine
derivatives 6, 11, 12, 14, 15, and 16 crystallize in the P3221 space group of the trigonal system while
derivative 18 crystallizes in the P212121 space group of the orthorhombic system and derivative 19
crystallizes in the P21 space group of the monoclinic system. These space groups are chiral since the
compounds contain an asymmetric carbon (C7) atom. The absolute configuration at the C7 atom is
S in all structures. The molecular structures of all colchicine derivatives (6, 11, 12, 14, 15, 16, 18 and
19) are illustrated in Supplementary Figure S60. The planar phenyl A and tropolone C rings in all
colchicine derivatives (6, 11, 12, 14, 15, 16, 18 and 19) are twisted around the C13–C16 bond with the
torsion angle describing the twisting conformation C1–C16–C13–C12 between ~53◦ and ~56◦ at 100
K and they do not differ significantly from the values at room temperature (Table 1). Ring B in all
colchicine derivatives exhibits a similar puckering pattern and the extent of its non-planarity is such
that it adopts a conformation, which is close to the twist-boat with a flattening caused by the fusion of
rings A and C (see Supplementary Figure S60). So the conformation of the fused A, B and C rings of
colchicine skeleton in the investigated derivatives is quite similar to that in colchicine itself [46].
Table 1. Selected torsion angles (◦) of colchicine derivatives 6, 11, 12, 14, 15, 16, 18 and 19 obtained by
X-ray analysis and DFT computation for a comparison.












































































































































The methoxy group -OCH3 linked to the phenyl ring at C3 is almost coplanar with the ring
in all structures of colchicine derivatives, whereas the other two methoxy groups linked at C1 and
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C2 atoms of the phenyl ring have different orientations in some colchicine derivatives (Table 1).
The N-methylamino group (-NHCH3) linked to tropolone C ring at C10 atom is almost coplanar
with the ring. The differences between the conformations of the investigated colchicine derivatives
are illustrated in Figure 1 and Table 1. For clarity, the colchicine derivatives have been divided
into two groups, according to the substituent in ring B at position C7; one group comprises the
derivatives with a chain substituent (Figure 1a) and the other group comprises the derivatives with
a substituent containing an aromatic ring (Figure 1b). Analysis of these results reveals a significant
difference in the torsion angle C17-O1-C1-C2 in compounds 18 (~−109◦) and 19 (~66◦) or the difference
between the calculated (~−103◦) and measured (~−77◦) torsion angle C18-O2 -C2-C3 in compound
19. These differences result from different approach to the description of the molecule conformations,
the X-ray analysis values refer to the conformation of molecules in crystals, in which the intermolecular
interactions play a significant role and leads crystallization and specific crystal packing, while the DFT
values refer to a single isolated molecule in the gas state with the intermolecular interactions not taken
into account.
Figure 1. Comparison of the X-ray structure of (a) derivatives with a chain substituent at position C7:
6 (blue), 11 (red), 18 (pink) and 19 (green) and (b) derivatives with a substituent containing an aromatic
ring at position C7: 12 (pink), 14 (blue), 15 (green) and 16 (red) showing the conformation of the colchicine
skeleton. The molecules are overlapped one over another so that the ring C1-C2-C3-C4-C15-C16 is at
the same position.
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2.3. Molecular Electrostatic Potential Map Analysis
The role of the trimethoxyphenyl ring A of colchicine as well as that of the tropolone ring C in
tubulin binding have been studied in great details. The tropolonoic ring C of the colchicine skeleton
is found to be crucial for the interaction with tubulin [47,48]. The molecular electrostatic potential
map (MESP) correlated with the electronic density in a molecule and is a powerful tool for analyzing
interactions [49–51]. It was, therefore, calculated for all structurally characterized colchicine derivatives.
Additionally, the gas-phase structures of all molecules were determined using the DFT optimization
with the Gaussian09 program package [52]. All calculations were carried out by the DFT method using
the Becke3-Lee–Yang–Parr correlation functional (B3LYP) [53–56] with the 6–31 + G basis set, starting
from the X-ray geometry of molecules. The gas-phase optimized conformations of all colchicine
derivatives are, in general, in good agreement with those obtained from the X-ray single crystal
investigation, however the optimized torsion angle C18–O2–C2–C3 describing the orientation of the
methoxy group is significantly smaller than that provided by the X-ray analysis (Table 1 and for more
details see Supplementary Table S2).
The region of tubulin that interacts with colchicine is near the αβ-tubulin/dimer interface [57].
In order to better understand the interaction of the colchicine derivatives with tubulin, the molecular
electrostatic potential was calculated for all structurally characterized colchicine derivatives as well
as, for comparison, for colchicine itself. The three-dimensional MESP maps for colchicine derivatives
and for colchicine itself were calculated on the basis of the DFT (B3LYP) optimized geometries of
molecules and mapped onto the total electron density isosurface (0.008 eÅ−3) for both molecules using
the GaussView 5.0 program (Figure 2). The color coding of MESP is in the range of −0.05 (red) to
0.05 eÅ-1 (blue). For all colchicine derivatives, the regions of negative MESP are usually associated with
the lone pair of electronegative atoms (O and N), whereas the regions of positive MESP are associated
with the electropositive atoms (Figure 2).
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Figure 2. Optimized conformation (left) and three-dimensional molecular electrostatic potential map
(right) for colchicine derivatives (a–h) and colchicine itself (i), for comparison. Color code: −0.05 eÅ−1
(red) to +0.05 eÅ−1 (blue).
The nucleophilic regions in colchicine derivatives are observed near oxygen atoms of all methoxy
and carbonyl groups. In addition, significantly less negative value of MESP than that near the
oxygen atoms spreads across the aromatic phenyl rings. The planar conformation of tropolone ring
C, showing the alternating single and double C-C bonds, is manifested as partial delocalization of
the π electrons resulting in a slightly negative value of MESP on both sides of the planar fragment of
colchicine derivatives. The molecular electrostatic potential for colchicine itself was also calculated for
comparison (Figure 2i). In all colchicine derivatives the methoxy (-OCH3) substituent in the tropolone
C ring is replaced by N-methylamino substituent (-NHCH3), therefore, MESP maps show a less
negative area near this group (Figure 2a–h) compared to the MESP map of colchicine itself (Figure 2i).
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Additionally, the replacement in colchicine molecule of the -NHC(O)CH3 group in ring B at C7 atom
with various substituents modified the size of the molecule and the maps of electrostatic potential.
This is particularly visible for derivatives 11, 14 and 18, 19 in which the -NHC(O)CH3 group is replaced
by -NHC(O)C2H4CF3, -NHC(O)C6H4F in 11 and 14, respectively, and in 18 and 19 by the substituents
containing sulfonyl group (-SO2R).
The DFT results, especially the three-dimensional molecular electrostatic potential map (MESP)
providing information on the distribution of the electron density of molecules are useful for predictions
of interactions between the tested compounds and homology modeled tubulin βI. The formation of
guest-host complexes (colchicine derivatives as guest and tubulin as host) depends on the guest’s fit into
the host cavity and their interactions that result from the mutual matching of electrostatic interactions.
2.4. In Vitro Determination of Drug-Induced Inhibition of Human Cancer Cell Line Growth
The synthesized colchicine derivatives 2–21 and starting material 1 were evaluated for their
in vitro antiproliferative effect on four human cancer cell lines, including one cell line displaying
various levels of drug resistance and additionally one normal murine embryonic fibroblast cells.
The majority of new derivatives of 1 showed antiproliferative activity in the nanomolar range
and were characterized by lower IC50 values than unmodified colchicine 1, as well as doxorubicin
and cisplatin, commonly used as antitumor agents in cancer chemotherapy (Table 2). From the set
of tested compounds, the ones most active against A549 tumor cell line were 2, 4–6, 8–14 and 18–19
(IC50 ≤ 15 nM), against MCF-7 tumor cell line-were 2, 9–17 and 19 (IC50 ≤ 13 nM), against LoVo
tumor cell line-were 2, 4–6, 8–16, 18–19 (IC50 ≤ 11 nM) of which the lowest IC50 values were shown
by compounds 9–10 and 13 (IC50 = 0.7–1.8 nM). Moreover, compound 13 was observed to be most
active towards the LoVo/DX line (IC50 = 9.6 nM), approx. 170 times more potent than unmodified
colchicine 1 (IC50 = 1646.6 nM). Compound 7 from amides and compound 20 from sulfonamides
showed the weakest activity (the highest IC50 values) against all cancer cell lines tested. The decrease
in cytotoxicity of compound 7 could be related to an increase in hydrophobicity (high calculated
octanol/water partition coefficient clogP = 8.7, see Table 3). It is well known that high clogP value
and therefore low hydrophilicity are responsible for poor absorption and permeation to the colchicine
binding pocket in β-tubulin. The high IC50 value for compound 20 may be due to the presence of a
morpholine ring which is a large volume substituent and can adopt different conformations. Although
these compounds were the least potent out of the whole series of tested derivatives (1–21), their IC50
values were in the micromolar range (see Table 2).
Table 2. Antiproliferative activity (IC50) of colchicine (1) and its derivatives (2–21) compared with
antiproliferative activity of standard anticancer drugs doxorubicin and cisplatin and the calculated
values of the resistance index (RI) of tested compounds.
Compound
A549 MCF-7 LoVo LoVo/DX BALB/3T3
IC50 [nM] IC50 [nM] IC50 [nM] IC50 [nM] RI IC50 [nM]
1 115.3 ± 23.6 22.6 ± 1.3 17.5 ± 2.5 1646.6 ± 314.0 93.9 115.3 ± 36.8
2 10.8 ± 1.3 8.6 ± 1.3 4.3 ± 1.3 271.3 ± 99.9 63.0 10.8 ± 1.3
3 16.9 ± 2.8 19.7 ± 1.7 14.0 ± 1.7 129.2 ± 11.8 9.2 19.7 ± 7.0
4 14.6 ± 2.4 14.6 ± 1.5 9.7 ± 1.5 271.8 ± 104.4 28.0 19.4 ± 4.1
5 14.1 ± 2.4 14.1 ± 1.4 9.6 ± 0.5 194.8 ± 51.9 20.2 16.4 ± 3.5
6 13.6 ± 1.4 15.9 ± 6.6 6.8 ± 3.9 102.3 ± 20.7 15.0 13.6 ± 2.3
7 613.8 ± 194.4 464.8 ± 186.7 62.4 ± 16.9 2435.7 ± 923.4 39.0 545.9 ± 104.4
8 11.7 ± 1.4 18.8 ± 9.9 7.0 ± 1.4 171.2 ± 41.3 24.3 28.1 ± 10.8
9 11.6 ± 2.8 9.2 ± 1.4 1.8 ± 0.4 62.4 ± 6.7 35.2 11.6 ± 2.3
10 8.6 ± 1.3 8.6 ± 1.2 1.5 ± 0.5 38.5 ± 21.6 25.8 10.7 ± 1.3
11 14.6 ± 2.1 12.7 ± 0.4 10.4 ± 1.3 289.6 ± 165.2 27.8 81.3 ± 20.4
12 13.0 ± 1.3 13.0 ± 1.3 8.5 ± 0.4 99.9 ± 10.0 11.8 13.0 ± 3.3
13 6.3 ± 3.2 9.2 ± 0.8 0.7 ± 0.1 9.6 ± 3.3 14.0 6.2 ± 1.6
14 10.7 ± 0.6 12.6 ± 1.3 8.6 ± 0.8 102.5 ± 24.9 12.0 12.6 ± 2.1
15 36.8 ± 12.1 13.0 ± 2.2 10.8 ± 1.3 832.1 ± 292.7 76.8 43.3 ± 29.7
16 17.3 ± 3.7 12.8 ± 0.9 10.8 ± 1.3 946.9 ± 260.5 87.4 52.0 ± 29.3
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17 56.6 ± 14.7 10.3 ± 3.9 21.1 ± 17.5 6466.0 ± 264.2 306.0 100.1 ± 24.1
18 10.6 ± 0.6 15.5 ± 1.7 9.3 ± 1.1 540.2 ± 107.2 57.8 14.2 ± 13.2
19 11.4 ± 1.7 13.0 ± 4.3 8.4 ± 0.7 306.7 ± 144.9 36.7 8.3 ± 3.8
20 800.3 ± 130.0 150.0 ± 25.3 268.4 ± 94.0 44385.7 ± 23852.0 165.4 991.1 ± 280.5
21 85.5 ± 5.4 134.3 ± 41.5 73.5 ± 15.7 6122.0 ± 825.1 83.3 87.6 ± 13.5
Doxorubicin 141.7 ± 46.0 204.2 ± 47.8 99.4 ± 41.0 8732.0 ± 2540.7 87.9 149.0 ±126.8
Cisplatin 5741.0 ± 968.0 7139.8 ± 1218.7 7076.3 ± 1596.2 8336.5 ± 1119.2 1.2 5665.1 ± 31.8
The IC50 value is defined as the concentration of a compound at which 50% growth inhibition is observed. The IC50
values shown are mean ± SD. Human lung adenocarcinoma (A549), human breast adenocarcinoma (MCF-7), human
colon adenocarcinoma cell line (LoVo) and doxorubicin-resistant subline (LoVo/DX), normal murine embryonic
fibroblast cell line (BALB/3T3). The RI (Resistance Index) indicates how many times more chemoresistant is a
resistant subline relative to its parental cell line. The RI was calculated for each compound using the formula: RI =
(IC50 for LoVo/DX cell line)/(IC50 for LoVo cell line). When RI is 0–2, the cells are sensitive to the compound tested,
RI in the range 2–10 means that the cells shows moderate sensitivity to the drug tested, RI above 10 indicates strong
drug resistance.
Table 3. Computational predictions of interactions between tested compounds (1–21) and homology
modeled tubulin βI. 3D representation and 2D layout of colchicine derivatives–tubulin protein
complex, binding energy (BE), calculated octanol/water partition coefficient (clogP) and active residues
are tabulated.
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Although the synthesized compounds are effective toward cancer cells, their potential is limited
against cells with developed drug resistance. The data presented in Table 2 show that unmodified
colchicine 1 and all of the colchicine derivatives 2–21 less effectively inhibited the proliferation of the
doxorubicin-resistant subline LoVo/DX than the sensitive LoVo cell line. The calculated values of RI
clearly confirmed that none of the tested amides and sulfonamides was able to overcome the drug
resistance of LoVo/DX cell line (RI ranges from 11.8 to 306.0). It can be explained by the upregulated
expression of efflux transporters in these cells, playing an important role in drug transport in many
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organs and determining the drug resistance of cancer cells. Because this type of resistance is one of the
mechanisms of cancer resistance [58], compounds 1–2 and 4–21 are probably good substrates for such
pumps. Increased efflux of compounds makes it impossible to reach their adequate concentrations in
the cell and consequently to exert efficient cytotoxic effect. The only compound which showed RI < 10
was derivative 3, having at position C7 a free amino group. Keeping in mind its good activity (IC50 <
20 nM for three cancer cells, see Table 2) it can be still considered as a good starting point for the chase
after antitumor agents active against drug resistant lines.
The selectivity index (SI) was calculated to evaluate the toxicity of the compounds studied against
normal cells and to predict their therapeutic potential (see Figure 3). High SI values result from large
differences between the cytotoxicity against cancer and normal cells and this means that cancer cells
will be killed at a higher rate than normal ones. From the set of tested compounds with methylamino
group at position C10 and alkyl chains at position C7 (2, 4–8, 19) the best selectivity index for A549,
MCF-7 and LoVo cells (SI = 1.5–4.0) showed 8 with short and branched substituent (isobutyric acid
derivative). The 4,4,4-trifluorobutyric acid derivative 11 (from compounds with alkyl chains of various
lengths containing halogen atoms 9–11) showed outstanding selectivity for three out of four cancer
cells (SI = 5.6–7.8). It should be emphasized that compound 11 was the only compound with SI values
greater than that of unmodified colchicine 1 for all tumor cell lines. Despite the fact that compounds 9,
10, and 13 stood out from the synthesized compounds in terms of IC50 values, their selectivity indices
were high only for LoVo lines (SI = 6.5–9.1), they were very cytotoxic also to non-cancerous BALB/3T3
cells (IC50 = 6.2–11.6 nM). Among aryl amides and sulfonamides 12–16 and 21, distinctive SI values were
derived for colchicine derivatives containingnicotinic and isonicotinic amide residue (SI ranges 3.0 to 4.8).
These results are noteworthy and suggest that extended and more detailed research of similar derivatives
is necessary to determine the importance of ring aromaticity, its size or heteroatom type. Especially high
SI values for MCF-7 were obtained for sulfamide 17 (SI = 9.8) and sulfonamide containing a morpholine
ring 20 (SI = 6.6). These results deserve special attention and require further studies to determine whether
the conversion of an amide bond to a sulfonamide bond with an appropriate substituent would allow
obtaining compounds highly selective towards MCF7 cells, compared to colchicine 1. As many as thirteen
of the obtained derivatives exhibited SI ≥ 2 for LoVo cell line (see Figure 3). The results indicated that
properly designed doubly modified (at C7 and C10 positions) colchicine derivatives can have greater
selectivity towards cancer cells than the parental compound.
Figure 3. Comparison of selectivity index (SI) values of the tested compounds. The SI was calculated
for each compound using the formula: SI = (IC50 for normal cell line BALB/3T3)/(IC50 for respective
cancerous cell line). A favorable SI > 1.0 indicates a drug with efficacy against tumor cells greater than
the toxicity against normal cells.
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2.5. In Silico Determination of the Molecular Mode of Action
In the present study, computational investigation including molecular docking, molecular
dynamics (MD) simulations, molecular mechanics generalized Born/surface area (MM/GBSA) binding
free energy calculations and decomposition of pair-wise free energy on a per-residue basis were
conducted to deeply explore the molecular basis for the binding of twenty novel double modified
colchicine amides and sulfonamides to β-tubulin. The latter is one of the subunits of microtubules
in the cytoskeleton structure of every eukaryotic cell, which is the target of many anticancer drugs.
The twenty structures of colchicine derivatives described above were docked into the βI-tubulin (the
most abundant isotype in most cancer tumors) colchicine binding site.
On the basis of our computational predictions, according to increasing binding energy,
the compounds are ordered as follows: 20 (−59.6), 18 (−54.6), 7 (−53.7), 9 (−44.0), 15 (−43.9), 4 (−43.4),
5 (−43.1), 10 (−41.8), 1 (−41.1), 13 (−40.1), 2 (−39.3), 16 (−38.3), 6 (−37.2), 12 (−35.2), 17 (−34.9), 11 (−34.7),
14 (−34.3), 8 (−32.3), 21 (−29.8), 19 (−23.4), 3 (−4.0) kcal/mol with the binding energies in the parenthesis
given in units of kcal/mol. Binding energies of these compounds are shown in Figure 4 and Table 3.
Figure 4. Comparison of binding energies of the tested compounds complexed with tubulin βI. Binding
energies have been estimated using the MM/GBSA method.
In view of the calculated binding energies, we can conclude that there is no strong correlation
(the lower the binding energy, the more biologically active the chemical compound) between in silico
computer calculations (BE values, Figure 4) and in vitro activity results (IC50 values, Table 2).
The lowest binding energies, −59.6 and −53.7 kcal/mol, were shown by sulfonamide 20 (derivative
with the morpholine ring) and amide 7 (derivative of palmitic acid), respectively. However, these
compounds showed the weakest antiproliferative activity (highest IC50 values) among all compounds
tested (1–21).
Compound 18 has the third lowest energy (−54.6 kcal/mol) and good cytotoxicity with IC50 from
9.3 to 15.5 nM for LoVo, A549 and MCF-7 cancer cells. The molecular-level computations indicate
that 18 fits well to βI-tubulin and probably uses this binding site as a target. The majority of the
other derivatives 2, 4–6, 8–17 exhibited binding energy less than −30.0 kcal/mol, so close to the energy
of unmodified colchicine 1 (BE = −41.1 kcal/mol), which is a compound known to inhibit tubulin
polymerization. These compounds bind to the active sites of βI-tubulin isotype and may therefore
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have a mechanism of action similar to 1 and may be colchicine binding site inhibitors, although their
in vitro activities towards various cells characterized by an IC50 value (Table 2) were lower than that of
colchicine 1.
Derivative 3 showed the highest binding energy value (BE = −4.0 kcal/mol), therefore its
antiproliferative activity is not exclusively the result of interaction with tubulin. This is an important
finding because compound 3 was the only one which showed any possibility of breaking the drug
resistance of the LoVo/DX line (RI = 9.2, see Table 2).
Therefore, we can see that the results only partly correlate with in vitro determined biological
activity of these compounds as indicated though the corresponding IC50 values. This may be explained
by several additional effects taking place in living cells compared to the computational simulations
that focus only on the binding mode of the compounds to the target. Primarily off-target interactions
involving efflux transporters with different affinities for the individual compounds and differences
in solubility of these colchicine derivatives or their membrane permeability. Additionally, the lack
of significant correlation may be due to the fact that in various cancer cells the expression of specific
β-tubulin isotypes significantly varies [59]. We propose the inclusion of binding affinity calculations
for these compounds with regard to not only other tubulin isotypes but also with respect to most
important efflux transporters in order to minimize them and hence increase the activity of the drug
in vitro and in vivo.
Schematic interactions of the compounds with CBS of βI-tubulin residues are shown in Table 3.
In 3D representation, the interacting residues predicted from pairwise per-residue binding free
energy decomposition calculations (E < −2 kcal/mol) are shown in stick presentation and their carbons
and the ribbon are colored as green. Tubulin is shown in cartoon representation. Hydrogen bonds and
their directionality are represented as black dashed arrows. The structures are color-coded as follows:
tubulin αI, brown; tubulin βI, beige. Compounds are displayed with sticks and the atoms are colored
as O (red), C (gray), N (blue), S (yellow), Cl (green) and F (pink). Binding energy defines the affinity
of binding for colchicine derivatives complexed with tubulin βI. Binding energies are predicted by
MM/GBSA method. The last column contains information about the active residues with the binding
free energy decomposition (Edecomp) less than −2 kcal/mol (the residues with Edecomp < −3 kcal/mol
are highlighted in boldface). The last line contains the graphical key to help interpret the 2D part of the
ligand interactions panel.
Derivative compounds are designed with different side chains at C7 position of colchicine 1.
Compounds 2, 4–8 have alkyl chains of various lengths, straight and branched and compound 19 has
an unsaturated alkyl chain. The second lowest binding energy compound 7 within all the compounds
is in this group (BE = −53.6 kcal/mol). Compound 7 appears to be engaged in some interactions with
α-tubulin (−3 < Edecomp < −2 kcal/mol). Most of the compounds in this group are bound through
Lys785, Lys687 and Leu688 residues.
Compounds 9–11 were designed with alkyl chains of various length containing halogen atoms
side chains at position C7 of colchicine 1. In this group, the common binding residues with (−3 <
Edecomp < −2 kcal/mol) are Ala179, Cys674, Asn691, while the strongest binding residues (Edecomp <
−3 kcal/mol) are Leu688 and Lys785.
Compounds 12–16, 21 were designed with an aromatic group side chain without or with
substituents at C7 position of colchicine 1. The same trend of strong binding of Leu688 and Lys785
residues with the compounds is seen in this group. The binding energies in this group are on the
higher side compared to the other compounds.
As the last group, compounds 17–18 and 20 contain the sulfonamide moieties at position C7 of
colchicine 1. The strongest binding residues in this group belong to both α-tubulin (Gln10 and Ser177)
in compound 17, (Gln10, Gly142, Gly143, Thr144 and Ser177) in compound 18 and (Asp68 and Asn100)
in compound 20 with (Edecomp < −3 kcal/mol) and β-tubulin (Asp684, Asn691, Lys785) in compound
17 and Lys687 in compound 20. The lowest binding energy between all the compounds characterizes
compounds 20 and 18, which mainly bind to α-tubulin.
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In the experimental part of the study, the highest IC50 values (the weakest activity) were found for
compound 7 from the amides and compound 20 from the sulfonamides studied against all cancer cell
lines tested. According to our computational analysis, although these compounds show the lowest
binding energies, they do not bind to the CBS, which is located in β-tubulin and has the tendency to go
beyond and also bind to α-tubulin.
3. Materials and Methods
3.1. General
All solvents, substrates and reagents were obtained from TriMen Chemicals (Poland) or Sigma
Aldrich and were used without further purification. CDCl3 and CD2Cl2 spectral grade solvents were
stored over 3 Å molecular sieves for several days. TLC analysis was performed using pre-coated glass
plates (0.2 mm thickness, GF-254, pore size 60 Å) from Agela Technologies and spots were visualized
by UV-light. Products were purified by flash chromatography using high-purity grade silica gel (pore
size 60 Å, 230–400 mesh particle size, 40–63 μm particle size) from SiliCycle Inc. Preparative HPLC
was performed on LC-20AP Shimadzu with ELSD-LTII detector equipped with Phenomenex Luna C18
250 × 21 mm, 5 μm column eluted with 20 mL/min flow over 20 min of acetonitrile in water. Solvents
were removed using a rotary evaporator.
3.2. Spectroscopic Measurements
NMR spectra were recorded on Bruker Avance DRX 500 (1H NMR at 500 MHz and 13C NMR
at 126 MHz) magnetic resonance spectrometers. 1H NMR spectra are reported in chemical shifts
downfield from TMS using the respective residual solvent peak as internal standard (CDCl3 δ 7.26 ppm,
CD2Cl2 δ 5.32 ppm, (CD3)2SO δ 2.50 ppm). 1H NMR spectra are described as follows: chemical shift (δ,
ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet
of triplets, dq = doublet of quartets, m =multiplet), coupling constant (J) in Hz, and integration. 13C NMR
spectra are described in chemical shifts downfield from TMS using the respective residual solvent peak as
internal standard (CDCl3 δ 77.16 ppm, CD2Cl2 δ 53.84 ppm and (CD3)2SO δ 39.52 ppm).
Electrospray ionization (ESI) mass spectra were obtained on a Waters Alliance 2695 separation
module with a PDA 2996 UV detector and Waters Micromass ZQ 2000 mass detector equipped with
Restek Ultra Biphenyl 50 × 3 mm, 3 μm column eluted with 0.3 mL/min flow of 3–100% gradient (over
6 min) of acetonitrile in water.
3.3. Synthesis
3.3.1. Synthesis of 2
To a solution of 1 (1.0 equiv.) in EtOH, a methylamine (solution 33% in EtOH, 10.0 equiv.) was
added. The mixture was stirred at reflux for 24 h and then concentrated under reduced pressure to
dryness. The residue was purified using column flash chromatography (silica gel; DCM/MeOH) and
next lyophilized from dioxane to give the pure product 2 as a yellow solid with a yield of 80%.
ESI-MS for C22H26N2O5 (m/z): [M +H]+ 399, [M +Na]+ 421, [2M +H]+ 797, [2M +Na]+ 819, [M –
H]− 397, [M + HCOO−]− 443.
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 6.4 Hz, 1H), 7.58 (s, 1H), 7.46 (d, J = 11.1 Hz, 1H),
7.28–7.25 (m, 1H), 6.58 (d, J = 11.3 Hz, 1H), 6.52 (s, 1H), 4.73–4.64 (m, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.61
(s, 3H), 3.08 (d, J = 5.4 Hz, 3H), 2.47–2.43 (m, 1H), 2.37–2.31 (m, 1H), 2.29–2.22 (m, 1H), 2.02–1.96 (m,
1H), 1.94 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 175.11, 170.19, 155.23, 152.91, 151.61, 151.10, 141.51, 139.37, 134.66,
130.42, 126.93, 122.81, 108.28, 107.20, 61.46, 61.40, 56.16, 52.72, 37.06, 30.15, 29.53, 22.74.
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3.3.2. Synthesis of 3
To a solution of compound 2 (1.0 equiv.) in dioxane, 2M HCl (10.0 equiv.) was added and
the mixture was stirred at reflux. Reaction progress was monitored by LC-MS. Then the reaction
mixture was neutralized with 4M NaOH to pH~10 and extracted four times with EtOAc. The organic
layers were combined, washed with brine, dried over Na2SO4, filtered and evaporated under reduced
pressure. The residue was purified using column flash chromatography (silica gel; DCM/MeOH) and
next lyophilized from dioxane to give the pure product 3 as a yellow solid with a yield of 73%.
ESI-MS for C20H24N2O4 (m/z): [M + H]+ 357, [M + Na]+ 379, [2M + Na]+ 735.
1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.33 (d, J = 11.1 Hz, 1H), 7.23–7.21 (m, 1H), 6.50 (s, 1H),
6.50 (d, J = 11.4 Hz, 2H), 3.87 (s, 3H), 3.87 (s, 3H), 3.75–3.72 (m, 1H), 3.59 (s, 3H), 3.05 (d, J = 5.5 Hz, 3H),
2.41–2.37 (m, 1H), 2.33–2.31 (m, 2H), 2.25 (s, 2H), 1.71–1.61 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 175.57, 154.99, 153.25, 152.76, 150.59, 141.06, 138.73, 135.41, 129.74,
126.63, 123.68, 107.35, 106.94, 61.19, 60.84, 56.06, 54.01, 40.90, 30.69, 29.48.
3.3.3. General Procedure for the Synthesis of Colchicine Derivatives 4, 8, 13, 15–16, 18 and 21
Compounds 4, 8, 13, 15–16, 18 and 21 were obtained directly from compound 3. To a solution
of compound 3 (1.0 equiv.) and Et3N (3.0 equiv.) in DCM in an ice bath, the corresponding
acid/sulfonyl/sulfamide chloride (1.1 equiv.) diluted with DCM was added slowly. Next the ice bath
was removed and the reaction mixture was stirred at RT. Reaction progress was monitored by LC-MS.
Then the reaction mixture was diluted with EtOAc, washed with H2O, 1M K2CO3, brine and dried
over Na2SO4. The residue was purified using column flash chromatography (silica gel; DCM/MeOH)
and next lyophilized from dioxane to give respective compound.
Compound 4
Yellow solid, yield 86%.
ESI-MS for C23H28N2O5 (m/z): [M + H]+ 413, [M + Na]+ 435, [2M + H]+ 825, [2M + Na]+ 847,
[M−H]− 411, [M + HCOO−]− 457.
1H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 7.53 (s, 1H), 7.44 (d, J = 11.1 Hz, 1H), 7.25–7.21 (m, 1H),
6.55 (d, J = 11.4 Hz, 1H), 6.50 (s, 1H), 4.72–4.65 (m, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.61 (s, 3H), 3.06 (d, J = 5.4
Hz, 3H), 2.44–2.40 (m, 1H), 2.33–2.30 (m, 1H), 2.26–2.17 (m, 3H), 1.94–1.88 (m, 1H), 1.05 (t, J = 7.6 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 175.09, 173.89, 155.20, 152.86, 151.64, 151.09, 141.49, 139.23, 134.67,
130.33, 126.95, 122.94, 108.14, 107.20, 61.44, 56.14, 52.37, 37.20, 30.18, 29.53, 29.11, 9.72.
Compound 8
Yellow solid, yield 96%.
ESI-MS for C24H30N2O5 (m/z): [M + H]+ 427, [M + Na]+ 449, [2M + H]+ 853, [2M + Na]+ 875,
[M−H]− 425, [M + HCOO−]− 471.
1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 11.2 Hz, 1H), 7.45 (s, 1H), 7.31–7.28 (m, 1H), 6.67 (d, J =
7.3 Hz, 1H), 6.59 (d, J = 11.3 Hz, 1H), 6.53 (s, 1H), 4.75–4.63 (m, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 3.63 (s,
3H), 3.10 (d, J = 5.4 Hz, 3H), 2.53–2.43 (m, 2H), 2.38–2.32 (m, 1H), 2.28–2.20 (m, 1H), 1.93–1.82 (m, 1H),
1.14 (t, J = 6.7 Hz, 6H).
13C NMR (126 MHz, CDCl3) δ 176.86, 175.21, 155.19, 152.85, 151.15, 141.56, 139.08, 134.55, 130.09,
126.97, 123.07, 107.91, 107.22, 61.51, 61.45, 56.13, 51.96, 37.56, 35.21, 30.19, 29.54, 19.70, 19.60.
Compound 13
Yellow solid, yield 86%.
ESI-MS for C27H27ClN2O5 (m/z): [M +H]+ 495/497, [M +Na]+ 517, [2M +H]+ 989/991, [M-H]−
493/495, [M + HCOO−]− 540.
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1H NMR (500 MHz, CD2Cl2) δ 8.12 (d, J = 7.5 Hz, 1H), 7.60 (s, 1H), 7.42–7.39 (m, 2H), 7.29–7.22
(m, 2H), 7.19 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 7.4 Hz, 1H), 6.60 (s, 1H), 6.53 (d, J = 11.3 Hz, 1H), 4.88–4.83
(m, 1H), 3.91 (s, 3H), 3.89 (s, 3H), 3.71 (s, 3H), 3.03 (d, J = 5.2 Hz, 3H), 2.52–2,48 (m, 1H), 2.42–2.31 (m,
2H), 2.14–2.04 (m, 1H).
13C NMR (126 MHz, CD2Cl2) δ 174.51, 165.99, 155.24, 153.11, 150.94, 150.51, 141.52, 139.19, 135.71,
134.71, 130.64, 130.43, 130.01, 129.60, 129.58, 126.83, 126.79, 123.26, 107.90, 107.46, 61.08, 61.07, 56.02,
52.86, 37.83, 30.11, 29.35.
Compound 15
Yellow solid, yield 23%.
ESI-MS for C26H27N3O5 (m/z): [M + H]+ 462, [M + Na]+ 484, [2M + H]+ 923, [2M + Na]+ 945,
[M-H]− 460, [M + HCOO−]− 506.
1H NMR (500 MHz, CDCl3) δ 9.35 (d, J = 7.0 Hz, 1H), 9.07 (d, J = 1.8 Hz, 1H), 8.48 (dd, J = 4.8,
1.5 Hz, 1H), 8.13–8.06 (m, 1H), 7.65 (s, 1H), 7.51 (d, J = 11.2 Hz, 1H), 7.31 (q, J = 5.1 Hz, 1H), 7.05 (dd, J =
7.9, 4.9 Hz, 1H), 6.61 (d, J = 11.4 Hz, 1H), 6.54 (s, 1H), 4.99–4.86 (m, 1H), 3.95 (s, 3H), 3.89 (s, 3H), 3.70 (s,
3H), 3.08 (d, J = 5.4 Hz, 3H), 2.51–2.45 (m, 1H), 2.40–2.34 (m, 1H), 2.33–2.27 (m, 1H), 2.17–2.09 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.69, 165.09, 155.37, 153.01, 151.82, 151.42, 151.15, 148.87, 141.59,
139.62, 134.89, 134.61, 130.41, 129.34, 126.86, 123.08, 122.79, 108.49, 107.27, 61.53, 61.48, 56.15, 53.22,
36.83, 30.28, 29.58.
Compound 16
Yellow solid, yield 39%.
ESI-MS for C26H27N3O5 (m/z): [M + H]+ 462, [M + Na]+ 484, [2M + H]+ 923, [2M + Na]+ 945,
[M-H]− 460, [M + HCOO−]− 506.
1H NMR (500 MHz, CDCl3) δ 9.71 (d, J = 6.6 Hz, 1H), 8.37 (d, J = 5.8 Hz, 2H), 7.69 (s, 1H), 7.64
(d, J = 5.8 Hz, 2H), 7.54 (d, J = 11.2 Hz, 1H), 7.32–7.28 (m, 1H), 6.65 (d, J = 11.4 Hz, 1H), 6.53 (s, 1H),
4.98–4.81 (m, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.71 (s, 3H), 3.10 (d, J = 5.4 Hz, 3H), 2.50–2.41 (m, 1H),
2.41–2.25 (m, 2H), 2.16–2.11 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.51, 164.91, 155.37, 153.05, 151.64, 151.17, 150.18, 141.59, 140.46,
139.81, 134.59, 130.64, 126.78, 122.68, 120.99, 108.68, 107.27, 61.55, 61.47, 56.14, 53.46, 36.50, 30.29, 29.60.
Compound 18
Yellow solid, yield 38%.
ESI-MS for C22H29N3O6S (m/z): [M +H]+ 464, [M +Na]+ 486, [2M +H]+ 927, [2M +Na]+ 949,
[M-H]− 462.
1H NMR (500 MHz, CDCl3) δ 7.85 (s, 1H), 7.45–7.41 (m, 2H), 6.58 (d, J = 11.3 Hz, 1H), 6.54 (s, 1H),
6.49–6.46 (m, 1H), 4.33–4.19 (m, 1H), 3.93–3.89 (m, 6H), 3.57 (s, 3H), 3.10 (d, J = 5.1 Hz, 3H), 2.58 (s, 6H),
2.49–2.39 (m, 2H), 2.35–2.26 (m, 1H), 2.01–1.90 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.73, 155.46, 153.08, 150.77, 150.08, 141.39, 139.41, 134.59, 129.64,
126.34, 124.53, 108.22, 107.43, 61.34, 60.80, 56.48, 56.05, 39.91, 37.95, 30.50, 29.57.
Compound 21
Yellow solid, yield 83%.
ESI-MS for C27H27F3N2O6S (m/z): [M + H]+ 565, [M + Na]+ 587, [2M + H]+ 1129, [2M + Na]+
1151, [M-H]− 563.
1H NMR (500 MHz, CDCl3) δ 8.72 (d, J = 7.5 Hz, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 7.84 (d, J = 8.2 Hz,
2H), 7.53 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 11.5 Hz, 1H), 6.66 (d, J = 11.8 Hz, 1H), 6.46 (s, 1H), 4.16 (q, J =
8.8 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.58 (s, 3H), 3.08 (d, J = 5.2 Hz, 3H), 2.45–2.31 (m, 1H), 2.31–2.18
(m, 2H), 2.16–2.10 (m, 1H).
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13C NMR (126 MHz, CDCl3) δ 170.13, 155.43, 153.53, 150.65, 150.15, 144.53, 141.35, 134.75, 133.34,
131.89, 127.57, 125.82, 125.79, 125.49, 124.38, 123.51, 122.21, 111.26, 107.42, 61.29, 60.95, 56.63, 56.04,
38.98, 30.26, 29.78.
3.3.4. General Procedure for the Synthesis of Colchicine Derivatives 5–7, 9–12 and 14
Compounds 5–7, 9–12 and 14 were obtained directly from compound 3. To a solution of compound
3 (1.0 equiv.) in DCM corresponding carboxylic acid (1.1 equiv.) and 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride (EDCI, 1.1 equiv.) were added. Reaction progress was monitored
by LC-MS. Then the reaction mixture was diluted with EtOAc, washed with H2O, 1M K2CO3,
brine and dried over Na2SO4. The residue was purified using column flash chromatography (silica gel;
DCM/MeOH) and next lyophilized from dioxane to give respective compound.
Compound 5
Yellow solid, yield 93%.
ESI-MS for C24H30N2O5 (m/z): [M + H]+ 427, [M + Na]+ 449, [2M + H]+ 853, [2M + Na]+ 875,
[M-H]− 425, [M + HCOO−]− 471.
1H NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.51 (s, 1H), 7.45 (d, J = 11.1 Hz, 1H), 7.27–7.25 (m, 1H),
6.56 (d, J = 11.3 Hz, 1H), 6.51 (s, 1H), 4.76–4.68 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.61 (s, 3H), 3.08 (d, J =
5.4 Hz, 3H), 2.45–2.41 (m, 1H), 2.35–2.27 (m, 1H), 2.25–2.17 (m, 3H), 1.91 –1.85 (m, 1H), 1.65–1.55 (m,
2H), 0.87 (t, J = 7.4 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 175.10, 172.96, 155.22, 152.87, 151.43, 151.13, 141.52, 139.20, 134.61,
130.31, 126.94, 123.10, 108.13, 107.22, 61.45, 56.13, 52.21, 38.22, 37.45, 30.18, 29.54, 19.09, 13.93.
Compound 6
Yellow solid, yield 73%.
ESI-MS for C25H32N2O5 (m/z): [M + H]+ 441, [M + Na]+ 463, [2M + H]+ 881, [2M + Na]+ 903,
[M-H]− 439, [M + HCOO−]− 485.
1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.50 (s, 1H), 7.44 (d, J = 11.1 Hz, 1H), 7.26–7.21 (m, 1H),
6.55 (d, J = 11.3 Hz, 1H), 6.51 (s, 1H), 4.76–4.68 (m, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.61 (s, 3H), 3.08 (d, J =
5.4 Hz, 3H), 2.45–2.41 (m, 1H), 2.36–2.30 (m, 1H), 2.25–2.18 (m, 3H), 1.93–1.84 (m, 1H), 1.58–1.51 (m,
2H), 1.30–1.22 (m, 2H), 0.81 (t, J = 7.3 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 175.19, 173.02, 155.19, 152.85, 151.32, 151.15, 141.54, 139.11, 134.59,
130.19, 126.98, 123.13, 107.97, 107.20, 61.44, 56.13, 52.20, 37.46, 36.05, 30.19, 29.53, 27.70, 22.46, 13.76.
Compound 7
Yellow solid, yield 24%.
ESI-MS for C36H54N2O5 (m/z): [M + H]+ 595, [2M + H]+ 1189, [M-H]− 593, [M + HCOO−]− 639.
1H NMR (500 MHz, CDCl3) δ 8.18–7.90 (m, 2H), 7.73–7.53 (m, 2H), 6.88 (d, J = 10.1 Hz, 1H), 6.55
(s, 1H), 4.74 (s, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.62 (s, 3H), 3.19 (s, 3H), 2.47 (d, J = 7.4 Hz, 1H), 2.39–2.08
(m, 5H), 1.54–1.49 (m, 2H), 1.28–1.16 (m, 26H), 0.86 (t, J = 7.0 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 175.09, 173.07, 155.23, 152.89, 151.32, 151.14, 141.55, 139.25, 134.58,
130.35, 126.91, 123.12, 108.24, 107.23, 61.45, 56.12, 52.16, 37.56, 36.39, 31.95, 30.18, 29.73, 29.69, 29.54,
29.53, 29.43, 29.39, 25.64, 22.72, 14.16.
Compound 9
Yellow solid, yield 83%.
ESI-MS for C22H25ClN2O5 (m/z): [M + H]+ 433/435, [M + Na]+ 455/457, [2M + H]+ 865, [2M +
Na]+ 887, [M-H]− 431.
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1H NMR (500 MHz, CDCl3) δ 8.60–8.38 (m, 1H), 7.48–7.39 (m, 2H), 7.29 (q, J = 5.2 Hz, 1H), 6.56 (d,
J = 11.4 Hz, 1H), 6.52 (s, 1H), 4.75–4.63 (m, 1H), 4.08–3.95 (m, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 3.60 (s, 3H),
3.07 (d, J = 5.3 Hz, 3H), 2.50–2.43 (m, 1H), 2.40–2.31 (m, 1H), 2.28–2.21 (m, 1H), 2.04–1.93 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 175.04, 166.12, 155.33, 152.97, 151.10, 150.18,141.57, 139.37, 134.41,
129.97, 126.80, 122.73, 108.18, 107.27, 61.45, 61.33, 56.14, 52.91, 42.63, 37.17, 30.02, 29.55.
Compound 10
Yellow solid, yield 46%.
ESI-MS for C22H24Cl2N2O5 (m/z): [M + H]+ 467/469, [M + Na]+ 489/491, [2M + H]+ 933/935, [2M
+ Na]+ 957/959, [M-H]− 465/467.
1H NMR (500 MHz, CDCl3) δ 9.53 (d, J = 7.2 Hz, 1H), 7.56 (s, 1H), 7.53 (d, J = 11.2 Hz, 1H), 7.34 (q,
J = 5.2 Hz, 1H), 6.64 (d, J = 11.4 Hz, 1H), 6.52 (s, 1H), 6.20 (s, 1H), 4.77–4.69 (m, 1H), 3.94 (s, 3H), 3.89 (s,
3H), 3.63 (s, 3H), 3.12 (d, J = 5.4 Hz, 3H), 2.46–2.44 (m, 1H), 2.38–2.23 (m, 2H), 1.97–1.91 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.73, 164.19, 155.51, 153.12, 151.17, 150.51, 141.69, 139.81, 134.31,
130.45, 126.66, 122.71, 108.80, 107.36, 66.56, 61.52, 61.48, 56.17, 53.28, 37.17, 30.06, 29.66.
Compound 11
Yellow solid, yield 89%.
ESI-MS for C24H27F3N2O5 (m/z): [M +H]+ 481, [M +Na]+ 503, [2M +H]+ 961, [2M +Na]+ 983,
[M-H]− 479, [M + HCOO−]− 525.
1H NMR (500 MHz, CDCl3) δ 8.77–8.65 (m, 1H), 7.56 (s, 1H), 7.49 (d, J = 11.2 Hz, 1H), 7.35–7.28
(m, 1H), 6.61 (d, J = 11.4 Hz, 1H), 6.51 (s, 1H), 4.75–4.70 (m, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.62 (s, 3H),
3.10 (d, J = 5.4 Hz, 3H), 2.56–2.46 (m, 2H), 2.45–2.27 (m, 4H), 2.25–2.20 (m, 1H), 1.90–1.84 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.99, 169.79, 155.36, 152.97, 151.33, 151.12, 141.57, 139.53, 134.54,
130.36, 127.98, 126.81, 122.89, 108.41, 107.25, 61.46, 61.34, 56.13, 52.52, 37.37, 30.16, 29.56, 29.33, 28.17.
Compound 12
Yellow solid, yield 89%.
ESI-MS for C27H28N2O5 (m/z): [M + H]+ 461, [M + Na]+ 483, [2M + H]+ 921, [2M + Na]+ 943,
[M-H]− 459, [M + HCOO−]− 505.
1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 7.3 Hz, 1H), 7.81 (d, J = 7.2 Hz, 2H), 7.68 (s, 1H), 7.49
(d, J = 11.2 Hz, 1H), 7.29–7.23 (m, 2H), 7.16 (t, J = 7.7 Hz, 2H), 6.57 (d, J = 11.4 Hz, 1H), 6.53 (s, 1H),
4.99–4.93 (m, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 3.70 (s, 3H), 3.06 (d, J = 5.4 Hz, 3H), 2.50–2.45 (m, 1H),
2.41–2.37 (m, 1H), 2.34–2.26 (m, 1H), 2.11–2.06 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 175.02, 167.10, 155.26, 152.91, 151.30, 151.20, 141.57, 139.18, 134.65,
133.84, 131.31, 130.17, 128.28, 127.17, 127.01, 123.23, 108.01, 107.28, 61.53, 61.49, 56.14, 52.85, 37.19, 30.30, 29.53.
Compound 14
Yellow solid, yield 57%.
ESI-MS for C27H27FN2O5 (m/z): [M +H]+ 479, [M +Na]+ 501, [2M +H]+ 957, [2M +Na]+ 979,
[M-H]− 477, [M + HCOO−]− 523.
1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 7.68 (s, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.53–7.47 (m, 2H),
7.31–7.26 (m, 1H), 7.10–7.05 (m, 1H), 6.97–6.92 (m, 1H), 6.61 (d, J = 11.4 Hz, 1H), 6.55 (s, 1H), 4.99–4.90
(m, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.70 (s, 3H), 3.09 (d, J = 5.4 Hz, 3H), 2.53–2.47 (m, 1H), 2.43–2.37 (m,
1H), 2.35–2.27 (m, 1H), 2.18–2.10 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 174.84, 165.56, 155.31, 152.98, 151.38, 151.20, 141.59, 139.42, 134.63,
130.36, 129.84, 126.92, 123.06, 122.53, 118.29, 118.12, 114.70, 114.52, 108.29, 107.27, 61.52, 61.50, 56.15,
53.09, 37.00, 30.31, 29.56.
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3.3.5. Synthesis of 17
Toasolutionofcompound3 (1.0equiv.) inDCM,N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-
1,4-dihydropyridin-1-ylsulfonyl]azanide (4.0 equiv.) was added and the mixture was stirred at RT. Reaction
progress was monitored by LC-MS. Then the reaction mixture was diluted with EtOAc, washed with H2O,
10% citric acid, 1M K2CO3, brine and dried over Na2SO4. The residue was purified using column flash
chromatography (silica gel; EtOAc/hexanes). To the obtained compound, 4M HCl/EtOAc was added
and the reaction mixture was stirred at RT overnight. Next the solvent was removed under reduced
pressure and the residue was purified using preparative HPLC (MeCN/H2O) and lyophilized from
dioxane to give the pure hydrochloride product 17 as a yellow solid with a yield of 21%.
ESI-MS for C20H25N3O6S (m/z): [M +H]+ 436, [M +Na]+ 458, [2M +H]+ 871, [2M +Na]+ 893,
[M-H]− 434.
1H NMR (500 MHz, CDCl3) δ 8.19 (s, 2H), 7.50–7.39 (m, 2H), 6.66 (s, 1H), 6.57 (s, 1H), 4.41–4.32 (m,
1H), 3.94 (m, 6H), 3.56 (s, 3H), 3.11 (s, 3H), 2.59–2.46 (m, 2H), 2.56–2.49 (s, 1H), 2.21 (s, 1H).
3.3.6. Synthesis of 19
To a solution of compound 3 (1.0 equiv.) and Et3N (3.0 equiv.) in DCM in an ice bath,
2-chloroethanesulfonyl chloride (1.2 equiv.) diluted with DCM was slowly added. Next, the ice bath
was removed and the reaction mixture was stirred at RT. Reaction progress was monitored by LC-MS.
Then the reaction mixture was diluted with EtOAc, washed with 1M K2CO3, brine and dried over
Na2SO4. The residue was purified using column flash chromatography (silica gel; EtOAc/MeOH) and
lyophilized from dioxane to give the pure product 19 as a yellow solid with a yield of 64%.
ESI-MS for C22H26N2O6S (m/z): [M + H]+ 447, [2M + H]+ 893, [2M + Na]+ 915, [M-H]− 445.
1H NMR (500 MHz, (CD3)2SO) δ 8.26 (d, J = 7.5 Hz, 1H), 8.04 (s, 1H), 7.41 (s, 1H), 7.23 (d, J = 11.2
Hz, 1H), 6.71 (s, 1H), 6.64 (d, J = 11.5 Hz, 1H), 6.48 (dd, J = 16.4, 9.9 Hz, 1H), 5.71 (dd, J = 21.1, 13.1 Hz, 2H),
3.84–3.76 (m, 4H), 3.73 (s, 3H), 3.37 (s, 3H), 2.95 (s, 3H), 2.49 (s, 1H), 2.11–2.01 (m, 2H), 1.88–1.82 (m, 1H).
13C NMR (126 MHz, (CD3)2SO) δ 173.10, 155.58, 153.04, 150.65, 149.28, 141.12, 139.36, 137.66,
134.78, 128.80, 126.48, 125.64, 123.98, 108.88, 108.07, 61.19, 60.73, 56.26, 55.99, 38.70, 29.82.
3.3.7. Synthesis of 20
Compound 20 was obtained directly from compound 19. To 19 in DCM, morpholine was added in
excess. Reaction progress was monitored by LC-MS. Then the mixture was diluted with EtOAc, washed
with H2O, brine and dried over Na2SO4. The residue was purified using column flash chromatography
(silica gel; DCM/MeOH) and subsequently lyophilized from dioxane to give the pure product 20 as a
yellow solid with a yield of 63%.
ESI-MS for C26H35N3O7S (m/z): [M + H]+ 534, [2M + H]+ 1067, [M-H]− 532.
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.43 (d, J = 11.2 Hz, 1H), 7.40–7.38 (m, 1H), 6.84–6.50
(m, 1H), 6.56 (d, J = 11.3 Hz, 1H), 6.53 (s, 1H), 4.48–4.35 (m, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.63 (t, J =
4.5 Hz, 4H), 3.58 (s, 3H), 3.17–3.11 (m, 1H), 3.10 (d, J = 5.4 Hz, 3H), 3.07–2.99 (m, 1H), 2.83–2.76 (m, 1H),
2.75–2.69 (m, 1H), 2.51–2.33 (m, 7H), 1.99–1.91 (m, 1H).
13C NMR (126 MHz, CDCl3) δ 175.05, 155.45, 153.09, 150.89, 149.61, 141.54, 139.38, 134.35, 129.35,
129.06, 128.25, 126.38, 124.07, 108.00, 107.38, 61.37, 61.02, 56.09, 55.65, 53.37, 52.68, 51.08, 39.95, 30.38, 29.56.
3.4. Single Crystal X-ray Measurement
The single crystals of colchicine derivatives (6, 11, 12, 14, 15, 16, 18 and 19) were used for data
collection on a four-circle KUMA KM4 diffractometer equipped with two-dimensional CCD area
detector at room (295(1) K) and low temperature (100(1) K. The graphite monochromatized Mo-Kα
radiation (λ = 0.71073 Å) and the ω-scan technique (Δω = 1◦) were used for data collection. Lattice
parameters were refined by the least-squares methods at all reflection positions. One image was
monitored as a standard after every 40 images for a control of the crystal stability. Data collection and
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reduction along with absorption correction were performed using the CrysAlis software package [60].
The structures were solved by direct methods using SHELXT [61] giving positions of almost all
non-hydrogen atoms. The structures were refined using SHELXL–2018 [62] with the anisotropic thermal
displacement parameters. Hydrogen atoms were refined as rigid. Visualizations of the structures were
made with the Diamond 3.0 program [63]. Details of the data collection parameters, crystallographic
data and final agreement parameters are collected in Supplementary Table S1. The structures have
been deposited with the Cambridge Crystallographic Data Center in the CIF format, no. CCDC
1980349–1980354 for 6, 11, 12, CCDC 1980341–1980344 for 14 and 15, CCDC 1980339–1980340 for 16
and CCDC 1980345–1980348 for 18 and 19 at 100 K and RT, respectively. Copies of this information can
be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax:
+44 1223 336 033); email: deposit@ccdc.cam.ac.uk or www:http://www.ccdc.cam.ac.uk).
3.5. DFT Molecular Modeling
Molecular orbital calculations with full geometry optimization of colchicine derivatives (6, 11, 12,
14, 15, 16, 18 and 19) were performed with the Gaussian09 program package [52]. All calculations were
carried out with the DFT level using the Becke3-Lee–Yang–Parr correlation functional (B3LYP) [53–56]
with the 6–31+G basis set assuming the geometry resulting from the X-ray diffraction study as the
starting structure. As convergence criteria, the threshold limits of 0.00025 and 0.0012 a.u. were
applied for the maximum force and the displacement, respectively. The three-dimensional molecular
electrostatic potential (3D MESP) maps are obtained on the basis of the DFT (B3LYP/6–31G) optimized.
The calculated 3D MESP is mapped onto the total electron density isosurface (0.008 eÅ-3) for each
molecule. The color code of MESP maps is in the range of −0.05 eÅ−1 (red) to +0.05 eÅ−1 (blue).
3.6. In Vitro Antiproliferative Activity
3.6.1. Cell Lines and Culturing Conditions
Four human cancer cell lines and one murine normal cell line were used to evaluate antiproliferative
activity of colchicine and its derivatives 1–21: human lung adenocarcinoma (A549), human breast
adenocarcinoma (MCF-7), human colon adenocarcinoma cell lines sensitive and resistant to doxorubicin
(LoVo) and (LoVo/DX) respectively, and normal murine embryonic fibroblast cell line (BALB/3T3).
The A549 cell line was purchased from the European Collection of Authenticated Cell Cultures (ECACC,
Salisbury, UK). The MCF-7, LoVo and LoVo/DX cell lines was purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). All the cell lines are maintained in the Institute of Immunology
and Experimental Therapy (IIET), Wroclaw, Poland.
Human lung adenocarcinoma cell line was cultured in a mixture of OptiMEM and RPMI 1640
(1:1) medium (IIET, Wroclaw, Poland), supplemented with 5% fetal bovine serum HyClone (GE
Healthcare, USA) and 2 mM L-glutamine (Sigma-Aldrich, Germany). Human breast adenocarcinoma
cell line was cultured in a mixture of Eagle medium (IIET, Wroclaw, Poland), supplemented with
10% fetal bovine serum, 2 mM l-glutamine, 8 μg/mL insulin and 1% amino acids (Sigma-Aldrich,
Germany). Human colon adenocarcinoma cell lines were cultured in a mixture of OptiMEM and
RPMI 1640 (1:1) medium (IIET, Wroclaw, Poland), supplemented with 5% fetal bovine serum HyClone
(GE Healthcare, USA), 2 mM l-glutamine, 1 mM sodium pyruvate (Sigma-Aldrich, Germany) and
10 μg/100 mL doxorubicin (Accord) for LoVo/DX. Murine embryonic fibroblast cells were cultured in
Dulbecco medium (Gibco), supplemented with 10% fetal bovine serum (GE Healthcare, USA) and
2 mM L-glutamine (Sigma-Aldrich, Germany). All culture media contained antibiotics: 100 U/mL
penicillin (Polfa-Tarchomin, Poland) and 0.1 mg/mL streptomycin (Sigma Aldrich, Germany). All cell
lines were cultured during entire experiment in humid atmosphere at 37 ◦C and 5% CO2.
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3.6.2. Cell Viability Assays
Twenty-four hours before adding the tested compounds, all cell lines were seeded in 96-well
plates (Sarstedt, Germany) in appropriate media with 0.5 × 104 cells per well for A549 cell line, 0.75 ×
104 cells per well for MCF-7 cell line and 1.0 × 104 cells per well for LoVo, LoVo/DX and BALB/3T3 cell
lines. All cell lines were exposed to each tested agent at different concentrations in the range 100–0.001
μg/mL for 72 h. The cells were also exposed to the reference drug cisplatin (Teva Pharmaceuticals,
Poland) and doxorubicin (Accord Healthcare Limited, UK). Additionally, all cell lines were exposed to
DMSO (solvent used for tested compounds) (POCh, Poland) at concentrations corresponding to those
present in dilutions of tested agents. After 72 h sulforhodamine B assay (SRB) was performed [64].
SRB
After 72 h of incubation with the tested compounds, the cells were fixed in situ by gently
adding of 50 μL per well of cold 50% trichloroacetic acid TCA (POCh, Poland) and were incubated
at room temperature for one hour. Then the wells were washed four times with water and air dried.
Next, 50 μL of 0.1% solution of sulforhodamine B (Sigma-Aldrich, Germany) in 1% acetic acid (POCh,
Poland) were added to each well and were incubated at room temperature for 0.5 h. After incubation
time, unbound dye was removed by washing plates four times with 1% acetic acid, whereas the
stain bound to cells was solubilized with 150 μL of 10 mM Tris base (Sigma-Aldrich, Germany).
Absorbance of each solution was read from a Synergy H4 Hybrid Multi-Mode Microplate Reader
(BioTek Instruments, USA) at the 540 nm wavelength.
Results are presented as mean IC50 (concentration of the tested compound that inhibits cell
proliferation by 50%) ± standard deviation. IC50 values were calculated in Cheburator 0.4, Dmitry
Nevozhay software (version 1.2.0 software by Dmitry Nevozhay, 2004–2014, http://www.cheburator.
nevozhay.com, freely available for each experiment [65]. Compounds at each concentration were
tested in triplicates in a single experiment and each experiment was repeated at least three times
independently. Results are summarized in Table 2.
3.7. Molecular Docking Studies
3.7.1. Ligand Preparation
The ligand structures were prepared using Ligprep from the Schrödinger suite [66]. Conformations
and tautomeric states were assigned to the ligands by following the ligand preparation protocol
implemented in Schrödinger suite with default settings. LigPrep generates variants of the same ligand
with different tautomeric, stereochemical, and ionization properties.
3.7.2. Tubulin Model
The tubulin crystal structures available in the PDB are those for bovine protein. The bovine
tubulin structure of tubulin (PDB ID: 1SA0) [67] was used as a template to construct the homology
model of human αβ-tubulin isotypes (βI (UniProtKb: P07437), which is the most abundant isotype in
most tumors using the Molecular Operating Environment (MOE) software package [68]. The sequence
corresponding to the gene TUBA1A (UniProt ID: Q71U36) was chosen as a reference sequence for
human tubulin, whereas gene TUBB associated to I isoform (UniProt ID: P07437) was chosen for
human tubulin. Homology modeling was performed using MOE by setting the number of generated
models to 10 and by selecting the final model based on MOE’s generalized Born/volume integral
(GB/VI) scoring function. The models used in the simulations performed for the present study were
developed earlier and described in our previous publications [69]. These earlier investigations can also
be considered to be validations of the computational model employed here since they were directly
compared to the corresponding experimental data.
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3.7.3. Molecular Dynamics Simulations
The missing hydrogens for heavy atoms were added using the tLEAP module of AMBER 14 with
the AMBER14SB force field [70]. The protonation states of all ionizable residues were determined at
pH = 7 using the MOE program [68]. Each protein model was solvated in a 12 Å box of TIP3P water.
In order to bring the salt concentration to the physiological value of 0.15 M, 93 Na+ ions and 57 Cl− ions
were added. Minimization of the structure was carried out in two steps, using the steepest descent and
conjugate gradient methods successively. At first, minimization was made in 2 ps on solvent atoms
only, by restraining the protein-ligand complex. Next, minimization was run without the restraint in
10 ps. After minimization, the molecular dynamics (MD) simulations were carried out in three steps:
heating, density equilibration, and production. At first, each solvated system was heated to 298 K for
50 ps, with weak restraints on all backbone atoms. Next, density equilibration was carried out for
50 ps of constant pressure equilibration at 298 K, with weak restraints. Finally, MD production runs
were performed for all systems for 70 ns. The root-mean-square deviation (RMSD) of both the entire
tubulin structure and the colchicine binding site were found to reach a plateau after 40 ns. Clustering
analysis of the last 30 ns of the generated MD trajectory was carried out using the Amber’s CPPTRAJ
program [71] to identify representative conformations of the tubulin dimer. Clustering was made via
the hierarchical agglomerative approach using the RMSD of atoms in the colchicine binding site as a
metric. An RMSD cutoff of 1.0 Å was set to differentiate the clusters. On the basis of the clustering
analysis, three representative structures of the tubulin dimer were found. The docking was performed
on all the three representative structures and the one with the highest docking score was selected,
which was the largest cluster (about 70% of the simulation) conformation of the tubulin structure.
During the modeling, the cofactors including GTP, GDP, colchicine, and the magnesium ion located at
the interface between α–and β–monomers were kept as part of the environment and included in the
refinement step.
3.7.4. Docking Simulations
We used the AutoDock Vina [72] program to predict the binding pose of the ligands under flexible
ligand and rigid receptor conditions. Dockbox package was used to facilitate preparing docking inputs
and post-processing of the docking results [73]. Docking simulations performed with a cubic box (size
30.0 Å) were centered at the center of binding pockets and the docking was run separately on tubulin
structure. Every generated pose was energy-minimized using Amber14 by keeping the protein fixed
and was re-scored using the MOE’s GBVI/WSA dG scoring function [68]. No constraints were applied
in the docking studies. For each compound/protein-structure pair, the pose with the best score was
identified and used as an initial configuration for molecular mechanics Gibbs–Boltzmann surface area
MM/GBSA computations.
3.7.5. Binding Energy and Pairwise Per-Residue Free Energy Decomposition Calculations Using
MM/GBSA Method
The MM/GBSA technique is used to calculate the free energy associated with the binding of double
modified colchicine amides and sulfonamides [74]. This method combines molecular mechanics with
continuum solvation models. We performed MM-GBSA integrated in Amber. The binding free energy
is estimated as:





where G is the average free energy of the complex, protein, and ligand, are calculated according to the equation:
G = EM+Gsolvation − TS (2)
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where EMM are determined with the SANDER program and represent the internal energy (bond,
angle, and dihedral), van der Waals and electrostatic interactions (see Equation (3)). TS is the entropy
contribution estimated using normal mode (nmode) analysis.
EM = Eint + Eelec + EvdW (3)
The solvation free energy can be calculated as the sum of polar and nonpolar contributions.
The polar parts are obtained by using the generalized-born (GB) model—resulting in the MM/GBSA
method, whereas the nonpolar terms are estimated from a linear relation (Equation (4)) to the solvent
accessible surface area (SASA).
Gnon−polar = γ SASA + b (4)
In the present study, a 2 ns-duration MD trajectory was run in TIP3P water using Amber14,
for every top pose generated at the end of the docking step. It is worth noting that to assess the
performance of MM/GBSA methodology [75], we evaluated the prediction accuracy of this method
by various simulation protocols including 1 ns MD production calculations using PDBbind data set.
Too long an MD simulation could be prejudicious for the overall success of the MM/GBSA method.
According to this study and the common practice to calculate binding energies using MM/GBSA,
we have decided to run MD production simulation for 2 ns. The MM/GBSA calculations were
performed on a subset of 200 frames collected at regular time intervals from the trajectory. For PB
calculations, an ionic strength of 0.0 nM (istrng = 0.0) and a solvent probe radius of 1.6 Å (prbrad =
1.6) were used. For GB calculations, the igb parameter was set to 5 that corresponds to a modified GB
model equivalent to model II in reference. Pairwise free energy decomposition analysis was performed
using the MM/GBSA decomposition process by the MM/GBSA program in AMBER 14 to compute
the interaction between the inhibitors and each residue. For each of the tested compounds, the active
residues estimated from MM/GBSA decomposition process and the best GB score out of the trajectories
associated with the representative structures of the tubulin dimer were collected and are reported in
Table 3 and Figure 4.
3.8. Calculation clogP
We used the Molinspiration online database (http://www.molinspiration.com, free of charge) to
predict the clogP values for all synthesized compounds and collected them in Table 3 [76].
4. Conclusions
In an attempt to discover novel potent inhibitors of microtubule dynamics, eighteen novel double
modified colchicine analogs comprising methylamine substituent at position C10 of ring C and amide
or sulfonamide substituents at position C7 of ring B were successfully synthesized, purified and their
structures were confirmed by spectroscopic analyses as well as X-ray measurements. Four human
cancer cell lines (A549, MCF-7, LoVo, LoVo/DX) were used to evaluate the anticancer potency of all
synthesized compounds.
Compared with unmodified colchicine, the majority of its studied derivatives exhibited excellent
potency against A549, MCF-7, and LoVo cell lines. The antiproliferative activity of colchicine derivatives
was in the nanomolar range and they also were characterized by lower IC50 values also than doxorubicin
and cisplatin, commonly used as antitumor agents in cancer chemotherapy. The preliminary SAR
revealed that the type of substituent at position C7 in ring B and the presence of –NHCH3 group at
position C10 in ring C of colchicine 1 were of cardinal importance to the compounds’ cytotoxicity.
The calculated values of the selectivity index (SI) clearly show that it is possible to design more
selective compounds than colchicine 1. The most active double-modified colchicine derivatives were
the compounds that included chloroacetamide and dichloroacetamide (9, 10) and 2–chlorobenzamide
(13) moiety (Table 2). However, in vitro tests showed that they did not have high SI values (except
towards the LoVo cells) and in vivo testing should be carried out to determine their therapeutic potential.
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But of all tested compounds, 4,4,4-trifluorobutyric amide of 10-N-methylaminocolchicine 11 was the
most prominent. Compound 11 showed high activity towards A549, MCF7 and LoVo cell lines,
with antiproliferative IC50 values ranging between 10.4 and 14.6 nM as well as SI values higher than 5
for these three cell lines. The most selective towards MCF-7 cell line was compound 17 (SI was almost
10) and towards LoVo cell line the most selective were compounds 7, 9, 10, and 13 (SI were over 6).
So we conclude that the appropriate modification of colchicine molecule and synthesis of its analogs
might overcome the toxicity, which is a major challenge in designing a potential colchicine-based
drug candidate.
Compound 11 was subsequently identified as the that with potentially the best therapeutic index
and therefore the most promising candidate for further development, as it showed strong in vitro
anticancer activities with high SI against three human cancer cell lines. However, further in vivo
studies should be conducted for the successful development of this compound.
Molecular docking study showed the ability of the obtained colchicine derivatives to bind into the
active sites of βI-tubulin isotype with the well-defined binding modes. It is worthy to mention that
10-N-methylaminocolchicine based compounds serve as useful templates for the further development
of the anticancer and antimitotic agents. Further evaluation should help to find more detailed
structure-activity relationships of microtubule-targeting drugs and CBS inhibitors, which can help in
rational drug design in future.
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chromatogram and mass spectra of 17; Figure S47: The 1H NMR spectrum of 17 in CDCl3; Figure S48: The LC-MS
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4 Department of Electroradiology, Poznań University of Medical Sciences, Garbary 15, 61–866 Poznań, Poland
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Abstract: Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized
as very promising anticancer drug candidates due to their activity against various types of cancer
cells, including multidrug-resistant populations. Ovarian cancer is the deadliest among gynecologic
malignancies, which is connected with the development of chemoresistant forms of the disease in
over 70% of patients after initial treatment regimen. Thus, we decided to examine the anticancer
properties of SAL and selected SAL derivatives against a series of drug-sensitive (A2780, SK-OV-3)
and derived drug-resistant (A2780 CDDP, SK-OV-3 CDDP) ovarian cancer cell lines. Although
SAL analogs showed less promising IC50 values than SAL, they were identified as the antitumor
agents that significantly overcome the resistance to platinum-based drugs in ovarian cancer, more
potent than unmodified SAL and commonly used anticancer drugs—5-fluorouracil, gemcitabine,
and cisplatin. Moreover, when compared with SAL used alone, our experiments proved for the first
time increased selectivity of SAL-based dual therapy with 5-fluorouracil or gemcitabine, especially
towards A2780 cell line. Looking closer at the results, SAL acted synergistically with 5-fluorouracil
towards the drug-resistant A2780 cell line. Our results suggest that combinations of SAL with other
antineoplastics may become a new therapeutic option for patients with ovarian cancer.
Keywords: salinomycin; anticancer activity; overcoming drug resistance; tumor specificity; synergy;
5-fluorouracil; gemcitabine; amides/esters; ovarian cancer
1. Introduction
Despite developing new therapeutic strategies and extensive knowledge about tumor biology,
ovarian cancer (OvCa) remains a leading cause of mortality among gynecologic malignancies;
asymptomatic early stages and lack of ambiguous biomarkers enabling detection of the disease
lead to late diagnosis, mostly at stage III and IV [1,2]. Five-year overall survival for advanced
OvCa is approximately 30% [3]. Most of the patients respond well to radical surgery and either
neoadjuvant or adjuvant chemotherapy. However, 75% of patients develop recurrence [4]. Prognosis
for patients with the recurrent disease is poor, especially for those diagnosed with the recurrence
earlier than six months after completion of the initial platinum-based therapy [5]. This state is called
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platinum-resistance in opposition to platinum-sensitive patients who develop recurrence more than six
months after completion of the initial therapy. The intrinsic and acquired resistance to platinum-based
chemotherapy is the main reason for OvCa treatment failure [6,7].
A few theories have been proposed to explain the development of chemoresistance in human
malignancies. The most likely one is related to cancer stem cell theory [8]. According to this concept, a
malignant tumor consists of two populations of cells, namely cancer stem cells (CSCs) and differentiated
cells. Self-renewal, repopulation, and resistance to irradiation and cytotoxic drugs are typical of the
first narrow population. Contrary to that, differentiated cancer cells are sensitive to treatment and
form a bulk population of the tumor cells. CSCs, similarly to pluripotent stem cells, have active
developmental signaling pathways, such as Hedgehog, Notch, and Wnt/β-catenin. The latter two seem
to be particularly responsible for OvCa platinum resistance [9,10]. Unfortunately, there is no single
universal marker capable of distinguishing CSCs from the differentiated cancer cells. Such a marker
could help to develop a highly specific targeted therapy against CSCs, which would improve OvCa
patient outcome. Therefore, the main focus of OvCa therapies should be the elimination of CSCs. One
of the molecules exhibiting anticancer potential and selective properties against CSCs is salinomycin
(SAL, 1, Figure 1).
Figure 1. Structure of salinomycin and its derivatives studied in this work.
This is a monocarboxylic polyether antibiotic naturally synthesized by Streptomyces albus
(strain no. 80614) [11]. SAL was identified in 2009 as the most active agent among 16,000 compounds
tested towards breast CSCs [12]. Since then, SAL has been found effective against many other types of
cancer cells and CSCs, including those displaying multidrug resistance (MDR) and has been used in a
small group of patients with advanced carcinoma of the head, neck, breast, and ovary [13]. SAL acts
as a sensitizer of malignant cells to radiotherapy or chemotherapy, i.e., colchicine, doxorubicin, and
etoposide [14–17].
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2. Results
2.1. Derivation of Cisplatin-Resistant Cell Lines
To test the usefulness of SAL and its derivatives in overcoming cisplatin-resistance, chemoresistant
OvCa sub-cell lines were established. MTT and RT-qPCR followed the cell exposure to cisplatin to
confirm derivation of stable phenotype of the resistant cell lines. A2780 CDDP and SK-OV-3 CDDP
lines responded with morphological changes and increased IC50 against cisplatin as compared with
their parental population (Figure 2A,B). Both resistant cell lines showed also enhanced expression of
ABCB1, ABCG2, and ABCC2 versus control (Figure 2C,D). ABCB4 expression boosted significantly in
SK-OV-3 CDDP cell line but only slightly in A2780 CDDP cell line.
Figure 2. Overview of cisplatin-resistant ovarian cancer cell lines (A2780, SK-OV-3).
(A,B) Morphological changes of both drug-resistant cancer sub-lines represent enlargement and
slight spindle-like shape. Survival curves indicate increased IC50 for both resistant variants (RI = 18.08
for A2780; RI = 1.56 for SK-OV-3). The pictures were taken under 200×magnification. (C,D) RT-qPCR
analysis of A2780 and SK-OV-3 revealed significantly increased expression of ABC drug transporters in
derived resistant variants.
2.2. In Vitro Activity of Cytotoxic Drugs, Salinomycin, and Its Derivatives Against OvCa Cells
It was clearly proven that chemical modification of SAL and other polyether ionophores may not
only increase the biological activity of resulting derivatives but also reduce their general toxicity [18–21].
Furthermore, SAL with a modified C1 carboxyl group (amides or esters) transports cations by a
biomimetic mechanism, while chemically unmodified SAL transports cations through biological
membranes via an electroneutral mechanism [22,23]. This change in ionophoretic properties may result
in better biological properties of SAL analogs than of those with a native structure.
We devised a library of SAL derivatives based on the most active SAL amides and esters obtained
in our previous studies by a chemical modification of C1 carboxyl group, i.e., amides 2 and 3, as well
as esters 5 and 6, respectively (Figure 1) [18–20]. To expand structural diversity at C1 position and to
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better determine the structure-activity relationship (SAR), we additionally analyzed propargyl amide 4
and propargyl ester 7 (Figure 1), as these structures had shown promising bioactivity [19].
Data gathered in Table 1 indicate that all tested compounds exhibited biological activity against
malignant cells. The effect towards ovarian A2780 cell line was distinctly better than that against
metastatic ovarian SK-OV-3 cell line. Briefly, the most effective was chemically unmodified SAL, the
activity of which was higher against A2780 cell line and comparable against SK-OV-3 cell line than that
of reference anticancer drug—cisplatin (CDDP) (Table 1). In OvCa cell lines A2780, SK-OV-3 as well as
their platinum-resistant sub-lines, all semi-synthetic derivatives of SAL (both from amide and ester
series) needed significantly higher IC50 values to induce comparable biological effects than SAL itself
(Table 1). The most active SAL analog was 4-fluorophenethyl amide 3 (Figure 1) but still its activity was
one order of magnitude lower than that of unmodified SAL (Table 1). As expected, cisplatin-resistant
sub-lines were more resistant to CDDP than both cisplatin-sensitive variants; thus, the anticancer
activity of compounds 3 and 5 (Figure 1) was higher than that exhibited by CDDP towards A2780
CDDP cell line (Table 1).
However, to the best of our knowledge, there are no reports describing the effects of a dual
therapy using SAL and 5-fluorouracil (5FU) or gemcitabine (GEM) towards OvCa cells. Therefore, we
decided to check if SAL shows desired results when combined with these commonly used anticancer
drugs. For this purpose, we prepared 1:1 molar mixtures of SAL and 5FU/GEM (1 + 5FU and 1 +
GEM, respectively) and tested their activity towards OvCa cell lines (Table 1). Interestingly, in both
cases we witnessed a strong interaction between SAL and either 5FU or GEM. IC50 values for 1 +
5FU and 1 + GEM against all OvCa cell lines reached a low micromolar concentration range and
were significantly lower than those exhibited by individual components (1 and 5FU) and reference
anticancer drug—CDDP (Table 1). More promising (lower) IC50 values were only obtained for GEM
(Table 1), which is recommended for treatment of recurrent OvCa.
To determine the real therapeutic potential of novel anticancer drug candidates, it is necessary to
check their effects (selectivity) towards normal cells. Judging by IC50 values, the tests performed in
normal diploid human MRC-5 cell line suggested that all SAL derivatives were significantly less toxic
towards non-malignant human cells than the chemically unmodified SAL (Table 1).
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2.3. Salinomycin and Its Derivatives Overcome Cisplatin Resistance and are More Selective Against
Cisplatin-Resistant OvCa Cells
To assess the effectiveness of the studied drugs in overcoming acquired cisplatin resistance, we
calculated the resistance index (RI), based on the IC50 of derived cell lines (Figure 3A). The RI indicates
how many more times a resistant sub-line (either A2780 CDDP or SK-OV-3 CDDP) is chemoresistant
as compared with its parental cell line (either A2780 or SK-OV-3, respectively). An RI between 0 and 2
indicates that the cells are sensitive to the tested compound. An RI in the range from 2 to 10 means
that the cells show moderate sensitivity to a drug. An RI above 10 indicates strong drug resistance [24].
None of the cancer cell lines developed strong resistance to the tested agents under the combinatory
treatment of SAL with either 5FU or GEM (Figure 3A). Contrary to GEM, both 1 + 5FU and 1 + GEM
co-treatments were capable of efficiently overcoming the drug resistance of OvCa cells, as manifested
by considerably lower values of RI (Figure 3A).
Deeper analysis of RI parameters revealed that cancer cell line A2780, in opposition to SK-OV-3,
developed some resistance to SAL (Figure 3A). This finding may indicate possible treatment failure on
SAL clinical application. On the other hand, almost no SAL derivatives (except for 6 and 7) developed
even mild resistance during our experiments in both OvCa cell lines (Figure 3A). Generally, A2780
and SK-OV-3 cell lines turned out more sensitive to amide analogs of SAL (compounds 2–4) than the
corresponding ester derivatives (compounds 6–7). The only exception to this rule was ester 5 (RI = 0.30
and RI = 0.50 for A2780 and SK-OV-3 cell line, respectively) (Figure 3A).
Figure 3. Calculated values of (A) the resistance indexes (RI), and (B) selectivity indexes (SI) of the
tested compounds.
Further, to establish therapeutic potential of the tested anticancer agents, we used the difference
in the antiproliferative activity towards the OvCa cell lines and the corresponding normal cell line to
calculate the values of the selectivity index (SI) (Figure 3B). The SI is an important pharmaceutical
parameter that facilitates the estimation of possible future clinical development; higher values of SI
indicate greater anticancer specificity, and the compounds displaying an SI above 3.0 are considered
highly selective agents [21,25]. Therefore, our study clearly proved that normal cells were less sensitive
to SAL used alone or its combinations with other cytotoxic agents (5FU or GEM) than to amide and
ester derivatives of SAL (Figure 3B).
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Selectivity of SAL as well as its amide and ester analogs was very promising, especially in
non-resistant and resistant to cisplatin A2780 cell lines (Figure 3B). However, the highest values of
SI were noted for SAL and its 1:1 molar mixture with GEM (1 + GEM, Figure 3B), and this effect
decreased with time of exposure to the anticancer agents. On the other hand, SAL turned out more
selective against SK-OV-3 cell line and its platinum-resistant variant than all analyzed amide and ester
derivatives (Figure 3B). A combinatory treatment of OvCa cells involving SAL and GEM (1 + GEM,
Figure 3B) yielded very high SI values. The combination of the cytotoxic agents (regardless of their
mechanism of anticancer action), either 5FU or GEM, with SAL was more effective than SAL or its
derivatives used alone (Table 1 and Figure 3).
As OvCa cells seemed highly sensitive to the action of both 1 + 5FU and 1 + GEM (Table 1 and
Figure 3), we decided to determine the exact effect (addictive, synergistic, or antagonistic) of the specific
compound combinations. Using the 1:1 molar mixtures of SAL and 5FU or GEM, we performed
standard viability assays and subjected the results to the analysis and determination of values of
the combination indexes (CI) (Table 2). As previously described for a pair of drugs [26,27], CI > 1.3
indicates antagonism, CI = 1.1–1.3 indicates moderate antagonism, CI = 0.9–1.1 indicates additive
effect, CI = 0.8–0.9 indicates slight synergism, CI = 0.6–0.8 indicates moderate synergism, CI = 0.4–0.6
indicates synergism, and CI = 0.2–0.4 indicates strong synergism. Interestingly, the results presented
in Table 2 indicated that SAL in combination with 5FU acted synergistically (CI = 0.56) in A2780
CDDP cell line, whereas in SK-OV-3 and SK-OV-3 CDDP cell lines, they only showed an additive effect
(CI = 1.09 and CI = 1.02, respectively).
Table 2. Calculated combination index (CI) values of simultaneously delivered salinomycin (SAL, 1)
and cytotoxic drugs (5-fluorouracil 5FU, gemcitabine GEM) in the 1:1 molar mixtures.
Combination of Compounds A2780 A2780 CDDP SK-OV-3 SK-OV-3 CDDP
1+5FU 1.57 0.56 1.09 1.02
1+GEM 2.86 1.60 691 360
After a primary screening of the compounds, SAL and its amides indicated in both OvCa cell
lines variants the most promising response. To confirm their effect, Western blot analysis for B-cell
lymphoma 2 (Bcl2), Bcl2 associated X protein (Bax), and caspase-3 (CASP3) was performed (Figure 4).
Figure 4. Western blot analysis of OvCa cell lines exposed to IC50 values of selected compounds for 72 h
(A–D). The expression of anti-apoptotic (Bcl2) and apoptotic proteins (Bax and CASP3) was evaluated.
The numbers describe the quantified level of band intensity normalized to expression of reference
protein GAPDH and the control population.
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In A2780 cells, the Bcl2 decreased in all groups in comparison with the control (Figure 4A). The
lowest expression was observed in the GEM and 1 + GEM variant, but their effect was similar. The
proapoptotic protein Bax also represented similar trends of expression as Bcl2. Interestingly, full
form of caspase-3 (CASP3) was decreased in cells treated with SAL, 5FU, and their combination,
but GEM and its combination with SAL, as well as amide derivatives of SAL, caused the enhanced
expression of that protein. The antagonistic effect of combined SAL with 5FU or GEM was observed
by decreasing expression of CASP3. In case of the A2780 CDDP variant, Bcl2 expression in cells
treated with SAL, 1 + 5FU, GEM, and 1 + GEM was decreased (Figure 4B). Surprisingly, the SAL
amides (3–5) caused increased Bcl2 expression. It is worth mentioning that a combination of 5FU with
SAL caused downregulation of Bcl2. In all tested compounds the expression of Bax was inhibited
in comparison with the control. Among them, a combination of SAL with 5FU caused decreased
expression of Bax compared to 5FU alone. A similar effect onto Bax expression was observed in the
GEM and its combination with SAL. In A2780 CDDP cell line, CASP3 expression in SAL and 5FU
was decreased, and their combination caused a similar effect in comparison to control. However, the
expression of that protein in GEM, 1 + GEM, 3, 4, and 5 variants was enhanced in comparison with the
control. The combination of SAL with 5FU caused the enhanced expression of the full form of CASP3,
which confirmed synergistic action of these compounds. On the other hand, the antagonistic effect
was observed in GEM and its combination with SAL, where the cytotoxic effect was enhanced in only
GEM-treated cells.
In SK-OV-3 cell line, Bcl2 expression was decreased in all studied compounds, except amide 4,
compared to control (Figure 4C). Among them, SAL, 5FU, and 1+GEM showed the lowest expression.
All tested compounds indicated decreased expression of Bax in comparison with control. The
combination of SAL and 5FU did not cause the upregulation of these proteins exciding the level
of compounds tested alone. The GEM indicated the highest expression level of Bax among tested
molecules. Amide derivatives of SAL did not indicate increased expression of Bax in comparison with
SAL. The similar tendencies of CASP3 expression were observed, excluding compound 2 and 3, which
exhibited its higher expression in comparison with SAL. These observations confirmed the antagonistic
effect in studied combinations of antineoplastic agents with SAL. In the case of SK-OV-3 CDDP cell
line exposed to distinct molecules, the expression of Bcl2 only in SAL and SAL combined with 5FU
was upregulated in comparison with the control (Figure 4D). Only the combination of SAL with GEM
caused enhanced downregulation of Bcl-2 compared to exposition to them alone. Bax expression in
those cells was decreased in comparison with the control. Among tested variants, 1 + 5FU exceeded the
level of its expression compared to 5FU, but not to SAL alone. Again, GEM used separately induced its
highest expression among all exposed compounds. The amide derivatives of SAL indicated lower
expression of Bax in comparison with SAL. The presence of Bax downregulation in cells exposed to
a combination of antineoplastics with SAL confirmed their antagonism. The expression of CASP3
and the action of compounds co-cultured with SK-OV-3 CDDP cells was similar to that of Bax. These
results confirmed earlier estimated effects of combined SAL with 5FU or GEM in studied cell lines.
3. Discussion
One of the major problems in ovarian cancer (OvCa) treatment is development of chemoresistant
residual cancer cells. Cancer stem cell (CSC)-targeted therapies should thus be developed [5]. One of
the promising compounds in this respect is salinomycin (SAL). Its short-lasting side effects and low
solubility in aqueous solutions may be avoided by some chemical modifications. These modifications
provide new SAL molecules with improved stability and unaffected selective properties against CSCs,
particularly effective in overcoming chemoresistant forms of the disease [28,29]. However, the synthesis
of selective SAL derivatives is complicated due to the presence of multiple functional groups and a
sensitive tricyclic 6-6-5 bis-spiroketal ring system in SAL structure [20,29,30].
In this study, we derived cisplatin-resistant cell lines A2780 CDDP and SK-OV-3 CDDP and
evaluated the antiproliferative activity of selected amides and esters of SAL, as well as SAL used
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alone or in combination with other commonly used cytostatic agents, such as 5-fluorouracil (5FU) and
gemcitabine (GEM), against these OvCa cells. To confirm the observed effect, Western blot analysis of
proteins related to apoptosis (Bcl2, Bax and CASP3) was also performed.
We obtained resistant variants of cancer cell lines, as confirmed by increased IC50 against cisplatin
estimated by MTT assay. These variants also showed elevated expression of genes related to drug
transporters. ABCB1, ABCB4, ABCG2, and ABCC2 are well-described markers of drug resistance
development in many cancers [31–35]. These proteins are characteristic of side populations of cells
that represent stem-cell-like features, and in some cancers, they are recognized as markers of CSCs.
They are responsible for active efflux of many anticancer agents causing treatment failure [35–37].
Our experiments provided interesting data regarding the activity of SAL and its derivatives
against platinum resistance developed in OvCa cell lines in vitro. Creation of platinum-resistant
OvCa cell line (SK-OV-3) did not induce the resistance of cancer cells to the action of SAL and its
derivatives. This indicated that different molecular mechanisms are responsible for either platinum
or SAL resistance, and additionally SAL could be identified as an effective agent in overcoming the
platinum resistance of OvCa cells. However, A2780 CDDP variant exhibited moderate sensitivity to
SAL and its 2,2,2-trifluoroethyl ester derivative (compound 6, Figure 1). This phenomenon could
be related to the increased expression of ABCB1 and ABCG2 in resistant variants of A2780 cancer
cell line. A study by the Boesch group revealed that in OvCa cell lines (A2780, IGROV1), selected
ABCB1 and ABCG2 positive cells exhibited protective mechanisms against ionophore antibiotics,
including SAL [38]. Contrary to that, a study in 2010 demonstrated that SAL treatments restored
doxorubicin sensitivity in human doxorubicin-resistant epithelial OvCa cell line (A2780/ADR) exposed
to doxorubicin either alone or in combination with SAL by inhibition of ABCB1 functionality [39].
Disparate results of these studies might be related to distinct co-activation of a group of genes in the
same chromosomal region, where ABCB1 activation occurs by various cytotoxic agents [31].
Our experiments did not confirm the high anticancer activity of SAL derivatives reported recently
in primary acute lymphoblastic leukemia (ALL) cells [20,40], which may be caused by a different type
of malignancies and their adverse biology; ALL represents a hematological malignancy, while OvCa
represents a malignant solid tumor. Until now, there have been only limited data showing the effects of
SAL and its derivatives on OvCa cells. The recent data indicated that SAL itself affects a wide spectrum
of mechanisms against OvCa biology, such as inhibition of the epithelial-mesenchymal transition (EMT)
process (responsible for the development of metastatic disease), eradication of the CSC population
(CD44+CD117+), and inhibition of the NF-kB signaling pathway (upregulation of proteins related to
that pathway correspond with poor clinical prognosis in OvCa) [41–44]. Our study, for the first time,
demonstrates that the combination of SAL with cytostatic agents (5FU and GEM) is more effective than
SAL used alone or its amide and ester derivatives. 5FU is not commonly used in OvCa treatment—a
few clinical trials revealed no significant improvement in clinical outcomes in advanced OvCa patients
receiving 5FU combined with cisplatin or leucovorin [45–47]. Of note is that SAL acted synergistically
with 5FU towards drug-resistant A2780 OvCa cell line. A similar effect was presented in studies
concerning colorectal and hepatocellular carcinoma, which indicated the neutral or synergistic effect of
the combination of SAL and 5FU [48,49]. In case of GEM, which is mostly used as a secondary line of
chemotherapy after the development of resistant disease in OvCa, we did not observe the synergistic
effect of combined SAL and GEM in both OvCa cell lines, as was found over their action in pancreatic
carcinoma cell lines [50,51]. We think that one of the causes was their high molar ratio 1:1 used in our
study versus 5 μM concentration of SAL and 5 μg·mL−1 applied in the pancreatic cancer cell lines [51].
The differences between the observed effects of these two nucleoside analogs in combination with
SAL might be related to a disturbance of their cellular uptake by an ion imbalance caused by SAL.
The concentrative nucleoside transporters (CNT) and equilibrative nucleoside transporters (ENT) are
mostly engaged in the transport of GEM, while for 5FU, only ENT proteins are involved [52–55]. The
mechanism of nucleoside transport by CNT proteins is Na+-dependent, whereas in the case of ENT,
they are mediated by facilitated diffusion [53,54]. SAL is responsible for the transport of potassium
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and sodium cations, which could lead to disturbance of the GEM uptake through CNT transporters
(indicating high affinity to GEM), decreasing its activity against cancer cells [29,54,55].
The effect of combination of SAL with GEM or 5FU was confirmed by Western blot analysis
of proteins related to apoptosis (Bcl2, Bax, and CASP3). Besides the same IC50 effect at distinct
concentrations of studied compounds, SAL amide derivatives (3–5) caused enhanced expression of
CASP3 in A2780 and A2780 CDDP cell lines, which could suggest different or more effective induction
of apoptosis by these molecules. We did not observe a similar effect in SK-OV-3 cells, which could be
related to intrinsic resistance mechanisms due to their metastatic origin. However, there is a lack of
detailed mechanistic studies explaining the differences between SAL and amide derivatives against
OvCa cell biology; thus, their further detailed characterization of action should be performed. On the
other hand, for SAL used alone, we obtained similar findings as the Parajuli group, where the A2780
CDDP variant was tested, and a decrease of the Bcl2, Bax, and CASP3 was noted at similar doses that
we used in our study; however, in their study, only after 1 μM of SAL, caspases were significantly
increased [44,56]. They also indicated that the cause of apoptosis is related to activation of death
receptor 5 (DR5) pathway, which was observed even at low doses of SAL (0.5 μM) [56]. In contrast, the
Kaplan group observed induction of apoptosis by upregulation of CASP3 in OVCAR3 cell line even at
0.1 μM of SAL [57].
In summary, all findings mentioned above corresponded well with our results. Potent anticancer
activity of SAL, lack of SAL resistance in platinum-resistant OvCa cell lines, and reversible SAL
resistance imply the possible application of SAL in overcoming either primary or acquired platinum
resistance (in platinum-resistant cell lines/patients). Further analyses of the SAL treatment used alone
or in combination with other anticancer drugs, such as 5FU and GEM, will require identification of
the most effective combination of SAL and the cytotoxic agent, and the mode of their administration
(synchronous or sequential). Our results may contribute to the development of anticancer therapy
based on SAL, which may give hope for heavily treated OvCa patients. Further studies should focus
on discovering the mechanisms of action for SAL and its derivatives.
4. Materials and Methods
4.1. Chemical Part
4.1.1. Isolation of Salinomycin
Salinomycin sodium salt was isolated from commercially available veterinary premix SACOX®
following acidic extraction, using the previously described procedure [18,19]. Briefly, isolated sodium
salt of salinomycin was dissolved in CH2Cl2 and stirred vigorously with a layer of aqueous sulfuric
acid (pH = 1.0). The organic layer containing salinomycin (SAL, 1, Figure 1) was washed with distilled
water. Then, CH2Cl2 was evaporated under reduced pressure to dryness giving SAL as clear oil. After
three cycles of evaporation with n-pentane, this oil was transformed into white amorphous solid.
Spectroscopic data for SAL were closely matched previously published data [22].
4.1.2. Synthesis of Salinomycin Derivatives
All SAL amides and esters (compounds 2–7, Figure 1) obtained by a chemical modification of
the C1 carboxyl group were prepared according to the procedures we described previously [18,19].
Spectroscopic data of all the compounds matched those found in the reference literature [18,19].
4.2. Biological Part
4.2.1. Cell Culture and Derivation of Cisplatin-Resistant Cell Lines
In this study, OvCa cell lines A2780 and SK-OV-3 (ATCC, Manassas, VA, USA) and human fetal
lung fibroblasts cell line (MRC-5 pd19; ECACC, Salisbury, United Kingdom) were used to evaluate
the antiproliferative activity of the tested compounds. OvCa cell lines were cultivated in RPMI 1640
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containing 25 mM HEPES and 5 mM l-glutamine with 10% fetal bovine serum (FBS) (all provided
from Biowest, Nuaillé, France) and 1% penicillin-streptomycin (Merck KGaA, Darmstadt, Germany).
MRC-5 pd19 was cultured in DMEM supplemented with 10% FBS, 2 mM l-glutamine (all provided
from Biowest, Nuaillé, France), 1% penicillin-streptomycin and 1% non-essential amino acids (NEAA)
(both provided from Merck KGa, Darmstadt, Germany). To generate the cisplatin-resistant cell lines
(A2780 CDDP; SK-OV-3 CDDP), increasing doses of cisplatin (CDDP) (Teva Pharmaceutical Industries
Ltd. Petach Tikwa, Israel) were added to the culture medium, starting from the concentration of
100 ng mL−1. Then, the cells were exposed to CDDP (3 cycles of 3 days each). After that, the cell
culture medium was replaced with the fresh one without drugs for the next 3 days or one week until
the cells recovered. After the 3 cycles, the dose of cisplatin was doubled until the concentration of
1000 ng·mL−1 was achieved. Then, to maintain a resistant phenotype, 1000 ng·mL−1 of CDDP was
added once per 2 weeks for 3 days.
4.2.2. Isolation of RNA and RT-qPCR
The cells (2.5 × 105) were washed twice in Dulbecco’s phosphate buffered saline (DPBS, Biowest,
Nuaillé, France) and suspended in TRI reagent (Sigma-Aldrich, St. Louis, MO, USA). Next, RNA
was isolated using Direct-zol RNA MiniPrep (Zymoresearch, Irvine, CA, USA) according to the
manufacturer’s instructions. Then 1 μg of RNA was collected to synthesize cDNA using iScript
kit (BioRAD, Hercules, CA, USA). The cDNA was diluted 20 times, and 2.5 μL was added to the
reaction mix composed of FastStart Essential DNA Probes Mix and specific probes (both provided
by Roche Molecular Systems, Inc, Basel, Switzerland). The RT-qPCR reaction was performed as
previously described [58]. The tested genes related to drug resistance included: ATP-binding cassette
subfamily B member 1 (ABCB1), ATP-binding cassette subfamily B member 4 (ABCB4), ATP-binding
cassette subfamily G member 2 (ABCG2), and ATP-binding cassette subfamily C member 2 (ABCC2).
Relative gene expression level was determined using reference gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The primers and molecular probes used in this study are listed in Table S1
(Supplementary Material).
4.2.3. Cell Viability Assay
For the evaluation of cell proliferation inhibition, we used the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previously described [59].
Briefly, A2780 WT and CDDP (2000 cells/well), SK-OV-3 WT and CDDP (800 cells/well), and MRC-5
pd19 (3000 cells/well) were seeded onto a 96-well plate for overnight until the cells attached. Next, the
cells were exposed to the estimated concentrations of SAL, its derivatives, and anticancer drugs for
72 h (Table S2, Supplementary Material). Then the cell culture medium was replaced with the fresh
one containing 0.5 mg·mL−1 of MTT (Affymetrix, Santa Clara, MA, USA) and left for 2 h at 37 ◦C. After
that, the medium was replaced with DMSO (VWR, Darmstadt, Germany) and left at 37 ◦C for 10 min
until the crystals were dissolved. The measurement was performed with a plate reader, Multiskan FC
(Thermofisher, San Jose CA, USA) at 570 and 690 nm. Then, IC50 and mean 95% CI were determined
using GraphPad Prism 6 (Graph Pad Software, San Diego, CA, USA). The values of resistance index
(RI), selectivity index (SI), and combination index (CI) were calculated as described previously [20,60].
4.2.4. Western Blot Analysis
After 72 h of exposure to IC50 concentration of selected compounds, the OvCa cell lines were lysed
using RIPA lysing buffer (Sigma Aldrich, St. Louis, MO, USA). For analysis, 10 μg of protein was used,
calculated using Pierce™ BCA Protein Assay Kit (Thermofisher, San Jose, CA, USA) according to the
manufacturer’s instructions. The procedure was performed as previously described [52]. Briefly, after
electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) membrane. After 2 h
of blocking with non-fat milk (Sigma Aldrich, St. Louis, MO, USA), the membrane was incubated
overnight at 4 ◦C with primary antibodies: anti-Bcl-2 (dilution 1:500; sc-509, Santa Cruz, Dallas, TX,
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USA), anti-Bax (dilution 1:500; sc-7480, Santa Cruz, Dallas, TX, USA), anti-CASP3 (full-form)(dilution
1:1000; no. ab49822, Abcam, Cambridge, UK), and reference protein GAPDH (dilution 1:500; no.
sc-47724, Santa Cruz, Dallas, TX, USA). On the next day, after washes, the membranes were incubated
with appropriate secondary antibodies conjugated with horseradish peroxidase (HRP) (dilution 1:1000;
no. 7076 and 7074, Cell Signaling Technology, Leiden, Netherlands). Then the protein bands were
visualized using WesternBright™ Quantum kit (Advansta, San Jose, CA, USA) and documented using
the ChemiDoc Touch Imaging System (Bio-Rad Laboratories Ltd., Hercules, CA, USA). The intensity
was measured using Image Lab Software (ver 6.0.1, Bio-Rad Laboratories Ltd., CA, USA). All buffers
and equipment used during Western blot analysis were provided from Bio-Rad Laboratories Ltd.,
CA, USA.
4.2.5. Statistical Analysis
The statistical analysis of genes expression (Student’s t-test) was performed using GraphPadPrism
6 package (Graph Pad Software, San Diego, CA, USA). The data were deemed significant at p < 0.05.
All experiments were repeated at least three times.
Supplementary Materials: The following are available online, Table S1: List of primers used in this study, Table
S2: Concentration of drugs, dilution range, and serial dilution factors used in this study.
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23. Antonenko, Y.N.; Rokitskaya, T.I.; Huczyński, A. Electrogenic and nonelectrogenic ion fluxes across lipid
and mitochondrial membranes mediated by monensin and monensin ethyl ester. Biochim. Biophys. Acta -
Biomembr. 2015, 1848, 995–1004. [CrossRef] [PubMed]
24. Harker, W.G.; Slade, D.L.; Dalton, W.S.; Meltzer, P.S.; Trent, J.M. Multidrug resistance in mitoxantrone-selected
HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989, 49, 4542–4549.
[PubMed]
25. Badisa, R.B.; Darling-Reed, S.F.; Joseph, P.; Cooperwood, J.S.; Latinwo, L.M.; Goodman, C.B. Selective
cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res.
2009, 29, 2993–2996.
26. Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method.
Cancer Res. 2010, 70, 440–446. [CrossRef]
27. Ichite, N.; Chougule, M.B.; Jackson, T.; Fulzele, S.V.; Safe, S.; Singh, M. Enhancement of Docetaxel Anticancer
Activity by a Novel Diindolylmethane Compound in Human Non-Small Cell Lung Cancer. Clin. Cancer Res.
2009, 15, 543–552. [CrossRef]
28. Dewangan, J.; Srivastava, S.; Rath, S.K. Salinomycin: A new paradigm in cancer therapy. Tumor Biol. 2017,
39, 101042831769503. [CrossRef]
29. Piperno, A.; Marrazzo, A.; Scala, A.; Rescifina, A. Chemistry and biology of salinomycin and its analogues.
salinomycin and its analogues. In Targets In Heterocyclic Systems; Attanasi, O.A., Merino, P., Spinelli, D., Eds.;
Società Chimica Italiana: Rome, Italy, 2015; Volume 19, pp. 177–213.
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Abstract: Multidrug resistance (MDR) that occurs in cancer cells constitutes one of the major reasons
for chemotherapy failure. The main molecular mechanism of MDR is overexpression of protein
transporters from the ATP-binding cassette (ABC) superfamily, such as ABCB1 (multidrug resistance
protein 1 (MDR1), P-glycoprotein). At the expense of ATP hydrolysis, ABCB1 pumps a diverse
range of substrates (including anticancer drugs) out of the cell, thereby reducing their intracellular
concentration. In the present study, the ability of two patented disiloxanes (SILA-409 and SILA-421) to
reverse drug resistance in human colon adenocarcinoma cell lines LoVo and LoVo/Dx was investigated.
It was demonstrated that both compounds in concentrations of 0.5–1 μM strongly increased the
sensitivity of LoVo/Dx cells to doxorubicin. By means of an accumulation test in which rhodamine
123 was used as an ABCB1 substrate analogue, both organosilicon compounds were also shown to
inhibit ABCB1 transport activity. The intracellular accumulation of doxorubicin was also increased,
and more drug entered the cellular nuclei of resistant cells in the presence of the studied compounds.
In conclusion, both SILA-409 and SILA-421 were demonstrated to be effective MDR reversal agents in
resistant human colon cancer cells.
Keywords: organosilicon compounds; SILA-409 (Alis-409); SILA-421 (Alis-421); multidrug resistance
(MDR) reversal; ABCB1 (P-glycoprotein); colon cancer
1. Introduction
Since chemotherapy continues to be a method of choice for the treatment of various types of
cancer, any factors that undermine its effectiveness constitute a serious therapeutic issue. In the
majority of patients, the initial response to chemotherapy is satisfactory; however, the occurrence of
multidrug resistance (MDR) during treatment results in a development of progressive disease [1,2].
Cells displaying the MDR phenotype are no longer vulnerable to cytotoxic actions of many functionally
and structurally dissimilar anti-cancer drugs.
Among several mechanisms that may lead to the development of MDR, the overexpression of
ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein, MDR1: multidrug resistance
protein 1), ABCC1 (MRP1: multidrug resistance-associated protein 1), and ABCG2 (BCRP: breast
cancer resistance protein) proteins seems to prevail [3,4]. It was recently reported that non-ABC
transporters such as Hedgehog receptor Patched were also engaged in doxorubicin (Dox) efflux and
conferred Dox resistance to cancer cells [5,6]. ABCB1 is a transporter that utilizes the energy gained
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from the hydrolysis of ATP to pump many structurally variable substrates (including xenobiotics and
chemotherapeutics) out of the cell [7]. Among the numerous strategies proposed to overcome MDR,
the most basic approach is the idea to use the inhibitor of a multidrug transporter (MDR modulator)
along with chemotherapy in hopes to increase the intracellular accumulation of an anti-cancer drug
and to improve the outcome of the treatment. Although this approach is yet to result in any clinical
success [8–10], the search for new substances that could serve as clinically applicable MDR modulators
is continuously ongoing.
Silicon is a metalloid, which is a group of chemical elements also called semi-metals [11]. It can
form chemical bonds with carbon and oxygen, and silicon-containing compounds are widely used in
medicine and engineering. Silicone is a synthetic polymer composed of repeating siloxane units. Due
to its high biocompatibility and favorable mechanical properties, silicone is used for the production of
various medical implants (e.g., breast or testicle), as well as contact lenses [11]. On the other hand, silica
materials are applied as controlled drug delivery systems and three-dimensional scaffolds for tissue
engineering [11]. The introduction of a silicon atom to a structure usually yields a molecule of higher
lipophilicity than its carbon analogue. The increased anti-cancer activity of silicon–indomethacin
derivatives was recorded, and it was claimed that the higher lipophilicity of silicon derivatives resulted
in their increased uptake by cancer cells [12]. New sila-organosulfur compounds were recently
synthesized that were reported to be effective anti-cancer and antibacterial agents [13].
SILA-409 and SILA-421 are water-soluble disiloxanes that were synthesized and patented as
putative MDR modulators [14]. They were previously demonstrated to increase fluorescent dye
accumulation in human ABCB1 gene-transfected mouse lymphoma cells and, to much lesser extent,
in colon carcinoma Colo320/MDR1-LRP cells, but not in ABCC1 expressing breast cancer (HTB-26/MRP1)
and stomach cancer (257P/MDR) cells, which was attributed to their specific interactions with the
ABCB1 transporter [15]. The specificity of disiloxanes toward ABCB1 was corroborated in a study by
Kars et al. conducted in a model system of breast cancer cells [16]. Recently, the synergism between
disiloxanes and amyloid β-protein in the inhibition of ABCB1 transporter activity was reported [17].
In an in vivo study on mice bearing human pancreatic cancer xenografts, the application of SILA-409
resulted in the reduction of tumor growth that was accompanied by increased apoptosis and a reduced
level of ABCB1 protein in cancer cells [18]. SILA-421 was found to cause cell-cycle arrest and apoptosis
in several non-MDR cancer cell lines [19]. The analysis of the global gene expression profile of HL-60
leukemia cells treated with this compound revealed multiple cellular pathways affected by SILA-421,
including DNA replication and transcription processes. Interference with these processes was also
attributed to the antimicrobial activity of SILA-409 and SILA-421 compounds [20–22], as well as their
ability to eliminate resistance-bearing plasmids from Escherichia coli strains [23]. Additionally, the weak
chemopreventive activity of disiloxanes was reported both in vitro and in vivo [24].
In the present work, the ability of SILA-409 and SILA-421 to reverse Dox resistance in human
adenocarcinoma cells LoVo/Dx was demonstrated. The disiloxanes inhibited the transport function of
ABCB1 protein both in LoVo/Dx cells and in Madin-Darby Canine Kidney (MDCK) cells expressing
human ABCB1 (MDCK-MDR1). The amount of Dox accumulated inside LoVo/Dx cells was also
elevated in the presence of studied compounds, and its distribution pattern was changed.
2. Results and Discussion
2.1. Cytotoxicity of Disiloxanes
A human adenocarcinoma cell line sensitive to Dox (LoVo) and its Dox-resistant counterpart
(LoVo/Dx) were employed as a model system. It was previously demonstrated that the increased
expression of ABCB1 transporter is mainly responsible for the resistance of LoVo/Dx cells [25].
The cytotoxicity of both SILA-409 and SILA-421 to LoVo and LoVo/Dx cells was comparable (Figure 1).
Both compounds were strongly cytotoxic to the cells in concentrations above 10 μM. The half maximal
inhibitory concentration (IC50) values of SILA-409 were 15.6 μM and 24.6 μM for LoVo and LoVo/Dx
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cells, respectively. For SILA-421, IC50 values were 8.4 μM in LoVo cells and 9.2 μM in LoVo/Dx cells.
SILA-421 was more toxic than SILA-409, which might be the result of the higher lipophilicity of
this compound.
Figure 1. Cytotoxicity of SILA-409 (A) and SILA-421 (B) to LoVo (open symbols) and LoVo/Dx cells
(full symbols). Means of three experiments ± SD are presented.
The cytotoxicity of both disiloxanes to MDCK cells and MDCK transfected with human ABCB1 gene
(MDCK-MDR1) was similar (Figure S1, Supplementary Materials). Both compounds in concentrations
below 5 μM slightly stimulated cell growth, whereas, in concentrations of 25 μM and higher, <10% of
cells survived. IC50 values of SILA-409 in MDCK and MDCK-MDR1 cells were 14.2 μM and 13.9 μM,
respectively. For SILA-421, the values of 11.6 μM and 12.1 μM were analogously recorded. Similarly to
the findings in colon cancer cells, IC50 values for SILA-421 were slightly lower than those for SILA-409.
The cytotoxicity of the studied disiloxanes to various cancer cell lines reported previously [15,19]
was similar to the results of the present study. The IC50 values of SILA-421 analyzed in several various
cancer cell lines, as well as in normal cells HEK-293, lay within the range 5–35 μM [19]. In another
study, the cytotoxicity of both SILA-409 and SILA-421 was assessed in a panel of multidrug resistant
cancer cell lines of different patterns of expression of MDR-associated transporters [15]. IC50 values
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varied from 8–80 μM depending on cell line. In three out of five cell lines studied, SILA-421 was found
to be slightly more cytotoxic than SILA-409.
The analysis of the disiloxanes’ chemical structures (Figure S3, Supplementary Materials) and
the calculation of their theoretical logP values, performed using the free web tool Molinspiration
(https://www.molinspiration.com/cgi-bin/properties), demonstrated that SILA-421 was more lipophilic
than SILA-409 (logP values were 5.83 and 9.60 for SILA-409 and SILA-421, respectively). Lipophilicity
was observed to positively correlate with the antiproliferative activity of various compounds toward
cancer cells [26,27]. However, in other experimental settings, molecular parameters other than
lipophilicity were found to affect cytotoxicity to the highest extent [28,29]. Therefore, a larger series
of disiloxanes and a characterization of more of their molecular descriptors would be required to
determine the effect of lipophilicity on the biological activity of these compounds.
2.2. Influence of Disiloxanes on Doxorubicin Cytotoxicity
Next, the influence of the studied modulators on Dox cytotoxicity was investigated (Figure 2).
SILA-409 and SILA-421 were applied in concentrations in which they killed <10% of LoVo/Dx cells.
The treatment of cells with a combination of either SILA-409 or SILA-421 with Dox significantly reduced
the survival rate of resistant colon cancer cells, i.e., the disiloxanes partially reversed Dox resistance.
Non-toxic concentrations of SILA-409 and SILA-421 were applied together with doxorubicin. Sensitive
LoVo cells were more vulnerable to this anticancer drug (IC50 Dox= 4.0μM) than ABCB1-overexpressing
LoVo/Dx cells (IC50 Dox = 30.0 μM) [30]. It was demonstrated that both compounds strongly increased
the sensitivity of LoVo/Dx cells to doxorubicin without changing the sensitivity of LoVo cells to
this drug. The value of IC50 for Dox was reduced to 5.7 μM in the presence of SILA-409 at 0.5 μM
concentration, and to 6.1 μM in the presence of SILA-421 (1 μM). The isobolographic analysis applied
to the obtained results revealed the existence of synergism between Dox and each of the studied
disiloxanes (Table 1).
Table 1. Combination of disiloxanes with Dox against LoVo/Dx cell growth.
Concentration (μM) Ratio Combination Index
Dox SILA-409
8.62 0.5 17.24:1 0.7772
17.24 0.5 34.48:1 0.6136
SILA-421
8.62 1 8.62:1 0.6467
17.24 1 17.24:1 0.5632
Dose and effect data were obtained from the sulforhodamine B (SRB) assay (mean values of three experiments) and
subjected to CompuSyn analysis. CI (combination index) values were generated by CompuSyn software. CI = 1
indicates additive effect, CI < 1 indicates synergism, and CI > 1 indicates antagonism.
374
Molecules 2020, 25, 1654
Figure 2. The changes in doxorubicin (Dox) cytotoxicity in LoVo (circles) and LoVo/Dx cells (squares)
caused by SILA-409 at 0.5 μM (A) and SILA-421 at 1 μM (B). Open symbols represent cells treated with
Dox only, whereas full symbols represent cells treated with Dox and the modulator. Means of three
experiments ± SD are presented.
The reduction of Dox cytotoxicity by SILA-409 and SILA 421 was previously observed in human
ABCB1 gene-transfected mouse lymphoma cells (L5718/MDR) and the resistant colon cancer cell line
(Colo320/MDR1-LRP) [15]. Synergism between disiloxanes and Dox was observed in these cell lines
but not in breast cancer cell lines MCF-7, T47-D, and HTB-26/MRP1. The authors concluded that
the presence of a functional ABCB1 transporter was essential for disiloxanes to be able to revert Dox
resistance [15]. This pointed to the specific interactions between SILA-409 and SILA-421 and ABCB1
protein. Similar synergistic interactions with appropriate anticancer drugs were also observed for
SILA-409 and SILA-421 in MCF-7 cell lines resistant to paclitaxel and docetaxel, but not in the sublines
resistant to Dox and vincristine [16].
Dox cytotoxicity was significantly lower (p < 0.05) in LoVo/Dx than in LoVo cells as determined by
Student’s t-test. Significant enhancement (p < 0.05) of Dox cytotoxicity was recorded for both SILA-409
and SILA-421in LoVo/Dx cells in the whole concentration range
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2.3. Intracellular Accumulation of Rhodamine 123 (R123)
Rhodamine 123 (R123) is popularly used as a fluorescent reporter substrate of the ABCB1
transporter. Both SILA-409 and SILA-421 caused an increase in R123 accumulation in LoVo/Dx and
MDCK-MDR1 cells (Figure 3) in a concentration-dependent manner, which suggested that both
compounds were inhibitors of ABCB1 transport activity. SILA-421 seemed to exert its inhibitory action
in lower concentrations than SILA-409, which significantly elevated fluorescence intensity ratio (FIR)
values only in concentrations above 10 μM in Dox-resistant colon cancer cells.
Figure 3. The influence of SILA-409 (gray) and SILA-421 (white) on R123 intracellular accumulation in
LoVo/Dx (A) and Madin-Darby Canine Kidney-multidrug resistance protein 1 (MDCK-MDR1) cells
(B). Means ± SD of three experiments are presented. The statistically significant differences from the
untreated cells were determined using Student’s t-test (* p < 0.05).
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Molnar et al. [15] also observed increased R123 accumulation in human ABCB1 gene-transfected
mouse lymphoma cells (L5718/MDR) treated with SILA-409 and SILA-421 in concentrations up to
2 μg/mL. Both compounds demonstrated similar activity in this respect. They were, however, unable
to affect R123 accumulation in sensitive breast and prostate cancer cells and it was again concluded
that the activity of disiloxanes can only be observed in cell lines that express a functional ABCB1
transporter [15]. In the study of Kars et al. [16], both disiloxanes were demonstrated to increase
R123 accumulation in a series of breast cancer cell lines resistant to paclitaxel, docetaxel, Dox, and
vincristine. In contrast to our findings, SILA-409 was observed to be more active then SILA-421 in this
experimental setting.
2.4. Intracellular Accumulation of Doxorubicin
Accumulation of Dox itself by human colon cancer cells was also investigated. As presented
in Figure 4, drug-sensitive LoVo cells accumulated more drug than Dox-resistant LoVo/Dx cells.
The treatment of cells by disiloxanes at a concentration of 5 μM resulted in a significant increase in Dox
accumulation by LoVo/Dx cells with apparently no effect observed in LoVo cells.
Figure 4. Intracellular doxorubicin (Dox) accumulation in LoVo (gray bars) and LoVo/Dx cells (white
bars) treated with SILA-409 and SILA-421 at 5 μM concentration. Means ± SD of three experiments are
presented. The statistically significant differences between untreated and disiloxane-treated cells were
determined using Student’s t-test (* p < 0.05).
Since Dox is characterized by strong intrinsic fluorescence, its intracellular accumulation may
also be examined directly by means of fluorescence microscopy. Again, LoVo cells accumulated
more Dox than LoVo/Dx cells (Figure 5 and Figure S2, Supplementary Materials), and the application
of disiloxanes at a concentration of 5 μM resulted in an increase in accumulation of the drug in
Dox-resistant cells but not in the sensitive ones. SILA-421 was more effective in this respect than
SILA-409. The intracellular distribution of Dox was also affected by organosilicon compounds. Dox that
was excluded from the nuclei of untreated resistant cells was demonstrated to localize within these
organelles in modulator-treated LoVo/Dx cells.
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Figure 5. Intensity of intracellular fluorescence of Dox, measured by ImageJ software, in LoVo (gray
bars) and LoVo/Dx cells (white bars) treated with 5 μM of SILA-409 and SILA-421 is presented as
the mean fluorescence values ± SD measured in 20 representative cells. The statistically significant
differences from the untreated cells were determined using Student’s t-test (* p < 0.05).
According to our best knowledge, the influence of SILA-409 and SILA-421 on Dox accumulation
and cellular localization was not previously studied. The pattern of changes in Dox accumulation
caused by disiloxanes was similar to the changes caused by verapamil (a well-known inhibitor of
ABCB1 protein) observed previously in the same colon cancer cell lines as those used in the present
work [25].
2.5. Expression of ABCB1 Transporter
Additionally, the influence of disiloxanes on ABCB1 transporter expression was analyzed by
Western blotting (Figure 6). Both SILA-409 and SILA-421 significantly decreased ABCB1 protein level
in LoVo/Dx cells during 48 h of treatment. SILA-421 turned out to be more active in this respect in
comparison with SILA-409. No effect of organosilicon compounds on ABCB1 protein level was noted
during 60 min of treatment with modulators (data not shown).
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Figure 6. Western blot analysis of ATP-binding cassette B1 (ABCB1) protein level (A) in LoVo/Dx
cells cultured with 0.5 μM SILA-409 and SILA-421 for 48 h. The molecular masses of the proteins are
indicated on the left side of the gel. β-Glucuronidase (β-GUS) was used as a reference protein. The
relative level of ABCB1 expression (B) was normalized to the control derived from non-treated LoVo/Dx
cells. The results of three experiments ± SD are presented. The statistically significant differences from
the untreated controls were determined using Student’s t-test (* p < 0.05).
The downregulation of ABCB1 expression was previously demonstrated using
immunohistochemical methods in pancreatic tumor samples isolated from mice treated with
SILA-409 [18]. On the other hand, no influence of disiloxanes (tested in concentrations of 380–500μg/mL)
on ABCB1 expression level was detected in mouse T-lymphoma cells transfected with human
ABCB1 [15].
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3. Materials and Methods
3.1. Chemicals
Orgasnosilicon compounds 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-morpholino-propyl)disiloxan
dihydrochloride (SILA-409) and 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-
bis{3-[1(4-butylpiperazinyl)]-propyl}-disiloxan tetrahydrochloride (SILA-421) were synthesized and
patented [14]. Their chemical structures are presented in Figure S3 (Supplementary Materials). Stock
solutions of organosilicon compounds were prepared in dimethyl sulfoxide (DMSO). Sulforhodamine
B (SRB), rhodamine 123 (R123), and doxorubicin (Dox) were obtained from Sigma-Aldrich (Poznan,
Poland) and dissolved in water.
3.2. Cell Culture
Human colorectal adenocarcinoma cell line, LoVo, and its resistant subline, LoVo/Dx, obtained by
prolonged exposure to Dox [31], were obtained from the Institute of Immunology and Experimental
Therapy of Polish Academy of Science (Wroclaw, Poland). Cultivation conditions were Ham’s F12
medium (with the addition of 10% fetal bovine serum, l-glutamine, antibiotics, and, in the case of
LoVo/Dx cells, Dox at 100 ng/mL), at 37 ◦C and 5% CO2.
Madin-Darby Canine Kidney cells (MDCK) and MDCK cells expressing human ABCB1
(MDCK-MDR1) [32] were purchased from the Netherlands Cancer Institute (NKI-AVL, Amsterdam,
the Netherlands). The cells were cultured in DMEM medium supplemented with 10% fetal bovine
serum, l-glutamine, and antibiotics at 37 ◦C and 5% CO2.
3.3. Cell Viability Assay
The SRB assay [33] with minor modifications was used for the estimation of the effect of the
studied compounds on cell growth. Cells were seeded in 96-well flat-bottom microtiter plates in 75 μL
of medium and allowed to attach (60 min, 37 ◦C). Then, 75 μL of medium containing an amount of
the studied compounds (such that a desired compound concentration was obtained in a final sample
volume) was added to each well, with the exception of the control wells, which contained medium
only. The culture plates were then incubated for 48 h at 37 ◦C. The further procedure was carried out
as previously described [34]. Cytotoxicity of DMSO to LoVo and LoVo/Dx cells was negligible.
3.4. Isobolographic Analysis
Combination index (CI) values were calculated using the CompuSyn software (www.combosyn.
com, ComboSyn, Inc., Paramus, USA) according to the classic median-effect equation as described by








where (Dx)1 is the dose of drug 1 alone that inhibits a system by x%, (Dx)2 is the dose of drug 2 alone
that inhibits a system by x%, and (D)1 + (D)2 are doses of drugs 1 and 2 in combination that also inhibit
a system by x%.
3.5. Accumulation of Rhodamine 123 in Cancer Cells
In order to determine R123 accumulation, the cells were harvested and incubated (300,000 cells/mL)
with the appropriate concentration of the studied compound (15 min; 25 ◦C). Next, R123 (10 μM) was
added, and the cells were incubated for 60 min at 37 ◦C. After centrifugation, the samples were washed
twice with ice-cold phosphate-buffered saline (PBS) and dissolved in lysis buffer (20 mM Tris-HCl,
0.2% SDS, pH = 7.7). Intracellular fluorescence (λex = 485 nm, λem = 538 nm) was collected with the use
of an Infinite M200Pro plate reader (Tecan Instruments, Maennedorf, Switzerland). Based on measured
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the fluorescence intensity (FL) of the treated and control samples (without modulator), the fluorescence
intensity ratio (FIR) was calculated according to the following equation:
FIR =
(FLLoVoDx or MDCK−MDR1 treated)/(FLLoVoDx or MDCK−MDR1 control)
(FLLoVo or MDCK treated)/(FLLoVo or MDCK control)
. (2)
3.6. Intracellular Accumulation of Doxorubicin
Intracellular Dox accumulation was detected with a fluorimetry based assay as described
previously [36]. Briefly, cells were seeded (800,000/well) onto a six-well plate and incubated for
24 h at 37 ◦C. Then, the cells were incubated in PBS containing Dox (4 μM) and treated with the
modulators. After 48 h of incubation, cells were washed twice in ice-cold PBS and detached. Next,
cells were centrifuged and lysed. The cellular protein content was determined using the standard
method of Bradford reaction [37]. Dox content was measured using an LS-5 spectrofluorimeter
(Perkin-Elmer, Beaconsfield, UK). Excitation and emission wavelengths were 475 and 553 nm,
respectively. Fluorescence was expressed in ng of Dox per mg of cellular protein with the use
of the calibration curve prepared previously.
For fluorescence microscopic experiments, LoVo and LoVo/Dx cells were cultivated on eight-well
μ-Slide microscopy chambers (Ibidi, Munich, Germany) for 48 h. For the experiment, a fresh portion
of F12 medium was added containing 50 μM Dox (plus 5 μM of the studied compounds in treated
samples), and cells were incubated for 60 min at 37 ◦C. After incubation, the chambers were washed
with PBS and with serum- and phenol red-free F12 medium. The images were collected with a Nikon
Eclipse TE2000-E microscope. Fluorescence was excited in the range 528–553 nm and collected in the
range 578–633 nm.
3.7. Expression of ABCB1 Protein
Cell lysates were prepared in ice-cold lysis buffer (1% Triton X-100, 50 mM Hepes, 150 mM NaCl,
1.5 mM MgCl2, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA),
1 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM NaF, 10 mM sodium pyrophosphate, 10 μg/mL
aprotinin, and 10% glycerol, pH 7.4). After centrifugation of whole-cell lysates (13,000× g, 10 min,
4 ◦C), the supernatants were taken for analysis. The standard method of Bradford reaction was used to
measure protein content (Bradford, 1976). The proteins were subjected to SDS-PAGE, transferred to
polyvinylidene difluoride (PVDF) membranes, and detected using primary antibodies in tris-buffered
saline with Tween (TBS-T) buffer (0.1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 1, pH 7.4) with 5%
bovine serum albumin (BSA). The anti-ABCB1 mouse monoclonal primary antibodies (C494) (Alexis)
were used at dilution 1:1000. The level of β-glucuronidase (β-GUS) was also determined as a reference
protein (anti-glucuronidase mouse monoclonal antibody, diluted 1:1000, Thermo Scientific). After
incubation (overnight at 4 ◦C), the membranes were washed in TBS-T and incubated with rabbit
anti-mouse immunoglobulin G (IgG) secondary antibody conjugated to horseradish peroxidase (HRP)
(dilution 1:1000, Thermo Scientific) for 30 min at 4 ◦C. The membranes were then washed with TBS-T,
and the proteins were visualized. The relative amount of protein normalized to the control (non-treated
cells) was determined. The optical density of the bands on the electrophoregram was detected with the
Image J softwar version 1.43m.
3.8. Statistical Analysis
Data represent the means ± standard deviation (SD) of at least three replications. Student’s t-test
was applied, and p-values less than 0.05 were considered to be statistically significant.
4. Conclusions
Organosilicon compounds, SILA-409 and SILA-421, were demonstrated to reverse doxorubicin
resistance in a human colon cancer cell line. Both compounds were inhibitors of the transport
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function of ABCB1 protein judging from the increased accumulation of R123 by modulator-treated
cells. Intracellular accumulation of Dox was also increased, and more drug entered cellular nuclei in
the presence of the studied compounds. SILA-421 demonstrated slightly higher activity than SILA-409.
Additionally, the decreased expression of ABCB1 protein after treatment with disiloxanes was recorded.
Therefore, the studied compounds acted as resistance-reversing agents via two mechanisms. They were
effective inhibitors of the ABCB1 transport function, and its reduction was easily observed after 60
min of disiloxane treatment (e.g., in fluorescence microscopy and R123 accumulation experiments).
Moreover, after prolonged treatment with SILA-409 and SILA-421, the reduction of ABCB1 protein
level that occurred certainly increased the MDR-reversing potency of these compounds. In conclusion,
both SILA-409 and SILA-421 were demonstrated to be effective anti-MDR agents in resistant human
colon cancer cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/7/1654/s1:
Figure S1: Cytotoxicity of SILA-409 (A) and SILA-421 (B) to MDCK (full symbols) and MDCK-MDR1 cells (open
symbols). Means of three experiments ± SD are presented; Figure S2: Fluorescence microscopy images illustrating
doxorubicin accumulation in LoVo (A) and LoVo/Dx (B) cells treated with 5 μM SILA-409 (C and D for LoVo and
LoVo/Dx, respectively) and with 5 μM SILA-421 (E and F). Scale bar is 50 μm. Illumination conditions were the
same for all images; Figure S3: Chemical structures of SILA-409 and SILA-421.
Author Contributions: Conceptualization, O.W. and K.M.; Validation, O.W.; Formal analysis, O.W. and K.Ś.-P.;
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Abstract: In this study, a new series of N-alkyl-3,6-dibromocarbazole and N-alkyl-5-bromoindole
derivatives have been synthesized and evaluated in vitro as anti-cancer and anti-migration agents.
Cytotoxic and anti-migratory effects of these compounds were evaluated in MCF-7 and MDA-MB-231
breast cancer cell lines and an insight on the structure-activity relationship was developed. Preliminary
investigations of their anti-cancer activity demonstrated that several compounds have moderate
antiproliferative effects on cancer cell lines with GI50 values in the range of 4.7–32.2 μM. Moreover,
carbazole derivatives 10, 14, 15, 23, and 24 inhibit migration activity of metastatic cell line MDA-MB-231
in the range of 18–20%. The effect of compounds 10, 14, and 15 in extension of invadopodia and
filopodia was evaluated by fluorescence microscopy and results demonstrated a reduction in
actin-based cell extensions by compounds 10 and 15.
Keywords: 3,6-dibromocarbazole; 5-bromoindole; carbazole; actin; breast cancer; migration
1. Introduction
In women, breast cancer is the leading cause of death, mainly due to metastasis [1]. If breast
cancer is detected and treated prior to metastasis, the patient has a higher probability of being cured of
their disease. Cancer cell invasion involves cell migration through the extracellular matrix (ECM) and
the accompanying degradation of the ECM [2]. Several proteins play a key role in this process, by the
extension of structures known as invadopodia. Invadopodia are actin-rich protrusive structures with
associated matrix degradation activity and are believed to be important for tumor cells to penetrate
the basement membrane of epithelia and blood vessels [3]. In cell migration, the reorganization of
the actin cytoskeleton produces the force necessary for cell migration [4]. The Rho GTPases, Rac,
and Cdc42 are key molecular switches activated by a myriad of cell surface receptors to promote
breast cancer cell migration/invasion, proliferation, and survival [5]. Unlike Ras, Rac and Cdc42 are
not mutated in breast cancer, but activated via the deregulation of expression and/or activity of their
upstream regulators, guanine nucleotide exchange factors (GEFs) [6]. The WASP family proteins are
key regulators of the actin cytoskeleton and cell migration through induction of membrane protrusions
at the leading edge [7]. In cancer cells, when N-WASP interacts and activates the Arp2/3 complex,
it catalyzes actin polymerization and assembly into filopodia and invadopodia [7,8]. To initiate this
process, the Rho GTPase Cdc42, in its GTP-activated form, binds and activates N-WASP by inducing
a conformational change that liberates the autoinhibited structure, thereby interacting with Arp2/3
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complex, and regulating the protrusive formation in membrane structures promoting extracellular
matrix (ECM) degradation [8]. Therefore, inhibition of these processes decreases cell motility and
invasion, and may greatly improve the potential therapeutic applications of such inhibitors against
cancer metastasis.
Natural and synthetic carbazole derivatives comprise a wide variety of biologically active
agents with diverse pharmacological activities, including antitumoral, antioxidant, anti-inflammatory,
antibacterial, anticonvulsant, antipsychotic, antidiabetic, and larvicidal properties [9–28]. Carbazoles
are tricyclic aromatic compounds with a benzene ring fused to the 2,3-positions of an indole ring [29].
The antitumor properties of carbazole derivatives have been correlated to their polycyclic, planar
aromatic structure, and large π-conjugated backbone that noncovalently bind with DNA base pairs,
hydrophobic pockets, and forms electrostatic interactions to intercalate into DNA [9,30]. In particular,
among a wide variety of carbazoles, a series of N-alkyl-3,6-disubstituted carbazole derivatives has
been discovered and evaluated for their potential as neuroprotective agents [31], antimalarial [32],
antitumoral [33,34], anti-apoptotic [35], and antibacterial activities [36]. Selected examples of bioactive
N-alkyl-3,6-disubstituted carbazole derivatives are represented in Figure 1.
 
Figure 1. Structure of representative N-alkyl-3,6-dihalogencarbazole derivatives.
The compound P7C3 (Figure 1) was discovered from a library of 200,000 drug-like molecules,
and showed proneurogenic and neuroprotective properties, stabilized mitochondrial membrane
potential, and inhibits neuronal apoptosis [37]. Several derivatives of P7C3 have been synthesized
with modifications at the linker chain. Replacement of the hydroxyl group with a fluorine atom, and
an additional methylene group between the hydroxyl group and the aniline, increases activity [37].
The aromatic ring was replaced with heteroaromatic groups, but activity was found to be less effective.
The commercially available TDR30137 (Figure 1) was discovered and characterized as an inhibitor of P.
falciparum K1 (Pf-K1) in human red blood cells with an IC50 of 57 nM [32]. However, TDR30137 was not
active in in vivo studies with the Plasmodium berghei mouse model. In structure-activity relationship
(SAR) studies, the importance of 3,6-halogen substitution, hydroxyl group, and the tertiary amine
correlated with improved activity on Pf-K1 strains [32]. A carbazole derivative named Wiskostatin
(Figure 1) was identified to bind within a pocket in the GBD regulatory module that maintains N-WASP
in an inactive, autoinhibited conformation [38]. In a pyrene-actin polymerization assay, using purified
proteins, it was demonstrated that Wiskostatin inhibited full-length N-WASP activation of the Arp2/3
complex at IC50 = 10 μM [38]. The specific binding site of Wiskostatin was determined to be within the
GBD of the autoinhibited conformation of N-WASP after performing the experiment with activated
Cdc42-GTP. Unfortunately, a recent report described that Wiskostatin inhibited other cellular functions
that are not believed to be N-WASP dependent [39]. These studies revealed that Wiskostatin caused
an irreversible decrease in cellular ATP levels, and that it does not function as a selective inhibitor of
N-WASP dependent functions in intact cells, and caused an overall change in the energy status of cells;
thus, inhibiting normal transport processes [39]. Herein, we designed and synthesized a new series of
N-alkyl-3,6-dibromocarbazole and 5-bromoindole derivatives, tested for their antiproliferative and
antimigratory activities in MCF-7 and MDA-MB-231 breast cancer cell lines, and analyzed the effect of
the most active migration inhibitor on actin dynamics and actin cytoskeleton rearrangement.
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2. Results and Discussion
The aim of this study is to design and synthesize a new series of N-alkyl-3,6-dibromocarbazole
and N-alkyl-5-bromoindole derivatives and analyze their cytotoxic effect and potential to
inhibit actin cytoskeleton rearrangement and cancer cell migration. The structural elements of
Wiskostatin and derivatives identified as pharmacophoric unit are a 3,6-dihalogen carbazole and a
dialkylamino-2-propanol chain. Our strategy was to design and synthesize a new series of compounds
with a 3,6-dibromocarbazole or 5-bromoindole ring connected, via a three-carbon atom aliphatic chain,
to an amide group. The influence of different N-alkyl or aromatic substituents at the amide group
was examined.
We screened all compounds to determine their cytotoxic effect against MCF-7 and MDA-MB-231
breast cancer cells using the Sulforhodamine B (SRB) assay [40] (Figure 2). In addition, anti-migratory
activity was determined using the wound healing assay (scratch method) [41] on the metastatic
MDA-MB-231 cancer cells. In this assay, the relative migration of MDA-MB-231 breast cancer cells
in the presence of carbazole or indole derivatives at a concentration of 10 μM (or at concentrations
that do not affect cell viability) was compared to the migration in the presence of vehicle (0.02%
DMSO). Representative photomicrographs of the migration inhibition of compounds 10, 14, 15, and
Wiskostatin are represented in Figure 3. Results show that in the vehicle-treated control experiment,
wound healing is progressing considerably, and after 24 h, the wound is completely healed. When
cells are incubated with compounds 10, 14, and 15 after 24 h, the wound healing is inhibited. However,
Wiskostatin did not elicit an inhibitory effect on wound healing when incubated with MDA-MB-231
cells after 24 h at a concentration of 2 μM. Actin and Arp2/3 regulation by active WASP induce de novo
actin polymerization and assembly to generate the F-actin structures filopodia and invadopodia used
for cell migration [42]. Therefore, to investigate the effect of compounds 10, 14, 15, and Wiskostatin
on actin dynamics, we performed immunofluorescence microscopy to detect polymerized actin on
MDA-MB-231 cancer cells (Figure 4). The structure and biological activities of new compounds are
summarized in Tables 1 and 2.
2.1. N-Alkyl-3,6-Dibromocarbazole Derivatives
The synthetic method to construct the 3,6-dibromocarbazole derivatives library is described
in Scheme 1 (see the Supplementary Materials for representative 1H and 13C NMR spectral
data). The N-alkyl-3,6-dibromocarbazole derivatives were generated in a three-step synthesis using
3,6-dibromocarbazole 1 as origin of the carbazole derivatives core. Compound 1 was reacted with
ethyl 4-bromobutyrate to introduce the aliphatic side chain by nucleophilic substitution (Scheme 1),
followed by hydrolysis to afford the corresponding 3,6-diromocarbazole-4-butyric acid 2. For the
generation of 3,6-dibromocarbazole-4-butyramide derivatives 3, compound 2 was therefore used
as starting material, which reacted with different amines via an amide coupling reaction using
N-(3-Dimethylaminopropyl)-N’-ethylcarbonate (EDAC) with Hydroxybenzotriazole (HOBt) as an
additive dissolved in methylene chloride (CH2Cl2).
 
Scheme 1. General synthetic procedure of 3,6-dibromocarbazole-4-butyramide derivatives 3. Reagents
and conditions: (a) (i) Ethyl 4-bromobutyrate, K2CO3, DMF, 80 ◦C, 2h; (ii) KOH, DMF/water, 80 ◦C, 2-6
h, 86%; (b) HOBt, EDAC, CH2Cl2, Et3N, rt, amine: R-NH2 or HNR1R2, 2-8 h.
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The in vitro anti-proliferative and anti-migratory activities of compounds 4–27, and Wiskostatin
are represented in Table 1. From the twenty-four compound derivatives of 3,6-dibromocarbazole, it can
be observed that in the MCF-7 (ER+) cancer cell line, compounds 6–10, 14, 16–21, and 32 showed good
to moderate antiproliferative activity with a GI50 in the range of 6.8–32.2 μM. In the MDA-MB-231 cell
line, compounds 6–10, 14, 16, 18, 20–21, and 23 inhibited cell proliferation with a GI50 in the range of
4.7–23 μM. The remaining compounds in that series had a GI50 above 50 μM in both breast cancer cell
lines. Compound 8 with a 2-piperazinyl ethyl butyramide chain showed very good anticancer activity
against both cancer cell lines MCF-7 and MDA-MB-231 with GI50 values of 8 and 4.7 μM, respectively.
Also, compound 18 with a piperazinyl amide showed significant anticancer activity against both cancer
cell lines with GI50 values of 7.5 and 6.7 μM, respectively. Similarly, compound 21, another piperazinyl
amide derivative, showed very good in vitro anticancer activity against both cancer cell lines with GI50
values of 6.5 and 8 μM, respectively. Shortening the aliphatic chain between the N-atom of the amide
group and the morpholine from C3 (9), over C2 (4), to C0 (12) led to a complete loss of antiproliferative
activity on both cancer cell lines. On the other hand, introduction of an aromatic ring or aromatic
heterocycle (22–27, Table 1) in the amide group led to lack of antiproliferative activity with GI50 above
50 μM on both cancer cell lines. Thus, in general, compounds with a piperazinyl butyramide group
attached to the N-atom of the carbazole appear to be more cytotoxic than compounds with other
butyramide group in this series of compounds. In addition, three compounds—8, 18, and 21—were
found to be more cytotoxic against both cancer cell lines MCF-7 and MDA-MB-231 than Wiskostatin,
which in this assay showed GI50 values of 9.7 and 8.3 μM, respectively (Table 1, Figure 2).
To further assess the anti-migratory activity of carbazole derivatives in vitro, we examined its
inhibitory effects on the migration of the metastatic breast cancer cell line MDA-MB-231 using the
wound-healing assay at concentrations that do not affect cell viability. We chose the MDA-MB-231 breast
cancer cells over MCF-7 due to its enhanced metastatic and migratory properties, with concomitant Rac
and Cdc42 expression, compared to the non-metastatic and poorly migrating MCF-7 cells. The relative
migration of treated cells with 3,6-dibromocarbazole derivatives compared with control (MDA-MB-231
cells) are summarized in Table 1.









>50 >50 99 ± 6.03
5
 
>50 >50 99 ± 5.98
6
 
16.8 16 94 ± 3.93
7
 
6.8 10 99 ± 0.03(at 2 μM)
8
 
8 4.7 97 ± 4.90(at 1 μM)
9
 
13.4 15.4 99 ± 1.58(at 3.1 μM)
10
 
8.1 10.5 87 ± 4.65(at 2.1 μM)
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>50 >50 99 ± 0.02
12
 
>50 >50 97 ± 6.41
13
 
>50 25 99 ± 0.03
14
 
11.8 16.7 81 ± 8.96
15
 
>50 >50 80 ± 5.87
16
 
18.2 23 82 ± 7.52
17  17.5 >50 99 ± 2.09
18
 
7.5 6.7 99 ± 0.02
19
 
12.4 >50 99 ± 0.97
20
 
9.1 13.4 99 ± 0.05(at 2.7 μM)
21
 
6.5 8 99 ± 0.48(at 1.6 μM)
22
 
>50 >50 97 ± 4.19
23
 
>50 19 90 ± 6.60
24
 
32.2 >50 82 ± 5.19
25
 
>50 >50 96 ± 4.69
26
 
>50 >50 99 ± 6.52
27
 
>50 >50 99 ± 0.05
Wiskostatin 9.7 8.3 95 ± 6.79(at 2 μM)
a GI50 = compound concentration required to inhibit MDA-MB-231 proliferation by 50% after 48 h treatment. Values
are expressed as the mean of triplicate experiments, and standard deviation (SD) is <10%. b After 24 h, MDA-MB-231
cellular migration was determined by measuring the distance traveled from the edge of the scratch toward the
center of the scratch, relative to control. c Percent relative migration values at 10 μM (or at concentrations that do
not affect cell viability). Results are presented as means ± SD of three independent experiments.
389
Molecules 2019, 24, 2686
Figure 2. Log-dose response curve for compounds 7, 8, 10, 18, 21, and Wiskostatin on MCF-7 and
MDA-MB-231 breast cancer cell lines. Each data point represents the mean of three replicates and error
bars represent ± SD. Each GI50 value was calculated based on sigmoidal curve fitting to the respective
data set.
Among the twenty-four compounds tested for their anti-migratory effect, five compounds (10, 14,
15, 23, 24) inhibited migration in the range of 10–20%. While compounds 7, 8, 18, and 21 were among the
most cytotoxic compounds tested against MDA-MB-231 and MCF-7 cancer cell lines, they did not show
significant anti-migratory effect. In contrast, compounds 14–16 and 24 inhibited migration in the range
of 18–20%, compared to Wiskostatin that inhibit 5% of migration at 2 μM. Compound 14, a carbazole
derivative with a piperidine-4-carbonitrile amide group that showed moderate anti-proliferative
activity on both MCF-7 and MDA-MB-231 cell lines, inhibit 19% of migration. Both compounds 15 and
16, with phenyl- and acetyl-piperazine amide group, respectively, showed comparable anti-migratory
activity with 20% and 18%, respectively. The anti-proliferative effect of 16 on both cancer cell lines was
moderate, compared to 15, which lacks cytotoxic activity. On the other hand, the 3-aminoquinoline
amide 24, showed anti-migratory activity of 18% with GI50 above 50 μM on MDA-MB-231 cell
line. When comparing Wiskostatin and carbazole derivatives from Table 1, compound 10 exhibited
anti-proliferative activity with GI50 values comparable with Wiskostatin on both cancer cell lines.
However, compound 10 showed higher anti-migratory potency with 13% at 2.1 μM, compared with 5%
anti-migratory effect of Wiskostatin at 2 μM on MDA-MB-231 breast cancer cells. Therefore, compound
10 exhibits similar cytotoxicity with improved anti-migratory potential compared to Wiskostatin.
Figure 3. Inhibitory effect of compounds 10, 14, 15, and Wiskostatin on MDA-MB-231 cells migration
detected by wound-healing assay. MDA-MB-231 cells were treated with vehicle or with compounds 10,
14, 15, and Wiskostatin. The photomicrographs were obtained at 0 and 24 h. Percent relative migration
values are the average of three independent experiments. Dotted lines show the area occupied by the
initial scraping for 0 h, and the wound edge for 24 h.
390
Molecules 2019, 24, 2686
The Rho GTPases are believed to stimulate plasma membrane protrusion by inducing actin
filament nucleation and polymerization on or close to membranes [43]. In particular, the Rho GTPase
protein Cdc42, through activation of N-WASP/Arp2/3 pathway, is an important mediator of actin
polymerization and filopodium extension [44,45]. Therefore, compounds that interfere with this
process might be potentially useful molecular probes for the study of cell migration and invasion.
To determine changes in actin cytoskeletal structures, we treated MDA-MB-231 breast cancer cells with
vehicle or compounds 10, 14, 15, and Wiskostatin at 10 μM for 24 h (Figure 4).
Figure 4. Effect of Wiskostatin and compounds 10, 14, and 15 on actin cytoskeleton of metastatic cancer
cell MDA-MB-231. MDA-MB-231 metastatic breast cancer cells were treated with vehicle or Wiskostatin
(2 μM) and compounds 10, 14, or 15 at 10 μM for 24 h to determine changes in actin cytoskeletal
structures. Cells were fixed, permeabilized, and stained with rhodamine phalloidin to visualize F-actin.
Arrows, lamellipodia; arrowheads, filopodia.
To identify F-actin based cell surface extensions, cells were stained with rhodamine phalloidin to
localize F-actin. The results showed that untreated cells (control) demonstrated a strong formation
of lamellipodia extensions, membrane ruffles, and stress fibers, with few filopodia. Wiskostatin and
compounds 14 and 15 moderately reduced lamellipodia extensions when compared with control cells
at concentrations that do not affect cell viability. In addition, compound 10, at concentrations that
inhibit 13% cell migration (2 μM), exhibited a marked reduction in lamellipodia formation when
compared to vehicle, and in particular with Wiskostatin, which inhibits cell migration in 5% at 2 μM
(Table 1). Compound 15 demonstrates a marked reduction in polymerized actin indicating inhibition
of Arp2/3 mediated actin nucleation. Specific inhibition of filopodia, as would be predicted by WASP
inhibition, could not be determined since the vehicle control cells exhibited more invadopodia and
lamellipodia than filopodia. In general, these results suggest that new N-alkyl-3,6-dibromocarbazoles
and compounds derivatives of Wiskostatin can be explored as new probes to study actin dynamics in
cancer cells, or to further develop new anti-cancer and anti-metastatic drugs.
2.2. N-alkyl-5-Bromoindole Derivatives
To further explore the N-alkyl-5-bromoindole butyramide derivative series, we synthesized
several compounds in which the carbazole core was replaced by a 5-bromoindole ring (Scheme 2).
The strategy is to analyze the effect of using a smaller ring system as a core connected to the C3 linker
side chain and the amide group. The synthesis of N-alkyl-5-bromoindole derivatives is described in
Scheme 2. The 5-bromoindole 28 was reacted with ethyl 4-bromobutyrate, followed by hydrolysis
to yield the corresponding 5-bromoindole-4-butyric acid 29. Since N-alkylation in indoles is more
difficult than in carbazoles, the reaction rate to obtain 29 was improved by using Cs2CO3 as a base
over K2CO3, where Cs2CO3 solubility is ten times higher in organic solvents than K2CO3. For the
generation of 5-bromoindole-4-butyramide derivative 30, carboxylic acid 29 was therefore used as
starting material, which reacted with different amines via an amide coupling reaction using reaction
conditions similar as described in Scheme 1 (see the Supplementary Materials for representative 1H
and 13C NMR spectral data).
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Scheme 2. General synthetic procedure of 5-bromoindole-4-butyramide derivative 30. Reagents and
conditions: (a) (i) Ethyl 4-bromobutyrate, Cs2CO3, DMF, 100 ◦C, 16 h; (ii) KOH, DMF/water, 80 ◦C,
2–6 h, 80%; (b) HOBt, EDAC, CH2Cl2, Et3N, rt, amine: R-NH2 or HNR1R2, 2-8 h.
The in vitro anti-proliferative and anti-migratory activities of compounds 31–34 are represented
in Table 2. In this assay, the replacement of the rigid carbazole ring core by an indole resulted in loss of
cytotoxic activity on both MCF-7 and MDA-MB-231 cell lines. For example, from the four representative
5-bromoindole derivatives synthesized, it can be observed that only compound 34 showed moderate
cytotoxic effect on MCF-7 cells with GI50 of 18.4 μM, while GI50 value on MDA-MB-231 breast cancer
cells was above 50 μM. Furthermore, the remaining compounds in that series had GI50s above 50 μM
in both breast cancer cell lines. Additionally, after 24 h treatment at 10 μM using the wound-healing
assay in the MDA-MB-231 cell line, no migration inhibition could be observed. Hence, the absence of
any activity of 5-bromoindole derivative series, together with the fact that several carbazole derivatives
show promising activity, a structure-activity relationship (SAR) can be established. For example, it
appears that the presence of a carbazole ring core, the C3 linker region, and amide group improve both
anti-proliferative and anti-migratory activity.










>50 >50 99 ± 0.05
32
 
>50 >50 99 ± 7.78
33
 
>50 >50 99 ± 0.02
34
 
18.4 >50 99 ± 6.60
a GI50 = compound concentration required to inhibit MDA-MB-231 proliferation by 50% after 48 h treatment. Values
are expressed as the mean of triplicate experiments, and standard deviation (SD) is <10%. b After 24 h, MDA-MB-231
cellular migration was determined by measuring the distance traveled from the edge of the scratch toward the
center of the scratch, relative to control. c Percent relative migration values at 10 μM. Results are presented as means
± SD of three independent experiments.
3. Materials and Methods
3.1. General Methods
All experiments were carried out in pre-dried glassware (≥1 h, 80–90 ◦C) under a nitrogen
atmosphere. Nuclear magnetic resonance (NMR) spectra were obtained using a 400 MHz Bruker
Avance UltraShield™ spectrometer. 1H (400 MHz) and 13C (100 MHz) NMR were recorded in CDCl3
or DMSO-d6, unless otherwise used, and the chemical shift was expressed in parts per million (ppm)
relative to CDCl3 (δ 7.26 for 1H and δ 77.0 for 13C) or DMSO-d6 (δ 2.50 for 1H and δ 39.5 for 13C) as the
internal standard. 1H NMR data is reported as position (δ), relative integral, multiplicity (s, singlet; d,
doublet; t, triplet; q, quartet; dt, doublet of triplets; dd, doublet of doublets; dq, doublet of quartets; m,
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multiplet; br, broad peak), coupling constant (J) in hertz (Hz), and the assignment of the atom. The shift
in ppm for multiplets correspond to the centermost value of the entire splitting pattern. 13C NMR
data are reported as position (δ) and assignment of the atom. Microwave reactions were conducted in
a CEM Discovery Microwave for Drug Discovery, SP- 1445. High resolution electrospray ionization
mass spectrometry (ESI-HRMS) data were obtained on a Thermo Scientific™ Q Exactive™ Hybrid
Quadrupole-Orbitrap Mass Spectrometer with high performance liquid chromatography (HPLC)
Agilent 1200 utilizing a Zorbax SB-C18 column (2.1 mm × 50 mm, 1.8μm) at 40 ◦C, and a mobile phase
of acetonitrile containing 5% Milli Q water at a flow rate of 0.35 mL/min (run time: 6.5 min), and 1 μL
injection volume.
3.2. Synthesis Methods
Progress of the reaction was monitored via TLC analysis using general purpose silica gel on glass
5 × 20 cm with UV indicator, 250 μm, 60 Å medium pore diameter, UV indicator, and visualized by
UV fluorescent Spectroline E Series Ultraviolet lamps, in most cases followed by staining with I2.
The compounds were purified via column chromatography over silica gel (70–230 mesh, 60 Å) with
the appropriate size column (24/40, 12 in. × 0.5 in.) or (24/40, 12 in. × 0.72 in.). Wiskostatin compound
was obtained from MilliporeSigma.
3.2.1. General Procedure for the Synthesis of 4-(3,6-Dibromo-Carbazol-9-yl)-Butyric Acid (2)
A 50 mL three-neck round-bottom flask, equipped with a reflux condenser, was charged with
3,6-dibromocarbazole 1 (0.325 g, 1.0 mmol), K2CO3 (0.1382 g, 1 mmol), and ethyl 4-bromobutyrate 2
(0.4436 mL, 3.1 mmol), dissolved in DMF (5 mL). After 15 min of stirring at room temperature, the
reaction mixture was refluxed at 80 ◦C for 2 h. After completion of the reaction (analyzed by TLC),
water (1 mL) and KOH (1.0 mmol) was added and the reaction mixture, refluxed at 80 ◦C for 2 h. After
the reaction was completed (analyzed by TLC), the mixture was allowed to reach room temperature.
The mixture was washed with water (20 mL) and the product was extracted using dichloromethane
(3 × 10 mL). The organic layer was washed with brine and dried with Na2SO4, and filtered and
concentrated under reduced pressure. The crude oil was purified via column chromatography
over silica gel and 50% ethyl acetate in hexane, and the product obtained as a white solid for the
precursor 4-(3,6-Dibromo-carbazol-9-yl)-butyric acid 2 (0.3535 g, 0.86 mmol, 86%). TLC analysis in
ethyl acetate-hexane (1:1), Rf = 0.19. 1H NMR (400 MHz, CDCl3) δ 1.98 (2H, m), 2.27 (2H, t, J = 7.2 Hz),
4.41 (2H, t, J = 7.2 Hz), 7.30 (2H, d, J = 8.9 Hz), 7.56 (2H, dd, J = 2.0, 8.8 Hz), 8.14 (1H, d, J = 2.0 Hz);
13C NMR (100 MHz, CDCl3) 24.2, 31.1, 42.2, 111.8, 112.0, 123.4, 123.9, 139.5, 174.3. HR-FTMS (ESI) m/z
calcd. for C16H13Br2NO2, [M + H]+ 411.9365, found 411.9365.
3.2.2. Synthesis of 3,6-Dibromocarbazole-4-butyramide Derivatives (4–27)
3.2.3. General Procedure for the Synthesis of
4-(3,6-Dibromocarbazol-9-yl)-N-(2-Morpholin-4-Ylethyl)Butyramide (4), and for Compounds 5–27
A 50 mL three-neck round-bottom flask was charged with 4-(3,6-Dibromo-carbazol-9-yl)-butyric
acid 2 (0.4111 g, 1.0 mmol), HOBT (0.2027 g, 1.5 mmol), and EDAC (0.2876 g, 1.5 mmol). The mixture
was dissolved in CH2Cl2 (10 mL), stirred for 30 min, and 2-(4-morpholinyl)ethanamine 2 (0.133 g,
1.0 mmol) was added. After 15 min, Et3N (0.43 mL, 3.0 mmol) was added and the mixture was
stirred at room temperature for 16 h. After completion of the reaction (analyzed by TLC), water
was added (30 mL) and the product was extracted using dichloromethane (3 × 10 mL). The organic
layer was washed with brine and dried with Na2SO4, and filtered and concentrated under reduced
pressure. The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.382 g, 0.73 mmol, 73%). TLC analysis in
CH2Cl2-MeOH (9:1), Rf = 0.26. 1H NMR (400 MHz, CDCl3) δ 2.0 (2H, m), 2.22 (2H, t, J = 6.8 Hz), 2.35
(2H, t, J = 4 Hz), 2.50 (4H, t, J = 1.6 Hz), 3.19 (2H, m), 3.56 (4H, t, J = 4.4 Hz), 4.39 (2H, t, J = 6.8 Hz),
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7.60 (2H, d, J = 1.6 Hz), 8.0 (2H, bs), 8.46 (2H, bs); 13C NMR (100 MHz, CDCl3) 24.0, 31.2, 34.3, 41.8,
53.15, 53.2, 54.9, 57.2, 66.1, 111.3, 111.5, 122.9, 123.4, 128.8, 139.0, 161.0. HR-FTMS (ESI) m/z calcd. for
C22H25Br2N3O2, [M + H]+ 524.0366, found 524.0367.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(2-methoxyethyl)butyramide (5)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.096 g, 0.21 mmol, 63%). TLC analysis in
CH2Cl2-MeOH (9:1), Rf = 0.56. 1H NMR (400 MHz, CDCl3) δ 1.63 (2H, bs), 2.15 (2H, t, J = 6.0 Hz), 2.21
(2H, m), 3.63 (3H, s), 3.46 (2H, d, J = 2.0 Hz), 4.39 (2H, t, J = 6.4 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.57 (2H,
dd, J = 1.6, 8.8 Hz), 8.16 (2H, d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3) 24.1, 32.4, 39.2, 42.3, 58.7, 71.0,
110.5, 112.1, 123.2, 123.4, 129.1, 139.2, 171.6. HR-FTMS (ESI) m/z calcd. for C19H20Br2N2O2, [M +H]+
468.9944, found 468.9947.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(3-imidazol-1-yl-propyl)butyramide (6)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.078 g, 0.15 mmol, 49%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.22. 1H NMR (400 MHz, CDCl3) δ 1.96 (2H, t, J = 6.8 Hz), 2.07 (2H, t,
J = 6.4 Hz), 2.20 (2H, m), 3.23 (2H, q, J = 6.4 Hz), 3.98 (2H, t, J = 6.8 Hz), 4.38 (2H, t, J = 6.8 Hz), 6.93
(1H, bs), 7.05 (1H, Bs), 7.33 (2H, d, J = 8.4 Hz), 7.51 (1H, bs), 7.56 (2H, dd, J = 2.0, 8.8 Hz), 8.15 (2H,
d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3) 24.0, 31.0, 32.3, 36.9, 42.2, 44.8, 110.5, 112.2, 112.3, 123.3,
123.4, 129.1, 129.3, 129.4, 139.3, 171.9. HR-FTMS (ESI) m/z calcd. for C22H22Br2N4O, [M +H]+ 519.0213,
found 519.0211.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(2-piperidin-1-ylethyl)butyramide (7)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1033 g, 0.2 mmol, 59%). TLC analysis in
CH2Cl2-MeOH (9:1), Rf = 0.47. 1H NMR (400 MHz, CDCl3) δ 1.43 (2H, q, J = 4. 9 Hz), 1.52 (4H, m),
2.11 (4H, dt, J = 3.3, 11.7 Hz), 2.34 (3H, bs), 2.38 (3H, t, J = 6.0 Hz), 3.31 (2H, q, J = 5.5 Hz), 4.29 (2H, t,
J = 6.4 Hz), 6.05 (1H, bs), 7.28 (2H, d, J = 8.7 Hz), 7.5 (2H, dd, J = 1.9, 8.7 Hz), 8.06 (2H, d, J = 1.9 Hz);
13C NMR (100 MHz, CDCl3) 24.0, 24.2, 32.2, 35.9, 42.2, 54.2, 57.0, 110.5, 112.0, 123.1, 123.2, 128.9, 139.2,
171.4. HR-FTMS (ESI) m/z calcd. for C23H27Br2N3O, [M + H]+ 522.0573, found 522.0572.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(2-piperazin-1-ylethyl)butyramide (8)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1425 g, 0.27 mmol, 71%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.23. 1H NMR (400 MHz, CDCl3) δ 1.9 (1H, bs), 2.11 (2H, t, J = 6.4 Hz),
2.20 (2H, m), 2.38 (3H, bs), 2.42 (4H, t, J = 5.9 Hz), 2.84 (4H, t, J = 4.7 Hz), 3.32 (2H, q, J = 5.4 Hz), 4.38
(2H, t, J = 6.7 Hz), 7.33 (2H, d, J = 8.7 Hz), 7.54 (2H, dd, J = 1.9, 10.6 Hz), 8.14 (2H, s); 13C NMR (100
MHz, CDCl3) 24.0, 32.2, 35.6, 42.4, 45.9, 54.1, 57.0, 110.6, 112.1, 123.2, 123.5, 139.4, 171.4. HR-FTMS (ESI)
m/z calcd. for C23H27Br2N3O, [M + H]+ 523.0526, found 523.0526.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(3-morpholin-4-ylpropyl)butyramide (9)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1496 g, 0.28 mmol, 69%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.59. 1H NMR (400 MHz, CDCl3) δ 1.56 (2H, m, J = 6.0 Hz), 1.95 (2H, t,
J = 6.8 Hz), 2.14 (4H, m), 2.23 (2H, bs), 2.36 (2H, t, J = 6.4 Hz), 3.25 (2H, q, J = 5.6 Hz), 3.42 (1H, bs), 4.31
(2H, t, J = 6.8 Hz), 7.31 (2H, d, J = 8.8 Hz), 7.54 (2H, dd, J = 2.0, 8.8 Hz), 8.12 (2H, d, J = 1.6 Hz); 13C
NMR (100 MHz, CDCl3) 24.0, 24.4, 32.3, 39.6, 42.1, 53.5, 58.0, 66.8, 110.6, 112.1, 123.2, 123.4, 129.1, 139.3,
171.1. HR-FTMS (ESI) m/z calcd. for C23H27Br2N3O2, [M + H]+ 538.0522, found 538.0521.
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Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(4-diethylamino-1-methylbutyl)butyramide (10)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0063 g, 0.040 mmol, 9.1%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.21. 1H NMR (400 MHz, CDCl3) δ 0.89 (2H, m), 1.19 (6H, t, J = 7.6 Hz),
1.64 (2H, m), 2.20 (3H, bs), 2.25 (2H, t, J = 6.8 Hz), 2.62 (2H, t, J = 6.4 Hz), 3.29 (4H, m), 3.60 (2H, t,
J = 7.20 Hz), 4.37 (2H, t, J = 7.20 Hz), 7.33 (2H, d, J = 8.8 Hz), 7.55 (2H, dd, J = 2.0, 8.8 Hz), 8.13 (2H, d,
J = 2.0 Hz), 9.28 (1H, bs); 13C NMR (100 MHz, CDCl3) 8.5, 21.2, 21.3, 24.4, 29.7, 32.7, 33.6, 42.6, 44.6,
47.0, 52.3, 110.7, 112.0, 123.2, 123.5, 129.1, 139.4, 172.0. HR-FTMS (ESI) m/z calcd. for C25H33Br2N3O2,
[M + H]+ 552.1043, found 552.1044.
Synthesis of 4-[4-(3,6-Dibromocarbazol-9-yl)-butyrylamino]piperidine-1-carboxylic acid ethyl ester (11)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1254 g, 0.22 mmol, 85.3%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.63. 1H NMR (400 MHz, CDCl3) δ 1.25 (3H, t, J = 7.2 Hz), 1.88 (2H, dd,
J = 2.8, 12.4 Hz), 2.08 (2H, t, J = 6.4 Hz), 2.19 (2H, m, J = 6.8 Hz), 2.88 (2H, t, J = 12.0 Hz), 3.92 (1H,
m, J = 3.6 Hz), 4.12 (4H, q, J = 6.8 Hz), 4.37 (2H, t, J = 6.8 Hz), 5.16 (1H, d, J = 7.6 Hz), 7.32 (2H, d,
J = 8.8 Hz), 7.55 (2H, dd, J = 2.0, 8.8 Hz), 8.14 (2H, d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3) 14.7, 24.0,
32.0, 32.4, 42.2, 42.7, 46.8, 61.4, 110.5, 112.2, 123.3, 123.5, 129.2, 139.3, 155.4, 170.1. HR-FTMS (ESI) m/z
calcd. for C24H27Br2N3O3, [M + H]+ 566.0471, found 566.0470.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-morpholin-4-ylbutan-1-one (12)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0768 g, 0.16 mmol, 52%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.94. 1H NMR (400 MHz, CDCl3) δ 2.15 (4H, t, J = 6.0 Hz), 2.21 (2H, m,
J = 6.8 Hz), 3.16 (2H, t, J = 4.8 Hz), 3.50 (2H, t, J = 4.4 Hz), 3.64 (4H, dt, J = 2.8, 6.4 Hz), 7.31 (2H, d,
J = 8.8 Hz), 7.55 (2H, dd, J = 1.6, 8.4 Hz), 8.14 (2H, d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3) 23.6, 28.6,
41.5, 41.9, 45.1, 65.9, 66.0, 111.3, 111.5, 122.9, 123.41, 128.8, 139.0, 170.0. HR-FTMS (ESI) m/z calcd. for
C20H20Br2N2O2, [M + H]+ 480.9944, found 480.9945.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-thiomorpholin-4-ylbutan-1-one (13)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0712 g, 0.41 mmol, 35%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.60. 1H NMR (400 MHz, CDCl3) δ 2.11 (2H, t, J = 6.3 Hz), 2.21 (2H, m),
2.34 (2H, t, J = 5.0 Hz), 2.62 (2H, t, J = 5.2 Hz), 3.46 (2H, t, J = 5.0 Hz), 3.89 (2H, t, J = 5.0 Hz), 4.41 (2H, t,
J = 6.7 Hz), 7.32 (2H, d, J = 8.6 Hz), 7.56 (2H, dd, J = 1.9, 8.7 Hz), 8.15 (2H, d, J = 1.7 Hz); 13C NMR
(100 MHz, CDCl3) 23.5, 27.3, 27.4, 29.0, 42.1, 44.3, 47.8, 110.6, 112.2, 123.3, 123.5, 129.1, 139.4, 169.9.
HR-FTMS (ESI) m/z calcd. for C20H20Br2N3OS, [M + H]+ 496.9715, found 496.9713.
Synthesis of 1-[4-(3,6-Dibromocarbazol-9-yl)butyryl]piperidine-4-carbonitrile (14)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0775 g, 0.16 mmol, 44%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.97. 1H NMR (400 MHz, CDCl3) δ 1.63 (2H, t, J = 5.6 Hz), 1.85 (1H, m),
2.15 (2H, m), 2.84 (2H, m), 3.14 (2H, dt, J = 5.2, 13.6 Hz), 3.35 (2H, dt, J = 6.0, 14.4 Hz), 3.63 (2H, dq,
J = 4.4, 13.6 Hz), 3.76 (2H, dq, J = 3.2, 13.6 Hz), 4.41 (2H, m), 7.31 (2H, d, J = 8.4 Hz), 7.54 (2H, dd,
J = 1.6, 8.4 Hz), 8.14 (2H, d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3) 23.4, 26.2, 28.1, 28.6, 28.7, 39.5, 42.1,
43.0, 110.6, 112.2, 120.5, 123.3, 123.5, 129.1, 139.4, 169.8. HR-FTMS (ESI) m/z calcd. for C22H21Br2N3O,
[M + H]+ 504.0104, found 504.0104.
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Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-(4-phenylpiperazin-1-yl)butan-1-one (15)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.2658 g, 0.27 mmol, 69%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.53. 1H NMR (400 MHz, CDCl3) δ 1.55 (2H, bs), 2.22 (2H, m), 2.97 (2H, t,
J = 5.3 Hz), 3.15 (2H, t, J = 4.9 Hz), 3.34 (2H, t, J = 4.5 Hz), 3.30 (2H, t, J = 4.7 Hz), 4.43 (2H, t, J = 3.4 Hz),
6.92 (2H, t, J = 7.9 Hz), 7.29 (3H, t, J = 7.9 Hz), 7.34 (2H, d, J = 8.7 Hz), 7.54 (2H, dd, J = 1.8, 8.6 Hz), 8.15
(2H, d, J = 1.7 Hz); 13C NMR (100 MHz, CDCl3) 23.6, 28.9, 41.6, 42.2, 45.1, 49.4, 49.5, 110.6, 112.1, 116.8,
120.7, 123.3, 123.5, 129.2, 129.3, 139.4, 150.9, 170.0. HR-FTMS (ESI) m/z calcd. for C26H25Br2N3O, [M +
H]+ 556.0417, found 556.0417.
Synthesis of 1-(4-Acetylpiperazin-1-yl)-4-(3,6-dibromocarbazol-9-yl)butan-1-one (16)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0775 g, 0.15 mmol, 62%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.67. 1H NMR (400 MHz, CDCl3) δ 1.57 (3H, s), 2.08 (2H, bs), 2.12 (2H, bs),
2.21 (2H, bs), 3.19 (2H, t, J = 5.3 Hz), 3.45 (2H, t, J = 6.2), 3.64 (2H, t, J = 5.0 Hz), 4.42 (2H, t, J = 6.6 Hz),
7.32 (2H, dd, J = 4.2, 8.7 Hz), 7.54 (2H, dd, J = 1.9, 8.7 Hz), 8.14 (2H, d, J = 1.8 Hz); 13C NMR (100 MHz,
CDCl3) 21.4, 28.8, 31.0, 41.5, 42.0, 42.2, 44.8, 45.9, 110.5, 112.2, 123.4, 129.1, 139.3, 169.3, 170.4. HR-FTMS
(ESI) m/z calcd. for C22H23Br2N3O2, [M + H]+ 522.0209, found 522.0209.
Synthesis of 4-[4-(3,6-Dibromocarbazol-9-yl)butyryl]piperazine-1-carboxylic acid tert-butyl ester (17)
The crude oil was purified via column chromatography over silica gel and hexane-ethyl acetate
(1:1) as the mobile phase, and the product obtained as a white solid (0.1977 g, 0.4 mmol, 80%). TLC
analysis in hexane-ethyl acetate (1:1), Rf = 0.35. 1H NMR (400 MHz, CDCl3) δ 1.47 (9H, s), 2.20 (4H, m),
3.16 (2H, bs), 3.26 (2H, bs), 3.40 (2H, t, J = 5.2 Hz), 3.60 (2H, t, J = 4.4 Hz), 4.41 (2H, t, J = 6.4 Hz), 7.32
(2H, d, J = 8.4 Hz), 7.54 (2H, dd, J = 1.6, 8.4 Hz), 8.14 (2H, d, J = 2.0 Hz); 13C NMR (100 MHz, CDCl3)
23.5, 28.4, 29.0, 41.4, 42.2, 45.0, 80.4, 110.5, 112.2, 123.3, 123.5, 129.1, 139.4, 154.5, 170.2. HR-FTMS (ESI)
m/z calcd. for C25H29Br2N3O3, [M + Na]+ 602.0447, found 602.0446.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-piperazin-1-ylbutan-1-one (18)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0383 g, 0.080 mmol, 80%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.38. 1H NMR (400 MHz, CDCl3) δ 1.25 (1H, s), 2.18 (4H, m), 2.68 (2H, t,
J = 4.8 Hz), 2.84 (2H, t, J = 5.2 Hz), 3.16 (2H, t, J = 4.8 Hz), 3.61 (2H, t, J = 5.2 Hz), 4.41 (2H, t, J = 6.4 Hz),
7.32 (2H, d, J = 8.4 Hz), 7.54 (2H, dd, J = 2.0, 8.8 Hz), 8.14 (2H, d, J = 1.6 Hz); 13C NMR (100 MHz,
CDCl3) 22.6, 23.6, 42.2, 42.7, 45.8, 46.0, 46.3, 110.6, 112.1, 123.3, 123.5, 129.1, 139.4, 170.0. HR-FTMS (ESI)
m/z calcd. for C20H21Br2N3O, [M + H]+ 480.0104, found 480.0101.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]butan-1-one (19)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.2036 g, 0.34 mmol, 76.4%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.52. 1H NMR (400 MHz, CDCl3) δ 2.12 (2H, t, J = 6.0 Hz), 2.18 (2H, t,
J = 7.2 Hz), 2.24 (2H, m), 2.44 (2H, t, J = 5.2 Hz), 2.48 (4H, t, J = 4.4 Hz), 3.17 (2H, t, J = 4.8 Hz), 3.63
(2H, t, J = 5.2 Hz), 3.70 (4H, t, J = 4.8 Hz), 4.41 (2H, t, J = 6.4 Hz), 7.28 (2H, d, J = 6.0 Hz), 7.37 (2H, dd,
J = 6.4 Hz, 8.8 Hz), 8.15 (2H, d, J = 2.1 Hz); 13C NMR (100 MHz, CDCl3) 23.5, 28.7, 41.6, 42.1, 45.0, 53.2,
53.3, 54.1, 55.4, 56.3, 66.9, 110.7, 112.1, 123.3, 123.4, 129.2, 139.4, 169.8. HR-FTMS (ESI) m/z calcd. for
C26H32Br2N4O2, [M + H]+ 593.0944, found 593.0945.
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Synthesis of 2-{4-[4-(3,6-Dibromocarbazol-9-yl)-butyryl]piperazin-1-yl}-N-isopropylacetamide (20)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.2273 g, 0.39 mmol, 87.3%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.68. 1H NMR (400 MHz, CDCl3) δ 1.17 (6H, d, J = 6.6 Hz), 2.10 (2H, t,
J = 6.3 Hz), 2.21 (2H, m), 2.26 (2H, t, J = 4.7 Hz), 2.47 (2H, t, J = 4.5 Hz), 3.15 (2H, t, J = 4.5 Hz), 3.64 (2H,
t, J = 4.5 Hz), 4.10 (1H, m), 4.43 (2H, t, J = 6.6 Hz), 6.73 (1H, bs), 7.31 (2H, d, J = 8.7 Hz), 7.54 (2H, dd,
J = 1.9, 8.7 Hz), 8.14 (2H, d, J = 1.9 Hz); 13C NMR (100 MHz, CDCl3) 22.8, 23.4, 28.7, 40.8, 41.6, 42.0,
45.0, 53.0, 53.1, 61.5, 110.64, 112.1, 123.3, 123.5, 129.2, 139.4, 168.4, 170.0. HR-FTMS (ESI) m/z calcd. for
C25H30Br2N4O2, [M + H]+ 579.0788, found 579.0790.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-1-[4-(2-dimethylaminoethyl)piperazin-1-yl]butan-1-one (21)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0228 g, 0.04 mmol, 7%). TLC analysis in
CH2Cl2-MeOH (9:1), Rf = 0.50. 1H NMR (400 MHz, CDCl3) δ 1.25 (6H, s), 2.12 (2H, t, J = 6.0 Hz), 2.19
(2H, m), 2.24 (4H, t, J = 5.6 Hz), 2.43 (4H, t, J = 4.8 Hz), 3.19 (2H, t, J = 4.4 Hz), 3.64 (2H, t, J = 4.4 Hz),
4.40 (2H, t, J = 6.4 Hz), 7.31 (2H, d, J = 8.8 Hz), 7.53 (2H, dd, J = 1.6, 8.4 Hz,), 8.21 (2H, d, J = 2.0 Hz); 13C
NMR (100 MHz, CDCl3) 23.5, 28.7, 41.5, 42.1, 45.0, 45.6, 53.1, 53.3, 56.1, 56.5, 110.6, 112.1, 123.2, 123.4,
129.2, 139.4, 170.0. HR-FTMS (ESI) m/z calcd. for C24H30Br2N4O, [M + H]+ 551.0839, found 551.0842.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(4-morpholin-4-ylphenyl)butyramide (22)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0689 g, 0.12 mmol, 40%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.80. 1H NMR (400 MHz, DMSO-d6) δ 2.05 (2H, t, J = 6.8 Hz), 2.30 (2H, m),
3.02 (4H, t, J = 4.8 Hz), 3.71 (4H, t, J = 4.4 Hz), 4.44 (2H, t, J = 6.8 Hz), 6.86 (2H, d, J = 8.8 Hz), 7.41 (2H,
d, J = 8.8 Hz), 7.61 (2H, dd, J = 0.8, 8.8 Hz), 7.64 (2H, d, J = 8.4 Hz), 8.48 (2H, s), 9.62 (1H, s); 13C NMR
(100 MHz, DMSO-d6) 24.1, 32.7, 42.0, 48.9, 66.1, 111.3, 111.6, 115.4, 120.3, 122.9, 123.4,128.8, 131.5, 139.0,
147.0, 169.7. HR-FTMS (ESI) m/z calcd. for C26H25Br2N3O2, [M + H]+ 572.0366, found 572.0365.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(3,4,5-trimethoxyphenyl)butyramide (23)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.051 g, 0.10 mmol, 30%). TLC analysis in
CH2Cl2-MeOH (9:1), Rf = 0.17. 1H NMR (400 MHz, DMSO-d6) δ 2.08 (2H, m), 2.28 (2H, t, J = 7.2 Hz),
3.60 (3H, s), 3.71 (3H, s), 3.72 (3H, s), 4.46 (2H, t, J = 6.8 Hz), 6.90 (2H, s), 7.60 (2H, dd, J = 1.6, 8.4 Hz),
7.64 (2H, d, J = 8.8 Hz), 8.47 (2H, d, J = 1.6 Hz), 9.71 (1H, s); 13C NMR (100 MHz, DMSO-d6) 6.96, 24.0,
32.0, 42.0, 55.6, 60.0, 96.9, 111.3, 111.6, 122.9, 123.4, 128.8, 133.3, 135.2, 139.1, 152.6, 170.1. HR-FTMS
(ESI) m/z calcd. for C25H24Br2N2O4, [M + H]+ 577.0155, found 577.0142.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-quinolin-3-ylbutyramide (24)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0275 g, 0.052 mmol, 15%). TLC analysis
in hexane-ethyl acetate (1:1), Rf = 0.20. 1H NMR (400 MHz, DMSO-d6) δ 2.13 (2H, m), 2.44 (2H, t,
J = 6.8 Hz), 4.50 (2H, t, J = 6.5 Hz), 7.41 (1H, t, J = 7.4 Hz), 7.54 (1H, t, J = 8.0 Hz), 7.62 (1H, t, J = 7.9 Hz),
7.67 (1H, d, J = 8.6 Hz), 7.71 (1H, d, J = 8.3 Hz), 7.92 (2H, t, J = 8.4 Hz), 7.98 (2H, d, J = 8.4 Hz), 8.47 (2H,
s), 8.64 (1H, s), 8.82 (1H, s), 10.3 (1H, s); 13C NMR (100 MHz, DMSO-d6) 23.9. 32.9, 42.0, 109.6, 111.4,
111.7, 119.2, 122.0, 123.0, 123.5, 124.5, 127.0, 127.4, 127.6, 127.7, 127.8, 128.5, 128.9, 132.8, 139.1, 144.1,
144.5, 171.3. HR-FTMS (ESI) m/z calcd. for C25H19Br2N3O, [M + H]+ 537.9947, found 537.9946.
397
Molecules 2019, 24, 2686
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(1H-indol-6-yl)butyramide (25)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1152 g, 0.22 mmol, 38%). TLC analysis
in hexane-ethyl acetate (1:1), Rf = 0.50. 1H NMR (400 MHz, DMSO-d6) δ 2.08 (2H, m), 2.35 (2H, t,
J = 7.1 Hz), 4.47 (2H, t, J = 7.0 Hz), 6.33 (1H, s), 6.97, (1H, d, J = 9.1 Hz), 7.24 (1H, s), 7.40 (1H, d,
J = 8.4 Hz), 7.61 (2H, d, J = 7.2 Hz), 7.66 (2H, d, J = 8.7 Hz), 7.95 (1H, s), 8.49 (2H, s), 9.75 (1H, s); 13C
NMR (100 MHz, DMSO-d6) 24.2, 32.9, 42.1, 100.9, 102.2, 111.3, 111.6, 112.3, 119.7, 123.0, 123.5, 123.7,
124.8, 128.9, 133.3, 135.9, 139.1. HR-FTMS (ESI) m/z calcd. for C24H19Br2N3O, [M + H]+ 525.9947,
found 9946.
Synthesis of N-(3H-Benzoimidazol-5-yl)-4-(3,6-dibromocarbazol-9-yl)butyramide (26)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.100 g, 0.20 mmol, 44%). TLC analysis in
hexane-ethyl acetate (1:1), Rf = 0.70. 1H NMR (400 MHz, DMSO-d6) δ 2.16 (2H, m, J = 7.2 Hz), 3.18 (2H,
t, J = 7.6 Hz), 4.52 (2H, t, J = 7.2 Hz), 6.66 (1H, dd, J = 2.0, 8.8 Hz), 7.60 (1H, dd, J = 2.0, 8.8 Hz), 7.68
(1H, d, J = 8.8 Hz), 8.05 (1H, s), 8.47 (1H, dd, J = 1.6, 8.0 Hz); 13C NMR (100 MHz, DMSO-d6) 23.6, 32.0,
42.3, 97.2, 111.8, 112.0, 114.3, 117.2, 122.3, 123.5, 124.0, 129.4, 139.5, 141.0, 141.2, 151.7, 173.0. HR-FTMS
(ESI) m/z calcd. for C23H18Br2N4O, [M + H]+ 526.9900, found 526.9904.
Synthesis of 4-(3,6-Dibromocarbazol-9-yl)-N-(4-methoxyphenyl)butyramide (27)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1830 g, 0.35 mmol, 94%). TLC analysis
in hexane-ethyl acetate (1:1), Rf = 0.64. 1H NMR (400 MHz, DMSO-d6) δ 2.05 (2H, m), 2.30 (2H, t,
J = 7.2 Hz), 3.70 (3H, s), 4.45 (2H, t, J = 7.2 Hz), 6.84 (2H, d, J = 9.2 Hz), 7.44 (2H, d, J = 9.2 Hz), 7.60 (2H,
dd, J = 2.0, 8.8 Hz), 7.65 (2H, d, J = 8.8 Hz), 8.48 (2H, d, J = 2.0 Hz), 9.68 (1H, s); 13C NMR (100 MHz,
DMSO-d6) 24.1, 32.7, 42.0, 55.1, 111.3, 111.6, 113.8, 120.7, 123.0, 123.5, 128.7, 132.3, 139.1, 155.1, 169.9.
HR-FTMS (ESI) m/z calcd. for C23H20Br2N2O2, [M + H]+ 516.9944, found 516.9941.
3.2.4. Synthesis of N-Alkyl-5-Bromoindole Derivatives (31–34)
3.2.5. General Procedure for the Synthesis of 4-(5-Bromoindol-1-yl)Butyric Acid (29)
A 50 mL three-neck round-bottom flask, equipped with a reflux condenser, was charged with
5-bromoindole 28 (0.1960 g, 1.0 mmol), Cs2CO3 (0.9770 g, 3 mmol) and ethyl 4-bromobutyrate (0.43 mL,
3.0 mmol), dissolved in DMF (3 mL). After 15 min of stirring at room temperature, the reaction mixture
was refluxed at 100 ◦C for 16 h. After completion of the reaction (analyzed by TLC), water (1 mL) and
KOH (1.0 mmol) were added and the reaction mixture refluxed at 80 ◦C for 2 h. After the reaction
was completed (analyzed by TLC), the mixture was allowed to reach room temperature and 1N HCl
solution was added until reach neutral pH. The mixture was washed with water (20 mL) and the
product was extracted using dichloromethane (3 × 10 mL). The organic layer was washed with brine
and dried with Na2SO4, and filtered and concentrated under reduced pressure. The crude oil was
purified via column chromatography over silica gel and 10% CH2Cl2 in MeOH, and the product
obtained as a white solid for the precursor 4-(5-Bromoindol-1-yl)Butyric acid 29 (0.2260 g, 0.801 mmol,
80%). TLC analysis in CH2Cl2-MeOH (9:1), Rf = 0.25. 1H NMR (400 MHz, CDCl3) δ 2.16 (2H, m),
2.34 (2H, t, J = 7.2 Hz), 4.20 (2H, t, J = 6.80 Hz), 6.44 (1H, d, J = 2.4 Hz), 7.08 (1H, 2, J = 3.2 Hz), 7.22
(1H, d, J = 6.4 Hz), 7.29 (1H, dd, J = 2.0, 8.8 Hz), 7.74 (1H, d, J = 1.6 Hz); 13C NMR (100 MHz, CDCl3)
25.1, 30.5, 45.3, 101.1, 110.7, 112.8, 123.5, 124.5, 128.9, 130.3, 134.6, 177.4. HR-FTMS (ESI) m/z calcd. for
C12H12BrNO2, [M + H]+ 284.0104, found 284.0102.
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3.2.6. General Procedure for the Synthesis of
4-(5-Bromoindol-1-yl)-N-(3-Morpholin-4-ylpropyl)Butyramide (31), and for Compounds 32–34
A 50 mL three-neck round-bottom flask was charged with 4-(5-Bromoindol-1-yl)Butyric acid 29
(0.098 g, 0.35 mmol), HOBT (0.2027 g, 1.5 mmol), and EDAC (0.2876 g, 1.5 mmol). The mixture was
dissolved in DMF (5 mL), stirred for 30 min, and 3-morpholinopropylamine (0.0512 mL, 0.35 mmol)
was added. After 15 min, Et3N (0.43 mL, 3.0 mmol) was added and the mixture stirred at room
temperature for 16 h. After the reaction was completed (analyzed by TLC), water was added (30 mL)
and the product was extracted using dichloromethane (3 × 10 mL). The organic layer was washed with
brine and dried with Na2SO4, and filtered and concentrated under reduced pressure. The crude oil
was purified via column chromatography over silica gel and 10% methanol in dichloromethane, and
the product obtained as a white solid (0.0748 g, 0.18 mmol, 53%). TLC analysis in hexane-ethyl acetate
(1:1), Rf = 0.36. 1H NMR (400 MHz, CDCl3) δ 1.62 (2H, m), 2.01 (2H, t, J = 6.8 Hz), 2.21 (2H, m), 2.35
(4H, bs), 2.42 (2H, t, J = 6.4 Hz), 3.32 (2H, q, J = 5.6 Hz), 3.47 (4H, bs), 4.39 (2H, t, J = 6.8 Hz), 7.0 (1H, bs),
7.26 (1H, d, J = 1.2 Hz), 7.32 (1H, d, J = 8.8 Hz), 7.55 (1H, dd, J = 2.0, 8.8 Hz), 8.14 (1H, d, J = 1.6 Hz); 13C
NMR (100 MHz, CDCl3) 24.5, 25.8, 32.6, 39.6, 45.2, 53.6, 58.0, 67.0, 101.1, 110.9, 112.6, 123.4, 124.3, 128.8,
130.2, 134.9, 171.2. HR-FTMS (ESI) m/z calcd. for C19H26BrN3O2, [M + H]+ 410.1261, found 410.1257.
Synthesis of 1-[4-(5-Bromoindol-1-yl)butyryl]piperidine-4-carbonitrile (32)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.0356 g, 0.10 mmol, 24.4%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.76. 1H NMR (400 MHz, DMSO-d6) δ 1.58 (4H, m), 1.81 (2H, bs), 1.94
(2H, t, J = 7.2 Hz), 2.26 (2H, t, J = 7.2 Hz), 3.07 (1H, m), 3.50 (2H, dt, J = 4.8, 15.2 Hz), 3.78 (2H, dt,
J = 4.8, 13.6Hz), 4.18 (2H, t, J = 6.8Hz), 6.42 (1H, d, J = 3.2 Hz), 7.24 (1H, dd, J = 2.0, 8.4 Hz), 7.41 (1H,
d, J = 3.2 Hz), 7.47 (1H, d, J = 8.8 Hz), 7.73 (1H, d, J = 2.0 Hz); 13C NMR (100 MHz, DMSO-d6) 22.7,
25.3, 28.2, 29.4, 29.7, 39.5, 43.1, 45.3, 101.0, 111.0, 112.7, 120.6, 123.5, 124.4, 128.9, 130.2, 134.9, 169.9.
HR-FTMS (ESI) m/z calcd. for C18H20BrN3O, [M + H]+ 376.0842, found 376.0837.
Synthesis of 4-(5-Bromoindol-1-yl)-N-(3-imidazol-1-yl-propyl)butyramide (33)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1255 g, 0.32 mmol, 57%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.44. 1H NMR (400 MHz, CDCl3) δ 1.81 (2H, m, J = 6.8 Hz), 1.98 (2H, m,
J = 6.8 Hz), 2.06 (2H, t, J = 6.4 Hz), 3.01 (2H, q, J = 5.6 Hz), 3.95 (2H, t, J = 6.8 Hz), 4.17 (2H, t, J = 7.2 Hz),
6.42 (1H, d, J = 2.8 Hz), 6.95 (1H, bs), 7.23 (2H, dd, J = 1.6, 8.4 Hz), 7.40 (1H, d, J = 2.8 Hz), 7.45 (1H, d,
J = 8.8 Hz), 7.72 (1H, d, J = 2.0 Hz), 7.90 (1H, t, J = 5.2 Hz); 13C NMR (100 MHz, CDCl3) 25.7, 31.0, 32.2,
36.5, 44.2, 45.6, 101.0, 111.0, 112.5, 119.1, 123.3, 124.4, 128.7, 128.8, 130.2, 134.7, 136.9, 172.4. HR-FTMS
(ESI) m/z calcd. for C18H21BrN4O, [M + H]+ 391.0951, found 391.0956.
Synthesis of 4-(5-Bromoindol-1-yl)-N-(2-piperidin-1-ylethyl)butyramide (34)
The crude oil was purified via column chromatography over silica gel and 10% methanol in
dichloromethane, and the product obtained as a white solid (0.1967 g, 0.50 mmol, 50%). TLC analysis
in CH2Cl2-MeOH (9:1), Rf = 0.47. 1H NMR (400 MHz, DMSO-d6) δ 1.35 (2H, m, J = 5.2 Hz), 1.47 (4H,
m, J = 5.6 Hz), 1.96 (2H, m, J = 6.4 Hz), 2.01 (2H, t, J = 6.0 Hz), 2.30 (2H, t, J = 6.8 Hz), 2.35 (2H, bs), 3.13
(2H, q, J = 6.4 Hz), 4.18 (2H, t, J = 6.4 Hz) 7.35 (1H, dd, J = 2.0, 8.8 Hz), 7.54 (2H, d, J = 2.4 Hz), 7.56
(1H, s), 7.68 (1H, s), 7.71 (1H, t, J = 5.6 Hz); 13C NMR (100 MHz, DMSO-d6) 24.1, 25.5, 25.7, 32.4, 35.7,
45.8, 54.3, 57.2, 100.8, 109.4, 111.0, 118.5, 120.3, 128.9, 129.0, 134.7, 171.7. HR-FTMS (ESI) m/z calcd. for
C25H30Br2N4O2, [M + H]+ 394.1312, found 394.1313.
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3.3. Biological Evaluation
3.3.1. Cell Culture
MCF-7 and MDA-MB-231 cells were cultured in Minimum Essential Medium Eagle (MEME) 10%
FBS supplemented with Earle’s Balanced Salt Solution (EBSS), Non-essential Amino Acids (NEAA),
Sodium Pyruvate, Pen/Strep, and L-glutamine 37 ◦C in 5% CO2.
3.3.2. Sulforhodamine B (SRB) Assay
A stock solution of compounds was prepared at 50 mM in 100% DMSO. For cell preparation, a flask
of 75 cm2 or 25 cm2 was used for 2.6 × 105 cells/mL or 1.44 × 105 cells/mL, respectively, with an 80–90%
confluence. Cells were washed with PBS and trypsinized. The concentration of cells was determined
using a 1:2 dilution with Trypan Blue and a hemocytometer. After cell count, the concentration was
adjusted to have a 7.0–10.0 × 104 cells/mL. Approximately 100 μL of cells suspension, compounds,
control positive and control negative were added in triplicates to a 96 well plate. The positive control
used was doxorubicin, and the negative control was DMSO 0.1%. All compounds at 50, 25, 12.5, 6.3,
and 1.6 μM were incubated with cells at 37 ◦C for 48 hrs. For fixation, cold TCA 50% was used and
incubated at 4 ◦C for 1 hr. Wells were washed and dried prior to tincture with 100 μL of SRB 0.4%.
To remove excess SRB, acetic acid was used. For analysis, TRIS-Base Solution (pH = 10.5) was used
and shaken prior to reading using an ELISA reader at 540 nm and the software SoftMax Pro 4.8. For
each compound, 50% growth inhibition (GI50) was calculated from sigmoidal dose-response curves
(variable-slope) that were generated with data obtained from experiments carried out in triplicates
(GI50 values were generated with GraphPad Prism V. 6.02, GraphPad Software, Inc.).
3.3.3. Wound Healing Assay (Scratch Method) Using MDA-MB-231 Cancer Cells
Prior to assays, cells were grown until 80–90% confluence was observed. We used a 75 cm2 flask
for 2.6 × 105 cells/mL in 10 mL, and for a 25 cm2 flask 1.44 × 105 cells/mL in 5 mL. The cells were
washed with PBS to remove all traces of FBS. We added trypsin at 2 mL for a 25 cm2 flask or 4 mL
for a 75 cm2 flask, and incubated 5–10 min at 37 ◦C. At the end of the incubation time, cells were
re-suspended and counted with hemocytometer using 1:2 dilutions with Trypan Blue. Subsequently,
cell viability was calculated. In a 12 multiwell plate. Cells were seeded at 1.5–2.2 × 105 cells/mL in
1 mL and incubated for 24 h. Cells were then rinsed with PBS and incubated in starving media (0.5%
FBS) overnight. All controls and drugs were tested in triplicate. The vehicle control for each drug was
prepared according to the drug’s DMSO concentration. Drugs were diluted and the final concentration
at each well was 10 μM (or GI50/5 on MDA-MB-231 cells). The wound was made using a sterile pipette
tip of 200 μL. Cells were then rinsed very gently with media without FBS and media with vehicle
controls or drugs were added. After a 24 h incubation, the gap distance was evaluated using the
software Lumera Infinity Analyze 6.4.0. Pictures were taken at 0, 8, 12, and 24 h using a 10X objective
in an Inverted Laboratory Microscope Leica DM IL LED, and an Infinity1-3 3.1 Megapixel USB 2.0
camera CMOS. The percentage of migration was calculated using the following formula:
100 − [ (X0⁄
..
X0)]*100 for time 0 h measurements
100 − [ (X24⁄⁄
..
X0)]*100 for time 24 h measurements
3.3.4. Actin Polymerization Assay
MDA-MB-231 cells were treated with vehicle or compound derivatives at 10 μM (or at
concentrations that do not affect cell viability) for 24 h at 37 ◦C in 5% CO2. Cells were fixed in
3.7% of formaldehyde, permeabilized using 0.2% Triton, and stained with Rhodamine Phalloidin to
visualize F-actin. Fluorescence micrographs were acquired at 60x in an Eclipse E400 fluorescence
microscope using a DS-Qi2 monochrome digital camera from Nikon for fluorescence imaging.
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4. Conclusions
In this study, a new series of N-alkyl-3,6-dibromocarbazole and N-alkyl-5-bromoindole derivatives
were designed, synthesized, and biologically evaluated for their anti-cancer and anti-migration effect
on MCF-7 and MDA-MB-231 cancer cells. In addition, the effect of compounds on the actin cytoskeleton
of MDA-MB-231 cancer cells was explored. From the results, we have established the Structure-Activity
Relationships of novel derivatives of the lead compound Wiskostatin. We found that the carbazole
moiety is needed for in vitro anti-cancer and anti-migratory potency. The replacement of the carbazole
by an indole ring resulted in loss of activity. Moreover, the aliphatic or aromatic amide group
was extended 3-carbon atoms away from the carbazole moiety. The most potent anti-proliferative
compounds were those bearing a 3,6-dibromocarbazole group with GI50 values between 7–32 μM
and 4.7–23 μM on MCF-7 and MDA-MB-231 cancer cells, respectively. The most promising results
in terms of anti-migratory effect was exhibited by carbazole derivatives 10, 23, 14–16, and 24 with
migration inhibition in the range of 10–20% on the highly metastatic breast cancer cells MDA-MB-231.
Future studies will improve these derivatives and also test their effects at higher concentrations and
shorter times of migration to reduce potential cytotoxic effects, which may confound inhibition of cell
migration. The carbazole derivatives 10, 14, and 15 were further examined as actin polymerization
inhibitors and results demonstrated reduction in actin polymerization and extension of F-actin based
structures. Further studies of mechanism of actions focused on the effect of these novel compounds in
the Cdc42/N-WASP/Arp2/3 pathway is needed to fully characterize and analyze the potential of this
new series of compounds as in vitro and in vivo anti-metastatic drugs.
Supplementary Materials: The following are available online. 1H and 13C NMR spectral data for representative
compounds. Figure S1: 1H NMR Spectral Data of 2; Figure S2: 13C NMR Spectral Data of 2; Figure S3: 1H NMR
Spectral Data of 7; Figure S4: 13C NMR Spectral Data of 7; Figure S5: 1H NMR Spectral Data of 12; Figure S6: 13C
NMR Spectral Data of 12; Figure S7: 1H NMR Spectral Data of 14; Figure S8: 13C NMR Spectral Data of 14; Figure
S9: 1H NMR Spectral Data of 16; Figure S10: 1H NMR Spectral Data of 22; Figure S11: 13C NMR Spectral Data
of 22; Figure S12: 1H NMR Spectral Data of 24; Figure S13: 13C NMR Spectral Data of 24; Figure S14: 1H NMR
Spectral Data of 29; Figure S15: 13C NMR Spectral Data of 29; Figure S16: 1H NMR Spectral Data of 33; Figure S17:
13C NMR Spectral Data of 33.
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Abstract: Bivalent and polyvalent inhibitors can be used as antitumor agents. In this experiment,
eight ligustrazine dimers and seven ligustrazine tetramers linked by alkane diamine with different
lengths of carbon chain lengths were synthesized. After screening their antiproliferation activities
against five cancer cell lines, most ligustrazine derivatives showed better cytotoxicity than the
ligustrazine monomer. In particular, ligustrazine dimer 8e linked with decane-1,10-diamine exhibited
the highest cytotoxicity in FaDu cells with an IC50 (50% inhibiting concentration) value of 1.36 nM.
Further mechanism studies suggested that 8e could induce apoptosis of FaDu cells through the
depolarization of mitochondrial membrane potential and S-phase cell cycle arrest. Inspired by these
results, twenty-seven additional small molecule heterocyclic dimers linked with decane-1,10-diamine
and nine cinnamic acid dimers bearing ether chain were synthesized and screened. Most monocyclic
and bicyclic aromatic systems showed highly selective anti-proliferation activity to FaDu cells and low
toxicity to normal MCF 10A cells. The structure-activity relationship revealed that the two terminal
amide bonds and the alkyl linker with a chain length of 8–12 carbon were two important factors to
maintain its antitumor activity. In addition, the ADMET calculation predicted that most of the potent
compounds had good oral bioavailability.
Keywords: bivalency; polyvalency; antitumor; apoptosis; cell cycle
1. Introduction
Natural products play a vital role in the development of the drug, especially anticancer drugs [1].
Ligustrazine (2,3,5,6-tetramethylpyrazine, TMP), an important component of the Chinese traditional
medicinal herb Chuanxiong (Ligusticum chuanxiong Hort), has been of wide clinical use for cardiovascular
and cerebrovascular diseases [2]. Recently, TMP has been reported to possess anticancer activity
in vitro and in vivo, inducing cancer cell apoptosis and cell cycle modulation [3,4]. More importantly,
the introduction of different substituted groups into ligustrazine has helped to improve the antitumor
activity. Many ligustrazine derivatives with potent antitumor activity have been developed in the past
few years, like monocarbonyl ligustrazine-curcumin hybrids [5], ligustrazine-betulinic acid hybrids [6],
and ligustrazine-rhein derivatives [7]. This advancement stimulated our interest in using TMP as the
scaffold to synthesize new antitumor agents.
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In the interaction between host and guest molecules, both bivalency and polyvalency could
enhance the affinity and activity of monovalent ligand [8,9]. This phenomenon has attracted attention in
drug design. Many effective bivalent anti-cancer drugs have been found, such as artemisinin-derivative
dimers [10], jesterone dimer [11], indole-3-carbinol dimer [12], bis-daunorubicin [13]. Previous work
in this field has designed and synthesized several ligustrazine dimers linked by cyclohexanone and
oxime [14], curcumin [15], or triterpenes [16], which had a good cytotoxic effect on human cancer
cells. The result showed that the dimerization of ligustrazine could obviously improve the antitumor
potency of its monomer.
With an effort to developing new antitumor agents, we designed and synthesized a series of novel
TMP dimers and tetramers linked with different alkyl diamines and screened their anti-proliferation
potential on a panel of human cancer cell lines, including HeLa, Hep G2, MCF-7, FaDu, and A549.
Based on these experimental results, according to the importance of small molecular heterocyclic rings
in drug discovery [17], additional dimers series of aromatic rings instead of ligustrazine, a total of
51 new compounds were synthesized, screened, and their structure-activity relationship was briefly
discussed. Meanwhile, through morphological observation and flow cytometric analysis, the antitumor
mechanisms of the most potent one were preliminarily discussed in this study. ADMET properties of
all compounds were also evaluated to explore the drug-likeness.
2. Results and Discussion
2.1. Chemistry
In this study, 51 novel designed compounds were synthesized. Series 6a–g and 8a–f were
obtained according to the synthetic method described in Schemes 1 and 2. The important intermediate
2-chloromethyl-3,5,6-trimethyl-pyrazine 5 was prepared from ligustrazine by the tandem reaction:
Boekelheide reaction [18] and deprotection and the chlorination reaction [19]. The key intermediate
2-carboxylic acid-3,5,6-trimethyl-pyrazine 7 was synthesized by the one-pot reaction, as previously
reported [20]. To explore the length effect, the TMP moieties, with 2–12 methylene alkyl chain as a
linker, were synthesized.
 
Scheme 1. Synthesis of the TMP complexes 6a–6i. Reagents and conditions: (a) 30% H2O2, CH3COOH,
95 ◦C, 2 h; (b) (CH3CO)2O, 140 ◦C, 2.5 h; (c) CH3ONa, CH3OH, r.t., 0.5 h; (d) SOCl2, CH2Cl2, r.t., 2.5 h;
(e) n-diaminoalkane (piperazine and monoethanolamine), K2CO3, CH3CN, 95 ◦C, 2 h.
 
Scheme 2. Synthesis of the Bis-TMP hybrids 8a–8f. Reagents and conditions: (f) KMnO4, H2O, 37 ◦C, 24
h; (g) n-diamino-alkane, EDCI/DMAP, r.t., 12 h.
Using heteroaromatic acids with decane-1,10-diamine as raw materials, the target
compounds 9e–35e (outlined in Scheme 3) linked by amide chain were synthesized
with EDCI (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and DMAP
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(4-Dimethylaminopyridine) in anhydrous CH2Cl2 at room temperature. Series 9d, 9f–l (shown in
Scheme 4) linked by ether chain or amide chain were synthesized by the above method. All the newly
synthesized compounds were characterized by 1H-NMR, 13C-NMR, and high-resolution mass spectra
(HRMS). Details were provided in the experimental part. The purity of the compounds was over 95%
measured by HPLC (Figure 1).
 
Scheme 3. Synthesis of compounds 9e–35e. Reagents and conditions: (h) decane-1,10-diamine,
EDCI/DMAP, r.t., 12 h.
 
Scheme 4. Synthesis of compounds 9d, 9f–9m. Reagents and conditions: (i) cinnamic acid, EDCI/DMAP,
r.t., 12 h.
Figure 1. The purity of compound 8e as a representative analyzed by HPLC (Kromasil C18 column,
eluted by methanol/water (80/20) containing 0.1% trifluoroacetic acid at a flow rate of 1 mL/min).
2.2. Anti-Proliferative Activity In Vitro
For the newly synthesized compounds, their anti-proliferative activity on human cancer cell
lines, HeLa (cervical carcinoma), Hep G2 (hepatoma carcinoma), MCF-7 (breast carcinoma), FaDu
(head and neck carcinoma), A549 (lung carcinoma), and normal mammary epithelial cell line MCF
10A, was screened by MTT assay [21] with doxorubicin (DOX) as the positive control. The IC50
values of these compounds are summarized in Table 1. Among the ligustrazine derivatives, 6a–g
and 8a–f, the tetramers 6f and 6g had broad-spectrum cytotoxic activities in all cell lines (IC50
407
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6.57–20.83 μM), and the cytotoxicity activities increased with the increase of carbon chain length.
The dimeric ligustrazine 8d, 8e, 8f showed the most promising anticancer activity in most tested
tumor cell lines with IC50 values between 0.00136 and 6.35 μM, a much better result than DOX and
TMP. In particular, compound 8e, two ligustrazine rings linked with decane-1,10-diamine, exhibited
the best anti-proliferative ability in cells (except Hep G2), and compared with other linkers, its
IC50 values were 1.42 ± 0.71 μM, 0.037 ± 0.001 μM, 0.00136 ± 0.00035 μM, 1.05 ± 0.05 μM, and
0.047 ± 0.008 μM against HeLa, MCF-7, FaDu, A549, and MCF 10A, respectively. In light of these
results, we replaced TMP with aromatic heterocycles similar to ligustrazine in electronic space.
The novel small aromatic molecule and heterocyclic dimers 9e–35e were synthesized, and their
anti-proliferative ability was evaluated. Compounds 9e, 10e, 11e, 17e, 18e, 21e, 22e, 23e, and 25e,
aromatic acid dimers (cinnamoyl, nicotinoyl, benzoyl, quinoline-3-carboxyl, quinoline-6-carboxyl,
benzofuran-2-carboxyl, benzothiophene-2-carboxyl, indol-3-carboxyl, chlorinated cinnamoyl), were
linked by decane-1,10-diamine, which had potent anti-proliferative ability in FaDu or A549 cell lines.
Their IC50 in FaDu cell lines were less than 1 μM, in the range of 20 nM (benzothiophene-2-carboxyl)
and 697 nM (benzofuran-2-carboxyl). Also, they had nearly no toxicity in normal cells like MCF
10A. In series 9d–n, compounds 9d–f (IC50 < 1 μM), two cinnamic acids linked by C8, C10, C12
chain with two terminal amide bonds, were more effective than compounds 9g–i (IC50 > 20 μM), two
cinnamic acids linked by the same alkyl chain with two terminal ester bonds instead of amide bonds.
This demonstrated the vital role of two-terminal amide bonds in antitumor activity. Compared with
compounds 9d–f, the inhibition of compounds 9j–m, two cinnamic acids linked by the similar length
ether chain instead of alky chain, was weaker in tumor cells (IC50 > 20 μM), which confirmed that the
alkyl chain played an important role in the structure. Then, we evaluated the position effect of the
substitution at the ortho, meta, or para positions of the same aromatic ring. Compounds 25–35e and
the unsubstituted compounds 9e and 11e were all derivatives of cinnamic acid or benzoic acid with
different substituents and electronic effects. The results of the compounds 26–27e or 28–29e confirmed
that the substituents had a general effect on the activity, -OH, -OCH3, -NH2, and other electron donor
groups could significantly reduce the activity, with the influence of -OH greater than that of -OCH3.
However, the electron attraction group like -Cl (25e) had no obvious effect. The compounds with
para-substituted analogs (31e, para position, IC50 = 5.594 μM) exhibited better cell growth inhibitory
activities in FaDu cells than ortho- and meta- substituted analogs (30e, 32e, ortho and meta position,
IC50 > 20 μM). It is worth noting that para -OCH3 substitution could enhance anticancer activity.
The IC50 value of compound 34e was 5.853 ± 0.408 μM, the IC50 value of para- OCH3 was half that of
the parent compound 33e, and the IC50 value of compound 33e was 10.393 ± 0.949 μM. Generally, there
were three crucial elements in the structure-activity relationship of these systems: alkyl chain linker,
two-terminal amide bonds, and heteroaromatic substituents. This SAR (structure-activity relationship)
study would help to discover more effective compounds in the future.
To study the selective antiproliferative activities of bivalent and polyvalent inhibitors in normal
cells and cancer cell lines, the cytotoxicity of compounds in FaDu cells and normal mammary epithelial
MCF 10A cells was measured. The results listed in Table 1 showed that although the ligustrazine
dimers 8d and 8e had high cytotoxicity in MCF 10A, their IC50 values were 2.69 ± 0.46 and 0.047
± 0.008 μM, while the IC50 values in FaDu cells were 110 ± 30 and 1.36 ± 0.035 nM, respectively,
which were far lower than that in MCF 10A. The selective index (SI) between MCF10A and Fadu
(IC50MCF 10A/IC50FaDu) was 24.45 and 34.56, respectively. In addition, the heteroaromatic acid dimers
9e–12e, 21e–23e, and 25e had the similar activity, which was stronger than doxorubicin in FaDu
cells, and had high selectivity in FaDu cells and MCF 10A cells with SI (IC50MCF 10A/IC50FaDu) values
over 28.69. In contrast, the SI (IC50MCF 10A/IC50FaDu) value of doxorubicin was 0.43. These results
encouraged us to further investigate the possible cellular mechanisms.
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Table 1. Inhibitory effects of synthetic compounds on the growth of different types of human cancer
cells and normal mammary epithelial cells.
Comp.
Antiproliferative Activity IC50 ± SEM (μM)
HeLa[a] Hep G2[b] MCF-7[c] FaDu[d] A549[e] MCF 10A[f] SI[g]
6a >100 >100 >100 >100 >100 90.29 ± 3.41 NCh
6b >100 >100 >100 >100 >100 >100 NCh
6c >100 >100 >100 >100 >100 >100 NCh
6d >100 >100 >100 >100 >100 >100 NCh
6e 62.67 ± 4.19 50.77 ± 1.35 66.36 ± 0.05 49.50 ± 1.61 >100 85.44 ± 2.28 1.73
6f 10.16 ± 0.55 10.72 ± 0.22 20.83 ± 0.14 10.94 ± 0.12 20.05 ± 0.41 12.97 ± 0.55 1.19
6g 7.89 ± 0.86 9.62 ± 0.11 9.83 ± 0.17 6.80 ± 0.05 9.23 ± 0.16 6.57 ± 0.30 0.97
6h >100 >100 >100 >100 >100 >100 NCh
6i >100 >100 >100 >100 >100 >100 NCh
8a >100 >100 >100 >100 >100 >100 NCh
8b >100 >100 >100 >100 >100 >100 NCh
8c >100 >100 >100 80.41 ± 1.36 >100 46.59 ± 0.65 NCh
8d 3.31 ± 0.14 >20 0.480 ± 0.003 0.11 ± 0.03 6.35 ± 0.05 2.69 ± 0.46 24.45
8e 1.42 ± 0.71 >20 0.037 ± 0.001 0.00136 ± 0.00035 1.05 ± 0.05 0.047 ± 0.008 34.56
8f 4.96 ± 1.62 >20 0.158 ± 0.009 0.174 ± 0.010 2.46 ± 0.05 0.051 ± 0.021 0.29
9e >100 >100 >100 0.054 ± 0.002 11.27 ± 0.81 >100 >1851.85
10e >100 >100 >100 0.25 ± 0.02 2.94 ± 0.25 38.60 ± 2.48 154.40
11e >100 >100 >100 0.50 ± 0.06 64.30 ± 3.46 80.54 ± 7.60 161.08
12e >100 >100 >100 1.33 ± 0.07 8.77 ± 0.47 >100 >75.19
13e >100 >100 >100 48.31 ± 3.17 >100 >100 >2.07
14e >100 97.75 ± 1.55 >100 6.33 ± 0.65 44.37 ± 0.29 19.82 ± 1.41 3.13
15e 37.74 ± 4.32 26.34 ± 5.36 21.48 ± 1.47 8.85 ± 0.45 23.08 ± 0.12 54.65 ± 5.92 6.18
16e >100 >100 >100 88.11 ± 1.37 >100 >100 NCh
17e >20 >20 >20 0.236 ± 0.005 >20 >20 >84.75
18e >20 >20 >20 0.697 ± 0.021 >20 >20 >28.69
19e >20 >20 >20 8.74 ± 0.44 >20 >20 >2.29
20e >20 >20 >20 >20 >20 >20 NCh
21e >20 >20 >20 0.665 ± 0.028 >20 >20 >30.08
22e >20 >20 >20 0.020 ± 0.002 >20 >20 >1000
23e >20 >20 >20 0.638 ± 0.089 >20 >20 >31.35
24e >20 >20 >20 5.296 ± 0.366 >20 >20 >3.78
25e >20 >20 >20 0.056 ± 0.016 >20 >20 >357.14
26e >20 >20 >20 >20 >20 >20 NCh
27e >20 >20 >20 4.621 ± 0.539 >20 >20 >4.33
28e >20 >20 >20 >20 >20 >20 NCh
29e >20 >20 >20 5.067 ± 0.461 >20 >20 >3.95
30e >20 >20 >20 >20 >20 >20 NCh
31e >20 >20 >20 5.594 ± 0.628 >20 >20 >3.58
32e >20 >20 >20 >20 >20 >20 NCh
33e >20 >20 >20 10.393 ± 0.949 >20 >20 >1.92
34e >20 >20 >20 5.853 ± 0.408 >20 >20 >3.42
35e >20 >20 >20 >20 >20 >20 NCh
9d >20 >20 >20 1.054 ± 0.091 >20 >20 >18.98
9f >20 >20 >20 0.027 ± 0.002 >20 >20 >740.74
9g >20 >20 >20 >20 >20 >20 NCh
9h >20 >20 >20 >20 >20 >20 NCh
9i >20 >20 >20 >20 >20 >20 NCh
9j >20 >20 >20 >20 >20 >20 NCh
9k >20 >20 >20 4.447 ± 0.208 >20 >20 >4.50
9l >20 >20 >20 >20 >20 >20 NCh
9m >20 >20 >20 >20 >20 >20 NCh
TMP >100 >100 >100 >100 >100 >100 NCh
DOX 11.39 ± 0.48 28.04 ± 1.09 6 ± 0.07 1.27 ± 0.13 >100 0.55 ± 0.03 0.43
[a] HeLa (cervical cancer cell line); [b] Hep G2 (hepatocarcinoma cell line); [c] MCF-7 (breast cancer cell line); [d]
FaDu (head and neck squamous carcinoma cell line); [e] A549 (epithelial cancer cell line); [f] MCF 10A (normal
mammary epithelial cell); [g] SI: selectivity index. It was calculated as: SI = IC50 (MCF 10A)/IC50 (FaDu); [h] NC:
not calculated.
2.3. Colony Formation Assay
As ligustrazine dimer 8e had the most potent antiproliferative activity in all synthesized
compounds, the colony formation assay in FaDu cells was conducted. As shown in Figure 2,
FaDu cells treated with compound 8e at concentrations 0.75 nM, 1.50 nM, 3 nM, 6 nM for 10 days
formed smaller and fewer colonies compared to untreated control group, indicating that compound
8e had a dose-dependent inhibition on the proliferation of FaDu cells, and the colony inhibition rate
reached around 85.4% at 6 nM.
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Figure 2. Effect of 8e on the colony formation in FaDu cells. (A) Representative images of FaDu colonies
after treatment at the indicated concentrations for 10 days; (B) The percentage of colonies compared
with control group, n = 3. **: p < 0.01; ***: p < 0.001 versus control.
2.4. Live/Dead Staining
Live-dead double staining experiment was conducted to visually evaluate the cell toxicity of
compound 8e, the most potent one obtained by MTT assay. Propidium iodide (PI)-stained dead cells
in red and calcein AM-stained living cells in green. The number of dead cells increased with the dose
of 8e while living cells decreased. Simultaneously, the densities of 8e-treated cells were much lower
than that of the control group. The concentration-dependent loss of FaDu cell viability was consistent
with the MTT results (Figure 3).
Figure 3. The confocal images of FaDu cells after incubation with compound 8e at concentrations of 0,
2, 5, and 10 nM for 24 h, respectively. Viable cells were stained in green with Calcein-AM, and dead
cells were stained in red with PI. The scale bar was 100 μm.
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2.5. Morphological Observation by Hoechst 33,342 Staining
To investigate whether the anti-proliferation behavior of 8e was related to the apoptosis pathway,
the interaction between 8e- and FaDu cells was analyzed through Hoechst 33,342 staining with a laser
scanning confocal microscope. As shown in Figure 4, cells without treatment as the control group
exhibited almost negligible apoptotic characteristics with homogenous and round blue-stained nuclei.
On the contrary, the typical apoptotic nuclei with irregular nuclear morphology and condensation
of chromatin (much brighter stained cells) were observed, and most FaDu cells were shrunken and
rounded up from the culture dish after exposure to 8e. The result demonstrated that inducing apoptosis
in FaDu cells might be one cause of cell growth inhibition by compound 8e.
Figure 4. Hoechst staining of FaDu cells treated with compound 8e, (A) Control group; (B) 20 nM group.
2.6. Apoptosis Analysis by Annexin V-FITC/PI Staining
To substantiate whether the cell death induced by the ligustrazine dimer 8e was associated
with apoptosis, the interaction of FaDu cells with 8e was further analyzed by an annexin V-FITC/PI
staining, and the apoptosis ratios were quantitated by flow cytometry. The cells were divided into
four quadrants: Q1 represented necrotic cells (annexin V−/PI+), Q2 represented late apoptotic cells
(annexin V+/PI+), Q3 represented early apoptotic cells (annexin V+/PI−), Q4 represented living cells
(annexin V−/PI−). As shown in Figure 5, after being exposed to different concentrations of 8e (2, 5, 10
nM) for 24 h in FaDu cells, the apoptotic cells (including the early and late apoptosis ratios) increased
gradually from 8.23% of the control to 34.2%, 57.7%, 79.5%, respectively. The results revealed that
8e could induce FaDu cells’ apoptosis in a dose-dependent manner. This was consistent with other
reports showing TMP and its derivatives could induce apoptosis of cancer cells [22–24].
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Figure 5. Flow cytometry analysis of apoptosis using annexin V-FITC/PI double staining in FaDu cells
treated with compound 8e at the indicated concentrations for 24 h. The percentage of cells was given in
the respective quadrants.
2.7. Mitochondrial Membrane Potential (ΔΨm) Analysis
Mitochondria play an essential role in cell apoptotic progression by regulating mitochondrial
membrane potential (ΔΨm). Depolarization of ΔΨm is considered an indicator of cell apoptosis [25]. To
better understand the mechanism of 8e-induced FaDu cells apoptosis, the depolarization of ΔΨm was
quantitated by JC-1 (tetraethylbenzimidazolylcarbocyanine iodide) dye. As a mitochondrial-specific
dual-fluorescence probe, JC-1 selectively entered the mitochondria. In healthy cells with high ΔΨm, it
accumulated in the mitochondrial matrix as J-aggregates with red fluorescence, while in the reduced
ΔΨm cells, it remained in the cytoplasm as a monomer with green fluorescence. The change of ΔΨm
could be easily detected by the change of fluorescence color. Flow cytometric analysis of FaDu cells
treated with different concentrations of 8e (2, 5, 10 nM) for 24 h revealed that the ratio of green to
red fluorescence was significantly higher than that of the control group in a concentration-dependent
manner, indicating that the number of lower ΔΨm cells increased (Figure 6). These results suggested
that 8e could induce apoptosis of FaDu cells by decreasing ΔΨm.
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Figure 6. Flow cytometry analysis of the mitochondrial membrane potential using the JC-1
(tetraethylbenzimidazolylcarbocyanine iodide) dye in FaDu cells treated with compound 8e at the
indicated concentrations for 24 h. The percentage of cells was given in the respective quadrants.
2.8. Cell Cycle Analysis
In order to investigate whether 8e induced cell cycle disturbances in FaDu cells, the flow cytometric
analysis was performed with PI staining. The fluorescence intensity was proportional to the content of
double-stranded DNA. The separation of cells in G0/G1, S, and G2/M was based upon the distribution
of DNA content. Cytometric profiles of the PI-stained DNA showed that after being treated with 8e
at different concentrations (2, 5, 10 nM) for 24 h, the cell cycle of FaDu cells was arrested. As shown
in Figure 7, the percentage of cells in the S phase (33.7%, 44.3%, and 54.7%) was markedly improved
compared with the control group (28.1%), and this effect was concentration-dependent in FaDu cells.
The population of the G0/G1 phase decreased from 51.9% to 41.8%, 44.2%, and 32.4%, respectively.
These data indicated that 8e significantly arrested cell cycle at S phase. This was different from the
previously reported cell cycle arrest in the G0/G1 phase induced by TMP [4], which revealed that the
dimerization of TMP could change the modulation of the cell cycle of its monomer.
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Figure 7. Flow cytometry analysis for cell cycle distribution of FaDu cells. (A) Representative cell
cycle distribution of FaDu cells with compound 8e treatment (0, 2, 5, and 10 nM) for 24 h. The tall
peak (left) represents cells in the G0/G1 phase, the small peak (right) represents cells in the G2/M
phase, and the middle area represents cells in the S phase. (B) Quantification of the percentage of cell
cycle distribution.
2.9. In Silico ADMET Prediction
ADMET prediction is becoming increasingly crucial as most drugs fail in clinical trials owing to
poor pharmacokinetic parameters [26,27]. Table 2 shows the ADMET calculated descriptors for our
synthesized compounds and two biplots shown in Figure 8. All compounds had 0–4 HBD (hydrogen
bond donor) and 4–10 HBA (hydrogen bond acceptor), which were under Lipinski’s rule of five (HBD
< 5, HBA < 10). PPB (plasma protein binding) was one of the key properties related to drug efficacy.
Except for compounds 10–15e, 17–24e, and 9d, most of the compounds had weak (<90%) binding with
plasma proteins in the blood, which were predicted to be non-inhibitors of cytochrome P450 2D6,
and participated in the good- metabolism of phase I metabolism. T1/2 of the target molecules was
in the range of 1.63–2.29 h, showing the characteristic of rapid metabolism. The HT (hepatotoxicity)
values estimated the hepatoxicity of the chemical compounds. HT values for series 6a–i, 13–14e, 20e,
29e, 31–35e, 9f, 9i, 9k, and 9m were zero, and there was no hepatoxicity, while other compounds
might be hepatotoxic. Moreover, the LD50 (median lethal dose) predicted that series 8a–f, 9–35e, and
9d–m were over 500 mg/kg, implying they were less toxic. In addition, an ADMET model formed
with descriptors 2D polar surface area (PSA) and AlogP98 could predict human intestinal absorption
and the blood-brain barrier penetration (BBB) at 95% and 99% confidence level. In the absorption
plot, compounds 6a–f, 6h–i, 8a–f, 9–11e, 13–19e, 23e, 30–33e, 9d, 9g, and 9j–m were predicted to be
easily absorbed by the intestine at 99% confidence level. While in the BBB plot, the most potent
compounds 8e and 8f were fallen out of the 99% ellipse (undefined), suggesting its poor blood-brain
barrier penetration ability. Therefore, these molecules might possess low or no side effects of the
central nervous system (CNS). In conclusion, ADMET prediction of the compounds might be helpful
for further designing new drugs with favorable oral bioavailability.
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Table 2. The ADMET properties of all synthetic compounds.
Comp. HBDa HBAb RBNc logPd logSe PSAf HIAg PPBh BBBi CYP3A4j T1/2 (h)
k HTl LD50(mg/kg)
m
6a 0 10 11 1.84 −2.23 96.79 0.81 0.68 0.94 0 2.02 0 459.04
6b 0 10 12 1.90 −1.93 96.79 0.80 0.67 0.91 0 2.13 0 429.48
6c 0 10 13 2.48 −2.05 96.79 0.80 0.68 0.91 0 2.14 0 462.17
6d 0 10 15 3.39 −2.02 96.79 0.80 0.65 0.91 0 2.12 0 447.58
6e 0 10 17 4.31 −1.90 96.79 0.80 0.65 0.91 0 2.14 0 425.74
6f 0 10 19 5.22 −1.67 96.79 0.80 0.66 0.91 0 2.18 0 460.97
6g 0 10 21 6.13 −1.35 96.79 0.80 0.67 0.91 0 2.23 0 508.77
6h 0 6 4 0.97 −2.49 51.75 0.79 0.67 0.98 0 2.00 0 664.69
6i 1 6 6 0.47 −1.52 69.21 0.78 0.70 0.75 0 1.77 0 1011.08
8a 2 6 6 −0.09 −1.53 105.27 0.69 0.78 0.98 0 1.81 1 1027.40
8b 2 6 7 0.49 −1.87 105.27 0.72 0.79 0.98 0 1.88 1 988.28
8c 2 6 9 1.40 −2.30 105.27 0.72 0.80 0.98 0 1.89 1 1033.87
8d 2 6 11 2.31 −2.67 105.27 0.72 0.83 0.98 0 1.92 1 1099.10
8e 2 6 13 3.22 −2.97 105.27 0.72 0.85 0.98 0 2.03 1 1278.93
8f 2 6 15 4.14 −3.21 105.27 0.72 0.85 0.98 0 2.01 1 1318.54
9e 2 2 15 6.21 −4.45 60.22 0.69 0.89 0.99 0 1.93 1 961.82
10e 2 4 13 2.97 −2.60 82.74 0.70 0.91 0.99 0 1.85 1 1075.58
11e 2 2 13 5.27 −4.27 60.22 0.68 0.91 1.00 0 1.96 1 1653.45
12e 2 2 13 7.09 −6.11 60.22 0.69 0.92 0.99 0 2.12 1 1818.99
13e 2 4 13 2.97 −2.60 82.74 0.72 0.91 0.99 0 1.89 0 1070.63
14e 2 2 13 4.06 −3.66 85.33 0.41 0.90 1.00 0 1.78 0 1145.12
15e 2 4 13 3.83 −3.35 82.74 0.70 0.91 0.99 0 1.89 1 1128.86
16e 2 6 13 1.53 −1.68 105.27 0.68 0.85 0.99 0 1.82 1 1461.77
17e 2 4 13 5.65 −5.10 82.74 0.70 0.95 0.98 0 2.22 1 1217.90
18e 2 4 13 5.65 −5.10 82.74 0.72 0.96 0.95 0 1.99 1 1254.91
19e 4 4 13 4.31 −4.38 112.85 0.69 0.90 0.94 0 1.91 1 1167.64
20e 2 6 13 5.33 −4.57 112.68 0.43 0.93 0.98 0 2.29 0 973.08
21e 2 2 13 6.46 −6.02 85.33 0.47 0.94 0.99 0 2.00 1 966.72
22e 2 2 13 7.40 −6.99 60.22 0.69 0.91 0.99 0 2.07 1 904.88
23e 2 2 13 6.27 −5.55 70.92 0.75 0.95 0.99 0 2.27 1 995.92
24e 4 2 13 5.86 −5.15 90.33 0.72 0.95 0.96 0 2.01 1 1072.61
25e 2 2 15 7.54 −5.78 60.22 0.67 0.89 0.99 0 1.98 1 1322.11
26e 4 6 17 5.69 −3.28 119.71 0.45 0.87 0.85 0 1.93 1 1249.90
27e 2 6 19 6.14 −3.64 95.94 0.54 0.82 0.98 0 1.82 1 1217.58
28e 4 8 19 5.66 −3.13 137.57 0.46 0.77 0.94 0 2.02 1 1163.97
29e 2 8 21 6.11 −3.08 113.80 0.54 0.73 0.96 0 1.95 0 927.46
30e 4 4 13 3.78 −2.74 113.30 0.59 0.90 0.99 0 1.96 1 849.92
31e 4 4 13 3.78 −2.69 113.30 0.64 0.90 0.97 0 1.93 0 951.43
32e 4 4 13 3.78 −2.72 113.30 0.64 0.90 0.98 0 1.94 0 853.84
33e 2 6 17 5.21 −3.97 95.94 0.53 0.81 0.99 0 1.76 0 1184.47
34e 2 8 19 5.18 −3.62 113.80 0.54 0.76 0.98 0 1.63 0 1073.30
35e 2 8 19 5.18 −3.67 113.80 0.53 0.76 0.97 0 1.72 0 1061.01
9d 2 2 13 5.30 −4.11 60.22 0.69 0.91 0.99 0 1.92 1 1523.97
9f 2 2 17 7.12 −4.73 60.22 0.69 0.87 0.99 0 1.95 0 1003.19
9g 0 4 15 6.59 −5.34 52.46 0.55 0.88 0.98 0 1.96 1 6181.36
9h 0 4 17 7.50 −5.69 52.46 0.55 0.86 0.98 0 1.96 1 4624.51
9i 0 4 19 8.42 −5.96 52.46 0.55 0.85 0.98 0 1.96 0 3127.76
9j 2 4 13 2.57 −2.06 78.08 0.37 0.86 0.99 0 1.97 1 1574.67
9k 2 5 16 2.44 −1.41 87.01 0.37 0.85 0.99 0 1.90 0 1693.04
9l 0 6 15 3.86 −2.96 70.32 0.50 0.88 0.98 0 1.89 1 4511.05
9m 0 7 18 3.73 −2.14 79.25 0.50 0.86 0.98 0 1.83 0 4493.16
DOX 6 12 5 −0.04 −4.80 209.31 0.02 0.78 0.02 0 2.71 1 324.50
TMP 0 2 0 0.66 −1.51 22.52 0.93 0.49 0.99 0 1.77 0 1194.46
a HBD (hydrogen bond donor), b HBA (hydrogen bond acceptor), c RBN (number of rotatable bonds), d logP (log
of the octanol/water partition coefficient), e log S (log of the aqueous solubility), and f PSA (polar surface area)
were predicted using Discovery Studio 2.0 software. g HIA (human intestinal absorption), h PPB (plasma protein
binding), I CYP3D4 (CYP3D4 inhibition), j T1/2 (half lifetime), k HT (human hepatoxicity), and l LD50 (median
lethal dose) were calculated via http://admet.scbdd.com/home/index/
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Figure 8. The plot of PSA (polar surface area) versus AlogP98 for the newly synthesized compounds
showing the 95% and 99% confidence limit ellipses corresponding to the intestinal absorption and
blood-brain barrier models.
3. Conclusions
Using ligustrazine, aromatic, or heteroaromatic acids as the main raw materials and linked by alkyl
or ether chain, bivalent antitumor agents were synthesized and screened from five different human
cancer cell lines and one normal mammary epithelial cell line. SAR revealed that the two terminal amide
bonds and the alky chain were the dominant factors with 10 C atom chain showing the most potent
antitumor effect. Among different aromatic moieties, the ligustrazine dimer 8e was the best candidate;
its IC50 was 1.36 nM in FaDu cell, it showed a broad-spectrum antitumor activity with IC50 in the range
of 0.00136–1.42 μM, and the selective ratio MCF 10A/FaDu was 34.56. The subsequent fluorescence
staining and flow cytometry analysis indicated that 8e could induce apoptosis through depolarization
of the mitochondrial membrane potential in FaDu cells. Further mechanism investigation showed that
8e could arrest cell cycle at the S phase in FaDu cells. Furthermore, ADMET predicted that most of
the potent compounds followed Lipinski’s law and became ‘drug-like’ molecules, further confirming
that the dimerization of ligustrazine could improve the antitumor activity of its monomer. The highly
selective inhibition of these dimers on the proliferation of FaDu cells might be related to the effect on
a specific target in FaDu cells. Based on the characteristics of FaDu cells, further targeted screening
would give insight into the selectivity of such potent compounds.
4. Materials and Methods
4.1. Chemistry
1H-NMR and 13C-NMR spectra were recorded on a Mercury Vx-300 (300 MHz) or AVANCE III
(400 MHz). Chemical shifts were reported in ppm (δ) using the residue solvent line as the internal
standard (for TMS: 0 ppm, 1H and 13C; for CHCl3-d: 7.26 ppm, 1H and 77.16 ppm, 13C). Coupling
constants were given in Hertz (J). High-resolution MS (HRMS) were recorded on an Agilent 6520 Q-TOF
LC/MS. Melting points were uncorrected and were determined on a digital melting point apparatus
(Shenguang WRS-1B, shanghai, China). Flash column chromatography was carried out by using
silica gel (200–300 mesh). Reactions were monitored by thin-layer chromatography (TLC) on silica gel
GF254 plates (Qingdao Haiyang Chemical Plant, Qingdao, China). Reagents and solvents were used
as purchased from commercial sources without further purification. The purity of the synthesized
compounds was over 95% analyzed by HPLC (Waters 2695 Alliance system, Waters Corp., Milford, MA,
USA), with the Kromasil C18 column eluted by methanol/water (80/20) containing 0.1% trifluoroacetic
acid at a flow rate of 1 mL/min. Compounds 4 and 5 were prepared, as reported previously [19].
1H-NMR, 13C-NMR and HR-MS spectra of compounds 6a–9m can be seen in supplementary materials.
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4.2. General Synthetic Procedure for 6a–g
A mixture of alkane-diamine (10 mmol), TMP-Cl (50 mmol), KOH (60 mmol), and
dimethylformamide (35 mL) was heated to reflux. The reaction progress was monitored via TLC. After
2 h, the reaction mixture was cooled to room temperature. Subsequently, the solid was filtered off, and
the filtrate was added with H2O (100 mL) and extracted with ethyl acetic acid three times. The organic
layers were combined and washed with H2O and brine, and then separated and dried over anhydrous
Na2SO4 for 8 h. The solvent was removed under reduced pressure; the resulting residue was separated
on flash column chromatography eluted by a mixture of petroleum ether/acetone in a volume ratio of
7:1–3:1, and further recrystallized from acetone to give pale white solid.
4.2.1. N1,N1,N2,N2-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Ethane-1,2-Diamine (6a)
Pale white solid, yield 28%, m.p. 207.6–208.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.60 (s, 8H),
2.67 (s, 4H), 2.43 (s, 12H), 2.41 (s, 12H), 2.23 (s, 12H); 13C-NMR (101 MHz, DMSO) δ: 149.91, 149.63,
148.37, 147.85, 58.75, 52.14, 50.83, 21.61, 21.42, 20.65; HRMS (ESI) m/z: 597.4134 [M + H]+, calcd. for
[C34H49N10]+ 597.4142.
4.2.2. N1,N1,N3,N3-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Propane-1,3-Diamine (6b)
Pale white solid, yield 27%, m.p. 113–114.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.65 (s, 8H), 2.46 (s,
12H), 2.43 (s, 12H), 2.41–2.38 (m, 4H), 2.32 (s, 12H), 1.81–1.71 (m, 2H). 13C-NMR (101 MHz, DMSO) δ:
149.93, 149.53, 148.51, 147.82, 58.63, 53.36, 21.61, 21.44, 20.70; HRMS (ESI) m/z: 611.4286 [M +H]+, calcd.
for [C35H51N10]+ 611.4298.
4.2.3. N1,N1,N4,N4-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Butane-1,4-Diamine (6c)
Pale white solid, yield 37%, m.p. 129.2–129.5 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.62 (s, 8H),
2.44 (s, 24H), 2.40–2.37 (m, 4H), 2.30 (s, 12H), 1.37 (s, 4H); 13C-NMR (101 MHz, DMSO) δ: 150, 149.53,
148.60, 147.79, 58.54, 54.85, 24.39, 21.64, 21.47, 20.71; HRMS (ESI) m/z: 625.4451 [M + H]+, calcd. for
[C36H53N10]+ 625.4455.
4.2.4. N1,N1,N6,N6-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Hexane-1,6-Diamine (6d)
Pale white solid, yield 43%, m.p. 146.7–147.9 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.67 (s, 8H),
2.46–2.45 (m, 24H), 2.43–2.40 (m, 4H), 2.34 (s, 12H), 1.43 (br, 4H), 1.04 (br, 4H); 13C-NMR (101 MHz,
DMSO) δ: 150.05, 149.48, 148.71, 147.77, 58.64, 54.93, 27.34, 26.56, 21.65, 21.48, 20.74; HRMS (ESI) m/z:
653.4765 [M + H]+, calcd. for [C38H57N10]+ 653.4768.
4.2.5. N1,N1,N8,N8-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Octane-1,8-Diamine (6e)
Pale white solid, yield 48%, m.p. 107.8–108.6 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.67 (s, 8H), 2.45
(br, 24H), 2.42–2.38 (m, 4H), 2.34 (s, 12H), 1.48–1.40 (m, 4H), 1.05 (br, 8H); 13C-NMR (101 MHz, CDCl3)
δ: 150.09, 149.47, 148.75, 147.76, 58.69, 54.90, 29.52, 27.46, 26.55, 21.65, 21.47, 20.73; HRMS (ESI) m/z:
681.5076 [M + H]+, calcd. for [C40H61N10]+ 681.5081.
4.2.6. N1,N1,N10,N10-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Decane-1,10-Diamine (6f)
Pale white solid, yield 76%, m.p. 67.4–68 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.69 (s, 8H), 2.46
(br, 24H), 2.41–2.39 (m, 4H), 2.35 (s, 12H), 1.47 (br, 4H), 1.11 (br, 12H); 13C-NMR (101 MHz, DMSO) δ:
150.10, 149.45, 148.78, 147.76, 58.71, 54.92, 29.73, 29.52, 27.48, 26.57, 21.64, 21.47, 20.74; HRMS (ESI) m/z:
709.5378 [M + H]+, calcd. for [C42H65N10]+ 709.5394.
4.2.7. N1,N1,N12,N12-Tetrakis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Dodecane-1,12-Diamine (6g)
Pale white solid, yield 76%, m.p. 84.7–85.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.69 (s, 8H), 2.46
(br, 24H), 2.44 (br, 4H), 2.35 (s, 12H), 1.47 (br, 4H), 1.15–1.12 (br, 16H); 13C-NMR (101 MHz, DMSO) δ:
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150.10, 149.44, 148.78, 147.74, 58.72, 54.89, 29.75, 29.53, 27.46, 26.56, 21.64, 21.47, 20.73; HRMS (ESI) m/z:
737.5689 [M + H]+, calcd. for [C44H69N10]+ 737.5707.
4.3. 1,4-Bis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Piperazine (6h)
A mixture of piperazine (0.800 g, 9.29 mmol), TMP-Cl (3.80 g, 22.29 mmol), KOH (1.56 g, 27.66
mmol), and dimethylformamide (20 mL) was heated under reflux for 2 h. The reaction was monitored
by TLC. The reaction was quenched, filtered, and the filtrate was added with 100 mL H2O and extracted
with ethyl acetate three times. The organic layers were combined, washed with H2O and brine, and
then dried over anhydrous Na2SO4 for 8 h. The solvent was evaporated in vacuo. The resulting
residue was separated on flash column chromatography with a mixture of petroleum ether/acetone
7:1–3:1(volume ratio) as eluent, and then further recrystallized from acetone to afford compound 6h.
Pale white solid, yield 62%, m.p. 155.8–156.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 3.58 (s, 4H), 2.55
(s, 8H), 2.47 (br, 18H); 13C-NMR (101 MHz, DMSO) δ: 150.01, 149.57, 148.10, 147.98, 61.88, 53.26, 50.70,
21.61, 21.51, 21.04; HRMS (ESI) m/z: 355.2610 [M + H]+, calcd. for [C20H31N6]+ 355.2610.
4.4. 2-(Bis((3,5,6-Trimethylpyrazin-2-yl)Methyl)Amino)Ethanol (6i)
A mixture of ethanolamine (0.500 g, 8.19 mmol), TMP-Cl (3.35 g, 19.65 mmol), K2CO3 (3.39 g,
24.56 mmol), and acetonitrile (20 mL) was heated under reflux for 3 h. The product formation was
monitored via TLC. After cooling, the mixture was filtered, and the filtrate was evaporated in vacuo.
The residue was purified by flash column chromatography with an eluent of petroleum ether/acetone
= 10:1–3:1 to afford compound 6i.
Light yellow oil, yield 72%; 1H-NMR (300 MHz, CDCl3) δ: 3.82 (13s, 4H), 3.66 (t, J = 5 Hz, 2H),
2.87 (t, J = 5.1 Hz, 2H), 2.41 (s, 6H), 2.37 (s, 6H), 2.35 (s, 6H); 13C-NMR (101 MHz, DMSO) δ: 149.54,
148.94, 148.27, 147.87, 59.67, 58.15, 57.36, 21.41, 21.21, 20.52; HRMS (ESI) m/z: 330.2290 [M + H]+, calcd.
for [C18H28N5O]+ 330.2294.
4.5. General Synthetic Procedure for 8a–f
Compound 7 was gained according to the method described by Wu [20]. A mixture of
tetramethylpyrazine acid (4.40 mmol), EDCI (4.72 mmol), triethylamine (12 mmol), DMAP (2.40
mmol), and anhydrous dichloromethane (10 mL) was stirred to dissolve, then diamino-alkane (2
mmol) was added and stirred at room temperature until the reaction was finished (monitored by TLC).
The reaction mixture was washed with brine and water, extracted with dichloromethane (20 mL),
dried over anhydrous sodium sulfate for 8 h, filtered, and the solvent was evaporated. The resulting
residue was purified by flash column chromatography with an eluent of petroleum ether/acetone =
15:1–3:1(volume ratio) to give pale white solid.
4.5.1. N,N′-(Propane-1,3-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8a)
Pale white solid, yield 16%, m.p. 125.4–126.4 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8.30 (t, J = 5.9
Hz, 2H), 3.58–3.52 (m, 4H), 2.92 (s, 6H), 2.56 (s, 6H), 2.50 (s, 6H), 1.99–1.90 (m, 2H); 13C-NMR (101
MHz, CDCl3) δ: 165.57, 154.09, 151.29, 147.80, 139.09, 36.89, 29.87, 22.94, 22.07, 21.47; HRMS (ESI) m/z:
371.2189 [M + H]+, calcd. for [C19H27N6O2]+ 371.2195.
4.5.2. N,N′-(Butane-1,4-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8b)
Pale white solid, yield 30%, m.p. 168.4–168.6 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8.07 (t, J = 5.5 Hz,
2H), 3.50–3.48 (m, 4H), 2.91 (s, 6H), 2.56 (s, 6H), 2.52 (s, 6H), 1.75–1.73 (m, 4H); 13C-NMR (101 MHz,
CDCl3) δ: 165.25, 154.15, 151.38, 147.75, 139.07, 50.90, 39.13, 27.49, 22.96, 22.06, 21.48; HRMS (ESI) m/z:
385.2352 [M + H]+, calcd. for [C20H29N6O2]+ 385.2352.
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4.5.3. N,N′-(Hexane-1,6-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8c)
Pale white solid, yield 47%, m.p. 114.2–114.7 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8.02 (t, J = 5.4
Hz, 2H), 3.45–3.38 (m, 4H), 2.90 (s, 6H), 2.55 (s, 6H), 2.51 (s, 6H), 1.67–1.63 (m, 4H), 1.47–1.43 (m, 4H);
13C-NMR (101 MHz, CDCl3) δ: 165.12, 154.03, 151.35, 147.63, 139.11, 39.33, 29.74, 26.82, 22.98, 22.06,
21.48; HRMS (ESI) m/z: 413.2662 [M + H]+, calcd. for [C22H33N6O2]+ 413.2665.
4.5.4. N,N′-(Octane-1,8-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8d)
Pale white solid, yield 68%, m.p. 113.6–113.8 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8 (t, J = 5.3 Hz,
2H), 3.45–3.38 (m, 4H), 2.91 (s, 6H), 2.56 (s, 6H), 2.52 (s, 6H), 1.65–1.60 (m, 4H), 1.37–1.37 (m, 8H);
13C-NMR (101 MHz, CDCl3) δ: 165.10, 154.02, 151.40, 147.65, 139.20, 39.45, 29.81, 29.34, 27.11, 23.01,
22.08, 21.53; HRMS (ESI) m/z: 441.2975 [M + H]+, calcd. for [C24H37N6O2]+ 441.2978.
4.5.5. N,N′-(Decane-1,10-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8e)
Pale white solid, yield 66%, m.p. 110.3–110.6 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8 (t, J = 5.2 Hz,
2H), 3.44–3.37 (m, 4H), 2.91 (s, 6H), 2.55 (s, 6H), 2.51 (s, 6H), 1.64–1.57 (m, 4H), 1.34–1.30 (m, 12H);
13C-NMR (101 MHz, CDCl3) δ: 165.07, 153.97, 151.33, 147.66, 139.21, 39.47, 29.80, 29.56, 29.39, 27.14,
22.94, 22.02, 21.49; HRMS (ESI) m/z: 469.3287 [M + H]+, calcd. for [C26H41N6O2]+ 469.3291.
4.5.6. N,N′-(Dodecane-1,12-Diyl)Bis(3,5,6-Trimethylpyrazine-2-Carboxamide) (8f)
Pale white solid, yield 72%, m.p. 98.3–99.1 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8 (t, J = 4.9 Hz, 2H),
3.45–3.38 (m, 4H), 2.91 (s, 6H), 2.56 (s, 6H), 2.52 (s, 6H), 1.67–1.57 (m, 4H), 1.34–1.27 (m, 16H); 13C-NMR
(101 MHz, CDCl3) δ: 165.07, 153.98, 151.37, 147.62, 139.22, 39.49, 29.83, 29.66, 29.44, 27.18, 22.99, 22.07,
21.51; HRMS (ESI) m/z: 497.3602 [M + H]+, calcd. for [C28H45N6O2]+ 497.3604.
4.6. General Synthetic Procedure for 9e–35e
Compounds 9e–35e were obtained by using one-pot reaction. A mixture of aromatic acid (6.30
mmol), EDCI (7.50 mmol), DMAP (0.60 mmol), and anhydrous dichloromethane (20 mL) was stirred to
dissolve, then decane-diamine (3 mmol) was added and stirred at room temperature for 12 h. The
mixture solution was filtered under reduced pressure. After that, the residue was washed with little
amount of CH2Cl2 and water successively, and dried to give the solid. Then, the residue was purified
on preparative TLC eluted with chloroform/methanol = 40:1–7:1 to yield compounds 26e, 28e, 30e,
and 31e.
4.6.1. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-Phenylacrylamide) (9e)
Pale white solid, yield 62%, m.p. 169.8–170.5 ◦C; 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 7.54
(d, J = 15.7 Hz, 2H), 7.49–7.46 (m, 4H), 7.36–7.31 (m, 6H), 6.47 (d, J = 15.6 Hz, 2H), 3.33–3.28 (m, 4H),
1.57–1.54 (m, 4H), 1.52–1.28 (m, 12H); 13C-NMR (101 MHz, CDCl3+CD3OD) δ: 150.10, 149.45, 148.78,
147.76, 58.71, 54.92, 29.73, 29.52, 27.48, 26.57, 21.64, 21.47, 20.74; HRMS (ESI) m/z: 433.2851 [M +H]+,
calcd. for [C28H45N6O2]+ 433.2855
4.6.2. N,N′-(Decane-1,10-Diyl)Dinicotinamide (10e)
Pale white solid, yield 67%, m.p. 167.4–167.8 ◦C; 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 8.84 (s,
2H), 8.55 (d, J = 3.9 Hz, 2H), 8.11 (dt, J = 8, 1.7 Hz, 2H), 7.35 (dd, J = 7.9, 4.9 Hz, 2H), 3.34 (t, J = 7.2 Hz,
4H), 1.58–1.51 (m, 4H), 1.27–1.24 (m, 12H); 13C-NMR (101 MHz, CDCl3+CD3OD) δ: 165.85, 151.29,
147.53, 135.93, 130.87, 123.79, 40.16, 29.28, 29.12, 26.86; HRMS (ESI) m/z: 383.2441 [M + H]+, calcd. for
[C28H45N6O2]+ 383.2447.
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4.6.3. N,N′-(Decane-1,10-Diyl)Dibenzamide (11e)
Pale white solid, yield 70%, m.p. 154.3–154.6 ◦C; 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 7.77–7.73
(m, 4H), 7.51–7.33 (m, 6H), 3.42–3.35 (m, 4H), 1.63–1.56 (m, 4H), 1.34–1.30 (m, 12H); 13C-NMR (101
MHz, CDCl3+CD3OD) δ: 168.39, 134.55, 131.36, 128.45, 126.86, 40.02, 29.36, 29.27, 29.13, 26.84. HRMS
(ESI) m/z: 381.2702 [M + H]+, calcd. for [C24H33N2O2]+ 381.2542.
4.6.4. N,N′-(Decane-1,10-Diyl)Bis(2-Naphthamide) (12e)
Pale white solid, yield 64%, m.p. 163.9–164 ◦C; 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 8.22–8.17
(m, 2H), 7.89–7.82 (m, 4H), 7.54–7.39 (m, 8H), 3.49–3.44 (m, 4H), 1.67–1.60 (m, 4H), 1.38–1.34 (m, 12H);
13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 170.38, 134.50, 133.56, 130.33, 129.96, 128.22, 126.89, 126.29,
125.10, 124.77, 124.65, 39.94, 29.36, 29.30, 29.11, 26.85. HRMS (ESI) m/z: 481.2853 [M +H]+, calcd. for
[C32H37N2O2]+ 481.2855.
4.6.5. N,N′-(Decane-1,10-Diyl)Diisonicotinamide (13e)
Pale white solid, yield 60%, m.p. 175.6–176.3 ◦C; 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 8.62 (d,
J = 5.6 Hz, 4H), 7.71 (dd, J = 6.1, 2.8 Hz, 4H), 3.41–3.33 (m, 4H), 1.64–1.57 (m, 4H), 1.33–1.31 (m, 12H);
13C-NMR (101 MHz, CDCl3+CD3OD) δ: 165.88, 149.48, 142.45, 121.46, 40.04, 29.16, 28.99, 26.71. HRMS
(ESI) m/z: 383.2445 [M + H]+, calcd. for [C22H31N4O2]+ 383.2447.
4.6.6. N,N′-(Decane-1,10-Diyl)Bis(Furan-2-Carboxamide) (14e)
Pale white solid, yield 62%, m.p. 132.6–133.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.41 (dd, J =
1.7, 0.8 Hz, 2H), 7.09 (dd, J = 3.5, 0.7 Hz, 2H), 6.48 (dd, J = 3.5, 1.7 Hz, 2H), 6.37 (br, 2H), 3.45–3.38
(m, 4H), 1.65–1.55 (m, 4H), 1.36–1.30 (m, 12H); 13C-NMR (101 MHz, CDCl3) δ: 158.53, 148.38, 143.77,
114.02, 112.22, 39.29, 29.80, 29.48, 29.33, 26.98. HRMS (ESI) m/z: 383.1944 [M + Na]+, calcd. for
[C20H28N2NaO4]+ 383.1947.
4.6.7. N,N′-(Decane-1,10-Diyl)Dipicolinamide (15e)
Pale white solid, yield 68%, m.p. 156.6–156.9 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 9.35 (d, J = 1.4
Hz, 2H), 8.69 (d, J = 2.5 Hz, 2H),.8.47–8.46 (m, 2H), 7.77 (br, 2H), 3.47–3.40 (m, 4H), 1.65–1.55 (m, 4H),
1.34–1.26 (m, 12H); 13C-NMR (101 MHz, CDCl3) δ: 163.01, 147.26, 144.76, 144.55, 142.58, 39.61, 29.68,
29.51, 29.34, 27.03. HRMS (ESI) m/z: 383.2441 [M + H]+, calcd. for [C22H31N4O2]+ 383.2447
4.6.8. N,N′-(Decane-1,10-Diyl)Bis(Pyrazine-2-Carboxamide) (16e)
Pale white solid, yield 70%, m.p. 77.6–80.1 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8.54–8.51 (m, 2H),
8.20–8.17 (m, 2H), 8.05 (br, 2H), 7.85–7.80 (m, 2H), 7.42–7.38 (m, 2H), 3.49–3.43 (m, 4H), 1.68–1.58 (m,
4H), 1.38–1.26 (m, 12H); 13C-NMR (101 MHz, CDCl3) δ: 164.31, 150.25, 148.09, 137.49, 126.13, 122.34,
39.61, 29.77, 29.56, 29.41, 27.11. HRMS (ESI) m/z: 385.2350 [M +H]+, calcd. for [C20H29N6O2]+ 385.2352.
4.6.9. N,N′-(Decane-1,10-Diyl)Bis(Quinoline-3-Carboxamide) (17e)
Pale white solid, yield 59%, m.p. 206.7–207.1 ◦C; 1H-NMR (300 MHz, DMSO-d6 + CD3OD) δ: 8.57
(d, J = 1.8 Hz, 2H), 8.09 (s, 2H), 7.39 (dd, J = 8.3, 3.1 Hz, 4H), 7.17 (t, J = 7.6 Hz, 2H), 7 (t, J = 7.4 Hz, 2H),
2.68 (t, J = 7 Hz, 4H), 0.99–0.88 (m, 4H), 0.76–0.62 (m, 12H). 13C-NMR (101 MHz, CDCl3) δ: 165.92,
148.01, 136.52, 131.47, 128.81, 127.93, 127.56, 127.35, 127.06, 40.11, 29.20, 29.15, 29.04, 26.78. HRMS (ESI)
m/z: 483.2756 [M + H]+, calcd. for [C30H35N4O2]+ 483.2760.
4.6.10. N,N′-(Decane-1,10-Diyl)Bis(Quinoline-6-Carboxamide) (18e)
Pale yellow solid, yield 73%, m.p. 197.7–198.3 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 8.71
(dd, J = 4.3, 1.6 Hz, 2H), 8.19 (d, J = 1.6 Hz, 2H), 8.16 (dd, J = 8.3, 1.3 Hz, 2H), 7.95 (dd, J = 8.8, 1.9
Hz, 2H), 7.91 (s, 2H), 7.35 (dd, J = 8.3, 4.3 Hz, 2H), 3.28 (t, J = 7.2 Hz, 4H), 1.53–1.45 (m, 5H), 1.22–1.13
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(m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 167.43, 151.15, 148.21, 137.99, 132.82, 128.38,
127.79, 127.71, 127.64, 121.81, 40.14, 29.19, 29.04, 26.78. HRMS (ESI) m/z: 483.2758 [M + H]+, calcd. for
[C30H35N4O2]+ 483.2760.
4.6.11. N,N′-(Decane-1,10-Diyl)Bis(1H-Benzo[d]Imidazole-6-Carboxamide) (19e)
Brick red solid, yield 75%, m.p. 229.7–230.3 ◦C; 1H-NMR (300 MHz, CDCl3+ CD3OD) δ: 8.11
(s, 2H), 8.07 (s, 2H), 7.73 (dd, J = 8.5, 1.6 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 3.42 (t, J = 7.1 Hz, 4H),
1.70–1.56 (m, 4H), 1.42–1.25 (m, 12H). 13C-NMR (101 MHz, CDCl3+ CD3OD) δ: 168.61, 142.46, 128.70,
121.15, 39.32, 28.66, 28.62, 28.50, 26.19. HRMS (ESI) m/z: 461.2662 [M + H]+, calcd. for [C26H33N6O2]+
461.2665.
4.6.12. N,N′-(Decane-1,10-Diyl)Bis(2-Oxo-2H-Chromene-3-Carboxamide) (20e)
Pale white solid, yield 60%, m.p. 208.9–209.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 8.90 (s, 2H), 8.80
(s, 2H), 7.71–7.61 (m, 4H), 7.43–7.32 (m, 4H), 3.45 (dd, J = 13, 7 Hz, 4H), 1.63 (dt, J = 14.4, 7.2 Hz, 4H),
1.44–1.26 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 161.74, 161.44, 154.23, 148.38, 134.16,
129.80, 125.30, 118.46, 117.97, 116.38, 39.69, 29.20, 29.02, 29.01, 26.77. HRMS (ESI) m/z: 517.2338 [M +
H]+, calcd. for [C30H33N2O6]+ 517.2339.
4.6.13. N,N′-(Decane-1,10-Diyl)Bis(Benzofuran-2-Carboxamide) (21e)
Pale white solid, yield 43%, m.p. 135.8–136.3 ◦C; 1H-NMR (300 MHz, DMSO-d6) δ: 8.64 (s, 2H),
7.74 (d, J = 7.7 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.49 (s, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.30 (t, J = 7.4
Hz, 2H), 3.25 (dd, J = 13.1, 6.6 Hz, 4H), 1.58–1.43 (m, 4H), 1.37–1.14 (m, 12H). 13C-NMR (101 MHz,
DMSO-d6) δ: 157.94, 154.13, 149.37, 127.17, 126.61, 123.59, 122.63, 111.70, 109.02, 38.68, 29.01, 28.91,
28.71, 26.39. HRMS (ESI) m/z: 461.2438 [M + H]+, calcd. for [C28H33N2O4]+ 461.2430.
4.6.14. N,N′-(Decane-1,10-Diyl)Bis(Benzo[b]Thiophene-2-Carboxamide) (22e)
Pale yellow solid, yield 46%, m.p. 175–175.7 ◦C; 1H-NMR (300 MHz, DMSO-d6) δ: 8.68 (s, 2H),
8.04 (s, 2H), 8.01–7.95 (m, 2H), 7.93–7.87 (m, 2H), 7.41 (p, J = 7 Hz, 4H), 3.25 (dd, J = 12.8, 6.6 Hz, 4H),
1.58–1.44 (m, 4H), 1.37–1.21 (m, 12H). 13C-NMR (101 MHz, DMSO-d6) δ: 161.28, 140.28, 140.07, 139.16,
126, 125.02, 124.80, 124.33, 122.72, 28.99, 28.92, 28.72, 26.43. HRMS (ESI) m/z: 493.1976 [M + H]+, calcd.
for [C28H33N2O2S2]+ 493.1983.
4.6.15. N,N′-(Decane-1,10-Diyl)Bis(1-Methyl-1H-Indole-3-Carboxamide) (23e)
Pale white solid, yield 43%, m.p. 192.8–193.2 ◦C; 1H-NMR (300 MHz, DMSO-d6 + CD3OD) δ: 8.08
(d, J = 7.7 Hz, 2H), 7.86 (s, 2H), 7.41 (d, J = 8 Hz, 2H), 7.20–7.13 (m, 2H), 7.13–7.06 (m, 2H), 3.78 (s, 6H),
3.22 (t, J = 7.1 Hz, 4H), 1.55–1.43 (m, 4H), 1.32–1.22 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD)
δ: 166.26, 137.01, 131.75, 125.56, 122.27, 121.03, 120.13, 109.63, 39.26, 32.62, 29.33, 29.07, 28.94, 26.66.
HRMS (ESI) m/z: 487.3064 [M + H]+, calcd. for [C30H39N4O2]+ 487.3073.
4.6.16. N,N′-(Decane-1,10-Diyl)Bis(1H-Indole-6-Carboxamide) (24e)
Pale white solid, yield 47%, m.p. 168.4–169.2 ◦C; 1H-NMR (300 MHz, DMSO-d6) δ: 11.32 (s, 2H),
8.30 (s, 2H), 7.92 (s, 2H), 7.59–7.41 (m, 6H), 6.46 (s, 2H), 3.25 (dd, J = 12.7, 6.4 Hz, 4H), 1.61–1.43 (m,
4H), 1.38–1.21 (m, 12H). 13C-NMR (101 MHz, DMSO) δ: 167.04, 135.24, 129.61, 127.74, 127.66, 119.27,
117.90, 111.07, 101.14, 39.21, 29.27, 29, 28.83, 26.55. HRMS (ESI) m/z: 459.2760 [M + H]+, calcd. for
[C28H35N4O2]+ 459.2760.
4.6.17. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-(4-Chlorophenyl)Acrylamide) (25e)
Pale white solid, yield 64%, m.p. 230.3–230.9 ◦C; 1H-NMR (300 MHz, CDCl3 +CF3COOD) δ: 7.64
(d, J = 13 Hz, 2H), 7.54–7.38 (m, 8H), 6.51 (d, J = 11.9 Hz, 2H), 3.62–3.37 (m, 4H), 1.73–1.54 (m, 4H),
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1.46–1.18 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CF3COOD) δ: 129.71, 118.78, 115.96, 113.13, 110.30,
29.22, 28.99, 26.64. HRMS (ESI) m/z: 501.2075 [M + H]+, calcd. for [C28H35Cl2N2O2]+ 501.2076.
4.6.18. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-(3-Hydroxy-4-Methoxyphenyl)Acrylamide) (26e)
Pale yellow solid, yield 35%, m.p. 192.9–195.3 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.42
(d, J = 15.3 Hz, 2H), 7.05 (s, 2H), 6.98 (d, J = 8.1 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 6.33 (d, J = 15.6 Hz,
2H), 3.89 (s, 6H), 3.29 (t, J = 7 Hz, 4H), 1.55–1.50 (m, 4H), 1.31–1.27 (m, 12H). 13C-NMR (101 MHz,
CDCl3 + CD3OD) δ: 167.37, 148.94, 146.05, 140.42, 128.11, 121.06, 118.25, 113.07, 111, 55.57, 39.50, 29.13,
28.98, 26.69. HRMS (ESI) m/z: 525.2951 [M + H]+, calcd. for [C30H41N2O6]+ 525.2965.
4.6.19. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-(3,4-Dimethoxyphenyl)Acrylamide) (27e)
Pale white solid, yield 59%, m.p. 168.9–169.9 ◦C; 1H-NMR (300 MHz, DMSO-d6) δ: 7.95 (br, 2H),
7.30 (br, 2H), 7.11 (br, 4H), 6.97 (br, 2H), 6.50 (br, 2H), 3.78 (br, 12H), 3.14 (br, 4H), 1.42 (br, 4H), 1.27 (br,
12H). 13C-NMR (101 MHz, CDCl3+ CD3OD) δ: 167.15, 150.31, 148.90, 140.25, 127.89, 121.77, 118.56,
111.04, 109.74, 55.66, 55.58, 39.47, 29.16, 29.14, 28.99, 26.69. HRMS (ESI) m/z: 553.3272 [M + H]+, calcd.
for [C32H45N2O6]+ 553.3278.
4.6.20. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-(4-Hydroxy-3,5-Dimethoxyphenyl)Acrylamide) (28e)
Pale yellow solid, yield 33%, m.p. 179.8–180.5 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.44
(d, J = 15.5 Hz, 3H), 6.76 (s, 4H), 6.37 (d, J = 15.6 Hz, 2H), 3.88 (s, 12H), 3.30 (t, J = 7.1 Hz, 4H), 1.61–1.49
(m, 4H), 1.38–1.24 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 166.94, 147.48, 141.03, 136.87,
126.16, 118.46, 104.99, 56.23, 39.63, 29.39, 29.21, 29.08, 26.79. HRMS (ESI) m/z: 585.3164 [M+H]+, calcd.
for [C32H45N2O8]+ 585.3176
4.6.21. (2E,2′E)-N,N′-(Decane-1,10-Diyl)Bis(3-(3,4,5-Trimethoxyphenyl)Acrylamide) (29e)
Pale white solid, yield 67%, m.p. 193.4–194.3 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.45 (d,
J = 15.4 Hz, 2H), 6.76 (s, 4H), 6.44 (d, J = 15.6 Hz, 2H), 3.88 (s, 12H), 3.85 (s, 6H), 3.31 (t, J = 7.1 Hz, 4H),
1.63–1.47 (m, 4H), 1.40–1.23 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 166.73, 153.26, 140.53,
139.33, 130.65, 120.18, 104.99, 60.81, 56, 39.63, 29.28, 29.21, 29.05, 26.76. HRMS (ESI) m/z:613.3472 [M +
H]+, calcd. for [C34H49N2O8]+ 613.3489.
4.6.22. N,N′-(Decane-1,10-Diyl)Bis(2-Aminobenzamide) (30e)
Pale white solid, yield 67%, m.p. 90.2–91 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.36
(dd, J = 7.8, 1.2 Hz, 2H), 7.22–7.15 (m, 2H), 6.79–6.60 (m, 4H), 3.35 (dt, J = 9.7, 5.5 Hz, 4H), 1.66–1.49
(m, 4H), 1.41–1.24 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 173.92, 151.77, 135.96, 131.40,
121.48, 121.28, 120.96, 43.54, 33.31, 33.26, 33.11, 30.83. HRMS (ESI) m/z:411.2759 [M +H]+, calcd. for
[C24H35N4O2]+ 411.2760.
4.6.23. N,N′-(Decane-1,10-Diyl)Bis(4-Aminobenzamide) (31e)
Pale yellow solid, yield 31%, m.p. 186.7–187.7 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.57
(d, J = 8.6 Hz, 4H), 6.66 (d, J = 8.6 Hz, 4H), 3.34 (t, J = 7.2 Hz, 4H), 1.63–1.53 (m, 4H), 1.31–1.26 (m,
12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 168.44, 150.01, 128.49, 123.39, 114.04, 39.77, 29.33, 29.18,
29.06, 26.76. HRMS (ESI) m/z: 411.2755 [M + H]+, calcd. for [C24H35N4O2]+ 411.2760.
4.6.24. N,N′-(Decane-1,10-Diyl)bis(3-Aminobenzamide) (32e)
Pale white solid, yield 57%, m.p. 135.7–136.3 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ:
7.30–6.97 (m, 6H), 6.83 (dd, J = 20.8, 7.2 Hz, 2H), 3.36 (t, J = 6.8 Hz, 4H), 1.67–1.47 (m, 4H), 1.46–1.06 (m,
12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 168.75, 146.84, 135.56, 129.27, 118.09, 116.55, 113.73,
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77.48, 77.16, 76.84, 49.31, 49.09, 48.88, 48.67, 48.45, 39.93, 29.29, 29.22, 29.09, 26.79. HRMS (ESI) m/z:
411.2758 [M + H]+, calcd. for [C24H35N4O2]+ 411.2760
4.6.25. N,N′-(Decane-1,10-Diyl)Bis(3,5-Dimethoxybenzamide) (33e)
Pale white solid, yield 56%, m.p. 143.4–144.2 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 6.79 (d,
J = 2.1 Hz, 4H), 6.43 (t, J = 1.9 Hz, 2H), 3.69 (s, 12H), 3.25 (t, J = 7.2 Hz, 4H), 1.50–1.45 (m, 4H), 1.25–1.15
(m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 168.01, 160.73, 136.74, 104.94, 103.34, 55.40, 40.03,
29.28, 29.26, 29.11, 26.82. HRMS (ESI) m/z: 501.2959 [M + H]+, calcd. for [C28H41N2O6]+ 501.2965.
4.6.26. N,N′-(Decane-1,10-Diyl)Bis(3,4,5-Trimethoxybenzamide) (34e)
Pale white solid, yield 63%, m.p. 194–194.9 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 6.91 (s,
4H), 3.72 (s, 12H), 3.67 (s, 6H), 3.22–3.16 (m, 4H), 1.50–1.36 (m, 4H), 1.22–1.08 (m, 12H). 1H-NMR (300
MHz, CDCl3 + CD3OD). δ: 6.91 (s, 4H), 3.72 (s, 12H), 3.67 (s, 6H), 3.22–3.16 (m, 4H), 1.50–1.36 (m, 4H),
1.22–1.08 (m, 12H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 167.81, 152.77, 129.84, 104.42, 60.53, 55.85,
40.01, 29.17, 29.03, 26.73. HRMS (ESI) m/z: 561.3169 [M + H]+, calcd. for [C30H45N2O8]+ 561.3176.
4.6.27. N,N′-(Decane-1,10-Diyl)Bis(2,3,4-Trimethoxybenzamide) (35e)
Pale white solid, yield 26%, m.p. 112.3–112.5 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.94 (s, 2H), 7.89
(d, J = 8.9 Hz, 2H), 6.76 (d, J = 9 Hz, 2H), 3.96 (s, 6H), 3.90 (s, 6H), 3.87 (s, 6H), 3.44 (dd, J = 12.7, 6.9 Hz,
4H), 1.62 (dt, J = 14.3, 7.1 Hz, 4H), 1.41–1.29 (m, 12H). 13C-NMR (101 MHz, CDCl3) δ: 164.90, 156.35,
152.42, 141.83, 126.76, 119.31, 107.67, 61.71, 61.08, 56.15, 39.71, 29.78, 29.65, 29.43, 27.24. HRMS (ESI)
m/z: 561.3172 [M + H]+, calcd. for [C30H45N2O8]+ 561.3176.
4.7. General Synthetic Procedure for 9d, 9f
A mixture of cinnamic acid (6.30 mmol), EDCI (7.50 mmol), DMAP (0.60 mmol), and anhydrous
dichloromethane (20 mL) was stirred to dissolve, then diamino-alkane (3 mmol) was added and stirred
at room temperature for 12 h. The mixture solution was filtered under reduced pressure. After that,
the residue was washed with dichloromethane and water successively, and then dried to give a pale
white solid. TLC indicated that it was a single point.
4.7.1. (2E,2′E)-N,N′-(Octane-1,8-Diyl)Bis(3-Phenylacrylamide) (9d)
Pale white solid, yield 63%, m.p. 186–186.4 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.58–7.29
(m, 12H), 6.53 (d, J = 15.7 Hz, 2H), 3.31 (t, J = 7.1 Hz, 4H), 1.59–1.55 (m, 4H), 1.35 (s, 8H). 13C-NMR (101
MHz, CDCl3 + CD3OD) δ: 166.96, 140.39, 134.78, 129.42, 128.59, 127.54, 120.60, 39.43, 29.04, 28.85, 26.57.
HRMS (ESI) m/z: 405.2537 [M + H]+, calcd. for [C26H33N2O2]+ 405.2542.
4.7.2. (2E,2′E)-N,N′-(Dodecane-1,12-Diyl)Bis(3-Phenylacrylamide) (9f)
Pale white solid, yield 49%, m.p. 164.7–165 ◦C; 1H-NMR (300 MHz, CDCl3 + CD3OD) δ: 7.56–7.49
(m, 6H), 7.40–7.28 (m, 6H), 6.53 (d, J = 15.7 Hz, 2H), 3.30 (t, J = 7.1 Hz, 4H), 1.62–1.51 (m, 4H), 1.38–1.23
(m, 16H). 13C-NMR (101 MHz, CDCl3 + CD3OD) δ: 166.94, 140.22, 134.73, 129.29, 128.47, 127.42, 120.54,
39.42, 29.19, 29.03, 28.99, 26.66. HRMS (ESI) m/z: 461.3166 [M +H]+, calcd. for [C30H41N2O2]+ 461.3168.
4.8. General Synthetic Procedure for 9g–9i
A mixture of cinnamic acid (6.30 mmol), EDCI (7.50 mmol), DMAP (0.60 mmol), and anhydrous
dichloromethane (20 mL) was stirred to dissolve, then alkane-diol (3 mmol) was added and stirred
at room temperature for 12 h. The mixture solution was filtered under reduced pressure. After that,
the residue was washed with dichloromethane and water successively, subsequently, purified by
preparative TLC eluted with petroleum ether/ethyl acetate = 5:1 to give pale white solid.
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4.8.1. Octane-1,8-Diyl (2E,2′E)-Bis(3-Phenylacrylate) (9g)
Pale white solid, yield 35%, m.p. 61.1–62.5 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.68 (d, J = 16 Hz,
2H), 7.58–7.46 (m, 4H), 7.43–7.30 (m, 6H), 6.45 (d, J = 16 Hz, 2H), 4.21 (t, J = 6.7 Hz, 4H), 1.77–1.68 (m,
4H), 1.46–1.40 (m, 8H). 13C-NMR (101 MHz, CDCl3) δ: 167.22, 144.72, 134.62, 130.35, 129.01, 128.19,
118.43, 64.79, 29.31, 28.85, 26.05. HRMS (ESI) m/z: 407.2223 [M + H]+, calcd. for [C26H31O4]+ 407.2222.
4.8.2. Decane-1,10-Diyl (2E,2′E)-Bis(3-Phenylacrylate) (9h)
Pale white solid, yield 33%, m.p. 118.6–119.2 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.68 (d, J = 16 Hz,
2H), 7.57–7.48 (m, 4H), 7.38 (dd, J = 6.6, 3.6 Hz, 6H), 6.45 (d, J = 16 Hz, 2H), 4.21 (t, J = 6.7 Hz, 4H),
1.77–1.62 (m, 4H), 1.48–1.25 (m, 12H). 13C-NMR (101 MHz, CDCl3) δ: 167.23, 144.69, 134.64, 130.35,
129.01, 128.19, 118.46, 64.85, 29.58, 29.40, 28.88, 26.12. HRMS (ESI) m/z: 435.2534 [M +H]+, calcd. for
[C28H35O4]+ 435.2535.
4.8.3. Dodecane-1,12-Diyl (2E,2′E)-Bis(3-Phenylacrylate) (9i)
Pale white solid, yield 28%, m.p. 63.1–64 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.68 (d, J = 16 Hz,
2H), 7.52 (dt, J = 4.6, 3.2 Hz, 4H), 7.42–7.33 (m, 6H), 6.45 (d, J = 16 Hz, 2H), 4.21 (t, J = 6.7 Hz, 4H),
1.77–1.65 (m, 4H), 1.43–1.25 (m, 16H). 13C-NMR (101 MHz, CDCl3) δ: 167.22, 144.68, 134.64, 130.34,
129.01, 128.18, 118.47, 64.87, 29.68, 29.66, 29.42, 28.87, 26.12. HRMS (ESI) m/z: 463.2851 [M + H]+, calcd.
for [C30H39O4]+ 463.2828.
4.9. General Synthetic Procedure for 9j–9m
A mixture of cinnamic acid (6.30 mmol), EDCI (7.50 mmol), DMAP (0.60 mmol), and anhydrous
dichloromethane (20 mL) was stirred to dissolve, then diamino-ether (3 mmol) was added and stirred
at room temperature for 12 h. Then, the solid was filtered off, the filtrate was added with H2O (50 mL)
and extracted by dichloromethane three times. The combined organic layers were washed with H2O
and brine, dried with anhydrous sodium sulfate for 8 h, filtered, and evaporated. The resulting residue
was purified by preparative TLC with petroleum ether/ethyl acetate = 2:1–1:1 to give pale white solid
or light yellow oil.
4.9.1. (2E,2′E)-N,N′-((Ethane-1,2-Diylbis(Oxy))Bis(Ethane-2,1-Diyl))Bis(3-Phenylacrylamide) (9j)
Pale white solid, yield 78%, m.p. 117.9–118.5 ◦C; 1H-NMR (300 MHz, CDCl3) δ: 7.62 (d, J = 15.6
Hz, 2H), 7.51–7.41 (m, 4H), 7.37–7.27 (m, 6H), 6.48 (d, J = 15.6 Hz, 2H), 3.65–3.60 (m, 12H). 13C-NMR
(101 MHz, CDCl3) δ: 166.26, 141.19, 134.95, 129.77, 128.92, 127.92, 120.82, 70.50, 70.05, 39.63. HRMS
(ESI) m/z: 409.2121 [M + H]+, calcd. for [C24H29N2O4]+ 409.2127.
4.9.2.
(2E,2′E)-N,N′-(((Oxybis(Ethane-2,1-Diyl))Bis(Oxy))Bis(Ethane-2,1-Diyl))Bis(3-Phenylacrylamide) (9k)
Light yellow oil, yield 28%; 1H-NMR (300 MHz, CDCl3) δ: 7.60 (d, J = 15.6 Hz, 2H), 7.45 (dd, J
= 6.5, 3.1 Hz, 4H), 7.32–7.30 (m, 4H), 6.71 (t, J = 5.7 Hz, 2H), 6.47 (d, J = 15.6 Hz, 2H), 3.65 (s, 8H),
3.63–3.54 (m, 8H). 13C-NMR (101 MHz, CDCl3) δ: 166.17, 140.96, 134.98, 129.70, 128.89, 127.86, 120.93,
70.49, 70.27, 70, 39.59. HRMS (ESI) m/z: 453.2387 [M + H]+, calcd. for [C26H33N2O5]+ 453.2389.
4.9.3. (Ethane-1,2-Diylbis(Oxy))Bis(Ethane-2,1-Diyl) (2E,2′E)-Bis(3-Phenylacrylate) (9l)
Light yellow oil, yield 65%; 1H-NMR (300 MHz, CDCl3) δ: 7.70 (d, J = 16 Hz, 2H), 7.54–7.48
(m, 4H), 7.40–7.34 (m, 6H), 6.48 (d, J = 16 Hz, 2H), 4.42–4.36 (m, 4H), 3.84–3.77 (m, 4H), 3.73 (s, 4H).
13C-NMR (101 MHz, CDCl3) δ: 167.03, 145.21, 134.50, 130.44, 129.01, 128.23, 118, 70.79, 69.48, 63.78.
HRMS (ESI) m/z: 411.1805 [M + H]+, calcd. for [C24H27O6]+ 411.1808.
424
Molecules 2019, 24, 4505
4.9.4. ((Oxybis(Ethane-2,1-Diyl))Bis(Oxy))Bis(Ethane-2,1-Diyl) (2E,2′E)-bis(3-Phenylacrylate) (9m)
Light yellow oil, yield 87%; 1H-NMR (300 MHz, CDCl3) δ: 7.70 (d, J = 16 Hz, 2H), 7.55–7.48 (m,
4H), 7.38 (dd, J = 3.8, 2.7 Hz, 6H), 6.48 (d, J = 16 Hz, 2H), 4.37 (dd, J = 5.5, 4.1 Hz, 4H), 3.81–3.74 (m,
4H), 3.70 (s, 8H). 13C-NMR (101 MHz, CDCl3) δ: 167.03, 145.19, 134.52, 130.45, 129.02, 128.23, 118.04,




The tested cells were obtained from Shanghai Institute of Biochemistry and Cell Biology of the
Chinese Academy of Sciences (Shanghai, China). HeLa and Hep G2 cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; gibco, Life Technologies, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS; Biological Industries), 100 U/mL penicillin-streptomycin (PS; gibco, Life
Technologies, Carlsbad, CA, USA). MCF-7 and A549 cell lines were maintained in RPMI-1640 media
(gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS and 100 U/mL PS. FaDu
cell lines were cultured in minimum essential medium (MEM; Gibco, Life Technologies, Carlsbad, CA,
USA) supplemented with 10% FBS and 100 U/mL PS. MCF 10A cell lines were maintained in Mammary
MEGM kit (Lonza/Clonetics) supplemented with 100 ng/mL cholera toxin (Sigma, Shanghai, China).
Cell lines were grown at 37 ◦C in a humidified atmosphere of 5% CO2.
4.10.2. Cell Viability Assay
The growth-inhibitory effects against HeLa, Hep G2, MCF-7, FaDu, and A549 cancer cells and
normal cell lines MCF 10A were determined by MTT assay [21]. All of the synthesized compounds
and the positive control drug doxorubicin were dissolved in 0.1% DMSO. Cells were seeded in 96 well
plates at a density of 1 × 104 cells per well and incubated for 24 h at 37 ◦C in a humidified atmosphere
of 5% CO2. The cells were then incubated with various concentrations of drugs for 48 h in a 5% CO2
incubator at 37 ◦C. After treatment with 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) solution for 4 h, the formazan crystals were dissolved in 100 μL DMSO in each well.
Plates were read on a microplate reader (Thermo Varioskan Flash 3001) at 490 nm. The experiment
was performed in triplicate. The inhibitory concentration at 50% (IC50) was calculated based on
concentration-inhibition relationships via regression using SPSS software (Version 17.0).
4.10.3. Colony Formation Assay
FaDu cells were seeded in a 6-well plate with 500 cells per well and incubated for 24 h. Then, the
cells were treated with compound 8e at various final concentrations of 0, 0.75, 1.50, 3 nM. Following
treatment for 10 days, the cells were washed with PBS twice and fixed with 4% paraformaldehyde
for 10 min at room temperature. Then, the cell colonies were visualized by staining with 0.1% crystal
violet for 10 min. The image was photographed with Handy camera, and the numbers of cell colonies
were analyzed using the open Image J software (Developed by National Institutes of Health). A group
of >50 cells was defined as one colony. Triplicate wells were set up for each concentration.
4.10.4. Live/Dead Staining
The Calcein AM/propidium iodide (PI) double staining was performed following the
manufacturer’s instructions (Dojindo Laboratory, Kumamoto, Japan). Briefly, FaDu cells were
seeded in 6-well plates overnight. Then, the 8e solutions at final concentrations of 2.5 nM, 5 nM, and 10
nM were added. After incubation for 24 h, the cells were collected, washed with PBS, and stained by a
mixture of 2 μM Calcein-AM (live cells, green) and 4.5 μM PI (dead cells, red) solution in the dark for
30 min at 37 ◦C (excitation 490 nm). Then, the cells were rinsed with PBS twice and re-suspended in the
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cell medium. Confocal fluorescence images were acquired using a laser scanning confocal microscope
(LSCM, Carl-Zeiss LSM 710).
4.10.5. Hoechst 33,342 Staining
For Hoechst staining, FaDu cells were seeded onto a glass-bottom of cell culture dish at a density
of 1 × 105 cells. After incubation for 24 h, the media containing 20 nM of the compound 8e was used to
replace the culture medium. Then, the cells were stained with Hoechst 33,342 solution (10 μg/mL in
the culture medium, Beyotime Institute of Biotechnology, Shanghai, China) at 37 ◦C in the dark for
20 min after treatment with 8e. Then, the cells were washed with the serum-free medium to remove
excess dye. LSCM (Carl-Zeiss LSM 710) was used to capture the images of nuclear morphological
changes to find apoptotic cells.
4.10.6. Flow Cytometric Analysis of Apoptosis by Annexin V-FITC/PI Staining
Apoptosis in FaDu cells was evaluated by an annexin V-FITC/PI apoptosis detection kit (Beyotime
Institute of Biotechnology, Shanghai, China). Briefly, FaDu cells were treated with various concentrations
of compound 8e (2, 5, 10 nM) or DMSO as vehicle control for 24 h at 37 ◦C; then, the cells were washed
twice with cold 1× PBS and centrifuged at 1000 rpm for 5 min. The harvested cells were resuspended
gently in 400 μL binding buffer, containing 5 μL annexin V-FITC and 10 μL PI. After incubating for 15
min in the dark at room temperature, the cells were analyzed with flow cytometry (CyFlow® Cube 6,
Sysmex). Data were shown as pseudo color graphs and analyzed using FlowJo Software (Tree Star Inc,
Ashland, OR).
4.10.7. Mitochondrial Membrane Potential (ΔΨm) Analysis
The mitochondrial membrane potential (ΔΨm) was detected by a mitochondrial membrane
potential assay kit with JC-1 (Beyotime Institute of Biotechnology, Shanghai, China). Briefly, after
treatment with various concentrations of compound 8e (2, 5, 10 nM) for 24 h, FaDu cells were harvested
and stained with 500 μL 1× JC-1 dye solution at 37 ◦C for 20 min in the dark. Then, the treated cells
were washed twice and resuspended by 1× JC-1 staining buffer. The fluorescence of approximately
1 × 104 cells was analyzed using flow cytometry (CyFlow® Cube 6, Sysmex).
4.10.8. Cell Cycle Analysis
The cell cycle analysis was carried out by a cell cycle and apoptosis analysis kit with a propidium
iodide (PI) staining method (Beyotime Institute of Biotechnology, Shanghai, China). Briefly, FaDu cells
were incubated with the above-mentioned doses of compound 8e for 24 h; all samples were collected,
washed once with cold 1× PBS, and fixed by 70% ice-cold ethanol at 4 ◦C for 12 h. Then, the fixed cells
were washed once with cold 1× PBS and stained with 500 μL 1× PI dye solution (containing 10 μL
RNase A) at 37 ◦C for 30 min in the dark. The red fluorescence was detected using a flow cytometer
(CyFlow® Cube 6, Sysmex). The data were analyzed using FlowJo Software (Tree Star Inc, Ashland,
OR, USA).
4.10.9. In Silico ADMET Prediction
A computational study of all synthesized compounds was carried out for the prediction of ADMET
(absorption, distribution, metabolism, excretion, and toxicity) properties. In this module, thirteen
mathematical models, such as HBD (hydrogen bond donor), HBA (hydrogen bond acceptor), RBN
(number of rotatable bonds), logP (log of the octanol/water partition coefficient), log S (log of the
aqueous solubility), and PSA (polar surface area) were predicted via Discovery Studio 2.0 Software
(Studio 2.5, Accelrys, Co. Ltd., San Diego, CA, USA) and HIA (human intestinal absorption), PPB
(plasma protein binding), CYP3D4 (CYP3D4 inhibition), T1/2 (half lifetime), HT (human hepatotoxicity),
and LD50 (median lethal dose) were calculated using web-based applications and then analyzed to
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predict the drug likeliness profile (Xiangya School of Pharmaceutical Sciences and Central South
University, http://admet.scbdd.com/home/index/) [28]. We also screened our novel derivatives through
the prediction model by Egan et al. [29,30]. Two molecular descriptors, AlogP98 and PSA, were
computed and plotted in a 2D plane to comprehensively evaluate the absorption and blood-brain
penetration of the compounds.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/24/4505/s1,
1H-NMR, 13C-NMR and HR-MS spectra of compounds.
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Abstract: New chrysin-De-allyl-Pac-1 hybrid analogues, tethered with variable heterocyclic systems
(4a–4o), were rationally designed and synthesized. The target compounds were screened for in vitro
antiproliferative efficacy in the triple-negative breast cancer (TNBC) cell line, MDA-MB-231, and
normal human mammary epithelial cells (HMECs). Two compounds, 4g and 4i, had the highest
efficacy and selectivity towards MDA-MB-231 cells, and thus, were further evaluated by mechanistic
experiments. The results indicated that both compounds 4g and 4i induced apoptosis by (1)
inducing cell cycle arrest at the G2 phase in MDA-MB-231 cells, and (2) activating the intrinsic
apoptotic pathways in a concentration-dependent manner. Physicochemical characterizations of
these compounds suggested that they can be further optimized as potential anticancer compounds
for TNBC cells. Overall, our results suggest that 4g and 4i could be suitable leads for developing
novel compounds to treat TNBC.
Keywords: triple-negative breast cancer; cytotoxicity; chrysin analogues; flavonoid; anticancer
compounds
1. Introduction
Breast cancer is the second leading cause of death among all cancers affecting women [1].
Triple-negative breast cancer (TNBC) lacks the expression of hormone receptors (estrogen (ER) or
progesterone (PR)) and/or human epidermal growth factor receptor 2 (HER2), which are more amenable
to targeted therapy [2]. TNBC often presents as a high-grade invasive ductal carcinoma (IDC) in
Molecules 2020, 25, 3063; doi:10.3390/molecules25133063 www.mdpi.com/journal/molecules429
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patients, accounting for one-fourth of all breast cancer deaths. Consequently, there is an urgent
need for the development of compounds that are efficacious and safe for the treatment of breast
cancer. Flavonoids are ubiquitous naturally occurring polyphenolic compounds that are commonly
found in fruits and vegetables [3]. Flavonoids comprise several classes of low molecular weight
compounds, including flavanones, anthocyanidins, flavonols, flavanols, isoflavones, dihydroflavonols,
and flavones [4–6]. Chrysin (5, 7-dihydroxyflavone, Figure 1) is a natural flavone found in many
plant extracts, such as the blue passionflower, as well as in honey and propolis [7,8]. Chrysin has
been reported to have properties, such as antioxidant [9], antihypertensive [10], antibacterial [11],
anti-inflammatory [12], antiviral [13], antiallergic [14], antidiabetic [15], anxiolytic [16], and anticancer
efficacy [17,18]. The activation of apoptosis plays a major role in producing the anticancer efficacy of
chrysin [19–21]. Mechanistically, apoptosis involves a cascade of initiator and effector caspases [22].
Among these caspases, caspase-3 and caspase-7 are downstream executioner caspases that play
an essential role in inducing apoptosis by cleaving a variety of cellular substrates [23]. Therefore,
caspase-dependent apoptosis pathways represent targets for the development of efficacious anticancer
drugs. Recently, a number of studies have been done to augment the pharmacological activity
of chrysin by producing synthetic analogues [24–29]. Moreover, there are studies indicating that
chrysin-based compounds have in vitro efficacy in breast cancer cells [30–32]. The compound, de-allyl
procaspase-activating compound 1 (PAC-1), induces apoptosis in different types of cancer cells by
activating caspase-3 and/or caspase-7 [33–36]. Previously, we reported that molecular hybridization
between chrysin and de-allyl PAC-1 can be used to produce novel hybrid molecules with cytotoxic
efficacy [29]. Molecular hybridization is a process that comprises the amalgamation of two or more
pharmacophoric moieties of different bioactive molecules into a single molecular framework [37,38].
 
Figure 1. Chemical structures of chrysin, de-allyl PAC-1, and a representative designed hybrid
molecule 4a.
In this study, new chrysin-de-allyl PAC-1 hybrid analogues, substituted with variable aromatic
heterocyclic cores, were synthesized and evaluated to identify a more potent bioactive hybrid against
breast cancer cells (Figure 1). The in silico parameters of the synthesized compounds were calculated to
predict their pharmacokinetic profile and drug-likeness using SwissSimilarity ADME, a web tool [39].
Subsequently, the target compounds were screened for antiproliferative efficacy in the human breast
cancer cell line MDA-MB-231, using the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
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Bromide) colorimetric assay. Finally, we determined the effects of the most potent compounds on the
cell cycle.
2. Results and Discussions
2.1. Chemistry
The target compounds (4a–4o) were prepared according to Scheme 1, starting from the
commercially available chrysin, using previously published synthetic procedures [29]. Briefly, chrysin
was added to methyl 2-bromoacetate at a low temperature in the presence of K2CO3, yielding the
desired alkylation product 2. The conversion of ester 2 into hydrazide 3 was accomplished using 80%
hydrazine hydrate and a few drops of hydrochloric acid at low temperature. 1H and 13C NMR data
confirmed the formation of hydrazide 3 as a pure single product. Target compounds (4a–4o) were
obtained by adding hydrazide 3 to an appropriate aldehyde in the presence of a catalytic amount of
hydrochloric acid at room temperature. All analogues gave adequate analytical and spectroscopic data,
which were in full accordance with their structures. 1H and 13C NMR spectra showed that compounds
4a–4o existed as geometrical isomers (E/Z isomers). The E:Z ratio for each compound was determined
from 1H NMR spectra utilizing the integration of the neat methylene group peaks that appeared
as two separated singlets for each isomer. Target compounds were analyzed using SwissSimilarity
(Swiss Institute of Bioinformatics, Lausanne, Switzerland). Compounds 4a–4j and 4n–4o were the
most structurally similar to apigenin, a flavonoid similar to chrysin. The physicochemical properties of
the compounds (4a–4o) are shown in Table 1.
Scheme 1. Reagents and conditions: (a) methyl 2-bromoacetate, K2CO3, DMF, 0 ◦C, 3 h; (b) hydrazine
hydrate 80%, EtOH, 0 ◦C, HCl (cat.), 1 h; (c) different substituted aldehydes, CH3OH, HCl (cat), rt, 1 h.
Table 1. Physiochemical properties of the compounds 4a–4o collected from Swiss ADME.
Compound MW













4a 430.41 Moderatelysoluble High No 0 2 1 3.14
4b 414.41 Moderatelysoluble High No 0 2 0 3.38
4c 444.44 Moderatelysoluble High No 0 3 0 3.62
4d 458.46 Moderatelysoluble High No 0 3 0 3.95
4e 430.41 Moderatelysoluble High No 0 2 1 3.07
4f 444.44 Moderatelysoluble High No 0 3 0 3.62
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Table 1. Cont.
Compound MW













4g 446.41 Moderatelysoluble Low No 0 2 2 2.71
4h 474.46 Moderatelysoluble High No 0 3 0 3.65
4i 462.41 Moderatelysoluble Low No 0 2 3 2.38
4j 462.41 Moderatelysoluble Low No 0 2 2 2.43
4k 404.37 Moderatelysoluble High No 0 2 0 2.81
4l 415.4 Moderatelysoluble High No 0 2 0 2.66
4m 415.4 Moderatelysoluble High No 0 2 0 2.72
4n 480.47 Poorlysoluble Low No 0 2 1 4.04
4o 475.41 Moderatelysoluble Low No 1 3 1 2.52
ESOL Class: Estimated Solubility Class [40]. GI Absorption: Gastrointestinal Absorption. BBB Permeant: Blood
Brain Barrier Permeant. Lipinski Violations examines orally active compounds to determine ranges for high
probability to be an oral drug. Lead-likeness Violations examines compounds’ likeliness to become a lead based on
a rule-based method [41]. PAINS Alerts: compounds that give false positives where the compound nonspecifically
binds to numerous biological targets, instead of one desired target [42]. Log P: partition coefficient measuring
lipophilicity [41].
2.2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide-Based Cytotoxicity Assay
The synthesized chrysin derivatives were evaluated for cytotoxic efficacy in the human breast
cancer cell line, MDA-MB-231, using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide
(MTT) colorimetric assay and doxorubicin was used as a reference anticancer drug. The IC50 values
(concentration of compound in μM required to reduce 50% of cell viability) are shown in Table 2.
Table 2. The effects of chrysin derivatives (4a–4o) on the survival of the MDA-MB-231 cancer cell line.















54.8 ± 5.7 a
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Table 2. Cont.
Compound Structure IC50 (μM)
4f
 




























Doxorubicin NA 0.2 ± 0.1
Cell survival was determined by MTT assay as described in materials and methods. The IC50 values are represented
as mean ± SD of two independent experiments performed in triplicate. a The data was taken from [29].
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As shown in Table 2, the structure–activity relationship (SAR) results indicated that the cytotoxic
efficacy of the synthesized compounds was affected by the modifications on the benzene ring (ring
D) of the parent compound 4a. Compound 4a, possessing a hydroxyl group at C-2 of ring D, had
cytotoxic efficacy, with an IC50 value of 6.8 μM. To determine the importance of the hydroxyl group at
the C-2 position, compound 4b was synthesized, and its efficacy was similar to compound 4a. The
methylation of the hydroxyl group in 4a yielded compound 4c, which had a lower efficacy than 4a and
4b, whereas ethylation of the hydroxyl group, which yielded compound 4d, produced a significant
decrease in cytotoxic efficacy, compared to compound 4a. Previously, we reported that the shifting
of the hydroxyl group from C-2 to C-4 (4e) produced a significant reduction in the cytotoxic efficacy
(IC50 > 50 μM). However, methylation of the hydroxyl group in 4e yielded compound 4f, which
was ~5 times more efficacious than 4e [29]. The addition of a second hydroxyl group at the C-4
position in 4a resulted in compound 4g (IC50 = 5.98 μM), which had cytotoxic efficacy similar to
compound 4a. Interestingly, the methylation of the two hydroxyl groups in 4g, yielding compound
4h, significantly decreased the cytotoxic efficacy. The addition of a third hydroxyl group to 4g at
position 3 of ring D, yielding compound 4i, did not significantly alter the antiproliferative efficacy
of the compound, whereas adding a third hydroxyl group at position 6 of ring D yielded a totally
inactive compound, 4j. Next, we determined the effect of ring D on the cytotoxic efficacy of the
synthesized compounds. Therefore, compounds 4k–4m were synthesized, where ring D was replaced
with aromatic heterocyclic moieties. Compounds 4k, 4l, and 4m, containing furan, 3-pyridine, and
2-pyridine moieties, respectively, did not have significant cytotoxic efficacy. Furthermore, adding
another fused benzene ring to ring D, while keeping the C-2 hydroxyl group (2-hydroxynaphthalene),
yielded the inactive compound, 4n. The addition of a nitro group at the C5-position of ring D in 4a
yielded compound 4o, which had an efficacy similar to compound 4a (IC50 = 7.9 μM).
Next, the cytotoxicity and selectivity of the most active compounds, 4g and 4i, were determined
in a panel of cell lines, including the normal cell lines, HMECs, and cancer cell lines, BT-20, U-251, and
HCT116, as shown in Figure 2 and Table 3. Compound 4g had antiproliferative efficacy in the BT-20,
U-251, and HCT116, with IC50 values of 5.32, 7.64, and 2.68, respectively. In contrast, compound 4i had
IC50 values ranging from 10–25 μM. The results indicated that although compound 4g is more potent
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Figure 2. The efficacy and selectivity of 4g and 4i in MDA-MB-231, BT-20, U-251, and HCT116, and
compared to the normal cell line, HMEC (A) the viability curves for cancer cells (MDA-MB-231,
BT-20, U-251, HCT116), and the normal cell line, HMEC; (B) the IC50 values of 4g and 4i for
these cell lines are also compared to the normal cell line. Cell survival was determined using
the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The IC50 values are
represented as the means ± SD of three independent experiments performed in triplicate with * p < 0.05,
**** p < 0.0001 vs. control group.
Table 3. The effects of the chrysin-like compounds (4a–4o) on the survival of cancer cell lines (breast,
glioblastoma, and colon) and a normal non-cancerous cell line (normal human mammary epithelial cells).
Compound Breast Cancer Brain Cancer Colon Cancer Normal Cells
BT-20 U-251 HCT116 HMEC
4a 4.41 ± 0.99 8.63 ± 4.86 2.88 ± 0.09 7.12 ± 4.55
4g 5.32 ± 0.72 7.64 ± 0.11 2.68 ± 0.15 8.00 ± 1.33
4i 10.43 ± 0.20 25.36 ± 7.53 20.09 ± 0.13 >100
4o 7.25 ± 1.82 11.27 ± 2.84 3.85 ± 0.34 7.17 ± 4.10
Cell survival was determined by MTT assay as described in the materials and methods. The IC50 values (μM) are
represented as the mean ± SEM of three independent experiments performed in triplicate. The compounds were
screened on breast (MDA-MB-231, BT-20), brain (U-251), and colon (HCT116) cancer cell lines and normal human
mammary epithelial cells (HMECs).
2.3. 4g and 4i Induce Apoptosis and G2 Cell Cycle Arrest in a Triple-Negative Breast Cancer Cell Line
Apoptosis, a type of programmed cell death, is one of the major mechanisms by which
chemotherapeutic drugs produce their therapeutic efficacy [43]. Morphologically, apoptosis is
characterized by cellular shrinkage, which is accompanied with nuclear chromatin condensation and
fragmentation followed by blebbing of the plasma membrane. This leads to the formation of small
apoptotic bodies that have an intact cellular membrane and unaltered organelle integrity. These bodies
are then released in the extracellular environment and removed by the process of phagocytosis [44,45].
Apoptosis can occur by two pathways: The extrinsic pathway and intrinsic pathway. In either pathway,
when the cell is exposed to certain extrinsic or intrinsic stimuli, the integrity of the inner mitochondrial
membrane of the cell is compromised, resulting in the loss of the mitochondrial membrane potential,
and causing the release of several apoptotic factors, including cytochrome c [46,47]. Numerous
studies indicate that during apoptosis, phosphatidylserine (PS), in the cytoplasmic side of the plasma
membrane, is translocated to the extracellular cell surface [48]. The flipped anionic PS binds to the
Ca2+-dependent phospholipid-binding protein, annexin V [49]. We discovered and reported several
potent apoptosis-inducing compounds [50–57]. In this study, the result of our morphological studies in
MDA-MB-231 cells after incubation with our lead compounds, 4g and 4i, indicated that apoptosis was
occurring (Figure 3A). At a concentration of 20 μM, both compounds decreased the number of adherent
435
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MDA-MB-231 cells and induced cellular shrinkage. The cells were rounded and loosely attached,
and apoptotic bodies were present. Similarly, the incubation of MDA-MB-231 cells with compounds 4g
or 4i for 24 h produced a significant loss of the mitochondrial membrane potential. For compound 4g,
the population of cells undergoing apoptosis increased from 14.30% at 0 μM to 26.56% and 58.05% at 5
and 10 μM, respectively (p value < 0.0001; Figure 3B,C). Compound 4i also produced a significant shift
in the apoptotic cell population in quadrant II, from 14.78% at 0 μM to 32.25% and 42.56% at 5 and
10 μM, respectively (p value < 0.0001, Figure 3B,C). Cell cycle analysis indicated that compounds 4g and
4i produced a significant disruption in the cell cycle of MDA-MB-231 cells (Figure 3D). Data obtained
using flow cytometry indicated that, when incubated with vehicle alone, MDA-MB-231 cells had a
normal cell cycle (5.43%, 83.4%, 4.63%, and 4.46% in the subG1, G1, S, and G2 phases, respectively).
However, incubation of MDA-MB-231 cells with compound 4g resulted in a significant shift towards
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Figure 3. Effects of 4g and 4i on cellular morphology, mitochondrial membrane potential, and cell cycle
(A) Morphological observations of MDA-MB-231 cells incubated with 0, 5, and 20 μM concentrations
of 4g and 4i at different time intervals of 0, 24, 48, and 72 h, respectively; (B) The MDA-MB-231 cells in
complete medium were incubated with 4g and 4i at 0, 5, or 10 μM for 24 h. Cells were then incubated
with the reagents of the MitoTracker Red and Alexa Fluor 488 annexin V kits for flow cytometry.
Representative results of MDA-MB-231 cells from two independent experiments, each performed in
triplicate, are shown; (C) Histograms quantitatively summarize the results following incubation with
4g and 4i, respectively; (D) The induction of cell cycle arrest in MDA-MB-231 cells by 4g and 4i is
shown. The MDA-MB-231 cells were incubated with different concentrations (0, 5, and 10 μM) of 4g
and 4i for 24 h and were subjected to cell cycle analysis by flow cytometry of PI (X axis)/cell counts
(Y axis); (E) A histogram quantitatively summarizing the change in % of cells in each phase of the
cell cycle due to incubation with 4g and 4i. The data represents means ± SEM of three independent
experiments performed in triplicate with **** p < 0.0001 vs. control group.
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2.4. Compounds 4g and 4i Activate Apoptosis by Activating the Intrinsic Apoptotic Pathway
Apoptosis can be induced by the activation of two major pathways: The intrinsic and extrinsic
apoptotic pathways [22]. The activation of the intrinsic apoptotic pathway induces the activation of
proapoptotic proteins, such as apoptosis regulator Bak (Bcl-2 homologous antagonist/killer) and Bax
(Bcl-2-associated X protein) [58]. The activated the Bax and Bak proteins subsequently permeabilize
the mitochondrial outer membrane by forming pores on its outer surface [58–60]. Consequently,
cytochrome c (Cyt C) is released into the cytosol, where it combines with the adaptor protein (Apaf-1)
to form an apoptosome [22]. The initiator caspases (i.e., caspase-2, caspase-8, caspase-9, or caspase-10)
are activated and recruited to large protein complexes, resulting in the cleavage of the executioner
caspases, caspase-3 or caspase-7 [61].
Since MDA-MB-231 cells incubated with compounds 4g and 4i had a decrease in the mitochondrial
membrane potential, which is an early event of intrinsic apoptosis, i.e., altered permeability of the
inner mitochondrial membrane, we conducted experiments to determine if these compounds altered
the expression of key apoptotic proteins, including cytochrome c, in MDA-MB-231 cells using Western
blotting analysis. Our results indicated that compounds 4g at 5 μM, and compound 4i at 10 μM
produced a significant increase in the expression of cytochrome c, compared to cells incubated with
vehicle (Figure 4A,B). This may be due to an increase in the expression of Bak following incubation with
4g and 4i (Figure 4A,B), compared to cells incubated in the absence of lead compounds. In addition,
both compounds (4g at 5 μM and 4i at 10 μM) produced significant cleavage of the initiator caspase,
caspase 9, in MDA-MB-231 cells, compared to cells incubated with vehicle (Figure 4A,B). These events
activated caspase 7 in breast cancer cells incubated with both concentrations of 4g and 10 μM of 4i,
compared to cells incubated with vehicle (Figure 4A,B). In contrast, there was no significant change
in the mammalian target of rapamycin (mTOR) expression, indicating that cell death induced by 4g
and 4i in MDA-MB-231 cells is not due to autophagy (Figure 4A,B). Thus, our results suggest that
cytochrome c release induces intracellular initiator caspase activation, followed by the activation of
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Figure 4. The effect on apoptosis induction at different concentrations of 4g and 4i in MDA-MB-231
cells. (A) Western blots for the proteins caspase 3, caspase 7, cleaved caspase 7, caspase 9, cleaved
caspase 9, Bak, cyt C and mTOR following incubation with 4g and 4i at 0, 5, or 10 μM. The values of the
proteins were normalized to β-actin levels. (B) Histograms summarizing the levels of each protein are
also shown. All the data are presented as the means ± SEM of three independent studies with * p < 0.05,
** p < 0.01, *** p < 0.001 vs. control group. Cleaved is abbreviated as Clvd.
3. Materials and Method
3.1. Chemistry
All chemicals and solvents were procured from commercial sources (reagent grade) and were used
without further purification. The reaction progress was monitored by thin layer chromatography (TLC)
using precoated TLC plates of silica gel 60 F254. 1H-NMR and 13C-NMR spectra were recorded using a
400 MHz Bruker Avance Ultrashield spectrometer. The spectra were obtained in ppm using automatic
calibration to the residual proton peak of the solvent, dimethyl-sulphoxide (DMSO-d6). The 1H NMR
data are presented as follows: Chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, m =multiplet), coupling constants (Hz), and integration. The 13C NMR analyses were
reported in terms of the chemical shift. The 1H and 13C NMR spectra for all compounds are included
in the supporting information (Figure S1). HRMS data were acquired using a Thermo QExactive
Plus mass spectrometer equipped with an electrospray ionization source (Thermo Fisher Scientific,
Greensboro, NC, USA).
3.1.1. Synthesis of methyl 2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetate (2)
The title compound was synthesized as previously described [62].
3.1.2. Synthesis of 2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetohydrazide (3)
The title compound was synthesized according to our previously published procedure [29].
3.1.3. General Procedure for the Synthesis of N’-arylidene-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-
7-yl)oxy)acetohydrazide (4a–4o)
To a stirred suspension of hydrazide 3 (1.0 g, 3.0 mmol) in anhydrous methanol (60 mL),
the appropriate aldehyde (3.0 mmol) was added, along with a few drops of concentrated hydrochloric
acid. After one hour, the reaction was completed and the formed precipitate was separated by filtration,
washed with methanol, and dried in air to give pure compounds in good yields.
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(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(2-hydroxybenzylidene)acetohydrazide (4a)
The product was obtained as a pale-yellow powder. Yield (64%). 1H NMR (DMSO-d6) (E:Z = 1:1):
δ 12.84–12.81 (m, 2H), 11.84 (s, 1H), 11.62 (s, 1H), 10.99 (s, 1H), 10.05 (s, 1H), 8.57 (s, 1H), 8.33 (s, 1H),
8.12–8.10 (d, J = 8 Hz, 4H), 7.77–7.55 (m, 8H), 7.31–7.24 (m, 2H), 7.07–6.85 (m, 8H), 6.51–6.42 (m, 2H),
5.31 (s, 2H), 4.87 (s, 2H). 13C NMR (DMSO-d6): δ 182.11, 182.06, 167.94, 164.42, 163.65, 163.61, 163.48,
163.37, 161.17, 161.07, 157.36, 157.22, 156.45, 148.27, 141.63, 132.18, 132.12, 131.59, 131.29, 130.57, 130.54,
129.18, 129.15, 129.11, 126.56, 126.47, 120.01, 119.40, 118.65, 116.39, 116.14, 105.44, 105.39, 105.31, 105.09,
98.81, 98.72, 93.62, 93.46, 66.57, 65.36. HRMS (ESI, m/z): calculated for C24H19N2O6 [M + H]+ 431.1237;
found 431.1238.
(E,Z)-N’-Benzylidene-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetohydrazide (4b)
The synthesis and full characterization of the title compound have been previously reported [29].
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(2-methoxybenzylidene)acetohydrazide (4c)
The product was obtained as a yellow powder. Yield (55%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.84–12.80 (m, 1.5H), 11.64 (s, 1.5H), 8.68 (s, 0.5H), 8.37 (s, 1H), 8.11–8.09 (d, J = 8 Hz, 3H), 7.91–7.89
(d, J = 8 Hz, 1H), 7.82–7.80 (d, J = 8 Hz, 0.5H), 7.63–7.55 (m, 4.5H), 7.44–7.4 (m, 1.5H), 7.12–7.0 (m, 4.5H),
6.88–6.84 (m, 1.5H), 6.5–6.42 (m, 1.5H), 5.32 (s, 2H), 4.82 (s, 1H), 3.86 (s, 4.5H). 13C NMR (DMSO-d6):
δ182.09, 182.03, 168.09, 164.43, 163.71, 163.60, 163.48, 163.22, 161.13, 161.05, 157.80, 157.64, 157.21,
143.56, 139.73, 132.15, 132.10, 131.72, 131.48, 130.55, 129.09, 126.45, 125.67, 125.53, 121.94, 120.72, 120.66,
111.84, 111.77, 105.42, 105.31, 105.06, 98.77, 98.70, 93.62, 93.45, 66.65, 65.36, 55.68, 54.87. HRMS (ESI,
m/z): calculated for C25H21N2O6 [M + H]+ 445.1394; found 445.1392.
(E,Z)-N’-(2-Ethoxybenzylidene)-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetohydrazide (4d)
The product was obtained as a light-brown powder. Yield (80%). 1H NMR (DMSO-d6) (E:Z= 1:0.5):
δ 12.84–12.80 (m, 1.5H), 11.68–11.62 (m, 1.5H), 8.66 (s, 0.5H), 8.40 (s, 1H), 8.11–8.10 (d, J = 4 Hz, 3H),
7.90–7.80 (m, 1.5H), 7.60–7.57 (m, 4.5H), 7.41–7.37 (m, 1.5H), 7.10–6.84 (m, 6H), 6.5–6.42 (m, 1.5H), 5.31
(s, 2H), 4.82 (s, 1H), 4.14–4.09 (q, J = 8 Hz, 3H), 1.39–1.35 (t, J = 8 Hz, 4.5H).13C NMR (DMSO-d6):
δ 182.08, 182.03, 168.03, 164.42, 163.77, 163.57, 163.46, 163.23, 161.14, 161.04, 157.20, 157.13, 156.98,
143.46, 140.01, 132.10, 131.67, 131.42, 130.54, 129.09, 126.45, 125.76, 125.58, 122.14, 122.09, 120.61, 112.75,
105.41, 105.29, 105.05, 98.71, 93.63, 93.45, 66.62, 65.36, 63.80,14.63. HRMS (ESI, m/z): calculated for
C26H23N2O6 [M + H]+ 459.1550; found 459.1548.
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(4-hydroxybenzylidene)acetohydrazide (3e)
The synthesis and full characterization of the title compound were previously published [29].
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(4-methoxybenzylidene)acetohydrazide (3f)
The synthesis and full characterization of the title compound were previously published [29].
(E,Z)-N’-(2,4-Dihydroxybenzylidene)-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-
yl)oxy)acetohydrazide (4g)
The product was obtained as an off-white powder. Yield (85%). 1H NMR (DMSO-d6) (E:Z = 1:0.8):
δ 12.84–12.80 (m, 1.8H), 11.67 (s, 1H), 11.43 (s, 0.8H), 11.15 (s, 1H), 9.98 (s, 1.8H), 9.83 (s, 0.8H), 8.42
(s, 1H), 8.20 (s, 0.8H), 8.12–8.10 (d, J = 8 Hz, 3.6H), 7.63–7.53 (m, 6.2H), 7.33–7.31 (d, J = 8 Hz, 1H),
7.08–7.06 (d, J = 8 Hz, 1.8H), 6.89 (d, J = 2 Hz, 1H), 6.8 (d, J = 2.4 Hz, 0.8H), 6.5 (d, J = 2 Hz, 1H), 6.4 (d,
J = 2 Hz, 0.8H), 6.36–6.30 (m, 3.6H), 5.26 (s, 1.6H), 4.83 (s, 2H). 13C NMR (DMSO-d6): δ182.10, 182.05,
167.42, 164.44, 163.68, 163.64, 163.50, 162.86, 161.14, 161.04, 160.86, 160.53, 159.35, 158.07, 157.23, 149.28,
142.68, 132.18, 132.12, 131.10, 130.55, 129.15, 129.12, 128.27, 126.47, 111.49, 110.37, 107.84, 107.77, 105.45,
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105.37, 105.32, 105.07, 102.60, 102.37, 98.81, 98.72, 93.63, 93.45, 66.59, 65.33. HRMS (ESI, m/z): calculated
for C24H19N2O7 [M + H]+ 447.1186; found 447.1187.
(E,Z)-N’-(2,4-Dimethoxybenzylidene)-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-
yl)oxy)acetohydrazide (4h)
The product was obtained as a yellow powder. Yield (96%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.81 (s, 1.5H), 11.49 (s, 1.5H), 8.58 (s, 0.5H), 8.27 (s, 1H), 8.11–8.10 (m, 3H), 7.84–7.57 (m, 6H), 7.05 (s,
1.5H), 6.88–6.84 (m, 1.5H), 6.63–6.41 (m, 4.5H), 5.29 (s, 2H), 4.79 (s, 1H), 3.86–3.82 (m, 9H). 13C NMR
(DMSO-d6): δ182.04, 167.79, 164.43, 163.69, 163.55, 163.44, 162.91, 162.55, 162.33, 161.09, 161.02, 159.19,
159.02, 157.18, 143.62, 139.82, 132.10, 130.53, 129.09, 126.78, 126.43, 114.76, 106.41, 105.38, 105.28, 105.02,
98.68, 98.24, 98.07, 93.59, 93.42, 66.66, 65.35, 55.74, 55.40.HRMS (ESI, m/z): calculated for C26H23N2O7
[M + H]+ 475.1499; found 475.1499.
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(2,3,4-
trihydroxybenzylidene)acetohydrazide (4i)
The product was obtained as a yellow powder. Yield (85%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.84–12.80 (m, 1.5H), 11.71 (s, 1H), 11.47 (s, 0.5H), 11.18 (s, 1H), 9.57–9.51 (m, 1.5H), 9.37 (s, 0.5H),
8.54–8.50 (m, 1.5H), 8.38 (s, 1H), 8.18–8.10 (m, 3.5H), 7.61–7.59 (m, 4.5H), 7.07–7.0 (m, 2H), 6.90–6.78 (m,
2.5H), 6.51–6.38 (m, 3H), 5.26 (s, 1H), 4.85 (s, 2H). 13C NMR (DMSO-d6): δ 182.12, 182.07, 167.34, 164.42,
163.68, 163.54, 162.93, 161.16, 161.07, 157.25, 150.45, 148.91, 148.42, 147.47, 146.65, 144.18, 132.76, 132.71,
132.21, 132.16, 130.56, 129.18, 126.49, 121.11, 118.36, 112.11, 110.70, 107.84, 107.73, 105.46, 105.40, 105.34,




The product was obtained as a brown powder. Yield (76%). 1H NMR (DMSO-d6) (E:Z = 1:0.2):
δ 12.83–12.79 (m, 1.2H), 11.65 (s, 1H), 11.48 (s, 0.2H), 10.99 (s, 2H), 10.32 (s, 0.4H), 9.85 (s, 1.2H), 8.72 (s,
1H), 8.41 (s, 0.2H), 8.09–8.08 (m, 2.4H), 7.59–7.58 (m, 3.6H), 7.04 (m, 1.2H), 6.88–6.84 (m, 1.2H), 6.5–6.42
(m, 1.2H), 5.86–5.83 (m, 2.4H), 5.2 (s, 0.4H), 4.82 (s, 2H). 13C NMR (DMSO-d6): δ 182.08, 166.56, 164.28,
163.61, 163.51, 162.55, 161.74, 161.46, 161.12, 161.04, 159.73, 159.24, 157.20, 147.32, 144.33, 132.15, 130.54,
129.13, 126.45, 105.43, 105.37, 105.11, 98.85, 98.79, 94.37, 93.61, 93.50, 66.58, 65.26. HRMS (ESI, m/z):
calculated for C24H19N2O8 [M + H]+ 463.1134; found 463.1134.
(E,Z)-N’-(Furan-2-ylmethylene)-2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetohydrazide(4k)
The product was obtained as a yellow powder. Yield (87%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.83–12.79 (m, 1.5H), 11.63–11.57 (m, 1.5H), 8.23 (s, 0.5H), 8.11–8.09 (d, J = 8 Hz, 3H), 7.92 (s, 1H),
7.85 (s, 1.5H), 7.63–7.55 (m, 4.5H), 7.06–7.05 (m, 1.5H), 6.95–6.83 (m, 3H), 6.64 (m, 1.5H), 6.49–6.39 (m,
1.5H), 5.24 (s, 2H), 4.83 (s, 1H). 13C NMR (DMSO-d6): δ182.03, 167.97, 164.34, 163.66, 163.59, 163.46,
163.35, 161.13, 161.02, 157.21, 149.12, 148.94, 145.34, 145.10, 137.86, 134.20, 132.11, 130.54, 129.09, 126.45,
113.95, 113.78, 112.16, 105.42, 105.29, 105.08, 98.70, 93.60, 93.38, 66.65, 65.14.HRMS (ESI, m/z): calculated
for C22H17N2O6 [M + H]+ 405.1081; found 405.1077.
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(pyridin-3-ylmethylene)acetohydrazide (4l)
The product was obtained as a yellow powder. Yield (86%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.82(bs, 1.5H), 11.98 (bs, 1.5H), 8.43 (s, 0.5H), 8.30–8.28 (d, J = 8 Hz, 3H), 8.13–7.96 (m, 7H), 7.62–7.55
(m, 4.5H), 7.07–7.06 (m, 1.5H), 6.88 (s, 1.5H), 6.5–6.45 (m, 1.5H), 5.39 (s, 2H), 4.9 (s, 1H). 13C NMR
(DMSO-d6): δ 182.12, 168.50, 164.42, 163.67, 163.55, 161.08, 157.27, 150.51, 148.52, 145.40, 141.22, 133.75,
132.20, 130.59, 129.96, 129.16, 126.51, 123.94, 105.36, 105.12, 98.76, 93.55, 66.61, 65.40. HRMS (ESI, m/z):
calculated for C23H18N3O5 [M + H]+ 416.1241; found 416.1240.
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(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-(pyridin-2-
ylmethylene)acetohydrazide (4m)
The product was obtained as a brown powder. Yield (52%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.84–12.81 (m, 1.5H), 11.89–11.87 (m, 1.5H), 8.61 (m, 1.5H), 8.35 (s, 0.5H), 8.11–8.03 (m, 5H), 7.94–7.87
(m, 2H), 7.62–7.55 (m, 4.5H), 7.44–7.41 (m, 1.5H), 7.07–7.06 (m, 1.5H), 6.88 (m, 1.5H), 6.51–6.45 (m, 1.5H),
5.37 (s, 2H), 4.88 (s, 1H). 13C NMR (DMSO-d6): δ 182.02, 168.45, 164.34, 163.75, 163.65, 163.59, 163.48,
161.13, 161.05, 157.21, 152.93, 152.78, 149.51, 149.44, 148.26, 144.45, 136.86, 136.75, 132.09, 130.53, 129.07,
126.44, 124.52, 124.34, 119.98, 119.90, 105.42, 105.30, 105.09, 98.70, 93.63, 93.48, 66.61, 65.30. HRMS (ESI,
m/z): calculated for C23H18N3O5 [M + H]+ 416.1241; found 416.1238.
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-((2-hydroxynaphthalen-1-
yl)methylene)acetohydrazide (4n)
The product was obtained as a yellow powder. Yield (54%). 1H NMR (DMSO-d6) (E:Z = 1:0.5):
δ 12.86–12.81 (m, 1.5H), 12.46 (s, 1H), 11.91 (s, 1H), 11.68 (s, 0.5H), 10.77 (s, 0.5H), 9.40 (s, 1H), 8.89 (s,
0.5H), 8.77–8.75 (d, J = 8 Hz, 0.5H), 8.30–8.28 (d, J = 8 Hz, 1H), 8.12–8.09 (m, 3H), 7.94–7.84 (m, 3H),
7.63–7.58 (m, 6H), 7.42–7.36 (m, 1.5H), 7.24–7.21 (m, 1.5H), 7.08–7.06 (m, 1.5H), 6.94–6.88 (m, 1.5H),
6.55–6.46 (m, 1.5H), 5.38 (s, 1H), 4.94 (s, 2H). 13C NMR (DMSO-d6): δ182.09, 182.03, 167.52, 164.38,
163.64, 163.54, 163.49, 163.17, 161.17, 161.06, 157.95, 157.23, 156.88, 147.37, 143.29, 132.91, 132.52, 132.16,
132.10, 131.59, 131.25, 130.53, 129.13, 128.89, 128.68, 128.13, 127.80, 127.75, 126.46, 123.54, 123.40, 120.97,
118.75, 118.13, 110.08, 108.45, 105.45, 105.33, 105.10, 98.87, 98.73, 93.68, 93.46, 66.72, 65.59.HRMS (ESI,
m/z): calculated for C28H21N2O6 [M + H]+ 481.1394; found 481.1394.
(E,Z)-2-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N’-((2-hydroxy-5-
nitrobenzylidene)acetohydrazide (4o)
The product was obtained as a yellow powder. Yield (91%). 1H NMR (DMSO-d6) (E:Z = 1:0.75):
δ 12.85–12.80 (m, 1.75H), 11.97 (bs, 2H), 11.78 (s, 1.5H), 8.64–8.54 (m, 2.75H), 8.33 (s, 1H), 8.15–8.10 (m,
5.25H), 7.64–7.55 (m, 5.25H), 7.08–7.04 (m, 3.25H), 6.90–6.86 (m, 1.75H), 6.52–6.44 (m, 1.75H), 5.39 (s,
2H), 4.89 (s, 1.5H). 13C NMR (DMSO-d6): δ 182.08, 182.03, 168.28, 164.42, 163.71, 163.61, 163.46, 162.04,
161.14, 161.04, 157.20, 144.30, 139.91, 138.65, 132.16, 132.10, 130.55, 129.12, 129.08, 126.73, 126.45, 123.37,
121.68, 120.98, 119.95, 117.10, 116.72, 105.43, 105.37, 105.30, 105.08, 98.78, 98.73, 93.62, 93.46, 66.53, 65.42.
HRMS (ESI, m/z): calculated for C24H18N3O8 [M + H]+ 476.1088; found 476.1089.
3.2. Biological Studies
3.2.1. Cell Lines and Cell Culture
A panel of cancer cell lines, including breast (MDA-MB-231, BT20), brain (U251), and colon
(HCT116), as well as a normal cell line (human mammary epithelial cells: HMECs), were grown as
adherent monolayers in flasks with Dulbecco’s Modified Eagle Medium (DMEM), supplemented with
10% fetal bovine serum (FBS) and 1% penicillin and streptomycin in a humidified incubator with 5%
CO2 at 37 ◦C.
3.2.2. MTT Assay
The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay was used to
determine the cytotoxicity of the 15 chrysin derivatives in the above-mentioned cell lines. Briefly,
cells were harvested with 0.05% trypsin, 2.21 mM ethylenediaminetetraacetic acid (EDTA), 1× from
Corning (Corning, NY, USA), and suspended at a final density of 5 × 103 cells/well. Cells were seeded
(180 μL/well) into 96-well plates. Initially, four different concentrations of each compound were added
to find the compounds with the greatest antiproliferative efficacy in the MDA-MB-231 cell line (0, 1,
10, and 100 μM). Subsequently, eight different concentrations (0.1, 0.3, 1, 3, 10, 30, and 100 μM) of
each compound were added to the remaining cell lines mentioned above. After 68 h of incubation,
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20 μL of the MTT solution (4 mg/mL) were added to each well, and the plates were incubated for 4 h.
This allowed viable cells to biotransform the yellow-colored MTT into dark-blue formazan crystals.
Subsequently, the medium was discarded, and 150 μL of DMSO were added to each well to dissolve
the formazan crystals. The absorbance was determined at 590 nm using a DTX 880 multimode detector
(Beckman Coulter life sciences, IN, USA). The IC50 ± SD concentrations were calculated from three
experiments performed in triplicate/duplicate. The IC50 values were calculated from the cell survival
percentages obtained for each compound tested at different concentrations. Similarly, the cytotoxicity
of the test compounds was compared to the normal cell line (HMEC).
3.2.3. Cell Cycle, Apoptosis, and Mitochondrial Membrane Potential Analysis
MDA-MB-231 cells were plated into 6-well plates at 2.5 × 105 cells/well. The cells were incubated
with 0, 5, or 10 μM of compounds 4g or 4i and incubated for 12 h. Next, the cells were trypsinized with
0.05% trypsin, 2.21 mM EDTA, 1×, washed, counted, and resuspended in 1 mL of ice-cold PBS. The cells
then were stained with propidium iodide (PI) dye and incubated for at least 15 min. The distribution
of the cells in each cell cycle phase for the different concentrations was measured using a BD Accuri™
C6 flow cytometer from BD Biosciences (Becton-Dickinson, San Jose, CA, USA) and analyzed using
FCS Express 5 plus De Novo software (Glendale, CA, USA).
MitoTracker Red and Alexa Fluor 488 annexin V kits for flow cytometry (Molecular Probes Inc.,
Invitrogen, Eugene, OR) were used to measure the mitochondrial membrane potential and apoptosis
in MDA-MB-231 cells. Briefly, cells were seeded into 6-well plates and incubated with 0, 5, or 10 μM
of compounds 4g and 4i for 12 h. The cells were then lysed using 0.05% trypsin, 2.21 mM EDTA,
1×, counted, and 4 μL of 10 μM of the MitoTracker Red working solution were added to 1 mL of the
harvested cells. The cells were incubated at 37 ◦C with 5% CO2 for 30 min. The cells were washed once
with PBS and resuspended in 100 μL of the annexin binding buffer. The cell suspensions were incubated
with 5 μL of Alexa Fluor 488 annexin V for 15 min. This was followed by the addition of 400 μL of the
annexin-binding buffer. Finally, flow cytometry was used to detect the fluorescence of stained cells at
the following excitation/emission maxima: Alexa Fluor® 488 annexin V: 499/521 nm; MitoTracker®
Red: 579/599 nm with the BD Accuri™ C6 flow cytometer from BD Biosciences (Becton-Dickinson, San
Jose, CA, USA) and analyzed using FCS express 5 plus De Novo software (Glendale, CA, USA).
3.2.4. Protein Expression Analysis Using Western Blot
To measure the expression of Bak, cytochrome c, caspase-7, caspase-9, and mTOR, Western blotting
was performed by lysing MDA-MB-231 cells using a lysis buffer (50 mM Tris–HCl, 150 mM NaCl,
1 mM EDTA, 0.5% NP-40, 1% Triton, 0.1% SDS) containing a protease inhibitor cocktail that consisted
of Aprotinin, Bestatin, E-64, Leupeptin, and Pepstatin A (Sigma-Aldrich Life Science, St. Louis, MO,
USA). The bicinchoninic acid (BCA) quantification assay was used to determine the protein levels
in the cell extracts (G-BIOSCIENCES, St. Louis, MO, USA). The extracted proteins were loaded
onto a 10–20% tris-glycine gel. After separation, the proteins were transferred from the gel onto
a polyvinylidene difluoride (PVDF) membrane. The membranes were blocked using 5% milk in
Tris-buffered saline Tween 20 for 30 min and incubated overnight with primary antibodies against
Bak (1:1000), cytochrome C (1:1000), caspase-3 (1:1000), caspase 7 (1:1000), caspase 9 (1:1000), mTOR
(1:1000), or B-actin (1:2000) in 5% BSA (bovine serum albumin) at 4 ◦C. The next day, membranes were
washed and incubated with horseradish peroxidase-labelled (HRP) anti-rabbit secondary antibody
(1:5000 dilutions). The membrane was incubated with the antibody for an additional 1 h. Subsequently,
the membranes were washed and developed by Clarity Western ECL substrate (Bio-Rad; Hercules, CA,
USA). Protein was detected using a ChemiDoc Imaging System (Bio-Rad). Densitometry analyses of
the blots for the detected protein were quantified using the ImageJ software. Data was calculated as
ratios of protein/β-actin.
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4. Conclusions
In conclusion, a series of novel chrysin derivatives were designed, synthesized, and characterized.
Upon screening these compounds for their antiproliferative efficacy in the TNBC cell line, MDA-MB-231,
and normal breast HMEC cells, two compounds, 4g and 4i, had the highest efficacy and selectivity
towards MDA-MB-231 cells. Upon investigating the mechanism by which these compounds produce
cytotoxicity, it was determined that 4g and 4i cause the death of MDA-MB-231 cells by inducing
apoptosis, producing cell cycle arrest at the G2 phase, and activating the intrinsic apoptotic pathway.
Physicochemical characterizations of these compounds suggested that they can be further optimized
as potential anticancer compounds for TNBC cells. The compounds were determined to have some
solubility issues that need to be overcome in the future design of additional compounds. Overall, our
results suggest that 4g and 4i could be suitable leads for developing novel compounds to treat TNBC.
Supplementary Materials: The following are available online, Figure S1: Chemical characterization of compounds
4a–4o.
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5. Hodnick, W.F.; MllosavljeviĆ, E.B.; Nelson, J.H.; Pardini, R.S. Electrochemistry of flavonoids: Relationships
between redox potentials, inhibition of mitochondrial respiration, and production of oxygen radicals by
flavonoids. Biochem. Pharmacol. 1988, 37, 2607–2611. [CrossRef]
6. Namdeo, A.G.; Boddu, S.H.; Amawi, H.; Ashby, C.R., Jr.; Tukaramrao, D.B.; Trivedi, P.; Tiwari, A.K.
Flavonoids as Multi-Target Compounds: A Special Emphasis on their Potential as Chemo-adjuvants in
Cancer Therapy. Curr. Pharm. Des. 2020, 26, 1712–1728. [CrossRef] [PubMed]
7. Rapta, P.; Mišík, V.; Staško, A.; Vrábel, I. Redox intermediates of flavonoids and caffeic acid esters from
propolis: An EPR spectroscopy and cyclic voltammetry study. Free Radic. Biol. Med. 1995, 18, 901–908.
[CrossRef]
8. Williams, C.A.; Harborne, J.B.; Newman, M.; Greenham, J.; Eagles, J. Chrysin and other leaf exudate
flavonoids in the genus Pelargonium. Phytochemistry 1997, 46, 1349–1353. [CrossRef]
9. Kuang, Y.H.; Patel, J.P.; Sodani, K.; Wu, C.P.; Liao, L.Q.; Patel, A.; Tiwari, A.K.; Dai, C.L.; Chen, X.;
Fu, L.W.; et al. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
Biochem. Pharmacol. 2012, 84, 766–774. [CrossRef]
445
Molecules 2020, 25, 3063
10. Cherkaoui-Tangi, K.; Lachkar, M.; Wibo, M.; Morel, N.; Gilani, A.; Lyoussi, B. Pharmacological studies
on hypotensive, diuretic and vasodilator activities of chrysin glucoside from Calycotome villosa in rats.
Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv. 2008, 22, 356–361.
11. Wang, J.; Qiu, J.; Dong, J.; Li, H.; Luo, M.; Dai, X.; Zhang, Y.; Leng, B.; Niu, X.; Zhao, S. Chrysin protects mice
from Staphylococcus aureus pneumonia. J. Appl. Microbial. 2011, 111, 1551–1558. [CrossRef]
12. Feng, X.; Qin, H.; Shi, Q.; Zhang, Y.; Zhou, F.; Wu, H.; Ding, S.; Niu, Z.; Lu, Y.; Shen, P. Chrysin attenuates
inflammation by regulating M1/M2 status via activating PPARγ. Biochem. Pharmacol. 2014, 89, 503–514.
[CrossRef] [PubMed]
13. Romier, B.; Van De Walle, J.; During, A.; Larondelle, Y.; Schneider, Y.-J. Modulation of signalling nuclear
factor-κB activation pathway by polyphenols in human intestinal Caco-2 cells. Br. J. Nutr. 2008, 100, 542–551.
[CrossRef] [PubMed]
14. Wadibhasme, P.G.; Ghaisas, M.M.; Thakurdesai, P.A. Anti-asthmatic potential of chrysin on
ovalbumin-induced bronchoalveolar hyperresponsiveness in rats. Pharm. Biol. 2011, 49, 508–515. [CrossRef]
15. Ahad, A.; Ganai, A.A.; Mujeeb, M.; Siddiqui, W.A. Chrysin, an anti-inflammatory molecule, abrogates renal
dysfunction in type 2 diabetic rats. Toxicol. Appl. Pharmacol. 2014, 279, 1–7. [CrossRef] [PubMed]
16. Zanoli, P.; Avallone, R.; Baraldi, M. Behavioral characterisation of the flavonoids apigenin and chrysin.
Fitoterapia 2000, 71, 117–123. [CrossRef]
17. Cardenas, M.; Marder, M.; Blank, V.C.; Roguin, L.P. Antitumor activity of some natural flavonoids and
synthetic derivatives on various human and murine cancer cell lines. Bioorg. Med. Chem. 2006, 14, 2966–2971.
[CrossRef]
18. Amawi, H.; Ashby, C.R.; Samuel, T.; Peraman, R.; Tiwari, A.K. Polyphenolic Nutrients in Cancer
Chemoprevention and Metastasis: Role of the Epithelial-to-Mesenchymal (EMT) Pathway. Nutrients
2017, 9, 911. [CrossRef]
19. Samarghandian, S.; Azimi Nezhad, M.; Mohammadi, G. Role of caspases, Bax and Bcl-2 in chrysin-induced
apoptosis in the A549 human lung adenocarcinoma epithelial cells. Anti-Cancer Agents Med. Chem. 2014, 14,
901–909. [CrossRef]
20. Burke, J.F.; Schlosser, L.; Chen, H.; Kunnimalaiyaan, M. Chrysin induces growth suppression through
apoptosis in neuroblastoma cells. J. Am. Coll. Surg. 2012, 215, S70. [CrossRef]
21. Zhang, T.; Chen, X.; Qu, L.; Wu, J.; Cui, R.; Zhao, Y. Chrysin and its phosphate ester inhibit cell proliferation
and induce apoptosis in Hela cells. Bioorg. Med. Chem. 2004, 12, 6097–6105. [CrossRef] [PubMed]
22. Riedl, S.J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol.
2004, 5, 897–907. [CrossRef] [PubMed]
23. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9, 459–470.
[CrossRef]
24. Zhu, Z.Y.; Wang, W.X.; Wang, Z.Q.; Chen, L.J.; Zhang, J.Y.; Liu, X.C.; Wu, S.P.; Zhang, Y.M. Synthesis and
antitumor activity evaluation of chrysin derivatives. Eur. J. Med. Chem. 2014, 75, 297–300. [CrossRef]
25. Liu, Y.; Song, X.; He, J.; Zheng, X.; Wu, H. Synthetic derivatives of chrysin and their biological activities.
Med. Chem. Res. 2014, 23, 555–563. [CrossRef]
26. Valdez-Calderón, A.; González-Montiel, S.; Martínez-Otero, D.; Martínez-Torres, A.; Vásquez-Pérez, J.M.;
Molina-Vera, C.; Torres-Valencia, J.M.; Alvarado-Rodríguez, J.G.; Cruz-Borbolla, J. Synthesis, structural
study and biological activity of new derivatives of chrysin containing a 2-mercaptopyridyl or
5-(trifluoromethyl)-2-mercaptopyridyl fragments. J. Mol. Struct. 2016, 1110, 196–207. [CrossRef]
27. Patel, R.V.; Mistry, B.; Syed, R.; Rathi, A.K.; Lee, Y.-J.; Sung, J.-S.; Shinf, H.-S.; Keum, Y.-S. Chrysin-piperazine
conjugates as antioxidant and anticancer agents. Eur. J. Pharm. Sci. 2016, 88, 166–177. [CrossRef]
28. Xuan, H.-Z.; Zhang, J.-H.; Wang, Y.-H.; Fu, C.-L.; Zhang, W. Anti-tumor activity evaluation of novel
chrysin–organotin compound in MCF-7 cells. Bioorg. Med. Chem. Lett. 2016, 26, 570–574. [CrossRef]
29. Al-Oudat, B.A.; Alqudah, M.A.; Audat, S.A.; Al-Balas, Q.A.; El-Elimat, T.; Hassan, M.A.; Frhat, I.N.;
Azaizeh, M.M. Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents
and caspase-3/7 activators. Drug Des. Deve. Ther. 2019, 13, 423–433. [CrossRef]
30. Srinivasan, R.; Manoharan, S. Chemopreventive Potential of Chrysin in 7, 12-dimethylbenz (A) anthracene
induced mammary carcinogenesis in sprague-dawley rats. J. Cell Tissue Res. 2011, 11, 2909.
446
Molecules 2020, 25, 3063
31. Lirdprapamongkol, K.; Sakurai, H.; Abdelhamed, S.; Yokoyama, S.; Athikomkulchai, S.; Viriyaroj, A.;
Awale, S.; Ruchirawat, S.; Svasti, J.; Saiki, I. Chrysin overcomes TRAIL resistance of cancer cells through
Mcl-1 downregulation by inhibiting STAT3 phosphorylation. Int. J. Oncol. 2013, 43, 329–337. [CrossRef]
[PubMed]
32. Yang, B.; Huang, J.; Xiang, T.; Yin, X.; Luo, X.; Huang, J.; Luo, F.; Li, H.; Li, H.; Ren, G. Chrysin inhibits
metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10,
epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J. Appl. Toxicol. 2014, 34, 105–112.
[CrossRef] [PubMed]
33. Woo, K.J.; Jeong, Y.-J.; Park, J.-W.; Kwon, T.K. Chrysin-induced apoptosis is mediated through caspase
activation and Akt inactivation in U937 leukemia cells. Biochem. Biophys. Res. Commun. 2004, 325, 1215–1222.
[CrossRef] [PubMed]
34. Khoo, B.Y.; Chua, S.L.; Balaram, P. Apoptotic effects of chrysin in human cancer cell lines. Int. J. Mol. Sci.
2010, 11, 2188–2199. [CrossRef]
35. Putt, K.S.; Chen, G.W.; Pearson, J.M.; Sandhorst, J.S.; Hoagland, M.S.; Kwon, J.-T.; Hwang, S.-K.; Jin, H.;
Churchwell, M.I.; Cho, M.-H. Small-molecule activation of procaspase-3 to caspase-3 as a personalized
anticancer strategy. Nat. Chem. Biol. 2006, 2, 543–550. [CrossRef]
36. Peterson, Q.P.; Hsu, D.C.; Goode, D.R.; Novotny, C.J.; Totten, R.K.; Hergenrother, P.J. Procaspase-3 activation
as an anti-cancer strategy: Structure− activity relationship of procaspase-activating compound 1 (PAC-1)
and Its cellular co-localization with caspase-3. Eur. J. Med. Chem. 2009, 52, 5721–5731. [CrossRef]
37. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular hybridization:
A useful tool in the design of new drug prototypes. Curr. Med. Chem. 2007, 14, 1829–1852. [CrossRef]
38. Fortin, S.; Bérubé, G. Advances in the development of hybrid anticancer drugs. Expert Opin. Drug Discov.
2013, 8, 1029–1047. [CrossRef]
39. Zoete, V.; Daina, A.; Bovigny, C.; Michielin, O. SwissSimilarity: A Web Tool for Low to Ultra High Throughput
Ligand-Based Virtual Screening; ACS Publications: Washington, DC, USA, 2016; pp. 1117–1121.
40. Delaney, J.S. ESOL: Estimating aqueous solubility directly from molecular structure. J. Chem. Inf. Comput. Sci.
2004, 44, 1000–1005. [CrossRef]
41. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness
and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [CrossRef]
42. Capuzzi, S.J.; Muratov, E.N.; Tropsha, A. Phantom PAINS: Problems with the Utility of Alerts for P an-A ssay
IN terference Compound, S.J. Chem. Inf. Model. 2017, 57, 417–427. [CrossRef] [PubMed]
43. Ricci, M.S.; Zong, W.-X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006, 11,
342. [CrossRef] [PubMed]
44. Elmore, S. Apoptosis: A review of programmed cell death. Exp. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef]
[PubMed]
45. Levi, C.A.; Ejere, V.C.; Asogwa, C.N.; Iweh, P.; Nwatu, K.U.; Levi, U.E. Apoptosis: Its physiological
implication and therapeutic possibilities. J. Pharm. Biolo Sci. 2014, 9, 38–45. [CrossRef]
46. Yang, J.; Liu, X.; Bhalla, K.; Kim, C.N.; Ibrado, A.M.; Cai, J.; Peng, T.-I.; Jones, D.P.; Wang, X. Prevention
of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997, 275, 1129–1132.
[CrossRef]
47. Ouyang, L.; Shi, Z.; Zhao, S.; Wang, F.T.; Zhou, T.T.; Liu, B.; Bao, J.K. Programmed cell death pathways in
cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012, 45, 487–498. [CrossRef]
48. Mariño, G.; Kroemer, G. Mechanisms of apoptotic phosphatidylserine exposure. Cell Res. 2013, 23, 1247.
[CrossRef]
49. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutellingsperger, C. A novel assay for apoptosis flow cytometric
detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V.
J. Immunol. Methods 1995, 184, 39–51. [CrossRef]
50. Manivannan, E.; Amawi, H.; Hussein, N.; Karthikeyan, C.; Fetcenko, A.; Narayana Moorthy, N.S.H.;
Trivedi, P.; Tiwari, A.K. Design and discovery of silybin analogues as antiproliferative compounds using a
ring disjunctive—Based, natural product lead optimization approach. Eur. J. Med. Chem. 2017, 133, 365–378.
[CrossRef]
447
Molecules 2020, 25, 3063
51. Amawi, H.; Hussein, N.; Boddu, S.H.S.; Karthikeyan, C.; Williams, F.E.; Ashby, C.R., Jr.; Raman, D.; Trivedi, P.;
Tiwari, A.K. Novel Thienopyrimidine Derivative, RP-010, Induces beta-Catenin Fragmentation and Is
Efficacious against Prostate Cancer Cells. Cancers 2019, 11, 711. [CrossRef]
52. Karthikeyan, C.; Amawi, H.; Viana, A.G.; Sanglard, L.; Hussein, N.; Saddler, M.; Ashby, C.R., Jr.; Moorthy, N.;
Trivedi, P.; Tiwari, A.K. lH-Pyrazolo[3,4-b]quinolin-3-amine derivatives inhibit growth of colon cancer cells
via apoptosis and sub G1 cell cycle arrest. Bioorg. Med. Chem. Lett. 2018, 28, 2244–2249. [CrossRef] [PubMed]
53. Amawi, H.; Hussein, N.A.; Karthikeyan, C.; Manivannan, E.; Wisner, A.; Williams, F.E.; Samuel, T.; Trivedi, P.;
Ashby, C.R., Jr.; Tiwari, A.K. HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer
Cells and Is Safe in Zebrafish Toxicity Studies. Front. Pharmacol. 2017, 8, 498. [CrossRef]
54. Balaji, N.V.; Ramani, M.V.; Viana, A.G.; Sanglard, L.P.; White, J.; Mulabagal, V.; Lee, C.; Gana, T.J.; Egiebor, N.O.;
Subbaraju, G.V.; et al. Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of
hispolon analogs. Bioorg. Med. Chem. 2015, 23, 2148–2158. [CrossRef] [PubMed]
55. Karthikeyan, C.; Amawi, H.; Ashby, C.R., Jr.; Khare, V.M.; Jones, V.; Hari Narayana Moorthy, N.S.; Trivedi, P.;
Tiwari, A.K. Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy
in ovarian cancer in vitro. Heliyon 2019, 5, e01603. [CrossRef] [PubMed]
56. Amawi, H.; Karthikeyan, C.; Pathak, R.; Hussein, N.; Christman, R.; Robey, R.; Ashby, C.R., Jr.; Trivedi, P.;
Malhotra, A.; Tiwari, A.K. Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis
induction, oxidative stress and mitotic catastrophe. Eur. J. Med. Chem. 2017, 138, 1053–1065. [CrossRef]
57. Amawi, H.; Ashby, C.R., Jr.; Tiwari, A.K. Cancer chemoprevention through dietary flavonoids: What’s
limiting? Chin. J. Cancer 2017, 36, 50. [CrossRef]
58. Westphal, D.; Dewson, G.; Czabotar, P.E.; Kluck, R.M. Molecular biology of Bax and Bak activation and
action. BBA-Mol. Cell Res. 2011, 1813, 521–531. [CrossRef]
59. Shamas-Din, A.; Kale, J.; Leber, B.; Andrews, D.W. Mechanisms of action of Bcl-2 family proteins. CSH
Perspect. Biol. 2013, 5, a008714. [CrossRef]
60. Delbridge, A.R.; Grabow, S.; Strasser, A.; Vaux, D.L. Thirty years of BCL-2: Translating cell death discoveries
into novel cancer therapies. Nat. Rev. Cancer 2016, 16, 99. [CrossRef]
61. Lamkanfi, M.; Kanneganti, T.-D. Caspase-7: A protease involved in apoptosis and inflammation. Intl. J.
Biochem. Cell Boil. 2010, 42, 21–24. [CrossRef] [PubMed]
62. Choe, H.; Kim, J.; Hong, S. Structure-based design of flavone-based inhibitors of wild-type and T315I mutant
of ABL. Bioorg. Med. Chem. Lett. 2013, 23, 4324–4327. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 4a, 4g, 4i and 4o are available from the authors on request.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Design and Synthesis of Flavonoidal Ethers and Their
Anti-Cancer Activity In Vitro
Lu Jin 1,2, Meng-Ling Wang 1, Yao Lv 3, Xue-Yi Zeng 1,2, Chao Chen 1,2, Hai Ren 1,2, Heng Luo 1,2,*
and Wei-Dong Pan 1,2,*
1 State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University,
Guiyang 550014, China; m18352807507@163.com (L.J.); WANGMENGLING417@163.com (M.-L.W.);
Xueyizeng@126.com (X.-Y.Z.); cc283818640@163.com (C.C.); renh0206@163.com (H.R.)
2 The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of
Sciences, Guiyang 550014, China
3 Bijie Medical College, Bijie 551700, China; Lvyao0918@163.com
* Correspondence: luoheng71050@aliyun.com (H.L.); wdpan@163.com (W.-D.P.)
Academic Editor: Qiao-Hong Chen
Received: 30 March 2019; Accepted: 3 May 2019; Published: 6 May 2019
Abstract: Flavonoids are well-characterized polyphenolic compounds with pharmacological and
therapeutic activities. However, most flavonoids have not been developed into clinical drugs, due
to poor bioavailability. Herein, we report a strategy to increase the drugability of flavonoids by
constructing C(sp2)-O bonds and stereo- as well as regioselective alkenylation of hydroxyl groups
of flavonoids with ethyl-2,3-butadienoate allenes. Twenty-three modified flavonoid derivatives
were designed, synthesized, and evaluated for their anti-cancer activities. The results showed that
compounds 4b, 4c, 4e, 5e, and 6b exhibited better in vitro inhibitory activity against several cancer
cell lines than their precursors. Preliminary structure–activity relationship studies indicated that,
in most of the cancer cell lines evaluated, the substitution on position 7 was essential for increasing
cytotoxicity. The results of this study might facilitate the preparation or late-stage modification of
complex flavonoids as anti-cancer drug candidates.
Keywords: flavonoids; allene; E-stereoselective; regioselective; anti-cancer activity
1. Introduction
Consisting of more than 9000 compounds, flavonoids represent the most widely distributed
polyphenols in nature [1,2]. In addition, flavonoids are ubiquitous in some medicinal plants and herbal
remedies used in traditional medicine around the world, especially in China [2–6]. The characteristic
skeleton of flavonoids is a phenylbenzopyrone moiety (C6-C3-C6), which could be further categorized
according to the saturation level and the presence or absence of the central pyran ring. Many studies
have confirmed that flavonoids are naturally occurring, pharmacologically active molecules. However,
most flavonoids have not been developed as clinical drugs because of poor bioavailability (less than
5%), toxicity, and induction or inhibition of some metabolic enzymes [7]. To overcome these problems,
structural modifications of the flavonoid skeletons have attracted great interest [8].
Allenes are highly reactive and have been used extensively in organic chemistry [9–15], due to the
electronic or steric effects and their 1,2-diene functionality. The transition-metal catalyzed chemistry of
allenes has become a recent focus of research [16,17]. We proposed that carbopalladation of allenes
would provide a highly convenient method for the formation of a conjugated aryl ether, following β-H
elimination by the introduction of a π-allyl palladium species.
In this research, we have developed a friendly and straightforward protocol to access various
novel flavonoidal ethers by employing allenes as important multifunctional modules. Notably, both
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electrophilic groups and aliphatic chains can be embedded in the flavonoid scaffold smoothly with the
above mentioned protocol. Therefore, more than 20 flavonoidal ethers were obtained successfully and
evaluated for anti-cancer activities.
2. Materials and Methods
2.1. Instruments and Materials
1H- and 13C-NMR spectra were obtained on a 400 MHz (Varian, Inc) or 500 MHz (WIPM, China)
spectrometer in CDCl3 or DMSO-d6 (tetramethylsilane (TMS) as internal standard). Chemical shifts
(δ) were expressed in parts per million (ppm), relative to TMS (0 ppm). High resolution mass
spectra (HRMS) were recorded on a ThermoFisher QE Focus apparatus. All the solvents were dried
using standard methods and distilled before being used. Reagents and solvents were purchased
from commercial sources. Solvents were purified according to the guidelines in the Purification of
Laboratory Chemicals.
2.2. General Procedure for the Synthesis of Flavonoidal Ether Derivatives
2.2.1. Synthesis of Allenes
Allenes were synthesized according to previously described protocols [16–18].
2.2.2. Optimization of Reaction Conditions
We selected chrysin 2a and ethyl ester allene 1a as the model substrates in this study and carried
out extensive screening of the reaction conditions. In an initial attempt, a variety of factors including
types of Pd catalysts, bases, solvents, and ligands were examined. After extensive optimization, the
product (3a) was obtained with an isolated yield of 41.7% in the presence of 10 mol% of PPh3/Pd(dba)2
as a catalyst, K2CO3 (2.0 equiv.) as a base, in a solution of MeCN under argon at 80 ◦C (Table 1, entry 1).
Further investigations of the solvent indicated that the yield could be slightly improved to 43.0%
by replacing MeCN with DMF (Table 1, entry 6). Furthermore, absence of Pd catalysts and ligands
resulted in lower yield (Table 1, entry 14). None of the desired product was obtained when the base
was abstracted away (Table 1, entries 15 and 16). Interestingly, only 11.2% yield of the expected product
was obtained at lower temperatures (Table 1, entry 17). It was worth noting that 3a was the only isomer
isolated, indicating a highly regio- and stereoselective process, in which the steric effect of the carbonyl
or the hydrogen bond effect between the carbonyl and oxygen atom at position 7 may be critical for the
highly regio- and stereoselective process.
Table 1. Optimization of reaction conditions.
 
Entry Catalyst Base Ligand Solvent Yield (%) Entry Catalyst Base Ligand Solvent Yield (%)
1 Pd(dba)2 K2CO3 PPh3 DMA [a] <5 10 Pd(dba)2 Cs2CO3 PPh3 DMF 18.4
2 Pd(dba)2 K2CO3 PPh3 EtOH 13.3 11 PdCl2 K2CO3 - DMF 15.8
3 Pd(dba)2 K2CO3 PPh3 MeCN 41.7 12 Pd(OAc)2 K2CO3 - DMF 24.1
4 Pd(dba)2 K2CO3 PPh3 DCM <5 13 PdCl2(PPh3)2 K2CO3 - DMF 13.3
5 Pd(dba)2 K2CO3 PPh3 DMA [b] 32.0 14 - K2CO3 - DMF 14.9
6 Pd(dba)2 K2CO3 PPh3 DMF 43.0 15 Pd(OAc)2 - - DMF NO.
7 Pd(dba)2 NaH PPh3 DMF 14.2 16 Pd(dba)2 - - DMF NO.
8 Pd(dba)2 NH(iPr)2 PPh3 DMF <5 17 Pd(dba)2 K2CO3 PPh3 DMF 11.2[c]
9 Pd(dba)2 Et3N PPh3 DMF 17.2 - - - - - -
Conditions: 1a (0.4 mmol), 2a (0.2 mmol), isolated yield. [a] N,N-Dimethylaniline; [b] N,N-Dimethylacetamide;
[c] Reaction occurred at rt.
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2.2.3. General Procedure for the Synthesis of Target Derivatives 3a–3i, 4a–4g, 5a–5e
Chrysin 2a (127.12 mg, 0.5 mmol), Pd(dba)2 (5.75 mg, 0.01 mmol), K2CO3 (138.21 mg, 1.0 mmol),
PPh3 (13.11 mg, 0.05 mmol), allene (112.13 mg, 1.0 mmol), and anhydrous DMF (5 mL) were added
to a 30 mL tube under argon, which was then sealed. The resulting mixture was stirred at 80 ◦C for
12 h. After completion, the reaction solution was cooled down to room temperature before 80 mL
water was added, followed by the addition of 1 N HCl aqueous solution at 0 ◦C, until the pH value
reached 7. Ethyl acetate (100 mL) was added to the reaction solution and the organic layer was washed
sequentially with a large amount of water (4 × 200 mL), and then brine, before being dried over
anhydrous Na2SO4. The solvent was evaporated under reduced pressure. The crude product was
purified by silica gel column chromatography (petroleum ether–ethylacetate, 5:1) to give 3a (78.8 mg,
43% yield). Compounds 3b–3i, 4a–4g, and 5a–5e were prepared according to similar procedures in
which the double-substitution is a byproduct. The products 4a–4g were generated in a shorter time
compared with the other products (within 10 h).
2.2.4. General Synthetic Procedure for 6a–6b Target Derivatives
The reaction with 1.0 mmol scale was carried out to assess the scalability of flavonoidal ether
formation (Scheme 1, 4a). Under standard conditions, the yield was lower than that of the small-scale
reaction. The reaction solution contained the following components: 4a (62.8 mg, 0.02 mmol), 1 mL
methanol, and 1 N sodium hydroxide solution (2.0 equiv). The solution was then stirred at 60 ◦C for
5 min and 1 mL water was added before heating at 60 ◦C for 12 h. After completion, the reaction
solution was cooled down to room temperature and 40 mL water as well as 30 mL ethyl acetate was
added sequentially. Aqueous HCl (1 N) was added to the water layer at 0 ◦C until the pH value reached
4. Other post-processing procedures were similar to those performed to synthesize 4a. The desired
product 6a was finally obtained (41.2 mg, 61% yield). The product 6b was prepared according to the
same general procedure.
Scheme 1. Synthesis of flavonoidal ether and derivatization.
Ethyl (E)-3-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) but-2-enoate (3a); yellow powder; yield
43.0%; HRMS(ESI): calcd. C21H17O6, m/z 365.1031 [M − H]−, found 365.1025; 1H-NMR (CDCl3,
500 MHz) δ(ppm): 7.88 (d, J = 7.0 Hz, 2H), 7.59–7.51 (m, 3H), 6.73 (s, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.49
(d, J = 2.0 Hz, 1H), 5.16 (s, 1H), 4.12 (q, J = 7.0 Hz, 2H), 2.49 (s, 3H), 1.23 (t, J = 7.0 Hz, 3H); 13C-NMR
(CDCl3, 125 MHz) δ(ppm): 182.9, 170.5, 167.1, 164.7, 162.6, 159.4, 157.4, 132.3, 131.0, 129.3, 126.5, 108.6,
106.3, 104.8, 100.0, 99.8, 60.0, 18.2, 14.4.
Ethyl (E)-3-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) but-2-enoate (3b); yellow powder; yield
43.9 %; HRMS(ESI): calcd. C21H17O7, m/z 381.0980 [M − H]−, found 381.0970; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 13.02 (s, 1H), 8.04 (d, J = 7.2 Hz, 2H), 7.59–7.52 (m, 3H), 6.97 (s, 1H), 6.69 (s, 1H),
4.80 (s, 1H), 3.97 (q, J = 7.2 Hz, 2H), 2.40 (s, 3H), 1.09 (t, J = 7.2 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz)
δ(ppm): 182.3, 170.7, 166.6, 163.7, 156.7, 154.2, 152.4, 132.2, 130.7, 129.2, 126.5, 123.8, 105.0, 104.4, 94.8,
93.3, 59.2, 17.6, 14.2.
Diethyl 3,3′-((5-hydroxy-4-oxo-2-phenyl-4H-chromene-6,7-diyl) bis (oxy)) (2E,2′E)-bis (but-2-enoate) (3c);
yellow powder; yield 29.3%; HRMS(ESI): calcd. C27H27O9, m/z 495.1650 [M + H]+, found 495.1647;
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1H-NMR (DMSO-d6, 500 MHz) δ(ppm): 11.76 (s, 1H), 8.04 (d, J = 6.0 Hz, 2H), 7.60–7.57 (m, 3H), 7.16 (s,
1H), 6.78 (s, 1 H), 4.77 (s, 1H), 4.63 (s, 1H), 4.01–3.94 (m, 4H), 2.44 (s, 3H), 2.39 (s, 3H), 1.16–1.03 (m, 6H);
13C-NMR (DMSO-d6, 125 MHz) δ(ppm): 174.7, 171.6, 170.4, 166.3, 166.2, 161.0, 155.4, 155.3, 143.0, 131.7,
131.3, 130.8, 129.1, 126.3, 109.8, 107.5, 102.7, 94.5, 93.9, 59.3, 59.1, 17.6, 17.3, 14.1.
Ethyl (E)-3-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenoxy)-2-methylacrylate (3d); yellow
powder; yield 25.9%; HRMS(ESI): calcd. C22H19O8, m/z 411.1085 [M − H]−, found 411.1078; 1H-NMR
(DMSO-d6, 500 MHz) δ(ppm): 12.87 (s, 1H), 10.88 (s, 1H), 8.03 (dd, J = 9.0, 2.5 Hz, 1H), 7.87 (d,
J = 2.5 Hz, 1H), 7.33 (d, J = 9 Hz, 1H), 6.95 (s, 1H), 6.52 (d, J = 2.0 Hz, 1H), 6.20 (d, J = 2.0 Hz, 1H), 4.66
(s, 1H), 3.99 (q, J = 7.0 Hz, 2H), 3.88 (s, 3H), 2.43 (s, 3H), 1.10 (t, J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6,
125 MHz) δ(ppm): 181.8, 171.6, 166.3, 164.3, 162.1, 161.4, 157.4, 153.9, 141.1, 126.0, 123.6, 121.1, 113.8,
104.3, 103.8, 99.0, 94.6, 94.2, 59.2, 56.3, 17.7, 14.1.
Ethyl (E)-3-((2-(3-(((E)-4-ethoxy-4-oxobut-2-en-2-yl) oxy)-4-methoxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)
oxy) but-2-enoate (3e); yellow powder; yield 21.2%; HRMS(ESI): calcd. C28H29O10, m/z 525.1755 [M +
H]+, found 525.1759; 1H-NMR (DMSO-d6, 500 MHz) δ(ppm): 12.94 (s, 1H), 8.05 (dd, J = 8.5, 2.0 Hz, 1H),
7.86 (d, J = 2.0 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 7.05 (s, 1H), 6.95 (d, J = 2.0 Hz, 1H), 6.51 (d, J = 2.0 Hz,
1H), 5.05 (s, 1H), 4.66 (s, 1H), 4.05–3.95 (m, 4H), 3.90 (s, 3H), 2.42 (d, J = 3.5 Hz, 6H), 1.21–1.10 (m, 6H).
13C-NMR (DMSO-d6, 125 MHz) δ(ppm): 181.8, 171.6, 166.3, 164.3, 162.1, 161.4, 157.4, 153.9, 141.1, 126.0,
123.6, 121.1, 113.8, 104.3, 103.8, 99.0, 94.6, 94.2, 59.2, 56.3, 39.7, 39.5, 39.4, 17.7, 14.1.
Ethyl (E)-3-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl) oxy) but-2-enoate (3f); yellow powder;
yield 30.3%; HRMS(ESI): calcd. C21H17O7, m/z 381.0980 [M −H]−, found 381.0986; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 13.10 (s, 1H), 10.45 (s, 1H), 7.97 (d, J = 8.0 Hz, 2H), 6.98–6.91 (m, 4H), 6.56 (s, 1H),
5.05 (s, 1H), 4.03 (q, J = 7.2 Hz, 2H), 2.42 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz)
δ(ppm): 182.3, 170.5, 166.1, 164.7, 161.6, 161.5, 158.4, 156.8, 128.8, 120.8, 116.0, 107.9, 104.0, 103.4, 100.2,
98.7, 59.4, 17.7, 14.1.
Ethyl (E)-3-(4-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl) phenoxy) but-2-enoate (3g); yellow powder; yield
28.3%; HRMS(ESI): calcd. C21H17O7, m/z 381.0980 [M − H]−, found 381.0976; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 12.82 (s, 1H), 10.96 (s, 1H), 8.17 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 6.99 (s,
1H), 6.52 (d, J = 2.0 Hz, 1H), 6.22 (d, J = 2.0 Hz, 1H), 4.79 (s, 1H), 4.01 (q, J = 7.2 Hz, 2H), 2.45 (s, 3H),
1.12 (t, J = 7.2 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz) δ(ppm): 181.9, 171.7, 166.2, 164.5, 162.4, 161.5,
157.5, 155.6, 128.8, 128.3, 122.2, 105.3, 103.9, 99.1, 96.9, 94.2, 59.3, 17.8, 14.2.
Ethyl 2-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methylbenzo [d] [1,3] dioxol-2-yl) acetate (3h); yellow
powder; yield 30.1%; HRMS(ESI): calcd. C21H17O8, m/z 397.0929 [M − H]−, found 397.0923; 1H-NMR
(CDCl3, 400 MHz) δ(ppm): 12.62 (s, 1H), 7.43 (dd, J = 8.4, 1.6 Hz, 1H), 7.26 (d, J = 1.2 Hz, 1H), 6.88 (d,
J = 8.4 Hz, 1H), 6.52 (s, 1H), 6.49 (d, J = 1.2 Hz, 1H), 6.38 (d, J = 1.6 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H),
3.06 (s, 2H), δ 1.88 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) δ(ppm): 182.5, 168.3,
164.1, 164.0, 162.1, 157.9, 150.5, 148.1, 124.8, 121.6, 117.6, 108.9, 106.4, 104.9, 104.0, 100.0, 94.6, 61.4, 44.0,
25.0, 14.1.
Ethyl 2-(2-methyl-5-(3,5,7-trihydroxy-4-oxo-4H-chromen-2-yl) benzo [d] [1,3] dioxol-2-yl) acetate (3i); yellow
powder; yield 30.1%; HRMS(ESI): calcd. C21H19O9, m/z 415.1024 [M + H]+, found 415.1018; 1H-NMR
(DMSO-d6, 500 MHz) δ(ppm): 12.40 (s, 1H), 10.83 (s, 1H), 9.57 (s, 1H), 7.74 (dd, J = 8.0, 1.5 Hz, 1H),
7.62 (d, J = 1.5 Hz, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.47 (d, J = 2.0 Hz, 1H), 6.19 (d, J = 2.0 Hz, 1H), 4.02
(q, J = 7.5 Hz, 2H), 3.13 (s, 2H), 1.78 (s, 3H), 1.10 (t, J = 7.5 Hz, 3H); 13C-NMR (DMSO-d6, 125 MHz)
δ(ppm): 176.0, 167.6, 164.1, 160.7, 156.2, 148.2, 147.1, 145.9, 136.3, 124.5, 122.6, 117.3, 108.3, 107.3, 103.1,
98.3, 93.6, 60.3, 43.1, 24.7, 13.9.
Benzyl (E)-3-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) but-2-enoate (4a); yellow powder; yield
33.0%; HRMS(ESI): calcd. C26H21O6, m/z 429.1333 [M + H]+, found 429.1324; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 12.93 (s, 1 H), 8.12 (d, J = 6.8 Hz, 2H), 7.74–7.56 (m, 3H), 7.32 (m, 5H), 7.07 (d,
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J = 2.0 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 5.10 (s, 1H), 5.07 (s, 2H), 2.46 (s, 3H); 13C-NMR (DMSO-d6,
100 MHz) δ(ppm): 182.7, 171.3, 166.1, 164.2, 161.6, 158.7, 157.1, 136.3, 132.5, 130.4, 129.3, 128.5, 128.3,
128.1, 126.8, 108.3, 105.8, 104.4, 100.7, 98.3, 65.3, 17.9.
Dibenzyl 3,3′-((4-oxo-2-phenyl-4H-chromene-5,7-diyl) bis (oxy)) (2E,2′E)-bis (but-2-enoate) (4b); white
powder; yield 29.8%; HRMS(ESI): calcd. C37H31O8, m/z 603.2013 [M + H]+, found 603.2010; 1H-NMR
(CDCl3, 400 MHz) δ(ppm): 7.85 (d, J = 6.8 Hz, 2H), 7.52 (d, J = 7.6 Hz, 3H), 7.33 (m, J = 10H), 7.12 (d,
J = 2.0 Hz, 1H), 6.71 (d, J = 2.0 Hz, 1H), 6.65 (s, 1H), 5.24 (s, 1H), 5.12 (s, 2H), 5.03 (s, 2H), 4.73 (s, 1H),
2.66 (s, 3H), 2.52 (s, 3H); 13C-NMR (CDCl3, 100 MHz) δ(ppm): 175.6, 174.0, 170.6, 167.0, 166.6, 162.3,
158.9, 157.5, 153.0, 136.3, 136.1 133.1, 131.9, 129.2, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 126.3, 114.7,
113.3, 108.9, 108.0, 100.2, 95.2, 66.1, 65.8, 18.6, 18.3.
Dibenzyl 3,3′-((5-hydroxy-4-oxo-2-phenyl-4H-chromene-6,7-diyl) bis (oxy)) (2E,2′E)-bis (but-2-enoate) (4c);
yellow powder; yield 24.2%; HRMS(ESI): calcd. C37H30O9Na, m/z 641.1782 [M + Na]+, found 641.1779;
1H-NMR (DMSO-d6, 400 MHz) δ(ppm): 13.17 (s, 1H), 8.16-8.11 (m, 2H), 7.76–7.53 (m, 3H), 7.39-7.23 (m,
10H), 7.18 (s, 1H), 5.14 (s, 1H), 5.04 (s, 1H), 5.01 (s, 2H), 4.96 (s, 1H), 2.43 (s, 3H), 2.42 (s, 3H); 13C-NMR
(DMSO-d6, 100 MHz) δ(ppm): 182.9, 170.4, 170.3, 166.1, 165.8, 164.5, 153.7, 152.9, 150.5, 136.1, 130.3,
129.2, 128.4, 128.2, 128.1, 128.0, 126.7, 109.4, 105.4, 101.8, 98.0, 94.3, 65.2, 65.1, 17.5, 17.4.
Benzyl (E)-3-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) but-2-enoate (4d); yellow powder; yield
16.0%; HRMS(ESI): calcd. C26H20O7Na, m/z 467.1101 [M + Na]+, found 467.1092; 1H-NMR (DMSO-d6,
500 MHz) δ(ppm): 13.06 (s, 1H), 11.37 (s, 1H), 8.08 (d, J = 6.0 Hz, 2H), 7.62–7.56 (m, 3H), 7.34-7.28 (m,
5H), 7.02 (s, 1H), 6.72 (s, 1H), 5.03 (s, 2H), 4.87 (s, 1H), 2.44 (s, 3H); 13C-NMR (DMSO-d6, 125 MHz)
δ(ppm): 182.3, 171.2, 166.4, 163.7, 156.6, 154.2, 152.4, 136.3, 132.2, 130.7, 129.2, 128.4, 128.3, 128.0, 126.6,
123.7, 105.0, 104.4, 94.8, 92.9, 65.1, 17.7.
Benzyl (E)-3-((5-hydroxy-2-(3-hydroxy-4methoxyphenyl)-4-oxo-4H-chromen-7yl) oxy) but-2-enoate (4e);
yellow powder; yield 32.5%; HRMS(ESI): calcd. C27H23O8, m/z 475.1387 [M + H]+, found 475.1375;
1H-NMR (DMSO-d6, 400 MHz) δ(ppm): 13.07 (s, 1H), 9.48 (s, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.46 (d,
J = 1.6 Hz, 1H), 7.32 (s, 5H), 7.08 (d, J = 8.4 Hz, 1H), 6.98 (s, 1H), 6.90 (s, 1H), 6.58 (d, J = 1.6 Hz, 1H),
5.10 (s, 1H), 5.06 (s, 2H), 3.87 (s, 3H), 2.45 (s, 3H); 13C-NMR (DMSO-d6, 100 MHz) δ(ppm): 182.3, 171.3,
166.0, 164.5, 161.6, 158.4, 156.9, 151.5, 146.8, 132.2, 128.4, 128.2, 128.0, 122.6, 119.1, 113.3, 112.1, 108.0,
104.2, 104.1, 100.4, 98.1, 65.2, 55.8, 17.9.
Benzyl (E)-3-(4-(3,5,7-trihydroxy-4-oxo-4H-chromen-2-yl) phenoxy) but-2-enoate (4f); yellow powder; yield
23.6%; HRMS(ESI): calcd. C26H20O8Na, m/z 483.1050 [M + Na]+, found 483.1047; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 12.24 (s, 1H), 10.96 (s, 1H), 10.40 (s, 1H), 7.78–7.76 (m, 2H), 7.32–7.30 (m, 5H),
6.95–6.93 (m, 2H), 6.48 (d, J = 2.0 Hz, 1H), 6.23 (d, J = 2.0 Hz, 1H), 5.28 (s, 1H), 5.01 (s, 2H), 2.44 (s, 3H);
13C-NMR (DMSO-d6, 100 MHz) δ(ppm): 175.0, 170.0, 166.3, 164.5, 161.1, 160.8, 156.8, 156.5, 136.2, 131.0,
130.1, 128.4, 128.3, 128.0, 119.5, 115.9, 104.1, 98.9, 94.8, 94.2, 65.1, 17.6.
Benzyl (E)-3-(4-(7-(((E)-3-(benzyloxy)-2-methyl-3-oxoprop-1-en-1-yl) oxy)-5-hydroxy-4-oxo-4H-chromen-2-yl)
phenoxy)-2-methylacrylate (4g); yellow powder; yield: 64.9%; HRMS(ESI) calcd. C37H31O9, m/z 619.1963
[M + H]+, found 619.1954; 1H-NMR (CDCl3, 500 MHz) δ (ppm): 12.75 (s, 1H), 7.91 (d, J = 7.5 Hz,
2H), 7.33 (s, 10H), 7.18 (d, J = 8.0 Hz, 2H), 6.68 (d, J = 14.5 Hz, 2H), 6.50 (s, 1H), 5.20 (s, 1H), 5.11 (d,
J = 7.5 Hz, 4H), 5.01 (s, 1H), 2.53 (d, J = 11.5 Hz, 6H); 13C-NMR (CDCl3, 125MHz) δ (ppm):182.7, 172.3,
171.2, 167.0, 166.9, 163.7, 162.6, 159.3, 157.3, 156.5, 136.19, 136.1, 128.6, 128.5, 128.4, 128.3, 122.4, 108.6,
106.2, 105.0, 100.1, 99.1, 97.5, 66.0, 65.9, 18.5, 18.3.
Ethyl (E)-3-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) hex-2-enoate (5a); yellow powder; yield
32.0%; HRMS(ESI): calcd. C23H22O6Na, m/z 417.1309 [M + Na]+, found 417.1305; 1H-NMR (CDCl3,
400 MHz) δ(ppm): 12.79 (s, 1H), 7.89 (dd, J = 8.0, 2.0 Hz, 2H), 7.57–7.50 (m, 3H), 6.74 (s, 1H), 6.67
(d, J = 2.0 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 5.08 (s, 1H), 4.11 (dd, J = 2H), 2.94–2.90 (m, 2H), 1.74 (m,
J = 15.2, 7.6 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.05 (t, J = 7.2 Hz, 3H); 13C-NMR (CDCl3, 100 MHz)
453
Molecules 2019, 24, 1749
δ(ppm): 182.9, 174.4, 166.9, 164.7, 162.6, 159.7, 157.5, 132.3, 131.0, 129.3, 126.5, 108.6, 106.3, 105.0, 100.1,
99.2, 60.0, 32.9, 20.9, 14.4, 13.9.
Ethyl (E)-3-((7-hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl) oxy) hex-2-enoate (5b); yellow powder; yield
40.0%; HRMS(ESI): calcd. C23H23O6, m/z 395.1489 [M + H]+, found 395.1482; 1H-NMR (DMSO-d6,
400 MHz) δ(ppm): 8.26–8.01 (m, 2H), 7.56 (d, J = 7.2 Hz, 3H), 6.98 (d, J = 2.2 Hz, 1H), 6.74 (s, 1H), 6.49 (d,
J = 2.2 Hz, 1H), 4.49 (s, 1H), 3.94 (dd, J = 14.4, 7.2 Hz, 2H), 2.94–2.90 (m, 2H), 1.76 (m, J = 2H), 1.09–0.99
(m, 6H), 1.00 (t, J = 7.2 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz) δ(ppm): 176.1, 174.6, 166.2, 162.6, 160.7,
158.8, 151.8, 131.6, 130.9, 129.1, 126.2, 109.5, 108.6, 107.7, 101.5, 93.7, 32.6, 59.1, 19.9, 14.1, 13.8.
Ethyl (E)-3-((7-(((Z)-1-ethoxy-1-oxohex-2-en-3-yl) oxy)-6-hydroxy-4-oxo-2-phenyl-4H-chromen-5-yl) oxy)
hex-2-enoate (5c); yellow powder; yield 7.0%; HRMS(ESI): calcd. C31H35O9, m/z 551.2276 [M + H]+,
found 551.2260; 1H-NMR (CDCl3, 400 MHz) δ(ppm): 8.40 (s, 1H), 7.83 (d, J = 6.4 Hz, 2H), 7.55–7.48 (m,
3H), 7.11 (s, 1H), 6.60 (s, 1H), 4.90 (s, 1H), 4.70 (s, 1H), 4.10–4.03 (m, 4H), 3.05–3.02 (m, 2H), 2.93–2.90 (m,
2H), 1.87–1.72 (m, 4H), 1.21–1.16 (m, J = 6H), 1.07–1.02 (m, 6H); 13C-NMR (CDCl3, 125 MHz) δ(ppm):
176.5, 175.5, 173.6, 167.3, 167.1, 162.5, 156.0, 154.6, 144.1, 132.0, 131.6, 131.0, 129.2, 126.3, 111.4, 107.8,
102.7, 95.6, 94.5, 60.1, 59.9, 33.6, 33.1, 21.2, 20.7, 14.4, 14.2.
Ethyl (E)-3-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) hex-2-enoate (5d); yellow powder; yield
11.2%; HRMS(ESI): calcd. C23H21O7, m/z 409.1293 [M − H]−, found 409.1289; 1H-NMR (DMSO-d6,
500 MHz) δ(ppm): 13.03 (s, 1H), 11.36 (s, 1H), 8.07 (d, J = 7.5 Hz, 2H), 7.61–7.56 (m, 3H), 7.01 (s, 1H),
6.70 (s, 1H), 4.74 (s, 1H), 3.98 (dd, J = 14.5, 6.0 Hz, 2H), 2.86 (t, J = 7.0 Hz, 2H), 1.71 (dd, J = 15.0, 7.5 Hz,
2H), 1.10 (t, J = 7.0 Hz, 3H), 1.00 (t, J = 7.5 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz) δ(ppm): 182.3,
173.8, 166.3, 163.6, 156.7, 154.1, 152.4, 132.1, 130.7, 129.2, 126.5, 123.7, 104.9, 104.4, 94.7, 92.8, 59.1, 32.3,
20.4, 14.1, 13.5.
Diethyl 3,3′-((5-hydroxy-4-oxo-2-phenyl-4H-chromene-6,7-diyl) bis (oxy)) (2E,2′E)-bis (hex-2-enoate) (5e);
yellow powder; yield 14.8%; HRMS(ESI): calcd. C31H34O9Na, m/z 573.2095 [M + Na]+, found 573.2106;
1H-NMR (CDCl3, 500 MHz) δ(ppm): 12.96 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.60–7.53 (m, 3H), 6.76 (d,
J = 9.0 Hz, 1H), 5.03 (s, 1H), 4.85 (s, 1H), 4.13–4.06 (m, 4H), 2.93–2.87 (m, 4H), 1.77–1.69 (m, 4H), 1.21
(dd, J = 15.2, 7.6 Hz, 6H), 1.06–1.00 (m, 6H); 13C-NMR(CDCl3, 125 MHz) δ(ppm): 182.9, 174.0, 173.8,
167.1, 166.7, 165.2, 154.1, 153.8, 151.8, 132.5, 130.9, 129.4, 128.4, 126.6, 109.5, 105.9, 100.7, 98.7, 94.5, 60.0,
59.7, 33.1, 32.8, 21.0, 20.9, 14.4, 14.0, 13.9.
(E)-3-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl) oxy) but-2-enoic acid (6a); yellow powder; yield 69.4%;
HRMS(ESI): calcd. C19H13O6, m/z 337.0718 [M + H]+, found 337.0711; 1H-NMR (DMSO-d6, 500 MHz)
δ(ppm): 12.93 (s, 1H), 8.14 (d, J = 6.4 Hz, 2H), 7.76–7.58 (m, 3H), 7.15 (s, 1H), 7.05 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.0 Hz, 1H), 5.09 (s, 1H), 2.41 (s, 3H); 13C-NMR (DMSO-d6, 125 MHz) δ(ppm): 182.8, 169.7,
167.6, 164.3, 161.7, 159.3, 157.2, 132.6, 130.6, 129.4, 126.9, 108.1, 105.9, 104.2, 100.7, 100.3, 17.7.
2-(2-methyl-5-(3,5,7-trihydroxy-4-oxo-4H-chromen-2-yl) benzo[d] [1,3] dioxol-2-yl) acetic acid (6b); yellow
powder; yield 43.7%; HRMS(ESI): calcd. C19H15O9, m/z 387.0711 [M + H]+, found 387.0707; 1H-NMR
(DMSO-d6, 500 MHz) δ(ppm): 12.40 (s, 1 H), 7.73 (dd, J = 10.5, 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.03
(d, J = 10.5 Hz, 1H), 6.46 (d, J = 2.5 Hz, 1H), 6.19 (d, J = 2.5 Hz, 1H), 3.02 (s, 2H), 1.78 (s, 3H); 13C-NMR
(DMSO-d6, 125 MHz) δ(ppm): 217.5, 176.0, 172.1, 169.2, 164.1, 160.7, 156.2, 148.2, 147.1, 146.0, 136.2,
124.8, 122.9, 117.6, 108.4, 107.3, 103.1, 98.3, 93.7, 24.5, 21.1.
2.3. Anti-Cancer Activity Assay
2.3.1. Cell Lines and Cell Culture
The human leukemia cell lines K562 and HEL, the non-small cell lung cancer A549, and the
prostate cancer cell line PC3 were obtained from the Key Laboratory of Chemistry for Natural Product
of Guizhou Province and Chinese Academy of Science (Guiyang, China). Cells were cultured as a
monolayer in DMEM (Hyclone, Germany), supplemented with 10% heat-inactivated research-grade
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fetal bovine serum (Hyclone, Germany) and penicillin/streptomycin (Sigma, St. Louis, MO, USA) at
37 ◦C in a humidified atmosphere, containing 5% CO2.
2.3.2. Cytotoxic Activity Assay
The cytotoxic activity of compounds was measured by MTT assay, using adriamycin as the
positive control. Cells were seeded in 96-well microculture plates at a density of 1 × 104 cells/well and
left to adhere for 24 h. The cells were then exposed to different concentrations of the compounds for
48 h. MTT was added to each well at a final concentration of 0.5 mg/mL and cells were incubated at
37 ◦C for an additional 4 h. The medium was then discarded and 200 μL Tris-DMSO solution was
added to each well. The dark blue formazan crystals formed were dissolved by slight shaking, and the
absorbance was measured at 490 nm, using an ELISA plate reader.
2.3.3. Statistical Analysis
The data were analyzed using SPSS 18.0 and reported as mean ± standard deviation (SD) of the
number of experiments indicated. For all the measurements, one-way ANOVA followed by a Student’s
t-test was used to assess the statistical significance of the differences between each group. The statistical
significance of the difference between two groups was assessed using the LSD method. p < 0.05 was
considered to indicate statistical significance. The data are presented as the mean ± standard error of
the mean (SEM) of three assays.
3. Results and Discussion
3.1. Synthesis
The optimal reaction conditions were established (Table 1, entry 6). The substrate scope was
further extended to other types of allenes (Figure 1). As expected, various substituent groups led to a
variety of products. When using either the monoallene (ethyl ester/benzyl ester) or diallene, the Pd
catalyst efficiently promoted this C-O functionalization. Intriguingly, the application of triethylamine
as a base instead of potassium carbonate was demonstrated to be more efficient for target product
purification (4e, 4f). However, completion of the reaction is hard to achieve. Starting flavonoids with
OH groups at positions 3′ and 4′ easily generated the 1,3-dioxolane byproducts, instead of the desired
ones. The key intermediates 1a–1c were prepared according to reported methods [18–20].
 
Figure 1. Types of allenes.
Under optimal conditions, as illustrated in Figure 2, a variety of flavonoid substrates was
investigated. For instance, flavones and flavonols were well tolerated, providing ample opportunities
for further anti-cancer activity evaluation of the derivatives. We found that the property of flavonoid
and the substituted phenolic hydroxyl groups had a great impact on the formation of the desired
products. Notably, it was more challenging to separate the analog products when more than two
hydroxyl groups were presented. Finally, the target products (3a–3i, 4a–4g, 5a–5e, 6a, 6b) were
successfully purified by silica gel column chromatography. The configuration of the C=C bond in
3a and 4a was determined by the NOE (Nuclear Overhauser Effect) study. The structures of final
compounds were characterized by 1H-, 13C-NMR, and MS spectrometry.
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Figure 2. Substrate scope of flavonoids and allenes.
3.2. Anti-Cancer Activity
The anti-tumor activity of all derivatives in vitro was summarized in Table 2. Results showed that
the inhibitory effect of compound 4e on the growth of K562 was six times stronger (p < 0.01) than that
of the substrate, diosmetin, which indicated that the anti-tumor activity of the diosmetin derivative
was associated with the more lipophilic benzyl ester than -OCH3 moiety at R6 position of the substrate.
Compounds 5e, 3h, and 6b showed better activity (p < 0.01) on the proliferation of HEL than that of
the substrates, baicalein, kaempferol, and quercetin, respectively. These results suggested that the
anti-leukemia activity may be improved by increasing steric hindrance, such as by introducing propyl
and 1,3-dioxolane groups onto baicalein. Compound 6b exhibited an enhanced inhibitory activity on
the growth of leukemia cells (K562 and HEL) and non-small cell lung cancer A549 compared with those
of 3i, which can be speculated as the enhanced water solubility associated with the carboxyl group.
We then synthesized compounds 3e, 4b, and 4c to improve the anti-cancer activity (p < 0.01) on the
proliferation of PC3 compared with the substrates, diosmetin, chrysin, and baicalein, respectively. The
results suggested that introducing an ethyl and benzyl esters could increase their anti-cancer activity.
Table 2. The anti-cancer activities of the synthetic derivatives.
Compd
Inhibition Rate % (5 μM)
K562 A549 HEL PC3
3a 34.1 ± 4.3 −23.3 ± 2.1 −2.5 ± 3.2 7.1 ± 3.2
3b 28.4 ± 4.9 −14.9 ± 2.8 27.5 ± 4.1 1.5 ± 3.4
3c 23.1 ± 3.2 3.8 ± 1.7 21.2 ± 2.3 16.1 ± 1.2
3d 14.0 ± 1.7 −39.6 ± 2.9 2.7 ± 1.9 36.6 ± 3.6
3e −45.0 ± 1.9 −20.5 ± 2.5 10.5 ± 2.9 51.7 ± 3.9 **
3f −13.7 ± 2.2 19.7 ± 2.6 −24.3 ± 2.4 40.4 ± 2.7
3g 26.2 ± 3.1 16.4 ± 2.4 24.9 ± 2.3 38.2 ± 2.5
3h 16.3 ± 3.4 −16.7 ± 2.3 58.6 ± 3.9 ** −15.9 ± 2.6
3i 26.2 ± 3.5 −60.4 ± 2.7 24.9 ± 3.8 42.2 ± 2.1
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Table 2. Cont.
Compd
Inhibition Rate % (5 μM)
K562 A549 HEL PC3
4a −33.6 ± 2.3 −36.9±2.0 24.6 ± 2.9 8.9 ± 2.6
4b −5.0 ± 1.7 −2.7 ± 1.2 −27.1 ± 2.7 56.2 ± 4.0 **
4c −22.8 ± 2.9 −6.6 ± 1.4 16.2 ± 2.6 51.0 ± 4.7 **
4d 17.3 ± 1.3 −1.9 ± 4.3 18.1 ± 2.5 28.4 ± 2.4
4e 61.9 ± 4.2 ** −3.7 ± 4.3 49.5 ± 2.4 21.9 ± 2.1
4f −22.6 ± 2.9 −17.5 ± 4.3 10.1 ± 2.1 28.8 ± 2.0
4g −23.3 ± 2.5 −14.5 ± 1.7 2.7 ± 2.3 36.6 ± 1.9
5a −8.4 ± 1.2 19.5 ± 1.9 24.6 ± 2.8 21.9± 1.2
5b 18.7 ± 3.5 14.0 ± 2.5 11.4 ± 1.9 32.9± 0.9
5c 19.3 ± 3.1 15.9 ± 2.7 21.3 ± 3.0 31.8 ± 1.2
5d −10.6 ± 3.0 17.5 ± 2.2 18.7 ± 3.2 30.6± 1.8
5e −13.4 ± 4.2 21.8 ± 2.1 49.5 ± 2.0 ** 39.5 ± 1.7
6a 4.3 ± 1.6 11.7 ± 0.9 28.3 ± 2.2 41.1 ± 1.9
6b 35.7 ± 1.7 38.2 ± 3.5 44.7 ± 1.7 ** 35.2 ± 2.6
Chrysin 51.0 ± 4.1 37.5 ± 1.8 21.9 ± 1.3 39.2 ± 2.8
Baicalein 17.7 ± 2.2 29.3 ± 2.1 19.2 ± 3.5 28.3±1.8
Quercetin −5.0 ± 3.6 8.2 ± 3.0 10.2 ± 3.4 11.3 ± 1.9
Diosmetin 10.9 ± 1.8 7.3 ± 1.2 9.2 ± 3.0 9.5 ± 2.1
Apigenin −1.5 ± 1.9 5.6 ± 1.1 6.4 ± 2.1 8.3 ± 2.5
Luteolin 19.1 ± 1.7 14.7 ± 1.4 20.4 ± 1.7 16.5 ± 1.7
Kaempferol −25.3 ± 2.1 8.6 ± 1.3 −24.0 ± 2.4 14.3 ± 2.2
Note: ** represents p < 0.01, vs. the inhibition of the substrate to the cancer cell lines. The data represented the
average of three independent experiments.
4. Conclusions
Twenty-three flavonoidal ether derivatives were synthesized without the steps of introducing
protective groups followed by deprotection. The in vitro tumor growth inhibitory activities of all the
derivatives were assayed using four human cancer cell lines, K562, A549, HEL, and PC3. In general,
compounds containing 1,3-dioxolane, such as 6b, possessed broad-spectrum inhibitory activity against
the above four cancer cells. Preliminary structure–activity relationship studies indicated that the
position-7 substituents were essential for the cytotoxicities of the derivatives. These results provided
new insight into developing flavonoid-derived anti-cancer agents.
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Abstract: Cancer patients frequently suffer from cancer-related fatigue (CRF), which is a complex
syndrome associated with weakness and depressed mood. Neuroinflammation is one of the major
inducers of CRF. The aim of this study is to find a potential agent not only on the treatment
of cancer, but also for reducing CRF level of cancer patients. In this study, total-thirty new
Dihydroartemisinin–Coumarin hybrids (DCH) were designed and synthesized. The in vitro
cytotoxicity against cancer cell lines (HT-29, MDA-MB-231, HCT-116, and A549) was evaluated.
Simultaneously, we also tested the anti-neuroinflammatory activity of DCH. DCH could inhibit the
activated microglia N9 release of NO, TNF-α, and IL-6. The docking analysis was shown that MD-2,
the coreceptor of TLR4, might be one of the targets of DCH.
Keywords: anticancer; anti-neuroinflammation; coumarin; dihydroartemisinin
1. Introduction
Chemotherapy is an important method in the therapy of cancer, but the adverse side effects of
anticancer agents should also be focused on. Gastrointestinal injury induced by chemotherapeutic
agents could result in bacterial/endotoxin translocation from the gut to the systemic blood
circulation [1,2]. The released endotoxin would cause a systemic inflammatory response including
neuroinflammation [3]. Cancer patients frequently suffer from cancer-related fatigue (CRF), which is
a complex syndrome associated with weakness and depressed mood. Diana M., Norden et al.
demonstrated that the neuroinflammation is one of the major reasons which induce CRF [4]. Currently,
there were no effective method to reduce CRF [5]. The aim of this study is to find a potential
anti-neuroinflammatory agents which might reduce CRF of cancer patients.
Central nervous system (CNS) consists of two major types of cells, nerve cells and glial cells.
Microglia is a major glial cell and plays an important role as the resident macrophage population
in the CNS [6,7]. There has been wide recognition that the fully activated microglial cells are
neurotoxic. They release reactive oxygen species, nitric oxide (NO), tumor necrosis factor-alpha
(TNF-α), and other potentially cytotoxic molecules [8,9]. It means that activation of microglia could
induce neuroinflammation.
Lipopolysaccharide (LPS), also known as endotoxin, is a natural Toll-like receptor 4 (TLR4)
ligand and it is also a potent microglial activator that can trigger the production of inflammatory
mediators. TLR-4, a transmembrane receptor, plays a vital role in the initiation and acceleration of
the inflammatory response induced by LPS [10,11]. TLR4 alone does not directly bind LPS and needs
Molecules 2019, 24, 1672; doi:10.3390/molecules24091672 www.mdpi.com/journal/molecules459
Molecules 2019, 24, 1672
the coreceptor MD-2 [12]. MD-2 is linked with the extracellular domain of TLR4 and is indispensable
for LPS recognition [13]. MD-2 is a member of the MD-2-related lipid-recognition protein family [14].
MD-2 directly binds to LPS in its hydrophobic cavity with high affinity [15].
Artemisinin and its derivatives have been the first-line antimalarial drug since the late 1990s.
Dihydroartemisinin (DHA) is the primary bioactive metabolite of artemisinin and its derivatives,
but not artemisinin per se [16]. Additionally, DHA has higher bioavailability and less side effects
than artemisinin [17]. Recent research showed that besides antimalarial activity, DHA also exhibits
anticancer and anti-inflammatory activity [18–21]. As the anti-inflammatory agent, DHA could
decrease LPS-induced protein expression of TLR4 [22].
Coumarins are widely distributed in different parts of plants. There are various pharmacological
activities of coumarins, which includes anti-inflammatory [23,24] and anticancer activity [25,26].
As the anticancer agents, coumarins were reported to exhibit negligible or mild side effects [27,28].
Substitution at the C-3 or C-4 position of coumarins exhibit good cytotoxic activity in various cancer
cell lines [26,29–31]. Additionally, as anti-inflammatory agents, some kinds of coumarins could also
target TLR4/MD-2 complex [32,33].
In our previous study, Dihydroartemisinin–Coumarin hybrids (DCH) were designed and
synthesized referring to the principle of hybridization [34,35]. Each of them contains coumarin
moiety, DHA moiety and a linker. DCH could inhibit HT-29 cells proliferation and arrest the G0/G1
phase of HT-29 cells [35]. They could also suppress cancer cell migration, and induce apoptosis and
ferroptosis of HT-29 cancer cells [35]. It also has been confirmed that the DCH having 1,2,3-triazole
linker generally exhibit better cytotoxicity exhibition than the others [35].
With this background, total-thirty new DCH were designed and synthesized, and the synthetic
approaches were shown in Figure 1. All of them contained 1,2,3-triazole linker. We focused on
the modifications of positions 3 and 4 of the coumarin moiety. Due to the new synthesized DCH
were for the cancer patients, we evaluated the in vitro cytotoxicity against cancer cell lines (HT-29,
MDA-MB-231, HCT-116, and A549). In addition, DCH could inhibit the activated N9 cell release of NO,
TNF-α and IL-6. Furthermore, to investigate the mechanism of the anti-neuroinflammatory activity,
docking analysis was applied. The results might support that the anti-neuroinflammatory activity was
related to inhibiting TLR4/MD-2 complex.
Figure 1. Structures of new designed Dihydroartemisinin–Coumarin hybrids.
2. Results and Discussion
2.1. Chemistry
The synthesis of the intermediates a–p and I–IV is presented in Scheme 1. The intermediates I and II
were obtained by 2-bromoethanol or 3-bromo-1-propanol, with dihydroartemisinin (DHA), respectively,
followed by treating the product with sodium azide. The intermediates III and IV were synthesized
by propargyl alcohol or 3-butyn-1-ol with DHA, respectively. The required 3-methylcoumarin
derivatives were obtained by substitution of salicylaldehyde with propionic anhydride in the
presence of sodium propionate and triethylamine. The substituted-3-bromomethylcoumarins were
prepared by the radical bromination of 3-methylcoumarin derivatives through the reaction with
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N-Bromosuccinimide (NBS) in the presence of dibenzoylperoxide [36]. The intermediates a–e
were synthesized by substituted-3-bromomethylcoumarins via azidation reaction. The required
substituted-4-chloromethylcoumarins were prepared by the Pechmann cyclisation [37] of substituted
phenols with 4-chloroethylacetoacetate using sulfuric acid as the condensing agent. The intermediates
f–i were synthesized by substituted-4-chloromethylcoumarin via azidation reaction. To synthesize
the intermediates j–p, several substituted-4-hydroxycoumarin were prepared by condensing the
substituted phenol with malonic acid [38]. Then the products were treated with 3-bromo-1-propyne in
the presence of potassium carbonate.
 
Scheme 1. Synthetic routes of intermediates. Reagents and conditions: (1) BF3.Et2O, CH2Cl2, 0 ◦C;
(2) NaN3, DMF, 60 ◦C; (3) CH3CH2COONa, Et3N, reflux; (4) NBS, BPO, CCl4, reflux; (5) 70% H2SO4,
r.t.; (6) ZnCl2, POCl3, 65 ◦C; and (7) K2CO3, DMF, 60 ◦C.
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The synthesis of the desired new compounds was presented in Scheme 2. The target compounds
1a–1e and 2a–2e were obtained by the reaction of the intermediates III or IV with a–e via click chemistry,
respectively. The target compounds 3f–3i and 4f–4i were synthesized by intermediates III or IV with
f–i via click chemistry, respectively. The target compounds 5j, 5l–5o, and 6j–6p were prepared by the
reaction of the intermediates I or II with j–p via click chemistry, respectively.
 
Scheme 2. Synthetic routes of target compounds. Reagents and conditions: (1) CuI, triethylamine,
dichloromethane, r.t.
2.2. Biological Assay
2.2.1. In Vitro Cytotoxic Activity of the Compounds
As the anti-neuroinflammatory agents for cancer patients, all newly synthesized compounds
were evaluated in vitro for antitumor activity against human breast cancer cell line MDA-MB-231,
colorectal cancer cells HT-29 and HCT-116, and lung cancer cell line A549 by using the standard MTT
method, respectively. Doxorubicin (DOX) and DHA were used as the reference standard. Additionally,
owing to the rapid proliferation, the tumor cells actually was always in hypoxia condition. Therefore,
the in vitro cytotoxicity was evaluated in two different conditions (hypoxia and normoxia). All data
are summarized in Table 1. Most of the target compounds exhibited moderate activities against the
tested cell lines and they showed a general promotion under hypoxia conditions.
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The structure–activity relationship was evaluated: (i) the series of compounds 5 and 6 generally
exhibited better cytotoxicity activity than that of the series of compounds 3 and 4, which indicated that
the 4-oxygen group in the coumarin moiety as a part of linker could improve the antitumor activity;
(ii) although compounds 3 and 4 did not exhibit good activity against three cell lines (MDA-MB-231,
HCT-116, and A549), they showed good activity against HT-29 like the other derivatives. Therefore,
4-methyl group in the coumarin moiety could improve the selectivity of DCH against HT-29.
In addition, almost all of the target compounds exhibited good cytotoxicity activity against HT-29.
Therefore, HT-29 was selected for the next explorations.
Table 1. IC50 (μM) of tested samples in MDA-MB-231, HT-29, HCT-116, and A549 cell lines.
HT-29 MDA-MB-231 HCT-116 A549
Hypoxia Normoxia Hypoxia Normoxia Hypoxia Normoxia Hypoxia Normoxia
DOX <0.1 0.11 0.69 1.37 >2 1.29 >2 >2
DHA 11.74 51.10 45.93 >100 25.89 10.33 >100 >100
1a 14.29 18.40 30.47 64.97 49.79 48.90 53.87 83.48
1b 13.14 21.35 >100 >100 >100 >100 >100 >100
1c 26.37 35.41 32.26 >100 40.38 60.30 48.70 73.49
1d 13.34 14.94 33.93 68.85 48.61 60.01 45.42 53.34
1e 26.95 15.32 45.46 77.89 >100 54.45 59.75 >100
2a 19.42 >100 >100 >100 >100 >100 >100 >100
2b 12.09 9.75 36.86 37.74 >100 55.99 60.16 >100
2c 19.61 17.46 32.47 43.98 64.37 49.48 66.87 87.15
2d 30.81 19.54 47.92 88.46 46.51 53.19 69.67 96.48
2e 13.92 38.52 44.14 >100 86.49 94.16 79.37 >100
3f 15.46 37.83 63.07 >100 67.74 >100 98.00 >100
3g 15.86 23.89 >100 >100 >100 >100 >100 >100
3h 32.04 >100 >100 >100 >100 >100 >100 >100
3i 8.57 16.36 22.81 >100 >100 64.99 62.27 >100
4f 11.30 32.30 78.79 >100 >100 >100 >100 >100
4g 9.33 13.85 22.71 >100 25.65 34.50 >100 >100
4h 56.35 >100 >100 >100 >100 >100 >100 >100
4i 39.02 >100 >100 >100 >100 >100 >100 >100
5j 12.25 30.03 69.41 100.00 >100 77.20 >100 >100
5l 3.76 2.78 >100 >100 >100 >100 >100 >100
5m 5.89 12.88 13.04 14.17 44.81 62.82 1.282 2.670
5n 8.90 10.19 11.68 11.04 32.92 25.64 2.443 2.107
5o 21.25 16.09 16.54 37.41 38.49 29.69 45.06 50.37
6j 7.42 10.49 33.40 67.42 32.84 25.90 49.03 53.37
6k 5.32 6.85 14.46 38.56 33.70 28.13 9.49 14.92
6l 3.40 8.41 6.85 1.17 27.92 26.90 9.78 6.88
6m 5.90 22.43 18.74 24.64 93.53 42.05 20.14 27.87
6n 4.19 9.16 10.84 13.35 33.74 22.51 0.039 30.40
6o 29.02 81.57 18.57 47.65 42.35 12.09 39.92 78.07
6p 12.48 7.49 10.33 22.08 38.05 35.33 18.82 18.85
2.2.2. Morphological Changes and Effect of Compound 5n on Cell Viability
As shown in A–F of Figure 2, there showed a concentration-dependent cell death after treatment
with compound 5n for 48 h. As the concentration up to 100 μM, the compound 5n could obviously
inhibit the proliferation of HT-29. As shown in the (G) of Figure 2, after HT-29 cells were treated with
different concentrations of 5n for 48 h, the cell viability decreased in a dose-dependent manner.
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Figure 2. Inhibition of compound 5n on cell viability in HT-29 cells by MTT staining. Cells were
treated with (A) 0 μM, (B) 6.25 μM, (C) 12.5 μM, (D) 25.0 μM, (E) 50.0 μM, and (F) 100.0 μM compound
5n for 48 h. Representative images were shown; 200×. (G) Cells were treated with 6.25, 12.5, 25,
50, and 100 μM compound 5n for 48 h. Data were shown as mean ± SD. * p < 0.05, ** p < 0.01 and
*** p < 0.001 compared with group 0 μM.
2.2.3. Anti-Neuroinflammatory Activity
The anti-neuroinflammatory activity of DCH was evaluated and then the representative
compounds were selected for the further study. As shown in Table 2, murine microglial N9 cells were
treated with 1μg/mL LPS for 48 h and the NO level in the medium was measured as the preliminary
screening. Most of the tested compounds exhibited good anti-inflammatory activity, and especially the
IC50 of some compounds were even less than 1 μM. Among them, compound 5n had the best activity
and the IC50 reached 0.22 μM. In addition, in order to exclude the death influence, MTT-IC20 of all the
compounds were measured. The results showed that DCH did not exhibit cytotoxic activity in N9 cells.
The exact reason was still unclear, but we supposed that it might be related to the homeostasis of cells.
The tumor cells actually were always in hypoxia condition, in which DCH could promote the cytotoxic
activity against tumor cells. In brief, DCH could reduce the release of NO caused by LPS-induced
microglial cells.
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Table 2. IC50 of tested samples in LPS-induced N9 cells for the inhibition of NO; IC20 of tested samples
in N9 cells for cytotoxic activity.


































Sodium nitroprusside (SNP) is a NO donor. In this experiment, the reason of the DCH reducing
NO level was preliminary explored. As shown in Figure 3, the results showed that the compounds
only partially reduced NO levels by direct NO capture. That means the main reason of the NO level
reduction is due to species-specific effect.
Figure 3. Compound 6l and 5n had NO radical scavenging activity. 6l (0.01 μM, 0.1 μM, 1 μM,
and 10 μM) or 5n (0.01 μM, 0.1 μM, 1 μM, and 10 μM) was added to a concentration of 0.5 mM SNP
solution. After reacted for 1 h under normal sun light at room temperature, Griess reagent was added
and the optical density was observed at 540 nm. Data were shown as mean ± SD. *** p < 0.001 compared
with control group.
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Effect of Representative Compounds on TNF-α and IL-6 Release
As shown in Table 3, four kinds of DCH were involved to measure the effect on the release of
TNF-α and IL-6 from the microglia cells which induced by LPS for 48 h. The results showed that
compounds 2b, 2c, 5n, and 6p could inhibit the release of TNF-α with the inhibition rate of 22% to 32%
and the release of IL-6 with the inhibition rate of 26% to 43%. The results indicated that the inhibition
effect of DCH on NO release was not only by nonspecific effects, but also by slightly influencing the
synthesis and release of upstream inflammatory pathway.
Table 3. The inhibition of compounds (1 μM) on cytokines release (48 h) of the murine microglial cell
line N9 induced by lipopolysaccharide (LPS) (1 μg/mL).
Group TNF-α (pg/mL) Inhibition (%) IL-6 (pg/mL) Inhibition (%)
Con 155.54 ± 79.61 – 0 –
LPS 4455.87 ± 518.24 # – 1154.44 ± 148.48 # –
2b 3285.99 ± 1062.40 27.20 797.52 ± 140.74 * 30.92
2c 3077.03 ± 375.48 32.06 850.24 ± 112.47 26.35
5n 3508.08 ± 368.72 22.04 656.75 ± 79.49 ** 43.11
6p 3451.29 ± 646.50 23.36 747.80 ± 125.56 * 35.22
# p < 0.001 compared with control group, * p < 0.05 ** p < 0.01 compared with LPS group.
Docking Analysis
Toll-like receptor 4 (TLR4) and its coreceptor—MD-2—are the target of LPS, which could influence
innate immune response to release potentially cytotoxic molecules. MD-2 is linked with the extracellular
domain of TLR4 and is indispensable for LPS recognition [13]. Therefore, this docking analysis was
applied to explore whether or not the target compounds inhibit MD-2 to reduce the release of
inflammatory mediators. Umeharu Ohto et al. [39] had revealed the crystal structure of mouse
TLR4/MD-2/LPS complex, which was shown in Figure 4. In their study, MD-2 directly bound to LPS
in its hydrophobic cavity with high affinity. With this background, compound 5n was used as the
ligand to explore the relationship between DCH and TLR4/MD-2/LPS complex. As shown in Figure 5,
compound 5n could integrate closely with the hydrophobic cavity of MD-2, which is the important
TLR4/MD-2/LPS binding position. That means the DCH might disturb the interactions between LPS
and TLR4/MD-2 complex. The minimum binding energy of (ΔG) is −10.08 kcal/mol. Given to this
result, we supposed TLR4/MD-2 complex is likely to be one of the drug targets of DCH.
Figure 4. The surface representation of LPS (red) and Toll-like receptor 4 (TLR4) (green)/MD-2 (cyan)
binding pocket (PDB: 3VQ2).
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Figure 5. Interaction diagrams of the selected docked conformations of compound 5n to TLR4/MD-2
complex. (A) The surface representation of compound 5n and TLR4 (limon)/MD-2 (yellow) binding
pocket. (B) The magnified representation of compound 5n (red) and TLR4 (limon)/MD-2 (cyan) binding
pocket. (C) The interface of compound 5n and TLR4/MD-2 complex; (D) 3D ligand interactions diagram.
Dotted line; pink: alkyl hydrophobic; blue: pi hydrophobic; green: hydrogen bond.
3. Conclusions
Total-thirty new DCH were designed and synthesized. Most of the target compounds exhibited
moderate activities against the tested cell lines and they showed a general promotion under hypoxia
conditions. Meanwhile, the new potential activity of DCH was found that DCH could exhibit
anti-neuroinflammatory activity. DCH could inhibit the release of NO, TNF-α, and IL-6, which were
induced by LPS. The docking analysis was shown that MD-2, the coreceptor of TLR4, might be one of
the targets of DCH. Additionally, DCH could also reduce NO levels by direct NO capture. In brief,
DCH were the potential anti-neuroinflammatory agents which might reduce CRF of cancer patients.
4. Experimental Section
4.1. Chemistry
Unless otherwise specified, all solvents and reagents were commercially available and used
without further purification. Analytical TLC was performed using silica gel precoated GF254 plates.
The 1H-NMR and 13C-NMR spectra were recorded at 600 MHz and 150 MHZ on a Bruker AV-400
spectrometer (Bruker Bioscience, Billerica, MA, USA), using CDCl3 as solvent with tetramethylsilane as
the internal standard. NMR spectra were analyzed using MestReNova. High-resolution mass spectra
(HRMS) were measured using an Agilent Accurate-Mass Q-TOF 6530 (Agilent, Santa Clara, CA, USA)
instrument in ESI mode. The 1H-NMR and 13C-NMR spectra of synthesized compounds, please see
the supplementary materials.
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4.1.1. General Procedure for the Synthesis of Compounds 1a–1e and 2a–2e
Substituted coumarin (a–e) (10 mmol), substituted DHA (III or IV) (10 mmol), and triethylamine
(10 mmol) were dissolved in 20 mL CH2Cl2. In addition, CuI (100 mg) was added and the reaction
mixture was stirred at room temperature for 8 h under the protection of nitrogen. The mixture was
filtered, washed with water, dried over Na2SO4 and evaporated to dryness. The crude product was
purified through column chromatography.
3-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (1a) White
solid; m.p. 73–75 ◦C; yield 52%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.77 (s, 1H), 7.68 (s, 1H), 7.56 (t,
J = 7.9 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 5.47 (s, 2H), 5.39
(s, 1H), 4.94 (d, J = 12.6 Hz, 1H), 4.92 (d, J = 3.5 Hz, 1H), 4.68 (d, J = 12.6 Hz, 1H), 2.67–2.60 (m, 1H),
2.38–2.31 (m, 1H), 2.01–1.97 (m, 1H), 1.85–1.81 (m, 1H), 1.77–1.68 (m, 3H), 1.59 (dd, J = 13.2, 3.4 Hz, 1H),
1.46–1.43 (m, 1H), 1.41 (s, 3H), 1.31–1.18 (m, 1H), 1.26–1.16 (m, 2H), 0.91 (d, J = 6.3 Hz, 3H), 0.88 (d,
J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 159.64, 152.65, 144.62, 141.31, 131.46, 127.30,
123.92, 122.67, 121.84, 117.53, 115.71, 103.10, 100.77, 86.93, 80.06, 76.22, 76.01, 75.80, 60.70, 51.47, 47.97,
43.33, 36.33, 35.36, 33.52, 29.78, 25.09, 23.59, 23.41, 19.30, 11.99; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C28H33N3O7Na: 546.2216. Found: 546.2181.
6-bromo-3-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (1b)
White solid; m.p. 78–80 ◦C; yield 48%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.75 (s, 1H), 7.64 (dd,
J = 8.8, 2.3 Hz, 1H), 7.61 (d, J = 2.3 Hz, 1H), 7.55 (s, 1H), 7.24 (d, J = 8.8 Hz, 1H), 5.47 (s, 2H), 5.39
(s, 1H), 4.94 (d, J = 12.7 Hz, 1H), 4.93 (d, J = 3.5 Hz, 1H), 4.69 (d, J = 12.8 Hz, 1H), 2.67–2.63 (m, 1H),
2.38–2.33 (m, 1H), 2.03–1.99 (m, 1H), 1.86–1.82 (m, 1H), 1.75–1.70 (m, 2H), 1.62–1.58 (m, 2H), 1.42 (s,
3H), 1.31–1.19 (m, 4H), 0.92 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ
(ppm): 158.90, 151.42, 144.74, 139.67, 134.18, 129.51, 123.17, 122.67, 119.00, 117.43, 116.53, 103.12, 100.87,
86.95, 80.06, 76.20, 75.99, 75.78, 60.76, 51.46, 47.82, 43.32, 36.36, 35.36, 33.52, 29.79, 25.10, 23.62, 23.42,
19.30, 12.00; ESI-HRMS [M + Na]+: (m/z) Calcd. for C28H32BrN3O7Na: 624.1321. Found: 624.1264.
6-chloro-3-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (1c)
White solid; m.p. 93–95 ◦C; yield 41%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.75 (s, 1H), 7.56 (s, 1H),
7.51 (dd, J = 8.8, 2.5 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.30 (d, J = 8.9 Hz, 1H), 5.47 (s, 2H), 5.39 (s, 1H),
4.95 (d, J = 12.7 Hz, 1H), 4.93 (d, J = 3.6 Hz, 1H), 4.69 (d, J = 12.6 Hz, 1H), 2.68–2.62 (m, 1H), 2.35
(td, J = 14.0, 4.0 Hz, 1H), 2.03–1.99 (m, 1H), 1.87–1.82 (m, 1H), 1.75–1.71 (m, 2H), 1.62–1.59 (m, 1H),
1.48–1.43 (m, 2H), 1.42 (s, 3H), 1.31–1.19 (m, 3H), 0.92 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 7.4 Hz, 3H); 13C
NMR (150 MHz, CDCl3) δ (ppm): 158.96, 150.95, 144.73, 139.79, 131.37, 129.27, 126.46, 123.19, 122.67,
118.51, 117.16, 103.12, 100.86, 86.95, 80.06, 76.21, 75.99, 75.78, 60.75, 51.47, 47.84, 43.33, 36.36, 35.36,
33.52, 29.79, 25.10, 23.62, 23.42, 19.30, 12.00; ESI-HRMS [M + Na]+: (m/z) Calcd. for C28H32ClN3O7Na:
580.1826. Found: 580.1788.
6,8-dichloro-3-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(1d) White solid; m.p. 113–115 ◦C; yield 60%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.75 (s, 1H), 7.61
(d, J = 2.3 Hz, 1H), 7.55 (s, 1H), 7.37 (d, J = 2.4 Hz, 1H), 5.48 (s, 2H), 5.37 (s, 1H), 4.96–4.92 (m, 2H),
4.70 (d, J = 12.7 Hz, 1H), 2.69–2.62 (m, 1H), 2.38–2.33 (m, 1H), 2.04–1.99 (m, 1H), 1.87–1.82 (m, 1H),
1.76–1.72 (m, 3H), 1.62–1.59 (m, 1H), 1.42 (s, 3H), 1.32–1.18 (m, 4H), 0.92 (d, J = 6.3 Hz, 3H), 0.89 (d,
J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 157.92, 146.92, 144.86, 139.45, 131.36, 129.12,
125.03, 124.04, 122.68, 121.71, 119.30, 103.13, 100.95, 86.94, 80.04, 76.20, 75.99, 75.78, 60.80, 51.44, 47.63,
43.31, 36.37, 35.35, 33.51, 29.79, 25.09, 23.61, 23.42, 19.28, 12.00; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C28H31Cl2N3O7Na: 614.1437. Found: 614.1428.
6,8-dibromo-3-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(1e) White solid; m.p. 103–105 ◦C; yield 61%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.90 (d, J = 2.2
Hz, 1H), 7.75 (s, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.52 (s, 1H), 5.48 (s, 2H), 5.37 (s, 1H), 4.96–4.92 (m, 2H),
4.70 (d, J = 12.7 Hz, 1H), 2.67–2.63 (m, 1H), 2.38–2.33 (m, 1H), 2.03–1.99 (m, 1H), 1.87–1.82 (m, 1H),
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1.76–1.72 (m, 2H), 1.62–1.58 (m, 4H), 1.42 (s, 3H), 1.25–1.19 (m, 2H), 0.92 (d, J = 6.3 Hz, 3H), 0.90 (d,
J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.01, 148.45, 144.87, 139.36, 136.89, 128.75,
123.97, 122.67, 119.74, 116.48, 110.29, 103.13, 100.97, 86.95, 80.04, 76.20, 75.99, 75.78, 60.82, 51.45, 47.56,
43.31, 36.37, 35.35, 33.51, 29.79, 25.09, 23.62, 23.42, 19.30, 12.00; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C28H31Br2N3O7Na: 702.0426. Found: 702.0421.
3-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (2a) White
solid; m.p. 143–145 ◦C; yield 66%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.65 (s, 1H), 7.63 (s, 1H), 7.56
(ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.47 (dd, J = 7.8, 1.6 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.30 (td, J = 7.5, 1.1
Hz, 1H), 5.44 (s, 2H), 5.29 (d, J = 9.7 Hz, 1H), 4.78 (d, J = 3.6 Hz, 1H), 4.13–4.09 (m, 1H), 3.69–3.65 (m,
1H), 3.07–2.97 (m, 2H), 2.61–2.55 (m, 1H), 2.33 (td, J = 14.0, 4.0 Hz, 1H), 2.01–1.97 (m, 1H), 1.85–1.81
(m, 1H), 1.71–1.67 (m, 2H), 1.59–1.56 (m, 1H), 1.41 (s, 3H), 1.40–1.38 (m, 1H), 1.28–1.16 (m, 3H), 0.91
(d, J = 6.3 Hz, 3H), 0.89–0.83 (m, 1H), 0.80 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm):
159.65, 152.64, 144.77, 141.15, 131.43, 127.30, 123.90, 121.98, 121.78, 117.52, 115.70, 103.03, 100.92, 86.84,
80.02, 76.21, 76.00, 75.78, 66.18, 51.47, 47.86, 43.28, 36.34, 35.36, 33.55, 29.79, 25.57, 25.14, 23.62, 23.34,
19.33, 11.93; ESI-HRMS [M + Na]+: (m/z) Calcd. for C29H35N3O7Na: 560.2373. Found: 560.2417.
6-bromo-3-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (2b)
White solid; m.p. 138–140 ◦C; yield 52%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.64 (dd, J = 8.8, 2.3 Hz,
1H), 7.61 (d, J = 2.3 Hz, 1H), 7.60 (s, 1H), 7.52 (s, 1H), 7.23 (d, J = 8.8 Hz, 1H), 5.43 (s, 2H), 5.28 (s, 1H),
4.79 (d, J = 3.5 Hz, 1H), 4.13–4.09 (m, 1H), 3.70–3.66 (m, 1H), 3.07–2.98 (m, 2H), 2.62–2.57 (m, 1H), 2.34
(td, J = 14.0, 4.0 Hz, 1H), 2.01–1.98 (m, 1H), 1.86–1.81 (m, 1H), 1.71–1.67 (m, 2H), 1.60–1.56 (m, 1H), 1.42
(s, 3H), 1.40–1.37 (m, 1H), 1.27–1.17 (m, 3H), 0.92 (d, J = 6.2 Hz, 3H), 0.89–0.85 (m, 1H), 0.82 (d, J = 7.3
Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.90, 151.40, 144.86, 139.50, 134.15, 129.51, 123.31,
121.76, 118.99, 117.41, 116.51, 103.06, 100.92, 86.85, 80.00, 76.20, 75.99, 75.78, 66.18, 51.45, 47.72, 43.26,
36.37, 35.35, 33.55, 29.78, 25.56, 25.14, 23.63, 23.35, 19.32, 11.95; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C29H34BrN3O7Na: 638.1478. Found: 638.1508.
6-chloro-3-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (2c)
White solid; m.p. 138–140 ◦C; yield 52%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.60 (s, 1H), 7.53 (s,
1H), 7.50 (dd, J = 8.8, 2.5 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 5.43 (d, J = 1.1
Hz, 2H), 5.28 (s, 1H), 4.79 (d, J = 3.6 Hz, 1H), 4.13–4.09 (m, 1H), 3.70–3.66 (m, 1H), 3.05–2.99 (m, 2H),
2.61–2.58 (m, 1H), 2.37–2.31 (m, 1H), 2.01–1.98 (m, 1H), 1.86–1.81 (m, 1H), 1.70–1.68 (m, 2H), 1.60–1.56
(m, 1H), 1.42 (s, 3H), 1.41–1.36 (m, 1H), 1.26–1.17 (m, 3H), 0.92 (d, J = 6.2 Hz, 3H), 0.89–0.85 (m, 1H),
0.82 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.97, 150.93, 144.87, 139.62, 131.34,
129.25, 126.47, 123.35, 121.76, 118.51, 117.14, 103.06, 100.93, 86.85, 80.00, 76.20, 75.99, 75.78, 66.19, 51.45,
47.72, 43.27, 36.37, 35.35, 33.56, 29.79, 25.57, 25.14, 23.63, 23.35, 19.32, 11.95; ESI-HRMS [M +Na]+: (m/z)
Calcd. for C29H34ClN3O7Na: 594.1983. Found: 594.2002.
6,8-dichloro-3-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(2d) White solid; m.p. 101–103 ◦C; yield 50%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.60 (d, J = 2.2 Hz,
2H), 7.52 (s, 1H), 7.37 (d, J = 2.3 Hz, 1H), 5.45 (s, 2H), 5.27 (s, 1H), 4.79 (d, J = 3.5 Hz, 1H), 4.13–4.08 (m,
1H), 3.71–3.67 (m, 1H), 3.04–3.01 (m, 2H), 2.61–2.59 (m, 1H), 2.34 (td, J = 14.0, 4.0 Hz, 1H), 2.02–1.98 (m,
1H), 1.85–1.82 (m, 1H), 1.71–1.68 (m, 2H), 1.60–1.58 (m, 1H), 1.42 (s, 3H), 1.41–1.36 (m, 1H), 1.26–1.17
(m, 3H), 0.92 (d, J = 6.1 Hz, 3H), 0.90–0.85 (m, 1H), 0.82 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz,
CDCl3) δ (ppm): 157.93, 146.90, 144.92, 139.29, 131.34, 129.12, 125.04, 124.16, 121.82, 121.70, 119.30,
103.07, 100.94, 86.86, 79.99, 76.20, 75.99, 75.78, 66.17, 51.44, 47.57, 43.26, 36.39, 35.35, 33.55, 29.78, 25.53,
25.13, 23.63, 23.35, 19.32, 11.95; ESI-HRMS [M +Na]+: (m/z) Calcd. for C29H33Cl2N3O7Na: 628.1593.
Found: 628.1360.
6,8-dibromo-3-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(2e) White solid; m.p. 93–95 ◦C; yield 44%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.83 (d, J = 2.1 Hz,
1H), 7.53 (s, 1H), 7.49 (d, J = 2.2 Hz, 1H), 7.42 (s, 1H), 5.38 (s, 2H), 5.21 (s, 1H), 4.73 (d, J = 3.4 Hz, 1H),
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4.06–4.02 (m, 1H), 3.64–3.60 (m, 1H), 2.97–2.94 (m, 2H), 2.56–2.51 (m, 1H), 2.30–2.25 (m, 1H), 1.95–1.91
(m, 1H), 1.79–1.75 (m, 1H), 1.64–1.60 (m, 2H), 1.52 (dd, J = 13.2, 3.3 Hz, 1H), 1.35 (s, 3H), 1.34–1.29 (m,
1H), 1.19–1.11 (m, 3H), 0.85 (d, J = 6.1 Hz, 3H), 0.83–0.78 (m, 1H), 0.75 (d, J = 7.4 Hz, 3H); 13C NMR
(150 MHz, CDCl3) δ (ppm): 158.01, 148.41, 144.96, 139.16, 136.85, 128.75, 124.12, 121.77, 119.74, 116.47,
110.26, 103.07, 100.93, 86.86, 80.00, 76.21, 76.00, 75.79, 66.19, 51.44, 47.48, 43.26, 36.39, 35.35, 33.55, 29.78,
25.56, 25.13, 23.63, 23.35, 19.33, 11.96; ESI-HRMS [M + Na]+: (m/z) Calcd. for C29H33Br2N3O7Na:
716.0583. Found: 716.0381.
4.1.2. General Procedure for the Synthesis of Compounds 3f–3i and 4f–4i
Substituted coumarin (f–i) (10 mmol), substituted DHA (III or IV) (10 mmol) and triethylamine
(10 mmol) were dissolved in 20 mL CH2Cl2. In addition, CuI (100 mg) was added and the reaction
mixture was stirred at room temperature for 8 h under the protection of nitrogen. The mixture was
filtered, washed with water, dried over Na2SO4 and evaporated to dryness. The crude product was
purified through column chromatography.
7-hydroxy-4-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (3f)
White solid; m.p. 165–167 ◦C; yield 54%; 1H NMR (600 MHz, CDCl3) δ (ppm): 9.61 (s, 1H), 7.68 (d,
J = 8.8 Hz, 1H), 7.67 (s, 1H), 6.99 (dd, J = 8.8, 2.4 Hz, 1H), 6.85 (d, J = 2.4 Hz, 1H), 6.15 (s, 1H), 5.76 (d, J
= 15.4 Hz, 1H), 5.57 (d, J = 15.3 Hz, 1H), 5.20 (s, 1H), 4.87 (d, J = 1.9 Hz, 1H), 4.86 (d, J = 7.4 Hz, 1H),
4.68 (d, J = 12.9 Hz, 1H), 2.62–2.60 (m, 1H), 2.34–2.29 (m, 1H), 2.02−1.98 (m, 1H), 1.82–1.78 (m, 1H),
1.66−1.61 (m, 3H), 1.61−1.57 (m, 1H), 1.45–1.42 (m, 1H), 1.40 (s, 3H), 1.20−1.08 (m, 3H), 0.84 (d, J = 7.4
Hz, 3H), 0.82 (d, J = 6.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 160.88, 159.75, 154.96, 146.45,
145.19, 124.19, 122.29, 112.78, 111.57, 108.80, 103.21, 103.04, 101.40, 86.91, 79.92, 76.20, 75.99, 75.78, 60.44,
51.32, 50.16, 43.18, 36.28, 35.26, 33.42, 29.74, 25.00, 23.53, 23.32, 19.26, 11.89; ESI-HRMS [M +Na]+: (m/z)
Calcd. for C28H33N3O8Na: 562.2165. Found: 562.2172.
5,7-dimethyl-4-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(3g) White solid; m.p. 133~135 ◦C; yield 57%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.56 (s, 1H), 7.07 (s,
1H), 6.95 (s, 1H), 5.90 (d, J = 17.0 Hz, 1H), 5.86 (d, J = 17.0 Hz, 1H), 5.51 (s, 1H), 5.41 (s, 1H), 4.98 (d,
J = 12.8 Hz, 1H), 4.93 (d, J = 3.5 Hz, 1H), 4.73 (d, J = 12.8 Hz, 1H), 2.68 (s, 3H), 2.40 (s, 3H), 2.35 (dd,
J = 14.0, 4.0 Hz, 1H), 2.05−2.01 (m, 1H), 1.88−1.85 (m, 1H), 1.75–1.70 (m, 2H), 1.60 (dd, J = 13.2, 3.4 Hz,
1H), 1.48–1.46 (m, 1H), 1.43 (s, 3H), 1.32−1.20 (m, 5H), 0.93 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 7.4 Hz,
3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.67, 154.26, 149.33, 145.35, 142.10, 133.93, 129.26, 122.10,
115.63, 113.36, 112.80, 103.16, 100.93, 86.98, 80.05, 76.21, 76.00, 75.79, 60.80, 52.05, 51.48, 43.31, 36.34,
35.36, 33.50, 29.78, 25.11, 23.61, 23.44, 23.28, 20.24, 19.31, 12.01; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C30H37N3O7Na: 574.2539. Found: 574.2553.
7-methyl-4-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (3h)
White solid; m.p. 107–109 ◦C; yield 50%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.58 (s, 1H), 7.50 (d,
J = 8.1 Hz, 1H), 7.19 (s, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.01 (s, 1H), 5.74 (d, J = 16.3 Hz, 1H), 5.64 (d,
J = 16.0 Hz, 1H), 5.30 (s, 1H), 4.92–4.88 (m, 2H), 4.72 (d, J = 12.9 Hz, 1H), 2.65–2.61 (m, 1H), 2.45 (s,
3H), 2.34 (td, J = 14.0, 4.0 Hz, 1H), 2.04–2.00 (m, 1H), 1.86–1.81 (m, 1H), 1.71–1.66 (m, 2H), 1.58–1.55
(m, 1H), 1.42 (s, 3H), 1.26–1.18 (m, 5H), 0.91 (d, J = 5.7 Hz, 3H), 0.86 (d, J = 7.3 Hz, 3H); 13C NMR
(150 MHz, CDCl3) δ (ppm): 159.01, 152.86, 146.75, 145.42, 143.16, 125.03, 122.23, 121.95, 116.71, 113.56,
113.41, 103.15, 101.10, 86.93, 80.00, 76.21, 75.99, 75.78, 60.90, 51.41, 49.29, 43.27, 36.34, 35.31, 33.47, 29.77,
25.06, 23.58, 23.38, 20.70, 19.30, 11.96; ESI-HRMS [M +Na]+: (m/z) Calcd. for C29H35N3O7Na: 560.2373.
Found: 560.2375.
6-methyl-4-((4-((10S)-dihydroartemisininoxy)methyl-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (3i)
White solid; m.p. 88–90◦C; yield 60%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.58 (s, 1H), 7.39 (d,
J = 8.8 Hz, 2H), 7.28 (d, J = 8.3 Hz, 1H), 6.01 (s, 1H), 5.75 (d, J = 16.3 Hz, 1H), 5.66 (d, J = 16.3 Hz, 1H),
5.32 (s, 1H), 4.92 (d, J = 12.8 Hz, 1H), 4.90 (d, J = 3.5 Hz, 1H), 4.73 (d, J = 12.8 Hz, 1H), 2.67–2.60 (m,
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1H), 2.41 (s, 3H), 2.34 (td, J = 14.0, 4.0 Hz, 1H), 2.04–1.99 (m, 1H), 1.86–1.81 (m, 1H), 1.72–1.68 (m, 2H),
1.57 (dd, J = 13.2, 3.1 Hz, 1H), 1.42 (s, 3H), 1.26–1.19 (m, 5H), 0.91 (d, J = 5.7 Hz, 3H), 0.86 (d, J = 7.3
Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.91, 150.87, 146.72, 145.41, 133.69, 132.71, 122.26,
121.95, 116.32, 115.68, 114.29, 103.15, 101.05, 86.94, 80.00, 76.21, 76.00, 75.78, 60.86, 51.42, 49.17, 43.27,
36.34, 35.31, 33.47, 29.76, 25.07, 23.59, 23.39, 20.01, 19.30, 11.96; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C29H35N3O7Na: 560.2373. Found: 560.2403.
7-hydroxy-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(4f) White solid; m.p. 121–123 ◦C; yield 54%; 1H NMR (600 MHz, CDCl3) δ (ppm): 9.98 (s, 1H), 7.68 (d,
J = 8.8 Hz, 1H), 7.49 (s, 1H), 7.01 (dd, J = 8.8, 2.4 Hz, 1H), 6.85 (d, J = 2.4 Hz, 1H), 6.16 (s, 1H), 5.68–5.59
(m, 2H), 5.20 (s, 1H), 4.71 (d, J = 3.5 Hz, 1H), 4.08–4.04 (m, 1H), 3.67–3.63 (m, 1H), 3.03–2.94 (m, 2H),
2.56–2.53 (m, 1H), 2.33 (td, J = 14.1, 4.0 Hz, 1H), 2.03–1.99 (m, 1H), 1.86–1.82 (m, 1H), 1.58–1.54 (m, 2H),
1.51–1.48 (m, 1H), 1.40 (s, 3H), 1.40–1.35 (m, 2H), 1.27–1.25 (m, 1H), 1.20–1.16 (m, 2H), 0.88 (d, J = 5.6
Hz, 3H), 0.68 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 161.02, 159.72, 155.05, 146.56,
145.44, 124.28, 121.23, 112.79, 111.51, 108.74, 103.16, 103.05, 100.88, 86.87, 79.91, 76.20, 75.99, 75.78, 65.75,
51.37, 50.15, 43.11, 36.37, 35.30, 33.45, 29.66, 25.24, 25.09, 23.62, 23.29, 19.29, 11.73; ESI-HRMS [M +
Na]+: (m/z) Calcd. for C29H35N3O8Na: 576.2322. Found: 576.2352.
5,7-dimethyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(4g) White solid; m.p. 135–137 ◦C; yield 52%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.41 (s, 1H), 7.06
(s, 1H), 6.94 (s, 1H), 5.84 (s, 2H), 5.54 (s, 1H), 5.28 (s, 1H), 4.80 (d, J = 3.4 Hz, 1H), 4.15–4.10 (m, 1H),
3.73–3.69 (m, 1H), 3.11–3.00 (m, 2H), 2.66 (s, 3H), 2.61–2.58 (m, 1H), 2.40 (s, 3H), 2.35 (td, J = 14.1, 4.0
Hz, 1H), 2.03–1.99 (m, 1H), 1.89–1.84 (m, 1H), 1.70–1.63 (m, 2H), 1.59–1.55 (m, 1H), 1.49–1.43 (m, 1H),
1.42 (s, 3H), 1.29–1.18 (m, 3H), 0.93 (d, J = 6.3 Hz, 3H), 0.87 (dd, J = 12.4, 4.6 Hz, 1H), 0.80 (d, J = 7.3 Hz,
3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.63, 154.30, 149.34, 145.42, 142.09, 133.98, 129.26, 121.15,
115.62, 113.33, 112.98, 103.07, 100.86, 86.87, 80.00, 76.21, 76.00, 75.79, 65.93, 52.03, 51.47, 43.25, 36.36,
35.37, 33.55, 29.76, 25.58, 25.15, 23.66, 23.32, 23.21, 20.24, 19.35, 11.98; ESI-HRMS [M + Na]+: (m/z)
Calcd. for C31H39N3O7Na: 588.2686. Found: 588.2680.
7-methyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one
(4h) White solid; m.p. 100–102 ◦C; yield 53%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.48 (d, J = 8.1 Hz,
1H), 7.40 (s, 1H), 7.18 (s, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.00 (s, 1H), 5.68–5.62 (m, 2H), 5.29 (d, J = 12.6 Hz,
1H), 4.76 (d, J = 3.5 Hz, 1H), 4.11–4.08 (m, 1H), 3.69–3.65 (m, 1H), 3.06–2.96 (m, 2H), 2.60–2.54 (m, 1H),
2.45 (s, 3H), 2.34 (td, J = 14.0, 4.0 Hz, 1H), 2.05–1.99 (m, 1H), 1.88–1.83 (m, 1H), 1.66–1.63 (m, 2H),
1.60–1.58 (m, 1H), 1.56–1.53 (m, 1H), 1.41 (s, 3H), 1.27–1.17 (m, 3H), 0.93 (d, J = 6.1 Hz, 3H), 0.89–0.84
(m, 1H), 0.74 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.98, 152.88, 146.91, 145.50,
143.18, 125.06, 122.27, 120.82, 116.69, 113.56, 113.35, 103.08, 100.86, 86.86, 79.97, 76.21, 76.00, 75.78, 65.94,
51.44, 49.21, 43.21, 36.36, 35.35, 33.54, 29.72, 25.55, 25.14, 23.65, 23.31, 20.69, 19.34, 11.86; ESI-HRMS [M
+ Na]+: (m/z) Calcd. for C30H37N3O7Na: 574.2529. Found: 574.2567.
6-methyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methyl)-2H-1-chromen-2-one (4i)
White solid; m.p. 100–102 ◦C; yield 43%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.40 (s, 1H), 7.40 (s, 1H),
7.38 (d, J = 1.9 Hz, 1H), 7.28 (d, J = 8.3 Hz, 1H), 6.00 (d, J = 1.2 Hz, 1H), 5.67 (s, 2H), 5.29 (s, 1H), 4.77
(d, J = 3.4 Hz, 1H), 4.13–4.09 (m, 1H), 3.71–3.67 (m, 1H), 3.05–2.99 (m, 2H), 2.61–2.56 (m, 1H), 2.41 (s,
3H), 2.36–2.32 (m, 1H), 2.03–2.00 (m, 1H), 1.88–1.84 (m, 1H), 1.66 (dd, J = 13.7, 3.5 Hz, 1H), 1.61 (d,
J = 4.2 Hz, 1H), 1.58–1.53 (m, 2H), 1.42 (s, 3H), 1.24–1.16 (m, 3H), 0.93 (d, J = 6.2 Hz, 3H), 0.88–0.85
(m, 1H), 0.75 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 158.88, 150.89, 146.89, 145.51,
133.70, 132.73, 122.29, 120.86, 116.31, 115.69, 114.22, 103.09, 100.87, 86.86, 79.98, 76.20, 75.99, 75.78, 65.94,
51.45, 49.06, 43.22, 36.37, 35.35, 33.54, 29.73, 25.57, 25.14, 23.65, 23.31, 20.03, 19.34, 11.86; ESI-HRMS [M
+ Na]+: (m/z) Calcd. for C30H37N3O7Na: 574.2529. Found: 574.2558.
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4.1.3. General Procedure for the Synthesis of Compounds 5j,5l–5o, and 6j–6p
Substituted coumarin (j–p) (10 mmol), substituted DHA (I or II) (10 mmol) and triethylamine
(10 mmol) were dissolved in 20 mL CH2Cl2. In addition, CuI (100 mg) was added and the reaction
mixture was stirred at room temperature for 8h under the protection of nitrogen. The mixture was
filtered, washed with water, dried over Na2SO4 and evaporated to dryness. The crude product was
purified through column chromatography.
4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-2-one (5j) White
solid; m.p. 91–93 ◦C; yield 51%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.79–7.75 (m, 2H), 7.55 (ddd,
J = 8.7, 7.3, 1.6 Hz, 1H), 7.33 (d, J = 8.3 Hz, 1H), 7.25–7.22 (m, 1H), 5.87 (s, 1H), 5.34 (d, J = 2.7 Hz, 2H),
5.16 (s, 1H), 4.77 (d, J = 3.6 Hz, 1H), 4.72–4.68 (m, 1H), 4.58–4.54 (m, 1H), 4.32–4.29 (m, 1H), 3.87–3.83
(m, 1H), 2.63–2.60 (m, 1H), 2.33 (td, J = 14.0, 4.0 Hz, 1H), 2.01–1.97 (m, 1H), 1.87–1.81 (m, 1H), 1.68–1.64
(m, 1H), 1.58–1.55 (m, 1H), 1.53–1.51 (m, 1H), 1.41 (s, 3H), 1.38 (d, J = 11.2 Hz, 1H), 1.26–1.18 (m, 3H),
0.91 (d, J = 5.9 Hz, 3H), 0.88–0.83 (m, 1H), 0.78 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm):
163.90, 161.51, 152.34, 140.45, 131.58, 122.86, 122.85, 122.04, 115.80, 114.40, 103.21, 101.15, 90.15, 86.86,
79.73, 76.20, 75.99, 75.78, 65.36, 61.67, 51.32, 49.57, 42.97, 36.35, 35.25, 33.41, 29.53, 25.06, 23.58, 23.32,
19.29, 11.80; ESI-HRMS [M + Na]+: (m/z) Calcd. for C29H35N3O8Na: 576.2322. Found: 576.2336.
5,7-dimethyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (5l) White solid; m.p. 111–113 ◦C; yield 49%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.74 (s, 1H),
6.98 (s, 1H), 6.83 (s, 1H), 5.75 (s, 1H), 5.28 (s, 2H), 5.14 (s, 1H), 4.76 (d, J = 3.6 Hz, 1H), 4.70–4.66 (m,
1H), 4.58–4.54 (m, 1H), 4.31–4.27 (m, 1H), 3.87–3.84 (m, 1H), 2.84 (s, 1H), 2.61–2.59 (m, 1H), 2.53 (s,
3H), 2.36 (s, 3H), 2.35–2.30 (m, 1H), 2.04–1.97 (m, 2H), 1.87–1.82 (m, 1H), 1.58–1.54 (m, 1H), 1.52–1.50
(m, 1H), 1.41 (s, 3H), 1.25–1.17 (m, 3H), 0.91 (d, J = 5.9 Hz, 3H), 0.88–0.85 (m, 1H), 0.76 (d, J = 7.4 Hz,
3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 166.97, 161.69, 153.91, 141.76, 140.42, 135.57, 127.92, 122.68,
114.43, 110.62, 103.21, 101.15, 89.15, 86.85, 79.74, 76.21, 76.00, 75.79, 65.38, 61.48, 51.33, 49.59, 42.97,
36.36, 35.25, 33.42, 29.53, 25.05, 23.58, 23.30, 22.49, 20.35, 19.30, 11.80; ESI-HRMS [M + Na]+: (m/z)
Calcd. for C31H39N3O8Na: 604.2635. Found: 604.2645.
6,8-dimethyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (5m) White solid; m.p. 111–113 ◦C; yield 49%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.77 (s, 1H),
7.39 (s, 1H), 7.22 (s, 1H), 5.83 (s, 1H), 5.32 (d, J = 2.5 Hz, 2H), 5.17 (s, 1H), 4.78 (d, J = 3.0 Hz, 1H),
4.72–4.68 (m, 1H), 4.59–4.55 (m, 1H), 4.33–4.29 (m, 1H), 3.87–3.83 (m, 1H), 2.64–2.58 (m, 1H), 2.41 (s,
3H), 2.37–2.33 (m, 1H), 2.33 (s, 3H), 2.02–1.98 (m, 1H), 1.88–1.82 (m, 1H), 1.68–1.63 (m, 1H), 1.58–1.53
(m, 1H), 1.53–1.48 (m, 1H), 1.41 (s, 3H), 1.41–1.38 (m, 1H), 1.28–1.16 (m, 3H), 0.91 (d, J = 5.9 Hz, 3H),
0.88–0.84 (m, 1H), 0.78 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 165.31, 162.94, 149.91,
141.55, 134.98, 133.03, 125.90, 123.94, 120.25, 114.82, 104.23, 102.18, 90.77, 87.87, 80.76, 77.24, 77.02, 76.81,
66.39, 62.54, 52.35, 50.58, 44.01, 37.37, 36.28, 34.44, 30.57, 26.07, 24.61, 24.35, 20.82, 20.31, 15.65, 12.84;
ESI-HRMS [M + Na]+: (m/z) Calcd. for C31H39N3O8Na: 604.2635. Found: 604.2639.
7,8-dimethyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (5n) White solid; m.p. 91–93 ◦C; yield 51%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.76 (s, 1H),
7.50 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 5.79 (s, 1H), 5.32 (d, J = 3.0 Hz, 2H), 5.15 (s, 1H), 4.77 (d,
J = 3.5 Hz, 1H), 4.71–4.67 (m, 1H), 4.58–4.53 (m, 1H), 4.33–4.27 (m, 1H), 3.86–3.82 (m, 1H), 2.63–2.58 (m,
1H), 2.37 (s, 3H), 2.36 (s, 3H), 2.34–2.30 (m, 1H), 2.01–1.97 (m, 1H), 1.86–1.81 (m, 1H), 1.68–1.62 (m,
1H), 1.58–1.53 (m, 1H), 1.51 (dd, J = 13.4, 3.5 Hz, 1H), 1.41 (s, 3H), 1.39–1.36 (m, 1H), 1.27–1.15 (m,
3H), 0.91 (d, J = 5.8 Hz, 3H), 0.88–0.82 (m, 1H), 0.77 (d, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ
(ppm): 165.56, 163.09, 151.58, 142.30, 141.69, 125.34, 124.53, 123.85, 119.71, 113.06, 104.24, 102.18, 89.91,
87.88, 80.78, 77.25, 77.04, 76.82, 66.39, 62.61, 52.37, 50.60, 44.02, 37.37, 36.29, 34.45, 30.58, 26.09, 24.61,
24.35, 20.46, 20.33, 12.85, 11.67; ESI-HRMS [M + Na]+: (m/z) Calcd. for C31H39N3O8Na: 604.2635.
Found: 604.2646.
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8-methyl-4-((4-(2-((10S)-dihydroartemisininoxy)ethyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen- 2-one
(5o) White solid; m.p. 84–86 ◦C; yield 43%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.77 (s, 1H), 7.61 (d,
J = 7.9 Hz, 1H), 7.39 (d, J = 7.4 Hz, 1H), 7.13 (t, J = 7.7 Hz, 1H), 5.85 (s, 1H), 5.33 (d, J = 2.8 Hz, 2H), 5.15
(s, 1H), 4.77 (d, J = 3.5 Hz, 1H), 4.71–4.67 (m, 1H), 4.58–4.54 (m, 1H), 4.33–4.27 (m, 1H), 3.86–3.82 (m,
1H), 2.62–2.59 (m, 1H), 2.45 (s, 3H), 2.33 (td, J = 14.1, 4.0 Hz, 1H), 2.01–1.97 (m, 1H), 1.86–1.81 (m, 1H),
1.65 (dd, J = 14.0, 3.6 Hz, 1H), 1.58–1.54 (m, 1H), 1.51 (dd, J = 13.4, 3.5 Hz, 1H), 1.41 (s, 3H), 1.40–1.35
(m, 1H), 1.27–1.17 (m, 3H), 0.90 (d, J = 5.8 Hz, 3H), 0.88–0.84 (m, 1H), 0.77 (d, J = 7.3 Hz, 3H); 13C NMR
(150 MHz, CDCl3) δ (ppm): 165.30, 162.70, 151.74, 141.60, 133.84, 126.28, 123.84, 123.42, 120.66, 115.15,
104.24, 102.18, 90.88, 87.89, 80.77, 77.25, 77.03, 76.82, 66.39, 62.71, 52.36, 50.60, 44.01, 37.38, 36.28, 34.45,
30.57, 26.09, 24.61, 24.35, 20.33, 15.76, 12.84; ESI-HRMS [M +Na]+: (m/z) Calcd. for C30H37N3O8Na:
590.2478. Found: 590.2477.
4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-2-one (6j)
White solid; m.p. 74–76 ◦C; yield 47%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.79 (dd, J = 8.0, 1.6 Hz,
1H), 7.72 (s, 1H), 7.55 (ddd, J = 8.7, 7.4, 1.6 Hz, 1H), 7.32 (dd, J = 8.4, 1.1 Hz, 1H), 7.26–7.23 (m, 1H), 5.86
(s, 1H), 5.41 (s, 1H), 5.34 (s, 2H), 4.79 (d, J = 3.6 Hz, 1H), 4.56–4.46 (m, 2H), 3.93–3.89 (m, 1H), 3.44–3.41
(m, 1H), 2.69–2.63 (m, 1H), 2.39–2.34 (m, 1H), 2.27–2.20 (m, 2H), 2.05–2.01 (m, 1H), 1.91–1.86 (m, 1H),
1.79–1.75 (m, 1H), 1.67–1.64 (m, 1H), 1.51–1.46 (m, 2H), 1.42 (s, 3H), 1.39–1.33 (m, 1H), 1.28–1.22 (m,
2H), 0.96 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 163.96,
161.59, 152.33, 140.41, 131.55, 122.89, 122.40, 122.13, 115.78, 114.42, 103.18, 101.19, 90.16, 86.93, 79.93,
76.21, 76.00, 75.79, 63.62, 61.66, 51.47, 46.73, 43.23, 36.45, 35.33, 33.53, 29.78, 29.43, 25.12, 23.64, 23.54,
19.33, 12.07; ESI-HRMS [M + Na]+: (m/z) Calcd. for C30H37N3O8Na: 590.2478. Found: 590.2463.
7-methyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-2-one
(6k) White solid; m.p. 80–82 ◦C; yield 51%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.71 (s, 1H), 7.65 (d,
J = 8.1 Hz, 1H), 7.12 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 5.80 (s, 1H), 5.41 (s, 1H), 5.32 (s, 2H), 4.79 (d, J = 3.6
Hz, 1H), 4.53–4.46 (m, 2H), 3.93–3.89 (m, 1H), 3.44–3.40 (m, 1H), 2.69–2.64 (m, 1H), 2.44 (s, 3H), 2.37
(td, J = 14.0, 4.0 Hz, 1H), 2.27–2.21 (m, 2H), 2.05–2.01 (m, 1H), 1.91–1.86 (m, 1H), 1.80–1.75 (m, 2H),
1.68–1.64 (m, 1H), 1.51–1.46 (m, 2H), 1.42 (s, 3H), 1.28–1.24 (m, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.94 (d, J
= 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): δ 164.21, 161.95, 152.44, 142.81, 140.51, 124.11,
122.39, 121.82, 115.88, 111.91, 103.19, 101.18, 89.25, 86.93, 79.94, 76.20, 75.99, 75.78, 63.62, 61.55, 51.47,
46.73, 43.24, 36.44, 35.33, 33.53, 29.78, 29.42, 25.12, 23.63, 23.53, 20.72, 19.33, 12.07; ESI-HRMS [M +
Na]+: (m/z) Calcd. for C31H39N3O8Na: 604.2635. Found: 604.2617.
5,7-dimethyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (6l) White solid; m.p. 86–88 ◦C; yield 42%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.68 (s, 1H),
6.98 (s, 1H), 6.83 (s, 1H), 5.74 (s, 1H), 5.40 (s, 1H), 5.28 (s, 2H), 4.78 (d, J = 3.7 Hz, 1H), 4.53–4.48 (m,
2H), 3.91–3.87 (m, 1H), 3.42–3.38 (m, 1H), 2.69–2.64 (m, 1H), 2.53 (s, 3H), 2.40–2.33 (m, 4H), 2.25–2.19
(m, 2H), 2.05–2.01 (m, 1H), 1.91–1.86 (m, 1H), 1.80–1.77 (m, 1H), 1.76–1.73 (m, 1H), 1.67–1.64 (m, 1H),
1.51–1.47 (m, 2H), 1.42 (s, 3H), 1.30–1.21 (m, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H); 13C
NMR (150 MHz, CDCl3) δ (ppm): 166.99, 161.73, 153.90, 141.72, 140.46, 135.57, 127.92, 122.26, 114.43,
110.63, 103.18, 101.15, 89.14, 86.91, 79.93, 76.21, 76.00, 75.78, 63.49, 61.58, 51.46, 46.66, 43.23, 36.46, 35.33,
33.53, 29.78, 29.42, 25.11, 23.64, 23.54, 22.46, 20.35, 19.33, 12.08; ESI-HRMS [M + Na]+: (m/z) Calcd. for
C32H41N3O8Na: 618.2791. Found: 618.2827.
6,8-dimethyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (6m) White solid; m.p. 90–92 ◦C; yield 55%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.71 (s, 1H),
7.40 (s, 1H), 7.21 (s, 1H), 5.82 (s, 1H), 5.41 (s, 1H), 5.32 (s, 2H), 4.79 (d, J = 3.6 Hz, 1H), 4.55–4.46 (m,
2H), 3.94–3.90 (m, 1H), 3.44–3.40 (m, 1H), 2.69–2.63 (m, 1H), 2.40 (s, 3H), 2.39–2.34 (m, 1H), 2.33 (s,
3H), 2.27–2.21 (m, 2H), 2.06–2.01 (m, 1H), 1.91–1.86 (m, 1H), 1.79–1.77 (m, 1H), 1.76–1.73 (m, 1H),
1.67–1.63 (m, 1H), 1.51–1.45 (m, 2H), 1.42 (s, 3H), 1.37–1.35 (m, 1H), 1.28–1.22 (m, 2H), 0.95 (d, J = 6.4
Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 165.37, 163.02, 149.90, 141.55,
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134.97, 133.07, 125.88, 123.45, 120.35, 114.83, 104.21, 102.21, 90.79, 87.96, 80.97, 77.25, 77.04, 76.83, 64.68,
62.56, 52.51, 47.77, 44.27, 37.47, 36.37, 34.56, 30.82, 30.47, 26.15, 24.67, 24.57, 20.83, 20.36, 15.66, 13.11;
ESI-HRMS [M + Na]+: (m/z) Calcd. for C32H41N3O8Na: 618.2791. Found: 618.2808.
7,8-dimethyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-
2-one (6n) White solid; m.p. 115–117 ◦C; yield 44%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.71 (s, 1H),
7.52 (d, J = 8.1 Hz, 1H), 7.04 (d, J = 8.1 Hz, 1H), 5.80 (s, 1H), 5.40 (s, 1H), 5.32 (s, 2H), 4.79 (d, J = 3.5
Hz, 1H), 4.56–4.45 (m, 2H), 3.93–3.89 (m, 1H), 3.44–3.40 (m, 1H), 2.69–2.64 (m, 1H), 2.39–2.34 (m, 7H),
2.27–2.19 (m, 2H), 2.06–2.01 (m, 1H), 1.92–1.86 (m, 1H), 1.81–1.77 (m, 1H), 1.74 (dd, J = 13.4, 3.5 Hz, 1H),
1.67–1.63 (m, 1H), 1.52–1.45 (m, 2H), 1.42 (s, 3H), 1.39–1.34 (m, 1H), 1.27–1.24 (m, 2H), 0.96 (d, J = 6.4
Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 165.61, 163.15, 151.58, 142.28,
141.66, 125.37, 124.51, 123.38, 119.78, 113.07, 104.21, 102.21, 89.92, 87.96, 80.97, 77.25, 77.04, 76.82, 64.66,
62.60, 52.51, 47.76, 44.27, 37.47, 36.37, 34.56, 30.82, 30.46, 26.15, 24.67, 24.57, 20.46, 20.37, 13.11, 11.67;
ESI-HRMS [M + Na]+: (m/z) Calcd. for C32H41N3O8Na: 618.2791. Found: 618.2793.
8-methyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-2-one
(6o) White solid; m.p. 143–145◦C; yield 38%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.71 (s, 1H), 7.63 (d,
J = 8.0 Hz, 1H), 7.39 (d, J = 7.3 Hz, 1H), 7.14 (t, J = 7.7 Hz, 1H), 5.85 (s, 1H), 5.40 (s, 1H), 5.33 (s, 2H),
4.79 (d, J = 3.7 Hz, 1H), 4.55–4.46 (m, 2H), 3.93–3.89 (m, 1H), 3.44–3.40 (m, 1H), 2.70–2.63 (m, 1H), 2.45
(s, 3H), 2.37 (td, J = 14.0, 3.9 Hz, 1H), 2.28–2.19 (m, 2H), 2.05–2.01 (m, 1H), 1.92–1.86 (m, 1H), 1.81–1.72
(m, 2H), 1.67–1.64 (m, 1H), 1.53–1.46 (m, 2H), 1.42 (s, 3H), 1.39–1.33 (m, 1H), 1.30–1.22 (m, 2H), 0.96 (d,
J = 6.4 Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 165.35, 162.77, 151.73,
141.56, 133.82, 126.25, 123.45, 123.40, 120.73, 115.17, 104.22, 102.21, 90.89, 87.96, 80.97, 77.24, 77.03, 76.82,
64.65, 62.69, 52.51, 47.76, 44.27, 37.48, 36.37, 34.56, 30.82, 30.46, 26.15, 24.67, 24.57, 20.37, 15.76, 13.11;
ESI-HRMS [M + Na]+: (m/z) Calcd. for C31H39N3O8Na: 604.2635. Found: 604.2646.
6-methyl-4-((4-(3-((10S)-dihydroartemisininoxy)propyl)-1H-1,2,3-triazol-1-yl)-methoxy)-2H-1-chromen-2-one
(6p) White solid; m.p. 80–82 ◦C; yield 45%; 1H NMR (600 MHz, CDCl3) δ (ppm): 7.72 (s, 1H), 7.56 (s,
1H), 7.35 (dd, J = 8.5, 2.0 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 5.84 (s, 1H), 5.41 (s, 1H), 5.33 (s, 2H), 4.80 (d,
J = 3.6 Hz, 1H), 4.55–4.47 (m, 2H), 3.94–3.90 (m, 1H), 3.45–3.41 (m, 1H), 2.70–2.64 (m, 1H), 2.40–2.33 (m,
4H), 2.27–2.21 (m, 2H), 2.06–2.01 (m, 1H), 1.91–1.87 (m, 1H), 1.80–1.73 (m, 2H), 1.65 (dd, J = 13.3, 3.4 Hz,
1H), 1.53–1.46 (m, 2H), 1.42 (s, 3H), 1.38–1.34 (m, 1H), 1.28–1.22 (m, 2H), 0.96 (d, J = 6.4 Hz, 3H), 0.94 (d,
J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm): 165.02, 162.88, 151.52, 141.46, 133.69, 133.59,
123.52, 122.80, 116.56, 115.08, 104.22, 102.22, 91.11, 87.97, 80.97, 77.24, 77.03, 76.82, 64.68, 62.60, 52.51,
47.80, 44.27, 37.48, 36.37, 34.57, 30.82, 30.48, 26.15, 24.67, 24.58, 20.90, 20.37, 13.12; ESI-HRMS [M +
Na]+: (m/z) Calcd. for C31H39N3O8Na: 604.2635. Found: 604.2621.
4.2. Biology
4.2.1. Storage and Preparation of Samples
All the target compounds were dissolved in dimethylsulfoxide and storage under −20 ◦C. They get
to be diluted to different concentration when they will be used.
4.2.2. Cell Culture
After recovery, the cells were cultured in 96-well plates for 24 h at 37 ◦C in a humidified atmosphere
with 95% air and 5% CO2. After treated with different tested compounds, the hypoxia groups were
placed in a sealed hypoxia incubator chamber (Stemcell Technologies, Inc., Vancouver, BC, Canada)
filled with 5% CO2 and 95% N2 for 24 h, and then transferred to the incubator chamber filled with air
for 72 h. On the contrary, the normoxia groups were cultured under air condition for 96h.
Cancer cells HT-29 (Human Colorectal Adenocarcinoma cell line), MDA-MB-231 (Human
Breast Cancer cell line), HCT-116 (Human Colorectal Carcinoma cell line), and A549 (Human Lung
Adenocarcinomic cell line) were from ATCC.
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4.2.3. MTT Assay
When the adherent cells reached 80% confluence, the culture medium was discarded. The cells
were digested by trypsin and collected after centrifugation. The fresh culture medium was gently blown
into it to form single-cell suspension. Cell suspension will be diluted to 1.5–3 × 104 cells/mL. Each hole
of 96-well plates was added 100 μL cell suspension and incubated for 24 h (5% CO2; 37 ◦C). Then the
holes were added different concentrations of tested compounds. The early screening concentration is
set to 100 μM, 50 μM, 25 μM, 12.5 μM, and 6.25 μM. Three replicates were made for each concentration
of the tested compounds. After the cells were grown for 96h, 20 μL MTT (5 mg/mL) was added
to each well and incubated for 4 h. The medium was discarded and each well was added 100 μL
DMSO to dissolve the formazan blue. Absorbance was measured at 570 nm with a microplate reader
(Synergy-HT, BioTek Instruments, Winooski, VT, USA).
Hypoxia condition: The cells were treated with different concentration of tested compounds,
placed in hypoxia chamber (Catalog Number 27310, Stemcell Technologies, Inc., Vancouver, BC,
Canada), and incubated for 24 h (5% air; 95% N2; 37 ◦C). Then the cells were placed in normoxia
condition (5% CO2; 37 ◦C) and incubated for 72 h.
4.2.4. Preparation of N9 Cells
The murine microglial cell line N9 was a kind gift from Dr. P. Ricciardi-Castagnoli (Universita
Degli Studi di Milano-Bicocca, Milan, Italy).
N9 cells, which were in the logarithmic phase, were incubated for 24 h by adherent culture.
Subsequently, the medium was changed to new one without serum. The cells were treated with
different concentration of tested compounds. After specific time in the LPS condition, the supernatants
were collected and analyzed.
4.2.5. Nitrite Measurement
The nitrite levels in medium were determined by Griess reaction. The absorbance was measured
at 540 nm using a microplate reader.
4.2.6. NO Capture Analysis
SNP was dissolved in PBS to prepare the 100 mM stock solution. In this experiment, SNP solution
of 25 μL was added to 975 μL PBS solution which included different concentration of tested compounds.
After 60 min under r.t. condition, the concentration of NO2− was tested using Griess assay.
4.2.7. Evaluation of Inflammatory Mediator
The secreted level of TNF-α and IL-6 was measured using mouse Th1/Th2/Th17 Cytokine Kit,
purchased from BD Pharningen. The data was analyzed by FCAP Array v3.0. IL-2, IL-4, IL-10, IL-17A,
and IFN-γ were not detected in the experiment.
4.2.8. Molecular Docking Simulations
The crystallographic structure of TLR4/MD-2 complex was retrieved from the Protein DataBank
(PDB ID: 3VQ2), which was optimized by removing water molecules, cofactors and heteroatoms.
Receptor grid was generally around the MD-2 active site. Docking calculations were accomplished
using AutoDock4. The docking results were further analyzed and visually optimized by Discovery
Studio 4.0 and PyMOL.
Supplementary Materials: The H and 13 C NMR spectra of synthesized compounds are available online.
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Abstract: Breast cancer is considered the most common and deadly cancer among women worldwide.
Nanomedicine has become extremely attractive in the field of cancer treatment. Due to the high
surface to volume ratio and other unique properties, nanomaterials can be specifically targeted to
certain cells and tissues to interact with the living systems. The strategic planning of this study is
based on using the nanoprecipitation method to prepare nanoparticles BZP-NPs (3.8–5.7 nm) of the
previously prepared benzofuran–pyrazole compound (IV) BZP which showed promising cytotoxic
activity. The capacity of BZP and BZP-NPs to suppress the growth of human breast tumor MCF-7 and
MDA-MB-231 cells was evaluated using MTT assay. The IC50 doses of BZP and BZP-NPs targeting
normal breast cells MCF-12A exceeded those targeting the cancer cells by >1000-fold, demonstrating
their reasonable safety profiles in normal cells. Furthermore, cell cycle analysis, apoptosis induction
detection, assessment of p53, Bcl-2, caspase-3, and PARP-1 levels of BZP and its nano-sized-BZP-NPs
particles were also evaluated. Although the obtained results were in the favor of compound IV in its
normal-sized particles, BZP-NPs appeared as a hit compound which showed improved cytotoxicity
against the tested human breast cancer cells associated with the induction of pre-G1 apoptosis as
well as cell cycle arrest at G2/M phase. The increase in caspase-3 level, upregulation of p53, and
downregulation of Bcl-2 protein expression levels confirmed apoptosis. Furthermore, ELISA results
exhibited that BZP-NPs produced a more favorable impact as a PARP-1 enzyme inhibitor than the
parent BZP.
Keywords: breast cancer; benzofuran–pyrazole; nanoparticles; cytotoxic activity; apoptosis;
PARP-1 inhibition
1. Introduction
Breast cancer is the most common malignancy in women, accounting for about 18% of female
cancers and over half a million new cases are diagnosed worldwide each year. Its incidence increases
with age and is currently rising. Although earlier diagnosis has improved the survival rates, saving
lives and elevating treatment rates, metastatic breast cancer is still considered as the major factor
of breast cancer-related mortality [1–4]. Despite the continuous development in the treatment of
cancer disease, the strategy for cancer management has remained essentially unchanged: surgical
resection of the malignant tumor followed by either chemotherapeutic administration, radiotherapy, or
Molecules 2019, 24, 2413; doi:10.3390/molecules24132413 www.mdpi.com/journal/molecules479
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a combination of the two. In fact, both of these therapies cause unselective and undesirable damage to
the healthy tissues. In addition, a number of factors can lead to treatment failure, such as the remaining
of some residual cells after the surgery, resistance to chemotherapies, physiological obstacles against
the treatments, such as the blood–brain barrier and cellular barriers which hamper the access to drug
targets, debilitating systemic toxicities, and poor pharmacokinetics of the chemotherapeutic [5–7].
Nanomedicine is defined as the use of nanotechnology for different medical purposes.
Nanotechnology deals with research of materials of dimensions ranges between 1 to 100 nm (National
Nanotechnology Initiative). This active protocol is applied in various science applications including
cancer chemotherapeutics [8]. Deep studies have shed light on the combination of nanotechnology
with cancer biology advances to gain novel techniques for cancer care. The concept that the strategy of
nanomedicines is based on improving the therapeutic index of anticancer drugs by optimizing their
pharmacokinetics and tissue distribution to facilitate and fasten delivery to the site of action is well
known and has been investigated clinically [9–11]. Smaller (sub-100 nm) nanomedicine systems and
lower molecular weight macromolecules have been shown to extravasate to a greater extent and/or
penetrate farther from the vasculature than larger systems. This size effect has also been associated
with improved efficacy [11,12]. Because of their sizes, the chemical properties and biodistribution of
the nanomaterials are different from bulky materials. Thus, in recent years, nanomedicine has been
considered as one of the most promising and important tools to defeat the problems obtained due to the
administration of the traditional antitumor drugs. In addition, nanoparticle formulations can reduce
or prevent systemic toxicities by specific delivery of the drugs to the cancer cells via size-mediated
passive targeting and physiologically mediated active targeting. They can overcome drug resistance
by the delivery of complimentary treatments and they can improve early detection of the disease using
targeted delivery of molecular imaging agents to tumors in order to improve the diagnostic imaging of
the tumor tissues, thus beginning the treatment before the onset of metastasis [13,14].
Inspired by the literature studies mentioned above and in continuation with our previous
efforts in developing new effective agents of significant anticancer activity [15–17], this study deals
with generating the previously prepared 1-(5-(3-(benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-4,5-
dihydro-3-(1H-pyrrol-2-yl)pyrazol-1-yl)ethanone (IV) BZP in nanoparticles BZP-NPs of sizes
3.8–5.7 nm (Figure 1).
 
Figure 1. The chemical structure of the benzofuran-pyrazole compound IV (BZP).
In our previous research, compound IV (BZP) was subjected, among other eight different
benzofuran-pyrazole derivatives, to NCI for in vitro anticancer evaluation targeting full 60 human
cancer cell lines using a single high dose concentration (10−5 M) under the drug discovery program
of the NCI [15]. The derivatives were chosen depending upon the degree of structural variations
and computer modeling techniques in NCI. Fortunately, compound IV (BZP) exhibited promising
cytotoxic potency against various cancer cell lines, so it was further evaluated by NCI team at five
different minimal concentrations (0.01, 0.1, 1, 10, and 100 μM). It displayed cell growth inhibition of
different breast cancer lines in the range of 45.95–55.44%. These data motivated the authors to convert
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compound IV (BZP) to nano-sized BZP-NPs to study the influence of the nanorange and whether
nano-sized particles enhance the cytotoxic potency of the benzofuran compound.
The anticancer activity of BZP compound IV was assessed in comparison with its nano-sized
BZP-NPs against MCF-7 and MDA-MB-231cancer cell lines. Various cellular mechanisms of action
were also studied, such as apoptosis, cell cycle analysis, detection of caspase-3, p53, and Bcl-2 intensities,
in addition to the efficiency of PARP-1 enzyme inhibition in the two types of the tested breast cancer
cell lines
2. Results and Discussion
2.1. Chemistry
The preparation approach of the benzofuran–pyrazole derivative IV was outlined in Scheme 1
according to the reported method [15]. Using the Vilsmeier–Haach reaction, the key starting
1-(benzofuran-2-yl)ethanone (I) was converted to the intermediate pyrazole-4-carbaldehyde (II).
The chalcone analogue III was obtained in a good yield by Claisen–Schmidt condensation of II with
2-acetylpyrrole in ethanolic sodium hydroxide solution. Cyclocondensation of III with hydrazine
hydrate in acetic acid yielded the target compound IV in 85% yield (Scheme 1).
Scheme 1. Synthetic route of the benzofuran–pyrazole derivative (IV).
The nano-sized benzofuran–pyrazole BZP-NPs of different sizes (3.8–5.7 nm) were synthesized
using the nanoprecipitation method [18]. The sizes and morphology of the nanobenzofuran–pyrazole
hybrid BZP-NPs were examined by dynamic light scattering (DLS) and transmission electron
microscopy (TEM). The results showed that nanoparticles were spherical in shape and their average size
was 3.8–5.7 nm (Figure 2). The stability of the BZP-NPs was further investigated by X-ray diffraction
(XRD) using a Pananalylical Empyrean X-ray Diffractometer and thermal analysis using a SDT Q600
V20.9 Build 20 thermal gravimetric instrument (Figures S1 and S2, Supplementary material).
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Benzofuran–pyrazole IV (BZP) 
 
Benzofuran–pyrazole IV (BZP-NPs) 
Figure 2. Electron micrograph of the BZP and BZP-NPs. The bar marker represents 50 nm.
Surface charge and stability of the nanoparticles were analyzed using the Malvern Zetasizer nano
Zs instrument (MAL1074157) and the zeta potential was −27.3 mV with a polydispersity index (PDI)
of 0.77 (Figure 3).
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Figure 3. Zeta potential distribution of BZP-NPs.
2.2. Biological Analysis
2.2.1. In Vitro Anticancer Activity
The sensitivity of two human breast cancer cell lines, MCF-7 and MDA-MB-231, was evaluated
against the benzofuran–pyrazole compound BZP and the target nano-sized benzofuran–pyrazole
nanoparticles BZP-NPs using MTT assay. Doxorubicin served as a standard drug [17]. The resultant
data were expressed as IC50 (nM) values which are the average of at least three independent experiments
and are tabulated in Table 1. The obtained results showed that compound IV (BZP) produced significant
cytotoxic activity against both breast cancer cell lines, with about 85- and 62-fold, respectively, greater
potency than that of doxorubicin. Dramatic increase in the activity was observed by about 620
and 1000-fold for targeting both types of cancer cells by BZP-NPs compared to the reference drug
doxorubicin. It could be detected that MDA-MB-231 cancer cells represented significant sensitivity
against the nano-sized particles BZP-NPs more than their sensitivity against BZP.




Compound IV (BZP) 7 ± 1 10 ± 1 87600 ± 335
Compound IV (BZP-NPs) 1 ± 0.4 0.6 ± 0.1 21540 ± 66
Doxorubicin 620 ± 31 620 ± 31
Despite the obvious benefits of chemotherapeutic drugs, there are several treatment-related
damages to the normal cells that should be considered before finalizing the cancer treatment strategy.
This study investigated the impact of compound IV (BZP) and BZP-NPs on normal breast cells
(MRC-12A) using MTT assay [16]. Interestingly, a significant increase in the IC50 doses of IV BZP
and BZP-NPs against the normal breast cells was detected when compared to their IC50 doses against
both cancer cell lines (>1000-fold) (Table 1). This result confirmed the significant safety profile
of the benzofuran-pyrazole compound IV either in the normal size particles or in its nano-sized
particles BZP-NPs.
2.2.2. Cell Cycle Analysis
Due to the antiproliferative efficacy of compound IV (BZP) and BZP-NPs, it was of interest
to study its modes of action in both tested types of cancer cells, including cell cycle progression
and apoptosis induction. Cell death occurs via different pathways, including apoptosis or type I
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cell-death, and autophagy or type II cell-death, which are both forms of programmed cell death,
whereas necrosis is a nonphysiological process resulting from an infection or injury [19,20]. Apoptosis
rate in MCF-7 and MDA-MB-231 cells was detected by flow cytometry, using propidium iodide (PI) and
an annexin-V–FITC double staining assay [21]. After incubation of both types of the tested cancer cells
for 24 h with BZP and BZP-NPs at their IC50 concentrations of 7 nM and 1 nM for MCF-7 cells and at
10 nM and 0.6 nM for MDA-MB-231 cells, they were labeled with the two dyes. The corresponding red
(PI) and green (FITC) fluorescence was detected using flow cytometry and the results were compared
to DMSO-treated cells which served as a negative control. Marked alterations in cell cycle phases
have occurred. There was a great enhancement in the percentage of apoptotic cells at the pre-G phase.
The tested particles (BZP) and (BZP-NPs) induced total apoptotic cells (annexin V+/PI− and annexin
V+/PI+) of percentages 9.18%, 21.54%, respectively, in MCF-7 cells vs. 2.64% in the control MCF-7 cells.
They also induced total apoptotic percentages of 11.09% and 23.17%, respectively, in MDA-MB-231
cells vs. 2.82% in the control MDA-MB-231cells. It is observable that the BZP-NPs produced a more
favorable impact about two-fold more potent than BZP particles against both types of the tested
cancer cells, especially MDA-MB-231 cells, which was consistent with the cytotoxicity assay results
(Figures 4 and 5). Also, exposure of MCF-7 and MDA-MB-231 cells to BZP and BZP-NPs led to an
interference with the cell cycle distribution, inducing a pronounced elevation in the percentage of cells
at the G2/M phase, reaching 11.26% and 17.52%, respectively, in MCF-7 vs. 6.28% in the control cells
and to 12.11% and 19.24% in MDA-MB-231 cells, respectively, vs. 4.92% in the negative control (Table 2).
Accordingly, it can be concluded that the compound IV (BZP) inhibits the cancer cells’ proliferation
with a synchronous significant arrest at the G2/M phase. The inhibition potency was signified by the
BZP-NPs (Figures 6 and 7). Accumulation of cells at G2/M phase is a remarkable hallmark of the
apoptotic role of BZP and BZP-NPs in both tested cancer cell lines.
Figure 4. Representative dot plots of MCF-7 and MDA-MB-231 cells treated with compound IV (BZP)
and BZP-NPs at their IC50 (μM) for 24 h, analyzed by flow cytometry after double staining of the cells
with annexin-V FITC and PI.
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Figure 5. Percentage of compound IV (BZP) and BZP-NPs in MCF-7 and MDA-MB-231 cancer cells.
 
(A): The effect of compound IV (BZP) on MCF-7 cancer cells 
 
(B): The effect of compound IV (BZP-NPs) on MCF-7 cancer cells 
Figure 6. Cont.
485
Molecules 2019, 24, 2413
 
(C): The effect of compound IV (BZP) on MDA-MB-231cancer cells 
 
(D): The effect of compound IV (BZP-NPs) on MDA-MB-231cancer cells 
 
(E): The negative control of MCF-7 cancer cells 
Figure 6. Cont.
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(F): The negative control of MDA-MB-231 cancer cells 
Figure 6. Flow cytometric analysis of compound IV (BZP) and BZP-NPs on MCF-7 and MDA-MB-231
cells. The orange color represents G1 phase percentage and red color represents G2/M phase percentage.
Figure 7. Cycle analysis of compound IV (BZP) and BZP-NPs in MCF-7 and MDA-MB-231 cancer cells.
Table 2. Determination of cell cycle inhibition of MCF-7 and MDA-MB-231 cancer cells by BZP and
BZP-NPs.
Compound Name Conc. (nM) %G0-G1 %S %G2-M %Pre-G1 Comment
BZP/MCF-7 7 64.52 24.22 11.26 9.18 PreG1apoptosis&Cellgrowth arrest@ G2/M
BZP-NPs/MCF-7 1 59.47 23.01 17.52 21.54 PreG1apoptosis&Cellgrowth arrest@ G2/M
BZP/MDA-MB-231 10 62.59 25.3 12.11 11.09 PreG1apoptosis&Cellgrowth arrest@ G2/M
BZP-NPs/MDA-MB-231 0.6 57.36 23.4 19.24 23.17 PreG1apoptosis&Cellgrowth arrest@ G2/M
MCF-7 69.55 24.17 6.28 2.64
MDA-MB-231 67.56 27.52 4.92 2.82
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2.2.3. Effect Compound IV (BZP) and BZP-NPs on the Levels of Caspase-3/p53/Bax/Bcl-2
Caspases are cysteine protease enzymes in humans. Their presence is critical in starting the phase
of programmed cell death (apoptosis). Some caspases initiate the intracellular cascade, whereas others
(effector caspases) produce their activities downstream by controlling the cellular break via splitting of
the structural proteins [19–21]. Caspase-3 displays an important role in the apoptotic process which
includes cell shrinkage, chromatin condensation, and DNA fragmentation [22,23]. Enzyme Linked
Immuno-Sorbent Assay (ELISA) was used to analyze the apoptotic events of both types of the tested
breast cancer cells [16]. Table 3 shows that 24 h treatment of MCF-7 with compound IV (BZP) and
BZP-NPs at concentrations of 7 nM and 1 nM and MDA-MB-231 cells at concentrations of 10 nM
and 0.6 nM led to significant overexpression of caspase-3 compared to the doxorubicin-treated cells.
BZP elevated the level of caspase-3 by six and five-fold compared to the untreated cells. A detectable
enhancement in the level of caspase-3 occurred upon treatment of the tested cells with BZP-NPs by 14
and 17-fold compared to the untreated MCF-7 and MDA-MB-231 cells (Table 3).
Table 3. Determination of caspase-3, p53, Bax, and Bcl-2 levels in the tested cancer cells.
Results (Fold Change)
Compound Name Caspase-3 p53 Bax Bcl-2
BZP/MCF-7 6.383836 7.453852 5.745321 0.272695
BZP-NPs/MCF-7 14.56524 12.51432 9.149760 0.131011
BZP/MDA-MB-231 5.399087 7.792609 7.553853 0.181989
BZP-NPs/MDA-MB-231 17.915 14.60536 13.19230 0.134738
MCF-7 1 1 1 1
MDA-MB-231 1 1 1 1
The tumor suppressor protein p53 serves as a transcription factor. It induces the expression of
several downstream targets which are very important in regulation of the cell cycle, apoptosis, and
DNA repair, among other mechanisms [24,25]. Cellular stress leads to the activation of the p53 pathway,
compromising tumor development and preventing the proliferation of the damaged cells of oncogenic
potential. p53 is considered as one of the most relevant tumor suppressor genes [26]. In addition,
the B-cell lymphoma protein 2 (Bcl-2) plays a key role in tumor progression via inhibition of the intrinsic
apoptotic pathway triggered by mitochondrial dysfunction. Cancer cells can resist apoptosis by
modulating the expression of Bcl-2 family proteins which in turn regulate the mitochondrial apoptotic
pathway via production Bcl-2 or downregulating pro-apoptotic proteins, such as Bax [26]. Accordingly,
in this study, the impact of IV (BZP) and BZP-NPs was assessed on the intrinsic apoptotic pathway
via measuring the levels of p53, Bax, and Bcl-2 after treatment of MCF-7 and MDA-MB-231 cells with
BZP and BZP-NPs at their IC50 concentrations for 24 h. In comparison to the untreated control, p53
level increased seven-fold in both types of the tested cancer cells upon BZP treatment, while the level
was doubled to 14-fold by the BZP-NPs. On the other hand, BZP and BZP-NPs elevated the level of
the proapoptotic protein Bax by 5.7–13.1-fold with concurrent reduction in the expression levels of the
antiapoptotic protein Bcl-2 by four to seven-fold in both tested cancer cell lines in comparison with the
untreated control (Table 3).
2.2.4. PARP-1 Cleavage Assay
Breast cancer is among the targets of a new class of drugs known as Poly (ADP-ribose) polymerase-1
(PARP-1) inhibitors. PARP-1 is a nuclear enzyme plays a role in the repair of single-stranded DNA
(ss DNA) breaks [26]. The rationale for the therapeutic benefit for the pharmacological inhibition of
PARP-1 in breast cancer comes from the following points: (a) sensitization of tumor cells to anticancer
therapies such as radiation and cytotoxic agents [27]; (b) certain polymorphisms in PARP-1 can lead
to breast cancer and negatively affect the efficacy of the hormone therapies; and (c) breast tumors
with deficiencies in DNA-repair genes such as BRCA-1 or BRCA-2 represent acute sensitivity in
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response to the inhibition of PARP-1. Interestingly, clinical evidence investigates that the usage of
PARP-1-inhibiting candidates are not limited to BRCA-1 or BRCA-2 mutated cancers, but they also
target non-BRCA mutated breast and ovarian cancers and produce a valuable impact in combination
therapy [28,29]. Thus, it was of interest to study the inhibitory effects of BZP and BZP-NPs against
PARP-1 enzyme in MCF-7 and MDA-MB-231 cancer cells using staurosporine as a standard drug.
The resulting data were expressed as IC50 (nM) values and are summarized in (Table 4). It should be
noted that BZP produced a slightly weaker inhibitory effect against PARP-than the reference drug,
with an IC50 of 40 nM vs. 10 nM for staurosporine in MCF-7 cells. A dramatic decrease, about 13-fold,
in the sensitivity was noticed in the case of MDA-MB-231 cancer cells against BZP which produced an
IC50 of 60 nM vs. 8 nM for staurosporine. On the other hand, an interesting increase in the inhibitory
potency was observed for the BZP-NPs, exhibiting an IC50 value of 10 nM, which is equal to that
obtained by the standard drug in MCF-7 cells. The suppression activity was intensified against PARP-1
in MDA-MB-231 cells, producing an IC50 of 6 nM vs. 8 nM for staurosporine.




BZP 40 ± 1 60 ±1
BZP-NPs 10 ± 4 6 ± 3
Staurosporine 10 ± 1 8 ± 1
3. Experimental
3.1. Synthesis of 1-(5-(3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-3-(1H-pyrrol-2-yl)
pyrazol-1-yl)ethanone (IV).
Compound IV was synthesized according to the previously reported procedure [15].
3.2. Preparation of Nanobenzofuran–Pyrazole BZP-NPs
The nanoparticles were prepared by the nanoprecipitation method [18]. The sizes and morphology
of the nanoparticles BZP-NPs were examined by transmission electron microscopy (TEM) (H-7600;
Hitachi Ltd., Tokyo, Japan). The results exhibited that the nanoparticles were spherical in shape and
their average size was 3.8–5.7 nm (Figure 2).
3.3. Physicochemical Characterization of the Nanobenzofuran–Pyrazole Compound BZP-NPs
3.3.1. Particle Size and Zeta Potential Using Photon Correlation Spectroscopy
Particle size was measured by dynamic light scattering (DLS) using a Zetasizer NANO-ZS
(Ver. 7.04, Serial Number: MAL 1074157, Malvern Instruments Ltd., London, United Kingdom) at
a wavelength of 633 nm with a 4.0 mW light source for collecting data at a fixed scattering angle
of 173◦. The electrophoretic mobility (zeta potential) measurements were made using a Zetasizer
NANO-ZS (Ver. 7.04, Serial Number: MAL 1074157, Malvern Instruments Ltd., United Kingdom)
at 25 ◦C. BZP-NPs morphology was determined using JEOL Transmission Electron Microscope
(JEM-1230, Tokyo, Japan) with 500,000 ×magnification power, 100 kV acceleration voltage, and 0.5 nm
resolving power.
3.3.2. In Vitro Anticancer Activity
In vitro evaluation of the anticancer activity of the BZP compound and BZP-NPs targeting
MCF-7 and MDA-MB-231 cells was performed using MTT assay according to a previously reported
method [19]. Each experiment was performed at least three times.
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3.4. Cell Cycle Analysis and Apoptosis Detection
Cell cycle analysis and apoptosis detection was carried out by flow cytometry (Beckman Coulter,
Brea, CA, USA) [19–21]. Apoptosis detection was performed using a FITC Annexin-V/PI commercial
kit (Becton Dickenson, Franklin Lakes, NJ, USA) following the manufacturer’s protocol.
3.5. Caspases-3 Assays
Caspase-3 activity was measured using a Caspase-3 (Active) (human) ELISA kit, Catalog #
KHO1091 (96 tests) (Invitrogen Corporation, Carlsbad, CA, USA) according to the manufacturer’s
instructions [16].
3.6. In Vitro Determination of p53, Bax, and Bcl-2 Levels
The levels of p53, Bax, and Bcl-2 markers were assessed using a BIORAD iScript TM One-Step
RT-PCR kit with SYBR® Green according to the manufacturer’s instructions [26,30].
3.7. In Vitro PARP-1 Assay
The procedure was done according to the supplied protocol of ab119690 Cleaved PARP Human
ELISA (Enzyme-Linked Immunosorbent Assay) kit for the quantitative measurement of the 89 kDa
fragment of Human PARP-1 in cell and tissue lysates [31].
4. Conclusions
This study demonstrates that the conversion of the benzofuran-pyrazole compound IV (BZP) to
nanoparticles BZP-NPs greatly intensified its cytotoxic activity against two breast cancer cell lines,
MCF-7 and MDA-MB-231, with respective IC50 values of 7 nM, 10 nM vs. nanoparticle IC50 values
of 1 nM, 0.6 nM. The IC50 value of DOX was 620 nM. Furthermore, the IC50 doses of BZP and
BZP-NPs against normal breast cells were >1000-fold greater than those against cancer cells, suggesting
acceptable safety profiles in normal cells. The resultant data of cell cycle and apoptosis determination
revealed that the tested derivative in both forms induced G2/M phase arrest, accompanied by an
increase in apoptosis in the tested cancer cells. Further modes of action of the target compound were
also predicted in both types of breast cancer cells. The biological results revealed that BZP significantly
increased p53, caspase-3, and Bax levels and decreased Bcl-2 levels, and their levels were intensified
upon treating the tested cancer cells with (BZP-NPs). The PARP1 enzyme assay showed that the
efficiency of PARP-1 inhibition by (BZP) was slightly less than that of staurosporine, while BZP-NPs
inhibited the enzyme efficiently as staurosporine in MCF-7 or to a greater extent in case of MDA-MB-231
cancer cells. It has been detected that the nanoparticles were more effective as an anticancer agent
against MDA-MB-231 cells than against MCF-7 cancer cells.
Supplementary Materials: The following are available online, Figure S1: Diffraction (XRD) of BZP-NPs, Figure S2:
Analysis of BZP-NPs.
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Abstract: The results of our previous research indicated that some derivatives of benzofurans,
particularly halogeno-derivatives, are selectively toxic towards human leukemia cells. Continuing
our work with this group of compounds we here report new data on the synthesis as well as regarding
the physico-chemical and biological characterization of fourteen new derivatives of benzofurans,
including six brominated compounds. The structures of all new compounds were established by
spectroscopic methods (1H- and, 13C-NMR, ESI MS), and elemental analyses. Their cytotoxicity
was evaluated against K562 (leukemia), MOLT-4 (leukemia), HeLa (cervix carcinoma), and normal
cells (HUVEC). Five compounds (1c, 1e, 2d, 3a, 3d) showed significant cytotoxic activity against all
tested cell lines and selectivity for cancer cell lines. The SAR analysis (structure-activity relationship
analysis) indicated that the presence of bromine introduced to a methyl or acetyl group that was
attached to the benzofuran system increased their cytotoxicity both in normal and cancer cells.
Keywords: benzofurans; chemical synthesis; cytotoxic properties; HeLa; MOLT-4; K562
1. Introduction
Benzofuran skeleton holds an important position in organic chemistry and it is considered
to be one of the most important heterocyclic systems because of its diverse profile of biological
activity. This structural unit is a central part of a variety of biologically active compounds. Natural
and synthetic benzofuran derivatives have been reported to possess wide therapeutic properties,
including antiviral, immunosuppressive, antioxidant, antifungal, anti-inflammatory, antimicrobial,
analgesic, antihyperglycemic, and antitumor activities [1–6]. Cicerfuran, Conocarpan, and Ailanthoidol
are the best known biologically active natural benzofurans (Figure 1). Specifically, the Cicerfuran
shows antifungal activity, Conocarpan has been reported as an antifungal and antitrypanosomal
agent, and Ailanthoidol exhibits anticancer, antiviral, immunosuppressive, antioxidant, and antifungal
activity [1,2,7]. The synthetic benzofuran derivatives are represented by Amiodarone (Figure 1), being
used in the treatment of ventricular and supraventricular arrhythmias, and by Bufuralol, which is a
non-specific β-adrenergic blocker with an affinity for β1 and β2-adrenergic receptors [3,4,7].
Nowadays, when cancer, after cardiovascular diseases, is the second most common cause of
death and still constitutes an unresolved problem of clinical medicine and pharmacology, extensive
research regarding new anticancer compounds is especially important. These new drugs should
possess improved pharmacokinetics and specifically destroy cancer cells, without causing negative
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side effects. Research in the group of benzofuran derivatives is justified, especially by the fact that one
can find many examples of data in the literature on benzofurans with anticancer activity. In many
cases, the benzofuran skeleton is fused with other heterocyclic or aromatic moieties (Figure 2).
 
Figure 1. Structures of natural and synthetic benzofuran derivatives with biological activity.
 
Figure 2. Structures of synthetic benofuran derivatives I–V with anticancer activity [7].
494
Molecules 2019, 24, 1529
There are several benzofuranyl imidazole derivatives among them (I and II), which were found
to be cytotoxic towards an ovarian carcinoma cell line (Skov-3). The study of N-(5-(2-bromobenzyl)
thiazole-2-yl) benzofuran-2-carboxamide (III) showed that this compound inhibited the growth of HCC
(human hepatocellular carcinoma) cells and induced their apoptosis. The synthetic derivative IV was
found to have antitumor activity and it was an effective chemopreventive and chemotherapeutic agent
against malignant T cells. Moreover, a series of triazole derivatives V showed moderate antitumor
activity. Recent data reported this type of benzofuran derivatives as potential therapeutic agents for
breast cancer [7].
These are only a few examples from a large group of benzofurans with anticancer activity. Moreover,
examples of compounds with cytotoxic activity were found among the simple derivatives of benzofuran
like 2- and 3-benzofuranocarboxylic acid derivatives VI–VII (Figure 3). The above-mentioned
compounds exhibit significant cytotoxic activity against human cancer cell lines [8].
 
Figure 3. Structures of 2- and 3-benzofurancarboxylic acid derivatives VI–VII with cytotoxic activity.
The literature survey shows that benzofurans containing halogens in their structure constitute an
important group of compounds, with antitumor, cytotoxic, spasmolytic, antiarrhythmic, and antifungal
activity [9–20]. Thus, this group of compounds is interesting for researchers, especially because the
presence of halogen can increase the activity and selectivity of derivatives. This is probably related
to the ability of halogens to create a “halogen bond”, which results from the formation of the σ-hole.
Although the halogen bonds are weaker than hydrogen bonds, they have specific effects and can lead
to significant gains in binding affinity. These interactions can be found in protein-receptor complexes
as well as in small molecules [21–24].
Furthermore, we have identified three bromo derivatives VIII–X (Figure 4) that showed selective
toxicity towards human leukemia cells in our previous studies [25,26]. Compound VIII is especially
cytotoxic towards K562 and HL-60 leukemic cell lines (IC50 5.0 and 0.1 μM, respectively), however
it is not toxic towards HeLa cancer cells and healthy endothelial cells (HUVEC) (IC50 > 1 mM).
Moreover, the observed remarkable cytotoxicity of VIII towards K562 cells resulted from cells
apoptosis. Compounds IX and X proved to be highly toxic towards cancer cells (IC50 in a few μM
range) and non-toxic towards endothelial cells (HUVEC) [25–27]. Unfortunately, these compounds are
poorly soluble in water, which limits their use in the cell culture or animal studies.
Figure 4. Structures of the benzofuran derivatives VIII–X, lead compounds used in the present studies.
Using VIII–X as the lead compounds, we designed and synthesized fourteen new derivatives
with hopes for their better solubility in aqueous solutions (of lower lipophilicity when compared
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to VIII–X). The biological activity (i.e., cytotoxicity, activation of apoptosis, interaction with DNA) of
these new derivatives was also evaluated.
2. Results
2.1. Synthesis
Our goal was to obtain a small library of new, less lipophilic derivatives/analogs of lead compounds
VIII–X. We designed the synthesis of a set of compounds containing a carboxyl (1), formamide (1a),
and methoxycarbonyl groups (1b), instead of an acetyl group in the position 2 of the parent benzofuran
ring to obtain new benzofuran VIII analogs.
Thus, the starting acid 1, which was obtained by the multistep synthesis according to the
previously reported procedures [28] was submitted either to oxalyl chloride and ammonium solution
treatment or methylated with dimethyl sulphate, delivering the amide derivative 1a and methyl ester
1b, respectively (Scheme 1). In the next step, compounds 1 and 1b were submitted to bromination.
For this purpose, ester 1b was reacted with molecular bromine in chloroform. Under these conditions,
hydrogen in the methyl group at position 3 was substituted by a bromine atom to give compound
1c, which only differed by the substituent in position 2 (methoxycarbonyl versus acetyl). During
bromination of the acid 1 using bromine in chloroform or NBS in CCl4, a mixture of products was
obtained, which was difficult to separate. Thus, the reaction conditions were changed and ethanol,
instead of CCl4, was used as a solvent in bromination reaction that was carried out in the presence
of the NBS, while acetic acid was used as a solvent in the respective reaction that was carried out in
the presence of bromine. Under these conditions, we managed to isolate the bromo-derivative 1d,
with satisfactory yield. Moreover, bromo-derivative 1e was also obtained, but only in the reaction that
was facilitated by NBS. The analyses of nuclear magnetic resonance spectra (1H- and 13C-NMR), mass
spectra, and elemental analysis showed that the structures of the received compounds were different
from the assumed ones (bromination of the methyl group at position 3). Instead, the derivatives in
which the carboxyl group was replaced by the bromine atom at the position 2 were isolated. Moreover,
we confirmed the formation of 1e, in which one bromine atom substituted the hydrogen atom in the
acetyl group of the benzene moiety of benzofuran ring. The use of polar protic solvents (acetic acid,
ethanol) could explain this substitution.
Scheme 1. Synthesis of analogues of compound VIII.
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Analysis of the calculated logP values (Table 1) has shown that carboxyl and formamide analogs
of lead compound VIII (1 and 1a, respectively) are much less lipophilic, while methoxycarbonyl
analogs 1b and 1c exhibit similar properties as VIII. In contrast, an introduction of the bromine atom at
position 2 of the furane ring resulted in significant increase of the benzofuran system hydrophobicity.




















Schemes 2 and 3 show the syntheses of analogs of compounds IX and X, respectively. The starting
material in both cases was 6-acetyl-5-hydroxy-2-methylbenzofuran-3-carboxylic acid (2), which was
subjected to multidirectional transformations (Scheme 2). In the first approach, the amide-derivative
2a was obtained in the reaction of the acid 2 with oxalyl chloride and ammonium hydroxide. Next,
the bromo-derivative 2b was obtained by the bromination of 2a with bromine in acetic acid as a solvent.
The nuclear magnetic resonance (1H- and 13C-NMR), mass spectrometry and elemental analyses
confirmed the substitution of hydrogen by bromine in aromatic ring in the position 4. We assume
that the presence of the OH group in position 5 of the benzene ring assisted in the electrophilic
substitution of bromide cation in its ortho position. In the second path, the acid 2 was brominated
in the same conditions and the bromo-derivative 2e, also with a bromine substitution to the benzene
ring, was obtained. In the third approach, an ester-derivative 2c, which was obtained in the reaction of
the acid 2 with dimethyl sulphate, was brominated by using NBS in CCl4 to give the derivative 2d,
with a bromomethyl group in the position 2. Interestingly, all of the obtained derivatives 2 (2a–2e)
exhibited lower clogP values, confirming the better water solubility of derivatives compared to lead
compound IX, and the most pronounced occurred primary carboxamides 2a and 2b.
To obtain analogs of compound X, the starting acid 2 was reacted with an excess of dimethyl
sulphate and the obtained derivative 3 was subjected to a multidirectional synthesis (Scheme 3). In the
first case, bromine was introduced into the methyl group to give a compound 3d, by reaction with NBS
in CCl4. In the reaction of the compound 3 with a bromine in acetic acid, the lead compound X was
obtained and then finally reduced to provide a hydroxyl-derivative 3a. In the third path, ester 3 was
hydrolyzed in alkaline conditions to acid 3b, and finally this derivative was converted to an amide 3c
by reaction with oxalyl chloride and ammonium hydroxide. Importantly, all of the new benzofuran
derivatives related to X are characterized by lower clogP values when compared to the lead compound,
indicating their improved solubility in aqueous media (Table 1).
The introduced substituents significantly affected the lipophilicity of the obtained benzofurans.
In most cases, the new derivatives had a lower clogP value in comparison with the lead compounds.
The exception are three derivatives 1c, 1d, 1e, where the substitution of bromine in the furan ring
(compounds 1d and 1e) or in the methyl group caused the clogP to increase (Table 2).
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Scheme 2. Synthesis of analogues of compound IX.
 
Scheme 3. Synthesis of analogues of compound X.
2.2. MTT Cytotoxicity Studies
Fourteen new benzofuran derivatives were tested for their cytotoxic properties in K562, MOLT-4
(leukemia, suspension cells), HeLa (cervix carcinoma, adherent cells), and normal endothelial cells
(HUVEC). First, we measured the viability of cells after 48 h incubation with the given compound
at the concentration of 100 μM. Next, for compounds that reduced cancer cells survival for more
than 50%, we determined IC50 values. Cells that were exposed to 1% DMSO (a vehicle) served as the
control with 100% survival. Cells treated with 1 μM staurosporine served as the internal control of the
cytotoxicity experiments.
We have identified five compounds 1c, 1e, 2d, 3a, and 3d in the initial screening, which, at the
concentration of 100 μM, reduced the viability of all tested cancer cells K562, HeLa and MOLT-4
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for more than 50% (data not shown). These compounds were also cytotoxic against human normal
endothelial cells, so these compounds did not show any selectivity between the cancer and normal cells.
Next, for compounds 1c, 1e, 2d, 3a, and 3d, the IC50 values were calculated (data given in Table 2).
The test compounds were similarly toxic toward both cancer and normal cells, with IC50 values in the
range of 20–85 μM. The exceptions were compounds 1c and 3d, which show IC50 out of this range
(180 μM for MOLT-4 and 6 μM for HUVEC cells, respectively). We did not observe any significant
differences in susceptibility between adherent and suspension cell lines.
Table 2. The IC50 values [μM] after 48 h incubation with cells.
Compound HeLa K562 MOLT-4 HUVEC
1c 50 25 180 30
1e 28 41 70 30
2d 35 20 35 30
3a 80 85 85 67
3d 35 28 55 6
For compounds 1c, 1e, 2d, and 3d, that exhibited the highest toxicity for K562 leukemia cells
(IC50 below 50 μM), we investigated whether they induce apoptosis in these cells. We have measured
the activity of caspases 3 and 7 (caspase 3/7), which are markers of programmed cell death. The K562
cells were treated with 1% DMSO (negative control), 1 μM staurosporine (positive control), or a test
compound at the concentration of 5 × IC50 for 18 h. The activity of caspase 3/7 was measured using
pro-fluorescent peptide substrate.
As shown in Figure 5, staurosporine, which is a strong inducer of apoptosis significantly increased
the activity of caspase 3/7 in K562 cells. On the other hand, 1% DMSO had no effect on the activation of
caspases. Interestingly, the incubation of cells with compound 1e resulted in nearly five-fold increase
in the activity of caspase 3/7, while compounds 1c and 2d activated caspase 3/7 to a lesser extent
(about two-fold increase). In the presence of compound 3d, the activation of caspases was minimal,
if any. Altogether, this result suggests that the cytotoxic activity of test benzofurans 1c, 1e, and 2d in
K562 cells may be due to the induction of death by apoptosis.
 
Figure 5. Activity of caspase 3 and 7 in K562 cells treated with the test benzofurans 1c, 1e, 2d, 3d, or
staurosporine for 18 h. Apoptosis was determined by Apo-ONE® Homogeneous Caspase-3/7 Assay
(Promega, Madison, WI, USA). Abbreviations: DMSO—K562 cells treated with 1% DMSO. The caspase
activation level in cells exposed to 1% DMSO was normalized to 1.0. Mean values +/− SD are shown.
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2.3. Interaction with DNA
The results of MTT cytotoxicity experiments indicated that compounds 1c, 1e, 2d, and 3d were
highly toxic towards the used cell lines. We hypothesized that a possible explanation of observed
cytotoxicity might be due to an interaction of test benzofurans with genomic DNA (e.g., by intercalation).
To verify this hypothesis, we investigated whether the test benzofurans have any effect on digestion of a
plasmid DNA (pcDNA3.1 HisC) with endonuclease BamH1. pcDNA3.1 HisC contains a unique BamH1
restriction site which allows for plasmid linearization. Plasmid DNA exists in linear, superhelical,
and circular forms that differ in electrophoretic mobility (Figure 6 lane 1). Plasmid DNA was converted
to a linear form upon digestion with BamH1 (lane 2). Daunorubicin, which is a strong intercalator
to double-stranded DNA, was used as a control in this experiment and it completely inhibited the
digestion of plasmid DNA with BamH1 (lane 3). In the presence of test compounds, pcDNA3.1 HisC
was partially digested with Bam H1 restriction enzyme (Figure 6 lanes 4–7). Most of the plasmid DNA
was converted to a linear form, however there is a circular form still present. These results suggest
that test benzofurans, to some extent, interact with DNA (especially compounds 1c, 1e, 2d), and this
interaction inhibits the digestion of double stranded DNA chain with restriction endonuclease.
Figure 6. Digestion of pcDNA3.1HisC (total length 5.5kbp) with BamH1 endonuclease. M—marker
DNA; 1—not digested plasmid DNA; 2—plasmid DNA digested with BamH1 (DNA present in linear
form); 3—plasmid DNA + daunorubicin + BamH1; 4—plasmid DNA + 1c + BamH1; 5—plasmid DNA
+ 2d + BamH1; 6—plasmid DNA + 1e + BamH1; and, 7—plasmid DNA + 3d + BamH1.
3. Discussion
We have previously identified benzofurans VIII, IX, and X (lead benzofurans), which efficiently
killed cancer cells and were not toxic toward normal endothelial cells [25–27]. Moreover, lead compound
VIII demonstrated selective toxicity toward leukemia cell lines. However, these compounds were
poorly soluble in aqueous solutions. Based on their structure, we have synthesized 14 new derivatives
with decreased lipophilicity. The polarity of new compounds was predicted based on the calculated logP
values. We tested their cytotoxic properties in human cells of cancer and normal origin. Five compounds,
1c, 1e, 2d, 3a, and 3d, displayed the highest cytotoxicity toward cancer cell lines. However, these
compounds were less toxic than lead compounds VIII, IX, X, and did not demonstrate any selectivity
toward leukemia cells (Table 2). Moreover, new derivatives exhibited significant toxicity in normal
endothelial cells. Cells death is usually carried out in one of the two major mechanisms: apoptosis or
necrosis. Apoptosis is a highly regulated and controlled process that does not elicit an inflammation
response at the site of cell death. Necrosis leads to sudden and uncontrolled cell disintegration that is
associated with release of the cellular content and massive inflammation [29]. Therefore, in the next
experiments, we investigated whether the cellular toxicity of new benzofurans is the result of apoptosis
or necrosis. Our data demonstrate that the activity of caspase 3/7 (an apoptosis marker) is significantly
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increased (1.5- to 5-fold) in the presence of benzofurans (Figure 5). It suggests that these derivatives
induce apoptosis in cancer cells. In the search of cellular targets for testing benzofurans, we examined
whether DNA may be such a target. Using biochemical assay, we found out that the incubation of test
compounds with plasmid DNA inhibited its cleavage with selected endonuclease (BamH1). A similar
result was obtained with daunorubicin, which is a strong DNA intercalating agent. The presence of
undigested plasmid DNA suggests that benzofurans intercalate to DNA (or bind DNA in other way).
However, a comparison of DNA digestion products clearly indicates that the binding of benzofurans
to DNA is much weaker than daunorubicin (Figure 6).
The presence of a bromine substituent in the alkyl chain attached to the furan ring is most likely
to be responsible for cytotoxic activity of compounds 1c, 2d, and 3d. The activity of compound 1e is
probably related to the presence of a bromoacetyl substituent in a benzene ring. Whilst the presence
of a halogen (bromine) directly substituted to the benzene ring or the furan skeleton does not seem
to increase the cytotoxic activity of the tested compounds, for example, 2e, 2b, and 1d. The amide
derivatives of benzofurans (compounds 2a, 3c, 1a) that lack halogen-containing alkyl substituents
(a bromine atom) did not show the cytotoxic properties toward cancer cell lines. A similar effect is
observed for derivatives with a free acidic group (compounds 1, 3b) and ester derivatives (1b).
We can observe a marked decrease in the activity and selectivity of these derivatives when
comparing the activity of bromo-derivatives 1c and 1e with the activity of the lead compound VIII.
This effect is probably due to the absence of the acetyl group at the 2-position of the furan ring.
The derivative 1c has an ester group and the compound 1e a bromine atom in this position. Thus,
it can be concluded that the arrangement of substituents: the acetyl group at the 2-position and the
bromomethyl at the three-position determines the activity and selectivity of the lead compound.
Analysis of the results for the active 2d derivative in comparison to its lead compound IX also
indicates that the structural modifications of 2d resulted in a loss of selectivity and decreased activity.
In this case, the derivatives differ in the location of the halogen atom. The 2d derivative contains
the bromomethyl substituent in the two-position and the acetyl group in the six-position of the
benzofuran system, while the IX contains the methyl group in the two-position and the bromoacetyl
substituent in the six-position of the benzofuran system. It can again be assumed that the presence of
a halogen atom substituted to an alkyl/acetyl moiety determines the activity of the derivatives, but
the appropriate positioning of substituents is important in their selectivity. Finally, by comparing the
active derivatives 3a and 3d with their lead compound X, we also observe a decrease in activity and
selectivity. The 3a compound differs from the leading compound by the presence of a hydroxyl group.
It can be hypothesized that the reduction of the keto group and the possibility of creating additional
hydrogen bonds, as well as an increase in the hydrophilicity could affect the activity of this derivative.
Compound 3d contains a bromomethyl substituent at the two-position and an acetyl group at the
six-position, while X contains a bromoacetyl group at the six-position and a methyl at the two-position.
Both of the compounds exhibit cytotoxicity, but the absence of the bromoacetyl substituent in compound
3d eliminated its selectivity and decreased cytotoxicity to the cancer cells.
4. Materials and Methods
4.1. Chemistry
All of the solvents, reagents, and chemicals used in these studies were purchased from Aldrich
Chemical (Saint Louis, MO, USA) and Merck AG (Saint Louis, MO, USA). The melting points were
determined with Electrothermal 9100 capillary apparatus and they are uncorrected. The nuclear
magnetic resonance spectra (University of Warsaw, Warsaw, Poland) were recorded in DMSO-d6 or
CDCl3 on VMNRS300 operating at 300 MHz (1H-NMR) and 75 MHz (13C-NMR). Chemical shifts
(δ) are expressed in parts per million relative to tetramethylsilane used as the internal reference.
The coupling constants (J) values are given in hertz (Hz) and spin multiples are given as s (singlet),
d (dublet), t (triplet), and m (multiplet). Mass spectral ESI (Electrospray Ionization) measurements
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were carried out on a MicrOTOF II, Bruker instrument with a TOF detector (Jagiellonian Univeristy
in Krakov, Poland). The spectra were obtained in the positive ion mode. Elemental analyses were
recorded with CHNS micro analyzer elementary model Vario Micro Cube with electronic microbalance
(Jagiellonian Univeristy in Krakow, Poland). Flash chromatography was performed on Merck Kieselgel
0.05–0.2 mm reinst (70–325 mesh ASTM, Saint Louis, MO, USA) silica gel using chloroform as eluent.
TLC monitored progress of the reactions described in the experimental section on silica gel (plates
with fluorescent indicator 254 nm, layer thickness 0.2 mm, Kieselgel G. Merck, Saint Louis, MO, USA),
using chloroform-methanol as an eluent system at the v/v ratio of 9.8:0.2 or 9.5:0.5.
4.2. General Synthetic Procedures
Procedure 1. Procedure for Synthesis of Amides.
An appropriate carboxylic acid (0.004 mol) was suspended in anhydrous dichlorometane (DCM)
(10 mL). Next, oxalyl chloride (0.43 mL, 0.005 mol) and the one drop of dimethylformamide (DMF)
were added to the solution. The reaction mixture was stirred at room temperature for 24 h. Then,
ammonium solution (aq. 30%, 5 mL) was added drop by drop and the mixture was stirred at room
temperature for additional 12 h. When the reaction was complete (TLC control) the resulting mixture
was diluted with water (50 mL) and extracted with DCM (3 × 50 mL). The organic extracts were dried
with magnesium sulfate and concentrated under reduced pressure. The resulting solid was purified by
a silica gel column chromatography (eluent: chloroform or chloroform:methanol; 50:0.2, v/v).
Procedure 2. Procedure for the Preparation of Methyl ester.
Procedure according to the method described earlier [11]. Thus, a mixture of appropriate
carboxylic acid (0.02 mol), K2CO3 (0.1 mol) and (CH3O)2SO2 (0.02 mol) in acetone was refluxed for
48 h. When the reaction was complete, the mixture was filtered and the solvent was removed on rotary
evaporator [11]. The residue was purified by a silica gel column chromatography (eluent: chloroform
or chloroform:methanol; 50:0.2 v/v).
Procedure 3. Procedure for Bromination by Using N-Bromosuccinimide (NBS).
In this method, the procedure was used, as described earlier [11]. Briefly, N-bromosuccinimide
(NBS) (0.02 mol) and the catalytic amount of benzoyl peroxide were added to a solution of the
appropriate ester or acid (0.02 mol) in dry carbon tetrachloride or alternatively in ethanol (50 mL).
The reaction mixture was refluxed for 24 h. When the reaction was complete (TLC monitoring),
the mixture was filtered and the solvent was removed under reduced pressure. Silica gel column
chromatography purified the residue (eluent: chloroform or chloroform:methanol; 50:0.2 v/v).
Procedure 4. Procedure for Bromination by Using Br2.
Method a. Procedure according to the method that was described earlier [11]. Thus, an appropriate
ester, amide, or acid (0.02 mol) was dissolved in CHCl3 (20 mL), and then a solution of bromine in
CHCl3 (0.02 mol in 10 mL) was added dropwise with stirring for 1 h. The obtained mixture was stirred
at room temperature for 24 h. When the reaction was finished, the solvent was removed under reduced
pressure. The residue was purified by a silica gel column chromatography (eluent: chloroform or
chloroform:methanol; 50:0.2 v/v).
Method b. Procedure according to the method described earlier [11]. Thus, an appropriate ester,
amide, or acid (0.02 mol) was dissolved in CH3COOH (80%, 20 mL), and then a solution of bromine
in CH3COOH (0.02 mol in 10 mL) was added dropwise with stirring for 1 h. The obtained mixture
was stirred at room temperature for 24 h. When the reaction was complete, the resulting mixture
was diluted by Na2S2O3 solution (10 mL) and extracted with DCM (3 × 50 mL). The obtained organic
extracts were dried with calcium chloride, filtered, and concentrated under reduced pressure. Silica gel
column chromatography purified the residue (eluent: chloroform or chloroform:methanol; 50:0.2 v/v).
Procedure 5. Procedure for Reduction.
A starting ketone (0.0024 mol) was dissolved in the peroxides-free dioxane (20 mL), and then
NABH(OAc)3 (0.0048 mol) was added. The mixture was stirred at room temperature for 24–48 h.
When the reaction was complete, the solvent was removed under reduced pressure. The solid residue
502
Molecules 2019, 24, 1529
was dissolved in CHCl3 (50 mL) and then washed with water (3 × 20 mL). The organic solution was
dried with magnesium sulfate, filtered, and concentrated under reduced pressure. Finally, silica gel
column chromatography purified the residue (eluent: chloroform or chloroform:methanol; 50:0.2 v/v).
4.2.1. Synthesis of Analogues of Compound VIII
Synthesis of 7-Acetyl-5,6-Dimethoxy-3-Methylbenzofuran-2-Carboxylic Acid (1)
7-Acetyl-5,6-dimethoxy-3-methylbenzofuran-2-carboxylic acid was obtained in the multistep
reaction according to the method described earlier [28].
M.W. = 278.2573; C14H14O6; Yield: 30%; white powder, m.p. 212–214 ◦C; 1H-NMR (300 MHz,
DMSO, δ/ppm): 2.50 (3H, s, -CH3), 2.62 (3H, s, -COCH3), 3.84 (3H, s, -OCH3), 3.92 (3H, s, -OCH3),
7.47 (1H, s, Ar-H), 13.41 (1H, br.s, -COOH); 13C-NMR: δ 9.15, 32.13, 56.43, 61.755, 105.50, 119.64,
124.39, 124.68, 142.19, 144.27, 147.40, 150.07, 160.76, 197.33;.HRMS (m/z): calculated value for [M + Na]
100% = 301.0683; found 100% = 301.0681+; Anal. Calc. for C14H14O6: 60.43% C; 5.07% H, found
59.25% C; 4.92% H.
Synthesis of 7-Acetyl-5,6-Dimethoxy-3-Methylbenzofuran-2-Carboxamide (1a)
7-Acetyl-5,6-dimethoxy-3-methylbenzofuran-2-carboxamide was obtained according to Procedure 1.
M.W. = 277.2726; C14H15NO5, Yield: 37%; white powder, m.p. 203–205 ◦C; 1H-NMR (300 MHz,
CDCl3, δ/ppm): 2.50 (3H, s, -CH3), 2.68 (3H, s, -COCH3), 3.80 (3H, s, -OCH3), 3.90 (3H, s, -OCH3), 7.41
(1H, s, Ar-H), 7.70 (2H, br.m, -NH2); 13C-NMR: δ 8.73, 32.47, 56.04, 61.85, 104.99, 120.02, 121.07, 125.07,
143.14, 144.08, 146.34, 150.07, 160.93, 197.55; HRMS (m/z): calculated value for [M+Na] 100%= 300.0842,
found 100% = 300.0842+. Anal. Calc. for C14H15NO5: 60.64% C; 5.45% H, 5.05% N, found 60.04% C;
4.537% H, 4.81% N.
Synthesis of Methyl 7-Acetyl-5,6-Dimethoxy-3-Methylbenzofuran-2-Carboxylate (1b)
Methyl 7-acetyl-5,6-dimethoxy-3-methyl-1-benzofuran-2-carboxylate was obtained according
to Procedure 2. M.W. = 292.2839; C15H16O6; Yield: 60%; white powder, m.p. 98–100 ◦C; 1H-NMR
(300 MHz, CDCl3, δ/ppm): 2.55 (3H, s, -CH3), 2.73 (3H, s, -COCH3), 3.94 (3H, s, -OCH3), 3.95 (3H, s,
-OCH3), 3.95 (3H, s, -COOCH3), 7.10 (1H, s, Ar-H); 13C-NMR: δ 9.22, 32.34, 51.84, 56.38, 62.40, 104.42,
120.28, 124.84, 125.43, 141.68, 145.57, 148.67, 150.58, 160.41, 197.50; HRMS (m/z): calculated value for
[M + Na] 100% = 315.0839, found 100% = 315.0839. Anal. Calc. for C15H16O6: 61.64% C; 5.52% H,
found 61.35% C; 5.516% H.
Synthesis of Methyl 7-Acetyl-3-(Bromomethyl)-5,6-Dimethoxybenzofuran-2-Carboxylate (1c)
Methyl 7-acetyl-3-(bromomethyl)-5,6-dimethoxybenzofuran-2-carboxylate was obtained
according to Procedure 4 (method a). M.W. = 371.1800; C15H15BrO6; Yield: 20%; white powder,
m.p. 124–125 ◦C; 1H-NMR (300 MHz, CDCl3, δ/ppm): 2.72 (3H, s, -COCH3), 3.97 (9H, m, -OCH3,
-OCH3, -COOCH3), 4.90 (2H, -CH2Br), 7.33 (1H, s, Ar-H); 13C-NMR: δ 20.46, 32.30, 52.35, 56.43, 62.41,
104.32, 120.53, 122.56, 124.99, 141.66, 145.71, 149.11, 151.01, 159.61, 197.15; HRMS (m/z): calculated
value for [M +Na] 100% = 392.9944, 99% = 394.9927, found 100% = 392.9945, 99% = 394.9926. Anal.
Calc. for C15H14 BrO6: 48.54% C; 4.07% H, found 48.82% C; 4.15% H.
Synthesis of 1-(2-Bromo-5,6-Dimethoxy-3-Methylbenzofuran-7-yl)ethanone (1d)
1-(2-Bromo-5,6-dimethoxy-3-methylbenzofuran-7-yl)ethanone was obtained according to
Procedure 3 (in ethanol) as well as Procedure 4 (method b). Yield: M.W. = 313.1439; C13H13BrO4; Yield:
27%; white powder, m.p. 94–95 ◦C; 1H-NMR (300 MHz, CDCl3, δ/ppm): 2.16 (3H, s, -CH3), 2.69 (3H, s,
-COCH3), 3.90 (3H, s, -OCH3), 3.93 (3H, s, -OCH3), 6.98 (1H, s, Ar-H); 13C-NMR: δ 8.69, 32.26, 56.47,
62.38, 103.39, 114.99, 119.83, 125.37, 126.39, 145.20, 1454.74, 150.22, 197.82; HRMS (m/z): calculated
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value for [M +Na] 100% = 334.9889, 99% = 336.9870, found 100% = 334.9897, 99% = 336.9869. Anal.
Calc. for C13H13BrO4: 49.86% C; 4.18% H, found 49.76% C; 4.159% H.
Synthesis of 2-Bromo-1-(2-Bromo-5,6-Dimethoxy-3-Methylbenzofuran-7-yl]ethanone (1e)
2-Bromo-1-(2-bromo-5,6-dimethoxy-3-methylbenzofuran-7-yl)ethanone was obtained according
to Procedure 3 (in ethanol). M.W. = 392.0399; C13H12Br2O4; Yield: 27%; white powder, m.p. 128–129 ◦C;
1H-NMR (300 MHz, CDCl3, δ/ppm): 2.17 (3H, s, -CH3), 3.94 (6H, s, -OCH3, -OCH3), 4.58 (2H, s,
-COCH2Br), 7.03 (1H, s, Ar-H); 13C-NMR: δ 8.69, 36.49, 56.53, 62.49, 104.60, 115.16, 116.09, 125.46,
126.66, 145.84, 145.95, 150.10, 190.29; HRMS (m/z): calculated value for [M + Na] 50% = 412.8995,
100% = 414.8975, 49% = 416.8956, found 50% = 412.8991, 100% = 414.8973, 49% = 416.8944. Anal. Calc.
for C13H12 Br2O4: 39.83% C; 3.09% H, found 40.21% C; 3.066% H.
4.2.2. Synthesis of Analogues of Compound IX
Synthesis of 6-Acetyl-5-Hydroxy-2-Methylbenzofuran-3-Carboxamide (2a)
6-Acetyl-5-hydroxy-2-methylbenzofuran-3-carboxamide was obtained according to Procedure 1.
M.W. = 233.2200; C12H11NO4; Yield: 50%; white powder, m.p. 268–267 ◦C; 1H-NMR (300 MHz, DMSO,
δ/ppm): 2.65 (3H, s, -COCH3), 2.68 (3H, s, -CH3), 7.22 (1H, s, Ar-H), 7.48 (2H, br.s, -NH2), 8.11 (1H,
s, Ar-H), 11.97 (1H, s, -OH); 13C-NMR: δ 14.20, 27.52, 107.03, 112.69, 112.74, 116.38, 133.39, 146.00,
157.39, 163.86, 164.22, 204.26; HRMS (m/z): calculated value for [M + Na] 100% = 256.0580, found
100% = 256.0582. Anal. Calc. for C12H11NO4: 61.80% C; 4.75% H, 6.01% N, found 60.85% C; 4.766% H,
5.83% N.
Synthesis of 6-Acetyl-4-Bromo-5-Hydroxy-2-Methylbenzofuran-3-Carboxamide (2b)
6-Acetyl-4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxamide was obtained according to
Procedure 4 (method b). M.W. = 312.1161; C12H10BrNO4; Yield: 40%; white powder, m.p. 249–248 ◦C;
1H-NMR (300 MHz, DMSO, δ/ppm): 2.50 (3H, s, -COCH3), 2.68 (3H, s, -CH3), 7.69 (1H, br.s, -NH2),
7.94 (1H, br.s, -NH2), 8.23 (1H, s, Ar-H), 12.88 (1H, s, -OH); 13C-NMR: δ 13.20, 27.05, 99.21, 112.59,
115.82, 115.86, 133.19, 145.62, 154.37, 160.33, 163.79, 204.99; HRMS (m/z): calculated value for [M + Na]
100%= 333.9685, 98%= 335.9666, found 100%= 333.9685, 98%= 335.9669. Anal. Calc. for C12H10BrNO4:
46.18% C; 3.23% H, 4.49% N, found 46.33% C; 3.265% H, 4.35% N.
Synthesis of Methyl 6-Acetyl-5-Hydroxy-2-Methylbenzofuran-3-Carboxylate (2c)
Methyl 6-acetyl-5-hydroxy-2-methylbenzofuran-3-carboxylate (2c) was obtained according to the
method described previously [11].
Synthesis of Methyl 6-Acetyl-2-(Bromomethyl)-5-Hydroxybenzofuran-3-Carboxylate (2d)
Methyl 6-acetyl-2-(bromomethyl)-5-hydroxybenzofuran-3-carboxylate was obtained according to
Procedure 3 (in CCl4). M.W. = 327.1274; C13H11BrO5; Yield: 30%; white powder, m.p. 94–95 ◦C (chyba
138–140); 1H-NMR (300 MHz, CDCl3, δ/ppm): 2.70 (3H, s, -COCH3), 3.99 (3H, s, -COOCH3), 4.94 (2H,
s, -CH2Br), 7.53 (1H, s, Ar-H), 7.88 (1H, s, Ar-H), 12.11 (1H, s, -OH); 13C-NMR: δ 14.19, 26.80, 52.08,
110.51, 112.63, 117.59, 132.64, 146.73, 155.99, 161.21, 162.63, 164.00, 203.35; HRMS (m/z): calculated
value for [M +Na] 100% = 348.9682, 99% = 350.9663, found 100% = 348.9683, 99% = 350.9663. Anal.
Calc. for C13H11BrO5: 47.73% C; 3.39% H, found 47.33% C; 3.265% H.
Synthesis of 6-Acetyl-4-Bromo-5-Hydroxy-2-Methylbenzofuran-3-Carboxylic Acid (2e)
6-Acetyl-4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylic acid was obtained according
Procedure 4 (method b). M.W. = 313.1008; C12H9BrO5; Yield: 30%; white powder, m.p. 196–197 ◦C;
1H-NMR (300 MHz, CDCl3, δ/ppm): 2.48 (3H, s, -COCH3), 2.69 (3H, s, -CH3), 7.72 (1H, s, Ar-H), 12.89
(1H, s, -OH); 13C-NMR: δ 13.20, 26.70, 94.45, 100.68, 111.33, 116.11, 132.08, 145.99, 155.30, 159.72, 203.35;
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HRMS (m/z): calculated value for [M + Na] 100% = 334.9526, 99% = 336.9506, found 100%= 334.9525,
99% = 336.9505. Anal. Calc. for C12H9BrO5: 46.03% C; 2.90% H, found 46.33% C; 2.265% H.
4.2.3. Synthesis of Analogues of Compound X
Synthesis of Methyl 6-Acetyl-5-Methoxy-2-Methylbenzofuran-3-Carboxylate (3) and Methyl
6-(Dibromoacetyl)-5-Methoxy-2-Methyl-1-Benzofuran-3-Carboxylate (X)
Methyl 6-acetyl-5-methoxy-2-methylbenzofuran-3-carboxylate (3) and methyl 6-(dibromoacetyl)-5-
methoxy-2-methylbenzofuran-3-carboxylate (X) were obtained according to the method described
previously [11].
Synthesis of Methyl 6-(2,2-Dibromo-1-Hydroxyethyl)-5-Methoxy-2-Methylbenzofuran-3-Carboxylate (3a)
Methyl 6-(2,2-dibromo-1-hydroxyethyl)-5-methoxy-2-methylbenzofuran-3-carboxylate (3a) was
obtained according to Procedure 5. M.W. = 422.0659; C14H14Br2O5; Yield: 70%; white powder, m.p.
170–172 ◦C; 1H-NMR (300 MHz, DMSO, δ/ppm): 2.74 (3H, s, -COOCH3), 3.18 (1H, br.s, -CH-), 3.93 (3H,
s, -OCH3), 3.94 (3H, s, -CH3), 5.34 (1H, br.s, –OH), 6.14 (1H, d, -CH-, J = 3 Hz), 7.41 (1H, s, Ar-H), 7.59
(1H, s, Ar-H); 13C-NMR: δ 14.73, 51.46, 51.77, 55.93, 75.00, 102.26, 108.96, 110.78, 123.97, 126.92, 148.14,
153.17, 164.71, 164.75; HRMS (m/z): calculated value for [M +Na] 50% = 442.9100, 100% = 444.9081,
50% = 446.9063, found 50% = 442.9094, 100% = 444.9079, 50% = 446.9065. Anal. Calc. for C14H14Br2O6:
39.84% C; 3.34% H, found 40.20% C; 3.37% H.
Synthesis of 6-Acetyl-5-Methoxy-2-Methylbenzofuran-3-Carboxylic Acid (3b)
A mixture of methyl 6-acetyl-5-methoxy-2-methylbenzofuran-3-carboxylate (0.0008 mol) and
2 M NaOH (0.6 mL, 0.0012 mol) in ethanol (1.2 mL) was heated for 1 h. The bulk of the solvent was
evaporated and the residue was acidified with 2 M HCl (1.2 mL) to give a fine precipitate. Next,
the mixture was cooled to room temperature and then filtered to give the product. M.W. = 248.2313;
C13H12O5; Yield: 30%; white powder, m.p. 249–250 ◦C; 1H-NMR (300 MHz, DMSO, δ/ppm): 2.55 (3H,
s, -COCH3), 2.71 (3H, s, -CH3), 3.90 (3H, s, -OCH3), 7.45 (1H, s, Ar-H), 7.69 (1H, s, Ar-H); 13C-NMR: δ
14.41, 31.61, 56.03, 103.27, 109.23, 111.32, 124.90, 130.79, 147.06, 155.84, 164.66, 166.58, 197.99; HRMS
(m/z): calculated value for [M + Na] 100% = 271.0577, found 100% = 270.0737. Anal. Calc. for
C13H12O5* 12 H2O: 60.50% C; 5.07% H, found 60.05% C; 4.715% H.
Synthesis of 6-Acetyl-5-Methoxy-2-Methylbenzofuran-3-Carboxamide (3c)
6-Acetyl-5-methoxy-2-methylbenzofuran-3-carboxamide was obtained according to Procedure 1.
M.W. = 247.2466; C13H13NO4; Yield: 30%; white powder, m.p. 223–224 ◦C; 1H-NMR (300 MHz,
DMSO, δ/ppm): 2.55 (3H, s, -COCH3), 2.68 (3H, s, -CH3), 3.98 (3H, s, -OCH3), 7.22 (1H, s, Ar-H), 7.53
(2H, br.s, -NH2), 7.70 (1H, s, Ar-H); 13C-NMR: δ 14.11, 31.61, 56.17, 103.10, 111.14, 112.81, 124.65, 130.56,
146.94, 155.49, 162.02, 164.42, 198.08; HRMS (m/z): calculated value for [M + Na] 100% = 270.0737,
found 100% = 270.0737. Anal. Calc. for C13H13NO4: 63.15% C; 5.30% H, 5.67% N, found 62.90% C;
5.245% H, 5.63% N.
Synthesis of Methyl 6-Acetyl-2-(Bromomethyl)-5-Methoxybenzofuran-3-Carboxylate (3d)
Methyl 6-acetyl-2-(bromomethyl)-5-methoxybenzofuran-3-carboxylate was obtained according to
Procedure 3 (in CCl4). M.W. = 341.1540; C14H13BrO5; Yield: 30%; white powder, m.p. 148–150 ◦C;
1H-NMR (300 MHz, CDCl3, δ/ppm): 2.65 (3H, s, -COCH3), 3.98 (3H, s, -OCH3), 4.01 (3H, s, -COOCH3),
4.91 (2H, s, -CH2Br), 7.50 (1H, s, Ar-H), 7.86 7.70 (1H, s, Ar-H); 13C-NMR: δ 20.94, 31.08, 52.07, 56.03,
103.76, 110.48, 112.98, 127.44, 129.80, 148.49, 156.56, 161.91, 163.30, 199.04; HRMS (m/z): calculated
value for [M +Na] 100% = 362.9839, 99% = 364.9820, found 100% = 362.9839, 99% = 364.9820. Anal.
Calc. for C14H13BrO5: 49.29% C; 3.84% H, found 48.87% C; 3.755% H.
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4.3. Anticancer Activity
4.3.1. Cells and Cytotoxicity Assay
Human umbilical vein endothelial cells (Life Technologies, Waltham, MA, USA) were cultured
(according to the manufacturer instructions) in Medium 200 supplemented with Low Serum Growth
Supplement. 1 × 104 HUVEC cells were seeded on each well on a 96-well plate (Nunc). The HeLa
(human cervix carcinoma) K562 and MOLT-4 (leukemia) cells were cultured in RPMI 1640 medium
supplemented with antibiotics and 10% fetal calf serum (HeLa, K562) in a 5% CO2-95% air atmosphere.
7 × 103 HeLa, K562, or MOLT-4 cells were seeded on each well on 96-well plate (Nunc). 24 h later cells
were treated with the test compounds and then incubated for an additional 48 hours. Stock solutions
of test compounds were freshly prepared in DMSO (dimethylsulfoxide). The final concentrations of
compounds that were tested in the cell cultures were: 2 × 10−1, 1 ×10−1, 5 × 10−2, 1 × 10−2, 1 × 10−3
and 1 × 10−4 mM. The concentration of DMSO in the cell culture medium was 1%.
The values of IC50 (the concentration of test compound that is required to reduce the cell survival
fraction to 50% of the control) were calculated from dose-response curves and used as a measure of
cellular sensitivity to a given treatment.
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, St. Louis, MO,
USA] assay determined the cytotoxicity of all the compounds, as described previously [30]. Briefly, after
24 h or 48 h of incubation with the drug, the cells were treated with the MTT reagent, and incubation
was continued for 2 h. MTT-formazan crystals were dissolved in 20% SDS and 50% DMF at pH 4.7
and absorbance was read at 570 and 650 nm on an ELISA-PLATE READER (FLUOstar Omega, BMG
LABTECH GmbH, Ortenberg, Germany). As a control (100% viability), cells that were grown in the
presence of medium vehicle only with 1% DMSO were used.
4.3.2. Induction of Cell Apoptosis Analyzed by Caspase-3/7 Assay
20 × 103 K562 cells were seeded on each well of 96-well plate in RPMI 1640 medium supplemented
with 10% fetal calf serum and antibiotics. Cells were grown for 24 h at 37 ◦C and 5% CO2. The test
compounds were dissolved in DMSO and added to the cell culture. The concentration of tested
benzo[b]furans in cell culture was 5 × IC50.
Cells treated with 1% DMSO served as a negative control, while cells incubated with staurosporine
(a strong inducer of apoptosis) were used as a positive control. Cells were exposed to test compounds
for 18 h at 37 ◦C and 5% CO2. Subsequently, Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega,
Madison, WI, USA) measured the activity of caspase 3 and 7, according to the manufacturer’s
instructions. Briefly, the cells were lysed and incubated for 1.5 h with profluorescent substrate for
caspase 3 and 7. Next, fluorescence was read at an excitation wavelength of 485 nm and emission of
520 nm with FLUOStar Omega plate reader (BMG-Labtech, Ortenberg, Germany).
4.3.3. Digestion of Plasmid DNA with BamHI Restriction Nuclease
0.5 μg of plasmid DNA (pcDNAHisC, total length 5.5 kbp) containing a unique BamHI restriction
site was dissolved in a 1× BamHI reaction buffer and then incubated overnight at 37 ◦C with the
test compounds or daunorubicin, a strong intercalating agent, which was used as a positive control.
The concentration of the test compounds and daunorubicin samples was 100 μM. In the next step,
the reaction mixtures were digested with BamHI restriction endonuclease (2 U/μL) for 3 h at 37 ◦C.
The total reaction volume was 10 μL. Products of the reaction were subjected to the 1% agarose gel
electrophoresis in TBE buffer. The gel was stained with ethidium bromide and DNA fragments were
visualized under a UV lamp (GBox, Syngene, Cambridge, UK).
5. Conclusions
We synthesized and tested a group of new benzofuran derivatives. The presence of bromine in
the alkyl group in the furan ring is most likely responsible for the cytotoxic properties of the tested
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derivatives (compounds 1c, 2d, 3d). Compound 1e shows the cytotoxic property, and contains an
acetyl halide substituent (bromine) in the benzene ring and a bromine atom that is directly attached to
the furan ring. The most active compounds 2d and 3d, showed increased polarity when compared to
the lead compounds VIII-X, but their cytotoxicity against human cancer cells decreased by 5–10 folds
and the toxicity against normal cells increased. The formation of amide derivatives of benzofurans
(compounds 1a, 2a, 2b, 3c) and the lack of a halogen-containing alkyl substituent in their structure
resulted in better water solubility but loss of cytotoxic properties towards the cancer cells studied.
A reduction of the bromoacetyl group in compound X increased its polarity but also eliminated the
selectivity of the compound and diminished its toxicity towards tumor cells.
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Synthesis and cytotoxic properties of halogen and aryl-/heteroarylpiperazinyl derivatives of benzofurans.
Anti Cancer Agents Med. Chem. 2015, 15, 115–121. [CrossRef]
26. Kossakowski, J.; Kuran, B.; Kazmierczak-Baranska, J.; Królewska, K.; Nawrot, B.; Krawiecka, M.; Cieslak, M.
Halogen derivatives of benzo[b]furans useful as anti-neoplastic or anti-proliferative drugs. Spanish Patent
EP 2631232 A1, 9 January 2013.
27. Królewska-Golińska, K.; Cieślak, M.J.; Sobczak, M.; Dolot, R.; Radzikowska-Cieciura, E.; Napiórkowska, M.;
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Abstract: In this study, some of new thiophenyl thienopyrimidinone derivatives 2–15 were prepared
and tested as anti-cancer agents by using thiophenyl thieno[2,3-d]pyrimidinone derivative 2 as a
starting material, which was prepared from cyclization of ethyl ester derivative 1 with formamide.
Treatment of 2 with ethyl- chloroacetate gave thienopyrimidinone N-ethylacetate 3, which was reacted
with hydrazine hydrate or anthranilic acid to afford acetohydrazide 4 and benzo[d][1,3]oxazin-4-one
5, respectively. Condensation of 4 with aromatic aldehydes or phenylisothiocyanate yielded Schiff
base derivatives 6,7, and thiosemicarbazise 10, which were treated with 2-mercaptoacetic acid or
chloroacetic acid to give the corresponding thiazolidinones 8, 9, and phenylimino-thiazolidinone
11, respectively. Treatment of 4 with ethylacetoacetate or acetic acid/acetic anhydride gave pyrazole
12 and acetyl acetohydrazide 13 derivatives, respectively. The latter compound 13 was reacted
with ethyl cycno-acetate or malononitrile to give 14 and 15, respectively. In this work, we have
studied the anti-cancer activity of the synthesized thienopyrimidinone derivatives against MCF-7 and
MCF-10A cancer cells. Furthermore, in vivo experiments showed that the synthesized compounds
significantly reduced tumor growth up to the 8th day of treatment in comparison to control animal
models. Additionally, the synthesized derivatives showed potential inhibitory effects against pim-1
kinase activities.
Keywords: thiopene; thienopyrimidinone; thiazolidinone; anticancer activity
1. Introduction
Cancer is a major health problem acting as a global killer, so synthesizing new compounds,
which may act as potent antitumor agents, is a great target for chemists working in this
field. In this study, we are interested in synthesizing and studying biological activities of
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Molecules 2019, 24, 2255
thieno[2,3-d]pyrimidinone derivatives [1–11]. Thienopyrimidinones are very important moieties
that act as keys for pharmacological and pharmaceutical properties. They are reported to cause
antiviral [12], antimicrobial [13], antihypertensive [14], analgesic, and anti-inflammatory activities [15].
They also inhibit various protein kinase enzymes, such as CK2 involved in particular anticancer
activity [16]. Additionally, the nitrogenous ring system was associated with some types of biological
activities such as: anti-inflammatory [17], insecticidal [18], antimicrobial and antituberculosis [19,20]
activities. On the other hand, thienopyrimidinones contain a thiophene ring fused with a pyrimidinone
nucleus. In general, this system was thought to be interesting in development of pharmaceutical
compounds [21,22], and was not only evaluated as cGMP phosphodiesterase inhibitors [23],
anti-viral [24], anti-inflammatory [25], anti-microbial agents [26], but also as kinase inhibitors and
potential anti-cancer agents [27,28]. In continuation to our previous work, and to extend our
research [1–11], from the above points, we have studied the anticancer activity of the newly synthesized
substituted thienopyrimidinone derivatives against MCF-7 and MCF-10A cancer cells. Furthermore,
the work was extended to evaluate the effects of synthesized derivatives on the inhibition of tumor
growth in an in vivo animal model. Finally, we evaluated the inhibitory effects of our synthesized
compounds against pim-1 kinase activity as a possible mechanism of their action.
2. Results and Discussion
2.1. Chemistry
A series of thiophenyl thienopyrimidinone derivatives 2–15 were prepared and tested as anti-cancer
agents. Cyclization of ethyl 5’-amino-[2,3’-bithiophene]-4’-carboxylate (1) with formamide gave
the corresponding thiophenylthieno[2,3-d]pyrimidinone derivative (2), which was treated with
ethylchloroacetate to give thienopyrimidinone N-ethylacetate 3. Reaction of 3 with hydrazine
hydrate or anthranilic acid afforded the corresponding hydrazide 4 and benzooxazinone 5 derivatives,
respectively (Scheme 1).
Scheme 1. Synthetic route for compounds 2–5.
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Condensation of 4 with aromatic aldehydes, namely, 2,3-dimethoxybenzaldehyde or
4-chlorobenzaldehyde gave the corresponding Schiff base derivatives 6 and 7, which were cyclized
via reaction with 2-mercaptoacetic acid in dry benzene to give the corresponding thiazolidinone
derivatives 8 and 9, respectively. Treatment of 4 with phenylisothiocyanate gave thiosemicarbazide
10, which was condensed with chloroacetic acid to afford phenyliminothiazolidinone derivative 11
(Scheme 2).
 
Scheme 2. Synthetic route for compounds 6–11.
Finally, treatment of 4 with ethylacetoacetate or acetic acid/acetic anhydride gave the corresponding
pyrazolyl derivative 12 and N-acetyl hydrazide 13, respectively. The latter compound 13 was reacted
with ethylcycnoacetate or malononitrile to give pyridine derivatives 14 and 15, respectively (Scheme 3).
511
Molecules 2019, 24, 2255
Scheme 3. Synthetic route for compounds 12–15.
2.2. Biological Evaluation
MCF-7 cells were used to investigate the potential in vitro anti-proliferative potential of the
synthesized compounds. With the exception of Cpd. 2 (data not shown), we found that all compounds
have promising activities when used in μM concentration. On the other hand, Cisplatin and Milaplatin
showed higher IC50 values (13.34 ± 0.11 and 18.43 ± 0.13 μM, respectively). DMSO at concentrations
of 0.1% and 0.5%, had little or no toxicity, whereas higher concentrations inhibited the growth
of MCF-7cells. Therefore, it seems DMSO could be solvents of choice acceptable to be used at
concentrations < 0.5% (v/v) towards the examined cells and possibly for other cell lines. Also, the effect
on cell viability was proportional to the concentration applied. From Figure 1, we can see that Cpd.
15, 14 and 8 (IC50, 1.18 ± 0.032, 1.19 ± 0.042, 1.26 ± 0.052 μM, respectively) followed by 9 and 11
(IC50, 2.37 ± 0.053 and 2.48 ± 0.054 μM respectively) produced the highest effect on cell viability.
Secondly, compounds 12, 10 and 13, showed moderate activities (IC50, 3.36 ± 0.063, 3.55 ± 0.065 and
3.64 ± 0.074 μM, respectively). Compounds 7, 6, 5, 4 and 3 were the least active ones (IC50, 4.33 ± 0.076,
4.52 ± 0.085, 4.76 ± 0.087, 4.87 ± 0.098 and 5.98 ± 0.099 μM, respectively). The order of activities can be
arranged as 15 > 14 > 8 > 9 > 11 > 12 > 10 > 13 > 7 > 6 > 5 > 4 > 3.
Results revealed that the substitution with pyridine moiety at the terminal NH improved
the cytotoxic effect than the pyrimidone derivatives. In contrast, substitution with 5-membered
di-heterocyclic ring system with aryl moiety decreased the obtained activities (methoxy phenyl >
chlorophenyl). Attaching five membered pyrazolinone ring system bearing no aryl moiety at terminal
NH (compound 12 decreased the activities than those containing aryl substitutions (compounds 9
and 11). Compounds 10, 7 and 6 that contain aromatic N-substitution still have more potent activity.
The increased effect of the aromatic ring may be attributed to ring aromaticity and electron resonance.
On the other hand, aliphatic side chains (compounds 4 and 3) or methylene bridges (Compound 5)
have less potent activities.
Additionally, results against non-tumorigenic MCF-10A proved that our derivatives have higher
degrees of safety towards normal cells.
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Figure 1. Obtained IC50 values for MCF-7 and MCF-10A cells.
In Vivo Xenograft Model
The in vivo anti-breast cancer activities of different synthesized derivatives were evaluated using
a breast cancer mouse xenograft model. Figure 2 shows the increase in percentage of inhibition in
tumor growth with treatment time when animals were exposed to different compounds. This was also
compared with tumor development in control animals. It can be seen, that our derivatives reduced
tumor growth starting day 2. The maximal effect was obtained after 8 days. Furthermore, the in vivo
effect showed also the same inhibitory pattern obtained in the in vitro experiments. The average
weight of each group of mice treated with drug and the control group summarized in Table 1.
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Figure 2. Relative percentage of decrease in tumor volume in response to prepared compounds.
Table 1. The average weight of each group of mice treated with drug and the control group.
Drugs
Average Weight of Animals in Grams after Days
0 2 4 6 8 10 12 14 16 18 20 22
Control 28 28 28 28 28.2 28. 28.3 28.4 28.4 28.4 28.4 28.4
3 28 28 28 28 28.2 27.9 27.8 27.7 27.7 27.6 27.7 27.7
4 24.2 24.2 24.1 24.0 23.9 23.9 23.7 23.7 23.6 23.6 23.6 236.
5 22.9 22.9 22.9 22.8 22.8 22.7 22.8 22.7 22.9 22.6 22.6 22.5
6 23.7 23.7 23.6 23.6 23.5 23.5 23.5 23.4 23.4 23.5 23.5 23.5
7 27.3 27.3 27.2 27.2 27.2 27.1 27.1 27.1 27.0 27.0 27.0 27.0
8 25.3 25.3 25.2 25.2 25.2 25.1 25.1 24.8 24.7 24.6 24.5 24.2
9 24.1 24.1 24.0 24.0 24.0 24.0 23.7 23.7 23.6 23.6 23.6 23.6
10 24.9 24.9 24.9 24.9 24.8 24.8 24.8 24.4 24.4 24.4 24.4 24.4
11 26.6 26.6 26.6 26.5 26.6 26.6 26.4 26.3 26.3 26.3 26.3 263.
12 27.4 27.4 27.4 27.3 27.3 27.3 27.2 27.2 27.2 27.1 27.1 27.1
13 25.4 25.4 25.4 25.4 25.4 25.3 25.3 25.3 25.3 25.3 25.3 25.3
14 26.5 26.4 26.3 26.2 26.1 25.9 25.9 25.9 25.8 25.8 25.7 25.7
15 26.1 26.1 26.1 25.8 25.8 25.7 25.7 25.6 25.6 25.5 25.5 25.2
The Provirus Integration in Maloney (Pim) kinases represents a family of constitutively active
serine/threonine kinases and includes three subtypes (pim-1, pim-2 and pim-3). Pim kinases regulate
many biological processes such as cell cycle, cell proliferation, apoptosis and drug resistance [29–32].
Being expressed in many types of solid and hematological cancers and almost absent in benign lesions,
pim kinases proved to be a successful anti-cancer drug target of low toxicity [33–40]. Results obtained
in Figure 3 showed that all synthesized compounds were showed potent inhibitory effects against
pim-1 kinase.
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μ
Figure 3. IC50 of the tested compounds against pim-1 Kinase.
3. Materials and Methods
3.1. Chemistry
“Melting points were determined in open glass capillary tubes with an Electro Thermal Digital
melting point apparatus (model: IA9100) and are uncorrected. Elemental microanalyses were carried
out in the microanalysis unit of NRC and were found within the acceptable limits of the calculated
values. Infrared spectra (KBr) were recorded on a Nexus 670 FTIR Nicolet, Fourier Transform infrared
spectrometer. 1H- and 13C NMR spectra were run in (DMSO-d6) on Jeol 500 MHz instruments. Mass
spectra were run on a MAT Finnigan SSQ 7000 spectrometer, using the electron impact technique (EI).”
Synthesis of 5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4(3H)-one (2). A mixture of compound 1 (1 mmol,
253 mg) and formamide (20 mL) was heated at 180 ◦C in oil bath for 2 h. The formed solid was
collected by filtration, washed with cold methanol, dried and crystallized from EtOH to give compound
2. Yield 80%, M.p 192–194 ◦C; IR (KBr, cm−1): ῡ 3323 (NH), 1659 (C=O). 1H NMR (DMSO-d6) δH:
7.11–7.72 (m, 4H, thiophene-H), 8.50 (s, 1H, CH-pyrimidine), 13.30 (s, 1H, NH, disappeared with D2O).
13C NMR: 119.98, 122.01, 122.17, 126.84, 127.75, 128.74, 131.26, 136.42, (8C, thiophene-C), 157.05 (1C,
pyrimidine-C), 165.56 (C=O). Mass spectrum, m/z (EI, %): 234 (M+, 100), 235 (M+ + 1, 11), 236 (M+ + 2,
9). Analysis for C10H6N2OS2 (234.29): Calculated: C, 51.27; H, 2.58; N, 11.96; S, 27.37. Found: C, 51.20;
H, 2.50; N, 11.90; S, 27.30.
Synthesis of ethyl 2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)acetate (3). A mixture of 2
(1 mmol, 234 mg), ethylchloroacetate (1 mmol, 122 mg) and anhydrous potassium carbonate (8 mmol)
in dry acetone (30 mL) was heated under reflux for 4h. The obtained solid was removed by filtration,
the filtrate was concentrated, the precipitate solid was filtered off, dried, and crystallized from EtOH to
give the ester derivative 3. Yield 70%, m.p 135–137 ◦C. IR (KBr, cm−1): ν 1753 (C=O, ester), 1655 (CO);
1H NMR (DMSO-d6), δ: 1.24 (t, 3H, CH3), 4.20 (s, 2H, CH2), 4.85 (q, 2H, CH2-ethyl), 7.10–7.72 (m, 4H,
thiophene-H), 8.50 (s, 1H, pyrimidine-H). 13C-NMR (DMSO)-d6) δc: 14.5 (CH3), 40.2 (CH2), 47.8 (CH2),
119.9, 122.2, 126.9, 127.8, 128.7, 128.9, 131.3, 136.4 (8C, thiophene-C), 157.0 (1C, pyrimidine-C), 165.6,
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168.3 (2C, 2CO). Mass spectrum, m/z (EI, %): 320 (M+, 100), 321 (M+ + 1, 18). Analysis for C14H12N2O3S2
(320.38): Calculated: C, 52.49; H, 3.78; N, 8.74; S, 20.01. Found: C, 52.40; H, 3.70; N, 8.68; S, 19.86.
Synthesis of 2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazide (4). To a solution of
3 (1 mmol, 320 mg) in ethanol (50 mL), hydrazine hydrate (4 mmol, 85%) was added and refluxed
for 8 h. The precipitated solid was collected by filteration, dried and crystallized from EtOH to give
compound 4. Yield 75%, m.p. 205–207 ◦C, IR (KBr, cm−1): ν 3322 (NH), 3246 (NH2), 1659 (C=O).
1H-NMR (DMSO-d6) δ: 3.39 (s, 2H, CH2), 4.65 (s, 2H, NH2, disappeared with D2O), 7.10–7.65 (m,
4H, thiophene-H), 8.17 (s, 1H, pyrimidine-H), 12.58 (s, 1H, NH, disappeared with D2O). 13C-NMR
(DMSOd6) δc: 40.1 (CH2), 120.5, 120.8, 126.6, 127.8, 128.7, 131.4, 133.5, 136.8 (8C, thiophene-C), 157.9 (1C,
pyrimidine-C), 166.3, 169.4 (2C, 2CO). Mass spectrum, m/z (EI, %): 306 (M+, 100), 307 (M+ + 1, 14).
Analysis for C12H10N4O2S2 (306.36): Calculated: C, 47.05; H, 3.29; N, 18.29; S, 20.93. Found: C, 46.85;
H, 3.20; N, 18.20; S, 20.85.
Synthesis of 2-((4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)methyl)-4H-benzo[d]-[1,3]
oxazin-4-one (5). A mixture of 3 (1 mmol, 320 mg) and anthranilic acid (1 mmol, 137 mg) was fused
together at 110 ◦C in an oil bath for 3hr. The residue was boiled with ethanol, the formed solid was
removed by filtration, the solid formed was filtered off, and crystallized from EtOH to give 5. Yield
60%, m.p. 225–227 ◦C. IR (KBr, Cm−1): ν 1750 (C=O), 1684 (C=O). 1H-NMR (DMSO d6) δH: 4.58 (s, 2H,
CH2), 7.10–7.54 (m, 4H, thiophene-H), 7.68-8.16 (m, 4H, Ph-H), 8.64 (s, 1H, pyrimidine-H). 13C-MNR
(DMSO-d6) δc: 43.0 (CH2), 120.0, 120.1, 121.3, 121.7, 126.7, 126.8, 127.7, 128.7, 131.3, 136.5, 136.6, 149.5,
149.7, 158.2 (14C, thiophene + Ph-C), 157.2 (1C, pyrimidine-C), 160.1, 165.6, 166.5 (3C, 3C=O). Mass
spectrum, m/z (EI, %): 393 (M+, 100). Analysis for C19H11N3O3S2 (393.44): Calculated: C, 58.00; H,
2.82; N, 10.68; S, 16.30. Found: C, 57.90; H, 2.78; N, 10.60; S, 16.25.
Synthesis of hydrazone derivatives 6 and 7. To a mixture of 4 (1 mmol, 306 mg) and aromatic aldehydes,
namely 3,4-dimethoxybenazaldehyed or 4-chlorobenzaldehyde (1 mmol) in ethanol (50 mL), few drops
of piperidine were added and refluxed for 5 h, with stirring. After cooling, the formed solid was
filtered off and recrystallized from dioxan to give the corresponding derivatives 6 and 7 respectively.
N′-(2,3-Dimethoxybenzylidene)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)-acetohydrazide (6).
Yield 68%, m.p. 248–250 ◦C. IR (KBr, cm−1): ν 3388 (NH), 1660 (C=O). 1H-NMR (DMSO-d6) δH: 3.72,
3.86 (2s, 6H, 2OCH3), 4.11 (s, 2H, CH2), 6.98-7.61 (m, 7H, thiophene + Ph-H), 8.60 (s, 1H, CH=N), 9.05
(s, 1H, pyrimidine-H), 10.51 (s, 1H, NH, disappeared with D2O). 13C-NMR (MDSO-d6) δc: 44.1 (1C,
CH2), 56.1, 60.1 (2C, OCH3), 114.3, 116.1, 119.5, 121.8, 124.0, 126.7, 127.7, 128.7, 129.3, 130.6, 131.3,
136.47, 149.07, 149.77 (14C, thiophene-C + Ph-C), 148.56 (1C, CH=N), 157.19 (1C, pyrimidine-C), 163.66,
169.74 (2C, 2C=O). Mass spectrum, m/z (EI, %): 454 (M+, 100). Analysis for C21H18N4O4S2 (454.52):
Calculated: C, 55.49; H, 3.99; N, 12.33; S, 14.11. Found: C, 55.40; H, 3.90; N, 12.25; S, 13.96.
N′-(4-Chlorobenzylidene)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazide (7). Yield
65%, m.p. 250–252 ◦C. IR (KBr, Cm−1): ν 3408 (NH), 1670 (CO), 1659 (CO). 1H-NMR (DMSO-d6) δH:
4.10 (s, 2H, CH2), 7.10–7.80 (m, 9H, Ar-H + CH=N), 9.05 (s, 1H, pyrimidine-H), 10.56 (s, 1H, NH,
disappeared with D2O). 13C-NMR (MDSO-d6) δc: 44.1 (1C, CH2), 145.2 (1C, CH=N), 119.5, 121.9,
124.0, 126.8, 127.8, 128.1, 129.3, 130.6, 131.3, 136.5, 149.1, 149.8 (14C, thiophene-C + Ph-C), 157.5 (1C,
pyrimidine-C), 162.7, 169.9 (2C, 2C=O). Mass spectrum, m/z (EI, %): 428 (M+, 100), 430 (M+ + 2, 40).
Analysis for C19H13ClN4O2S2 (428.91): Calculated: C, 53.21; H, 3.06; N, 13.06; S, 14.95. Found: C, 53.12;
H, 3.00; N, 13.00; S, 14.88.
Synthesis of thiazolidinone derivatives 8 and 9. To a stirred solution of 6 or 7 (1 mmol) in dry benzene
(40 mL), thioglycollic acid (1 mmol, 92 mg) in dry benzene (10 mL) was added and refluxed for 12 h.
The solvent was evaporated to dryness. The formed product was collected, and crystallized with
dioxan to obtain the corresponding products 8 and 9, respectively.
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N-(2-(2,3-Dimethoxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-
yl)acetamide (8). Yield 60%, m.p. 280–282 ◦C. IR (KBr, cm−1): ν 3417 (NH), 1670, 1680, 1630 (3 C=O).
1H-NMR (DMSO-d6) δH: 3.65, 3.90 (2s, 6H, 2OCH3), 4.66 (s, 2H, CH2), 4.77 (s, 2H, CH2), 5.86 (s, 1H,
CH), 6.95-7.65 (m, 7H, thiophene + Ph-H), 8.49 (s, 1H, pyrimidine-H), 10.84 (s, 1H, NH, disappeared
with D2O). 13C-NMR (DMSO-d6) δc: 35.9, 47.4 (2C, 2CH2), 56.5, 58.42 (2C, 2OCH3), 59.2 (1C, CH), 113.4,
117.9, 118.9, 120.7, 121.8, 126.8, 127.5, 128.7, 130.7, 131.0, 136.5, 145.3, 149.5, 149.9 (14C, thiophene-C +
Ph-C), 156.9 (1C, pyrimidine-C), 162.5, 165.4, 169.2 (3C, 3C=O). Mass spectrum, m/z (EI, %): 528 (M+,
100), 529 (M+ + 1, 30). Analysis for C23H20N4O5S3 (528): Calculated: C, 52.26; H, 3.81; N, 10.60; S,
18.19. Found: C, 52.18; H, 3.75; N, 10.52; S, 18.10.
N-(2-(4-Chlorophenyl)-4-oxothiazolidin-3-yl)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]-pyrimidin-3(4H)-yl)-
acetamide (9). Yield 75%, m.p. 175-177 ◦C. IR (KBr, cm−1): ν 3417 (NH), 1720, 1630, 1660 (3C=O).
1H-NMR (DMSO-d6) δH: 3.81, 5.16 (2s, 4H, 2CH2), 5.90 (s, 1H, CH), 7.08–7.72 (m, 8H, thiophene-H +
Ph-H), 8.50 (s, 1H, pyrimidine-H), 10.92 (s, 1H, NH, disappeared with D2O). 13CNMR (DMSO-d6)
δc: 40.1, 48.2 (2C, 2CH2), 65.2 (1C, CH), 120.0, 121.8, 127.7, 128.7, 129.3, 129.4, 131.3, 133.3, 135.0,
136.5, 143.5, 149.7 (14C, thiophene-C + Ph-C), 157.2 (1C, pyrimidine-C), 163.8, 165.6, 169.9 (3C, 3C=O).
Mass spectrum, m/z (EI, %): 503 (M+, 100), 505 (M+ + 2, 34). Analysis for C21H15ClN4O3S3 (503.01):
Calculated: C, 50.14; H, 3.01; N, 11.14; S, 19.12. Found: C, 50.02; H, 3.00; N, 11.04; S, 19.06.
Synthesis of 2-(2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)acetyl)-N-phenylhydrazine-1-
carbothioamide (10). A mixture of 4 (1mmol, 306 mg) and phenylisothiocynate (1 mmol, 135 mg)
in dry dioxan (50 mL) was refluxed for 6 h. The obtained solid was filtered off, washed with ether, dried
and recrystallized from ethanol to give thiosemicarbazide 10. Yield 60%, m.p. 240–242 ◦C. IR (KBr,
cm−1): ν 3414-3323 (NH), 1680, 1660 (2CO). 1H-NMR (DMSO-d6) δH: 4.66 (s, 2H, CH2), 6.95-7.58 (m,
9H, thiophene + Ph-H), 8.49 (s, 1H, pyrimidine-H), 8.70, 10.71, 12.78 (3s, 3H, 3NH, disappeared with
D2O). 13CNMR (DMSO-d6) δc: 40.16 (CH2), 119.9, 121.8, 126.8, 127.9, 128.8, 129.1, 130.2, 131.3, 134.1,
136.5, 137.9, 149.9 (14C, thiophene + Ph-C), 156.5 (1C, pyrimimidine-C), 166.5, 169.1 (2C, 2C=O), 171.0
(1C, C=S). Mass spectrum, m/z (EI, %): 441 (M+, 100), 442 (M+ + 1, 26). Analysis for C19H15N5O2S3
(441.54): Calculated: C, 51.68; H, 3.42; N, 15.86; S, 21.78. Found: C, 51.60; H, 3.40; N, 15.80; S, 21.70.
Synthesis of N-(4-oxo-2-(phenylimino)thiazolidin-3-yl)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]-pyrimidin-
3(4H)-yl)acetamide (11). A mixture of 10 (1 mmol, 441 mg) and chloroacetic acid (1 mmol, 94 mg)
in absolute ethanol (30 mL) was heated under reflux for 8 h. The solid formed was filtered off and
crystallized with dioxane to give thiazole derivative 11. Yield 60%, m.p. 255–257 ◦C. IR (KBr, cm−1):
ν 3420 (NH), 1720, 1630 (2C=O). 1H-NMR (DMSO-d6) δH: 3.76 (s, 2H, CH2), 4.85 (s, 2H, CH2), 6.95-7.65
(m, 9H, thiophene-H + Ph-H), 8.50 (s, 1H, pyrimidine-H), 11.10 (s, 1H, NH, disappeared with D2O).
13CNMR (DMSO-d6) δc: 40.2 (CH2), 56.8 (CH2), 120.0, 122.0, 126.7, 128.7, 130.7, 131.3, 132.5, 136.4, (8C,
thiophene-C), 145.2, 149.3, 150.8, 151.9 (6C, Ph-C), 156.6 (1C, pyrimidine-C), 158.1 (1C, C=N), 163.4,
165.7, 169.6 (3C, 3C=O). Mass spectrum, m/z (EI, %): 481 (M+. 100), 482 (M+ + 1, 24). Analysis for
C21H15N5O3S3 (481.56): Calculated: C, 52.38; H, 3.14; N, 14.54; S, 19.97. Found: C, 52.30; H, 3.10; N,
14.50; S, 19.90.
Synthesis of 3-(2-(3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl)-5-(thiophen-2-yl)thieno-
[2,3-d]pyrimidin-4(3H)-one (12). A mixture of compound 4 (1 mmol, 306 mg) and ethylacetoacetate
(1 mmol, 130 mg) in ethanolic sodium hydroxide (0.5 mmol/50 mL) was refluxed with stirring for 6 h.
The precipitate was collected by filtration and crystallized from dioxane to give pyrazole derivative 12.
Yield 80%, m.p. 225–227 ◦C. IR (KBr, cm−1): ν 3417 (NH), 1650, 1630 (2C=O). 1H-NMR (DMSOd6)
δH: 1.70 (s, 3H, CH3), 4.35 (s, 2H, CH2), 5.65 (s, 1H, pyrazole-CH), 7.51–7.69 (m, 4H, thiophene-H),
8.46 (s, 1H, pyrimidine-H), 12.93 (s, 1H, NH, disappeared with D2O). 13C-NMR (DMSO-d6) δc: 34.4
(CH3), 47.0 (CH2), 120.0, 123.8, 127.7, 128.7, 129.4, 130.9, 132.6, 136.5 (8C, thiophene), 98.3, 151.9 (2C,
Pyrazole-C), 156.6 (1C, pyrimidine-C), 163.4, 166.5, 169.7 (3C, 3C=O). Mass spectrum, m/z (EI, %): 372
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(M+, 100), 373 (M+ + 1, 18). Analysis for C16H12N4O3S2 (372.42): Calculated: C, 51.60; H, 3.25; N,
15.04; S, 17.22. Found: C, 51.50; H, 3.20; N, 15.00; S, 17.16.
Synthesis of N′-acetyl-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]pyrimidin-3(4H)-yl)aceto-hydrazide (13).
A solution of 4 (1 mmol, 306 mg) in a mixture of AcOH acid and Ac2O (50 m, 1:1 v/v) was refluxed
with stirring for 8 h. The reaction mixture was dropped onto iced-water. The obtained precipitate was
filtered off, washed with water, and recrystallized from ethanol to give N-acetyl derivative 13. Yield
70%, m.p. 235–237 ◦C. IR (KBr, cm−1): ν 3369-3232 (NH, NH), 1732 (C=O). 1H-NMR (DMSOd6) δH:
1.86 (s, 3H, CH3), 4.68 (s, 2H, CH2), 7.10–7.70 (m, 4H, thiophene-H), 8.44 (s, 1H, pyrimidine-H), 10.70,
10.82 (2s, 2NH, disappeared with D2O). 13C-NMR (DMSO-d6) δc: 20.1 (CH3), 50.1 (CH2), 119.9, 122.0,
122.2, 126.8, 127.8, 128.7, 131.3, 136.4 (8C, thiophene-C), 157.0 (1C, pyrimidine-C), 162.8, 165.6, 169.1
(3C, 3C=O). Mass spectrum, m/z (EI, %): 348 (M+, 100), 349 (M+ + 1, 16). Analysis for C14H12N4O3S2
(348.40): Calculated: C, 48.27; H, 3.47; N, 16.08; S, 18.40. Found: C, 48.20; H, 3.40; N, 16.00; S, 18.32.
Synthesis of compounds 14 and 15. To a mixture of 13 (1 mmol, 348 mg) and ethylcyanoacetate or
malononitrile (1 mmol) in EtOH (40 mL), a few drops of triethylamine were refluxed for 8 h, poured
into iced-water. The precipitate was filtered off, and crystallized from EtOH to obtain compounds 14
and 15, respectively.
N-(6-Amino-4-hydroxy-2-oxopyridin-1(2H)-yl)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]-pyrimidin-3(4H)-
yl)acetamide (14). Yield 75%, m.p. 280–282 ◦C. IR (KBr, cm−1): ν 3492-3196 (OH, NH2, NH), 1420, 1680,
1653 (3 C=O). 1H-NMR (DMSO-d6) δH: 4.15 (s, 2H, CH2), 4.95, 5.70 (2s, 2H, 2CH), 6.50 (s, 2H, NH2,
disappeared with D2O), 7.15–7.74 (m, 4H, thiophene-H), 8.50 (s, 1H, pyrimidine-H), 10.25 (s, 1H, OH,
disappeared with D2O), 10.65 (s, 1H, NH, disappeared with D2O). 13C-NMR (DMSO-d6) δc: 49.00
(CH2), 116.1, 120.2, 121.8, 126.7, 127.9, 128.9, 131.3, 136.5 (8C, thiophene-C), 86.5, 100.2, 145.5, 158.7 (4C,
pyridine-C), 156.2 (1C, pyrimidine-C), 164.1, 165.5, 169.5 (3C, 3CO). Mass spectrum, m/z (EI, %): 415
(M+, 75). Analysis for C17H13N5O4S2 (415.44): Calculated: C, 49.15; H, 3.15; N, 16.86; S, 15.43. Found:
C, 49.05; H, 3.10; N, 16.80; S, 15.35.
N-(2,4-Diaminopyridin-1(2H)-yl)-2-(4-oxo-5-(thiophen-2-yl)thieno[2,3-d]-pyrimidin-3(4H)-yl)acetamide (15).
Yield 75%, m.p. 290–292 ◦C, IR (KBr, cm−1). ν 3460-3345 (NH, NH2), 1680, 1653 (2C=O). 1H-NMR
(DMSO-d6) δH: 4.13 (s, 2H, CH2), 4.60 (s, 2H, NH2, exchangeable with D2O), 5.60–6.10 (m, 4H, 4CH),
7.10–8.72 (m, 4H, thiophene-H), 8.47 (s, 1H, pyrimidine-H), 9.12 (s, 2H, NH2, disappeared with D2O),
10.32 (s, 1H, NH, disappeared with D2O). 13C-NMR (DMSO-d6) δc: 48.00 (CH2), 115.1, 120.0, 121.8,
126.8, 127.7, 128.7, 131.3, 136.5 (8C, thiophene-C), 78.5, 105.1, 118.5, 139.7, 150.0 (5C, pyridine-C), 157.0
(1C, pyrimidine-C), 165.6, 169.3 (2C, 2CO). Mass spectrum, m/z (EI, %): 400 (M+, 50). Analysis for




“Human breast cancer cells (MCF-7) and normal non-tumorigenic MCF-10A cells were used
throughout the work. Cells were obtained from ATCC, Gaithersburg, MD, USA. Standard MTT assay
was used to explore the possible cytotoxic effects of the synthesized compounds [41,42]. Medium
composition, cultivation conditions and assay performance were exactly the same as our previous
work [43,44]. Cells were treated with varying concentrations (0–1 μM) of the compounds prepared in
DMSO. After MTT addition, the absorbance of the dissolved formazan crystals was read at 570 nm [45].
The IC50 values were obtained with linear regression equations using Origin® 6.1 software (Origin Lab
Corporation, Northampton, MA, USA)”.
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3.2.2. Human Breast Cancer Xenograft Animal Model
“In this work, MCF-7 mouse xenograft model was used. The animal protocol was approved by
the Institutional Animal Use Ethics and Care Committee of the University of Alabama at Birmingham
(50-01-05-08B). Female athymic pathogen-free nude mice (nu/nu, 4–6 weeks) were purchased from
Frederick Cancer Research and Development Center (Frederick, MD, USA). To establish MCF-7
human breast cancer xenografts, each of the female nude mice was first implanted with a 60-day
(subcutaneously, s.c.) slow release estrogen pellet (SE-121, 1.7 mg 17α-estradiol/pellet; Innovative
Research of America, Sarasota, FL, USA). After 24 h, grown cells were harvested, washed twice
with serum-free medium, resuspended, and injected subcutaneously (5 million cells/0.2 mL) into the
left inguinal area of the mice. During the experiment, animals were checked periodically and the
percentages of tumor growth, as well as animal weights, were recorded. Every 48 h, the size of the
tumor was recorded by measuring two perpendicular diameters of the tumor and tumor volume was
calculated according to Wang et al. [46]”.
“Treated animals and control groups (7–10 mice/group) received different compounds and vehicles,
respectively. The tested compounds were dissolved in PEG400:ethanol:saline (57.1:14.3:28.6, v/v/v),
and injected intraperitoneal (i.p.) at doses of 5 and 10 μM/kg/d, 3 d/wk for 3 weeks. The higher dose
(10 μM/kg/d, 3 d/wk) inhibited MCF-7 xenograft tumor growth”.
3.2.3. Pim-1 Kinase Inhibitory Activity
Materials and Methods
“The kinase inhibitory activity of the synthesized compounds was determined using the Kinexus
compound profiling service, Canada. Compounds were tested at 50 nM concentration. The kinase used
was cloned, expressed and purified using proprietary methods. Quality control testing is routinely
performed to ensure compliance to acceptable standards. 33P-ATP was purchased from PerkinElmer.
All other materials were of standard laboratory grade”.
Pim-1 Kinase Protein Assay
“The protein kinase target profiling was executed via employing a radioisotope assay format.
All the assays were performed in a prepared radioactive working area. The protein kinase profiling
assays were performed at room temperature for 20–30 min in a final volume of 25 μL according to the
reported method [47]”.
4. Conclusions
During the current work, different new 14 thiophenyl thienopyrimidinone derivatives were
synthesized using variable cyclization and condensation routes. The synthesized derivatives showed
promising potential biological potentials for their use in the pharmaceutical industry. They revealed
higher in vitro cytotoxic activities against breast cancer cell line MCF-7 in comparison to known drugs,
e.g., Cisplatin and Milaplatin. Furthermore, the prepared derivatives proved to be less toxic against the
non-tumorigenic MCF-10A cell line. In vivo studies also showed potential reduction in tumor growth
in animal models for all synthesized derivatives compared to control animals. Finally, mechanism of
action studies showed that the newly synthesized derivatives exert their anticancer effects through the
inhibition of pim-1 kinase enzymes.
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Abstract: In this study, a series of newly synthesized substituted pyridine 9, 11–18, naphthpyridine
derivative 10 and substituted pyrazolopyridines 19–23 by using cycnopyridone 8 as a starting
material. Some of the synthesized candidates are evaluated as anticancer agents against different
cancer cell lines. In vitro cytotoxic activities against hepatocellular and cervical carcinoma cell lines
were evaluated using standard MTT assay. Different synthesized compounds exhibited potential
in vitro cytotoxic activities against both HepG2 and HeLa cell lines. Furthermore, compared to
standard positive control drugs, compounds 13 and 19 showed the most potent cytotoxic effect with
IC50 values of 8.78 ± 0.7, 5.16 ± 0.4 μg/mL, and 15.32 ± 1.2 and 4.26 ± 0.3 μg/mL for HepG2 and HeLa
cells, respectively.
Keywords: cyanopyridone; substituted pyridine; pyridotriazine; pyrazolopyridine; thioxotriazopyridine;
anticancer activity; HepG2; HeLa
1. Introduction
Multicomponent reactions (MCR) “in which three or more starting materials react to form a
product” play a significant role in the synthesis of heterocyclic compounds with pharmaceutical
and chemical importance [1]. Several nicotinonitriles have been constructed via (MCR) and showed
antitumor [2], antimicrobial [3], and antioxidant [4] activities. Also nicotinonitriles have been utilized as
a scaffold for the synthesis of heterocyclic compounds containing a pyridine moiety with antimicrobial
and antiviral activities [5]. A series of nicotinonitriles 1–3 (Figure 1) and have been synthesized and
anti-proliferative [6], anti-Alzheimer’s [7], and anti-inflammatory [8] activities.
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Figure 1. Nicotinonitriles with anti-proliferative, anti-Alzheimer’s anti-inflammatory activities.
The pyrazole moiety is both pharmacologically and medicinally significant [9]. A series of
pyrazoles 4–7 (Figure 2) has been reported as anti-inflammatory activity by Bekhit et al. [10],
they observed that the synthesized pyrazoles showed more anti-inflammatory activity than the standard
indomethacin [11]. Trisubstituted pyrazoles have been constructed by Christodoulou et al. (2010) [11]
and evaluated as anti-angiogenic agents; these derivatives showed a potent anti-angiogenic efficacy
and moreover inhibited the growth of Mammary gland breast cancer (MCF-7) and cervical carcinoma
(Hela) [12]. Recently novel derivatives of pyrazoles 5,6 have been prepared as antimicrobial [13] and
anticonvulsant [14] agents. The pyrazole 7 has been prepared by Bonesi et al. (2010) [15] and showed
effective Angiotensin -1-Converting Enzyme (ACE) inhibitor activity [15].
Figure 2. Pyrazoles as anti-inflammatory antimicrobial and anticonvulsant activities.
Based on the previous facts about the importance of pyrazoles and nicotinonitriles in medicinal
chemistry, we have herein synthesized of some novel heterocyclic candidates containing nicotinonitrile
and pyrazole moieties and tested their anticancer activity.
2. Results
2.1. Chemistry
The nicotinonitriles were obtained by two different ways, from the reaction of chalcone with
ethylcyanoacetate, ammonium acetate and drops of piperidine as a base and from one pot four
components reaction of methylketone, aldehyde, ethylcyanoacetate, ammonium acetate and drops
of piperidine as a base [15]. In prolongation of our work in the synthesis of heterocyclic compounds
and evaluation of their medicinal importance [16–27] and based on the literature survey about the
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pharmacological and medicinal importance of pyrazoles and nicotinonitriles, we have devoted our
efforts to design and synthesize novel heterocyclic compounds containing pyrazol and nicotine-nitrile
moieties, 4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-hydroxy-6-(naphthalen-1-yl)-nicotinenitrile
8 has been obtained by reacting of 1-acetylnaphthalene (A), 3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-carbaldehyde (B), ethyl 2-cyanoacetate, ammonium acetate and piperidine (Scheme 1).
 
Scheme 1. Synthesis of compound 8 as starting material.
The structure of the nicotinonitrile 8 has been confirmed from its spectral data. IR spectrum
showing absorption frequencies at ν 3159 cm−1, 2220 cm−1 and ν 1647 cm−1 for OH, C≡N and
C=N groups, respectively. Also, 1H-NMR spectrum of the assigned compound displayed signals
at δ 12.89 ppm (disappeared with D2O) corresponding to acidic OH. A compelling evidence for the
structure of 8 was provided by 13C-NMR spectrum that showed a singlet signal at δ 149.8, 139.3 and
139.3 ppm for C-OH, C=N and C≡N groups respectively. Mass spectra of 8 showed [M+] at m/z (%)
482 (22). Treatment of 8 with ethylchloroacetate afforded compound 9, which was hydrazinolysis with
NH2NH2 to give the corresponding cyclized product 10.
Remediation of the nicotinonitrile derivative 8 with malononitrile in the presence of few drops of
piperidine afforded 1,8-naphthyridine-3-carbonitrile derivative 11. Chlorination of 8 by a mixture of
(POCl3/PCl5) afforded 2-chloronicotinonitrile derivative 12, which was reacted with malono nitrile as a
carbon nucleophile gave the nicotinonitrile derivative 13. Reaction of 12 with primary and secondary
amines, namely, o-aminothiophenol, morpholine, 1-methylpiperazine and hydrazine hydrate gave
novel nicotinonitriles 14, 15a, b and 16 (Scheme 2). The mechanism formation route of compound 11
has been shown in Figure 3.
 
Figure 3. The mechanism formation route of compound 11.
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Scheme 2. Synthetic route for compounds 9–16.
Compound 16 was utilized as a building block for novel nicotinonitriles containing two pyrazole
moieties. 2-Pyrazolyl nicotinonitrile derivatives 17 and 18 were prepared by treatment of 16 with acetyl
acetone and 4,4,4,-trifluoro-1-(thiophen-2-yl)butane-1,3-dione, respectively. Treatment of 16 with acetic
anhydride and acetic acid afforded pyrazolopyridine derivative 19. The derivative 16 was treated
with acetic anhydride to afford the N-acetyl pyrazolopyridine as a sole product 20. The structure of
compound 20 was confirmed chemically by acetylation of the amino pyrazopyridine 19 (Scheme 3).
Treatment of 16 with 4-chlorobenzaldehyde and/or tetrachlorophthalic anhydride in the presence
of acetic acid afforded the cyclized 19 followed by condensation to give the Schiff’s base 21 and
tetra chloroisoindoline 22, respectively. The structures of 21 and 22 were confirmed chemically by
condensation of compound 19 with 4-chlorobenzaldehyde and/or tetrachlorophthalic anhydride to
provide compounds 21 and 22, respectively. Treatment of hydrazinyl derivative 16 with CS2 in the
presence of alcoholic KOH provided thioxotriazolo pyridine derivative 23 (Scheme 3).
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Scheme 3. Synthetic route for compounds 17–23.
2.2. Cytotoxic Activity
The newly synthesized compounds were screened for their anticancer potentials against
hepatocellular carcinoma HepG2 and cervical carcinoma HeLa. The cytotoxicity of the compounds
was determined using MTT assay and DOX as a positive control [28–31].
The cytotoxic activities of the novel synthesized compounds 8–23 were estimated and the obtained
results are presented in Figure 4. In general, it can be seen that all synthesized compounds exhibited
cytotoxic activities against both tested cancer cell lines. Moreover, it can be seen that both cells reacted
in a dose-dependent manner toward the applied concentrations. Additionally, both tested cell lines
varied in their response toward different synthesized compounds. Furthermore, based on the IC50
values (Table 1) obtained for the tested compounds, it can be seen that cytotoxic activities ranged
from very strong to non-cytotoxic. Compounds 13 and 19 exhibited the most potent cytotoxic effect
(very strong activity) with IC50 8.78 ± 0.7, 5.16 ± 0.4 μg/mL, and 15.32 ± 1.2 and 4.26 ± 0.3 μg/mL
for HepG2 and HeLa cells, respectively. Furthermore, it can be noticed that Cpd. 19 exhibited more
or less stronger activity similar to DOX towards HepG2 cells, (IC50 5.16 ± 0.4 and 4.50 ± 0.2 μg/mL,
respectively). On the other hand, it was stronger by about 23.5% than DOX against HeLa cells (4.50 ±
527
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0.2 and 5.57 ± 0.4 μg/mL, respectively). Additionally, Cpd. 18 showed very strong activity towards
HeLa cells with IC50value of 7.67 ± 0.6 μg/mL, while it exhibited strong activity towards HepG2
cells (IC50 16.70 ± 1.3 μg/mL). Moreover, Cpd. 14 showed strong cytotoxic activities towards both
tested cell lines (IC50values 12.20 ± 1.0 and 19.44 ± 1.4 μg/mL for HepG2 and HeLa cells, respectively).
Meanwhile, Cpds. 16 and 22 showed moderate and strong activities towards both cell lines. Cpd. 16
showed IC50value of 33.45 ± 2.3 and 10.37 ± 0.9 μg/mL against HepG2 and HeLa cells, respectively.
Also, Cpd. 22 showed IC50 of 26.64 ± 1.9 and 9.33 ± 0.8 μg/mL for HepG2 and HeLa cells, respectively.
On the other hand, Cpd. 17 showed strong activity towards HepG2 cells (IC50 20.00 ± 1.7 μg/mL) and
moderate activity towards HeLa cells (IC50 35.58 ± 2.6 μg/mL). Finally, Cpds. 9, 10, 11, 12, 15a, b, 17,
20, 21 and 23 showed activities ranging from moderate to non-cytotoxic, with IC50 values ranging from
24.83 ± 1.8 to >100 μg/mL.
μ
Figure 4. Relative viabilities of HepG2 and HeLa cells as affected by different synthesized compounds.
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8 20.00 ± 1.7 35.58 ± 2.6
9 42.95 ± 3.2 55.00 ± 3.7
10 56.57 ± 3.4 47.02 ± 3.4
11 30.22 ± 2.1 43.64 ± 3.3
12 83.82 ± 4.5 89.72 ± 4.7
13 8.87 ± 0.70 15.32 ± 1.2
14 12.20 ± 1.0 19.44 ± 1.4
15a 90.05 ± 5.1 >100
15b 68.19 ± 3.7 75.05 ± 4.5
16 33.45 ± 2.3 10.37 ± 0.9
17 49.66 ± 3.2 65.91 ± 4.1
18 16.70 ± 1.3 7.67 ± 0.60
19 5.16 ± 0.40 4.26 ± 0.30
20 64.39 ± 3.6 28.15 ± 2.2
21 37.42 ± 2.5 24.83 ± 1.8
22 26.64 ± 1.9 9.33 ± 0.80
23 73.48 ± 4.0 62.07 ± 3.9
Doxorubicin 4.50 ± 0.20 5.57 ± 0.40
* IC50: 1–10 is (very strong), 11–20 is (strong), 21–50 is (moderate), 51–100 is (weak) and above is 100 (non-cytotoxic).
3. Discussion
During current work, multi-component reaction strategy was used to synthesize of compound 8,
which was used as a building block for preparing 16 new derivatives. The cytotoxic potential of the
new prepared compounds has been evaluated against HepG2 and HeLa cells. Results obtained showed
potential cytotoxic activities against both cell lines. Compounds 13 and 19 showed the most cytotoxic
effects (IC50 8.78 ± 0.7 and 5.16 ± 0.4 μg/mL, for HepG2 cells, and 15.32 ± 1.2 and 4.26 ± 0.3 μg/mL
for HeLa cells, respectively). Also, results showed that both tested cell lines varied in their response
toward different synthesized compounds. This can be attributed to the inherent differences in both
cell lines in terms of membrane structure and organization, hence different cell lines react differently
towards different compounds [32–35].
Different activities of the prepared compounds may be attributed to the structure–activity
relationship of these compounds. It can be seen that conversion of Cpd. 12 to 13, 14 and 16, 18,
19 and 22 altered the cytotoxicity from weak to moderate and strong activity towards two cell lines.
This explained due to the introduction of two more nitrile groups, which significantly increased the
activity. Compound 14 exhibited very strong activity due to the entity of the SH and NH groups,
which may be added to any unsaturated group in DNA (thia or aza Michael addition) or the formation
of hydrogen bonds with either one of the nucleo-bases of the DNA, thus causing DNA damage.
Furthermore, the cytotoxicity of Cpd. 16 may be due to the intermolecular hydrogen bonding of NH
and NH2 groups with DNA moieties. Additionally, conversion of Cpd. 16 to 18, 19 and 22 increased
their cytotoxic activities against both cell lines. Introducing thiophene ring increases the cytotoxic
effect of Cpd. 18 beside the effect of the pyrazole ring and the trifluoromethyl group. Additionally,
introducing pyrazole ring bearing NH2 group to Cpd. 16 increases the cytotoxic effect of Cpd. 19 to
very strong effect against both cell lines. The introduction of chloroiso- indoline-1,3-dione increases the
cytotoxic effects of Cpd. 22. The chloro- group, with more electron withdrawing properties, may be
the crucial for tumor cell inhibition beside the effect of the isoindoline-1,3-dioneas moderate cytokine
inhibitor in cancer cells.
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4. Materials and Methods
4.1. Chemistry
“Melting points reported are inaccurate. IR spectra were registered on Shimadzu FT-IR 8300 E
(Shimadzu Corporation, Kyoto, Japan) spectrophotometer using the (KBr) disk technique. 1H-NMR
spectra were determined on a Varian Spectrophotometer at 400 MHz using (TMS) as an internal
reference and DMSO-d6 as solvent using (TMS) as internal standard. All chemical shifts (δ) are uttered
in ppm. The mass spectra were determined using (MP) model MS-5988 and Shimadzu single focusing
mass spectrophotometer (70 eV). Elemental analysis was investigated by Elemental analyzer Vario
EL III”.
4.1.1. Synthesis of 4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-hydroxy-6-(naphthalen-1-yl)-
nicotinenitrile (8)
A mixture of 1-acetyl naphthalene (A) (1.7 g, 0.01 mol), ethyl cyanoacetate (1.3 g, 0.01 mol),
aldehyde (B) (3.6 g, 0.01 mol), ammonium acetate (5.40 g, 0.07 mol) and three drops of piperidine in
ethanol (20 mL) was heated under reflux for 3 h. The obtained precipitate was filtered off, washed with
cold water, dried and crystallized from ethanol/dioxane to give compound 8. Yield 75%, yellow powder,
m.p. > 300 ◦C; IR (KBr): ν (cm−1) 3159 (OH), 2220 (C≡N), 1647 (C=N); 1H-NMR (DMSO-d6): δ
(ppm) 12.89 (s, 1H, OH, disappeared by D2O), 9.80 (s, 1H, pyrazole-H), 8.39–7.78 (m, 7H, Ar-H for
naphthalene), 7.75–7.37 (m, 10H, Ar-H). 13C NMR (DMSO-d6): δ (ppm) 149.8 (C-OH), 139.3 (C=N),
119.3 (C≡N), 139.4, 134.3, 133.8, 133.5, 131.6, 131.2, 131.0, 130.9, 130.4, 130.3, 130.2, 129.9, 129.4, 129.3,
129.2, 129.1, 128.9, 128.2, 127.8, 127.6, 127.0, 125.6, 125.1, 117.4, 114.8 (Ar-CH), 40.6, 39.9 (aliph-C);
MS m/z (ESI): 482 [M+] (22), 465 (21), 440 (12), 237 (100), 204; Anal. Calcd. for C31H19FN4O (482.50): C,
77.17; H, 3.97; N, 11.61. Found C, 76.98; H, 3.78; N, 11.52%.
4.1.2. Synthesis of ethyl 2-(3-cyano-4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalene-1-
yl)-2-oxopyridin-1(2H)-yl)acetate (9)
A mixture of 8 (4.84 g, 0.01 mol), ethylchloroacetate (1.22 g, 0.01 mol) and K2CO3 (2.2 g, 0.015 mol)
in (CH3)2O (40 mL) was heated under reflux for 24 h, concentrated and poured on water; the obtained
precipitate was collected by filteration off, dried and crystallized from EtOH/dioxane to give 9. Yield
74%, m.p. 158–160 ◦C; IR (KBr): ν (cm−1) 2204 (C≡N), 1751 (C=O ester), 1651 (C=O pyridine); 1H-NMR
(DMSO-d6): δ (ppm) 9.15 (s, 1H, pyrazole-5H), 8.10–7.49 (m, 7H, Ar-H for naphthalene), 7.48–7.33 (m,
10H, Ar-H), 4.16 (q, 2H, -CH2 ester), 3.40 (s, 2H, -CH2), 1.20 (t, 3H, -CH3, ester); MS m/z (ESI): 568 [M+]
(2.5), 495 (65), 237 (80), 127 (100); Anal. Calcd. for C35H25FN4O3 (568.60): C, 73.93; H, 4.43, N, 9.85.
Found C, 73.80; H, 4.21; N, 9.64%.
4.1.3. Synthesis of 8-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-3-oxo-3,4-
dihydro-2H-pyrido[2,1-c][1,2,4]triazine-9-carbonitrile (10)
A mixture of 9 (5.7 g, 0.01 mol), NH2NH2ηH2O (2 mL, 0.04 mol) and EtOH (20 mL) was heated
under reflux for 3 h. The outward appearance solid was filtered off, dried and crystallized from
EtOH/dioxane to give 10. Yield 71%, yellow powder, m.p. > 300 ◦C; IR (KBr): ν (cm−1) 3209 (NH),
2218 (C≡N), 1647 (C=O); 1H-NMR (DMSO-d6): δ (ppm) 12.38 (s, 1H, NH, disappeared in D2O), 9.13 (s,
1H, pyrazole-5H), 8.87–7.65 (m, 7H, Ar-H for naphthalene), 7.63–6.85 (m, 10H, Ar-H), 6.10 (s, 2H, CH2).
13C-NMR (DMSO-d6): δ (ppm) 165.8 (C=O), 139.7 (C=N), 136.1 (C=N), 133.8, 133.4, 131.7, 130.9, 130.8,
130.7, 130.6, 130.3, 130.2, 130.1, 129.9, 129.7, 129.2, 129.1, 128.8, 128.5, 128.1, 127.3, 126.8, 125.8, 125.6,
119.2, 119.1, 118.9, 118.5, 117.6 (Ar-CH), 119.3 (C≡N), 40.5, 39.9 (2CH), 17.6 (CH2); MS m/z (ESI): 519
[M+ − OH] (82), 393 (64), 284 (100), 237 (68), 127 (56); Anal. Calcd. for C33H21FN6O (536.50): C, 73.87;
H, 3.94; N, 15.66. Found C, 73.68; H, 3.24; N, 15.06%.
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4.1.4. Synthesis of 5-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-7-(naphthalen-1-yl)-2-oxo-1,2-
dihydro-1,8-naphthyridine-3-carbonitrile (11)
Refluxing of compound 8 (4.84 g, 0.01 mol) with malononitrile (0.015 mol) in ethanol (20 mL)
in the presence of drops of TEA for 5 h, then cooled, poured on ice/water, neutralized with drops of
conc. HCl. The obtained solid was collected by filtration, crystallized from EtOH/dioxane to afford
11. Yield 71%, pale brown powder, m.p. > 300 ◦C; IR (KBr): ν (cm−1) 3386, 3273 (NH2), 3158 (NH),
2218 (C≡N), 1646 (C=O), 1H-NMR (DMSO-d6): δ (ppm) 12.89 (s, 1H, NH, disappeared by D2O), 9.08 (s,
1H, pyrazole-5H), 8.07–7.61 (m, 7H, Ar-H for naphthalene), 7.60–7.37 (m, 10H, Ar-H), 6.22 (s, 2H, NH2,
disappeared in D2O). 13C-NMR (DMSO-d6): δ (ppm) 149.9 (C=O), 139.3 (C=N), 133.8, 133.5, 131.2,
131.1, 131.00 (2), 130.9, 130.4, 130.3 (2), 130.2, 129.9 (2), 129.4, 129.1, 128.9 (2), 128.2, 127.8(2), 127.6, 127.1
(2), 125.6, 125.2 (2), 117.4, 116.8, 110.0 (Ar-CH), 119.3 (C≡N), 40.6, 39.9 (2CH); MS m/z (ESI): 532 [M+ −
NH3] (82), 516 (76), 440 (28), 310 (20), 237 (100); Anal. Calcd. for C34H21FN6O (548.50): C, 74.44; H,
3.89; N, 15.32. Found C, 74.24; H, 3.25; N, 14.98%.
4.1.5. Synthesis of 2-chloro-4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-
nicotinenitrile (12)
A mixture of 8 (4.82 g, 0.01 mol), PCl5 (3 g, 0.03 mol) and POCl3 (5 mL, 0.03 mol) was heated
under reflux for 8 h, then it was poured on crushed ice. The formed solid was filtered off, dried and
crystallized from EtOH/dioxane to give 12. Yield 61%, yellow powder, m.p. 164–166 ◦C; IR (KBr): ν
(cm−1) 2227 (C≡N), 1628 (C=N); 1H-NMR (DMSO-d6): δ (ppm) 9.16 (s, 1H, pyrazole-5H), 8.35–7.63
(m, 7H, Ar-H for naphthalene), 7.61–7.39 (m, 10H, Ar-H). 13C-NMR (DMSO-d6): δ (ppm) 152.7, 150.0,
148.4, 139.2 (C=N), 135.3(C=N), 133.8, 131.5, 131.0, 130.4, 130.3, 130.2, 129.8, 129.5, 129.2 (2), 129.1, 127.9,
127.6, 126.9, 125.8 (2), 125.4, 125.1, 119.3 (C≡N), 116.6, 115.5, 107.8 (Ar-CH), 40.6, 39.9 (2CH); MS m/z
(ESI): 503 [M+ + 2] (6), 501 [M+] (50), 465 (100), 237 (82); Anal. Calcd. for C31H18ClFN4 (500.90): C,
74.32; H, 3.62; N, 11.84. Found C, 74.12; H, 3.26; N, 11.42%.
4.1.6. Synthesis of 2-[4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-3-cyano-
pyridinyl]malononitrile (13)
To a solution of 12 (5.0 g, 0.01 mol) in EtOH (20 mL), malononitrile (0.01 mol) and TEA (1 mL)
were added. The reaction mixture was heated under for 3 h. After cooling, it was poured on water
and neutralized with diluted HCl. The obtained solid was separated by filtration, washed with water,
dried and crystallized from EtOH/dioxane to yield 13. Yield 76%, pale brown powder, m.p. 194–196 ◦C;
IR (KBr): ν (cm−1) 2203 (C≡N), 1H-NMR (DMSO-d6): δ (ppm) 9.15 (s, 1H, pyrazole-5H), 8.11–7.66
(m, 7H, Ar-H for naphthalene), 7.65–7.36 (m, 10H, Ar-H), 7.07 (s, 1H, CH of CH(CN)2), MS m/z (ESI):
530 [M+] (12), 440 (100), 237 (76), 204 (31); Anal. Calcd. for C34H19FN6 (530.50): C, 76.97; H, 3.61; N,
15.84. Found C, 76.78; H, 3.42; N, 15.24%.
4.1.7. Synthesis of 14 and 15a,b
A mixture of 2-chloronicotinonitrile 12 (5.0 g, 0.01 mol) and the appropriate amine, namely,
o-aminothiophenol, morpholine or 2-methylpiperidine (0.01 mol) in EtOH (20 mL) was heated under
reflux for 3 h, then it was poured on cold water, filtered off and crystallized from EtOH/dioxane to
afford 14 and 15a,b, respectively.
4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-(2-mercaptophenylamino)-6-(naphthalen-1-yl)
nicotinonitrile (14). Yield 74%, brown powder, m.p. 108–110 ◦C; IR (KBr): ν (cm−1) 3330 (NH),
2208 (C≡N), 1H-NMR (DMSO-d6): δ (ppm) 9.29 (s, 1H, pyrazole-5H), 9.06–8.54 (m, 4H, Ar-H,
thionyl-H), 8.26–7.66 (m, 7H, Ar-H for naphthalene), 7.60–6.66 (m, 10H, Ar-H), 3.34 (s, 1H, NH,
disappeared in D2O), 1.20 (s, 1H, SH, disappeared in D2O). MS m/z (ESI): 589 [M+] (32), 465 (82),
441 (62), 237 (100), 127(12), 124 (20); Anal. Calcd. for C37H24FN5O (589.60): C, 75.36, H, 4.10; N, 11.88.
Found C, 75.18; H, 4.05; N, 11.73%.
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4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-morpholino-6-(naphthalen-1-yl)nicotino-
nitrile (15a). Yield 65%, pale brown powder, m.p. 130–133 ◦C; IR (KBr): ν (cm−1) 2226 (C≡N), 1H-NMR
(DMSO-d6): δ (ppm) 9.16 (s, 1H, pyrazole-5H), 8.71–7.56 (m, 7H, Ar-H for naphthalene), 7.55–7.15
(m, 10H, Ar-H), 3.76 (t, 4H, J = 8.8 Hz), 3.05 (t, 4H, J = 8.8 Hz), MS m/z (ESI): 552 [M+] (52), 465 (28),
237 (100), 230 (7), 127 (12), 87 (22); Anal. Calcd. for C35H26FN5O (551.60): C, 76.21; H, 4.75; N, 12.70.
Found C, 75.98; H, 4.26; N, 12.31%.
4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-(4-methylpiperazin-1-yl)-6-(naphthalen-1-yl)
nicotinonitrile (15b). Yield 61%, brown powder, m.p. 156–158 ◦C; IR (KBr): ν (cm−1) 2918 (aliph-H),
2227 (C≡N), 1H-NMR (DMSO-d6): δ (ppm) 9.18 (s, 1H, pyrazole-5H), 8.71–7.65 (m, 7H, Ar-H for
naphthalene), 7.64–7.12 (m, 10H, Ar-H), 3.30–3.25 (m, 4H, 2CH2), 2.43–2.23 (m, 4H, 2CH2), 2.24 (s, 3H,
CH3), MS m/z (ESI): 564 [M+] (27), 538 (25), 439 (12), 237 (100), 100 (23); Anal. Calcd. for C35H29FN6
(564.60): C, 76.58, H, 5.18; N, 14.88. Found C, 75.98; H, 4.92; N, 14.72%.
4.1.8. Synthesis of 4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-hydrazinyl-6-(naphthalen-1-yl)
nicotinonitrile (16)
A mixture of the 2-chloronicotinonitrile 12 (5.0 g, 0.01 mol) and NH2NH2·H2O (0.04 mol) in
EtOH (20 mL) was heated under reflux for 4h. The obtained solid was collected by filtration,
dried and crystallized from EtOH/dioxane to yield 16. Yield 86%, yellow powder, m.p. 164–168 ◦C;
IR (KBr): ν (cm−1) 3417, 3310 (NH2), 3199 (NH), 2206 (C≡N), 1H-NMR (DMSO-d6): δ (ppm) 9.16 (s,
1H, pyrazole-5H), 8.35–7.97 (m, 7H, Ar-H for naphthalene), 7.96–6.88 (m, 10H, Ar-H), 4.82 (s, 1H,
NH, disappeared in D2O), 3.43 (s, 2H, NH2, disappeared in D2O). 13C-NMR (DMSO-d6): δ (ppm)
149.3 (C-NHNH2), 148.3, 139.7 (C≡N), 139.2, 138.5, 136.1 (C=N), 135.3, 134.0, 133.8, 131.7, 131.5, 131.0,
130.9, 130.4, 130.2, 130.1, 129.5, 129.1, 128.1, 127.9, 127.6, 127.3, 126.9, 126.7, 126.4, 125.8, 125.4, 119.3
(C≡N), 118.2 (Ar-CH), 40.6, 40.0 (2CH); MS m/z (ESI): 496 [M+] (12), 465 (81), 440 (100), 237 (20), 204 (76);
Anal. Calcd. for C31H21FN6 (496.55): C, 74.99; H, 4.26; N, 16.93. Found C, 74.86; H, 4.12; N, 16.78%.
4.1.9. Synthesis of 17 and 18
A mixture of 16 (4.9 g, 0.01 mol), acetylacetone or 4,4,4-trifluoro-1-(thiophen-2-yl)butane-1,3-dione
(0.01 mol) in EtOH (10 mL) and AcOH (4 mL) was heated reflux for 3 h. After cooling, the solid
obtained was filtered off, dried and crystallized from EtOH/dioxane to afford 17 and 18, respectively.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-
(naphthalen-1-yl)nicotinonitrile (17). Yield 85%, pale orange powder, m.p. 270–272 ◦C; IR (KBr): ν
(cm−1) 2209 (C≡N), 1620 (C=N), 1H-NMR (DMSO-d6): δ (ppm) 9.24 (s, 1H, pyrazole-5H), 8.17–7.96 (m,
7H, Ar-H for naphthalene), 7.66–7.35 (m, 10H, Ar-H), 7.25 (s, 1H, pyrazole-4H), 2.48 (s, 6H, 2 CH3);
MS m/z (ESI): 560 [M+] (13), 533 (26), 438 (62), 237 (15), 95 (100); Anal. Calcd. for C36H25FN6 (560.60):
C, 77.13; H, 4.49; N, 14.99. Found C, 76.92; H, 4.32; N, 14.81%.
4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-2-(5-(thiophen-2-yl)-3-(tri-
fluoromethyl)-1H-pyrazol-1-yl)nicotinonitrile (18). Yield 82%, dark yellow powder, m.p. 117–119 ◦C;
IR (KBr): ν (cm−1) 2209 (C≡N), 1H-NMR (DMSO-d6): δ (ppm) 8.92 (s, 1H, pyrazole-5H), 8.03–7.89
(m, 7H, Ar-H for naphthalene), 7.59–7.54 (m, 3H, thionyl-H), 7.53–7.33 (m, 10H, Ar-H), 6.88 (s, 1H,
pyrazole-4H); MS m/z (ESI): 583 [M+] (10), 465 (72), 237 (100), 299 (8), 217 (5); Anal. Calcd. for
C39H22F4N6S (682.60): C, 68.61; H, 3.25; N, 12.31. Found C, 68.02; H, 3.12; N, 12.03%.
4.1.10. Synthesis of 19 and 20
A solution of 16 (4.9 g, 0.01 mol) in a mixture of AcOH/Ac2O (10 mL) or in glacial AcOH (10
mL) was refluxed for 2 h, poured on ice/water, filtered off and crystallized from EtOH/dioxane to give
19 and 20, respectively. Also, refluxing of 19 (0.5 g, 0.01 mol) in acetic anhydride (7 mL) afforded
compound 20.
4-(3-(4-Flurophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-1H-pyrazolo[3,4-b]pyridin-3-
amine (19). Yield 84%, pale yellow powder, m.p. 140–143 ◦C; IR (KBr): ν (cm−1) 3425–3354 (NH2),
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3198 (NH), 1H-NMR (DMSO-d6): δ (ppm) 8.92 (s, 1H, pyrazole-5H), 8.22–7.90 (m, 7H, Ar-H for
naphthalene), 7.66–7.34 (m, 10H, Ar–H), 5.02 (s, 2H, NH2, disappeared in D2O), 4.63 (s, 1H, NH,
disappeared in D2O); MS m/z (ESI): 496 [M+] (28), 479 (76), 244 (50), 237 (100); Anal. Calcd. for
C31H21FN6 (496.52): C, 74.99; H, 4.26; N, 16.93. Found C, 74.76; H, 4.15; N, 16.82%.
N-(4-(3-(4-Flurophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-1H-pyrazolo-[3,4-b]
pyridin-3-yl)acetamide (20). Yield 78%, yellow powder, m.p. 138–140 ◦C; IR (KBr): ν (cm−1) 3196
(NH), 1690 (C=O), 1H-NMR (DMSO-d6): δ (ppm) 12.37 & 10.31 (s, NH, OH), 8.88 (s, 1H, pyrazole- 5H),
7.98–7.59 (m, 7H, Ar-H for naphthalene), 7.57–6.88 (m, 10H, Ar-H), 4.82 (s, 1H, NH, disappeared in
D2O), 2.73 (s, 3H, acetyl); MS m/z (ESI): 538 [M+] (20), 479 (36), 244 (20), 237 (100); Anal. Calcd. for
C33H23FN6O (538.59): C, 73.59; H, 4.30; N, 15.60. Found C, 73.28; H, 4.19; N, 15.32%.
4.1.11. Synthesis of N-(4-chlorobenzylidene)-4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-
(naphthalen-1-yl)-1H-pyrazolo[3,4-b]pyridine-3-amine (21)
A solution of 16 or 19 (0.01 mol) in AcOH (10 mL) in the presence of 4-chlorobenzaldehyde (0.01
mol) was heated under reflux for 2 h, left to precipitate, filtered and crystallized from EtOH/ dioxane
to afford 21. Yield 58%, yellow powder, m.p. 158–160 ◦C; IR (KBr): ν (cm−1) 3192 (NH), 1H-NMR
(DMSO-d6): δ (ppm) 9.89 (s, 1H, pyrazole-5H), 9.06 (s, 1H, N=C-H), 8.87–7.56 (m, 7H, Ar-H for
naphthalene), 7.52–6.88 (m, 14H, Ar-H), 4.82 (s, 1H, NH, disappeared in D2O); MS m/z (ESI): 621 [M+]
(15), 619 (48), 479 (20), 237 (80), 139 (35), 137 (100); Anal. Calcd. for C38H24ClFN6 (619.10): C, 73.72; H,
3.91; N, 13.57. Found C, 73.25; H, 3.82; N, 13.27%.
4.1.12. Synthesis of 2-(4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(naphthalen-1-yl)-1H-
pyrazolo[3,4-b]-pyridin-3-yl)isoindoline-1,3-dione (22)
A mixture of 16 or 19 (0.01 mol) and tetrachlorophthalic anhydride (0.01 mol) in glacial acetic acid
(10 mL) was refluxed for 1 h, poured on ice water, filtered off and crystallized from EtOH/dioxane to
yield 22. Yield 94%, yellow powder, m.p. 115–117 ◦C; IR (KBr): ν (cm−1) 3196 (NH), 1785, 1731 (C=O);
1H-NMR (DMSO-d6): δ (ppm) 8.87 (s, 1H, pyrazole-5H), 8.04–7.56 (m, 7H, Ar-H for naphthalene),
7.55–7.33 (m, 10H, Ar-H), 4.28 (s, 1H, NH, disappeared in D2O); Anal. Calcd. for C39H19Cl4FN6O2
(764.42): C, 61.28; H, 2.51; N, 10.99. Found C, 61.00; H, 2.42; N, 10.89%.
4.1.13. Synthesis of 7-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(naphthalen-1-yl)-3-thioxo-
2,3-dihydro[1,2,4]triazolo[4,3-a]pyridine-8-carbonitrile (23)
Solution of hydrazinyl derivative 16 (4.9 g, 0.01 mol) in alcoholic KOH (10%, 20 mL) and CS2
(0.01 mol) was refluxed for 2 h, lift overnight, then poured on ice water, filtered off the solid obtained
and crystallized from EtOH/dioxane to afford 23. Yield 47% yellow powder, m.p. 288–290 ◦C; IR (KBr):
ν (cm−1) 3192 (NH), 2218 (C≡N), 1240 (C=S); 1H-NMR (DMSO-d6): δ (ppm) 8.73 (s, 1H, pyrazole-5H),
7.97–7.63 (m, 7H, Ar-H for naphthalene), 7.53–6.77 (m, 10H, Ar-H), 3.76 (s, 1H, NH, disappeared in
D2O). 13C-NMR (DMSO-d6): δ (ppm) 148.1 (C=S), 142.3, 138.7 (C=N), 133.8 (2), 133.4 (C=N), 131.7
(2), 131.2, 130.6 (2), 130.1, 129.9 (2), 129.4, 129.2 (2), 128.9, 128.4 (2), 126.9, 126.4 (2), 126.3 (2), 125.9 (2),
119.1 (C≡N), 110.0 (Ar-CH), 40.5, 39.9 (2CH); MS m/z (ESI): 538 [M+] (45), 494 (18), 479 (10), 453 (50),
237 (100); Anal. Calcd. for C32H19FN6S (538.60): C, 71.36; H, 3.56; N, 15.60. Found C, 71.31; H, 3.52;
N, 15.58%.
4.2. Cytotoxicity Assay
4.2.1. Materials and Cell Lines
Hepatocellular carcinoma (HepG2) and cervical Carcinoma (HeLa) cell lines, ATCC, VA, USA,
were used throughout the work. All used chemicals and reagents were of high purity-cell culture grade.
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4.2.2. MTT Assay
Cytotoxic assay depends on the formation of purple formazan crystals by the action of
dehydrogenase in living cells. Cells were cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum, antibiotic solution (100 units/mL penicillin, 100 μg/mL streptomycin) at 37 ◦C
in a 5% CO2 incubator. Cells were seeded in a 96-well plate (104 cells/well), and the plates were
incubated for 48 h. Afterwards, cells were exposed to variable concentrations of prepared derivatives
and incubation proceeded for further 24 h. After treatment, 20 μL of MTT solution (5 mg/mL) was
added and incubated for 4 h. DMSO (100 μL/well) is added and the developed color density was
measured at 570 nm using a plate reader (ELx 800, BioTek, Winuski, VT, USA). Relative cell viability
was calculated as (Atreated/Auntreated) ×100 [36,37]. Results were compared with doxorubicin as a
positive control.
5. Conclusions
During the current investigation, we synthesized a new building block; namely
4-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-2-hydroxy-6-(naphthalen-1-yl)nicotinonitril, with the
help of multicomponent reaction systems. From that compound, a series of 16 different nicotinonitril
derivatives were synthesized, and their structural and spectral data were elucidated. Furthermore,
in vitro cytotoxic activities against hepatocellular and cervical carcinoma cell lines were investigated.
Obtained results revealed that different synthesized compounds showed promising in vitro cytotoxic
activities against both HepG2 and HeLa cell lines. Compounds 13 and 19 showed the most potent
cytotoxic effect (IC50: 8.78 ± 0.7, 5.16 ± 0.4 μg/mL, and 15.32 ± 1.2 and 4.26 ± 0.3 μg/mL for HepG2 and
HeLa cells, respectively.
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Abstract: To discover new antiproliferative agents with high efficacy and selectivity, a new series of
1-aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea derivatives (7a–7t) were designed, synthesized and
evaluated for their antiproliferative activity against A549, HCT-116 and PC-3 cancer cell lines in vitro.
Most of the target compounds demonstrated significant antiproliferative effects on all the selective
cancer cell lines. Among them, the target compound, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-
{4-{{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}thio}phenyl}urea (7i) was identified to be
the most active one against three cell lines, which was more potent than the positive control with an IC50
value of 1.53 ± 0.46, 1.11 ± 0.34 and 1.98 ± 1.27 μM, respectively. Further cellular mechanism studies
confirmed that compound 7i could induce the apoptosis of A549 cells in a concentration-dependent
manner and elucidated compound 7i arrests cell cycle at G1 phase by flow cytometry analysis. Herein,
the studies suggested that the 1-aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea skeleton might be
regarded as new chemotypes for designing effective antiproliferative agents.
Keywords: antiproliferative agent; urea; synthesis; antiproliferative activity; apoptosis
1. Introduction
Cancer is a major public health problem in developed countries and will become the most serious
life-threatening disease worldwide in the near future [1]. Some advances in cancer treatment by
molecule-targeted drugs, such as imatinib, gefitinib, and trastuzumab, were expected to improve cancer
cure rates and also to reduce severe adverse reactions because of the high specificity of the targeted
molecules, which are expressed and have critical roles in cancer cells, but not in normal cells. However,
the clinical effect was found to be limited and did not last for a long time period because of the acquired
resistance of the tumor cells. Furthermore, these molecules often cause on-target and/or off-target
severe toxicity [2]. Therefore, the development of more target-specific therapy, with minimum toxicity,
is warranted to extend disease-free survival and improve the quality of life of cancer patients.
In recent years, proton pump inhibitors (PPIs) as potential anticancer agents were intensively
studied in cancer treatment. Lugini et al. compared the anti-tumor efficacy of different PPIs, including
omeprazole, esomeprazole, lansoprazole, rabeprazole and pantoprazole in vitro and in vivo. The
Molecules 2019, 24, 2108; doi:10.3390/molecules24112108 www.mdpi.com/journal/molecules537
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result indicated that all the PPIs have shown different degrees of antitumor efficacy and lansoprazole
showed a higher anti-tumor effect when compared to the other PPIs. [3]. Recently, the research by
Zeng and Zheng et al. indicated that T-cell originated protein kinase (TOPK) activities were inhibited
by pantoprazole and ilaprazole with high affinity and selectivity [4,5]. TOPK (also known as PBK or
PDZ-binding kinase) was first reported by Abe et al. in 2000 [6], and it is a Ser/Thr protein kinase
overexpressed in hematologic tumors, breast cancer, melanoma, colorectal cancer, prostate cancer,
cervical cancer, bladder cancer and lung cancer [7–14]. The results of their studies demonstrated
that pantoprazole can suppress the growth of colorectal cancer cells as a TOPK inhibitor both in vitro
and in vivo, and also showed that the TOPK activities were inhibited by ilaprazole in HCT-116, ES-2,
A549, SW1990 cancer cells in vitro [4,5]. As shown in Figure 1, all of the PPIs molecules contain
thiomethylpyridine fragments. It can be predicted that these fragments should play an important role
in the antiproliferative activity of proton pump inhibitors.
 
Figure 1. Chemical structures of proton pump inhibitors (PPIs).
As known, the diaryl urea is a fragment of great importance in medicinal chemistry and can be used
for the synthesis of numerous heterocyclic compounds with diversified biological activities, including
antithrombotic [15], antimalarial [16], antibacterial [17,18] and anti-inflammatory [19] properties, and
it is characterized by its ability to form hydrogen bond interactions with drug targets [20–22]. The
carbonyl oxygen atom acts as a proton acceptor while the two amide nitrogen atoms are proton donors
(Figure 2). This unique type of structure endows urea derivatives with the ability to bind a variety of
enzymes and receptors in the biological systems. Remarkably, the diaryl urea moiety is widely used in
the design of anticancer drugs, such as sorafenib, regorafenib, linifanib and tivozanib (Figure 3).
Figure 2. H-bond acceptor and donors within the diaryl urea scaffold.
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Figure 3. Some anticancer drugs of the diaryl urea moiety.
Molecular hybridization strategy is a useful concept in drug design and development based on the
combination of pharmacophoric moieties of different bioactive substances to produce a new structure,
the affinity and efficacy would be improved, when compared to the parent drugs [23]. These above
interesting findings and our continuous quest to identify more potent antiproliferative agents led to
the molecular hybridization of diaryl urea and thiomethylpyridine to integrate them in one molecular
platform to generate a new hybrid, as shown in Figure 4, and expected that taking this way could get
the antiproliferative agents with highly inhibitory activity.
 
 
Figure 4. Rational design of the target compounds based on molecular hybridization strategy.
2. Results and Discussion
2.1. Chemistry
The general synthetic route is illustrated in Scheme 1. The reaction of the commercially
available 4-nitrobenzenethiol (1) with 2-(chloromethyl)pyridine derivatives (2) in ethanol at r.t. (room
temperature) obtained compounds 3a–3d [24], which converted to key intermediates 4a–4d via Pd-C
catalytic hydrogenation reduction [25]. The aryl isocyanates 6a–6e were prepared by reaction between
aromatic amines and bis(trichloromethyl)carbonate (BTC) [26]. Finally, treatment of 4a–4d with aryl
isocyanates 6a–6e in methylene dichloride yielded 1-aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea
derivatives (7a–7t) as the target compounds [26]. The structures of the target compounds were
characterized by infraredspectra (IR), proton nuclear magnetic resonance spectra (1H-NMR), carbon
nuclear magnetic resonance spectra (13C-NMR), electrospray ionization mass spectra (ESI-MS) and
high-resolution mass spectra (HRMS).
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Scheme 1. Synthetic route of the target compounds 7a–7t. Reagents and conditions: (a) NaOH (aq.
2M), EtOH, r.t.; (b) H2, 1 atm, 10% Pd-C, MeOH, r.t.; (c) BTC, Et3N, CH2Cl2, r.t.; (d) intermediate 4, aryl
isocyanates 6a–6e, CH2Cl2, r.t.
2.2. Biological Evaluation
2.2.1. Antiproliferative Activity
Using sorafenib as a positive control, all of the target compounds were evaluated for the
antiproliferative activity in vitro against cancer cell lines, including A549 (lung cancer), HCT-116
(colorectal cancer), and PC-3 (prostate cancer) cell lines by MTT assay. The antiproliferative assay
results evaluated as IC50 value (Table 1) and demonstrated that several target compounds have shown
moderate to excellent potency against A549, HCT-116, and PC-3 cancer cell lines. Among the target
compounds7i showed the more potent inhibitory effect against three cancer cell lines than positive
control with IC50 values of 1.53 ± 0.46, 1.11 ± 0.34 and 1.98 ± 1.27 μM, respectively.
All the target compounds could be divided into four classes according to different substituents
on the pyridine ring (Figure 5). The analyses of the structure-activity relationships (SARs) were
summarized as follows: (1) The results of cytostatic activity assay showed that the substitutions of
the 4 (R4) and 5 (R5) positions of the C ring had a weak effect on the inhibitory activity. However, if
the 3-position (R3) hydrogen atom of the C ring was substituted by a methoxy group, the inhibitory
activity was significantly decreased. At the same time, it could be seen that the inhibitory activity was
better than other classes when the 4-position (R4) of the C ring was occupied by the trifluoroethoxy
group. (2) The substituents on the A ring had a significant effect on the inhibitory activity of each class.
When the substituents on C ring were the same, if there was no substituent on A ring, the inhibitory
activity was worst in each class, such as compound 7a, 7f, 7k and 7p. Moreover, when the substituents
in A ring were electron-withdrawing groups, such as 4-Cl or 3-CF3, the inhibitory activity was better
than that substitution of the electron-donating groups, such as 4-OCH3 in each class. Furthermore,
when the two electron-withdrawing groups coexist on the A ring, the target compounds displayed the
strongest inhibitory activity, such as compound 7d, 7i, 7n and 7s.
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Figure 5. SARs summary for the target compounds.
Table 1. The chemical structures and inhibitory activities of the target compounds.




7a H -CH3 -O(CH2)3OCH3 H 12.31 ± 1.90 29.26 ± 4.53 27.22 ± 3.36
7b 4-chloro -CH3 -O(CH2)3OCH3 H 3.03 ± 2.79 4.80 ± 1.57 6.00 ± 0.22
7c 4-methoxy -CH3 -O(CH2)3OCH3 H 6.35 ± 0.51 5.29 ± 0.22 6.95 ± 1.24
7d 4-chloro-3-trifluoromethyl -CH3 -O(CH2)3OCH3 H 2.02 ± 2.20 1.94 ± 3.45 3.97 ± 1.02
7e 3-trifluoromethyl -CH3 -O(CH2)3OCH3 H 2.90 ± 0.36 3.78 ± 1.41 11.48 ± 0.98
7f H -CH3 -OCH2CF3 H 14.29 ± 1.77 19.31 ± 3.64 20.40 ± 2.89
7g 4-chloro -CH3 -OCH2CF3 H 2.23 ± 1.27 3.04 ± 0.37 6.78 ± 0.23
7h 4-methoxy -CH3 -OCH2CF3 H 4.71 ± 0.11 12.09 ± 1.46 15.65 ± 0.69
7i 4-chloro-3-trifluoromethyl -CH3 -OCH2CF3 H 1.53 ± 0.46 1.11 ± 0.34 1.98 ± 1.27
7j 3-trifluoromethyl -CH3 -OCH2CF3 H 4.22 ± 0.99 10.69 ± 0.87 14.33 ± 3.24
7k H -CH3 -OCH3 -CH3 13.37 ± 0.81 >100 >100
7l 4-chloro -CH3 -OCH3 -CH3 2.23 ± 1.38 3.20 ± 2.75 5.97 ± 0.55
7m 4-methoxy -CH3 -OCH3 -CH3 5.27 ± 1.01 3.49 ± 0.78 6.95 ± 0.35
7n 4-chloro-3-trifluoromethyl -CH3 -OCH3 -CH3 2.63 ± 1.25 2.51 ± 0.15 6.32 ± 1.68
7o 3-trifluoromethyl -CH3 -OCH3 -CH3 4.88 ± 1.02 3.50 ± 0.13 7.18 ± 1.58
7p H -OCH3 -OCH3 H 26.98 ± 4.12 45.93 ± 6.65 30.95 ± 5.41
7q 4-chloro -OCH3 -OCH3 H 14.52 ± 2.67 5.15 ± 1.01 18.57 ± 2.34
7r 4-methoxy -OCH3 -OCH3 H 16.47 ± 4.51 33.10 ± 2.90 22.51 ± 3.07
7s 4-chloro-3-trifluoromethyl -OCH3 -OCH3 H 6.23 ± 0.60 5.61 ± 0.66 10.05 ± 2.23
7t 3-trifluoromethyl -OCH3 -OCH3 H 14.13 ± 1.82 17.37 ± 1.69 19.77 ± 0.74
sorafenib 2.12 ± 0.18 2.25 ± 0.71 3.60 ± 1.08
a Inhibitory activity was assayed by exposure for 72 h to substance and expressed as the concentration
required to inhibit tumor cell proliferation by 50% (IC50). Data are presented as the means ± SEMs of three
independent experiments.
2.2.2. Cell Apoptosis Assay
The acceptable antiproliferative activity of compound 7i promoted us to investigate its effect on
cell apoptosis. To explore the effect of compound 7i on cell apoptosis, the apoptotic analysis was
performed with Annexin V-FITC/PI double staining and analyzed with flow-cytometry calculation.
Treatment of A549 cells with compound 7i resulted in a concentration-dependent apoptosis increase,
as shown in Figure 6. Specifically, the percentage of early/primary apoptotic cells was about 4.33%
for the low concentration (1 μM) of compound 7i. When treated with high concentration (10 μM) of
compound 7i, around 29.47% of early/primary apoptosis rate was observed. While the late apoptosis
rate of A549 cells was not changed significantly with increasing concentrations.
2.2.3. Cell Cycle Analysis
The effect of compound 7i on the cell cycle was also evaluated. After treatment of A549 cells with
compound 7i for 24 h at indicated concentrations (1, 5, 10 μM), the percentage of cells in G1 phase were
60.77%, 78.05% and 90.65%, respectively (Figure 7), suggesting that compound 7i caused an obvious
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G1 arrest in a concentration-dependent manner with a concomitant decrease in terms of the number of
cells in other phases of the cell cycle.
 
Figure 6. Compound 7i induced apoptosis of A549 cells. (A) Apoptosis effect on A549 cell line induced
by compound 7i for 24 h using Annexin V-FITC/PI double staining and flow-cytometry calculation.
The lower left quadrant represents live cells, the lower right is for early/primary apoptotic cells, upper
right is for late/secondary apoptotic cells, and the upper left represents cells damaged during the
procedure; (B) Quantitative analysis of apoptotic cells. The experiments were performed three times,
and a representative experiment is shown.
Figure 7. Effects of compound 7i on A549 cell cycle progress for 24 h. (A) Treatment of A549 cells with
compound 7i at different concentrations (1 μM, 5 μM, 10 μM) for 24 h. (B) Quantitative analysis of cell
cycle. The experiments were performed three times, and a representative experiment is shown.
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3. Materials and Methods
3.1. Synthesis
All reagents were obtained from commercial suppliers and used without further purification.
Reaction progress was monitored by thin layer chromatography (TLC) on silica gel plates. The spots
were visualized by ultraviolet (UV) light (254 nm). The column chromatography was performed
using 200−300 mesh silica gel (Qingdao PUKE, Qingdao, China). Melting points were obtained by
X-5 micro-melting point apparatus (Beijing Zhongyi Boteng Technology Co., Ltd., Beijing, China) and
were uncorrected. 1H-NMR and 13C-NMR spectra were recorded on Bruker NMR spectrophotometers
(Karlsruhe, Germany) using DMSO-d6 as the solvent and TMS as the internal standard. Mass spectra
were measured with an electrospray (ESI-MS) on a Waters spectrometer (Waters Corporation, Milford,
MA, USA). High resolution mass spectrometry (HRMS) analyses were performed on an Agilent
Technologies 6530 Accurate-Mass Q-TOF Mass Spectrometer (Santa Clara, CA, USA). The purities
were determined by high-performance liquid chromatography (HPLC) using an Agilent 1100 series
HPLC (Santa Clara, CA, USA).
The original figures of 1H-NMR, 13C-NMR, MS and HRMS of all the target compounds as the
Supplementary Materials are available online.
3.1.1. General Procedure for the Preparation of 2-{[(4-nitrophenyl)thio]methyl}pyridine
Derivatives (3a–3d)
4-Nitrobenzenethiol 1 (1.55 g, 0.01 mol), and 2-(chloromethyl)pyridine hydrochloride derivatives 2
(0.01 mol) were dissolved in EtOH (100 mL), then aqueous NaOH (2M) was added dropwise. After the
addition completed, the solution was stirred for 8 h at room temperature. Upon completion, the excess
ethanol was evaporated to give the residue. A large number of white solids have been precipitated
when 200 mL of water was added. The Precipitate was filtered off and washed with water to obtain the
intermediates (3a–3d), which was used for next step without further purification.
4-(3-Methoxypropoxy)-3-methyl-2-{[(4-nitrophenyl)thio]methyl}pyridine (3a) by using compound 1 (1.55 g,
0.01 mol) and 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine hydrochloride (2.66 g,
0.01 mol), obtained a yellow solid (3.12 g) in 89.7% yield. ESI-MS (m/z): 349.3 ([M + H]+).
3-Methyl-2-{[(4-nitrophenyl)thio]methyl}-4-(2,2,2-trifluoroethoxy)pyridine (3b) by using compound 1 (1.55 g,
0.01 mol) and 2-(chloromethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride (2.76 g,
0.01 mol), obtained a yellow solid (3.26 g) in 91.2% yield. ESI-MS (m/z): 359.1 ([M + H]+).
4-Methoxy-3,5-dimethyl-2-{[(4-nitrophenyl)thio]methyl}pyridine (3c) by using compound 1 (1.55 g, 0.01 mol)
and 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride (2.22 g, 0.01 mol), obtained a
yellow solid (2.69 g) in 88.5% yield. ESI-MS (m/z): 305.0 ([M + H]+).
3,4-Dimethoxy-2-{[(4-nitrophenyl)thio]methyl}pyridine (3d) by using compound 1 (1.55 g, 0.01 mol) and
2-(chloromethyl)-3,4-dimethoxypyridine hydrochloride (2.24 g, 0.01 mol), obtained a yellow solid
(2.86 g) in 93.5% yield. ESI-MS (m/z): 307.4 ([M + H]+).
3.1.2. General Procedure for the Preparation of 4-{[(pyridin-2-yl)methyl]thio}aniline
Derivatives (4a–4d)
A mixture of 3a–3d (5 mmol) and 0.1 g of preequilibrated 10% palladium/carbon in MeOH (50 mL)
was hydrogenated at room temperature and atmospheric pressure. The reaction was completely
monitored by TLC. When the reaction has completed, the mixture was filtered, and the filtrate was
evaporated to yield intermediate (4a–4d) as yellowish oil, which was used for the next step without
further purification.
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4-{{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}thio}aniline (4a) by using compound 3a (1.74 g,
5 mmol), H2 and 10% Pd-C, obtained a yellowish oil (1.52 g) in 95.4% yield. ESI-MS (m/z): 319.3
([M + H]+).
4-{{[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}thio}aniline (4b) by using compound 3b (1.79 g,
5 mmol), H2 and 10% Pd-C, obtained a yellowish oil (1.58 g) in 96.1% yield. ESI-MS (m/z):
329.6 ([M + H]+).
4-{[(4-Methoxy-3,5-dimethylpyridin-2-yl)methyl]thio}aniline (4c) by using compound 3c (1.52 g, 5 mmol),
H2 and 10% Pd-C, obtained a yellowish oil (1.30 g) in 94.8% yield. ESI-MS (m/z): 275.2 ([M + H]+).
4-{[(3,4-Dimethoxypyridin-2-yl)methyl]thio}aniline (4d) by using compound 3d (1.53 g, 5 mmol), H2 and
10% Pd-C, obtained a yellowish oil (1.30 g) in 94.2% yield. ESI-MS (m/z): 276.1 ([M + H]+).
3.1.3. General Procedure for the Preparation of the Target Compounds (7a–7t)
To a solution of BTC (1 mmol) in CH2Cl2 (20 mL) was added dropwise to primary aromatic
amine 5 (1 mmol) in CH2Cl2 (20 mL) followed by the dropwise addition of triethylamine (1 mL)
in CH2Cl2 (10 mL). The solvent was evaporated. The resulting residue was dissolved in CH2Cl2
(20 mL), and intermediates (4a–4d) (1 mmol) in CH2Cl2 (10 mL) was added dropwise. The mixture
was stirred for about 3 h, monitored by TLC. After the reaction completed, the solvent was washed
with water and brine, then dried over anhydrous magnesium sulfate. The mixture was filtered, the












Compound 7a was prepared according to the general procedure by using compound 4a (0.32 g, 1 mmol)
and aniline (0.10 g, 1 mmol), obtained a white solid (0.20 g) in 45.1% yield. m.p. 105.2–106.8 ◦C. IR
(KBr, cm−1): υ 3421.1, 2922.7, 2852.4, 1596.1, 1545.1, 1492.4, 1460.8, 1440.3, 1398.2, 1385.2, 1309.3, 1231.3,
1174.2, 1092.1, 1006.7, 894.6, 832.0, 799.2, 751.9, 693.4, 617.3, 507.5. 1H-NMR (400 MHz, DMSO-d6) δ
8.74 (s, 1H), 8.69 (s, 1H), 8.17 (d, J = 5.6 Hz, 1H), 7.46 (s, 1H), 7.44 (s, 1H), 7.41 (s, 1H), 7.39 (s, 1H), 7.32
(s, 1H), 7.31-7.29 (m, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 6.97 (t, J = 7.3 Hz, 1H), 6.90 (d, J = 5.7 Hz, 1H),
4.22 (s, 2H), 4.09 (t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.12 (s, 3H), 2.02–1.94 (m, 2H).
13C-NMR (101 MHz, DMSO-d6) δ 163.17, 156.31, 152.87, 147.91, 140.07, 131.77, 129.23, 128.07, 122.34,
120.30, 119.09, 118.69, 106.49, 68.79, 65.48, 58.44, 31.14, 29.16, 10.88. ESI-MS (m/z): 438.4 ([M + H]+),
460.2 ([M + Na]+). HRMS (ESI) (m/z): Calcd. for C24H27N3O3S, 438.1846 ([M + H]+), found: 438.1856
([M + H]+). Purity (HPLC): 99.27%.
1-(4-Chlorophenyl)-3-{4-{{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}thio}phenyl}urea (7b)
 
Compound 7b was prepared according to the general procedure by using compound 4a (0.32 g, 1 mmol)
and 4-chloroaniline (0.13 g, 1 mmol), obtained a white solid (0.36 g) in 75.3% yield. m.p. 191.7–192.5 ◦C.
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IR (KBr, cm−1): υ 3428.1, 2923.1, 2852.9, 1631.8, 1490.8, 1398.9, 1384.8, 1298.9, 1273.5, 1237.0, 1174.2,
1121.4, 1086.2, 1008.0, 881.2, 832.1, 702.8, 619.7, 506.0. 1H-NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H),
8.77 (s, 1H), 8.17 (d, J = 5.6 Hz, 1H), 7.49 (d, J = 2.2 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.40 (d, J = 2.0 Hz,
1H), 7.39 (d, J = 2.1 Hz, 1H), 7.34 (s, 1H), 7.33 (s, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.31 (s, 1H), 6.90 (d,
J = 5.7 Hz, 1H), 4.22 (s, 2H), 4.08 (t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.12 (s, 3H),
2.00–1.94 (m, 2H). 13C-NMR (101 MHz, DMSO-d6) δ 163.09, 156.35, 152.77, 147.99, 139.09, 138.88, 131.62,
129.07, 128.41, 125.86, 120.22, 119.24, 106.47, 68.80, 65.45, 58.43, 31.14, 29.16, 10.89. ESI-MS (m/z): 473.3
([M + H]+), 495.2 ([M + Na]+). HRMS (ESI) (m/z): Calcd. for C24H26ClN3O3S, 472.1456 ([M + H]+),
found: 472.1467 ([M + H]+). Purity (HPLC): 98.66%.
1-(4-Methoxyphenyl)-3-{4-{{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}thio}phenyl}urea (7c)
 
Compound 7c was prepared according to the general procedure by using compound 4a (0.32 g,
1 mmol) and 4-methoxyaniline (0.12 g, 1 mmol), obtained a white solid (0.22 g) in 46.3% yield. m.p.
144.8–146.6 ◦C. IR (KBr, cm−1): υ 3428.6, 2984.7, 2923.0, 2852.7, 1635.5, 1599.5, 1562.6, 1510.7, 1492.7,
1461.8, 1441.3, 1398.1, 1289.8, 1245.2, 1173.5, 1120.3, 1093.5, 1035.2, 1005.6, 800.0, 617.1, 548.4, 522.7.
1H-NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.47 (s, 1H), 8.16 (d, J = 5.7 Hz, 1H), 7.39 (d, J = 1.9 Hz,
1H), 7.37 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.30 (d, J = 2.1 Hz, 1H),
7.29 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 5.6 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.86 (d, J = 2.2 Hz, 1H), 4.21 (s,
2H), 4.08 (t, J = 6.2 Hz, 2H), 3.71 (s, 3H), 3.48 (t, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.12 (s, 3H), 2.00–1.94
(m, 2H). 13C-NMR (101 MHz, DMSO-d6) δ 163.06, 156.41, 154.97, 153.07, 148.01, 139.37, 133.09, 131.78,
127.82, 120.52, 120.22, 118.98, 114.44, 106.44, 68.79, 65.42, 58.43, 55.63, 31.14, 29.16, 10.88. ESI-MS (m/z):
468.4 ([M + H]+), 490.2 ([M + Na]+). HRMS (ESI) (m/z): Calcd. for C25H29N3O4S, 468.1952 ([M + H]+),




Compound 7d was prepared according to the general procedure by using compound 4a (0.32 g, 1 mmol)
and 3-chloro-4-(trifluoromethyl)aniline (0.20 g, 1 mmol), obtained a white solid (0.24 g) in 43.8% yield.
m.p. 136.0–137.2 ◦C. IR (KBr, cm−1): υ 3425.2, 2922.0, 2852.7, 1590.1, 1546.1, 1482.2, 1463.1, 1384.5,
1306.6, 1175.4, 1117.7, 1034.4, 820.6. 1H-NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.89 (s, 1H), 8.16
(d, J = 5.6 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.63 (d, J = 2.2 Hz, 1H), 7.62 (s, 1H), 7.42 (d, J = 2.0 Hz,
1H), 7.40 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 5.7 Hz, 1H),
4.23 (s, 2H), 4.09 (t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.13 (s, 3H), 2.00–1.94 (m, 2H).
13C-NMR (101 MHz, DMSO-d6) δ 163.08, 156.34, 152.76, 148.01, 139.76, 138.48, 132.45, 131.46, 128.91,
123.55, 122.80, 120.24, 119.57, 117.23, 106.48, 68.80, 65.44, 58.43, 31.14, 29.16, 10.89. ESI-MS (m/z): 540.2
([M + H]+), 562.0 ([M + Na]+). HRMS (ESI) (m/z): Calcd. for C25H25ClF3N3O3S, 540.1330 ([M + H]+),
found: 540.1320 ([M + H]+). Purity (HPLC): 97.33%.
1-{4-{{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}thio}phenyl}-3-[3-(trifluoromethyl)phenyl]urea (7e)
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Compound 7e was prepared according to the general procedure by using compound 4a (0.32 g, 1 mmol)
and 3-(trifluoromethyl)aniline (0.16 g, 1 mmol), obtained a white solid (0.27 g) in 53.1% yield. m.p.
136.1–137.9 ◦C. IR (KBr, cm−1): υ 3327.8, 2958.7, 2927.8, 2859.0, 2377.4, 2350.2, 2311.0, 1724.0, 1648.5,
1585.5, 1552.2, 1492.5, 1465.2, 1397.5, 1338.6, 1295.8, 1230.8, 1166.2, 1116.1, 1092.4, 1068.9, 1005.4, 890.0,
804.1, 732.9, 699.2, 602.3, 505.8. 1H-NMR (400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.84 (s, 1H), 8.17 (d,
J = 5.6 Hz, 1H), 8.09 (s, 0H), 8.00 (d, J = 2.3 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H),
7.42 (d, J = 2.0 Hz, 1H), 7.40 (s, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.30 (s, 1H), 6.90
(d, J = 5.7 Hz, 1H), 4.23 (s, 2H), 4.09 (t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.25 (s, 3H), 2.13 (s,
3H), 2.01–1.94 (m, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 163.11, 156.32, 152.85, 147.97, 140.98, 138.68,
131.55, 130.34, 129.10, 128.64, 122.30, 120.25, 119.40, 118.53, 106.46, 68.79, 65.44, 58.42, 31.13, 29.16, 10.88.
ESI-MS (m/z): 506.3 ([M +H]+). HRMS (ESI) (m/z): Calcd. for C25H26F3N3O3S, 506.1720 ([M +H]+),
found: 506.1728 ([M + H]+). Purity (HPLC): 97.09%.
1-{4-{{[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}thio}phenyl}-3-phenylurea (7f)
 
Compound 7f was prepared according to the general procedure by using compound 4b (0.33 g, 1 mmol)
and aniline (0.10 g, 1 mmol), obtained a white solid (0.18 g) in 39.9% yield. m.p. 143.3–145.1 ◦C.
IR (KBr, cm−1): υ 3424.1, 2923.9, 2852.6, 1687.8, 1639.9, 1600.0, 1548.5, 1495.9, 1441.2, 1399.4, 1384.7,
1307.8, 1284.4, 1266.4, 1232.1, 1176.6, 1112.2, 970.6, 915.9, 854.7, 836.1, 801.5, 783.1, 751.0, 696.2, 657.1,
618.8, 574.4. 1H-NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.67 (s, 1H), 8.24 (d, J = 5.7 Hz, 1H), 7.46
(s, 1H), 7.44 (s, 1H), 7.41 (s, 1H), 7.39 (s, 1H), 7.32 (s, 1H), 7.30 (s, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 7.03
(d, J = 5.7 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 4.89 (q, J = 8.7 Hz, 2H), 4.25 (s, 2H), 2.16 (s, 3H). 13C-NMR
(101 MHz, DMSO-d6) δ 161.62, 157.24, 152.87, 148.00, 140.05, 139.22, 131.90, 129.23, 127.85, 125.66,
122.90, 122.35, 120.44, 119.10, 118.71, 107.07, 64.92, 31.13, 10.74. ESI-MS (m/z): 448.4 ([M +H]+), 470.2
([M + Na]+). HRMS (ESI) (m/z): Calcd. for C22H20F3N3O2S, 448.1301 ([M + H]+), found: 448.1295
([M + H]+). Purity (HPLC): 97.04%.
1-(4-Chlorophenyl)-3-{4-{{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}thio}phenyl}urea (7g)
 
Compound 7g was prepared according to the general procedure by using compound 4b (0.33 g,
1 mmol) and 4-chloroaniline (0.13 g, 1 mmol), obtained a white solid (0.29 g) in 61.0% yield. m.p.
203.6–205.2 ◦C. IR (KBr, cm−1): υ 3424.1, 2984.9, 2923.1, 2851.9, 2350.0, 2311.0, 1611.4, 1548.6, 1491.9,
1440.3, 1399.6, 1384.9, 1370.1, 1311.1, 1268.3, 1172.6, 1111.7, 1051.4, 1004.4, 897.2, 798.3, 668.5, 615.4.
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1H-NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.75 (s, 1H), 8.23 (d, J = 5.7 Hz, 1H), 7.48 (d, J = 2.1
Hz, 1H), 7.47 (d, J = 2.2 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.38 (s, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.32
(d, J = 2.2 Hz, 1H), 7.31 (s, 1H), 7.30 (d, J = 1.9 Hz, 1H), 7.03 (d, J = 5.7 Hz, 1H), 4.88 (q, J = 8.7 Hz,
2H), 4.25 (s, 2H), 2.16 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 161.62, 157.22, 152.77, 148.00, 139.08,
138.98, 131.80, 129.07, 128.11, 125.87, 122.90, 120.43, 120.23, 119.23, 107.08, 65.09, 31.14, 10.74. ESI-MS
(m/z): 482.6 ([M + H]+), 504.3 ([M + Na]+). HRMS (ESI) (m/z): Calcd. for C22H19ClF3N3O2S, 482.0911
([M + H]+), found: 482.0916 ([M + H]+). Purity (HPLC): 99.19%.
1-(4-Methoxyphenyl)-3-{4-{{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}thio}phenyl}urea (7h)
Compound 7h was prepared according to the general procedure by using compound 4b (0.33 g,
1 mmol) and 4-methoxyaniline (0.12 g, 1 mmol), obtained a white solid (0.22 g) in 45.9% yield. m.p.
171.3–172.1 ◦C. IR (KBr, cm−1): υ 3383.8, 2922.1, 2851.4, 2377.6, 2349.6, 1703.0, 1656.7, 1619.2, 1591.3,
1546.4, 1511.1, 1492.7, 1465.5, 1399.3, 1312.1, 1264.5, 1231.2, 1175.1, 1112.8, 1040.3, 1006.7, 970.2, 918.1,
897.2, 831.5, 799.7, 658.3. 1H-NMR (400 MHz, ) δ 8.64 (s, 1H), 8.47 (s, 1H), 8.16 (d, J = 5.7 Hz, 1H),
7.39 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.30
(d, J = 2.1 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 5.6 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.86 (d,
J = 2.2 Hz, 1H), 4.91-4.85 (m, 2H), 4.21 (s, 2H), 3.71 (s, 3H), 2.12 (s, 3H). 13C-NMR (101 MHz, DMSO-d6)
δ 161.84, 156.03, 154.81, 153.88, 153.39, 148.09, 133.72, 133.38, 125.65, 121.84, 120.37, 120.33, 115.40,
114.43, 108.04, 65.10, 55.63, 31.13, 10.44. ESI-MS (m/z): 478.3 ([M + H]+). HRMS (ESI) (m/z): Calcd. for




Compound 7i was prepared according to the general procedure by using compound 4b (0.33 g, 1 mmol)
and 3-chloro-4-(trifluoromethyl)aniline (0.20 g, 1 mmol), obtained a white solid (0.27 g) in 49.5% yield.
m.p. 142.0–143.0 ◦C. IR (KBr, cm−1): υ 3422.3, 2922.1, 2852.6, 1587.4, 1547.6, 1480.8, 1419.0, 1309.8,
1263.9, 1177.2, 1111.0, 1035.5, 974.7, 819.3, 618.3. 1H-NMR (400 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.90 (s,
1H), 8.24 (d, J = 5.7 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.64 (dd, J = 8.9, 2.2 Hz, 1H), 7.61 (d, J = 8.7 Hz,
1H), 7.42 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 2.1 Hz, 1H),
7.04 (d, J = 5.7 Hz, 1H), 4.89 (q, J = 8.7 Hz, 2H), 2.16 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 161.61,
157.18, 152.75, 148.00, 139.74, 138.60, 132.42, 131.64, 128.58, 127.33, 127.02, 125.65, 123.53, 122.80, 120.44,
119.55, 117.28, 117.22, 107.07, 64.79, 39.69, 10.72. ESI-MS (m/z): 550.1, 552.1, 553.1 ([M +H]+). HRMS
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Compound 7j was prepared according to the general procedure C by using compound 4b (0.33 g,
1 mmol) and 3-(trifluoromethyl)aniline (0.16 g, 1 mmol), obtained a white solid (0.34 g) in 66.1% yield.
m.p. 174.7–176.4 ◦C. IR (KBr, cm−1): υ 3421.4, 2985.6, 2924.1, 2852.9, 2349.2, 2311.0, 1614.9, 1491.8,
1445.1, 1399.1, 1339.8, 1313.1, 1288.0, 1264.6, 1231.2, 1173.2, 1114.6, 1071.2, 1006.3, 976.0, 832.4, 798.2,
700.6, 616.4. 1H-NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.87 (s, 1H), 8.24 (d, J = 5.7 Hz, 1H), 8.01 (d,
J = 2.0 Hz, 1H), 7.60–7.54 (m, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 2.1 Hz,
1H), 7.33 (d, J = 2.1 Hz, 1H), 7.33–7.31 (m, 1H), 7.30 (d, J = 1.7 Hz, 1H), 7.04 (d, J = 5.7 Hz, 1H), 4.89 (q,
J = 8.7 Hz, 2H), 4.26 (s, 2H), 2.16 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 161.66, 157.16, 152.86, 147.96,
140.97, 138.80, 131.76, 130.35, 130.15, 129.84, 128.31, 122.30, 120.47, 119.40, 118.54, 114.59, 107.09, 65.09,
49.05, 31.13, 10.73. ESI-MS (m/z): 516.2 ([M + H]+). HRMS (ESI) (m/z): Calcd. for C23H19F6N3O2S,
516.1175 ([M + H]+), found: 516.1174 ([M + H]+). Purity (HPLC): 97.29%.
1-{4-{[(4-Methoxy-3,5-dimethylpyridin-2-yl)methyl]thio}phenyl}-3-phenylurea (7k)
 
Compound 7k was prepared according to the general procedure by using compound 4c (0.27 g, 1
mmol) and aniline (0.10 g, 1 mmol), obtained a white solid (0.23 g) in 57.3% yield. m.p. 188.1–188.9 ◦C.
IR (KBr, cm−1): υ 3422.4, 2923.8, 2852.4, 2351.0, 2321.9, 1644.0, 1597.4, 1553.7, 1494.2, 1441.5, 1398.0,
1312.9, 1270.7, 1237.5, 1173.3, 1127.7, 1073.5, 1002.5, 798.1, 755.7, 738.0, 694.0, 616.4. 1H-NMR (400 MHz,
DMSO-d6) δ 8.72 (s, 1H), 8.67 (s, 1H), 8.12 (s, 1H), 7.45 (d, J = 1.3 Hz, 1H), 7.44-7.42 (m, 1H), 7.40
(d, J = 2.1 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.28 (s,
1H), 7.26 (d, J = 1.6 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 4.21 (s, 2H), 3.70 (s, 3H), 2.18 (s, 6H). 13C-NMR
(101 MHz, DMSO-d6) δ 163.86, 155.80, 152.86, 148.97, 140.05, 139.16, 131.86, 129.24, 127.98, 125.19, 125.03,
122.35, 119.11, 118.70, 60.17, 31.15, 13.38, 11.34. ESI-MS (m/z): 394.6 ([M + H]+), 416.3 ([M + Na]+).




Compound 7l was prepared according to the general procedure by using compound 4c (0.27 g, 1 mmol)
and 4-chloroaniline (0.13 g, 1 mmol), obtained a white solid (0.28 g) in 66.2% yield. m.p. 206.8–208.2 ◦C.
IR (KBr, cm−1): υ 3422.5, 2923.0, 2852.0, 2377.1, 2349.6, 2310.8, 1630.4, 1547.7, 1491.7, 1439.7, 1399.2,
1385.1, 1309.9, 1270.9, 1235.5, 1173.0, 1124.1, 1051.3, 1004.6, 832.1, 798.2, 702.1, 668.3, 617.0. 1H-NMR
(400 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.75 (s, 1H), 8.11 (s, 1H), 7.48 (d, J = 2.1 Hz, 1H), 7.46 (d, J = 2.2 Hz,
1H), 7.40 (d, J = 2.0 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.32 (s, 1H), 7.31 (s,
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1H), 7.30 (d, J = 2.1 Hz, 1H), 4.21 (s, 2H), 3.70 (s, 3H), 2.18 (s, 3H), 2.18 (s, 3H). 13C-NMR (101 MHz,
DMSO-d6) δ 163.86, 155.79, 152.77, 148.97, 139.08, 138.94, 131.76, 129.07, 127.98, 128.25, 125.87, 125.19,
125.03, 120.23, 119.25, 60.17, 31.14, 13.37, 11.33. ESI-MS (m/z): 428.7 ([M + H]+). HRMS (ESI) (m/z):
Calcd. for C22H22ClN3O2S, 428.1194 ([M + H]+), found: 428.1199 ([M + H]+). Purity (HPLC): 99.53%.
1-{4-{[(4-Methoxy-3,5-dimethylpyridin-2-yl)methyl)]thio}phenyl}-3-(4-methoxyphenyl)urea (7m)
 
Compound 7m was prepared according to the general procedure by using compound 4c (0.27 g,
1 mmol) and 4-methoxyaniline (0.12 g, 1 mmol), obtained a white solid (0.21 g) in 49.2% yield. m.p.
171.4–172.6 ◦C. IR (KBr, cm−1): υ 3422.5, 2921.1, 2850.5, 1642.5, 1593.2, 1547.5, 1493.7, 1468.2, 1439.0,
1397.7, 1311.5, 1292.4, 1270.1, 1240.4, 1173.4, 1073.2, 1053.2, 1031.3, 1003.9, 828.2, 797.9, 616.3. 1H-NMR
(400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.50 (s, 1H), 8.15 (s, 1H), 7.39 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 2.1 Hz,
1H), 7.35 (d, J = 2.0 Hz, 1H), 7.33 (d, J = 2.2 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H),
6.87 (d, J = 2.3 Hz, 1H), 6.86 (d, J = 2.2 Hz, 1H), 4.21 (s, 2H), 3.73 (s, 3H), 3.71 (s, 3H), 2.20 (s, 3H), 2.17
(s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 164.47, 155.40, 154.98, 153.08, 148.27, 139.64, 133.09, 132.28,
127.19, 125.70, 125.46, 125.41, 120.49, 118.95, 118.40, 114.46, 60.30, 55.65, 31.14, 13.45, 11.35. ESI-MS
(m/z): 424.3 ([M + H]+). HRMS (ESI) (m/z): Calcd. for C23H25N3O3S, 424.1689 ([M + H]+), found:




Compound 7n was prepared according to the general procedure by using compound 4c (0.27 g, 1 mmol)
and 3-chloro-4-(trifluoromethyl)aniline (0.20 g, 1 mmol), obtained a white solid (0.35 g) in 70.1% yield.
m.p. 152.3–153.1 ◦C. IR (KBr, cm−1): υ 3422.2, 2921.6, 2852.2, 1719.2, 1593.8, 1546.4, 1480.4, 1419.8,
1384.6, 1311.1, 1265.2, 1229.0, 1174.6, 1130.8, 1073.5, 1031.7, 823.3, 619.9. 1H-NMR (400 MHz, DMSO-d6)
δ 9.18 (s, 1H), 8.91 (s, 1H), 8.12 (s, 1H), 8.10 (d, J = 2.0 Hz, 1H), 7.64 (d, J = 8.9 Hz, 1H), 7.62 (s, 1H), 7.42
(d, J = 2.1 Hz, 1H), 7.40 (d, J = 2.1 Hz, 1H), 7.33 (s, 1H), 7.31 (d, J = 1.9 Hz, 1H), 4.22 (s, 2H), 3.70 (s, 3H),
2.19 (s, 3H), 2.18 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 164.07, 154.69, 154.49, 153.03, 149.00, 140.01,
132.84, 132.38, 126.45, 126.36, 124.20, 123.34, 122.49, 121.03, 115.40, 60.18, 31.13, 13.43, 11.00. ESI-MS
(m/z): 496.1; 497.1; 498.1; 499.1 ([M +H]+). HRMS (ESI) (m/z): Calcd. for C23H21ClF3N3O2S, 496.1068
([M + H]+), found: 496.1066 ([M + H]+). Purity (HPLC): 98.56%.
1-{4-{[(4-Methoxy-3,5-dimethylpyridin-2-yl)methyl]thio}phenyl}-3-[3-(trifluoromethyl)pHenyl]urea (7o)
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Compound 7o was prepared according to the general procedure by using compound 4c (0.27 g, 1 mmol)
and 3-(trifluoromethyl)aniline (0.16 g, 1 mmol), obtained a white solid (0.30 g) in 64.7% yield. m.p.
156.9–158.1 ◦C. IR (KBr, cm−1): υ 3420.6, 2984.8, 2922.8, 2851.8, 2350.3, 2321.1, 1609.8, 1491.8, 1443.2,
1398.4, 1369.9, 1338.2, 1311.7, 1271.2, 1229.2, 1172.1, 1124.2, 1072.1, 1002.9, 797.9, 698.2, 616.0. 1H-NMR
(400 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.84 (s, 1H), 8.12 (s, 1H), 8.00 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 8.8 Hz,
1H), 7.51 (t, J = 7.8 Hz, 1H), 7.42 (d, J = 1.9 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.33 (s, 1H), 7.32 (s, 1H), 7.30
(d, J = 2.6 Hz, 1H), 4.22 (s, 2H), 3.70 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ
163.88, 155.76, 152.85, 148.95, 140.97, 138.73, 131.69, 130.35, 128.51, 125.21, 125.05, 123.31, 122.32, 119.43,
118.58, 114.64, 60.16, 31.13, 13.36, 11.33. ESI-MS (m/z): 462.3 ([M + H]+). HRMS (ESI) (m/z): Calcd. for
C23H22F3N3O2S, 462.1458 ([M + H]+), found: 462.1469 ([M + H]+). Purity (HPLC): 99.79%.
1-{4-{[(3,4-Dimethoxypyridin-2-yl)methyl]thio}phenyl}-3-phenylurea (7p)
 
Compound 7p was prepared according to the general procedure by using compound 4d (0.28 g, 1 mmol)
and aniline (0.10 g, 1 mmol), obtained a white solid (0.18 g) in 45.8% yield. m.p. 127.7–128.5 ◦C. IR
(KBr, cm−1): υ 3287.2, 2937.3, 1654.0, 1593.7, 1548.0, 1487.0, 1442.7, 1421.2, 1379.4, 1297.9, 1270.4, 1231.6,
1175.0, 1071.7, 997.3, 932.8, 829.0, 782.9, 742.9, 692.4, 618.5, 516.5. 1H-NMR (400 MHz, DMSO-d6) δ 8.72
(s, 1H), 8.67 (s, 1H), 8.12 (d, J = 5.5 Hz, 1H), 7.49–7.45 (m, 1H), 7.44 (s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.40
(d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 1.9 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.28–7.25 (m,
1H), 7.03 (d, J = 5.5 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 4.17 (s, 2H), 3.87 (s, 3H), 3.74 (s, 3H). 13C-NMR
(101 MHz, DMSO-d6) δ 158.52, 152.88, 151.53, 145.72, 143.40, 138.98, 131.39, 129.24, 128.54, 122.33,
119.17, 118.69, 108.29, 60.99, 56.34, 36.37, 31.14. ESI-MS (m/z): 396.3 ([M + H]+), 418.2 ([M + Na]+).




Compound 7q was prepared according to the general procedure by using compound 4d (0.28 g,
1 mmol) and 4-chloroaniline (0.13 g, 1 mmol), obtained a white solid (0.21 g) in 49.1% yield. m.p.
141.7–142.9 ◦C. IR (KBr, cm−1): υ 3345.3, 3096.8, 2924.2, 2852.2, 1711.6, 1631.2, 1590.8, 1535.1, 1490.0,
1449.2, 1427.9, 1399.4, 1300.6, 1284.5, 1237.1, 1195.2, 1174.0, 1087.1, 1067.2, 996.9, 828.3, 703.0, 509.1.
1H-NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.76 (s, 1H), 8.11 (d, J = 5.5 Hz, 1H), 7.49 (s, 1H), 7.47 (s,
1H), 7.41 (s, 1H), 7.39 (s, 1H), 7.34-7.31 (m, 2H), 7.03 (d, J = 5.5 Hz, 1H), 4.17 (s, 2H), 3.87 (s, 3H), 3.74
(s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 158.52, 152.78, 151.50, 145.71, 143.40, 139.10, 138.75, 131.29,
129.07, 128.79, 125.85, 120.21, 119.30, 108.30, 60.99, 56.34, 36.29, 31.14. ESI-MS (m/z): 430.6 ([M + H]+),
452.1 ([M +Na]+). HRMS (ESI) (m/z): Calcd. for C21H20ClN3O3S, 430.0987 ([M +H]+), found: 430.0993
([M + H]+). Purity (HPLC): 99.33%.
1-{4-{[(3,4-Dimethoxypyridin-2-yl)methyl]thio}phenyl}-3-(4-methoxyphenyl)urea (7r)
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Compound 7r was prepared according to the general procedure by using compound 4d (0.28 g,
1 mmol) and 4-methoxyaniline (0.12 g, 1 mmol), obtained a white solid (0.20 g) in 47.9% yield. m.p.
179.0–180.6 ◦C. IR (KBr, cm−1): υ 3428.5, 2985.2, 2923.2, 2851.3, 1630.7, 1587.2, 1557.0, 1510.3, 1490.9,
1442.6, 1398.6, 1299.7, 1270.7, 1232.4, 1173.6, 1072.2, 1033.0, 1000.9, 934.0, 829.1, 799.5, 617.4, 549.0, 523.3.
1H-NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.46 (s, 1H), 8.11 (d, J = 5.5 Hz, 1H), 7.39 (d, J = 2.0 Hz,
1H), 7.38 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.2 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H),
7.30 (d, J = 2.0 Hz, 1H), 7.03 (d, J = 5.5 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 4.15
(s, 2H), 3.87 (s, 3H), 3.74 (s, 3H), 3.71 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 158.51, 154.98, 153.07,
151.55, 145.73, 143.40, 139.22, 133.08, 131.45, 128.24, 120.54, 119.06, 114.46, 108.30, 60.99, 56.35, 55.65,
36.43, 31.15. ESI-MS (m/z): 426.3 ([M + H]+). HRMS (ESI) (m/z): Calcd. for C22H23N3O4S, 426.1482
([M + H]+), found: 426.1489 ([M + H]+). Purity (HPLC): 98.84%.
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-{4-{[(3,4-dimethoxypyridin-2-yl)methyl]thio}pHenyl}urea (7s)
 
Compound 7s was prepared according to the general procedure by using compound 4d (0.28 g, 1 mmol)
and 3-chloro-4-(trifluoromethyl)aniline (0.20 g, 1 mmol), obtained a white solid (0.32 g) in 64.5% yield.
m.p. 188.1–189.2 ◦C. IR (KBr, cm−1): υ 3425.5, 2921.9, 2852.4, 1589.9, 1545.2, 1485.2, 1419.2, 1384.4,
1306.1, 1229.2, 1175.6, 1132.0, 1068.8, 1033.0, 824.9. 1H-NMR (400 MHz, DMSO-d6) δ 9.15 (s, 1H), 8.88 (s,
1H), 8.11 (d, J = 5.5 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.62–7.58 (m, 1H), 7.42
(d, J = 2.0 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.34 (d, J = 2.2 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.03 (d,
J = 5.5 Hz, 1H), 4.17 (s, 2H), 3.88 (s, 3H), 3.74 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 158.52, 152.76,
151.47, 145.73, 143.40, 139.76, 138.36, 132.44, 131.12, 129.28, 123.53, 122.78, 119.62, 117.24, 108.32, 61.00,
56.35, 36.17, 31.14. ESI-MS (m/z): 498.2 ([M +H]+). HRMS (ESI) (m/z): Calcd. for C22H19ClF3N3O3S,
498.0861 ([M + H]+), found: 498.0844 ([M + H]+). Purity (HPLC): 98.10%.
1-{4-{[(3,4-Dimethoxypyridin-2-yl)methyl]thio}phenyl}-3-[3-(trifluoromethyl)phenyl]urea (7t)
 
Compound 7t was prepared according to the general procedure by using compound 4d (0.28 g, 1 mmol)
and 3-(trifluoromethyl)aniline (0.16 g, 1 mmol), obtained a white solid (0.21 g) in 44.3% yield. m.p.
198.4–199.8 ◦C. IR (KBr, cm−1): υ 3422.2, 2985.4, 2377.5, 2349.8, 2320.7, 2024.8, 1712.9, 1594.1, 1564.4,
1537.2, 1491.3, 1445.8, 1399.4, 1370.2, 1316.3, 1273.6, 1230.1, 1173.8, 1124.9, 1068.3, 1002.1, 932.4, 892.8,
828.2, 798.3, 743.3, 697.8, 615.6. 1H-NMR (400 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.83 (s, 1H), 8.11 (d,
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J = 5.5 Hz, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.60–7.54 (m, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.43 (d, J = 2.0 Hz,
1H), 7.41 (d, J = 2.2 Hz, 1H), 7.34 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 2.5 Hz, 1H), 7.30 (s, 1H), 7.03 (d,
J = 5.6 Hz, 1H), 4.17 (s, 2H), 3.88 (s, 3H), 3.75 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 158.52, 152.87,
151.50, 145.72, 143.41, 140.98, 138.55, 131.22, 130.34, 129.08, 122.31, 119.49, 118.56, 114.65, 108.31, 60.99,
56.34, 36.24, 31.12. ESI-MS (m/z): 464.2 ([M + H]+). Purity (HPLC): 98.85%.
3.2. Biological Evaluation
3.2.1. Antiproliferative Activity Assays
The antiproliferative activities of target compounds were determined using a standard MTT
assay [27–30]. Exponentially growing cells A549 (3 × 103 cells/well), HCT-116 (1 × 104 cells/well) and
PC-3 (8 × 103 cells/well) were seeded into 96-well plates and incubated for 24 h to allow the cells to
attach. After 24 h of incubation, the culture medium was removed and fresh medium containing
various concentrations of the candidate compounds was added to each well. The cells were then
incubated for 72 h, thereafter MTT assays were performed and cell viability was assessed at 570 nm by
a microplate reader (ThermoFisher Scientific (Shanghai) Instrument Co., Ltd., Shanghai, China).
3.2.2. Cell Apoptosis Assay
A549 cells were seeded into a 6-well plate (2 × 105/well) and incubated for 24 h. Then the cells
were treated with different concentrations of the tested compound 7i for 24 h. Thereafter, the cells
were collected and the Annexin-V-FITC/PI apoptosis kit (Biovision, Milpitas, CA, USA) was used
according to the manufacturer’s protocol. The cells were analyzed by Accuri C6 flow cytometric
(Becton Dickinson, Franklin Lakes, NJ, USA) [31].
3.2.3. Cell Cycle Analysis
For flow cytometric analysis of DNA content, 5 × 105 A549 cells in exponential growth were
treated with different concentrations of the compound 7i for 24 or 48 h. After an incubation period, the
cells were collected, centrifuged and fixed with ice cold ethanol (70%). The cells were then treated with
buffer containing RNAse A and 0.1% Triton X-100 and then stained with the propidium iodide (PI).
The samples were analyzed on Accuri C6 flow cytometer (Becton Dickinson). [32].
4. Conclusions
In summary, a new series of 1-aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea derivatives were
designed and synthesized based on molecular hybridization strategy. Majority of target compounds
showed moderate to good growth inhibition against the tested cancer cells. Particularly, compound 7i
exhibited more potent antiproliferative activity than well-known anticancer drug sorafenib against all
three cancer cell lines (A549, HCT-116 and PC-3). The preliminary mechanism investigation showed
that compound 7i could induce A549 cells to apoptosis, and halted cell cycle progression at the
G1 phase. The SARs illustrated that these target compounds in this work might serve as bioactive
fragments, and compound 7i could be used as a lead compound for the development of potent cancer
chemotherapeutic agents in the drug discovery process.
Supplementary Materials: The following are available online. 1H-NMR, 13C-NMR, ESI-MS and HRMS of the
target compounds, respectively.
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Abstract: Twenty-seven L-shaped ortho-quinone analogs were designed and synthesized using a
one pot double-radical synthetic strategy followed by removing methyl at C-3 of the furan ring and
introducing a diverse side chain at C-2 of the furan ring. The synthetic derivatives were investigated
for their cytotoxicity activities against human leukemia cells K562, prostate cancer cells PC3, and
melanoma cells WM9. Compounds TB1, TB3, TB4, TB6, TC1, TC3, TC5, TC9, TC11, TC12, TC14,
TC15, TC16, and TC17 exhibited a better broad-spectrum cytotoxicity on three cancer cells. TB7 and
TC7 selectively displayed potent inhibitory activities on leukemia cells K562 and prostate cancer cells
PC3, respectively. Further studies indicated that TB3, TC1, TC3, TC7, and TC17 could significantly
induce the apoptosis of PC3 cells. TC1 and TC17 significantly induced apoptosis of K562 cells. TC1,
TC11, and TC14 induced significant apoptosis of WM9 cells. The structure-activity relationships
evaluation showed that removing methyl at C-3 of the furan ring and introducing diverse side chains
at C-2 of the furan ring is an effective strategy for improving the anticancer activity of L-shaped
ortho-quinone analogs.
Keywords: ortho-quinones; antitumor activity; beta-lapachone; tanshione IIA
1. Introduction
Over several decades, cancer continues to be the most awful disease due to its uncontrolled cell
growth and the fact that it is a dominate killer of human beings worldwide [1]. Especially in China,
millions of deaths have been caused by tumor. The common cancer types in Chinese male, in 2018,
were lung, stomach, colorectum, liver, and esophageal cancer. Additionally, breast, lung, colorectum,
thyroid, and stomach cancer were the common types in Chinese female [2]. The incidence of colorectal
cancer in males and females has increased, however, the incidence of esophageal, stomach, and liver
cancer has decreased between 2000 and 2011 [3]. Meanwhile, the incidence and mortality of prostate
cancer and bladder cancer in males, together with obesity and hormonal exposure-related cancers,
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namely thyroid, breast, and ovarian cancer in females have shown a rising trend [3]. However, the
standardized treatments of cancer, including surgery, chemotherapy, and radiation therapy, show
many limitations, such as severe adverse effects, recurrence, and increasing drug resistance [4].
Currently, phytochemicals have become a valuable source of anticancer drugs. Actually, over 75%
of nonbiological anticancer drugs approved are either plant-derived natural products or developed
based on these products [5]. Therefore, natural products have continued to be a hot research topic for
the development of new antitumor drugs [6–9].
Tanshinone IIA is a natural ortho-quinone isolated from the rhizome of Salvia miltiorrhiza Bunge with
antineoplastic activity, such as gastric cancer, breast cancer, osteosarcoma, etc. [10–13]. These various
properties demonstrate that tanshinone IIA is a potential antitumor drug candidate. Furthermore,
beta-lapachone is another natural ortho-quinone which has been reported to selectively kill many
human cancer cells [14], however, the pyran ring of beta-lapachone has been found to be unstable
during metabolism in the human body, and may led to side effects on normal tissues [15,16]. Recently,
studies have revealed that some tanshinone analogs show similar or stronger antitumor activity when
the ring-A is removed but the furan ring is retained [17,18]. You et al. [19,20] discovered that the binding
site for quinone oxidoreductase-1 (NQO1) substrates was an L-shaped pocket (Figure 1B) which binds
well with tanshinone analogs, and showed higher antitumor activities than the planar compound 1 and
beta-lapachone. Therefore, we surmise that removing methyl at C-3 of the furan ring is more suitable
for the binding site, and we anticipate that a novel L-shaped molecule without methyl at C-3 of the furan
ring could provide better antitumor activities. Considering that some nitrogen, oxygen-substituted,
and amino acid substrates can improve aqueous solubility and antitumor activities [21–25], we have
attempted to introduce a great diversity of oxygen-substituted, nitrogen-containing groups and amino
acids. Thus, in this work, we developed quinone-directed agents by removing methyl at C-3 of the
furan ring and introducing a diverse side chain at C-2 of the furan ring, culminating in the discovery of
a promising scaffold. The inhibitory activity was assessed in vitro using three cell lines including K562,
PC3, and WM9.
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Figure 1. (A) Structural design strategy and (B) l-shaped pocket. The figure is available in reference [19].
2. Discussion and Results
2.1. Chemistry
The synthesis of two substituted naphtho[1,2-b]furan-4,5-diones is outlined in Scheme 1. Briefly,
treatment of lawsone 6 with allyl bromide followed by subsequent Claisen rearrangement afforded 7,
which was then cyclized to get the ortho-quinone 8 by using Lewis acid NbCl5 at room temperature [26].
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TB 9 derivatives TC 18 derivatives
Scheme 1. Synthesis of L-shaped ortho-quinone analogs.
Initially, dealing 8 with N-bromosuccinimide (NBS) and 2,2′-azobis(2-methylpropionitrile) (AIBN)
afforded only trace amounts of 8a. Another intermediate, 8b, was obtained by Nelson’s method [27]
as shown in Scheme 1. Then, compound 9 was obtained from 8b through a second radical reaction.
Considering the same reaction condition, we successfully got 9 from 8 through a bis-radical reaction.
The brominated intermediate 9 was reacted with substituted phenol or amine to provide ortho-quinone
derivatives TB1–TB9 and TC1–TC18, respectively. All the structures of ortho-quinone derivatives
were identified through 1H, 13C, and HRMS.
In summary, we successfully established an effective synthetic strategy, which removed the methyl
at C-3 of the furan ring and introduced diverse side chains at C-2 of the furan ring. In addition, we
replaced the bromide of 9 with a variety of oxygen-substituted, nitrogen-containing group, and amino
acid by a nucleophilic substitution.
2.2. In Vitro Cytotoxicity Assay
The cytotoxic activities of 5 μmol/L of the synthesized l-shaped ortho-quinone analogs were
determined by using three cancer cell lines (Table 1). The results revealed that compounds TB1, TB3,
TB4, TB6, TC1, TC3, TC5, TC9, TC11, TC12, TC15, TC16, and TC17 showed a broad-spectrum potent
inhibitory activity on the proliferation of the cancer cell lines, with a more than 70% inhibition rate,
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and TB7 showed better inhibitory activity on K562 cells as compared with other cells. Moreover, we
observed that TC7 inhibited the growth of PC3 cells more efficiently than other cells.
Table 1. The structures and inhibitory rates after treating cancer cell lines with 5 μmol/L of target




TB1 92.078 ± 1.885 88.641 ± 3.055 80.287 ± 6.354
TB2 58.700 ± 29.309 20.642 ± 16.695 9.216 ± 2.449
TB3 91.861 ± 2.125 83.613 ± 10.448 54.153 ± 3.948
TB4 92.224 ± 1.811 91.192 ± 1.479 87.963 ± 2.430
TB5 30.673 ± 54.356 49.127 ± 33.985 64.870 ± 2.894
TB6 87.165 ± 1.953 82.901 ± 1.484 89.843 ± 2.010
TB7 −7.664 ± 10.055 81.835 ± 1.553 31.754 ± 6.422
TB8 9.692 ± 11.981 7.191 ± 4.705 49.307 ± 3.791
TB9 −17.125 ± 11.619 15.334 ± 9.484 −0.591 ± 1.055
TC1 91.027 ± 0.553 83.717 ± 3.469 84.117 ± 2.686
TC2 −0.437 ± 1.129 25.032±2.579 16.431±1.583
TC3 78.849 ± 13.221 83.518 ± 12.045 81.670 ± 0.994
TC4 24.242 ± 18.544 0.082 ± 15.067 15.453 ± 1.508
TC5 89.676 ± 0.331 81.950 ± 12.469 72.452 ± 8.039
TC6 43.133 ± 11.878 31.137 ± 16.045 63.384 ± 8.949
TC7 82.402 ± 4.585 30.087 ± 20.307 16.191 ± 2.699
TC8 44.842 ± 25.172 28.448 ± 30.220 0.468 ± 5.166
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TC9 89.869 ± 1.839 81.545 ± 6.968 83.003 ± 2.806
TC10 −6.375 ± 8.094 −9.749 ± 17.889 1.005 ± 2.601
TC11 90.214 ± 0.520 85.766 ± 1.737 85.807 ± 3.752
TC12 82.522 ± 9.039 83.688 ± 8.252 61.839 ± 3.448
TC13 74.681 ± 2.470 84.251 ± 1.430 39.955 ± 6.425
TC14 4.453 ± 5.002 84.497 ± 0.876 90.717 ± 1.184
TC15 84.916 ± 1.761 84.185 ± 0.419 90.135 ± 1.602
TC16 78.720 ± 7.560 84.323 ± 1.273 90.520 ± 2.108
TC17 86.637 ± 2.482 83.999 ± 0.943 72.021 ± 6.850
TC18 −5.220 ± 13.979 8.854 ± 12.236 1.410 ± 5.093
tanshinone IIA 89.458 ± 1.987 82.215 ± 4.069 85.236 ± 3.654
Paclitaxel 81.589 ± 1.763 91.315 ± 2.467 78.369 ± 6.380
The concentration inhibition curves (Figure 2) were analyzed to calculate the IC50 values of the
selected active compounds. The results indicated there was a dose-dependent trend of the inhibitory
response of all active compounds on three cancer cells for treating 48 h. The IC50 values were
summarized in Table 2 and show that the cytotoxicity of compounds TB3, TC1, TC3, TC7, TC9, and
TC17 on PC3 were better (P < 0.05) than that of the positive control (tanshinone IIA and paclitaxel),
and another active compound exhibited similar activity to that of the positive control. The inhibition
activity of TC1 against the growth of K562 was better than that of the positive control, paclitaxel,
and tanshinone IIA. Compounds TB6, TC1, TC11, TC14, and TC15 inhibited the growth of WM9
better (P < 0.05) than that of tanshinone IIA and paclitaxel. In summary, most of novel L-shaped
ortho-quinone analogs exhibited relatively better cytotoxicity activity as compared with the two
positive controls, which indicated that the analogs containing L-shaped ortho-quinone as the core
structure, possessed stronger anticancer activity. This result provided a preliminary biological activity
basis for the investigation of anticancer candidate agents.
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Figure 2. Growth inhibition induced by the active L-shaped ortho-quinone analogs on PC3, K562,
and WM9 cells by MTT assay. The IC50 values (μM) of the compounds were determined according
to these curves at different incubation times. The 100 μL tested compounds were added to 96-well
microculture plates and 100 μL cells (a final concentration of 5 × 104/well) were incubated for 48 h at 37
◦C. Cell survival was evaluated by MTT assay. The inhibition ratio (%) was calculated as described in
the Methods section. Data was presented as mean ± SD of three independent experiments.




TB1 2.809 ± 0.413 3.157 ± 0.947 ** 4.841 ± 0.301
TB3 1.121 ± 0.731 ** 2.580 ± 0.285 ** NA a
TB4 3.348 ± 0.347 3.103 ± 0.702 ** 3.358 ± 0.297
TB6 3.249 ± 0.464 2.964 ± 0.168 * 2.774 ± 0.299 **
TB7 NA 2.981 ± 0.368 ** NA
TC1 0.347 ± 0.290 ** 0.379 ± 0.138 0.406 ± 0.117 **
TC3 1.778 ± 0.835 ** 4.647 ± 0.647 ** 4.990 ± 0.360
TC5 3.018 ± 0.452 3.448 ± 0.224 ** NA
TC7 1.507 ± 0.369 ** NA NA
TC9 0.469 ± 0.281 ** 4.194 ± 0.139 ** 4.027 ± 0.341
TC11 2.578 ± 0.957 3.565 ± 0.344 ** 2.127 ± 0.582 **
TC12 2.963 ± 0.261 4.157 ± 0.677 ** NA
TC13 3.433 ± 0.444 4.719 ± 0.984 NA
TC14 NA 3.100 ± 0.320 ** 2.261 ± 0.111 **
TC15 3.696 ± 0.492 3.644 ± 0.524 ** 3.050 ± 0.230 *
TC16 3.874 ± 0.557 2.640 ± 0.642 ** 4.324 ± 0.292
TC17 1.914 ± 0.224 ** 1.927 ± 0.414 NA
tanshinone IIA 3.162 ± 3.160 4.638 + 1.270 4.261 ± 0.182
Paclitaxel 4.323 ± 0.929 2.149 ± 0.406 4.835 ± 0.359
Note: * represents p < 0.05 and ** represents p < 0.01, vs. the inhibition of the positive control to the cancer cell lines.
The data represented the average of three independent experiments.
2.3. Structure-Activity Relationships Study
To obtain two series of analogs, we successfully built an effective synthetic strategy by removing
the methyl at C-3 of the furan ring and introducing diverse side chains at C-2 of the furan ring. On the
basis of the cytotoxicity results (Tables 1 and 2), a preliminary structure-activity relationships could
be established. The TB series molecules bearing electron-withdrawing groups or multi-substituted
groups such as compounds TB3, TB4, and TB6 showed a better inhibitory effect on PC3 cell lines,
K562 cell lines, and WM9 cell lines, whereas the TB series molecules bearing alkane groups at the
2-position showed decreased cytotoxicity in PC3 cell lines, K562 cell lines, and WM9 cell lines, such as
compounds TB9. The TC series molecules with electron-withdrawing groups, saturate six-membered
rings, or multi-substituted groups emerged greater inhibitory effects on three cancer cell lines, such as
TC11, TC12, TC15, and TC16, whereas the TC series molecules bearing donating groups or alkane
groups at the 2-position showed reduced cytotoxicity in three cancer cell lines. The structure-activity
relationships evaluation also showed that removing methyl at C-3 of the furan ring and introducing
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diverse side chains at C-2 of the furan ring were good strategies for improving the anticancer activity
of L-shaped ortho-quinone analogs.
2.4. Effects of Active Compounds on Cell Apoptosis
According to the above IC50 values of all active compounds, we selected six active compounds
(TB3, TC1, TC3, TC7, TC9, and TC17) for PC3, three active compounds (TB6, TC1, and TC17) for
K562, and four active compounds (TB6, TC1, TC11, and TC14) for WM9, based on their higher
activities than that of the positive control and better selectivity and, then, studied their effects on
cell apoptosis by microscope observation (Figure 3) and flow cytometry (Figure 4). The microscopic
observations (Figure 3A) showed that the number of PC3 cells was significantly reduced by treatments
with 2.5 μmol/L of TB3, TC1, TC3, and TC7; the apoptotic bodies and cell fragments were significantly
observed as compared with the control group. The PC3 cells treated with TC9 showed that the number
of cells were significantly reduced, while fewer cells died and there were no significant apoptotic bodies.
The PC3 cells treated with TC7 showed a significant decrease in the number of cells, meanwhile, some
cells died, apoptotic bodies appeared obviously, and the morphology of some cells became an irregular
shape of spindle length. Above all, the inhibitory activity of TB3, TC1, TC3, and TC7 may be through
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Figure 3. Effects of the active compounds on PC3 (A), K562 (B), and WM9 (C) cell growth and apoptosis.
Cell number and morphological appearance of the two types of cell lines treated with 2.5 μmol/L of
active compounds, then, it was observed by a fluorescent inverted microscope after 24 h. Scale bar =
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Figure 4. Effects of the active compounds on PC3 (A), K562 (B), and WM9 (C) cell growth and apoptosis.
Cell apoptosis induced by the compounds and tested by flow cytometry and the date was analyzed
with Origin Pro 9.0 (D) and presented as means ± SEM from at least three independent experiments.
* p < 0.05, ** p < 0.01 (n = 3) as compared with the control.
The K562 cells treated with TC1 were obviously dead and dispersed, with the appearance of
apoptotic bodies as comparing with the control group (Figure 3B). The cells treated with TB6 had a
significantly reduced number of cells and most cells clumped growth similar to the control cells. For
the cells treated with TC17 we observed both dead cells and fewer clumps of cells. Furthermore, for the
WM9 cell lines treated with TB6, TC1, TC11, and TC14 (Figure 3C), we observed that the cells treated
with TC1 and TC11 were obviously dead with a large number of apoptotic bodies and dispersed cells;
the cells treated with TB6 showed a significant decrease in the number of cells and fewer dead cells.
Observation of the cells treated with TC14 showed that the number of cells was significantly reduced,
while some cells were obviously dead with apoptotic bodies appearing, and the morphology of some
cells also became an irregular shape of spindle length. The above results indicated that TC1 can induce
apoptosis for K562 and WM9 cells to inhibit the growth; TB6, TC11, TC14, and TC17 can jointly inhibit
the proliferation of cell through a variety of mechanisms.
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Flow cytometry analyzed results (Figure 4) confirmed that TB3 (p < 0.01), TC1 (p < 0.01), TC3
(p < 0.01), TC7 (p < 0.01), and TC17 (p < 0.05) could significantly induce the apoptosis of PC3 cells
(Figure 4A), while TC9 did not. TC1 (p < 0.01) and TC17 (p < 0.05) significantly induced apoptosis
of K562 cells (Figure 4B), while TB6 had no significant effect on apoptosis of K562 and WM9 cells.
TC1 (p < 0.01), TC11 (p < 0.05), and TC14 (p < 0.01) could potently induce apoptosis for WM9 cells
(Figure 4C).
3. Materials and Methods
3.1. Instruments and Materials
High-resolution mass spectra (HRMS) were obtained on an electrospray ionization (ESI) mode on
a Bruker ESI-QTOF mass spectrometry. Nuclear magnetic resonance (NMR) spectra were recorded on
a Bruker Avance NEO (1H NMR, 600 MHz; 13C NMR, 150 MHz, Bruker, Switzerland) with TMS as an
internal standard. The IR spectra were recorded by using a FTIR Spectrometer (IR 200 Fourier Energy
Spectrum Technology Co., Ltd., TianJin, China) and the KBr disk method was adopted. The melting
points (mp) were determined on an WRX-4 microscope melting point apparatus. The column
chromatography was performed on silica gel (Qingdao, 200–300 mesh) and the thin-layer (0.25 mm)
chromatography (TLC) analysis was carried out on silica gel plates (Qingdao, China). Other reagents
were analytical grade or guaranteed reagent commercial product and used without further purification,
unless otherwise noted.
3.2. Methods of Synthesis
3.2.1. Synthesis of 2-Allyl-3-hydroxy-1,4-naphthoquinone (7)
A mixture of lawsone 6 (10.0 g, 57.42 mmol) and anhydrous K2CO3 (7.94 g, 57.42 mmol) in
anhydrous DMF (100 mL) were stirred for 15 min at room temperature. Allyl bromide (17.37 g,
143.55 mmol) in DMF (5 mL) was added dropwise and stirred for 15 min at 0 ◦C. The mixture was
refluxed at 120 ◦C for 3 h and then cooled to room temperature before it was poured into water
and extracted with EA. The organic phase was washed with brine, dried over Na2SO4, filtered, and
concentrated in vacuo. The crude product was purified by column chromatography on silica gel
(eluent: petroleum ether/EtOAc 15:1) to afford 7 (7.8 g, 63% yield) as a light yellow solid. Other data
was found in reference [26].
3.2.2. Synthesis of 2-Methyl-2,3-dihydrolnaphthol[1,2-b]furan-4,5-dione (8)
NbCl5 (18.92 g, 70.02 mmol) was added into 7 (3.0 g, 14.00 mmol) in anhydrous DCM (50 mL)
at 0 ◦C. After stirring for 45 min at 30 ◦C, the mixture was poured into ice water and extracted with
DCM. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated in
vacuo. The crude product was purified by column chromatography on silica gel (eluent: petroleum
ether/EtOAc 4:1) to afford 8 (2.16 g, 72% yield) as red solid. Other data was found in reference [26].
3.2.3. Synthesis of 2-Bromomethyl-naphtho[1-b]furan-4,5-dione (9)
A mixture of 8 (1.5 g, 7.00 mmol), anhydrous N-bromosuccinimide (2.49 g, 1.40mmol), and
2,2′-azobis(2-methylpropionitrile) (114.98 mg, 1.40 mmol) in anhydrous CCl4 (50 mL) was stirred under
argon at 70 ◦C, until 8 were disappeared. Then, the mixture was cooled to room temperature, and
anhydrous N-bromosuccinimide (2.49 g, 1.40 mmol) and 2,2′-azobis(2-methylpropionitrile) (114.98 mg,
1.40 mmol) were added and stirred at 70 ◦C for 2 h. The mixture was cooled to room temperature, and
poured into water, extracted with EA, washed with brine, dried over Na2SO4, filtered, and concentrated
in vacuo. The crude product was purified by column chromatography on silica gel (eluent: petroleum
ether/EtOAc 12:1) to afford 9 (1.0 g, 67% yield) as red solid. Mp: 169–170 ◦C. 1H NMR (600 MHz,
CDCl3) δ 8.09 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H),
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and 6.83 (s, 1H), 4.55 (s, 2H). 13C NMR (150 MHz, CDCl3) δ 180.06, 174.13, 160.94, 153.46, 135.56, 130.74,
130.69, 129.03, 127.98, 122.69, 122.34, 108.04, and 21.87. IR (ν, cm−1): 3118.33, 2920.28, 2339.32, 1670.84,
1551.16, and 691.42. HRMS (ESI) calcd. for [M + Na]+ C13H7O3BrNa+: 312.9471, found 312.9460.
3.2.4. Synthesis of TB1–9 and TC1–18
A mixture of the corresponding amines or alcohols (0.52 mmol), K2CO3 (142 mg, 1.03 mmol), and
9 (100 mg, 0.34 mmol) in THF (5 mL) was stirred at 30 ◦C to 50 ◦C for 4 h. After cooling, the mixture
was poured into water and extracted with EA. The combined organic layer was washed with brine and
dried over anhydrous Na2SO4, filtered, and concentrated to afford a crude product which was purified
through column chromatography on silica gel.
TB1: 2-(((4-methoxyphenyl)oxy)methyl)naphtho[1-b]furan-4,5-dione. Red solid, yield: 34%. Mp:
112–113 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.09 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.5
Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 6.94–6.92 (m, 2H), 6.87–6.85 (m, 2H), 6.83 (s, 1H), 5.04 (s, 2H), and
3.78 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 180.34, 174.38, 160.88, 154.72, 153.82, 151.95, 135.47, 130.66,
130.50, 128.98, 128.28, 122.59, 122.12, 116.34, 114.81, 108.37, 63.03, and 55.73. IR (ν, cm−1): 3445.32,
2358.40, 2339.32, 1671.47, 1598.48, 1253.20, 1219.81, 1161.58, and 1057.34. HRMS (ESI) calcd. for [M +
Na]+ C20H14O5Na+: 357.0733, found 357.0723.
TB2: 2-(((4-acetylphenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Light orange solid, yield: 40%.
Mp: 190–191 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.13 (d, J = 6.4 Hz, 1H), 8.00 (d, J = 8.9 Hz, 2H), 7.78 (d,
J = 9.1 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.06 (d, J = 8.9 Hz, 2H), 6.94 (s, 1H), 5.19
(s, 2H), and 2.60 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 196.71, 180.20, 174.31, 161.58, 161.10, 152.60,
135.53, 131.28, 130.74, 130.70, 129.02, 128.11, 122.64, 122.08, 114.48, 108.98, 61.92, and 26.43. IR (ν, cm−1):
3445.93, 2358.51, 2341.16, 1671.86, 1599.84, 1249.41, 1217.01, 1178.57, and 1008.47. HRMS (ESI) calcd.
for [M + Na]+ C21H14O5Na+: 369.0733, found 369.0721.
TB3: 2-(((4-propiophenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Orange solid, yield: 37%. Mp:
179–180 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.11 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 8.9 Hz, 2H), 7.77 (d,
J = 6.4 Hz, 1H), 7.71–7.68 (m, 1H), 7.53–7.50 (m, 1H), 7.06 (d, J = 8.9 Hz, 2H), 6.93 (s, 1H), 5.18 (s, 2H),
2.99 (q, J = 7.2 Hz, 2H), and 1.24 (t, J = 7.3 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 199.42, 180.20, 174.30,
161.40, 161.06, 152.68, 135.53, 130.98, 130.72, 130.68, 130.36, 129.01, 128.11, 122.63, 122.08, 114.47, 108.92,
61.90, 31.53, and 8.38. IR (ν, cm−1): 3447.03, 2358.62, 2341.16, 1669.65, 1601.07, 1222.31, 1180.35, and
1002.86. HRMS (ESI) calcd. for [M + Na]+ C22H16O5Na+: 383.0890, found 383.0876.
TB4: 2-(((4-nitrophenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 48%. Mp:
205–206 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 8.25 (d, J = 9.3 Hz, 2H), 7.96 (d, J = 7.6 Hz, 1H), 7.77–7.74
(m, 2H), 7.59–7.55 (m, 1H), 7.34 (d, J = 9.3 Hz, 2H), 7.18 (s, 1H), and 5.42 (s, 2H). 13C NMR (150 MHz,
DMSO-d6) δ 179.58, 174.56, 163.29, 160.07, 152.42, 141.83, 135.43, 130.84, 130.17, 129.83, 127.89, 126.41,
122.50, 122.36, 115.94, 110.32, and 62.45. IR (ν, cm−1): 3445.75, 2358.70, 2341.16, 1681.37,1592.17, 1507.95,
1384.15, 1340.19, 1277.67, and 1110.13. HRMS (ESI) calcd. for [M + Na]+ C19H11O6NNa+: 372.0479,
found 372.0465.
TB5: 2-(((2-methoxyl-4-formyl)phenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield:
34%. Mp: 203–204 ◦C. 1H NMR (600 MHz, CDCl3) δ 9.91 (s, 1H), 8.13 (d, J = 6.4 Hz, 1H), 7.77 (d, J = 7.6
Hz, 1H), 7.72–7.68 (m, 1H), 7.54–7.48 (m, 3H), 7.15 (d, J = 8.0 Hz, 1H), 6.96 (s, 1H), 5.28 (s, 2H), and
3.97 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 190.88, 180.19, 174.31, 161.15, 152.50, 152.42, 150.30, 135.52,
131.28, 130.75, 129.67, 129.03, 128.10, 122.68, 122.09, 115.30, 112.93, 109.87, 109.40, 62.85, and 56.09. IR
(ν, cm−1): 3446.32, 2358.18, 2341.16, 1702.84, 1676.79, 1586.53, 1508.23, 1267.05, 1236.25, 1137.10, and
999.76. HRMS (ESI) calcd. for [M + Na]+ C21H14O6Na+: 385.0683, found 385.0668.
TB6: 2-(((4-formylphenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Orange solid, yield: 30%. Mp:
212–213 ◦C. 1H NMR (600 MHz, CDCl3) δ 9.95 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 8.9 Hz, 2H),
7.78 (d, J = 7.8 Hz, 1H), 7.73–7.69 (m, 1H), 7.56–7.51 (m, 1H), 7.14 (d, J = 8.7 Hz, 2H), 6.96 (s, 1H), and
5.21 (s, 2H). 13C NMR (150 MHz, CDCl3) δ 190.71, 180.17, 174.30, 162.67, 161.14, 152.36, 135.53, 132.10,
130.82, 130.77, 130.74, 129.05, 128.09, 122.64, 122.08, 115.06, 109.11, and 61.99. IR (ν, cm−1): 3446.21,
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2358.24, 2337.30, 1687.41, 1671.45, 1598.48, 1253.19, 1219.95, 1161.49, and 1057.40. HRMS (ESI) calcd.
for [M + Na]+ C20H12O5Na+: 355.0577, found 355.0565.
TB7: 2-(((4-bromo-2-formyl)phenyl)oxy)methyl)naphtho[1,2-b]furan-4,5-dione. Light orange solid,
yield: 33%. Mp: 201–202 ◦C. 1H NMR (600 MHz, CDCl3) δ 10.43 (s, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.99
(d, J = 2.7 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.73–7.69 (m, 2H), 7.57–7.51 (m, 1H), 7.06 (d, J = 8.7 Hz,
1H), 6.96 (s, 1H), and 5.24 (s, 2H). 13C NMR (150 MHz, CDCl3) δ 187.86, 180.06, 174.25, 161.30, 158.94,
151.80, 138.27, 135.59, 131.52, 130.87, 130.82, 129.07, 127.95, 126.84, 122.64, 121.99, 115.01, 114.95, 109.43,
and 62.80. IR (ν, cm−1): 3445.63, 2358.34, 2337.30, 1671.90, 1599.56, 1556.29, 1249.42, 1217.50, 1178.60,
and 1008.51. HRMS (ESI) calcd. for [M + Na]+ C20H11O5BrNa+: 432.9682, found 432.9673.
TB8: 2-(methoxymethyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 12%. Mp: 53–54 ◦C. 1H
NMR (600 MHz, CDCl3) δ 8.11 (dd, J = 7.8, 1.5 Hz, 1H), 7.78 (dd, J = 7.7, 1.4 Hz, 1H), 7.70–7.66 (m,
1H), 7.52–7.48 (m, 1H), 6.80 (s, 1H), 4.51 (s, 2H), and 3.46 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 180.43,
174.46, 160.91, 154.77, 135.45, 130.64, 130.44, 128.96, 128.34, 122.59, 122.05, 107.97, 66.02, and 58.32. IR
(ν, cm−1): 3446.10, 2358.55, 2337.96, 1677.60, 1276.65, 1216.21, 1153.22, and 1082.89. HRMS (ESI) calcd.
for [M + Na]+ C14H10O4Na+: 265.0471, found 265.0463.
TB9: 2-(ethoxymethyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 11%. Mp: 60–61 ◦C. 1H NMR
(600 MHz, CDCl3) δ 8.10 (dd, J = 8.2, 1.3 Hz, 1H), 7.77 (dd, J = 7.6, 1.2 Hz, 1H), 7.71–7.65 (m, 1H),
7.52–7.46 (m, 1H), 6.78 (s, 1H), 4.55 (s, 2H), 3.63 (q, J = 7.0 Hz, 2H), and 1.29 (t, J = 7.0 Hz, 3H). 13C
NMR (150 MHz, CDCl3) δ 180.47, 174.45, 160.81, 155.23, 135.45, 130.61, 130.37, 128.90, 128.39, 122.59,
122.08, 107.66, 66.26, 64.25, and 15.10. IR (ν, cm−1): 3446.08, 2358.74, 2342.78, 1681.54, 1275.43, 1215.49,
1159.01, and 1083.47. HRMS (ESI) calcd. for [M + Na]+ C15H12O4Na+: 279.0628, found 279.0621.
TC1: 2-(diethylaminomethyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 51%. Mp: 78–79 ◦C. 1H
NMR (600 MHz, CDCl3) δ 8.07 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.65 (t, J = 7.0 Hz, 1H), 7.46
(t, J = 7.6 Hz, 1H), 6.66 (s, 1H), 3.77 (s, 2H), 2.62 (q, J = 7.2 Hz, 4H), and 1.14 (t, J = 7.2 Hz, 6H). 13C
NMR (150 MHz, CDCl3) δ 180.65, 174.55, 160.34, 156.44, 135.41, 130.55, 130.12, 128.74, 128.58, 122.45,
122.21, 107.11, 48.69, 47.10, and 12.01. IR (ν, cm−1): 3445.24, 2953.88, 2358.48, 2339.23, 1700.91, 1676.52,
1216.10, and 1111.39. HRMS (ESI) calcd. for [M + Na]+ C17H18O3Na+: 284.1281, found 284.1271.
TC2: 2-(diisopropylaminomethyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 18%. Mp: 69–70 ◦C.
1H NMR (600 MHz, CDCl3) δ 8.06 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 6.2 Hz, 1H), 7.64 (t, J = 7.5 Hz, 1H),
7.44 (t, J = 6.7 Hz, 1H), 6.66 (s, 1H), 3.72 (s, 2H), 3.13 (p, J = 6.5 Hz, 2H), and 1.08 (d, J = 6.7 Hz, 12H). 13C
NMR (150 MHz, CDCl3) δ 180.88, 174.66, 161.17, 159.76, 135.37, 130.50, 129.81, 128.91, 128.65, 122.50,
122.09, 105.12, 49.12, 42.36, and 20.81. IR (ν, cm−1): 3445.80, 2966.49, 2358.61, 2337.30, 1676.07, 1558.32,
1215.85, and 1149.51. HRMS (ESI) calcd. for [M + Na]+ C19H22O3Na+: 312.1594, found 312.1583.
TC3: 2-((l-methionine methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 12%.
Mp: 52–53 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.08 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.66 (t, J
= 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 6.66 (s, 1H), 3.95 (d, J = 15.1 Hz, 1H), 3.79 (d, J = 15.1 Hz, 1H),
3.74 (s, 3H), 3.52 (dd, J = 8.4, 5.0 Hz, 1H), 2.64 (t, J = 7.2 Hz, 2H), 2.10 (s, 3H), 2.02–1.97 (m, 1H) and
1.89–1.82 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 180.55, 175.18, 174.44, 160.36, 157.00, 135.44, 130.58,
130.19, 128.80, 128.47, 122.35, 122.17, 106.00, 59.14, 52.14, 44.65, 32.68, 30.48, and 15.38. IR (ν, cm−1):
3446.14, 2923.56, 2358.62, 2335.37, 1698.61, 1670.40, 1215.45, and 1147.65. HRMS (ESI) calcd. for [M +
Na]+ C19H19O5NSNa+: 396.0876, found 396.0865.
TC4: 2-((l-alanine methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 27%. Mp:
83–84 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.07 (d, J = 6.9 Hz, 1H), 7.73 (d, J = 4.9 Hz, 1H), 7.65 (d, J = 8.6
Hz, 1H), 7.46 (t, J = 6.6 Hz, 1H), 6.66 (s, 1H), 3.94 (d, J = 14.1 Hz, 1H), 3.81 (d, J = 14.9 Hz, 1H), 3.74
(s, 3H), 3.46 (q, J = 6.9 Hz, 1H), and 1.37 (d, J = 6.6 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 180.52,
175.63, 174.42, 160.36, 156.93, 135.40, 130.56, 130.18, 128.80, 128.46, 122.39, 122.18, 105.99, 55.69, 52.05,
44.26, and 19.13. IR (ν, cm−1): 3328.35, 2958.60, 2358.44, 2337.30, 1735.12, 1676.39, 1216.30, and 1139.72.
HRMS (ESI) calcd. for [M + Na]+ C17H15O5NNa+: 336.0842, found 336.0831.
TC5: 2-((l-isoleucinate methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 39%.
Mp: 112–113 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.07 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.67–7.62
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(m, 1H), 7.48–7.43 (m, 1H), 6.65 (s, 1H), 3.92 (d, J = 15.1 Hz, 1H), 3.72 (d, J = 16.4 Hz, 4H), 3.17 (d, J = 5.8
Hz, 1H), 1.57–1.50 (m, 1H), 1.26–1.16 (m, 2H), and 0.93–0.88 (m, 6H). 13C NMR (150 MHz, CDCl3) δ
180.60, 175.16, 174.46, 160.27, 157.37, 135.45, 130.55, 130.15, 128.78, 128.52, 122.32, 122.19, 105.82, 65.31,
51.64, 45.08, 38.47, 25.39, 15.66, and 11.49. IR (ν, cm−1): 3445.72, 2924.70, 2358.43, 2341.16,1732.42,
1682.86, 1209.15, and 1150.10. HRMS (ESI) calcd. for [M + Na]+ C20H21O5NNa+: 378.1312, found
378.1299.
TC6: 2-((l-valine methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 41%. Mp:
54–55 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.09 (d, J = 6.2 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.70–7.64 (m,
1H), 7.50–7.45 (m, 1H), 6.67 (s, 1H), 3.95 (d, J = 15.3 Hz, 1H), 3.77–3.72 (m, 4H), 3.11 (d, J = 5.8 Hz, 1H),
2.02–1.95 (m, 1H), and 0.98 (t, J = 6.3 Hz, 7H). 13C NMR (150 MHz, CDCl3) δ 180.62, 175.22, 174.49,
160.28, 157.39, 135.43, 130.59, 130.14, 128.82, 128.56, 122.32, 122.22, 105.83, 66.36, 51.70, 45.16, 31.75,
19.28, and 18.35. IR (ν, cm−1): 3425.42, 2923,62, 2358.56, 2337.30, 1698.57, 1670.37, 1187.10, and 1118.00.
HRMS (ESI) calcd. for [M + Na]+ C19H19O5NNa+: 364.1155, found 364.1141.
TC7: 2-((l-glycine methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 17%. Mp:
55–56 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.06 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 6.4 Hz, 1H), 7.68–7.62 (m,
1H), 7.49–7.43 (m, 1H), 6.67 (s, 1H), 3.93 (s, 2H), 3.75 (s, 3H), and 3.50 (s, 2H). 13C NMR (150 MHz,
CDCl3) δ 180.49, 174.42, 172.45, 160.49, 156.62, 135.44, 130.57, 130.25, 128.79, 128.39, 122.41, 122.14,
106.25, 52.03, 49.50, and 45.38. IR (ν, cm−1): 3328.36, 2958.26, 2358.57, 2337.30, 1735.10, 1676.24, 1216.29,
and 1180.25. HRMS (ESI) calcd. for [M + Na]+ C16H13O5NNa+: 322.0686, found 322.0680.
TC8: 2-((l-leucinate methyl ester-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 19%.
Mp: 54–55 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.09 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.67 (t, J =
7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 6.66 (s, 1H), 3.94 (d, J = 15.1 Hz, 1H), 3.77 (d, J = 15.1 Hz, 1H), 3.73
(s, 3H), 3.38 (t, J = 7.2 Hz, 1H), 1.82–1.77 (m, 1H), 1.52 (t, J = 7.4 Hz, 2H), 0.95 (d, J = 6.7 Hz, 3H), and
0.90 (d, J = 6.7 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 180.59, 176.01, 174.47, 160.32, 157.18, 135.42,
130.59, 130.17, 128.84, 128.51, 122.32, 122.20, 105.94, 59.08, 51.88, 44.63, 42.75, 24.89, 22.78, and 22.09. IR
(ν, cm−1): 3434.68, 2958.49, 2358.68, 2339.23, 1670.06, 1518.72, 1211.01, and 1107.62. HRMS (ESI) calcd.
for [M + Na]+ C20H21O5NNa+: 378.1312, found 378.1302.
TC9: 2-((4-boc-piperazin-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 26%. Mp: 56–57
◦C. 1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 7.4 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H),
7.48 (t, J = 7.6 Hz, 1H), 6.70 (s, 1H), 3.68 (s, 2H), 3.49 (s, 4H), 2.52 (s, 4H), and 1.47 (s, 9H). 13C NMR
(150 MHz, CDCl3) δ 180.53, 174.48, 160.57, 155.01, 154.68, 135.44, 130.64, 130.29, 128.81, 128.46, 122.53,
122.17, 107.66, 79.88, 54.60, 52.60, and 28.42. IR (ν, cm−1): 3434.73, 2358.58, 2339.23, 1669.96, 1518.77,
1211.18, and 1107.93. HRMS (ESI) calcd. for [M + H]+ C22H25O5N2+: 397.1758, found 397.1751.
TC10: 2-((pyrrolidin-1-yl)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 24%. Mp: 62–63 ◦C.
1H NMR (600 MHz, CDCl3) δ 8.08 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H),
7.46 (t, J = 7.6 Hz, 1H), 6.68 (s, 1H), 3.76 (s, 2H), 2.69–2.63 (m, 4H), and 1.89–1.83 (m, 4H). 13C NMR
(150 MHz, CDCl3) δ 180.64, 174.54, 160.39, 156.44, 135.40, 130.56, 130.14, 128.80, 128.56, 122.55, 122.24,
106.71, 54.01, 51.84, and 23.53. IR (ν, cm−1): 3388.30, 3110.62, 2358.68, 2337.30, 1660.65, 1510.49, 1222.52,
and 1091.51. HRMS (ESI) calcd. for [M + H]+ C17H16O3N+: 282.1125, found 282.1115.
TC11: 2-(morpholinomethyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 38%. Mp: 98–99 ◦C. 1H
NMR (600 MHz, CDCl3) δ 8.09 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.69–7.64 (m, 1H), 7.51–7.45
(m, 1H), 6.70 (s, 1H), 3.78–3.74 (m, 4H), 3.66 (s, 2H), and 2.61–2.55 (m, 4H). 13C NMR (150 MHz, CDCl3)
δ 180.50, 174.46, 160.50, 155.01, 135.36, 130.59, 130.23, 128.86, 128.47, 122.46, 122.21, 107.64, 66.79, 54.93,
and 53.28. IR (ν, cm−1): 3438.84, 2807.27, 2358.54, 2342.76, 1676.47, 1557.77, 1215.99, 1111.32, and
1006.63. HRMS (ESI) calcd. for [M + Na]+ C17H15O4NNa+: 320.0893, found 320.0886.
TC12: 2-(((4-fluorophenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Dark red solid, yield: 51%.
Mp: 174–175 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 7.92 (d, J = 7.3 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.65
(d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 6.94 (t, J = 8.9 Hz, 2H), 6.74 (s, 1H), 6.73–6.68 (m, 2H), 6.20 (t,
J = 6.4 Hz, 1H), and 4.37 (d, J = 6.0 Hz, 2H). 13C NMR (150 MHz, DMSO-d6) δ 179.86, 174.62, 159.03,
157.32, 155.16 (d, J = 231.0 Hz), 145.06, 135.47, 130.37, 129.85, 129.69, 128.27, 122.42, 122.06, 115.77 (d,
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J = 21.0 Hz), 113.88 (d, J = 6.0 Hz), and 105.93. IR (ν, cm−1): 3378.05, 2923.56, 2358.52, 2335.37, 1662.70,
1514.18, 1215.45, and 1161.45. HRMS (ESI) calcd. for [M + Na]+ C19H12O3NFNa+: 344.0693, found
344.0681.
TC13: 2-(((3-fluorophenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Dark red solid, yield: 45%.
Mp: 169–170 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 7.92 (d, J = 7.6 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.65
(d, J = 7.6 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.10 (q, J = 8.0 Hz, 1H), 6.78 (s, 1H), 6.61 (t, J = 6.3 Hz, 1H),
6.54 (d, J = 8.2 Hz, 1H), 6.50 (d, J = 12.2 Hz, 1H), 6.35 (t, J = 8.4 Hz, 1H), and 4.41 (d, J = 6.2 Hz, 2H). 13C
NMR (150 MHz, DMSO-d6) δ 179.83, 174.63, 163.90 (d, J = 238.5 Hz), 159.09, 156.86, 150.51 (d, J = 10.5
Hz), 135.46, 130.79 (d, J = 9.0 Hz), 130.40, 129.85, 129.73, 128.25, 122.42, 122.04, 109.34, 106.10, 102.99 (d,
J = 21.0 Hz), and 99.24 (d, J = 27.0 Hz). IR (ν, cm−1): 3390.68, 3105.83, 2360.44, 2337.30, 1665.28, 1618.38,
1220.09, and 1152.73. HRMS (ESI) calcd. for [M + Na]+ C19H12O3NFNa+: 344.0693, found 344.0688.
TC14: 2-(((2-fluorophenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Dark red solid, yield: 46%.
Mp: 170–171 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.08 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.66 (t,
J = 7.4 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.05–7.00 (m, 2H), 6.79 (t, J = 8.5 Hz, 1H), 6.75–6.72 (m, 1H), 6.71
(s, 1H), and 4.51 (d, J = 6.4 Hz, 2H). 13C NMR (150 MHz, CDCl3) δ 180.39, 174.38, 160.36, 155.98, 151.74
(d, J = 237.0 Hz), 135.45, 135.22 (d, J = 12.0 Hz), 130.63, 130.29, 128.79, 128.36, 124.67 (d, J = 4.5 Hz),
122.26 (d, J = 15.0 Hz), 118.16 (d, J = 6.0 Hz), 114 (d, J = 19.5 Hz), 112.52, 112.50, 106.03, and 40.74. IR (ν,
cm−1): 3425.04, 2923.94, 2358.97, 2854,13, 1670.34, 1513.50, 1186.96, and 1117.57. HRMS (ESI) calcd. for
[M + Na]+ C19H12O3NFNa+: 344.0693, found 344.0684.
TC15: 2-(((2,4-difluorophenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 33%. Mp:
154–155 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.67 (t,
J = 7.4 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.14 (t, J = 8.1 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.71 (s, 2H), 6.59
(d, J = 8.2 Hz, 1H), and 4.46 (d, J = 6.4 Hz, 2H). 13C NMR (150 MHz, CDCl3) δ 180.36, 174.38, 160.42,
155.83 (d, J = 9.0 Hz), 154.24 (d, J = 10.5 Hz), 151.95 (d, J = 12.0 Hz), 150.34 (d, J = 12.0 Hz), 135.49,
131.73 (d, J = 12.0 Hz), 130.52 (d, J = 46.5 Hz), 129.67, 128.55 (d, J = 73.5 Hz), 122.24 (d, J = 24 Hz),
115.33, 112.73 (dd, J = 12.0 Hz), 110.86 (dd, J = 25.5 Hz), 106.09, 103.90 (dd, J = 49.5 Hz), and 41.22. IR
(ν, cm−1): 3434.72, 2358.46, 2337.30, 1689.86, 1518.53, 1210.93, 1107.68, and 957.02. HRMS (ESI) calcd.
for [M + Na]+ C19H11O3NF2Na+: 362.0599, found 362.0589.
TC16: 2-(((2,4,6-trimethylphenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Red solid, yield: 33%.
Mp: 173–174 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 7.6 Hz, 1H), 7.67 (d, J = 3.8 Hz, 2H), 7.50–7.46
(m, 1H), 6.85 (s, 2H), 6.60 (s, 1H), 4.21 (s, 2H), 2.29 (s, 6H), and 2.25 (s, 3H). 13C NMR (150 MHz, CDCl3)
δ 180.53, 174.47, 160.18, 157.50, 141.61, 135.47, 132.42, 130.65, 130.23, 130.13, 129.64, 128.84, 128.47,
122.23, 122.18, 105.72, 44.94, 20.62, and 18.23. IR (ν, cm−1): 3445.76, 2357.38, 2327.66, 1670.28, 1557.44,
1215.32, 1147.47, and 1025.94. HRMS (ESI) calcd. for [M + Na]+ C22H19O3NNa+: 368.1257, found
368.1250.
TC17: 2-(((4-chlorophenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Dark red solid, yield: 28%.
Mp: 205–206 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 7.92 (d, J = 6.8 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.65
(d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.1 Hz, 1H), 7.12 (d, J = 8.9 Hz, 2H), 6.75 (s, 1H), 6.72 (d, J = 8.9 Hz, 2H),
6.49 (t, J = 6.3 Hz, 1H), and 4.40 (d, J = 6.2 Hz, 2H). 13C NMR (150 MHz, DMSO-d6) δ: 179.82, 174.61,
159.06, 156.95, 147.33, 135.46, 130.39, 129.84, 129.72, 129.09, 128.24, 122.41, 122.05, 120.26, 114.42, and
106.08. IR (ν, cm−1): 3388.22, 3110.62, 2358.84, 2342.68, 1660.69, 1510.19, 1222.68 and 1118.65. HRMS
(ESI) calcd. for [M + Na]+ C19H12O3NClNa+, 360.0398, found 360.0384.
TC18: 2-(((4-methoxyphenyl)amino)methyl)naphtho[1,2-b]furan-4,5-dione. Dark solid, yield: 64%. Mp:
112–113 ◦C. 1H NMR (600 MHz, CDCl3) δ 8.08 (d, J = 6.4 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.69–7.63 (m,
1H), 7.50–7.44 (m, 1H), 6.82 (d, J = 8.9 Hz, 2H), 6.70–6.67 (m, 3H), 4.42 (s, 2H), and 3.77 (s, 3H). 13C
NMR (150 MHz, CDCl3) δ 180.49, 174.43, 160.22, 156.83, 152.98, 140.82, 135.43, 130.62, 130.21, 128.77,
128.46, 122.27, 115.00, 114.74, 105.84, 55.77, and 42.13. IR (ν, cm−1): 3370.45, 3105.23, 2358.89, 2337.30,
1660.16, 1514.41, 1234.80, and 1040.25. HRMS (ESI) calcd. for [M + Na]+ C20H15O4NNa+: 356.0893,
found 356.0883.
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3.3. In Vitro Cytotoxicity Assay
The human cancer cell lines, including prostate cancer cells PC3, leukemia cells K562, and melanoma
cells WM9, were stored in the biology laboratory of the Key Laboratory of Chemistry for Natural
Products of Guizhou Province and Chinese Academy of Sciences (Guiyang, China). All cells were
cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin
(Sijiqing, Hangzhou, China) and incubated at 37 ◦C under 5% CO2, 95% air, and 95% humidity.
Cytotoxicity was evaluated by performing the MTT assay [24]. Briefly, the cells were seeded in 96-well
microculture plates at a density from 4 × 103 to 8 × 103 cells/well. Cells were then exposed to different
concentrations of the assayed compounds for 48 h. Then, 20 μL of MTT solution (5 mg/mL) was added
to each well and incubated at 37 ◦C for an additional 4 h. The medium was then removed and 200 μL
Tris-DMSO solution was added. Plates were lightly shaking up to dissolve the dark blue formazan
crystals and the absorbance was measured in an ELISA plate reader at 570 nm.
3.4. Flow Cytometry Assay
Cell apoptosis was determined by an inverted fluorescence microscope observation and flow
cytometry as describe in our previous study [28]. Briefly, the cancer cells treated with compounds
were harvested for centrifugation at 1000 rpm for 5 min at room temperature, washed twice with
PBS and resuspended with binding buffer, and then PI (Sigma, St. Louis, MO, USA) was added to a
final concentration of 20 mg/mL. The cell lines were analyzed by flow cytometry (Becton Dickinson,
Franklin Lakes, NJ, USA).
3.5. Statistical Analysis
The IC50 values were calculated from the semilogarithmic dose-response curves. The data
were analyzed using SPSS 18.0 and reported as mean ± SD of the number of experiments indicated.
For all measurements, one-way ANOVA followed by Student’s t-test was used to assess the statistical
significance of the difference between each group. The LSD method was used to assess the statistical
significance of the difference between the two groups. A statistically significant difference was
considered at the level of P < 0.05. The data are presented as the mean ± SEM of three assays.
4. Conclusions
In this study, 27 novel L-shaped ortho-quinone analogs were synthesized and evaluated for their
anti-cancer activities. Compounds TB1, TB3, TB4, TB6, TC1, TC3, TC5, TC9, TC11, TC12, TC14,
TC15, TC16, and TC17 possessed broad-spectrum potent cytotoxicity against PC3, K562, and WM9
cells. With more than a 70% inhibitory rate, TB7 showed better inhibitory activity of K562 cells
as compared with other cells. Moreover, we observed that TC7 inhibited the growth of PC3 cells
more efficiently than other cells. Some of the active compounds such as TB3, TC1, TC3, and TC7
inhibited cell proliferation mainly through inducing apoptosis. The structure-activity relationships
evaluation showed that removing methyl at C-3 of the furan ring and introducing diverse side chains
at C-2 of the furan ring is an effective strategy for improving the anticancer activity of L-shaped
ortho-quinone analogs.
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Abstract: The current study was chiefly designed to examine the antiproliferative and antioxidant
activities of some novel quinazolinone(thione) derivatives 6–14. The present work focused on two
main points; firstly, comparing between quinazolinone and quinazolinthione derivatives. Whereas,
antiproliferative (against two cell lines namely, HepG2 and MCF-7) and antioxidant (by two methods;
ABTS and DPPH) activities of the investigated compounds, the best quinazolinthione derivatives
were 6 and 14, which exhibited excellent potencies comparable to quinazolinone derivatives 5 and 9,
respectively. Secondly, we compared the activity of four series of Schiff bases which included the
quinazolinone moiety (11a–d). In addition, the antiproliferative and antioxidant activities of the
compounds with various aryl aldehyde hydrazone derivatives (11a–d) analogs were studied. The
compounds exhibited potency that increased with increasing electron donating group in p-position
(OH > OMe > Cl) due to extended conjugated systems. Noteworthy, most of antiproliferative and
antioxidant activities results for the tested compounds are consistent with the DFT calculations.
Keywords: quinazolin-4(3H)-one; quinazolin-4(3H)-thione; Schiff base; antiproliferative activity;
antioxidant activity; DFT study
1. Introduction
Cancer is the second leading cause of death globally, and the contribution of cancer disease to the
overall mortality rate is increasing. Economically, the total annual cost of cancer in 2010 was estimated
at approximately US$ 1.16 trillion [1]. So that, more rational design, synthesis, and evaluation of new
compounds as anticancer, with higher efficiency is considered as urgent mission in the medicinal
chemistry field.
Quinazoline and quinazolinone derivatives are considered as tremendous targets for the
medicinal chemists, due to the fact that they are the scaffold of different potent anticancer drugs,
such as Gefitinib (trade name Iressa®), Erlotinib (trade name Tarceva®) [2–4], Methaqualone [5],
Afloqualone (as anticonvulsant activity) [6,7], Chloroqualone (as antitussive), and Diproqualone
(as sedative-hypnotic agents) [8] (Figure 1).
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Figure 1. Some structures of synthetic drugs scaffold quinazoline and quinazolinone derivatives.
In the last decades and until now, various compounds including quinazolinone moiety
conspicuously exhibited broad spectrum in numerous pharmacological activities such as
anticancer [9–14], anticonvulsants [15], antiproliferative [16], anti-inflammatory [17],
antihypertensive [18], antifungal [19], antibacterial, antioxidant [20], antimicrobial [21], anti-allergic [22],
antimalarial [23], antileishmanial [24], and treatment of Alzheimer’s disease (AD) [25].
Generally, the natural products are considered as one of the most interesting sources of biologically
active compounds. Among them, naturally occurring quinazolin-4(3H)-one derivatives, which
can be isolated from various plants and microorganisms such as Luotonin A (sources; Peganum
nigellastrum) [26], 2-(heptan-3-yl)quinazolinone (sources; Bacillus cereus) [27], Dictyoquinazol A (sources;
Dictyophora indusiata) [28], and Echinozolinone (sources; Echinops echinatus) [29] (Figure 2).
Figure 2. Some structures of naturally occurring quinazolin-4(3H)-one derivatives.
Quinazolinones have been synthesized by different methodologies [28,30–37], in the present
study, the conventional methodology to construct novel qunizolinone compounds has been adopted,
followed by the study of the antiproliferative activity, antioxidant activity, and DFT calculations for the
synthesized compounds.
2. Results and Discussion
2.1. Chemistry
In this interesting work, curing of anthranilic acid 1 with hexanoyl chloride 2 in dry pyridine
afforded the corresponding N-hexanoyl derivative 3 [38], which was cyclized by heating in distilled
acetic anhydride to give 2-pentyl-4H-benzo[d][1,3]oxazin-4-one 4 [39,40] (Scheme 1).
Scheme 1. The strategy for synthesis of compound 4.
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Benzoxazinone derivative 4 was utilized in situ as a precursor to construct new quinazolinone
derivatives. For instance, reaction of benzoxazinone derivative 4 with formamide afforded
2-pentylquinazolin-4(3H)-one 5 [41] (Scheme 2). The 1H NMR spectrum of 5 exhibited a singlet
peak at 12.13 ppm exchangeable with D2O corresponding to NH proton, two doublet and two triplet
peaks in the aromatic region at 8.05–7.42 ppm corresponding to four aromatic protons, and four
characteristic peaks upfield at 2.56–0.84 ppm for n-pentyl protons.
Afterwards, sulfuration of 2-pentylquinazolin-4(3H)-one 5 by utilizing of phosphorus pentasulfide
in dry toluene afforded 2-pentylquinazoline-4(3H)-thione 6 (Scheme 2). The formation of compound
6 was unambiguously elaborated by the presence of intense band at 1236 cm−1 corresponding to
υc=s and the absence of the stretching band of υc=o in the IR spectrum. On the other hand, the
incorporation of β-d-glucose pentaacetate with quinazolinone derivative 5 at the nitrogen atom of the
later awarded N-(β-d-glucopyranosyl-2,3,4,6-tetraacetate)-2-pentyl quinazolin-4(3H)-one 7 (Scheme 2),
via attacking of the lone pair of nitrogen atom of quinazolinone derivative 5 at the anomeric carbon
(C1) of β-d-glucose pentaacetate, followed by ring opening and then ring closure with expulsion of
acetate as a leaving group.
The chemical structure of compound 7 was explained by the IR spectrum, whereas it showed a
band at 1746 cm−1 compatible with υC=O of the acetate groups and lacked the absorption band for the
NH group. Moreover, this structure was also interpreted by the 1H-NMR spectrum which revealed
seven signals at 5.92–3.51 ppm and four singlet signals at 1.97–1.91 ppm all of them corresponding to
the protons of β-d-glucopyranosyl-2,3,4,6-tetraacetate moiety.
Curing of the benzoxazinone derivative 4 with ethanolamine under reflux for 3 h afforded
3-(2-hydroxyethyl)-2-pentylquinazolin-4(3H)-one 8 as the sole product. The IR spectrum of compound
8 showed a broad band at 3395 cm−1 corresponding to OH functionality. Furthermore, the 1H-NMR
spectrum appreciably emerged a triplet peak at 4.95 ppm exchangeable with D2O corresponding to
OH proton, triplet, and quartet peaks at 4.11 and 3.65 ppm, respectively, compatible with ethyl protons
of 2-hydroxyethyl moiety. As well, the 13C-NMR spectrum exhibited two peaks at 58.8 and 46.1 ppm
corresponding to the two carbons of 2-hydroxyethyl moiety.
3-Amino-2-pentylquinazolin-4(3H)-one 9 was commenced by refluxing of compound 4 with
hydrazine monohydrate in absolute ethanol for 4 h (Scheme 2). The formation of compound 9 was
confirmed by spectroscopic and elemental data. In particular, the 1H-NMR spectrum of compound 9
manifested a singlet signal commutable in D2O at 5.70 ppm corresponding to NH2 protons.
Scheme 2. Synthetic route to compounds 5–9.
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Reaction of 3-amino-2-pentylquinazolin-4(3H)-one 9 with various aldehydes 10a–d gave Schiff
bases 11a–d as the sole product in each case (Scheme 3). The 1H-NMR spectra of compounds 11a–d
exhibited the appearance of a singlet signal in the region between 8.81–8.69 ppm compatible with
methine proton of N=CH group.
The thiazolidin-4-one moiety 12 was constructed by the reaction of Schiff base 11a with methyl
thioglycolate in absolute ethanol including a small amount of piperidine as a catalyst for 3 h (Scheme 3).
The prospective structure 12 is in keeping with its spectral and elemental analyses.
Additionally, the nucleophilicity of the amino group of compound 9 was also estimated by fusion of
it with 4,5,6,7-tetrachloroisobenzofuran-1,3-dione in oil bath for an hour and that afforded phthalimido
derivative 13 in an excellent yield (Scheme 3). The foreseeable structure of compound 13 was elucidated
by their spectral data and elemental analysis. Obviously, its IR spectrum showed stretching absorption
bands at 1788, and 1746 cm−1 corresponding to the carbonyl groups of phthalimido moiety and at 1707
cm−1 corresponding to carbonyl group of the quinazolinone moiety. The 1H-NMR spectrum exhibited
four peaks for four aromatic protons and another four peaks for n-pentyl protons. Furthermore, its
13C-NMR spectrum emerged variant peaks, all of them fit with the proposed structure.
Eventually, the thione derivative 14 was obtained via sulfuration of compound 9 by utilizing
phosphorus pentasulfide as the above pervious method (Scheme 3). The structure of 14 was
unequivocally explained via the existence of a peak in the 13C NMR spectrum at 182.1 ppm compatible
with the carbon of the thione functional group.
Scheme 3. Synthetic route to compounds 11–14.
576
Molecules 2019, 24, 3787
2.2. Biological Evaluation
2.2.1. Antiproliferative Screening
Twelve compounds possessing quinazolinone(thione) moieties 5–14 along with compound 3
were screened against two cell lines, namely hepatocellular carcinoma (HepG2) and mammary gland
(MCF-7) in vitro by utilizing MTT assay [42,43]. The latter assay is a colorimetric test based on the
change of the yellow MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) to a purple
formazan derivative by mitochondrial succinate dehydrogenase in viable cells and the Doxorubicin
(DOX) was used as a standard reference.
The results listed in Table 1 and illustrated in Figure 3, demonstrate that compounds 6 and 11d
have a very strong efficacy against HePG2 cell line with IC50 values at 5.20 ± 0.5 and 7.63 ± 0.6 μM,
respectively. Meanwhile, compounds 6, 11d, and 14 have a very strong efficacy against the MCF-7 cell
line with IC50 values at 6.88 ± 0.4, 8.60 ± 0.7, and 10.78 ± 0.9 μM, respectively. Compounds 11b, 11c
have a strong efficacy against both cell lines with IC50 values in the range (12.54 ± 1.1–19.68 ± 1.6 μM).
For the HePG2 cell line, compounds 5, 9, 11a, and 14 have a moderate efficacy with IC50 values in
the range (23.75 ± 1.9–41.92 ± 2.8 μM). Where, for the MCF-7 cell line, compounds 3, 5, 9, and 11a
have a moderate efficacy with IC50 in the range (21.98 ± 1.8–47.53 ± 2.9 μM). Ultimately, the remaining
compounds in both cases have weak efficacies with IC50 values > 50 μM.
Table 1. Cytotoxic efficacy of thirteen compounds against hepatocellular carcinoma (HePG2) and
mammary gland (MCF-7) cell lines.
Compounds
In Vitro Cytotoxicity IC50 (μM)
HePG2 MCF-7
DOX 4.50 ± 0.3 4.17 ± 0.2
3 52.01 ± 3.3 47.53 ± 2.9
5 23.75 ± 1.9 21.98 ± 1.8
6 5.20 ± 0.5 6.88 ± 0.4
7 66.84 ± 4.0 54.23 ± 3.2
8 85.55 ± 4.5 70.86 ± 4.1
9 33.27 ± 2.5 28.69 ± 2.2
11a 41.92 ± 2.8 33.39 ± 2.5
11b 17.27 ± 1.4 19.68 ± 1.6
11c 12.54 ± 1.1 14.10 ± 1.3
11d 7.63 ± 0.6 8.60 ± 0.7
12 76.14 ± 4.3 59.15 ± 3.8
13 60.34 ± 3.8 56.28 ± 3.5
14 27.39 ± 2.3 10.78 ± 0.9
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Figure 3. Cytotoxic efficacy of thirteen compounds against HePG2 and MCF-7 cell lines.
Through our screening of the antiproliferative efficacy of the synthesized compounds, it was
determined that the average of relative viability of cells (%) with different concentrations such as 100, 50,
25, 12.5, 6.25, 3.125, and 1.56 μM against two cell lines (HePG2 and MCF-7) as shown in Figures 4 and 5.
Figure 4. Average of relative viability of HePG-2 cell line (%) with different concentrations.
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Figure 5. Average of relative viability of MCF-7 cell line (%) with different concentrations.
Structure Activity Relationship (SAR)
By comparing the antiproliferative efficacy of the thirteen synthesized compounds in this study to
their chemical structures, it was concluded that the following structure activity relationship’s (SAR’s)
is hypothesized:
1. Conversion of quinazolin-4(3H)-one derivative 5 to quinazolin-4(3H)-thione derivative
6 enhanced the antiproliferative activity against both cell lines from moderate activity to very
strong activity.
2. Similarly, conversion of 3-amino-2-pentylquinazolin-4(3H)-one 9 to 3-amino-
2-pentylquinazoline-4(3H)-thione 14 enhanced the antiproliferative activity against both cell lines.
3. Reaction of 9 with various aryl aldehydes afforded hydrazone derivatives (11a–d) analoges
with variable potencies according to the following sequence: 3,5-(OMe)2-4-OH-C6H2 11d >
3-OH-4-(OMe)-C6H3 11c> 4-(OMe)-C6H4 11b> 4-Cl-C6H4 11a, whereas, the OH group in p-position is
more electron donating group than the OMe group and Cl atom (i.e., the delocalization of n-π electrons
decreased in the above sequence).
4. Construction of the thiazolidinone ring in compound 12 decreased the antiproliferative activity
comparable with the hydrazone derivative 11a, due to decreasing of the delocalization of n-π electrons
after replacement of the C=N group (electron attracting group) by the thiazolidinone ring.
2.2.2. Antioxidant Activity Screening
One of the aims of this work is the screening of all synthesized compounds for antioxidant
activity using two different methods, namely ABTS [2,2′-azino-bis(3-ethyl benzothiazoline-6-sulfonic
acid)] and DPPH assays. DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) free radical assay based
on electron-transfer that produces a violet solution in ethanol. This free radical is stable at ambient
temperature and reduced in the presence of an antioxidant molecule, leading to colorless ethanol
solution. After investigation of these results as listed in Table 2 and Figure 6, it was realized that,
compounds 6 and 11d have promising activity through using ABTS assay. Meanwhile, in the case of
using DPPH assay, compounds 6, 11d and 14 have also very high activity. Ascorbic acid was used as a
reference through the antioxidant activity screening.
The results depicted in Table 2 and Figure 6 demonstrated that, DPPH assay findings are very
approximately related to those of ABTS assay with only one exception, compound 14 has an excellent
antioxidant activity against DPPH (IC50 = 26.87 ± 0.23 μM) than that of the ABTS method (IC50 = 71.42
± 0.52 μM). Noteworthy, all the screened compounds in the case of the DPPH method exhibited IC50
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smaller than the corresponding ones of the same compounds in the case of the ABTS method, and it
proposed that these compounds are more promising scavengers of the DPPH radical than those of the
ABTS radical.
By comparing the antioxidant efficacy of the thirteen synthesized compounds in this study to their
chemical structures, it was concluded that the following structure antioxidant activity relationship’s
(SAR’s) is hypothesized:
1. The presence of C=S enhanced antioxidant activity than the presence of C=O, as shown in
compounds 6 and 14 comparable with compounds 5 and 9, respectively.
2. The hydrazone derivatives (11a–d) analogs have variable potencies according to the following
sequence: 3,5-(OMe)2-4-OH-C6H2 11d > 3-OH-4-(OMe)-C6H3 11c > 4-(OMe)-C6H4 11b > 4-Cl-C6H4
11a, whereas, OH group in p-position is a more electron donating group (has more conjugated system)
than OMe group and Cl atom.
3. In compound 12, replacement of C=N group by the thiazolidinone ring decreased the antioxidant
activity comparable with 11a, because of the lack of the conjugated system.
Table 2. Antioxidant activities of all synthesized compounds by using 2,2′-azino-bis(3-ethyl
benzothiazoline-6-sulfonic acid (ABTS) and 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) methods.
Compounds ABTS IC50 (μM) DPPH IC50 (μM)
Ascorbic acid 31.26 ± 0.20 16.83 ± 0.15
3 93.24 ± 0.70 52.14 ± 0.65
5 65.13 ± 0.46 41.16 ± 0.42
6 35.48 ± 0.23 19.25 ± 0.18
7 114.63 ± 0.73 59.43 ± 0.68
8 160.92 ± 0.94 92.36 ± 0.76
9 77.38 ± 0.56 46.23 ± 0.48
11a 89.10 ± 0.64 50.12 ± 0.54
11b 58.03 ± 0.41 38.47 ± 0.37
11c 52.87 ± 0.36 32.69 ± 0.29
11d 46.25 ± 0.28 22.91 ± 0.21
12 154.51 ± 0.85 73.03 ± 0.72
13 131.95 ± 0.77 65.58 ± 0.66
14 71.42 ± 0.52 26.87 ± 0.23
Figure 6. Antioxidant activities of all synthesized compounds by using ABTS and DPPH methods.
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Previous reports of structurally similar compounds (in quinazoline ring) but with different
substituents have demonstrated different results in antiproliferative and antioxidant activities from
our results [9,33,44].
2.3. Density Functional Theory
According to the frontier molecular orbital (FMO) theory, the highest occupied molecular orbital
(HOMO) acts as an electron-donor and the lowest unoccupied molecular orbital (LUMO) acts as
an electron-acceptor [45]. Meanwhile, both play remarkable roles in the electronic studies by using
quantum chemical calculations and they are also of significant importance in modern biochemistry and
molecular biology [46]. A molecule is considered as a softer and has an excellent chemical reactivity
when it has a smaller energy gap. Meanwhile, a molecule is considered to have a higher chemical
hardness and assumed to have good stability when it has a larger energy gap [47–51].
The quantum chemical calculations were implemented by the density functional theory (DFT)
method by using the Gaussian(R) 09 program at the B3LYP level in conjunction with 6-31G(d,p) basis
set and computed parameters are summarized in Table 3.
By computing and using the energy gap (ΔE = ELUMO − EHOMO) and dipole moment values
beside another quantum chemical parameters such as ionization energy (I = −EHOMO), electron affinity
(A=−ELUMO) [52], chemical hardness (η= (I−A)/2), chemical softness (S= 1/η) [53], and binding energy,
we can rationally explicate the relation between the chemical structure and the antiproliferative activity
(SAR’s). Whereas, the energy gap of compound 6 (ΔE = 3.98 eV) is smaller than that corresponding of
compound 5 (ΔE = 4.85 eV) and also compound 6 has a higher chemical softness value (S = 0.50 eV−1)
than that corresponding of compound 5 (S = 0.41 eV−1). These results are matching with the results of
the antiproliferative screening whereas, compound 6 has a higher potency comparable with compound
5 for both cell lines (HepG2 and MCF-7) as shown in Table 1 and Figure 3. Similarly, compound 14
has a smaller energy gap and a higher chemical softness than that corresponding to compound 9 as
listed in Table 2. In addition, in vitro compound 14 showed a remarkable higher efficacy comparable
with compound 9 as shown in Table 1 and Figure 3. Notably, the dipole moment values of compounds
6 (μ = 3.4641 D) and 14 (μ = 1.852 D) are higher than that of compounds 5 (μ = 3.2867 D) and 9
(μ = 1.764 D), respectively.
On the other hand, compounds 11a–d possess antiproliferative activity in the following order 11d
> 11c > 11b > 11a, meanwhile, the energy gaps of these compounds increase in the following order
11a (ΔE = 2.99 eV) < 11d (ΔE = 3.05 eV) < 11c (ΔE = 3.10 eV) < 11b (ΔE = 3.13 eV). The lower of the
antiproliferative activity of compound 11a may be explained by values of the dipole moment whereas;
the dipole moment of compound 11a is smaller than that of compounds 11b–d as shown in Table 3.
Table 3. Quantum chemical parameters of the selected compounds with Density Functional Theory
(DFT) at B3LYP/6-31G (d,p) basis set.
Comp. No.
5 6 9 14 11a 11b 11c 11d
E HOMO (eV) −5.9432 −5.6352 −5.9405 −4.7724 −5.7277 −5.6363 −5.6717 −5.6602
E LUMO (eV) −1.0917 −1.6515 −1.1298 −1.6836 −2.7301 −2.4983 −2.5709 −2.6009
(ΔE) Energy gap (eV) 4.8515 3.9837 4.8107 3.0888 2.9976 3.1380 3.1008 3.0593
(I) Ionization energy (eV) 5.9432 5.6352 5.9405 4.7724 5.7277 5.6363 5.6717 5.6602
(A) Electron affinity (eV) 1.0917 1.6515 1.1298 1.6836 2.7301 2.4983 2.5709 2.6009
(η) Chemical hardness (eV) 2.4258 1.9919 2.4054 1.5444 1.49881 1.56901 1.5504 1.52969
(S) Chemical softness (eV−1) 0.4122 0.5020 0.4157 0.6475 0.6672 0.6374 0.6450 0.6537
(ET) Binding energy (a.u) −689.79 −1012.73 −745.11 −1068.05 −1473.81 −1128.73 −1203.94 −1318.44
(μ) Dipole moment (D) 3.2867 3.4641 1.764 1.852 3.2722 4.4472 4.1944 6.232
The distributions of the HOMO and LUMO orbitals of the selected compounds are computed at
the same level of the DFT theory and are provided in Figures 7 and 8. The results manifested that
possible reactive sites exist as shown below:
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1. The HOMO of compounds 5 and 9 are nearly similar and the distribution of orbitals are
mainly situated on the quinazolinone moiety, also, the LUMO of these compounds are situated on the
same moiety.
2. The HOMO of compounds 6 and 14 are nearly similar and the distribution of orbitals
are mainly situated on C=S, while, the LUMO of these compounds are mainly situated on the
quinazolinthione moiety.
3. The HOMO of compounds 11a–d are nearly similar and the distribution of orbitals are mainly
situated on the quniazolinone moiety, meanwhile, the LUMO of these compounds are mainly situated
on the aryl aldehyde hydrazone system.
Figure 7. Schematic representation of HOMO and LUMO coefficient distribution of compounds 5, 6, 9,
and 14.
Figure 8. Schematic representation of highest occupied molecular orbital (HOMO) and loest unoccupied
molecular orbital (LUMO) coefficient distribution of compounds 11a–d.
3. Materials and Methods
3.1. Chemistry
The melting point is uncorrected and was measured on a Stuart SMP 30 advanced digital electric
melting point apparatus (Cole-Parmer, Staffordshire, UK). All reactions were monitored by TLC
(Kieselgel 60 F254, Merck, Munchen, Germany) and spots were visualized using UV (254 nm), In
the region (400−4000 cm−1), the IR spectrum was measured in the KBr phase by using the Nicolet
iS10 FT-IR spectrometer (Shimadzu Corporation, Kyoto, Japan). The 1H-NMR (at 400 MHz) and
13C-NMR (at 100 MHz) spectra were performed at chemical warfare labs, Egypt, with a Varian Gemini
spectrometer (Metrohim, California, United States) in DMSO-d6 as a solvent by using tetramethylsilane
(TMS) as a reference. Perkin-Elmer 2400 CHN elemental analyzer (Waltham, MA, USA) was used to
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record CHN elemental analysis at the Faculty of Science, Cairo University, Egypt. The mass spectrum
was measured on Shimadzu GC-MS QP1000EX apparatus (Shimadzu Corporation, Kyoto, Japan) at
the central analytical lab, Ain Shams University, Cairo, Egypt.
3.1.1. 2-Hexanamidobenzoic Acid 3
Hexanoyl chloride 2 (1.39 mL, 0.01 mol) was added dropwise to anthranilic acid 1 (1.37 g, 0.01 mol)
dissolved in dry pyridine (20 mL) at ambient temperature with stirring. The stirring was continued
for an hour, and then the resulting emulsion was acidified with cold 10% HCl solution. The white
solid which separated was collected by filtration and then recrystallized from benzene to give 3 [38] as
white crystals; m.p.: 92–95 ◦C (Lit. m.p.: 93−95 ◦C) [38], yield: 92%. IR (KBr, cm−1): 3426−2463 (br)
(OH), 3206 (NH), 2959, 2934, 2861 (CHaliph.), 1691, 1637 (C=O). 1H-NMR (400 MHz, DMSO-d6) δ (ppm):
13.51 (br.s, 1H, OH, exchangeable with D2O), 11.09 (s, 1H, NH, exchangeable with D2O), 8.48 (d, 1H,
Ar-H, Ha, J = 8.8 Hz), 7.95 (d, 1H, Ar-H, Hd, J = 8.0 Hz), 7.55 (t, 1H, Ar-H, Hc, J = 7.8 Hz, J = 8.0 Hz),
7.11 (t, 1H, Ar-H, Hb, J = 7.4 Hz, J = 7.8 Hz), 2.35 (t, 2H, COCH2, J = 7.2 Hz, J = 7.6 Hz), 1.60 (quintet,
2H, COCH2CH2, J = 7.2 Hz, J = 7.6 Hz), 1.31−1.26 (m, 4H, CH3CH2CH2), 0.85 (t, 3H, CH3, J = 6.8 Hz,
J = 7.2 Hz), MS m/z (%): 235 (M.+; 29.4). Anal. Calcd. for C13H17NO3 (235.28): C, 66.36; H, 7.28; N, 5.95.
Found: C, 66.36; H, 7.28; N, 5.95.
3.1.2. 2-Pentyl-4H-benzo[d][1,3]oxazin-4-one 4
A suspension of 2-hexanamidobenzoic acid 3 (2.35 g, 0.01 mol) in freshly distilled acetic anhydride
(10 mL) was heated in water bath for an hour followed by a concentration of the mixture in vacuo and
used in situ [39,40].
3.1.3. 2-Pentylquinazolin-4(3H)-one 5
A solution of benzoxazinone 4 (2.17 g, 0.01 mol) in formamide (15 mL) was refluxed for 7 h. After
cooling, the reaction mixture was poured onto ice cold water, the obtained solid was filtered off, dried,
and recrystallized from petroleum ether 60–80 ◦C to give 5 [41] as white crystals; m.p.: 142–144 ◦C
(Lit. m.p.: 153–154 ◦C) [41], yield: 92%. IR (KBr, cm−1): 3171 (NH), 2958, 2928, 2860 (CHaliph.), 1680
(C=O), 1614 (C=N or C=C). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.13 (s, 1H, NH, exchangeable
with D2O), 8.05 (d, 1H, Ar-H, Ha, J = 8.0 Hz), 7.74 (t, 1H, Ar-H, Hc, J = 7.6 Hz, J = 7.8 Hz), 7.56 (d, 1H,
Ar-H, Hd, J = 8 Hz), 7.42 (t, 1H, Ar-H, Hb, J = 7.6 Hz), 2.56 (t, 2H, N=CCH2, J = 7.6 Hz, J = 8.0 Hz),
1.70 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.30–1.26 (m, 4H, CH3CH2CH2), 0.84 (t, 3H,
CH3, J = 6.8 Hz, J = 7.2 Hz). 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 162.2, 157.9, 149.4, 134.7, 127.2,
126.3, 126.1, 121.2, 34.9, 31.1, 26.9, 22.2, 14.2. MS m/z (%): 216 (M.+; 26.3). Anal. Calcd. for C13H16N2O
(216.28): C, 72.19; H, 7.46; N, 12.95. Found: C, 72.26; H, 7.49; N, 12.86.
3.1.4. 2-Pentylquinazoline-4(3H)-thione 6
To a solution of quinazolinone 5 (2.16 g, 0.01 mol) in dry toluene (30 mL), P2S5 (2.22 g, 0.01 mol)
was added. The reaction mixture was refluxed for 1 h, and then filtered off. The obtained filtrate
was evaporated under reduced pressure, the formed solid was collected by filtration, dried, and
recrystallized from ethanol to give 6 as light brown crystals; m.p.: 101–103 ◦C, yield: 76%. IR (KBr,
cm−1): 3184, 3141 (NH), 2967, 2935, 2852 (CHaliph.), 1618 (C=N), 1604 (C=C), 1236 (C=S). 1H-NMR
(400 MHz, DMSO-d6) δ (ppm): 13.69 (s, 1H, NH, exchangeable with D2O), 8.52 (d, 1H, Ar-H, Hd,
J = 8.4 Hz), 7.83 (t, 1H, Ar-H, Hc, J = 7.6 Hz), 7.63 (d, 1H, Ar-H, Ha, J = 8.4 Hz), 7.52 (t, 1H, Ar-H, Hb,
J = 7.4 Hz, J = 7.8 Hz), 2.70 (t, 2H, N=CCH2, J = 7.6 Hz, J = 8.0 Hz), 1.72 (quintet, 2H, N=CCH2CH2,
J = 7.6 Hz, J = 7.2 Hz), 1.31−1.26 (m, 4H, CH3CH2CH2), 0.85 (t, 3H, CH3, J = 6.8 Hz). MS m/z (%): 232
(M.+; 16.7). Anal. Calcd. for C13H16N2S (232.35): C, 67.20; H, 6.94; N, 12.06; S, 13.80. Found: C, 67.31;
H, 7.03; N, 12.01; S, 13.85.
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3.1.5. N-(β-d-Glucopyranosyl-2,3,4,6-tetraacetate)-2-pentylquinazolin-4(3H)-one 7
Quinazolinone 5 (2.16 g, 0.01 mol) was refluxed with β-d-glucose pentaacetate (3.90 g, 0.01 mol) in
absolute ethanol (50 mL) for 3 h. the solid obtained after slow evaporation of the resulting solution was
collected and recrystallized from ethanol to give 7 as white crystals; m.p.: 135–137 ◦C, yield: 62%. IR
(KBr, cm−1): 2955, 2924, 2854 (CHaliph.), 1746 (C=Oester), 1678 (C=Oquinazolinone), 1613 (C=N). 1H-NMR
(400 MHz, DMSO-d6) δ (ppm): 8.05 (d, 1H, Ar-H, Ha, J = 8.0 Hz), 7.74 (t, 1H, Ar-H, Hc, J = 8.4 Hz,
J = 6.8 Hz), 7.56 (d, 1H, Ar-H, Hd, J = 8.4 Hz), 7.43 (t, 1H, Ar-H, Hb, J = 8.0 Hz, J = 7.2 Hz), 5.92 (d,
1H, C1-H, J = 8.4 Hz), 5.39 (t, 1H, C2-H, J = 9.6 Hz), 4.93 (t, 1H, C3-H, J = 9.6 Hz), 4.90 (t, 1H, C4-H,
J = 8.4 Hz, J = 10.0 Hz), 4.14, 412 (d,d, 1H, C6-H, J = 10.4 Hz, J = 5.6 Hz), 3.97 (d, 1H, C6-H, J = 10.4 Hz),
3.51 (m, 1H, C5-H), 2.56 (t, 2H, N=CCH2, J = 8.0 Hz, J = 7.6 Hz), 1.978 (s, 3H, CH3), 1.973 (s, 3H, CH3),
1.961 (s, 3H, CH3), 1.917 (s, 3H, CH3), 1.69 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz, J = 6.8 Hz), 1.31−1.26
(m, 4H, CH3CH2CH2), 0.84 (t, 3H, CH3, J = 6.8 Hz, J = 7.2 Hz). MS m/z (%): 546 (M+; 32.4). Anal.
Calcd. for C27H34N2O10 (546.57): C, 59.33; H, 6.27; N, 5.13. Found: C, 59.18; H, 6.21; N, 5.08.
3.1.6. 3-(2-Hydroxyethyl)-2-pentylquinazolin-4(3H)-one 8
A solution of benzoxazinone 4 (2.17 g, 0.01 mol) in ethanolamine (15 mL) was heated under reflux
for 3 h. The reaction mixture was poured onto ice cold water, the obtained solid was filtered off, dried,
and then recrystallized from ethanol to give 8 as white crystals; m.p.: 84–85 ◦C, yield: 47%. IR (KBr,
cm−1): 3395 (OH), 2953, 2931, 2872 (CHaliph.), 1648 (C=O), 1611 (C=N). 1H-NMR (400 MHz, DMSO-d6)
δ (ppm): 8.07 (d, 1H, Ar-H, Ha, J = 8.0 Hz), 7.75 (t, 1H, Ar-H, Hc, J = 7.8 Hz, J = 7.6 Hz), 7.57 (d, 1H,
Ar-H, Hd, J = 8.0 Hz), 7.44 (t, 1H, Ar-H, Hb, J = 7.6 Hz, J = 7.2 Hz), 4.95 (t, 1H, OH, exchangeable with
D2O, J = 5.6 Hz), 4.11 (t, 2H, CH2CH2OH, J = 5.6 Hz, J = 6.0 Hz), 3.65 (q, 2H, CH2OH, J = 6.0 Hz,
J = 5.6 Hz), 2.93 (t, 2H, N=CCH2, J = 7.6 Hz, J = 8.0 Hz), 1.75 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz,
J = 7.6 Hz), 1.40−1.32 (m, 4H, CH3CH2CH2), 0.88 (t, 3H, CH3, J = 7.2 Hz). 13C-NMR (100 MHz,
DMSO-d6) δ (ppm): 161.7, 158.4, 147.4, 134.6, 127.1, 126.5, 126.4, 120.4, 58.8, 46.1, 34.6, 31.3, 26.3, 22.4,
14.3. MS m/z (%): 260 (M+; 41.2). Anal. Calcd. for C15H20N2O2 (260.34): C, 69.20; H, 7.74; N, 10.76.
Found: C, 69.17; H, 7.68; N, 10.81.
3.1.7. 3-Amino-2-pentylquinazolin-4(3H)-one 9
A mixture of benzoxazinone 4 (2.17 g, 0.01 mol) and hydrazine hydrate (1.5 mL) in absolute
ethanol (20 mL) was refluxed for 3 h. The mixture was poured onto ice cold water, the formed solid
was filtered off, and recrystallized from ethanol to give 9 as buff crystals; m.p.: 58–60 ◦C, yield: 43%.
IR (KBr, cm−1): 3306, 3263 (NH2), 2954, 2931, 2910, 2856 (CHaliph.), 1673 (C=O), 1630 (C=N). 1H NMR
(400 MHz, DMSO-d6) δ (ppm): 8.08 (d, 1H, Ar-H, Ha, J = 7.8 Hz), 7.75 (t, 1H, Ar-H, Hc, J = 7.4 Hz,
J = 7.8 Hz), 7.59 (d, 1H, Ar-H, Hd, J = 7.6 Hz), 7.45 (t, 1H, Ar-H, Hb, J = 7.2 Hz, J = 7.6 Hz), 5.70 (s,
2H, NH2, exchangeable with D2O), 2.90 (t, 2H, N=CCH2, J = 7.2 Hz, J = 8.0 Hz), 1.74 (quintet, 2H,
N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.37−1.30 (m, 4H, CH3CH2CH2), 0.87 (t, 3H, CH3, J = 6.4 Hz,
J =7.2 Hz). 13C-NMR (400 MHz, DMSO-d6) δ (ppm): 160.9, 158.8, 147.0, 134.3, 127.2, 126.39, 126.31,
120.2, 34.0, 31.4, 26.0, 22.3, 14.3. MS m/z (%): 231 (M+; 41.1). Anal. Calcd. for C13H17N3O (231.30): C,
67.51; H, 7.41; N, 18.17. Found: C, 67.39; H, 7.34; N, 18.24.
3.1.8. General Procedure for Synthesis of 11a–d
A mixture of compound 9 (2.31 g, 0.01 mol) and the appropriate aldehydes 10a–d (0.01 mol) in
absolute ethanol (30 mL) was refluxed for 4−6 h. The reaction mixture was evaporated under reduced
pressure; the obtained residue was collected and recrystallized from the proper solvent to give the
corresponding benzylidene derivatives 11a–d, respectively.
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3-((4-Chlorobenzylidene)amino)-2-pentylquinazolin-4(3H)-one 11a
Yellow crystals; m.p.: 176–178 ◦C (ethanol), yield: 72%. IR (KBr, cm−1): 2943, 2866 (CHaliph.), 1667
(C=O), 1624 (C=N). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.69 (s, 1H, N=CH), 7.95 (d, 1H, Ar-H,
Ha, J = 7.8 Hz), 7.88 (d, 2H, Ar-H, HE +HF, J = 8.8 Hz), 7.66 (t, 1H, Ar-H, Hc, J = 8.4 Hz), 7.57 (d, 3H,
Ar-H, Hd +HX +HZ), 7.46 (t, 1H, Ar-H, Hb, J = 8.4 Hz), 2.34 (t, 2H, N=CCH2, J = 7.6 Hz), 1.60 (quintet,
2H, N=CCH2CH2, J = 7.2 Hz), 1.31−1.26 (m, 4H, CH3CH2CH2), 0.85 (t, 3H, CH3, J = 6.8 Hz). MS m/z
(%): 353 (M+; 4.0). Anal. Calcd. for C20H20ClN3O (353.85): C, 67.89; H, 5.70; Cl, 10.02; N, 11.88. Found:
C, 67.78; H, 5.62; Cl, 9.89; N, 11.79.
3-((4-Methoxybenzylidene)amino)-2-pentylquinazolin-4(3H)-one 11b
White crystals; m.p.: 83–84 ◦C (petroleum ether 60–80 ◦C), yield: 64%. IR (KBr, cm−1): 2946, 2912,
2882, 2843 (CHaliph.), 1669 (C=O), 1606 (C=N or C=C). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.81 (s,
1H, N=CH), 8.12 (d, 1H, Ar-H, Ha, J = 7.8 Hz), 7.89 (d, 2H, Ar-H, HE + HF, J = 8.8 Hz), 7.80 (t, 1H,
Ar-H, Hc, J = 8.2, Hz, J = 7.4 Hz), 7.65 (d, 1H, Ar-H, Hd, J = 8.0 Hz), 7.50 (t, 1H, Ar-H, Hb, J = 7.6, Hz,
J = 7.4 Hz), 7.12 (d, 2H, Ar-H, HX +HZ, J = 8.8 Hz), 3.85 (s, 3H, OCH3), 2.80 (t, 2H, N=CCH2, J = 7.6 Hz,
J = 8.0 Hz), 1.71 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.33−1.26 (m, 4H, CH3CH2CH2),
0.81 (t, 3H, CH3, J = 7.2 Hz). MS m/z 7(%): 349 (M+; 11.). Anal. Calcd. for C21H23N3O2 (349.43): C,
72.18; H, 6.63; N, 12.03. Found: C, 72.29; H, 6.69; N, 11.88.
3-((3-Hydroxy-4-methoxybenzylidene)amino)-2-pentylquinazolin-4(3H)-one 11c
White crystals; m.p.: 150–152 ◦C (ethanol), yield: 57%. IR (KBr, cm−1): 3277 (OH), 2956, 2927,
2892, 2863, 2845 (CHaliph.), 1678 (C=O), 1603 (C=N or C=C). 1H-NMR (400 MHz, DMSO-d6) δ (ppm):
9.49 (s, 1H, OH, exchangeable with D2O), 8.70 (s, 1H, N=CH), 8.12 (d, 1H, Ar-H, Ha, J = 8.0 Hz), 7.79 (t,
1H, Ar-H, Hc, J = 8.0 Hz, J =8.4 Hz), 7.65 (d, 1H, Ar-H, Hd, J = 7.6 Hz), 7.49 (t, 1H, Ar-H, Hb, J = 8.0 Hz,
J = 7.2 Hz), 7.42 (d, 1H, HF, Jm = 2 Hz), 7.30, 7.28 (d,d, 1H, Ar-H, HE, Jo = 8.4 Hz, Jm = 2 Hz), 7.07 (d,
1H, Ar-H, HX, J = 8.4 Hz), 3.85 (s, 3H, OCH3), 2.78 (t, 2H, N=CCH2, J = 7.6 Hz), 1.71 (quintet, 2H,
N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.31−1.28 (m, 4H, CH3CH2CH2), 0.81 (t, 3H, CH3, J = 6.8 Hz,
J = 7.2 Hz). MS m/z (%): 365 (M+; 23.4). Anal. Calcd. for C21H23N3O3 (365.43): C, 69.02; H, 6.34; N,
11.50. Found: C, 68.88; H, 6.28; N, 11.62.
3-((4-Hydroxy-3,5-dimethoxybenzylidene)amino)-2-pentylquinazolin-4(3H)-one 11d
White crystals; m.p.: 148–150 ◦C (benzene), yield: 61%. IR (KBr, cm−1): 3408 (OH), 2952, 2911,
2844 (CHaliph.), 1668 (C=O), 1591 (C=N or C=C). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 9.36 (br.s,
1H, OH, exchangeable with D2O), 8.72 (s, 1H, N=CH), 8.12 (d, 1H, Ar-H, Ha, J = 8.2 Hz), 7.79 (t, 1H,
Ar-H, Hc, J = 8.0 Hz, J = 7.4 Hz), 7.65 (d, 1H, Ar-H, Hd, J = 7.6 Hz), 7.50 (t, 1H, Ar-H, Hb, J = 8.0 Hz,
J = 7.2 Hz), 7.23 (s, 2H, HE +HF), 3.82 (s, 6H, 2OCH3), 2.81 (t, 2H, N=CCH2, J = 7.6 Hz, J = 8.0 Hz), 1.72
(quintet, 2H, N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.36−1.26 (m, 4H, CH3CH2CH2), 0.81 (t, 3H, CH3,
J = 6.8 Hz, J =7.2 Hz). 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 169.8, 158.0, 156.5, 148.6 (2), 146.7,
140.8, 134.6, 127.4, 127.0, 126.7, 122.8, 121.3, 106.8 (2), 56.5 (2), 34.5, 31.3, 26.0, 22.2, 14.2. MS m/z (%):
395 (M+; 62.1), Anal. Calcd. for C22H25N3O4 (395.46): C, 66.82; H, 6.37; N, 10.63. Found: C, 66.95; H,
6.41; N, 10.58.
3.1.9. 2-(4-Chlorophenyl)-3-(4-oxo-2-pentylquinazolin-3(4H)-yl)thiazolidin-4-one 12
A mixture of compound 11a (3.53 g, 0.01 mol) and methyl thioglycolate (0.89 mL, 0.01 mol) in
absolute ethanol (30 mL) containing piperidine (0.5 mL) was refluxed for 3 h. The obtained solid
after evaporation of the solvent was collected and recrystallized from petroleum ether 60–80 ◦C to
give 12 as pale yellow crystals; m.p.: 78–80 ◦C, yield: 47%. IR (KBr, cm−1): 2951, 2925, 2868 (CHaliph.),
1736 (C=Othiazolidinone), 1671 (C=Oquinazolinone), 1608 (C=N or C=C). 1H-NMR (100 MHz, DMSO-d6) δ
(ppm): 8.13 (d, 1H, Ar-H, Ha, J = 8.2 Hz), 7.96 (d, 2H, Ar-H, HE + HF, J = 8.0 Hz), 7.80 (t, 1H, Ar-H,
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Hc, J = 7.6 Hz), 7.65 (d, 1H, Ar-H, Hd, J = 8.0 Hz), 7.64 (d, 2H, Ar-H, HX +HZ, J = 8.4 Hz), 7.51 (t, 1H,
Ar-H, Hb, J = 7.6 Hz, J = 7.8 Hz), 5.70 (s, 1H, SCH), 3.75, 3.67 (d,d, 2H, CH2(thiazolidinone), J = 23.6 Hz,
J = 23.2 Hz), 2.81 (t, 2H, N=CCH2, J = 8.0 Hz, J = 7.6 Hz), 1.71 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz,
J = 8.0 Hz), 1.35−1.17 (m, 4H, CH3CH2CH2), 0.80 (t, 3H, CH3, J = 7.2 Hz). MS m/z (%): 427 (M+; 11.8).
Anal. Calcd. for C22H22ClN3O2S (427.95): C, 61.75; H, 5.18; Cl, 8.28; N, 9.82; S, 7.49. Found: C, 61.66;
H, 5.12; Cl, 8.31; N, 9.75; S, 7.55.
3.1.10. 4,5,6,7-Tetrachloro-2-(4-oxo-2-pentylquinazolin-3(4H)-yl)isoindoline-1,3-dione 13
Compound 9 (2.31 g, 0.01 mol) was fused with 4,5,6,7-tetrachloroisobenzofuran-1,3-dione (2.85 g,
0.01 mol) in oil bath for an hour. The resulting solid was recrystallized from ethanol to give 13 as orange
crystals; m.p.: 178–180 ◦C, yield: 86%. IR (KBr, cm−1): 2943, 2856 (CHaliph.), 1788, 1746 (C=Oimide),
1705 (C=Oquinazolinone), 1606 (C=N or C=C). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.08 (d, 1H,
Ar-H, Ha, J = 8 Hz), 7.94 (t, 1H, Ar-H, Hc, J = 8.0 Hz, J = 7.2 Hz), 7.76 (d, 1H, Ar-H, Hd, J = 8.0 Hz),
7.60 (t, 1H, Ar-H, Hb, J = 7.6 Hz), 2.73 (t, 2H, N=CCH2, J = 6.8 Hz, J = 8.0 Hz), 1.70−1.60 (m, 2H,
N=CCH2CH2), 1.29−1.27 (m, 4H, CH3CH2CH2), 0.81 (t, 3H, CH3, J = 6.8 Hz, J =7.2 Hz). 13C-NMR
(100 MHz, DMSO-d6) δ (ppm): 161.5, 161.3, 157.9, 157.7, 147.4, 146.7, 140.0, 138.8, 136.6 (2), 128.2 (2),
128.0, 127.1, 126.8, 119.8, 32.6, 30.9, 26.0, 22.2, 14.2. MS m/z (%): 231 (M+; 41.1). Anal. Calcd. for
C21H15Cl4N3O3 (499.17): C, 50.53; H, 3.03; Cl, 28.41; N, 8.42. Found: C, 50.61; H, 3.09; Cl, 28.37; N, 8.53.
3.1.11. 3-Amino-2-pentylquinazoline-4(3H)-thione 14
A mixture of compound 9 (2.31 g, 0.01 mol) and P2S5 (2.22 g, 0.01 mol) in dry toluene (15 mL) was
heated under reflux for 4 h. The mixture was filtered off, the filtrate was evaporated under reduced
pressure, the obtained solid was collected, dried, and recrystallized from ethanol to give 14 as yellow
crystals; m.p.: 57–59 ◦C, yield: 53%. IR (KBr, cm−1): 3240, 3200 (NH2), 2925, 2855 (CHaliph.), 1591
(C=N or C=C), 1238 (C=S). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.51 (d, 1H, Ar-H, Ha, J = 8.2 Hz),
7.82 (t, 1H, Ar-H, Hc, J = 7.6 Hz, J = 7.8 Hz), 7.69 (d, 1H, Ar-H, Hd, J = 7.6 Hz), 7.57 (t, 1H, Ar-H, Hb,
J = 7.6 Hz), 7.04 (s, 2H, NH2, exchangeable with D2O), 3.06 (t, 2H, N=CCH2, J = 7.2 Hz, J = 8.0 Hz),
1.81 (quintet, 2H, N=CCH2CH2, J = 7.6 Hz, J = 7.2 Hz), 1.42−1.32 (m, 4H, CH3CH2CH2), 0.88 (t, 3H,
CH3, J = 6.8 Hz, J =7.2 Hz). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 182.1, 155.5, 142.0, 134.5, 130.6,
128.1 (2), 127.4, 34.4, 31.3, 25.5, 22.4, 14.3. MS m/z (%): 247 (M+; 74.3). Anal. Calcd. for C13H17N3S
(247.36): C, 63.12; H, 6.93; N, 16.99; S, 12.96. Found: C, 63.19; H, 6.96; N, 17.11; S, 12.82.
3.2. Cytotoxicity and Antiproliferative Evaluation
MTT Assay
The implement of MTT methodology for the antiproliferative screening of quinazolinone
derivatives 5–14 along with compound 3 against two cell lines, namely, hepatocellular carcinoma
(HepG2) and mammary gland (MCF-7) were obtained from ATCC through the Holding company for
biological products and vaccines (VACSERA), Cairo, Egypt. The reference anticancer drug used was
Doxorubicin. The MTT assay was carried out at the pharmacology department, Faculty of pharmacy,
Mansoura University, Egypt according to the reported literatures [42,43,54]. The cells were cultured in a
RPMI-1640 medium with 10% fetal bovine serum, followed by the addition of antibiotics (100 units/mL
penicillin and 100 μg/mL streptomycin) at 37 ◦C in a 5% CO2 incubator. The cells were seeded in a
96-well plate at a density of (1.0 × 104 cells/well) at 37 ◦C for 48 h under 5% CO2. Treatment of cells
with different concentrations of compounds such as 100, 50, 25, 12.5, 6.25, 3.125, and 1.56 μM was
carried out and placed in the incubator for 24 h. Then, 20 μL of MTT solution at 5 mg/mL was added
and incubated for 4 h. DMSO (100 μL) was added into each well to dissolve the purple formazan
formed. At 570 nm absorbance the colorimetric assay was measured and recorded by using a plate
reader (BioTek EL ×800 Microplate Reader, BioTek Instruments, Inc, Winooski, VT, USA).
Calculation of the relative cell viability (%) = (A of treated samples /A of untreated sample) × 100.
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3.3. Antioxidant Assay
3.3.1. Antioxidant Activity Screening Assay
ABTS Method
By the bleaching of ABTS derived radical cations, the detections of antioxidant activities
were estimated. The radical cation was prepared by the reaction of ABTS [2,2′-azino-bis(3-ethyl
benzothiazoline-6-sulfonic acid)] (60 μL) with MnO2 (3 mL, 25 mg/mL) in a phosphate buffer solution
(10 μM, pH 7, 5 mL). The solution was shaken for 3 min, centrifuged, filtered, and recorded at λmax
734 nm the absorbance A(control) of the resulting ABTS radical solution (green-blue). Upon the addition
of the tested sample solution (20 μl) with different concentrations of compounds such as 200, 100, 50, 25,
and 12.5 μM in spectroscopic grade MeOH/buffer (1:1 v/v) to the ABTS solution, the absorbance A(test)
was measured. The decreasing in the absorbance is expressed as % inhibition which was calculated
according to the following equation [55]:
% Inhibition = [A(control) − A(test)/A(control)] × 100 (1)
where; the reference and standard antioxidant compound in this test is the ascorbic acid solution
(20 μL, 2 mM) and the blank sample was performed by the solvent without ABTS.
DPPH Method
According to the methodology described by Brand-Williams et al. [56], the measurement of the
DPPH radical scavenging activity was implemented. The samples with different concentrations of
compounds such as 200, 100, 50, 25, and 12.5 μM were allowed to react with the stable DPPH radical
in ethanol solution. Whereas, the reaction mixture consisted of sample (0.5 mL), absolute ethanol
(3 mL), and DPPH radical solution (0.3 mL) 0.5 mM in ethanol. DPPH is reduced when it reacts with
an antioxidant compound, which can donate hydrogen. The changes in color (from deep violet to light
yellow) were recorded [absorbance (Abs)] at λmax 517 nm after 100 min of reaction using a UV-Vis
spectrophotometer (Schimadzu Co., Tokyo, Japan). The blank solution was prepared by mixing ethanol
(3.3 mL) and the sample (0.5 mL). Meanwhile, the mixture of ethanol (3.5 mL) and DPPH radical
solution (0.3 mL) serve as a positive control.
The scavenging activity percentage (AA %) was determined according to Mensor et al. [57]:
AA % = 100 − [(Abs(sample) − Abs(blankl)/Abs(control)) × 100] (2)
3.4. Computational Procedures
All theoretical calculations and results of the studied compounds were implemented by utilizing
Gaussian(R) 09 D.01 [58] (Semichem Inc., Shawnee Mission, KS, USA) by applying the DFT operation
with the hybrid functional B3LYP level [59,60] in conjunction with the 6−31G(d,p) basis set. The
visualization of these results was achieved using GaussView 6.0.16 software (Semichem Inc., Shawnee
Mission, KS, USA).
4. Conclusions
In conclusion, this work focused on the study of the antiproliferative and antioxidant activities
in vitro in addition to the theoretical calculation of the DFT theory of some novel quinazolinone(thione)
derivatives 6–14. Two main points were the principal targets; firstly, by comparing the activities of
quinazolinone and quinazolinthione derivatives. Secondly, comparing the activities of four series of
Schiff bases, that have quinazolinone moiety. The results of this study imply that the quinazolinthione
derivatives 6 and 14 have promising potent antiproliferative activity comparable with quinazolinone
derivatives 5 and 9, respectively. According to the DFT study, compounds 6 and 14 have a smaller
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energy gap and a higher chemical softness than that of compounds 5 and 9, respectively. Additionally,
screening of various aryl aldehyde hydrazone derivatives (11a–d) analogs exhibited that the potency
increased with increasing the electron donating group in p-position due to increasing of the conjugated
system, and that was supported by the DFT study.
On the other hand, compounds 6 and 11d showed promising antioxidant activity using ABTS
assay. While in the DPPH assay, compounds 6, 11d, and 14 have showed potent activities comparable to
the ascorbic acid which was used as a reference drug. Noteworthy, the results of both antiproliferative
and antioxidant activities for each compound individually are nearly the same.
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